PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chaturvedi, P; Singh, AP; Batra, SK				Chaturvedi, Pallavi; Singh, Ajay P.; Batra, Surinder K.			Structure, evolution, anal biology of the MUC4 mucin	FASEB JOURNAL			English	Review						cell-cell matrix interactions; cell-extracellular matrix interactions; metastasis; receptor tyrosine kinases; HER2; cell signaling; tumor microenvironment	HUMAN PANCREATIC ADENOCARCINOMA; ACCESSORY DIGESTIVE GLANDS; SQUAMOUS-CELL CARCINOMA; GENE-EXPRESSION; SIALOMUCIN COMPLEX; EPITHELIAL-CELLS; ERBB RECEPTORS; MUC4/SIALOMUCIN COMPLEX; MOLECULAR-CLONING; TUMOR-CELLS	Mucins are high-molecular-weight glycoproteins and are implicated in diverse biological functions. MUC4, a member of transmembrane mucin family, is expressed in airway epithelial cells and body fluids like saliva, tear film, ear fluid, and breast milk. In addition to its normal expression, an aberrant expression of MUC4 has been reported in a variety of carcinomas. Among various potential domains of MUC4, epidermal growth factor (EGF) -like domains are hypothesized to interact with and activate the ErbB2 receptors, suggesting an intramembrane-growth factor function for MUC4. The heavily glycosylated tandem repeat domain provides the structural rigidity to the extended extracellular region. MUC4, by virtue of its extended structure, serves as a barrier for some cell-cell and cell-extracellular matrix interactions and as a potential reservoir for certain growth factors. An intricate relationship between MUC4 and growth factor signaling is also reflected in the transcriptional regulation of MUC4. The MUC4 promoter has binding sites for different transcription factors, which are responsible for the regulation of its expression in different tissues. The interferon-gamma, retinoic acid, and transforming growth factor-beta signaling pathways regulate MUC4 expression in a partially interdependent manner. Taken together, all of these features of MUC4 strongly support its role as a potential candidate for diagnostic and therapeutic applications in cancer and other diseases.	[Chaturvedi, Pallavi; Singh, Ajay P.; Batra, Surinder K.] Univ Nebraska, Med Ctr, Eppley Canc Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Eppley Canc Ctr, Dept Biochem & Mol Biol, 600 S 42nd St, Omaha, NE 68198 USA.	sbatra@unmc.edu	Singh, Ajay/AAF-4414-2020	Singh, Ajay/0000-0003-3492-6330	NATIONAL CANCER INSTITUTE [R01CA078590] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-78590, R01 CA078590, R01 CA078590-11S1] Funding Source: Medline; PHS HHS [C-A111294] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Agrawal B, 1998, CANCER RES, V58, P4079; Aksoy N, 2004, MACROMOL BIOSCI, V4, P483, DOI 10.1002/mabi.200300099; Alos L, 2005, AM J SURG PATHOL, V29, P806, DOI 10.1097/01.pas.0000155856.84553.c9; Andrianifahanana M, 2005, ONCOGENE, V24, P6143, DOI 10.1038/sj.onc.1208756; Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Arul GS, 2000, GUT, V47, P753, DOI 10.1136/gut.47.6.753; Asker N, 1998, J BIOL CHEM, V273, P18857, DOI 10.1074/jbc.273.30.18857; Bax DA, 2004, J CLIN PATHOL, V57, P1267, DOI 10.1136/jcp.2004.017020; Bhattacharyya SN, 2004, INFLAMMATION, V28, P67, DOI 10.1023/B:IFLA.0000033022.66289.04; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; Buisine MP, 1999, INFLAMM BOWEL DIS, V5, P24, DOI 10.1097/00054725-199902000-00004; Buisine MP, 1998, GUT, V43, P519, DOI 10.1136/gut.43.4.519; Buisine MP, 2001, GUT, V49, P544, DOI 10.1136/gut.49.4.544; Buisine MP, 2000, J HISTOCHEM CYTOCHEM, V48, P1667, DOI 10.1177/002215540004801210; Buisine MP, 2000, J HISTOCHEM CYTOCHEM, V48, P1657, DOI 10.1177/002215540004801209; Buisine MP, 1999, AM J RESP CELL MOL, V20, P209, DOI 10.1165/ajrcmb.20.2.3259; Carraway KL, 2001, BIOCHEM SOC T, V29, P162, DOI 10.1042/BST0290162; Carraway KL, 2003, BIOESSAYS, V25, P66, DOI 10.1002/bies.10201; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARRAWAY KL, 1989, BIOESSAYS, V10, P117, DOI 10.1002/bies.950100406; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; Chauhan SC, 2006, MODERN PATHOL, V19, P1386, DOI 10.1038/modpathol.3800646; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Choudhury A, 2000, J BIOCHEM-TOKYO, V128, P233, DOI 10.1093/oxfordjournals.jbchem.a022746; Choudhury A, 2004, BRIT J CANCER, V90, P657, DOI 10.1038/sj.bjc.6601604; Choudhury A, 2001, TERATOGEN CARCIN MUT, V21, P83, DOI 10.1002/1520-6866(2001)21:1<83::AID-TCM8>3.0.CO;2-3; Ciccarelli FD, 2002, TRENDS BIOCHEM SCI, V27, P113, DOI 10.1016/S0968-0004(01)02049-7; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; Corfield AP, 1995, BIOCHEM SOC T, V23, P840, DOI 10.1042/bst0230840; Corfield AP, 2001, FRONT BIOSCI-LANDMRK, V6, pD1321, DOI 10.2741/Corfield; Corrales RM, 2003, CURR EYE RES, V27, P323, DOI 10.1076/ceyr.27.5.323.17221; Damera G, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-39; Damera G, 2006, BIOSCIENCE REP, V26, P55, DOI 10.1007/s10540-006-9000-5; Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020; DUNN GA, 1984, NATURE, V312, P63, DOI 10.1038/312063a0; Duraisamy S, 2006, GENE, V373, P28, DOI 10.1016/j.gene.2005.12.021; Escande F, 2002, EUR J BIOCHEM, V269, P3637, DOI 10.1046/j.1432-1033.2002.03032.x; Firth LC, 2003, CURR BIOL, V13, pR773, DOI 10.1016/j.cub.2003.09.020; Fukuda M, 2002, BBA-GEN SUBJECTS, V1573, P394, DOI 10.1016/S0304-4165(02)00409-9; Fukuda M, 1996, CANCER RES, V56, P2237; Funes M, 2006, J BIOL CHEM, V281, P19310, DOI 10.1074/jbc.M603225200; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; Gipson IK, 1997, BIOL REPROD, V56, P999, DOI 10.1095/biolreprod56.4.999; Gipson IK, 2001, FRONT BIOSCI-LANDMRK, V6, pD1245, DOI 10.2741/Gipson; Gipson IK, 2004, EXP EYE RES, V78, P379, DOI 10.1016/S0014-4835(03)00204-5; Godl K, 2002, J BIOL CHEM, V277, P47248, DOI 10.1074/jbc.M208483200; GROSS MS, 1992, ANN GENET-PARIS, V35, P21; Guillem P, 2000, INT J CANCER, V88, P856, DOI 10.1002/1097-0215(20001215)88:6<856::AID-IJC3>3.0.CO;2-D; Habte HH, 2007, NEONATOLOGY, V92, P96, DOI 10.1159/000100808; Handra-Luca A, 2005, AM J SURG PATHOL, V29, P881, DOI 10.1097/01.pas.0000159103.95360.e8; Hanisch FA, 2001, BIOL CHEM, V382, P143, DOI 10.1515/BC.2001.022; Harington KJ, 2000, ANN SURG ONCOL, V7, P783, DOI 10.1007/s10434-000-0783-5; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; HOLLEY RW, 1968, P NATL ACAD SCI USA, V60, P300, DOI 10.1073/pnas.60.1.300; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Hsuan J J, 1989, Prog Growth Factor Res, V1, P23, DOI 10.1016/0955-2235(89)90039-2; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Idris N, 1999, BIOL REPROD, V61, P1431, DOI 10.1095/biolreprod61.6.1431; Jepson S, 2002, ONCOGENE, V21, P7524, DOI 10.1038/sj.onc.1205970; Jonckheere N, 2004, ONCOGENE, V23, P5729, DOI 10.1038/sj.onc.1207769; Juusola J, 2005, FORENSIC SCI INT, V152, P1, DOI 10.1016/j.forsciint.2005.02.020; Khorrami AM, 2002, J BIOCHEM, V131, P21, DOI 10.1093/oxfordjournals.jbchem.a003073; Klos KS, 2006, CANCER RES, V66, P2028, DOI 10.1158/0008-5472.CAN-04-4559; Komatsu M, 2002, BIOCHEM J, V368, P41, DOI 10.1042/BJ20020862; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 2001, ONCOGENE, V20, P461, DOI 10.1038/sj.onc.1204106; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Koscinski I, 2006, HUM REPROD, V21, P2238, DOI 10.1093/humrep/del189; Lamblin G, 2001, GLYCOCONJUGATE J, V18, P661, DOI 10.1023/A:1020867221861; Leikauf GD, 2002, CHEST, V121, p166S, DOI 10.1378/chest.121.5_suppl.166S; Liu B, 1998, BIOCHEM BIOPH RES CO, V250, P757, DOI 10.1006/bbrc.1998.9390; Liu B, 2002, J HISTOCHEM CYTOCHEM, V50, P811, DOI 10.1177/002215540205000607; Llinares K, 2004, MODERN PATHOL, V17, P150, DOI 10.1038/modpathol.3800027; Lopez-Ferrer A, 2001, AM J RESP CELL MOL, V24, P22, DOI 10.1165/ajrcmb.24.1.4294; Mariette C, 2004, BIOCHEM J, V377, P701, DOI 10.1042/BJ20031132; Mayer U, 1998, ANN NY ACAD SCI, V857, P130, DOI 10.1111/j.1749-6632.1998.tb10113.x; McInnes C, 1997, BIOPOLYMERS, V43, P339, DOI 10.1002/(SICI)1097-0282(1997)43:5<339::AID-BIP2>3.0.CO;2-W; Moniaux N, 2007, BRIT J CANCER, V97, P345, DOI 10.1038/sj.bjc.6603868; Moniaux N, 2000, EUR J BIOCHEM, V267, P4536, DOI 10.1046/j.1432-1327.2000.01504.x; Moniaux N, 2004, BRIT J CANCER, V91, P1633, DOI 10.1038/sj.bjc.6602163; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Otvos L, 2003, MINI-REV MED CHEM, V3, P703, DOI 10.2174/1389557033487809; Patton S, 1995, BBA-REV BIOMEMBRANES, V1241, P407, DOI 10.1016/0304-4157(95)00014-3; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Piessen G, 2007, BIOCHEM J, V402, P81, DOI 10.1042/BJ20061461; Pino V, 2006, J BIOL CHEM, V281, P29411, DOI 10.1074/jbc.M604858200; Pochampalli MR, 2007, ONCOGENE, V26, P1693, DOI 10.1038/sj.onc.1209976; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; Price-Schiavi SA, 2005, J CELL PHYSIOL, V203, P44, DOI 10.1002/jcp.20200; Ramsauer VP, 2006, MOL BIOL CELL, V17, P2931, DOI 10.1091/mbc.E05-09-0895; Reid CJ, 1997, AM J RESP CELL MOL, V17, P592, DOI 10.1165/ajrcmb.17.5.2798; RUGGERI ZM, 1993, FASEB J, V7, P308, DOI 10.1096/fasebj.7.2.8440408; Ruvoen-Clouet N, 2006, BIOCHEM J, V393, P627, DOI 10.1042/BJ20050898; Satoh S, 2000, INT J CANCER, V88, P507, DOI 10.1002/1097-0215(20001115)88:4<507::AID-IJC1>3.0.CO;2-0; SCHROTEN H, 1992, INFECT IMMUN, V60, P2893, DOI 10.1128/IAI.60.7.2893-2899.1992; Singh AP, 2007, ONCOGENE, V26, P30, DOI 10.1038/sj.onc.1209764; Singh AP, 2007, CANCER RES, V67, P433, DOI 10.1158/0008-5472.CAN-06-3114; Singh AP, 2006, PROSTATE, V66, P421, DOI 10.1002/pros.20372; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; STOKER MGP, 1973, NATURE, V246, P200, DOI 10.1038/246200a0; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Sweeney C, 2000, ONCOGENE, V19, P5568, DOI 10.1038/sj.onc.1203913; Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1; Taylor-Papadimitriou J, 2002, J MAMMARY GLAND BIOL, V7, P209, DOI 10.1023/A:1020360121451; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; Tsutsumida H, 2007, LUNG CANCER, V55, P195, DOI 10.1016/j.lungcan.2006.10.013; Van Zoelen E J, 2000, Vitam Horm, V59, P99, DOI 10.1016/S0083-6729(00)59005-0; Vinall LE, 1998, HUM GENET, V102, P357, DOI 10.1007/s004390050705; Vinals F, 1999, MOL CELL BIOL, V19, P2763; Warren CM, 2006, CELL SIGNAL, V18, P923, DOI 10.1016/j.cellsig.2005.12.007; Watanabe Hitoshi, 2002, Cornea, V21, pS17, DOI 10.1097/00003226-200203001-00005; Weed DT, 2004, LARYNGOSCOPE, V114, P1, DOI 10.1097/00005537-200408001-00001; Weed DT, 2004, HEAD NECK-J SCI SPEC, V26, P353, DOI 10.1002/hed.10387; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; WILLE JJ, 1982, CANCER RES, V42, P5139; YOLKEN RH, 1992, J CLIN INVEST, V90, P1984, DOI 10.1172/JCI116078; Zhang J, 2005, J CELL PHYSIOL, V204, P166, DOI 10.1002/jcp.20277	124	161	167	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					966	981		10.1096/fj.07-9673rev	http://dx.doi.org/10.1096/fj.07-9673rev			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	18024835	Green Accepted			2022-12-28	WOS:000254581000004
J	Firuzi, O; Zhuo, JM; Chinnici, CM; Wisniewski, T; Pratio, D				Firuzi, Omidreza; Zhuo, Jiamin; Chinnici, Cinzia M.; Wisniewski, Thomas; Pratio, Domenico			5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						gamma-secretase; Tg2576; A beta; amyloid-beta precursor protein; leukotrienes	LIPID-PEROXIDATION; PLAQUE-FORMATION; TRANSGENIC MICE; GAMMA-SECRETASE; UP-REGULATION; IN-VIVO; PROTEIN; BRAIN; EXPRESSION; A-BETA-42	5-Lipoxygenase (5LO), by producing leukotrienes, is a proinflammatory enzyme, and there is evidence suggesting that it is up-regulated with aging and may be involved in Alzheimer's disease (AD). In this paper, we studied the effect of 5LO-targeted gene disruption on the amyloid phenotype of a transgenic mouse model of AD, the Tg2576. Amyloid-beta (A beta) deposition in the brains of Tg2576 mice lacking 5LO was reduced by 64-80% compared with Tg2576 controls. This reduction was associated with a similar significant decrease in A beta levels measured by sandwich ELISA. Absence of 5LO did not induce any significant change in amyloid-beta precursor protein (APP) levels and processing, or A beta catabolic pathways. Furthermore, in vitro studies showed that 5LO activation or 5LO metabolites increase, whereas 5LO inhibition decreases, A beta formation, secondary to correspondent changes in gamma-secretase activity. These data establish for the first time a novel functional role for 5LO in the pathogenesis of AD-like amyloidosis, thereby modulating gamma-secretase activity. Our work suggests that pharmacological inhibition of 5LO could provide a novel therapeutic tool for AD.	[Firuzi, Omidreza; Zhuo, Jiamin; Chinnici, Cinzia M.; Pratio, Domenico] Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; [Wisniewski, Thomas] NYU, Sch Med, Dept Neurol Psychiat & Pathol, New York, NY USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; New York University	Wisniewski, T (corresponding author), Temple Univ, Sch Med, Dept Pharmacol, 3420 N Broad St,Med Res Bldg,Room 706A, Philadelphia, PA 19140 USA.	praticod@temple.edu	Firuzi, Omidreza/A-1025-2012; Zhuo, Jia-Min/M-7546-2014; Wisniewski, Thomas/Q-6525-2019	Zhuo, Jia-Min/0000-0001-9199-5485; Wisniewski, Thomas/0000-0002-3379-8966; Firuzi, Omidreza/0000-0002-2248-5198; chinnici, cinzia/0000-0001-9318-6606	NATIONAL INSTITUTE ON AGING [R01AG022203, R01AG015408, P30AG008051] Funding Source: NIH RePORTER; NIA NIH HHS [AG15408, R01 AG022203, AG22203, R01 AG022203-05, AG008051, P30 AG008051, P30 AG008051-14, R01 AG015408-09, R01 AG015408] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Burkert E, 2003, J LEUKOCYTE BIOL, V73, P191, DOI 10.1189/jlb.0702354; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; Chinnici CM, 2007, NEUROBIOL AGING, V28, P1457, DOI 10.1016/j.neurobiolaging.2006.06.007; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Firuzi O, 2006, ANN NEUROL, V59, P219, DOI 10.1002/ana.20774; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Golde TE, 2003, J CLIN INVEST, V111, P11, DOI 10.1172/JCI200317527; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; Lammers CH, 1996, J NEUROCHEM, V66, P147; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Liang XB, 2005, J NEUROSCI, V25, P10180, DOI 10.1523/JNEUROSCI.3591-05.2005; Manev H, 1998, RESTOR NEUROL NEUROS, V12, P81; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; Mhatre M, 2006, DRUG FUTURE, V31, P83, DOI 10.1358/dof.2006.031.01.963590; Morris AAM, 1998, LANCET, V352, P1487, DOI 10.1016/S0140-6736(05)60322-4; PIOMELLI D, 1994, CRIT REV NEUROBIOL, V8, P65; Pratico D, 2004, AM J PATHOL, V164, P1655, DOI 10.1016/S0002-9440(10)63724-8; Pratico D, 1998, FASEB J, V12, P1777, DOI 10.1096/fasebj.12.15.1777; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Qu TY, 2000, NEUROBIOL AGING, V21, P647, DOI 10.1016/S0197-4580(00)00167-6; Qu TY, 2001, J NEUROPSYCH CLIN N, V13, P304, DOI 10.1176/appi.neuropsych.13.2.304; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; SIMMET T, 1990, BRAIN RES, V515, P79, DOI 10.1016/0006-8993(90)90579-Z; Sung S, 2004, AM J PATHOL, V165, P2197, DOI 10.1016/S0002-9440(10)63269-5; Sung S, 2003, FASEB J, V17, P323, DOI 10.1096/fj.03-0961fje; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uz T, 1998, FASEB J, V12, P439, DOI 10.1096/fasebj.12.6.439; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Yagishita S, 2006, BIOCHEMISTRY-US, V45, P3952, DOI 10.1021/bi0521846; Yermakova AV, 2001, NEUROBIOL AGING, V22, P823, DOI 10.1016/S0197-4580(01)00303-7; Zhou Y, 2006, LIFE SCI, V79, P1645, DOI 10.1016/j.lfs.2006.05.022	37	142	146	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1169	1178		10.1096/fj.07-9131.com	http://dx.doi.org/10.1096/fj.07-9131.com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	17998412	Green Accepted			2022-12-28	WOS:000254581000022
J	Barbosa, MTP; Soares, SM; Novak, CM; Sinclair, D; Levine, JA; Aksoy, P; Chini, EN				Barbosa, Maria Thereza P.; Soares, Sandra M.; Novak, Colleen M.; Sinclair, David; Levine, James A.; Aksoy, Pinar; Chini, Eduardo Nunes			The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced obesity	FASEB JOURNAL			English	Article						sirtuins; SIRT1; PGC1 alpha; nicotinamide adenine dinucleotide; knockout mice; liver	CYCLIC ADP-RIBOSE; PGC-1-ALPHA; INCREASES; FAMILY; GROWTH; CELL	Obesity is one of the major health problems of our times. Elucidating the signaling mechanisms by which high-fat caloric diet induces obesity is critical for the understanding of this condition and for the development of therapeutic strategies for its treatment. Here, we demonstrate a novel role for protein CD38 as a regulator of body weight during a high-fat diet. CD38 is a ubiquitous enzyme that catalyzes the synthesis of second messengers and has been implicated in the regulation of a wide variety of signaling pathways. We report that CD38-deficient mice are protected against high-fat diet-induced obesity owing to enhanced energy expenditure. In fact, calorimetric studies indicate that CD38-deficient animals have a higher metabolic rate compared to control mice. Analysis of the mechanism revealed that this resistance to diet-induced obesity is mediated at least in part via a NAD-dependent activation of SIRT-PGC1 alpha axis, a well-established cascade, involved in the regulation of mitochondrial biogenesis and energy homeostasis. Thus, together these results identify a novel pathway regulating body weight and clearly show that CD38 is a nearly obligatory component of the cellular cascade that led to diet-induced obesity.	Mayo Clin & Mayo Fdn, Coll Med, Dept Anesthesiol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Endocrinol, Rochester, MN 55905 USA; Harvard Univ, Sch Med, Paul F Glenn Labs Biol Mech Aging, Boston, MA USA	Mayo Clinic; Mayo Clinic; Harvard University; Harvard Medical School	Chini, EN (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Anesthesiol, 200 1st St SW, Rochester, MN 55905 USA.	chini.eduardo@mayo.edu		Sinclair, David/0000-0002-9936-436X; Herrmann, Sandra/0000-0002-3700-4537; Novak, Colleen/0000-0002-8542-1677				Aksoy P, 2006, BIOCHEM BIOPH RES CO, V349, P353, DOI 10.1016/j.bbrc.2006.08.066; Aksoy P, 2006, BIOCHEM BIOPH RES CO, V345, P1386, DOI 10.1016/j.bbrc.2006.05.042; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Cai GW, 2004, HUM BIOL, V76, P651, DOI 10.1353/hub.2005.0001; Chini EN, 2002, BRAZ J MED BIOL RES, V35, P543, DOI 10.1590/S0100-879X2002000500005; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fernandez-Zapico ME, 2003, EMBO J, V22, P4748, DOI 10.1093/emboj/cdg470; FOLCH J, 1957, J BIOL CHEM, V226, P497; Galione A, 2000, Sci STKE, V2000, ppe1; Johnson JD, 2006, DIABETES, V55, P2737, DOI 10.2337/db05-1455; Kato I, 1999, J BIOL CHEM, V274, P1869, DOI 10.1074/jbc.274.4.1869; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Liang HY, 2006, ADV PHYSIOL EDUC, V30, P145, DOI 10.1152/advan.00052.2006; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mai A, 2005, J MED CHEM, V48, P7789, DOI 10.1021/jm050100l; Novak CM, 2006, J NEUROENDOCRINOL, V18, P594, DOI 10.1111/j.1365-2826.2006.01454.x; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Puigserver P, 2005, INT J OBESITY, V29, pS5, DOI 10.1038/sj.ijo.0802905; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497; Thompson M, 2004, AM J PHYSIOL-ENDOC M, V287, pE1142, DOI 10.1152/ajpendo.00122.2004; Webb DL, 1996, J BIOL CHEM, V271, P19074, DOI 10.1074/jbc.271.32.19074	23	166	175	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3629	3639		10.1096/fj.07-8290com	http://dx.doi.org/10.1096/fj.07-8290com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17585054				2022-12-28	WOS:000250517800025
J	Barraud-Lange, V; Naud-Barriant, N; Bomsel, M; Wolf, JP; Ziyyat, A				Barraud-Lange, Virginie; Naud-Barriant, Nathalie; Bomsel, Morgane; Wolf, Jean-Philippe; Ziyyat, Ahmed			Transfer of oocyte membrane fragments to fertilizing spermatozoa	FASEB JOURNAL			English	Article						trogocytosis; gamete fusion; tetraspanin; lipid transfer; protein transfer	TETRASPANIN WEB; EWI-2; CD9; FUSION; SPERM	Several families of molecules are implicated in the membrane fusion process between sperm and oocyte. Among these, CD9 tetraspanin, a membrane-organizing molecule, plays a crucial role, since the fertilizing ability of CD9-/- oocytes is dramatically impaired. CD9 controls alpha6-beta1 integrin relocation involved in the membrane reorganization that occurs on oocyte fertilization but is not expressed on sperm. We report here that, together with several other proteins, the CD9 tetraspanin is transferred from the oocyte to the fertilizing spermatozoa present in the perivitelline space before fertilization. Transfer of CD9 from oocyte to sperm from CD9-/- male mice still occurs. CD9 acquisition by sperm results from a transfer of membrane fragments from the plasma membrane of the oocyte, in a process similar to trogocytosis, the recently described mechanism of intercellular exchange of membrane patches. Acquisition of CD9 by the sperm may be crucial for the membrane reorganization in sperm required for fusion with the oocyte, a process that is similar to the role CD9 plays in oocyte membrane reorganization.	Univ Paris 13, Reprod Biol Lab, UFR SMBH, F-93017 Bobigny, France; Hop Jean Verdier, AP HP, Bondy, France; INSERM, U567, Paris, France	Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Wolf, JP (corresponding author), Univ Paris 13, Reprod Biol Lab, UFR SMBH, 74 Rue Marcel Cachin, F-93017 Bobigny, France.	jean-philippe.wolf@jvr.ap-hop-paris.fr	Bomsel, Morgane/GSN-1948-2022; ZIYYAT, Ahmed/F-7617-2019; ZIYYAT, Ahmed/ABB-1861-2021	ZIYYAT, Ahmed/0000-0001-9724-3831; ZIYYAT, Ahmed/0000-0001-9724-3831; Barraud-Lange, Virginie/0000-0001-8507-7303; Bomsel, Morgane/0000-0002-9577-7474				Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Charrin S, 2003, BIOCHEM J, V373, P409, DOI 10.1042/BJ20030343; Inoue N, 2005, NATURE, V434, P234, DOI 10.1038/nature03362; Joly E, 2003, NAT IMMUNOL, V4, P815, DOI 10.1038/ni0903-815; Kaji K, 2000, NAT GENET, V24, P279, DOI 10.1038/73502; Kolesnikova TV, 2004, BLOOD, V103, P3013, DOI 10.1182/blood-2003-07-2201; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Runge KE, 2007, DEV BIOL, V304, P317, DOI 10.1016/j.ydbio.2006.12.041; Sala-Valdes M, 2006, J BIOL CHEM, V281, P19665, DOI 10.1074/jbc.M602116200; Stipp CS, 2001, J BIOL CHEM, V276, P40545, DOI 10.1074/jbc.M107338200; Toshimori K, 1998, BIOL REPROD, V59, P22, DOI 10.1095/biolreprod59.1.22; Zhu GZ, 2002, DEVELOPMENT, V129, P1995; Ziyyat A, 2006, J CELL SCI, V119, P416, DOI 10.1242/jcs.02730	14	52	55	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3446	3449		10.1096/fj.06-8035hyp	http://dx.doi.org/10.1096/fj.06-8035hyp			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17575263				2022-12-28	WOS:000250517800007
J	Clark, N; Keeble, J; Fernandes, ES; Starr, A; Liang, L; Sugden, D; de Winter, P; Brain, SD				Clark, Natalie; Keeble, Julie; Fernandes, Elizabeth S.; Starr, Anna; Liang, Lihuan; Sugden, David; de Winter, Patricia; Brain, Susan D.			The transient receptor potential vanilloid 1 (TRPV1) receptor protects against the onset of sepsis after endotoxin	FASEB JOURNAL			English	Article						mouse sensory nerves; knockout; substance P; capsaicin	GENE-RELATED PEPTIDE; NITRIC-OXIDE SYNTHASE; VANILLOID RECEPTOR-1; CAPSAICIN RECEPTORS; MICE LACKING; MECHANISM; INJURY; PAIN; PHARMACOLOGY; ACTIVATION	Transient potential vanilloid 1 (TRPV1) receptor is an ion channel receptor primarily localized on sensory nerves and activated by specific stimuli to initiate and amplify pain and inflammation, as typified by murine models of scald and arthritis. Little is known of the role of TRPV1 in sepsis, an infective disease associated with inflammation. Through use of a sublethal murine model of lipopolysaccharide-induced peritoneal sepsis, we provide novel evidence that genetic deletion of TRPV1 leads to an enhanced onset of various pathological components of systemic endotoxemia. Paired studies of TRPV1 knockout (KO) and wild-type mice demonstrate significantly enhanced hypotension (56 +/- 2% vs. 38 +/- 6% decrease in blood pressure, n = 12), hypothermia (13 +/- 3% vs. 7 +/- 1% decrease in core temperature, n = 6), and peritoneal exudate mediator levels (TNF-alpha, 0.78 +/- 0.2 vs. 0.38 +/- 0.1 ng/ ml; nitrite, for NO, 35 +/- 10 vs. 15 +/- 3 mu M; n = 8) in TRPV1 KO mice, indicating loss of protective effect. Findings correlated with liver edema and raised plasma levels of aspartate aminotransferase in TRPV1 KO mice. These data suggest that TRPV1 may play an important regulatory role in sepsis independent of the major sensory neuropeptide substance P. The findings are relevant to developing strategies that increase the beneficial, and reduce the harmful, components of sepsis to prevent and treat this often fatal condition.	Kings Coll London, Div Cardiovasc, London SE1 9NH, England; Kings Coll London, Reprod & Endocrinol Div, London WC2R 2LS, England	University of London; King's College London; University of London; King's College London	Brain, SD (corresponding author), Kings Coll London, Div Cardiovasc, Franklin Wilkins Bldg,Waterloo Campus,150 Stamfor, London SE1 9NH, England.	sue.brain@kcl.ac.uk	Fernandes, Elizabeth S/J-9397-2012; Brain, Susan/L-3681-2013; Fernandes, Elizabeth S./Q-7276-2019	Fernandes, Elizabeth S./0000-0002-0567-2514; Brain, Susan/0000-0002-9684-8342; Keeble, Julie/0000-0002-8891-1129				Arnalich F, 1996, REGUL PEPTIDES, V65, P115, DOI 10.1016/0167-0115(96)00080-8; Beer S, 2002, CRIT CARE MED, V30, P1794, DOI 10.1097/00003246-200208000-00020; Bowden JJ, 1996, AM J PHYSIOL-LUNG C, V270, pL393; Bryant P, 2003, J SURG RES, V112, P152, DOI 10.1016/S0022-4804(03)00154-9; Cao T, 1999, AM J PHYSIOL-REG I, V277, pR476, DOI 10.1152/ajpregu.1999.277.2.R476; Cao T, 2000, J IMMUNOL, V164, P5424, DOI 10.4049/jimmunol.164.10.5424; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cesare P, 1999, P NATL ACAD SCI USA, V96, P7658, DOI 10.1073/pnas.96.14.7658; Chen CW, 2003, BRIT J PHARMACOL, V140, P1077, DOI 10.1038/sj.bjp.0705533; Chu CJ, 2003, J BIOL CHEM, V278, P13633, DOI 10.1074/jbc.M211231200; CUNHA FQ, 1994, IMMUNOLOGY, V81, P211; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Demirbilek S, 2004, ANESTH ANALG, V99, P1501, DOI 10.1213/01.ANE.0000132975.02854.65; Dogan MD, 2004, BRIT J PHARMACOL, V143, P1023, DOI 10.1038/sj.bjp.0705977; Franco-Penteado CF, 2005, J PHARMACOL EXP THER, V313, P440, DOI 10.1124/jpet.104.078147; Gilroy DW, 2005, CIRCULATION, V111, P2, DOI 10.1161/01.CIR.0000152696.25879.CE; Gomes RN, 2005, SHOCK, V24, P590, DOI 10.1097/01.shk.0000183395.29014.7c; Grant AD, 2002, J PHYSIOL-LONDON, V543, P1007, DOI 10.1113/jphysiol.2002.018846; Harada N, 2006, THROMB HAEMOSTASIS, V95, P788, DOI 10.1160/TH05-09-0636; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Iida T, 2005, NEUROSCI LETT, V378, P28, DOI 10.1016/j.neulet.2004.12.007; Joe B, 1997, LIPIDS, V32, P1173, DOI 10.1007/s11745-997-0151-8; JOYCE CD, 1990, SURGERY, V108, P1097; Keeble J, 2005, ARTHRITIS RHEUM, V52, P3248, DOI 10.1002/art.21297; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGGI CA, 1991, J AUTON PHARMACOL, V11, P173, DOI 10.1111/j.1474-8673.1991.tb00317.x; Mailman D, 2002, SHOCK, V18, P177, DOI 10.1097/00024382-200208000-00015; Moriyama T, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-3; Olah Z, 2001, J BIOL CHEM, V276, P31163, DOI 10.1074/jbc.M101607200; Puneet P, 2006, J IMMUNOL, V176, P3813, DOI 10.4049/jimmunol.176.6.3813; Ralevic V, 2002, LIFE SCI, V71, P2577, DOI 10.1016/S0024-3205(02)02086-6; RANG HP, 1991, BRIT MED BULL, V47, P534, DOI 10.1093/oxfordjournals.bmb.a072491; ROGER GH, 1990, COMPTES RENDUS SOC B, V2, P646; Rousseau E, 2005, AM J PHYSIOL-LUNG C, V288, pL460, DOI 10.1152/ajplung.00252.2004; Scotland RS, 2004, CIRC RES, V95, P1027, DOI 10.1161/01.RES.0000148633.93110.24; Shimozawa N, 2006, GASTROENTEROLOGY, V131, P1826, DOI 10.1053/j.gastro.2006.09.005; Szallasi A, 1999, PHARMACOL REV, V51, P159; Szolcsanyi J, 2004, NEUROPEPTIDES, V38, P377, DOI 10.1016/j.npep.2004.07.005; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Vlach KD, 2000, COMPARATIVE MED, V50, P160; Wadachi R, 2006, J DENT RES, V85, P49, DOI 10.1177/154405910608500108	43	80	84	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3747	3755		10.1096/fj.06-7460com	http://dx.doi.org/10.1096/fj.06-7460com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17601984				2022-12-28	WOS:000250517800036
J	Hostettler, N; Naggi, A; Torri, G; Ishai-Michaeli, R; Casu, B; Vlodavsky, I; Borsig, L				Hostettler, Nina; Naggi, Annamaria; Torri, Giangiacomo; Ishai-Michaeli, Riva; Casu, Benito; Vlodavsky, Israel; Borsig, Lubor			P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins	FASEB JOURNAL			English	Article						thrombin generation; LMWH; selectin interactions; heparin derivatives	MOLECULAR-WEIGHT HEPARIN; TISSUE FACTOR PATHWAY; CHEMICALLY-MODIFIED HEPARIN; TUMOR-METASTASIS; VENOUS THROMBOEMBOLISM; MAMMALIAN HEPARANASE; ADVANCED MALIGNANCY; CANCER METASTASIS; ANGIOGENESIS; SURVIVAL	Vascular cell adhesion molecules, P- and L-selectins, facilitate metastasis of cancer cells in mice by mediating interactions with platelets, endothelium, and leukocytes. Heparanase is an endoglycosidase that degrades heparan sulfate of extracellular matrix, thereby promoting tumor invasion and metastasis. Heparin is known to efficiently attenuate metastasis in different tumor models. Here we identified modified, nonanticoagulant species of heparin that specifically inhibit selectin-mediated cell-cell interactions, heparanase enzymatic activity, or both. We show that selective inhibition of selectin interactions or heparanase with specific heparin derivatives in mouse models of MC-38 colon carcinoma and B16-BL6 melanoma attenuates metastasis. Selectin-specific heparin derivatives attenuated metastasis of MC-38 carcinoma, but heparanase-specific derivatives had no effect, in accordance with the virtual absence of heparanase activity in these cells. Heparin derivatives had no further effect on metastasis in mice deficient in P- and L-selectin, indicating that selectins are the primary targets of heparin antimeta-static activity. Selectin-specific and heparanase-specific derivatives attenuated metastasis of B16-BL6 melanomas to a similar extent. When mice were injected with a derivative containing both heparanase and selectin inhibitory activity, no additional attenuation of metastasis could be observed. Thus, selectin-specific heparin derivatives efficiently attenuated metastasis of both tumor cell types whereas inhibition of heparanase led to reduction of metastasis only in tumor cells producing heparanase.	Univ Zurich, Inst Physiol, Zurich Ctr Integrat Human Physiol, CH-8057 Zurich, Switzerland; G Ronzoni Inst Chem & Biochem Res, Milan, Italy; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel	University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Borsig, L (corresponding author), Univ Zurich, Inst Physiol, Zurich Ctr Integrat Human Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	lborsig@access.unizh.ch		Torri, Giangiacomo/0000-0002-2077-1203; Borsig, Lubor/0000-0003-2263-9545				Alban S, 2001, SEMIN THROMB HEMOST, V27, P503, DOI 10.1055/s-2001-17952; Altinbas M, 2004, J THROMB HAEMOST, V2, P1266, DOI 10.1111/j.1538-7836.2004.00871.x; BARNER M, 1985, INT J CANCER, V35, P483, DOI 10.1002/ijc.2910350411; Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; Cohen I, 2006, INT J CANCER, V118, P1609, DOI 10.1002/ijc.21552; Cosgrove RH, 2002, SEMIN THROMB HEMOST, V28, P79, DOI 10.1055/s-2002-20566; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Gao YG, 2005, MOL CELLS, V19, P350; Hettiarachchi RJK, 1999, THROMB HAEMOSTASIS, V82, P947, DOI 10.1055/s-0037-1615937; HONN KV, 1992, CANCER METAST REV, V11, P325, DOI 10.1007/BF01307186; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Im JH, 2004, CANCER RES, V64, P8613, DOI 10.1158/0008-5472.CAN-04-2078; Jayson GC, 1997, BRIT J CANCER, V75, P9, DOI 10.1038/bjc.1997.3; Kakkar AK, 2004, J CLIN ONCOL, V22, P1944, DOI 10.1200/JCO.2004.10.002; Kim YJ, 1998, P NATL ACAD SCI USA, V95, P9325, DOI 10.1073/pnas.95.16.9325; Klerk CPW, 2005, J CLIN ONCOL, V23, P2130, DOI 10.1200/JCO.2005.03.134; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Kragh M, 2005, ONCOL REP, V14, P99; Lapierre F, 1996, GLYCOBIOLOGY, V6, P355, DOI 10.1093/glycob/6.3.355; Laubli H, 2006, CANCER RES, V66, P1536, DOI 10.1158/0008-5472.CAN-05-3121; Lazo-Langner A, 2007, J THROMB HAEMOST, V5, P729, DOI 10.1111/j.1538-7836.2007.02427.x; Lee AYY, 2003, NEW ENGL J MED, V349, P146, DOI 10.1056/NEJMoa025313; Lee AYY, 2005, J CLIN ONCOL, V23, P2123, DOI 10.1200/JCO.2005.03.133; Lever R, 2002, NAT REV DRUG DISCOV, V1, P140, DOI 10.1038/nrd724; Ley K, 2003, TRENDS MOL MED, V9, P263, DOI 10.1016/S1471-4914(03)00071-6; Lowe JB, 2003, CURR OPIN CELL BIOL, V15, P531, DOI 10.1016/j.ceb.2003.08.002; Ludwig RJ, 2004, CANCER RES, V64, P2743, DOI 10.1158/0008-5472.CAN-03-1054; MANNORI G, 1995, CANCER RES, V55, P4425; Mousa SA, 2004, THROMB HAEMOSTASIS, V92, P627, DOI 10.1160/TH04-02-0069; Mousa SA, 2004, SEMIN THROMB HEMOST, V30, P25; Mousa SA, 2002, SEMIN THROMB HEMOST, V28, P45, DOI 10.1055/s-2002-20559; NAGASAWA K, 1978, BIOCHIM BIOPHYS ACTA, V544, P430, DOI 10.1016/0304-4165(78)90110-1; Naggi A, 2005, J BIOL CHEM, V280, P12103, DOI 10.1074/jbc.M414217200; Ohyama C, 1999, EMBO J, V18, P1516, DOI 10.1093/emboj/18.6.1516; Ono K, 2002, BRIT J CANCER, V86, P1803, DOI 10.1038/sj.bjc.6600307; Parish CR, 1999, CANCER RES, V59, P3433; Rickles FR, 2006, PATHOPHYSIOL HAEMO T, V35, P103, DOI 10.1159/000093551; Singh R, 2001, CIRC RES, V89, P71, DOI 10.1161/hh1301.092508; Smorenburg SM, 1999, THROMB HAEMOSTASIS, V82, P1600; Smorenburg SM, 2001, PHARMACOL REV, V53, P93; Stevenson JL, 2005, CLIN CANCER RES, V11, P7003, DOI 10.1158/1078-0432.CCR-05-1131; Tobu M, 2005, CLIN APPL THROMB-HEM, V11, P37, DOI 10.1177/107602960501100104; VALENTIN S, 1994, THROMB RES, V75, P173, DOI 10.1016/0049-3848(94)90066-3; Varki NM, 2002, SEMIN THROMB HEMOST, V28, P53, DOI 10.1055/s-2002-20564; VLODAVSKY I, 1994, INVAS METAST, V14, P290; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Vlodavsky I, 2006, PATHOPHYSIOL HAEMO T, V35, P116, DOI 10.1159/000093553; Wang LC, 2002, J CLIN INVEST, V110, P127, DOI 10.1172/JCI200214996; Yoshitomi Y, 2004, CANCER LETT, V207, P165, DOI 10.1016/j.canlet.2003.11.037; Zacharski LR, 1998, THROMB HAEMOSTASIS, V80, P10; Zacharski LR, 2000, SEMIN THROMB HEMOST, V26, P69, DOI 10.1055/s-2000-9499; Zacharski LR, 2002, CANCER LETT, V186, P1, DOI 10.1016/S0304-3835(02)00258-6	54	94	100	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3562	3572		10.1096/fj.07-8450com	http://dx.doi.org/10.1096/fj.07-8450com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17557930	Green Accepted			2022-12-28	WOS:000250517800019
J	Jia, SJ; Omelchenko, M; Garland, D; Vasiliou, V; Kanungo, J; Spencer, M; Wolf, Y; Koonin, E; Piatigorsky, J				Jia, Sujuan; Omelchenko, Marina; Garland, Donita; Vasiliou, Vasilis; Kanungo, Jyotshnabala; Spencer, Michael; Wolf, Yuri; Koonin, Eugene; Piatigorsky, Joram			Duplicated gelsolin family genes in zebrafish: a novel scinderin-like gene (scinla) encodes the major corneal crystallin	FASEB JOURNAL			English	Article						gene duplication; evolution; tissue-specific expression	ACTIN-BINDING PROTEINS; FILAMENT-SEVERING PROTEIN; CHROMAFFIN CELL SCINDERIN; RAY-FINNED FISHES; GENOME DUPLICATION; LENS CRYSTALLINS; ALDEHYDE DEHYDROGENASE; RECOMBINANT SCINDERIN; REGULATORY PROTEIN; ANABLEPS-ANABLEPS	We have previously identified a gelsolin-like protein ( C/L-gelsolin) as a corneal crystallin in zebrafish. Here we show by phylogenetic analysis that there are at least six genes encoding gelsolin-like proteins based on their gelsolin domains in zebrafish: gsna and gsnb group with the vertebrate gelsolin gene, scina and scinb group with the scinderin ( adseverin) gene, and scinla ( C/L-gelsolin) and scinlb are novel scinderin-like genes. RT-PCR showed that scinla, scinlb, and gsnb are preferentially expressed in the adult cornea whereas gsna is expressed to a similar extent in cornea, lens, brain, and heart; scina and scinb expression were detectable only in whole zebrafish and not in these adult tissues. Quantitative RT-PCR and 2-dimensional polyacrylamide gel electrophoresis followed by MALDI/TOF mass spectroscopy confirmed high expression of beta-actin and scinla, moderate expression of scinlb, and very low expression of gsna and gsnb in the cornea. Finally, transgenic zebrafish carrying a green fluorescent protein reporter transgene driven by a 4 kb scinla promoter fragment showed expression in the cornea, snout, dorsal fin, and tail fin of 3-day-old zebrafish larvae. Our data suggest that scinla and scinlb are diverged paralogs of the vertebrate scinderin gene and show that scinla encodes the zebrafish corneal crystallin previously called C/L-gelsolin. - Jia, S., Omelchenko, M., Garland, D., Vasiliou, V., Kanungo, J., Spencer, M., Wolf, Y., Koonin, E., Piatigorsky, J. Duplicated gelsolin family genes in zebrafish: a novel scinderin-like gene ( scinla) encodes the major corneal crystallin.	NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; NEI, Lab Retinal Cellular & Mol Biol, NIH, Bethesda, MD 20892 USA; NIH, Natl Lib Med, Bethesda, MD 20892 USA; Univ Colorado, Hlth Sci Ctr, Sch Pharm, Denver, CO 80262 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Piatigorsky, J (corresponding author), NEI, Mol & Dev Biol Lab, NIH, 7 Mem Dr,Bldg 7,Rm 100, Bethesda, MD 20892 USA.	joramp@nei.nih.gov		vasiliou, vasilis/0000-0003-2552-3118; Wolf, Yuri/0000-0002-0247-8708	NATIONAL EYE INSTITUTE [R01EY011490, R29EY011490, Z01EY000259, Z01EY000126] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 EY000126-26] Funding Source: Medline; NEI NIH HHS [EY11490, R01 EY011490, R29 EY011490] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; ADACHI J, 1992, MOLPHYS PROGRAMS MOL; ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Arai M, 1999, DEV DYNAM, V215, P297, DOI 10.1002/(SICI)1097-0177(199908)215:4<297::AID-AJA2>3.3.CO;2-9; Archer SK, 2005, BIOESSAYS, V27, P388, DOI 10.1002/bies.20200; Arora PD, 2004, MOL BIOL CELL, V15, P588, DOI 10.1091/mbc.E03-07-0468; BADER MF, 1986, J CELL BIOL, V102, P636, DOI 10.1083/jcb.102.2.636; Bloemendal H, 2004, PROG BIOPHYS MOL BIO, V86, P407, DOI 10.1016/j.pbiomolbio.2003.11.012; Christoffels A, 2004, MOL BIOL EVOL, V21, P1146, DOI 10.1093/molbev/msh114; Culp WD, 2006, J PROTEOME RES, V5, P1332, DOI 10.1021/pr060059q; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DELCASTILLO AR, 1990, EMBO J, V9, P43, DOI 10.1002/j.1460-2075.1990.tb08078.x; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Hough RB, 2004, MOL CELL BIOL, V24, P1324, DOI 10.1128/MCB.24.3.1324-1340.2004; Jaillon O, 2004, NATURE, V431, P946, DOI 10.1038/nature03025; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Kanungo J, 2004, EXP EYE RES, V79, P949, DOI 10.1016/j.exer.2004.04.002; Kanungo J, 2003, P NATL ACAD SCI USA, V100, P3287, DOI 10.1073/pnas.0634473100; King G, 1998, J EXP ZOOL, V282, P12; Kurita R, 2003, DEV BIOL, V255, P113, DOI 10.1016/S0012-1606(02)00079-9; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P8239; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; Lejen T, 2002, ANN NY ACAD SCI, V971, P248, DOI 10.1111/j.1749-6632.2002.tb04469.x; Lueck A, 1998, J CELL SCI, V111, P3633; MAEKAWA S, 1989, J BIOL CHEM, V264, P7458; Marcu MG, 1996, BLOOD, V87, P20; MARCU MG, 1994, MOL CELL BIOCHEM, V141, P153, DOI 10.1007/BF00926179; Marcu MG, 1998, J BIOL CHEM, V273, P3661, DOI 10.1074/jbc.273.6.3661; McGough AM, 2003, FEBS LETT, V552, P75, DOI 10.1016/S0014-5793(03)00932-3; NAKAMURA S, 1994, J BIOL CHEM, V269, P5890; Naruse K, 2004, GENOME RES, V14, P820, DOI 10.1101/gr.2004004; Nees DW, 2002, MOL CELL BIOL, V22, P849, DOI 10.1128/MCB.22.3.849-855.2002; Oberemm A, 2005, TOXICOLOGY, V206, P33, DOI 10.1016/j.tox.2004.06.061; Paunio T, 1997, FEBS LETT, V406, P49, DOI 10.1016/S0014-5793(97)00237-8; Pene TD, 2005, J NEUROCHEM, V92, P780, DOI 10.1111/j.1471-4159.2004.02907.x; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; Piatigorsky J, 2001, CORNEA, V20, P853, DOI 10.1097/00003226-200111000-00015; Postlethwait J, 2004, TRENDS GENET, V20, P481, DOI 10.1016/j.tig.2004.08.001; Robbens J, 1998, MOL CELL BIOL, V18, P4589, DOI 10.1128/MCB.18.8.4589; SAKURAI T, 1990, NEUROSCIENCE, V38, P743, DOI 10.1016/0306-4522(90)90067-E; SAKURAI T, 1991, J BIOL CHEM, V266, P15979; Silacci P, 2004, CELL MOL LIFE SCI, V61, P2614, DOI 10.1007/s00018-004-4225-6; Soules KA, 2005, BMC DEV BIOL, V5, DOI 10.1186/1471-213X-5-12; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Sun HQ, 1997, J CELL BIOL, V138, P811, DOI 10.1083/jcb.138.4.811; Svensson C, 2002, BIOCHEM BIOPH RES CO, V291, P1194, DOI 10.1006/bbrc.2002.6582; Svensson C, 2001, MOL PHARMACOL, V60, P135, DOI 10.1124/mol.60.1.135; Swamynathan SK, 2003, FASEB J, V17, P1996, DOI 10.1096/fj.03-0122com; Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303; Taylor JS, 2001, TRENDS GENET, V17, P299, DOI 10.1016/S0168-9525(01)02318-6; TCHAKAROV L, 1990, FEBS LETT, V268, P209, DOI 10.1016/0014-5793(90)81010-L; Trifaro JM, 2002, NEUROCHEM RES, V27, P1371, DOI 10.1023/A:1021627800918; Vandepoele K, 2004, P NATL ACAD SCI USA, V101, P1638, DOI 10.1073/pnas.0307968100; VASILIOU V, 1992, BIOCHEM BIOPH RES CO, V187, P413, DOI 10.1016/S0006-291X(05)81508-6; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; Waddell Peter J, 2002, Genome Inform, V13, P82; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; Woods IG, 2005, GENOME RES, V15, P1307, DOI 10.1101/gr.4134305; Xu YS, 2000, J BIOL CHEM, V275, P24645, DOI 10.1074/jbc.M001159200; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409; YOSHIKAWA S, 2006, INVEST OPHTHALMOL VI, V47; Zhang L, 1996, NEURON, V17, P287, DOI 10.1016/S0896-6273(00)80160-9; Zhao XPC, 2006, INVEST OPHTH VIS SCI, V47, P4341, DOI 10.1167/iovs.05-1611; Zhao YX, 2005, ANAL CHEM, V77, P5324, DOI 10.1021/ac050354e; Zieske JD, 2004, INT J DEV BIOL, V48, P903, DOI 10.1387/ijdb.041860jz; Zunino R, 2001, BLOOD, V98, P2210, DOI 10.1182/blood.V98.7.2210	70	16	18	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3318	3328		10.1096/fj.07-8172com	http://dx.doi.org/10.1096/fj.07-8172com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17548429	Green Accepted			2022-12-28	WOS:000249781600032
J	Nicolas, O; Gavin, R; Braun, N; Urena, JM; Fontana, X; Soriano, E; Aguzzi, A; del Rio, JA				Nicolas, Oriol; Gavin, Rosalina; Braun, Nathalie; Urena, Jesus Mariano; Fontana, Xavier; Soriano, Eduardo; Aguzzi, Adriano; del Rio, Jose Antonio			Bcl-2 overexpression delays caspase-3 activation and rescues cerebellar degeneration in prion-deficient mice that overexpress amino-terminally truncated prion	FASEB JOURNAL			English	Article						cerebellar syndrome; granule cells; oxidative damage; prion protein	PURKINJE-CELL DEGENERATION; PRP KNOCKOUT MICE; PROTEIN PRPC; NEURITE OUTGROWTH; DOPPEL PROTEIN; NEURONS; EXPRESSION; STAUROSPORINE; APOPTOSIS; TOXICITY	Prnp knockout mice that overexpress an amino-truncated form of PrPc (Delta PrP) are ataxic and display cerebellar cell loss and premature death. Studies on the molecular and intracellular events that trigger cell death in these mutants may contribute to elucidate the functions of PrPc and to the design of treatments for prion disease. Here we examined the effects of Bcl-2 overexpression in neurons on the development of the neurological syndrome and cerebellar pathology of Delta PrP. We show that Delta PrP overexpression activates the stress-associated kinases ERK1 -2 in reactive astroglia, p38 and the phosphorylation of p53, which leads to the death of cerebellar neurons in mutant mice. We found that the expression of Delta PrP in cell lines expressing very low levels of PrPc strongly induces the activation of apoptotic pathways, thereby leading to caspase-3 activation and cell death, which can be prevented by coexpressing Bcl-2. Finally, we corroborate in vivo that neuronal-directed Bcl-2 overexpression in Delta PrP mice (Delta PrP Bcl-2) markedly reduces caspase-3 activation, glial activation, and neuronal cell death in cerebellum by improving locomotor deficits and life expectancy.	Univ Barcelona, Inst Res Biomed, Dept Cell Biol, Samitier 1-5, E-08028 Barcelona, Spain; Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; University of Zurich; University Zurich Hospital	del Rio, JA (corresponding author), Univ Barcelona, Inst Res Biomed, Dept Cell Biol, Samitier 1-5, E-08028 Barcelona, Spain.	jadelrio@pcb.ub.es	Del Rio Fernandez, Jose A/AAD-1121-2020; del rio, jose antonio/L-9232-2014; Urena, Jesus/R-5385-2017; Gavín, Rosalina/D-4341-2014; Aguzzi, Adriano/A-3351-2008; Soriano, Eduardo/AAB-3216-2019	del rio, jose antonio/0000-0002-5214-4909; Urena, Jesus/0000-0003-1408-6039; Gavín, Rosalina/0000-0003-1982-2162; Soriano, Eduardo/0000-0002-3204-9285; Aguzzi, Adriano/0000-0002-0344-6708				Anderson L, 2004, P NATL ACAD SCI USA, V101, P3644, DOI 10.1073/pnas.0308681101; Baumann F, 2007, EMBO J, V26, P538, DOI 10.1038/sj.emboj.7601510; Behrens A, 2002, TRENDS NEUROSCI, V25, P150, DOI 10.1016/S0166-2236(00)02089-0; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 2002, J NEUROSCI RES, V67, P211, DOI 10.1002/jnr.10118; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Chattopadhyay M, 2005, J AM CHEM SOC, V127, P12647, DOI 10.1021/ja053254z; Chen SZ, 2003, MOL CELL NEUROSCI, V22, P227, DOI 10.1016/S1044-7431(02)00014-3; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Chiesa R, 2005, P NATL ACAD SCI USA, V102, P238, DOI 10.1073/pnas.0406173102; Cregan SP, 1999, J NEUROSCI, V19, P7860; Cui T, 2003, MOL CELL NEUROSCI, V23, P144, DOI 10.1016/S1044-7431(03)00017-4; ER E, 2006, BIOCH BIOPHYS ACTA; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Flechsig E, 2003, EMBO J, V22, P3095, DOI 10.1093/emboj/cdg285; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; Gavin R, 2005, FEBS LETT, V579, P4099, DOI 10.1016/j.febslet.2005.06.037; Lee DC, 2006, MICROBIOL IMMUNOL, V50, P203, DOI 10.1111/j.1348-0421.2006.tb03787.x; Li AM, 2007, EMBO J, V26, P548, DOI 10.1038/sj.emboj.7601507; Li AM, 2007, J NEUROSCI, V27, P852, DOI 10.1523/JNEUROSCI.4244-06.2007; Li AM, 2000, AM J PATHOL, V157, P1447, DOI 10.1016/S0002-9440(10)64782-7; Maglio LE, 2004, MOL BRAIN RES, V131, P58, DOI 10.1016/j.molbrainres.2004.08.004; Mange A, 2002, FEBS LETT, V514, P159, DOI 10.1016/S0014-5793(02)02338-4; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McLennan NF, 2004, AM J PATHOL, V165, P227, DOI 10.1016/S0002-9440(10)63291-9; Paitel E, 2004, J BIOL CHEM, V279, P612, DOI 10.1074/jbc.M310453200; Paitel E, 2003, J BIOL CHEM, V278, P10061, DOI 10.1074/jbc.M211580200; Paitel E, 2002, J NEUROCHEM, V83, P1208, DOI 10.1046/j.1471-4159.2002.01234.x; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Radovanovic I, 2005, J NEUROSCI, V25, P4879, DOI 10.1523/JNEUROSCI.0328-05.2005; Rambold AS, 2006, MOL BIOL CELL, V17, P3356, DOI 10.1091/mbc.E06-01-0083; Roucou X, 2004, J NEUROSCI RES, V75, P153, DOI 10.1002/jnr.10864; Sakudo A, 2006, MINI-REV MED CHEM, V6, P589, DOI 10.2174/138955706776876159; Sakudo A, 2005, BIOCHEM BIOPH RES CO, V328, P14, DOI 10.1016/j.bbrc.2004.12.132; Sakudo A, 2003, BIOCHEM BIOPH RES CO, V307, P678, DOI 10.1016/S0006-291X(03)01239-7; Santuccione A, 2005, J CELL BIOL, V169, P341, DOI 10.1083/jcb.200409127; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Steele AD, 2006, P NATL ACAD SCI USA, V103, P3416, DOI 10.1073/pnas.0511290103; Sunyach C, 2007, J BIOL CHEM, V282, P1956, DOI 10.1074/jbc.M609663200; Taylor DR, 2005, J CELL SCI, V118, P5141, DOI 10.1242/jcs.02627; Vassallo N, 2003, J NEUROCHEM, V86, P538, DOI 10.1046/j.1471-4159.2003.01882.x; Watt NT, 2005, J BIOL CHEM, V280, P35914, DOI 10.1074/jbc.M507327200; Weise J, 2004, NEUROSCI LETT, V372, P146, DOI 10.1016/j.neulet.2004.09.030; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; Yin SM, 2006, J BIOL CHEM, V281, P10698, DOI 10.1074/jbc.M511819200; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	48	31	33	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3107	3117		10.1096/fj.06-7827com	http://dx.doi.org/10.1096/fj.06-7827com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17494993				2022-12-28	WOS:000249781600012
J	Chambraud, B; Belabes, H; Fontaine-Lenoir, V; Fellous, A; Baulieu, EE				Chambraud, Beatrice; Belabes, Hamida; Fontaine-Lenoir, Virginie; Fellous, Arlette; Baulieu, Etienne Emile			The immunophilin FKBP52 specifically binds to tubulin and prevents microtubule formation	FASEB JOURNAL			English	Article						cytoskeleton; neurite differentiation; microtubule dynamics; FK506 binding protein	HEAT-SHOCK-PROTEIN; GLUCOCORTICOID-RECEPTOR; FK506-BINDING PROTEIN; STEROID-RECEPTOR; HSP90-BINDING IMMUNOPHILINS; DYNEIN INTERACTION; COMPONENT; HSP90; CALMODULIN; TRANSPORT	The FK506 binding protein FKBP52 belongs to the large family of immunophilins and is known as a steroid receptor- associated protein. Previous data suggest that FKBP52 is associated with the motor protein dynein and with the cytoskeleton during mitosis. Here we demonstrate a specific and direct interaction between FKBP52 and tubulin. The region of FKBP52 located between aa 267 and 400, which includes the tetratricopeptide repeat domain, is required for tubulin binding. We provide evidence that FKBP52 prevents tubulin polymerization and that an 84 residue sequence located in the C- terminal part of the molecule ( aa 375 - 458) is necessary and sufficient for its microtubule depolymerization activity. In colocalization experiments in PC12 cells, FKBP52 is associated with tubulin in motile cellular compartments. Furthermore, we suggest that, by using siRNA, a decrease of FKBP52 expression in PC12 cells may lead to differentiated cell phenotype characterized by neurite extensions. Collectively, our data define an unexpected property of FKBP52 as a novel regulator of microtubule dynamics. The possible role of microtubule formation and tubulin binding of other immunophilins such as FKBP12 and FKBP51 is discussed.	Univ Paris 11, INSERM, UMR 788, F-94276 Le Kremlin Bicetre, France; Univ Bicetre, Ctr Hosp, MAPREG Co, Le Kremlin Bicetre, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP	Baulieu, EE (corresponding author), Univ Paris 11, INSERM, UMR 788, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	baulieu@kb.inserm.fr						Baas PW, 2005, TRENDS CELL BIOL, V15, P518, DOI 10.1016/j.tcb.2005.08.004; Bareille O, 1998, MEC IND MATER, V51, P52; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; Castoldi M, 2003, PROTEIN EXPRES PURIF, V32, P83, DOI 10.1016/S1046-5928(03)00218-3; CHAMBRAUD B, 1993, BIOCHEM BIOPH RES CO, V196, P160, DOI 10.1006/bbrc.1993.2229; Cheung-Flynn J, 2005, MOL ENDOCRINOL, V19, P1654, DOI 10.1210/me.2005-0071; Cheung-Flynn J, 2003, J BIOL CHEM, V278, P17388, DOI 10.1074/jbc.M300955200; Christner C., 2001, Mini-Reviews in Medicinal Chemistry, V1, P377, DOI 10.2174/1389557013406675; Clement MJ, 2005, BIOCHEMISTRY-US, V44, P14616, DOI 10.1021/bi0512492; CZAR MJ, 1994, MOL ENDOCRINOL, V8, P1731, DOI 10.1210/me.8.12.1731; Davies TH, 2005, INT J BIOCHEM CELL B, V37, P42, DOI 10.1016/j.biocel.2004.03.013; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fontaine-Lenoir V, 2006, P NATL ACAD SCI USA, V103, P4711, DOI 10.1073/pnas.0600113103; Galat A, 2004, COMPUT BIOL CHEM, V28, P129, DOI 10.1016/j.compbiolchem.2004.01.004; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; Gold BG, 1999, J PHARMACOL EXP THER, V289, P1202; Gold BG, 2003, CURR TOP MED CHEM, V3, P1368, DOI 10.2174/1568026033451880; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harrell JM, 2004, J BIOL CHEM, V279, P54647, DOI 10.1074/jbc.M406863200; Klettner A, 2003, CNS NEUROL DISORD-DR, V2, P153, DOI 10.2174/1568007033482878; Krebs A, 2005, EMBO REP, V6, P227, DOI 10.1038/sj.embor.7400360; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LEBIHAN S, 1993, BIOCHEM BIOPH RES CO, V195, P600, DOI 10.1006/bbrc.1993.2088; LEE YC, 1982, J BIOL CHEM, V257, P6306; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LUCKENBILLEDDS L, 1979, J NEUROCYTOL, V8, P493, DOI 10.1007/BF01214805; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; MASSOL N, 1992, BIOCHEM BIOPH RES CO, V187, P1330, DOI 10.1016/0006-291X(92)90448-T; Mattson MP, 1999, J NEUROSCI RES, V57, P577, DOI 10.1002/(SICI)1097-4547(19990901)57:5<577::AID-JNR1>3.0.CO;2-H; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PERROTAPPLANAT M, 1995, J CELL SCI, V108, P2037; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RICHTERLANDSBERG C, 1984, DEV NEUROSCI-BASEL, V6, P32; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Sinars CR, 2003, P NATL ACAD SCI USA, V100, P868, DOI 10.1073/pnas.0231020100; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; Sosa I, 2005, EXP NEUROL, V195, P7, DOI 10.1016/j.expneurol.2005.04.016; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; Teng JL, 2001, J CELL BIOL, V155, P65, DOI 10.1083/jcb.200106025; Tranguch S, 2005, P NATL ACAD SCI USA, V102, P14326, DOI 10.1073/pnas.0505775102; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; Wochnik GM, 2005, J BIOL CHEM, V280, P4609, DOI 10.1074/jbc.M407498200; Wu BL, 2004, P NATL ACAD SCI USA, V101, P8348, DOI 10.1073/pnas.0305969101; Zhao WH, 2006, VIROLOGY, V353, P283, DOI 10.1016/j.virol.2006.04.042	56	73	75	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2787	2797		10.1096/fj.06-7667com	http://dx.doi.org/10.1096/fj.06-7667com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17435176				2022-12-28	WOS:000249237500020
J	Quaranta, MG; Napolitano, A; Sanchez, M; Giordani, L; Mattioli, B; Viora, M				Quaranta, Maria Giovanna; Napolitano, Alfonso; Sanchez, Massimo; Giordani, Luciana; Mattioli, Benedetta; Viora, Marina			HIV-1 Nef impairs the dynamic of DC/NK crosstalk: different outcome of CD56(dim) and CD56(bright) NK cell subsets	FASEB JOURNAL			English	Article						AIDS; innate immunity; immune evasion	NATURAL-KILLER-CELLS; HUMAN-IMMUNODEFICIENCY-VIRUS; DISTINCT FUNCTIONAL-RESPONSES; INTERFERON-GAMMA PRODUCTION; CHEMOKINE RECEPTOR CX3CR1; HUMAN DENDRITIC CELLS; CD8(+) T-CELLS; IFN-ALPHA-BETA; SIGNALING PATHWAY; INFECTED CELLS	Dendritic cells ( DCs) and natural killer ( NK) cells are essential components of the innate immunity and play a critical role in the first phase of host defense against infection. Interactions between DCs and NK cells have been demonstrated in a variety of settings, with evidence emerging of complex bidirectional crosstalk between the two cell types. The accessory HIV-1 Nef protein is a crucial determinant for viral replication and pathogenesis. We previously demonstrated that Nef, hijacking DC functional activity, subverts the DC arm of immune response to escape the adaptive immune attack. Here, we monitor the effect of Nef on the outcome of the innate immune response, focusing on the impact of Nef on DC/NK crosstalk. We demonstrate that Nef up-regulates the ability of DCs to stimulate the immunoregulatory NK cells ( CD56(bright)) as assessed by the activated phenotype, up-regulation of their proliferative response and INF-gamma release. On the other hand, Nef-pulsed DCs inhibit cytotoxic NK cells ( CD56(dim)), as assessed by the reduced HLA-DR surface expression, reduced proliferation and cytotoxic activity. Moreover, in the presence of Nef-pulsed DCs, we found a significant up-regulation of TNF-alpha secretion and a significant reduction of IL-10, GM-CSF, MIP-1 alpha and RANTES secretion. Our findings suggest that the Nef-induced dysregulation in the DC/NK cell crosstalk may represent a potential mechanism through which HIV escapes innate immune surveillance.	Ist Super Sanita, Dept Drug Res & Evaluat, I-00161 Rome, Italy; Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)	Viora, M (corresponding author), Ist Super Sanita, Dept Drug Res & Evaluat, Viale Regina Elena 299, I-00161 Rome, Italy.	viora@iss.it	Sanchez, Massimo/AAD-1746-2021	Sanchez, Massimo/0000-0003-3696-7582; Quaranta, Maria Giovanna/0000-0002-1077-1488				Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; ALLAVENA P, 1994, EUR J IMMUNOL, V24, P3233, DOI 10.1002/eji.1830241249; Alter G, 2006, CURR MOL MED, V6, P621, DOI 10.2174/156652406778195035; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barlic J, 2003, BLOOD, V102, P3494, DOI 10.1182/blood-2003-03-0946; Bonaparte MI, 2003, AIDS, V17, P487, DOI 10.1097/00002030-200303070-00003; Campbell JJ, 2001, J IMMUNOL, V166, P6477, DOI 10.4049/jimmunol.166.11.6477; Carson WE, 1997, EUR J IMMUNOL, V27, P354, DOI 10.1002/eji.1830270203; Castriconi R, 2003, P NATL ACAD SCI USA, V100, P4120, DOI 10.1073/pnas.0730640100; Chen N, 2006, EUR J IMMUNOL, V36, P278, DOI 10.1002/eji.200535487; Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Cooper GJS, 2001, AUST J DAIRY TECHNOL, V56, P97; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Cooper MA, 2001, EUR J IMMUNOL, V31, P792, DOI 10.1002/1521-4141(200103)31:3<792::AID-IMMU792>3.0.CO;2-U; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; Fauci AS, 2005, NAT REV IMMUNOL, V5, P835, DOI 10.1038/nri1711; Ferlazzo G, 2004, J IMMUNOL, V172, P1455, DOI 10.4049/jimmunol.172.3.1455; Ferlazzo G, 2003, EUR J IMMUNOL, V33, P306, DOI 10.1002/immu.200310004; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; FONTANA L, 1986, IMMUNOBIOLOGY, V171, P425, DOI 10.1016/S0171-2985(86)80074-2; Fortis C, 2005, IMMUNOL RES, V33, P1, DOI 10.1385/IR:33:1:001; Fujii Y, 1996, FEBS LETT, V393, P93, DOI 10.1016/0014-5793(96)00859-9; Giordani L, 2000, CLIN EXP IMMUNOL, V122, P358, DOI 10.1046/j.1365-2249.2000.01388.x; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; Goodier MR, 2003, CLIN EXP IMMUNOL, V134, P470, DOI 10.1111/j.1365-2249.2003.02329.x; Greenway AL, 2003, J BIOSCIENCES, V28, P323, DOI 10.1007/BF02970151; Gupta N, 2005, VIROLOGY, V332, P491, DOI 10.1016/j.virol.2004.12.018; Hanna J, 2004, J IMMUNOL, V173, P6547, DOI 10.4049/jimmunol.173.11.6547; Jacobs R, 2001, EUR J IMMUNOL, V31, P3121, DOI 10.1002/1521-4141(2001010)31:10<3121::AID-IMMU3121>3.0.CO;2-4; JEWETT A, 1993, CELL IMMUNOL, V151, P257, DOI 10.1006/cimm.1993.1236; Kinter A, 1996, IMMUNOL RES, V15, P1, DOI 10.1007/BF02918280; Kottilil S, 2003, J INFECT DIS, V187, P1038, DOI 10.1086/368222; Kottilil S, 2006, J IMMUNOL, V176, P1107, DOI 10.4049/jimmunol.176.2.1107; Lande R, 2003, J IMMUNOL, V170, P1174, DOI 10.4049/jimmunol.170.3.1174; Lazdins JK, 1997, J EXP MED, V185, P81, DOI 10.1084/jem.185.1.81; Lieberman J, 2002, CURR OPIN IMMUNOL, V14, P478, DOI 10.1016/S0952-7915(02)00366-7; Loza MJ, 2004, J IMMUNOL, V172, P88, DOI 10.4049/jimmunol.172.1.88; MACCARIO R, 1987, INFECTION, V15, P99, DOI 10.1007/BF01650205; Mavilio D, 2006, J EXP MED, V203, P2339, DOI 10.1084/jem.20060894; MCWILLIAM AS, 1994, J EXP MED, V179, P1331, DOI 10.1084/jem.179.4.1331; Meier UC, 2005, J VIROL, V79, P12365, DOI 10.1128/JVI.79.19.12365-12374.2005; Moretta A, 2002, NAT REV IMMUNOL, V2, P957, DOI 10.1038/nri956; Nguyen KB, 2002, J IMMUNOL, V169, P4279, DOI 10.4049/jimmunol.169.8.4279; Parato KG, 2002, AIDS, V16, P1251, DOI 10.1097/00002030-200206140-00007; Poggi A, 2002, J IMMUNOL, V168, P95, DOI 10.4049/jimmunol.168.1.95; POLI G, 1992, AIDS RES HUM RETROV, V8, P191, DOI 10.1089/aid.1992.8.191; Portales P, 2003, AIDS, V17, P495, DOI 10.1097/00002030-200303070-00004; Qiao XG, 2006, NAT IMMUNOL, V7, P302, DOI 10.1038/ni1302; Quaranta MG, 2006, FASEB J, V20, P2198, DOI 10.1096/fj.06-6260rev; Quaranta MG, 1999, EXP CELL RES, V250, P112, DOI 10.1006/excr.1999.4494; Quaranta MG, 2004, FASEB J, V18, P1459, DOI 10.1096/fj.04-1633fje; Quaranta MG, 2003, FASEB J, V17, P2025, DOI 10.1096/fj.03-0272com; Quaranta MG, 2002, EXP CELL RES, V275, P243, DOI 10.1006/excr.2002.5497; ROSENBERG ZF, 1990, IMMUNOL TODAY, V11, P176, DOI 10.1016/0167-5699(90)90070-P; Schierloh P, 2005, J IMMUNOL, V175, P6852, DOI 10.4049/jimmunol.175.10.6852; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; SCOTTALGARA D, 1992, CLIN EXP IMMUNOL, V90, P181; Sechler JM, 2004, CELL IMMUNOL, V230, P99, DOI 10.1016/j.cellimm.2004.10.001; Steinman RM, 2003, CURR TOP MICROBIOL, V276, P1; Suzuki S, 2000, MICROBIOL IMMUNOL, V44, P111, DOI 10.1111/j.1348-0421.2000.tb01254.x; Swingler S, 2003, NATURE, V424, P213, DOI 10.1038/nature01749; Tarazona R, 2002, J CLIN IMMUNOL, V22, P176, DOI 10.1023/A:1015476114409; Trotta R, 2005, BLOOD, V105, P3011, DOI 10.1182/blood-2004-10-4072; TYLER DS, 1990, J IMMUNOL, V144, P3375; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Vitale M, 2003, BRIT J HAEMATOL, V120, P337, DOI 10.1046/j.1365-2141.2003.04053.x	68	22	22	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2323	2334		10.1096/fj.06-7883com	http://dx.doi.org/10.1096/fj.06-7883com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17431094				2022-12-28	WOS:000248454400007
J	Siner, JM; Jiang, G; Cohen, ZI; Shan, PY; Zhang, XC; Lee, CG; Elias, JA; Lee, PJ				Siner, Jonathan M.; Jiang, Ge; Cohen, Zaza I.; Shan, Peiying; Zhang, Xuchen; Lee, Chun Geun; Elias, Jack A.; Lee, Patty J.			VEGF-induced heme oxygenase-1 confers cytoprotection from lethal hyperoxia in vivo	FASEB JOURNAL			English	Article						oxidant injury; angiogenesis; endothelial; acute lung injury	ENDOTHELIAL GROWTH-FACTOR; GENE-TRANSFER; VASCULAR-PERMEABILITY; CELL-DEATH; LUNG; EXPRESSION; PROTECTS; OVEREXPRESSION; INJURY; INTERLEUKIN-11	Prolonged exposure to hyperoxia results in hyperoxic acute lung injury (HALI). Vascular endothelial growth factor ( VEGF) has been shown to have cytoprotective effects and prolong survival in an in vivo model of HALI. Heme oxygenase- 1 ( HO-1) has protective effects in hyperoxia; therefore, we hypothesized that induction of HO- 1 would be an important contributor to VEGF- induced cytoprotection. Using inducible, lung- specific VEGF overexpressing transgenic mice, we demonstrated that VEGF is a potent inducer of HO-1 mRNA and protein in mouse lung. To evaluate the effect of inhibition of HO-1 on injury, VEGF transgenic mice were treated with HO-1 short interfering RNA ( HO-1 siRNA) and exposed to hyperoxia. Total lung lavage protein concentration, TUNEL staining, lipid peroxidation, and wet- to- dry ratio were all increased, consistent with increased injury. These findings were corroborated by survival studies in which inhibition of HO-1 function using tin-protoporphryin or silencing of HO-1 with lentiviral HO-1 short hairpin RNA ( ShRNA) significantly decreased survival in hyperoxia. We conclude from these data that VEGF- induced HO-1 is an important contributor to cytoprotection in this in vivo model of acute lung injury and that alterations in VEGF function in the lung are likely to be important determinants of the outcome of acute lung injury.	Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Div Pulm & Crit Care, Newark, NJ 07103 USA	Yale University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Lee, PJ (corresponding author), Yale Univ, Sch Med, Pulm & Crit Care Med Sect, POB 208057, New Haven, CT 06520 USA.	patty.lee@yale.edu	zhang, xu/GYE-3558-2022; Lee, Chun Geun/AAC-2838-2021	Zhang, Xuchen/0000-0002-1484-4672; Lee, Chun Geun/0000-0002-9514-3658	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071595, F32HL078127] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071595, 5 F32 HL078127] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abadie Y, 2005, EUR RESPIR J, V25, P139, DOI 10.1183/09031936.04.00065504; ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BUSSOLATI B, 2003, BLOOD; Christofidou-Solomidou M, 2003, AM J PHYSIOL-LUNG C, V285, pL283, DOI 10.1152/ajplung.00021.2003; Corne J, 2000, J CLIN INVEST, V106, P783, DOI 10.1172/JCI9674; Deramaudt BMJM, 1998, J CELL BIOCHEM, V68, P121, DOI 10.1002/(SICI)1097-4644(19980101)68:1<121::AID-JCB12>3.0.CO;2-K; Fernandez M, 2003, BRIT J PHARMACOL, V139, P634, DOI 10.1038/sj.bjp.0705272; FISHER AB, 1980, AM REV RESPIR DIS, V122, P61, DOI 10.1164/arrd.1980.122.5P2.61; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; He CH, 2005, J CLIN INVEST, V115, P1039, DOI 10.1172/JCI200523004; Jozkowicz A, 2003, ANTIOXID REDOX SIGN, V5, P155, DOI 10.1089/152308603764816514; Kaner RJ, 2000, AM J RESP CELL MOL, V22, P657, DOI 10.1165/ajrcmb.22.6.3779; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kasahara Y, 2001, AM J RESP CRIT CARE, V163, P737, DOI 10.1164/ajrccm.163.3.2002117; Klekamp JG, 1999, AM J PATHOL, V154, P823, DOI 10.1016/S0002-9440(10)65329-1; Langouche L, 2005, J CLIN INVEST, V115, P2277, DOI 10.1172/JCI25385; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Maitre B, 2001, EUR RESPIR J, V18, P100, DOI 10.1183/09031936.01.00074701; Maniscalco WM, 1997, AM J RESP CELL MOL, V16, P557, DOI 10.1165/ajrcmb.16.5.9160838; MARCZIN N, 2003, DIS MARKERS EXHALED; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Perkowski S, 2003, AM J RESP CELL MOL, V28, P682, DOI 10.1165/rcmb.4692; Ray P, 1997, J CLIN INVEST, V100, P2501, DOI 10.1172/JCI119792; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Stapleton RD, 2005, CHEST, V128, P525, DOI 10.1378/chest.128.2.525; Taylor JL, 1998, AM J PHYSIOL-LUNG C, V274, pL582, DOI 10.1152/ajplung.1998.274.4.L582; Thickett DR, 2002, AM J RESP CRIT CARE, V166, P1332, DOI 10.1164/rccm.2105057; Thickett DR, 2001, AM J RESP CRIT CARE, V164, P1601, DOI 10.1164/ajrccm.164.9.2011071; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Ward NS, 1999, CHEST, V116, p26S, DOI 10.1016/S0012-3692(15)30647-4; Waxman AB, 1998, J CLIN INVEST, V101, P1970, DOI 10.1172/JCI1337; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yamada N, 2000, AM J HUM GENET, V66, P187, DOI 10.1086/302729; Yang LM, 1999, AM J PHYSIOL-LUNG C, V277, pL127, DOI 10.1152/ajplung.1999.277.1.L127; Zhang XC, 2005, J IMMUNOL, V175, P4834, DOI 10.4049/jimmunol.175.8.4834; Zhang XC, 2004, J BIOL CHEM, V279, P10677, DOI 10.1074/jbc.M312941200; Zhang XC, 2003, AM J RESP CELL MOL, V28, P305, DOI 10.1165/rcmb.2002-0156OC; Zhang XC, 2006, FASEB J, V20, P2156, DOI 10.1096/fj.06-5668fje	40	58	58	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1422	1432		10.1096/fj.06-6661com	http://dx.doi.org/10.1096/fj.06-6661com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264168				2022-12-28	WOS:000246117000018
J	Beck, V; Jaburek, M; Demina, T; Rupprecht, A; Porter, RK; Jezek, P; Pohl, EE				Beck, Valeri; Jaburek, Martin; Demina, Tatiana; Rupprecht, Anne; Porter, Richard K.; Jezek, Petr; Pohl, Elena E.			Polyunsaturated fatty acids activate human uncoupling proteins 1 and 2 in planar lipid bilayers	FASEB JOURNAL			English	Article						mitochondria; anion transporter; proton transport; artificial bilayer membranes; reactive oxygen species	MITOCHONDRIAL PROTON CONDUCTANCE; FLIP-FLOP; TRANSPORT MECHANISM; PURINE NUCLEOTIDES; H+ TRANSPORT; UCP2; MEMBRANES; LONG; MICE; RECONSTITUTION	Uncoupling proteins 1 (UCP1) and 2 (UCP2) belong to the family of mitochondrial anion transporters and share 59% sequence identity with each other. Whereas UCP1 was shown to be responsible for the rapid production of heat in brown adipose tissue, the primary function and transport properties of ubiquitously expressed UCP2 are controversially discussed. Here, for the first time, the activation pattern of the recombinant human UCP2 in comparison to the recombinant human UCP1 are studied using a well-defined system of planar lipid bilayers. It is shown that despite apparently different physiological functions, hUCP2 exhibited its protonophoric function similar to hUCP1-exclusively in the presence of long-chain fatty acids ( FA). The calculated hUCP2 transport rate of 4.5 s(-1) is the same order of magnitude, as shown previously for UCP1. It leads to the conclusion that the differences in the activity of both proteins in living mitochondria are based exclusively on their different expression level. Both proteins are activated much more effectively by polyunsaturated than by saturated FA. The proton and total membrane conductances increased in the range palmitic < oleic < eicosatrienoic < linoleic < retinoic < arachidonic acids. The higher uncoupling protein (UCP)-dependent conductance in the presence of polyunsaturated FA is explained on the basis of the FA cycling hypothesis.	Charite, Inst Cell Biol & Neurobiol, Ctr Anat, Charitepl 1, D-10117 Berlin, Germany; Acad Sci Czech Republic, Inst Physiol, Dept Membrane Transport Biophys, Prague, Czech Republic; Univ Dublin Trinity Coll, Sch Biochem & Immunol, Dublin 2, Ireland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Trinity College Dublin	Pohl, EE (corresponding author), Charite, Inst Cell Biol & Neurobiol, Ctr Anat, Charitepl 1, D-10117 Berlin, Germany.	elena.pohl@charite.de	Jaburek, Martin/B-9652-2012; Pohl, Elena E./A-4025-2009; Beck, Valeri/B-6658-2015; Jezek, Petr/B-9264-2012; Jabůrek, Martin/H-1114-2019	Pohl, Elena E./0000-0002-0604-5950; Beck, Valeri/0000-0003-1866-6559; Jezek, Petr/0000-0002-2720-9395; Jabůrek, Martin/0000-0002-4357-1116; Porter, Richard/0000-0001-9854-5161				Andrews ZB, 2005, J NEUROSCI, V25, P184, DOI 10.1523/JNEUROSCI.4269-04.2005; Armstrong VT, 2003, ARCH BIOCHEM BIOPHYS, V414, P74, DOI 10.1016/S0003-9861(03)00159-0; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Bechmann I, 2002, BIOCHEM PHARMACOL, V64, P363, DOI 10.1016/S0006-2952(02)01166-8; Beck V, 2006, BBA-BIOENERGETICS, V1757, P474, DOI 10.1016/j.bbabio.2006.03.006; Bezaire V, 2001, AM J PHYSIOL-ENDOC M, V281, pE975, DOI 10.1152/ajpendo.2001.281.5.E975; Bienengraeber M, 1998, BIOCHEMISTRY-US, V37, P3, DOI 10.1021/bi972463w; Blanc J, 2003, CIRCULATION, V107, P388, DOI 10.1161/01.CIR.0000051722.66074.60; Brand MD, 2005, CELL METAB, V2, P85, DOI 10.1016/j.cmet.2005.06.002; Brand MD, 1999, INT J OBESITY, V23, pS4, DOI 10.1038/sj.ijo.0800936; Breen EP, 2006, J BIOL CHEM, V281, P2114, DOI 10.1074/jbc.M511575200; Brunaldi K, 2005, J LIPID RES, V46, P245, DOI 10.1194/jlr.M400155-JLR200; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; Carroll AM, 2005, J BIOL CHEM, V280, P15534, DOI 10.1074/jbc.M413315200; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Chomiki N, 2001, EUR J BIOCHEM, V268, P903, DOI 10.1046/j.1432-1327.2001.01946.x; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Esteves TC, 2005, BBA-BIOENERGETICS, V1709, P35, DOI 10.1016/j.bbabio.2005.06.002; Feller SE, 2002, J AM CHEM SOC, V124, P318, DOI 10.1021/ja0118340; FUKS B, 1994, BIOPHYS J, V66, P1404, DOI 10.1016/S0006-3495(94)80931-2; Garlid KD, 1998, FEBS LETT, V438, P10, DOI 10.1016/S0014-5793(98)01246-0; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Goglia F, 2003, FASEB J, V17, P1585, DOI 10.1096/fj.03-0159hyp; Gonzalez-Barroso MM, 1998, J BIOL CHEM, V273, P15528, DOI 10.1074/jbc.273.25.15528; GUTKNECHT J, 1987, J BIOENERG BIOMEMBR, V19, P427; GUTKNECHT J, 1988, J MEMBRANE BIOL, V106, P83, DOI 10.1007/BF01871769; Hagen T, 2002, Minerva Med, V93, P41; HEATON GM, 1976, BIOCHEM J, V156, P635, DOI 10.1042/bj1560635; Hinz W, 1999, FEBS LETT, V462, P411, DOI 10.1016/S0014-5793(99)01568-9; Horimoto M, 2004, HEPATOLOGY, V39, P386, DOI 10.1002/hep.20047; Horvath B, 2002, BIOCHEM PHARMACOL, V64, P369, DOI 10.1016/S0006-2952(02)01167-X; Horvath TL, 2003, INT J OBESITY, V27, P433, DOI 10.1038/sj.ijo.0802257; Jaburek M, 2004, J BIOL CHEM, V279, P53097, DOI 10.1074/jbc.M405339200; Jaburek M, 2003, J BIOL CHEM, V278, P25825, DOI 10.1074/jbc.M302126200; Jaburek M, 2001, J BIOL CHEM, V276, P31897, DOI 10.1074/jbc.M103507200; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jezek P, 2004, PHYSIOL RES, V53, pS199; Kleinfeld AM, 1997, BIOCHEMISTRY-US, V36, P14146, DOI 10.1021/bi971440e; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Klingenberg M, 2001, BBA-BIOENERGETICS, V1504, P128, DOI 10.1016/S0005-2728(00)00242-5; Klingenberg M, 1999, INT J OBESITY, V23, pS24, DOI 10.1038/sj.ijo.0800939; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; Matthias A, 2000, J BIOL CHEM, V275, P25073, DOI 10.1074/jbc.M000547200; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Nedergaard J, 1999, J BIOENERG BIOMEMBR, V31, P475, DOI 10.1023/A:1005400507802; Nedergaard J, 2003, EXP PHYSIOL, V88, P65, DOI 10.1113/eph8802502; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Paradis E, 2003, TRENDS MOL MED, V9, P522, DOI 10.1016/j.molmed.2003.10.009; Pohl EE, 2000, BIOCHEMISTRY-US, V39, P1834, DOI 10.1021/bi9919549; Porter Jr, 2001, POPTRONICS, V2, P3; Rial E, 2004, BBA-BIOENERGETICS, V1608, P122, DOI 10.1016/j.bbabio.2003.11.001; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; Ricquier D, 1999, J INTERN MED, V245, P637, DOI 10.1046/j.1365-2796.1999.00492.x; Ruzicka M, 2005, INT J BIOCHEM CELL B, V37, P809, DOI 10.1016/j.biocel.2004.10.016; Schmider W, 2000, J LIPID RES, V41, P775; Separovic F, 1996, BIOPHYS J, V71, P274, DOI 10.1016/S0006-3495(96)79223-8; Shabalina IG, 2004, J BIOL CHEM, V279, P38236, DOI 10.1074/jbc.M402375200; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Stuart JA, 2001, J BIOL CHEM, V276, P18633, DOI 10.1074/jbc.M011566200; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; Urbankova E, 2003, J BIOL CHEM, V278, P32497, DOI 10.1074/jbc.M303721200; Vogler S, 2005, J MOL MED, V83, P806, DOI 10.1007/s00109-005-0661-5; WINKLER E, 1994, J BIOL CHEM, V269, P2508; Zackova M, 2003, J BIOL CHEM, V278, P20761, DOI 10.1074/jbc.M212850200; Zackova M, 2002, BIOSCIENCE REP, V22, P33, DOI 10.1023/A:1016009022186; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X	68	79	82	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1137	1144		10.1096/fj.06-7489com	http://dx.doi.org/10.1096/fj.06-7489com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17242157				2022-12-28	WOS:000245650400018
J	Zarse, K; Schulz, TJ; Birringer, M; Ristow, M				Zarse, Kim; Schulz, Tim J.; Birringer, Marc; Ristow, Michael			Impaired respiration is positively correlated with decreased life span in Caenorhabditis elegans models of Friedreich Ataxia	FASEB JOURNAL			English	Article						mitochondria; oxygen; frataxin; hormesis	OXIDATIVE STRESS; FRATAXIN; LONGEVITY; RESTRICTION; INTERFERENCE; EXPRESSION; EXTENDS	Impaired expression of mitochondrial genes causes alterations in life span of the nematode Caenorhabditis elegans. Intriguingly, although some of these genes have been shown to extend life expectancy and reduce aging processes, others are known to shorten life span in the same model organism. Reduced expression of a mitochondrial protein called frataxin causes a neurodegenerative disorder named Friedreich Ataxia, which decreases life span in humans. Surprisingly, reduced expression of the C. elegans frataxin homologue frh-1 has been associated with both increased as well as decreased life span by different laboratories. To further elucidate these conflicting findings, here we show that different RNA interference (RNAi) constructs directed against frh-1 reduce C. elegans life span. Moreover, we show that frh-1-inhibiting RNAi impairs oxygen consumption and that respiratory rate is positively correlated with life span in this multicellular eukaryote (r = 0.8566), suggesting that > 73% of life span variance in C. elegans is explained by changes in respiratory rate. Taken together, impaired mitochondrial metabolism due to RNAi-mediated inhibition of the frataxin homologue frh-1 causes both impaired respiration as well as decreased life span in the multicellular eukaryote C. elegans.	Univ Jena, Dept Human Nutr, Inst Nutr, D-07743 Jena, Germany; German Inst Human Nutr, Nuethetal, Germany	Friedrich Schiller University of Jena; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE)	Ristow, M (corresponding author), Univ Jena, Dept Human Nutr, Inst Nutr, 29 Dornburger St, D-07743 Jena, Germany.	mristow@mristow.org	Ristow, Michael/O-9858-2014; Schulz, Tim/F-4842-2013; Zarse, Kim/D-2133-2016	Ristow, Michael/0000-0003-2109-2453; Schulz, Tim/0000-0002-8413-3972; Zarse, Kim/0000-0003-2542-6123; Birringer, Marc/0000-0003-0343-4704				Anson RM, 2004, AGING CELL, V3, P29, DOI 10.1111/j.1474-9728.2003.00077.x; Ausubel F, 1997, SHORT PROTOCOLS MOL; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cossee M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219; Dhe-Paganon S, 2000, J BIOL CHEM, V275, P30753, DOI 10.1074/jbc.C000407200; EPSTEIN HF, 1995, MODERN BIOL ANAL ORG; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Ingram DK, 2004, ANN NY ACAD SCI, V1019, P412, DOI 10.1196/annals.1297.074; Isaya G, 2004, ACTA PAEDIATR, V93, P68, DOI 10.0180/08035320310021318; Johnson TE, 2002, J INHERIT METAB DIS, V25, P197, DOI 10.1023/A:1015677828407; Kaeberlein M, 2005, PLOS GENET, V1, P614, DOI 10.1371/journal.pgen.0010069; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; McKusick V. A., 2006, ONLINE MENDELIAN INH; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Nemoto S, 2006, J BIOL CHEM, V281, P10555, DOI 10.1074/jbc.M511626200; Pearl R., 1928, RATE LIVING BEING AC; Rea S, 2003, DEV CELL, V5, P197, DOI 10.1016/S1534-5807(03)00242-9; Rea SL, 2005, NAT GENET, V37, P894, DOI 10.1038/ng1608; Ristow M, 2000, P NATL ACAD SCI USA, V97, P12239, DOI 10.1073/pnas.220403797; Shoichet SA, 2002, HUM MOL GENET, V11, P815, DOI 10.1093/hmg/11.7.815; Sinclair DA, 2005, MECH AGEING DEV, V126, P987, DOI 10.1016/j.mad.2005.03.019; Southam CM, 1943, PHYTOPATHOLOGY, V33, P517; Thierbach R, 2005, HUM MOL GENET, V14, P3857, DOI 10.1093/hmg/ddi410; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; Vazquez-Manrique RP, 2005, FASEB J, V19, P172, DOI 10.1096/fj.05-4212fje; Ventura N, 2005, AGING CELL, V4, P109, DOI 10.1111/j.1474-9726.2005.00149.x; Ventura N, 2006, FASEB J, V20, P1029, DOI 10.1096/fj.06-0505ufm; Vorgerd M, 2000, NEUROMUSCULAR DISORD, V10, P430, DOI 10.1016/S0960-8966(00)00108-5; Weindruch R., 1988, RETARDATION AGING DI	35	41	42	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1271	1275		10.1096/fj.06-6994com	http://dx.doi.org/10.1096/fj.06-6994com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17215485				2022-12-28	WOS:000245650400031
J	de la Vega, MR; Sevilla, RG; Hermoso, A; Lorenzo, J; Tanco, S; Diez, A; Fricker, LD; Bautista, JM; Aviles, FX				de la Vega, Monica Rodriguez; Sevilla, Rafael G.; Hermoso, Antoni; Lorenzo, Julia; Tanco, Sebastian; Diez, Amalia; Fricker, Lloyd D.; Bautista, Jose M.; Aviles, Francesc X.			Nna1-like proteins are active metallocarboxypeptidases of a new and diverse M14 subfamily	FASEB JOURNAL			English	Article						peptidase classification; CCP; tubulin processing degradome; tubulinyl-Tyr carboxypeptidase	TUBULIN-TYROSINE-LIGASE; CARBOXYPEPTIDASE-A; ALPHA-TUBULIN; CRYSTAL-STRUCTURE; SEQUENCE ALIGNMENT; SUBSTRATE-BINDING; FOLD RECOGNITION; GENE-TRANSFER; ASSAY; CLONING	Nna1 has some sequence similarity to metallocarboxypeptidases, but the biochemical characterization of Nna1 has not previously been reported. In this work we performed a detailed genomic scan and found > 100 Nna1 homologues in bacteria, Protista, and Animalia, including several paralogs in most eukaryotic species. Phylogenetic analysis of the Nna1-like sequences demonstrates a major divergence between Nna1-like peptidases and the previously known metallocarboxypeptidases subfamilies: M14A, M14B, and M14C. Conformational modeling of representative Nna1-like proteins from a variety of species indicates an unusually open active site, a property that might facilitate its action on a wide variety of peptide and protein substrates. To test this, we expressed a recombinant form of one of the Nna1-like peptidases from Caenorhabditis elegans and demonstrated that this protein is a fully functional metallocarboxypeptidase that cleaves a range of C-terminal amino acids from synthetic peptides. The enzymatic activity is activated by ATP/ADP and salt-inactivated, and is preferentially inhibited by Z-Glu-Tyr dipeptide, which is without precedent in metallocarboxypeptidases and resembles tubulin carboxypeptidase functioning; this hypothesis is strongly reinforced by the results depicted in Kalinina et aL published as accompanying paper in this journal (1). Our findings demonstrate that the M14 family of metaBocarboxypeptidases is more complex and diverse than expected, and that Nna1-like peptidases are functional variants of such enzymes, representing a novel subfamily (we propose the name M14D) that contributes substantially to such diversity.	Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Bellaterra 08193, Barcelona, Spain; Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Bellaterra 08193, Barcelona, Spain; Univ Complutense Madrid, Fac Vet, Dept Biochem & Mol Biol 4, Madrid, Spain; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA	Autonomous University of Barcelona; Autonomous University of Barcelona; Complutense University of Madrid; Yeshiva University; Albert Einstein College of Medicine	Aviles, FX (corresponding author), Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Bellaterra 08193, Barcelona, Spain.	jmbau@vet.ucm.es; FrancescXavier.Aviles@uab.es	Avilés, Francesc Xavier/A-2664-2015; Tanco, Sebastian Martin/R-2528-2016; Pulido, Toni Hermoso/K-3701-2015; Rodriguez de la Vega Otazo, Monica Margarita/H-7008-2015; Bautista, José M./B-7899-2013; Diez, Amalia/AAG-4274-2021; Aviles, Francesc Xavier/F-3482-2019; Diez, Amalia/I-4852-2014; Lorenzo, Julia/E-9015-2011	Avilés, Francesc Xavier/0000-0002-1399-6789; Tanco, Sebastian Martin/0000-0003-2130-4401; Pulido, Toni Hermoso/0000-0003-2016-6465; Rodriguez de la Vega Otazo, Monica Margarita/0000-0002-1061-3471; Bautista, José M./0000-0001-8926-881X; Diez, Amalia/0000-0002-2619-9252; Aviles, Francesc Xavier/0000-0002-1399-6789; Diez, Amalia/0000-0002-2619-9252; Lorenzo, Julia/0000-0001-5659-6008				Abascal F, 2005, BIOINFORMATICS, V21, P2104, DOI 10.1093/bioinformatics/bti263; ALFA CE, 1991, CELL MOTIL CYTOSKEL, V18, P86, DOI 10.1002/cm.970180203; Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aravind L, 2003, CELL, V115, P771, DOI 10.1016/S0092-8674(03)01023-7; ARGARANA CE, 1978, MOL CELL BIOCHEM, V19, P17; ASLANIDIS C, 1990, NUCLEIC ACIDS RES, V18, P6069, DOI 10.1093/nar/18.20.6069; Badin-Larcon AC, 2004, P NATL ACAD SCI USA, V101, P5577, DOI 10.1073/pnas.0307917101; Barrett A.J., 1999, HDB PROTEOLYTIC ENZY; Bateman A, 2000, J MOL BIOL, V299, P1113, DOI 10.1006/jmbi.2000.3778; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Bayes A, 2005, P NATL ACAD SCI USA, V102, P16602, DOI 10.1073/pnas.0505489102; Birney E, 2006, NUCLEIC ACIDS RES, V34, pD556, DOI 10.1093/nar/gkj133; Bloom K, 2004, P NATL ACAD SCI USA, V101, P6839, DOI 10.1073/pnas.0401266101; Bosc C, 1996, P NATL ACAD SCI USA, V93, P2125, DOI 10.1073/pnas.93.5.2125; Cho JH, 2001, BIOCHEMISTRY-US, V40, P10197, DOI 10.1021/bi010807j; CHRISTIANSON DW, 1986, P NATL ACAD SCI USA, V83, P7568, DOI 10.1073/pnas.83.20.7568; Contin MA, 2000, NEUROCHEM RES, V25, P27, DOI 10.1023/A:1007579113813; DeLano W.L, PYMOL MOL GRAPHICS S; Durbin R., 1998, BIOL SEQUENCE ANAL P; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Erck C, 2005, P NATL ACAD SCI USA, V102, P7853, DOI 10.1073/pnas.0409626102; Estebanez-Perpina E, 2001, J MOL BIOL, V313, P629, DOI 10.1006/jmbi.2001.5076; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Felsenstein J., 2004, PHYLIP PHYLOGENY INF; Fernandez-Gonzalez A, 2002, SCIENCE, V295, P1904, DOI 10.1126/science.1068912; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Garcia-Saez I, 1997, EMBO J, V16, P6906, DOI 10.1093/emboj/16.23.6906; GARDELL SJ, 1985, NATURE, V317, P551, DOI 10.1038/317551a0; Gomis-Ruth FX, 1999, EMBO J, V18, P5817, DOI 10.1093/emboj/18.21.5817; GUNDERSEN GG, 1987, J CELL BIOL, V105, P251, DOI 10.1083/jcb.105.1.251; HALLAK ME, 1977, FEBS LETT, V73, P147, DOI 10.1016/0014-5793(77)80968-X; Han PJ, 2004, EXP NEUROL, V189, P293, DOI 10.1016/j.expneurol.2004.03.010; Harris A, 2000, MOL CELL NEUROSCI, V16, P578, DOI 10.1006/mcne.2000.0900; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; HOURDOU ML, 1993, BIOCHEM J, V292, P563, DOI 10.1042/bj2920563; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KALININA E, 2007, IN PRESS FASEB J, V20; KIM H, 1990, BIOCHEMISTRY-US, V29, P5546, DOI 10.1021/bi00475a019; Koonin EV, 2001, ANNU REV MICROBIOL, V55, P709, DOI 10.1146/annurev.micro.55.1.709; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; McLysaght A, 2002, NAT GENET, V31, P200, DOI 10.1038/ng884; Meyer A, 1999, CURR OPIN CELL BIOL, V11, P699, DOI 10.1016/S0955-0674(99)00039-3; Mizuguchi K, 1998, BIOINFORMATICS, V14, P617, DOI 10.1093/bioinformatics/14.7.617; Mock WL, 1996, ANAL BIOCHEM, V239, P218, DOI 10.1006/abio.1996.0318; Mock WL, 2002, BIOORG MED CHEM LETT, V12, P1193, DOI 10.1016/S0960-894X(02)00128-2; MULLINS FH, 1994, J NEUROCHEM, V62, P227; Nicholas KB, 1997, EMBNEW NEWS, V4, P14; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; PETERSON LM, 1982, ANAL BIOCHEM, V125, P420, DOI 10.1016/0003-2697(82)90024-0; PLUMMER TH, 1980, ANAL BIOCHEM, V108, P348, DOI 10.1016/0003-2697(80)90598-9; Rawlings ND, 2006, NUCLEIC ACIDS RES, V34, pD270, DOI 10.1093/nar/gkj089; REES DC, 1981, P NATL ACAD SCI-BIOL, V78, P5455, DOI 10.1073/pnas.78.9.5455; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Snell EA, 2006, P ROY SOC B-BIOL SCI, V273, P401, DOI 10.1098/rspb.2005.3263; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Too CKL, 2001, ENDOCRINOLOGY, V142, P1357, DOI 10.1210/en.142.3.1357; Vendrell J., 2004, HDB METALLOPROTEINS, P167; Ventura S, 1999, J BIOL CHEM, V274, P19925, DOI 10.1074/jbc.274.28.19925; Walhout AJM, 2000, METHOD ENZYMOL, V328, P575, DOI 10.1016/S0076-6879(00)28419-X; Wang TY, 2006, MOL CELL NEUROSCI, V33, P200, DOI 10.1016/j.mcn.2006.07.009; WEBSTER DR, 1992, BIOCHEMISTRY-US, V31, P5849, DOI 10.1021/bi00140a021; WEBSTER DR, 2004, HDB PROTEOLYTIC ENZY, P2111; WEHLAND J, 1987, J CELL SCI, V88, P185; Wei SW, 2002, J BIOL CHEM, V277, P14954, DOI 10.1074/jbc.M112254200; Wu CH, 2003, NUCLEIC ACIDS RES, V31, P345, DOI 10.1093/nar/gkg040	74	78	83	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					851	865		10.1096/fj.06-7330com	http://dx.doi.org/10.1096/fj.06-7330com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17244817				2022-12-28	WOS:000244686400022
J	Greenberg, Y; King, M; Kiosses, WB; Ewalt, K; Yang, X; Schimmel, P; Reader, JS; Tzima, E				Greenberg, Y.; King, M.; Kiosses, W. B.; Ewalt, K.; Yang, X.; Schimmel, P.; Reader, J. S.; Tzima, E.			The novel fragment of tyrosyl tRNA synthetase, mini-TyrRS, is secreted to induce an angiogenic response in endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; vascular endothelial growth factor receptor 2; noncanonical	NITRIC-OXIDE SYNTHASE; FLUID SHEAR-STRESS; GROWTH-FACTOR; CXC CHEMOKINE; IN-VITRO; RECEPTOR; TRANSACTIVATION; ACTIVATION; PHOSPHORYLATION; KDR/FLK-1	Aminoacyl tRNA synthetases-enzymes that catalyze the first step of protein synthesis-in mammalian cells are now known to have expanded functions, including activities in signal transduction pathways, such as those for angiogenesis and inflammation. The native synthetases themselves are procytokines, having no signal transduction activities. After alternative splicing or natural proteolysis, specific fragments that are potent cytokines and that interact with specific receptors on cell surfaces are released. In this manner, a natural fragment of human tyrosyl tRNA synthetase (TyrRS), mini-TyrRS, has been shown to act as a proangiogenic cytokine. The mechanistic basis for the action of mini-TyrRS in angiogenesis has yet to be established. Here, we show that mini-TyrRS is exported from endothelial cells when they are treated with tumor necrosis factor-alpha. Mini-TyrRS binds to vascular endothelial cells and activates an array of angiogenic signal transduction pathways. Mini-TyrRS-induced angiogenesis requires the activation of vascular endothelial growth factor receptor-2 (VEGFR2/Flk-1/KDR). Mini-TyrRS stimulates VEGFR2 phosphorylation in a VEGF-independent manner, suggesting VEGFR2 transactivation. Transactivation of VEGFR2 and downstream angiogenesis require an intact Glu-Leu-Arg (ELR) motif in mini-TyrRS, which is important for its cytokine activity. These studies therefore suggest a mechanism by which mini-TyrRS induces angiogenesis in endothelial cells and provide further insight into the role of mini-TyrRS as a link between translation and angiogenesis.	[Greenberg, Y.; King, M.; Tzima, E.] Scripps Res Inst, Dept Cell & Mol Physiol, La Jolla, CA 92037 USA; [Kiosses, W. B.; Ewalt, K.; Yang, X.; Schimmel, P.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Reader, J. S.] Univ N Carolina, Dept Med, Chapel Hill, NC USA; [Reader, J. S.; Tzima, E.] Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC USA	Scripps Research Institute; Scripps Research Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Tzima, E (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, 103 Mason Farm Rd, Chapel Hill, NC 27599 USA.	etzima@med.unc.edu	Tzima, Ellie/L-9256-2017; Yang, Xiang-Lei/AAR-7107-2020	Tzima, Ellie/0000-0002-3437-0902; Yang, Xiang-Lei/0000-0003-2554-084X				Bauer PM, 2003, J BIOL CHEM, V278, P14841, DOI 10.1074/jbc.M211926200; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Daniel TO, 2000, ANNU REV PHYSIOL, V62, P649, DOI 10.1146/annurev.physiol.62.1.649; Ewalt KL, 2002, BIOCHEMISTRY-US, V41, P13344, DOI 10.1021/bi020537k; Folkman J, 1998, CIRCULATION, V97, P1108, DOI 10.1161/01.CIR.97.12.1108; Fujita Y, 2006, ENDOCRINOLOGY, V147, P1377, DOI 10.1210/en.2005-0644; Halwani R, 2004, J VIROL, V78, P7553, DOI 10.1128/JVI.78.14.7553-7564.2004; Howard OMZ, 2002, J EXP MED, V196, P781, DOI 10.1084/jem.20020186; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; Jordanova A, 2006, NAT GENET, V38, P197, DOI 10.1038/ng1727; Kraling BM, 1999, J CELL SCI, V112, P1599; Miura S, 2003, HYPERTENSION, V41, P1118, DOI 10.1161/01.HYP.0000064345.33807.57; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Nangle LA, 2007, P NATL ACAD SCI USA, V104, P11239, DOI 10.1073/pnas.0705055104; Otani A, 2002, P NATL ACAD SCI USA, V99, P178, DOI 10.1073/pnas.012601899; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Papapetropoulos A, 1997, AM J PATHOL, V150, P1835; Park BJ, 2005, CELL, V120, P209, DOI 10.1016/j.cell.2004.11.054; Park SG, 2006, IUBMB LIFE, V58, P556, DOI 10.1080/15216540600735974; Park SG, 2005, TRENDS BIOCHEM SCI, V30, P569, DOI 10.1016/j.tibs.2005.08.004; Presta M, 1999, CANCER RES, V59, P2417; Puyraimond A, 1999, J CELL SCI, V112, P1283; Rottinger E, 2004, DEVELOPMENT, V131, P1075, DOI 10.1242/dev.01000; Seburn KL, 2006, NEURON, V51, P715, DOI 10.1016/j.neuron.2006.08.027; Seye CI, 2004, J BIOL CHEM, V279, P35679, DOI 10.1074/jbc.M401799200; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; STRIETER RM, 1995, SHOCK, V4, P155, DOI 10.1097/00024382-199509000-00001; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; Tzima E, 2005, J BIOL CHEM, V280, P2405, DOI 10.1074/jbc.C400431200; Tzima E, 2003, P NATL ACAD SCI USA, V100, P14903, DOI 10.1073/pnas.2436330100; Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; Wakasugi K, 2002, J BIOL CHEM, V277, P20124, DOI 10.1074/jbc.C200126200; Wakasugi K, 2002, P NATL ACAD SCI USA, V99, P173, DOI 10.1073/pnas.012602099; Wakasugi K, 1999, J BIOL CHEM, V274, P23155, DOI 10.1074/jbc.274.33.23155; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Xie W, 2007, P NATL ACAD SCI USA, V104, P9976, DOI 10.1073/pnas.0703908104; Yang XL, 2004, TRENDS BIOCHEM SCI, V29, P250, DOI 10.1016/j.tibs.2004.03.002; YANG XL, 2007, IN PRESS CHEM BIOL	46	48	83	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1597	1605		10.1096/fj.07-9973com	http://dx.doi.org/10.1096/fj.07-9973com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18165356				2022-12-28	WOS:000255898700031
J	Zhou, G; Dada, LA; Chandel, NS; Iwai, K; Lecuona, E; Ciechanover, A; Sznajder, JI				Zhou, Guofei; Dada, Laura A.; Chandel, Navdeep S.; Iwai, Kazuhiro; Lecuona, Emilia; Ciechanover, Aaron; Sznajder, Jacob I.			Hypoxia-mediated Na-K-ATPase degradation requires von Hippel Lindau protein	FASEB JOURNAL			English	Article						hypoxia inducible factor; pVHL	TUMOR-SUPPRESSOR PROTEIN; UBIQUITIN LIGASE; HIF-ALPHA; VHL; IDENTIFICATION; COMPLEX; BINDING; UBIQUITYLATION; HYDROXYLATION; NA,K-ATPASE	Hypoxia inhibits Na-K-ATPase activity and leads to its degradation in mammalian cells. Von Hippel Lindau protein (pVHL) and hypoxia inducible factor (HIF) are key mediators in cellular adaptation to hypoxia; thus, we set out to investigate whether pVHL and HIF participate in the hypoxia-mediated degradation of plasma membrane Na-K-ATPase. We found that in the presence of pVHL hypoxia decreased Na-K-ATPase activity and promoted the degradation of plasma membrane Na-K-ATPase. In pVHL-deficient cells, hypoxia did not decrease the Na-K-ATPase activity and the degradation of plasma membrane Na-K-ATPase was prevented. pVHL-mediated degradation of Na-K-ATPase required the functional pVHL E3 ligase and Ubc5 since pVHL mutants and dominant-negative Ubc5 prevented Na-K-ATPase from degradation. The generation of reactive oxygen species was necessary for pVHL-mediated Na-K-ATPase degradation during hypoxia. Desferrioxamine, which stabilizes HIFI/2 alpha, did not affect the half-fife of plasma membrane Na-K-ATPase. In addition, stabilizing HIF1/2 alpha by infecting mammalian cells with adenoviruses containing the oxygen-dependent degradation domain of HIF1 alpha did not affect the plasma membrane Na-K-ATPase degradation. In cells with suppression of pVHL by short hairpin RNA, the Na-K-ATPase was not degraded during hypoxia, whereas cells with knockdown of HIF1/2 alpha retained the ability to degrade plasma membrane Na-K-ATPase. These findings suggest that pVHL participates in the hypoxia-mediated degradation of plasma membrane Na-K-ATPase in a HIF-independent manner.	[Zhou, Guofei; Dada, Laura A.; Chandel, Navdeep S.; Lecuona, Emilia; Sznajder, Jacob I.] Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care, Chicago, IL 60611 USA; [Iwai, Kazuhiro] Osaka City Univ, Grad Sch Med, Dept Mol Cell Biol, Abeno Ku, Osaka 558, Japan; [Ciechanover, Aaron] Technion Israel Inst Technol, Fac Med, Vasc & Tumor Biol Res Ctr, Haifa, Israel	Northwestern University; Feinberg School of Medicine; Osaka Metropolitan University; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Sznajder, JI (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care, 240 E Huron,McGaw Pavil M-300, Chicago, IL 60611 USA.	i-sznaider@northwestern.edu	Ciechanover, Aaron J/C-9166-2017; IWAI, KAZUHIRO/GSN-7385-2022	Iwai, Kazuhiro/0000-0001-5620-5951	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL071643] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-071643] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bell EL, 2007, J CELL BIOL, V177, P1029, DOI 10.1083/jcb.200609074; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bertorello AM, 1999, AM J PHYSIOL-LUNG C, V276, pL20, DOI 10.1152/ajplung.1999.276.1.L20; Bianchi L, 1999, NUCLEIC ACIDS RES, V27, P4223, DOI 10.1093/nar/27.21.4223; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; Block K, 2007, J BIOL CHEM, V282, P8019, DOI 10.1074/jbc.M611569200; Boutilier RG, 2000, COMP BIOCHEM PHYS A, V126, P481, DOI 10.1016/S1095-6433(00)00234-8; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Comellas AP, 2006, CIRC RES, V98, P1314, DOI 10.1161/01.RES.0000222418.99976.1d; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5; Gonen H, 1999, J BIOL CHEM, V274, P14823, DOI 10.1074/jbc.274.21.14823; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kamura T, 2002, J BIOL CHEM, V277, P30388, DOI 10.1074/jbc.M203344200; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Li ZB, 2002, J BIOL CHEM, V277, P4656, DOI 10.1074/jbc.M108269200; Litvan J, 2006, J BIOL CHEM, V281, P19892, DOI 10.1074/jbc.M602064200; Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Mekhail K, 2006, CELL CYCLE, V5, P2401, DOI 10.4161/cc.5.20.3387; Michiels C, 2004, AM J PATHOL, V164, P1875, DOI 10.1016/S0002-9440(10)63747-9; Na X, 2003, EMBO J, V22, P4249, DOI 10.1093/emboj/cdg410; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Planes C, 1996, AM J PHYSIOL-LUNG C, V271, pL70, DOI 10.1152/ajplung.1996.271.1.L70; Semenza GL, 2006, MOL CELL, V22, P437, DOI 10.1016/j.molcel.2006.05.001; Semenza GL, 2004, J APPL PHYSIOL, V96, P1173, DOI 10.1152/japplphysiol.00770.2003; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Vivona ML, 2001, AM J RESP CELL MOL, V25, P554, DOI 10.1165/ajrcmb.25.5.4420; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Yan Q, 2004, J BIOL CHEM, V279, P43019, DOI 10.1074/jbc.M408018200; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001	41	31	31	3	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1335	1342		10.1096/fj.07-8369com	http://dx.doi.org/10.1096/fj.07-8369com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18073334				2022-12-28	WOS:000255898700007
J	Cho, CH; Parashurama, N; Park, EYH; Suganuma, K; Nahniias, Y; Park, J; Tilles, AW; Berthiaume, F; Yarmush, ML				Cho, Cheul H.; Parashurama, Natesh; Park, Eric Y. H.; Suganuma, Kazuhiro; Nahniias, Yaakov; Park, Jaesung; Tilles, Arno W.; Berthiaume, FranCois; Yarmush, Martin L.			Homogeneous differentiation of hepatocyte-like cells from embryonic stem cells: applications for the treatment of liver failure	FASEB JOURNAL			English	Article						coculture; endoderm; animal model; bioartificial liver device	IN-VITRO DIFFERENTIATION; DEFINITIVE ENDODERM; GROWTH-FACTOR; HEPATIC DIFFERENTIATION; SANDWICH CONFIGURATION; BIOARTIFICIAL LIVER; COLLAGEN SANDWICH; ENDOTHELIAL-CELLS; CONTROLLED-TRIAL; GENE-EXPRESSION	One of the major hurdles of cellular therapies for the treatment of liver failure is the low availability of functional human hepatocytes. While embryonic stem (ES) cells represent a potential cell source for therapy, current methods for differentiation result in mixed cell populations or low yields of the cells of interest. Here we describe a rapid, direct differentiation method that yields a homogeneous population of endoderm-like cells with 95% purity. Mouse ES cells cultured on top of collagen-sandwiched hepatocytes differentiated and proliferated into a uniform and homogeneous cell population of endoderm-like cells. The endoderm-like cell population was positive for Foxa2, Sox17, and AFP and could be further differentiated into hepatocyte-like cells, demonstrating hepatic morphology, functionality, and gene and protein expression. Incorporating the hepatocyte-like cells into a bioartificial liver device to treat fulminant hepatic failure improved animal survival, thereby underscoring the therapeutic potential of these cells.-Cho, C. H., Parashurama, N., Park, E. Y. H., Sugamuna, K, Nahmias, Y., Park, J., Tilles, A. W., Berthiaume, F., Yarmush, M. L. Homogeneous differentiation of hepatocyte-like cells from embryonic stem cells: applications for the treatment of liver failure.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med,Shriners Hosp Children, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Shriners Hosp Children,Dept Surg, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Tilles, AW (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med,Shriners Hosp Children, 51 Blossom St, Boston, MA 02114 USA.	arno-tilles@hms.harvard.edu; ireis@sbi.org	Nahmias, Yaakov/AAM-3872-2020; Berthiaume, Francois/ABD-2139-2020; Nahmias, Yaakov/H-4725-2013	Nahmias, Yaakov/0000-0002-6051-616X; Nahmias, Yaakov/0000-0002-6051-616X; Yarmush, Martin/0000-0003-4986-8444	NIDDK NIH HHS [R01 DK43371, K18 DK076819, P30 DK040561, P30 DK040561-12, K08 DK066040] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K18DK076819, P30DK040561, K08DK066040, R01DK043371] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANG SL, 1993, DEVELOPMENT, V119, P1301; Asahina K, 2004, GENES CELLS, V9, P1297, DOI 10.1111/j.1365-2443.2004.00809.x; Ball EMA, 2001, DEV BIOL, V238, P1, DOI 10.1006/dbio.2001.0399; Berthiaume F, 1996, FASEB J, V10, P1471, DOI 10.1096/fasebj.10.13.8940293; Bhatia SN, 1999, FASEB J, V13, P1883, DOI 10.1096/fasebj.13.14.1883; Cathey JC, 1998, EVOLUTION, V52, P1224, DOI [10.1111/j.1558-5646.1998.tb01850.x, 10.2307/2411253]; Chan C, 2004, LIVER TRANSPLANT, V10, P1331, DOI 10.1002/lt.20229; Chinzei R, 2002, HEPATOLOGY, V36, P22, DOI 10.1053/jhep.2002.34136; D'Amour KA, 2005, NAT BIOTECHNOL, V23, P1534, DOI 10.1038/nbt1163; DEMETRIOU AA, 1986, P NATL ACAD SCI USA, V83, P7475, DOI 10.1073/pnas.83.19.7475; Demetriou AA, 2004, ANN SURG, V239, P660, DOI 10.1097/01.sla.0000124298.74199.e5; DUNN JCY, 1989, FASEB J, V3, P174, DOI 10.1096/fasebj.3.2.2914628; DUNN JCY, 1991, BIOTECHNOL PROGR, V7, P237, DOI 10.1021/bp00009a007; DUNN JCY, 1992, J CELL BIOL, V116, P1043, DOI 10.1083/jcb.116.4.1043; Endo D, 2004, J HEPATOL, V40, P399, DOI 10.1016/j.jhep.2003.11.019; Fair JH, 2005, P NATL ACAD SCI USA, V102, P2958, DOI 10.1073/pnas.0409840102; FONTAINE M, 1995, J PEDIATR SURG, V30, P56, DOI 10.1016/0022-3468(95)90610-X; Fox IJ, 1998, NEW ENGL J MED, V338, P1422, DOI 10.1056/NEJM199805143382004; GRESSNER AM, 1993, LIVER, V13, P86; Hamazaki T, 2001, FEBS LETT, V497, P15, DOI 10.1016/S0014-5793(01)02423-1; Henderson JM, 2004, ANN SURG, V239, P667; Hisatomi Y, 2004, HEPATOLOGY, V39, P667, DOI 10.1002/hep.20063; Imamura T, 2004, TISSUE ENG, V10, P1716, DOI 10.1089/ten.2004.10.1716; Ishii T, 2005, EXP CELL RES, V309, P68, DOI 10.1016/j.yexcr.2005.05.028; Jang YY, 2004, NAT CELL BIOL, V6, P532, DOI 10.1038/ncb1132; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Jones EA, 2002, EXP CELL RES, V272, P15, DOI 10.1006/excr.2001.5396; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Kubo A, 2004, DEVELOPMENT, V131, P1651, DOI 10.1242/dev.01044; Lange C, 2005, WORLD J GASTROENTERO, V11, P4497, DOI 10.3748/wjg.v11.i29.4497; Maguire T, 2006, BIOTECHNOL BIOENG, V93, P581, DOI 10.1002/bit.20748; Maguire T, 2007, BIOTECHNOL BIOENG, V98, P631, DOI 10.1002/bit.21435; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Novik EI, 2006, TISSUE ENG, V12, P1515, DOI 10.1089/ten.2006.12.1515; Odorico JS, 2001, STEM CELLS, V19, P193, DOI 10.1634/stemcells.19-3-193; Park J, 2007, LAB CHIP, V7, P1018, DOI 10.1039/b704739h; Popovic J R, 2000, Vital Health Stat 13, P1; Rambhatla L, 2003, CELL TRANSPLANT, V12, P1, DOI 10.3727/000000003783985179; SCHMIDTCHEN A, 1990, BIOCHEM J, V265, P289, DOI 10.1042/bj2650289; Schwartz RE, 2002, J CLIN INVEST, V109, P1291, DOI 10.1172/JCI200215182; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Sharma NS, 2006, BIOTECHNOL BIOENG, V94, P1053, DOI 10.1002/bit.20936; Shaw CN, 2003, J MAMMAL, V84, P123, DOI 10.1644/1545-1542(2003)084&lt;0123:ARMMOG&gt;2.0.CO;2; Shirahashi H, 2004, CELL TRANSPLANT, V13, P197, DOI 10.3727/000000004783984016; Shito M, 2003, J SURG RES, V111, P53, DOI 10.1016/S0022-4804(03)00048-9; Skrtic S, 2000, LIVER, V20, P157, DOI 10.1034/j.1600-0676.2000.020002157.x; STORY MT, 1989, IN VITRO CELL DEV B, V25, P402; Strom SC, 1997, TRANSPLANTATION, V63, P559, DOI 10.1097/00007890-199702270-00014; Tada S, 2005, DEVELOPMENT, V132, P4363, DOI 10.1242/dev.02005; Wang X, 2003, P NATL ACAD SCI USA, V100, P11881, DOI 10.1073/pnas.1734199100; Wells JM, 2000, DEVELOPMENT, V127, P1563; Wells JM, 1999, ANNU REV CELL DEV BI, V15, P393, DOI 10.1146/annurev.cellbio.15.1.393; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Yarmush M L, 1992, Cell Transplant, V1, P323; YASUDA H, 1993, J CLIN INVEST, V92, P1491, DOI 10.1172/JCI116727; Zaret K, 1999, DEV BIOL, V209, P1, DOI 10.1006/dbio.1999.9228; Zaret KS, 2002, NAT REV GENET, V3, P499, DOI 10.1038/nrg837; Zaret KS, 2001, CURR OPIN GENET DEV, V11, P568, DOI 10.1016/S0959-437X(00)00234-3; Zhang BM, 1997, J HEPATOL, V26, P1348, DOI 10.1016/S0168-8278(97)80471-0	61	58	62	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					898	909		10.1096/fj.06-7764com	http://dx.doi.org/10.1096/fj.06-7764com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17942827				2022-12-28	WOS:000254143700028
J	Kindt, N; Menzebach, A; Van de Wouwer, MV; Betz, I; De Vriese, A; Conway, EM				Kindt, Nele; Menzebach, Axel; Van de Wouwer, Marlies; Betz, Inge; De Vriese, Astrid; Conway, Edward M.			Protective role of the inhibitor of apoptosis protein, survivin, in toxin-induced acute renal failure	FASEB JOURNAL			English	Article						caspase; cisplatin; kidney; transgenic mice; p53; hydrodynamic gene therapy	TUBULAR EPITHELIAL-CELLS; ISCHEMIA-REPERFUSION INJURY; HEPATOCYTE GROWTH-FACTOR; MOLECULAR-MECHANISMS; TRANSGENIC MICE; UP-REGULATION; DEATH; EXPRESSION; KIDNEY; P53	Acute renal failure (ARF) is a major worldwide cause of morbidity and mortality, lacking specific targeted, effective therapies. Renal tubular cell apoptosis has been recognized to play a critical role in the pathogenesis of ARF, yet few studies have evaluated whether intervention in apoptotic pathways can ameliorate the deterioration in renal function associated with ARF. Using transgenic mice with diminished levels of the inhibitor of apoptosis protein, survivin, we show that survivin is required to protect the kidney from apoptosis, to suppress renal expression of p53, and to ameliorate renal dysfunction in two models of ARF. Gene delivery of survivin to wild-type mice and mice with 50% levels of survivin, prior to or at the time of induction of ARF, interferes with the deterioration of renal function and preserves the integrity of the kidneys and the renal tubular cells by inhibiting activation of apoptotic pathways in the kidneys and suppressing expression of p53. These results encourage further evaluation of survivin, its active structural domains, and other inhibitors of apoptosis proteins, for preventing and/or treating acute renal failure.	[Kindt, Nele; Menzebach, Axel; Van de Wouwer, Marlies; Betz, Inge; De Vriese, Astrid; Conway, Edward M.] Katholieke Univ Leuven VIB, Dept Transgene Technol & Gene Therapy, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven	Conway, EM (corresponding author), Katholieke Univ Leuven VIB, Dept Transgene Technol & Gene Therapy, Ctr Transgene Technol & Gene Therapy, Herestr 49, B-3000 Louvain, Belgium.	ed.conway@med.kuleuven.be		Conway, Edward/0000-0003-0081-0305				Alino SF, 2003, GENE THER, V10, P1672, DOI 10.1038/sj.gt.3302065; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; Beltrami E, 2004, J BIOL CHEM, V279, P2077, DOI 10.1074/jbc.M309479200; Bonegio R, 2002, CURR OPIN NEPHROL HY, V11, P301, DOI 10.1097/00041552-200205000-00006; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Conway EM, 2003, AM J PATHOL, V163, P935, DOI 10.1016/S0002-9440(10)63453-0; Conway EM, 2002, GASTROENTEROLOGY, V123, P619, DOI 10.1053/gast.2002.34753; Daemen MARC, 1999, J CLIN INVEST, V104, P541, DOI 10.1172/JCI6974; Dai CS, 2002, J AM SOC NEPHROL, V13, P411, DOI 10.1681/ASN.V132411; de Vries B, 2003, AM J PATHOL, V163, P47, DOI 10.1016/S0002-9440(10)63629-2; Deng JP, 2001, KIDNEY INT, V60, P2118, DOI 10.1046/j.1523-1755.2001.00043.x; Devarajan P, 2003, MOL GENET METAB, V80, P365, DOI 10.1016/j.ymgme.2003.09.012; Dohi T, 2006, EMBO REP, V7, P438, DOI 10.1038/sj.embor.7400640; Dohi T, 2005, CELL CYCLE, V4, P21, DOI 10.4161/cc.4.1.1367; Evenepoel Pieter, 2004, Best Pract Res Clin Anaesthesiol, V18, P37, DOI 10.1016/j.bpa.2003.09.007; Faubel S, 2004, KIDNEY INT, V66, P2202, DOI 10.1111/j.1523-1755.2004.66010.x; Fiaschi-Taesch NM, 2004, J AM SOC NEPHROL, V15, P112, DOI 10.1097/01.ASN.0000102470.12285.C6; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Ito T, 2000, HEPATOLOGY, V31, P1080, DOI 10.1053/he.2000.6496; Jiang M, 2006, ONCOGENE, V25, P4056, DOI 10.1038/sj.onc.1209440; Justo P, 2006, KIDNEY INT, V70, P1750, DOI 10.1038/sj.ki.5001866; Justo P, 2003, KIDNEY INT, V64, pS52, DOI 10.1046/j.1523-1755.64.s86.10.x; Kaushal GP, 2003, SEMIN NEPHROL, V23, P425, DOI 10.1016/S0270-9295(03)00086-X; Kawai H, 2004, AM J PATHOL, V165, P1603, DOI 10.1016/S0002-9440(10)63417-7; Kelly KJ, 2004, AM J PHYSIOL-RENAL, V287, pF760, DOI 10.1152/ajprenal.00050.2004; Kelly KJ, 2003, J AM SOC NEPHROL, V14, P128, DOI 10.1097/01.ASN.0000040596.23073.01; Kelly KJ, 2001, J CLIN INVEST, V108, P1291, DOI 10.1172/JCI13018; KLINGLER EL, 1980, ARCH PATHOL LAB MED, V104, P87; Li FZ, 2006, J CELL PHYSIOL, V208, P476, DOI 10.1002/jcp.20634; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li SY, 2005, AM J PHYSIOL-RENAL, V289, pF469, DOI 10.1152/ajprenal.00038.2005; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Liu KD, 2003, CRIT CARE MED, V31, pS572, DOI 10.1097/01.CCM.0000081592.36382.BC; Liu MC, 2006, J AM SOC NEPHROL, V17, P765, DOI 10.1681/ASN.2005010102; Nogae S, 1998, J AM SOC NEPHROL, V9, P620; Oberbauer R, 1999, J AM SOC NEPHROL, V10, P2006; Olie RA, 2000, CANCER RES, V60, P2805; Ortiz A, 2000, KIDNEY INT, V57, P969, DOI 10.1046/j.1523-1755.2000.00925.x; Ortiz A., 2002, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V2, P181; Padanilam BJ, 2003, AM J PHYSIOL-RENAL, V284, pF608, DOI 10.1152/ajprenal.00284.2002; Perco P, 2006, EUR J CLIN INVEST, V36, P753, DOI 10.1111/j.1365-2362.2006.01729.x; Sabbatini M, 2004, J AM SOC NEPHROL, V15, P901, DOI 10.1097/01.ASN.0000119573.01290.AE; Santos NAG, 2008, CANCER CHEMOTH PHARM, V61, P145, DOI 10.1007/s00280-007-0459-y; Schwarz C, 2002, LAB INVEST, V82, P941, DOI 10.1097/01.LAB.0000021174.66841.4C; Sheikh-Hamad D, 2004, ARCH TOXICOL, V78, P147, DOI 10.1007/s00204-003-0521-4; Silvester W, 2001, CRIT CARE MED, V29, P1910, DOI 10.1097/00003246-200110000-00010; Tamm I, 1998, CANCER RES, V58, P5315; Tsuruya K, 2003, AM J PHYSIOL-RENAL, V285, pF208, DOI 10.1152/ajprenal.00311.2002; Tsuruya K, 2003, KIDNEY INT, V63, P72, DOI 10.1046/j.1523-1755.2003.00709.x; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Wan B, 2006, EXP MOL PATHOL, V81, P211, DOI 10.1016/j.yexmp.2006.02.005; Wan Li, 2003, Curr Opin Crit Care, V9, P496, DOI 10.1097/00075198-200312000-00006; Wei QQ, 2006, AM J PHYSIOL-RENAL, V290, pF35, DOI 10.1152/ajprenal.00184.2005; Xia CY, 2002, MOL CANCER THER, V1, P687; Xie J, 2007, AM J PHYSIOL-RENAL, V292, pF107, DOI 10.1152/ajprenal.00083.2006	60	36	40	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					510	521		10.1096/fj.07-8882com	http://dx.doi.org/10.1096/fj.07-8882com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17804696				2022-12-28	WOS:000252822600021
J	Rosenzweig, D; Smith, D; Opperdoes, F; Stern, S; Olafson, RW; Zilberstein, D				Rosenzweig, Doron; Smith, Derek; Opperdoes, Fred; Stern, Shay; Olafson, Robert W.; Zilberstein, Dan			Retooling Leishmania metabolism: from sand fly gut to human macrophage	FASEB JOURNAL			English	Article						proteomics; metabolomics; intracellular differentiation; gene expression	AXENIC AMASTIGOTES; ENZYME-ACTIVITIES; GENE-EXPRESSION; MEXICANA; PROMASTIGOTES; PARASITE; DONOVANI; PROTEIN; DIFFERENTIATION; IDENTIFICATION	To survive extremely different environments, intracellular parasites require highly adaptable physiological and metabolic systems. Leishmania donovani extracellular promastigotes reside in a glucose-rich, slightly alkaline environment in the sand fly vector alimentary tract. On entry into human macrophage phagolysosomes, promastigotes differentiate into intracellular amastigotes. These cope with an acidic milieu, where glucose is scarce while amino acids are abundant. Here, we use an axenic differentiation model and a novel high-coverage, comparative proteomic methodology to analyze in detail protein expression changes throughout the differentiation process. The analysis identified and quantified 21% of the parasite proteome across 7 time points during differentiation. The data reveal a delayed increase in gluconeogenesis enzymes, coinciding with a decrease in glycolytic capacity. At the same time, beta-oxidation, amino acid catabolism, tricarboxylic acid cycle, mitochondrial respiration chain, and oxidative phosphorylation capacities are all up-regulated. The results indicate that the differentiating parasite shifts from glucose to fatty acids and amino acids as its main energy source. Furthermore, glycerol and amino acids are used as precursors for sugar synthesis, compensating for lack of exogenous sugars. These changes occur while promastigotes undergo morphological transformation. Our findings provide new insight into changes occurring in single-cell organisms during a developmental process.	[Rosenzweig, Doron; Zilberstein, Dan] Technion Israel Inst Technol, Fac Biol, IL-32000 Haifa, Israel; [Stern, Shay; Olafson, Robert W.] Technion Israel Inst Technol, Fac Chem Engn, Haifa, Israel; [Smith, Derek] Univ Victoria, UVic Proteome Ctr, Victoria, BC V8W 2Y2, Canada; [Opperdoes, Fred] Catholic Univ Louvain, Brussels, Belgium; [Opperdoes, Fred] Christian Duve Inst Cellular Pathol, Trop Dis Res Unit, Brussels, Belgium	Technion Israel Institute of Technology; Technion Israel Institute of Technology; University of Victoria; Universite Catholique Louvain	Zilberstein, D (corresponding author), Technion Israel Inst Technol, Fac Biol, IL-32000 Haifa, Israel.	danz@tx.technion.ac.il	Opperdoes, Frederik R/C-8897-2018; Opperdoes, Fred/N-9922-2019	Opperdoes, Frederik R/0000-0003-1984-3764; Opperdoes, Fred/0000-0003-1984-3764				Akopyants NS, 2004, MOL BIOCHEM PARASIT, V136, P71, DOI 10.1016/j.molbiopara.2004.03.002; Almeida R, 2004, MOL BIOCHEM PARASIT, V136, P87, DOI 10.1016/j.molbiopara.2004.03.004; Barak E, 2005, MOL BIOCHEM PARASIT, V141, P99, DOI 10.1016/j.molbiopara.2005.02.004; BATES PA, 1993, FEMS MICROBIOL LETT, V107, P53, DOI 10.1111/j.1574-6968.1993.tb06003.x; Bente M, 2003, PROTEOMICS, V3, P1811, DOI 10.1002/pmic.200300462; Besteiro S, 2006, J BIOL CHEM, V281, P11384, DOI 10.1074/jbc.M512307200; Besteiro S, 2007, INT J PARASITOL, V37, P1063, DOI 10.1016/j.ijpara.2007.03.008; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; COOMBS GH, 1982, MOL BIOCHEM PARASIT, V5, P199, DOI 10.1016/0166-6851(82)90021-4; Debrabant A, 2004, INT J PARASITOL, V34, P205, DOI 10.1016/j.ijpara.2003.10.011; Dillon RJ, 1997, COMP BIOCHEM PHYS B, V116, P35, DOI 10.1016/S0305-0491(96)00195-2; HART DT, 1982, EXP PARASITOL, V54, P397, DOI 10.1016/0014-4894(82)90049-2; HASSAN HF, 1985, COMP BIOCHEM PHYS B, V81, P1037, DOI 10.1016/0305-0491(85)90110-5; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Holzer TR, 2006, MOL BIOCHEM PARASIT, V146, P198, DOI 10.1016/j.molbiopara.2005.12.009; Hubel A, 1997, MOL CELL BIOL, V17, P5987; HUBEL A, 1995, MOL BIOCHEM PARASIT, V70, P107, DOI 10.1016/0166-6851(95)00012-P; Huynh C, 2006, J EXP MED, V203, P2363, DOI 10.1084/jem.20060559; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; Melanson JE, 2006, PROTEOMICS, V6, P4466, DOI 10.1002/pmic.200600112; MOTTRAM JC, 1985, EXP PARASITOL, V59, P151, DOI 10.1016/0014-4894(85)90067-0; MUKKADA AJ, 1974, J PROTOZOOL, V21, P393, DOI 10.1111/j.1550-7408.1974.tb03676.x; MUKKADA AJ, 1985, SCIENCE, V229, P1099, DOI 10.1126/science.4035350; Naderer T, 2006, P NATL ACAD SCI USA, V103, P5502, DOI 10.1073/pnas.0509196103; Nugent PG, 2004, MOL BIOCHEM PARASIT, V136, P51, DOI 10.1016/j.molbiopara.2004.02.009; Onn I, 2006, J BIOL CHEM, V281, P37468, DOI 10.1074/jbc.M606374200; OPPERDOES FR, 2007, TRENDS PARASITOL; Saar Y, 1998, MOL BIOCHEM PARASIT, V95, P9, DOI 10.1016/S0166-6851(98)00062-0; Saxena A, 2007, MOL BIOCHEM PARASIT, V152, P53, DOI 10.1016/j.molbiopara.2006.11.011; Shamir R, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-232; VANSCHAFTINGEN E, 1985, EUR J BIOCHEM, V153, P403, DOI 10.1111/j.1432-1033.1985.tb09316.x; Walker J, 2006, MOL BIOCHEM PARASIT, V147, P64, DOI 10.1016/j.molbiopara.2006.01.008; Wiese M, 1998, EMBO J, V17, P2619, DOI 10.1093/emboj/17.9.2619; Zhang WW, 1996, MOL BIOCHEM PARASIT, V78, P79, DOI 10.1016/S0166-6851(96)02612-6	36	209	209	2	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					590	602		10.1096/fj.07-9254com	http://dx.doi.org/10.1096/fj.07-9254com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17884972				2022-12-28	WOS:000252822600029
J	Skarpen, E; Flinder, LI; Rosseland, CM; Orstavik, S; Wierod, L; Oksvold, MP; Skalhegg, BS; Huitfeldt, HS				Skarpen, Ellen; Flinder, Liv Ingrid; Rosseland, Carola Maria; Orstavik, Sigurd; Wierod, Lene; Oksvold, Morten Pedersen; Skalhegg, Bjorn Steen; Huitfeldt, Henrik Sverre			MEK1 and MEK2 regulate distinct functions by sorting ERK2 to different intracellular compartments	FASEB JOURNAL			English	Article						proliferation; survival; hepatocytes; adhesion	ACTIVATED PROTEIN-KINASE; CROSS-CASCADE ACTIVATION; GROWTH-FACTOR; NUCLEAR TRANSLOCATION; MAP KINASE; FEEDBACK PHOSPHORYLATION; TRANSPORT; COMPLEX; BINDING; RAC	In this study, we provide novel insight into the mechanism of how ERK2 can be sorted to different intracellular compartments and thereby mediate different responses. MEK1-activated ERK2 accumulated in the nucleus and induced proliferation. Conversely, MEK2-activated ERK2 was retained in the cytoplasm and allowed survival. Localization was a determinant for ERK2 functions since MEK1 switched from providing proliferation to be a mediator of survival when ERK2 was routed to the cytoplasm by the attachment of a nuclear export site. MEK1-mediated ERK2 nuclear translocation and proliferation were shown to depend on phosphorylation of S298 and T292 sites in the MEK1 proline-rich domain. These sites are phosphorylated on cellular adhesion in MEK1 but not MEK2. Whereas p21-activated kinase phosphorylates S298 and thus enhances the MEK1-ERK2 association, ERK2 phosphorylates T292, leading to release of active ERK2 from MEK1. On the basis of these results, we propose that the requirement of adhesion for cells to proliferate in response to growth factors, in part, may be explained by the MEK1 S298/T292 control of ERK2 nuclear translocation. In addition, we suggest that ERK2 intracellular localization determines whether growth factors mediate proliferation or survival and that the sorting occurs in an adhesion-dependent manner.	[Skarpen, Ellen; Flinder, Liv Ingrid; Rosseland, Carola Maria; Wierod, Lene; Oksvold, Morten Pedersen; Huitfeldt, Henrik Sverre] Univ Oslo, Rikshosp, Radiumhosp Med Ctr, Inst Pathol,Lab Toxicopathol, N-0027 Oslo, Norway; [Orstavik, Sigurd; Skalhegg, Bjorn Steen] Univ Oslo, Inst Basal Med Sci, Dept Nutr Res, Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo	Skarpen, E (corresponding author), Univ Hosp, Rikshosp, Radiumhosp Med Ctr, Inst Pathol,Lab Toxicopathol, N-0027 Oslo, Norway.	ellen.skarpen@medisin.uio.no	Skålhegg, Bjørn Steen/AAZ-2976-2021	Skålhegg, Bjørn Steen/0000-0002-3481-8084				Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Belanger LF, 2003, MOL CELL BIOL, V23, P4778, DOI 10.1128/MCB.23.14.4778-4787.2003; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Burack WR, 2005, J BIOL CHEM, V280, P3832, DOI 10.1074/jbc.M410031200; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Eblen ST, 2004, MOL CELL BIOL, V24, P2308, DOI 10.1128/MCB.24.6.2308-2317.2004; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Hirsch E, 2002, J CELL BIOL, V157, P481, DOI 10.1083/jcb.200111065; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Rescan C, 2001, MOL BIOL CELL, V12, P725, DOI 10.1091/mbc.12.3.725; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Rosseland CM, 2005, HEPATOLOGY, V42, P200, DOI 10.1002/hep.20762; Skarpen E, 2000, MOL CARCINOGEN, V28, P84, DOI 10.1002/1098-2744(200006)28:2<84::AID-MC4>3.0.CO;2-X; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Ussar S, 2004, J BIOL CHEM, V279, P43861, DOI 10.1074/jbc.M406240200; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029	30	35	35	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					466	476		10.1096/fj.07-8650com	http://dx.doi.org/10.1096/fj.07-8650com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17928366				2022-12-28	WOS:000252822600017
J	Tanaka, K; Sata, M; Natori, T; Kim-Kaneyama, J; Nose, K; Shibanuma, M; Hirata, Y; Nagai, R				Tanaka, Kimie; Sata, Masataka; Natori, Takeshi; Kim-Kaneyama, Joo-ri; Nose, Kiyoshi; Shibanuma, Motoko; Hirata, Yasunobu; Nagai, Ryozo			Circulating progenitor cells contribute to neointimal formation in nonirradiated chimeric mice	FASEB JOURNAL			English	Article						smooth muscle cell; irradiation; stem cells; vascular repair; parabiosis	HEMATOPOIETIC STEM-CELLS; BONE-MARROW-CELLS; SMOOTH-MUSCLE-CELLS; X-RAY-IRRADIATION; VASCULAR INJURY; POTENTIAL CONTRIBUTION; VESSEL WALL; ATHEROSCLEROSIS; RESTENOSIS; DISEASE	Recent evidence suggests that bone marrow-derived cells may contribute to repair and lesion formation following vascular injury. In most studies, bone marrow- derived cells were tracked by transplanting exogenous cells into bone marrow that had been compromised by irradiation. It remains to be determined whether endogenous circulating progenitors actually contribute to arterial remodeling under physiological conditions. Here, we established a parabiotic model in which two mice were conjoined subcutaneously without any vascular anastomosis. When wild-type mice were joined with transgenic mice that expressed green fluorescent protein (GFP) in all tissues, GFP-positive cells were detected not only in the peripheral blood but also in the bone marrow of the wild-type mice. The femoral arteries of the wild-type mice were mechanically injured by insertion of a large wire. At 4 wk, there was neointima hyperplasia that mainly consisted of alpha-smooth muscle actin-positive cells. GFP-positive cells were readily detected in the neointima (14.8 +/- 4.5%) and media (31.1 +/- 8.8%) of the injured artery. Some GFP-positive cells expressed alpha-smooth muscle actin or an endothelial cell marker. These results indicate that circulating progenitors contribute to re-endothelialization and neointimal formation after mechanical vascular injury even in nonirradiated mice.	[Tanaka, Kimie; Sata, Masataka; Hirata, Yasunobu; Nagai, Ryozo] Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Adv Clin Sci & Therapeut, Tokyo 1138655, Japan; [Sata, Masataka; Natori, Takeshi] Univ Tokyo, Grad Sch Med, Dept Surg, Tokyo 1138655, Japan; [Kim-Kaneyama, Joo-ri; Nose, Kiyoshi; Shibanuma, Motoko] Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Tokyo 142, Japan; [Tanaka, Kimie] Japan Hlth Sci Fdn, Tokyo, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Showa University	Sata, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	msata-circ@umin.net						Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Bentzon JF, 2006, ARTERIOSCL THROM VAS, V26, P2696, DOI 10.1161/01.ATV.0000247243.48542.9d; BILLINGHAM ME, 1987, TRANSPLANT P, V19, P19; Caplice NM, 2003, P NATL ACAD SCI USA, V100, P4754, DOI 10.1073/pnas.0730743100; Cheng SWK, 1999, AM J SURG, V178, P323, DOI 10.1016/S0002-9610(99)00184-1; DONSKOY E, 1992, J IMMUNOL, V148, P1604; Frickhofen N, 1996, BONE MARROW TRANSPL, V17, P131; Fukuda D, 2005, CIRCULATION, V111, P926, DOI 10.1161/01.CIR.0000155612.47040.17; Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504; Han CL, 2001, J VASC RES, V38, P113, DOI 10.1159/000051038; Harris RBS, 1997, AM J PHYSIOL-REG I, V272, pR1809; Hoofnagle MH, 2006, ARTERIOSCL THROM VAS, V26, P2579, DOI 10.1161/01.ATV.0000249623.79871.bc; Hoofnagle MH, 2004, J CLIN INVEST, V113, P1249, DOI 10.1172/JCI200421761; Iwata H, 2007, FRONT BIOSCI, V12, P4157, DOI 10.2741/2377; Jabs A, 2005, J VASC RES, V42, P174, DOI 10.1159/000084406; Kearney M, 1997, CIRCULATION, V95, P1998, DOI 10.1161/01.CIR.95.8.1998; KONEFF AA, 1952, ENDOCRINOLOGY, V51, P249, DOI 10.1210/endo-51-3-249; KOSTANECKI W, 1976, ARCH DERMATOL RES, V256, P297, DOI 10.1007/BF00572496; Liu X, 2005, J TRAUMA, V59, P682, DOI 10.1097/01.ta.0000177674.55388.40; McKinney-Freeman S, 2004, EXP HEMATOL, V32, P868, DOI 10.1016/j.exphem.2004.06.010; Mert M, 2003, Z KARDIOL, V92, P682, DOI 10.1007/s00392-003-0943-2; NIH, 1985, NIH PUBL; NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9; Ohtani K, 2004, CIRCULATION, V110, P2444, DOI 10.1161/01.CIR.0000145123.85083.66; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Okada S, 2000, INT IMMUNOL, V12, P861, DOI 10.1093/intimm/12.6.861; ORZAN F, 1993, BRIT HEART J, V69, P496; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sahara M, 2005, STEM CELLS, V23, P874, DOI 10.1634/stemcells.2005-0012; Saiura A, 2001, NAT MED, V7, P382, DOI 10.1038/86394; Sarjeant JM, 2002, CARDIOVASC PATHOL, V11, P263, DOI 10.1016/S1054-8807(02)00125-4; Sata M, 2000, J MOL CELL CARDIOL, V32, P2097, DOI 10.1006/jmcc.2000.1238; Sata M, 2006, ARTERIOSCL THROM VAS, V26, P1008, DOI 10.1161/01.ATV.0000206123.94140.f3; Sata M, 2003, CIRC J, V67, P983, DOI 10.1253/circj.67.983; Sata M, 2003, TRENDS CARDIOVAS MED, V13, P249, DOI 10.1016/S1050-1738(03)00106-3; Sata M, 2003, CIRCULATION, V107, pE106, DOI 10.1161/01.CIR.0000067691.89615.F9; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; Sata M, 1998, P NATL ACAD SCI USA, V95, P1213, DOI 10.1073/pnas.95.3.1213; Schafer K, 2006, ARTERIOSCL THROM VAS, V26, P1254, DOI 10.1161/01.ATV.0000215982.14003.b7; Schober A, 2003, CIRCULATION, V108, P2491, DOI 10.1161/01.CIR.0000099508.76665.9A; Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121; Shoji M, 2004, CARDIOVASC PATHOL, V13, P306, DOI 10.1016/j.carpath.2004.08.004; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; Tanaka K, 2005, J AM COLL CARDIOL, V46, P134, DOI 10.1016/j.jacc.2005.03.058; Tanaka K, 2003, CIRC RES, V93, P783, DOI 10.1161/01.RES.0000096651.13001.B4; Togni M, 2004, CIRCULATION, V110, P135, DOI 10.1161/01.CIR.0000134956.96543.4F; Veinot JP, 1996, HUM PATHOL, V27, P766, DOI 10.1016/S0046-8177(96)90447-5; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081; Yeh ETH, 2004, CIRCULATION, V109, P3122, DOI 10.1161/01.CIR.0000133187.74800.B9; Yoshioka T, 2006, CARDIOVASC RES, V70, P61, DOI 10.1016/j.cardiores.2005.12.013	53	53	54	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					428	436		10.1096/fj.06-6884com	http://dx.doi.org/10.1096/fj.06-6884com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17848623				2022-12-28	WOS:000252822600013
J	Gingis-Velitski, S; Ishai-Michaeli, R; Vlodavsky, I; Ilan, N				Gingis-Velitski, Svetlana; Ishai-Michaeli, Rivka; Vlodavsky, Israel; Ilan, Neta			Anti-heparanase monoclonal antibody enhances heparanase enzymatic activity and facilitates wound healing	FASEB JOURNAL			English	Article						heparan sulfate; cell invasion; cell migration; stimulatory antibody	EPIDERMAL-GROWTH-FACTOR; SULFATE PROTEOGLYCANS; CANCER METASTASIS; FACTOR EXPRESSION; CELL-MIGRATION; KEY ENZYME; TUMOR; ANGIOGENESIS; INHIBITION; IDENTIFICATION	Heparanase is a mammalian endo-beta-D-glucuronidase capable of cleaving HS side chains at a limited number of sites, activity that is strongly implicated in tumor metastasis, neovascularization, inflammation, and autoimmunity. Clinically, up- regulation of heparanase mRNA and protein expression has been documented in a variety of primary human tumors, correlating with reduced postoperative survival and increased lymph node and distant metastasis, thus providing strong clinical support for the prometastatic feature of the enzyme and making it an attractive target for the development of anticancer and anti- inflammatory drugs. Screening a panel of monoclonal antibodies for their ability to inhibit heparanase enzymatic activity, we noted that one hybridoma, 6F8, exhibited the opposite effect and significantly enhanced heparanase activity. Here, we provide evidence that antibody 6F8 enhances the activity of recombinant and cellular heparanase, facilitates invasion of tumor- derived cells in vitro, and improves wound healing in a mouse punch model in vivo. These results support a role of heparanase in the course of wound healing and, moreover, suggest that monoclonal antibodies can be applied clinically for the enhancement, rather than inhibition, of certain enzymes.	Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; Hebrew Univ Jerusalem, Med Ctr, Dept Oncol, IL-91905 Jerusalem, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Hebrew University of Jerusalem	Vlodavsky, I (corresponding author), Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il			NCI NIH HHS [R01-CA106456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albini A, 2007, NAT PROTOC, V2, P504, DOI 10.1038/nprot.2006.466; BARNER M, 1987, BLOOD, V70, P551; Bernard D, 2001, J INVEST DERMATOL, V117, P1266, DOI 10.1046/j.1523-1747.2001.15401.x; Edovitsky E, 2006, BLOOD, V107, P3609, DOI 10.1182/blood-2005-08-3301; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Ferro V, 2004, MINI-REV MED CHEM, V4, P693, DOI 10.2174/1389557043403729; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P44084, DOI 10.1074/jbc.M402131200; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P23536, DOI 10.1074/jbc.M400554200; Goldschmidt O, 2003, FASEB J, V17, P1015, DOI 10.1096/fj.02-0773com; Goldshmidt O, 2004, J PATHOL, V203, P594, DOI 10.1002/path.1554; He XT, 2004, CANCER RES, V64, P3928, DOI 10.1158/0008-5472.CAN-03-2718; Hulett MD, 2000, BIOCHEMISTRY-US, V39, P15659, DOI 10.1021/bi002080p; Ilan N, 2006, INT J BIOCHEM CELL B, V38, P2018, DOI 10.1016/j.biocel.2006.06.004; Kram V, 2006, J CELL PHYSIOL, V207, P784, DOI 10.1002/jcp.20625; Levidiotis V, 2005, NEPHROLOGY, V10, P167, DOI 10.1111/j.1440-1797.2005.00388.x; Levidiotis V, 2001, KIDNEY INT, V60, P1287, DOI 10.1046/j.1523-1755.2001.00934.x; Levy-Adam F, 2005, J BIOL CHEM, V280, P20457, DOI 10.1074/jbc.M414546200; Levy-Adam F, 2003, BIOCHEM BIOPH RES CO, V308, P885, DOI 10.1016/S0006-291X(03)01478-5; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; McKenzie EA, 2007, BRIT J PHARMACOL, V151, P1, DOI 10.1038/sj.bjp.0707182; Miao HQ, 2006, CURR MED CHEM, V13, P2101, DOI 10.2174/092986706777935230; Myler HA, 2006, J BIOCHEM, V139, P339, DOI 10.1093/jb/mvj061; Nadir Y, 2006, J THROMB HAEMOST, V4, P2443, DOI 10.1111/j.1538-7836.2006.02212.x; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; Oliveira S, 2006, EXPERT OPIN BIOL TH, V6, P605, DOI 10.1517/14712598.6.6.605; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; Saijo M, 2003, HISTOCHEM CELL BIOL, V120, P493, DOI 10.1007/s00418-003-0589-1; Sanderson RD, 2005, J CELL BIOCHEM, V96, P897, DOI 10.1002/jcb.20602; Sanderson RD, 2004, MATRIX BIOL, V23, P341, DOI 10.1016/j.matbio.2004.08.004; Sandler A, 2006, CLIN CANCER RES, V12, p4421S, DOI 10.1158/1078-0432.CCR-06-0796; Shafat I, 2006, BIOCHEM BIOPH RES CO, V341, P958, DOI 10.1016/j.bbrc.2006.01.048; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; Vlodavsky I., 1999, PROTOCOLS CELL BIOL, V1; Vlodavsky I, 2006, PATHOPHYSIOL HAEMO T, V35, P116, DOI 10.1159/000093553; Waterman M, 2007, MODERN PATHOL, V20, P8, DOI 10.1038/modpathol.3800710; Zcharia E, 2005, FASEB J, V19, P211, DOI 10.1096/fj.04-1970com; Zetser A, 2006, CANCER RES, V66, P1455, DOI 10.1158/0008-5472.CAN-05-1811; Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068; Zetser A, 2003, CANCER RES, V63, P7733	42	15	17	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3986	3993		10.1096/fj.07-8866com	http://dx.doi.org/10.1096/fj.07-8866com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17628014				2022-12-28	WOS:000251283500023
J	Marneros, AG; She, H; Zambarakji, H; Hashizume, H; Connolly, EJ; Kim, I; Gragoudas, ES; Miller, JW; Olsen, BR				Marneros, Alexander G.; She, Haicheng; Zambarakji, Hadi; Hashizume, Hiroya; Connolly, Edward J.; Kim, Ivana; Gragoudas, Evangelos S.; Miller, Joan W.; Olsen, Bjorn R.			Endogenous endostatin inhibits choroidal neovascularization	FASEB JOURNAL			English	Article						angiogenesis; collagen XVIII; Bruch's membrane; age-related macular degeneration	ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; COLLAGEN-XVIII; MACULAR DEGENERATION; TUMOR-GROWTH; FACTOR VEGF; BASEMENT-MEMBRANE; FACTOR EXPRESSION; KNOBLOCH-SYNDROME; AGE	Endostatin, a fragment of the basement membrane component collagen XVIII, exhibits antiangiogenic properties in vitro and in vivo when high doses are administered. It is not known whether endogenous endostatin at physiological levels has a protective role as an inhibitor of pathological angiogenesis, such as choroidal neovascularization ( CNV) in age- related macular degeneration. Using a laser injury model, we induced CNV in mice lacking collagen XVIII/ endostatin and in control mice. CNV lesions in mutant mice were similar to 3-fold larger than in control mice and showed increased vascular leakage. These differences were independent of age- related changes at the choroid-retina interface. Ultrastructural analysis of the choroidal vasculature in mutant mice excluded morphological vascular abnormalities as a cause for the larger CNV lesions. When recombinant endostatin was administered to collagen XVIII/ endostatin- deficient mice, CNV lesions were similar to those seen in control mice. In control mice treated with recombinant endostatin, CNV lesions were almost undetectable. These findings demonstrate that endogenous endostatin is an inhibitor of induced angiogenesis and that administration of endostatin potently inhibits CNV growth and vascular leakage. Endostatin may have a regulatory role in the pathogenesis of CNV and could be used therapeutically to inhibit growth and leakage of CNV lesions.	Harvard Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA; Harvard Med Sch, Dept Cell Biol, Boston, MA USA; Harvard Med Sch, Massachusetts Eye & Ear Infirm, Angiogenesis Lab & Retina Serv, Boston, MA USA; Niigata Univ, Postgrad Sch Med & Dental Sci, Div Microscop Anatomy & Bioimaging, Niigata, Japan	Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Niigata University	Marneros, AG (corresponding author), Harvard Sch Dent Med, Dept Dev Biol, 188 Longwood Ave, Boston, MA 02115 USA.	alexander_marneros@yahoo.com	Zambarakji, Hadi/AAM-6095-2020	Marneros, Alexander/0000-0003-3866-020X; Kim, Ivana/0000-0003-0310-6129; Miller, Joan/0000-0003-2046-3996	NEI NIH HHS [P30EY14104] Funding Source: Medline; NIAMS NIH HHS [AR36820] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY014104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036820, R01AR036820] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671; Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582; BERNFIELD M, 1984, CIBA F SYMP, V108, P179; Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007; Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862; Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3; Brankin B, 2005, EXP EYE RES, V81, P22, DOI 10.1016/j.exer.2005.01.005; Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655; Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; Ferreras M, 2000, FEBS LETT, V486, P247, DOI 10.1016/S0014-5793(00)02249-3; Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535; Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X; Gogat K, 2004, INVEST OPHTH VIS SCI, V45, P7, DOI 10.1167/iovs.02-1096; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; HOOK M, 1984, CIBA F SYMP, V108, P44; Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7; Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723; Kisker O, 2001, CANCER RES, V61, P7669; Li Q, 2004, AM J PATHOL, V165, P415, DOI 10.1016/S0002-9440(10)63307-X; Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X; Marneros AG, 2005, FASEB J, V19, P716, DOI 10.1096/fj.04-2134rev; Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014; Marneros AG, 2003, INVEST OPHTH VIS SCI, V44, P2367, DOI 10.1167/iovs.02-1180; Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2; Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5; Nicolo M, 2003, AM J OPHTHALMOL, V135, P7, DOI 10.1016/S0002-9394(02)01839-1; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1; Sertie AL, 2000, HUM MOL GENET, V9, P2051, DOI 10.1093/hmg/9.13.2051; Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7; Suzuki OT, 2002, AM J HUM GENET, V71, P1320, DOI 10.1086/344695; Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje; Wang H, 2003, INVEST OPHTH VIS SCI, V44, P2199, DOI 10.1167/iovs.02-0435; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641; Yi XJ, 1998, EXP BRAIN RES, V118, P155, DOI 10.1007/s002210050267	40	54	60	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3809	3818		10.1096/fj.07-8422com	http://dx.doi.org/10.1096/fj.07-8422com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17526870				2022-12-28	WOS:000251283500005
J	Wallace, JL; Dicay, M; McKnight, W; Martin, GR				Wallace, John L.; Dicay, Michael; McKnight, Webb; Martin, Gary R.			Hydrogen sulfide enhances ulcer healing in rats	FASEB JOURNAL			English	Article						resolution; nonsteroidal antiinflammatory drugs; nitric oxide; mucosal defense	K-ATP CHANNELS; NITRIC-OXIDE; GASTROINTESTINAL-TRACT; MUCOSAL LESIONS; GROWTH-FACTOR; STIMULATION; INHIBITION; INJURY; DRUGS; CELLS	Hydrogen sulfide is an endogenous mediator that relaxes vascular smooth muscle, exhibits several antiinflammatory activities, and contributes to gastric mucosal defense. This study was performed to examine the role of hydrogen sulfide in the resolution of injury; specifically, the healing of gastric ulcers. Ulcers were induced in rats by serosal application of acetic acid. This elicited a marked increase in gastric expression of the two key enzymes in hydrogen sulfide synthesis (cystathionine- beta-synthase and cystathionine-gamma- lyase) and in hydrogen sulfide synthesis. Twice-daily treatment for a week with hydrogen sulfide donors significantly increased the extent of healing of gastric ulcers as compared to vehicle-treatment. Similar treatment with L-cysteine, a precursor for hydrogen sulfide, also accelerated healing of the ulcers, and the effect was abolished by cotreatment with an inhibitor of cystathionine-gamma- lyase. The beneficial effects of hydrogen sulfide on ulcer healing were not dependent on nitric oxide synthesis, nor did they appear to occur through activation of ATP-sensitive K+ channels. These results suggest that hydrogen sulfide is produced in the gastric mucosa in response to injury and acts to promote healing. The results further suggest that drugs releasing hydrogen sulfide could be employed to accelerate healing of gastric ulcers, and possibly of other wounds. -Wallace, J. L., Dicay, M., McKnight, W., Martin, G. R. Hydrogen sulfide enhances ulcer healing in rats.	Univ Calgary, Inflammat Res Network, Calgary, AB, Canada	University of Calgary	Wallace, JL (corresponding author), Univ Calgary, Dept Pharm & Therapeut, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	wallacej@ucalgary.ca	Wallace, John/AAL-3763-2021					Abe K, 1996, J NEUROSCI, V16, P1066; Blackstone E, 2005, SCIENCE, V308, P518, DOI 10.1126/science.1108581; BOYD SC, 1981, LIFE SCI, V28, P2987, DOI 10.1016/0024-3205(81)90276-9; BRZOZWSKI T, 1995, DIGESTION, V56, P463, DOI 10.1159/000201277; Distrutti E, 2006, J PHARMACOL EXP THER, V316, P325, DOI 10.1124/jpet.105.091595; ELLIOTT SN, 1995, GASTROENTEROLOGY, V109, P524, DOI 10.1016/0016-5085(95)90341-0; FERREIRA SH, 1991, EUR J PHARMACOL, V201, P121, DOI 10.1016/0014-2999(91)90333-L; Fiorucci S, 2005, GASTROENTEROLOGY, V129, P1210, DOI 10.1053/j.gastro.2005.07.060; Fiorucci S, 2006, GASTROENTEROLOGY, V131, P259, DOI 10.1053/j.gastro.2006.02.033; Goubern M, 2007, FASEB J, V21, P1699, DOI 10.1096/fj.06-7407com; Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878; KONTUREK SJ, 1988, GASTROENTEROLOGY, V94, P1300, DOI 10.1016/0016-5085(88)90667-1; Ma L, 1999, AM J PHYSIOL-GASTR L, V276, pG238, DOI 10.1152/ajpgi.1999.276.1.G238; Ma L, 2000, AM J PHYSIOL-GASTR L, V279, pG341, DOI 10.1152/ajpgi.2000.279.2.G341; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; OKABE S, 1971, AM J DIG DIS, V16, P277, DOI 10.1007/BF02235252; Peura DA, 2004, AM J MED, V117, p63S, DOI 10.1016/j.amjmed.2004.07.010; Qu K, 2006, STROKE, V37, P889, DOI 10.1161/01.STR.0000204184.34946.41; SANDOR Z, 1995, SCAND J GASTROENTERO, V30, P19, DOI 10.3109/00365529509090263; Satoh H, 1997, JPN J PHARMACOL, V73, P59, DOI 10.1254/jjp.73.59; STADLER P, 1991, DIGEST DIS SCI, V36, P594, DOI 10.1007/BF01297025; Tang GH, 2005, MOL PHARMACOL, V68, P1757, DOI 10.1124/mol.105.017467; Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264; WALLACE JL, 1994, EUR J PHARMACOL, V271, P525, DOI 10.1016/0014-2999(94)90814-1; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; Zanardo RCO, 2006, FASEB J, V20, P2118, DOI 10.1096/fj.06-6270fje	26	176	188	3	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4070	4076		10.1096/fj.07-8669com	http://dx.doi.org/10.1096/fj.07-8669com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17634391				2022-12-28	WOS:000251283500031
J	Alikhani-Koupaei, R; Fouladkou, F; Fustier, P; Cenni, B; Sharma, AM; Deter, HC; Frey, BM; Frey, FJ				Alikhani-Koupaei, Rasoul; Fouladkou, Fatemeh; Fustier, Pierre; Cenni, Bruno; Sharma, Arya M.; Deter, Hans-Christian; Frey, Brigitte M.; Frey, Felix J.			Identification of polymorphisms in the human 11beta-hydroxysteroid dehydrogenase type 2 gene promoter: functional characterization and relevance for salt sensitivity	FASEB JOURNAL			English	Article						hypertension; NF1; glucocorticoid receptor; glucocorticoid responsive element; microsatellite	TRANSCRIPTIONAL ACTIVATION; HYPERTENSION; EXPRESSION; RECEPTOR; ELEMENTS; CELLS	Reduced activity of 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) plays a role in essential hypertension and the sensitivity of blood pressure to dietary salt. Nonconservative mutations in the coding region are extremely rare and do not explain the variable 11beta-HSD2 activity. We focused therefore on the 5'-regulatory region and identified and characterized the first promoter polymorphisms. Transfections of variants G-209A and G-126A into SW620 cells reduced promoter activity and affinity for activators nuclear factor 1 ( NF1) and Sp1. Chromatin immunoprecipitation revealed Sp1, NF1, and glucocorticoid receptor (GR) binding to the HSD11B2 promoter. Dexamethasone induced expression of mRNA and activity of HSD11B2. GR and/or NF1 overexpression increased endogenous HSD11B2 mRNA and activity. GR complexes cooperated with NF1 to activate HSD11B2, an effect diminished in the presence of the G-209A variant. When compared to salt-resistant subjects ( 96), salt-sensitive volunteers ( 54) more frequently had the G-209A variant, higher occurrence of alleles A4/A7 of polymorphic microsatellite marker, and higher urinary ratios of cortisol to cortisone metabolites. First, we conclude that the mechanism of glucocorticoid-induced HSD11B2 expression is mainly mediated by cooperation between GR and NF1 on the HSD11B2 promoter and, second, that the newly identified promoter variants reduce activity and cooperation of cognate transcription factors, resulting in diminished HSD11B2 transcription, an effect favoring salt sensitivity.	Univ Hosp Bern, Inselspital, Dept Hypertens & Nephrol, CH-3010 Bern, Switzerland; Univ Hosp Bern, Inst Clin Chem, CH-3010 Bern, Switzerland; McMaster Univ, Hamilton Gen Hosp, Canada Res Chair Cardiovasc Obes Res & Management, Hamilton, ON, Canada; Charite Campus Benjamin Franklin, Dept Psychosomat & Psychotherapy, Berlin, Germany	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; McMaster University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Frey, BM (corresponding author), Univ Hosp Bern, Inselspital, Dept Hypertens & Nephrol, Freiburgstr 15, CH-3010 Bern, Switzerland.	brigitte.frey@dkf.unibe.ch	Deter, Hans-Christian/AAH-4350-2021; Deter, Hans-Christian/ABB-9989-2020	Deter, Hans-Christian/0000-0001-8575-4570; Deter, Hans-Christian/0000-0001-8575-4570; Fustier, Pierre/0000-0003-3220-2582; Cenni, Bruno/0000-0002-8603-2032				Agarwal AK, 2000, ENDOCR RES, V26, P289, DOI 10.3109/07435800009066168; Aittomaki S, 2000, J IMMUNOL, V164, P5689, DOI 10.4049/jimmunol.164.11.5689; ALLAN GF, 1991, J BIOL CHEM, V266, P5905; Brand E, 1999, J HYPERTENS, V17, P1563, DOI 10.1097/00004872-199917110-00009; Carvajal CA, 2005, J HYPERTENS, V23, P71, DOI 10.1097/00004872-200501000-00015; Chaudhry AZ, 1998, J BIOL CHEM, V273, P18538, DOI 10.1074/jbc.273.29.18538; Darnel AD, 1999, J STEROID BIOCHEM, V70, P203, DOI 10.1016/S0960-0760(99)00116-8; DelMonaco M, 1997, J INVEST DERMATOL, V108, P938, DOI 10.1111/1523-1747.ep12295241; Escher G, 1997, J EXP MED, V186, P189, DOI 10.1084/jem.186.2.189; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Hebbar PB, 2003, MOL CELL BIOL, V23, P887, DOI 10.1128/MCB.23.3.887-898.2003; Jain S, 2002, J BIOL CHEM, V277, P36889, DOI 10.1074/jbc.M204732200; Lanz CB, 2001, HYPERTENSION, V37, P160, DOI 10.1161/01.HYP.37.1.160; Liu AG, 2004, J BIOL CHEM, V279, P17449, DOI 10.1074/jbc.M311267200; Luft FC, 2001, DRUG METAB DISPOS, V29, P500; Persu A, 2005, J HYPERTENS, V23, P29, DOI 10.1097/00004872-200501000-00007; Rebuffat A, 2001, NAT BIOTECHNOL, V19, P1155, DOI 10.1038/nbt1201-1155; Schorr U, 2000, J HYPERTENS, V18, P855, DOI 10.1097/00004872-200018070-00006; Sharma AM, 1996, NEPHROL DIAL TRANSPL, V11, P927; Suzuki S, 2003, AM J RESP CRIT CARE, V167, P1244, DOI 10.1164/rccm.200210-1139OC; van Beek JP, 2004, J CLIN ENDOCR METAB, V89, P5614, DOI 10.1210/jc.2004-0113; Williams TA, 2005, KIDNEY INT, V67, P631, DOI 10.1111/j.1523-1755.2005.67119.x	22	40	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3618	3628		10.1096/fj.07-8140com	http://dx.doi.org/10.1096/fj.07-8140com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17551100				2022-12-28	WOS:000250517800024
J	Partridge, J; Carlsen, H; Enesa, K; Chaudhury, H; Zakkar, M; Luong, L; Kinderlerer, A; Johns, M; Blomhoff, R; Mason, JC; Haskard, DO; Evans, PC				Partridge, Jason; Carlsen, Harald; Enesa, Karine; Chaudhury, Hera; Zakkar, Mustafa; Luong, Le; Kinderlerer, Anne; Johns, Mike; Blomhoff, Rune; Mason, Justin C.; Haskard, Dorian O.; Evans, Paul C.			Laminar shear stress acts as a switch to regulate divergent functions of NF-kappa B in endothelial cells	FASEB JOURNAL			English	Article						atherosclerosis; blood flow; proinflammatory activation; cytoprotection	NECROSIS-FACTOR-ALPHA; ADHESION MOLECULE-1 GENE; EXPRESSION; ACTIVATION; APOPTOSIS; PATHWAY; SENSITIVITY; MECHANISM; REGIONS; RABBIT	Regions of the arterial tree exposed to laminar flow, which exerts high shear stress, are protected from inflammation, endothelial cell (EC) death and atherosclerosis. TNF alpha activates NF-kappa B transcription factors, which potentially exert dual functions by inducing both proinflammatory and cytoprotective transcripts. We assessed whether laminar shear stress protects EC by modulating NF-kappa B function. Human umbilical vein EC ( HUVEC) were cultured under shear stress (12 dynes/cm(2) for 16 h) using a parallel-plate flow chamber or were maintained in static conditions. Comparative real-time PCR revealed that preshearing significantly alters transcriptional responses to TNF alpha by enhancing the expression of cytoprotective molecules (Bcl-2, MnSOD, GADD45 beta, A1) and suppressing proinflammatory transcripts (E-selectin, VCAM-1, IL-8). We demonstrated using assays of nuclear localization, NF-kappa B subunit phosphorylation, DNA-binding, and transcriptional activity that NF-kappa B is activated by TNF alpha in presheared HUVEC. Furthermore, a specific inhibitor revealed that NF-kappa B is essential for the induction of cytoprotective transcripts in presheared EC. Finally, we observed that NF-kappa B can be activated in vascular endothelium exposed to laminar shear stress in NF-kappa B-luciferase reporter mice, thus validating our cell culture experiments. We conclude that shear stress primes EC for enhanced NF-alpha B-dependent cytoprotective responsiveness while attenuating proinflammatory activation. Thus modulation of NF-alpha B function may underlie the atheroprotective effects of laminar shear stress.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, BHF Cardiovasc Med Unit, London W12 0NN, England; Univ Oslo, Inst Nutr Res, Oslo, Norway	Imperial College London; University of Oslo	Evans, PC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, BHF Cardiovasc Med Unit, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	paul.evans@imperial.ac.uk		Mason, Justin/0000-0001-7783-1660; Carlsen, Harald/0000-0001-5123-5756				Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; Anrather J, 2005, J BIOL CHEM, V280, P244, DOI 10.1074/jbc.M409344200; Aoudjit F, 1997, CELL GROWTH DIFFER, V8, P335; Campbell J, 2004, J IMMUNOL, V173, P6928, DOI 10.4049/jimmunol.173.11.6928; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; Cheng C, 2005, BLOOD, V106, P3691, DOI 10.1182/blood-2005-06-2326; Chiu JJ, 2004, ARTERIOSCL THROM VAS, V24, P73, DOI 10.1161/01.ATV.0000106321.63667.24; Cunningham KS, 2005, LAB INVEST, V85, P9, DOI 10.1038/labinvest.3700215; Dai GH, 2004, P NATL ACAD SCI USA, V101, P14871, DOI 10.1073/pnas.0406073101; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Dimmeler S, 1996, FEBS LETT, V399, P71, DOI 10.1016/S0014-5793(96)01289-6; Dion C, 2005, INT IMMUNOL, V17, P1257, DOI 10.1093/intimm/dxh302; Duriez PJ, 2000, J BIOL CHEM, V275, P18099, DOI 10.1074/jbc.M908925199; Edelstein LC, 2005, J BIOL CHEM, V280, P11192, DOI 10.1074/jbc.M412997200; Evans PC, 2000, TRANSPLANTATION, V70, P928, DOI 10.1097/00007890-200009270-00010; Foxwell B, 1998, P NATL ACAD SCI USA, V95, P8211, DOI 10.1073/pnas.95.14.8211; FRANGOS JA, 1988, BIOTECHNOL BIOENG, V32, P1053, DOI 10.1002/bit.260320812; Grabowski EF, 2001, ARTERIOSCL THROM VAS, V21, P157, DOI 10.1161/01.ATV.21.1.157; Hajra L, 2000, P NATL ACAD SCI USA, V97, P9052, DOI 10.1073/pnas.97.16.9052; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Huo Y, 2001, ACTA PHYSIOL SCAND, V173, P35, DOI 10.1046/j.1365-201X.2001.00882.x; Iiyama K, 1999, CIRC RES, V85, P199, DOI 10.1161/01.RES.85.2.199; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lin K, 2000, P NATL ACAD SCI USA, V97, P9385, DOI 10.1073/pnas.170282597; Natarajan R, 2001, EXP CELL RES, V266, P203, DOI 10.1006/excr.2001.5218; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; Sasaki CY, 2005, J BIOL CHEM, V280, P34538, DOI 10.1074/jbc.M504943200; SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132; Sheikh S, 2003, BLOOD, V102, P2828, DOI 10.1182/blood-2003-01-0080; Sheikh S, 2005, BRIT J PHARMACOL, V145, P1052, DOI 10.1038/sj.bjp.0706281; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; Spiecker M, 2000, J IMMUNOL, V164, P3316, DOI 10.4049/jimmunol.164.6.3316; Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Yamawaki H, 2003, CIRCULATION, V108, P1619, DOI 10.1161/01.CIR.0000089373.49941.C4; Zhang N, 2005, J BIOL CHEM, V280, P21400, DOI 10.1074/jbc.M411952200; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	42	108	109	2	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3553	3561		10.1096/fj.06-8059com	http://dx.doi.org/10.1096/fj.06-8059com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17557931				2022-12-28	WOS:000250517800018
J	Joshi, MB; Ivanov, D; Philippova, M; Erne, P; Resink, TJ				Joshi, Manjunath B.; Ivanov, Danila; Philippova, Maria; Erne, Paul; Resink, Therese J.			Integrin-linked kinase is an essential mediator for T-cadherin-dependent signaling via Akt and GSK3 beta in endothelial cells	FASEB JOURNAL			English	Article						GPI-anchored protein; signal transduction; active beta-catenin accumulation; proliferation; survival	GLYCOGEN-SYNTHASE KINASE-3-BETA; PROTEIN-KINASE; GROWTH-FACTOR; BETA-CATENIN; EXTRACELLULAR-MATRIX; TUMOR ANGIOGENESIS; PLASMA-MEMBRANE; VASCULAR CELLS; LIPID RAFTS; IN-VITRO	Glycosylphosphatidylinositol-anchored T-cadherin (T-cad) influences several parameters of angiogenesis including endothelial cell (EC) differentiation, migration, proliferation, and survival. This presupposes signal transduction networking via mediatory regulators and molecular adaptors since T-cad lacks transmembrane and cytosolic domains. Here, using pharmacological inhibition of PI3K, adenoviral-mediated T-cad-overexpression, siRNA-mediated T-cad-depletion, and agonistic antibody-mediated ligation, we demonstrate signaling by T-cad through PI3K-Akt-GSK3 beta pathways in EC. T-cad-overexpressing EC exhibited increased levels and nuclear accumulation of active beta-catenin, which was transcriptionally active as shown by increased Lef/ Tcf reporter activity and cyclin D1 levels. Cotransduction of EC with constitutively active GSK3 beta (S9A-GSK3 beta) abrogated the stimulatory effects of T-cad on active beta-catenin accumulation, proliferation, and survival. Integrin-linked kinase (ILK), a membrane proximal upstream regulator of Akt and GSK3 beta, was considered a candidate signaling mediator for T-cad. T-cad was present in anti-ILK immunoprecipitates, and confocal microscopy revealed colocalization of T-cad and ILK within lamellipodia of migrating cells. ILK-siRNA abolished T-cad-dependent effects on (Ser-473)Akt/ (Ser-9)GSK3 beta phosphorylation, active beta-catenin accumulation, and survival. We conclude ILK is an essential mediator for T-cad signaling via Akt and GSK3 beta in EC. This is the first demonstration that ILK can regulate inward signaling by GPI-anchored proteins. Furthermore, ILK-GSK3 beta-dependent modulation of active beta-catenin levels by GPI-anchored T-cad represents a novel mechanism for controlling cellular beta-catenin activity.	Univ Basel Hosp, Cardiovasc Labs, Res Dept, CH-4031 Basel, Switzerland; Luzern Kantonsspital, Div Cardiol, Luzern, Switzerland	University of Basel; Lucerne Cantonal Hospital	Resink, TJ (corresponding author), Univ Basel Hosp, Cardiovasc Labs, Res Dept, Hebelstr 20, CH-4031 Basel, Switzerland.	therese-j.resink@unibas.ch	Joshi, Manjunath B/G-2052-2012; Filippova, Maria/GXH-7313-2022	Joshi, Manjunath/0000-0002-1310-5480; Filippova, Maria/0000-0003-3124-3155				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Cavallaro U, 2006, EXP CELL RES, V312, P659, DOI 10.1016/j.yexcr.2005.09.019; Cavallaro U, 2004, ANN NY ACAD SCI, V1014, P58, DOI 10.1196/annals.1294.006; Cho HJ, 2005, ARTERIOSCL THROM VAS, V25, P1154, DOI 10.1161/01.ATV.0000164312.20008.93; Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Friedrich EB, 2004, MOL CELL BIOL, V24, P8134, DOI 10.1128/MCB.24.18.8134-8144.2004; Gong R, 2006, KIDNEY INT, V69, P1166, DOI 10.1038/sj.ki.5000246; Gonzalez E, 2006, J BIOL CHEM, V281, P3210, DOI 10.1074/jbc.M510434200; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hashimoto M, 2002, J BIOL CHEM, V277, P32985, DOI 10.1074/jbc.M202803200; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Huang JA, 2006, BIOCHEM J, V396, P193, DOI 10.1042/BJ20051772; Ivanov D, 2004, CARDIOVASC RES, V64, P132, DOI 10.1016/j.cardiores.2004.06.010; Ivanov D, 2004, EXP CELL RES, V293, P207, DOI 10.1016/j.yexcr.2003.09.030; Ivanov D, 2001, HISTOCHEM CELL BIOL, V115, P231; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Joshi MB, 2005, FASEB J, V19, P1737, DOI 10.1096/fj.05-3834fje; Kaneko Y, 2004, J CELL SCI, V117, P407, DOI 10.1242/jcs.00871; Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200; Kudrjashova E, 2002, HISTOCHEM CELL BIOL, V118, P281, DOI 10.1007/s00418-002-0463-6; Kuzmenko YS, 1998, FEBS LETT, V434, P183, DOI 10.1016/S0014-5793(98)00977-6; Lee SP, 2006, CIRCULATION, V114, P150, DOI 10.1161/CIRCULATIONAHA.105.595918; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Lucero HA, 2004, ARCH BIOCHEM BIOPHYS, V426, P208, DOI 10.1016/j.abb.2004.03.020; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nho RS, 2005, J BIOL CHEM, V280, P26630, DOI 10.1074/jbc.M411798200; Oloumi A, 2006, ONCOGENE, V25, P7747, DOI 10.1038/sj.onc.1209752; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Philippova M, 2005, FASEB J, V19, P588, DOI 10.1096/fj.04-2430fje; Philippova M, 2003, HISTOCHEM CELL BIOL, V120, P353, DOI 10.1007/s00418-003-0584-6; Philippova M, 2006, ARTERIOSCL THROM VAS, V26, P2222, DOI 10.1161/01.ATV.0000238356.20565.92; Philippova MP, 1998, FEBS LETT, V429, P207, DOI 10.1016/S0014-5793(98)00598-5; Riou P, 2006, FASEB J, V20, P2291, DOI 10.1096/fj.06-6085com; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Salas TR, 2003, J BIOL CHEM, V278, P41338, DOI 10.1074/jbc.M302972200; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Skurk C, 2005, CIRC RES, V96, P308, DOI 10.1161/01.RES.0000156273.30274.f7; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Torres MA, 2000, J CELL BIOL, V149, P1433, DOI 10.1083/jcb.149.7.1433; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; VESTAL DJ, 1992, J CELL BIOL, V119, P451, DOI 10.1083/jcb.119.2.451; Vouret-Craviari V, 2004, J CELL SCI, V117, P4559, DOI 10.1242/jcs.01331; Watanabe M, 2005, BIOL PROCED ONLINE, V7, P41, DOI 10.1251/bpo104; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wyder L, 2000, CANCER RES, V60, P4682; Zajchowski LD, 2002, EUR J BIOCHEM, V269, P737, DOI 10.1046/j.0014-2956.2001.02715.x; Zervas CG, 2002, CURR BIOL, V12, pR350, DOI 10.1016/S0960-9822(02)00856-4; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007	62	49	53	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3083	3095		10.1096/fj.06-7723com	http://dx.doi.org/10.1096/fj.06-7723com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17485554				2022-12-28	WOS:000249781600010
J	Deshpande, DA; Pascual, RM; Wang, SW; Eckman, DM; Riemer, EC; Funk, CD; Penn, RB				Deshpande, Deepak A.; Pascual, Rodolfo M.; Wang, Si-Wei; Eckman, Delrae M.; Riemer, Ellen C.; Funk, Colin D.; Penn, Raymond B.			PKC-dependent regulation of the receptor locus dominates functional consequences of cysteinyl leukotriene type 1 receptor activation	FASEB JOURNAL			English	Article						G protein-coupled receptor; cysteinyl leukotriene; protein kinase C; desensitization; airway smooth muscle	GENE-TARGETED MICE; ANALGESIC TOLERANCE; CYSLT(1) RECEPTOR; KINASE 1; PROTEIN; EXPRESSION; DESENSITIZATION; RESPONSIVENESS; CELLS; SUPERSENSITIVITY	Leukotrienes are important lipid mediators of asthma that contribute to airway inflammation and bronchoconstriction. Critical mechanisms for physiological regulation of the main G protein-coupled receptor ( GPCR) mediating the leukotriene responses in asthma, cysteinyl leukotriene type 1 receptor ( CysLT1R), have not been delineated. Although desensitization of GPCRs is a well-established phenomenon, studies demonstrating its physiological relevance are lacking. Here, we demonstrate that relief of PKC-mediated desensitization of endogenous CysLT1Rs augments multiple LTD4- stimulated cellular functions, with associated increases in intracellular signaling events. In analyses of airway smooth muscle contraction ex vivo, PKC inhibition augmented LTD4- stimulated contraction, and increased phosphoinositide hydrolysis and calcium flux in both murine and human airway smooth muscle cells. Similarly, for human monocytes, PKC inhibition augmented LTD4- stimulated calcium flux and cell migration assessed in transwell chamber experiments and also augmented LTD4- induced production of monocyte chemotactic protein assessed by ELISA. In contrast, PKC inhibition had no effect or slightly attenuated these cell functions and signaling events promoted by other receptor agonists, suggesting that despite antithetical effects on downstream events, desensitization of the CysLT1R is the principal mechanism by which PKC regulates the functional consequences of CysLT1R activation.	Wake Forest Univ, Sch Med, Ctr Human Genom, Winston Salem, NC 27157 USA; Wake Forest Univ, Dept Internal Med, Winston Salem, NC USA; Wake Forest Univ, Ctr Human Genet, Winston Salem, NC USA; Wake Forest Univ, Dept Pathol, Winston Salem, NC USA; Queens Univ, Dept Physiol, Kingston, ON, Canada; Queens Univ, Dept Biochem, Kingston, ON, Canada	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University; Queens University - Canada; Queens University - Canada	Penn, RB (corresponding author), Wake Forest Univ, Sch Med, Ctr Human Genom, Med Ctr Blvd, Winston Salem, NC 27157 USA.	rpenn@wfubmc.edu	Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059755] Funding Source: NIH RePORTER; NIAID NIH HHS [AI059755] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Austen K Frank, 2005, Novartis Found Symp, V271, P166; Beller TC, 2004, P NATL ACAD SCI USA, V101, P3047, DOI 10.1073/pnas.0400235101; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Braz JC, 2004, NAT MED, V10, P248, DOI 10.1038/nm1000; Deshpande DA, 2005, AM J RESP CELL MOL, V32, P149, DOI 10.1165/rcmb.2004-0243OC; Dorn GW, 2002, ANNU REV PHYSIOL, V64, P407, DOI 10.1146/annurev.physiol.64.081501.155903; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; Funk CD, 2005, NAT REV DRUG DISCOV, V4, P664, DOI 10.1038/nrd1796; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; Gainetdinov RR, 2003, NEURON, V38, P291, DOI 10.1016/S0896-6273(03)00192-2; Harnett KM, 2005, AM J PHYSIOL-GASTR L, V288, pG407, DOI 10.1152/ajpgi.00398.2004; HOSEY MM, 1995, LIFE SCI, V56, P951; Ichiyama T, 2005, CLIN EXP ALLERGY, V35, P1214, DOI 10.1111/j.1365-2222.2005.02323.x; Iwata K, 2005, J BIOL CHEM, V280, P2197, DOI 10.1074/jbc.M408834200; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; Loza MJ, 2006, BLOOD, V107, P2052, DOI 10.1182/blood-2005-08-3265; Lynch KR, 1999, NATURE, V399, P789; McLaughlin JP, 2004, J BIOL CHEM, V279, P1810, DOI 10.1074/jbc.M305796200; METTERS KM, 1994, J PHARMACOL EXP THER, V270, P399; Milligan G, 2001, TRENDS PHARMACOL SCI, V22, P513, DOI 10.1016/S0165-6147(00)01801-0; Murphy Stephen, 2005, Cardiol Rev, V13, P3; Naik S, 2005, J BIOL CHEM, V280, P8722, DOI 10.1074/jbc.M413014200; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; PENN RB, 1998, HDB PHYSL, P125; Premont RT, 2005, NEUROMOL MED, V7, P129, DOI 10.1385/NMM:7:1-2:129; Rockman HA, 1998, J BIOL CHEM, V273, P18180, DOI 10.1074/jbc.273.29.18180; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Shenoy S.K., 2005, SCI STKE, V2005, pcm10; Tani Eiichi, 2004, Current Vascular Pharmacology, V2, P13, DOI 10.2174/1570161043476492; Terman GW, 2004, BRIT J PHARMACOL, V141, P55, DOI 10.1038/sj.bjp.0705595; Thivierge M, 2001, J IMMUNOL, V167, P2855, DOI 10.4049/jimmunol.167.5.2855; Thivierge M, 2006, J ALLERGY CLIN IMMUN, V117, P1155, DOI 10.1016/j.jaci.2005.12.1342; von Zastrow M, 2004, NEUROPHARMACOLOGY, V47, P286, DOI 10.1016/j.neuropharm.2004.05.007; Willets JM, 2001, MOL PHARMACOL, V60, P321, DOI 10.1124/mol.60.2.321; Yang GC, 2004, AM J PHYSIOL-LUNG C, V286, pL992, DOI 10.1152/ajplung.00367.2003	37	22	22	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2335	2342		10.1096/fj.06-8060com	http://dx.doi.org/10.1096/fj.06-8060com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17392478				2022-12-28	WOS:000248454400008
J	Yuzuriha, H; Inui, A; Asakawa, A; Ueno, N; Kasuga, M; Meguid, MM; Miyazaki, JI; Ninomiya, M; Herzog, H; Fujimiya, M				Yuzuriha, Hideki; Inui, Akio; Asakawa, Akihiro; Ueno, Naohiko; Kasuga, Masato; Meguid, Michael M.; Miyazaki, Jun-ichi; Ninomiya, Maiko; Herzog, Herbert; Fujimiya, Mineko			Gastrointestinal hormones (anorexigenic peptide YY and orexigenic ghrelin) influence neural tube development	FASEB JOURNAL			English	Article						neural tube defect; transgenic mice; gut hormone	BODY-WEIGHT REGULATION; FOOD-INTAKE; PANCREATIC-POLYPEPTIDE; MICE; EXPRESSION; RECEPTORS; APPETITE; DEFECTS; STOMACH; MOTILIN	Gastrointestinal (GI) hormones play an important role in GI secretion, motility, and eating behaviors. It was recently suggested that GI hormones may have a trophic role in GI tract. Here we demonstrate that two principal GI hormones, anorexigenic peptide YY (PYY) and orexigenic ghrelin, affect neural tube development. Chronic administration into the pregnant mice or transgenic overexpression of PYY led to a neural tube defect (NTD) in the embryos that was blocked by ghrelin. PYY Y1 receptor antagonist prevented the occurrence of NTD induced not only by PYY but also by vitamin A, a well-known teratogen in humans and animals. Y1 receptor deficiency also engendered NTDs, indicating the need to maintain normal Y1 receptor signaling. The present study is the first linking GI hormones to the leading cause of infant mortality and provides a novel insight for neurogenesis in which materno-fetal communication through GI hormones appears to be important.	Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Behav Med, Kagoshima, Japan; Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis, Kobe, Hyogo, Japan; SUNY Upstate Med Univ, Dept Neurosci & Surg, Syracuse, NY USA; Osaka Univ, Grad Sch Med, Dept Physiol Chem & Nutr, Osaka, Japan; Shiga Univ Med Sci, Dept Anat, Otsu, Shiga 52021, Japan; Garvan Inst Med Res, Neurobiol Program, Sydney, NSW, Australia	Kagoshima University; Kobe University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Osaka University; Shiga University of Medical Science; Garvan Institute of Medical Research	Inui, A (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Behav & Internal Med, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.	inui@m.kufm.kagoshima-u.ac.jp	Herzog, Herbert/B-8294-2008; Miyazaki, Jun-ichi/N-1976-2015; Ueno, Naohiko/W-1723-2017	Miyazaki, Jun-ichi/0000-0003-2475-589X; Ueno, Naohiko/0000-0003-2946-1524; , Herbert/0000-0002-1713-1029				ADRIAN TE, 1985, GASTROENTEROLOGY, V89, P494, DOI 10.1016/0016-5085(85)90442-1; Asakawa A, 2001, GASTROENTEROLOGY, V120, P337, DOI 10.1053/gast.2001.22158; Asakawa A, 2003, GUT, V52, P947, DOI 10.1136/gut.52.7.947; Asakawa A, 2003, GASTROENTEROLOGY, V124, P1325, DOI 10.1016/S0016-5085(03)00216-6; Batterham RL, 2002, NATURE, V418, P650, DOI 10.1038/nature00887; Batterham RL, 2003, NEW ENGL J MED, V349, P941, DOI 10.1056/NEJMoa030204; Botto LD, 1999, NEW ENGL J MED, V341, P1509, DOI 10.1056/NEJM199911113412006; Fujimiya M, 1997, HISTOCHEM CELL BIOL, V107, P105, DOI 10.1007/s004180050094; FUJIMIYA M, 1995, PEPTIDES, V16, P939, DOI 10.1016/0196-9781(95)00062-O; Gualillo O, 2001, ENDOCRINOLOGY, V142, P788, DOI 10.1210/en.142.2.788; Harris MJ, 1999, TERATOLOGY, V60, P292, DOI 10.1002/(SICI)1096-9926(199911)60:5<292::AID-TERA10>3.3.CO;2-Y; Hogan B, 1994, MANIPULATING MOUSE E; Inui A, 2000, PHARMACOL REV, V52, P35; Inui A, 2001, NAT REV NEUROSCI, V2, P551, DOI 10.1038/35086018; JAZIN EE, 1993, DEV BRAIN RES, V76, P105, DOI 10.1016/0165-3806(93)90128-W; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Leroux P, 2002, J COMP NEUROL, V442, P35, DOI 10.1002/cne.1420; Michel MC, 1998, PHARMACOL REV, V50, P143; Nakahara K, 2006, ENDOCRINOLOGY, V147, P1333, DOI 10.1210/en.2005-0708; Neary NM, 2004, J CLIN ENDOCR METAB, V89, P2832, DOI 10.1210/jc.2003-031768; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Rindi G, 2002, HISTOCHEM CELL BIOL, V117, P511, DOI 10.1007/s00418-002-0415-1; ROTHMAN KJ, 1995, NEW ENGL J MED, V333, P1369, DOI 10.1056/NEJM199511233332101; Sainsbury A, 2002, P NATL ACAD SCI USA, V99, P8938, DOI 10.1073/pnas.132043299; TATEMOTO K, 1980, NATURE, V285, P417, DOI 10.1038/285417a0; TAYLOR IL, 1989, HDB PHYSL 6, V2, P475; Tomasetto C, 2000, GASTROENTEROLOGY, V119, P395, DOI 10.1053/gast.2000.9371; Ueno N, 1999, GASTROENTEROLOGY, V117, P1427, DOI 10.1016/S0016-5085(99)70293-3; UPCHURCH BH, 1994, DEVELOPMENT, V120, P245; Zhao Q, 1996, NAT GENET, V13, P275, DOI 10.1038/ng0796-275	31	17	32	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					2108	2112		10.1096/fj.06-7621com	http://dx.doi.org/10.1096/fj.06-7621com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17400914				2022-12-28	WOS:000247500300020
J	Gershon, E; Hourvitz, A; Reikhav, S; Maman, E; Dekel, N				Gershon, Eran; Hourvitz, Ariel; Reikhav, Sharon; Maman, Ettie; Dekel, Nava			Low expression of COX-2, reduced cumulus expansion, and impaired ovulation in SULT1E1-deficient mice	FASEB JOURNAL			English	Article						estrogen sulfotransferase; cyclooxygenase-2	HUMAN CHORIONIC-GONADOTROPIN; MESSENGER-RIBONUCLEIC-ACID; ESTROGEN-RECEPTOR-BETA; GENE-EXPRESSION; PREOVULATORY FOLLICLES; GRANULOSA-CELLS; CYTOSOLIC SULFOTRANSFERASES; STEROID SULFOTRANSFERASES; TARGETED DISRUPTION; MENSTRUAL-CYCLE	The SULT1E1-encoded estrogen sulfotransferase ( EST) catalyzes sulfation of estrogen, resulting in its inactivation. Reduced fertility observed in SULT1E1 knockout ( KO) female mice has previously been attributed to the deleterious effect of chronic exposure to high levels of circulating estrogen on placental function. We herein suggest that, in addition to placental dysfunction, this phenotype demonstrates that an excess of estrogen impairs ovulation. The role of SULT1E1 in ovulation is suggested by the substantially low ovulatory response in hCG- treated SULT1E1 KO mice; a similar effect was observed when 17 beta-estradiol was administered to wild-type (WT) females. The normal rate of ovulation in SULT1E1 KO females may be restored by PGE2. Along this line, ovaries of human Chorionic Gonadotropin (hCG)-treated SULT1E1 KO mice expressed low levels of cyclooxygenase-2 (COX- 2) and its downstream TSG6; moreover, their ovaries contained a reduced number of expanded cumuli. Our results demonstrate, for the first time, that estrogen inactivation may allow the expression of COX- 2 and subsequent cumulus expansion, enabling normal ovulation. Our findings may be applied to novel treatments of human ovulatory failure.-Gershon, E., Hourvitz, A., Reikhav, S., Maman, E., Dekel, N. Low expression of COX- 2, reduced cumulus expansion, and impaired ovulation in SULT1E1- deficient mice.	Weizmann Inst Sci, Dept Biol Regulat, IL-76100 Rehovot, Israel; Chaim Sheba Med Ctr, Dept Obstet & Gynecol, In Vitro Fertilizat Unit, Ramat Gan, Israel	Weizmann Institute of Science; Chaim Sheba Medical Center	Dekel, N (corresponding author), Weizmann Inst Sci, Dept Biol Regulat, POB 26, IL-76100 Rehovot, Israel.	nava.dekel@weizmann.ac.il	DEKEL, NAVA/R-8817-2019		NICHD NIH HHS [HD 4276] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS JB, 1991, BIOCHIM BIOPHYS ACTA, V1076, P282, DOI 10.1016/0167-4838(91)90279-9; Breivik K, 2002, SCI TOTAL ENVIRON, V290, P181, DOI 10.1016/S0048-9697(01)01075-0; Brown KA, 2006, ENDOCRINOLOGY, V147, P4222, DOI 10.1210/en.2006-0420; BUIRCHELL BJ, 1975, J STEROID BIOCHEM, V6, P1489, DOI 10.1016/0022-4731(75)90202-2; Coughtrie M. W. H., 2002, Pharmacogenomics Journal, V2, P297; Dallinga JW, 2002, HUM REPROD, V17, P1973, DOI 10.1093/humrep/17.8.1973; Davis BJ, 1999, ENDOCRINOLOGY, V140, P2685, DOI 10.1210/en.140.6.2685; Espey LL, 2000, BIOL REPROD, V62, P390, DOI 10.1095/biolreprod62.2.390; FALANY CN, 1989, BIOCHEM J, V260, P641, DOI 10.1042/bj2600641; Falany CN, 1997, FASEB J, V11, P1; Falany JL, 1996, CANCER RES, V56, P1551; Fisher CR, 1998, P NATL ACAD SCI USA, V95, P6965, DOI 10.1073/pnas.95.12.6965; Fitzpatrick SL, 1999, ENDOCRINOLOGY, V140, P2581, DOI 10.1210/en.140.6.2581; FITZPATRICK SL, 1991, ENDOCRINOLOGY, V129, P1452, DOI 10.1210/endo-129-3-1452; Gaytan F, 2003, BIOL REPROD, V69, P99, DOI 10.1095/biolreprod.102.013755; Hernandez-Gonzalez I, 2006, MOL ENDOCRINOL, V20, P1300, DOI 10.1210/me.2005-0420; Hertrampf T, 2005, MOL CELL ENDOCRINOL, V243, P51, DOI 10.1016/j.mce.2005.08.007; HICKEY GJ, 1988, ENDOCRINOLOGY, V122, P1426, DOI 10.1210/endo-122-4-1426; HOBKIRK R, 1983, BIOCHEM J, V216, P451, DOI 10.1042/bj2160451; HOBKIRK R, 1985, CAN J BIOCHEM CELL B, V63, P1127, DOI 10.1139/o85-141; HORI T, 1970, ENDOCRINOL JAPON, V17, P489; Hourvitz A, 2006, J ENDOCRINOL, V188, P531, DOI 10.1677/joe.1.06231; Jefferson WN, 2000, BIOL REPROD, V62, P310, DOI 10.1095/biolreprod62.2.310; Jo MS, 2004, ENDOCRINOLOGY, V145, P5384, DOI 10.1210/en.2004-0407; KATZ Y, 1976, ENDOCRINOLOGY, V99, P1442, DOI 10.1210/endo-99-6-1442; Kester MHA, 2000, ENDOCRINOLOGY, V141, P1897, DOI 10.1210/en.141.5.1897; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Luu-The V, 2005, J STEROID BIOCHEM, V93, P269, DOI 10.1016/j.jsbmb.2005.01.003; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; OEDA T, 1992, MOL ENDOCRINOL, V6, P1216, DOI 10.1210/me.6.8.1216; Qian YM, 1999, ENDOCRINOLOGY, V140, P1048, DOI 10.1210/en.140.3.1048; Qian YM, 2001, ENDOCRINOLOGY, V142, P5342, DOI 10.1210/en.142.12.5342; Richards JS, 2005, MOL CELL ENDOCRINOL, V234, P75, DOI 10.1016/j.mce.2005.01.004; Robker RL, 2000, P NATL ACAD SCI USA, V97, P4689, DOI 10.1073/pnas.080073497; Rosselli M, 2000, HUM REPROD UPDATE, V6, P332, DOI 10.1093/humupd/6.4.332; Rubin GL, 1999, MOL HUM REPROD, V5, P995, DOI 10.1093/molehr/5.11.995; Safe S, 2004, TOXICOLOGY, V205, P3, DOI 10.1016/j.tox.2004.06.032; Schirman-Hildesheim TD, 2005, ENDOCRINOLOGY, V146, P3401, DOI 10.1210/en.2005-0240; SINGER SS, 1976, ENDOCRINOLOGY, V99, P1346, DOI 10.1210/endo-99-5-1346; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SIROIS J, 1994, ENDOCRINOLOGY, V135, P841, DOI 10.1210/en.135.3.841; Song WC, 1997, ENDOCRINOLOGY, V138, P5006, DOI 10.1210/en.138.11.5006; SONG WC, 1995, ENDOCRINOLOGY, V136, P2477, DOI 10.1210/en.136.6.2477; Spano M, 2005, HUM REPROD, V20, P3488, DOI 10.1093/humrep/dei297; Takehara K, 2001, ARCH BIOCHEM BIOPHYS, V394, P201, DOI 10.1006/abbi.2001.2545; Tong MH, 2005, NAT MED, V11, P153, DOI 10.1038/nm1184; Tong MH, 2004, ENDOCRINOLOGY, V145, P2487, DOI 10.1210/en.2003-1237; Tong MH, 2002, ENDOCRINOLOGY, V143, P3144, DOI 10.1210/en.143.8.3144	49	35	35	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1893	1901		10.1096/fj.06-7688com	http://dx.doi.org/10.1096/fj.06-7688com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17341680				2022-12-28	WOS:000246866500030
J	Klinge, L; Laval, S; Keers, S; Haldane, F; Straub, V; Barresi, R; Bushby, K				Klinge, Lars; Laval, Steve; Keers, Sharon; Haldane, Faye; Straub, Volker; Barresi, Rita; Bushby, Kate			From T-tubule to sarcolemma: damage-induced dysferlin translocation in early myogenesis	FASEB JOURNAL			English	Article						membrane repair; muscular dystrophy; T-tubulogenesis	GIRDLE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; MEMBRANE REPAIR; TRANSVERSE TUBULES; MIYOSHI MYOPATHY; SYSTEM FORMATION; CAVEOLIN-3; PROTEIN; CELLS; GENE	The dysferlin gene is mutated in limb-girdle muscular dystrophy type 2B, Miyoshi myopathy, and distal anterior compartment myopathy. In mature skeletal muscle, dysferlin is located predominantly at the sarcolemma, where it plays a role in membrane fusion and repair. To investigate the role of dysferlin during early muscle differentiation, its localization was studied at high resolution in a muscle cell line. This demonstrated that dysferlin is not expressed at the plasmalemma of myotubes but mostly localizes to the T-tubule network. However, dysferlin translocated to the site of injury and toward the plasma membrane in a Ca2+- dependent fashion in response to a newly designed in vitro wounding assay. This reaction was specific to the full-length protein, as heterologously expressed deletion mutants of distinct C2 domains of dysferlin did not show this response. These results shed light on the dynamics of muscle membrane repair and are highly indicative of a specific role of dysferlin in this process in early myogenesis.-Klinge, L., Laval, S., Keers, S., Haldane, F., Straub, V., Barresi, R., Bushby, K. From T- tubule to sarcolemma: damage-induced dysferlin translocation in early myogenesis.	Univ Newcastle Upon Tyne, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England	Newcastle University - UK	Bushby, K (corresponding author), Univ Newcastle Upon Tyne, Inst Human Genet, Int Ctr Life, Ctr Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.	kate.bushby@ncl.ac.uk	Barresi, Rita/AAB-9569-2022	Barresi, Rita/0000-0001-7351-959X; Straub, Volker/0000-0001-9046-3540				Achanzar WE, 1997, J CELL SCI, V110, P1073; Ampong Beryl N, 2005, Acta Myol, V24, P134; Anderson LVB, 2000, NEUROMUSCULAR DISORD, V10, P553, DOI 10.1016/S0960-8966(00)00143-7; Anderson LVB, 1999, HUM MOL GENET, V8, P855, DOI 10.1093/hmg/8.5.855; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; Bushby KMD, 2000, ACTA NEUROL BELG, V100, P142; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Carozzi AJ, 2000, TRAFFIC, V1, P326, DOI 10.1034/j.1600-0854.2000.010406.x; Davis DB, 2002, J BIOL CHEM, V277, P22883, DOI 10.1074/jbc.M201858200; de Luna N, 2006, J BIOL CHEM, V281, P17092, DOI 10.1074/jbc.M601885200; Detrait ER, 2000, J NEUROSCI RES, V62, P566, DOI 10.1002/1097-4547(20001115)62:4<566::AID-JNR11>3.3.CO;2-W; Doherty KR, 2005, DEVELOPMENT, V132, P5565, DOI 10.1242/dev.02155; Doherty KR, 2003, TRENDS MOL MED, V9, P327, DOI 10.1016/S1471-4914(03)00136-9; Engel A.G., 2004, MYOLOGY; FLUCHER BE, 1993, DEV BIOL, V160, P135, DOI 10.1006/dbio.1993.1292; FLUCHER BE, 1991, DEV BIOL, V145, P77, DOI 10.1016/0012-1606(91)90214-N; Galbiati F, 2001, J BIOL CHEM, V276, P21425, DOI 10.1074/jbc.M100828200; Hernandez-Deviez DJ, 2006, HUM MOL GENET, V15, P129, DOI 10.1093/hmg/ddi434; HUANG Y, 2006, FASEB J; Huang YC, 2005, EUR J HUM GENET, V13, P721, DOI 10.1038/sj.ejhg.5201414; Illa I, 2001, ANN NEUROL, V49, P130, DOI 10.1002/1531-8249(200101)49:1<130::AID-ANA22>3.0.CO;2-0; ISHIKAWA H, 1968, J CELL BIOL, V38, P51, DOI 10.1083/jcb.38.1.51; Laval SH, 2004, NEUROPATH APPL NEURO, V30, P91, DOI 10.1111/j.1365-2990.2004.00555.x; Lee EY, 2002, SCIENCE, V297, P1193, DOI 10.1126/science.1071362; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Lennon NJ, 2003, J BIOL CHEM, V278, P50466, DOI 10.1074/jbc.M307247200; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Matsuda C, 2005, J NEUROPATH EXP NEUR, V64, P334, DOI 10.1093/jnen/64.4.334; Matsuda C, 2001, HUM MOL GENET, V10, P1761, DOI 10.1093/hmg/10.17.1761; McNally EM, 1998, HUM MOL GENET, V7, P871, DOI 10.1093/hmg/7.5.871; MCNEIL PL, 1987, J CELL SCI, V88, P669; McNeil PL, 2005, NAT REV MOL CELL BIO, V6, P499, DOI 10.1038/nrm1665; McNeil PL, 2003, ANNU REV CELL DEV BI, V19, P697, DOI 10.1146/annurev.cellbio.19.111301.140101; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; Muller AJ, 2003, MOL CELL BIOL, V23, P4295, DOI 10.1128/MCB.23.12.4295-4306.2003; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; Piccolo F, 2000, ANN NEUROL, V48, P902, DOI 10.1002/1531-8249(200012)48:6<902::AID-ANA11>3.3.CO;2-Q; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; SCHIAFFINO S, 1977, TISSUE CELL, V9, P437, DOI 10.1016/0040-8166(77)90004-0; Selcen D, 2001, NEUROLOGY, V56, P1472, DOI 10.1212/WNL.56.11.1472; Takekura H, 2001, DEV BIOL, V239, P204, DOI 10.1006/dbio.2001.0437; Washington NL, 2006, J CELL SCI, V119, P2552, DOI 10.1242/jcs.02980; Yasuda S, 2005, NATURE, V436, P1025, DOI 10.1038/nature03844; Yasunaga S, 1999, NAT GENET, V21, P363, DOI 10.1038/7693	47	72	73	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2007	21	8					1768	1776		10.1096/fj.06-7659com	http://dx.doi.org/10.1096/fj.06-7659com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17363620				2022-12-28	WOS:000246866500019
J	Hattermann, K; Picard, S; Borgeat, M; Leclerc, P; Pouliot, M; Borgeat, P				Hattermann, Kim; Picard, Serge; Borgeat, Mathieu; Leclerc, Patrick; Pouliot, Marc; Borgeat, Pierre			The toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B-4, prostaglandin E-2 and platelet-activating factor biosynthesis	FASEB JOURNAL			English	Article						PMN; lipid mediators	HUMAN POLYMORPHONUCLEAR LEUKOCYTES; 5-LIPOXYGENASE ENZYME-ACTIVITY; ARACHIDONIC-ACID AVAILABILITY; CYTOSOLIC PHOSPHOLIPASE A(2); COACTOSIN-LIKE PROTEIN; CYCLOOXYGENASE-2 EXPRESSION; CPG DNA; MACROPHAGES; RELEASE; CELLS	Toll-like receptors (TLR) recognize pathogen-associated molecular patterns and play important roles in the innate immune system. While single-stranded viral RNA is the natural ligand of TLR7/TLR8, the imidazoquinoline resiquimod (R-848) is recognized as a potent synthetic agonist of TLR7/ TLR8. We investigated the effects of TLR7/ 8 activation on lipid mediator production in polymorphonuclear leukocytes exposed to R-848. Although R-848 had minimal effects by itself, it strongly enhanced leukotriene B-4 formation on subsequent stimulation by fMLP, platelet-activating factor, and the ionophore A23187. R-848 acted via TLR8 but not TLR7 as shown by the lack of effect of the TLR7-specific ligand imiquimod. Priming with R-848 also resulted in enhanced arachidonic acid release and platelet-activating factor formation following fMLP stimulation, as well as enhanced prostaglandin E-2 synthesis following the addition of arachidonic acid. Western blot analysis demonstrated that R-848 induced the phosphorylation of the cytosolic phospholipase A(2)alpha, promoted 5-lipoxygenase translocation and potently stimulated the expression of the type 2 cyclooxygenase. Bafilomycin A1, an inhibitor of endosomal acidification, efficiently inhibited all R-848-induced effects. These studies demonstrate that TLR8 signaling strongly promotes inflammatory lipid mediator biosynthesis and provide novel insights on innate immune response to viral infections.	CHU Laval, CHUQ Res Ctr, Ctr Rech Rhumatol & Immunol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada	Laval University; Laval University	Borgeat, P (corresponding author), CHU Laval, CHUQ Res Ctr, Ctr Rech Rhumatol & Immunol, 2705 Blvd Laurier,Local T1-49, Quebec City, PQ G1V 4G2, Canada.	pierre.borgeat@crchul.ulaval.ca	Pouliot, Marc/G-4103-2016	Pouliot, Marc/0000-0002-2466-5424				Behera AK, 1998, BIOCHEM BIOPH RES CO, V251, P704, DOI 10.1006/bbrc.1998.9537; BENGTSSON T, 1991, J LEUKOCYTE BIOL, V49, P236, DOI 10.1002/jlb.49.3.236; BORGEAT P, 1990, METHOD ENZYMOL, V187, P98; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Cadieux JS, 2005, J CELL SCI, V118, P1437, DOI 10.1242/jcs.01737; Chang YJ, 2005, J IMMUNOL, V175, P8242, DOI 10.4049/jimmunol.175.12.8242; Chen YJ, 2001, INT IMMUNOL, V13, P1013, DOI 10.1093/intimm/13.8.1013; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; CHRISTMAN BW, 1993, J IMMUNOL, V151, P2096; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; DIPERSIO JF, 1988, J IMMUNOL, V140, P4315; Dockrell DH, 2001, J ANTIMICROB CHEMOTH, V48, P751, DOI 10.1093/jac/48.6.751; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; Fenteany G, 2004, CURR OPIN HEMATOL, V11, P15, DOI 10.1097/00062752-200401000-00004; Fischer L, 2005, BBA-MOL CELL BIOL L, V1736, P109, DOI 10.1016/j.bbalip.2005.07.006; Flamand L, 2004, J INFECT DIS, V189, P2001, DOI 10.1086/386374; Flamand N, 2006, J BIOL CHEM, V281, P129, DOI 10.1074/jbc.M506513200; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Ghosh DK, 2001, INFECT IMMUN, V69, P7703, DOI 10.1128/IAI.69.12.7703-7710.2001; Gorden KB, 2005, J IMMUNOL, V174, P1259, DOI 10.4049/jimmunol.174.3.1259; Gosselin J, 2005, J IMMUNOL, V174, P1587, DOI 10.4049/jimmunol.174.3.1587; Gosselin J, 1997, BLOOD, V89, P2122, DOI 10.1182/blood.V89.6.2122; Harrison KA, 1999, J MASS SPECTROM, V34, P330, DOI 10.1002/(SICI)1096-9888(199904)34:4<330::AID-JMS798>3.0.CO;2-#; Hayashi F, 2003, BLOOD, V102, P2660, DOI 10.1182/blood-2003-04-1078; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Krump E, 1997, J EXP MED, V186, P1401, DOI 10.1084/jem.186.8.1401; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; McCurdy JD, 2003, J IMMUNOL, V170, P1625, DOI 10.4049/jimmunol.170.4.1625; Nagase H, 2003, J IMMUNOL, V171, P3977, DOI 10.4049/jimmunol.171.8.3977; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Nataraj C, 2001, J CLIN INVEST, V108, P1229, DOI 10.1172/JCI13640; NOKTA MA, 1995, VIROLOGY, V208, P590, DOI 10.1006/viro.1995.1190; PALMBLAD J, 1981, BLOOD, V58, P658; Pouliot M, 1998, FASEB J, V12, P1109, DOI 10.1096/fasebj.12.12.1109; Pouliot M, 1996, EUR J BIOCHEM, V238, P250, DOI 10.1111/j.1432-1033.1996.0250q.x; Provost P, 1999, P NATL ACAD SCI USA, V96, P1881, DOI 10.1073/pnas.96.5.1881; Provost P, 2001, J BIOL CHEM, V276, P16520, DOI 10.1074/jbc.M011205200; Qi HY, 2005, J BIOL CHEM, V280, P38969, DOI 10.1074/jbc.M509352200; Radmark O, 2005, BIOCHEM BIOPH RES CO, V338, P102, DOI 10.1016/j.bbrc.2005.08.013; Radsak MP, 2004, J IMMUNOL, V172, P4956, DOI 10.4049/jimmunol.172.8.4956; Rakonjac M, 2006, P NATL ACAD SCI USA, V103, P13150, DOI 10.1073/pnas.0605150103; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Rubin BB, 2005, J BIOL CHEM, V280, P7519, DOI 10.1074/jbc.M407438200; SALARI H, 1985, INFLAMMATION, V9, P127, DOI 10.1007/BF00917585; Schlaepfer E, 2006, J IMMUNOL, V176, P2888, DOI 10.4049/jimmunol.176.5.2888; Serhan CN, 2003, CHEM IMMUNOL, V83, P115; Suram S, 2006, J BIOL CHEM, V281, P5506, DOI 10.1074/jbc.M509824200; SURETTE ME, 1993, J EXP MED, V178, P1347, DOI 10.1084/jem.178.4.1347; Surette ME, 1998, FASEB J, V12, P1521, DOI 10.1096/fasebj.12.14.1521	54	51	54	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1575	1585		10.1096/fj.06-7457com	http://dx.doi.org/10.1096/fj.06-7457com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264163				2022-12-28	WOS:000246117000032
J	Jansen, PL; Kever, M; Rosch, R; Krott, E; Jansen, M; Alfonso-Jaume, A; Dooley, S; Klinge, U; Lovett, DH; Mertens, PR				Jansen, Petra Lynen; Kever, Mona; Rosch, Raphael; Krott, Ellen; Jansen, Marc; Alfonso-Jaume, Alexandra; Dooley, Steven; Klinge, Uwe; Lovett, David H.; Mertens, Peter R.			Polymeric meshes induce zonal regulation of matrix metalloproteinase-2 gene expression by macrophages and fibroblasts	FASEB JOURNAL			English	Article						polymers; wound healing; cell-specific gene regulation; transgene	GLOMERULAR MESANGIAL CELLS; GELATINASE-A TRANSCRIPTION; Y-BOX PROTEIN-1; IV COLLAGENASE; ENHANCER; YB-1; ACTIVATION; MMP-2; INHIBITION; HERNIA	Matrix metalloproteinase-2 (MMP-2) is a key regulator in wound healing that orchestrates tissue remodeling. In the present study the spatial and temporal distribution of MMP-2 gene transcription, protein synthesis, and enzymatic activity were analyzed following polymeric mesh (polyglactin, polypropylene) implantation in transgenic reporter mice harboring MMP-2 regulatory sequences -1686/+423 or -1241/+423. Polymers induced MMP-2 promoter activity in macrophages within the foreign body granuloma via sequences -1686/+423 with concomitantly up-regulated protein synthesis and enzymatic activity. Macrophages distant from mesh filaments exhibited low MMP-2 expression levels. Fibroblasts surrounding mesh material displayed strong MMP-2 gene transcription independent of the included promoter sequences, whereas fibroblasts without close contact to mesh material had low MMP-2 synthesis rates due to silencing activity of sequences -1686/+1241. In vitro studies support a cellular crosstalk concept, as macrophages trans-repressed MMP-2 gene transcription in fibroblasts. The zonal and cell-specific regulation of MMP-2 gene transcription illuminates an intimate cellular crosstalk in foreign body reaction that may provide a new approach for mesh modification.	Univ Hosp, Interdisciplinary Ctr Clin Res BIOMAT, D-52074 Aachen, Germany; Univ Hosp, RWTH Aachen, Dept Surg, Aachen, Germany; William Middleton Mem Univ Wisconsin, Dept Med, Madison, WI USA; Univ Hosp, Dept Med 2, Mannheim, Germany; Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA; Univ Hosp, Dept Nephrol & Clin Immunol, Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; University of Wisconsin System; Ruprecht Karls University Heidelberg; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; RWTH Aachen University; RWTH Aachen University Hospital	Jansen, PL (corresponding author), Univ Hosp, Interdisciplinary Ctr Clin Res BIOMAT, Pauwelsstr 30, D-52074 Aachen, Germany.	plynen@ukaachen.de	Dooley, Steven/T-6491-2018; Mertens, Peter/AAI-7310-2020	Dooley, Steven/0000-0002-4840-6240; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039776, R56DK039776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK039776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGREN MS, 1994, BRIT J DERMATOL, V131, P634, DOI 10.1111/j.1365-2133.1994.tb04974.x; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Baum CL, 2005, DERMATOL SURG, V31, P674; Bellon JM, 2001, ANN SURG, V233, P287, DOI 10.1097/00000658-200102000-00020; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chapman HA, 2004, J CLIN INVEST, V113, P148, DOI 10.1172/JCI200420729; Chellat F, 2005, BIOMATERIALS, V26, P961, DOI 10.1016/j.biomaterials.2004.04.006; Cheng SF, 2002, BIOCHEM J, V366, P807, DOI 10.1042/BJ20020202; Cheng SF, 2003, AM J PATHOL, V162, P1937, DOI 10.1016/S0002-9440(10)64327-1; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; Dooley S, 2006, J BIOL CHEM, V281, P1784, DOI 10.1074/jbc.M510215200; Ecrola LM, 2005, J HEART LUNG TRANSPL, V24, P426, DOI 10.1016/j.healun.2004.01.013; En-Nia A, 2002, BIOCHEM J, V362, P693, DOI 10.1042/0264-6021:3620693; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; Harendza S, 2000, J BIOL CHEM, V275, P19552, DOI 10.1074/jbc.M001322200; Inagaki Y, 2005, GASTROENTEROLOGY, V129, P259, DOI 10.1053/j.gastro.2005.03.088; Ishikawa T, 2005, BRIT J PHARMACOL, V144, P133, DOI 10.1038/sj.bjp.0706054; Jansen PL, 2004, SURGERY, V136, P1, DOI 10.1016/j.surg.2004.01.004; Junge K, 2004, LANGENBECK ARCH SURG, V389, P17, DOI 10.1007/s00423-003-0429-8; Junge K, 2002, WORLD J SURG, V26, P1472, DOI 10.1007/s00268-002-6444-z; Kato T, 2001, FEBS LETT, V508, P187, DOI 10.1016/S0014-5793(01)02897-6; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; Klinge U, 1999, EUR J SURG, V165, P665; Klinge U, 1999, BIOMATERIALS, V20, P613, DOI 10.1016/S0142-9612(98)00211-7; Klinge U, 2001, BIOMATERIALS, V22, P1415, DOI 10.1016/S0142-9612(00)00299-4; Kuzuya Masafumi, 2003, J Atheroscler Thromb, V10, P275; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Lee JG, 2005, P NATL ACAD SCI USA, V102, P16345, DOI 10.1073/pnas.0508085102; Mandal M, 2003, MOL CELL BIOCHEM, V252, P305, DOI 10.1023/A:1025526424637; MARTI HP, 1993, BIOCHEM J, V291, P441, DOI 10.1042/bj2910441; MARTI HP, 1994, AM J PATHOL, V144, P82; Matsumura S, 2005, J CLIN INVEST, V115, P599, DOI 10.1172/JCI200522304; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Turck J, 1996, J BIOL CHEM, V271, P15074, DOI 10.1074/jbc.271.25.15074; Witte MB, 1998, SURGERY, V124, P464, DOI 10.1016/S0039-6060(98)70154-0; Woessner JF, 2002, MOL BIOTECHNOL, V22, P33, DOI 10.1385/MB:22:1:033; Zhu P, 2005, ARTHRITIS RES THER, V7, pR1023, DOI 10.1186/ar1778; ZIATS NP, 1988, BIOMATERIALS, V9, P5, DOI 10.1016/0142-9612(88)90063-4	48	21	22	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1047	1057		10.1096/fj.06-6755com	http://dx.doi.org/10.1096/fj.06-6755com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17215487				2022-12-28	WOS:000245650400009
J	Muller, M; Obeyesekere, M; Mills, GB; Ram, PT				Muller, Melissa; Obeyesekere, Mandri; Mills, Gordon B.; Ram, Prahlad T.			Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R	FASEB JOURNAL			English	Article						computational modeling; proteomics; melanoma	GROWTH-FACTOR; ADJUVANT CHEMOTHERAPY; PHOSPHORYLATION SITES; DEPENDENT ACTIVATION; KINASE ACTIVATION; TYROSINE KINASE; BRAF MUTATIONS; MAP KINASE; CAMP; MELANOMA	Activation of the fibroblast growth factor (FGFR) and melanocyte stimulating hormone (MC1R) receptors stimulates B-Raf and C-Raf isoforms that regulate the dynamics of MAPK1,2 signaling. Network topology motifs in mammalian cells include feed-forward and feedback loops and bifans where signals from two upstream molecules integrate to modulate the activity of two downstream molecules. We computationally modeled and experimentally tested signal processing in the FGFR/MC1R/B-Raf/C-Raf/MAPK1,2 network in human melanoma cells; identifying 7 regulatory loops and a bifan motif. Signaling from FGFR leads to sustained activation of MAPK1,2, whereas signaling from MC1R results in transient activation of MAPK1,2. The dynamics of MAPK activation depends critically on the expression level and connectivity to C-Raf, which is critical for a sustained MAPK1,2 response. A partially incoherent bifan motif with a feedback loop acts as a logic gate to integrate signals and regulate duration of activation of the MAPK signaling cascade. Further reducing a 106-node ordinary differential equations network encompassing the complete network to a 6-node network encompassing rate-limiting processes sustains the feedback loops and the bifan, providing sufficient information to predict biological responses.	[Muller, Melissa; Obeyesekere, Mandri; Mills, Gordon B.; Ram, Prahlad T.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Unit 950, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center	Ram, PT (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Unit 950, 7435 Fannin St, Houston, TX 77054 USA.	pram@mdanderson.org		Ram, Prahlad/0000-0003-4739-3166	NCI NIH HHS [P50 CA093459, P50 CA098258, P30 CA016672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA093459, P50CA098258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alon U, 2003, SCIENCE, V301, P1866, DOI 10.1126/science.1089072; Balan V, 2006, MOL BIOL CELL, V17, P1141, DOI 10.1091/mbc.E04-12-1123; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Bhalla US, 2002, BIOPHYS J, V83, P740, DOI 10.1016/S0006-3495(02)75205-3; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Brummer T, 2003, ONCOGENE, V22, P8823, DOI 10.1038/sj.onc.1207185; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x; Dumaz N, 2003, J BIOL CHEM, V278, P29819, DOI 10.1074/jbc.C300182200; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Gao L, 2006, CANCER RES, V66, P7880, DOI 10.1158/0008-5472.CAN-06-0254; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026; Goydos JS, 2005, J AM COLL SURGEONS, V200, P362, DOI 10.1016/j.jamcollsurg.2004.10.032; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Hornberg JJ, 2004, EUR J BIOCHEM, V271, P3905, DOI 10.1111/j.1432-1033.2004.04327.x; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; Kashtan N, 2005, P NATL ACAD SCI USA, V102, P13773, DOI 10.1073/pnas.0503610102; Landi MT, 2006, SCIENCE, V313, P521, DOI 10.1126/science.1127515; LoRusso PM, 2005, J CLIN ONCOL, V23, P5281, DOI 10.1200/JCO.2005.14.415; Ma'ayan A, 2005, SCIENCE, V309, P1078, DOI 10.1126/science.1108876; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Motzer RJ, 2006, J CLIN ONCOL, V24, P16, DOI 10.1200/JCO.2005.02.2574; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Ratain MJ, 2006, J CLIN ONCOL, V24, P2505, DOI 10.1200/JCO.2005.03.6723; Robubi A, 2005, BIOL CHEM, V386, P1165, DOI 10.1515/BC.2005.133; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Santos SDM, 2007, NAT CELL BIOL, V9, P324, DOI 10.1038/ncb1543; Sasagawa S, 2005, NAT CELL BIOL, V7, P365, DOI 10.1038/ncb1233; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sidovar MF, 2000, J BIOL CHEM, V275, P28688, DOI 10.1074/jbc.M909351199; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Strumberg D, 2005, DRUGS TODAY, V41, P773, DOI 10.1358/dot.2005.41.12.937959; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tsao H, 2000, CANCER RES, V60, P1800; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yamaguchi T, 2004, J BIOL CHEM, V279, P40419, DOI 10.1074/jbc.M405079200	53	19	19	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1393	1403		10.1096/fj.07-9100com	http://dx.doi.org/10.1096/fj.07-9100com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18171696				2022-12-28	WOS:000255898700012
J	Etxeberria, A; Aivar, P; Rodriguez-Alfaro, JA; Alaimo, A; Villace, P; Gomez-Posada, JC; Areso, P; Villarroel, A				Etxeberria, Ainhoa; Aivar, Paloma; Rodriguez-Alfaro, Jose Angel; Alaimo, Alessandro; Villace, Patricia; Gomez-Posada, Juan Camilo; Areso, Pilar; Villarroel, Alvaro			Calmodulin regulates the trafficking of KCNQ2 potassium channels	FASEB JOURNAL			English	Article						channelolpathies; epilepsy; BFNC; Kv7; benign; familial neonatal convulsions	SURFACE EXPRESSION; K+ CHANNELS; I-KS; MECHANISM; SUBUNIT; DETERMINANTS; EXCITABILITY; KCNQ2/KCNQ3; SUPPRESSION; NEUROGRANIN	Voltage-dependent potassium KCNQ2 (Kv7.2) channels play a prominent role in the control of neuronal excitability. These channels must associate with calmodulin to function correctly and, indeed, a mutation (R353G) that impairs this association provokes the onset of a form of human neonatal epilepsy known as benign familial neonatal convulsions (BFNC). We show here that perturbation of calmodulin binding leads to endoplasmic reticulum (ER) retention of KCNQ2, reducing the number of channels that reach the plasma membrane. Interestingly, elevating the expression of calmodulin in the BFNC mutant partially restores the intracellular distribution of the KCNQ channel. In contrast, overexpression of a Ca2+-binding incompetent calmodulin or sequestering of calmodulin promotes the retention of wild-type channels in the ER. Thus, a direct interaction with Ca2+-calmodulin appears to be critical for the correct activity of KCNQ2 potassium channels as it controls the channels' exit from the ER.	[Etxeberria, Ainhoa; Aivar, Paloma; Rodriguez-Alfaro, Jose Angel; Alaimo, Alessandro; Villace, Patricia; Gomez-Posada, Juan Camilo; Villarroel, Alvaro] Univ Basque Country, CSIC, EHU, Unidad Biofis, Leioa 48940, Spain; [Areso, Pilar] Univ Basque Country, UPV EHU, Dept Farmacol, Leioa 48940, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country	Villarroel, A (corresponding author), Univ Basque Country, CSIC, EHU, Unidad Biofis, Barrio Sarriena S-N, Leioa 48940, Spain.	gbxvimua@lg.ehu.es	Messier, Claude/A-2322-2008; Alaimo, Alessandro/C-6334-2016; Villarroel, Alvaro/H-5580-2015	Messier, Claude/0000-0002-4791-1763; Alaimo, Alessandro/0000-0002-5888-6268; 				BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; Chung HJ, 2006, P NATL ACAD SCI USA, V103, P8870, DOI 10.1073/pnas.0603376103; Devaux JJ, 2004, J NEUROSCI, V24, P1236, DOI 10.1523/JNEUROSCI.4512-03.2004; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Etxeberria A, 2004, J NEUROSCI, V24, P9146, DOI 10.1523/JNEUROSCI.3194-04.2004; Gamper N, 2003, J GEN PHYSIOL, V122, P17, DOI 10.1085/jgp.200208783; Ghosh S, 2006, CIRC RES, V98, P1048, DOI 10.1161/01.RES.0000218863.44140.f2; Heusser K, 2005, CURR OPIN NEUROBIOL, V15, P364, DOI 10.1016/j.conb.2005.04.001; Hu H, 2002, J PHYSIOL-LONDON, V545, P783, DOI 10.1113/jphysiol.2002.029249; Jentsch TJ, 2000, NAT REV NEUROSCI, V1, P21, DOI 10.1038/35036198; Joiner WJ, 2001, J BIOL CHEM, V276, P37980; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Lee WS, 2003, J BIOL CHEM, V278, P25940, DOI 10.1074/jbc.M302091200; MANDERS EMM, 1992, J CELL SCI, V103, P857; Martire M, 2004, J NEUROSCI, V24, P592, DOI 10.1523/JNEUROSCI.3143-03.2004; Mori MX, 2004, SCIENCE, V304, P432, DOI 10.1126/science.1093490; Mu YY, 2003, NEURON, V40, P581, DOI 10.1016/S0896-6273(03)00676-7; NeunerJehle M, 1996, BRAIN RES, V733, P149, DOI 10.1016/0006-8993(96)00786-X; Pan ZM, 2006, J NEUROSCI, V26, P2599, DOI 10.1523/JNEUROSCI.4314-05.2006; Peretz A, 2005, MOL PHARMACOL, V67, P1053, DOI 10.1124/mol.104.007112; Peters HC, 2005, NAT NEUROSCI, V8, P51, DOI 10.1038/nn1375; Richards MC, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.013938; Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649; Schroeder BC, 1998, NATURE, V396, P687, DOI 10.1038/25367; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Schwake M, 2006, J NEUROSCI, V26, P3757, DOI 10.1523/JNEUROSCI.5017-05.2006; Schwake M, 2000, J BIOL CHEM, V275, P13343, DOI 10.1074/jbc.275.18.13343; Schwarz JR, 2006, J PHYSIOL-LONDON, V573, P17, DOI 10.1113/jphysiol.2006.106815; Shahidullah M, 2005, P NATL ACAD SCI USA, V102, P16454, DOI 10.1073/pnas.0503966102; Shamgar L, 2006, CIRC RES, V98, P1055, DOI 10.1161/01.RES.0000218979.40770.69; Soldovieri MV, 2006, J BIOL CHEM, V281, P418, DOI 10.1074/jbc.M510980200; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Tran QK, 2003, J BIOL CHEM, V278, P24247, DOI 10.1074/jbc.C300165200; Villace P, 2004, NUCLEIC ACIDS RES, V32, P2411, DOI 10.1093/nar/gkh552; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; Wen H, 2002, J NEUROSCI, V22, P7991, DOI 10.1523/jneurosci.22-18-07991.2002; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Xia ZG, 2005, NAT REV NEUROSCI, V6, P267, DOI 10.1038/nrn1647; Yus-Najera E, 2002, J BIOL CHEM, V277, P28545, DOI 10.1074/jbc.M204130200; Zhabotinsky AM, 2006, J NEUROSCI, V26, P7337, DOI 10.1523/JNEUROSCI.0729-06.2006	40	83	84	2	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1135	1143		10.1096/fj.07-9712com	http://dx.doi.org/10.1096/fj.07-9712com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	17993630				2022-12-28	WOS:000254581000019
J	Roze, E; Betuing, S; Deyts, C; Marcon, E; Brami-Cherrier, K; Pages, C; Humbert, S; Merienne, K; Caboche, J				Roze, Emmanuel; Betuing, Sandrine; Deyts, Carole; Marcon, Estelle; Brami-Cherrier, Karen; Pages, Christiane; Humbert, Sandrine; Merienne, Karine; Caboche, Jocelyne			Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death	FASEB JOURNAL			English	Article						Huntington's disease; polyglutamine; histone modifications; nucleosomal response; c-Fos	SIGNAL-REGULATED KINASE; EARLY GENE INDUCTION; HISTONE H3 PHOSPHORYLATION; DISEASE TRANSGENIC MICE; MOUSE MODEL; STATUS EPILEPTICUS; BRAIN; MSK1; EXPRESSION; NEURONS	Huntington's disease (HD) is a neurodegenerative disorder due to an abnormal polyglutamine expansion in the N-terminal region of huntingtin protein (Exp-Htt). This expansion causes protein aggregation. and neuronal dysfunction and death. Transcriptional dysregulation due to Exp-Htt participates in neuronal death in HD. Here, using the R6/2 transgenic mouse model of HD, we identified a new molecular alteration that could account for gene dysregulation in these mice. Despite a nuclear activation of the mitogen activated protein ldnase/extracellular regulated kinase (ERK) along with Elk-1 and cAMP responsive element binding, two transcription factors involved in c-Fos transcription, we failed to detect any histone H3 phosphorylation, which is expected after nuclear ERK activation. Accordingly, we found in the striatum of these mice a deficiency of mitogen- and stress-activated kinase-1 (MSK-1), a kinase downstream ERR, critically involved in H3 phosphorylation and c-Fos induction. We extended this observation to Exp-Htt-expressing striatal neurons and postmortem brains of HD patients. In vitro, knocking out MSK 1 expression potentiated Exp-Htt induced striatal death. Its overexpression induced H3 phosphorylation and c-Fos expression and totally protected against striatal neurodegeneration induced by Exp-Htt. We propose that MSK 1 deficiency is involved in transcriptional dysregulation and striatal degeneration. Restoration of its expression and activity may be a new therapeutic target in HD.	[Roze, Emmanuel; Betuing, Sandrine; Deyts, Carole; Marcon, Estelle; Pages, Christiane; Caboche, Jocelyne] Univ Paris 06, CNRS, UMR 7102, F-75005 Paris, France; [Roze, Emmanuel] Hop St Antoine, Assitance Publ Hop Paris, Serv Neurol, F-75571 Paris, France; [Brami-Cherrier, Karen] Univ Paris 06, INSERM, UMRS 839, F-75005 Paris, France; [Merienne, Karine] CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, Dept Mol Pathol,U596,UMR 7104, Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Caboche, J (corresponding author), Univ Paris 06, CNRS, UMR 7102, 9 Quai St, F-75005 Paris, France.	jocelyne.caboche@snv.jussieu.fr	Betuing, Sandrine/X-2179-2018; brami-cherrier, karen/I-9263-2014; Humbert, Sandrine/S-2981-2016; Longo, Kenneth A/A-5631-2010; Betuing, Sandrine/F-2967-2013; Betuing, Sandrine/X-1957-2019	brami-cherrier, karen/0000-0002-3009-3821; Merienne, Karine/0000-0003-2549-2315; Humbert, Sandrine/0000-0002-9501-2658				ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; Apostol BL, 2006, HUM MOL GENET, V15, P273, DOI 10.1093/hmg/ddi443; Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Benchoua A, 2006, MOL BIOL CELL, V17, P1652, DOI 10.1091/mbc.E05-07-0607; Brami-Cherrier K, 2002, J NEUROSCI, V22, P8911; Brami-Cherrier K, 2005, J NEUROSCI, V25, P11444, DOI 10.1523/JNEUROSCI.1711-05.2005; Brami-Cherrier K, 2007, J NEUROCHEM, V101, P697, DOI 10.1111/j.1471-4159.2006.04352.x; Charvin D, 2005, P NATL ACAD SCI USA, V102, P12218, DOI 10.1073/pnas.0502698102; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Crosio C, 2000, NAT NEUROSCI, V3, P1241, DOI 10.1038/81767; Crosio C, 2003, J CELL SCI, V116, P4905, DOI 10.1242/jcs.00804; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Drobic B, 2004, CANCER RES, V64, P9076, DOI 10.1158/0008-5472.CAN-04-2369; Ferrante RJ, 2003, J NEUROSCI, V23, P9418; Garcia M, 2002, J NEUROSCI, V22, P2174, DOI 10.1523/JNEUROSCI.22-06-02174.2002; Gardian G, 2005, J BIOL CHEM, V280, P556, DOI 10.1074/jbc.M410210200; Heffron D, 2005, MOL BRAIN RES, V136, P134, DOI 10.1016/j.molbrainres.2005.01.014; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Huang YF, 2002, J NEUROSCI, V22, P8422; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Lievens JC, 2002, MOL CELL NEUROSCI, V20, P638, DOI 10.1006/mcne.2002.1152; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Markou T, 2002, BIOCHEM J, V365, P757, DOI 10.1042/BJ20011828; McCoy CE, 2005, BIOCHEM J, V387, P507, DOI 10.1042/BJ20041501; Obrietan K, 2004, J NEUROSCI, V24, P791, DOI 10.1523/JNEUROSCI.3493-03.2004; Putignano E, 2007, NEURON, V53, P747, DOI 10.1016/j.neuron.2007.02.007; Quinn N, 1998, J NEUROL, V245, P709, DOI 10.1007/s004150050272; Rakhit S, 2005, MOL PHARMACOL, V67, P1158, DOI 10.1124/mol.104.005447; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Ryu H, 2006, P NATL ACAD SCI USA, V103, P19176, DOI 10.1073/pnas.0606373103; Sadri-Vakili G, 2007, HUM MOL GENET, V16, P1293, DOI 10.1093/hmg/ddm078; Sgambato V, 1998, J NEUROSCI, V18, P214; Sgambato V, 1998, J NEUROSCI, V18, P8814; Sng JCG, 2006, EUR J NEUROSCI, V23, P1269, DOI 10.1111/j.1460-9568.2006.04641.x; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Spektor BS, 2002, MOL BRAIN RES, V102, P118, DOI 10.1016/S0169-328X(02)00216-4; Stack EC, 2007, HUM MOL GENET, V16, P1164, DOI 10.1093/hmg/ddm064; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sugars KL, 2003, TRENDS GENET, V19, P233, DOI 10.1016/S0168-9525(03)00074-X; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Tsankova NM, 2004, J NEUROSCI, V24, P5603, DOI 10.1523/JNEUROSCI.0589-04.2004; Valjent E, 2000, J NEUROSCI, V20, P8701; Vanhoutte P, 1999, MOL CELL BIOL, V19, P136; Vanhoutte P, 2001, J BIOL CHEM, V276, P5189, DOI 10.1074/jbc.M006678200; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Vonsattel JPG, 1998, J NEUROPATH EXP NEUR, V57, P369; Yu M, 2003, J PHYSIOL-LONDON, V546, P327, DOI 10.1113/jphysiol.2002.034223; Zhang JH, 2002, NAT GENET, V30, P416, DOI 10.1038/ng859; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199	51	71	77	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2008	22	4					1083	1093		10.1096/fj.07-9814	http://dx.doi.org/10.1096/fj.07-9814			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	18029446				2022-12-28	WOS:000254581000014
J	Maynadier, M; Ramirez, JM; Cathiard, AM; Platet, N; Gras, D; Gleizes, M; Sheikh, MS; Nirde, P; Garcia, M				Maynadier, Marie; Ramirez, Jean-Marie; Cathiard, Ame-Marie; Platet, Nadine; Gras, Delphine; Gleizes, Michel; Sheikh, M. Saeed; Nirde, Philippe; Garcia, Marcel			Unliganded estrogen receptor alpha inhibits breast cancer cell growth through interaction with a cyclin-dependent kinase inhibitor (p21(WAF1))	FASEB JOURNAL			English	Article						cell cycle; steroid; proliferation	TRANSCRIPTIONAL ACTIVITY; PROGESTERONE-RECEPTOR; HORMONE RECEPTORS; DOWN-REGULATION; P53 EXPRESSION; ER-ALPHA; ACTIVATION; CARCINOMA; PROGNOSIS; P21	Estrogens are mitogenic in human breast cancer cells, but the presence of estrogen receptor alpha (ER alpha) is associated with a favorable prognosis in primary tumors and the molecular basis for this paradoxical relationship remains unknown. Here we show that ER alpha and ER alpha mutants devoid of ligand and DNA-binding domains inhibit cell growth in three-dimensional matrix as well as tumor formation in nude mice. Using in vitro and intracellular approaches, we have found that ER alpha, via its amino acids 184-283, interacts with cyclin-dependent kinase inhibitor p21(WAF1). Both proteins exhibit mutual interactions in the absence of estrogens or in the presence of pure antiestrogen ICI182,780, whereas estradiol treatment disrupts their interactions. Cross-linking experiments reveal that these proteins are present in a larger complex of similar to 200 kDa that also contains cdk2 and cyclin E. We further demonstrate that the unliganded full-length ER alpha or the variant having the p21(WAF1) interaction region significantly increases p21(WAF1) expression, whereas ER alpha silencing reduces p21(WAF1) levels and silencing of p21(WAF1) is sufficient to prevent ER alpha-induced growth inhibition. Taken together, our results point to an antiproliferative function of the unliganded ER alpha through its physical interactions with p21(WAF1) that may also explain the favorable prognosis of ER alpha-positive breast cancers.	[Maynadier, Marie; Ramirez, Jean-Marie; Cathiard, Ame-Marie; Platet, Nadine; Gras, Delphine; Nirde, Philippe; Garcia, Marcel] INSERM, U 826, CRLC, F-34298 Montpellier, France; [Maynadier, Marie; Ramirez, Jean-Marie; Cathiard, Ame-Marie; Platet, Nadine; Gras, Delphine; Gleizes, Michel; Nirde, Philippe; Garcia, Marcel] Univ Montpellier I, Montpellier, France; [Sheikh, M. Saeed] SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Garcia, M (corresponding author), INSERM, U 826, CRLC, 208 Rue Apothicaires, F-34298 Montpellier, France.	marcel.garcia@valdorel.fnclcc.fr	Gras, Delphine/A-7062-2017; Gras, Delphine/AAP-7248-2020	Gras, Delphine/0000-0002-6630-2955				Allred DC, 1998, MODERN PATHOL, V11, P155; BERGER U, 1991, CANCER RES, V51, P239; Caffo O, 1996, CLIN CANCER RES, V2, P1591; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; deMedeiros SRB, 1997, J BIOL CHEM, V272, P18250, DOI 10.1074/jbc.272.29.18250; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Erenburg I, 1997, MOL ENDOCRINOL, V11, P2004, DOI 10.1210/me.11.13.2004; FISHER B, 1988, J CLIN ONCOL, V6, P1076, DOI 10.1200/JCO.1988.6.7.1076; Fritah A, 2005, MOL CELL BIOL, V25, P2419, DOI 10.1128/MCB.25.6.2419-2430.2005; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; Glondu M, 2002, ONCOGENE, V21, P5127, DOI 10.1038/sj.onc.1205657; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Gustafsson JA, 1999, J ENDOCRINOL, V163, P379, DOI 10.1677/joe.0.1630379; Hanrahan EO, 2006, J CLIN ONCOL, V24, P2113, DOI 10.1200/JCO.2005.02.8035; HARPER JW, 1993, CELL, V75, P805; HENDERSON BE, 1981, LANCET, V2, P363; Herynk MH, 2004, ENDOCR REV, V25, P869, DOI 10.1210/er.2003-0010; Jiang M, 1997, INT J CANCER, V74, P529, DOI 10.1002/(SICI)1097-0215(19971021)74:5<529::AID-IJC9>3.0.CO;2-5; Karaiskou A, 2001, J BIOL CHEM, V276, P36028, DOI 10.1074/jbc.M104722200; KELSEY JL, 1988, CANCER RES, V48, P5615; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; LIPPMAN M, 1976, CANCER RES, V36, P4595; MADER S, 1993, NUCLEIC ACIDS RES, V21, P1125, DOI 10.1093/nar/21.5.1125; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428; Oh YL, 2001, PATHOL INT, V51, P94, DOI 10.1046/j.1440-1827.2001.01173.x; OSBORNE CK, 1985, CANCER RES, V45, P584; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Platet N, 2000, MOL ENDOCRINOL, V14, P999, DOI 10.1210/me.14.7.999; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Prall OWJ, 2001, J BIOL CHEM, V276, P45433, DOI 10.1074/jbc.M104752200; Sasano H, 1999, ENDOCR-RELAT CANCER, V6, P197, DOI 10.1677/erc.0.0060197; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Sisci D, 2004, ONCOGENE, V23, P8920, DOI 10.1038/sj.onc.1208098; Skildum AJ, 2002, J BIOL CHEM, V277, P5145, DOI 10.1074/jbc.M109179200; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Teyssier C, 2001, J BIOL CHEM, V276, P36361, DOI 10.1074/jbc.M101806200; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	48	19	20	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					671	681		10.1096/fj.07-9322com	http://dx.doi.org/10.1096/fj.07-9322com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17911387				2022-12-28	WOS:000254143700006
J	Brunelli, R; Papi, M; Arcovito, G; Bompiani, A; Castagnola, M; Parasassi, T; Sampaolese, B; Vincenzoni, F; De Spirito, M				Brunelli, Roberto; Papi, Massimiliano; Arcovito, Giuseppe; Bompiani, Adriano; Castagnola, Massimo; Parasassi, Tiziana; Sampaolese, Beatrice; Vincenzoni, Federica; De Spirito, Marco			Globular structure of human ovulatory cervical mucus	FASEB JOURNAL			English	Article						atomic force microscopy; hydrophobicity; MUC5B; recurrence analysis	SCANNING-ELECTRON-MICROSCOPY; GASTRIC MUCIN; SPERM; CYCLE; PH; MICROSTRUCTURES; ULTRASTRUCTURE; AGGREGATION; LIGHT	Human cervical mucus is a heterogeneous mixture of mucin glycoproteins whose relative concentration changes during the ovulatory phases, thereby producing different mucus aggregation structures that can periodically permit the transit of spermatozoa for fertilization. In preovulatory phase, mucus is arranged in compact fiber- like structures where sperm transit is hindered. Previously, through observations made of fixed and dehydrated samples, a permissive structure in the ovulatory phase was attributed to the larger diameters of pores in the mucus network. Instead, by means of atomic force microscopy, we can show, for the first time, that unfixed ovulatory mucus is composed by floating globules of mucin aggregates. This finding sheds new light on the mechanism that governs spermatozoa transit toward the uterine cavity. In addition, we demonstrate that the switch from globular ovulatory to fibrous preovulatory mucus largely depends on a pH- driven mechanism. Analysis of mucin 5B primary sequence, the main mucin in ovulatory mucus, highlights pH- sensitive domains that are associated to flexible regions prone to drive aggregation. We suggest an involvement of these domains in the fiber- to- globule switch in cervical mucus.	Univ Roma La Sapienza, Dipartimento Sci Ginecol Perinatol Puericultura, Rome, Italy; Univ Cattolica Sacro Cuore, Ist Fis, Rome, Italy; Univ Cattolica Sacro Cuore, Fac Med & Chirurg, Ist Biochim & Biochim Clin, Rome, Italy; Ist Sci Int Paolo IV, Rome, Italy; CNR, Inst Chim Riconsimento Mol, Rome, Italy; CNR, Ist Neurobiol Med Mol, Rome, Italy	Sapienza University Rome; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR); Consiglio Nazionale delle Ricerche (CNR)	De Spirito, M (corresponding author), Univ Cattolica Sacro Cuore, Fac Med & Chirurg, Ist Fis, Largo V Vito 1, I-00168 Rome, Italy.	m.despirito@rm.unicatt.it	Papi, Massimiliano/B-3168-2012; SAMPAOLESE, BEATRICE/O-5505-2019; Papi, Massimiliano/AAC-3657-2022; Castagnola, Massimo/AAB-2825-2019; De Spirito, Marco/U-3817-2019; Sampaolese, Beatrice/H-7704-2013; De Spirito, Marco/C-5386-2008; Castagnola, Massimo/AAM-6355-2021	SAMPAOLESE, BEATRICE/0000-0001-7833-1801; Papi, Massimiliano/0000-0002-0029-1309; Castagnola, Massimo/0000-0002-0959-7259; De Spirito, Marco/0000-0003-4260-5107; De Spirito, Marco/0000-0003-4260-5107; Parasassi, Tiziana/0000-0002-9795-0568; Vincenzoni, Federica/0000-0002-0124-2234				Bansil R, 1997, P SOC PHOTO-OPT INS, V2982, P116, DOI 10.1117/12.273605; BHASKAR KR, 1992, NATURE, V360, P458, DOI 10.1038/360458a0; Cao XX, 1999, BIOPHYS J, V76, P1250, DOI 10.1016/S0006-3495(99)77288-7; Ceric F, 2005, J ELECTRON MICROSC, V54, P479, DOI 10.1093/jmicro/dfh106; CHRETIEN FC, 1991, HUM REPROD, V6, P1192, DOI 10.1093/oxfordjournals.humrep.a137511; CHRETIEN FC, 1973, FERTIL STERIL, V24, P746; CHRETIEN FC, 1989, HUM REPROD, V4, P359, DOI 10.1093/oxfordjournals.humrep.a136908; EGGERTKRUSE W, 1993, FERTIL STERIL, V59, P617; Gasteiger E., 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Gipson IK, 1999, BIOL REPROD, V60, P58, DOI 10.1095/biolreprod60.1.58; Gipson IK, 2001, J CLIN ENDOCR METAB, V86, P594, DOI 10.1210/jc.86.2.594; Giuliani A, 2000, BIOPHYS J, V78, P136, DOI 10.1016/S0006-3495(00)76580-5; HONG Z, 2002, AM PHYS SOC ANN APS; Hong ZN, 2005, BIOMACROMOLECULES, V6, P3458, DOI 10.1021/bm0505843; Lagow E, 1999, HUM REPROD UPDATE, V5, P280, DOI 10.1093/humupd/5.4.280; Menarguez M, 2003, HUM REPROD, V18, P1782, DOI 10.1093/humrep/deg382; MOGHISSI KS, 1972, FERTIL STERIL, V23, P295; ODEBLAD E, 1968, ACTA OBSTET GYN SCAN, VS 47, P57, DOI 10.3109/00016346809156845; ODEBLAD E, 1961, ACTA OBSTET GYNEC S2, V45, P127; PAPANICOLAOU GN, 1946, AM J OBSTET GYNECOL, V51, P316, DOI 10.1016/S0002-9378(16)40012-8; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; RYDBERG E, 1948, ACTA OBSTET GYN SCAN, V28, P172; WEBBER CL, 1994, J APPL PHYSIOL, V76, P965, DOI 10.1152/jappl.1994.76.2.965; WOLF DP, 1978, FERTIL STERIL, V30, P163; YUDIN AI, 1989, BIOL REPROD, V40, P661, DOI 10.1095/biolreprod40.3.661; YUREWICZ EC, 1982, J BIOL CHEM, V257, P2314; ZANEVELD LJD, 1975, OBSTET GYNECOL, V46, P419; Zbilut JP, 2003, BIOPHYS J, V85, P3544, DOI 10.1016/S0006-3495(03)74774-2	28	69	73	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2007	21	14					3872	3876		10.1096/fj.07-8189com	http://dx.doi.org/10.1096/fj.07-8189com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17606809				2022-12-28	WOS:000251283500012
J	Voloboueva, LA; Killilea, DW; Atamna, H; Ames, BN				Voloboueva, Ludmila A.; Killilea, David W.; Atamna, Hani; Ames, Bruce N.			N-tert-butyl hydroxylamine, a mitochondrial antioxidant, protects human retinal pigment epithelial cells from iron overload: relevance to macular degeneration	FASEB JOURNAL			English	Article						calcitrol; cognition; depression; nutrition; brain development; cytokine theory	CYTOCHROME-C-OXIDASE; TRANSFERRIN RECEPTOR; OXIDATIVE STRESS; INDUCED APOPTOSIS; FERRITIN; GLUTATHIONE; TOXICITY; DAMAGE; CERULOPLASMIN; ACCUMULATION	Age-related macular degeneration (AMD) is the leading cause of severe visual impairment in the elderly in developed countries. AMD patients have elevated levels of iron within the retinal pigment epithelia (RPE), which may lead to oxidative damage to mitochondria, disruption of retinal metabolism, and vision impairment or loss. As a possible model for iron-induced AMD, we investigated the effects of excess iron in cultured human fetal RPE cells on oxidant levels and mitochondrial cytochrome c oxidase (complex IV) function and tested for protection by N-tert-butyl hydroxylamine (Nt-BHA), a known mitochondrial antioxidant. RPE exposure to ferric ammonium citrate resulted in a time-and dose-dependent increase in intracellular iron, which increased oxidant production and decreased glutathione (GSH) levels and mitochondrial complex IV activity. NtBHA addition to iron-overloaded RPE cells led to a reduction of intracellular iron content, oxidative stress, and partial restoration of complex IV activity and GSH content. NtBHA might be useful in AMD due to its potential to reduce oxidative stress, mitochondrial damage, and age-related iron accumulation, which may damage normal RPE function and lead to loss of vision.-Voloboueva, L. A., Killilea, D. W., Atamna, H., Ames, B. N. N-tert-butyl hydroxylamine, a mitochondrial antioxidant, protects human retinal pigment epithelial cells from iron overload: relevance to macular degeneration.	Childrens Hosp Oakland, Res Inst, Nutr & Metabol Ctr, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Ames, BN (corresponding author), Childrens Hosp Oakland, Res Inst, Nutr & Metabol Ctr, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	bames@chori.org		Killilea, David/0000-0002-8929-6527	NEI NIH HHS [R21 EY016101-01, R21 EY016101-01A1, R01 EY002205-24, R01 EY002205, R21 EY016101, R21 EY016101-02, R37 EY002205, EY02205] Funding Source: Medline; NATIONAL EYE INSTITUTE [R21EY016101, R01EY002205, R37EY002205] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011; Atamna H, 2006, P NATL ACAD SCI USA, V103, P3381, DOI 10.1073/pnas.0600134103; Atamna H, 2000, J BIOL CHEM, V275, P6741, DOI 10.1074/jbc.275.10.6741; Atamna H, 2002, ARCH BIOCHEM BIOPHYS, V397, P345, DOI 10.1006/abbi.2001.2671; Atamna H, 2001, FASEB J, V15, P2196, DOI 10.1096/fj.01-0134com; Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5; Bishop GM, 2001, BRAIN RES, V907, P175, DOI 10.1016/S0006-8993(01)02303-4; Brubacher JL, 2001, J IMMUNOL METHODS, V251, P81, DOI 10.1016/S0022-1759(01)00308-8; Chen HY, 2006, INT J BIOCHEM CELL B, V38, P1402, DOI 10.1016/j.biocel.2006.02.006; Chen JJ, 1998, BBA-GEN SUBJECTS, V1380, P336, DOI 10.1016/S0304-4165(98)00002-6; Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246; DAVIS KJA, 1991, OXIDATIVE DAMAGE REP; De Domenico I, 2006, EMBO J, V25, P5396, DOI 10.1038/sj.emboj.7601409; Dhanasekaran A, 2004, J BIOL CHEM, V279, P37575, DOI 10.1074/jbc.M404003200; DOLY M, 1986, OPHTHALMIC RES, V18, P21, DOI 10.1159/000265409; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029; Dunn LL, 2007, TRENDS CELL BIOL, V17, P93, DOI 10.1016/j.tcb.2006.12.003; Eaton JW, 2002, FREE RADICAL BIO MED, V32, P833, DOI 10.1016/S0891-5849(02)00772-4; Epsztejn S, 1997, ANAL BIOCHEM, V248, P31, DOI 10.1006/abio.1997.2126; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; GARDNER HW, 1989, FREE RADICAL BIO MED, V7, P65, DOI 10.1016/0891-5849(89)90102-0; GREEN WR, 1985, OPHTHALMOLOGY, V92, P615; GUTTERIDGE JMC, 1989, CLIN HAEMATOL, V2, P195; Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101; Hahn P, 2004, MOL VIS, V10, P598; Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099; Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776; Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019; Harvey PT, 2003, GERONTOLOGY, V49, P1, DOI 10.1159/000066507; Henle ES, 1996, J BIOL CHEM, V271, P21177, DOI 10.1074/jbc.271.35.21177; Hoepken HH, 2004, J NEUROCHEM, V88, P1194, DOI 10.1046/j.1471-4159.2003.02236.x; Huang XP, 2006, CHEM-BIOL INTERACT, V163, P68, DOI 10.1016/j.cbi.2006.05.007; HUNT RC, 1992, J CELL PHYSIOL, V152, P102, DOI 10.1002/jcp.1041520114; Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192; Killilea DW, 2003, ANTIOXID REDOX SIGN, V5, P507, DOI 10.1089/152308603770310158; Kim HJ, 2005, REDOX REP, V10, P287, DOI 10.1179/135100005X83662; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; LAKHANPAL V, 1984, OPHTHALMOLOGY, V91, P443; Lee JH, 2004, CARCINOGENESIS, V25, P1435, DOI 10.1093/carcin/bgh139; Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622; Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]; Maurer I, 2000, NEUROBIOL AGING, V21, P455, DOI 10.1016/S0197-4580(00)00112-3; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; MORITA H, 1995, ANN NEUROL, V37, P646, DOI 10.1002/ana.410370515; PARADIES G, 1994, FEBS LETT, V350, P213, DOI 10.1016/0014-5793(94)00763-2; RAPP LM, 1982, PROBLEMS NORMAL GENE, P109; Roca-Santiago H.M., 2006, Arch Soc Esp Oftalmol, V81, P73; Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7; SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448; Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101; TAWARA A, 1986, INVEST OPHTH VIS SCI, V27, P226; VERGARA O, 1989, EXP EYE RES, V49, P1115, DOI 10.1016/S0014-4835(89)80030-2; Voloboueva LA, 2005, INVEST OPHTH VIS SCI, V46, P4302, DOI 10.1167/iovs.04-1098; Walter PB, 2002, P NATL ACAD SCI USA, V99, P2264, DOI 10.1073/pnas.261708798; Wang ZJ, 1998, INVEST OPHTH VIS SCI, V39, P631; Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547; Watts RN, 2006, P NATL ACAD SCI USA, V103, P7670, DOI 10.1073/pnas.0602515103; Wetli HA, 2006, CHEM BIOL, V13, P965, DOI 10.1016/j.chembiol.2006.08.005; Yefimova MG, 2002, INVEST OPHTH VIS SCI, V43, P537; Yefimova MG, 2000, INVEST OPHTH VIS SCI, V41, P2343; [于健 Yu Jian], 2003, [第四军医大学学报, Journal of the Fourth Military Medical University], V24, P805	71	29	29	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4077	4086		10.1096/fj.07-8396com	http://dx.doi.org/10.1096/fj.07-8396com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17656467	Green Accepted			2022-12-28	WOS:000251283500032
J	Koch-Nolte, F; Reyelt, J; Schossow, B; Schwarz, N; Scheuplein, F; Rothenburg, S; Haag, F; Alzogaray, V; Cauerhff, A; Goldbaum, FA				Koch-Nolte, Friedrich; Reyelt, Jan; Schoessow, Britta; Schwarz, Nicole; Scheuplein, Felix; Rothenburg, Stefan; Haag, Friedrich; Alzogaray, Vanina; Cauerhff, Ana; Goldbaum, Fernando A.			Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo	FASEB JOURNAL			English	Article						recombinant antibodies; leukocyte ecto-enzymes; enzyme inhibitors; ADP-ribosylation	NICOTINAMIDE ADENINE-DINUCLEOTIDE; HEAVY-CHAIN ANTIBODIES; MEMBRANE-PROTEINS; BACTERIAL TOXINS; SURFACE-PROTEINS; LIGHT-CHAINS; RIBOSYLATION; MOUSE; ACTIVATION; CD38	The purpose of our study was to develop a tool for blocking the function of a specific leukocyte ecto-enzyme in vivo. ART2.2 is a toxin-related ectoenzyme that transfers the ADP-ribose moiety from NAD onto other cell surface proteins. ART2.2 induces T cell death by activating the cytolytic P2 x 7 purinoceptor via ADP-ribosylation. Here, we report the generation of ART2.2-blocking single domain antibodies from an immunized llama. The variable domain of heavy-chain antibodies (VHH domain) represents the smallest known antigen-binding unit generated by adaptive immune responses. Their long CDR3 endows VHH domains with the extraordinary capacity to extend into and block molecular clefts. Following intravenous injection, the ART2.2-specific VHH domains effectively shut off the enzymatic and cytotoxic activities of ART2.2 in lymphatic organs. This blockade was highly specific ( blocking ART2.2 but not the related enzymes ART1 or ART2.1), rapid ( within 15 min after injection), and reversible ( 24 h after injection). Our findings constitute a proof of principle that opens up a new avenue for targeting leukocyte ecto-enzymes in vivo and that can serve as a model also for developing new antidotes against ADP-ribosylating toxins.	Univ Med Ctr Hamburg Eppendorf, Dept Clin Pathol, Inst Immunol, Ctr Diagnost, D-20246 Hamburg, Germany; Consejo Nacl Invest Cient & Tecn, Fdn Inst Leloir, Buenos Aires, DF, Argentina	University of Hamburg; University Medical Center Hamburg-Eppendorf; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute	Koch-Nolte, F (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Clin Pathol, Inst Immunol, Ctr Diagnost, Martinistr 52, D-20246 Hamburg, Germany.	nolte@uke.uni-hamburg.de	Rothenburg, Stefan/A-8340-2008	Scheuplein, Felix/0000-0002-2691-0796; Goldbaum, Fernando/0000-0001-6235-3002; Cauerhff, Ana/0000-0001-9686-9883; Koch-Nolte, Friedrich/0000-0003-1730-6674				Aktories K, 2005, NAT REV MICROBIOL, V3, P397, DOI 10.1038/nrmicro1150; BANASIK M, 1992, J BIOL CHEM, V267, P1569; Bannas P, 2005, BLOOD, V105, P3663, DOI 10.1182/blood-2004-08-3325; Baral TN, 2006, NAT MED, V12, P580, DOI 10.1038/nm1395; BOERSMA WJA, 1992, RES IMMUNOL, V143, P503, DOI 10.1016/0923-2494(92)80061-O; Brekke OH, 2003, NAT REV DRUG DISCOV, V2, P52, DOI 10.1038/nrd984; Cockayne DA, 1998, BLOOD, V92, P1324, DOI 10.1182/blood.V92.4.1324.416k26_1324_1333; Corda D, 2003, EMBO J, V22, P1953, DOI 10.1093/emboj/cdg209; Cortez-Retamozo V, 2004, CANCER RES, V64, P2853, DOI 10.1158/0008-5472.CAN-03-3935; De Genst E, 2006, P NATL ACAD SCI USA, V103, P4586, DOI 10.1073/pnas.0505379103; Deaglio S, 2006, BLOOD, V108, P1135, DOI 10.1182/blood-2006-01-013003; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Elliott JI, 2005, NAT CELL BIOL, V7, P808, DOI 10.1038/ncb1279; Garton KJ, 2006, J LEUKOCYTE BIOL, V79, P1105, DOI 10.1189/jlb.0106038; Glowacki G, 2002, PROTEIN SCI, V11, P1657, DOI 10.1110/ps.0200602; Goding JW, 1998, IMMUNOL REV, V161, P5, DOI 10.1111/j.1600-065X.1998.tb01567.x; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Harmsen MM, 2000, MOL IMMUNOL, V37, P579, DOI 10.1016/S0161-5890(00)00081-X; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; Janssens R, 2006, P NATL ACAD SCI USA, V103, P15130, DOI 10.1073/pnas.0601108103; Jobling SA, 2003, NAT BIOTECHNOL, V21, P77, DOI 10.1038/nbt772; Kahl S, 2000, J IMMUNOL, V165, P4463, DOI 10.4049/jimmunol.165.8.4463; Kawamura H, 2005, J IMMUNOL, V174, P1971, DOI 10.4049/jimmunol.174.4.1971; Koch-Nolte F, 1999, J IMMUNOL, V163, P6014; Koch-Nolte F, 2005, CELL IMMUNOL, V236, P66, DOI 10.1016/j.cellimm.2005.08.033; Koch-Nolte F, 2006, ANN MED, V38, P188, DOI 10.1080/07853890600655499; KochNolte F, 1996, J BIOL CHEM, V271, P7686, DOI 10.1074/jbc.271.13.7686; Krebs C, 2005, J IMMUNOL, V174, P3298, DOI 10.4049/jimmunol.174.6.3298; Krebs C, 2003, ANAL BIOCHEM, V314, P108, DOI 10.1016/S0003-2697(02)00640-1; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; Mueller-Dieckmann C, 2002, J MOL BIOL, V322, P687, DOI 10.1016/S0022-2836(02)00818-5; Muruganandam A, 2001, FASEB J, V15, P240, DOI 10.1096/fj.01-0343fje; MUYLDERMANS S, 1994, PROTEIN ENG, V7, P1129, DOI 10.1093/protein/7.9.1129; Muyldermans S, 2001, J Biotechnol, V74, P277; Muyldermans S, 2001, TRENDS BIOCHEM SCI, V26, P230, DOI 10.1016/S0968-0004(01)01790-X; Okazaki IJ, 1996, BLOOD, V88, P915; Reinhold D, 2002, BIOL CHEM, V383, P1133, DOI 10.1515/BC.2002.123; Ritter H, 2003, BIOCHEMISTRY-US, V42, P10155, DOI 10.1021/bi034625w; Salmi M, 2005, NAT REV IMMUNOL, V5, P760, DOI 10.1038/nri1705; Schuber F, 2004, CURR MOL MED, V4, P249, DOI 10.2174/1566524043360708; Seman M, 2004, CURR MED CHEM, V11, P857, DOI 10.2174/0929867043455611; Seman M, 2003, IMMUNITY, V19, P571, DOI 10.1016/S1074-7613(03)00266-8; Waldmann TA, 2003, NAT MED, V9, P269, DOI 10.1038/nm0303-269; WU TT, 1993, PROTEINS, V16, P1, DOI 10.1002/prot.340160102; Yates SP, 2006, TRENDS BIOCHEM SCI, V31, P123, DOI 10.1016/j.tibs.2005.12.007; Zarebski LM, 2005, J MOL BIOL, V349, P814, DOI 10.1016/j.jmb.2005.03.072; Zolkiewska A, 2005, PHYSIOLOGY, V20, P374, DOI 10.1152/physiol.00028.2005	48	86	113	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3490	3498		10.1096/fj.07-8661com	http://dx.doi.org/10.1096/fj.07-8661com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17575259				2022-12-28	WOS:000250517800012
J	Sakao, S; Taraseviciene-Stewart, L; Cool, CD; Tada, Y; Kasahara, Y; Kurosu, K; Tanabe, N; Takiguchi, Y; Tatsumi, K; Kuriyama, T; Voelkel, NF				Sakao, Seiichiro; Taraseviciene-Stewart, Laimute; Cool, Carlyne D.; Tada, Yuji; Kasahara, Yasunori; Kurosu, Katsushi; Tanabe, Nobuhiro; Takiguchi, Yuichi; Tatsumi, Koichiro; Kuriyama, Takayuki; Voelkel, Norbert F.			VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34(+) precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells	FASEB JOURNAL			English	Article						pulmonary hypertension; human pulmonary microvascular endothelial cells	SEVERE PULMONARY-HYPERTENSION; HEMATOPOIETIC STEM-CELLS; ADULT BONE-MARROW; RECEPTOR TYROSINE KINASE; GROWTH-FACTOR; IN-VITRO; PROGENITOR CELLS; C-KIT; ATHEROSCLEROTIC LESIONS; ENCODING CD34	Severe pulmonary hypertension (PH) is characterized by complex precapillary arteriolar lesions, which contain phenotypically altered smooth muscle ( SM) and endothelial cells (EC). We have demonstrated that VEGF receptor blockade by SU5416 {3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin 2-one} in combination with chronic hypoxia causes severe angioproliferative PH associated with arterial occlusion in rats. We postulate that endothelial-mesenchymal transdifferentiation can take place in the occlusive lesions and that endothelium-derived mesenchymal cells can further differentiate toward a SM phenotype. To examine this hypothesis, we incubated human pulmonary microvascular endothelial cells (HPMVEC) with SU5416 and analyzed these cells utilizing quantitative-PCR, immunofluorescent staining and flow cytometry analysis. In vitro studies in HPMVEC demonstrated that SU5416 suppressed PGI(2)S gene expression while potently inducing COX-2, VEGF, and TGF-beta(1) expression; and caused transdifferentiation of mature vascular endothelial cells (defined by Dil-ac-LDL, Lectin and Factor VIII) to SM-like (as defined by expression of alpha-SM actin) "transitional" cells, coexpressing both endothelial and SM markers. SU5416 expanded the number of CD34 and/or c-kit positive cells and caused transdifferentiation of CD34 positive cells but not negative cells. In conclusion, our data show that SU5416 generated a selection pressure that killed some EC and expanded progenitor-like cells to transdifferentiate to SM-like and neuronal-like cells.	Chiba Univ, Sch Med, Dept Respirol B2, Grad Sch Med,Chuo Ku, Chiba 2608670, Japan; Univ Colorado, Hlth Sci Ctr, Pulm Hypertens Ctr, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO USA	Chiba University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sakao, S (corresponding author), Chiba Univ, Sch Med, Dept Respirol B2, Grad Sch Med,Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	sakaos@faculty.chiba-u.jp			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066254] Funding Source: NIH RePORTER; NHLBI NIH HHS [5P01 HL66254-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCINIEGAS E, 1992, J CELL SCI, V103, P521; ASHMAN LK, 1994, J CELL PHYSIOL, V158, P545, DOI 10.1002/jcp.1041580321; Baluk P, 2004, AM J PATHOL, V165, P1071, DOI 10.1016/S0002-9440(10)63369-X; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Catalano A, 2005, EMBO J, V24, P170, DOI 10.1038/sj.emboj.7600502; Cool C.D., 2004, AM J RESP CRIT CARE, V167, pA844; Cool CD, 1999, AM J PATHOL, V155, P411, DOI 10.1016/S0002-9440(10)65137-1; DELIA D, 1993, BLOOD, V81, P1001; Doyonnas R, 2005, BLOOD, V105, P4170, DOI 10.1182/blood-2004-10-4077; Egan KM, 2004, SCIENCE, V306, P1954, DOI 10.1126/science.1103333; Frid MG, 2002, CIRC RES, V90, P1189, DOI 10.1161/01.RES.0000021432.70309.28; Geraci MW, 2001, CIRC RES, V88, P555, DOI 10.1161/01.RES.88.6.555; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Glaser R, 2002, CIRCULATION, V106, P17, DOI 10.1161/01.CIR.0000021923.58307.8F; Golpon HA, 2001, AM J PATHOL, V158, P955, DOI 10.1016/S0002-9440(10)64042-4; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Guo P, 2001, CANCER RES, V61, P8569; Hautmann MB, 1999, ARTERIOSCL THROM VAS, V19, P2049, DOI 10.1161/01.ATV.19.9.2049; Hu YH, 2004, J CLIN INVEST, V113, P1258, DOI 10.1172/JCI200419628; Hu YH, 2002, CIRC RES, V91, pE13, DOI 10.1161/01.RES.0000037090.34760.EE; Hu YH, 2002, CIRCULATION, V106, P1834, DOI 10.1161/01.CIR.0000031333.86845.DD; Jin H, 2006, J CLIN INVEST, V116, P652, DOI 10.1172/JCI24751; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kerosuo L, 2004, BRIT J HAEMATOL, V124, P809, DOI 10.1111/j.1365-2141.2004.04840.x; Koide Y, 2002, J MED CHEM, V45, P4629, DOI 10.1021/jm020080c; Krause DS, 1996, BLOOD, V87, P1; KRAUSE DS, 1994, BLOOD, V84, P691; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; LEE SL, 1991, CIRC RES, V68, P1362, DOI 10.1161/01.RES.68.5.1362; LERNER NB, 1991, BLOOD, V77, P1876; Licht T, 2003, BLOOD, V102, P2099, DOI 10.1182/blood-2002-12-3634; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Muller AM, 2002, EXP MOL PATHOL, V72, P221, DOI 10.1006/exmp.2002.2424; Okada K, 1998, AM J RESP CRIT CARE, V158, P939, DOI 10.1164/ajrccm.158.3.9710007; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; RUFAIHAH AJ, 2007, J GENE MED; Sakao S, 2005, CHEST, V128, p610S, DOI 10.1378/chest.128.6_suppl.610S-a; Sakao S, 2005, FASEB J, V19, P1178, DOI 10.1096/fj.04-3261fje; Sakao S, 2006, AM J PHYSIOL-LUNG C, V291, pL362, DOI 10.1152/ajplung.00111.2005; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sanchez-Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; SATTERTHWAITE AB, 1992, GENOMICS, V12, P788, DOI 10.1016/0888-7543(92)90310-O; Sauter B, 1998, J HISTOCHEM CYTOCHEM, V46, P165, DOI 10.1177/002215549804600205; SCHLINGEMANN RO, 1990, LAB INVEST, V62, P690; Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121; SIMMONS DL, 1992, J IMMUNOL, V148, P267; Simper D, 2002, CIRCULATION, V106, P1199, DOI 10.1161/01.CIR.0000031525.61826.A8; Sugita M, 2002, CANCER RES, V62, P3971; Sundberg C, 2001, AM J PATHOL, V158, P1145, DOI 10.1016/S0002-9440(10)64062-X; Tang K, 2004, PHYSIOL GENOMICS, V18, P63, DOI 10.1152/physiolgenomics.00023.2004; Tang KC, 2004, J APPL PHYSIOL, V97, P1559, DOI 10.1152/japplphysiol.00221.2004; Taraseviciene-Stewart L, 2001, FASEB J, V15, P427, DOI 10.1096/fj.00-0343com; Tuder RM, 1999, AM J RESP CRIT CARE, V159, P1925, DOI 10.1164/ajrccm.159.6.9804054; Tuder RM, 2001, J PATHOL, V195, P367, DOI 10.1002/path.953; Tuder RM, 2001, CLIN CHEST MED, V22, P405, DOI 10.1016/S0272-5231(05)70280-X; Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; WYPYCH J, 1995, BLOOD, V85, P66, DOI 10.1182/blood.V85.1.66.bloodjournal85166; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; Zamora MR, 1996, AM J PHYSIOL-LUNG C, V270, pL101, DOI 10.1152/ajplung.1996.270.1.L101	61	66	68	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3640	3652		10.1096/fj.07-8432com	http://dx.doi.org/10.1096/fj.07-8432com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17567571				2022-12-28	WOS:000250517800026
J	Belloni, D; Scabini, S; Foglieni, C; Veschini, L; Giazzon, A; Colombo, B; Fulgenzi, A; Helle, KB; Ferrero, ME; Corti, A; Ferrero, E				Belloni, Daniela; Scabini, Silvia; Foglieni, Chiara; Veschini, Lorenzo; Giazzon, Alessio; Colombo, Barbara; Fulgenzi, Alessandro; Helle, Karen B.; Ferrero, Maria Elena; Corti, Angelo; Ferrero, Elisabetta			The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration	FASEB JOURNAL			English	Article						ERK/MAPK; capillary-like structures	TUMOR-GROWTH; MAP KINASES; ANGIOGENESIS; IDENTIFICATION; MORPHOGENESIS; ACTIVATION; PHENOTYPE; ADHESION; SYSTEM; MATRIX	A growing body of evidence suggests that chromogranin A (CgA), a secretory protein released by many neuroendocrine cells and frequently used as a diagnostic and prognostic serum marker for a range of neuroendocrine tumors, is a precursor of several bioactive fragments. This work was undertaken to assess whether the N-terminal fragment CgA(1-76) (called vasostatin I) can inhibit the proangiogenic activity of vascular endothelial growth factor (VEGF), a factor involved in tumor growth. The effect of recombinant human vasostatin I (VS-1) on VEGF-induced human umbilical endothelial cells (HUVEC) signaling, proliferation, migration, and organization has been investigated. We have found that VS-1 (3 mu g/ ml; 330 nM) can inhibit VEGF-induced ERK phosphorylation, as well as cell migration, proliferation, morphogenesis, and invasion of collagen gels in various in vitro assays. In addition, VS-1 could inhibit the formation of capillary-like structures in Matrigel plugs in a rat model. VS-1 could also inhibit basal ERK phosphorylation and motility of HUVEC, leading to a more quiescent state in the absence of VEGF, without inducing apoptotic or necrotic effects. Conclusion: These findings suggest that vasostatin I may play a novel role as a regulator of endothelial cell function and homeostasis.	Ist Sci San Raffaele, DIBIT, Cardiovasc Dept, I-20132 Milan, Italy; Ist Sci San Raffaele, Dept Oncol, I-20132 Milan, Italy; Ist Sci San Raffaele, IIT Network Res Unit Mol Neurosci, I-20132 Milan, Italy; Univ Bergen, Dept Biomed, Bergen, Norway; CNR, Inst Gen Pathol, I-20133 Milan, Italy; CNR, Ctr Studies Cellular Pathol, I-20133 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Istituto Italiano di Tecnologia - IIT; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Bergen; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR)	Ferrero, E (corresponding author), Ist Sci San Raffaele, DIBIT, Cardiovasc Dept, Via Olgettina 60, I-20132 Milan, Italy.	elisabetta.ferrero@hsr.it	Colombo, Barbara/AAN-5045-2020; Ferrero, Elisabetta/G-5690-2013; fulgenzi, alessandro/AAN-6722-2020; Belloni, Daniela/AAN-6718-2020; Corti, Angelo/F-7046-2012; Foglieni, Chiara/O-2339-2015	Colombo, Barbara/0000-0002-5887-5868; fulgenzi, alessandro/0000-0003-1343-6965; Belloni, Daniela/0000-0002-3487-4203; Corti, Angelo/0000-0002-0893-6191; Foglieni, Chiara/0000-0002-5155-6426; Veschini, Lorenzo/0000-0003-3820-7472; Subba, Rajkrishna/0000-0003-0051-0062				AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bernini GP, 2001, BRIT J CANCER, V84, P636, DOI 10.1054/bjoc.2000.1659; Blois A, 2006, REGUL PEPTIDES, V134, P30, DOI 10.1016/j.regpep.2005.11.003; BLOIS A, 2006, REGUL PEPTIDES, V135, P554; Bullard LE, 2003, INVEST OPHTH VIS SCI, V44, P1722, DOI 10.1167/iovs.01-1193; Cai J, 2006, MICROVASC RES, V71, P20, DOI 10.1016/j.mvr.2005.10.004; Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478; Ceconi C, 2002, EUR HEART J, V23, P967, DOI 10.1053/euhj.2001.2977; Chow S, 2001, CYTOMETRY, V46, P72, DOI 10.1002/cyto.1067; Colombo B, 2002, CANCER RES, V62, P941; Colombo B, 2002, J BIOL CHEM, V277, P45911, DOI 10.1074/jbc.M202637200; Corti A, 1997, EUR J BIOCHEM, V248, P692, DOI 10.1111/j.1432-1033.1997.00692.x; Corti A, 2000, ADV EXP MED BIOL, V482, P351; Corti Angelo, 2004, Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents, V4, P161, DOI 10.2174/1568013043357626; DEFTOS LJ, 1991, ENDOCR REV, V12, P181, DOI 10.1210/edrv-12-2-181; Ferrero E, 2004, FASEB J, V18, P554, DOI 10.1096/fj.03-0922fje; FERRERO E, 1995, FEBS LETT, V374, P323, DOI 10.1016/0014-5793(95)01110-Z; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Heissig B, 2003, CURR OPIN HEMATOL, V10, P136, DOI 10.1097/00062752-200303000-00007; HELLE KB, 1994, ACTA PHYSIOL SCAND, V152, P1, DOI 10.1111/j.1748-1716.1994.tb09779.x; Helle KB, 2004, BIOL REV, V79, P769, DOI 10.1017/S146479310400644X; Hoefen RJ, 2002, VASC PHARMACOL, V38, P271, DOI 10.1016/S1537-1891(02)00251-3; HSIAO RJ, 1990, AM J MED, V88, P607, DOI 10.1016/0002-9343(90)90526-J; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; IACANGELO AL, 1995, REGUL PEPTIDES, V58, P65, DOI 10.1016/0167-0115(95)00069-N; Kaneko Y, 2004, J CELL SCI, V117, P407, DOI 10.1242/jcs.00871; Kang YK, 1997, FEBS LETT, V404, P87, DOI 10.1016/S0014-5793(97)00099-9; Meadows KN, 2004, ONCOGENE, V23, P192, DOI 10.1038/sj.onc.1206921; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; METZBOUTIGUE MH, 2001, CURR MED CHEM IMMUNO, V1, P119; Michiels C, 2003, J CELL PHYSIOL, V196, P430, DOI 10.1002/jcp.10333; OCONNOR DT, 1984, NEW ENGL J MED, V311, P764, DOI 10.1056/NEJM198409203111204; Orr AW, 2003, J CELL SCI, V116, P2917, DOI 10.1242/jcs.00600; Patan S, 2000, J NEURO-ONCOL, V50, P1, DOI 10.1023/A:1006493130855; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; Prewett M, 1999, CANCER RES, V59, P5209; Ratti S, 2000, J BIOL CHEM, V275, P29257, DOI 10.1074/jbc.M003796200; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Strasly M, 2004, BLOOD, V103, P40, DOI 10.1182/blood-2003-05-1387; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; White CR, 2005, AM J PHYSIOL-HEART C, V289, pH2350, DOI 10.1152/ajpheart.01229.2004; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; Wong C, 2005, J BIOL CHEM, V280, P33262, DOI 10.1074/jbc.M503198200; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J; Zachary I, 2003, BIOCHEM SOC T, V31, P1171; ZIEGLER MG, 1990, KIDNEY INT, V37, P1357, DOI 10.1038/ki.1990.122	49	70	72	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3052	3062		10.1096/fj.06-6829com	http://dx.doi.org/10.1096/fj.06-6829com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17566084				2022-12-28	WOS:000249781600007
J	Huang, RQ; Qu, YH; Ke, WL; Zhu, JH; Pei, YY; Jiang, C				Huang, Rong-Qin; Qu, Ying-Hua; Ke, Wei-Lun; Zhu, Jian-Hua; Pei, Yuan-Ying; Jiang, Chen			Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer	FASEB JOURNAL			English	Article						brain targeting; PAMAM; transferrin	DRUG-DELIVERY; IN-VIVO; PAMAM DENDRIMER; BARRIER; LIPOSOMES; RECEPTOR; DNA; TRANSFECTION; ENDOCYTOSIS; TRANSPORT	The blood-brain barrier (BBB) poses great difficulties for gene delivery to the brain. To circumvent the BBB, we investigated a novel brain-targeting gene vector based on the nanoscopic high-branching dendrimer, polyamidoamine ( PAMAM), in vitro and in vivo. Transferrin (Tf) was selected as a brain-targeting ligand conjugated to PAMAM via bifunctional polyethyleneglycol ( PEG), yielding PAMAM-PEG-Tf. UV and nuclear magnetic resonance (NMR) spectroscopy were used to evaluate the synthesis of vectors. The characteristics and biodistribution of gene vectors were evaluated by fluorescent microscopy, flow cytometry, and a radiolabeling method. The transfection efficiency of vector/DNA complexes in brain capillary endothelial cells (BCECs) was evaluated by fluorescent microscopy and determination of luciferase activity. The potency of vector/DNA complexes was evaluated by using frozen sections and measuring tissue luciferase activity in Balb/c mice after i.v. administration. UV and NMR results demonstrated the successful synthesis of PAMAM-PEG-Tf. This vector showed a concentration- dependent manner in cellular uptake study and a 2.25-fold brain uptake compared with PAMAM and PAMAM-PEG in vivo. Transfection efficiency of PAMAM-PEG-Tf/DNA complex was much higher than PAMAM/DNA and PAMAM-PEG/DNA complexes in BCECs. Results of tissue expression experiments indicated the widespread expression of an exogenous gene in mouse brain after i.v. administration. With a PAMAM/DNA weight ratio of 10: 1, the brain gene expression of the PAMAM-PEG-Tf/DNA complex was similar to 2-fold higher than that of the PAMAM/DNA and PAMAM-PEG/DNA complexes. These results suggested that PAMAM-PEG-Tf can be exploited as a potential nonviral gene vector targeting to brain via noninvasive administration.	Fudan Univ, Sch Pharm, Dept Pharmaceut, Shanghai 200032, Peoples R China	Fudan University	Jiang, C (corresponding author), Fudan Univ, Sch Pharm, Dept Pharmaceut, POB 130, Shanghai 200032, Peoples R China.	jiangchen@shmu.edu.cn	Huang, Rongqin/C-4165-2014					Bhadra D, 2003, INT J PHARM, V257, P111, DOI 10.1016/S0378-5173(03)00132-7; Bielinska AU, 1999, BIOCONJUGATE CHEM, V10, P843, DOI 10.1021/bc990036k; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun CS, 2005, J PHARM SCI-US, V94, P423, DOI 10.1002/jps.20251; Cheng YY, 2005, EUR J MED CHEM, V40, P1390, DOI 10.1016/j.ejmech.2005.08.002; Choi JS, 2004, J CONTROL RELEASE, V99, P445, DOI 10.1016/j.jconrel.2004.07.027; Ding Jun-Jun, 2005, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V27, P499; Eichman, 2000, Pharm Sci Technol Today, V3, P232, DOI 10.1016/S1461-5347(00)00273-X; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Harashima H, 2001, EUR J PHARM SCI, V13, P85, DOI 10.1016/S0928-0987(00)00211-6; Hatakeyama H, 2004, INT J PHARMACEUT, V281, P25, DOI 10.1016/j.ijpharm.2004.05.025; JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0; Kang HM, 2005, PHARM RES-DORDR, V22, P2099, DOI 10.1007/s11095-005-8330-5; Kitchens KM, 2005, ADV DRUG DELIVER REV, V57, P2163, DOI 10.1016/j.addr.2005.09.013; Kobayashi H, 1999, BIOCONJUGATE CHEM, V10, P103, DOI 10.1021/bc980091d; Li HY, 2002, MED RES REV, V22, P225, DOI 10.1002/med.10008; Lu W, 2005, J CONTROL RELEASE, V107, P428, DOI 10.1016/j.jconrel.2005.03.027; Luo D, 2002, MACROMOLECULES, V35, P3456, DOI 10.1021/ma0106346; Majoros IJ, 2005, J MED CHEM, V48, P5892, DOI 10.1021/jm0401863; Olivier JC, 2002, PHARMACEUT RES, V19, P1137, DOI 10.1023/A:1019842024814; Pardridge WM, 1999, J NEUROVIROL, V5, P556, DOI 10.3109/13550289909021285; Pardridge WM, 2002, NEURON, V36, P555, DOI 10.1016/S0896-6273(02)01054-1; Pardridge WM, 2002, DRUG DISCOV TODAY, V7, P223; Pardridge WM, 2001, JPN J PHARMACOL, V87, P97, DOI 10.1254/jjp.87.97; Pardridge WM, 2001, DRUG DISCOV TODAY, V6, P1, DOI 10.1016/S1359-6446(00)01583-X; Qian ZM, 2002, PHARMACOL REV, V54, P561, DOI 10.1124/pr.54.4.561; Sako K, 2005, J NEUROIMMUNOL, V158, P40, DOI 10.1016/j.jneuroim.2004.08.013; Schlachetzki F, 2004, NEUROLOGY, V62, P1275, DOI 10.1212/01.WNL.0000120551.38463.D9; Shi NY, 2000, P NATL ACAD SCI USA, V97, P7567, DOI 10.1073/pnas.130187497; Smith MW, 2006, J DRUG TARGET, V14, P191, DOI 10.1080/10611860600650086; Xie Y, 2005, J CONTROL RELEASE, V105, P106, DOI 10.1016/j.jconrel.2005.03.005; XU YQ, 1996, NUCL TECHNOL, V19, P309; Youk HJ, 2005, J CONTROL RELEASE, V107, P43, DOI 10.1016/j.jconrel.2005.05.014; Zhang Y, 2003, MOL THER, V7, P11, DOI 10.1016/S1525-0016(02)00018-7	34	272	294	2	89	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1117	1125		10.1096/fj.06-7380com	http://dx.doi.org/10.1096/fj.06-7380com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17218540				2022-12-28	WOS:000245650400016
J	Nakada, T; Westhoff, CM; Kato, A; Hirose, S				Nakada, Tsutomu; Westhoff, Connie M.; Kato, Akira; Hirose, Shigehisa			Ammonia secretion from fish gill depends on a set of Rh glycoproteins	FASEB JOURNAL			English	Article						RhAG; rhesus glycoprotein; ammonium transporter; mitochondria-rich cell; teleost	TRANSPORTER; EXCRETION; KIDNEY; OSMOREGULATION; IDENTIFICATION; EXPRESSION; CELLS	Ammonia excretion from the gill in teleost fish is essential for nitrogen elimination. Although numerous physiological studies have measured ammonia excretion, the mechanism of ammonia movement through the membranes of gill epithelial cells is still unknown. Mammalian Rh glycoproteins are members of a family of proteins that mediate ammonia transport in bacteria, yeast, and plants. We identified the Rh glycoprotein homologs, fRhag, fRhbg, fRhcg1, and fRhcg2, of the pufferfish, Takifugu rubripes. Northern blot, in situ hybridization, and immunohistochemistry revealed that the pufferfish erythroid Rh glycoprotein homologue fRhag was present in red blood cells and the hematological organs ( spleen and kidney) in fish. All four pufferfish Rh glycoproteins are specifically localized in the gill and line the pillar cells, pavement cells, and the mitochondrion-rich cells. Heterologous expression in Xenopus oocytes showed that they mediate methylammonium ( an analog of ammonium) transport. These results suggest that pufferfish Rh glycoproteins are involved in ammonia excretion from the gill. These findings challenge the classic view that ammonia excretion in the fish gill occurs by passive diffusion.	Tokyo Inst Technol, Dept Sci Biol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Amer Red Cross, Philadelphia, PA USA	Tokyo Institute of Technology; University of Pennsylvania; American Red Cross	Hirose, S (corresponding author), Tokyo Inst Technol, Dept Sci Biol, Midori Ku, 4259-B-19 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.	shirose@bio.titech.ac.jp	Kato, Akira/E-6328-2010	Kato, Akira/0000-0002-9083-1443				Eladari D, 2002, J AM SOC NEPHROL, V13, P1999, DOI 10.1097/01.ASN.0000025280.02386.9D; Evans DH, 2005, PHYSIOL REV, V85, P97, DOI 10.1152/physrev.00050.2003; GARVIN JL, 1988, AM J PHYSIOL, V255, pF56; KUDO H, 2007, IN PRESS J HISTOCHEM; KURTZ I, 1986, AM J PHYSIOL, V250, pF497, DOI 10.1152/ajprenal.1986.250.3.F497; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Ludewig U, 2004, J PHYSIOL-LONDON, V559, P751, DOI 10.1113/jphysiol.2004.067728; Mak DOD, 2006, AM J PHYSIOL-RENAL, V290, pF297, DOI 10.1152/ajprenal.00147.2005; MARINI AM, 1994, EMBO J, V13, P3456, DOI 10.1002/j.1460-2075.1994.tb06651.x; Marini AM, 2000, NAT GENET, V26, P341, DOI 10.1038/81656; Mistry AC, 2001, AM J PHYSIOL-REG I, V281, pR1594, DOI 10.1152/ajpregu.2001.281.5.R1594; Nakada T, 2005, AM J PHYSIOL-REG I, V289, pR575, DOI 10.1152/ajpregu.00725.2004; NINNEMANN O, 1994, EMBO J, V13, P3464, DOI 10.1002/j.1460-2075.1994.tb06652.x; Quentin F, 2003, J AM SOC NEPHROL, V14, P545, DOI 10.1097/01.ASN.0000050413.43662.55; Randall DJ, 1999, AM J PHYSIOL-REG I, V277, pR1562, DOI 10.1152/ajpregu.1999.277.6.R1562; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; Verlander JW, 2003, AM J PHYSIOL-RENAL, V284, pF323, DOI 10.1152/ajprenal.00050.2002; Westhoff CM, 2004, J BIOL CHEM, V279, P17443, DOI 10.1074/jbc.M311853200; Westhoff CM, 2002, J BIOL CHEM, V277, P12499, DOI 10.1074/jbc.C200060200; Wilkie MP, 2002, J EXP ZOOL, V293, P284, DOI 10.1002/jez.10123; Wood C, 2002, BBA-BIOMEMBRANES, V1566, P72, DOI 10.1016/S0005-2736(02)00595-3; WRIGHT PA, 1995, J EXP BIOL, V198, P273	22	150	159	2	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1067	1074		10.1096/fj.06-6834com	http://dx.doi.org/10.1096/fj.06-6834com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17218543				2022-12-28	WOS:000245650400011
J	Yao, L; Korteweg, C; Hsueh, W; Go, J				Yao, Lu; Korteweg, Christine; Hsueh, Wei; Go, Jiang			Avian influenza receptor expression in H5N1-infected and noninfected human tissues	FASEB JOURNAL			English	Article						sialic acid; human influenza virus receptors; lectin	HUMAN AIRWAY EPITHELIUM; LOWER RESPIRATORY-TRACT; A H5N1 INFECTION; SIALIC-ACID; BINDING SPECIFICITY; VIRUS; HEMAGGLUTININ; CELL; HOST; TRANSMISSION	Avian and human influenza viruses preferentially bind to alpha-2,3-linked and alpha-2,6-linked sialic acids, respectively. Until today, the distributions of these two receptor types had never been investigated in H5N1-infected human tissue samples. Here, the expression of avian (AIV-Rs) and human influenza receptors (HuIV-Rs) is studied in various organs (upper and lower respiratory tracts, brain, placenta, liver, kidney, heart, intestines, and spleen) of two H5N1 cases and 14 control cases. Histochemical stains using biotinylated Maackia amurensis lectin 11 and Sambucus nigra agglutinin were performed to localize AIV-Rs and HuIV-Rs, respectively. Immunohistochemical stainings were performed to identify the receptor-bearing cells. AIV-Rs were detected on type II pneumocytes; a limited number of epithelial cells of the upper respiratory tract; and the bronchi, bronchioli, and trachea; as well as on Kupffer cells, glomerular cells, splenic T cells, and neurons in the brain and intestines. HuIV-Rs were abundantly present in the respiratory tract and lungs. They were also detected on Hofbauer cells, glomerular cells, splenic B cells, and in the liver. Moreover, endothelial cells of all organs examined expressed both receptor types. In conclusion, the distribution pattern of AIV-Rs is partially inconsistent with the pattern of infected cells as detected in previous studies, which suggests there may be other receptors or mechanisms involved in H5N1 infection. In addition, the diffuse presence of receptors on endothelial cells may account for the multiple organ involvement in H5N1 influenza. Finally, the relative lack of AIV-Rs in the upper airway may be a one of the factors preventing efficient human-to-human transmission of H5N1 influenza.	[Yao, Lu; Korteweg, Christine; Go, Jiang] Peking Univ, Sch Basic Med Sci, Dept Pathol, Beijing 100083, Peoples R China; [Go, Jiang] Peking Univ, Ctr Infect Dis, Beijing 100871, Peoples R China; [Hsueh, Wei] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL USA	Peking University; Peking University; Northwestern University; Feinberg School of Medicine	Go, J (corresponding author), Peking Univ, Sch Basic Med Sci, Dept Pathol, 38 Xuwyuan Rd, Beijing 100083, Peoples R China.	jianggu@bjmu.edu.cn		Yao, Lu/0000-0002-6430-8712; Gu, Jiang/0000-0002-0706-8329				BAUM LG, 1990, ACTA HISTOCHEM, P35; Beigel H, 2005, NEW ENGL J MED, V353, P1374, DOI 10.1056/NEJMra052211; Cerna A, 2002, ACTA HISTOCHEM, V104, P339, DOI 10.1078/0065-1281-00669; Chokephaibulkit K, 2005, PEDIATR INFECT DIS J, V24, P162, DOI 10.1097/01.inf.0000151037.25237.1e; de Jong MD, 2005, NEW ENGL J MED, V352, P686, DOI 10.1056/NEJMoa044307; de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477; Eash S, 2004, AM J PATHOL, V164, P419, DOI 10.1016/S0002-9440(10)63132-X; Glaser L, 2005, J VIROL, V79, P11533, DOI 10.1128/JVI.79.17.11533-11536.2005; Gu J, 2007, LANCET, V370, P1137, DOI 10.1016/S0140-6736(07)61515-3; Harvey R, 2004, J VIROL, V78, P502, DOI 10.1128/JVI.78.1.502-507.2004; Ibricevic A, 2006, J VIROL, V80, P7469, DOI 10.1128/JVI.02677-05; Juckett G, 2006, AM FAM PHYSICIAN, V74, P783; KAWAOKA Y, 1989, J VIROL, V63, P4603, DOI 10.1128/JVI.63.11.4603-4608.1989; Matrosovich M, 2007, VIROLOGY, V361, P384, DOI 10.1016/j.virol.2006.11.030; Matrosovich MN, 2004, P NATL ACAD SCI USA, V101, P4620, DOI 10.1073/pnas.0308001101; Muramoto Y, 2006, MICROBIOL IMMUNOL, V50, P73, DOI 10.1111/j.1348-0421.2006.tb03764.x; NELSON J, 1993, VIRUS RES, V29, P155, DOI 10.1016/0168-1702(93)90056-S; Nicholls JM, 2007, NAT MED, V13, P147, DOI 10.1038/nm1529; Ponnio M, 2004, MICROSC RES TECHNIQ, V65, P292, DOI 10.1002/jemt.20132; Reid AH, 2004, NAT REV MICROBIOL, V2, P909, DOI 10.1038/nrmicro1027; ROGERS GN, 1983, NATURE, V304, P76, DOI 10.1038/304076a0; SATA T, 1991, AM J PATHOL, V139, P1435; Shinya K, 2006, NATURE, V440, P435, DOI 10.1038/440435a; Shu YL, 2006, NEW ENGL J MED, V354, P1421, DOI 10.1056/NEJMc053524; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Stevens J, 2006, SCIENCE, V312, P404, DOI 10.1126/science.1124513; Suzuki Y, 2005, BIOL PHARM BULL, V28, P399, DOI 10.1248/bpb.28.399; Thompson CI, 2006, J VIROL, V80, P8060, DOI 10.1128/JVI.00384-06; To KF, 2001, J MED VIROL, V63, P242, DOI 10.1002/1096-9071(200103)63:3&lt;242::AID-JMV1007&gt;3.0.CO;2-N; Uiprasertkul M, 2005, EMERG INFECT DIS, V11, P1036, DOI 10.3201/eid1107.041313; Ungchusak K, 2005, NEW ENGL J MED, V352, P333, DOI 10.1056/NEJMoa044021; van Riel D, 2006, SCIENCE, V312, P399, DOI 10.1126/science.1125548; Yamada S, 2006, NATURE, V444, P378, DOI 10.1038/nature05264; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9; Zhang LQ, 2005, J VIROL, V79, P1113, DOI 10.1128/JVI.79.2.1113-1124.2005; Zhou Chao, 2006, Zhonghua Jiehe He Huxi Zazhi, V29, P9; 2007, CUMULATIVE NUMBER CO	37	103	108	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					733	740		10.1096/fj.06-7880com	http://dx.doi.org/10.1096/fj.06-7880com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17925493				2022-12-28	WOS:000254143700012
J	Basting, D; Lorch, M; Lehner, I; Glaubitz, C				Basting, Daniel; Lorch, Mark; Lehner, Ines; Glaubitz, Clemens			Transport cycle intermediate in small multidrug resistance protein is revealed by substrate fluorescence	FASEB JOURNAL			English	Article						bacteriorhodopsin; EmrE; ethidium bromide; TBsmr	ESCHERICHIA-COLI; EMRE; BINDING; SITE; MODEL; H+; BACTERIORHODOPSIN; SECONDARY; GLUTAMATE; VESICLES	Efflux pumps of the small multidrug resistance family bind cationic, lipophilic antibiotics and transport them across the membrane in exchange for protons. The transport cycle must involve various conformational states of the protein needed for substrate binding, translocation, and release. A fluorescent substrate will therefore experience a significant change of environment while being transported, which influences its fluorescence properties. Thus the substrate itself can report intermediate states that form during the transport cycle. We show the existence of such a substrate-transporter complex for the EmrE homolog Mycobacterium tuberculosis TBsmr and its substrate ethidium bromide. The pH gradient needed for antiport has been generated by co-reconstituting TBsmr with bacteriorhodopsin. Sample illumination generates a Delta pH, which results in enhanced ethidium fluorescence intensity, which is abolished when Delta pH or Delta Psi is collapsed or when the essential residue Glu-13 in TBsmr is exchanged with Ala. This observation shows the formation of a pH-dependent, transient substrate-protein complex between binding and release of ethidium. We have further characterized this state by determining the K-d, by inhibiting ethidium transport through titration with nonfluorescent substrate and by fluorescence anisotropy measurements. Our findings support a model with a single occluded intermediate state in which the substrate is highly immobile.	[Basting, Daniel; Lorch, Mark; Lehner, Ines; Glaubitz, Clemens] Goethe Univ Frankfurt, Inst Biophys Chem, D-60438 Frankfurt, Germany; [Basting, Daniel; Lorch, Mark; Lehner, Ines; Glaubitz, Clemens] Goethe Univ Frankfurt, Ctr Biomol Magnet Resonance, D-60438 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Glaubitz, C (corresponding author), Goethe Univ Frankfurt, Inst Biophys Chem, Max von Laue Str 9, D-60438 Frankfurt, Germany.	glaubitz@em.uni-frankfurt.de	Glaubitz, Clemens/D-5714-2011	Glaubitz, Clemens/0000-0002-3554-6586	Engineering and Physical Sciences Research Council [EP/C508912/1] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i; Barth A, 2002, BIOPHYS J, V83, P2864, DOI 10.1016/S0006-3495(02)75295-8; BEAUGE LA, 1979, NATURE, V280, P510, DOI 10.1038/280510a0; De Rossi E, 1998, J BACTERIOL, V180, P6068, DOI 10.1128/JB.180.22.6068-6071.1998; GENEST D, 1985, NUCLEIC ACIDS RES, V13, P2603, DOI 10.1093/nar/13.7.2603; GRINIUS L, 1992, PLASMID, V27, P119, DOI 10.1016/0147-619X(92)90012-Y; Guan L, 2004, P NATL ACAD SCI USA, V101, P12148, DOI 10.1073/pnas.0404936101; GUENZA M, 1988, SPECTROCHIM ACTA A, V44, P1359, DOI 10.1016/0584-8539(88)80182-X; Kaback HR, 2007, P NATL ACAD SCI USA, V104, P491, DOI 10.1073/pnas.0609968104; Koteiche HA, 2003, BIOCHEMISTRY-US, V42, P6099, DOI 10.1021/bi0342867; Lorch M, 2005, BIOCHEM SOC T, V33, P873, DOI 10.1042/BST0330873; Luedtke NW, 2005, CHEM-EUR J, V11, P495, DOI 10.1002/chem.200400559; Mason AJ, 2005, FEBS J, V272, P2152, DOI 10.1111/j.1742-4658.2005.04633.x; MAYCOX PR, 1990, EMBO J, V9, P1465, DOI 10.1002/j.1460-2075.1990.tb08263.x; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; Ninio S, 2003, J BIOL CHEM, V278, P12000, DOI 10.1074/jbc.M213119200; Ninio S, 2001, J BIOL CHEM, V276, P48250, DOI 10.1074/jbc.M108231200; Noguchi N, 1999, FEMS MICROBIOL LETT, V172, P247, DOI 10.1111/j.1574-6968.1999.tb13475.x; Oesterhelt D, 1974, Methods Enzymol, V31, P667; OLMSTED J, 1977, BIOCHEMISTRY-US, V16, P3647, DOI 10.1021/bi00635a022; PEROZO E, 1993, BIOCHEMISTRY-US, V32, P10471, DOI 10.1021/bi00090a025; RACKER E, 1974, J BIOL CHEM, V249, P662; Rapp M, 2007, SCIENCE, V315, P1282, DOI 10.1126/science.1135406; Rotem D, 2004, J BIOL CHEM, V279, P48787, DOI 10.1074/jbc.M408187200; Schuldiner S, 2007, TRENDS BIOCHEM SCI, V32, P252, DOI 10.1016/j.tibs.2007.04.002; Schwaiger M, 1998, EUR J BIOCHEM, V254, P610, DOI 10.1046/j.1432-1327.1998.2540610.x; Siarheyeva A, 2006, BIOCHEMISTRY-US, V45, P6203, DOI 10.1021/bi0524870; Soskine M, 2002, P NATL ACAD SCI USA, V99, P12043, DOI 10.1073/pnas.192392899; SUBCZYNSKI WK, 1994, BIOCHEMISTRY-US, V33, P7670, DOI 10.1021/bi00190a022; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Ubarretxena-Belandia I, 2003, EMBO J, V22, P6175, DOI 10.1093/emboj/cdg611; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; Yerushalmi H, 2000, FEBS LETT, V476, P93, DOI 10.1016/S0014-5793(00)01677-X; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yin Y, 2006, BIOPHYS J, V91, P3972, DOI 10.1529/biophysj.106.085993	38	11	11	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					365	373		10.1096/fj.07-9162com	http://dx.doi.org/10.1096/fj.07-9162com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17873100				2022-12-28	WOS:000252822600006
J	Kemmner, W; Wan, KY; Ruttinger, S; Ebert, B; Macdonald, R; Klamm, U; MoestaO, KT				Kemmner, Wolfgang; Wan, Kayiu; Ruettinger, Steffen; Ebert, Bernd; Macdonald, Rainer; Klamm, Ursula; MoestaO, K. Thomas			Silencing of human ferrochelatase causes abundant protoporphyrin-IX accumulation in colon cancer	FASEB JOURNAL			English	Article						heme metabolism; gastrointestinal carcinomas; siRNA silencing; cytoplasmatic red fluorescence	HIGH-GRADE DYSPLASIA; ACID-INDUCED PROTOPORPHYRIN; 5-AMINOLEVULINIC ACID; PHOTODYNAMIC THERAPY; BARRETTS-ESOPHAGUS; RNA INTERFERENCE; GENE-EXPRESSION; FLUORESCENCE; PORPHYRINS; LESIONS	Hemes and heme proteins are vital components of essentially every cell of virtually every eukaryote organism. Previously, we demonstrated accumulation of the heme precursor protoporphyrin-IX (PpIX) in gastrointestinal tumor tissues. To elucidate the mechanisms of PpIX accumulation by quantitative reverse transcriptase-polymerase chain reaction (RTPCR), we studied expression of the relevant enzymes of the heme synthetic pathway. Here, we describe a significant down-regulation of ferrochelatase (FECH) mRNA expression in gastric, colonic, and rectal carcinomas. Accordingly, in an in vitro model of several carcinoma cell lines, ferrochelatase down-regulation and loss of enzymatic activity corresponded with an enhanced PpIX-dependent fluorescence. Direct detection of PpIX in minute amounts was achieved by a specifically developed pulsed solid-state laser dual delay fluorimetry setup. Silencing of FECH using small interfering RNA (siRNA) technology led to a maximum 50-fold increased PpIX accumulation, imageable by a specifically adapted two-photon microscopy unit. Our results show that in malignant tissue a transcriptional down-regulation of FECH occurs, which causes endogenous PpIX accumulation. Furthermore, accumulation of intracellular PpIX because of FECH siRNA silencing provides a small-molecule-based approach to molecular imaging and molecular therapy.	[Kemmner, Wolfgang; Wan, Kayiu] Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; [Ruettinger, Steffen; Ebert, Bernd; Macdonald, Rainer] Phys Tech Bundesanstalt, Dept Biomed Opt, Berlin, Germany; [Klamm, Ursula; MoestaO, K. Thomas] Charite Univ Med Berlin, Clin Surg Oncol, Robert Roessle Clin, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Physikalisch-Technische Bundesanstalt (PTB); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kemmner, W (corresponding author), Max Delbruck Ctr Mol Med, Robert Roessle Str 10, D-13125 Berlin, Germany.	wkemmner@mdc-berlin.de						Barr H, 1996, LANCET, V348, P584, DOI 10.1016/S0140-6736(96)03054-1; Cardoso ALC, 2007, J GENE MED, V9, P170, DOI 10.1002/jgm.1006; DAILEY HA, 1984, BIOCHEM J, V223, P441, DOI 10.1042/bj2230441; Dailey HA, 2000, CELL MOL LIFE SCI, V57, P1909, DOI 10.1007/PL00000672; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Endlicher E, 2004, PHOTOCHEM PHOTOBIOL, V79, P189, DOI 10.1562/0031-8655(2004)079<0189:DODLBF>2.0.CO;2; Endlicher E, 2001, GUT, V48, P314, DOI 10.1136/gut.48.3.314; Gossner L, 1999, CANCER, V86, P1921, DOI 10.1002/(SICI)1097-0142(19991115)86:10<1921::AID-CNCR7>3.3.CO;2-E; Gupta S, 2004, P NATL ACAD SCI USA, V101, P1927, DOI 10.1073/pnas.0306111101; Hinnen P, 1998, BRIT J CANCER, V78, P679, DOI 10.1038/bjc.1998.559; HUA ZX, 1995, CANCER RES, V55, P1723; Koenig F, 2001, SCIENCE, V292, P1401, DOI 10.1126/science.292.5520.1401; Krieg RC, 2000, PHOTOCHEM PHOTOBIOL, V72, P226, DOI 10.1562/0031-8655(2000)072<0226:CTSPIM>2.0.CO;2; Liu YYL, 2004, LIFE SCI, V75, P2035, DOI 10.1016/j.lfs.2004.03.027; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Magness ST, 2000, BLOOD, V95, P3568, DOI 10.1182/blood.V95.11.3568.011k40_3568_3577; Mahmood U, 2003, MOL CANCER THER, V2, P489; Moesta KT, 2001, CANCER RES, V61, P991; Mortelmaier M, 2002, SINGLE MOL, V3, P225, DOI 10.1002/1438-5171(200208)3:4<225::AID-SIMO225>3.0.CO;2-K; Rao AU, 2005, P NATL ACAD SCI USA, V102, P4270, DOI 10.1073/pnas.0500877102; Rozema DB, 2007, P NATL ACAD SCI USA, V104, P12982, DOI 10.1073/pnas.0703778104; Taketani S, 2000, EUR J BIOCHEM, V267, P4685, DOI 10.1046/j.1432-1327.2000.01519.x; VANHILLEGERSBERG R, 1992, GASTROENTEROLOGY, V103, P647, DOI 10.1016/0016-5085(92)90860-2; Walther W, 2006, HUM GENE THER, V17, P611, DOI 10.1089/hum.2006.17.611; Weissleder R, 2006, SCIENCE, V312, P1168, DOI 10.1126/science.1125949; Yuste R, 2005, NAT METHODS, V2, P902, DOI 10.1038/nmeth1205-902; Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100	27	77	83	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					500	509		10.1096/fj.07-8888com	http://dx.doi.org/10.1096/fj.07-8888com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17875605				2022-12-28	WOS:000252822600020
J	Breit, JF; Ault-Ziel, K; Al-Mehdi, AB; Gillespie, MN				Breit, Jeffrey F.; Ault-Ziel, Katheryn; Al-Mehdi, Abu-Bakr; Gillespie, Mark N.			Nuclear protein-induced bending and flexing of the hypoxic response element of the rat vascular endothelial growth factor promoter	FASEB JOURNAL			English	Article						DNA topography; VEGF expression	RESONANCE ENERGY-TRANSFER; SMOOTH-MUSCLE-CELLS; GENE-EXPRESSION; PULMONARY-HYPERTENSION; INDUCIBLE FACTOR-1; VEGF GENE; DNA; TRANSCRIPTION; ENDONUCLEASE; FLEXIBILITY	Bending and flexing of DNA may contribute to transcriptional regulation. Because hypoxia and other physiological signals induce formation of an abasic site at a key base within the hypoxic response element (HRE) of the vascular endothelial growth factor (VEGF) gene (FASEB J. 19, 387-394, 2005) and because abasic sites can introduce flexibility in model DNA sequences, in the present study we used a fluorescence resonance energy transfer-based reporter system to assess topological changes in a wild-type (WT) sequence of the HRE of the rat VEGF gene and in a sequence harboring a single abasic site mimicking the effect of hypoxia. Binding of the hypoxia-inducible transcriptional complex present in hypoxic pulmonary artery endothelial cell nuclear extract to the WT sequence failed to alter sequence topology whereas nuclear protein binding to the modified HRE engendered considerable sequence flexibility. Topological effects of nuclear proteins on the modified VEGF HRE were dependent on the transcription factor hypoxia- inducible factor-1 and on formation of a single-strand break at the abasic site mediated by the coactivator, Ref-1/Ape1. These observations suggest that oxidative base modifications in the VEGF HRE evoked by physiological signals could be a precursor to single-strand break formation that has an impact on gene expression by modulating sequence flexibility.-Breit, J. F., Ault-Ziel, K., Al-Mehdi, A.-B., Gillespie, M. N. Nuclear protein-induced bending and flexing of the hypoxic response element of the rat vascular endothelial growth factor promoter.	[Breit, Jeffrey F.; Ault-Ziel, Katheryn; Al-Mehdi, Abu-Bakr; Gillespie, Mark N.] Univ S Alabama, Coll Med, Dept Pharmacol, Mobile, AL 36688 USA; [Breit, Jeffrey F.; Ault-Ziel, Katheryn; Al-Mehdi, Abu-Bakr; Gillespie, Mark N.] Univ S Alabama, Coll Med, Ctr Lung Biol, Mobile, AL 36688 USA	University of South Alabama; University of South Alabama	Breit, JF (corresponding author), Univ S Alabama, Coll Med, Dept Pharmacol, MSB 3366, Mobile, AL 36688 USA.	mgillesp@jaguar1.usouthal.edu	Al-Mehdi, Abu-Bakr/A-8636-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066299, R01HL058234, R01HL073244] Funding Source: NIH RePORTER; NHLBI NIH HHS [R21 HL084521, P01 HL066299, R01 HL073244, R01 HL058234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ayadi L, 2000, J BIOMOL STRUCT DYN, V17, P645, DOI 10.1080/07391102.2000.10506555; Barsky D, 2000, NUCLEIC ACIDS RES, V28, P2613, DOI 10.1093/nar/28.13.2613; Berney C, 2003, BIOPHYS J, V84, P3992, DOI 10.1016/S0006-3495(03)75126-1; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Cheng XL, 2005, J AM CHEM SOC, V127, P13906, DOI 10.1021/ja052542s; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; Dong WJ, 2003, J BIOL CHEM, V278, P8686, DOI 10.1074/jbc.M212886200; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Gillespie MN, 2007, AM J PHYSIOL-LUNG C, V292, pL1, DOI 10.1152/ajplung.00275.2006; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Grishko V, 2001, FASEB J, V15, P1267, DOI 10.1096/fj.00-0755fje; HAGERMAN PJ, 1990, J MOL BIOL, V212, P351, DOI 10.1016/0022-2836(90)90130-E; Haince JF, 2006, SCIENCE, V312, P1752, DOI 10.1126/science.1129808; Hardwidge PR, 2003, BIOPOLYMERS, V69, P110, DOI 10.1002/bip.10321; HAYS JB, 1970, J MOL BIOL, V48, P297, DOI 10.1016/0022-2836(70)90162-2; Hu B, 1997, MOL CELL BIOL, V17, P851, DOI 10.1128/MCB.17.2.851; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Killilea DW, 2000, AM J PHYSIOL-LUNG C, V279, pL408, DOI 10.1152/ajplung.2000.279.2.L408; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Lin MJ, 2004, CIRC RES, V95, P496, DOI 10.1161/01.RES.0000138952.16382.ad; Liu JQ, 2006, AM J PHYSIOL-LUNG C, V290, pL2, DOI 10.1152/ajplung.00135.2005; Liu JQ, 2003, AM J PHYSIOL-LUNG C, V285, pL322, DOI 10.1152/ajplung.00337.2002; Mol CD, 2000, MUTAT RES-DNA REPAIR, V460, P211, DOI 10.1016/S0921-8777(00)00028-8; Parkhurst LJ, 2004, METHOD ENZYMOL, V379, P235; Parkhurst LJ, 2001, BIOPOLYMERS, V61, P180; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; Robinson JM, 2003, J MOL BIOL, V329, P371, DOI 10.1016/S0022-2836(03)00424-8; Ruchko M, 2005, AM J PHYSIOL-LUNG C, V288, pL530, DOI 10.1152/ajplung.00255.2004; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; She MD, 1998, EUR J BIOCHEM, V252, P600, DOI 10.1046/j.1432-1327.1998.2520600.x; Vologodskaia M, 2002, J MOL BIOL, V317, P205, DOI 10.1006/jmbi.2001.5366; Williams SL, 2006, NUCLEIC ACIDS RES, V34, P1028, DOI 10.1093/nar/gkj498; Wilson DM, 2001, MUTAT RES-DNA REPAIR, V485, P283, DOI 10.1016/S0921-8777(01)00063-5; Yang DI, 2004, BRIT J PHARMACOL, V141, P988, DOI 10.1038/sj.bjp.0705687; Zhang YL, 2003, BIOPHYS J, V84, P136, DOI 10.1016/S0006-3495(03)74838-3; Ziel KA, 2005, FASEB J, V19, P387, DOI 10.1096/fj.04-2805com; Ziel KA, 2004, FASEB J, V18, P986, DOI 10.1096/fj.03-1160fje	38	17	20	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					19	29		10.1096/fj.07-8102com	http://dx.doi.org/10.1096/fj.07-8102com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17766324				2022-12-28	WOS:000252309900005
J	Zhao, WQ; De Felice, FG; Fernandez, S; Chen, H; Lambert, MP; Quon, MJ; Krafft, GA; Klein, WL				Zhao, Wei-Qin; De Felice, Fernanda G.; Fernandez, Sara; Chen, Hui; Lambert, Mary P.; Quon, Michael J.; Krafft, Grant A.; Klein, William L.			Amyloid beta oligomers induce impairment of neuronal insulin receptors	FASEB JOURNAL			English	Review						insulin resistance; calcium; NMDA receptor; receptor loss; Akt serine(473); tyrosine phosphorylation	PROTEIN-KINASE-C; HIPPOCAMPAL SYNAPTIC PLASTICITY; LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; A-BETA; DIABETES-MELLITUS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; SECRETED OLIGOMERS; GABA(A) RECEPTORS	Recent studies have indicated an association between Alzheimer's disease (AD) and central nervous system (CNS) insulin resistance. However, the cellular mechanisms underlying the link between these two pathologies have not been elucidated. Here we show that signal transduction by neuronal insulin receptors (IR) is strikingly sensitive to disruption by soluble A beta oligomers (also known as ADDLs). ADDLs are known to accumulate in AD brain and have recently been implicated as primary candidates for initiating deterioration of synapse function, composition, and structure. Using mature cultures of hippocampal neurons, a preferred model for studies of synaptic cell biology, we found that ADDLs caused a rapid and substantial loss of neuronal surface IRs specifically on dendrites bound by ADDLs. Removal of dendritic IRs was associated with increased receptor immunoreactivity in the cell body, indicating redistribution of the receptors. The neuronal response to insulin, measured by evoked IR tyrosine autophosphorylation, was greatly inhibited by ADDLs. Inhibition also was seen with added glutamate or potassium-induced depolarization. The effects on IR function were completely blocked by NMDA receptor antagonists, tetrodotoxin, and calcium chelator BAPTA-AM. Downstream from the IR, ADDLs induced a phosphorylation of Akt at serine(473), a modification associated with neurodegenerative and insulin resistance diseases. These results identify novel factors that affect neuronal IR signaling and suggest that insulin resistance in AD brain is a response to ADDLs, which disrupt insulin signaling and may cause a brain-specific form of diabetes as part of an overall pathogenic impact on CNS synapses.	[Zhao, Wei-Qin; De Felice, Fernanda G.; Fernandez, Sara; Lambert, Mary P.; Klein, William L.] Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; [Zhao, Wei-Qin; Quon, Michael J.] Blanchette Rockefeller Neurosci Inst, Rockville, MD USA; [Zhao, Wei-Qin] Acumen Pharmaceut, San Francisco, CA USA; [De Felice, Fernanda G.] Univ Fed Rio de Janeiro, Inst Med Biochem, Rio De Janeiro, RJ, Brazil; [Chen, Hui] NIH, NCCAM, Bethesda, MD 20892 USA	Northwestern University; Universidade Federal do Rio de Janeiro; National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Zhao, WQ (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, 2205 Tech Dr,Hogan 5-110, Evanston, IL 60208 USA.	w-zhao@northwestern.edu	De Felice, Fernanda G/M-1074-2017; Quon, Michael/B-1970-2008	Quon, Michael/0000-0002-9601-9915; QUON, MICHAEL/0000-0002-5289-3707	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [Z01AT000002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018877] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIA NIH HHS [R01-AG18877] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Almeida CG, 2005, NEUROBIOL DIS, V20, P187, DOI 10.1016/j.nbd.2005.02.008; Anderson E.W., 1998, J SERV RES-US, V1, P5, DOI DOI 10.1177/109467059800100102; Ashe KH, 2001, LEARN MEMORY, V8, P301, DOI 10.1101/lm.43701; Assini A, 2004, NEUROLOGY, V63, P828, DOI 10.1212/01.WNL.0000137040.64252.ED; Avignon A, 1996, DIABETES, V45, P1396, DOI 10.2337/diabetes.45.10.1396; Bi XN, 2005, AM J PATHOL, V167, P1081, DOI 10.1016/S0002-9440(10)61197-2; Biddinger SB, 2006, ANNU REV PHYSIOL, V68, P123, DOI 10.1146/annurev.physiol.68.040104.124723; Biessels GJ, 1996, DIABETES, V45, P1259, DOI 10.2337/diabetes.45.9.1259; Bloch-Damti A, 2006, DIABETOLOGIA, V49, P2463, DOI 10.1007/s00125-006-0349-6; Bossenmaier B, 1997, DIABETOLOGIA, V40, P863, DOI 10.1007/s001250050761; Boutaud O, 2006, J NEUROCHEM, V96, P917, DOI 10.1111/j.1471-4159.2005.03586.x; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Chowdhury S, 2006, NEURON, V52, P445, DOI 10.1016/j.neuron.2006.08.033; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Collingridge GL, 2004, NAT REV NEUROSCI, V5, P952, DOI 10.1038/nrn1556; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2938, DOI 10.1172/JCI118001; CRAFT S, 1993, BEHAV NEUROSCI, V107, P926; Craft S, 2004, LANCET NEUROL, V3, P169, DOI 10.1016/S1474-4422(04)00681-7; Craft S, 2006, ALZ DIS ASSOC DIS, V20, P298, DOI 10.1097/01.wad.0000213866.86934.7e; Craig AM, 2006, TRENDS NEUROSCI, V29, P8, DOI 10.1016/j.tins.2005.11.002; De Felice FG, 2007, J BIOL CHEM, V282, P11590, DOI 10.1074/jbc.M607483200; de la Monte SM, 2006, J ALZHEIMERS DIS, V10, P89; DEFELICE FG, 2007, NEUROBIOL AGING; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Dou JT, 2005, LEARN MEMORY, V12, P646, DOI 10.1101/lm.88005; DRAZNIN B, 1989, ENDOCRINOLOGY, V125, P2341, DOI 10.1210/endo-125-5-2341; FROGUEL P, 1993, DIABETES METAB, V19, P1; Frolich L, 1999, ANN NY ACAD SCI, V893, P290, DOI 10.1111/j.1749-6632.1999.tb07839.x; Gambassi G, 1998, NEUROLOGY, V51, P925, DOI 10.1212/WNL.51.3.925-b; Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102; Gines S, 2003, J BIOL CHEM, V278, P50514, DOI 10.1074/jbc.M309348200; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Griffin RJ, 2005, J NEUROCHEM, V93, P105, DOI 10.1111/j.1471-4159.2004.02949.x; Grimble RF, 2002, CURR OPIN CLIN NUTR, V5, P551, DOI 10.1097/00075197-200209000-00015; Haan MN, 2006, NAT CLIN PRACT NEURO, V2, P159, DOI 10.1038/ncpneuro0124; Hajduch E, 2001, FEBS LETT, V492, P199, DOI 10.1016/S0014-5793(01)02242-6; Haring HU, 1996, DIABETES, V45, pS115, DOI 10.2337/diab.45.1.S115; HEIDENREICH KA, 1983, J BIOL CHEM, V258, P8527; HEIDENREICH KA, 1988, MOL CELL ENDOCRINOL, V56, P255, DOI 10.1016/0303-7207(88)90068-8; HENDRICKS SA, 1984, J NEUROCHEM, V43, P1302, DOI 10.1111/j.1471-4159.1984.tb05387.x; Hepler RW, 2006, BIOCHEMISTRY-US, V45, P15157, DOI 10.1021/bi061850f; Hotamisligil GS, 2003, INT J OBESITY, V27, pS53, DOI 10.1038/sj.ijo.0802502; Hoyer S, 2000, EXP GERONTOL, V35, P1363, DOI 10.1016/S0531-5565(00)00156-X; Hsieh H, 2006, NEURON, V52, P831, DOI 10.1016/j.neuron.2006.10.035; KATO H, 1993, J BIOL CHEM, V268, P2655; KELLERER M, 1990, BIOCHEM BIOPH RES CO, V172, P446, DOI 10.1016/0006-291X(90)90693-H; Kelly BL, 2005, J BIOL CHEM, V280, P31746, DOI 10.1074/jbc.M503259200; Kim D, 2002, J BIOCHEM MOL BIOL, V35, P106; Klein William L, 2006, Alzheimers Dement, V2, P43, DOI 10.1016/j.jalz.2005.11.003; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; KLEIN WL, 2007, MEMORIES MIL CIRCUIT; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; LACOR PN, 2007, J NEUROSCI; Lambert MP, 2007, J NEUROCHEM, V100, P23, DOI 10.1111/j.1471-4159.2006.04157.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Launer Lenore J, 2005, Curr Diab Rep, V5, P59, DOI 10.1007/s11892-005-0069-1; Le Roith D, 2001, DIABETES CARE, V24, P588, DOI 10.2337/diacare.24.3.588; Lee YH, 2004, ARCH PHARM RES, V27, P361, DOI 10.1007/BF02980074; Lin JW, 2000, NAT NEUROSCI, V3, P1282, DOI 10.1038/81814; Lipton SA, 2006, NAT REV DRUG DISCOV, V5, P160, DOI 10.1038/nrd1958; LOWE W, 1986, ENDOCRINOLOGY, V118, P1669, DOI 10.1210/endo-118-4-1669; Luchsinger JA, 2004, NEUROLOGY, V63, P1187, DOI 10.1212/01.WNL.0000140292.04932.87; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Matsui T, 2003, CELL CYCLE, V2, P220, DOI 10.4161/cc.2.3.381; MATSUMOTO H, 1990, J NEUROCHEM, V54, P347, DOI 10.1111/j.1471-4159.1990.tb13321.x; Mattson MP, 2002, J NEUROVIROL, V8, P539, DOI 10.1080/13550280290100978; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; MENEILLY GS, 1993, J AM GERIATR SOC, V41, P710, DOI 10.1111/j.1532-5415.1993.tb07458.x; Messier C, 2003, EXP GERONTOL, V38, P941, DOI 10.1016/S0531-5565(03)00153-0; Mielke JG, 2005, J NEUROCHEM, V92, P103, DOI 10.1111/j.1471-4159.2004.02841.x; Morisco C, 2005, CIRC RES, V96, P180, DOI 10.1161/01.RES.0000152968.71868.c3; Nakai M, 2001, NEUROCHEM INT, V38, P593, DOI 10.1016/S0197-0186(00)00126-1; Oddo S, 2006, J BIOL CHEM, V281, P1599, DOI 10.1074/jbc.M507892200; Odetti P, 2005, J ALZHEIMERS DIS, V8, P243; OLEFSKY JM, 1995, AM J CLIN NUTR, V61, p980S, DOI 10.1093/ajcn/61.4.980S; Park CR, 2001, NEUROSCI BIOBEHAV R, V25, P311, DOI 10.1016/S0149-7634(01)00016-1; Pedersen WA, 2004, NEUROBIOL DIS, V17, P500, DOI 10.1016/j.nbd.2004.08.003; Pedersen WA, 2006, EXP NEUROL, V199, P265, DOI 10.1016/j.expneurol.2006.01.018; Perkinton MS, 2002, J NEUROCHEM, V80, P239, DOI 10.1046/j.0022-3042.2001.00699.x; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Qiao LY, 1999, J BIOL CHEM, V274, P10625, DOI 10.1074/jbc.274.15.10625; QUON MJ, 1992, BIOCHEMISTRY-US, V31, P9947, DOI 10.1021/bi00156a013; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Rickle A, 2004, NEUROREPORT, V15, P955, DOI 10.1097/00001756-200404290-00005; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Schubert M, 2004, P NATL ACAD SCI USA, V101, P3100, DOI 10.1073/pnas.0308724101; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shemer I, 2006, EUR J NEUROSCI, V23, P2035, DOI 10.1111/j.1460-9568.2006.04733.x; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Steen E, 2005, J ALZHEIMERS DIS, V7, P63, DOI 10.3233/jad-2005-7107; STEVENS GR, 1998, THESIS NW U, P101; Syed NA, 2002, J CELL BIOCHEM, V86, P118, DOI 10.1002/jcb.10189; Takahashi RH, 2004, J NEUROSCI, V24, P3592, DOI 10.1523/JNEUROSCI.5167-03.2004; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; Tanimukai S, 2002, NEUROREPORT, V13, P549, DOI 10.1097/00001756-200203250-00037; Teplow DB, 2006, METHOD ENZYMOL, V413, P20, DOI 10.1016/S0076-6879(06)13002-5; Tian R, 2005, CIRC RES, V96, P139, DOI 10.1161/01.RES.0000156076.17807.1F; Townsend M, 2006, J PHYSIOL-LONDON, V572, P477, DOI 10.1113/jphysiol.2005.103754; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X; Watson GS, 2004, EUR J PHARMACOL, V490, P97, DOI 10.1016/j.ejphar.2004.02.048; Xie L, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0001.2002; Zhao WQ, 1999, J BIOL CHEM, V274, P34893, DOI 10.1074/jbc.274.49.34893; Zhao WQ, 2004, J NEUROCHEM, V90, P609, DOI 10.1111/j.1471-4159.2004.02509.x; Zhao WQ, 2001, MOL CELL ENDOCRINOL, V177, P125, DOI 10.1016/S0303-7207(01)00455-5; Zhou Q, 2001, P NATL ACAD SCI USA, V98, P1261, DOI 10.1073/pnas.031573798	110	441	466	1	51	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					246	260		10.1096/fj.06-7703com	http://dx.doi.org/10.1096/fj.06-7703com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17720802				2022-12-28	WOS:000252309900027
J	Johann, AM; Barra, V; Kuhn, AM; Weigert, A; von Knethen, A; Brune, B				Johann, Axel M.; Barra, Vera; Kuhn, Anne-Marie; Weigert, Andreas; von Knethen, Andreas; Bruene, Bernhard			Apoptotic cells induce arginase II in macrophages, thereby attenuating NO production	FASEB JOURNAL			English	Article						phagocytosis; inflammation; alternative activation; inducible NO synthase	NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR-BETA; ENDOTHELIAL-CELLS; L-ARGININE; ACTIVATION; RECOGNITION; MECHANISMS; EXPRESSION; CLEARANCE; SUBSTRATE	In recent years it has become apparent that removal of apoptotic cells ( AC) by professional phagocytes alters the macrophage phenotype. This change is characterized by attenuated proinflammatory cytokine expression and NO production, which mechanistically remained unexplained. With the intention to explore molecular mechanisms underlying reduced NO formation, we showed that NO production in IFN gamma-stimulated murine RAW264.7 macrophages exposed to AC but not to either necrotic or viable human Jurkat cells was significantly reduced although iNOS expression remained high compared with controls. Analyzing iNOS activity in the cell extracts by using the radioactive L- arginine/ citrulline conversion assay revealed increased ornithine production over citrulline in cells exposed to AC. RT- PCR, Western blot, and luciferase reporter analysis supported the idea of an arginase II increase in response to AC. The involvement of arginase in modulating NO formation in response to AC was substantiated by the arginase inhibitor N omega- hydroxy-nor-L- arginine. Moreover, knockdown of arginase II by siRNA allowed recovery of NO production. Experiments with AC- conditioned medium demonstrated that a soluble lipid factor, rather than phagocytosis of AC, modulated NO production in macrophages. We conclude that AC release a lipid factor to modulate NO formation in macrophages via arginase II up- regulation, thereby contributing to innate immune regulation.	Goethe Univ Frankfurt, Fac Med, Inst Biochem 1, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Brune, B (corresponding author), Goethe Univ Frankfurt, Fac Med, Inst Biochem 1, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	bruene@zbc.kgu.de	Weigert, Andreas/E-6540-2010	Weigert, Andreas/0000-0002-7529-1952				Balanco JMD, 2001, CURR BIOL, V11, P1870, DOI 10.1016/S0960-9822(01)00563-2; Barksdale AR, 2004, SURGERY, V135, P527, DOI 10.1016/j.surg.2003.10.007; Blaise GA, 2005, TOXICOLOGY, V208, P177, DOI 10.1016/j.tox.2004.11.032; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; BOUTARD V, 1995, J IMMUNOL, V155, P2077; Closs EI, 2000, MOL PHARMACOL, V57, P68; CORRALIZA IM, 1995, BIOCHEM BIOPH RES CO, V206, P667, DOI 10.1006/bbrc.1995.1094; El-Gayar S, 2003, J IMMUNOL, V171, P4561, DOI 10.4049/jimmunol.171.9.4561; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Freire-de-Lima CG, 2006, J BIOL CHEM, V281, P38376, DOI 10.1074/jbc.M605146200; Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208; Gobert AP, 2002, J IMMUNOL, V168, P4692, DOI 10.4049/jimmunol.168.9.4692; Topal JLG, 2006, J PHARMACOL EXP THER, V318, P1368, DOI 10.1124/jpet.106.103747; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gotoh T, 1999, J CELL BIOL, V144, P427, DOI 10.1083/jcb.144.3.427; Gotoh T, 1996, FEBS LETT, V395, P119, DOI 10.1016/0014-5793(96)01015-0; Johann AM, 2006, CELL DEATH DIFFER, V13, P1533, DOI 10.1038/sj.cdd.4401832; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Li HG, 1998, MOL PHARMACOL, V53, P630, DOI 10.1124/mol.53.4.630; Lopez V, 2005, FEBS J, V272, P4540, DOI 10.1111/j.1742-4658.2005.04874.x; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; McDonald PP, 1999, J IMMUNOL, V163, P6164; Morris SM, 2004, J NUTR, V134, p2743S, DOI 10.1093/jn/134.10.2743S; MORRIS SM, 1998, AM J PHYSIOL, V375, pE740; Munder M, 1999, J IMMUNOL, V163, P3771; Ratovitski EA, 1999, J BIOL CHEM, V274, P30250, DOI 10.1074/jbc.274.42.30250; Ratovitski EA, 1999, J BIOL CHEM, V274, P993, DOI 10.1074/jbc.274.2.993; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Schneemann M, 2002, NAT IMMUNOL, V3, P102, DOI 10.1038/ni0202-102a; Stuehr DJ, 2004, J NUTR, V134, p2748S, DOI 10.1093/jn/134.10.2748S; Tenu JP, 1999, NITRIC OXIDE-BIOL CH, V3, P427, DOI 10.1006/niox.1999.0255; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Weigert A, 2006, BLOOD, V108, P1635, DOI 10.1182/blood-2006-04-014852; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Xu WL, 2004, FASEB J, V18, P1746, DOI 10.1096/fj.04-2317fje; Zamboni DS, 2004, INFECT IMMUN, V72, P2075, DOI 10.1128/IAI.72.4.2075-2080.2004	39	53	53	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2704	2712		10.1096/fj.06-7815com	http://dx.doi.org/10.1096/fj.06-7815com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17456784				2022-12-28	WOS:000249237500012
J	Ge, RB; Heinonen, JE; Svahn, MG; Mohamed, AJ; Lundin, KE; Smith, CIE				Ge, Rongbin; Heinonen, Juhana E.; Svahn, Mathias G.; Mohamed, Abdalla J.; Lundin, Karin E.; Smith, C. I. Edvard			Zorro locked nucleic acid induces sequence-specific gene silencing	FASEB JOURNAL			English	Article						peptide nucleic acid; gene transcription; PNA/LNA; DNA binding; oligonucleotide	TRIPLEX-FORMING OLIGONUCLEOTIDES; GREEN FLUORESCENT PROTEIN; STRAND-DISPLACEMENT; ANTISENSE OLIGONUCLEOTIDES; DUPLEX DNA; IN-VITRO; TRANSCRIPTION; PNA; INHIBITION; BINDING	Locked nucleic acids (LNAs) are synthetic analogs of nucleic acids that contain a bridging methylene carbon between the 2' and 4' positions of the ribose ring. In this study, we generated a novel sequence-specific antigene molecule "Zorro LNA", which simultaneously binds to both strands, and that induced effective and specific strand invasion into DNA duplexes and potent inhibition of gene transcription, also in a cellular context. By comparing the Zorro LNA with linear LNA as well as an optimized bisPNA ( peptide nucleic acid) oligonucleotide directed against the same target sites, respectively, we found that the Zorro LNA construct was unique in its ability to arrest gene transcription in mammalian cells. To our knowledge, this is the first time that in mammalian cells, gene transcription was blocked by a nucleic acid analog in a sequence-specific way using low but saturated binding of a blocking agent. This offers a novel type of antigene drug that is easy to synthesize.-Ge, R., Heinonen, J. E., Svahn, M. G., Mohamed, A. J., Lundin, K. E., Smith, C. I. E. Zorro locked nucleic acid induces sequence-specific gene silencing.	Karolinska Univ Hosp, Karolinska Inst, Dept Lab Med, Clin Res Ctr, SE-14186 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Ge, RB (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Dept Lab Med, Clin Res Ctr, SE-14186 Stockholm, Sweden.	ge.rongbin@ki.se; edvard.smith@ki.se	Svahn, Mathias/AAQ-1784-2020	SMITH, C. I. Edvard/0000-0003-1907-3392				Andreatta C, 2001, BIOTECHNIQUES, V30, P656, DOI 10.2144/01303dd03; Bentin T, 2003, BIOCHEMISTRY-US, V42, P13987, DOI 10.1021/bi0351918; Besch R, 2004, CURR DRUG TARGETS, V5, P691, DOI 10.2174/1389450043345100; Boffa LC, 1996, J BIOL CHEM, V271, P13228, DOI 10.1074/jbc.271.22.13228; Boffa LC, 2000, CANCER RES, V60, P2258; Braasch DA, 2002, NUCLEIC ACIDS RES, V30, P5160, DOI 10.1093/nar/gkf651; Braasch DA, 2001, CHEM BIOL, V8, P1, DOI 10.1016/S1074-5521(00)00058-2; Brunet E, 2005, NUCLEIC ACIDS RES, V33, P4223, DOI 10.1093/nar/gki726; Brunet E, 2005, J BIOL CHEM, V280, P20076, DOI 10.1074/jbc.M500021200; Catapano CV, 2000, BIOCHEMISTRY-US, V39, P5126, DOI 10.1021/bi992185w; CHERNY DY, 1993, P NATL ACAD SCI USA, V90, P1667, DOI 10.1073/pnas.90.5.1667; Christensen L, 1995, J Pept Sci, V1, P175; Crinelli R, 2004, NUCLEIC ACIDS RES, V32, P1874, DOI 10.1093/nar/gkh503; Cutrona G, 2000, NAT BIOTECHNOL, V18, P300, DOI 10.1038/73745; DEMIDOV VV, 1995, P NATL ACAD SCI USA, V92, P2637, DOI 10.1073/pnas.92.7.2637; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; Dervan PB, 2003, CURR OPIN STRUC BIOL, V13, P284, DOI 10.1016/S0959-440X(03)00081-2; Diviacco S, 2001, FASEB J, V15, P2660, DOI 10.1096/fj.01-0440com; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; Faria M, 2000, P NATL ACAD SCI USA, V97, P3862, DOI 10.1073/pnas.97.8.3862; Faria M, 2001, J MOL BIOL, V306, P15, DOI 10.1006/jmbi.2000.4386; Frieden M, 2003, NUCLEIC ACIDS RES, V31, P6365, DOI 10.1093/nar/gkg820; Grunweller A, 2003, NUCLEIC ACIDS RES, V31, P3185, DOI 10.1093/nar/gkg409; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; Hertoghs KML, 2003, NUCLEIC ACIDS RES, V31, P5817, DOI 10.1093/nar/gkg801; Janowski BA, 2005, NAT CHEM BIOL, V1, P216, DOI 10.1038/nchembio725; Kaihatsu K, 2003, BIOCHEMISTRY-US, V42, P13996, DOI 10.1021/bi035194k; Koshkin AA, 1998, J ORG CHEM, V63, P2778, DOI 10.1021/jo972239c; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Lundin KE, 2006, ADV GENET, V56, P1, DOI 10.1016/S0065-2660(06)56001-8; Lundin KE, 2005, BIOMOL ENG, V22, P185, DOI 10.1016/j.bioeng.2005.07.003; Lundin KE, 2004, BIOMOL ENG, V21, P51, DOI 10.1016/j.bioeng.2003.10.003; MOLLEGAARD NE, 1994, P NATL ACAD SCI USA, V91, P3892, DOI 10.1073/pnas.91.9.3892; Mologni L, 1999, BIOCHEM BIOPH RES CO, V264, P537, DOI 10.1006/bbrc.1999.1548; Ng PS, 2005, NANO LETT, V5, P107, DOI [10.1021/nl048246f, 10.1012/nl048246f]; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; Nielsen PE, 2004, MOL BIOTECHNOL, V26, P233, DOI 10.1385/MB:26:3:233; NIELSEN PE, 1994, GENE, V149, P139, DOI 10.1016/0378-1119(94)90422-7; Obika S, 1998, TETRAHEDRON LETT, V39, P5401, DOI 10.1016/S0040-4039(98)01084-3; Parekh-Olmedo H, 2002, CHEM BIOL, V9, P1073, DOI 10.1016/S1074-5521(02)00236-3; PEFFER NJ, 1993, P NATL ACAD SCI USA, V90, P10648, DOI 10.1073/pnas.90.22.10648; Petersson B, 2005, J AM CHEM SOC, V127, P1424, DOI 10.1021/ja0458726; Schmidt KS, 2004, NUCLEIC ACIDS RES, V32, P5757, DOI 10.1093/nar/gkh862; Singh SK, 1998, J ORG CHEM, V63, P6078, DOI 10.1021/jo9806658; Svahn MG, 2007, OLIGONUCLEOTIDES, V17, P80, DOI 10.1089/oli.2006.0045; Svahn MG, 2004, J GENE MED, V6, pS36, DOI 10.1002/jgm.510; Vasquez KM, 2002, P NATL ACAD SCI USA, V99, P5848, DOI 10.1073/pnas.082193799; Vester B, 2002, J AM CHEM SOC, V124, P13682, DOI 10.1021/ja0276220; Vester B, 2004, BIOCHEMISTRY-US, V43, P13233, DOI 10.1021/bi0485732; Wahlestedt C, 2000, P NATL ACAD SCI USA, V97, P5633, DOI 10.1073/pnas.97.10.5633; Wang G, 1999, NUCLEIC ACIDS RES, V27, P2806, DOI 10.1093/nar/27.13.2806	51	21	23	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1902	1914		10.1096/fj.06-7225com	http://dx.doi.org/10.1096/fj.06-7225com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314142				2022-12-28	WOS:000246866500031
J	Zlatanova, J; Seebart, C; Tomschik, M				Zlatanova, Jordanka; Seebart, Corrine; Tomschik, Miroslav			Nap1: taking a closer look at a juggler protein of extraordinary skills	FASEB JOURNAL			English	Review						histone chaperone; nucleosome assembly; transcription	NUCLEOSOME ASSEMBLY PROTEIN-1; HISTONE (H3-H4)(2) TETRAMER; POLYMERASE-II HOLOENZYME; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-TRANSPORT; H2A-H2B DIMERS; CORE PARTICLE; CELL-CYCLE; IN-VITRO	The nucleosome assembly protein Nap1 is used extensively in the chromatin field to reconstitute nucleosomal templates for structural and functional studies. Beyond its role in facilitating experimental investigation of nucleosomes, the highly conserved Nap1 is one of the best- studied members of the histone chaperone group. Here we review its numerous functions, focusing mainly on its roles in assembly and disassembly of the nucleosome particle, and its interactions with chromatin remodeling factors. Its presumed role in transcription through chromatin is also reviewed in detail. An attempt is made to clearly discriminate between fact and fiction, and to formulate the unresolved questions that need further attention. It is beyond doubt that the numerous, seemingly unrelated functions of this juggler protein have to be precisely channeled, coordinated, and regulated. Why nature endowed this specific protein with so many functions may remain a mystery. We are aware of the enormous challenge to the scientific community that understanding the mechanisms underlying these activities presents.	Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA	University of Wyoming	Zlatanova, J (corresponding author), Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA.	jordanka@uwyo.edu	Zlatanova, Jordanka/B-3273-2009; , Miroslav/AAD-9416-2020; Palicka, Vladimir/N-1802-2017	, Miroslav/0000-0002-0758-6169; Palicka, Vladimir/0000-0001-7236-1647				Abu-Daya A, 2005, BLOOD, V106, P514, DOI 10.1182/blood-2005-02-0598; Altman R, 1997, J CELL BIOL, V138, P119, DOI 10.1083/jcb.138.1.119; An WJ, 2002, MOL CELL, V9, P811, DOI 10.1016/S1097-2765(02)00497-5; Archambault V, 2004, MOL CELL, V14, P699, DOI 10.1016/j.molcel.2004.05.025; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; Asahara H, 2002, MOL CELL BIOL, V22, P2974, DOI 10.1128/MCB.22.9.2974-2983.2002; Ausio Juan, 2006, Briefings in Functional Genomics & Proteomics, V5, P228, DOI 10.1093/bfgp/ell020; Belotserkovskaya R, 2004, CURR OPIN GENET DEV, V14, P139, DOI 10.1016/j.gde.2004.02.004; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Carroll CW, 1998, J CELL BIOL, V143, P709, DOI 10.1083/jcb.143.3.709; Chandra BR, 2005, MOL BIOCHEM PARASIT, V142, P237, DOI 10.1016/j.molbiopara.2005.04.006; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; Chiolo I, 2005, MOL CELL BIOL, V25, P5738, DOI 10.1128/MCB.25.13.5738-5751.2005; Collins I, 2001, MOL CELL BIOL, V21, P8437, DOI 10.1128/MCB.21.24.8437-8451.2001; Dong AW, 2005, PLANT PHYSIOL, V138, P1446, DOI 10.1104/pp.105.060509; Dong AW, 2003, PLANTA, V216, P561, DOI 10.1007/s00425-002-0910-6; English CM, 2005, BIOCHEMISTRY-US, V44, P13673, DOI 10.1021/bi051333h; Fyodorov DV, 2004, GENE DEV, V18, P170, DOI 10.1101/gad.1139604; Gal TZ, 2005, J PARASITOL, V91, P691, DOI 10.1645/GE-402R; Gavin AC, 2006, NATURE, V440, P631, DOI 10.1038/nature04532; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gemmen GJ, 2005, J MOL BIOL, V351, P89, DOI 10.1016/j.jmb.2005.05.058; Georges SA, 2002, MOL CELL BIOL, V22, P127, DOI 10.1128/MCB.22.1.127-137.2002; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Hamiche A, 1996, P NATL ACAD SCI USA, V93, P7588, DOI 10.1073/pnas.93.15.7588; Harp JM, 2000, ACTA CRYSTALLOGR D, V56, P1513, DOI 10.1107/S0907444900011847; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hodges JL, 2005, MOL BIOL CELL, V16, P3200, DOI 10.1091/mbc.E04-11-0990; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1983, J BIOCHEM-TOKYO, V94, P735, DOI 10.1093/oxfordjournals.jbchem.a134414; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; Ito T, 2000, GENE DEV, V14, P1899; Ito T, 1996, MOL CELL BIOL, V16, P3112; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Ito T, 1996, J BIOL CHEM, V271, P25041, DOI 10.1074/jbc.271.40.25041; Iwase M, 2004, CELL STRUCT FUNCT, V29, P1, DOI 10.1247/csf.29.1; Iwase M, 2001, GENES GENET SYST, V76, P335, DOI 10.1266/ggs.76.335; JACKSON V, 2004, CHROMATIN STRUCTURE, P467; JI HB, 2000, SHENG WU HUA XUE YU, V32, P4; Jin JJ, 2005, TRENDS BIOCHEM SCI, V30, P680, DOI 10.1016/j.tibs.2005.10.003; Kamakaka RT, 2005, GENE DEV, V19, P295, DOI 10.1101/gad.1272805; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; Kepert JF, 2005, J BIOL CHEM, V280, P34063, DOI 10.1074/jbc.M507322200; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Kong SE, 2005, J BIOL CHEM, V280, P4299, DOI 10.1074/jbc.M411071200; Kouzine F, 2004, NAT STRUCT MOL BIOL, V11, P1092, DOI 10.1038/nsmb848; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Krogan NJ, 2004, MOL CELL, V13, P225, DOI 10.1016/S1097-2765(04)00003-6; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Lankenau S, 2003, GENETICS, V163, P611; Levchenko V, 2005, BIOCHEMISTRY-US, V44, P5357, DOI 10.1021/bi047786o; Levchenko V, 2004, BIOCHEMISTRY-US, V43, P2359, DOI 10.1021/bi035737q; Li MF, 1999, J MOL BIOL, V293, P1067, DOI 10.1006/jmbi.1999.3207; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Longtine MS, 2000, MOL CELL BIOL, V20, P4049, DOI 10.1128/MCB.20.11.4049-4061.2000; Lorch Y, 2006, P NATL ACAD SCI USA, V103, P3090, DOI 10.1073/pnas.0511050103; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Marheineke K, 1998, J BIOL CHEM, V273, P15279, DOI 10.1074/jbc.273.24.15279; Mazurkiewicz J, 2006, J BIOL CHEM, V281, P16462, DOI 10.1074/jbc.M511619200; McBryant SJ, 2004, BIOCHEMISTRY-US, V43, P10592, DOI 10.1021/bi035881b; McBryant SJ, 2003, J BIOL CHEM, V278, P44574, DOI 10.1074/jbc.M305636200; McQuibban GA, 1998, J BIOL CHEM, V273, P6582, DOI 10.1074/jbc.273.11.6582; Miyaji-Yamaguchi M, 2003, MOL CELL BIOL, V23, P6672, DOI 10.1128/MCB.23.18.6672-6684.2003; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Mondal N, 2001, NATURE, V413, P435, DOI 10.1038/35096590; Mortensen EM, 2002, MOL BIOL CELL, V13, P2091, DOI 10.1091/mbc.01-10-0500; Mosammaparast N, 2002, J BIOL CHEM, V277, P862, DOI 10.1074/jbc.M106845200; Mosammaparast N, 2005, MOL CELL BIOL, V25, P1764, DOI 10.1128/MCB.25.5.1764-1778.2005; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; Mosammaparast N, 2002, EMBO J, V21, P6527, DOI 10.1093/emboj/cdf647; Mosammaparast N, 2001, J CELL BIOL, V153, P251, DOI 10.1083/jcb.153.2.251; Nakagawa T, 2001, J BIOL CHEM, V276, P27384, DOI 10.1074/jbc.M101331200; Navadgi VM, 2006, J BIOL CHEM, V281, P16978, DOI 10.1074/jbc.M602243200; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; Ohkuni K, 2003, GENETICS, V165, P517; Ohkuni K, 2003, BIOCHEM BIOPH RES CO, V306, P5, DOI 10.1016/S0006-291X(03)00907-0; Okuwaki M, 2005, MOL CELL BIOL, V25, P10639, DOI 10.1128/MCB.25.23.10639-10651.2005; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Park YJ, 2006, P NATL ACAD SCI USA, V103, P1248, DOI 10.1073/pnas.0508002103; Park YJ, 2005, J BIOL CHEM, V280, P1817, DOI 10.1074/jbc.M411347200; Park YJ, 2004, J BIOL CHEM, V279, P24274, DOI 10.1074/jbc.M313152200; Pilon J, 1997, PROTEIN EXPRES PURIF, V10, P132, DOI 10.1006/prep.1996.0716; Regnard C, 2000, J BIOL CHEM, V275, P15969, DOI 10.1074/jbc.M000045200; Rehtanz M, 2004, MOL CELL BIOL, V24, P2153, DOI 10.1128/MCB.24.5.2153-2168.2004; Reinberg D, 2006, J BIOL CHEM, V281, P23297, DOI 10.1074/jbc.R600007200; Rodriguez P, 1997, GENOMICS, V44, P253, DOI 10.1006/geno.1997.4868; Rodriguez P, 2004, J CELL BIOCHEM, V93, P398, DOI 10.1002/jcb.20163; Rodriguez P, 2000, J MOL BIOL, V298, P225, DOI 10.1006/jmbi.2000.3674; Rogner UC, 2000, NAT GENET, V25, P431, DOI 10.1038/78124; Saeki H, 2005, P NATL ACAD SCI USA, V102, P5697, DOI 10.1073/pnas.0409824102; Sarma K, 2005, NAT REV MOL CELL BIO, V6, P139, DOI 10.1038/nrm1567; Shields CM, 2003, CURR GENET, V44, P184, DOI 10.1007/s00294-003-0442-z; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; Shimizu Y, 2000, GENE, V246, P395, DOI 10.1016/S0378-1119(00)00067-6; Shintomi K, 2005, P NATL ACAD SCI USA, V102, P8210, DOI 10.1073/pnas.0500822102; Steer WM, 2003, MECH DEVELOP, V120, P1045, DOI 10.1016/S0925-4773(03)00176-X; Terrell AR, 2002, J BIOL CHEM, V277, P31038, DOI 10.1074/jbc.M204662200; Thambirajah AA, 2006, J BIOL CHEM, V281, P20036, DOI 10.1074/jbc.M601975200; Titz B, 2006, NUCLEIC ACIDS RES, V34, P955, DOI 10.1093/nar/gkj493; Tjandra H, 1998, CURR BIOL, V8, P991, DOI 10.1016/S0960-9822(07)00419-8; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Toth KF, 2005, J BIOL CHEM, V280, P15690, DOI 10.1074/jbc.M413329200; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; van Holde K, 2006, J BIOL CHEM, V281, P12197, DOI 10.1074/jbc.R500025200; van Holde K, 1999, BIOESSAYS, V21, P776, DOI 10.1002/(SICI)1521-1878(199909)21:9<776::AID-BIES9>3.3.CO;2-Q; Wagner G, 2005, BIOPHYS J, V89, P3647, DOI 10.1529/biophysj.105.062786; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; Workman JL, 2006, GENE DEV, V20, P2009, DOI 10.1101/gad.1435706; Wunsch A, 2005, BIOCHEMISTRY-US, V44, P16351, DOI 10.1021/bi050876o; Yoon HW, 1995, MOL GEN GENET, V249, P465, DOI 10.1007/BF00290572; Zimmerman ZA, 2001, MOL BIOL CELL, V12, P201, DOI 10.1091/mbc.12.1.201; Zlatanova J, 1998, BIOPHYS J, V74, P2554, DOI 10.1016/S0006-3495(98)77963-9	117	95	100	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1294	1310		10.1096/fj.06-7199rev	http://dx.doi.org/10.1096/fj.06-7199rev			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17317729				2022-12-28	WOS:000246117000006
J	Marsche, G; Semlitsch, M; Hammer, A; Frank, S; Weigle, B; Demling, N; Schmidt, K; Windischhofer, W; Waeg, G; Sattler, W; Malle, E				Marsche, Gunther; Semlitsch, Michaela; Hammer, Astrid; Frank, Sasa; Weigle, Bernd; Demling, Nina; Schmidt, Kurt; Windischhofer, Werner; Waeg, Georg; Sattler, Wolfgang; Malle, Ernst			Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway	FASEB JOURNAL			English	Article						AOPP; hypochlorous acid; inflammation; myeloperoxidase	GLYCATION END-PRODUCTS; OXIDATION PROTEIN PRODUCTS; HIGH-DENSITY-LIPOPROTEIN; MONOCYTE CHEMOATTRACTANT PROTEIN-1; HUMAN ATHEROSCLEROTIC LESIONS; SCAVENGER RECEPTOR; ENDOTHELIAL-CELLS; WHHL RABBITS; MYELOPEROXIDASE; INFLAMMATION	Signal transduction via the endothelial receptor for advanced glycation end products ( RAGE) plays a key role in vascular inflammation. Recent observations have shown that the myeloperoxidase-H2O2-chloride system of activated phagocytes is highly up-regulated under inflammatory conditions where hypochlorous acid (HOCl) is formed as the major oxidant. Albumin, an in vivo carrier for myeloperoxidase is highly vulnerable to oxidation and a major representative of circulating advanced oxidized proteins during inflammatory diseases. Immunohistochemical studies performed in the present study revealed marked colocalization of HOCl-modified epitopes with RAGE and albumin in sections of human atheroma, mainly at the endothelial lining. We show that albumin modified with physiologically relevant concentrations of HOCl, added as reagent or generated by the myeloperoxidase-H2O2-chloride system, is a high affinity ligand for RAGE. Albumin, modified by HOCl in the absence of free amino acids/carbohydrates/lipids to exclude formation of AGE-like structures, induced a rapid, RAGE-dependent activation of extracellular signal-regulated kinase 1/2 and up-regulation of the proinflammatory mediator monocyte chemoattractant protein-1. Cellular activation could be blocked either by a specific polyclonal anti-RAGE IgG and/or a specific mitogen-activated protein-kinase kinase inhibitor. The present study demonstrates that HOCl-modified albumin acts as a ligand for RAGE and promotes RAGE-mediated inflammatory complications.	Med Univ Graz, Ctr Mol Med, Inst Mol Biol & Biochem, A-8010 Graz, Austria; Inst Mol Biol & Biochem, Graz, Austria; Inst Cell Biol Histol & Embryol, Graz, Austria; Univ Childrens Hosp, Res Unit Osteol Res & Analyt Mass Spect, Graz, Austria; Tech Univ Dresden, Inst Immunol, D-8027 Dresden, Germany; Karl Franzens Univ Graz, Graz, Austria; Inst Pharmaceut Sci, Dept Pharmacol & Toxicol, Graz, Austria; Inst Mol Biosci, Graz, Austria	Medical University of Graz; Technische Universitat Dresden; University of Graz	Malle, E (corresponding author), Med Univ Graz, Ctr Mol Med, Inst Mol Biol & Biochem, Harrachgasse 21, A-8010 Graz, Austria.	ernst.malle@meduni-graz.at	Malle, Ernst/D-3071-2013	Marsche, Gunther/0000-0002-2422-5381	Austrian Science Fund FWF [P 19074, P 17013] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; Brasen JH, 2003, ATHEROSCLEROSIS, V166, P13, DOI 10.1016/S0021-9150(02)00130-2; Capeillere-Blandin C, 2004, BBA-MOL BASIS DIS, V1689, P91, DOI 10.1016/j.bbadis.2004.02.008; Chen DR, 1999, J NANOPART RES, V1, P115, DOI 10.1023/A:1010087311616; Cipollone F, 2003, CIRCULATION, V108, P1070, DOI 10.1161/01.CIR.0000086014.80477.0D; Demling N, 2006, CELL TISSUE RES, V323, P475, DOI 10.1007/s00441-005-0069-0; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hsieh HL, 2004, BIOCHEM BIOPH RES CO, V316, P949, DOI 10.1016/j.bbrc.2004.02.135; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Lau D, 2005, P NATL ACAD SCI USA, V102, P431, DOI 10.1073/pnas.0405193102; Liu SX, 2006, ARTERIOSCL THROM VAS, V26, P1156, DOI 10.1161/01.ATV.0000214960.85469.68; Liu Y, 2002, IMMUNOL LETT, V80, P27, DOI 10.1016/S0165-2478(01)00291-7; Malle E, 2006, ARCH BIOCHEM BIOPHYS, V445, P245, DOI 10.1016/j.abb.2005.08.008; Malle E, 2000, EUR J BIOCHEM, V267, P4495, DOI 10.1046/j.1432-1327.2000.01498.x; MALLE E, 1995, ARTERIOSCL THROM VAS, V15, P982, DOI 10.1161/01.ATV.15.7.982; Malle E, 2001, BIOCHEM BIOPH RES CO, V289, P894, DOI 10.1006/bbrc.2001.6074; Marsche G, 2001, FASEB J, V15, P1095, DOI 10.1096/fj.00-0532fje; Marsche G, 2004, ARTERIOSCL THROM VAS, V24, P2302, DOI 10.1161/01.ATV.0000148703.43429.25; Marsche G, 2002, J BIOL CHEM, V277, P32172, DOI 10.1074/jbc.M200503200; Murakami S, 2002, ATHEROSCLEROSIS, V163, P79, DOI 10.1016/S0021-9150(01)00764-X; Naka Y, 2004, ARTERIOSCL THROM VAS, V24, P1342, DOI 10.1161/01.ATV.0000133191.71196.90; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Peters W, 2001, CURR OPIN LIPIDOL, V12, P175, DOI 10.1097/00041433-200104000-00011; RITTHALER U, 1995, AM J PATHOL, V146, P688; Rodriguez-Ayala E, 2005, ATHEROSCLEROSIS, V180, P333, DOI 10.1016/j.atherosclerosis.2004.12.007; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI200114002; Srikrishna G, 2002, J NEUROCHEM, V80, P998, DOI 10.1046/j.0022-3042.2002.00796.x; Strauss JG, 2003, BIOCHEM J, V371, P981, DOI 10.1042/BJ20021437; TAKATA K, 1988, J BIOL CHEM, V263, P14819; Tiruppathi C, 2004, P NATL ACAD SCI USA, V101, P7699, DOI 10.1073/pnas.0401712101; Valencia JV, 2004, ANAL BIOCHEM, V324, P68, DOI 10.1016/j.ab.2003.09.013; Wautier JL, 2004, CIRC RES, V95, P233, DOI 10.1161/01.RES.0000137876.28454.64; Witko-Sarsat V, 1998, J IMMUNOL, V161, P2524; Witko-Sarsat W, 2003, KIDNEY INT, V64, P82, DOI 10.1046/j.1523-1755.2003.00044.x; WitkoSarsat V, 1996, KIDNEY INT, V49, P1304, DOI 10.1038/ki.1996.186; Yan SF, 2003, CIRC RES, V93, P1159, DOI 10.1161/01.RES.0000103862.26506.3D; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	40	46	49	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1145	1152		10.1096/fj.06-7439com	http://dx.doi.org/10.1096/fj.06-7439com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17218539	Green Accepted			2022-12-28	WOS:000245650400019
J	Sharples, RA; Vella, LJ; Nisbet, RM; Naylor, R; Perez, K; Barnham, KJ; Masters, CL; Hill, AF				Sharples, Robyn A.; Vella, Laura J.; Nisbet, Rebecca M.; Naylor, Ryan; Perez, Keyla; Barnham, Kevin J.; Masters, Colin L.; Hill, Andrew F.			Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes	FASEB JOURNAL			English	Article						Alzheimer's disease; protein processing; APP; secretases	CELL-DERIVED EXOSOMES; ALZHEIMERS-DISEASE; BETA-PROTEIN; ALPHA-SECRETASE; MULTIVESICULAR BODIES; TRANSGENIC MICE; PEPTIDE LEVELS; HUMAN BRAIN; CLEAVAGE; APP	Alzheimer's disease (AD) is the most common form of dementia and is associated with the deposition of the 39- to 43-amino acid beta-amyloid peptide (A beta) in the brain. C-terminal fragments (CTFs) of amyloid precursor protein (APP) can accumulate in endosomally derived multivesicular bodies (MVBs). These intracellular structures contain intraluminal vesicles that are released from the cell as exosomes when the MVB fuses with the plasma membrane. Here we have investigated the role of exosomes in the processing of APP and show that these vesicles contain APP-CTFs, as well as A beta. In addition, inhibition of gamma-secretase results in a significant increase in the amount of alpha-and beta-secretase cleavage, further increasing the amount of APP-CTFs contained within these exosomes. We identify several key members of the secretase family of proteases (BACE, PS1, PS2, and ADAM10) to be localized in exosomes, suggesting they may be a previously unidentified site of APP cleavage. These results provide further evidence for a novel pathway in which APP fragments are released from cells and have implications for the analysis of APP processing and diagnostics for Alzheimer's disease.	[Sharples, Robyn A.; Vella, Laura J.; Nisbet, Rebecca M.; Naylor, Ryan; Hill, Andrew F.] Univ Melbourne, Dept Biochem & Mol Biol, Bio21 Mol Sci & Biotechnol Inst, Parkville, Vic 3010, Australia; [Vella, Laura J.; Nisbet, Rebecca M.; Naylor, Ryan; Perez, Keyla; Barnham, Kevin J.; Masters, Colin L.; Hill, Andrew F.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; [Vella, Laura J.; Nisbet, Rebecca M.; Naylor, Ryan; Perez, Keyla; Barnham, Kevin J.; Masters, Colin L.; Hill, Andrew F.] Mental Hlth Res Inst, Parkville, Vic, Australia	University of Melbourne; University of Melbourne; Florey Institute of Neuroscience & Mental Health	Hill, AF (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Bio21 Mol Sci & Biotechnol Inst, Parkville, Vic 3010, Australia.	a.hill@unimelb.edu.au	Hill, Andrew F./AAH-2854-2020; Nisbet, Rebecca/P-6492-2017; Hill, Andrew F./GZL-4124-2022; Hill, Andrew F/B-4527-2009; Vella, laura/N-2733-2017	Nisbet, Rebecca/0000-0002-3751-9119; Hill, Andrew F./0000-0001-5581-2354; Hill, Andrew F/0000-0001-5581-2354; Vella, laura/0000-0002-1869-6291; Naylor, Ryan/0000-0001-6880-6463				Abusamra AJ, 2005, BLOOD CELL MOL DIS, V35, P169, DOI 10.1016/j.bcmd.2005.07.001; Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1; Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Culvenor JG, 2004, EUR J BIOCHEM, V271, P375, DOI 10.1046/j.1432-1033.2003.03936.x; de Gassart A, 2003, BLOOD, V102, P4336, DOI 10.1182/blood-2003-03-0871; Denzer K, 2000, J IMMUNOL, V165, P1259, DOI 10.4049/jimmunol.165.3.1259; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Eckman CB, 1997, HUM MOL GENET, V6, P2087, DOI 10.1093/hmg/6.12.2087; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; Evin G, 2002, PEPTIDES, V23, P1285, DOI 10.1016/S0196-9781(02)00063-3; Faure J, 2006, MOL CELL NEUROSCI, V31, P642, DOI 10.1016/j.mcn.2005.12.003; Fevrier B, 2004, P NATL ACAD SCI USA, V101, P9683, DOI 10.1073/pnas.0308413101; Findeis MA, 2000, BBA-MOL BASIS DIS, V1502, P76, DOI 10.1016/S0925-4439(00)00034-X; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gastpar R, 2005, CANCER RES, V65, P5238, DOI 10.1158/0008-5472.CAN-04-3804; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Keller S, 2006, IMMUNOL LETT, V107, P102, DOI 10.1016/j.imlet.2006.09.005; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Kowalska A, 2003, FOLIA NEUROPATHOL, V41, P35; Kwok JBJ, 2000, ANN NEUROL, V47, P249, DOI 10.1002/1531-8249(200002)47:2<249::AID-ANA18>3.3.CO;2-#; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Langui D, 2004, AM J PATHOL, V165, P1465, DOI 10.1016/S0002-9440(10)63405-0; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Masciopinto F, 2004, EUR J IMMUNOL, V34, P2834, DOI 10.1002/eji.200424887; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Murakami K, 2002, BIOCHEM BIOPH RES CO, V294, P5, DOI 10.1016/S0006-291X(02)00430-8; Pisitkun T, 2004, P NATL ACAD SCI USA, V101, P13368, DOI 10.1073/pnas.0403453101; Potolicchio A, 2005, J IMMUNOL, V175, P2237, DOI 10.4049/jimmunol.175.4.2237; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Saura CA, 2005, J NEUROSCI, V25, P6755, DOI 10.1523/JNEUROSCI.1247-05.2005; SCHUBERT D, 1993, BRAIN RES, V629, P275, DOI 10.1016/0006-8993(93)91331-L; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Selkoe DJ, 1996, COLD SPRING HARB SYM, V61, P587; Serpell LC, 2000, J MOL BIOL, V299, P225, DOI 10.1006/jmbi.2000.3650; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Shi XP, 2003, J BIOL CHEM, V278, P21286, DOI 10.1074/jbc.M209859200; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Stoeck A, 2006, BIOCHEM J, V393, P609, DOI 10.1042/BJ20051013; Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Thery C, 2002, NAT IMMUNOL, V3, P1156, DOI 10.1038/ni854; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; van Niel G, 2002, AM J PHYSIOL-GASTR L, V283, pG251, DOI 10.1152/ajpgi.00102.2002; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vella LJ, 2007, J PATHOL, V211, P582, DOI 10.1002/path.2145; Vingtdeux V, 2007, J BIOL CHEM, V282, P18197, DOI 10.1074/jbc.M609475200; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; White AR, 2006, J BIOL CHEM, V281, P17670, DOI 10.1074/jbc.M602487200; Wolfe MS, 2002, INT IMMUNOPHARMACOL, V2, P1919, DOI 10.1016/S1567-5769(02)00179-0; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Yamazaki T, 1996, J CELL SCI, V109, P999; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2; Zhang M, 2006, FASEB J, V20, P1176, DOI 10.1096/fj.05-5531fje	79	203	206	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1469	1478		10.1096/fj.07-9357com	http://dx.doi.org/10.1096/fj.07-9357com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18171695				2022-12-28	WOS:000255898700019
J	Bousquet, M; Saint-Pierre, M; Julien, C; Salem, N; Cicchetti, F; Calon, F				Bousquet, M.; Saint-Pierre, M.; Julien, C.; Salem, N., Jr.; Cicchetti, F.; Calon, F.			Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease	FASEB JOURNAL			English	Article						MPTP; neuroprotection; DHA; dopamine	DOCOSAHEXAENOIC ACID; DOPAMINE TRANSPORTER; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; MOUSE MODEL; TYROSINE-HYDROXYLASE; MONOAMINERGIC NEUROTRANSMISSION; INDUCED DYSKINESIAS; SUBSTANTIA-NIGRA; LEARNING-ABILITY	In this study, we examined whether omega-3 (n-3) polyunsaturated fatty acids (PUFAs) may exert neuroprotective action in Parkinson's disease, as previously shown in Alzheimer's disease. We exposed mice to either a control or a high n-3 PUFA diet from 2 to 12 months of age and then treated them with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 140 mg/kg in 5 days). High n-3 PUFA dietary consumption completely prevented the MPTP-induced decrease of tyrosine hydroxylase (TH)-labeled nigral cells (P<0.01 vs. MPTP mice on control diet), Nurr1 mRNA (P<0.01 vs. MPTP mice on control diet), and dopamine transporter mRNA levels (P<0.05 vs. MPTP mice on control diet) in the substantia nigra. Although n-3 PUFA dietary treatment had no effect on striatal dopaminergic terminals, the high n-3 PUFA diet protected against the MPTP-induced decrease in dopamine (P<0.05 vs. MPTP mice on control diet) and its metabolite dihydroxyphenylacetic acid (P<0.05 vs. MPTP mice on control diet) in the striatum. Taken together, these data suggest that a high n-3 PUFA dietary intake exerts neuroprotective actions in an animal model of Parkinsonism.	[Bousquet, M.; Julien, C.; Calon, F.] CHUQ, CHU Laval, Ctr Res Endocrinol Mol & Oncol, Quebec City, PQ G1V 4G2, Canada; [Saint-Pierre, M.; Cicchetti, F.] CHUQ, CHU Laval, Ctr Res Neurosci, Quebec City, PQ, Canada; [Bousquet, M.; Julien, C.; Calon, F.] Univ Laval, Fac Pharm, Quebec City, PQ, Canada; [Cicchetti, F.] Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada; [Salem, N., Jr.] NIAAA, Sect Nutr Neurosci, Lab Membrane Biochem & Biophys, Div Intramural Clin & Biol Res, Rockville, MD 20852 USA	Laval University; Laval University; McGill University; Laval University; Laval University; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Calon, F (corresponding author), CHUQ, CHU Laval, Res Ctr, T2-05,2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	francesca.cicchetti@crchul.ulaval.ca; frederic.calon@crchul.ulaval.ca	Julien, Carl/AAU-5309-2021; Calon, Frederic/AAF-4390-2020; soler, martha maricel m gomez/L-6025-2014	soler, martha maricel m gomez/0000-0002-4412-8108; Calon, Frederic/0000-0002-4203-0887; Cicchetti, Francesca/0000-0001-5490-1961				Akbar M, 2005, P NATL ACAD SCI USA, V102, P10858, DOI 10.1073/pnas.0502903102; Akbar M, 2002, J NEUROCHEM, V82, P655, DOI 10.1046/j.1471-4159.2002.01015.x; [Anonymous], [No title captured]; Bazan NG, 2005, BRAIN PATHOL, V15, P159; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; Bezard E, 1997, EXP NEUROL, V148, P288, DOI 10.1006/exnr.1997.6648; Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; BRECKENRIDGE WC, 1973, BIOCHIM BIOPHYS ACTA, V320, P681, DOI 10.1016/0304-4165(73)90148-7; Calon F, 2006, CAN MED ASSOC J, V174, P483, DOI 10.1503/cmaj.050663; Calon F, 2005, EUR J NEUROSCI, V22, P617, DOI 10.1111/j.1460-9568.2005.04253.x; Calon F, 2004, NEURON, V43, P633, DOI 10.1016/j.neuron.2004.08.013; Calon F, 2003, MOVEMENT DISORD, V18, P241, DOI 10.1002/mds.10343; Calon F, 2001, SYNAPSE, V40, P225, DOI 10.1002/syn.1045; Chalon S, 1998, J NUTR, V128, P2512, DOI 10.1093/jn/128.12.2512; Chan CS, 2007, NATURE, V447, P1081, DOI 10.1038/nature05865; Chen H, 2003, AM J EPIDEMIOL, V157, P1007, DOI 10.1093/aje/kwg073; CHRISTENSEN O, 1988, ACTA PSYCHIAT SCAND, V78, P587, DOI 10.1111/j.1600-0447.1988.tb06388.x; Costantini LC, 2001, EUR J NEUROSCI, V13, P1085, DOI 10.1046/j.0953-816x.2001.01473.x; Danthi SJ, 2005, BIOCHEM BIOPH RES CO, V327, P485, DOI 10.1016/j.bbrc.2004.12.033; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dawson TM, 2002, NEURON, V35, P219, DOI 10.1016/S0896-6273(02)00780-8; de Lau LML, 2005, NEUROLOGY, V64, P2040, DOI 10.1212/01.WNL.0000166038.67153.9F; Delion S, 1997, J LIPID RES, V38, P680; Di Monte DA, 2002, NEUROTOXICOLOGY, V23, P487, DOI 10.1016/S0161-813X(02)00099-2; Ethier I, 2004, BIOL PSYCHIAT, V56, P522, DOI 10.1016/j.biopsych.2004.06.036; Fedorova I, 2006, PROSTAG LEUKOTR ESS, V75, P271, DOI 10.1016/j.plefa.2006.07.006; FOLCH J, 1957, J BIOL CHEM, V226, P497; Freund-Levi Y, 2006, ARCH NEUROL-CHICAGO, V63, P1402, DOI 10.1001/archneur.63.10.1402; Gainetdinov RR, 1997, J NEUROCHEM, V69, P1322; Glaser JR, 2000, J CHEM NEUROANAT, V20, P115, DOI 10.1016/S0891-0618(00)00073-9; Green KN, 2007, J NEUROSCI, V27, P4385, DOI 10.1523/JNEUROSCI.0055-07.2007; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; Hashimoto M, 2005, J NUTR, V135, P549, DOI 10.1093/jn/135.3.549; Hashimoto M, 2002, J NEUROCHEM, V81, P1084, DOI 10.1046/j.1471-4159.2002.00905.x; Hogan SA, 2003, J MICROENCAPSUL, V20, P675, DOI 10.1080/0265204031000151974; Horrocks LA, 2004, PROSTAG LEUKOTR ESS, V70, P361, DOI 10.1016/j.plefa.2003.12.011; Huot P, 2007, J NEUROCHEM, V101, P1441, DOI 10.1111/j.1471-4159.2006.04430.x; Jaber M, 1999, EUR J NEUROSCI, V11, P3499, DOI 10.1046/j.1460-9568.1999.00764.x; Jourdain S, 2005, J NEUROENDOCRINOL, V17, P509, DOI 10.1111/j.1365-2826.2005.01337.x; Joyce JN, 1997, MOVEMENT DISORD, V12, P885, DOI 10.1002/mds.870120609; Julien C, 2006, NEUROCHEM INT, V48, P404, DOI 10.1016/j.neuint.2005.12.002; Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; Kaul S, 2003, EUR J NEUROSCI, V18, P1387, DOI 10.1046/j.1460-9568.2003.02864.x; Kim HY, 2007, J BIOL CHEM, V282, P18661, DOI 10.1074/jbc.R700015200; Kolanowski W, 2004, INT J FOOD SCI NUTR, V55, P333, DOI 10.1080/09637480410001725157; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; Le W, 1999, J NEUROCHEM, V73, P2218; Lee MA, 2002, NEUROSCI LETT, V333, P74, DOI 10.1016/S0304-3940(02)00981-3; Lim GP, 2005, J NEUROSCI, V25, P3032, DOI 10.1523/JNEUROSCI.4225-04.2005; Maclean C H, 2005, Evid Rep Technol Assess (Summ), P1; Maes M, 1996, J AFFECT DISORDERS, V38, P35, DOI 10.1016/0165-0327(95)00092-5; Mandavilli BS, 2000, BRAIN RES, V885, P45, DOI 10.1016/S0006-8993(00)02926-7; Mao LM, 2001, DEV BRAIN RES, V131, P57, DOI 10.1016/S0165-3806(01)00260-7; Masood A, 2005, J LIPID RES, V46, P2299, DOI 10.1194/jlr.D500022-JLR200; McGeer PL, 2001, ADV NEUROL, V86, P83; McNamara RK, 2006, PROSTAG LEUKOTR ESS, V75, P237, DOI 10.1016/j.plefa.2006.07.009; Miller GW, 1999, TRENDS PHARMACOL SCI, V20, P424, DOI 10.1016/S0165-6147(99)01379-6; Mizuno Y, 2001, ADV NEUROL, V86, P13; Moriguchi T, 2004, J LIPID RES, V45, P1437, DOI 10.1194/jlr.M400087-JLR200; Morris MC, 2003, ARCH NEUROL-CHICAGO, V60, P940, DOI 10.1001/archneur.60.7.940; MURRAY AM, 1995, ANN NEUROL, V37, P300, DOI 10.1002/ana.410370306; Nakahara T, 2001, NEUROSCIENCE, V108, P601, DOI 10.1016/S0306-4522(01)00441-9; *NEW ALZH CLIN TRI, 2006, AM J ALZHEIMERS DIS, V21, P460; Oksman M, 2006, NEUROBIOL DIS, V23, P563, DOI 10.1016/j.nbd.2006.04.013; Pawlosky RJ, 2001, ALCOHOL CLIN EXP RES, V25, P1758, DOI 10.1097/00000374-200112000-00011; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Przedborski S, 2003, ANN NY ACAD SCI, V991, P189; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Samadi P, 2006, ANN NEUROL, V59, P282, DOI 10.1002/ana.20738; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Schaefer EJ, 2006, ARCH NEUROL-CHICAGO, V63, P1545, DOI 10.1001/archneur.63.11.1545; SCHAPIRA AHV, 1994, MOVEMENT DISORD, V9, P125, DOI 10.1002/mds.870090202; Seebungkert B, 2002, EUR J NEUROSCI, V16, P2085, DOI 10.1046/j.1460-9568.2002.02288.x; Soderstrom K, 2006, CELL TRANSPLANT, V15, P251, DOI 10.3727/000000006783982025; Su KP, 2003, EUR NEUROPSYCHOPHARM, V13, P267, DOI 10.1016/S0924-977X(03)00032-4; SUNDSTROM E, 1987, BRAIN RES, V405, P26; Suzuki H, 1997, INT J VITAM NUTR RES, V67, P272; Tanner CM, 1996, NEUROL CLIN, V14, P317, DOI 10.1016/S0733-8619(05)70259-0; Tanner CM, 2003, ADV NEUROL, V91, P133; TREEN M, 1992, ARCH BIOCHEM BIOPHYS, V294, P564, DOI 10.1016/0003-9861(92)90726-D; Tremblay ME, 2006, NEUROBIOL AGING, V27, P862, DOI 10.1016/j.neurobiolaging.2005.04.004; Vreugdenhil M, 1996, P NATL ACAD SCI USA, V93, P12559, DOI 10.1073/pnas.93.22.12559; Wheaton DH, 2003, ARCH OPHTHALMOL-CHIC, V121, P1269, DOI 10.1001/archopht.121.9.1269; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Yavin E, 2002, NUTR NEUROSCI, V5, P149, DOI 10.1080/10284150290003159; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	89	173	182	0	31	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1213	1225		10.1096/fj.07-9677com	http://dx.doi.org/10.1096/fj.07-9677com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	18032633				2022-12-28	WOS:000254581000026
J	Khan, EM; Lanir, R; Danielson, AR; Goldkorn, T				Khan, Elaine M.; Lanir, Roni; Danielson, Aaron R.; Goldkorn, Tzipora			Epidermal growth factor receptor exposed to cigarette smoke is aberrandy activated and undergoes perinuclear trafficking	FASEB JOURNAL			English	Article							ALPHA-CONVERTING ENZYME; LUNG EPITHELIAL-CELLS; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; TYROSINE KINASES; HUMAN CANCER; CBL; PATHWAY; POLYUBIQUITYLATION; INTERNALIZATION	Exposure to hydrogen peroxide (H2O2), one of the reactive oxidants in the gas phase of cigarette smoke (CS), induces aberrant phosphorylation of the epidermal growth factor receptor (EGFR), resulting in the lack of ubiquitination by c-Cbl, and impaired degradation. EGFR activation without the feedback regulation of normal degradation leads to uncontrolled cell growth and tumor promotion. Using immunoprecipitation, immunoblotting, and confocal microscopy, we now demonstrate that the pattern of EGFR activation by CS is similar to H2O2. We found that exposure of human airway epithelial cells to CS, as with exposure to H2O2, not only results in an increase in EGFR activation over time, but the EGFR activated by H2O2 or CS is neither ubiquitinated nor subsequently degraded due to its inability to bind the E3 ubiquitin ligase, c-Cbl, either directly or indirectly via the Grb2 adapter protein. Moreover, the stabilized H2O2- and CS-activated EGFR remains plasma membrane-bound, while a population of the receptor is trafficked to a perinuclear region. Concomitantly, CS exposure results in the activation of downstream Akt and ERKI/2 survival and proliferation pathways. Therefore, exposure to CS, like exposure to H2O2, results in prolonged signaling by the EGFR and may contribute to uncontrolled lung cell growth-Ehan, E. M., Lanir, R., Danielson, A. R., Goldkorn, T. Epidermal growth factor receptor exposed to cigarette smoke is aberrandy activated and undergoes perinuclear trafficking.	[Khan, Elaine M.; Lanir, Roni; Danielson, Aaron R.; Goldkorn, Tzipora] Univ Calif Davis, Dept Internal Med, Sch Med,Signal Transduct Lab, Genome & Biomed Sci Facil, Davis, CA 95616 USA	University of California System; University of California Davis	Goldkorn, T (corresponding author), Univ Calif Davis, Dept Internal Med, Sch Med,Signal Transduct Lab, Genome & Biomed Sci Facil, Rm 6321,451 E Hlth Sci Dr, Davis, CA 95616 USA.	ttgoldkorn@ucdavis.edu			NHLBI NIH HHS [T32 HL007013, T32 HL07013, R01 HL071871, R01 HL066189, HL-71871, HL-66189] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071871, R01HL066189, T32HL007013] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Diamonti AJ, 2002, P NATL ACAD SCI USA, V99, P2866, DOI 10.1073/pnas.052709799; ECCLES SA, 1994, INVAS METAST, V14, P337; Franklin WA, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.31520; Henson ES, 2006, CELL SIGNAL, V18, P2089, DOI 10.1016/j.cellsig.2006.05.015; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Huang FT, 2005, MOL BIOL CELL, V16, P1268, DOI 10.1091/mbc.E04-09-0832; Huang RP, 2001, MOL CARCINOGEN, V30, P209, DOI 10.1002/mc.1030; Jiang XJ, 2003, TRAFFIC, V4, P529, DOI 10.1034/j.1600-0854.2003.t01-1-00109.x; Khan EM, 2006, J BIOL CHEM, V281, P14486, DOI 10.1074/jbc.M509332200; Lavrentiadou SN, 2001, AM J RESP CELL MOL, V25, P676, DOI 10.1165/ajrcmb.25.6.4321; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Mendez-Alvarez E, 1998, J APPL TOXICOL, V18, P443, DOI 10.1002/(SICI)1099-1263(199811/12)18:6<443::AID-JAT530>3.3.CO;2-G; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; NAKAYAMA T, 1984, GANN, V75, P95; Ravid T, 2004, J BIOL CHEM, V279, P37153, DOI 10.1074/jbc.M403210200; Ravid T, 2002, J BIOL CHEM, V277, P31214, DOI 10.1074/jbc.M204677200; Shao MXG, 2004, AM J PHYSIOL-LUNG C, V287, pL420, DOI 10.1152/ajplung.00019.2004; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; Vicent S, 2004, BRIT J CANCER, V90, P1047, DOI 10.1038/sj.bjc.6601644; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Zhang Q, 2005, AM J RESP CELL MOL, V32, P72, DOI 10.1165/rcmb.2004-0198OC	24	74	74	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2008	22	3					910	917		10.1096/fj.06-7729com	http://dx.doi.org/10.1096/fj.06-7729com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17971399	Green Accepted			2022-12-28	WOS:000254143700029
J	Kajiya, K; Huggenberger, R; Drinnenberg, I; Ma, BJ; Detmar, M				Kajiya, Kentaro; Huggenberger, Reto; Drinnenberg, Ines; Ma, Beijia; Detmar, Michael			Nitric oxide mediates lymphatic vessel activation via soluble guanylate cyclase alpha 1 beta 1-impact on inflammation	FASEB JOURNAL			English	Article						lymphangiogenesis; vascular endothelial growth factor-A; UVB; endothelium; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; FUNCTIONAL EXPRESSION; LYMPHANGIOGENESIS; ANGIOGENESIS; GLYCOPROTEIN; PURIFICATION; PHYSIOLOGY; SYNTHASE	The lymphatic vascular system regulates tissue fluid homeostasis and the afferent phase of the immune response, and it is also involved in tumor metastasis. There is increasing evidence that lymphatic vessels also mediate acute and chronic inflammation. However, the mechanisms and functional consequences of lymphangiogenesis under inflammatory conditions are largely unknown. Here, we show that lymphatic endothelial cells (LECs) specifically express the alpha 1 beta 1 isoform of soluble guanylate cyclase (sGC), that vascular endothelial growth factor-A potently induces sGC alpha 1 beta 1, and that nitric oxide (NO)-induced LEC proliferation, migration, and cGMP production in LECs are specifically dependent on sGC alpha 1 beta 1. Moreover, the specific sGC inhibitor NS-2028 completely prevents ultraviolet B-irradiation-induced lymphatic vessel enlargement, edema formation, and skin inflammation in vivo. These findings identify a crucial role of the NO/sGC alpha 1 beta 1/cGMP pathway in modulating lymphatic vessel function. The blockade of sGC alpha 1 beta 1 signaling might serve as a novel therapeutic strategy for inhibiting lymphangiogenesis and inflammation, in addition to its effects on the blood vasculature.	[Kajiya, Kentaro; Huggenberger, Reto; Drinnenberg, Ines; Ma, Beijia; Detmar, Michael] ETH, Swiss Fed Inst Technol, Inst Pharmaceut Sci, CH-8093 Zurich, Switzerland; [Kajiya, Kentaro] Shiseido Life Sci Res Ctr, Yokohama, Kanagawa, Japan	Swiss Federal Institutes of Technology Domain; ETH Zurich; Shiseido Company, Limited	Detmar, M (corresponding author), ETH, Swiss Fed Inst Technol, Inst Pharmaceut Sci, Wolfgang Pauli Str 10,HCI H303, CH-8093 Zurich, Switzerland.	michael.detmar@pharma.ethz.ch		Kajiya, Kentaro/0000-0002-5224-7051	NCI NIH HHS [CA69184, CA92644] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069184, P01CA092644] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Baluk P, 2005, J CLIN INVEST, V115, P247, DOI 10.1172/JCI200522037; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Boon EM, 2005, NAT CHEM BIOL, V1, P53, DOI 10.1038/nchembio704; Cudmore M, 2006, BIOCHEM BIOPH RES CO, V345, P1275, DOI 10.1016/j.bbrc.2006.04.031; Cueni LN, 2006, J INVEST DERMATOL, V126, P2167, DOI 10.1038/sj.jid.5700464; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Evgenov OV, 2006, NAT REV DRUG DISCOV, V5, P755, DOI 10.1038/nrd2038; Franchi A, 2006, J PATHOL, V208, P439, DOI 10.1002/path.1892; Hirakawa S, 2003, AM J PATHOL, V162, P575, DOI 10.1016/S0002-9440(10)63851-5; HIRAKAWA S, 2006, BLOOD, V126, P919; Jadeski LC, 2000, INT J CANCER, V86, P30, DOI 10.1002/(SICI)1097-0215(20000401)86:1<30::AID-IJC5>3.0.CO;2-I; Kajiya K, 2005, EMBO J, V24, P2885, DOI 10.1038/sj.emboj.7600763; Kajiya K, 2006, J INVEST DERMATOL, V126, P919, DOI 10.1038/sj.jid.5700126; Kajiya K, 2006, AM J PATHOL, V169, P1496, DOI 10.2353/ajpath.2006.060197; Kerjaschki D, 2004, J AM SOC NEPHROL, V15, P603, DOI 10.1097/01.ASN.0000113316.52371.2E; Kerjaschki D, 2006, NAT MED, V12, P230, DOI 10.1038/nm1340; Kim-Shapiro DB, 2006, ARTERIOSCL THROM VAS, V26, P697, DOI 10.1161/01.ATV.0000204350.44226.9a; Kosarikov DN, 2001, ARCH BIOCHEM BIOPHYS, V388, P185, DOI 10.1006/abbi.2001.2284; Kunstfeld R, 2004, BLOOD, V104, P1048, DOI 10.1182/blood-2003-08-2964; Lee YC, 2000, P NATL ACAD SCI USA, V97, P10763, DOI 10.1073/pnas.190333697; Morbidelli L, 2003, CURR PHARM DESIGN, V9, P521, DOI 10.2174/1381612033391405; Ohhashi T, 2005, PHARMACOL THERAPEUT, V105, P165, DOI 10.1016/j.pharmthera.2004.10.009; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Podgrabinska S, 2002, P NATL ACAD SCI USA, V99, P16069, DOI 10.1073/pnas.242401399; Pyriochou A, 2006, J PHARMACOL EXP THER, V319, P663, DOI 10.1124/jpet.106.108878; Russwurm M, 2001, J BIOL CHEM, V276, P44647, DOI 10.1074/jbc.M105587200; SATO Y, 1986, AM J PATHOL, V125, P431; Schacht V, 2005, AM J PATHOL, V166, P913, DOI 10.1016/S0002-9440(10)62311-5; Shirasawa Y, 2000, AM J PHYSIOL-GASTR L, V278, pG551, DOI 10.1152/ajpgi.2000.278.4.G551; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Tobler NE, 2006, J LEUKOCYTE BIOL, V80, P691, DOI 10.1189/jlb.1105653; Yano K, 2004, J INVEST DERMATOL, V122, P201, DOI 10.1046/j.0022-202X.2003.22101.x; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002; Zabel U, 1998, BIOCHEM J, V335, P51, DOI 10.1042/bj3350051	35	28	29	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					530	537		10.1096/fj.07-8873com	http://dx.doi.org/10.1096/fj.07-8873com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17855621				2022-12-28	WOS:000252822600023
J	McDunn, JE; Muenzer, JT; Rachdi, L; Chang, KC; Davis, CG; Dunne, WM; Piwnica-Worms, D; Bernal-Mizrachi, E; Hotchkiss, RS				McDunn, Jonathan E.; Muenzer, Jared T.; Rachdi, Latif; Chang, Katherine C.; Davis, Chris G.; Dunne, W. Michael; Piwnica-Worms, David; Bernal-Mizrachi, Ernesto; Hotchkiss, Richard S.			Peptide-mediated activation of Akt and extracellular regulated kinase signaling prevents lymphocyte apoptosis	FASEB JOURNAL			English	Article							IMPROVES SURVIVAL; CECAL LIGATION; TCL1 FAMILY; SEPSIS; PROTEIN; IDENTIFICATION; DEATH; BCL-2; MICE	Lymphocyte apoptosis is a hallmark of sepsis and contributes to disease mortality. In other acute injuries, such as myocardial and cerebral ischemia/reperfusion, apoptosis plays a significant role in disease-associated morbidity and mortality. We previously showed that constitutive activation of the potent antiapoptotic Akt/protein kinase B signaling pathway in lymphocytes both reduces sepsis-induced lymphocyte apoptosis and confers a significant survival advantage compared to wild-type littermates. Here, we demonstrate a therapeutic approach to acutely augment Akt activity in a wild-type animal. A cell-permeable peptide conjugated to the Akt-binding domain of the endogenous Akt coactivator, Tcl-1, prolongs Akt activity, activates extracellular regulated kinase (ERK) signaling and protects lymphocytes from numerous apoptotic stimuli both in vitro and in vivo. Molecular approaches to activate the antiapoptotic Akt and ERK signaling pathways may provide a novel tool to study these signaling pathways, as well as a new antiapoptotic strategy for the treatment of sepsis and other acute injuries.	[McDunn, Jonathan E.; Chang, Katherine C.; Davis, Chris G.; Hotchkiss, Richard S.] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; [McDunn, Jonathan E.; Hotchkiss, Richard S.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; [Muenzer, Jared T.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Rachdi, Latif; Bernal-Mizrachi, Ernesto; Hotchkiss, Richard S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Dunne, W. Michael] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; [Piwnica-Worms, David; Hotchkiss, Richard S.] Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; [Piwnica-Worms, David] Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, Mol Imaging Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	McDunn, JE (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, Campus Box 8054,660 S Euclid Ave, St Louis, MO 63110 USA.	mcdunnj@wustl.edu	Rachdi, Latif/I-1988-2017; McDunn, Jonathan/A-6816-2009	Rachdi, Latif/0000-0002-1089-2837; McDunn, Jonathan/0000-0001-8792-828X	NCI NIH HHS [CA-82841, P50 CA094056-019003, P50 CA094056, CA-94056, R01 CA082841] Funding Source: Medline; NEI NIH HHS [R01 EY019587, R01 EY019587-11] Funding Source: Medline; NIGMS NIH HHS [R01 GM044118, GM-044188, R01 GM055194, R01 GM044118-10, GM-055194, R01 GM055194-12] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082841, P50CA094056] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY019587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055194, R01GM044118] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Auguin D, 2004, J BIOL CHEM, V279, P35890, DOI 10.1074/jbc.M400364200; Ayala A, 1996, BLOOD, V87, P4261, DOI 10.1182/blood.V87.10.4261.bloodjournal87104261; BAKER CC, 1983, SURGERY, V94, P331; Bommhardt U, 2004, J IMMUNOL, V172, P7583, DOI 10.4049/jimmunol.172.12.7583; Chung TP, 2006, J AM COLL SURGEONS, V203, P585, DOI 10.1016/j.jamcollsurg.2006.06.028; Gammon ST, 2003, BIOCONJUGATE CHEM, V14, P368, DOI 10.1021/bc0256291; Hiramatsu M, 1997, SHOCK, V7, P247, DOI 10.1097/00024382-199704000-00002; Hiromura M, 2004, J BIOL CHEM, V279, P53407, DOI 10.1074/jbc.M403775200; Hotchkiss RS, 2006, NAT REV IMMUNOL, V6, P813, DOI 10.1038/nri1943; Hotchkiss RS, 2006, J IMMUNOL, V176, P5471, DOI 10.4049/jimmunol.176.9.5471; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741; Hotchkiss RS, 1999, J IMMUNOL, V162, P4148; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Hoyer KK, 2005, J IMMUNOL, V175, P864, DOI 10.4049/jimmunol.175.2.864; Iwata A, 2003, J IMMUNOL, V171, P3136, DOI 10.4049/jimmunol.171.6.3136; Janes KA, 2003, MOL CELL PROTEOMICS, V2, P463, DOI 10.1074/mcp.M300045-MCP200; Kunstle G, 2002, MOL CELL BIOL, V22, P1513, DOI 10.1128/MCB.22.5.1513-1525.2002; Li B, 2002, GENE THER, V9, P233, DOI 10.1038/sj.gt.3301641; Matsui T, 2001, CIRCULATION, V104, P330; Mende I, 2001, ONCOGENE, V20, P4419, DOI 10.1038/sj.onc.1204486; Parrillo J E, 1993, N Engl J Med, V328, P1471; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; Sampson WR, 1999, J PEPT SCI, V5, P403, DOI 10.1002/(SICI)1099-1387(199909)5:9<403::AID-PSC213>3.0.CO;2-S; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shiojima I, 2005, J CLIN INVEST, V115, P2108, DOI 10.1172/JCI24682; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Teitell MA, 2005, NAT REV CANCER, V5, P640, DOI 10.1038/nrc1672; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530	30	17	19	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					561	568		10.1096/fj.07-8283com	http://dx.doi.org/10.1096/fj.07-8283com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17855622	Green Accepted			2022-12-28	WOS:000252822600026
J	Paugh, BS; Paugh, SW; Bryan, L; Kapitonov, D; Wilczynska, KM; Gopalan, SM; Rokita, H; Milstien, S; Spiegel, S; Kordula, T				Paugh, Barbara S.; Paugh, Steven W.; Bryan, Lauren; Kapitonov, Dmitri; Wilczynska, Katarzyna M.; Gopalan, Sunita M.; Rokita, Hanna; Milstien, Sheldon; Spiegel, Sarah; Kordula, Tomasz			EGF regulates plasminogen activator inhibitor-1 (PAI-1) by a pathway involving c-Src, PKC delta, and sphingosine kinase 1 in glioblastoma cells	FASEB JOURNAL			English	Article						glioma; invasiveness	EPIDERMAL-GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR GENE; HUMAN-BRAIN-TUMORS; UROKINASE-TYPE; ONCOSTATIN-M; KAPPA-B; EXPRESSION; INVASION; SYSTEM	Patients with gliomas expressing high levels of epidermal growth factor receptor ( EGFR) and plasminogen activator inhibitor-1 (PAI-1) have a shorter overall survival prognosis. Moreover, EGF enhances PAI-1 expression in glioma cells. Although multiple known signaling cascades are activated by EGF in glioma cells, we show for the first time that EGF enhances expression of PAI-1 via sequential activation of c-Src, protein kinase C delta (PKC delta), and sphingosine kinase 1 (SphK1), the enzyme that produces sphingosine-1-phosphate. EGF induced rapid phosphorylation of c-Src and PKC delta and concomitant translocation of PKC delta as well as SphK1 to the plasma membrane. Down-regulation of PKC delta abolished EGF-induced SphK1 translocation and up-regulation of PAI-1 by EGF; whereas, down-regulation of PKC alpha had no effect on the EGF-induced PAI-1 activation but enhanced its basal expression. Similarly, inhibition of c-Src activity by PP2 blocked both EGF-induced translocation of SphK1 and PKC delta to the plasma membrane and up-regulation of PAI-1 expression. Furthermore, SphK1 was indispensable for both EGF-induced c-Jun phosphorylation and PAI-1 expression. Collectively, our results provide a functional link between three critical downstream targets of EGF, c-Src, PKC delta, and SphK1 that have all been implicated in regulating motility and invasion of glioma cells.	[Paugh, Barbara S.; Paugh, Steven W.; Bryan, Lauren; Kapitonov, Dmitri; Wilczynska, Katarzyna M.; Gopalan, Sunita M.; Spiegel, Sarah; Kordula, Tomasz] Virginia Commonwealth Univ, Sch Med, Massey Canc Ctr, Dept Biochem & Mol Biol, Richmond, VA 23298 USA; [Rokita, Hanna] Jagiellonian Univ, Fac Biotechnol, Krakow, Poland; [Milstien, Sheldon] NIMH, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	Virginia Commonwealth University; Jagiellonian University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Kordula, T (corresponding author), Virginia Commonwealth Univ, Sch Med, Massey Canc Ctr, Dept Biochem & Mol Biol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	tkordula@vcu.edu	Paugh, Barbara/B-3625-2009; Paugh, Steven/A-7739-2008	Paugh, Steven/0000-0001-5697-9228; Rokita, Hanna/0000-0003-2675-2393; Kapitonov, Dmitri/0000-0001-9177-5239	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [P30 CA016059, R01 CA061774-14, P30 CA16059, R01 CA61774, R01 CA061774, R01 CA061774-15] Funding Source: Medline; NINDS NIH HHS [R01 NS044118-04, R01 NS044118-02, R01 NS044118-03, R01 NS044118] Funding Source: Medline; PHS HHS [NSO44118, NSO46280] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016059, R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH001039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044118] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Angers-Loustau A, 2004, MOL CANCER RES, V2, P595; Anteby EY, 2004, MOL HUM REPROD, V10, P229, DOI 10.1093/molehr/gah031; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Bektas M, 2005, ONCOGENE, V24, P178, DOI 10.1038/sj.onc.1208019; Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Czekay RP, 2004, EXP BIOL MED, V229, P1090, DOI 10.1177/153537020422901102; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Foekens JA, 2000, CANCER RES, V60, P636; Frederick L, 2000, CANCER RES, V60, P1383; Gopalan S, 2005, J NEUROCHEM, V94, P763, DOI 10.1111/j.1471-4159.2005.03204.x; Guerrero J, 2004, EXP CELL RES, V292, P201, DOI 10.1016/j.yexcr.2003.08.011; Hjortland GO, 2004, EXP CELL RES, V294, P130, DOI 10.1016/j.yexcr.2003.10.013; HOPKINS WE, 1991, NUCLEIC ACIDS RES, V19, P163, DOI 10.1093/nar/19.1.163; Hou BD, 2004, J BIOL CHEM, V279, P18127, DOI 10.1074/jbc.M310438200; JANICKE F, 1991, SEMIN THROMB HEMOST, V17, P303, DOI 10.1055/s-2007-1002624; Kasza A, 2001, CYTOKINE, V16, P187, DOI 10.1006/cyto.2001.0957; Kasza A, 2002, J NEUROCHEM, V83, P696, DOI 10.1046/j.1471-4159.2002.01163.x; Kordula T, 1998, J BIOL CHEM, V273, P4112, DOI 10.1074/jbc.273.7.4112; Lakka SS, 2005, J BIOL CHEM, V280, P21882, DOI 10.1074/jbc.M408520200; LANDAU BJ, 1994, CANCER RES, V54, P1105; Levicar N, 2003, ACTA NEUROCHIR, V145, P825, DOI 10.1007/s00701-003-0097-z; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MAWATARI M, 1991, EXP CELL RES, V192, P574, DOI 10.1016/0014-4827(91)90078-9; Mazar A P, 1999, Angiogenesis, V3, P15, DOI 10.1023/A:1009095825561; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; Mueller MM, 2003, ACTA NEUROCHIR, V145, P999, DOI 10.1007/s00701-003-0132-0; Muracciole X, 2002, INT J RADIAT ONCOL, V52, P592, DOI 10.1016/S0360-3016(01)02699-2; Nagamine Y, 2005, THROMB HAEMOSTASIS, V93, P661, DOI 10.1160/TH04-12-0814; Nakada M, 2003, FRONT BIOSCI, V8, pE261, DOI 10.2741/1016; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; PLATASALAMAN CR, 1991, PEPTIDES, V12, P653, DOI 10.1016/0196-9781(91)90115-6; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Quan AL, 2005, INT J RADIAT ONCOL, V63, P695, DOI 10.1016/j.ijrobp.2005.03.051; Rao JS, 2005, MOL CANCER THER, V4, P1399, DOI 10.1158/1535-7163.MCT-05-0082; Rooprai HK, 1997, ANTICANCER RES, V17, P4151; Samad F, 2006, DIABETES, V55, P2579, DOI 10.2337/db06-0330; Samarakoon R, 2005, J CELL PHYSIOL, V204, P236, DOI 10.1002/jcp.20279; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SEEBACHER T, 1992, EXP CELL RES, V203, P504, DOI 10.1016/0014-4827(92)90029-8; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Valter MM, 1999, INT J DEV NEUROSCI, V17, P565, DOI 10.1016/S0736-5748(99)00048-9; Van Brocklyn JR, 2005, J NEUROPATH EXP NEUR, V64, P695, DOI 10.1097/01.jnen.0000175329.59092.2c; Van Brocklyn JR, 2003, CANCER LETT, V199, P53, DOI 10.1016/S0304-3835(03)00334-3; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; VONDEIMLING A, 1992, J NEUROSURG, V77, P295, DOI 10.3171/jns.1992.77.2.0295; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Yamaguchi K, 2005, CANCER CHEMOTH PHARM, V56, P585, DOI 10.1007/s00280-005-1030-3	50	65	70	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					455	465		10.1096/fj.07-8276com	http://dx.doi.org/10.1096/fj.07-8276com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17855624	Green Accepted			2022-12-28	WOS:000252822600016
J	Gomez, BP; Riggins, RB; Shajahan, AN; Klimach, U; Wang, A; Crawford, AC; Zhu, Y; Zwart, A; Wang, M; Clarke, R				Gomez, Bianca P.; Riggins, Rebecca B.; Shajahan, Ayesha N.; Klimach, Uwe; Wang, Aifen; Crawford, Anatasha C.; Zhu, Yuelin; Zwart, Alan; Wang, Mingyue; Clarke, Robert			Human X-Box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines	FASEB JOURNAL			English	Article						apoptosis; aromatase; cell cycle; Faslodex; SERM; SERD; unfolded protein response; Tamoxifen; proliferation; XBPI	REGULATORY-FACTOR-I; FACTOR-KAPPA-B; TRANSCRIPTION FACTOR XBP-1; GENE-EXPRESSION PROFILES; CYTOCHROME-C RELEASE; FALSE DISCOVERY RATE; PERMEABILITY TRANSITION; ENDOPLASMIC-RETICULUM; AROMATASE INHIBITORS; TISSUE MICROARRAYS	Human X-box binding protein-1 (XBP1) is an alternatively spliced transcription factor that participates in the unfolded protein response (UPR), a stress-signaling pathway that allows cells to survive the accumulation of unfolded proteins in the endoplasmic reticulum lumen. We have previously demonstrated that XBP1 expression is increased in antiestrogen-resistant breast cancer cell lines and is coexpressed with estrogen receptor alpha (ER) in breast tumors. The purpose of this study is to investigate the role of XBP1 and the UPR in estrogen and antiestrogen responsiveness in breast cancer. Overexpression of spliced XBP1 [XBP1(S)] in ER-positive breast cancer cells leads to estrogen-independent growth and reduced sensitivity to growth inhibition induced by the antiestrogens Tamoxifen and Faslodex in a manner independent of functional p53. Data from gene expression microarray analyses imply that XBP1(S) acts through regulation of the expression of ER, the antiapoptotic gene BCL2, and several other genes associated with control of the cell cycle and apoptosis. Testing this hypothesis, we show that overexpression of XBP1(S) prevents cell cycle arrest and antiestrogen-induced cell death through the mitochondrial apoptotic pathway. XBP1 and/or the UPR may be a useful molecular target for the development of novel predictive and therapeutic strategies in breast cancer. -Gomez, B. P., Riggins, R. B., Shajahan, A., Klimach, U., Wang, A., Crawford, A. C., Zhu, Y., Zwart, A., Wang, M., Clarke, R. Human X-Box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines.	Georgetown Univ, Sch Med, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA; Georgetown Univ, Sch Med, Dept Physiol & Biophys, Washington, DC 20057 USA	Georgetown University; Georgetown University	Clarke, R (corresponding author), Georgetown Univ, Sch Med, Dept Oncol, W405A Res Bldg, 3970 Reservoir Rd, NW, Washington, DC 20057 USA.	clarker@georgetown.edu	Clarke, Robert/A-6485-2008; Zhu, Yuelin/ABD-5743-2021; Riggins, Rebecca/GQH-4466-2022	Clarke, Robert/0000-0002-9278-0854; Zhu, Yuelin/0000-0003-2762-0755; Shajahan-Haq, Ayesha/0000-0001-7616-320X; Zwart, Alan/0000-0001-6834-9290; Riggins, Rebecca/0000-0002-1555-4431	NATIONAL CANCER INSTITUTE [P30CA051008, R01CA096483] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA51008-14, R01-CA096483] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe O, 1998, LANCET, V352, P930; Auer H, 2003, NAT GENET, V35, P292, DOI 10.1038/ng1203-292; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bertucci F, 2002, HUM MOL GENET, V11, P863, DOI 10.1093/hmg/11.8.863; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Bouker KB, 2005, CARCINOGENESIS, V26, P1527, DOI 10.1093/carcin/bgi113; Bouker KB, 2004, CANCER RES, V64, P4030, DOI 10.1158/0008-5472.CAN-03-3602; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Breen EC, 2003, J CELL BIOCHEM, V88, P848, DOI 10.1002/jcb.10398; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Clarke M, 1998, LANCET, V351, P1451; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Clarke R, 2001, PHARMACOL REV, V53, P25; CLAUSS IM, 1993, DEV DYNAM, V197, P146, DOI 10.1002/aja.1001970207; Clauss IM, 1996, NUCLEIC ACIDS RES, V24, P1855, DOI 10.1093/nar/24.10.1855; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; Cross SS, 2005, HISTOPATHOLOGY, V46, P256, DOI 10.1111/j.1365-2559.2005.02097.x; Deming SL, 2000, BRIT J CANCER, V83, P1688, DOI 10.1054/bjoc.2000.1522; Dent P, 2005, J CELL BIOCHEM, V95, P712, DOI 10.1002/jcb.20502; Ding LH, 2003, NUCLEIC ACIDS RES, V31, P5266, DOI 10.1093/nar/gkg731; DuRose JB, 2006, MOL BIOL CELL, V17, P3095, DOI 10.1091/mbc.E06-01-0055; Elstner E, 2002, BREAST CANCER RES TR, V74, P155, DOI 10.1023/A:1016114026769; Frank D, 2002, P NATL ACAD SCI USA, V99, P7490, DOI 10.1073/pnas.122039999; Fu YP, 2003, CANCER RES, V63, P2440; Fujimoto Takashi, 2003, Breast Cancer, V10, P301, DOI 10.1007/BF02967649; Gu ZP, 2002, CANCER RES, V62, P3428; Howell A, 2002, J CLIN ONCOL, V20, P3396, DOI 10.1200/JCO.2002.10.057; HOWELL A, 1995, LANCET, V345, P29, DOI 10.1016/S0140-6736(95)91156-1; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jamerson MH, 2004, J MAMMARY GLAND BIOL, V9, P27, DOI 10.1023/B:JOMG.0000023586.69263.0b; Jenkins DE, 2005, BREAST CANCER RES, V7, pR444, DOI 10.1186/bcr1026; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lebedeva IV, 2003, ONCOGENE, V22, P8758, DOI 10.1038/sj.onc.1206891; Lee K, 2001, MRS INTERNET J N S R, V6, P1; Lee MP, 1998, CANCER RES, V58, P1052; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; Loo LWM, 2004, CANCER RES, V64, P8541, DOI 10.1158/0008-5472.CAN-04-1992; Mueller O., 2004, AGIL APPL NOTE, V2011, P1, DOI DOI 10.1186/1471-2199-7-3; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Newman JRS, 2003, SCIENCE, V300, P2097, DOI 10.1126/science.1084648; Nicholson RI, 2001, ENDOCR-RELAT CANCER, V8, P175, DOI 10.1677/erc.0.0080175; Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; Real PJ, 2004, CANCER RES, V64, P7947, DOI 10.1158/0008-5472.CAN-04-0945; Reimold AM, 2000, GENE DEV, V14, P152; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Riggins RB, 2005, VITAM HORM, V71, P201, DOI 10.1016/S0083-6729(05)71007-4; Riggins RB, 2005, MOL CANCER THER, V4, P33; Sakamoto M, 2001, Hum Cell, V14, P305; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Scheid S, 2005, BIOINFORMATICS, V21, P2921, DOI 10.1093/bioinformatics/bti436; Smider V, 1997, Semin Immunol, V9, P189, DOI 10.1006/smim.1997.0070; Sriburi R, 2004, J CELL BIOL, V167, P35, DOI 10.1083/jcb.200406136; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; TAYLOR IW, 1983, CANCER RES, V43, P4007; TAYLOR IW, J BIOL CHEM, V16, P452; Taylor J, 2005, BIOSTATISTICS, V6, P111, DOI 10.1093/biostatistics/kxh021; Thiantanawat A, 2003, CANCER RES, V63, P8037; Tsai CA, 2003, BIOMETRICS, V59, P1071, DOI 10.1111/j.0006-341X.2003.00123.x; Venditti M, 2002, INT J CANCER, V99, P35, DOI 10.1002/ijc.10269; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wang ZY, 2003, J VLSI SIG PROC SYST, V35, P255, DOI 10.1023/B:VLSI.0000003024.13494.40; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Willis S, 2003, J CELL SCI, V116, P4053, DOI 10.1242/jcs.00754; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zhang KZ, 2006, NEUROLOGY, V66, pS102, DOI 10.1212/01.wnl.0000192306.98198.ec; Zhu YL, 2006, INT J ONCOL, V28, P67; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0; 2006, GENE CARD IRF 1	74	134	148	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2007	21	14					4013	4027		10.1096/fj.06-7990com	http://dx.doi.org/10.1096/fj.06-7990com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17660348				2022-12-28	WOS:000251283500026
J	Paruch, S; Heinis, M; Lemay, J; Hoeffel, G; Maranon, C; Hosmalin, A; Perianin, A				Paruch, Sylvain; Heinis, Mylene; Lemay, Julie; Hoeffel, Guillaume; Maranon, Conception; Hosmalin, Anne; Perianin, Axel			CCR5 signaling through phospholipase D involves p44/42 MAP-kinases and promotes HIV-1 LTR-directed gene expression	FASEB JOURNAL			English	Article						HIV-1 coreceptors; signal transducers; infection	HUMAN-IMMUNODEFICIENCY-VIRUS; PHORBOL-MYRISTATE ACETATE; ACTIVATED PROTEIN-KINASE; CHEMOKINE RECEPTOR CCR5; NF-KAPPA-B; HUMAN-NEUTROPHILS; HTLV-III; T-CELLS; TRANSACTIVATOR GENE; D DEFINES	The chemokine receptor CCR5 plays an important role as an entry gate for the human immunodeficiency virus-1 (HIV-1) and for viral postentry events. Among signal transducers used by chemoattractant receptors, the phosphatidylcholine-specific phospholipase D (PLD) produces large amounts of second messengers in most cell types. However, the relevance of PLD isoforms to CCR5 signaling and HIV-1 infection process remains unexplored. We show here that CCR5 activation by MIP-1 beta in HeLa-MAGI cells triggered a rapid and substantial PLD activity, as assessed by mass choline production. This activity required the activation of ERK1/2-MAP kinases and involved both PLD1 and PLD2. MIP-1 beta also promoted the activation of an HIV-1 long terminal repeat (LTR) by the transactivator Tat in HeLa P4.2 cells through a process involving ERK1/2. Expression of wild-type and catalytically inactive PLDs dramatically boosted and inhibited the LTR activation, respectively, without altering Tat expression. Wild-type and inactive PLDs also respectively potentiated and inhibited HIV-1(BAL) replication in MAGI cells. Finally, in monocytic THP-1 cells, antisense oligo-nucleotides to both PLDs dramatically inhibited the HIV-1 replication. Thus, PLD is activated downstream of ERK1/2 upon CCR5 activation and plays a major role in promoting HIV-1 LTR transactivation and virus replication, which may open novel perspectives to anti-HIV-1 strategies.-Paruch, S., Heinis, M., Lemay, J., Hoeffel, G., Maranon, C., Hosmalin, A., Perianin, A. CCR5 signaling through phospholipase D involves p44/42 MAP-kinases and promotes HIV-1 LTR-directed gene expression.	Univ Paris 05, Inst Cochin, CNRS, UMR 8104, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Perianin, A (corresponding author), Inst Cochin, Dept Biol Cellulaire, Pavillon G Roussy 5eme Etage, P502, 27, rue du Faubourg, St Jacques, F-75014 Paris, France.	perianin@cochin.inserm.fr	Hoeffel, Guillaume/ABG-4881-2021; Hosmalin, Anne/AAF-8561-2019; C, maranon/E-1484-2013	Hoeffel, Guillaume/0000-0002-2534-4972; Hosmalin, Anne/0000-0001-9021-3488; C, maranon/0000-0002-7827-6301; Lemay, Julie/0000-0002-4029-9911				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Arthos J, 2000, J VIROL, V74, P6418, DOI 10.1128/JVI.74.14.6418-6424.2000; Bar S, 2004, J VIROL, V78, P811, DOI 10.1128/JVI.78.2.811-820.2004; Benelli R, 2000, J INFECT DIS, V182, P1643, DOI 10.1086/317597; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BRUNET A, 1994, ONCOGENE, V9, P3379; Bukrinskaya A, 1998, J EXP MED, V188, P2113, DOI 10.1084/jem.188.11.2113; Chackerian B, 1997, J VIROL, V71, P3932, DOI 10.1128/JVI.71.5.3932-3939.1997; DANG PMC, 1995, BIOCHEM BIOPH RES CO, V212, P664, DOI 10.1006/bbrc.1995.2020; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Djerdjouri B, 1999, BIOCHEM BIOPH RES CO, V264, P371, DOI 10.1006/bbrc.1999.1533; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; Francois F, 2003, J VIROL, V77, P2539, DOI 10.1128/JVI.77.4.2539-2549.2003; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Gutkind J.S, 2000, SCI STKE; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HARADA S, 1986, VIROLOGY, V154, P249, DOI 10.1016/0042-6822(86)90451-4; Hu QH, 2002, BIOCHEM BIOPH RES CO, V292, P325, DOI 10.1006/bbrc.2002.6675; JAKOBOVITS A, 1990, EMBO J, V9, P1165, DOI 10.1002/j.1460-2075.1990.tb08223.x; Klebanoff SJ, 1999, BLOOD, V93, P350, DOI 10.1182/blood.V93.1.350.401k18_350_356; Kreisberg JF, 2006, J EXP MED, V203, P865, DOI 10.1084/jem.20051856; Kutsch O, 2002, J VIROL, V76, P8776, DOI 10.1128/JVI.76.17.8776-8786.2002; Kwan WH, 2005, J VIROL, V79, P7291, DOI 10.1128/JVI.79.12.7291-7299.2005; Kwun HJ, 2003, FEBS LETT, V544, P38, DOI 10.1016/S0014-5793(03)00446-0; LEUNG DW, 1995, P NATL ACAD SCI USA, V92, P4813, DOI 10.1073/pnas.92.11.4813; Lin YL, 2006, AIDS, V20, P1369, DOI 10.1097/01.aids.0000233570.51899.e2; Lin YL, 2002, P NATL ACAD SCI USA, V99, P15590, DOI 10.1073/pnas.242134499; LISCOVITCH M, 1993, J LIPID MEDIATOR, V8, P177; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; MCCUNE JM, 1995, CELL, V82, P183, DOI 10.1016/0092-8674(95)90305-4; Mueller A, 2004, FEBS LETT, V570, P126, DOI 10.1016/j.febslet.2004.04.100; Muthalif MM, 2000, J PHARMACOL EXP THER, V293, P268; Oppermann M, 2004, CELL SIGNAL, V16, P1201, DOI 10.1016/j.cellsig.2004.04.007; Paruch S, 2005, FASEB J, V19, P142, DOI 10.1096/fj.05-3881fje; Pedruzzi E, 1998, CELL SIGNAL, V10, P481, DOI 10.1016/S0898-6568(97)00174-5; Pereira LA, 2000, NUCLEIC ACIDS RES, V28, P663, DOI 10.1093/nar/28.3.663; Pirounaki M, 2000, J VIROL METHODS, V85, P151, DOI 10.1016/S0166-0934(99)00163-9; Powner DJ, 2005, J CELL SCI, V118, P2975, DOI 10.1242/jcs.02432; Rizzi C, 2006, J IMMUNOL, V176, P999, DOI 10.4049/jimmunol.176.2.999; Rohr O, 2003, J LEUKOCYTE BIOL, V74, P736, DOI 10.1189/jlb.0403180; Su SB, 1999, BLOOD, V93, P3885, DOI 10.1182/blood.V93.11.3885.411k19_3885_3892; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; West MJ, 2001, J VIROL, V75, P8524, DOI 10.1128/JVI.75.18.8524-8537.2001; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	53	13	16	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4038	4046		10.1096/fj.06-7325com	http://dx.doi.org/10.1096/fj.06-7325com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17627030				2022-12-28	WOS:000251283500028
J	Thomas, CP; Andrews, JI; Liu, KZ				Thomas, Christie P.; Andrews, Janet I.; Liu, Kang Z.			Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta	FASEB JOURNAL			English	Article						angiogenesis; soluble VEGF receptor; preeclampsia	CIRCULATING ANGIOGENIC FACTORS; MESSENGER-RNA POLYADENYLATION; EPITHELIAL SODIUM-CHANNEL; GROWTH-FACTOR RECEPTOR-1; TROPHOBLAST CELLS; ENDOTHELIAL-CELLS; VEGF RECEPTOR-1; ALPHA-SUBUNIT; ALU ELEMENTS; PREECLAMPSIA	The gene FLT1 produces at least two transcripts from a common transcription start site: full- length Flt1 contains 30 exons encoding a membrane-bound VEGF receptor; soluble Flt1 ( sFlt1) shares the first 13 exons but utilizes poly( A) signal sequences within intron 13 to create a transcript that lacks downstream exons. To address the mechanisms that regulate human sFlt1, we mapped the 3' end of sFlt1 mRNA and defined the full extent of its 3' untranslated region ( UTR). We identified a 3.2 Kb sFlt1 transcript that is cleaved within an alternatively spliced exon downstream of exon 14 and is predicted to encode a C- terminal variant of sFlt1 with an unusual polyserine tail. sFlt1 mRNA cleavage sites within intron 13 were identified in human placenta and in vascular endothelium by ribonuclease protection assay ( RPA). A proximal and two distal mRNA cleavage sites were identified by RPA downstream of consensus polyadenylation signals that create variant transcripts with a 3' UTR ranging from 30 bases to similar to 4 Kb. Northern blot analysis and 3' rapid amplification of cDNA ends ( RACE) in placenta confirmed the existence of distal intronic sFlt1 cleavage sites that give rise to a sFlt1 transcript of similar to 7 Kb. The identity of the distal signal sequences were then confirmed by mutagenesis of putative signal elements in a polyadenylation reporter assay. We demonstrate the heterogeneity of human sFlt1 that arises from alternate splicing and from alternative polyadenylation directed by strong intronic poly( A) signal sequences leading to C-terminal variants and to an sFlt1 transcript with a large 3' UTR containing several AU rich elements and poly( U) regions that may regulate mRNA stability.	Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Gynecol & Obstet, Iowa City, IA 52242 USA; Univ Iowa, Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Thomas, CP (corresponding author), Univ Iowa, Caver Coll Med, E300 GH, Grad Program Mol & Cellular Biol, 200 Hawkins Dr, Iowa City, IA 52242 USA.	christie-thomas@uiowa.edu		Andrews, Janet/0000-0003-0868-928X; Thomas, Christie/0000-0002-5989-9685	NHLBI NIH HHS [R01 HL071664, HL71664] Funding Source: Medline; NIDDK NIH HHS [DK52617] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK052617] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad S, 2004, CIRC RES, V95, P884, DOI 10.1161/01.RES.0000147365.86159.f5; Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249; Aref S, 2005, HEMATOLOGY, V10, P131, DOI 10.1080/10245330500065797; BARLEON B, 1994, J CELL BIOCHEM, V54, P56, DOI 10.1002/jcb.240540107; Beaudoing E, 2000, GENOME RES, V10, P1001, DOI 10.1101/gr.10.7.1001; Beaudoing E, 2001, GENOME RES, V11, P1520, DOI 10.1101/gr.190501; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; BISHOP DF, 1988, P NATL ACAD SCI USA, V85, P3903, DOI 10.1073/pnas.85.11.3903; Clark DE, 1998, BIOL REPROD, V59, P1540, DOI 10.1095/biolreprod59.6.1540; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Detmar M, 1997, J INVEST DERMATOL, V108, P263, DOI 10.1111/1523-1747.ep12286453; Graber JH, 1999, P NATL ACAD SCI USA, V96, P14055, DOI 10.1073/pnas.96.24.14055; GRAHAM CH, 1993, EXP CELL RES, V206, P204, DOI 10.1006/excr.1993.1139; Graubert MD, 2001, AM J PATHOL, V158, P1399, DOI 10.1016/S0002-9440(10)64091-6; Hasler J, 2006, NUCLEIC ACIDS RES, V34, P5491, DOI 10.1093/nar/gkl706; Huckle WR, 2004, J CELL BIOCHEM, V93, P120, DOI 10.1002/jcb.20142; ITANI OA, 2005, AM J PHYSL RENAL PHY; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; Kohany O, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-474; Kondo K, 1998, GENE, V208, P297, DOI 10.1016/S0378-1119(98)00006-7; Lam C, 2005, HYPERTENSION, V46, P1077, DOI 10.1161/01.HYP.0000187899.34379.b0; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; Li H, 2005, PLACENTA, V26, P210, DOI 10.1016/j.placenta.2004.05.004; Li WG, 2004, CIRCULATION, V109, P2221, DOI 10.1161/01.CIR.0000127956.43874.F2; Lopez F, 2006, RNA, V12, P1794, DOI 10.1261/rna.136206; Luttun A, 2003, J CLIN INVEST, V111, P600, DOI 10.1172/JCI200318015; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Mick VE, 2001, MOL ENDOCRINOL, V15, P575, DOI 10.1210/me.15.4.575; Nagamatsu T, 2004, ENDOCRINOLOGY, V145, P4838, DOI 10.1210/en.2004-0533; Natalizio BJ, 2002, J BIOL CHEM, V277, P42733, DOI 10.1074/jbc.M208070200; Nelson DM, 1999, AM J OBSTET GYNECOL, V180, P896, DOI 10.1016/S0002-9378(99)70661-7; Pau E, 2006, HUM REPROD, V21, P1453, DOI 10.1093/humrep/del005; Redman CW, 2005, SCIENCE, V308, P1592, DOI 10.1126/science.1111726; Robinson CJ, 2001, J CELL SCI, V114, P853; Rosonina E, 2006, GENE DEV, V20, P1050, DOI 10.1101/gad.1431606; Rowold DJ, 2000, GENETICA, V108, P57, DOI 10.1023/A:1004099605261; Roy-Engel AM, 2005, CYTOGENET GENOME RES, V110, P365, DOI 10.1159/000084968; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; SHIBUYA M, 1990, ONCOGENE, V5, P519; Stepan H, 2006, BIOL REPROD, V74, P772, DOI 10.1095/biolreprod.105.045997; Tabaska JE, 1999, GENE, V231, P77, DOI 10.1016/S0378-1119(99)00104-3; Thomas CP, 1998, AM J PHYSIOL-CELL PH, V274, pC1312, DOI 10.1152/ajpcell.1998.274.5.C1312; Tian B, 2005, NUCLEIC ACIDS RES, V33, P201, DOI 10.1093/nar/gki158; Tsatsaris V, 2003, J CLIN ENDOCR METAB, V88, P5555, DOI 10.1210/jc.2003-030528; van Hoof A, 2002, CURR BIOL, V12, pR285, DOI 10.1016/S0960-9822(02)00802-3; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zhou Y, 2002, AM J PATHOL, V160, P1405, DOI 10.1016/S0002-9440(10)62567-9	50	56	60	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2007	21	14					3885	3895		10.1096/fj.07-8809com	http://dx.doi.org/10.1096/fj.07-8809com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17615362				2022-12-28	WOS:000251283500014
J	Ahmad, M; Attoub, S; Singh, MN; Martin, FL; El-Agnaf, OMA				Ahmad, Mushfika; Attoub, Samir; Singh, Maneesh N.; Martin, Francis L.; El-Agnaf, Omar M. A.			gamma-synuclein and the progression of cancer	FASEB JOURNAL			English	Review						biomarker; apoptosis; invasion	MUTANT ALPHA-SYNUCLEIN; MITOTIC CHECKPOINT KINASE; LEWY BODY DISEASE; A-BETA COMPONENT; GENE CPG ISLAND; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; SUBCELLULAR-LOCALIZATION; MESSENGER-RNA; MATRIX METALLOPROTEINASES	The synucleins are a small, soluble, highly conserved group of neuronal proteins that have been implicated in both neurodegenerative diseases and cancer. The synuclein family consists of alpha-, beta-, and gamma-synucleins (gamma-syn). They are a natively unfolded group of proteins that share sequence homologies and structural properties ( 1, 2). So far, the biological functions of the synucleins are still unclear, but their involvement in neurodegenerative diseases and cancer may provide insights into the pathological processes that result from these two groups of debilitating diseases, and present the possibility to use them as potential targets for early diagnosis and treatment. Recently, elevated levels of gamma-syn proteins have been detected in various types of cancer, especially in advanced stages of the disease. Furthermore, studies to date indicate that overexpression of gamma-syn compromises normal mitotic checkpoint controls, resulting in multinucleation as well as faster cell growth. gamma-Syn has also been shown to promote invasion and metastasis in in vitro assays as well as in animal models. Overexpression of gamma-syn also interferes with drug-induced apoptotic responses. These observations raise questions about the involvement of gamma-syn in the process of tumorigenesis and metastasis, and efforts have already been made to use gamma-syn as a marker for assessing breast cancer progression ( 3). This review will discuss the involvement of gamma-syn in cancer progression, metastasis and its potential as a marker.	United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Biochem, Al Ain, U Arab Emirates; United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Pharmcol & Therapeut, Al Ain, U Arab Emirates; Univ Lancaster, Dept Biol Sci, Biomed Sci Unit, Lancaster, England	United Arab Emirates University; United Arab Emirates University; Lancaster University	El-Agnaf, OMA (corresponding author), United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Biochem, POB 17666, Al Ain, U Arab Emirates.	o.elagnaf@uaeu.ac.ae	Martin, Francis L/J-4585-2019; Attoub, Samir/N-6852-2018	Martin, Francis L/0000-0001-8562-4944; Singh, Maneesh/0000-0003-0852-7475				Amer DAM, 2006, EXP BRAIN RES, V173, P223, DOI 10.1007/s00221-006-0539-y; Beyer K, 2006, ACTA NEUROPATHOL, V112, P237, DOI 10.1007/s00401-006-0104-6; Bloomston M, 2002, ANN SURG ONCOL, V9, P668, DOI 10.1245/aso.2002.9.7.668; Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Buchman VL, 1998, NAT NEUROSCI, V1, P101, DOI 10.1038/349; Buchman VL, 1998, J NEUROSCI, V18, P9335; Cairns RA, 2003, CURR MOL MED, V3, P659, DOI 10.2174/1566524033479447; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Choi W, 2004, FEBS LETT, V576, P363, DOI 10.1016/j.febslet.2004.09.038; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; da Costa CA, 2003, J BIOL CHEM, V278, P37330, DOI 10.1074/jbc.M306083200; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Duesberg P, 2000, CELL MOTIL CYTOSKEL, V47, P81; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eissa S, 1999, CLIN BIOCHEM, V32, P321, DOI 10.1016/S0009-9120(99)00025-9; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; El-Agnaf OMA, 2006, FASEB J, V20, P419, DOI 10.1096/fj.03-1449com; Fan Y, 2006, HUM MOL GENET, V15, P3002, DOI 10.1093/hmg/ddl242; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; Fortin DL, 2004, J NEUROSCI, V24, P6715, DOI 10.1523/JNEUROSCI.1594-04.2004; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Fung KM, 2003, ACTA NEUROPATHOL, V106, P167, DOI 10.1007/s00401-003-0718-x; Galvin JE, 1999, P NATL ACAD SCI USA, V96, P13450, DOI 10.1073/pnas.96.23.13450; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; George JM, 2002, GENOME BIOL, V3; Ghobrial IM, 2005, CA-CANCER J CLIN, V55, P178, DOI 10.3322/canjclin.55.3.178; Giasson BI, 2001, EXP NEUROL, V172, P354, DOI 10.1006/exnr.2001.7805; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Goers J, 2003, BIOCHEMISTRY-US, V42, P8465, DOI 10.1021/bi0341152; Gupta A, 2003, ONCOGENE, V22, P7593, DOI 10.1038/sj.onc.1206880; Gupta A, 2003, CANCER RES, V63, P664; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hashimoto M, 2004, GENE THER, V11, P1713, DOI 10.1038/sj.gt.3302349; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Hirai Y, 2004, FEBS LETT, V572, P227, DOI 10.1016/j.febslet.2004.07.046; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hodara R, 2004, J BIOL CHEM, V279, P47746, DOI 10.1074/jbc.M408906200; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; Inaba S, 2005, BREAST CANCER RES TR, V94, P25, DOI 10.1007/s10549-005-6938-0; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Iwaki H, 2004, CANCER SCI, V95, P955, DOI 10.1111/j.1349-7006.2004.tb03183.x; Iwatsubo T, 2003, J NEUROL, V250, P11, DOI 10.1007/s00415-003-1303-x; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Ji HJ, 1997, CANCER RES, V57, P759; Jia TL, 1999, CANCER RES, V59, P742; Jiang YF, 2003, CANCER RES, V63, P3899; Jiang YF, 2004, CANCER RES, V64, P4539, DOI 10.1158/0008-5472.CAN-03-3650; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Kim SH, 2004, PARKINSONISM RELAT D, V10, pS9, DOI 10.1016/j.parkreldis.2003.11.005; Kramer A, 2001, ONKOLOGIE, V24, P538, DOI 10.1159/000055141; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kruger R, 2001, NEUROSCI LETT, V310, P191, DOI 10.1016/S0304-3940(01)02127-9; Kubo S, 2005, J BIOL CHEM, V280, P31664, DOI 10.1074/jbc.M504894200; Kwabi-Addo B, 2004, ENDOCR-RELAT CANCER, V11, P709, DOI 10.1677/erc.1.00535; Ladislas R, 2000, Pathol Oncol Res, V6, P3; Lavedan C, 1998, GENOMICS, V54, P173, DOI 10.1006/geno.1998.5556; Lavedan C, 1998, HUM GENET, V103, P106, DOI 10.1007/s004390050792; Lee G, 2004, J BIOL CHEM, V279, P6834, DOI 10.1074/jbc.M312760200; Lee PH, 2006, J NEURAL TRANSM, V113, P1435, DOI 10.1007/s00702-005-0427-9; Li J, 2001, BIOCHEMISTRY-US, V40, P11604, DOI 10.1021/bi010616g; Li JY, 2002, NEUROSCIENCE, V113, P463, DOI 10.1016/S0306-4522(02)00143-4; Li ZK, 2004, CANCER-AM CANCER SOC, V101, P58, DOI 10.1002/cncr.20321; Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089; Liu JW, 2000, BREAST CANCER RES TR, V62, P99, DOI 10.1023/A:1006418219012; Liu SM, 2004, EMBO J, V23, P4506, DOI 10.1038/sj.emboj.7600451; Lotharius J, 2002, HUM MOL GENET, V11, P2395, DOI 10.1093/hmg/11.20.2395; Lotharius J, 2002, J BIOL CHEM, V277, P38884, DOI 10.1074/jbc.M205518200; Lu AP, 2002, J BIOL CHEM, V277, P31364, DOI 10.1074/jbc.M201060200; Lu AP, 2001, ONCOGENE, V20, P5173, DOI 10.1038/sj.onc.1204668; Mao YH, 2003, CELL, V114, P87, DOI 10.1016/S0092-8674(03)00475-6; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Martin FL, 2004, PROTEIN PEPTIDE LETT, V11, P229, DOI 10.2174/0929866043407138; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; McLean PJ, 2000, J NEURAL TRANSM-SUPP, P53; Mori F, 2002, ACTA NEUROPATHOL, V103, P145, DOI 10.1007/s004010100443; Mori F, 2002, BRAIN RES, V941, P118, DOI 10.1016/S0006-8993(02)02643-4; Mukaetova-Ladinska EB, 2006, MECH AGEING DEV, V127, P188, DOI 10.1016/j.mad.2005.09.014; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Myerowitz R, 2004, MOL GENET METAB, V83, P288, DOI 10.1016/j.ymgme.2004.06.020; NAKAJO S, 1994, MOL BRAIN RES, V27, P81, DOI 10.1016/0169-328X(94)90187-2; NAKAMURA T, 2001, BIOCHEM BIOPH RES CO, V280, P1805; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; NAYLOR MS, 1994, INT J CANCER, V58, P50, DOI 10.1002/ijc.2910580110; Ninkina N, 2003, MOL CELL BIOL, V23, P8233, DOI 10.1128/MCB.23.22.8233-8245.2003; Ninkina NN, 1998, HUM MOL GENET, V7, P1417, DOI 10.1093/hmg/7.9.1417; Norris EH, 2003, J BIOL CHEM, V278, P27230, DOI 10.1074/jbc.M212436200; Ohtake H, 2004, NEUROLOGY, V63, P805, DOI 10.1212/01.WNL.0000139870.14385.3C; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200; Pandey N, 2006, EXP NEUROL, V197, P515, DOI 10.1016/j.expneurol.2005.10.019; Papachroni K, 2005, J MOL NEUROSCI, V25, P157, DOI 10.1385/JMN:25:2:157; Park JY, 2003, BIOCHEMISTRY-US, V42, P3696, DOI 10.1021/bi020604a; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Quilty MC, 2003, EXP NEUROL, V182, P195, DOI 10.1016/S0014-4886(03)00108-0; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; Rockenstein E, 2001, BRAIN RES, V914, P48, DOI 10.1016/S0006-8993(01)02772-X; Saha AR, 2000, EUR J NEUROSCI, V12, P3073, DOI 10.1046/j.1460-9568.2000.00210.x; Saito Y, 2003, J NEUROPATH EXP NEUR, V62, P644, DOI 10.1093/jnen/62.6.644; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Saunders W, 2005, SEMIN CANCER BIOL, V15, P25, DOI 10.1016/j.semcancer.2004.09.003; SEGREST JP, 1992, J LIPID RES, V33, P141; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; Shin HJ, 2003, CANCER CELL, V4, P483, DOI 10.1016/S1535-6108(03)00302-7; Shin MS, 2002, ONCOGENE, V21, P4129, DOI 10.1038/sj.onc.1205527; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Song DD, 2004, EXP NEUROL, V186, P158, DOI 10.1016/S0014-4886(03)00342-X; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Specht CG, 2005, MOL CELL NEUROSCI, V28, P326, DOI 10.1016/j.mcn.2004.09.017; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; SPILLANTINI MG, 1995, GENOMICS, V27, P379, DOI 10.1006/geno.1995.1063; Surgucheva I, 2005, CELL MOL NEUROBIOL, V25, P1051, DOI 10.1007/s10571-005-8474-1; Surgucheva I, 2002, J NEUROSCI RES, V68, P97, DOI 10.1002/jnr.10198; Surgucheva IG, 2003, ARCH BIOCHEM BIOPHYS, V410, P167, DOI 10.1016/S0003-9861(02)00664-1; Surgucheva I, 2006, CELL MOTIL CYTOSKEL, V63, P447, DOI 10.1002/cm.20135; Surguchov A, 2001, J NEUROSCI RES, V65, P68, DOI 10.1002/jnr.1129; Surguchov A, 2001, CELL MOTIL CYTOSKEL, V49, P218, DOI 10.1002/cm.1035; Tabrizi SJ, 2000, HUM MOL GENET, V9, P2683, DOI 10.1093/hmg/9.18.2683; Thompson CB, 2005, COLD SH Q B, V70, P357, DOI 10.1101/sqb.2005.70.011; Tokuda T, 2006, BIOCHEM BIOPH RES CO, V349, P162, DOI 10.1016/j.bbrc.2006.08.024; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; UEDA K, 1994, BIOCHEM BIOPH RES CO, V205, P1366, DOI 10.1006/bbrc.1994.2816; Uversky VN, 2002, J BIOL CHEM, V277, P11970, DOI 10.1074/jbc.M109541200; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Windisch M, 2004, J MOL NEUROSCI, V24, P155, DOI 10.1385/JMN:24:1:155; Windisch M, 2002, J MOL NEUROSCI, V19, P63, DOI 10.1007/s12031-002-0012-8; Wu K, 2006, BREAST CANC RES TREA, V101, P259; Wu KJ, 2003, CANCER EPIDEM BIOMAR, V12, P920; Xia Y, 2001, J ALZHEIMERS DIS, V3, P485, DOI 10.3233/JAD-2001-3508; Xu SL, 2006, BIOCHEM BIOPH RES CO, V342, P330, DOI 10.1016/j.bbrc.2006.01.148; Yanagawa N, 2004, CLIN CANCER RES, V10, P2447, DOI 10.1158/1078-0432.CCR-03-0107; Yu S, 2005, MOL NEUROBIOL, V31, P243, DOI 10.1385/MN:31:1-3:243; Zapata JM, 2001, J BIOL CHEM, V276, P24242, DOI 10.1074/jbc.M100354200; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zeng PY, 2005, CANCER BIOL THER, V4, P961, DOI 10.4161/cbt.4.9.1912; Zhao W, 2006, INT J ONCOL, V28, P1081; Zhou CQ, 2003, WORLD J GASTROENTERO, V9, P1900, DOI 10.3748/wjg.v9.i9.1900	143	68	81	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3419	3430		10.1096/fj.07-8379rev	http://dx.doi.org/10.1096/fj.07-8379rev			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17567567				2022-12-28	WOS:000250517800004
J	Zhang, ZH; Liao, B; Xu, M; Jin, Y				Zhang, Zhihong; Liao, Bing; Xu, Ming; Jin, Ying			Post-translational modification of POU domain transcription factor Oct-4 by SUMO-1	FASEB JOURNAL			English	Article						embryonic stem cells; sumoylation; protein stability; cYes	EMBRYONIC STEM-CELLS; KAPPA-B ACTIVATION; SELF-RENEWAL; GENE-EXPRESSION; UBIQUITIN; DIFFERENTIATION; PLURIPOTENCY; CONJUGATION; STABILITY; INTEGRITY	POU domain transcription factor Oct-4 plays a crucial role in maintaining self-renewal and pluripotency of embryonic stem (ES) cells in a concentration-dependent manner. However, the molecular mechanism controlling Oct-4 levels in ES cells remains largely unknown. To explore the molecular mechanism regulating Oct-4 function, we constructed a mouse ES cell cDNA library and performed yeast two-hybrid screening using the POU domain of Oct-4 as bait. Here, we present novel evidence for Oct-4 interaction with Ubc9, an E2 conjugation enzyme for SUMO modification, and its modification by SUMO-1. The SUMO acceptor site was identified at lysine residue 118. Importantly, disruption of Oct-4 sumoylation reduced Oct-4 protein stability and self-renewal capacity in ES cells. Interestingly, expression of cYes was found to reduce when Oct-4 sumoylation was disrupted or Oct-4 expression downregulated in ES cells. We further demonstrate that Oct-4 was recruited to the cYes promoter region, suggesting that cYes might be a novel downstream gene of Oct-4. Taken together, we first demonstrate the post-translational modification of endogenous Oct-4 by SUMO and the role of sumoylation in regulating Oct-4 protein stability and function. Our findings provide new evidence for the important role of post-translational modification in controlling Oct-4 function in ES cells.	Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci, Shanghai 200025, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Inst Stem Cell Res, Shanghai 200025, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Stem Cell Biol, Shanghai, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	Zhang, ZH (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci, 225 S Chongqing Rd, Shanghai 200025, Peoples R China.	yjin@sibs.ac.cn	zhang, zh/GWV-4677-2022; Xu, Ming/AAR-1681-2021; Xu, Ming/L-4044-2019	Xu, Ming/0000-0002-4477-939X; Liao, Bing/0000-0003-1279-1682; , jin ying/0000-0003-0070-2048				Anneren C, 2004, J BIOL CHEM, V279, P31590, DOI 10.1074/jbc.M403547200; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Gidekel S, 2003, CANCER CELL, V4, P361, DOI 10.1016/S1535-6108(03)00270-8; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Gresko E, 2005, BIOCHEM BIOPH RES CO, V329, P1293, DOI 10.1016/j.bbrc.2005.02.113; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Humphrey RK, 2004, STEM CELLS, V22, P522, DOI 10.1634/stemcells.22-4-522; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Nacerddine K, 2005, DEV CELL, V9, P769, DOI 10.1016/j.devcel.2005.10.007; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Ramos-Mejia V, 2005, DEV DYNAM, V232, P180, DOI 10.1002/dvdy.20211; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; SMITH AG, 1992, DEV BIOL, V151, P339, DOI 10.1016/0012-1606(92)90174-F; Taylor KM, 2005, DEV CELL, V9, P593, DOI 10.1016/j.devcel.2005.09.016; Tsuruzoe S, 2006, BIOCHEM BIOPH RES CO, V351, P920, DOI 10.1016/j.bbrc.2006.10.130; Ulrich HD, 2005, TRENDS CELL BIOL, V15, P525, DOI 10.1016/j.tcb.2005.08.002; Wang J, 2004, J BIOL CHEM, V279, P49091, DOI 10.1074/jbc.M407494200; Xu HM, 2004, J BIOL CHEM, V279, P23495, DOI 10.1074/jbc.M400516200; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7	33	52	58	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3042	3051		10.1096/fj.06-6914com	http://dx.doi.org/10.1096/fj.06-6914com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17496161				2022-12-28	WOS:000249781600006
J	Patel, HH; Tsutsumi, YM; Head, BP; Niesman, IR; Jennings, M; Horikawa, Y; Huang, D; Moreno, AL; Patel, PM; Insel, PA; Roth, DM				Patel, Hemal H.; Tsutsumi, Yasuo M.; Head, Brian P.; Niesman, Ingrid R.; Jennings, Michelle; Horikawa, Yousuke; Huang, Diane; Moreno, Ana L.; Patel, Piyush M.; Insel, Paul A.; Roth, David M.			Mechanisms of cardiac protection from ischemia/reperfusion injury: a role for caveolae and caveolin-1	FASEB JOURNAL			English	Article						protein tyrosine kinase; Src; phosphorylation heart	NITRIC-OXIDE SYNTHASE; PROTEIN-COUPLED RECEPTOR; ADENYLYL-CYCLASE; IN-VIVO; ISOFLURANE; PHOSPHORYLATION; ACTIVATION; EXPRESSION; MICRODOMAINS; ISCHEMIA	Caveolae, small invaginations in the plasma membrane, contain caveolins (Cav) that scaffold signaling molecules including the tyrosine kinase Src. We tested the hypothesis that cardiac protection involves a caveolin-dependent mechanism. We used in vitro and in vivo models of ischemia-reperfusion injury, electron microscopy ( EM), transgenic mice, and biochemical assays to address this hypothesis. We found that Cav-1 mRNA and protein were expressed in mouse adult cardiac myocytes (ACM). The volatile anesthetic, isoflurane, protected ACM from hypoxia-induced cell death and increased sarcolemmal caveolae. Hearts of wild-type (WT) mice showed rapid phosphorylation of Src and Cav-1 after isoflurane and ischemic preconditioning. The Src inhibitor PP2 reduced phosphorylation of Src (Y416) and Cav-1 in the heart and abolished isoflurane-induced cardiac protection in WT mice. Infarct size ( percent area at risk) was reduced by isoflurane in WT (30.5 +/- 4 vs. 44.2 +/- 3, n = 7, P < 0.05) but not Cav-1(-/-) mice (46.6 +/- 5 vs. 41.7 +/- 3, n = 7). Cav-1(-/-) mice exposed to isoflurane showed significant alterations in Src phosphorylation and recruitment of C-terminal Src kinase, a negative regulator of Src, when compared to WT mice. The results indicate that isoflurane modifies cardiac myocyte sarcolemmal membrane structure and composition and that activation of Src and phosphorylation of Cav-1 contribute to cardiac protection. Accordingly, therapies targeted to posttranslational modification of Src and Cav-1 may provide a novel approach for such protection.	Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Cellular & Mol Med, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92103 USA; Vet Affairs San Diego Healthcare Syst, San Diego, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Roth, DM (corresponding author), VASDHS 125, 3350 La Jolla Village Dr, La Jolla, CA 92161 USA.	droth@ucsd.edu	Tsutsumi, Yasuo M/G-1972-2012; Patel, Hemal/C-7325-2019	Niesman, Ingrid/0000-0001-9767-6629; Patel, Hemal/0000-0001-6722-9625; Tsutsumi, Yasuo/0000-0002-1997-082X	NHLBI NIH HHS [1P01 HL66941-01] Funding Source: Medline; NINDS NIH HHS [R01 NS 047570] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047570] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ander AN, 2004, DNA CELL BIOL, V23, P586, DOI 10.1089/1044549041939241; Ballard-Croft C, 2006, AM J PHYSIOL-HEART C, V291, pH658, DOI 10.1152/ajpheart.01354.2005; Belhomme D, 1999, CIRCULATION, V100, P340; Cao HM, 2004, EXP CELL RES, V294, P159, DOI 10.1016/j.yexcr.2003.11.010; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DEADY JE, 1981, ANESTH ANALG, V60, P380; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 2006, CARDIOVASC RES, V69, P788, DOI 10.1016/j.cardiores.2005.12.014; Feron O, 2001, CIRC RES, V88, P129; Feron O, 1998, J BIOL CHEM, V273, P30249, DOI 10.1074/jbc.273.46.30249; Fryer RM, 2001, J PHARMACOL EXP THER, V299, P477; Fryer RM, 1999, AM J PHYSIOL-HEART C, V276, pH1229, DOI 10.1152/ajpheart.1999.276.4.H1229; Hausenloy DJ, 2006, CARDIOVASC RES, V70, P240, DOI 10.1016/j.cardiores.2006.01.017; Head BP, 2005, J BIOL CHEM, V280, P31036, DOI 10.1074/jbc.M502540200; Head BP, 2006, J BIOL CHEM, V281, P26391, DOI 10.1074/jbc.M602577200; Hu GC, 2006, ANESTHESIOLOGY, V104, P777, DOI 10.1097/00000542-200604000-00023; Juhaszova M, 2004, J CLIN INVEST, V113, P1535, DOI 10.1172/JCI200419906; Kamoun WS, 2006, HEPATOLOGY, V43, P182, DOI 10.1002/hep.20940; Kersten JR, 1997, ANESTHESIOLOGY, V87, P361, DOI 10.1097/00000542-199708000-00024; Krajewska WM, 2004, CELL MOL BIOL LETT, V9, P195; Lasley RD, 2000, J BIOL CHEM, V275, P4417, DOI 10.1074/jbc.275.6.4417; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Lu TL, 2006, CELL SIGNAL, V18, P1977, DOI 10.1016/j.cellsig.2006.03.002; Ludwig LM, 2004, ANESTHESIOLOGY, V100, P532, DOI 10.1097/00000542-200403000-00011; Ludwig LM, 2003, ANESTHESIOLOGY, V98, P705, DOI 10.1097/00000542-200303000-00019; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ostrom RS, 1999, CIRC RES, V84, P1110, DOI 10.1161/01.RES.84.9.1110; PALADE GE, 1953, J APPL PHYS, V24, P1424; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; Patel HH, 2006, AM J PHYSIOL-HEART C, V291, pH344, DOI 10.1152/ajpheart.01100.2005; Raikar LS, 2006, J CELL BIOCHEM, V98, P861, DOI 10.1002/jcb.20732; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sanguinetti AR, 2003, BIOCHEM J, V376, P159, DOI 10.1042/BJ20030336; Sanguinetti AR, 2003, CELL SIGNAL, V15, P289, DOI 10.1016/S0898-6568(02)00090-6; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Swaney JS, 2006, J BIOL CHEM, V281, P17173, DOI 10.1074/jbc.M513097200; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tsutsumi YM, 2006, ANESTHESIOLOGY, V104, P495, DOI 10.1097/00000542-200603000-00017; Williams TM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-214; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962	50	119	129	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1565	1574		10.1096/fj.06-7719com	http://dx.doi.org/10.1096/fj.06-7719com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17272740				2022-12-28	WOS:000246117000031
J	Pavlovic, D; Fuller, W; Shattock, MJ				Pavlovic, Davor; Fuller, William; Shattock, Michael J.			The intracellular region of FXYD1 is sufficient to regulate cardiac Na/K ATPase	FASEB JOURNAL			English	Article						ion pumps; Na/K pump; protein kinase A; protein phosphorylation; phospholemman; FXYD	PHOSPHOLEMMAN CHANNEL MOLECULES; GAMMA-SUBUNIT; ION CURRENTS; XENOPUS OOCYTES; SODIUM-PUMP; NA,K-ATPASE; PROTEIN; PHOSPHORYLATION; EXPRESSION; NA+,K+-ATPASE	FXYD1 is a transmembrane protein predominantly expressed in excitable tissues that associates with and regulates Na/K ATPase. PKA phosphorylates FXYD1 at serine 68 ( S68), however, the effects of phosphorylation on Na/K ATPase activity are not fully characterized. The objectives of this study were to characterize Na/K ATPase currents in FXYD1 wild-type (WT) and knockout ( KO) adult mouse ventricular myocytes, and investigate the effects of FXYD1 on Na/ K ATPase currents using the whole-cell patch-clamp technique. A peptide representing the 19 C-terminal residues of FXYD1 ( FXYD1(54-72)) was introduced into the interior of FXYD1 KO and WT myocytes through the patch pipette. K-sensitive Na/K ATPase currents were higher in KO myocytes ( 2.9 +/- 0.1 pA/pF; n = 4) compared with WT ( 1.9 +/- 0.1 pA/pF; n = 4). Unphosphorylated FXYD1(54-72), at a concentration of 4 mu M, reduced the currents in WT ( from 2.1 +/- 0.1 to 1.3 +/- 0.1 pA/pF; P < 0.05, n = 7) and KO ( from 2.9 +/- 0.1 to 1.7 + 0.1 pA/ pF; P < 0.05, n = 5), whereas, 1 mu M of FXYD1(54-72) phosphorylated at S68 increased currents in WT ( from 1.91 +/- 0.09 to 3.1 +/- 0.5 pA/ pF; P < 0.05, n = 6) and KO ( from 2.7 +/- 0.11 to 3.8 +/- 0.2 pA/ pF; P < 0.05, n = 6) myocytes. Coimmunoprecipitation studies demonstrated that S68 phosphorylated and unphosphorylated FXYD1(54-72) associates with Na/ K ATPase alpha 1 subunit. We conclude that unphosphorylated FXYD1 inhibits Na/ K ATPase, whereas S68 phosphorylated FXYD1 stimulates Na/ K ATPase to a level above that seen in the absence of FXYD1.	Kings Coll London, St Thomas Hosp, Rayne Inst, Div Cardiovasc, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Shattock, MJ (corresponding author), Kings Coll London, St Thomas Hosp, Rayne Inst, Div Cardiovasc, London SE1 7EH, England.	michael.shattock@kcl.ac.uk		Fuller, William/0000-0002-5883-4433; Shattock, Michael/0000-0001-6242-7585; Pavlovic, Davor/0000-0002-3171-3551	British Heart Foundation [RG/07/001/22628] Funding Source: Medline	British Heart Foundation(British Heart Foundation)		BERRY RG, 2006, J MOL CELL CARDIOL, V40, P997; Bossuyt J, 2006, J BIOL CHEM, V281, P32765, DOI 10.1074/jbc.M606254200; Chen ZH, 1999, RECEPTOR CHANNEL, V6, P435; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; Davis CE, 2004, NEUROCHEM RES, V29, P177, DOI 10.1023/B:NERE.0000010447.24128.ac; Despa S, 2005, CIRC RES, V97, P252, DOI 10.1161/01.RES.0000176532.97731.e5; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; Fuller W, 2004, FASEB J, V18, P197, DOI 10.1096/fj.03-0213fje; Gao J, 1999, J PHYSIOL-LONDON, V516, P377, DOI 10.1111/j.1469-7793.1999.0377v.x; Geering K, 2005, J BIOENERG BIOMEMBR, V37, P387, DOI 10.1007/s10863-005-9476-x; Jia LG, 2005, AM J PHYSIOL-HEART C, V288, pH1982, DOI 10.1152/ajpheart.00142.2004; Kowdley GC, 1997, BIOPHYS J, V72, P141, DOI 10.1016/S0006-3495(97)78653-3; Li CM, 2004, J BIOL CHEM, V279, P38895, DOI 10.1074/jbc.M406697200; Lifshitz Y, 2006, J BIOL CHEM, V281, P15790, DOI 10.1074/jbc.M601993200; Lindzen M, 2006, J BIOL CHEM, V281, P5947, DOI 10.1074/jbc.M512063200; Mahmmoud YA, 2003, J BIOL CHEM, V278, P37427, DOI 10.1074/jbc.M305126200; MOORMAN JR, 1995, NATURE, V377, P737, DOI 10.1038/377737a0; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; Mounsey JP, 1999, BBA-MOL CELL RES, V1451, P305, DOI 10.1016/S0167-4889(99)00102-0; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PRESTI CF, 1985, J BIOL CHEM, V260, P3860; Sha Q, 2001, J PHYSIOL-LONDON, V535, P407, DOI 10.1111/j.1469-7793.2001.t01-1-00407.x; Silverman BD, 2005, CARDIOVASC RES, V65, P93, DOI 10.1016/j.cardiores.2004.09.005; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Zhang XQ, 2006, J APPL PHYSIOL, V100, P212, DOI 10.1152/japplphysiol.00757.2005; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429; Zouzoulas A, 2003, J BIOL CHEM, V278, P40437, DOI 10.1074/jbc.M308610200	28	39	43	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1539	1546		10.1096/fj.06-7269com	http://dx.doi.org/10.1096/fj.06-7269com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17283221				2022-12-28	WOS:000246117000028
J	Kaplan, D				Kaplan, David			POINT: Statistical analysis in NIH peer review - identifying innovation	FASEB JOURNAL			English	Editorial Material									Case Western Reserve Univ, Case Sch Med, Cleveland, OH 44106 USA	Case Western Reserve University	Kaplan, D (corresponding author), Case Western Reserve Univ, Case Sch Med, 2103 Cornell Rd, Cleveland, OH 44106 USA.	david.kaplan@case.edu						ARMSTRONG D, 2005, PEER REV ADV COMM M; Dennis C, 2004, NATURE, V430, P10, DOI 10.1038/430010a; MAYR E, 1991, ONE LONG ARGUMENT C; *NIH OFF EXTR RES, 1997, M PEER REV OV GROUP; YALOW RS, 1978, SCIENCE, V200, P1236, DOI 10.1118/1.594477; Zerhouni E, 2003, SCIENCE, V302, P63, DOI 10.1126/science.1091867	6	9	9	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2007	21	2					305	308		10.1096/fj.07-0204ufm	http://dx.doi.org/10.1096/fj.07-0204ufm			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17267383				2022-12-28	WOS:000244686300002
J	Gaillard, D; Laugerette, F; Darcel, N; El-Yassimi, A; Passilly-Degrace, P; Hichami, A; Khan, NA; Montmayeur, JP; Besnard, P				Gaillard, Dany; Laugerette, Fabienne; Darcel, Nicolas; El-Yassimi, Abdelghani; Passilly-Degrace, Patricia; Hichami, Aziz; Khan, Naim Akhtar; Montmayeur, Jean-Pierre; Besnard, Philippe			The gustatory pathway is involved in CD36-mediated orosensory perception of long-chain fatty acids in the mouse	FASEB JOURNAL			English	Article						dietary lipid perception; gustation; feeding behavior; obesity risk	CONDITIONED TASTE-AVERSION; FOS-LIKE IMMUNOREACTIVITY; CIRCUMVALLATE PAPILLAE; ALPHA-GUSTDUCIN; CORN-OIL; EXPRESSION; CD36; PREFERENCE; MICE; RAT	The sense of taste informs the body about the quality of ingested foods. Tastant-mediated signals are generated by a rise in free intracellular calcium levels ([Ca2+]i) in the taste bud cells and then are transferred to the gustatory area of brain via connections between the gustatory nerves (chorda tympani and glossopharyngeal nerves) and the nucleus of solitary tract in the brain stem. We have recently shown that lingual CD36 contributes to fat preference and early digestive secretions in the mouse. We show here that 1) the induction of an increase in [Ca2+]i by linoleic acid is CD36-dependent in taste receptor cells, 2) the spontaneous preference for or conversely conditioned aversion to linoleic acid requires intact gustatory nerves, and 3) the activation of gustatory neurons in the nucleus of the solitary tract elicited by a linoleic acid deposition on the tongue in wild-type mice cannot be reproduced in CD36-null animals. We conclude that the CD36-mediated perception of long-chain fatty acids involves the gustatory pathway, suggesting that the mouse may have a "taste" for fatty foods. This system would constitute a potential physiological advantage under conditions of food scarcity by leading the mouse to select and absorb fatty foods. However, it might also lead to a risk of obesity and associated diseases in a context of constantly abundant food.	[Gaillard, Dany; Laugerette, Fabienne; Passilly-Degrace, Patricia; Besnard, Philippe] Univ Bourgogne 1, Ecole Natl Super Biol Appl Nutr & Alimentat, INSERM, UMR,U 866, F-21000 Dijon, France; [Laugerette, Fabienne; Montmayeur, Jean-Pierre] Univ Bourgogne, INRA 1214, Ctr Europeen Sci Gout, Ctr Natl Rech Sci,UMR 5170, Dijon, France; [Darcel, Nicolas] Inst Natl Agron Paris Grignon, UMR 914, INRA, Paris, France; [El-Yassimi, Abdelghani; Hichami, Aziz; Khan, Naim Akhtar] Univ Bourgogne, UPRES, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; INRAE; Institut Agro; AgroSup Dijon; Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne; AgroParisTech; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Universite de Bourgogne	Besnard, P (corresponding author), Univ Bourgogne 1, Ecole Natl Super Biol Appl Nutr & Alimentat, INSERM, UMR,U 866, Esplanade Erasme, F-21000 Dijon, France.	pbesnard@u-bourgogne.fr	Montmayeur, Jean-Pierre R/A-5723-2009; Darcel, Nicolas P/B-5071-2013; Passilly-Degrace, Patricia/AAF-5903-2021	Montmayeur, Jean-Pierre/0000-0002-0942-1114; hichami, aziz/0000-0003-4331-5152; Gaillard, Dany/0000-0002-6875-025X				Baillie AGS, 1996, J MEMBRANE BIOL, V153, P75, DOI 10.1007/s002329900111; Berthoud HR, 2002, NEUROSCI BIOBEHAV R, V26, P393, DOI 10.1016/S0149-7634(02)00014-3; Boughter JD, 1997, J NEUROSCI, V17, P2852; Chale-Rush A, 2007, CHEM SENSES, V32, P423, DOI 10.1093/chemse/bjm007; DREWNOWSKI A, 1985, PHYSIOL BEHAV, V35, P617, DOI 10.1016/0031-9384(85)90150-7; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Fukuwatari T, 1997, FEBS LETT, V414, P461, DOI 10.1016/S0014-5793(97)01055-7; Fukuwatari T, 2003, PHYSIOL BEHAV, V78, P579, DOI 10.1016/S0031-9384(03)00037-4; Gilbertson TA, 2003, NEUROREPORT, V14, P905, DOI 10.1097/01.wnr.0000074346.81633.76; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guagliardo NA, 2007, J COMP NEUROL, V504, P206, DOI 10.1002/cne.21436; HAMOSH M, 1990, NUTRITION, V6, P421; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; Harrer MI, 1996, BRAIN RES, V711, P125, DOI 10.1016/0006-8993(95)01410-1; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Huang YJ, 2001, ANAT EMBRYOL, V204, P493, DOI 10.1007/s429-001-8006-1; INGRAM DK, 1982, J GEN PSYCHOL, V106, P233; Kawai T, 2003, AM J PHYSIOL-REG I, V285, pR447, DOI 10.1152/ajpregu.00729.2002; Laugerette F, 2005, J CLIN INVEST, V115, P3177, DOI 10.1172/JCI25299; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mattes RD, 2005, PHYSIOL BEHAV, V86, P691, DOI 10.1016/j.physbeh.2005.08.058; Mattes RD, 2001, PHYSIOL BEHAV, V74, P343, DOI 10.1016/S0031-9384(01)00578-9; McCormack DN, 2006, PHYSIOL BEHAV, V87, P582, DOI 10.1016/j.physbeh.2005.12.004; MELA DJ, 1991, AM J CLIN NUTR, V53, P908, DOI 10.1093/ajcn/53.4.908; MELA DJ, 1988, APPETITE, V10, P37, DOI 10.1016/S0195-6663(88)80031-X; MOREAU H, 1988, GASTROENTEROLOGY, V95, P1221, DOI 10.1016/0016-5085(88)90354-X; Morris-Wiman J, 1999, DEV BRAIN RES, V116, P141, DOI 10.1016/S0165-3806(99)00086-3; Paxinos G, 2000, MOUSE BRAIN STEREOTA; Pittman D, 2007, BRAIN RES, V1151, P74, DOI 10.1016/j.brainres.2007.03.027; Rolls ET, 2005, PHYSIOL BEHAV, V85, P45, DOI 10.1016/j.physbeh.2005.04.012; Sclafani A, 2007, AM J PHYSIOL-REG I, V293, pR1504, DOI 10.1152/ajpregu.00364.2007; Sollars SI, 1996, PHYSIOL BEHAV, V60, P65, DOI 10.1016/0031-9384(95)02235-X; Spencer CM, 2001, MOL BRAIN RES, V93, P113, DOI 10.1016/S0169-328X(01)00173-5; STJOHN SJ, 1995, AM J PHYSIOL-REG I, V269, pR141, DOI 10.1152/ajpregu.1995.269.1.R141; Takeda M, 2000, LIFE SCI, V67, P197, DOI 10.1016/S0024-3205(00)00614-7; Takeda M, 1996, CELL TISSUE RES, V286, P55, DOI 10.1007/s004410050674; Takeda M, 2001, LIFE SCI, V69, P847, DOI 10.1016/S0024-3205(01)01180-8; Takeda M, 2001, NUTRITION, V17, P117, DOI 10.1016/S0899-9007(00)00513-X; Tedder TF, 2002, BIOCHEM SOC T, V30, P807, DOI 10.1042/bst0300807; Travers SP, 2002, AM J PHYSIOL-REG I, V282, pR1798, DOI 10.1152/ajpregu.00590.2001; Tsuruta M, 1999, PHYSIOL BEHAV, V66, P285, DOI 10.1016/S0031-9384(98)00299-6; Zhang XQ, 2003, LAB INVEST, V83, P317, DOI 10.1097/01.LAB.0000059923.67198.BA	42	167	173	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1458	1468		10.1096/fj.07-8415com	http://dx.doi.org/10.1096/fj.07-8415com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18162488				2022-12-28	WOS:000255898700018
J	Wang, N; Yvan-Charvet, L; Lutjohann, D; Mulder, M; Vanmierlo, T; Kim, TW; Tall, AR				Wang, Nan; Yvan-Charvet, Laurent; Luetjohann, Dieter; Mulder, Monique; Vanmierlo, Tim; Kim, Tae-Wan; Tall, Alan R.			ATP-binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain	FASEB JOURNAL			English	Article						Abcg1; Abcg4; astrocyte; neuron; apolipoprotein E; efflux	NEWLY SYNTHESIZED CHOLESTEROL; CENTRAL-NERVOUS-SYSTEM; CARDIOVASCULAR-DISEASE; ABCA1; ABCG1; MICE; ATHEROSCLEROSIS; EXPRESSION; CELLS; MOUSE	Transporters in the ABCG family appear to be involved in the cellular excretion of cholesterol and other sterols in a cell- and tissue-specific fashion. Overexpression of ATP-binding cassette transporters G1 (Abcg1) and G4 (Abcg4) can promote cellular cholesterol efflux to high-density lipoprotein (HDL), but the in vivo functions of Abcg4 are poorly understood. We used mice with knockouts of Abcg1 or Abcg4 singly or together to further elucidate the function of these transporters. Abcg1 and Abcg4 are highly expressed in the brain and are found in both astrocytes and neurons. Whereas Abcg2(-/-) or Abcg4(-/-) mice showed essentially normal levels of brain sterols, in Abcg1(-/-)/Abcg4(-/-) mice, levels of several sterol intermediates in the cholesterol biosynthetic pathway, namely desmosterol, lathosterol, and lanosterol, as well as 27-OH cholesterol, were increased 2- to 3-fold. Overexpression of Abcg1 or Abcg4 promoted efflux of desmosterol and cholesterol from cells to HDL, and combined deficiency of these transporters led to defective efflux and accumulation of these sterols in primary astrocytes. Consistent with defective efflux and sterol accumulation, cholesterol biosynthesis was reduced in Abcg1(-/-)/Abcg4(-/-) astrocytes. The accumulation of desmosterol, a known liver-X receptor (LXR) activator, was associated with increased expression of LXR target genes, including ATP-binding cassette transporter Al, and increased apolipoprotein E secretion in Abcg1(-/-)/ Abcg4-/- astrocytes. Our findings provide the first in vivo demonstration of a role for Abcg4 in sterol efflux in the brain and show that Abcg1 and Abcg4 have overlapping functions in astrocytes, promoting efflux of cholesterol, desmosterol, and possibly other sterol biosynthetic intermediates to HDL.	[Wang, Nan; Yvan-Charvet, Laurent; Tall, Alan R.] Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA; [Kim, Tae-Wan] Columbia Univ, Dept Pathol, New York, NY 10032 USA; [Luetjohann, Dieter] Univ Bonn, Inst Clin Biochem & Pharmacol, D-5300 Bonn, Germany; [Mulder, Monique] Maastricht Univ, Dept Basic Neurosci, Maastricht, Netherlands	Columbia University; Columbia University; University of Bonn; Maastricht University	Wang, N (corresponding author), Columbia Univ, Dept Med, Div Mol Med, PS 8-401,630 W 168th St, New York, NY 10032 USA.	nw30@columbia.edu	Vanmierlo, Tim/C-7773-2013; Tall, Alan/AAT-8528-2021	Vanmierlo, Tim/0000-0003-2912-0578; Yvan-Charvet, Laurent/0000-0002-7748-4942				Abildayeva K, 2006, J BIOL CHEM, V281, P12799, DOI 10.1074/jbc.M601019200; Aiello RJ, 2003, ARTERIOSCL THROM VAS, V23, P972, DOI 10.1161/01.ATV.0000054661.21499.FB; Baldan A, 2006, CURR OPIN LIPIDOL, V17, P227, DOI 10.1097/01.mol.0000226113.89812.bb; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bjorkhem I, 2004, ARTERIOSCL THROM VAS, V24, P806, DOI 10.1161/01.ATV.0000120374.59826.1b; Brunham LR, 2006, ANNU REV NUTR, V26, P105, DOI 10.1146/annurev.nutr.26.061505.111214; Chen WL, 2007, CELL METAB, V5, P73, DOI 10.1016/j.cmet.2006.11.012; Cserepes J, 2004, BIOCHEM BIOPH RES CO, V320, P860, DOI 10.1016/j.bbrc.2004.06.037; DIETSCHY JM, 1967, J LIPID RES, V8, P97; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI 10.1194/jlr.R400004-JLR200; Engelking LJ, 2006, J CLIN INVEST, V116, P2356, DOI 10.1172/JCI28988; Graf GA, 2003, J BIOL CHEM, V278, P48275, DOI 10.1074/jbc.M310223200; Heverin M, 2007, ARTERIOSCL THROM VAS, V27, P2191, DOI 10.1161/ATVBAHA.107.149823; Hirsch-Reinshagen V, 2005, J BIOL CHEM, V280, P43243, DOI 10.1074/jbc.M508781200; Hirsch-Reinshagen V, 2004, J BIOL CHEM, V279, P41197, DOI 10.1074/jbc.M407962200; Hobbs HH, 2002, COLD SPRING HARB SYM, V67, P499, DOI 10.1101/sqb.2002.67.499; IGNATIUS MJ, 1987, SCIENCE, V236, P959, DOI 10.1126/science.3576212; JOHNSON WJ, 1995, J BIOL CHEM, V270, P25037, DOI 10.1074/jbc.270.42.25037; Karten B, 2006, J BIOL CHEM, V281, P4049, DOI 10.1074/jbc.M508915200; Kennedy MA, 2005, CELL METAB, V1, P121, DOI 10.1016/j.cmet.2005.01.002; Kim WS, 2007, J BIOL CHEM, V282, P2851, DOI 10.1074/jbc.M607831200; Lee JY, 2005, CURR OPIN LIPIDOL, V16, P19, DOI 10.1097/00041433-200502000-00005; Lusa S, 2003, J BIOL CHEM, V278, P19844, DOI 10.1074/jbc.M212503200; Mutka AL, 2004, J BIOL CHEM, V279, P48654, DOI 10.1074/jbc.M405345200; Oram JF, 2005, PHYSIOL REV, V85, P1343, DOI 10.1152/physrev.00005.2005; Oram JF, 2006, CIRC RES, V99, P1031, DOI 10.1161/01.RES.0000250171.54048.5c; Radhakrishnan A, 2007, P NATL ACAD SCI USA, V104, P6511, DOI 10.1073/pnas.0700899104; Ranalletta M, 2006, ARTERIOSCL THROM VAS, V26, P2308, DOI 10.1161/01.ATV.0000242275.92915.43; Riddell DR, 2007, MOL CELL NEUROSCI, V34, P621, DOI 10.1016/j.mcn.2007.01.011; Savary S, 1996, MAMM GENOME, V7, P673, DOI 10.1007/s003359900203; Singaraja RR, 2003, ARTERIOSCL THROM VAS, V23, P1322, DOI 10.1161/01.ATV.0000078520.89539.77; Tachikawa M, 2005, J NEUROCHEM, V95, P294, DOI 10.1111/j.1471-4159.2005.03369.x; Tall AR, 2002, J CLIN INVEST, V110, P899, DOI 10.1172/JCI200216391; Terasaka N, 2007, P NATL ACAD SCI USA, V104, P15093, DOI 10.1073/pnas.0704602104; Thelen KM, 2006, J PHARMACOL EXP THER, V316, P1146, DOI 10.1124/jpet.105.094136; Van Eck M, 2002, P NATL ACAD SCI USA, V99, P6298, DOI 10.1073/pnas.092327399; Wahrle SE, 2004, J BIOL CHEM, V279, P40987, DOI 10.1074/jbc.M407963200; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wang N, 2006, ARTERIOSCL THROM VAS, V26, P1310, DOI 10.1161/01.ATV.0000218998.75963.02; Wechsler A, 2003, SCIENCE, V302, P2087, DOI 10.1126/science.1090776; Yang CD, 2006, J BIOL CHEM, V281, P27816, DOI 10.1074/jbc.M603781200; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999	44	130	137	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1073	1082		10.1096/fj.07-9944com	http://dx.doi.org/10.1096/fj.07-9944com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	18039927				2022-12-28	WOS:000254581000013
J	Krammer, C; Suhre, MH; Kremmer, E; Diemer, C; Hess, S; Schatzl, HM; Scheibel, T; Vorberg, I				Krammer, Carmen; Suhre, Michael H.; Kremmer, Elisabeth; Diemer, Claudia; Hess, Simone; Schaetzl, Hermann M.; Scheibel, Thomas; Vorberg, Ina			Prion protein/protein interactions: fusion with yeast Sup35p-NM modulates cytosolic PrP aggregation in mammalian cells	FASEB JOURNAL			English	Article						amyloid; protein misfolding; seeding; nucleation	SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; IN-VITRO; PROTEIN AGGREGATION; PSI+ PRION; N-TERMINUS; INHERITANCE; DETERMINANT; DISEASE; PROPAGATION	In mammalian prion diseases, an abnormally folded, aggregated form of the prion protein (PrPSc) appears to catalyze a conformational switch of its cellular isoform (PrPC) to an aggregated state. A similar prion-like phenomenon has been reported for the Saccharomyces cerevisiae translation termination factor Sup35p that can adopt a self-propagating conformation. We have compared aggregation propensities of chimeric proteins derived from the Sup35p prion domain NM and PrP in vitro and in the cytosol of mammalian cells. Sup35p-NM and PrP displayed strikingly different aggregation behaviors when expressed in mammalian cells, with NM remaining soluble and cytosolic PrP spontaneously aggregating due to the globular domain of PrP. When fused to PrP90-230, Sup35p-M exhibited an inhibitory effect for nucleation but increased aggregate growth, potentially by facilitating recruitment of newly synthesized chimeric proteins into the growing aggregates. This effect, however, could, to some extent, be counteracted by the prionforming region Sup35p-N, thereby increasing aggregate frequency. Interestingly, a lowered nucleation rate was also observed in the presence of the amino-terminal region of PrP, suggesting that Sup35p-M and PrP23-90 share some biological function in prion protein assembly. Our results provide new insights into prion protein aggregation behaviors, demonstrating the impact of dynamic interactions between prion domains and suggesting that aggregation of yeast and mammalian prion proteins is strongly influenced by yet unidentified cellular conditions or factors.	[Krammer, Carmen; Diemer, Claudia; Schaetzl, Hermann M.; Vorberg, Ina] Tech Univ Munich, Inst Virol, D-81675 Munich, Germany; [Suhre, Michael H.; Hess, Simone; Scheibel, Thomas] Tech Univ Munich, Dept Chem, D-8046 Garching, Germany; [Kremmer, Elisabeth] GSF Natl Res Ctr Environm & Hlth, Inst Mol Immunol, Munich, Germany	Technical University of Munich; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Vorberg, I (corresponding author), Tech Univ Munich, Inst Virol, Trogerstr 30, D-81675 Munich, Germany.	vorberg@lrz.tum.de	Suhre, Michael H./C-5145-2009; Nussbaum-Krammer, Carmen/AAY-3081-2020; Scheibel, Thomas/I-1170-2014; Schatzl, Hermann/G-4958-2011	Suhre, Michael H./0000-0002-2279-7765; Nussbaum-Krammer, Carmen/0000-0002-8689-1363; Scheibel, Thomas/0000-0002-0457-2423; Schatzl, Hermann/0000-0003-4972-8740				Aguzzi A, 2003, SCIENCE, V302, P814, DOI 10.1126/science.1087348; Bousset L, 2002, MICROBES INFECT, V4, P461, DOI 10.1016/S1286-4579(02)01561-7; Caughey B, 2006, NATURE, V443, P803, DOI 10.1038/nature05294; Chernoff Y, 2004, CURR OPIN CHEM BIOL, V8, P665, DOI 10.1016/j.cbpa.2004.09.002; Chesebro B, 2005, SCIENCE, V308, P1435, DOI 10.1126/science.1110837; Chien P, 2004, ANNU REV BIOCHEM, V73, P617, DOI 10.1146/annurev.biochem.72.121801.161837; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Derkatch IL, 2004, P NATL ACAD SCI USA, V101, P12934, DOI 10.1073/pnas.0404968101; Derkatch IL, 1996, GENETICS, V144, P1375; Derkatch IL, 2000, EMBO J, V19, P1942, DOI 10.1093/emboj/19.9.1942; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Eaglestone SS, 1999, EMBO J, V18, P1974, DOI 10.1093/emboj/18.7.1974; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Grenier C, 2006, J NEUROCHEM, V97, P1456, DOI 10.1111/j.1471-4159.2006.03837.x; Heller U, 2003, J BIOL CHEM, V278, P36139, DOI 10.1074/jbc.M304002200; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kang SW, 2006, CELL, V127, P999, DOI 10.1016/j.cell.2006.10.032; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; Kochneva-Pervukhova NV, 1998, CURR GENET, V34, P146, DOI 10.1007/s002940050379; Kochneva-Pervukhova NV, 1998, EMBO J, V17, P5805, DOI 10.1093/emboj/17.19.5805; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Krishnan R, 2005, NATURE, V435, P765, DOI 10.1038/nature03679; Kristiansen M, 2005, J BIOL CHEM, V280, P38851, DOI 10.1074/jbc.M506600200; Krzewska J, 2006, EMBO J, V25, P822, DOI 10.1038/sj.emboj.7600985; Kushnirov VV, 1998, CELL, V94, P13, DOI 10.1016/S0092-8674(00)81216-7; Li LM, 2000, SCIENCE, V287, P661, DOI 10.1126/science.287.5453.661; Liebman SW, 2001, NATURE, V410, P161, DOI 10.1038/35065778; Liu JJ, 2002, P NATL ACAD SCI USA, V99, P16446, DOI 10.1073/pnas.252652099; Liu JJ, 1999, NATURE, V400, P573, DOI 10.1038/23048; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Mishra RS, 2003, J ALZHEIMERS DIS, V5, P15, DOI 10.3233/JAD-2003-5103; Nunziante M, 2005, J CELL SCI, V118, P4959, DOI 10.1242/jcs.02609; Nunziante M, 2003, J BIOL CHEM, V278, P3726, DOI 10.1074/jbc.M206313200; Orsi A, 2006, J BIOL CHEM, V281, P30431, DOI 10.1074/jbc.M605320200; Osherovich LZ, 2001, CELL, V106, P183, DOI 10.1016/S0092-8674(01)00440-8; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; Proske D, 2002, CHEMBIOCHEM, V3, P717, DOI 10.1002/1439-7633(20020802)3:8<717::AID-CBIC717>3.0.CO;2-C; Prusiner SB, 1997, ANNU REV GENET, V31, P139, DOI 10.1146/annurev.genet.31.1.139; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Rajan RS, 2001, P NATL ACAD SCI USA, V98, P13060, DOI 10.1073/pnas.181479798; Rane NS, 2004, EMBO J, V23, P4550, DOI 10.1038/sj.emboj.7600462; Ross ED, 2005, NAT CELL BIOL, V7, P1039, DOI 10.1038/ncb1105-1039; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Scheibel T, 2004, P NATL ACAD SCI USA, V101, P2287, DOI 10.1073/pnas.0308754101; Scheibel T, 2001, CURR BIOL, V11, P366, DOI 10.1016/S0960-9822(01)00099-9; Scheibel T, 2001, NAT STRUCT BIOL, V8, P958, DOI 10.1038/nsb1101-958; Shorter J, 2005, NAT REV GENET, V6, P435, DOI 10.1038/nrg1616; Si K, 2003, CELL, V115, P879, DOI 10.1016/S0092-8674(03)01020-1; Sigurdson C, 2005, NEURODEGENER DIS, V2, P1, DOI 10.1159/000086425; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; Soto C, 2006, TRENDS BIOCHEM SCI, V31, P150, DOI 10.1016/j.tibs.2006.01.002; True HL, 2000, NATURE, V407, P477, DOI 10.1038/35035005; VENDRELY C, 2006, PRIONS NEW RES, P251; Walker LC, 2006, TRENDS NEUROSCI, V29, P438, DOI 10.1016/j.tins.2006.06.010; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 2004, ANNU REV GENET, V38, P681, DOI 10.1146/annurev.genet.38.072902.092200; Wigley WC, 1999, J CELL BIOL, V145, P481; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765; Zhou P, 2001, MOL MICROBIOL, V39, P37, DOI 10.1046/j.1365-2958.2001.02224.x	66	15	16	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					762	773		10.1096/fj.07-8733com	http://dx.doi.org/10.1096/fj.07-8733com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17928365				2022-12-28	WOS:000254143700015
J	Akhavan, A; Crivelli, SN; Singh, M; Lingappa, VR; Muschler, JL				Akhavan, Armin; Crivelli, Silvia N.; Singh, Manisha; Lingappa, Vishwanath R.; Muschler, John L.			SEA domain proteolysis determines the functional composition of dystroglycan	FASEB JOURNAL			English	Article						mucin; laminin; autoproteolysis; muscular dystrophy	PROTEIN-STRUCTURE PREDICTION; DYSTROPHIN-GLYCOPROTEIN COMPLEX; SECONDARY STRUCTURE PREDICTION; MUSCULAR-DYSTROPHIES; ALPHA-DYSTROGLYCAN; BETA-DYSTROGLYCAN; EPITHELIAL-CELLS; LAMININ; GLYCOSYLATION; CLEAVAGE	Post-translational modifications of the extracellular matrix receptor dystroglycan (DG) determine its functional state, and defects in these modifications are linked to muscular dystrophies and cancers. A prominent feature of DG biosynthesis is a precursor cleavage that segregates the ligand-binding and transmembrane domains into the noncovalently attached alpha-and beta-subunits. We investigate here the structural determinants and functional significance of this cleavage. We show that cleavage of DG elicits a conspicuous change in its ligand-binding activity. Mutations that obstruct this cleavage result in increased capacity to bind laminin, in part, due to enhanced glycosylation of alpha-DG. Reconstitution of DG cleavage in a cell-free expression system demonstrates that cleavage takes place in the endoplasmic reticulum, providing a suitable regulatory point for later processing events. Sequence and mutational analyses reveal that the cleavage occurs within a full SEA (sea urchin, enterokinase, agrin) module with traits matching those ascribed to autoproteolysis. Thus, cleavage of DG constitutes a control point for the modulation of its ligand-binding properties, with therapeutic implications for muscular dystrophies. We provide a structural model for the cleavage domain that is validated by experimental analysis and discuss this cleavage in the context of mucin protein and SEA domain evolution.	[Akhavan, Armin; Singh, Manisha; Lingappa, Vishwanath R.; Muschler, John L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94107 USA; [Crivelli, Silvia N.] Lawrence Berkeley Natl Lab, Berkeley, CA USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Muschler, JL (corresponding author), Calif Pacific Med Ctr, Res Inst, 475 Brannan St,Ste 220, San Francisco, CA 94107 USA.	muschler@cpmcri.org		Lingappa, Vishwanath R./0000-0003-0962-6571; Muschler, John/0000-0001-9916-5937	NCI NIH HHS [R01 CA109579] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109579] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barresi R, 2006, J CELL SCI, V119, P199, DOI 10.1242/jcs.02814; Barresi R, 2004, NAT MED, V10, P696, DOI 10.1038/nm1059; Boffi A, 2001, BBA-PROTEIN STRUCT M, V1546, P114, DOI 10.1016/S0167-4838(01)00131-5; BORK P, 1995, PROTEIN SCI, V4, P1421, DOI 10.1002/pro.5560040716; Cohn RD, 2002, CELL, V110, P639, DOI 10.1016/S0092-8674(02)00907-8; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; Crivelli S, 2004, J COMPUT AID MOL DES, V18, P271, DOI 10.1023/B:JCAM.0000046822.54719.4f; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; Deng WM, 2003, DEVELOPMENT, V130, P173, DOI 10.1242/dev.00199; Dickens NJ, 2002, CURR BIOL, V12, pR197, DOI 10.1016/S0960-9822(02)00748-0; Duraisamy S, 2006, GENE, V373, P28, DOI 10.1016/j.gene.2005.12.021; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Esapa CT, 2003, FEBS LETT, V555, P209, DOI 10.1016/S0014-5793(03)01230-4; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; Holt KH, 2000, FEBS LETT, V468, P79, DOI 10.1016/S0014-5793(00)01195-9; Jayasinha V, 2003, NEUROMUSCULAR DISORD, V13, P365, DOI 10.1016/S0960-8966(03)00040-3; Johnson RP, 2006, DEVELOPMENT, V133, P1911, DOI 10.1242/dev.02363; Kanagawa M, 2004, CELL, V117, P953, DOI 10.1016/j.cell.2004.06.003; Karplus K, 2005, PROTEINS, V61, P135, DOI 10.1002/prot.20730; Levitin F, 2005, J BIOL CHEM, V280, P33374, DOI 10.1074/jbc.M506047200; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; Macao B, 2006, NAT STRUCT MOL BIOL, V13, P71, DOI 10.1038/nsmb1035; Maeda T, 2004, J BIOL CHEM, V279, P13174, DOI 10.1074/jbc.M309417200; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Moore SA, 2002, NATURE, V418, P422, DOI 10.1038/nature00838; Pereboev AV, 2001, BBA-GEN SUBJECTS, V1527, P54, DOI 10.1016/S0304-4165(01)00147-7; Rohl CA, 2004, METHOD ENZYMOL, V383, P66; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Saito F, 2003, NEURON, V38, P747, DOI 10.1016/S0896-6273(03)00301-5; Singh J, 2004, CANCER RES, V64, P6152, DOI 10.1158/0008-5472.CAN-04-1638; Tremblay MR, 2006, J BIOL CHEM, V281, P13365, DOI 10.1074/jbc.M600912200; Watanabe N, 2007, GENES CELLS, V12, P75, DOI 10.1111/j.1365-2443.2006.01033.x; Weir ML, 2006, J CELL SCI, V119, P4047, DOI 10.1242/jcs.03103; Wreschner DH, 2002, PROTEIN SCI, V11, P698, DOI 10.1110/ps.16502; Xu Jinbo, 2003, J Bioinform Comput Biol, V1, P95, DOI 10.1142/S0219720003000186; YOST CS, 1983, CELL, V34, P759; Zhang Y, 2005, P NATL ACAD SCI USA, V102, P1029, DOI 10.1073/pnas.0407152101	41	37	38	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2008	22	2					612	621		10.1096/fj.07-8354com	http://dx.doi.org/10.1096/fj.07-8354com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17905726				2022-12-28	WOS:000252822600031
J	Hoffmann, D; Seebach, J; Cosma, A; Goebel, FD; Strimmer, K; Schatzl, HM; Erfle, V				Hoffmann, Dieter; Seebach, Judith; Cosma, Antonio; Goebel, Frank D.; Strimmer, Korbinian; Schatzl, Hermann M.; Erfle, Volker			Therapeutic vaccination reduces HIV sequence variability	FASEB JOURNAL			English	Article						Nef; genetic diversity; selection	CELL RESPONSES; T-CELLS; DENDRITIC CELLS; NEF SEQUENCES; VIRUS; EVOLUTION; SELECTION; AIDS; VARIANTS; VACCINES	With HIV persisting lifelong in infected persons, therapeutic vaccination is a novel alternative concept to control virus replication. Even though CD8 and CD4 cell responses to such immunizations have been demonstrated, their effects on virus replication are still unclear. In view of this fact, we studied the impact of a therapeutic vaccination with HIV nef delivered by a recombinant modified vaccinia Ankara vector on viral diversity. We investigated HIV sequences derived from chronically infected persons before and after therapeutic vaccination. Before immunization the mean +/- SE pairwise variability of patient-derived Nef protein sequences was 0.1527 +/- 0.0041. After vaccination the respective value was 0.1249 +/- 0.0042, resulting in a significant (P< 0.0001) difference between the two time points. The genes vif and 5' gag tested in parallel and nef sequences in control persons yielded a constant amino acid sequence variation. The data presented suggest that Nef immunization induced a selective pressure, limiting HIV sequence variability. To our knowledge this is the first report directly linking therapeutic HIV vaccination to decreasing diversity in patient-derived virus isolates.	[Hoffmann, Dieter; Seebach, Judith; Schatzl, Hermann M.] Tech Univ Munich, Inst Virol, Munich, Germany; [Cosma, Antonio; Erfle, Volker] Tech Univ Munich, GSF Natl Res Ctr Environm & Hlth, Clin Cooperat Grp Immune Monitoring, Munich, Germany; [Cosma, Antonio; Erfle, Volker] GSF Natl Res Ctr Environm & Hlth, Inst Mol Virol, Neuherberg, Germany; [Goebel, Frank D.] Univ Munich, Med Poliklin, D-8000 Munich, Germany; [Strimmer, Korbinian] Univ Leipzig, IMISE, Leipzig, Germany	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Leipzig University	Hoffmann, D (corresponding author), Tech Univ Munich, Inst Virol, Munich, Germany.	dieter.hoffmann@lrz.tum.de	Strimmer, Korbinian/C-1522-2009; Schatzl, Hermann/G-4958-2011	Strimmer, Korbinian/0000-0001-7917-2056; Schatzl, Hermann/0000-0003-4972-8740; Cosma, Antonio/0000-0002-3686-8034				Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003; Allen TM, 2005, J VIROL, V79, P13239, DOI 10.1128/JVI.79.21.13239-13249.2005; Autran B, 2004, SCIENCE, V305, P205, DOI 10.1126/science.1100600; Ayyavoo V, 2000, AIDS, V14, P1, DOI 10.1097/00002030-200001070-00001; Barouch DH, 2001, IMMUNOL LETT, V79, P57, DOI 10.1016/S0165-2478(01)00266-8; Bazykin GA, 2006, P NATL ACAD SCI USA, V103, P19396, DOI 10.1073/pnas.0609484103; Betts MR, 2002, DNA CELL BIOL, V21, P665, DOI 10.1089/104454902760330200; Choi HJ, 2004, J BIOL CHEM, V279, P51688, DOI 10.1074/jbc.M410068200; Cornelissen M, 2007, AIDS, V21, P807, DOI 10.1097/QAD.0b013e3280f3c08a; Cosma A, 2003, VACCINE, V22, P21, DOI 10.1016/S0264-410X(03)00538-3; Couillin I, 2001, VIROLOGY, V279, P136, DOI 10.1006/viro.2000.0705; Deeks SG, 2006, BMJ-BRIT MED J, V332, P1489, DOI 10.1136/bmj.332.7556.1489; Doron-Faigenboim A, 2005, BIOINFORMATICS, V21, P2101, DOI 10.1093/bioinformatics/bti259; Dorrell L, 2006, J VIROL, V80, P4705, DOI 10.1128/JVI.80.10.4705-4716.2006; Edwards CTT, 2006, GENETICS, V174, P1441, DOI 10.1534/genetics.105.052019; Erfle V, 2005, MICROBES INFECT, V7, P1400, DOI 10.1016/j.micinf.2005.07.015; Fletcher TM, 1997, EMBO J, V16, P5123, DOI 10.1093/emboj/16.16.5123; Ganeshan S, 1997, J VIROL, V71, P663, DOI 10.1128/JVI.71.1.663-677.1997; Gilliam BL, 2003, CURR TOP MED CHEM, V3, P1536, DOI 10.2174/1568026033451772; GOLDMAN N, 1994, MOL BIOL EVOL, V11, P725; Gudmundsdotter L, 2006, SPRINGER SEMIN IMMUN, V28, P221, DOI 10.1007/s00281-006-0029-0; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Harrer E, 2005, ANTIVIR THER, V10, P285; Johnson WE, 2002, ANNU REV MED, V53, P499, DOI 10.1146/annurev.med.53.082901.104053; Joseph AM, 2005, CURR HIV RES, V3, P87, DOI 10.2174/1570162052773013; Kimata JT, 1999, NAT MED, V5, P535, DOI 10.1038/8414; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; Kondo M, 2005, J INFECT DIS, V192, P56, DOI 10.1086/430739; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1549, DOI 10.1089/aid.1992.8.1549; KORBER B, 2000, COMPUTATIONAL ANAL H, P55, DOI DOI 10.1007/B112102; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Lehmann MH, 2006, J CELL SCI, V119, P4520, DOI 10.1242/jcs.03231; Lehmann MH, 2006, EXP CELL RES, V312, P3659, DOI 10.1016/j.yexcr.2006.08.008; Lemey P, 2006, AIDS REV, V8, P125; Lichterfeld M, 2004, AIDS, V18, P1383, DOI 10.1097/01.aids.0000131329.51633.a3; McGrath KM, 2001, VIRUS RES, V76, P137, DOI 10.1016/S0168-1702(01)00271-4; Montaner JSG, 2006, LANCET, V368, P531, DOI 10.1016/S0140-6736(06)69162-9; Mordelet E, 2004, FASEB J, V18, P1851, DOI 10.1096/fj.04-2308com; NEI M, 1986, MOL BIOL EVOL, V3, P418; Noe A, 2005, J ANTIMICROB CHEMOTH, V55, P410, DOI 10.1093/jac/dki038; O'Neill E, 2006, J VIROL, V80, P1311, DOI 10.1128/JVI.80.3.1311-1320.2006; Overbaugh J, 2001, SCIENCE, V292, P1106, DOI 10.1126/science.1059128; Priceputu E, 2007, J VIROL, V81, P4677, DOI 10.1128/JVI.02691-06; Quaranta MG, 2006, FASEB J, V20, P2198, DOI 10.1096/fj.06-6260rev; Quaranta MG, 2004, FASEB J, V18, P1459, DOI 10.1096/fj.04-1633fje; Quaranta MG, 2003, FASEB J, V17, P2025, DOI 10.1096/fj.03-0272com; Resch W, 2005, J VIROL, V79, P10638, DOI 10.1128/JVI.79.16.10638-10649.2005; Richman DD, 2004, J ANTIMICROB CHEMOTH, V53, P555, DOI 10.1093/jac/dkh157; Sagar M, 2003, J VIROL, V77, P12921, DOI 10.1128/JVI.77.23.12921-12926.2003; Schindler M, 2006, CELL, V125, P1055, DOI 10.1016/j.cell.2006.04.033; Simon V, 2006, LANCET, V368, P489, DOI 10.1016/S0140-6736(06)69157-5; Singh MK, 2001, AIDS RES HUM RETROV, V17, P1265, DOI 10.1089/088922201750461320; Smith RA, 2004, J BIOL CHEM, V279, P26726, DOI 10.1074/jbc.M314038200; Stott EJ, 1996, J ANTIMICROB CHEMOTH, V37, P185, DOI 10.1093/jac/37.suppl_B.185; Suyama M, 2006, NUCLEIC ACIDS RES, V34, pW609, DOI 10.1093/nar/gkl315; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Troyer RM, 2005, J VIROL, V79, P9006, DOI 10.1128/JVI.79.14.9006-9018.2005; Villefroy P, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-65; Visco-Comandini U, 2001, J BIOL REG HOMEOS AG, V15, P299; Yang ZH, 2000, GENETICS, V155, P431	60	7	8	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					437	444		10.1096/fj.06-7975com	http://dx.doi.org/10.1096/fj.06-7975com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17932027				2022-12-28	WOS:000252822600014
J	Schildknecht, S; Daiber, A; Ghisla, S; Cohen, RA; Bachschmid, MM				Schildknecht, Stefan; Daiber, Andreas; Ghisla, Sandro; Cohen, Richard A.; Bachschmid, Markus M.			Acetaminophen inhibits prostanoid synthesis by scavenging the PGHS-activator peroxynitrite	FASEB JOURNAL			English	Article						endothelium; cyclooxygenase; superoxide; nitric oxide; peroxide tone	PROSTAGLANDIN-H SYNTHASE; N-ACYLPHENOLAMINE AM404; PROSTACYCLIN SYNTHESIS; NITRIC-OXIDE; CYCLOOXYGENASE; MECHANISM; MACROPHAGES; NITRATION; CELLS; PARACETAMOL	The primary pharmacological target of acetaminophen is prostaglandin endoperoxide H-2 synthase (PGHS). The enzymatic catalytic mechanism is radical-based, initiated, and maintained by the persistent presence of peroxides, particularly peroxynitrite, which is termed "peroxide tone". Whereas the prevailing concept assumes a direct reduction of the active, oxidized enzyme by acetaminophen, here we show that acetaminophen is a potent scavenger of peroxynitrite (peroxynitrite- mediated phenol nitration, IC50 approximate to 72 mu M; Sin-1-mediated DHR123 oxidation, IC50 approximate to 11 mu M) and thus inhibits PGHS by eliminating the peroxide tone. Nanomolar concentrations of peroxynitrite increased the activity of isolated PGHS and prostacyclin formation by aortic endothelial cells. This elevated activity was efficiently inhibited by pharmacologically relevant concentrations of acetaminophen ( IC50 approximate to 10 mu M for 6-keto-PGF(1 alpha)) and other free radical scavengers. However, when the peroxide tone was provided by H2O2 or tert-butyl-OOH, acetaminophen had only negligible inhibitory effects. Our concept could help to explain the efficacy of acetaminophen to inhibit PGHS in cell types with moderate oxidant formation. However, high levels of peroxynitrite or other peroxides such as lipid peroxides formed at inflammatory sites might overwhelm the ability of acetaminophen to decrease PGHS activation. The concept presented herein provides a molecular basis to explain the excellent analgesic and antipyretic properties of acetaminophen together with its minimal anti-inflammatory effects.-Schildknecht, S., Daiber, A., Ghisla, S., Cohen, R. A., Bachschmid, M. M. Acetaminophen inhibits prostanoid synthesis by scavenging the PGHS-activator peroxynitrite.	[Schildknecht, Stefan; Cohen, Richard A.; Bachschmid, Markus M.] Boston Univ, Sch Med, Dept Med, Vasc Biol Unit, Boston, MA 02118 USA; [Daiber, Andreas] Johannes Gutenberg Univ Mainz, Dept Cardiol, Mainz, Germany; [Ghisla, Sandro] Univ Konstanz, Dept Biochem, Constance, Germany	Boston University; Johannes Gutenberg University of Mainz; University of Konstanz	Bachschmid, MM (corresponding author), Boston Univ, Sch Med, Dept Med, Vasc Biol Unit, 650 Albany St X720, Boston, MA 02118 USA.	bach@bu.edu		/0000-0002-1070-6408; Bachschmid, Markus Michael/0000-0002-0748-5528	NCRR NIH HHS [P41RR10888-6] Funding Source: Medline; NHLBI NIH HHS [P01 HL 68758, N01-HV-28178, P01 HL081738] Funding Source: Medline; NIA NIH HHS [R01 AG027080] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028178] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR010888] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027080] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aronoff DM, 2006, CLIN PHARMACOL THER, V79, P9, DOI 10.1016/j.clpt.2005.09.009; Aronoff DM, 2003, J PHARMACOL EXP THER, V304, P589, DOI 10.1124/jpet.102.042853; Bachschmid M, 2003, FASEB J, V17, P914, DOI 10.1096/fj.02-0530fje; Bakovic M, 1996, J BIOL CHEM, V271, P2048, DOI 10.1074/jbc.271.4.2048; Bambai B, 2000, J BIOL CHEM, V275, P27608; Caballero FJ, 2007, BIOCHEM PHARMACOL, V73, P1013, DOI 10.1016/j.bcp.2006.12.001; Catella-Lawson F, 2001, NEW ENGL J MED, V345, P1809, DOI 10.1056/NEJMoa003199; CUSHMAN DW, 1976, BIOCHIM BIOPHYS ACTA, V424, P449, DOI 10.1016/0005-2760(76)90034-5; Daiber A, 1998, NITRIC OXIDE-BIOL CH, V2, P259, DOI 10.1006/niox.1998.0186; DEWHIRST FE, 1980, PROSTAGLANDINS, V20, P209, DOI 10.1016/S0090-6980(80)80040-2; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; FELDBERG W, 1973, J PHYSIOL-LONDON, V228, P41, DOI 10.1113/jphysiol.1973.sp010071; FELDBERG W, 1973, J PHYSIOL-LONDON, V234, P279, DOI 10.1113/jphysiol.1973.sp010346; Greco A, 2003, J NEUROSCI RES, V71, P844, DOI 10.1002/jnr.10543; GREEN K, 1989, PROSTAG OTH LIPID M, V37, P311, DOI 10.1016/0090-6980(89)90001-4; Guhring H, 2002, EUR J PHARMACOL, V454, P153, DOI 10.1016/S0014-2999(02)02485-8; HANEL AM, 1982, BIOCHEM PHARMACOL, V31, P3307, DOI 10.1016/0006-2952(82)90565-2; Harvison P J, 1986, Adv Exp Med Biol, V197, P739; HARVISON PJ, 1988, CHEM-BIOL INTERACT, V64, P251, DOI 10.1016/0009-2797(88)90101-9; Hogestatt ED, 2005, J BIOL CHEM, V280, P31405, DOI 10.1074/jbc.M501489200; Kiefer JR, 2000, NATURE, V405, P97, DOI 10.1038/35011103; Kim SF, 2005, SCIENCE, V310, P1966, DOI 10.1126/science.1119407; Kis B, 2005, AM J PHYSIOL-REG I, V288, pR897, DOI 10.1152/ajpregu.00613.2004; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Lakshmi VM, 2000, CHEM RES TOXICOL, V13, P891, DOI 10.1021/tx000115g; Lucas R, 2005, FASEB J, V19, P635, DOI 10.1096/fj.04-2437fje; Merrill GF, 2001, BASIC RES CARDIOL, V96, P423, DOI 10.1007/s003950170023; Moldeus P, 1981, Adv Exp Med Biol, V136 Pt B, P1099; Ouellet M, 2001, ARCH BIOCHEM BIOPHYS, V387, P273, DOI 10.1006/abbi.2000.2232; POTTER DW, 1987, J BIOL CHEM, V262, P974; ROBAK J, 1978, BIOCHEM PHARMACOL, V27, P393, DOI 10.1016/0006-2952(78)90367-2; ROBERTS DW, 1987, J PHARMACOL EXP THER, V241, P527; Schildknecht S, 2006, BIOCHEM BIOPH RES CO, V340, P318, DOI 10.1016/j.bbrc.2005.12.009; Schildknecht S, 2005, FASEB J, V19, P1169, DOI 10.1096/fj.04-3465fje; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; THOMAS DJ, 1990, MOL PHARMACOL, V37, P255; Trostchansky A, 2007, FREE RADICAL BIO MED, V42, P1029, DOI 10.1016/j.freeradbiomed.2007.01.009; van Dalen CJ, 2000, J BIOL CHEM, V275, P11638, DOI 10.1074/jbc.275.16.11638; Van Dyke K, 1998, J BIOLUM CHEMILUM, V13, P339; WELLER PE, 1985, ARCH BIOCHEM BIOPHYS, V243, P633, DOI 10.1016/0003-9861(85)90541-7; ZENSER TV, 1978, METABOLISM, V27, P227, DOI 10.1016/0026-0495(78)90168-3	41	40	41	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					215	224		10.1096/fj.06-8015com	http://dx.doi.org/10.1096/fj.06-8015com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17724253	Green Submitted			2022-12-28	WOS:000252309900024
J	Lopez, CI; Belmonte, SA; De Blas, GA; Mayorga, LS				Lopez, Cecilia I.; Belmonte, Silvia A.; De Blas, Gerardo A.; Mayorga, Luis S.			Membrane-permeant Rab3A triggers acrosomal exocytosis in living human sperm	FASEB JOURNAL			English	Article						membrane-permeant proteins; arginine-rich peptides; Rab3A; acrosome reaction	ARGININE-RICH PEPTIDES; CELL-PENETRATING PEPTIDES; GTP-BINDING PROTEIN; HUMAN SPERMATOZOA; PLASMA-MEMBRANE; MOUSE SPERM; KINASE-A; TRANSLOCATION; TRANSDUCTION; INVOLVEMENT	The acrosome reaction is a regulated Ca2+-dependent secretion event required for sperm-egg interaction. Previous studies indicate that the process requires Rab3-dependent tethering of membranes, SNARE complex assembly, and Ca2+-mediated activation of synaptotagmin. Sperm are transcriptionally and translationally inactive; hence, most studies of the exocytosis mechanism are limited to membrane-permeant reagents. The effect of proteins involved in exocytosis has been assessed only in permeabilized cells. Polyarginine peptides are a powerful tool for delivering macromolecules to cells. Most reports indicate that membrane translocation of arginine-containing proteins requires endocytosis; therefore, this strategy might not be useful in sperm. However, our results indicate that GST and Rab3A, when fused with an arginine-rich peptide, were able to translocate into sperm. Moreover, membrane-permeant Rab3A initiated exocytosis when prenylated and activated with GTP. We show here that a key event after the cytoplasmic Ca2+ increase caused by progesterone is the activation of Rab3A. When active Rab3A is introduced into sperm, Ca2+ in the extracellular medium and in the cytoplasm is dispensable. However, a Ca2+ efflux from inside the acrosome is still required to achieve exocytosis. In conclusion, arginine-containing proteins can penetrate the sperm plasma membrane and thus are valuable tools to study sperm physiology in intact cells.-Lopez, C. I., Belmonte, S. A., De Blas, G. A., Mayorga, L. S. Membrane-permeant Rab3A triggers acrosomal exocytosis in living human sperm.	Univ Nacl Cuyo, Fac Ciencias Med, Inst Histol & Embriol, Biol Cellulaire & Mol Lab, Mendoza, Argentina	University Nacional Cuyo Mendoza	Mayorga, LS (corresponding author), Casilla Correo 56, RA-5500 Mendoza, Argentina.	lmayorga@fcm.uncu.edu.ar	Belmonte, Silvia Alejandra Alejandra/AAW-5131-2021	Mayorga, Luis S/0000-0002-5995-0671				BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; Barclay JW, 2005, CELL CALCIUM, V38, P343, DOI 10.1016/j.ceca.2005.06.012; Belmonte SA, 2005, DEV BIOL, V285, P393, DOI 10.1016/j.ydbio.2005.07.001; Branham MAT, 2006, J BIOL CHEM, V281, P8656, DOI 10.1074/jbc.M508854200; Breitbart H, 2003, CELL MOL BIOL, V49, P321; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Cross NL, 1999, MOL REPROD DEV, V53, P92, DOI 10.1002/(SICI)1098-2795(199905)53:1<92::AID-MRD11>3.3.CO;2-H; Darszon A, 2001, DEV BIOL, V240, P1, DOI 10.1006/dbio.2001.0387; De Blas G, 2002, J BIOL CHEM, V277, P49326, DOI 10.1074/jbc.M208587200; De Blas GA, 2005, PLOS BIOL, V3, P1801, DOI 10.1371/journal.pbio.0030323; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0; DOWNING MA, 2005, J MORPHOL, V263, P179; Fawcett D. W., 1970, Biol Reprod, V2, P90, DOI 10.1095/biolreprod2.Supplement_2.90; FICHARD JP, 2003, J BIOL CHEM, V278, P585; Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Garde J, 1996, FEBS LETT, V391, P263, DOI 10.1016/0014-5793(96)00749-1; Harrison DA, 2000, BIOL REPROD, V62, P811, DOI 10.1095/biolreprod62.3.811; Herrick SB, 2005, J CELL PHYSIOL, V202, P663, DOI 10.1002/jcp.20172; Iida H, 1999, DEV BIOL, V211, P144, DOI 10.1006/dbio.1999.9302; Jimenez-Gonzalez C, 2006, HUM REPROD UPDATE, V12, P253, DOI 10.1093/humupd/dmi050; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; Katterle Y, 2004, BRIT J CANCER, V90, P230, DOI 10.1038/sj.bjc.6601506; Kirkman-Brown JC, 2003, DEV BIOL, V259, P71, DOI 10.1016/S0012-1606(03)00137-4; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; MENDOZA C, 1992, J REPROD FERTIL, V95, P755; Michaut M, 2000, P NATL ACAD SCI USA, V97, P9996, DOI 10.1073/pnas.180206197; Michod D, 2004, ONCOGENE, V23, P8971, DOI 10.1038/sj.onc.1207999; Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010; Narita K, 2005, FASEB J, V19, P1558, DOI 10.1096/fj.04-2714fje; Pereira-Leal JB, 2001, FEBS LETT, V498, P197, DOI 10.1016/S0014-5793(01)02483-8; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Pooga M, 1998, FASEB J, V12, P67, DOI 10.1096/fasebj.12.1.67; Pooga M, 2001, FASEB J, V15, P1451, DOI 10.1096/fj.00-0780fje; Roggero CM, 2005, DEV BIOL, V285, P422, DOI 10.1016/j.ydbio.2005.07.007; Saalik P, 2004, BIOCONJUGATE CHEM, V15, P1246, DOI 10.1021/bc049938y; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; TOMES C, 2006, MOL MECH EXOCYTOSIS, P117; Tomes CN, 2005, MOL HUM REPROD, V11, P43, DOI 10.1093/molehr/gah126; Travis AJ, 2002, J CLIN INVEST, V110, P731, DOI [10.1172/JCI200216392, 10.1172/JCI0216392]; Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Ward CR, 1999, MOL REPROD DEV, V53, P413, DOI 10.1002/(SICI)1098-2795(199908)53:4&lt;413::AID-MRD7&gt;3.0.CO;2-W; Yunes R, 2000, BIOL REPROD, V62, P1084, DOI 10.1095/biolreprod62.4.1084	46	39	40	2	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4121	4130		10.1096/fj.06-7716com	http://dx.doi.org/10.1096/fj.06-7716com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17625073				2022-12-28	WOS:000251283500037
J	Zeira, E; Manevitch, A; Manevitch, Z; Kedar, E; Gropp, M; Daudi, N; Barsuk, R; Harati, M; Yotvat, H; Troilo, PJ; Griffiths, TG; Pacchione, SJ; Roden, DF; Niu, Z; Nussbaum, O; Zamir, G; Papo, O; Hemo, I; Lewis, A; Galun, E				Zeira, Evelyne; Manevitch, Alexandra; Manevitch, Zakharia; Kedar, Eli; Gropp, Michal; Daudi, Nili; Barsuk, Rimma; Harati, Menahem; Yotvat, Hagit; Troilo, Philip J.; Griffiths, Thomas G., II; Pacchione, Stephen J.; Roden, Dana F.; Niu, Zhutian; Nussbaum, Ofer; Zamir, Gideon; Papo, Orit; Hemo, Izhack; Lewis, Aaron; Galun, Eithan			Femtosecond laser: a new intradermal DNA delivery method for efficient, long-term gene expression and genetic immunization	FASEB JOURNAL			English	Article						gene delivery; vaccination; HBV; antitumor	ELECTROPORATION; THERAPY; SKIN; VACCINATION; VACCINES; BIOLOGY; MOUSE; MODEL; CELL	A femtosecond laser beam gene transduction (SG-LBGT) system is described as a novel and efficient method of intradermal (i.d.)non viralgene delivery in mice by permeabilizing cells utilizing femtosecond laser pulses. Using this approach, significant gene expression and efficient dermal transduction lasting for > 7 months were obtained. The ability of this new DNA gene transfer method to enhance genetic vaccination was tested in BALB/C mice. A single i.d. injection of a plasmid (10 mu g) containing the hepatitis B virus (HBV) surface antigen (HBsAg), followed by pulses of laser, induced high titers of HBsAg-specific antibodies lasting for > 210 days and increased levels of IgG1, IgG2a, IFN gamma, and IL-4, indicating the activation of both Th1 and Th2 cells. Moreover, mice vaccinated using the SG-LBGT followed by challenge with pHBV showed increased protection against viral challenge, as detected by decreased levels of HBV DNA, suggesting an efficient Th1 effect against HBV-infected replicating cells. Tumor growth retardation was induced in vaccinated mice challenged with an HBsAg-expressing syngeneic tumor. In most of the parameters tested, administration of plasmid followed by laser application was significantly more effective and prolonged than that of plasmid alone. Tissue damage was not detected and integration of the plasmid into the host genomic DNA probably did not occur. We suggest that the LBGT method is an efficient and safe technology for in vivo gene expression and vaccination and emphasizes its potential therapeutic applications for i.d. nonviral gene delivery.	Hadassah Hebrew Univ Hosp, Goldyne Savad Inst Gene Therapy, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem Engn & Comp Sci, Selim & Rachel Benin Sch, Dept Appl Phys, Fac Nat Sci, Jerusalem, Israel; Hadassah Laser Ctr, Dept Ophthalmol, Jerusalem, Israel; Hadassah Hebrew Univ Hosp, Liver Unit, Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91010 Jerusalem, Israel; Merck & Co Inc, Merck Res Labs, Dept Biol Safety Assessment, West Point, PA USA; XTL Biopharmaceut Ltd, Rehovot, Israel; Hadassah Hebrew Univ Hosp, Dept Surg, Jerusalem, Israel; Hadassah Hebrew Univ Hosp, Dept Pathol, Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Merck & Company; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center	Galun, E (corresponding author), Hadassah Univ Hosp, Goldyne Savad Inst Gene Therapy, POB 12000, IL-91120 Jerusalem, Israel.	eithang@hadassah.org.il	Galun, Eithan/AAD-9117-2022	Galun, Eithan/0000-0002-6243-6702				BERNS MW, 1981, SCIENCE, V213, P505, DOI 10.1126/science.7017933; BERNS MW, 1991, INT REV CYTOL, V129, P1; Chow YH, 1998, J IMMUNOL, V160, P1320; Donnelly JJ, 1995, ANN NY ACAD SCI, V772, P40, DOI 10.1111/j.1749-6632.1995.tb44730.x; Duguez S, 2002, AM J PHYSIOL-ENDOC M, V282, pE802, DOI 10.1152/ajpendo.00343.2001; Glasspool-Malone J, 2000, MOL THER, V2, P140, DOI 10.1006/mthe.2000.0107; Haupt K, 2002, EXP BIOL MED, V227, P227, DOI 10.1177/153537020222700403; Honigman A, 2001, MOL THER, V4, P239, DOI 10.1006/mthe.2001.0437; Ilan E, 1999, HEPATOLOGY, V29, P553, DOI 10.1002/hep.510290228; Ilan Y, 2000, BONE MARROW TRANSPL, V26, P633, DOI 10.1038/sj.bmt.1702571; Ketzinel-Gilad M, 2006, HEPATOL RES, V34, P228, DOI 10.1016/j.hepres.2006.01.008; Kim JJ, 2001, CLIN CANCER RES, V7, p882S; Kwissa M, 2000, VACCINE, V18, P2337, DOI 10.1016/S0264-410X(00)00030-X; Ledwith BJ, 2000, INTERVIROLOGY, V43, P258, DOI 10.1159/000053993; Lee WR, 2006, J CONTROL RELEASE, V115, P344, DOI 10.1016/j.jconrel.2006.08.012; Lucas ML, 2001, DNA CELL BIOL, V20, P183, DOI 10.1089/104454901300069040; Pavselj N, 2005, J CONTROL RELEASE, V106, P407, DOI 10.1016/j.jconrel.2005.05.003; Regnier V, 2000, J CONTROL RELEASE, V67, P337, DOI 10.1016/S0168-3659(00)00223-6; ROBERTSON JS, 1994, VACCINE, V12, P1526, DOI 10.1016/0264-410X(94)90077-9; SMITH HA, 1994, VACCINE, V12, P1515, DOI 10.1016/0264-410X(94)90075-2; Spirito F, 2001, J GENE MED, V3, P21, DOI 10.1002/1521-2254(2000)9999:9999<::AID-JGM156>3.0.CO;2-I; Stevenson D, 2006, OPT EXPRESS, V14, P7125, DOI 10.1364/OE.14.007125; Tirlapur UK, 2002, NATURE, V418, P290, DOI 10.1038/418290a; van Slooten ML, 2001, BBA-MOL CELL BIOL L, V1531, P99, DOI 10.1016/S1388-1981(01)00092-0; Vogel JC, 2000, HUM GENE THER, V11, P2253, DOI 10.1089/104303400750035780; WEICHSELBAUM RR, 1994, CANCER RES, V54, P4266; Weiss L, 2002, CYTOKINE, V19, P85, DOI 10.1006/cyto.2002.1956; Wells DJ, 2004, GENE THER, V11, P1363, DOI 10.1038/sj.gt.3302337; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Zeira E, 2003, MOL THER, V8, P342, DOI 10.1016/S1525-0016(03)00184-9	30	33	36	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3522	3533		10.1096/fj.06-7528com	http://dx.doi.org/10.1096/fj.06-7528com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17575264				2022-12-28	WOS:000250517800015
J	Lutgens, SPM; Cleutjens, KBJM; Daemen, MJAP; Heeneman, S				Lutgens, Suzanne P. M.; Cleutjens, Kitty B. J. M.; Daemen, Mat J. A. P.; Heeneman, Sylvia			Cathepsin cysteine proteases in cardiovascular disease	FASEB JOURNAL			English	Review						atherosclerosis; extracellular matrix; lipid metabolism; diagnostic tool; therapeutic potential	ABDOMINAL AORTIC-ANEURYSMS; LOW-DENSITY-LIPOPROTEIN; CYSTATIN-C DEFICIENCY; SMOOTH-MUSCLE-CELLS; MATRIX METALLOPROTEINASES; ANTIGEN PRESENTATION; INVARIANT CHAIN; BONE-RESORPTION; REDUCES ATHEROSCLEROSIS; PROTEOLYTIC ACTIVITY	Extracellular matrix (ECM) remodeling is one of the underlying mechanisms in cardiovascular diseases. Cathepsin cysteine proteases have a central role in ECM remodeling and have been implicated in the development and progression of cardiovascular diseases. Cathepsins also show differential expression in various stages of atherosclerosis, and in vivo knockout studies revealed that deficiency of cathepsin K or S reduces atherosclerosis. Furthermore, cathepsins are involved in lipid metabolism. Cathepsins have the capability to degrade low-density lipoprotein and reduce cholesterol efflux from macrophages, aggravating foam cell formation. Although expression studies also demonstrated differential expression of cathepsins in cardiovascular diseases like aneurysm formation, neointima formation, and neovascularization, in vivo studies to define the exact role of cathepsins in these processes are lacking. Evaluation of the feasibility of cathepsins as a diagnostic tool revealed that serum levels of cathepsins L and S seem to be promising as biomarkers in the diagnosis of atherosclerosis, whereas cathepsin B shows potential as an imaging tool. Furthermore, cathepsin K and S inhibitors showed effectiveness in (pre) clinical evaluation for the treatment of osteoporosis and osteoarthritis, suggesting that cathepsin inhibitors may also have therapeutic effects for the treatment of atherosclerosis.	Maastricht Univ, CARIM, Dept Pathol, NL-6200 MD Maastricht, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC)	Heeneman, S (corresponding author), Maastricht Univ, CARIM, Dept Pathol, POB 616, NL-6200 MD Maastricht, Netherlands.	s.heeneman@path.unimaas.nl		Daemen, Mat/0000-0003-1076-199X				Abbenante Giovanni, 2005, Med Chem, V1, P71, DOI 10.2174/1573406053402569; Alcorn HG, 1996, ARTERIOSCL THROM VAS, V16, P963, DOI 10.1161/01.ATV.16.8.963; ARONSON NN, 1978, BIOCHEM J, V171, P759, DOI 10.1042/bj1710759; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bania J, 2003, P NATL ACAD SCI USA, V100, P6664, DOI 10.1073/pnas.1131604100; Beers C, 2005, J IMMUNOL, V174, P1205, DOI 10.4049/jimmunol.174.3.1205; Beers C, 2003, J EXP MED, V197, P169, DOI 10.1084/jem.20020978; Bengtsson E, 2005, ARTERIOSCL THROM VAS, V25, P2151, DOI 10.1161/01.ATV.0000179600.34086.7d; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; Burns-Kurtis CL, 2004, CARDIOVASC RES, V62, P610, DOI 10.1016/j.cardiores.2004.02.002; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Chen JQ, 2002, CIRCULATION, V105, P2766, DOI 10.1161/01.CIR.0000017860.20619.23; Cheng XW, 2006, AM J PATHOL, V168, P685, DOI 10.2353/ajpath.2006.050295; Cheng XW, 2004, AM J PATHOL, V164, P243, DOI 10.1016/S0002-9440(10)63114-8; Chwieralski CE, 2006, APOPTOSIS, V11, P143, DOI 10.1007/s10495-006-3486-y; Deussing J, 1998, P NATL ACAD SCI USA, V95, P4516, DOI 10.1073/pnas.95.8.4516; Dubin G, 2005, CELL MOL LIFE SCI, V62, P653, DOI 10.1007/s00018-004-4445-9; Everts V, 1998, J BONE MINER RES, V13, P1420, DOI 10.1359/jbmr.1998.13.9.1420; Everts V, 1999, FASEB J, V13, P1219, DOI 10.1096/fasebj.13.10.1219; Everts V, 2006, J BONE MINER RES, V21, P1399, DOI 10.1359/JBMR.060614; Fach EM, 2004, MOL CELL PROTEOMICS, V3, P1200, DOI 10.1074/mcp.M400160-MCP200; Gacko M, 2005, MED SCI MONITOR, V11, pCR211; Gacko M, 1998, CLIN CHIM ACTA, V271, P171, DOI 10.1016/S0009-8981(97)00246-5; Gacko M, 1998, CLIN CHEM LAB MED, V36, P449, DOI 10.1515/CCLM.1998.075; Gacko Marek, 1999, Polish Journal of Pathology, V50, P83; Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; Hall A, 1998, BIOCHEMISTRY-US, V37, P4071, DOI 10.1021/bi971197j; Hart TC, 1999, J MED GENET, V36, P881; Herrmann J, 2006, ARTERIOSCL THROM VAS, V26, P1948, DOI 10.1161/01.ATV.0000233387.90257.9b; Honey K, 2003, NAT REV IMMUNOL, V3, P472, DOI 10.1038/nri1110; Hristov M, 2007, CIRC RES, V100, P590, DOI 10.1161/01.RES.0000259043.42571.68; Hsieh CS, 2002, J IMMUNOL, V168, P2618, DOI 10.4049/jimmunol.168.6.2618; Hsing LC, 2005, IMMUNOL REV, V207, P229, DOI 10.1111/j.0105-2896.2005.00310.x; Ix JH, 2007, CIRCULATION, V115, P173, DOI 10.1161/CIRCULATIONAHA.106.644286; Johnson JL, 2006, CIRCULATION, V113, P2435, DOI 10.1161/CIRCULATIONAHA.106.613281; Johnson JL, 2005, P NATL ACAD SCI USA, V102, P15575, DOI 10.1073/pnas.0506201102; Jormsjo S, 2002, AM J PATHOL, V161, P939, DOI 10.1016/S0002-9440(10)64254-X; Kadoglou NP, 2004, CURR MED RES OPIN, V20, P419, DOI 10.1185/030079904125003143; Keeling W Brent, 2005, Vasc Endovascular Surg, V39, P457, DOI 10.1177/153857440503900601; Khurana R, 2005, CIRCULATION, V112, P1813, DOI 10.1161/CIRCULATIONAHA.105.535294; Klemencic I, 2000, EUR J BIOCHEM, V267, P5404, DOI 10.1046/j.1432-1327.2000.01592.x; KOGA H, 1992, CHEM PHARM BULL, V40, P965; Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015; Li W, 2004, ANN NY ACAD SCI, V1030, P427, DOI 10.1196/annals.1329.053; Li W, 1998, ARTERIOSCL THROM VAS, V18, P177, DOI 10.1161/01.ATV.18.2.177; Li W, 2001, ARTERIOSCL THROM VAS, V21, P1124, DOI 10.1161/hq0701.092145; Lijnen HR, 2003, PATHOPHYSIOL HAEMO T, V33, P275, DOI 10.1159/000083814; Lindstedt L, 2003, BIOCHEM BIOPH RES CO, V312, P1019, DOI 10.1016/j.bbrc.2003.11.020; Liu J, 2006, ATHEROSCLEROSIS, V184, P302, DOI 10.1016/j.atherosclerosis.2005.05.012; Liu JA, 2004, ARTERIOSCL THROM VAS, V24, P1359, DOI 10.1161/01.ATV.0000134530.27208.41; Liu J, 2006, ATHEROSCLEROSIS, V186, P411, DOI 10.1016/j.atherosclerosis.2005.08.001; Liu N, 2003, EMBO J, V22, P5313, DOI 10.1093/emboj/cdg510; Lutgens E, 2002, ARTERIOSCL THROM VAS, V22, P975, DOI 10.1161/01.ATV.0000019729.39500.2F; Lutgens E, 2006, CIRCULATION, V113, P98, DOI 10.1161/CIRCULATIONAHA.105.561449; Lutgens SPM, 2006, J PATHOL, V210, P334, DOI 10.1002/path.2054; MACIEWICZ RA, 1990, FEBS LETT, V269, P189, DOI 10.1016/0014-5793(90)81151-D; Moreno PR, 2006, CIRCULATION, V113, P2245, DOI 10.1161/CIRCULATIONAHA.105.578955; Nakagawa TY, 1999, IMMUNITY, V10, P207, DOI 10.1016/S1074-7613(00)80021-7; NEURATH H, 1976, P NATL ACAD SCI USA, V73, P3825, DOI 10.1073/pnas.73.11.3825; Newby AC, 2005, PHYSIOL REV, V85, P1, DOI 10.1152/physrev.00048.2003; Okaji M, 2003, J PHARMACOL SCI, V91, P285; Ondr JK, 2004, J BIOL CHEM, V279, P27525, DOI 10.1074/jbc.M400304200; Oorni K, 2004, J BIOL CHEM, V279, P34776, DOI 10.1074/jbc.M310814200; Platt MO, 2007, AM J PHYSIOL-HEART C, V292, pH1479, DOI 10.1152/ajpheart.00954.2006; Platt MO, 2006, ARTERIOSCL THROM VAS, V26, P1784, DOI 10.1161/01.ATV.0000227470.72109.2b; Premzl A, 2006, J CELL BIOCHEM, V97, P1230, DOI 10.1002/jcb.20720; Punturieri A, 2000, J EXP MED, V192, P789, DOI 10.1084/jem.192.6.789; Purushothaman KR, 2006, CURR MOL MED, V6, P549, DOI 10.2174/156652406778018671; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; Riese RJ, 1998, J CLIN INVEST, V101, P2351, DOI 10.1172/JCI1158; Rodgers KJ, 2006, ARTERIOSCL THROM VAS, V26, P851, DOI 10.1161/01.ATV.0000203526.75772.4b; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Schwartz RS, 2002, REV CARDIOVASC ME S5, V3, P4; SHI GP, 1992, J BIOL CHEM, V267, P7258; Shi GP, 2000, J EXP MED, V191, P1177, DOI 10.1084/jem.191.7.1177; Shi GP, 2003, CIRC RES, V92, P493, DOI 10.1161/01.RES.0000060485.20318.96; Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5; Shi GP, 1999, J CLIN INVEST, V104, P1191, DOI 10.1172/JCI7709; Shimizu K, 2006, ARTERIOSCL THROM VAS, V26, P987, DOI 10.1161/01.ATV.0000214999.12921.4f; Shorey S, 2004, BONE, V35, P909, DOI 10.1016/j.bone.2004.06.002; Sukhova GK, 2006, ANN NY ACAD SCI, V1085, P161, DOI 10.1196/annals.1383.028; Sukhova GK, 2005, CIRC RES, V96, P368, DOI 10.1161/01.RES.0000155964.34150.F7; Sukhova GK, 2003, J CLIN INVEST, V111, P897, DOI 10.1172/JCI200314915; Sukhova GK, 1998, J CLIN INVEST, V102, P576, DOI 10.1172/JCI181; Taleb S, 2005, FASEB J, V19, P1540, DOI 10.1096/fj.05-3673fje; Tang CH, 2006, MOL CELL BIOL, V26, P2309, DOI 10.1128/MCB.26.6.2309-2316.2006; Tertov VV, 1997, EXP MOL PATHOL, V64, P127, DOI 10.1006/exmp.1997.2216; Tung WS, 2001, J VASC SURG, V34, P143, DOI 10.1067/mva.2001.113310; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Turk B, 1997, BIOL CHEM, V378, P141; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Urbich C, 2005, NAT MED, V11, P206, DOI 10.1038/nm1182; van Vlijmen-van Keulen CJ, 2003, EUR J VASC ENDOVASC, V26, P205, DOI 10.1053/ejvs.2002.1874; Wang B, 2006, J BIOL CHEM, V281, P6020, DOI 10.1074/jbc.M509134200; Yamashita DS, 2006, J MED CHEM, V49, P1597, DOI 10.1021/jm050915u; Yasuda Y, 2004, J BIOL CHEM, V279, P36761, DOI 10.1074/jbc.M403986200; Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013; ZARINS CK, 1983, CIRC RES, V53, P502, DOI 10.1161/01.RES.53.4.502	100	240	267	2	31	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3029	3041		10.1096/fj.06-7924com	http://dx.doi.org/10.1096/fj.06-7924com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17522380				2022-12-28	WOS:000249781600005
J	Eijken, M; Swagemakers, S; Koedam, M; Steenbergen, C; Derkx, P; Uitterlinden, AG; van der Spek, PJ; Visser, JA; de Jong, FH; Pols, HAP; van Leeuwen, JPTM				Eijken, Marco; Swagemakers, Sigrid; Koedam, Marijke; Steenbergen, Cobie; Derkx, Pieter; Uitterlinden, Andre G.; van der Spek, Peter J.; Visser, Jenny A.; de Jong, Frank H.; Pols, Huibert A. P.; van Leeuwen, Johannes P. T. M.			The activin A-follistatin system: potent regulator of human extracellular matrix mineralization	FASEB JOURNAL			English	Article						osteoblasts; vascular smooth muscle cells; microarray; autocrine	BONE-MORPHOGENETIC PROTEIN; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR-BETA; OSTEOBLAST DIFFERENTIATION; FAMILY-MEMBERS; DIRECT BINDING; INHIBIN; CALCIFICATION; CULTURES; FETAL	Bone quality is an important determinant of osteoporosis, and proper osteoblast differentiation plays an important role in the control and maintenance of bone quality. We investigated the impact of activin signaling on human osteoblast differentiation, extracellular matrix formation, and mineralization. Activins belong to the transforming growth factor-beta superfamily and activin A treatment strongly inhibited mineralization in osteoblast cultures, whereas the activin antagonist follistatin increased mineralization. Osteoblasts produced activin A and follistatin in a differentiation-dependent manner, leading to autocrine regulation of extracellular matrix formation and mineralization. In addition, mineralization in a vascular smooth muscle cell-based model for pathological calcification was inhibited. Comparative activin A and follistatin gene expression profiling showed that activin signaling changes the expression of a specific range of extracellular matrix proteins prior to the onset of mineralization, leading to a matrix composition with reduced or no mineralizing capacity. These findings demonstrate the regulation of osteoblast differentiation and matrix mineralization by the activin A-follistatin system, providing the possibility to control bone quality as well as pathological calcifications such as atherosclerosis by using activin A, follistatin, or analogs thereof.-Eijken, M., Swagemakers, S., Koedam, M., Steenbergen, C., Derkx, P., Uitterlinden, A. G., van der Spek, P. J., Visser, J. A., de Jong, F. H., Pols, H. A. P., van Leeuwen, J. P. T. M. The activin A- follistatin system: potent regulator of human extracellular matrix mineralization.	Erasmus MC, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands; Erasmus MC, Dept Bioinformat, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	van Leeuwen, JPTM (corresponding author), Erasmus MC, Dept Internal Med, Rm Ee585,POB 2040, NL-3000 CA Rotterdam, Netherlands.	vanleeuwen@erasmusmc.nl	De Jong, Frank H/A-9876-2011; van Leeuwen, Johannes/D-5015-2014; Visser, Jenny A./F-8156-2011	De Jong, Frank H/0000-0003-3578-1065; van Leeuwen, Johannes/0000-0002-2282-4006; Eijken, Marco/0000-0002-9043-3971				Abedin M, 2004, ARTERIOSCL THROM VAS, V24, P1161, DOI 10.1161/01.ATV.0000133194.94939.42; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Beck GR, 2003, EXP CELL RES, V288, P288, DOI 10.1016/S0014-4827(03)00213-1; Bilezikjian LM, 2004, MOL CELL ENDOCRINOL, V225, P29, DOI 10.1016/j.mce.2004.02.010; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250; Chen YG, 2006, EXP BIOL MED, V231, P534; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Eijken M, 2006, MOL CELL ENDOCRINOL, V248, P87, DOI 10.1016/j.mce.2005.11.034; Eijken M, 2005, MOL ENDOCRINOL, V19, P621, DOI 10.1210/me.2004-0212; El-Abbadi M, 2005, CURR OPIN NEPHROL HY, V14, P519, DOI 10.1097/01.mnh.0000168335.29381.23; Engelse MA, 1999, CIRC RES, V85, P931; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Fratzl-Zelman N, 1998, BONE, V23, P511, DOI 10.1016/S8756-3282(98)00139-2; Gaddy-Kurten D, 2002, ENDOCRINOLOGY, V143, P74, DOI 10.1210/en.143.1.74; Govoni KE, 2005, PEDIATR NEPHROL, V20, P261, DOI 10.1007/s00467-004-1658-y; Guo QX, 1998, MOL ENDOCRINOL, V12, P96, DOI 10.1210/mend.12.1.0053; HARRIS SE, 1994, J BONE MINER RES, V9, P855; Harrison CA, 2005, TRENDS ENDOCRIN MET, V16, P73, DOI 10.1016/j.tem.2005.01.003; HASHIMOTO M, 1992, J BIOL CHEM, V267, P4999; Hirotani H, 2002, CALCIFIED TISSUE INT, V70, P330, DOI 10.1007/s00223-001-2037-3; Ichida F, 2004, J BIOL CHEM, V279, P34015, DOI 10.1074/jbc.M403621200; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; Ikenoue T, 1999, J CELL BIOCHEM, V75, P206, DOI 10.1002/(SICI)1097-4644(19991101)75:2<206::AID-JCB3>3.3.CO;2-K; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004-0001; KANZAKI M, 1995, MOL CELL ENDOCRINOL, V108, P11, DOI 10.1016/0303-7207(94)03451-X; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067; Martens JWM, 1997, ENDOCRINOLOGY, V138, P2928, DOI 10.1210/en.138.7.2928; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; OGAWA Y, 1992, J BIOL CHEM, V267, P14233; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; Oshima A, 2002, J CELL BIOCHEM, V86, P792, DOI 10.1002/jcb.10272; OURSLER MJ, 1994, J BONE MINER RES, V9, P443; Pierre A, 2005, REPROD NUTR DEV, V45, P419, DOI 10.1051/rnd:2005031; Raggi P, 2000, CIRCULATION, V101, P850, DOI 10.1161/01.CIR.101.8.850; Robey P.G., 2006, PRIMER METABOLIC BON; Sakai R, 2000, BONE, V27, P91, DOI 10.1016/S8756-3282(00)00307-0; Sakai R, 1999, BONE, V25, P191, DOI 10.1016/S8756-3282(99)00152-0; SAKAI R, 1993, BIOCHEM BIOPH RES CO, V195, P39, DOI 10.1006/bbrc.1993.2006; Sakai R, 2001, MOL CELL ENDOCRINOL, V180, P183, DOI 10.1016/S0303-7207(01)00496-8; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077; Shao JS, 2005, J CLIN INVEST, V115, P1210, DOI 10.1172/JCI200524140; SHIOI A, 1995, ARTERIOSCL THROM VAS, V15, P2003, DOI 10.1161/01.ATV.15.11.2003; SPENCER SJ, 1992, J CLIN INVEST, V90, P142, DOI 10.1172/JCI115827; Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070; TENENBAUM HC, 1987, BONE MINER, V2, P43; Wain HM, 2002, GENOMICS, V79, P464, DOI 10.1006/geno.2002.6748; WATSON KE, 1994, J CLIN INVEST, V93, P2106, DOI 10.1172/JCI117205; WEWER UM, 1994, J CELL BIOL, V127, P1767, DOI 10.1083/jcb.127.6.1767; XU JM, 1995, J BIOL CHEM, V270, P6308, DOI 10.1074/jbc.270.11.6308; Young A, 2005, BIOINFORMATICS, V21, P275, DOI 10.1093/bioinformatics/bth495; Zhang YQ, 2004, DIABETES, V53, P2024, DOI 10.2337/diabetes.53.8.2024	58	132	154	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2949	2960		10.1096/fj.07-8080com	http://dx.doi.org/10.1096/fj.07-8080com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17449718				2022-12-28	WOS:000249237500035
J	Liu, CH; Huang, SN; Cui, JK; Kim, YR; Farrar, CT; Moskowitz, MA; Rosen, BR; Liu, PK				Liu, Christina H.; Huang, Shuning; Cui, Jiankun; Kim, Young R.; Farrar, Christian T.; Moskowitz, Michael A.; Rosen, Bruce R.; Liu, Philip K.			MR contrast probes that trace gene transcripts for cerebral ischemia in live animals	FASEB JOURNAL			English	Article						cardiac arrest; immediate early genes; oxidative stress; nanotechnology; signal transduction	FOS MESSENGER-RNA; BLOOD-BRAIN-BARRIER; C-FOS; ANTISENSE OLIGONUCLEOTIDE; IN-VIVO; MOUSE-BRAIN; FOREBRAIN ISCHEMIA; CARDIAC-ARREST; EXPRESSION; PROTEIN	The aim of this research was to validate transcription magnetic resonance (MR) imaging (MRI) for gene transcript targeting in acute neurological disorders in live subjects. We delivered three MR probe variants with superparamagnetic iron oxide nanoparticles (SPION, a T-2 susceptibility agent) linked to a phosphorothioate-modified oligodeoxynucleotide (sODN) complementary to c-fos mRNA (SPION-cfos) or beta-actin mRNA (SPION-beta-actin) and to sODN with random sequence (SPION-Ran). Each probe (1 mu g Fe in 2 mu l) was delivered via intracerebroventricular infusion to the left cerebral ventricle of male C57Black6 mice. We demonstrated SPION retention, measured as decreased T-2* signal or increased R-2* value (R-2* = 1/T-2*). Animals that received the SPION-beta-actin probe exhibited the highest R-2* values, followed ( in descending order) by SPION- cfos and SPION- Ran. SPION- cfos retention was localized in brain regions where SPION-cfos was present and where hybrids of SPION- cfos and its target c-fos mRNA were detected by in situ reverse transcription PCR. In animals that experienced cerebral ischemia, SPION- cfos retention was significantly increased in locations where c-fos mRNA increased in response to the ischemic insult; these elevations were not observed for SPION-beta-actin and SPION-Ran. This study should enable MR detection of mRNA alteration in disease models of the central nervous system.-Liu, C. H., Huang, S., Cui, J., Kim, Y. R., Farrar, C. T., Moskowitz, M. A., Rosen. B. R., Liu, P. K. MR contrast probes that trace gene transcripts for cerebral ischemia in live animals.	Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA; Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT)	Liu, PK (corresponding author), Massachusetts Gen Hosp, Dept Radiol, 149 13th St,Rm 2410, Charlestown, MA 02129 USA.	philipl@nmr.mgh.harvard.edu		Liu, Christina/0000-0002-5723-177X; Farrar, Christian/0000-0001-6623-8220	NATIONAL CANCER INSTITUTE [T32CA009502] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P01AT002048] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR014075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [T32EB001680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS057556, R01NS045845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K25AG029415] Funding Source: NIH RePORTER; NCCIH NIH HHS [P01AT002048, P01 AT002048] Funding Source: Medline; NCI NIH HHS [5T32CA009502, T32 CA009502] Funding Source: Medline; NCRR NIH HHS [P41 RR014075, 5P41RR14075] Funding Source: Medline; NIA NIH HHS [K25 AG029415-04, K25 AG029415, K25 AG029415-01A1, K25 AG029415-05, K25 AG029415-03, K25 AG029415-02] Funding Source: Medline; NIBIB NIH HHS [T32 EB001680] Funding Source: Medline; NINDS NIH HHS [R01 NS045845-04, R21 NS057556-01A1S1, R01 NS045845, R01NS45845, R21 NS057556, R21 NS057556-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; Ayata C, 2004, J CEREBR BLOOD F MET, V24, P1172, DOI 10.1097/01.WCB.0000137057.92786.F3; Back T, 2004, J NEUROL, V251, P388, DOI 10.1007/s00415-004-0399-y; Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141; Chauhan NB, 2002, ANTISENSE NUCLEIC A, V12, P353, DOI 10.1089/108729002761381320; CHIASSON BJ, 1992, EUR J PHARM-MOLEC PH, V227, P451, DOI 10.1016/0922-4106(92)90167-T; Cho S, 2005, J CEREBR BLOOD F MET, V25, P493, DOI 10.1038/sj.jcbfm.9600058; Clark AW, 1997, NEUROSCI LETT, V238, P53, DOI 10.1016/S0304-3940(97)00859-8; Cui JK, 1999, J NEUROCHEM, V73, P1164, DOI 10.1046/j.1471-4159.1999.0731164.x; Cui JK, 2001, J BIOMED SCI, V8, P336, DOI 10.1007/BF02258375; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fujii M, 1997, STROKE, V28, P1805, DOI 10.1161/01.STR.28.9.1805; Gu ZZ, 1997, NEUROCHEM INT, V30, P417, DOI 10.1016/S0197-0186(96)00077-0; Huang CY, 2001, STROKE, V32, P741, DOI 10.1161/01.STR.32.3.741; Huang DY, 2000, FASEB J, V14, P407, DOI 10.1096/fasebj.14.2.407; Liu CH, 2004, MAGN RESON MED, V51, P978, DOI 10.1002/mrm.20047; LIU CH, IN PRESS MOL IMAGING; Liu CH, 2007, J NEUROSCI, V27, P713, DOI 10.1523/JNEUROSCI.4660-06.2007; LIU PK, 1993, MUTAT RES, V288, P229, DOI 10.1016/0027-5107(93)90089-X; LIU PK, 1994, ANN NEUROL, V36, P566, DOI 10.1002/ana.410360405; Liu PK, 2001, TRENDS NEUROSCI, V24, P581, DOI 10.1016/S0166-2236(00)01918-4; Liu PK, 1996, J NEUROSCI, V16, P6795; Louie AY, 2000, NAT BIOTECHNOL, V18, P321, DOI 10.1038/73780; Lynch JR, 2004, STROKE, V35, P57, DOI 10.1161/01.STR.0000105927.62344.4C; MacGregor DG, 2003, J NEUROCHEM, V85, P1402, DOI 10.1046/j.1471-4159.2003.01772.x; McGirt MJ, 2002, NEUROSURGERY, V51, P1128, DOI 10.1097/00006123-200211000-00005; Morrow BA, 1999, J NEUROSCI, V19, P5666; MOSELEY ME, 1993, STROKE, V24, pI60; MOSSAKOWSKI MJ, 1994, ACTA NEUROCHIR, P274; Muldoon LL, 2004, NEUROPATH APPL NEURO, V30, P70, DOI 10.1046/j.0305-1846.2003.00512.x; Natt O, 2002, J NEUROSCI METH, V120, P203, DOI 10.1016/S0165-0270(02)00211-X; Neigh GN, 2004, EUR J NEUROSCI, V20, P1865, DOI 10.1111/j.1460-9568.2004.03649.x; NGUYEN TV, 1992, P NATL ACAD SCI USA, V89, P4270, DOI 10.1073/pnas.89.10.4270; Noguchi A, 1998, FEBS LETT, V433, P169, DOI 10.1016/S0014-5793(98)00837-0; Overhoff M, 2005, J MOL BIOL, V348, P871, DOI 10.1016/j.jmb.2005.03.012; PARDRIDGE WM, 1991, FEBS LETT, V288, P30, DOI 10.1016/0014-5793(91)80996-G; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; Saini S, 2000, CLIN RADIOL, V55, P690, DOI 10.1053/crad.2000.0504; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Shi NY, 2000, P NATL ACAD SCI USA, V97, P14709, DOI 10.1073/pnas.250332397; Tolliver BK, 2000, EUR J NEUROSCI, V12, P3399, DOI 10.1046/j.1460-9568.2000.00214.x; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; Weisbrot-Lefkowitz M, 1998, MOL BRAIN RES, V53, P333, DOI 10.1016/S0169-328X(97)00313-6; Wu CR, 2001, J NEUROSCI METH, V107, P101, DOI 10.1016/S0165-0270(01)00356-9; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212; Zhang MK, 2000, J CELL BIOCHEM, V76, P290, DOI 10.1002/(SICI)1097-4644(20000201)76:2<290::AID-JCB12>3.0.CO;2-V; Zhang Y, 1999, BRAIN RES, V832, P112, DOI 10.1016/S0006-8993(99)01459-6	50	22	23	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					3004	3015		10.1096/fj.07-8203com	http://dx.doi.org/10.1096/fj.07-8203com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17478745	Green Accepted			2022-12-28	WOS:000249237500040
J	Chorny, M; Polyak, B; Alferiev, IS; Walsh, K; Friedman, G; Levy, RJ				Chorny, Michael; Polyak, Boris; Alferiev, Ivan S.; Walsh, Kenneth; Friedman, Gary; Levy, Robert J.			Magnetically driven plasmid DNA delivery with biodegradable polymeric nanoparticles	FASEB JOURNAL			English	Article						GFP plasmid; magnetic nanoparticles; ion-pair complex; polyethylenimine; adiponectin	TARGETING GENE DELIVERY; IN-VITRO; MAGNETOFECTION; FORMULATION; ACID); SIZE; POLYETHYLENIMINE; TRANSFECTION; ADIPONECTIN; PARTICLES	Targeting gene therapy remains a challenge. The use of magnetic force to achieve this was investigated in the present study. It was hypothesized that nanoparticles with both controllable particle size and magnetic properties would enable magnetically driven gene delivery. We investigated this hypothesis by creating a family of novel biodegradable polymeric superparamagnetic nanoparticle ( MNP) formulations. Polylactide MNP were formulated using a modified emulsification-solvent evaporation methodology with both the incorporation of oleate-coated iron oxide and a polyethylenimine ( PEI) oleate ionpair surface modification for DNA binding. MNP size could be controlled by varying the proportion of the tetrahydrofuran cosolvent. Magnetically driven MNP-mediated gene transfer was studied using a green fluorescent protein reporter plasmid in cultured arterial smooth muscle cells and endothelial cells. MNP-DNA internalization and trafficking were examined by confocal microscopy. Cell growth inhibition after MNP-mediated adiponectin plasmid transfection was studied as an example of a therapeutic end point. MNP-DNA complexes protected DNA from degradation and efficiently transfected quiescent cells under both low and high serum conditions after a 15 min exposure to a magnetic field ( 500 G). There was negligible transfection with MNP in the absence of a magnetic field. Larger sized MNP ( 375 nm diameter) exhibited higher transfection rates compared with 185 nm- and 240 nm- sized MNP. Internalized larger sized MNP escaped lysosomal localization and released DNA in the perinuclear zone. Adiponectin plasmid DNA delivery using MNP resulted in a dose-dependent growth inhibition of cultured arterial smooth muscle cells. It is concluded that magnetically driven plasmid DNA delivery can be achieved using biodegradable MNP containing oleate-coated magnetite and surface modified with PEI oleate ion-pair complexes that enable DNA binding.	Childrens Hosp Philadelphia, Div Cardiol Res, Philadelphia, PA 19104 USA; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA USA; Drexel Univ, Sch Biomed Engn & Hlth Sci, Philadelphia, PA USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Boston University; Drexel University	Levy, RJ (corresponding author), Childrens Hosp Philadelphia, Div Cardiol Res, Abramson Res Bldg,Ste 702,3615 Civic Ctr Blvd, Philadelphia, PA 19104 USA.	levyr@email.chop.edu	Chorny, Michael/O-1313-2017		NHLBI NIH HHS [HL72108, R01 HL072108, R56 HL072108] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072108, R56HL072108] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexiou C, 2000, CANCER RES, V60, P6641; Barry ME, 1999, HUM GENE THER, V10, P2461, DOI 10.1089/10430349950016816; Bivas-Benita M, 2004, EUR J PHARM BIOPHARM, V58, P1, DOI 10.1016/j.ejpb.2004.03.008; Brownlie A, 2004, INT J PHARMACEUT, V274, P41, DOI 10.1016/j.ijpharm.2003.12.029; Chorny M, 2002, J CONTROL RELEASE, V83, P389, DOI 10.1016/S0168-3659(02)00211-0; Clamme JP, 2003, BBA-BIOMEMBRANES, V1617, P52, DOI 10.1016/j.bbamem.2003.09.002; Dean DA, 2005, GENE THER, V12, P881, DOI 10.1038/sj.gt.3302534; Dunlap DD, 1997, NUCLEIC ACIDS RES, V25, P3095, DOI 10.1093/nar/25.15.3095; Ferrari ME, 2001, NUCLEIC ACIDS RES, V29, P1539, DOI 10.1093/nar/29.7.1539; Fishbein I, 2001, ARTERIOSCL THROM VAS, V21, P1434, DOI 10.1161/hq0901.095567; Goodwin SC, 2001, TOXICOL SCI, V60, P177, DOI 10.1093/toxsci/60.1.177; Hafeli UO, 2002, EUR CELLS MATER, V3, P24; Kim IS, 2005, INT J PHARMACEUT, V298, P255, DOI 10.1016/j.ijpharm.2005.04.017; Krotz F, 2003, J VASC RES, V40, P425, DOI 10.1159/000073901; Kuhn SJ, 2006, ANN BIOMED ENG, V34, P51, DOI 10.1007/s10439-005-9004-5; Lechardeur D, 1999, GENE THER, V6, P482, DOI 10.1038/sj.gt.3300867; Lemke AJ, 2004, EUR RADIOL, V14, P1949, DOI 10.1007/s00330-004-2445-7; Lubbe AS, 1996, CANCER RES, V56, P4686; Matsuda M, 2002, J BIOL CHEM, V277, P37487, DOI 10.1074/jbc.M206083200; Medina-Kauwe LK, 2005, GENE THER, V12, P1734, DOI 10.1038/sj.gt.3302592; Messai I, 2003, COLLOID SURFACE B, V32, P293, DOI 10.1016/S0927-7765(03)00182-6; Moghimi SM, 2005, MOL THER, V11, P990, DOI 10.1016/j.ymthe.2005.02.010; Plank C, 2003, J LIPOSOME RES, V13, P29, DOI 10.1081/LPR-120017486; Plank C, 2003, EXPERT OPIN BIOL TH, V3, P745, DOI 10.1517/14712598.3.5.745; Plank C, 2003, BIOL CHEM, V384, P737, DOI 10.1515/BC.2003.082; Quintanar-Guerrero D, 1998, DRUG DEV IND PHARM, V24, P1113, DOI 10.3109/03639049809108571; QuintanarGuerrero D, 1997, COLLOID POLYM SCI, V275, P640, DOI 10.1007/s003960050130; Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253; Rolland Alain, 2006, Expert Opin Drug Deliv, V3, P1, DOI 10.1517/17425247.3.1.1; Scherer F, 2002, GENE THER, V9, P102, DOI 10.1038/sj.gt.3301624; Song CX, 1997, J CONTROL RELEASE, V43, P197, DOI 10.1016/S0168-3659(96)01484-8; Trimaille T, 2003, COLLOID SURFACE A, V221, P39, DOI 10.1016/S0927-7757(03)00105-5; Wang Y, 2005, J BIOL CHEM, V280, P18341, DOI 10.1074/jbc.M501149200; WEHRLE P, 1995, EUR J PHARM BIOPHARM, V41, P19; Xenariou S, 2006, GENE THER, V13, P1545, DOI 10.1038/sj.gt.3302803; Yellen BB, 2005, CIRCULATION, V112, pU715; Yellen BB, 2005, P NATL ACAD SCI USA, V102, P8860, DOI 10.1073/pnas.0500409102	37	92	95	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2510	2519		10.1096/fj.06-8070com	http://dx.doi.org/10.1096/fj.06-8070com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17403937	Green Accepted			2022-12-28	WOS:000248454400025
J	Shemesh, Y; Cohen, M; Bloch, G				Shemesh, Yair; Cohen, Mira; Bloch, Guy			Natural plasticity in circadian rhythms is mediated by reorganization in the molecular clockwork in honeybees	FASEB JOURNAL			English	Article						social behavior; clock gene; Apis mellifera	DIVISION-OF-LABOR; LOCOMOTOR BEHAVIOR; PERIOD EXPRESSION; GENE-EXPRESSION; ORGANIZATION; COLONY; LIGHT; CHRONOBIOLOGY; TIMELESS; BRAIN	Various animals naturally switch to considerable periods of around-the-clock activity with no apparent ill effects. Such plasticity in overt circadian rhythms might be observed because the clock is masked by the influence of external factors, is uncoupled from behavioral outputs, or results from genuine plasticity in the clock machinery. We studied honeybees in which plasticity in circadian rhythms is socially modulated and associated with the division of labor. We confirm that "nurse" bees care for the brood around-the-clock even when experiencing a light: dark illumination regime. However, nurses transferred from the hive to individual cages in constant conditions have robust circadian rhythms in locomotor activity with an onset of activity at the subjective morning. These data indicate that circadian rhythmicity in nurses depends on their environment, and suggest that some clockwork components were entrained even in nurses active around the clock while in the hive. Brain oscillations in transcript abundance for the putative clock genes Period, Cryptochrome-m, Cycle, and Timeout were attenuated or totally suppressed in nurses as compared to behaviorally rhythmic foragers, irrespective of the illumination regime. These findings provide the first support for the hypothesis that natural plasticity in circadian rhythms is associated with reorganization of the internal clock-work.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Evolut Systemat & Ecol, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Bloch, G (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Evolut Systemat & Ecol, Berman 114,Givat Ram Campus, IL-91904 Jerusalem, Israel.	bloch@vms.huji.ac.il	Bloch, Guy/I-5861-2019	Bloch, Guy/0000-0003-1624-4926				ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Barnes JW, 2003, SCIENCE, V302, P439, DOI 10.1126/science.1086593; Bloch G, 2004, INSECT BIOCHEM MOLEC, V34, P879, DOI 10.1016/j.ibmb.2004.05.004; Bloch G, 2001, NATURE, V410, P1048, DOI 10.1038/35074183; Bloch G, 2001, J BIOL RHYTHM, V16, P444, DOI 10.1177/074873001129002123; Bloch G, 2007, J COMP PHYSIOL A, V193, P181, DOI 10.1007/s00359-006-0179-5; Devlin PF, 2001, ANNU REV PHYSIOL, V63, P677, DOI 10.1146/annurev.physiol.63.1.677; Dunlap J.C., 2004, CHRONOBIOLOGY BIOL T; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Edery I, 2000, PHYSIOL GENOMICS, V3, P59, DOI 10.1152/physiolgenomics.2000.3.2.59; Field MD, 2000, NEURON, V25, P437, DOI 10.1016/S0896-6273(00)80906-X; Gotter AL, 2000, NAT NEUROSCI, V3, P755, DOI 10.1038/77653; Grima B, 2004, NATURE, V431, P869, DOI 10.1038/nature02935; Lin Y, 2004, J NEUROSCI, V24, P7951, DOI 10.1523/JNEUROSCI.2370-04.2004; Lyamin O, 2005, NATURE, V435, P1177, DOI 10.1038/4351177a; Menaker M, 2006, P NATL ACAD SCI USA, V103, P3015, DOI 10.1073/pnas.0600360103; Moore D, 2001, J INSECT PHYSIOL, V47, P843, DOI 10.1016/S0022-1910(01)00057-9; Moore D, 1998, BEHAV ECOL SOCIOBIOL, V43, P147, DOI 10.1007/s002650050476; Ohta H, 2005, NAT NEUROSCI, V8, P267, DOI 10.1038/nn1395; PAGE RE, 1988, ANIM BEHAV, V36, P944, DOI 10.1016/S0003-3472(88)80181-7; Panda S, 2002, NATURE, V417, P329, DOI 10.1038/417329a; Rubin EB, 2006, GENOME RES, V16, P1352, DOI 10.1101/gr.5094806; Stoleru D, 2005, NATURE, V438, P238, DOI 10.1038/nature04192; Stoleru D, 2004, NATURE, V431, P862, DOI 10.1038/nature02926; Takumi T, 1999, GENES CELLS, V4, P67, DOI 10.1046/j.1365-2443.1999.00238.x; Toma DP, 2000, P NATL ACAD SCI USA, V97, P6914, DOI 10.1073/pnas.97.12.6914; van der Veen DR, 2006, P NATL ACAD SCI USA, V103, P3393, DOI 10.1073/pnas.0507825103; van Oort BEH, 2005, NATURE, V438, P1095, DOI 10.1038/4381095a; von Frisch K., 1967, DANCE LANGUAGE ORIEN; Weinstock GM, 2006, NATURE, V443, P931, DOI 10.1038/nature05260; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Yerushalmi S, 2006, J EXP BIOL, V209, P1044, DOI 10.1242/jeb.02125; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5	33	53	55	1	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2304	2311		10.1096/fj.06-8032com	http://dx.doi.org/10.1096/fj.06-8032com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17360847				2022-12-28	WOS:000248454400005
J	Maillet, EL; Pellegrini, N; Valant, C; Bucher, B; Hibert, M; Bourguignon, JJ; Galzi, JL				Maillet, Emeline L.; Pellegrini, Nadia; Valant, Celine; Bucher, Bernard; Hibert, Marcel; Bourguignon, Jean-Jacques; Galzi, Jean-Luc			A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties	FASEB JOURNAL			English	Article						allosterism; signal transduction; GPCR; neurokinin; drug discovery	PROTEIN-COUPLED RECEPTORS; PHOSPHATIDYLINOSITOL HYDROLYSIS; DOPAMINE-RECEPTOR; AGONIST; ACTIVATION; RESPONSES; ANTAGONIST; MULTIPLE; MUTATION; CALCIUM	The orthosteric agonist neurokinin A (NKA) interacts with the tachykinin NK2 receptors (NK2Rs) via an apparent sequential binding process, which stabilizes the receptor in at least two different active conformations (A1L and A2L). The A1L conformation exhibits fast NKA dissociation kinetics and triggers intracellular calcium elevation; the A2L conformation exhibits slow NKA dissociation kinetics and triggers cAMP production. The new compound LPI805 is a partial and noncompetitive inhibitor of NKA binding to NK2Rs. Analysis of NKA dissociation in the presence of LPI805 suggests that LPI805 decreases the number of NKA-NK2R complexes in A2L conformation while increasing those in the A1L conformation. Analysis of signaling pathways of NK2Rs shows that LPI805 dramatically inhibits the NKA-induced cAMP response while slightly enhancing the NKA-induced calcium response. Analysis of NKA association kinetics reveals that LPI805 promotes strong and specific destabilization of the NKA-NK2R complexes in the A2L conformation whereas access of NKA to the A1L conformations is unchanged. Thus, to our knowledge, LPI805 is the first example of a conformation-specific allosteric antagonist of a G-protein-coupled receptor. This work establishes the use of allosteric modulators in order to promote functional selectivity on certain agonist-receptor interactions.	Univ Strasbourg, CNRS, UMR 7175, Inst Gilbert Laustriat, Strasbourg, France; ESBS, Dept Recepteurs & Prot Membraines, Illkirch Graffenstaden, France; Fac Pharm, Dept Pharmacol & Physicochim Interact Cellulaires, Illkirch Graffenstaden, France; Fac Pharm, Dept Pharmacochim Commun Cellulaire, Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Maillet, EL (corresponding author), Mt Sinai Sch Med, Dept Neurosci, 1425 Madison Ave,Box 1065, New York, NY 10029 USA.	emeline.maillet@mssm.edu	maillet, emeline/G-5177-2012	maillet, emeline/0000-0003-0129-6328; Valant, Celine/0000-0002-2509-7465				Bartl FJ, 2005, J BIOL CHEM, V280, P34259, DOI 10.1074/jbc.M505260200; Befort K, 2001, J BIOL CHEM, V276, P3130, DOI 10.1074/jbc.M006352200; Christopoulos A, 2002, NAT REV DRUG DISCOV, V1, P198, DOI 10.1038/nrd746; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; Ciucci A, 1997, FEBS LETT, V416, P335, DOI 10.1016/S0014-5793(97)01236-2; Claeysen S, 2001, EMBO REP, V2, P61, DOI 10.1093/embo-reports/kve003; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; Durocher Y, 2000, ANAL BIOCHEM, V284, P316, DOI 10.1006/abio.2000.4698; EISTETTER HR, 1991, CELL REGUL, V2, P767, DOI 10.1091/mbc.2.10.767; EMONDSALT X, 1992, LIFE SCI, V50, pPL101, DOI 10.1016/0024-3205(92)90352-P; Evans PD, 1995, PROG BRAIN RES, V106, P259; GALZI J, 2000, Patent No. 2005059036; GALZI JL, 2003, Patent No. 03107004; Gao ZG, 2006, DRUG DISCOV TODAY, V11, P191, DOI 10.1016/S1359-6446(05)03689-5; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Hall DA, 2000, MOL PHARMACOL, V58, P1412, DOI 10.1124/mol.58.6.1412; HEIDMANN T, 1980, BIOCHEM BIOPH RES CO, V97, P889, DOI 10.1016/0006-291X(80)91460-6; Hermans E, 2003, PHARMACOL THERAPEUT, V99, P25, DOI 10.1016/S0163-7258(03)00051-2; Holst B, 2001, J BIOL CHEM, V276, P19793, DOI 10.1074/jbc.M100621200; Ilien B, 2003, J NEUROCHEM, V85, P768, DOI 10.1046/j.1471-4159.2003.01717.x; Jiang PH, 2004, J BIOL CHEM, V279, P45068, DOI 10.1074/jbc.M406779200; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Kenakin T, 2003, TRENDS PHARMACOL SCI, V24, P346, DOI 10.1016/S0165-6147(03)00167-6; Kobilka BK, 2002, J PEPT RES, V60, P317, DOI 10.1034/j.1399-3011.2002.21062.x; Lecat S, 2002, J BIOL CHEM, V277, P42034, DOI 10.1074/jbc.M203606200; Lefkowitz RJ, 2002, MOL PHARMACOL, V62, P971, DOI 10.1124/mol.62.5.971; Lezcano N, 2000, SCIENCE, V287, P1660, DOI 10.1126/science.287.5458.1660; MAGGI CA, 1991, J PHARMACOL EXP THER, V257, P1172; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; Ostrom RS, 2004, BRIT J PHARMACOL, V143, P235, DOI 10.1038/sj.bjp.0705930; Palanche T, 2001, J BIOL CHEM, V276, P34853, DOI 10.1074/jbc.M104363200; Rees S, 2002, RECEPTOR CHANNEL, V8, P261, DOI 10.1080/10606820214640; Riitano D, 1997, J BIOL CHEM, V272, P7646, DOI 10.1074/jbc.272.12.7646; Sexton PM, 2001, CELL SIGNAL, V13, P73, DOI 10.1016/S0898-6568(00)00143-1; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Vauquelin G, 2005, FUND CLIN PHARMACOL, V19, P45, DOI 10.1111/j.1472-8206.2005.00319.x; Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838; Vollmer JY, 1999, J BIOL CHEM, V274, P37915, DOI 10.1074/jbc.274.53.37915; Wiens BL, 1998, MOL PHARMACOL, V54, P435, DOI 10.1124/mol.54.2.435	39	66	70	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2124	2134		10.1096/fj.06-7683com	http://dx.doi.org/10.1096/fj.06-7683com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17371796				2022-12-28	WOS:000247500300022
J	Song, Y; Cone, RD				Song, Youngsup; Cone, Roger D.			Creation of a genetic model of obesity in a teleost	FASEB JOURNAL			English	Article						melanocortin receptor; zebrafish; AgRP; energy homeostasis	AGOUTI-RELATED PROTEIN; MELANOCORTIN-4 RECEPTOR; FRAMESHIFT MUTATION; MORBID-OBESITY; DANIO-RERIO; FOOD-INTAKE; ZEBRAFISH; GHRELIN; BRAIN; MOUSE	The adipostat is the mechanism by which the brain detects and maintains constant levels of energy stored in adipocytes in the form of lipids. Key elements of the adipostat include the adipocyte-derived hormone leptin that is expressed in proportion to energy levels and serves to communicate this information to the central nervous system and the central circuits, which sense and respond to leptin. Blockade of one of these circuits, the central melanocortin system, disrupts leptin action and causes a distinct obesity syndrome in mice and humans, characterized by increased adiposity as well as increased linear growth. We show here that transgenic zebrafish overexpressing the endogenous melanocortin antagonist agouti-related protein (AgRP) also exhibit obesity, increased linear growth, and adipocyte hypertrophy. These findings demonstrate that key elements of the adipostat originated before the evolution of mammals. Furthermore, transgenic overexpression of AgRP in zebrafish yields a new model system for the genetic analysis of energy homeostasis in a simple vertebrate system.	Oregon Hlth & Sci Univ, Ctr Study Weight Regulat & Associated Disorders, Portland, OR 97239 USA	Oregon Health & Science University	Cone, RD (corresponding author), Oregon Hlth & Sci Univ, Ctr Study Weight Regulat & Associated Disorders, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	cone@ohsu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK075721] Funding Source: NIH RePORTER; NIDDK NIH HHS [R56DK075721] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiyoshi H, 2004, ZOOL SCI, V21, P841, DOI 10.2108/zsj.21.841; Butler AA, 2001, NAT NEUROSCI, V4, P605, DOI 10.1038/88423; Butler AA, 2000, ENDOCRINOLOGY, V141, P3518, DOI 10.1210/en.141.9.3518; Cerda-Reverter JM, 2003, ENDOCRINOLOGY, V144, P2336, DOI 10.1210/en.2002-0213; Cerda-Reverter JM, 2003, ENDOCRINOLOGY, V144, P4552, DOI 10.1210/en.2003-0453; Chiba A, 2001, GEN COMP ENDOCR, V122, P287, DOI 10.1006/gcen.2001.7628; DORES RM, 1990, PROG CLIN BIOL RES, V342, P22; Fan T, 2000, ENDOCRINOLOGY, V141, P3072; Farooqi IS, 2000, J CLIN INVEST, V106, P271, DOI 10.1172/JCI9397; Graham M, 1997, NAT GENET, V17, P273, DOI 10.1038/ng1197-273; Hansen IA, 2003, BIOCHEM BIOPH RES CO, V303, P1121, DOI 10.1016/S0006-291X(03)00475-3; Higashijima S, 1997, DEV BIOL, V192, P289, DOI 10.1006/dbio.1997.8779; Hinney A, 1999, J CLIN ENDOCR METAB, V84, P1483, DOI 10.1210/jc.84.4.1483; Howard V., 2005, UNBIASED STEREOLOGY; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; Kurokawa T, 2005, PEPTIDES, V26, P745, DOI 10.1016/j.peptides.2004.12.017; Logan DW, 2003, GENOMICS, V81, P184, DOI 10.1016/S0888-7543(02)00037-x; Mizuno TM, 1999, ENDOCRINOLOGY, V140, P814, DOI 10.1210/en.140.2.814; NAGELE U, 1984, J CLIN CHEM CLIN BIO, V22, P165; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Ringholm A, 2002, J NEUROCHEM, V82, P6, DOI 10.1046/j.1471-4159.2002.00934.x; Song Y, 2003, ENDOCRINE, V22, P257, DOI 10.1385/ENDO:22:3:257; TAKAHASHI A, 1995, BIOCHEM BIOPH RES CO, V213, P490, DOI 10.1006/bbrc.1995.2158; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; VOLFOFF H, 2003, BRAIN RES, V972, P90; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325; Yaswen L, 1999, NAT MED, V5, P1066, DOI 10.1038/12506; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	35	141	145	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2042	2049		10.1096/fj.06-7503com	http://dx.doi.org/10.1096/fj.06-7503com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17341684				2022-12-28	WOS:000247500300014
J	Loukin, SH; Kung, C; Saimi, Y				Loukin, Stephen H.; Kung, Ching; Saimi, Yoshiro			Lipid perturbations sensitize osmotic down-shock activated Ca2+ influx, a yeast "deletome" analysis	FASEB JOURNAL			English	Article						calcium flux; lipids; membrane mechanics; osmotic force; mechanosensitive channels; yeast deletants	CROSS-PATHWAY REGULATION; P-TYPE ATPASE; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPID METHYLATION; PROTEIN-KINASE; GENE; CHANNEL; COMPLEX; GROWTH; BIOSYNTHESIS	Osmotic down shock causes an immediate influx of Ca2+ in yeast, likely through a membrane stretch-sensitive channel. To see how this channel is constituted and regulated, we screened the collection of 4,906 yeast gene deletants for major changes in this response by luminomtery. We discovered deletants that responded very strongly to much milder down shocks than wild-type required, but show little changes in up-shock response. Of all the possibilities (general metabolism, ion distribution, cytoskeleton, cell wall, membrane receptors, etc.), most of the over-responders turned out to be deleted of proteins functioning in the biogenesis of phospholipids, sphingolipids, or ergosterol. Other over-responders are annotated to have vesicular transport defects, traceable to lipid defects in some cases. The deletant lacking the de novo synthesis of phosphatidylcholine, opi3 Delta, is by far the strongest over-responder. opi3 deletion does not cause nonspecific leakage but greatly sensitizes the force-sensing Ca2+- influx mechanism. Choline supplementation normalizes the opi3 Delta response. Thus, the osmotic-pressure induced stretch force apparently controls channel activities through lipids. This unbiased examination of the yeast genome supports the view that forces intrinsic to the bilayer are determined by the geometry of the lipids and these forces, in turn, govern the activities of proteins embedded therein.-Loukin, S. H, Kung, C., Saimi, Y. Lipid perturbations sensitize osmotic downshock activated Ca2+ influx, a yeast " deletome" analysis.	Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Loukin, SH (corresponding author), Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA.	shloukin@wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047856] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54867, GM 47856] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; Boumann HA, 2006, MOL BIOL CELL, V17, P1006, DOI 10.1091/mbc.E05-04-0344; Brink-van der Laan EV, 2004, BBA-BIOMEMBRANES, V1666, P275, DOI 10.1016/j.bbamem.2004.06.010; Chen CY, 1999, J CELL BIOL, V147, P1223, DOI 10.1083/jcb.147.6.1223; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; Deutschbauer AM, 2002, P NATL ACAD SCI USA, V99, P15530, DOI 10.1073/pnas.202604399; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Gable K, 2000, J BIOL CHEM, V275, P7597, DOI 10.1074/jbc.275.11.7597; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Guo WJ, 1999, AAPS PHARMSCI, V1; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; KEMPLE MD, 1990, EUR J BIOCHEM, V187, P131, DOI 10.1111/j.1432-1033.1990.tb15286.x; Kung C, 2005, NATURE, V436, P647, DOI 10.1038/nature03896; LOUBBARDI A, 1995, J BACTERIOL, V177, P1817, DOI 10.1128/jb.177.7.1817-1823.1995; MCGRAW P, 1989, GENETICS, V122, P317; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Palmer CP, 2001, P NATL ACAD SCI USA, V98, P7801, DOI 10.1073/pnas.141036198; Patel AJ, 2001, CURR OPIN CELL BIOL, V13, P422, DOI 10.1016/S0955-0674(00)00231-3; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Peterson MR, 2001, TRAFFIC, V2, P476, DOI 10.1034/j.1600-0854.2001.20705.x; Ramu Y, 2006, NATURE, V442, P696, DOI 10.1038/nature04880; Saito K, 2004, MOL BIOL CELL, V15, P3418, DOI 10.1091/mbc.E03-11-0829; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Slessareva JE, 2006, CELL, V126, P191, DOI 10.1016/j.cell.2006.04.045; STACK JH, 1994, J BIOL CHEM, V269, P31552; Stolz J, 1999, J BIOL CHEM, V274, P18747, DOI 10.1074/jbc.274.26.18747; SUKHAREV S, 2004, SCI STKE, pRE4; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; SUMMERS EF, 1988, GENETICS, V120, P909; Tamas MJ, 1999, MOL MICROBIOL, V31, P1087, DOI 10.1046/j.1365-2958.1999.01248.x; Tricoire L, 2006, P NATL ACAD SCI USA, V103, P9500, DOI 10.1073/pnas.0603176103; White WH, 2001, J BIOL CHEM, V276, P10794, DOI 10.1074/jbc.M009804200; Yamaji-Hasegawa A, 2006, BIOL PHARM BULL, V29, P1547, DOI 10.1248/bpb.29.1547; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; Zhou XL, 2005, EUR BIOPHYS J BIOPHY, V34, P413, DOI 10.1007/s00249-005-0465-0	41	10	10	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1813	1820		10.1096/fj.06-7898com	http://dx.doi.org/10.1096/fj.06-7898com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314135				2022-12-28	WOS:000246866500023
J	Luo, K; Ehrlich, E; Xiao, ZX; Zhang, WY; Ketner, G; Yu, XF				Luo, Kun; Ehrlich, Elana; Xiao, Zuoxiang; Zhang, Wenyan; Ketner, Gary; Yu, Xiao-Fang			Adenovirus E4orF6 assembles with Cullin5-ElonginB-ElonginC E3 ubiquitin ligase through an HIV/SIV Vif-like BC-box to regulate p53	FASEB JOURNAL			English	Article						proteasomal degradation; substrate receptor; virology	ZINC-BINDING DOMAIN; SOCS-BOX; E1B 55-KILODALTON; COMPLEX; PROTEINS; DEGRADATION; ONCOPROTEINS; CONJUGATION; EXPRESSION; INACTIVATE	The adenovirus protein E4orf6 targets p53 for polyubiquitination and proteasomal degradation and is known to form a complex with the Cul5-ElonginB- ElonginC E3 ubiquitin ligase. However, whether Cul5 is directly responsible for the E4orf6-mediated degradation of p53 remains unclear. By using a dominant-negative mutant of Cul5 and silencing Cul5 expression through RNA interference, we have now demonstrated that E4orf6- mediated p53 degradation requires Cul5. Furthermore, we have identified a lentiviral Vif-like BC-box motif in E4orf6 that is highly conserved among adenoviruses from multiple species. More importantly, we have shown that this Vif-like BC- box is essential for the recruitment of Cul5-ElonginB-ElonginC E3 ubiquitin ligase by E4orf6 and is also required for E4orf6- mediated p53 degradation. E4orf6 selectively recruited Cul5 despite the lack of either a Cul5-box, which is used by cellular substrate receptors to recruit Cul5, or a newly identified HCCH zinc-binding motif, which is used by primate lentiviral Vif to recruit Cul5. Therefore, adenovirus E4orf6 molecules represent a novel family of viral BC- box proteins the cellular ancestor of which is as yet unknown.-Luo, K., Ehrlich, E., Xiao, Z., Zhang, W., Ketner, G., Yu, X-F. Adenovirus E4orf6 assembles with Cullin5-ElonginB-ElonginC E3 ubiquitin ligase through an HIV/SIV Vif-like BC-box to regulate p53.	Johns Hopkins Bloomberg Sch Publ Hlth, Dept Microbiol & Immunol, Baltimore, MD 21205 USA; Zhejiang Univ, Sch Med, Affiliated Hosp 2, Zhejiang, Peoples R China	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Zhejiang University	Yu, XF (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Microbiol & Immunol, 615 N Wolfe St, Baltimore, MD 21205 USA.	xfyu@jhsph.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI062644, R01AI062644] Funding Source: NIH RePORTER; NIAID NIH HHS [AI062644] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; Blanchette P, 2004, MOL CELL BIOL, V24, P9619, DOI 10.1128/MCB.24.21.9619-9629.2004; Boyer JL, 2000, J BIOL CHEM, V275, P14969, DOI 10.1074/jbc.M000566200; Cathomen T, 2000, J VIROL, V74, P11407, DOI 10.1128/JVI.74.23.11407-11412.2000; Dettenhofer M, 1999, J VIROL, V73, P1460, DOI 10.1128/JVI.73.2.1460-1467.1999; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Liu BD, 2005, J VIROL, V79, P9579, DOI 10.1128/JVI.79.15.9579-9587.2005; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Luo K, 2005, P NATL ACAD SCI USA, V102, P11444, DOI 10.1073/pnas.0502440102; Mehle A, 2004, GENE DEV, V18, P2861, DOI 10.1101/gad.1249904; Mehle A, 2006, J BIOL CHEM, V281, P17259, DOI 10.1074/jbc.M602413200; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; Nevels M, 2000, J VIROL, V74, P5168, DOI 10.1128/JVI.74.11.5168-5181.2000; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Ridgway PJ, 1997, VIROLOGY, V237, P404, DOI 10.1006/viro.1997.8782; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; Shen YQ, 2001, J VIROL, V75, P4297, DOI 10.1128/JVI.75.9.4297-4307.2001; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; STEEGE MW, 1998, PROVEN PRACTICE PREV, V1, P4; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Wada H, 1999, J BIOL CHEM, V274, P36025, DOI 10.1074/jbc.274.50.36025; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Woo JL, 2007, J VIROL, V81, P575, DOI 10.1128/JVI.01725-06; Xiao ZX, 2006, VIROLOGY, V349, P290, DOI 10.1016/j.virol.2006.02.002; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Yu YK, 2004, GENE DEV, V18, P2867, DOI 10.1101/gad.1250204	39	43	44	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1742	1750		10.1096/fj.06-7241com	http://dx.doi.org/10.1096/fj.06-7241com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17351129				2022-12-28	WOS:000246866500016
J	Ohba, S; Ikeda, T; Kugimiya, F; Yano, F; Lichtler, AC; Nakamura, K; Takato, T; Kawaguchi, H; Chung, UI				Ohba, Shinsuke; Ikeda, Toshiyuki; Kugimiya, Fumitaka; Yano, Fumiko; Lichtler, Alexander C.; Nakamura, Kozo; Takato, Tsuyoshi; Kawaguchi, Hiroshi; Chung, Ung-il			Identification of a potent combination of osteogenic genes for bone regeneration using embryonic stem (ES) cell-based sensor	FASEB JOURNAL			English	Article						osteogenesis; screening; biosensor; cell sheet	IN-VITRO; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTOR; BETA INTERACTS; RUNX2; OVEREXPRESSION; MARROW; GROWTH; REPAIR; MECHANISMS	To identify potent bioactive factors for in vivo tissue regeneration by comprehensive screening remains a challenge for regenerative medicine. Here we report the development of an ES cell-based monitoring system for osteogenic differentiation, the identification of a potent combination of osteogenic genes using such a system, and an evaluation of its therapeutic potentials. ES cells were isolated from mice carrying a transgene expressing GFP driven by the 2.3 kb fragment of rat type I collagen alpha( 1) promoter. Using these cells engineered to fluoresce on osteogenic differentiation, we screened cDNA libraries and combinations of major osteogenesis-related genes. Among them, the combination of constitutively active activin receptorlike kinase 6 (caALK6) and runt-related transcription factor 2 ( Runx2) was the minimal unit that induced fluorescence. The combination efficiently induced osteogenic differentiation in various cell types, including terminally differentiated nonosteogenic cells. The cooperative action of the combination occurred through protein stabilization of core binding factor beta (Cbfb), induction of Runx2-Cbfb complex formation, and its DNA binding. Furthermore, transplantation of a monolayer sheet of fibroblasts transduced with the combination achieved bone regeneration within 4 wk in mouse calvarial bone defects. Thus, we successfully identified the potent combination of genes for bone regeneration, which helped broaden cell sources.-Ohba, S., Ikeda, T., Kugimiya, F., Yano, F., Lichtler, A. C., Nakamura, K., Takato, T., Kawaguchi, H., Chung, U. I. Identification of a potent combination of osteogenic genes for bone regeneration using embryonic stem ( ES) cell-based sensor.	Univ Tokyo, Fac Med, Ctr Dis Biol & Integrat Med, Bunkyo Ku, Tokyo 1130033, Japan; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06032 USA; Univ Tokyo, Fac Med, Div Sensory & Motor Syst Med, Bunkyo Ku, Tokyo 1130033, Japan; Japan Soc Promot Sci, Chiyoda Ku, Tokyo, Japan	University of Tokyo; University of Connecticut; University of Tokyo; Japan Society for the Promotion of Science	Chung, UI (corresponding author), Univ Tokyo, Fac Med, Ctr Dis Biol & Integrat Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	uichung-tky@umin.ac.jp	Ikeda, Toshiyuki/GVS-5588-2022	Ohba, Shinsuke/0000-0002-6874-8539				Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Balint E, 2003, J CELL BIOCHEM, V89, P401, DOI 10.1002/jcb.10515; Bauer TW, 2002, CLIN ORTHOP RELAT R, P11; BEE JS, 2006, IN PRESS J CELL BIOC; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Bridwell KH, 2004, J BONE JOINT SURG AM, V86A, P1587, DOI 10.2106/00004623-200407000-00033; Bruder S. P., 2000, PRINCIPLES TISSUE EN, P683; Buttery LDK, 2001, TISSUE ENG, V7, P89, DOI 10.1089/107632700300003323; Byers BA, 2004, TISSUE ENG, V10, P1757, DOI 10.1089/ten.2004.10.1757; Byers BA, 2002, J BONE MINER RES, V17, P1931, DOI 10.1359/jbmr.2002.17.11.1931; Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958; Franceschi RT, 2000, J CELL BIOCHEM, V78, P476, DOI 10.1002/1097-4644(20000901)78:3<476::AID-JCB12>3.0.CO;2-5; Geesink RGT, 1999, J BONE JOINT SURG BR, V81B, P710, DOI 10.1302/0301-620X.81B4.9311; GEY GO, 1952, CANCER RES, V12, P264; Hirata K, 2003, BONE, V32, P502, DOI 10.1016/S8756-3282(03)00054-1; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; Jayme D W, 1985, Adv Biotechnol Processes, V5, P1; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15; Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601-0825.2002.01829.x; KAUFMAN M, 1994, ATLAS MOUSE DEV, P495; Kojima H, 2005, J BIOL CHEM, V280, P2944, DOI 10.1074/jbc.M311598200; Komori T, 2003, J BONE MINER METAB, V21, P193, DOI 10.1007/s00774-002-0408-0; Krebsbach PH, 2000, HUM GENE THER, V11, P1201, DOI 10.1089/10430340050015248; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Kugimiya F, 2005, J BIOL CHEM, V280, P35704, DOI 10.1074/jbc.M505166200; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623-200206000-00022; Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006; Long FX, 2001, DEVELOPMENT, V128, P5099; Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168-9525(03)00176-8; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Ogasawara T, 2004, MOL CELL BIOL, V24, P6560, DOI 10.1128/mcb.24.15.6560-6568.2004; Ogata N, 2000, J CLIN INVEST, V105, P935, DOI 10.1172/JCI9017; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Otto WR, 2004, CELL PROLIFERAT, V37, P97, DOI 10.1111/j.1365-2184.2004.00303.x; Patel MS, 2002, NEW ENGL J MED, V346, P1572, DOI 10.1056/NEJM200205163462011; Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109; Salgado AJ, 2005, BIODEGRADABLE SYSTEMS IN TISSUE ENGINEERING AND REGENERATIVE MEDICINE, P457; Sekiya I, 2002, P NATL ACAD SCI USA, V99, P4397, DOI 10.1073/pnas.052716199; Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602-587; VERBRUGGEN LA, 1980, ARCH DERMATOL RES, V269, P111, DOI 10.1007/BF00406531; Vleminckx K, 1999, MECH DEVELOP, V81, P65, DOI 10.1016/S0925-4773(98)00225-1; Yamato M, 2002, BIOMATERIALS, V23, P561, DOI 10.1016/S0142-9612(01)00138-7; Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705; Yano F, 2005, BIOCHEM BIOPH RES CO, V333, P1300, DOI 10.1016/j.bbrc.2005.06.041; Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015; zur Nieden NI, 2003, DIFFERENTIATION, V71, P18, DOI 10.1046/j.1432-0436.2003.700602.x	50	24	24	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1777	1787		10.1096/fj.06-7571com	http://dx.doi.org/10.1096/fj.06-7571com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17317722				2022-12-28	WOS:000246866500020
J	Lim, LHK; Pervaiz, S				Lim, Lina H. K.; Pervaiz, Shazib			Annexin 1: the new face of an old molecule	FASEB JOURNAL			English	Review						inflammation; glucocorticoids; apoptosis; cancer	PROSTATIC INTRAEPITHELIAL NEOPLASIA; HUMAN RECOMBINANT LIPOCORTIN-1; SQUAMOUS-CELL CARCINOMA; N-TERMINAL PEPTIDE; HUMAN LUNG; LEUKOCYTE LIPOCORTIN-1; NEUTROPHIL MIGRATION; MEMBRANE AGGREGATION; RHEUMATOID-ARTHRITIS; PHOSPHOLIPASE A(2)	The annexin superfamily consists of 13 calcium or calcium and phospholipid binding proteins with a significant degree of biological and structural homology (40-60%). First described in the late 1970s and subsequently referred to as macrocortin, renocortin, lipomodulin, lipocortin-1, and more recently Annexin 1, this 37 kDa calcium and phospholipid binding protein is a strong inhibitor of glucocorticoid-induced eicosanoid synthesis and PLA2. Recent interest in the biological activity of this intriguing molecule has unraveled important functional attributes of Annexin 1 in a variety of inflammatory pathways, on cell proliferation machinery, in the regulation of cell death signaling, in phagocytic clearance of apoptosing cells, and most importantly in the process of carcinogenesis. Here we attempt to present a short review on these diverse biological activities of an interesting and important molecule, which could be a potential target for novel therapeutic intervention in a host of disease states.	Natl Univ Singapore, Dept Physiol, Yong Loo Lin Sch Med, Singapore 117597, Singapore; Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore 117548, Singapore	National University of Singapore; National University of Singapore	Pervaiz, S (corresponding author), Natl Univ Singapore, Dept Physiol, Yong Loo Lin Sch Med, 2 Med Dr,Bldg MD9, Singapore 117597, Singapore.	phssp@nus.edu.sg	Pervaiz, Shazib/C-4188-2015	Lim, Lina/0000-0002-2935-2275				Ahn SH, 1997, CLIN EXP METASTAS, V15, P151, DOI 10.1023/A:1018452810915; Alldridge LC, 2003, EXP CELL RES, V290, P93, DOI 10.1016/S0014-4827(03)00310-0; Alldridge LC, 1999, J BIOL CHEM, V274, P37620, DOI 10.1074/jbc.274.53.37620; Arur S, 2003, DEV CELL, V4, P587, DOI 10.1016/S1534-5807(03)00090-X; Bai XF, 2004, WORLD J GASTROENTERO, V10, P1466; BASTIAN BC, 1993, J INVEST DERMATOL, V101, P359, DOI 10.1111/1523-1747.ep12365541; Bitto E, 2000, BIOCHEMISTRY-US, V39, P13469, DOI 10.1021/bi001275u; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; Canaider S, 2000, LIFE SCI, V66, pPL265, DOI 10.1016/S0024-3205(00)00500-2; Carollo M, 1998, ONCOL RES, V10, P245; CHANG J, 1987, BIOCHEM PHARMACOL, V36, P2429, DOI 10.1016/0006-2952(87)90512-0; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; CIRINO G, 1993, BRIT J PHARMACOL, V108, P573, DOI 10.1111/j.1476-5381.1993.tb12843.x; CIRINO G, 1989, P NATL ACAD SCI USA, V86, P3428, DOI 10.1073/pnas.86.9.3428; CROXTALL J, 1993, J LIPID MEDIATOR, V6, P295; CROXTALL JD, 1993, INT J CANCER, V54, P153, DOI 10.1002/ijc.2910540124; CROXTALL JD, 1995, BIOCHEM PHARMACOL, V50, P465, DOI 10.1016/0006-2952(95)00156-T; Cuzzocrea S, 1997, J IMMUNOL, V159, P5089; Das AM, 1997, BRIT J PHARMACOL, V121, P97, DOI 10.1038/sj.bjp.0701122; DAVIDSON J, 1991, BRIT J PHARMACOL, V102, P7, DOI 10.1111/j.1476-5381.1991.tb12122.x; DE BK, 1986, J BIOL CHEM, V261, P3784; de Coupade C, 2000, HEPATOLOGY, V31, P371, DOI 10.1002/hep.510310217; Dorovkov MV, 2004, J BIOL CHEM, V279, P50643, DOI 10.1074/jbc.C400441200; ERRASFA M, 1989, BRIT J PHARMACOL, V97, P1051, DOI 10.1111/j.1476-5381.1989.tb12561.x; Falini B, 2004, LANCET, V363, P1869, DOI 10.1016/S0140-6736(04)16356-3; Fan XX, 2004, MOL BIOL CELL, V15, P2863, DOI 10.1091/mbc.E03-09-0670; Ferreira SH, 1997, BRIT J PHARMACOL, V121, P883, DOI 10.1038/sj.bjp.0701211; Gavins FNE, 2003, BLOOD, V101, P4140, DOI 10.1182/blood-2002-11-3411; Gavins FNE, 2004, FASEB J, V18, P100, DOI 10.1096/fj.04-2178fje; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Getting SJ, 1997, BRIT J PHARMACOL, V120, P1075, DOI 10.1038/sj.bjp.0701029; GOULDING NJ, 1992, ARTHRITIS RHEUM, V35, P1395, DOI 10.1002/art.1780351126; Hannon R, 2002, FASEB J, V16, P253, DOI 10.1096/fj.02-0239fje; HARRIS JG, 1995, EUR J PHARMACOL, V279, P149, DOI 10.1016/0014-2999(95)00145-B; HIRATA F, 1981, P NATL ACAD SCI-BIOL, V78, P3190, DOI 10.1073/pnas.78.5.3190; Hsiang CH, 2006, PROSTATE, V66, P1413, DOI 10.1002/pros.20457; Hu N, 2004, CLIN CANCER RES, V10, P6013, DOI 10.1158/1078-0432.CCR-04-0317; Ishido M, 2005, REGUL PEPTIDES, V124, P45, DOI 10.1016/j.regpep.2004.06.027; Kang JS, 2002, CLIN CANCER RES, V8, P117; KIM KM, 1994, FEBS LETT, V343, P251, DOI 10.1016/0014-5793(94)80566-0; Lambert O, 1997, J MOL BIOL, V272, P42, DOI 10.1006/jmbi.1997.1183; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; LOXLEY HD, 1993, J NEUROENDOCRINOL, V5, P51, DOI 10.1111/j.1365-2826.1993.tb00363.x; Mailliard WS, 1996, J BIOL CHEM, V271, P719, DOI 10.1074/jbc.271.2.719; MCKANNA JA, 1995, ANAT REC, V242, P1, DOI 10.1002/ar.1092420102; MCLEOD JD, 1995, BIOCHEM PHARMACOL, V50, P1103, DOI 10.1016/0006-2952(95)00234-Q; MORAND EF, 1994, ARTHRITIS RHEUM, V37, P207, DOI 10.1002/art.1780370209; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; Mulla A, 2004, CLIN ENDOCRINOL, V60, P107, DOI 10.1111/j.1365-2265.2004.01936.x; Oliani SM, 2001, AM J PATHOL, V158, P603, DOI 10.1016/S0002-9440(10)64002-3; Patton KT, 2005, HISTOPATHOLOGY, V47, P597, DOI 10.1111/j.1365-2559.2005.02300.x; Paweletz CP, 2000, CANCER RES, V60, P6293; Pedrero JMG, 2004, AM J PATHOL, V164, P73, DOI 10.1016/S0002-9440(10)63098-2; PEERS SH, 1993, BRIT J PHARMACOL, V108, P66, DOI 10.1111/j.1476-5381.1993.tb13441.x; PERRETTI M, 1995, BIOCHEM PHARMACOL, V50, P1037, DOI 10.1016/0006-2952(95)00238-U; PERRETTI M, 1993, J IMMUNOL, V151, P4306; Perretti M, 1996, BRIT J PHARMACOL, V118, P605, DOI 10.1111/j.1476-5381.1996.tb15444.x; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; PERRETTI M, 1994, PHARMACOL RES, V30, P53, DOI 10.1016/1043-6618(94)80087-1; Perretti M, 1996, BRIT J PHARMACOL, V117, P1145, DOI 10.1111/j.1476-5381.1996.tb16709.x; Petrella A, 2005, CELL DEATH DIFFER, V12, P1358, DOI 10.1038/sj.cdd.4401645; Philip JG, 1997, NEUROREPORT, V8, P1871, DOI 10.1097/00001756-199705260-00016; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Rescher U, 2002, J IMMUNOL, V169, P1500, DOI 10.4049/jimmunol.169.3.1500; Rodrigo JP, 2005, AM J RHINOL, V19, P483, DOI 10.1177/194589240501900511; Rosengarth A, 2001, J MOL BIOL, V306, P489, DOI 10.1006/jmbi.2000.4423; ROTHHUT B, 1983, BIOCHEM BIOPH RES CO, V117, P878, DOI 10.1016/0006-291X(83)91678-9; Sakamoto T, 1996, BIOCHEM BIOPH RES CO, V220, P643, DOI 10.1006/bbrc.1996.0457; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; Shen DJ, 2006, HUM PATHOL, V37, P1583, DOI 10.1016/j.humpath.2006.06.001; Shen DJ, 2005, BIOCHEM BIOPH RES CO, V326, P218, DOI 10.1016/j.bbrc.2004.10.214; Sheng KH, 2006, PROTEOMICS, V6, P1058, DOI 10.1002/pmic.200402015; Skouteris GG, 1996, J BIOL CHEM, V271, P27266, DOI 10.1074/jbc.271.44.27266; SMITH SF, 1995, J APPL PHYSIOL, V79, P121, DOI 10.1152/jappl.1995.79.1.121; SMITH SF, 1990, ENVIRON HEALTH PERSP, V85, P135, DOI 10.2307/3430676; Smitherman AB, 2004, J UROLOGY, V171, P916, DOI 10.1097/01.ju.0000104674.70170.cd; SOLITO E, 1994, BRIT J PHARMACOL, V112, P347, DOI 10.1111/j.1476-5381.1994.tb13075.x; Solito E, 2003, FASEB J, V17, P1544, DOI 10.1096/fj.02-0941fje; Solito E, 2003, ENDOCRINOLOGY, V144, P1164, DOI 10.1210/en.2002-220592; Solito E, 2001, BRIT J PHARMACOL, V133, P217, DOI 10.1038/sj.bjp.0704054; STRIJBOS PJLM, 1993, AM J PHYSIOL, V265, pE289, DOI 10.1152/ajpendo.1993.265.2.E289; TAYLOR AD, 1993, NEUROENDOCRINOLOGY, V58, P430, DOI 10.1159/000126572; Teixeira MM, 1998, BRIT J PHARMACOL, V123, P538, DOI 10.1038/sj.bjp.0701625; vanHal PTW, 1996, J APPL PHYSIOL, V81, P548, DOI 10.1152/jappl.1996.81.2.548; VARTICOVSKI L, 1988, BIOCHEMISTRY-US, V27, P3682, DOI 10.1021/bi00410a024; Vishwanatha JK, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-8; Wu YL, 2000, BRIT J HAEMATOL, V111, P807, DOI 10.1046/j.1365-2141.2000.02397.x; Xia SH, 2002, ONCOGENE, V21, P6641, DOI 10.1038/sj.onc.1205818; Xiao GS, 2007, INT J CANCER, V120, P111, DOI 10.1002/ijc.22164; Xin W, 2003, AM J PATHOL, V162, P255, DOI 10.1016/S0002-9440(10)63816-3; Yang YH, 1997, INFLAMMATION, V21, P583, DOI 10.1023/A:1027330021479; Yang YH, 1997, J RHEUMATOL, V24, P1758; Zhi HY, 2003, INT J CANCER, V106, P327, DOI 10.1002/ijc.11225	93	314	344	0	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					968	975		10.1096/fj.06-7464rev	http://dx.doi.org/10.1096/fj.06-7464rev			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17215481				2022-12-28	WOS:000245650400002
J	Rachakonda, PS; Veit, M; Korte, T; Ludwig, K; Bottcher, C; Huang, Q; Schmidt, MFG; Herrmann, A				Rachakonda, P. Sivaramakrishna; Veit, Michael; Korte, Thomas; Ludwig, Kai; Boettcher, Christoph; Huang, Qiang; Schmidt, Michael F. G.; Herrmann, Andreas			The relevance of salt bridges for the stability of the influenza virus hemagglutinin	FASEB JOURNAL			English	Article						conformational change; fusion; ectodomain; influenza virus HA; stability	MEMBRANE-FUSION ACTIVITY; COILED-COIL REGION; CONFORMATIONAL-CHANGE; RECEPTOR-BINDING; DISULFIDE BONDS; PH; GLYCOPROTEIN; PROTEINS; SUBTYPES; PEPTIDE	Hemagglutinin ( HA) of influenza virus undergoes an irreversible conformational change at acidic pH, mediating viral fusion with the host endosomal membrane. To unravel the molecular basis of the pH-dependent stability of HA, we demonstrate by mutagenesis of the prototype HA of virus strain X31 (H3 subtype) that salt bridges, especially a tetrad salt bridge within the monomers, are crucial for folding and stability of the trimeric ectodomain. This complex ( tetrad) salt bridge is highly conserved among influenza virus subtypes. Introducing additional sites of electrostatic attraction between monomers in the distal region enhanced the stability of ectodomain at low pH mimicking the natural variant H2 subtype. We propose that distinct salt bridges in the distal domain may contribute to the enhanced stability of HA of natural virus variants. This hypothesis may provide clues to understanding adaptations of virus strains ( for example, avian influenza viruses) in order to preserve stability of the protein in the host-specific environment.	Humboldt Univ, Mat Naturwissensch Fak 1, Inst Biol Biophys, D-10115 Berlin, Germany; Free Univ Berlin, Inst Immunol & Mol Biol, Vet Med Fak, Berlin, Germany; Free Univ Berlin, Forsch Zentrum Elek Mikroskopie, Berlin, Germany; Fudan Univ, State Key Lab Genet Engn, Sch Life Sci, Shanghai 200433, Peoples R China	Humboldt University of Berlin; Free University of Berlin; Free University of Berlin; Fudan University	Herrmann, A (corresponding author), Humboldt Univ, Mat Naturwissensch Fak 1, Inst Biol Biophys, Invalidenstr 43, D-10115 Berlin, Germany.	andreas.herrmann@rz.hu-berlin.de	Ludwig, Kai/AAA-9017-2022; Veit, Michael/G-6492-2010	Ludwig, Kai/0000-0001-6808-8107; Rachakonda, Sivaramakrishna/0000-0002-2319-2821; Veit, Michael/0000-0002-7638-1829				BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; Bentz J, 2000, BIOPHYS J, V78, P886, DOI 10.1016/S0006-3495(00)76646-X; Bottcher C, 1999, FEBS LETT, V463, P255, DOI 10.1016/S0014-5793(99)01475-1; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chen J, 1998, CELL, V95, P409, DOI 10.1016/S0092-8674(00)81771-7; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; Crowley PB, 2005, PROTEINS, V59, P231, DOI 10.1002/prot.20417; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DOMS RW, 1985, J BIOL CHEM, V260, P2973; Durrer P, 1996, J BIOL CHEM, V271, P13417, DOI 10.1074/jbc.271.23.13417; Gamblin SJ, 2004, SCIENCE, V303, P1838, DOI 10.1126/science.1093155; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; GODLEY L, 1992, CELL, V68, P635, DOI 10.1016/0092-8674(92)90140-8; Gruenke JA, 2002, J VIROL, V76, P4456, DOI 10.1128/JVI.76.9.4456-4466.2002; Ha Y, 2002, EMBO J, V21, P865, DOI 10.1093/emboj/21.5.865; Hoffman LR, 1997, J VIROL, V71, P8808, DOI 10.1128/JVI.71.11.8808-8820.1997; Huang Q, 2003, BBA-BIOMEMBRANES, V1614, P3, DOI 10.1016/S0005-2736(03)00158-5; Huang Q, 2002, BIOPHYS J, V82, P1050, DOI 10.1016/S0006-3495(02)75464-7; HUANG RTC, 1981, VIROLOGY, V110, P243, DOI 10.1016/0042-6822(81)90030-1; Isin B, 2002, BIOPHYS J, V82, P569, DOI 10.1016/S0006-3495(02)75422-2; KEMBLE GW, 1992, J VIROL, V66, P4940, DOI 10.1128/JVI.66.8.4940-4950.1992; Korte T, 1999, J VIROL, V73, P4567, DOI 10.1128/JVI.73.6.4567-4574.1999; Korte T, 1997, J BIOL CHEM, V272, P9764; Kozlov MM, 1998, BIOPHYS J, V75, P1384, DOI 10.1016/S0006-3495(98)74056-1; LUNEBERG J, 1995, J BIOL CHEM, V270, P27606; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Mayne L, 1998, J AM CHEM SOC, V120, P10643, DOI 10.1021/ja981592c; Mittal A, 2002, BIOPHYS J, V83, P2652, DOI 10.1016/S0006-3495(02)75275-2; MUSAFIA B, 1995, J MOL BIOL, V254, P761, DOI 10.1006/jmbi.1995.0653; PROESCH S, 1990, Febs Letters, V267, P19; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; Puthavathana P, 2005, J GEN VIROL, V86, P423, DOI 10.1099/vir.0.80368-0; Qiao H, 1998, J CELL BIOL, V141, P1335, DOI 10.1083/jcb.141.6.1335; Russell RJ, 2004, VIROLOGY, V325, P287, DOI 10.1016/j.virol.2004.04.040; SCHOLTISSEK C, 1988, ARCH VIROL, V101, P119, DOI 10.1007/BF01314656; Shangguan T, 1998, BIOPHYS J, V74, P54, DOI 10.1016/S0006-3495(98)77766-5; Shental-Bechor D, 2002, BBA-BIOMEMBRANES, V1565, P81, DOI 10.1016/S0005-2736(02)00511-4; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Staschke KA, 1998, VIROLOGY, V248, P264, DOI 10.1006/viro.1998.9273; STEINHAUER DA, 1991, P NATL ACAD SCI USA, V88, P11525, DOI 10.1073/pnas.88.24.11525; Stevens J, 2006, SCIENCE, V312, P404, DOI 10.1126/science.1124513; Stevens J, 2004, SCIENCE, V303, P1866, DOI 10.1126/science.1093373; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	47	57	58	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					995	1002		10.1096/fj.06-7052hyp	http://dx.doi.org/10.1096/fj.06-7052hyp			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17218542				2022-12-28	WOS:000245650400004
J	Zador, Z; Magzoub, M; Jin, S; Manley, GT; Papadopoulos, MC; Verkman, AS				Zador, Zsolt; Magzoub, Mazin; Jin, Songwan; Manley, Geoffrey T.; Papadopoulos, Marios C.; Verkman, A. S.			Microfiberoptic fluorescence photobleaching reveals size-dependent macromolecule diffusion in extracellular space deep in brain	FASEB JOURNAL			English	Article						central nervous system; aquaporin 4	CENTRAL-NERVOUS-SYSTEM; VOLUME FRACTION; RAT NEOCORTEX; TORTUOSITY; AQUAPORIN-4; POTASSIUM; PROTEOGLYCANS; MICRODOMAINS; ANISOTROPY; DECREASES	Diffusion in brain extracellular space (ECS) is important for nonsynaptic intercellular communication, extracellular ionic buffering, and delivery of drugs and metabolites. We measured macromolecular diffusion in normally light-inaccessible regions of mouse brain by microfiberoptic epifluorescence photo-bleaching, in which a fiberoptic with a micron-size tip is introduced deep in brain tissue. In brain cortex, the diffusion of a noninteracting molecule [fluorescein isothiocyanate (FITC)-dextran, 70 kDa] was slowed 4.5 +/- 0.5-fold compared with its diffusion in water (D-o/D), and was depth-independent down to 800 mu m from the brain surface. Diffusion was significantly accelerated (D-o/D of 2.9+/-0.3) in mice lacking the glial water channel aquaporin-4. FITC-dextran diffusion varied greatly in different regions of brain, with D-o/D of 3.5 +/- 0.3 in hippocampus and 7.4 +/- 0.3 in thalamus. Remarkably, D-o/D in deep brain was strongly dependent on solute size, whereas diffusion in cortex changed little with solute size. Mathematical modeling of ECS diffusion required nonuniform ECS dimensions in deep brain, which we call "heterometricity," to account for the size-dependent diffusion. Our results provide the first data on molecular diffusion in ECS deep in brain in vivo and demonstrate previously unrecognized hindrance and heterometricity for diffusion of large macromolecules in deep brain.	[Zador, Zsolt; Magzoub, Mazin; Jin, Songwan; Papadopoulos, Marios C.; Verkman, A. S.] Univ Calif San Francisco, Dept Physiol & Med, San Francisco, CA 94143 USA; [Zador, Zsolt; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Papadopoulos, Marios C.] Univ London St Georges Hosp, Acad Neurosurg Unit, London, England	University of California System; University of California San Francisco; University of California System; University of California San Francisco; St Georges University London	Verkman, AS (corresponding author), Univ Calif San Francisco, Dept Physiol & Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	alan.verkman@ucsf.edu		Papadopoulos, Marios/0000-0001-9174-4176; Zador, Zsolt/0000-0001-9767-3372; zador, zsolt/0000-0003-4297-616X	NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, R01HL073856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, P30DK072517, R01DK035124] Funding Source: NIH RePORTER; NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL73856, HL59198] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK72517, DK35124] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Binder DK, 2006, GLIA, V53, P631, DOI 10.1002/glia.20318; Binder DK, 2004, J NEUROSCI, V24, P8049, DOI 10.1523/JNEUROSCI.2294-04.2004; Chen KC, 2000, P NATL ACAD SCI USA, V97, P8306, DOI 10.1073/pnas.150338197; CORDINGLEY GE, 1978, BRAIN RES, V151, P291, DOI 10.1016/0006-8993(78)90886-7; Costa C, 2007, J CHEM NEUROANAT, V33, P111, DOI 10.1016/j.jchemneu.2007.01.006; CSERR HF, 1991, J PHYSIOL-LONDON, V442, P277, DOI 10.1113/jphysiol.1991.sp018793; Dauty E, 2005, J BIOL CHEM, V280, P7823, DOI 10.1074/jbc.M412374200; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; Hiroaki Y, 2006, J MOL BIOL, V355, P628, DOI 10.1016/j.jmb.2005.10.081; Hrabe J, 2004, BIOPHYS J, V87, P1606, DOI 10.1529/biophysj.103.039495; Hrabetova S, 2004, NEUROCHEM INT, V45, P467, DOI 10.1016/j.neuint.2003.11.011; Hrabetova S, 2003, J NEUROSCI, V23, P8351; Hrabetova S, 2000, J CEREBR BLOOD F MET, V20, P1306, DOI 10.1097/00004647-200009000-00005; Kume-Kick J, 2002, J PHYSIOL-LONDON, V542, P515, DOI 10.1113/jphysiol.2002.017541; LEHMENKUHLER A, 1993, NEUROSCIENCE, V55, P339, DOI 10.1016/0306-4522(93)90503-8; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mazel T, 1998, NEUROREPORT, V9, P1299; MCBAIN CJ, 1990, SCIENCE, V249, P674, DOI 10.1126/science.2382142; Murakami T, 2003, ARCH HISTOL CYTOL, V66, P195, DOI 10.1679/aohc.66.195; Nandigam RK, 2007, BIOPHYS J, V92, P3368, DOI 10.1529/biophysj.106.095547; Nicholson C, 2000, PROG BRAIN RES, V125, P129; NICHOLSON C, 1981, J PHYSIOL-LONDON, V321, P225, DOI 10.1113/jphysiol.1981.sp013981; Padmawar P, 2005, NAT METHODS, V2, P825, DOI 10.1038/NMETH801; Papadopoulos MC, 2004, NEUROSCIENCE, V129, P1011, DOI 10.1016/j.neuroscience.2004.05.044; Papadopoulos MC, 2004, FASEB J, V18, P425, DOI 10.1096/fj.04-2834fje; Papadopoulos MC, 2005, BIOPHYS J, V89, P3660, DOI 10.1529/biophysj.105.068114; RICE ME, 1991, J NEUROPHYSIOL, V65, P264, DOI 10.1152/jn.1991.65.2.264; Rusakov DA, 1998, P NATL ACAD SCI USA, V95, P8975, DOI 10.1073/pnas.95.15.8975; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; SOMJEN GG, 1979, ANNU REV PHYSIOL, V41, P159, DOI 10.1146/annurev.ph.41.030179.001111; Sykova E, 2004, NEUROCHEM INT, V45, P453, DOI 10.1016/j.neuint.2003.11.009; Sykova E, 2002, HIPPOCAMPUS, V12, P269, DOI 10.1002/hipo.1101; Sykova E, 2000, PROG BRAIN RES, V125, P155; Tao A, 2005, J THEOR BIOL, V234, P525, DOI 10.1016/j.jtbi.2004.12.009; Tao L, 2004, J THEOR BIOL, V229, P59, DOI 10.1016/j.jtbi.2004.03.003; Thiagarajah JR, 2006, NAT METHODS, V3, P275, DOI 10.1038/NMETH863; Thorne RG, 2006, P NATL ACAD SCI USA, V103, P5567, DOI 10.1073/pnas.0509425103; VANHARREVELD A, 1968, J CELL SCI, V3, P579; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018; Wen H, 1999, EUR J NEUROSCI, V11, P935, DOI 10.1046/j.1460-9568.1999.00502.x	42	37	42	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					870	879		10.1096/fj.07-9468com	http://dx.doi.org/10.1096/fj.07-9468com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17965267				2022-12-28	WOS:000254143700025
J	Honaramooz, A; Megee, S; Zeng, WX; Destrempes, MM; Overton, SA; Luo, JP; Galantino-Homer, H; Modelski, M; Chen, FP; Blash, S; Melican, DT; Gavin, WG; Ayres, S; Yang, F; Wang, PJ; Echelard, Y; Dobrinski, I				Honaramooz, Ali; Megee, Susan; Zeng, Wenxian; Destrempes, Margret M.; Overton, Susan A.; Luo, Jinping; Galantino-Homer, Hannah; Modelski, Mark; Chen, Fangping; Blash, Stephen; Melican, David T.; Gavin, William G.; Ayres, Sandra; Yang, Fang; Wang, P. Jeremy; Echelard, Yann; Dobrinski, Ina			Adeno-associated virus (AAV)-mediated transduction of male germ line stem cells results in transgene transmission after germ cell transplantation	FASEB JOURNAL			English	Article						transgenesis; testis; mouse; goat	LENTIVIRAL TRANSDUCTION; VECTOR TRANSDUCTION; GENE-TRANSFER; SELF-RENEWAL; AAV; INTEGRATION; EXPRESSION; MICE; PIGS; SPERMATOGENESIS	We explored whether exposure of mammalian germ line stem cells to adeno-associated virus (AAV), a gene therapy vector, would lead to stable transduction and transgene transmission. Mouse germ cells harvested from experimentally induced cryptorchid donor testes were exposed in vitro to AAV vectors carrying a GFP transgene and transplanted to germ cell-depleted syngeneic recipient testes, resulting in colonization of the recipient testes by transgenic donor cells. Mating of recipient males to wild-type females yielded 10% transgenic offspring. To broaden the approach to nonrodent species, AAV-transduced germ cells from goats were transplanted to recipient males in which endogenous germ cells had been depleted by fractionated testicular irradiation. Transgenic germ cells colonized recipient testes and produced transgenic sperm. When semen was used for in vitro fertilization (IVF), 10% of embryos were transgenic. Here, we report for the first time that AAV-mediated transduction of mammalian germ cells leads to transmission of the transgene through the male germ line. Equally important, this is also the first report of transgenesis via germ cell transplantation in a nonrodent species, a promising approach to generate transgenic large animal models for biomedical research.	[Honaramooz, Ali; Megee, Susan; Zeng, Wenxian; Luo, Jinping; Galantino-Homer, Hannah; Modelski, Mark; Chen, Fangping; Dobrinski, Ina] Univ Penn, Ctr Anim Transgenesis & Germ Cell Res, Dept Clin Sci, New Bolton Ctr, Kennett Sq, PA 19348 USA; [Yang, Fang; Wang, P. Jeremy] Univ Penn, Sch Vet Med, Dept Anim Biol, Kennett Sq, PA 19348 USA; [Ayres, Sandra] Tufts Univ, Cummings Sch Vet Med, North Grafton, MA USA; [Destrempes, Margret M.; Overton, Susan A.; Blash, Stephen; Melican, David T.; Gavin, William G.; Echelard, Yann] GTC Biotherapeutics, Framingham, MA USA	University of Pennsylvania; University of Pennsylvania; Tufts University	Dobrinski, I (corresponding author), Univ Penn, Ctr Anim Transgenesis & Germ Cell Res, Dept Clin Sci, New Bolton Ctr, 382 W State Rd, Kennett Sq, PA 19348 USA.	dobrinsk@vet.upenn.edu	Zeng, Wen/GPS-8058-2022	Galantino-Homer, Hannah/0000-0002-1435-100X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R42HD044780] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR017359] Funding Source: NIH RePORTER; NCRR NIH HHS [5 R01 RR17359-05] Funding Source: Medline; NICHD NIH HHS [2 R42 HD044780-02] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arruda VR, 2001, MOL THER, V4, P586, DOI 10.1006/mthe.2001.0491; Bartlett JS, 1999, NAT BIOTECHNOL, V17, P181, DOI 10.1038/6185; Berns KI, 1996, CURR TOP MICROBIOL, V218, P1; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11303, DOI 10.1073/pnas.91.24.11303; Chen WY, 1997, P NATL ACAD SCI USA, V94, P5798, DOI 10.1073/pnas.94.11.5798; Dean FB, 2002, P NATL ACAD SCI USA, V99, P5261, DOI 10.1073/pnas.082089499; Dobrinski I, 1999, MOL REPROD DEV, V53, P142, DOI 10.1002/(SICI)1098-2795(199906)53:2&lt;142::AID-MRD3&gt;3.0.CO;2-O; Dobrinski I, 2006, Soc Reprod Fertil Suppl, V62, P331; Donsante A, 2007, SCIENCE, V317, P477, DOI 10.1126/science.1142658; Echelard Y, 2006, BIOPHARM INT, V19, P36; Gordon JW, 1998, MOL MED TODAY, V4, P468, DOI 10.1016/S1357-4310(98)01323-9; Gordon JW, 2003, GENE THER, V10, P43, DOI 10.1038/sj.gt.3301850; Halbert CL, 2002, NAT BIOTECHNOL, V20, P697, DOI 10.1038/nbt0702-697; Hamra FK, 2005, P NATL ACAD SCI USA, V102, P17430, DOI 10.1073/pnas.0508780102; Hamra FK, 2002, P NATL ACAD SCI USA, V99, P14931, DOI 10.1073/pnas.222561399; Hendrie PC, 2005, MOL THER, V12, P9, DOI 10.1016/j.ymthe.2005.04.006; Hirata RK, 2004, CLONING STEM CELLS, V6, P31, DOI 10.1089/15362300460743817; Honaramooz A, 2005, J ANDROL, V26, P698, DOI 10.2164/jandrol.05032; Honaramooz A, 2003, BIOL REPROD, V69, P1260, DOI 10.1095/biolreprod.103.018788; Honaramooz A, 2003, MOL REPROD DEV, V64, P422, DOI 10.1002/mrd.10205; Jakob M, 2005, J GENE MED, V7, P630, DOI 10.1002/jgm.718; Jellerette T, 2006, THERIOGENOLOGY, V65, P1575, DOI 10.1016/j.theriogenology.2005.08.025; Kanatsu-Shinohara M, 2006, P NATL ACAD SCI USA, V103, P8018, DOI 10.1073/pnas.0601139103; Kubota H, 2004, P NATL ACAD SCI USA, V101, P16489, DOI 10.1073/pnas.0407063101; Lavitrano M, 2002, P NATL ACAD SCI USA, V99, P14230, DOI 10.1073/pnas.222550299; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; MCCARREY JR, 1992, DEV BIOL, V154, P160, DOI 10.1016/0012-1606(92)90056-M; McCarty DM, 2004, ANNU REV GENET, V38, P819, DOI 10.1146/annurev.genet.37.110801.143717; McEvoy TG, 2003, REPRODUCTION, P167; Mehrle S, 2004, VIRUS GENES, V28, P61, DOI 10.1023/B:VIRU.0000012264.54212.f5; Nagano M, 2002, FEBS LETT, V524, P111, DOI 10.1016/S0014-5793(02)03010-7; Nagano M, 2001, P NATL ACAD SCI USA, V98, P13090, DOI 10.1073/pnas.231473498; Nagano M, 2000, FEBS LETT, V475, P7, DOI 10.1016/S0014-5793(00)01606-9; Nagano MC, 2003, BIOL REPROD, V69, P701, DOI 10.1095/biolreprod.103.016352; Nakanishi T, 1999, FEBS LETT, V449, P277, DOI 10.1016/S0014-5793(99)00433-0; NICOLSON GL, 1975, J CELL BIOL, V66, P263, DOI 10.1083/jcb.66.2.263; NISHIMUNE Y, 1978, FERTIL STERIL, V29, P95; Ogawa T, 1997, INT J DEV BIOL, V41, P111; Orwig KE, 2002, BIOL REPROD, V67, P874, DOI 10.1095/biolreprod.102.005538; Park KW, 2002, BIOL REPROD, V66, P1001, DOI 10.1095/biolreprod66.4.1001; Russell DW, 1999, BLOOD, V94, P864, DOI 10.1182/blood.V94.3.864.415k34_864_874; Ryu BY, 2007, J ANDROL, V28, P353, DOI 10.2164/jandrol.106.001511; Seisenberger G, 2001, SCIENCE, V294, P1929, DOI 10.1126/science.1064103; Shinohara T, 2000, DEV BIOL, V220, P401, DOI 10.1006/dbio.2000.9655; Srivastava A, 2002, J CELL BIOCHEM, P39, DOI 10.1002/jcb.10053; Trobridge G, 2005, HUM GENE THER, V16, P522, DOI 10.1089/hum.2005.16.522; Villuendas G, 2001, INT J ANDROL, V24, P300, DOI 10.1046/j.1365-2605.2001.00302.x; XU KP, 1993, HUM REPROD, V8, P2206, DOI 10.1093/oxfordjournals.humrep.a138004	49	59	70	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					374	382		10.1096/fj.07-8935com	http://dx.doi.org/10.1096/fj.07-8935com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17873102				2022-12-28	WOS:000252822600007
J	Leuner, K; Kazanski, V; Muller, M; Essin, K; Henke, B; Gollasch, M; Harteneck, C; Muller, WE				Leuner, Kristina; Kazanski, Victor; Mueller, Margarethe; Essin, Kirill; Henke, Bettina; Gollasch, Maik; Harteneck, Christian; Mueller, Walter E.			Hyperforin - a key constituent of St. John's wort specifically activates TRPC6 channels	FASEB JOURNAL			English	Article						calcium; neurite outgrowth	NONSELECTIVE CATION CHANNELS; NERVE GROWTH CONES; DOUBLE-BLIND; PC12 CELLS; MAJOR DEPRESSION; EXTRACT WS-5570; BRAIN; EFFICACY; MOUSE; TRIAL	Hyperforin, a bicyclic polyprenylated acylphloroglucinol derivative, is the main active principle of St. John's wort extract responsible for its antidepressive profile. Hyperforin inhibits the neuronal serotonin and norepinephrine uptake comparable to synthetic antidepressants. In contrast to synthetic antidepressants directly blocking neuronal amine uptake, hyperforin increases synaptic serotonin and norepinephrine concentrations by an indirect and yet unknown mechanism. Our attempts to identify the molecular target of hyperforin resulted in the identification of TRPC6. Hyperforin induced sodium and calcium entry as well as currents in TRPC6-expressing cells. Sodium currents and the subsequent breakdown of the membrane sodium gradients may be the rationale for the inhibition of neuronal amine uptake. The hyper-forin-induced cation entry was highly specific and related to TRPC6 and was suppressed in cells expressing a dominant negative mutant of TRPC6, whereas phylogenetically related channels, i. e., TRPC3 remained unaffected. Furthermore, hyperforin induces neuronal axonal sprouting like nerve growth factor in a TRPC6-dependent manner. These findings support the role of TRPC channels in neurite extension and identify hyperforin as the first selective pharmacological tool to study TRPC6 function. Hyperforin integrates inhibition of neurotransmitter uptake and neurotrophic property by specific activation of TRPC6 and represents an interesting lead-structure for a new class of antidepressants. -Leuner, K., Kazanski, V., Muller, M., Essin, K., Henke, B., Gollasch, M., Harteneck, C., Muller, W. E. Hyperforin -a key constituent of St. John's wort specifically activates TRPC6 channels.	Pharmakol Inst Naturwissenschaftler, Bioctr Niederursel, Frankfurt, Germany; Univ Berlin, Mol Pharmakol & Zellbiol, Berlin, Germany; Charite, Franz Volhard Clin, Max Delbruck Ctr, Sect Nephrol Intens Care, Berlin, Germany	Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Leuner, K (corresponding author), Pharmakol Inst Naturwissenschaftler, Max-von-Laue-Strasse 9, D-60438 Frankfurt, Germany.	pharmacolnat@em.uni-frankfurt.de	Friedland, Kristina/G-4651-2015	Friedland, Kristina/0000-0001-8603-5957; Muller, Werner E.G./0000-0002-8223-3689				Biber A, 1998, PHARMACOPSYCHIATRY, V31, P36, DOI 10.1055/s-2007-979344; Caraveo G, 2006, SCIENCE, V314, P122, DOI 10.1126/science.1127815; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Duman RS, 2004, BIOL PSYCHIAT, V56, P140, DOI 10.1016/j.biopsych.2004.02.033; Greka A, 2003, NAT NEUROSCI, V6, P837, DOI 10.1038/nn1092; Grimm C, 2003, J BIOL CHEM, V278, P21493, DOI 10.1074/jbc.M300945200; Harteneck C, 2005, N-S ARCH PHARMACOL, V371, pR54; Harteneck C, 2005, N-S ARCH PHARMACOL, V371, P307, DOI 10.1007/s00210-005-1034-x; Hellwig N, 2005, J CELL SCI, V118, P917, DOI 10.1242/jcs.01675; Hisatsune C, 2004, J BIOL CHEM, V279, P18887, DOI 10.1074/jbc.M311274200; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Jung S, 2003, J BIOL CHEM, V278, P3562, DOI 10.1074/jbc.M211484200; Kasper S, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-14; Keller JH, 2003, ANAL CHEM, V75, P6084, DOI 10.1021/ac034520z; KIM JY, 2006, J BIOL CHEM, V314, P122; Kraft R, 2005, PFLUG ARCH EUR J PHY, V451, P204, DOI 10.1007/s00424-005-1428-0; Kunert-Keil C, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-159; KWAN CY, 1990, J BIOL CHEM, V265, P678; Large WA, 2002, J CARDIOVASC ELECTR, V13, P493, DOI 10.1046/j.1540-8167.2002.00493.x; Lecrubier Y, 2002, AM J PSYCHIAT, V159, P1361, DOI 10.1176/appi.ajp.159.8.1361; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Li Y, 2005, NATURE, V434, P894, DOI 10.1038/nature03477; Linde K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000448.pub3; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Muller WE, 2003, PHARMACOL RES, V47, P101, DOI 10.1016/S1043-6618(02)00266-9; Mwanjewe J, 2004, BIOCHEM J, V378, P975, DOI 10.1042/BJ20031187; Ohta T, 2004, NEUROSCI LETT, V358, P161, DOI 10.1016/j.neulet.2004.01.028; Riccio A, 2002, MOL BRAIN RES, V109, P95, DOI 10.1016/S0169-328X(02)00527-2; Singer A, 1999, J PHARMACOL EXP THER, V290, P1363; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Szegedi A, 2005, BMJ-BRIT MED J, V330, P503, DOI 10.1136/bmj.38356.655266.82; Tesfai Y, 2001, BIOCHEM J, V358, P717, DOI 10.1042/0264-6021:3580717; Treiber K, 2005, BRIT J PHARMACOL, V145, P75, DOI 10.1038/sj.bjp.0706155; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Wang GX, 2005, NATURE, V434, P898, DOI 10.1038/nature03478; Williams John W Jr, 2005, BMJ, V330, pE350, DOI 10.1136/bmj.330.7500.E350; Wonnemann M, 2000, NEUROPSYCHOPHARMACOL, V23, P188, DOI 10.1016/S0893-133X(00)00102-0	39	184	190	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4101	4111		10.1096/fj.07-8110com	http://dx.doi.org/10.1096/fj.07-8110com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17666455				2022-12-28	WOS:000251283500035
J	Tang, C; Ang, BT; Pervaiz, S				Tang, Carol; Ang, Beng T.; Pervaiz, Shazib			Cancer stem cell: target for anti-cancer therapy	FASEB JOURNAL			English	Review						tumor stem cell; side population; CD133; ROS	MANGANESE SUPEROXIDE-DISMUTASE; ACUTE MYELOID-LEUKEMIA; DRUG-INDUCED APOPTOSIS; PEROXIDE-INDUCED APOPTOSIS; INTRACELLULAR REDOX STATUS; TUMOR-INITIATING CELLS; HYDROGEN-PEROXIDE; SIDE-POPULATION; PROGENITOR CELLS; PROSPECTIVE IDENTIFICATION	Cancer has long been viewed as a heterogeneous population of cells. While the great majority of cells that make up tumors are destined to differentiate, albeit aberrantly, and eventually stop dividing, only a minority population of cells, termed cancer stem cells, possess extensive self- renewal capability and can recapitulate tumor pathophysiology in an immune- compromised animal model. Tumor- initiating cells have been identified and isolated in a variety of cancers of the blood, breast, central nervous system, pancreas, skin, head and neck, colon, and prostate. In this review we present scientific evidence supporting the cancer stem cell model of tumor progression, and discuss the experimental and therapeutic implications. The concept of cancer stem cells may have profound implications for our understanding of tumor biology and for the design of novel treatments targeted toward these cells. Current therapeutic strategies include targeting the cancer stem cell as well as its microenvironmental niche. We present an interesting, novel strategy that takes into account the reactive oxygen species status in cancer stem cells and how it might serve as a method for eradicating these cells in tumor growth.	Natl Inst Neurosci, Dept Res, Singapore 308433, Singapore; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117597, Singapore; Natl Inst Neurosci, Singapore, Singapore; Singapore Inst Clin Sci, Agcy Sci Technol & Res, Singapore, Singapore; Natl Univ Singapore, NUS, Grad Sch Integrat Sci & Engn, Singapore 117548, Singapore; Singapore MIT Alliance, Singapore, Singapore; Duke NUS, Grad Sch Med, Singapore, Singapore	National Neuroscience Institute (NNI); National University of Singapore; National Neuroscience Institute (NNI); Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Institute for Clinical Sciences (SICS); National University of Singapore; Massachusetts Institute of Technology (MIT); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Singapore-MIT Alliance for Research & Technology Centre (SMART); National University of Singapore	Tang, C (corresponding author), Natl Inst Neurosci, Dept Res, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	carolt@pacific.net.sg; phssp@nus.edu.sg	Pervaiz, Shazib/C-4188-2015	Tang, Carol/0000-0002-1835-5083				Ahmad KA, 2004, CANCER RES, V64, P7867, DOI 10.1158/0008-5472.CAN-04-0648; Ahmad KA, 2003, ANN NY ACAD SCI, V1010, P365, DOI 10.1196/annals.1299.067; Akram S, 2006, CELL DEATH DIFFER, V13, P628, DOI 10.1038/sj.cdd.4401775; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Burdon RH, 1996, BIOCHEM SOC T, V24, P1028, DOI 10.1042/bst0241028; BURDON RH, 1989, FREE RADICAL RES COM, V7, P149, DOI 10.3109/10715768909087937; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Clement MV, 2003, CELL DEATH DIFFER, V10, P1273, DOI 10.1038/sj.cdd.4401302; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Cullen JJ, 2003, CANCER RES, V63, P1297; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Grichnik JM, 2006, J INVEST DERMATOL, V126, P142, DOI 10.1038/sj.jid.5700017; Hirpara JL, 2001, J BIOL CHEM, V276, P514, DOI 10.1074/jbc.M004687200; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim M, 2003, J NEUROSCI, V23, P10703; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oberley LW, 2001, ANTIOXID REDOX SIGN, V3, P461, DOI 10.1089/15230860152409095; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Pervaiz S, 2002, BIOCHEM BIOPH RES CO, V290, P1145, DOI 10.1006/bbrc.2001.6274; Pervaiz S, 2004, CURR PHARM DESIGN, V10, P1969, DOI 10.2174/1381612043384411; Pervaiz S, 2002, METHOD ENZYMOL, V352, P150; Pervaiz S, 2001, ONCOGENE, V20, P6263, DOI 10.1038/sj.onc.1204840; Pervaiz S, 1999, FEBS LETT, V459, P343, DOI 10.1016/S0014-5793(99)01258-2; Pervaiz S, 2006, CURR PHARM DESIGN, V12, P4469, DOI 10.2174/138161206779010503; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Reynolds BA, 2005, NAT METHODS, V2, P333, DOI 10.1038/nmeth758; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; SHIBANUMA M, 1988, J CELL PHYSIOL, V136, P379, DOI 10.1002/jcp.1041360224; Singec I, 2006, NAT METHODS, V3, P801, DOI 10.1038/nmeth926; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; SLAGA TJ, 1981, SCIENCE, V213, P1023, DOI 10.1126/science.6791284; Smith J, 2000, P NATL ACAD SCI USA, V97, P10032, DOI 10.1073/pnas.170209797; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Taylor MD, 2005, CANCER CELL, V8, P323, DOI 10.1016/j.ccr.2005.09.001; TRUSH MA, 1991, FREE RADICAL BIO MED, V10, P201, DOI 10.1016/0891-5849(91)90077-G; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; van Rhenen A, 2005, CLIN CANCER RES, V11, P6520, DOI 10.1158/1078-0432.CCR-05-0468; Weydert C, 2003, MOL CANCER THER, V2, P361; Woodward WA, 2007, P NATL ACAD SCI USA, V104, P618, DOI 10.1073/pnas.0606599104; Zhao YF, 2001, CANCER RES, V61, P6082; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028; SCIENCE	66	193	204	1	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3777	3785		10.1096/fj.07-8560rev	http://dx.doi.org/10.1096/fj.07-8560rev			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17625071				2022-12-28	WOS:000251283500002
J	Fujino, H; Hiramatsu, H; Tsuchiya, A; Niwa, A; Noma, H; Shiota, M; Umeda, K; Yoshimoto, M; Ito, M; Heike, T; Nakahata, T				Fujino, Hisanori; Hiramatsu, Hidefumi; Tsuchiya, Atsunori; Niwa, Akira; Noma, Haruyoshi; Shiota, Mitsutaka; Umeda, Katsutsugu; Yoshimoto, Momoko; Ito, Mamoru; Heike, Toshio; Nakahata, Tatsutoshi			Human cord blood CD34(+) cells develop into hepatocytes in the livers of NOD/SCID/gamma(null)(c) mice through cell fusion	FASEB JOURNAL			English	Article						liver regeneration; hematopoietic stem/progenitor cell; mature hepatocyte; bone marrow-derived cell	HEMATOPOIETIC STEM-CELLS; BONE-MARROW; MYELOMONOCYTIC CELLS; PROGENITOR CELLS; C-MET; DIFFERENTIATE; MOUSE; REGENERATION; RECRUITMENT; EXPRESSION	Several studies have shown that hepatocytes can be generated from hematopoietic stem cells, but this event is believed to be rare and to require hepatic damage. To investigate this phenomenon in human cells, we used a NOD/SCID/gamma(null)(c) ( NOG) mouse model that can achieve a tremendously high level of chimerism when transplanted with human hematopoietic cells. Even without hepatotoxic treatment other than irradiation, human albumin and alpha-1-antitrypsin-positive cells were invariably detected in the livers of NOG mice after i.v. transplantation of human cord blood CD34(+) cells. Human albumin was detected in the murine sera, indicating functional maturation of the human hepatocytes. Flow cytometric analysis of recipient liver cells in single-cell suspension demonstrated that human albumin-positive cells were also positive for both murine and human MHC and were negative for human CD45. PCR analysis of recipient livers revealed the expression of a wide variety of human hepatocyte- or cholangiocyte-specific mRNAs. These results show that human CD34(+) cells fuse with hepatocytes of NOG mice without liver injury, lose their hematopoietic phenotype, and begin hepatocyte-specific gene transcription. These phenomena were not observed when CD34(+) cells were transplanted. Thus, our model revealed a previously unidentified pathway of human hematopoietic stem/progenitor cell differentiation.	Kyoto Univ, Dept Pediat, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan; Cent Inst Expt Anim, Kawasaki, Kanagawa, Japan	Kyoto University	Nakahata, T (corresponding author), Kyoto Univ, Dept Pediat, Grad Sch Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	tnakaha@kuhp.kyoto-u.ac.jp	Yoshimoto, Momoko/AFP-3523-2022; Yoshimoto, Momoko/N-4238-2014	Yoshimoto, Momoko/0000-0002-7272-6682; Yoshimoto, Momoko/0000-0002-7272-6682				Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Camargo FD, 2004, J CLIN INVEST, V113, P1266, DOI 10.1172/JCI200421301; Cramer T, 2004, LIVER INT, V24, P335, DOI 10.1111/j.1478-3231.2004.0926.x; Fausto N, 2004, HEPATOLOGY, V39, P1477, DOI 10.1002/hep.20214; Harris RG, 2004, SCIENCE, V305, P90, DOI 10.1126/science.1098925; Hiramatsu H, 2003, BLOOD, V102, P873, DOI 10.1182/blood-2002-09-2755; Ishikawa F, 2003, ANN NY ACAD SCI, V996, P174, DOI 10.1111/j.1749-6632.2003.tb03245.x; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Jang YY, 2004, NAT CELL BIOL, V6, P532, DOI 10.1038/ncb1132; Kakinuma S, 2003, STEM CELLS, V21, P217, DOI 10.1634/stemcells.21-2-217; Kambe N, 2004, BLOOD, V103, P860, DOI 10.1182/blood-2003-04-1160; Kollet O, 2003, J CLIN INVEST, V112, P160, DOI 10.1172/JCI200317902; Korbling M, 2002, NEW ENGL J MED, V346, P738, DOI 10.1056/NEJMoa3461002; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Ljubimova JY, 1997, J HISTOCHEM CYTOCHEM, V45, P79, DOI 10.1177/002215549704500111; Manz MG, 2002, P NATL ACAD SCI USA, V99, P11872, DOI 10.1073/pnas.172384399; Newsome PN, 2003, GASTROENTEROLOGY, V124, P1891, DOI 10.1016/S0016-5085(03)00401-3; Ng IOL, 2003, HEPATOLOGY, V38, P989, DOI 10.1053/jhep.2003.50395; Nonome K, 2005, AM J PHYSIOL-GASTR L, V289, pG1091, DOI 10.1152/ajpgi.00049.2005; Selzner N, 2003, GASTROENTEROLOGY, V124, P692, DOI 10.1053/gast.2003.50098; Sharma AD, 2005, AM J PATHOL, V167, P555, DOI 10.1016/S0002-9440(10)62997-5; Tanabe Y, 2004, BIOCHEM BIOPH RES CO, V324, P711, DOI 10.1016/j.bbrc.2004.09.115; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; TOMITA M, 1994, HEPATOLOGY, V20, P317, DOI 10.1002/hep.1840200208; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2002, AM J PATHOL, V161, P565, DOI 10.1016/S0002-9440(10)64212-5; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wang XL, 2003, BLOOD, V101, P4201, DOI 10.1182/blood-2002-05-1338; Willenbring H, 2004, NAT MED, V10, P744, DOI 10.1038/nm1062; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	32	37	44	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3499	3510		10.1096/fj.06-6109com	http://dx.doi.org/10.1096/fj.06-6109com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17576850	Green Submitted			2022-12-28	WOS:000250517800013
J	Milgram, NW; Araujo, JA; Hagen, TM; Treadwell, BV; Ames, BN				Milgram, N. W.; Araujo, J. A.; Hagen, T. M.; Treadwell, B. V.; Ames, B. N.			Acetyl-L-carnitine and alpha-lipoic acid supplementation of aged beagle dogs improves learning in two landmark discrimination tests	FASEB JOURNAL			English	Article						LA; ALC; cognitive aging; mitochondria; visuo-spatial working memory	SHORT-TERM-MEMORY; OLD RATS; MITOCHONDRIAL DECAY; OXIDATIVE DAMAGE; DIABETIC POLYNEUROPATHY; COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; MODEL; BRAIN; DYSFUNCTION	Beagle dogs between 7.6 and 8.8 years of age administered a twice daily supplement of alpha-lipoic acid (LA) and acetyl-L-carnitine (ALC) over similar to 2 months made significantly fewer errors in reaching the learning criterion on two landmark discrimination tasks compared to controls administered a methylcellulose placebo. Testing started after a 5 day wash-in. The dogs were also tested on a variable delay version of a previously acquired spatial memory task; results were not significant. The improved performance on the landmark task of dogs supplemented with LA + ALC provides evidence of the effectiveness of this supplement in improving discrimination and allocentric spatial learning. We suggest that long-term maintenance on LA and ALC may be effective in attenuating age-associated cognitive decline by slowing the rate of mitochondrial decay and cellular aging.	CanCog Technol, Toronto, ON M5A 4K2, Canada; Univ Toronto, Div Life Sci, Scarborough, ON M1C 1A4, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON, Canada; Oregon State Univ, Linus Pauling Inst Sci & Med, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Juvenon Inc, Incline Village, NV USA; Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA; Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	University of Toronto; University Toronto Scarborough; University of Toronto; Oregon State University; University of California System; University of California Berkeley; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Milgram, NW (corresponding author), CanCog Technol, 120 Carlton St,Suite 204, Toronto, ON M5A 4K2, Canada.	milgram@psych.utoronto.ca						Adams B, 2000, BEHAV BRAIN RES, V108, P47, DOI 10.1016/S0166-4328(99)00132-1; Adams B, 2000, PROG NEURO-PSYCHOPH, V24, P675, DOI 10.1016/S0278-5846(00)00101-9; Ametov AS, 2003, DIABETES CARE, V26, P770, DOI 10.2337/diacare.26.3.770; Ando S, 2001, J NEUROSCI RES, V66, P266, DOI 10.1002/jnr.1220; BACHEVALIER J, 1991, NEUROBIOL AGING, V12, P99, DOI 10.1016/0197-4580(91)90048-O; BARTUS RT, 1978, J GERONTOL, V33, P858, DOI 10.1093/geronj/33.6.858; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; CAPRIOLI A, 1995, J GERONTOL A-BIOL, V50, pB232, DOI 10.1093/gerona/50A.4.B232; Chan ADF, 2002, BEHAV NEUROSCI, V116, P443, DOI 10.1037//0735-7044.116.3.443; Christie LA, 2005, PROG NEURO-PSYCHOPH, V29, P361, DOI 10.1016/j.pnpbp.2004.12.002; COGAN DG, 1979, AM J OPHTHALMOL, V88, P361, DOI 10.1016/0002-9394(79)90634-2; Cummings BJ, 1996, NEUROBIOL AGING, V17, P259, DOI 10.1016/0197-4580(95)02060-8; GIACCONE G, 1990, NEUROSCI LETT, V114, P178, DOI 10.1016/0304-3940(90)90068-K; Hagen TM, 1998, ANN NY ACAD SCI, V854, P214, DOI 10.1111/j.1749-6632.1998.tb09904.x; Hagen TM, 1999, FASEB J, V13, P411, DOI 10.1096/fasebj.13.2.411; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Hagen TM, 1998, P NATL ACAD SCI USA, V95, P9562, DOI 10.1073/pnas.95.16.9562; Hagen TM, 2002, P NATL ACAD SCI USA, V99, P1870, DOI 10.1073/pnas.261708898; Hagen TM, 2000, ANTIOXID REDOX SIGN, V2, P473, DOI 10.1089/15230860050192251; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; Head E, 2000, NEUROBIOL AGING, V21, P89, DOI 10.1016/S0197-4580(00)00093-2; HEAD E, 1995, BEHAV NEUROSCI, V109, P851, DOI 10.1037/0735-7044.109.5.851; Head E, 2002, J NEUROCHEM, V82, P375, DOI 10.1046/j.1471-4159.2002.00969.x; Head E, 2001, FUNCT NEUROBIOL AGIN, V2001, P457; IMPERATO A, 1991, ANN N Y ACAD SCI, V621, P90; Konrad T, 1999, DIABETES CARE, V22, P280, DOI 10.2337/diacare.22.2.280; Lieberman HR, 2006, NUTR REV, V64, pS10, DOI 10.1111/j.1753-4887.2006.tb00252.x; Liu JK, 2002, P NATL ACAD SCI USA, V99, P1876, DOI 10.1073/pnas.261709098; Liu JK, 2002, P NATL ACAD SCI USA, V99, P2356, DOI 10.1073/pnas.261709299; MARRIOTT JG, 1980, AGE, V3, P7, DOI 10.1007/BF02434999; Milgram NW, 1999, LEARN MEMORY, V6, P54; Milgram NW, 2002, NEUROBIOL AGING, V23, P737, DOI 10.1016/S0197-4580(02)00020-9; Milgram NW, 2002, NEUROSCI BIOBEHAV R, V26, P679, DOI 10.1016/S0149-7634(02)00039-8; MILGRAM NW, 1994, BEHAV NEUROSCI, V108, P57, DOI 10.1037/0735-7044.108.1.57; Montgomery SA, 2003, INT CLIN PSYCHOPHARM, V18, P61, DOI 10.1097/00004850-200303000-00001; Rapp PR, 1997, NEUROREPORT, V8, P1923, DOI 10.1097/00001756-199705260-00026; RAPP PR, 1989, J NEUROSCI, V9, P3568; Schulz R, 2006, ENCY AGING; Sharma M, 2003, EUR NEUROPSYCHOPHARM, V13, P241, DOI 10.1016/S0924-977X(03)00008-7; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Sima AAF, 2005, DIABETES CARE, V28, P89, DOI 10.2337/diacare.28.1.89; Studzinski CM, 2006, NEUROBIOL LEARN MEM, V86, P197, DOI 10.1016/j.nlm.2006.02.005; Tapp P. D, 2006, HDB MODELS HUMAN AGI, P415, DOI DOI 10.1016/B978-012369391-4/50036-9; Tapp PD, 2003, LEARN MEMORY, V10, P64, DOI 10.1101/lm.54403; Tetewsky SJ, 1999, NEUROLOGY, V52, P958, DOI 10.1212/WNL.52.5.958; WHITE HL, 1990, NEUROCHEM RES, V15, P597, DOI 10.1007/BF00973749; Yasui F, 2002, NEUROSCI LETT, V334, P177, DOI 10.1016/S0304-3940(02)01127-8; Ziegler D, 2004, DIABETIC MED, V21, P114, DOI 10.1111/j.1464-5491.2004.01109.x	48	38	40	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3756	3762		10.1096/fj.07-8531com	http://dx.doi.org/10.1096/fj.07-8531com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17622567				2022-12-28	WOS:000250517800037
J	Wrobel, S				Wrobel, Sylvia			Science, serotonin, and sadness: the biology of antidepressants - A series for the public	FASEB JOURNAL			English	Editorial Material												sylviawrobel@comcast.net							0	6	6	2	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3404	3417		10.1096/fj.07-1102ufm	http://dx.doi.org/10.1096/fj.07-1102ufm			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17967927				2022-12-28	WOS:000250517800002
J	Glauser, DA; Schlegel, W				Glauser, Dominique A.; Schlegel, Werner			Sequential actions of ERK1/2 on the AP-1 transcription factor allow temporal integration of metabolic signals in pancreatic beta cells	FASEB JOURNAL			English	Article						Langerhans islets; c-fos; protein stability; proteolysis	ACTIVATED PROTEIN-KINASE; GLUCAGON-LIKE PEPTIDE-1; C-FOS; REGULATED KINASE; GENE-EXPRESSION; GLUCOINCRETIN PEPTIDES; INSULIN-SECRETION; BINDING-PROTEIN; GLUCOSE; PHOSPHORYLATION	The AP-1 transcription factor composed of fos and jun gene products mediates transcriptional responses to hormonal and metabolic stimulations of pancreatic beta cells. Here, we investigated the mechanisms that dynamically control expression of AP-1 subunit proteins. In MIN6 cells, glucose and GLP-1 raised c-FOS protein with biphasic kinetics, an initial peak being followed by a plateau that persisted as long as stimuli were maintained. ERK1/2 activation paralleled c-FOS expression. Whereas initial induction of c-FOS protein required ERK1/2-dependent activation of c-fos transcription and de novo protein synthesis, persistent accumulation of c-FOS under sustained stimulation did not. Indeed, dependent on ERK1/2 activation, c-FOS accumulated in its hyperphosphorylated form protected from degradation through the proteasome pathway. The implication of ERK1/2 in the accumulation of c-FOS protein was confirmed in rat primary beta cells, and the functional consequences of this mechanism were demonstrated with DNA-binding and reporter assays. Altogether these findings reveal a sequential regulation of AP-1 by ERK1/2, which initially increases transcription of c-fos and, if stimulation persists, stabilizes freshly synthesized c-FOS protein to efficiently activate the transcription of AP-1-regulated genes. This ERK1/2-AP-1 module can function as a temporal integrator converting metabolic stimuli of different durations into differential transcriptional outputs.	Univ Geneva, Fdn Rech Med, CH-1211 Geneva, Switzerland	University of Geneva	Schlegel, W (corresponding author), Univ Geneva, Fdn Rech Med, Av Roseraie 64, CH-1211 Geneva, Switzerland.	werner.schlegel@medecine.unige.ch	Glauser, Dominique/B-3918-2012	Glauser, Dominique/0000-0002-3228-7304				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Acquaviva C, 2002, ANN NY ACAD SCI, V973, P426, DOI 10.1111/j.1749-6632.2002.tb04677.x; Arnette D, 2003, J BIOL CHEM, V278, P32517, DOI 10.1074/jbc.M301174200; Benes C, 1999, BIOCHEM J, V340, P219, DOI 10.1042/0264-6021:3400219; Bernal-Mizrachi E, 2001, AM J PHYSIOL-ENDOC M, V281, pE1286, DOI 10.1152/ajpendo.2001.281.6.E1286; Borge PD, 2002, DIABETES, V51, pS427, DOI 10.2337/diabetes.51.2007.S427; Briaud I, 2003, DIABETES, V52, P974, DOI 10.2337/diabetes.52.4.974; Burch PM, 2004, MOL CELL BIOL, V24, P4696, DOI 10.1128/MCB.24.11.4696-4709.2004; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen RH, 1996, ONCOGENE, V12, P1493; Coronella-Wood J, 2004, J BIOL CHEM, V279, P33567, DOI 10.1074/jbc.M404013200; Drucker DJ, 2006, CELL METAB, V3, P153, DOI 10.1016/j.cmet.2006.01.004; Fujita T, 2007, NUCLEIC ACIDS RES, V35, P1007, DOI 10.1093/nar/gkl1138; Glauser DA, 2006, NUCLEIC ACIDS RES, V34, P5175, DOI 10.1093/nar/gkl654; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hinke SA, 2004, J PHYSIOL-LONDON, V558, P369, DOI 10.1113/jphysiol.2004.064881; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Jonas JC, 2001, J BIOL CHEM, V276, P35375, DOI 10.1074/jbc.M105020200; Jones PM, 1998, ENDOCR REV, V19, P429, DOI 10.1210/er.19.4.429; Lawrence MC, 2005, J BIOL CHEM, V280, P26751, DOI 10.1074/jbc.M503158200; Lilla V, 2003, ENDOCRINOLOGY, V144, P1368, DOI 10.1210/en.2002-220916; Lin YF, 2003, DNA REPAIR, V2, P1, DOI 10.1016/S1568-7864(02)00183-0; Lingohr MK, 2002, DIABETES, V51, P966, DOI 10.2337/diabetes.51.4.966; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; Montrose-Rafizadeh C, 1999, ENDOCRINOLOGY, V140, P1132, DOI 10.1210/en.140.3.1132; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Reffas S, 2000, BIOCHEM J, V352, P701, DOI 10.1042/0264-6021:3520701; Ryser S, 2007, J BIOL CHEM, V282, P5075, DOI 10.1074/jbc.M607847200; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Schuit F, 2002, DIABETES, V51, pS326, DOI 10.2337/diabetes.51.2007.S326; Steinmetz R, 2004, MOL ENDOCRINOL, V18, P2570, DOI 10.1210/me.2004-0082; Susini S, 2000, FASEB J, V14, P128, DOI 10.1096/fasebj.14.1.128; Susini S, 1998, FASEB J, V12, P1173, DOI 10.1096/fasebj.12.12.1173; Thorens B, 1995, DIABETES METAB, V21, P311; Torres C, 2000, J CELL BIOCHEM, V80, P11; Webb GC, 2000, P NATL ACAD SCI USA, V97, P5773, DOI 10.1073/pnas.100126597; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; Yamamoto T, 2006, CURR BIOL, V16, P1171, DOI 10.1016/j.cub.2006.04.044	44	28	29	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3240	3249		10.1096/fj.06-7798com	http://dx.doi.org/10.1096/fj.06-7798com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17504975				2022-12-28	WOS:000249781600024
J	Chiti, Z; Teschemacher, AG				Chiti, Zohreh; Teschemacher, Anja G.			Exocytosis of norepinephrine at axon varicosities and neuronal cell bodies in the rat brain	FASEB JOURNAL			English	Article						brainstem; amperometry; organotypic slice culture; viral vector; neurosecretion	DENSE-CORE VESICLES; VESICULAR MONOAMINE TRANSPORTER-2; ADRENAL CHROMAFFIN CELLS; QUANTAL SIZE; TIME-COURSE; TRANSMITTER RELEASE; SYNAPTIC VESICLES; GANGLION NEURONS; SUBSTANTIA-NIGRA; DOPAMINE NEURONS	Norepinephrine secretion from central neurons was widely assumed to occur by exocytosis, but the essential characteristics of this process remained unknown. We developed an approach to study it directly by amperometry using carbon fiber microelectrodes in organotypic rat brainstem slice cultures. Noradrenergic neurons from areas A1 and A2 were fluorescently labeled by an adenoviral vector with noradrenergic-specific promoter. Quantal events, consistent with exocytotic release of norepinephrine, were registered at noradrenergic axonal varicosities as well as at cell bodies. According to their charge integrals, events were grouped into two populations. The majority ( similar to 40 fC) were compatible with full exocytotic fusion of small clear and dense core vesicles shown in previous morphometric studies. The quantal size distribution was modulated by treatment with reserpine and amitriptyline. In addition, much larger quantal events (> 1 pC) occurred at predominantly axonal release sites. The time course of signals was severalfold faster than in adrenal chromaffin cells, suggesting profound differences in the release machinery between these cell types. Tetrodotoxin eliminated the majority of events, indicating that release was partially, but not entirely, action potential driven. In conclusion, central norepinephrine release has unique characteristics, distinguishing it from those of other monoaminergic cells in periphery and brain.	Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol Heart Inst, Bristol BS8 1TD, Avon, England	University of Bristol	Teschemacher, AG (corresponding author), Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol Heart Inst, Univ Walk, Bristol BS8 1TD, Avon, England.	anja.teschemacher@bristol.ac.uk			British Heart Foundation [FS/04/003] Funding Source: Medline; Wellcome Trust Funding Source: Medline	British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome TrustEuropean Commission)		Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; Amatore C, 2005, BIOPHYS J, V88, P4411, DOI 10.1529/biophysj.104.053736; BLOOM FE, 1968, J PHARMACOL EXP THER, V159, P261; Bruns D, 2000, NEURON, V28, P205, DOI 10.1016/S0896-6273(00)00097-0; Castren E, 2005, NAT REV NEUROSCI, V6, P241, DOI 10.1038/nrn1629; Chen BT, 2001, J NEUROSCI, V21, P7841, DOI 10.1523/JNEUROSCI.21-19-07841.2001; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Colliver TL, 2000, J NEUROSCI, V20, P5276, DOI 10.1523/JNEUROSCI.20-14-05276.2000; Crivellato E, 2005, ANAT EMBRYOL, V210, P25, DOI 10.1007/s00429-005-0002-z; EGAN TM, 1983, J PHYSIOL-LONDON, V345, P477, DOI 10.1113/jphysiol.1983.sp014990; FILLENZ M, 1990, NORADRENERGIC NEURON; Finnegan JM, 1996, J NEUROCHEM, V66, P1914; Gong LW, 2003, J NEUROSCI, V23, P7917; Grabner CP, 2005, J NEUROPHYSIOL, V94, P2093, DOI 10.1152/jn.00316.2005; GROVES PM, 1980, J COMP NEUROL, V193, P853, DOI 10.1002/cne.901930403; GRUNEWALD RA, 1993, BRAIN RES REV, V18, P123, DOI 10.1016/0165-0173(93)90010-W; Huang LYM, 1996, NEURON, V17, P135, DOI 10.1016/S0896-6273(00)80287-1; Hwang DY, 2001, HUM GENE THER, V12, P1731, DOI 10.1089/104303401750476230; Jaffe EH, 1998, J NEUROSCI, V18, P3548; JANCSAR SM, 1983, BIOCHEM PHARMACOL, V32, P1569, DOI 10.1016/0006-2952(83)90329-5; JANKOWSKI JA, 1993, J BIOL CHEM, V268, P14694; Klyachko VA, 2002, NATURE, V418, P89, DOI 10.1038/nature00852; Lonergan T, 2005, PHYSIOL GENOMICS, V20, P165, DOI 10.1152/physiolgenomics.00120.2004; Ludwig M, 2005, J PHYSIOL-LONDON, V564, P515, DOI 10.1113/jphysiol.2005.083931; Mosharov EV, 2005, NAT METHODS, V2, P651, DOI 10.1038/nmeth782; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; NIRENBERG MJ, 1995, P NATL ACAD SCI USA, V92, P8773, DOI 10.1073/pnas.92.19.8773; Nirenberg MJ, 1997, SYNAPSE, V26, P194; OCONNOR DT, 1991, BRAIN RES, V567, P188, DOI 10.1016/0006-8993(91)90795-W; Olson VG, 2006, SCIENCE, V311, P1017, DOI 10.1126/science.1119311; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; Pickel VM, 1996, J NEUROCYTOL, V25, P843, DOI 10.1007/BF02284846; Pothos EN, 1998, J NEUROSCI, V18, P4106; Puopolo M, 2001, NEURON, V30, P211, DOI 10.1016/S0896-6273(01)00274-4; Rettig J, 2002, SCIENCE, V298, P781, DOI 10.1126/science.1075375; SCHROEDER TJ, 1992, ANAL CHEM, V64, P3077, DOI 10.1021/ac00048a003; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; Schulte A, 1996, ANAL CHEM, V68, P3054, DOI 10.1021/ac960210n; Singewald N, 1996, TRENDS PHARMACOL SCI, V17, P356, DOI 10.1016/S0165-6147(96)10042-0; Staal RGW, 2004, NAT NEUROSCI, V7, P341, DOI 10.1038/nn1205; Stjarne L, 2000, J AUTONOM NERV SYST, V81, P236, DOI 10.1016/S0165-1838(00)00119-3; Sulzer D, 2005, NEURON, V46, P1, DOI 10.1016/j.neuron.2005.03.013; Teschemacher AG, 2005, EXP PHYSIOL, V90, P61, DOI 10.1113/expphysiol.2004.028191; Teschemacher AG, 2005, AUTON NEUROSCI-BASIC, V117, P1, DOI 10.1016/j.autneu.2004.10.002; Teschemacher AG, 2005, ADV DRUG DELIVER REV, V57, P79, DOI 10.1016/j.addr.2004.05.004; Teschemacher AG, 2000, J NEUROSCI, V20, P4776; TESCHEMACHER AG, 2004, J PHYSL, V555, pC40; Travis ER, 1998, ANNU REV BIOPH BIOM, V27, P77, DOI 10.1146/annurev.biophys.27.1.77; Walker A, 1996, PFLUG ARCH EUR J PHY, V431, P729, DOI 10.1007/s004240050058; Walker A, 1996, PFLUG ARCH EUR J PHY, V432, P885, DOI 10.1007/s004240050212; Wightman RM, 2002, ANN NY ACAD SCI, V971, P620, DOI 10.1111/j.1749-6632.2002.tb04540.x; WIGHTMAN RM, 1995, BIOPHYS J, V68, P383, DOI 10.1016/S0006-3495(95)80199-2; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; Yamaguchi M, 1999, ANAL BIOCHEM, V270, P296, DOI 10.1006/abio.1999.4079; Zhou Z, 1996, BIOPHYS J, V70, P1543, DOI 10.1016/S0006-3495(96)79718-7; ZHOU Z, 1995, P NATL ACAD SCI USA, V92, P6938, DOI 10.1073/pnas.92.15.6938	58	35	37	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2540	2550		10.1096/fj.06-7342com	http://dx.doi.org/10.1096/fj.06-7342com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17405853				2022-12-28	WOS:000248454400028
J	Springer, ML; Banfi, A; Ye, JQ; von Degenfeld, G; Kraft, PE; Saini, SA; Kapasi, NK; Blau, HM				Springer, Matthew L.; Banfi, Andrea; Ye, Jianqin; von Degenfeld, Georges; Kraft, Peggy E.; Saini, Shereen A.; Kapasi, Neel K.; Blau, Helen M.			Localization of vascular response to VEGF is not dependent on heparin binding	FASEB JOURNAL			English	Article						angiogenesis factor; blood vessels; myoblasts; vascular endothelial growth factor A	ENDOTHELIAL GROWTH-FACTOR; MEDIATED GENE-TRANSFER; DIFFERENTIAL EXPRESSION; THERAPEUTIC ANGIOGENESIS; TUMOR ANGIOGENESIS; PRIMARY MYOBLASTS; SPLICE VARIANTS; MICE LACKING; FACTOR-A; IN-VIVO	The major vascular endothelial growth factor (VEGF) isoforms are splice variants from a single gene that differ in their extent of heparin affinity due to the absence of the heparin binding domain in the smallest isoform (mouse VEGF120, human VEGF121). A long-held assumption that has guided the use of VEGF isoforms clinically has been that their differences in heparin binding dictate their ability to diffuse through tissue, with VEGF121 moving most freely and that the distribution of recombinant VEGF would have therapeutically relevant consequences. To test this assumption, we delivered the genes encoding these isoforms by myoblast-mediated gene transfer, a means of delivering genes to highly localized sites within muscle. Surprisingly, all isoforms induced comparable extremely localized physiological effects. Significantly, irrespective of the isoform delivered, the vessels passing within several micrometers of muscle fibers expressing VEGF displayed sharply delineated changes in morphology. The induction of capillary wrapping around VEGF-producing fibers, and of vascular malformations in the muscle at high levels, did not differ among isoforms. These results indicate that heparin binding is not essential for the localization of VEGF in adult tissue and suggest that the preferential delivery of VEGF121 cDNA for clinical applications may not have a physiological basis.	Univ Calif San Francisco, Div Cardiol, Dept Med, San Francisco, CA 94143 USA; Stanford Univ, Baxter Lab Genet Pharmacol, Dept Mol Pharmacol, Stanford, CA 94305 USA; Stanford Univ, Baxter Lab Genet Pharmacol, Dept Microbiol & Immunol, Stanford, CA 94305 USA	University of California System; University of California San Francisco; Stanford University; Stanford University	Springer, ML (corresponding author), Univ Calif San Francisco, Div Cardiol, Dept Med, Box 0124,513 Parnassus Ave,Rm S1136, San Francisco, CA 94143 USA.	matt.springer@medicine.ucsf.edu	Banfi, Andrea/B-8720-2008	Banfi, Andrea/0000-0001-5737-8811	NHLBI NIH HHS [HL65572] Funding Source: Medline; NIA NIH HHS [AG009521, AG024987, AG020961] Funding Source: Medline; NIBIB NIH HHS [EB005011] Funding Source: Medline; NICHD NIH HHS [HD018179] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB005011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG009521, R01AG009521, R01AG024987, R01AG020961] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arsic N, 2003, MOL THER, V7, P450, DOI 10.1016/S1525-0016(03)00034-0; BACIC M, 1995, GROWTH FACTORS, V12, P11, DOI 10.3109/08977199509003209; Banfi A, 2002, METHOD ENZYMOL, V346, P145; Banfi Andrea, 2005, Curr Atheroscler Rep, V7, P227, DOI 10.1007/s11883-005-0011-7; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Blau HM, 2001, NAT MED, V7, P532, DOI 10.1038/87850; BOENSCH C, 1995, J BIOL CHEM, V270, P1807, DOI 10.1074/jbc.270.4.1807; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Chang DS, 2003, MOL THER, V7, P44, DOI 10.1016/S1525-0016(02)00035-7; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Dhawan J, 1996, SOMAT CELL MOLEC GEN, V22, P363, DOI 10.1007/BF02369893; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Gorski DH, 2003, J AM COLL SURGEONS, V197, P408, DOI 10.1016/S1072-7515(03)00388-0; Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000; Guo P, 2001, CANCER RES, V61, P8569; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Lee RJ, 2000, CIRCULATION, V102, P898; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925-4773(01)00601-3; Maes C, 2004, J CLIN INVEST, V113, P188, DOI 10.1172/JCI200419383; Mattot V, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000013925.19218.7B; Ng YS, 2001, DEV DYNAM, V220, P112, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D; Ozawa CR, 2004, J CLIN INVEST, V113, P516, DOI 10.1172/JCI200418420; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; Rajagopalan S, 2001, CIRCULATION, V104, P753, DOI 10.1161/hc3201.095192; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Rebar EJ, 2002, NAT MED, V8, P1427, DOI 10.1038/nm795; Robinson CJ, 2001, J CELL SCI, V114, P853; Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7; Springer ML, 2006, CURR OPIN INVEST DR, V7, P243; Springer ML, 2000, J GENE MED, V2, P279; Springer ML, 2003, MOL THER, V7, P441, DOI 10.1016/S1525-0016(03)00010-8; Springer ML, 2002, CELL MOTIL CYTOSKEL, V51, P177, DOI 10.1002/cm.10022; Springer ML, 1998, MOL CELL, V2, P549, DOI 10.1016/S1097-2765(00)80154-9; Springer ML, 1997, SOMAT CELL MOLEC GEN, V23, P203, DOI 10.1007/BF02721371; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; Stewart DJ, 2006, GENE THER, V13, P1503, DOI 10.1038/sj.gt.3302802; Takeshita S, 1996, LAB INVEST, V75, P487; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tokunaga T, 1998, BRIT J CANCER, V77, P998, DOI 10.1038/bjc.1998.164; von Degenfeld G, 2003, BRIT J PHARMACOL, V140, P620, DOI 10.1038/sj.bjp.0705492; von Degenfeld G, 2006, FASEB J, V20, P2657, DOI 10.1096/fj.06-6568fje; Whitlock PR, 2004, MOL THER, V9, P67, DOI 10.1016/j.ymthe.2003.09.014; Yuan A, 2001, J CLIN ONCOL, V19, P432, DOI 10.1200/JCO.2001.19.2.432; Zelzer E, 2002, DEVELOPMENT, V129, P1893; Zhang HT, 2000, BRIT J CANCER, V83, P63	55	16	16	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					2074	2085		10.1096/fj.06-7700com	http://dx.doi.org/10.1096/fj.06-7700com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17325231				2022-12-28	WOS:000247500300017
J	Wang, YC; Szczesna-Cordary, D; Craig, R; Diaz-Perez, Z; Guzman, G; Miller, T; Potter, JD				Wang, Yingcai; Szczesna-Cordary, Danuta; Craig, Roger; Diaz-Perez, Zoraida; Guzman, Georgianna; Miller, Todd; Potter, James D.			Fast skeletal muscle regulatory light chain is required for fast and slow skeletal muscle development	FASEB JOURNAL			English	Article						RLC-f; knock-out mouse; myofibril structure; histology	MYOSIN HEAVY-CHAIN; GROWTH-FACTOR RECEPTOR-3; INDIRECT FLIGHT-MUSCLE; GENE; EXPRESSION; HEART; CONTRACTION; DROSOPHILA; FREQUENCY; DEFICITS	In skeletal muscle, the myosin molecule contains two sets of noncovalently attached low molecular weight proteins, the regulatory (RLC) and essential (ELC) light chains. To assess the functional and developmental significance of the fast skeletal isoform of the RLC (RLC-f), the murine fast skeletal RLC gene (Mylpf) was disrupted by homologous recombination. Heterozygotes containing an intronic neo cassette (RLC-/+) had approximately one-half of the amount of the RLC-f mRNA compared to wild-type (WT) mice but their muscles were histologically normal in both adults and neonates. In contrast, homozygous mice (RLC-/+) had no RLC-f mRNA or protein and completely lacked both fast and slow skeletal muscle. This was likely due to interference with mRNA processing in the presence of the neo cassette. These RLC-f null mice died immediately after birth, presumably due to respiratory failure since their diaphragms lacked skeletal muscle. The body weight of newborn RLC-f null mice was decreased 30% compared to heterozygous or WT newborn mice. The lack of skeletal muscle formation in the null mice did not affect the development of other organs including the heart. In addition, we found that WT mice did not express the ventricular/slow skeletal RLC isoform (RLC-v/s) until after birth, while it was expressed normally in the embryonic heart. The lack of skeletal muscle formation observed in RLC-f null mice indicates the total dependence of skeletal muscle development on the presence of RLC-f during embryogenesis. This observation, along with the normal function of the RLC-v/s in the heart, implicates a coupled, diverse pathway for RLC-v/s and RLC-f during embryogenesis, where RLC-v/s is responsible for heart development and RLC-f is necessary for skeletal muscle formation. In conclusion, in this study we demonstrate that the Mylpf gene is critically important for fast and slow skeletal muscle development.	Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA USA	University of Miami; University of Massachusetts System; University of Massachusetts Worcester	Szczesna-Cordary, D (corresponding author), Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Rm 6085A RMSB,1600 NW 10th Ave, Miami, FL 33136 USA.	dszczesna@med.miami.edu; jdpotter@miami.edu			NHLBI NIH HHS [R01 HL071778-01A1, R01 HL071778-04, R01 HL071778, HL-071778] Funding Source: Medline; NIAMS NIH HHS [AR-034711, AR-45183] Funding Source: Medline; NIDDK NIH HHS [DK32520] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071778] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR034711, R01AR045183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROOKE MH, 1970, ARCH NEUROL-CHICAGO, V23, P369, DOI 10.1001/archneur.1970.00480280083010; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Chen J, 1998, J BIOL CHEM, V273, P1252, DOI 10.1074/jbc.273.2.1252; Crawford K, 2002, MOL CELL BIOL, V22, P5887, DOI 10.1128/MCB.22.16.5887-5896.2002; DEFREITAS F, 2006, BIOPHYS J, pA421; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Dickinson MH, 1997, BIOPHYS J, V73, P3122, DOI 10.1016/S0006-3495(97)78338-3; FAERMAN A, 1993, DEVELOPMENT, V118, P919; FAERMAN A, 1993, DEV DYNAM, V196, P165, DOI 10.1002/aja.1001960303; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; LEE KJ, 1992, J BIOL CHEM, V267, P15875; LOUGHNA PT, 1990, DEVELOPMENT, V109, P217; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MACERA MJ, 1992, GENOMICS, V13, P829, DOI 10.1016/0888-7543(92)90161-K; Minamisawa S, 1999, J BIOL CHEM, V274, P10066, DOI 10.1074/jbc.274.15.10066; Moore JR, 2000, BIOPHYS J, V78, P1431, DOI 10.1016/S0006-3495(00)76696-3; Morano I, 1999, J MOL MED-JMM, V77, P544, DOI 10.1007/s001099900031; PERIASAMY M, 1985, J BIOL CHEM, V260, P5856; PERIASAMY M, 1984, J BIOL CHEM, V259, P3573; Rottbauer W, 2006, CIRC RES, V99, P323, DOI 10.1161/01.RES.0000234807.16034.fe; SZCESNA D, 1996, BIOPHYS J, V70, pA380; Szczesna Danuta, 2003, Current Drug Targets - Cardiovascular & Haematological Disorders, V3, P187, DOI 10.2174/1568006033481474; Wang YC, 1999, P NATL ACAD SCI USA, V96, P4455, DOI 10.1073/pnas.96.8.4455; WARMKE J, 1992, J CELL BIOL, V119, P1523, DOI 10.1083/jcb.119.6.1523; Zhi G, 2005, P NATL ACAD SCI USA, V102, P17519, DOI 10.1073/pnas.0506846102	25	28	30	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2205	2214		10.1096/fj.06-7538com	http://dx.doi.org/10.1096/fj.06-7538com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17356007				2022-12-28	WOS:000247500300029
J	Goubern, M; Andriamihaja, M; Nubel, T; Blachier, F; Bouillaud, F				Goubern, Marc; Andriamihaja, Mireille; Nubel, Tobias; Blachier, Francois; Bouillaud, Frederic			Sulfide, the first inorganic substrate for human cells	FASEB JOURNAL			English	Article						mitochondria; oxidation; cytochrome oxidase; gut epithelium; colon	SULFATE-REDUCING BACTERIA; HYDROGEN-SULFIDE; ULCERATIVE-COLITIS; CHROMATIUM-VINOSUM; HUMAN-COLON; OXIDATIVE-PHOSPHORYLATION; QUINONE REDUCTASE; ARENICOLA-MARINA; LARGE-INTESTINE; MITOCHONDRIA	Hydrogen sulfide ( H2S) is produced inside the intestine and is known as a poison that inhibits cellular respiration at the level of cytochrome oxidase. However, sulfide is used as an energetic substrate by many photo- and chemoautotrophic bacteria and by animals such as the lugworm Arenicola marina. The concentrations of sulfide present in their habitats are comparable with those present in the human colon. Using permeabilized colonic cells to which sulfide was added by an infusion pump we show that the maximal respiratory rate of colonocyte mitochondria in presence of sulfide compares with that obtained with succinate or L- alpha-glycerophosphate. This oxidation is accompanied by mitochondrial energization. In contrast, other cell types not naturally exposed to high concentration of sulfide showed much lower oxidation rates. Mitochondria showed a very high affinity for sulfide that permits its use as an energetic substrate at low micromolar concentrations, hence, below the toxic level. However, if the supply of sulfide exceeds the oxidation rate, poisoning renders mitochondria inefficient and our data suggest that an anaerobic mechanism involving partial reversion of Krebs cycle already known in invertebrates takes place. In conclusion, this work provides additional and compelling evidence that sulfide is not only a toxic compound. According to our study, sulfide appears to be the first inorganic substrate for mammalian cells characterized thus far.-Goubern, M., Andriamihaja, M., Nubel, T., Blachier, F., Bouillaud, F. Sulfide, the first inorganic substrate for human cells.	Univ Paris 05, CNRS, UPR9078, F-75730 Paris 15, France; INRA, Ecole Prat Hautes Etud, UR909, F-78352 Jouy En Josas, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Bouillaud, F (corresponding author), Univ Paris 05, CNRS, UPR9078, Site Necker 156 Rue Vaugirard, F-75730 Paris 15, France.	bouillaud@necker.fr	Bouillaud, Frédéric R/L-3238-2017	Bouillaud, Frédéric R/0000-0002-7518-9237				Attene-Ramos MS, 2006, MOL CANCER RES, V4, P9, DOI 10.1158/1541-7786.MCR-05-0126; Bronstein M, 2000, J BACTERIOL, V182, P3336, DOI 10.1128/JB.182.12.3336-3344.2000; Cortes P, 2000, BBA-BIOENERGETICS, V1456, P67, DOI 10.1016/S0005-2728(99)00109-7; Doeller JE, 2001, J EXP BIOL, V204, P3755; Fiorucci S, 2005, GASTROENTEROLOGY, V129, P1210, DOI 10.1053/j.gastro.2005.07.060; Fiorucci S, 2006, GASTROENTEROLOGY, V131, P259, DOI 10.1053/j.gastro.2006.02.033; FLORIN T, 1991, GUT, V32, P766, DOI 10.1136/gut.32.7.766; Furne J, 2001, BIOCHEM PHARMACOL, V62, P255, DOI 10.1016/S0006-2952(01)00657-8; Gaudio E, 1999, DIGEST DIS SCI, V44, P1458, DOI 10.1023/A:1026620322859; GIBSON GR, 1988, J APPL BACTERIOL, V65, P241, DOI 10.1111/j.1365-2672.1988.tb01891.x; Griesbeck C, 2002, BIOCHEMISTRY-US, V41, P11552, DOI 10.1021/bi026032b; Grieshaber MK, 1998, ANNU REV PHYSIOL, V60, P33, DOI 10.1146/annurev.physiol.60.1.33; Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Leschelle X, 2005, BBA-GEN SUBJECTS, V1725, P201, DOI 10.1016/j.bbagen.2005.06.002; Leung FW, 2000, DIGEST DIS SCI, V45, P1472, DOI 10.1023/A:1005545128954; Levine J, 1998, AM J GASTROENTEROL, V93, P83, DOI 10.1111/j.1572-0241.1998.083_c.x; Levitt MD, 2002, J APPL PHYSIOL, V92, P1655, DOI 10.1152/japplphysiol.00907.2001; MACFARLANE GT, 1992, J APPL BACTERIOL, V72, P57, DOI 10.1111/j.1365-2672.1992.tb05187.x; Magee EA, 2000, AM J CLIN NUTR, V72, P1488; NICHOLLS P, 1975, BIOCHIM BIOPHYS ACTA, V396, P24, DOI 10.1016/0005-2728(75)90186-3; Pattaragulwanit K, 1998, ARCH MICROBIOL, V169, P434, DOI 10.1007/s002030050594; PETERSEN LC, 1977, BIOCHIM BIOPHYS ACTA, V460, P299, DOI 10.1016/0005-2728(77)90216-X; Pitcher MCL, 2000, GUT, V46, P64, DOI 10.1136/gut.46.1.64; Pitcher MCL, 1996, GUT, V39, P1, DOI 10.1136/gut.39.1.1; Pott AS, 1998, MICROBIOL-SGM, V144, P1881, DOI 10.1099/00221287-144-7-1881; POWELL MA, 1986, SCIENCE, V233, P563, DOI 10.1126/science.233.4763.563; Ramasamy S, 2006, AM J PHYSIOL-GASTR L, V291, pG288, DOI 10.1152/ajpgi.00324.2005; Reinartz M, 1998, ARCH MICROBIOL, V170, P59, DOI 10.1007/s002030050615; Roediger WEW, 1997, DIGEST DIS SCI, V42, P1571, DOI 10.1023/A:1018851723920; SVENSON A, 1980, ANAL BIOCHEM, V107, P51, DOI 10.1016/0003-2697(80)90490-X; Theissen U, 2003, MOL BIOL EVOL, V20, P1564, DOI 10.1093/molbev/msg174; Vande Weghe JG, 1999, J BIOL CHEM, V274, P13250, DOI 10.1074/jbc.274.19.13250; VIDAL H, 1988, J BIOL CHEM, V263, P9206; Volkel S, 1996, EUR J BIOCHEM, V235, P231, DOI 10.1111/j.1432-1033.1996.00231.x; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; WATT J, 1973, GUT, V14, P506, DOI 10.1136/gut.14.6.506; Yong R, 2001, COMP BIOCHEM PHYS B, V129, P129, DOI 10.1016/S1096-4959(01)00309-8; ZWEIBAUM A, 1985, J CELL PHYSIOL, V122, P21, DOI 10.1002/jcp.1041220105	40	297	310	1	47	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2007	21	8					1699	1706		10.1096/fj.06-7407com	http://dx.doi.org/10.1096/fj.06-7407com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314140				2022-12-28	WOS:000246866500011
J	Meriin, AB; Zhang, X; Alexandrov, IM; Salnikova, AB; Ter-Avanesian, MD; Chernoff, YO; Sherman, MY				Meriin, Anatoli B.; Zhang, XiaoQian; Alexandrov, Ilya M.; Salnikova, Alexandra B.; Ter-Avanesian, Michael D.; Chernoff, Yury O.; Sherman, Michael Y.			Endocytosis machinery is involved in aggregation of proteins with expanded polyglutamine domains	FASEB JOURNAL			English	Article						Huntington's disease	YEAST PSI+ PRION; SACCHAROMYCES-CEREVISIAE; MUTANT HUNTINGTIN; ACTIN CYTOSKELETON; ARP2/3 COMPLEX; BUDDING YEAST; DYNAMICS; LOCALIZATION; DEGRADATION; ASSOCIATION	The cell's failure to refold or break down abnormal polypeptides often leads to their aggregation, which could cause toxicity and various pathologies. Here we investigated cellular factors involved in protein aggregation in yeast and mammalian cells using model polypeptides containing polyglutamine domains. In yeast, a number of mutations affecting the complex responsible for formation of the endocytic vesicle reduced the aggregation. Components of the endocytic complex (EC) Sla1, Sla2, and Pan1 were seen as clusters in the polyglutamine aggregates. These proteins associate with EC at the later stages of its maturation. In contrast, Ede1 and Ent1, the elements of EC at the earlier stages, were not found in the aggregates, suggesting that late ECs are involved in polyglutamine aggregation. Indeed, stabilization of the late complexes by inhibition of actin polymerization enhanced aggregation of polypeptides with polyglutamine domains. Similarly, in mammalian cells, inhibitors of actin polymerization, as well as depletion of a mediator of actin polymerization, Arp2, strongly enhanced the aggregation. In contrast, destabilization of EC by depletion or inhibition of a scaffolding protein N-WASP effectively suppressed the aggregation. Therefore, EC appears to play a pivotal role in aggregation of cytosolic polypeptides with polyglutamine domains in both yeast and mammalian cells.-Meriin, A. B., Zhang, X., Alexandrov, I. M., Salnikova, A. B., Ter-Avanesian, M. D., Chernoff, Y. O., Sherman, M. Y. Endocytosis machinery is involved in aggregation of proteins with expanded polyglutamine domains.	Boston Univ, Sch Med, Dept Biochem, Boston, MA USA; Georgia Inst Technol, Inst Bioengn & Biosci, Atlanta, GA USA; Georgia Inst Technol, Sch Biol, Atlanta, GA USA; Cardiol Res Ctr, Moscow, Russia	Boston University; University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; National Medical Research Center of Cardiology	Sherman, MY (corresponding author), 715 Albany St K323, Boston, MA 02118 USA.	sherma1@bu.edu	Chernoff, Yury O/J-2833-2014	Meriin, Anatoli/0000-0003-0087-814X; Sherman, Michael/0000-0003-3345-073X; Chernoff, Yury/0000-0002-8934-9051				Aguilar RC, 2003, J BIOL CHEM, V278, P10737, DOI 10.1074/jbc.M211622200; Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Ayscough KR, 2004, CURR BIOL, V14, pR124, DOI 10.1016/j.cub.2004.01.021; Bailleul PA, 1999, GENETICS, V153, P81; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; Diamond MI, 2000, P NATL ACAD SCI USA, V97, P657, DOI 10.1073/pnas.97.2.657; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Gagny B, 2000, J CELL SCI, V113, P3309; Ganusova EE, 2006, MOL CELL BIOL, V26, P617, DOI 10.1128/MCB.26.2.617-629.2006; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Goehler H, 2004, MOL CELL, V15, P853, DOI 10.1016/j.molcel.2004.09.016; Gokhale KC, 2005, J BIOL CHEM, V280, P22809, DOI 10.1074/jbc.M500390200; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Kim M, 1999, NEUROSCIENCE, V89, P1159, DOI 10.1016/S0306-4522(98)00400-X; Kryndushkin DS, 2003, J BIOL CHEM, V278, P49636, DOI 10.1074/jbc.M307996200; Machesky LM, 1999, CURR OPIN CELL BIOL, V11, P117, DOI 10.1016/S0955-0674(99)80014-3; Meriin AB, 2003, MOL CELL BIOL, V23, P7554, DOI 10.1128/MCB.23.21.7554-7565.2003; Meriin AB, 2002, J CELL BIOL, V157, P997, DOI 10.1083/jcb.200112104; Meriin AB, 2001, J CELL BIOL, V153, P851, DOI 10.1083/jcb.153.4.851; Merrifield CJ, 2004, TRENDS CELL BIOL, V14, P352, DOI 10.1016/j.tcb.2004.05.008; Miki H, 2003, J BIOCHEM, V134, P309, DOI 10.1093/jb/mvg146; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Newpher TM, 2005, DEV CELL, V9, P87, DOI 10.1016/j.devcel.2005.04.014; Osherovich LZ, 2001, CELL, V106, P183, DOI 10.1016/S0092-8674(01)00440-8; Peters PJ, 2002, NAT CELL BIOL, V4, P240, DOI 10.1038/ncb761; Peterson JR, 2004, NAT STRUCT MOL BIOL, V11, P747, DOI 10.1038/nsmb796; Pollard TD, 2002, CURR OPIN STRUC BIOL, V12, P768, DOI 10.1016/S0959-440X(02)00396-2; Pollitt SK, 2003, NEURON, V40, P685, DOI 10.1016/S0896-6273(03)00697-4; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimohata T, 2002, NEUROSCI LETT, V323, P215, DOI 10.1016/S0304-3940(02)00162-3; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Smith MG, 2001, J CELL SCI, V114, P1505; Takahashi J, 2003, NEUROBIOL DIS, V13, P230, DOI 10.1016/S0969-9961(03)00080-9; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; Vidair CA, 1996, INT J HYPERTHER, V12, P681, DOI 10.3109/02656739609027676; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Webb JL, 2004, INT J BIOCHEM CELL B, V36, P2541, DOI 10.1016/j.biocel.2004.02.003; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Wigley WC, 1999, J CELL BIOL, V145, P481; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wojcik C, 1996, EUR J CELL BIOL, V71, P311; Yarar D, 2005, MOL BIOL CELL, V16, P964, DOI 10.1091/mbc.e04-09-0774	52	57	57	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1915	1925		10.1096/fj.06-6878com	http://dx.doi.org/10.1096/fj.06-6878com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17341688				2022-12-28	WOS:000246866500032
J	Kramer, OH; Muller, S; Reichardt, S; Heinzel, T				Kraemer, Oliver H.; Mueller, Sylvia; Reichardt, Sigrid; Heinzel, Thorsten			Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RAR alpha	FASEB JOURNAL			English	Article						proteasomal degradation; RLIM; siah-1; UbcH8; HDAC-inhibitor VPA	ACUTE MYELOID-LEUKEMIA; HISTONE DEACETYLASE INHIBITORS; ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; VALPROIC ACID; TRANSCRIPTIONAL REPRESSION; MAMMALIAN HOMOLOGS; N-COR; DEGRADATION; ACETYLATION	The chromosomal translocation products AML1-ETO and PML-RAR alpha contribute to the pathogenesis of leukemias. Here, we demonstrate that both AML1-ETO and PML-RAR alpha are degraded by the ubiquitin-proteasome system and that their turnover critically depends on the E2-conjugase UbcH8 and the E3-ligase SIAH-1. Contrary to its role in HDAC2 degradation, the E3-ligase RLIM does not target AML1-ETO and PML-RAR alpha for ubiquitin-dependent elimination. RLIM rather is a substrate of SLAH-1, which indicates that these E3-ligases operate in a hierarchical order. Remarkably, proteasomal degradation of leukemia fusion proteins, in addition to the block of histone deacetylase (HDAC) enzymatic activity is a consequence of HDAC-inhibitor treatment. The former requires the induction of UbcH8 expression and each of these processes might be beneficial for leukemia treatment. Our observations shed light on the mechanism determining the interplay between E2-conjugases, E3-ligases, and their substrates and suggest a strategy for utilizing the ubiquitylation machinery in a therapeutic setting.	[Kraemer, Oliver H.; Mueller, Sylvia; Reichardt, Sigrid; Heinzel, Thorsten] Univ Jena, Inst Biochem & Biophys, D-07743 Jena, Germany	Friedrich Schiller University of Jena	Kramer, OH (corresponding author), Univ Jena, Inst Biochem & Biophys, Philosophenweg 12, D-07743 Jena, Germany.	o.kraemer@uni-jena.de	Krämer, Oliver H/L-9266-2015; Heinzel, Thorsten/B-1013-2015	Krämer, Oliver H/0000-0003-3973-045X; 				Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Bug G, 2005, CANCER, V104, P2717, DOI 10.1002/cncr.21589; Bursen A, 2004, ONCOGENE, V23, P6237, DOI 10.1038/sj.onc.1207837; Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210; Driever PH, 1999, KLIN PADIATR, V211, P323, DOI 10.1055/s-2008-1043809; Fanelli M, 2004, J BIOL CHEM, V279, P5374, DOI 10.1074/jbc.M306407200; Garcia-Manero G, 2006, BLOOD, V108, P3271, DOI 10.1182/blood-2006-03-009142; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; George P, 2005, BLOOD, V105, P1768, DOI 10.1182/blood-2004-09-3413; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Gozzini A, 2003, CANCER RES, V63, P8955; Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; Hu G, 1999, MOL CELL BIOL, V19, P724; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; Kuendgen A, 2006, CANCER-AM CANCER SOC, V106, P112, DOI 10.1002/cncr.21552; Lane AA, 2003, CELL, V115, P305, DOI 10.1016/S0092-8674(03)00852-3; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Ostendorff HP, 2002, NATURE, V416, P99, DOI 10.1038/416099a; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Slack JL, 2000, ANN HEMATOL, V79, P227, DOI 10.1007/s002770050585; Sugimoto T, 2000, AM J HEMATOL, V64, P101, DOI 10.1002/(SICI)1096-8652(200006)64:2<101::AID-AJH5>3.0.CO;2-X; Tou LQ, 2004, MOL CELL BIOL, V24, P3132, DOI 10.1128/MCB.24.8.3132-3139.2004; Wheeler TC, 2002, J BIOL CHEM, V277, P10273, DOI 10.1074/jbc.M107857200; Xie Q, 2002, NATURE, V419, P167, DOI 10.1038/nature00998; Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443; Yang G, 2007, ONCOGENE, V26, P91, DOI 10.1038/sj.onc.1209760; Yeung MC, 2002, BIOTECHNIQUES, V33, P734, DOI 10.2144/02334bm03; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775; Zhao C, 2004, P NATL ACAD SCI USA, V101, P7578, DOI 10.1073/pnas.0402528101; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X; [No title captured]	44	63	66	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2008	22	5					1369	1379		10.1096/fj.06-8050com	http://dx.doi.org/10.1096/fj.06-8050com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18073335				2022-12-28	WOS:000255898700010
J	Reagan-Shaw, S; Nihal, M; Ahmad, N				Reagan-Shaw, Shannon; Nihal, Minakshi; Ahmad, Nihal			Dose translation from animal to human studies revisited	FASEB JOURNAL			English	Article						drug dose conversion; body surface area	BODY-SURFACE AREA; CHEMOTHERAPY; RESVERATROL; FORMULA; WEIGHT; ADULTS	As new drugs are developed, it is essential to appropriately translate the drug dosage from one animal species to another. A misunderstanding appears to exist regarding the appropriate method for allometric dose translations, especially when starting new animal or clinical studies. The need for education regarding appropriate translation is evident from the media response regarding some recent studies where authors have shown that resveratrol, a compound found in grapes and red wine, improves the health and life span of mice. Immediately after the online publication of these papers, the scientific community and popular press voiced concerns regarding the relevance of the dose of resveratrol used by the authors. The animal dose should not be extrapolated to a human equivalent dose (HED) by a simple conversion based on body weight, as was reported. For the more appropriate conversion of drug doses from animal studies to human studies, we suggest using the body surface area (BSA) normalization method. BSA correlates well across several mammalian species with several parameters of biology, including oxygen utilization, caloric expenditure, basal metabolism, blood volume, circulating plasma proteins, and renal function. We advocate the use of BSA as a factor when converting a dose for translation from animals to humans, especially for phase I and phase II clinical trials.	[Reagan-Shaw, Shannon; Nihal, Minakshi; Ahmad, Nihal] Univ Wisconsin, Dept Dermatol, Madison, WI 53706 USA; [Nihal, Minakshi; Ahmad, Nihal] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI USA; [Ahmad, Nihal] Univ Wisconsin, Mol Environm Toxicol Ctr, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ahmad, N (corresponding author), Univ Wisconsin, Dept Dermatol, B-25 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.	nahmad@wisc.edu	Ahmad, Nihal/AAR-4249-2021	Ahmad, Nihal/0000-0002-4239-9887				Baker SD, 2002, JNCI-J NATL CANCER I, V94, P1883, DOI 10.1093/jnci/94.24.1883; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; *CTR DRUG EV RES C, 2002, EST SAF START DOS CL; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; DuBois D, 1915, ARCH INTERN MED, V15, P868; DuBois E, 1936, BASAL METABOLISM HLT; FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; Gurney H, 2002, BRIT J CANCER, V86, P1297, DOI 10.1038/sj.bjc.6600139; Kaestner SA, 2007, CLIN ONCOL-UK, V19, P23, DOI 10.1016/j.clon.2006.10.010; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; PINKEL D, 1958, CANCER RES, V18, P853; Rubner M., 1883, Z BIOL, V19, P535; Sawyer M, 2001, INVEST NEW DRUG, V19, P171, DOI 10.1023/A:1010639201787; SCHEIN PS, 1970, CLIN PHARMACOL THER, V11, P3; Verbraecken J, 2006, METABOLISM, V55, P515, DOI 10.1016/j.metabol.2005.11.004; WADE N, 2006, NEW YORK TIMS   0927; Wang JF, 2004, EUR J APPL PHYSIOL, V92, P13, DOI 10.1007/s00421-004-1074-9; 2006, MSNBC           0927; 2007, MAYO CLIN HLTH LETT, V5, P4	20	4111	4438	32	378	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2008	22	3					659	661		10.1096/fj.07-9574LSF	http://dx.doi.org/10.1096/fj.07-9574LSF			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17942826				2022-12-28	WOS:000254143700004
J	Shultz, T; Shmuel, M; Hyman, T; Altschuler, Y				Shultz, Tamar; Shmuel, Miriam; Hyman, Tehila; Altschuler, Yoram			beta-tubulin cofactor D and ARL2 take part in apical junctional complex disassembly and abrogate epithelial structure	FASEB JOURNAL			English	Article						MDCK; tight junction; adherens junctions	PROTEIN PHOSPHATASE 2A; TIGHT JUNCTION; FOLDING COFACTORS; MICROTUBULES; ORGANIZATION; CYTOSKELETON; OCCLUDIN; LOCALIZATION; MAINTENANCE; NUCLEATION	In epithelial cells, the apical junctional complex (AJC), composed of tight junctions (TJs) and adherens junctions (AJs), maintains cell-surface polarity by forming a fence that prevents lateral movement and diffusion of proteins and lipids between the apical and basolateral PM and holds the epithelial monolayer intact through cell-cell contacts. Disassembly of this complex is a prime event in development and cell transformation. Maintenance of the AJC has been shown to involve mainly the actin cytoskeleton. Recent findings also point to the involvement of the microtubule (MT) system. Here we show the first evidence that in polarized epithelial MDCK cells, ARF-like protein 2 (ARL2) and beta-tubulin cofactor D, known to be involved in MT dynamics, have a role in disassembly of the AJC followed by cell dissociation from the epithelial monolayer, which is not dependent on MT depolymerization. In addition, we show that beta-tubulin cofactor D is partially localized to the lateral PM through its 15 C-terminal amino acids and intact MTs. ARL2 inhibited beta-tubulin cofactor D-dependent cell dissociation from the monolayer and AJC disassembly. To our knowledge, this is the first evidence that beta-tubulin cofactor D plays a role in cells independent of its presumed role in folding tubulin heterodimers. We conclude that ARL2 and beta-tubulin cofactor D participate in AJC disassembly and epithelial depolarization. -Shultz, T., Shmuel, M., Hyman, T., and Altschuler, Y. beta-tubulin cofactor D and ARL2 take part in apical junctional complex disassembly and abrogate epithelial structure.	[Shultz, Tamar; Shmuel, Miriam; Hyman, Tehila; Altschuler, Yoram] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol, Jerusalem, Israel	Hebrew University of Jerusalem	Altschuler, Y (corresponding author), Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol, Jerusalem, Israel.	yoram11@md.huji.ac.il						Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; Antoshechkin I, 2002, DEV CELL, V2, P579, DOI 10.1016/S1534-5807(02)00146-6; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; Bhamidipati A, 2000, J CELL BIOL, V149, P1087, DOI 10.1083/jcb.149.5.1087; Bowzard JB, 2005, METHOD ENZYMOL, V404, P453, DOI 10.1016/S0076-6879(05)04040-1; Capaldo CT, 2007, MOL BIOL CELL, V18, P189, DOI 10.1091/mbc.E06-05-0471; Chausovsky A, 2000, NAT CELL BIOL, V2, P797, DOI 10.1038/35041037; Chen N, 2003, NEUROSCIENCE, V120, P163, DOI 10.1016/S0306-4522(03)00259-8; Chen YH, 2002, MOL BIOL CELL, V13, P1227, DOI 10.1091/mbc.01-08-0423; Coates JC, 2003, TRENDS CELL BIOL, V13, P463, DOI 10.1016/S0962-8924(03)00167-3; Desai LP, 2004, AM J PHYSIOL-LUNG C, V287, pL1134, DOI 10.1152/ajplung.00022.2004; Dohner K, 2005, TRENDS MICROBIOL, V13, P320, DOI 10.1016/j.tim.2005.05.010; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Feldman GJ, 2005, ADV DRUG DELIVER REV, V57, P883, DOI 10.1016/j.addr.2005.01.009; GONZALEZMARISCAL L, 1990, AM J PHYSIOL, V259, pC978, DOI 10.1152/ajpcell.1990.259.6.C978; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hyman A, 1998, J CELL SCI, V111, P2077; Ivanov AI, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-12; Ivanov AI, 2004, MOL BIOL CELL, V15, P2639, DOI 10.1091/mbc.E04-02-0163; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; Kohler K, 2005, BIOL CELL, V97, P659; Lewis SA, 1997, TRENDS CELL BIOL, V7, P479, DOI 10.1016/S0962-8924(97)01168-9; Lopez-Fanarraga M, 2001, J STRUCT BIOL, V135, P219, DOI 10.1006/jsbi.2001.4386; Luton F, 2004, MOL BIOL CELL, V15, P1134, DOI 10.1091/mbc.E03-10-0751; Martin L, 2000, FEBS LETT, V470, P93, DOI 10.1016/S0014-5793(00)01293-X; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; MEADS T, 1995, CELL MOTIL CYTOSKEL, V32, P273, DOI 10.1002/cm.970320404; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; Musch A, 2004, TRAFFIC, V5, P1, DOI 10.1046/j.1600-0854.2003.00149.x; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; Nunes FD, 2006, J CELL SCI, V119, P4819, DOI 10.1242/jcs.03233; Sharma M, 2006, J BIOL CHEM, V281, P17140, DOI 10.1074/jbc.M513027200; Shern JF, 2003, J BIOL CHEM, V278, P40829, DOI 10.1074/jbc.M308678200; Steinborn K, 2002, GENE DEV, V16, P959, DOI 10.1101/gad.221702; Takahashi K, 2006, J CELL PHYSIOL, V206, P814, DOI 10.1002/jcp.20524; Tian GL, 1997, J CELL BIOL, V138, P821, DOI 10.1083/jcb.138.4.821; Tian GL, 1999, J BIOL CHEM, V274, P24054, DOI 10.1074/jbc.274.34.24054; Tzafrir I, 2002, PLANT PHYSIOL, V128, P38, DOI 10.1104/pp.010911; WANG AZ, 1990, J CELL SCI, V95, P153; Yanagisawa M, 2004, J BIOL CHEM, V279, P9512, DOI 10.1074/jbc.M310895200; Yon C, 2005, J BIOL CHEM, V280, P27412, DOI 10.1074/jbc.M501393200; Zahraoui A, 2000, J CELL BIOL, V151, pF31, DOI 10.1083/jcb.151.5.F31	43	17	20	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					168	182		10.1096/fj.06-7786com	http://dx.doi.org/10.1096/fj.06-7786com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17704193				2022-12-28	WOS:000252309900020
J	Lerner-Marmarosh, N; Miralem, T; Gibbs, PEM; Maines, MD				Lerner-Marmarosh, Nicole; Miralem, Tihomir; Gibbs, Peter E. M.; Maines, Mahin D.			Regulation of TNF-alpha-activated PKC-zeta signaling by the human biliverdin reductase: identification of activating and inhibitory domains of the reductase	FASEB JOURNAL			English	Article						heme oxygenase; protein kinase C-zeta	PROTEIN-KINASE-C; NF-KAPPA-B; HEME OXYGENASE-1; TYROSINE PHOSPHORYLATION; CRYSTAL-STRUCTURE; CELLS; INDUCTION; BILIRUBIN; TRANSCRIPTION; PURIFICATION	Human biliverdin reductase ( hBVR) is a dual function enzyme: a catalyst for bilirubin formation and a S/T/Y kinase that shares activators with protein kinase C (PKC)-zeta, including cytokines, insulin, and reactive oxygen species ( ROS). Presently, we show that hBVR increases PKC-zeta autophosphorylation, stimulation by TNF-alpha, as well as cytokine stimulation of NF-kappa B DNA binding and promoter activity. S-149 in hBVR S/T kinase domain and S-230 in (YLSF)-F-230 in hBVR's docking site for the SH2 domain of signaling proteins are phosphorylation targets of PKC-zeta. Two hBVR- based peptides, (KRNRYLSF)-F-230 (# 1) and KKRILHC281 (# 2), but not their S -> A or C -> A derivatives, respectively, blocked PKC-zeta stimulation by TNF-alpha and its membrane translocation. The C- terminal- based peptide KYCCSRK296 (# 3), enhanced PKC-zeta stimulation by TNF-alpha; for this, Lys(296) was essential. In metabolically P-32-labeled HEK293 cells transfected with hBVR or PKC-zeta, TNF-alpha increased hBVR phosphorylation. TNF-alpha did not stimulate PKC-zeta in cells infected with small interfering RNA for hBVR or transfected with hBVR with a point mutation in the nucleotide-binding loop (G(17)), S149, or S230; this was similar to the response of "kinase-dead" PKC-zeta(K281R). We suggest peptide #1 blocks PKC-zeta-docking site interaction, peptide #2 disrupts function of the PKC-zeta C1 domain, and peptide # 3 alters ATP presentation to the kinase. The findings are of potential significance for development of modulators of PKC-zeta activity and cellular response to cytokines.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Maines, MD (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, 601 Elmwood Ave, Rochester, NY 14642 USA.	mahin_maines@urmc.rochester.edu	Miralem, Tihomir/F-7576-2013	Miralem, Tihomir/0000-0001-7705-0442	NIEHS NIH HHS [ES-04066, ES-012187] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004066, R01ES012187] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; BELL JE, 1988, ARCH BIOCHEM BIOPHYS, V263, P1, DOI 10.1016/0003-9861(88)90607-8; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Cariou B, 2002, MOL CELL BIOL, V22, P6959, DOI 10.1128/MCB.22.20.6959-6970.2002; Choi AMK, 2005, AM J RESP CRIT CARE, V171, P1318, DOI 10.1164/ajrccm.171.11.953; Dulak J, 2004, ANTIOXID REDOX SIGN, V6, P858, DOI 10.1089/1523086041797980; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; FAKHRAI H, 1992, J BIOL CHEM, V267, P4023; Farese RV, 2005, EXP BIOL MED, V230, P593; GSCHWENDT M, 1991, TRENDS BIOCHEM SCI, V16, P167, DOI 10.1016/0968-0004(91)90064-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hansen TWR, 1996, PEDIATR RES, V39, P1072, DOI 10.1203/00006450-199606000-00023; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; Immenschuh S, 2006, HISTOL HISTOPATHOL, V21, P679, DOI 10.14670/HH-21.679; Kamiya A, 2004, HEPATOLOGY, V40, P527, DOI 10.1002/hep.20362; Kikuchi A, 2001, NAT STRUCT BIOL, V8, P221, DOI 10.1038/84955; Kim YB, 2003, DIABETES, V52, P1935, DOI 10.2337/diabetes.52.8.1935; Korichneva I, 2002, J BIOL CHEM, V277, P44327, DOI 10.1074/jbc.M205634200; Kravets A, 2004, J BIOL CHEM, V279, P19916, DOI 10.1074/jbc.M314251200; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lerner-Marmarosh N, 2005, P NATL ACAD SCI USA, V102, P7109, DOI 10.1073/pnas.0502173102; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Maines MD, 2007, J BIOL CHEM, V282, P8110, DOI 10.1074/jbc.M513427200; Maines MD, 2005, PHYSIOLOGY, V20, P382, DOI 10.1152/physiol.00029.2005; MAINES MD, 1993, ARCH BIOCHEM BIOPHYS, V300, P320, DOI 10.1006/abbi.1993.1044; Maines MD, 1996, EUR J BIOCHEM, V235, P372, DOI 10.1111/j.1432-1033.1996.00372.x; Mancuso C, 2004, ANTIOXID REDOX SIGN, V6, P878, DOI 10.1089/1523086041798097; Miralem T, 2005, J BIOL CHEM, V280, P17084, DOI 10.1074/jbc.M413121200; Mochly-Rosen D, 1998, FASEB J, V12, P35; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Moscat J, 2006, CELL DEATH DIFFER, V13, P702, DOI 10.1038/sj.cdd.4401823; Moscat J, 2002, ADV ENZYME REGUL, V42, P173, DOI 10.1016/S0065-2571(01)00029-2; Myers MG, 1996, MOL CELL BIOL, V16, P4147; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ohno S, 2002, J BIOCHEM, V132, P509, DOI 10.1093/oxfordjournals.jbchem.a003249; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Rahman A, 2000, AM J PHYSIOL-CELL PH, V279, pC906, DOI 10.1152/ajpcell.2000.279.4.C906; Salim M, 2001, J BIOL CHEM, V276, P10929, DOI 10.1074/jbc.M010753200; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Sheftel AD, 2007, J BIOL CHEM, V282, P10480, DOI 10.1074/jbc.M700240200; Spitaler M, 2000, J BIOL CHEM, V275, P33289, DOI 10.1074/jbc.M002742200; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Sun RH, 2005, CANCER RES, V65, P1433, DOI 10.1158/0008-5472.CAN-04-1163; Szczesna-Skorupa E, 2004, J BIOL CHEM, V279, P13953, DOI 10.1074/jbc.M312170200; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5; Whitby FG, 2002, J MOL BIOL, V319, P1199, DOI 10.1016/S0022-2836(02)00383-2; WILLIAMS B, 1993, J CLIN INVEST, V92, P2889, DOI 10.1172/JCI116911; Wooten MW, 2001, MOL CELL BIOL, V21, P8414, DOI 10.1128/MCB.21.24.8414-8427.2001; Wyatt TA, 1997, AM J PHYSIOL-LUNG C, V273, pL1007, DOI 10.1152/ajplung.1997.273.5.L1007; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033	58	38	41	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2007	21	14					3949	3962		10.1096/fj.07-8544com	http://dx.doi.org/10.1096/fj.07-8544com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17639074				2022-12-28	WOS:000251283500020
J	Zolnerciks, JK; Wooding, C; Linton, KJ				Zolnerciks, Joseph K.; Wooding, Carol; Linton, Kenneth J.			Evidence for a Sav1866-like architecture for the human multidrug transporter P-glycoprotein	FASEB JOURNAL			English	Article						ATP binding cassette transporter; drug efflux; ABC protein; MDR1; ABCB1	NUCLEOTIDE-BINDING DOMAIN; ABC-TRANSPORTER; ATP-BINDING; CATALYTIC CYCLE; ESCHERICHIA-COLI; TRANSMEMBRANE DOMAINS; CYSTIC-FIBROSIS; DRUG-BINDING; HEMOLYSIN-B; RESISTANCE	The recently reported structures of the bacterial multidrug exporter Sav1866 suggest a domain architecture in which both nucleotide- binding domains ( NBDs) of this ATP binding cassette ( ABC) transporter contact both transmembrane domains ( TMDs). Such a domain arrangement is particularly unexpected because it is not found in the structures of three solute importers BtuCD, HI1470/ 1, and ModBC from the same protein family. There is also no precedent for such an arrangement from biochemical studies with any ABC transporter. Sav1866 is homologous with the clinically relevant human P- glycoprotein ( ABCB1). If the structure proposed for Sav1866 is physiologically relevant, the long intracellular loops of P- glycoprotein TMD2 should contact NBD1. We have tested this by using cysteine mutagenesis and chemical cross- linking to verify proximal relationships of the introduced sulfhydryls across the proposed interdomain interface. We report the first biochemical evidence in support of the domain arrangement proposed for the multidrug resistance class of ABC transporters. With a domain arrangement distinctly different from the three solute importers it seems likely that the TMDs of ABC importers and exporters have evolved different mechanisms to couple to common conformational changes at conserved NBDs.	Hammersmith Hosp, Imperial Coll, MRC Clin Sci Ctr, London W12 ONN, England	Imperial College London	Linton, KJ (corresponding author), Hammersmith Hosp, Imperial Coll, MRC Clin Sci Ctr, Du Cane Rd, London W12 ONN, England.	kenneth.linton@csc.mrc.ac.uk			MRC [MC_U120088463] Funding Source: UKRI; Medical Research Council [MC_U120088463] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aleksandrov AA, 2000, J PHYSIOL-LONDON, V528, P259, DOI 10.1111/j.1469-7793.2000.00259.x; Benabdelhak H, 2005, BIOCHEM J, V386, P489, DOI 10.1042/BJ20041282; BHALLA K, 1994, LEUKEMIA, V8, P465; Blott EJ, 1999, EMBO J, V18, P6800, DOI 10.1093/emboj/18.23.6800; CHANG G, 2006, RETRACT SCI, V315, P1875; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Davidson AL, 1996, J BIOL CHEM, V271, P4858; Dawson RJP, 2007, FEBS LETT, V581, P935, DOI 10.1016/j.febslet.2007.01.073; Dawson RJP, 2006, NATURE, V443, P180, DOI 10.1038/nature05155; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Dixon PH, 2000, HUM MOL GENET, V9, P1209, DOI 10.1093/hmg/9.8.1209; Fellner S, 2002, J CLIN INVEST, V110, P1309, DOI 10.1172/JCI200215451; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Higgins CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/nsmb836; Holland IB, 2005, MOL MEMBR BIOL, V22, P29, DOI 10.1080/09687860500042013; Hollenstein K, 2007, NATURE, V446, P213, DOI 10.1038/nature05626; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Linton KJ, 2007, PFLUG ARCH EUR J PHY, V453, P555, DOI 10.1007/s00424-006-0126-x; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2005, J BIOENERG BIOMEMBR, V37, P501, DOI 10.1007/s10863-005-9499-3; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Martin C, 2000, MOL PHARMACOL, V58, P624, DOI 10.1124/mol.58.3.624; Martin C, 2003, BRIT J CANCER, V89, P1581, DOI 10.1038/sj.bjc.6601300; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Pinkett HW, 2007, SCIENCE, V315, P373, DOI 10.1126/science.1133488; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Rothnie A, 2001, EUR BIOPHYS J BIOPHY, V30, P430, DOI 10.1007/s002490100156; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; SCHINKEL AH, 1995, EUR J CANCER, V31A, P1295, DOI 10.1016/0959-8049(95)00130-B; Schmitt L, 2003, J MOL BIOL, V330, P333, DOI 10.1016/S0022-2836(03)00592-8; Seibert FS, 1997, J BIOENERG BIOMEMBR, V29, P429, DOI 10.1023/A:1022478822214; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; Stenham DR, 2003, FASEB J, V17, P2287, DOI 10.1096/fj.03-0107fje; Taylor AM, 2001, BRIT J PHARMACOL, V134, P1609, DOI 10.1038/sj.bjp.0704400; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; Verdon G, 2003, J MOL BIOL, V330, P343, DOI 10.1016/S0022-2836(03)00575-8; Yang RY, 2003, J BIOL CHEM, V278, P30764, DOI 10.1074/jbc.M304118200; Zaitseva J, 2005, BIOCHEM SOC T, V33, P990, DOI 10.1042/BST0330990; Zaitseva J, 2005, BIOCHEMISTRY-US, V44, P9680, DOI 10.1021/bi0506122; Zaitseva J, 2005, EMBO J, V24, P1901, DOI 10.1038/sj.emboj.7600657	47	100	104	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3937	3948		10.1096/fj.07-8610com	http://dx.doi.org/10.1096/fj.07-8610com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17627029				2022-12-28	WOS:000251283500019
J	Rieg, T; Bundey, RA; Chen, Y; Deschenes, G; Junger, W; Insel, PA; Vallon, V				Rieg, Timo; Bundey, Richard A.; Chen, Yu; Deschenes, George; Junger, Wolfgang; Insel, Paul A.; Vallon, Volker			Mice lacking P2Y(2) receptors have salt-resistant hypertension and facilitated renal Na+ and water reabsorption	FASEB JOURNAL			English	Article						aTP; epithelial sodium channel ENaC; vasopressin	AVP-INDEPENDENT REGULATION; MEDULLARY COLLECTING DUCT; P2 RECEPTORS; PROSTAGLANDIN E-2; EPITHELIAL-CELLS; DEHYDRATED RATS; LUMINAL P2Y(2); INNER MEDULLA; IMCD FUNCTION; MOUSE KIDNEY	Extracellular nucleotides (e. g., ATP) regulate many physiological and pathophysiological processes through activation of nucleotide (P2) receptors in the plasma membrane. Here we report that genetargeted (knockout) mice that lack P2Y(2) receptors have salt-resistant arterial hypertension in association with an inverse relationship between salt intake and heart rate, indicating intact baroreceptor function. Knockout mice have multiple alterations in their handling of salt and water: these include suppressed plasma renin and aldosterone concentrations, lower renal expression of the aldosterone-induced epithelial sodium channel alpha-ENaC, greater medullary expression of the Na-K-2Cl-cotransporter NKCC2, and greater furosemide-sensitive Na+ reabsorption in association with greater renal medullary expression of aquaporin-2 and vasopressin-dependent renal cAMP formation and water reabsorption despite similar vasopressin levels compared with wild type. Of note, smaller increases in plasma aldosterone were required to adapt renal Na+ excretion to restricted intake in knockout mice, suggesting a facilitation in renal Na+ retention. The results thus identify a previously unrecognized role for P2Y(2) receptors in blood pressure regulation that is linked to an inhibitory influence on renal Na+ and water reabsorption. Based on these findings in knockout mice, we propose that a blunting in P2Y(2) receptor expression or activity is a new mechanism for salt-resistant arterial hypertension.	Univ Calif San Diego, Dept Med, La Jolla, CA 92161 USA; Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Surg, La Jolla, CA 92093 USA; Hop Trousseau, Dept Pediat Nephrol, F-75571 Paris, France	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego; University of California System; University of California San Diego; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite	Vallon, V (corresponding author), Univ Calif San Diego, Dept Med, 3350 La Jolla Village Dr 9151, La Jolla, CA 92161 USA.	vvallon@ucsd.edu	Rieg, Timo/W-7478-2019; Junger, Wolfgang G/I-1932-2013	Rieg, Timo/0000-0001-6082-662X; Junger, Wolfgang G/0000-0003-3350-8452; deschenes, georges/0000-0002-5158-2915; Vallon, Volker/0000-0002-9211-2063	NIDDK NIH HHS [DK-28602, DK-56248] Funding Source: Medline; NIGMS NIH HHS [GM-66232] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056248, R01DK028602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066232] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akizuki N, 2001, AM J PHYSIOL-RENAL, V280, pF79, DOI 10.1152/ajprenal.2001.280.1.F79; Arthur DB, 2005, P NATL ACAD SCI USA, V102, P19138, DOI 10.1073/pnas.0505913102; Bailey MA, 2000, KIDNEY INT, V58, P1893, DOI 10.1111/j.1523-1755.2000.00361.x; Bailey MA, 2004, NEPHRON PHYSIOL, V96, P79, DOI [10.1159/000076753, DOI 10.1159/000076753]; Bonny O, 1999, J CLIN INVEST, V104, P967, DOI 10.1172/JCI6821; Buscher R, 2006, PHARMACOGENET GENOM, V16, P199; Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006; Capasso G, 2005, AM J PHYSIOL-RENAL, V288, pF1173, DOI 10.1152/ajprenal.00228.2004; CHASE LR, 1967, P NATL ACAD SCI USA, V58, P518, DOI 10.1073/pnas.58.2.518; Chen Y, 2004, J LEUKOCYTE BIOL, V76, P245, DOI 10.1189/jlb.0204066; Chen Y, 2006, SCIENCE, V314, P1792, DOI 10.1126/science.1132559; CHOU CL, 1995, AM J PHYSIOL-RENAL, V269, pF78, DOI 10.1152/ajprenal.1995.269.1.F78; Cressman VL, 1999, J BIOL CHEM, V274, P26461, DOI 10.1074/jbc.274.37.26461; Deetjen P, 2000, J AM SOC NEPHROL, V11, P1798, DOI 10.1681/ASN.V11101798; Erb L, 2006, PFLUG ARCH EUR J PHY, V452, P552, DOI 10.1007/s00424-006-0069-2; FERRANDI M, 1990, BIOCHIM BIOPHYS ACTA, V1021, P13, DOI 10.1016/0005-2736(90)90377-Z; Folkow Bjorn, 1998, Blood Pressure, V7, P133; GORDON FJ, 1983, AM J PHYSIOL, V245, pH210, DOI 10.1152/ajpheart.1983.245.2.H210; Guns PJDF, 2006, BRIT J PHARMACOL, V147, P569, DOI 10.1038/sj.bjp.0706642; GUYTON AC, 1992, HYPERTENSION, V19, pI2, DOI 10.1161/01.HYP.19.1_Suppl.I2; Hoagland KM, 2004, HYPERTENSION, V43, P860, DOI 10.1161/01.HYP.0000120123.44945.47; Homolya L, 1999, J BIOL CHEM, V274, P26454, DOI 10.1074/jbc.274.37.26454; Huang DY, 2006, AM J PHYSIOL-REG I, V290, pR935, DOI 10.1152/ajpregu.00382.2005; Huang DY, 2004, J AM SOC NEPHROL, V15, P885, DOI 10.1097/01.ASN.0000120368.59693.A8; Huang DY, 2000, N-S ARCH PHARMACOL, V362, P201, DOI 10.1007/s002100000282; Hummler E, 2005, J AM SOC NEPHROL, V16, P3160, DOI 10.1681/ASN.2005040450; Jackson EK, 2004, ANNU REV PHYSIOL, V66, P571, DOI 10.1146/annurev.physiol.66.032102.111604; Kishore BK, 2005, AM J PHYSIOL-RENAL, V288, pF1164, DOI 10.1152/ajprenal.00199.2004; Kishore BK, 1995, AM J PHYSIOL-RENAL, V269, pF863, DOI 10.1152/ajprenal.1995.269.6.F863; Kishore BK, 2000, AM J PHYSIOL-RENAL, V278, pF43, DOI 10.1152/ajprenal.2000.278.1.F43; Kunzelmann K, 2005, FASEB J, V19, P969, DOI 10.1096/fj.04-2469fje; Lehrmann H, 2002, J AM SOC NEPHROL, V13, P10, DOI 10.1681/ASN.V13110; Leipziger J, 2003, AM J PHYSIOL-RENAL, V284, pF419, DOI 10.1152/ajprenal.00075.2002; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Lu M, 2000, J GEN PHYSIOL, V116, P299, DOI 10.1085/jgp.116.2.299; Ma HP, 2002, AM J PHYSIOL-RENAL, V282, pF501, DOI 10.1152/ajprenal.00147.2001; Ma XY, 2002, AM J PHYSIOL-REG I, V283, pR1033, DOI 10.1152/ajpregu.00768.2001; MANNING CJ, 2002, HDB VIBRATIONAL SPEC, V1, P283; Matos JE, 2005, J PHYSIOL-LONDON, V564, P269, DOI 10.1113/jphysiol.2004.080002; McDonough AA, 2003, ANN NY ACAD SCI, V986, P669, DOI 10.1111/j.1749-6632.2003.tb07281.x; MIYAJIMA E, 1986, CLIN EXP HYPERTENS A, V8, P1049, DOI 10.3109/10641968609044085; NADLER SP, 1992, AM J PHYSIOL, V262, pF229, DOI 10.1152/ajprenal.1992.262.2.F229; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; Rieg T, 2005, J PHARMACOL EXP THER, V313, P403, DOI 10.1124/jpet.104.080432; Rieg T, 2007, EUR J PHARMACOL, V555, P174, DOI 10.1016/j.ejphar.2006.10.039; ROMAN RJ, 1981, AM J PHYSIOL, V241, pF53; Roman RM, 1999, AM J PHYSIOL-GASTR L, V276, pG1391, DOI 10.1152/ajpgi.1999.276.6.G1391; ROSE BD, 1986, AM J MED, V81, P1033, DOI 10.1016/0002-9343(86)90401-8; Rouch AJ, 2000, AM J PHYSIOL-RENAL, V279, pF294, DOI 10.1152/ajprenal.2000.279.2.F294; ROUSE D, 1994, AM J PHYSIOL, V267, pF289, DOI 10.1152/ajprenal.1994.267.2.F289; Rubera I, 2003, J CLIN INVEST, V112, P554, DOI 10.1172/JCI200316956; Sabirov RZ, 2004, JPN J PHYSIOL, V54, P7, DOI 10.2170/jjphysiol.54.7; Schwiebert EM, 2001, AM J PHYSIOL-RENAL, V280, pF945, DOI 10.1152/ajprenal.2001.280.6.F945; Shirley DG, 2005, AM J PHYSIOL-RENAL, V288, pF1243, DOI 10.1152/ajprenal.00152.2004; Sonalker PA, 2004, J PHARMACOL EXP THER, V311, P1052, DOI 10.1124/jpet.104.071209; Sun RJ, 2005, AM J PHYSIOL-RENAL, V289, pF585, DOI 10.1152/ajprenal.00050.2005; THORNTON RM, 1989, HYPERTENSION, V14, P518, DOI 10.1161/01.HYP.14.5.518; Unwin RJ, 2003, NEWS PHYSIOL SCI, V18, P237, DOI 10.1152/nips.01436.2003; Vallon V, 2005, P NATL ACAD SCI USA, V102, P17864, DOI 10.1073/pnas.0505860102; Vallon V, 2005, AM J PHYSIOL-REG I, V289, pR395, DOI 10.1152/ajpregu.00731.2004; VALLON V, 2003, NEPHRON PHYSIOL, V94, P1; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Welch BD, 2003, AM J PHYSIOL-RENAL, V285, pF711, DOI 10.1152/ajprenal.00096.2003	63	134	135	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3717	3726		10.1096/fj.07-8807com	http://dx.doi.org/10.1096/fj.07-8807com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17575258				2022-12-28	WOS:000250517800033
J	Gorfe, AA; Caflisch, A				Gorfe, Alemayehu A.; Caflisch, Amedeo			Ser170 controls the conformational multiplicity of the loop 166-175 in prion proteins: implication for conversion and species barrier	FASEB JOURNAL			English	Article						elk; flexibility; mouse; molecular dynamics; allosteric control	CHRONIC WASTING DISEASE; BOVINE SPONGIFORM ENCEPHALOPATHY; MOLECULAR-DYNAMICS SIMULATIONS; ROCKY-MOUNTAIN ELK; NMR STRUCTURES; MULE DEER; TRANSGENIC MICE; SCRAPIE PRION; TRANSMISSION; SUSCEPTIBILITY	The self-perpetuating conversion of cellular prion proteins (PrPC) into an aggregated beta-sheet rich conformation is associated with transmissible spongiform encephalopathies (TSE). The loop 166 -175 (L1) in PrPC, which displays sequence and structural variation among species, has been suggested to play a role in species barrier, in particular against transmission of TSE from cervids to domestic and laboratory animals. L1 is ordered in elk PrP, as well as in a mouse/elk hybrid (in which L1 of mouse is replaced by elk) but not in other species such as mice, humans, and bovine. To investigate the source and significance of L1 dynamics, we carried out explicit solvent molecular dynamics simulations (approximate to 0.5 mu s in total) of the mouse prion protein, the mouse/elk hybrid, and control simulations, in which the mouse sequence is reintroduced into the structure of the mouse/elk hybrid. We found that the flexibility of L1 correlates with the backbone dynamics of Ser170. Furthermore, L1 mobility promotes a substantial displacement of Tyr169, rupture of the Asp178-Tyr128 and Asp178-Tyr169 side chain hydrogen bonds, as well as disruption of Tyr169-Phe175 pi-stacking interaction. The simulation results go beyond the available experimental data because they highlight the dependence of this network of interactions on residue 170 and L1 plasticity.	Univ Zurich, Dept Biochem, Zurich, Switzerland	University of Zurich	Gorfe, AA (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Urey Hall,Rm 4218,MC 0365, La Jolla, CA 92093 USA.	abebe@mccammon.ucsd.edu	Caflisch, Amedeo/I-3459-2012					Alonso DOV, 2001, P NATL ACAD SCI USA, V98, P2985, DOI 10.1073/pnas.061555898; ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; Armen RS, 2004, P NATL ACAD SCI USA, V101, P11622, DOI 10.1073/pnas.0401781101; Belay ED, 2004, EMERG INFECT DIS, V10, P977, DOI 10.3201/eid1006.031082; Billeter M, 1997, P NATL ACAD SCI USA, V94, P7281, DOI 10.1073/pnas.94.14.7281; Bishop MT, 2006, LANCET NEUROL, V5, P393, DOI 10.1016/S1474-4422(06)70413-6; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; Bruce ME, 2000, NAT MED, V6, P258, DOI 10.1038/73098; Calzolai L, 2000, P NATL ACAD SCI USA, V97, P8340, DOI 10.1073/pnas.97.15.8340; Calzolai L, 2005, P NATL ACAD SCI USA, V102, P651, DOI 10.1073/pnas.0408939102; Dima RI, 2002, BIOPHYS J, V83, P1268, DOI 10.1016/S0006-3495(02)73899-X; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Eghiaian F, 2004, P NATL ACAD SCI USA, V101, P10254, DOI 10.1073/pnas.0400014101; Ferguson N, 2006, P NATL ACAD SCI USA, V103, P16248, DOI 10.1073/pnas.0607815103; Fox KA, 2006, J GEN VIROL, V87, P3451, DOI 10.1099/vir.0.81999-0; Garcia FL, 2000, P NATL ACAD SCI USA, V97, P8334, DOI 10.1073/pnas.97.15.8334; Goldmann W, 2006, J GEN VIROL, V87, P3741, DOI 10.1099/vir.0.82083-0; Gorfe AA, 2005, STRUCTURE, V13, P1487, DOI 10.1016/j.str.2005.06.015; Gorfe AA, 2002, PROTEINS, V46, P41, DOI 10.1002/prot.10027; Gossert AD, 2005, P NATL ACAD SCI USA, V102, P646, DOI 10.1073/pnas.0409008102; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Gsponer J, 2001, J MOL GRAPH MODEL, V20, P169, DOI 10.1016/S1093-3263(01)00117-6; Horiuchi M, 2001, J BIOL CHEM, V276, P15489, DOI 10.1074/jbc.M100288200; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Kuwata K, 2003, P NATL ACAD SCI USA, V100, P14790, DOI 10.1073/pnas.2433563100; Laurent M, 1998, BIOPHYS CHEM, V72, P211, DOI 10.1016/S0301-4622(98)00135-5; Lysek DA, 2005, P NATL ACAD SCI USA, V102, P640, DOI 10.1073/pnas.0408937102; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; Miller MW, 1998, J WILDLIFE DIS, V34, P532, DOI 10.7589/0090-3558-34.3.532; Miller MW, 2000, J WILDLIFE DIS, V36, P676, DOI 10.7589/0090-3558-36.4.676; Miller MW, 2002, VET REC, V151, P610, DOI 10.1136/vr.151.20.610; Miller MW, 2004, CURR TOP MICROBIOL, V284, P193; Miller MW, 2004, EMERG INFECT DIS, V10, P1003, DOI 10.3201/eid1006.040010; O'Rourke KI, 1999, J GEN VIROL, V80, P2765, DOI 10.1099/0022-1317-80-10-2765; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Raymond GJ, 2000, EMBO J, V19, P4425, DOI 10.1093/emboj/19.17.4425; Riek R, 1998, P NATL ACAD SCI USA, V95, P11667, DOI 10.1073/pnas.95.20.11667; Ronga L, 2006, CHEM BIOL DRUG DES, V68, P139, DOI 10.1111/j.1747-0285.2006.00427.x; Santini S, 2004, CELL MOL LIFE SCI, V61, P951, DOI 10.1007/s00018-003-3455-3; Scott MR, 2005, J VIROL, V79, P5259, DOI 10.1128/JVI.79.9.5259-5271.2005; Weissmann C, 1996, COLD SPRING HARB SYM, V61, P511; Williams ES, 2002, REV SCI TECH OIE, V21, P305, DOI 10.20506/rst.21.2.1340; Williams ES, 2003, REV SCI TECH OIE, V22, P145, DOI 10.20506/rst.22.1.1385; Windl O, 2005, J VIROL, V79, P14971, DOI 10.1128/JVI.79.23.14971-14975.2005; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145	51	29	30	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3279	3287		10.1096/fj.07-8292com	http://dx.doi.org/10.1096/fj.07-8292com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17522379				2022-12-28	WOS:000249781600028
J	Chen, ZS; Gu, J				Chen, Zhengshan; Gu, Jiang			Immunoglobulin G expression in carcinomas and cancer cell lines	FASEB JOURNAL			English	Article						in situ hybridization; laser microdissection	INDUCED CYTIDINE DEAMINASE; CLASS SWITCH RECOMBINATION; V(D)J RECOMBINATION; IMMUNOLOGICAL ENHANCEMENT; GERMINAL CENTER; TUMOR; AID; GENE; ANTIBODIES; CHAIN	The traditional view that immunoglobulin is produced only by differentiated B lymphocytes has been challenged as immunoglobulin genes have been found to be expressed in nonhematopoietic human cancer cells. However, this phenomenon has not been widely accepted, and knowledge about this newly discovered concept is limited. In this study, we investigated the IgG1 heavy chain (IGHG1) constant region gene and IgG protein expression in 6 cell lines, including epithelial cancer cells, and in tissues from 66 hyperplasias, adenomas, and carcinomas. We also studied the mechanism of IgG production in these cells by examining the expression of RAG1 ( recombination activating gene 1), RAG2, and AID (activation-induced cytidine deaminase). In cancer cell lines, mRNA of the IGHG1 constant region and I gamma-C gamma sterile transcript were detected by nested RT-PCR, and Ig gamma and Ig kappa proteins were detected by immunofluorescence and Western blot. In surgically resected carcinoma tissues, we detected mRNA of the IGHG1 constant region by in situ hybridization, and by laser microdissection-assisted nested RT-PCR. Ig gamma and Ig kappa proteins were detected by immunohistochemistry. The V( D)J recombination of IgH and IgL loci, the S gamma 1/2-S mu switch circle, and the expression of RAG1 and RAG2 were also found in these cancer cell lines. These data suggest that cancer cells are capable of producing IgG. Because of its potential biological and clinical significance, this phenomenon warrants further investigation.-Chen, Z. and Gu, J. Immunoglobulin G expression in carcinomas and cancer cell lines.	Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Pathol, Beijing 100083, Peoples R China	Peking University	Gu, J (corresponding author), Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Pathol, 38 Xueyuan Rd,Haidian Dist, Beijing 100083, Peoples R China.	Jianggu@bjmu.edu.cn	Chen, Zhengshan/J-7499-2014	Gu, Jiang/0000-0002-0706-8329				Babbage G, 2006, CANCER RES, V66, P3996, DOI 10.1158/0008-5472.CAN-05-3704; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Cerutti A, 2002, J IMMUNOL, V169, P6594, DOI 10.4049/jimmunol.169.11.6594; Cerutti A, 1998, J IMMUNOL, V160, P2145; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Gercel-Taylor C, 2001, GYNECOL ONCOL, V81, P71, DOI 10.1006/gyno.2000.6102; Goebel P, 2001, J EXP MED, V194, P645, DOI 10.1084/jem.194.5.645; HELLSTROM I, 1969, P NATL ACAD SCI USA, V62, P362, DOI 10.1073/pnas.62.2.362; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KALISS N, 1958, CANCER RES, V18, P992; Kimoto Y, 1998, GENE CHROMOSOME CANC, V22, P83, DOI 10.1002/(SICI)1098-2264(1998)22:1<83::AID-GCC12>3.0.CO;2-O; Liu HD, 2007, CELL SIGNAL, V19, P419, DOI 10.1016/j.cellsig.2006.07.012; Liu YJ, 1996, IMMUNITY, V4, P241, DOI 10.1016/S1074-7613(00)80432-X; Luborsky JL, 2005, AM J REPROD IMMUNOL, V54, P55, DOI 10.1111/j.1600-0897.2005.00287.x; LYNCH S, 1995, EUR J IMMUNOL, V25, P1143, DOI 10.1002/eji.1830250502; Maizels N, 2005, ANNU REV GENET, V39, P23, DOI 10.1146/annurev.genet.39.073003.110544; Margni RA, 1998, IMMUNOL REV, V163, P77, DOI 10.1111/j.1600-065X.1998.tb01189.x; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Oettinger MA, 1999, CURR OPIN CELL BIOL, V11, P325, DOI 10.1016/S0955-0674(99)80044-1; Okazaki IM, 2002, NATURE, V416, P340, DOI 10.1038/nature727; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Prehn RT, 1996, CANCER RES, V56, P937; PREHN RT, 1994, CANCER RES, V54, P908; Qiu XY, 2003, CANCER RES, V63, P6488; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Schreiber H, 2000, SEMIN CANCER BIOL, V10, P351, DOI 10.1006/scbi.2000.0331; SJOGREN HO, 1971, P NATL ACAD SCI USA, V68, P1372, DOI 10.1073/pnas.68.6.1372; Snapper CM, 1997, IMMUNITY, V6, P217, DOI 10.1016/S1074-7613(00)80324-6; SNELL GD, 1957, CANCER RES, V17, P2; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Zenclussen AC, 2001, AM J REPROD IMMUNOL, V45, P289, DOI 10.1111/j.8755-8920.2001.450504.x	35	105	116	2	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2931	2938		10.1096/fj.07-8073com	http://dx.doi.org/10.1096/fj.07-8073com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17475920				2022-12-28	WOS:000249237500033
J	Sennvik, K; Boekhoorn, K; Lasrado, R; Terwel, D; Verhaeghe, S; Korr, H; Schmitz, C; Tomiyama, T; Mori, H; Krugers, H; Joels, M; Ramakers, GJA; Lucassen, PJ; Van Leuven, F				Sennvik, Kristina; Boekhoorn, Karin; Lasrado, Reena; Terwel, Dick; Verhaeghe, Steven; Korr, Hubert; Schmitz, Christoph; Tomiyama, Takami; Mori, Hiroshi; Krugers, Harm; Joels, Marian; Ramakers, Ger J. A.; Lucassen, Paul J.; Van Leuven, Fred			Tau-4R suppresses proliferation and promotes neuronal differentiation in the hippocampus of tau knockin/knockout mice	FASEB JOURNAL			English	Article						transgenic mice; neurogenesis; cognition; primary cultures	LONG-TERM POTENTIATION; AMYLOID PRECURSOR PROTEIN; TRANSGENIC MICE; ALZHEIMERS-DISEASE; DENTATE GYRUS; CULTURED NEURONS; ISOFORMS; BRAIN; NEUROGENESIS; HYPERPHOSPHORYLATION	Differential isoform expression and phosphorylation of protein tau are believed to regulate the assembly and stabilization of microtubuli in fetal and adult neurons. To define the functions of tau in the developing and adult brain, we generated transgenic mice expressing the human tau-4R/2N (htau-4R) isoform on a murine tau null background, by a knockout/knockin approach (tau-KOKI). The main findings in these mice were the significant increases in hippocampal volume and neuronal number, which were sustained throughout adult life and paralleled by improved cognitive functioning. The increase in hippocampal size was found to be due to increased neurogenesis and neuronal survival. Proliferation and neuronal differentiation were further analyzed in primary hippocampal cultures from tau-KOKI mice, before and after htau-4R expression onset. In absence of tau, proliferation increased and both neurite and axonal outgrowth were reduced. Htau-4R expression suppressed proliferation, promoted neuronal differentiation, and restored neurite and axonal outgrowth. We suggest that the tau-4R isoform essentially contributes to hippocampal development by controlling proliferation and differentiation of neuronal precursors.	Katholieke Univ Leuven, Expt Genet Grp, Dept Human Genet, B-3000 Louvain, Belgium; Swammerdam Inst Life Sci, Neurobiol Sect, Amsterdam, Netherlands; Univ Aachen, Rhein Westfal TH Aachen, Dept Anat & Cell Biol, D-5100 Aachen, Germany; Sch Med, Dept Neurosci, Osaka, Japan; Netherlands Inst Brain Res, Amsterdam, Netherlands	KU Leuven; University of Amsterdam; RWTH Aachen University; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Van Leuven, F (corresponding author), Katholieke Univ Leuven, Expt Genet Grp, Dept Human Genet, Campus Gasthuisberg ON1-06-602, B-3000 Louvain, Belgium.	fredvl@med.kuleuven.be	Lucassen, Paul/ABA-3113-2020; Joëls, Marian/P-6415-2016	Lucassen, Paul/0000-0001-9708-9133; Verhaeghe, Sofie/0000-0002-2063-5033; Joels, Marian/0000-0002-4826-6209				Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Andorfer CA, 2000, DEV NEUROSCI-BASEL, V22, P303, DOI 10.1159/000017454; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; Boekhoorn K, 2006, J NEUROSCI, V26, P3514, DOI 10.1523/JNEUROSCI.5425-05.2006; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; Dawson HN, 2001, J CELL SCI, V114, P1179; Dewachter I, 2002, J NEUROSCI, V22, P3445; Goedert M, 1996, ANN NY ACAD SCI, V777, P121, DOI 10.1111/j.1749-6632.1996.tb34410.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Gotz J, 2004, MOL PSYCHIATR, V9, P664, DOI 10.1038/sj.mp.4001508; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; Heine VM, 2004, NEUROBIOL AGING, V25, P361, DOI 10.1016/S0197-4580(03)00090-3; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; LARCHER JC, 1992, DEV BIOL, V154, P195, DOI 10.1016/0012-1606(92)90059-P; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Levy SF, 2005, J BIOL CHEM, V280, P13520, DOI 10.1074/jbc.M413490200; Liu CWA, 1999, CELL MOTIL CYTOSKEL, V43, P232, DOI 10.1002/(SICI)1097-0169(1999)43:3<232::AID-CM6>3.0.CO;2-7; Lucassen PJ, 2004, BIOL PSYCHIAT, V55, P789, DOI 10.1016/j.biopsych.2003.12.014; Ramakers GJA, 1998, DEV BRAIN RES, V108, P205, DOI 10.1016/S0165-3806(98)00050-9; Schmitz C, 2000, EXP GERONTOL, V35, P429, DOI 10.1016/S0531-5565(00)00094-2; Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103; Spittaels K, 1999, AM J PATHOL, V155, P2153, DOI 10.1016/S0002-9440(10)65533-2; Spittaels K, 2002, NEUROSCIENCE, V113, P797, DOI 10.1016/S0306-4522(02)00236-1; STANFIELD BB, 1979, J COMP NEUROL, V185, P423, DOI 10.1002/cne.901850303; Takei Y, 2000, J CELL BIOL, V150, P989, DOI 10.1083/jcb.150.5.989; Takuma H, 2003, DEV BRAIN RES, V142, P121, DOI 10.1016/S0165-3806(03)00056-7; Terwel D, 2005, J BIOL CHEM, V280, P3963, DOI 10.1074/jbc.M409876200; Umans L, 1999, NEUROSCIENCE, V94, P315, DOI 10.1016/S0306-4522(99)00242-0; Utton MA, 2001, J BIOL CHEM, V276, P34288, DOI 10.1074/jbc.M011384200; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; Vandebroek T, 2005, BIOCHEMISTRY-US, V44, P11466, DOI 10.1021/bi0506775; WEST RW, 1993, CARCINOGENESIS, V14, P285, DOI 10.1093/carcin/14.2.285	33	51	52	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					2149	2161		10.1096/fj.06-7735com	http://dx.doi.org/10.1096/fj.06-7735com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17341679				2022-12-28	WOS:000247500300024
J	Aoudjehane, L; Podevin, P; Scatton, O; Jaffray, P; Dusanter-Fourt, I; Feldmann, G; Massault, PP; Grira, L; Bringuier, A; Dousset, B; Chouzenoux, S; Soubrane, O; Calmus, Y; Conti, F				Aoudjehane, Lynda; Podevin, Philippe; Scatton, Olivier; Jaffray, Patrick; Dusanter-Fourt, Isabelle; Feldmann, Gerard; Massault, Pierre-Philippe; Grira, Lilia; Bringuier, Annie; Dousset, Bertrand; Chouzenoux, Sandrine; Soubrane, Olivier; Calmus, Yvon; Conti, Filomena			Interleukin-4 induces human hepatocyte apoptosis through a Fas-independent pathway	FASEB JOURNAL			English	Article						liver transplantation; IL-4	HEPATITIS-C; LIVER-TRANSPLANTATION; ENDOTHELIAL-CELLS; CYTOKINE PROFILES; MAST-CELLS; T-CELLS; IL-4; EXPRESSION; GENE; ACTIVATION	IL-4 is overexpressed in liver grafts during severe recurrent hepatitis C and rejection. Hepatocyte apoptosis is involved in both these phenomena. We therefore examined the proapoptotic effect of IL-4 on HepG2 cells and human hepatocytes in vitro, together with the underlying mechanisms. We first measured IL-4 receptor expression, STAT6 activation by IL-4, and STAT6 inhibition by an anti-IL-4 antibody or by STAT6 siRNA transfection. We then focused on the pathways involved in IL-4-mediated apoptosis and the role of STAT6 activation in apoptosis initiation. The IL-4 receptor was expressed on both cell types, and STAT6 was activated by IL-4. Both anti- IL-4 and STAT-6 siRNA inhibited this activation. IL- 4 induced apoptosis of both HepG2 cells ( P = 0.008 vs. untreated control) and human hepatocytes ( P< 0.001 vs. untreated control). IL-4 reduced the mitochondrial membrane potential, activated Bid and Bax, and augmented caspase 3, 8, and 9 activity. STAT6 blockade inhibited IL-4- induced apoptosis. Expression of Fas and Fas ligand was unaffected when HepG2 cells and hepatocytes were cultured with IL-4, and Fas/ FasL pathway blockade failed to inhibit IL-4-induced apoptosis. These results show that IL-4 induces apoptosis of human hepatocytes through IL-4 receptor binding, STAT6 activation, decreased mitochondrial membrane potential, and increased caspase activation, independently of the Fas pathway. IL-4 might thus contribute to the progression of severe liver graft damage.	Hop Cochin, APHP, Serv Chirurg, F-75674 Paris 14, France; Univ Paris 05, UPRES 1833, Biol Cellulaire Lab, F-75270 Paris 06, France; Inst Cochin Genet Mol, INSERM U567, Dept Hematol, F-75014 Paris, France; Fac Xavier Bichat, INSERM U327, Biol Cellulaire Lab, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Aoudjehane, L (corresponding author), Hop Cochin, APHP, Serv Chirurg, 27 Rue Faubourg St Jacques, F-75674 Paris 14, France.	filomena.conti@cch.aphp.fr	Dusanter-Fourt, Isabelle/P-4558-2017; Soubrane, Olivier/ABB-4434-2021; Soubrane, Olivier/H-7799-2016	Dusanter-Fourt, Isabelle/0000-0002-9286-1021; Aoudjehane, lynda/0000-0003-4191-0564; Dousset, Bertrand/0000-0003-2526-7345				Bai Li, 2004, Chin J Dig Dis, V5, P175, DOI 10.1111/j.1443-9573.2004.00178.x; Bailey DP, 2004, EXP HEMATOL, V32, P52, DOI 10.1016/j.exphem.2003.10.011; Berenguer M, 2001, J HEPATOL, V35, P666, DOI 10.1016/S0168-8278(01)00179-9; Bertoletti A, 1997, GASTROENTEROLOGY, V112, P193, DOI 10.1016/S0016-5085(97)70235-X; Boleslawski E, 2004, TRANSPLANTATION, V77, P1815, DOI 10.1097/01.tp.0000129914.75547.b3; Bouton LA, 2004, EXP HEMATOL, V32, P1137, DOI 10.1016/j.exphem.2004.09.002; Chaloupka R, 1999, FEBS LETT, V462, P295, DOI 10.1016/S0014-5793(99)01538-0; Conti F, 1999, J HEPATOL, V30, P935, DOI 10.1016/S0168-8278(99)80150-0; Conti F, 2003, TRANSPLANTATION, V76, P210, DOI 10.1097/01.TP.0000067530.95852.67; CONTI F, 1995, TRANSPLANTATION, V60, P1104, DOI 10.1097/00007890-199511270-00008; Curry MP, 2004, TRANSPLANTATION, V78, P955, DOI 10.1097/01.TP.0000140927.63952.58; DELEEUW WJF, 1989, NUCLEIC ACIDS RES, V17, P10137, DOI 10.1093/nar/17.23.10137; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Ethier MF, 2005, FASEB J, V19, P154, DOI 10.1096/fj.05-4031fje; Feray C, 2004, J HEPATOL, V41, P862, DOI 10.1016/j.jhep.2004.09.002; Galka E, 2004, J SURG RES, V122, P14, DOI 10.1016/j.jss.2004.05.004; Gomez-Lechon MJ, 2004, BIOCHEM PHARMACOL, V68, P2427, DOI 10.1016/j.bcp.2004.08.028; Guillot C, 2001, J IMMUNOL, V166, P5225, DOI 10.4049/jimmunol.166.8.5225; Guiter C, 2004, BLOOD, V104, P543, DOI 10.1182/blood-2003-10-3545; Higuchi H, 2003, CURR MOL MED, V3, P483, DOI 10.2174/1566524033479528; HILLAIRE S, 1994, GASTROENTEROLOGY, V107, P781, DOI 10.1016/0016-5085(94)90127-9; Jaruga B, 2003, J IMMUNOL, V171, P3233, DOI 10.4049/jimmunol.171.6.3233; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kim J, 2003, MOL CELLS, V16, P92; Kornberg A, 2005, INT IMMUNOPHARMACOL, V5, P107, DOI 10.1016/j.intimp.2004.09.010; Kountouras J, 2003, J VIRAL HEPATITIS, V10, P335, DOI 10.1046/j.1365-2893.2003.00452.x; Lamboley C, 2000, CELL MOL BIOL, V46, P13; Lee YW, 2000, FEBS LETT, V485, P122, DOI 10.1016/S0014-5793(00)02208-0; Lee YW, 2004, MOL MED, V10, P19, DOI 10.2119/2004-00024.Lee; Li BF, 2006, HEPATOLOGY, V43, P1211, DOI 10.1002/hep.21174; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; MANGAN DF, 1992, J IMMUNOL, V148, P1812; McPartland JL, 2005, INT J EXP PATHOL, V86, P19, DOI 10.1111/j.0959-9673.2005.00411.x; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Napoli J, 1996, HEPATOLOGY, V24, P759; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Oskeritzian CA, 1999, J IMMUNOL, V163, P5105; OTHMAN SB, HEPATOLOGY, V42, pA483; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PARRY SL, 1994, J IMMUNOL, V152, P2821; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Rajashekhar G, 2003, GYNECOL ONCOL, V91, P101, DOI 10.1016/S0090-8258(03)00397-4; Ramirez F, 1996, J IMMUNOL, V156, P2406; Rippmann JF, 2005, FEBS LETT, V579, P173, DOI 10.1016/j.febslet.2004.11.071; Rivero M, 2002, AM J GASTROENTEROL, V97, P1501, DOI 10.1016/S0002-9270(02)04153-9; Rodrigues DBR, 2005, REV SOC BRAS MED TRO, V38, P483, DOI 10.1590/S0037-86822005000600007; Rudi J, 1998, J CLIN INVEST, V102, P1506, DOI 10.1172/JCI2808; Sasaki Y, 2003, CANCER RES, V63, P8145; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Shimoda M, 2004, LIVER TRANSPLANT, V10, P1478, DOI 10.1002/lt.20303; TALAL AC, 2004, TRENDS MOL MED, V10, P494; THAI NL, 1995, TRANSPLANTATION, V59, P274; van der Velden VHJ, 1998, CYTOKINE, V10, P803, DOI 10.1006/cyto.1998.0365; Vella V, 2004, J CLIN ENDOCR METAB, V89, P2880, DOI 10.1210/jc.2003-031639; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wurster AL, 2000, ONCOGENE, V19, P2577, DOI 10.1038/sj.onc.1203485; Zekry A, 2002, LIVER TRANSPLANT, V8, P292, DOI 10.1053/jlts.2002.31655; ZUBER CE, 1990, CELL IMMUNOL, V129, P329, DOI 10.1016/0008-8749(90)90209-A	60	45	47	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1433	1444		10.1096/fj.06-6319com	http://dx.doi.org/10.1096/fj.06-6319com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17283223				2022-12-28	WOS:000246117000019
J	Pescatori, M; Broccolini, A; Minetti, C; Bertini, E; Bruno, C; D'amico, A; Bernardini, C; Mirabella, M; Silvestri, G; Giglio, V; Modoni, A; Pedemonte, M; Tasca, G; Galluzzi, G; Mercuri, E; Tonali, PA; Ricci, E				Pescatori, Mario; Broccolini, Aldobrando; Minetti, Carlo; Bertini, Enrico; Bruno, Claudio; D'amico, Adele; Bernardini, Camilla; Mirabella, Massimiliano; Silvestri, Gabriella; Giglio, Vincenzo; Modoni, Anna; Pedemonte, Marina; Tasca, Giorgio; Galluzzi, Giuliana; Mercuri, Eugenio; Tonali, Pietro A.; Ricci, Enzo			Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression	FASEB JOURNAL			English	Article						microarrays; Duchenne muscular dystrophy; human disease; Wnt, Notch, and BMP signaling	DUCHENNE MUSCULAR-DYSTROPHY; MESSENGER-RNA EXPRESSION; GROWTH-FACTOR-I; SKELETAL-MUSCLE; TISSUE INHIBITORS; TRANSFORMING GROWTH-FACTOR-BETA-1; EXTRACELLULAR-MATRIX; TIME-COURSE; STEM-CELLS; TGF-BETA	Genome-wide gene expression profiling of skeletal muscle from Duchenne muscular dystrophy (DMD) patients has been used to describe muscle tissue alterations in DMD children older than 5 years. By studying the expression profile of 19 patients younger than 2 years, we describe with high resolution the gene expression signature that characterizes DMD muscle during the initial or "presymptomatic" phase of the disease. We show that in the first 2 years of the disease, DMD muscle is already set to express a distinctive gene expression pattern considerably different from the one expressed by normal, age-matched muscle. This "dystrophic" molecular signature is characterized by a coordinate induction of genes involved in the inflammatory response, extracellular matrix (ECM) remodeling and muscle regeneration, and the reduced transcription of those involved in energy metabolism. Despite the lower degree of muscle dysfunction experienced, our younger patients showed abnormal expression of most of the genes reported as differentially expressed in more advanced stages of the disease. By analyzing our patients as a time series, we provide evidence that some genes, including members of three pathways involved in morphogenetic signaling-Wnt, Notch, and BMP-are progressively induced or repressed in the natural history of DMD.	Catholic Univ, Inst Neurol, I-00184 Rome, Italy; Univ Genoa, G Gaslini Inst, Dept Pediat, Neuromuscular Dis Unit, Genoa, Italy; Bambino Gesu Childrens Hosp IRCCS, Unit Mol Med & Pathol, Rome, Italy; Catholic Univ, Inst Anat & Cell Biol, Rome, Italy; St Paolo Hosp, Div Cardiol, Civitavecchia, Italy; St Paolo Hosp, ICU, Civitavecchia, Italy; UILDM, Ctr Neuromuscular Dis, Rome, Italy; ONLUS, Don Gnocchi Fdn, Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Genoa; IRCCS Istituto Giannina Gaslini; IRCCS Bambino Gesu; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Fondazione Don Carlo Gnocchi Onlus	Pescatori, M (corresponding author), Catholic Univ, Inst Neurol, L Go A Gemeilli 8, I-00184 Rome, Italy.	m.pescatori@rm.unicatt.it; ericci@rm.unicatt.it	Broccolini, Aldobrando/ABE-1311-2021; Silvestri, Gabriella/N-6588-2013; Ricci, Enzo/AAC-4448-2020; Silvestri, Gabriella/J-8713-2018; Bertini, Enrico/ABG-1278-2020; Giglio, Vincenzo/AAA-8762-2021; Minetti, Carlo/K-4666-2018; MIRABELLA, Massimiliano/AAC-4016-2020; Bertini, Enrico/A-2284-2014; d'amico, adele/J-9203-2016; Bruno, Claudio/A-3148-2015; Tasca, Giorgio/J-5153-2018	Silvestri, Gabriella/0000-0002-1950-1468; Minetti, Carlo/0000-0002-0640-1804; MIRABELLA, Massimiliano/0000-0002-7783-114X; Bertini, Enrico/0000-0001-9276-4590; d'amico, adele/0000-0003-2438-2624; Bruno, Claudio/0000-0002-3426-2901; Tasca, Giorgio/0000-0003-0849-9144; RICCI, Enzo/0000-0003-3092-3597; Pedemonte, Marina/0000-0001-8410-6918				Arthur MJP, 1999, ALCOHOL CLIN EXP RES, V23, P940, DOI 10.1111/j.1530-0277.1999.tb04208.x; Bakay M, 2002, NEUROMUSCULAR DISORD, V12, pS125, DOI 10.1016/S0960-8966(02)00093-7; Bakay M, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-4; Balagopal P, 2006, AM J PHYSIOL-ENDOC M, V290, pE530, DOI 10.1152/ajpendo.00412.2005; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; BERNASCONI P, 1995, J CLIN INVEST, V96, P1137, DOI 10.1172/JCI118101; Bonuccelli G, 2003, AM J PATHOL, V163, P1663, DOI 10.1016/S0002-9440(10)63523-7; Broccolini A, 2004, J NEUROPATH EXP NEUR, V63, P650, DOI 10.1093/jnen/63.6.650; CHELLY J, 1990, CELL, V63, P1239, DOI 10.1016/0092-8674(90)90419-F; Chen YW, 2005, NEUROLOGY, V65, P826, DOI 10.1212/01.wnl.0000173836.09176.c4; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Combaret L, 1996, FEBS LETT, V393, P292, DOI 10.1016/0014-5793(96)00910-6; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573; Dahlqvist C, 2003, DEVELOPMENT, V130, P6089, DOI 10.1242/dev.00834; Davis E, 2004, CURR BIOL, V14, P1858, DOI 10.1016/j.cub.2004.09.079; Engvall E, 2003, FASEB J, V17, P1579, DOI 10.1096/fj.02-1215rev; Garces C, 1999, DIFFERENTIATION, V64, P103, DOI 10.1007/s002580050265; Goetsch SC, 2003, PHYSIOL GENOMICS, V14, P261, DOI 10.1152/physiolgenomics.00056.2003; Gosselin LE, 2004, MUSCLE NERVE, V30, P645, DOI 10.1002/mus.20150; Greenberg SA, 2002, NEUROLOGY, V59, P1170, DOI 10.1212/WNL.59.8.1170; GROUNDS MD, 1991, PATHOL RES PRACT, V187, P1; GU Y, 1988, NEURON, V1, P117, DOI 10.1016/0896-6273(88)90195-X; Gueders MM, 2006, EUR J PHARMACOL, V533, P133, DOI 10.1016/j.ejphar.2005.12.082; Haslett JN, 2003, NEUROGENETICS, V4, P163, DOI 10.1007/s10048-003-0148-x; Haslett JN, 2002, P NATL ACAD SCI USA, V99, P15000, DOI 10.1073/pnas.192571199; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Honke Kazuya, 1997, No To Hattatsu, V29, P13; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jackman RW, 2004, AM J PHYSIOL-CELL PH, V287, pC834, DOI 10.1152/ajpcell.00579.2003; Katoh M, 2006, INT J MOL MED, V17, P795; KOMINAMI E, 1987, AM J PATHOL, V127, P461; KORN EL, 2003, J STAT PLAN INFER, V124, P2448; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836; Lundberg I, 1995, J NEUROIMMUNOL, V63, P9, DOI 10.1016/0165-5728(95)00122-0; Matecki S, 2004, AM J PHYSIOL-REG I, V287, pR961, DOI 10.1152/ajpregu.00146.2004; Messina S, 2006, EXP NEUROL, V198, P234, DOI 10.1016/j.expneurol.2005.11.021; Messina S, 2006, AM J PATHOL, V168, P918, DOI 10.2353/ajpath.2006.050673; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; Muntoni F, 2002, NEUROMUSCULAR DISORD, V12, pS162, DOI 10.1016/S0960-8966(02)00101-3; Musaro A, 2004, P NATL ACAD SCI USA, V101, P1206, DOI 10.1073/pnas.0303792101; Musgrave DS, 2001, BONE, V28, P499, DOI 10.1016/S8756-3282(01)00413-6; NISHIO H, 1990, BRAIN DEV-JPN, V12, P390, DOI 10.1016/S0387-7604(12)80071-4; Oexle K, 2001, NEUROPEDIATRICS, V32, P123, DOI 10.1055/s-2001-16613; Okamoto O, 1999, BIOCHEM J, V337, P537, DOI 10.1042/0264-6021:3370537; Paoni NF, 2002, PHYSIOL GENOMICS, V11, P263, DOI 10.1152/physiolgenomics.00110.2002; Pavlidis P, 2002, J COMPUT BIOL, V9, P401, DOI 10.1089/10665270252935539; Pizon V, 2005, EMBO J, V24, P3781, DOI 10.1038/sj.emboj.7600842; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Porter JD, 2004, HUM MOL GENET, V13, P257, DOI 10.1093/hmg/ddh033; Porter JD, 2003, HUM MOL GENET, V12, P1813, DOI 10.1093/hmg/ddg197; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; Seale P, 2003, CELL CYCLE, V2, P418, DOI 10.4161/cc.2.5.498; Shurin GV, 2005, J IMMUNOL, V174, P5490, DOI 10.4049/jimmunol.174.9.5490; SIMON R, 2003, DESIGN ANAL DNA MICR; SIMON R, BRB ARRAY TOOLS USER, P1012; Smas CM, 1997, MOL CELL BIOL, V17, P977, DOI 10.1128/MCB.17.2.977; Spencer MJ, 2002, HUM MOL GENET, V11, P2645, DOI 10.1093/hmg/11.21.2645; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; t' Hoen PAC, 2006, PHARMACOGENOMICS, V7, P281, DOI 10.2217/14622416.7.3.281; Tagliafico E, 2004, J CELL SCI, V117, P4377, DOI 10.1242/jcs.01291; Tezak Z, 2002, J IMMUNOL, V168, P4154, DOI 10.4049/jimmunol.168.8.4154; Tidball JG, 2000, INT J BIOCHEM CELL B, V32, P1, DOI 10.1016/S1357-2725(99)00095-3; Torrente Y, 2004, J CLIN INVEST, V114, P182, DOI 10.1172/JCI200420325; von Moers A, 2005, ACTA NEUROPATHOL, V109, P285, DOI 10.1007/s00401-004-0941-0; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Winn N, 2002, COLD SPRING HARB SYM, V67, P507, DOI 10.1101/sqb.2002.67.507; YAMAZAKI M, 1994, AM J PATHOL, V144, P221; Yan Z, 2003, J BIOL CHEM, V278, P8826, DOI 10.1074/jbc.M209879200; Zanotti S, 2005, BRAIN, V128, P2546, DOI 10.1093/brain/awh635; Zhou BP, 2003, SEMIN ONCOL, V30, P38, DOI 10.1053/j.seminoncol.2003.08.006; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	76	166	169	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1210	1226		10.1096/fj.06-7285com	http://dx.doi.org/10.1096/fj.06-7285com			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17264171				2022-12-28	WOS:000245650400025
J	Jeon, JH; Kim, KY; Kim, JH; Baek, A; Cho, H; Lee, YH; Kim, JW; Kim, D; Han, SH; Lim, JS; Kim, KI; Yoon, DY; Kim, SH; Oh, GT; Kim, E; Yang, Y				Jeon, Jun Ho; Kim, Kun-Yong; Kim, Jae Hyeong; Baek, Ahmi; Cho, Hyungin; Lee, Young Ho; Kim, Jong Wan; Kim, Dohee; Han, Seung Hyun; Lim, Jong-Seok; Kim, Keun Il; Yoon, Do Young; Kim, Soo-Hyun; Oh, Goo Taeg; Kim, Eunjoon; Yang, Young			A novel adipokine CTRP1 stimulates aldosterone production	FASEB JOURNAL			English	Article						hypertension; adipocytes; obesity; CYP11B2	HUMAN ADRENOCORTICAL-CELLS; RAT ADRENAL-CORTEX; ANGIOTENSIN-II; ADIPOSE-TISSUE; MACULAR DEGENERATION; HYPERTENSION; OBESITY; PROTEIN; MECHANISMS; RECEPTORS	Complement-C1q TNF-related protein 1 (CTRP1), a member of the CTRP superfamily, is expressed at high levels in adipose tissues of obese Zucker diabetic fatty (fa/fa) rats, and CTRP1 expression is induced by proinflammatory cytokines, including TNF-alpha and IL-1 beta. In the present study, we investigated stimulation of aldosterone production by CTRP1, since it was observed that CTRP1 was specifically expressed in the zona glomerulosa of the adrenal cortex, where aldosterone is produced. Increased aldosterone production by CTRP1 in cells of the human adrenal cortical cell line H295R was dose-dependent. Expression levels of aldosterone synthase CYP11B2 were examined to investigate the molecular mechanisms by which CTRP1 enhances the production of aldosterone. The expression of CYP11B2 was greatly increased by treatment with CTRP1, as was the expression of the transcription factors NGFIB and NURR1, which play critical roles in stimulation of CYP11B2 gene expression. It was also revealed that angiotensin H-induced aldosterone production is, at least in part, mediated by the stimulation of CTRP1 secretion, not by the increase of CTRP1 mRNA transcription. In addition, the levels of CTRP1 were significantly up-regulated in hypertensive patients' serum. As CTRP1 was highly expressed in obese subjects as wen as up-regulated in hypertensive patients, CTRP1 may be a newly identified molecular link between obesity and hypertension.	[Jeon, Jun Ho; Kim, Kun-Yong; Kim, Jae Hyeong; Baek, Ahmi; Cho, Hyungin; Lim, Jong-Seok; Kim, Keun Il; Kim, Eunjoon; Yang, Young] Sookmyung Womens Univ, Dept Life Sci, Res Ctr Womens Dis, Seoul 140742, South Korea; [Lee, Young Ho] Chungnam Natl Univ, Coll Med, Dept Anat & Pathol, Taejon, South Korea; [Kim, Jong Wan; Kim, Dohee] Dankook Univ, Coll Med, Dept Internal Med, Cheonan, South Korea; [Han, Seung Hyun] Seoul Natl Univ, Sch Dent, Dept Oral Microbiol & Immunol, Seoul, South Korea; [Han, Seung Hyun] Seoul Natl Univ, Sch Dent, Dent Res Inst, Seoul, South Korea; [Yoon, Do Young; Kim, Soo-Hyun] Konkuk Univ, Dept Biosci & Biotechnol, Seoul, South Korea; [Oh, Goo Taeg] Ewha Womans Univ, Div Life & Pharmaceut Sci, Seoul, South Korea; [Kim, Kun-Yong; Kim, Eunjoon] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Sookmyung Women's University; Chungnam National University; Dankook University; Seoul National University (SNU); Seoul National University (SNU); Konkuk University; Ewha Womans University; Korea Advanced Institute of Science & Technology (KAIST)	Yang, Y (corresponding author), Sookmyung Womens Univ, Dept Life Sci, Res Ctr Womens Dis, Seoul 140742, South Korea.	yyang@sookmyung.ac.kr	KIM, KEUN IL/D-2959-2011; Oh, Goo Taeg/AAQ-9995-2021; Kim, Eunjoon/C-1566-2011	Yang, Young/0000-0003-4239-0804; Kim, Jae Hyeong/0000-0003-4675-5305; Lim, Jong-Seok/0000-0003-4024-6868				ABAYASEKARA DRE, 1989, J ENDOCRINOL, V122, P625, DOI 10.1677/joe.0.1220625; Aguilera G, 1996, ENDOCR RES, V22, P433, DOI 10.1080/07435809609043729; Bassett MH, 2004, MOL ENDOCRINOL, V18, P279, DOI 10.1210/me.2003-0005; Blume A, 2001, CURR OPIN NEPHROL HY, V10, P239, DOI 10.1097/00041552-200103000-00013; Booth RE, 2002, ADV PHYSIOL EDUC, V26, P8, DOI 10.1152/advan.00051.2001; Cherradi N, 1998, EUR J ENDOCRINOL, V139, P249, DOI 10.1530/eje.0.1390249; Cooper R, 1997, J HUM HYPERTENS, V11, P107, DOI 10.1038/sj.jhh.1000391; Ehrhart-Bornstein M, 2003, P NATL ACAD SCI USA, V100, P14211, DOI 10.1073/pnas.2336140100; Foster RH, 1997, GEN PHARMACOL, V28, P647, DOI 10.1016/S0306-3623(96)00290-X; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Ganguly A, 1998, NEW ENGL J MED, V339, P1828, DOI 10.1056/NEJM199812173392507; Goodfriend TL, 1998, ENDOCR RES, V24, P789, DOI 10.3109/07435809809032689; Goodfriend TL, 1999, OBES RES, V7, P355, DOI 10.1002/j.1550-8528.1999.tb00418.x; Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289; Jones BH, 1997, AM J PHYSIOL-REG I, V273, pR236, DOI 10.1152/ajpregu.1997.273.1.R236; Jonsson J R, 1994, Blood Press, V3, P72; Karlsson C, 1998, J CLIN ENDOCR METAB, V83, P3925, DOI 10.1210/jc.83.11.3925; Kaschina E, 2003, BLOOD PRESSURE, V12, P70, DOI 10.1080/08037050310001057; Kim KY, 2006, FEBS LETT, V580, P3953, DOI 10.1016/j.febslet.2006.06.034; Lamounier-Zepter V, 2004, HORM METAB RES, V36, P376, DOI 10.1055/s-2004-814583; Lasser G, 2006, BLOOD, V107, P423, DOI 10.1182/blood-2005-04-1425; Li JH, 2003, J BIOL CHEM, V278, P52355, DOI 10.1074/jbc.M305232200; Maeda T, 2006, J CELL PHYSIOL, V206, P537, DOI 10.1002/jcp.20493; Mitani F, 1996, ENDOCR RES, V22, P421, DOI 10.1080/07435809609043728; Ngarmukos C, 2001, AM J PHYSIOL-ENDOC M, V281, pE1122, DOI 10.1152/ajpendo.2001.281.6.E1122; Okubo S, 1997, J CLIN INVEST, V99, P855, DOI 10.1172/JCI119249; PASCOE L, 1992, P NATL ACAD SCI USA, V89, P4996, DOI 10.1073/pnas.89.11.4996; Pausova Z, 2006, CURR OPIN NEPHROL HY, V15, P173, DOI 10.1097/01.mnh.0000214775.42103.a5; Romero DG, 2004, PHYSIOL GENOMICS, V19, P106, DOI 10.1152/physiolgenomics.00097.2004; Schinner S, 2007, INT J OBESITY, V31, P864, DOI 10.1038/sj.ijo.0803508; Shu XH, 2006, HUM MOL GENET, V15, P1680, DOI 10.1093/hmg/ddl091; Stewart PM, 1999, LANCET, V353, P1341, DOI 10.1016/S0140-6736(98)06102-9; Takeda Y, 2000, HYPERTENSION, V36, P495, DOI 10.1161/01.HYP.36.4.495; TREMBLAY A, 1992, ENDOCRINOLOGY, V130, P3152, DOI 10.1210/en.130.6.3152; Unger T, 1999, J HYPERTENS, V17, P1775, DOI 10.1097/00004872-199917121-00001; Vasan RS, 2004, NEW ENGL J MED, V351, P33, DOI 10.1056/NEJMoa033263; Weigert J, 2005, FEBS LETT, V579, P5565, DOI 10.1016/j.febslet.2005.09.022	37	128	138	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1502	1511		10.1096/fj.07-9412com	http://dx.doi.org/10.1096/fj.07-9412com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18171693				2022-12-28	WOS:000255898700022
J	Shirokova, E; Raguse, JD; Meyerhof, W; Krautwurst, D				Shirokova, Elena; Raguse, Jan Dirk; Meyerhof, Wolfgang; Krautwurst, Dietmar			The human vomeronasal type-1 receptor family - detection of volatiles and cAMP signaling in HeLa/Olf cells	FASEB JOURNAL			English	Article						pheromones; key aroma volatiles; G protein	PUTATIVE PHEROMONE RECEPTORS; MULTIGENE FAMILY; OLFACTORY RECEPTORS; ADENYLYL-CYCLASE; SOCIAL SIGNALS; GENES; IDENTIFICATION; ACTIVATION; EXPRESSION; ODORANT	The human genome harbors 5 remnant genes coding for vomeronasal type-1 receptors, compared with 187 of such receptors in mice. In rodents, vomeronasal type-1 receptors are typically expressed in the vomeronasal organ. They are believed to be highly selective and sensitive pheromone detectors, as may be inferred from one receptor, V1rb2, responding to picomolar concentrations of the mouse pheromone 2-heptanone. Expression patterns, ligands, and signal transduction of human vomeronasal type-1 receptors have, however, remained largely obscure. Our aim was to deorphan and functionally characterize these 5 putative human pheromone receptors. Here, we report functional expression for all 5 receptors in HeLa/Olf cells. The recombinant, N-terminally tagged receptors expressed at the plasma membrane of HeLa/Olf cells and responded differentially to 19 of 140 odorants in a combinatorial way. C9-C10 aliphatic alcohols or aldehydes emerged as the best agonists at submicromolar concentrations above human odorant thresholds. Surprisingly, and in contrast to mouse V1rb2, all human vomeronasal type-1 receptors activated cAMP signaling via G protein alpha olf, when expressed in HeLa/Olf cells. While a biological function of human vomeronasal type-1 receptors is still elusive, our data show that their major functional characteristics are similar to those of odorant receptors.	[Shirokova, Elena; Meyerhof, Wolfgang; Krautwurst, Dietmar] German Inst Human Nutr Potsdam Rehbrucke, Dept Mol Genet, D-14558 Nuthetal, Germany; [Raguse, Jan Dirk] Charite, Clin Oral & Maxillofacial Surg & Plast Surg, D-13353 Berlin, Germany	Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Krautwurst, D (corresponding author), German Inst Human Nutr Potsdam Rehbrucke, Dept Mol Genet, Arthur Scheunert Allee 114-116, D-14558 Nuthetal, Germany.	dietmark@dife.de	Krautwurst, Dietmar/AAD-5579-2019	Krautwurst, Dietmar/0000-0002-3350-8682				Belluscio L, 1999, CELL, V97, P209, DOI 10.1016/S0092-8674(00)80731-X; Berghard A, 1996, P NATL ACAD SCI USA, V93, P2365, DOI 10.1073/pnas.93.6.2365; Bergstrom L, 1996, ASTROPART PHYS, V5, P263, DOI 10.1016/0927-6505(96)00027-8; Bernier UR, 2000, ANAL CHEM, V72, P747, DOI 10.1021/ac990963k; Boschat C, 2002, NAT NEUROSCI, V5, P1261, DOI 10.1038/nn978; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buettner A, 2001, J AGR FOOD CHEM, V49, P2387, DOI 10.1021/jf001363l; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Gaillard I, 2002, EUR J NEUROSCI, V15, P409, DOI 10.1046/j.0953-816x.2001.01871.x; Halpern M, 2003, PROG NEUROBIOL, V70, P245, DOI 10.1016/S0301-0082(03)00103-5; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Insel PA, 2003, CELL MOL NEUROBIOL, V23, P305, DOI 10.1023/A:1023684503883; Karunadasa DK, 2006, EUR J NEUROSCI, V23, P2563, DOI 10.1111/j.1460-9568.2006.04795.x; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Krieger J, 1999, J BIOL CHEM, V274, P4655, DOI 10.1074/jbc.274.8.4655; Leinders-Zufall T, 2004, SCIENCE, V306, P1033, DOI 10.1126/science.1102818; Leinders-Zufall T, 2000, NATURE, V405, P792, DOI 10.1038/35015572; Liberles SD, 2006, NATURE, V442, P645, DOI 10.1038/nature05066; Lin DY, 2005, NATURE, V434, P470, DOI 10.1038/nature03414; Lucas P, 2003, NEURON, V40, P551, DOI 10.1016/S0896-6273(03)00675-5; Luo MM, 2003, SCIENCE, V299, P1196, DOI 10.1126/science.1082133; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Milligan G, 2003, TRENDS PHARMACOL SCI, V24, P87, DOI 10.1016/S0165-6147(02)00027-5; Rodriguez I, 2000, NAT GENET, V26, P18, DOI 10.1038/79124; Rodriguez I, 2002, CURR BIOL, V12, pR409, DOI 10.1016/S0960-9822(02)00909-0; Runnenburger K, 2002, EUR J CELL BIOL, V81, P539, DOI 10.1078/0171-9335-00277; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Sam M, 2001, NATURE, V412, P142, DOI 10.1038/35084137; Schiniedeberg K, 2007, J STRUCT BIOL, V159, P400, DOI 10.1016/j.jsb.2007.04.013; Shi P, 2005, J MOL EVOL, V60, P566, DOI 10.1007/s00239-004-0172-y; Shirokova E, 2005, J BIOL CHEM, V280, P11807, DOI 10.1074/jbc.M411508200; Spehr M, 2006, J NEUROSCI, V26, P1961, DOI 10.1523/JNEUROSCI.4939-05.2006; THASTRUP O, 1994, AGENTS ACTIONS, V43, P187, DOI 10.1007/BF01986687; Vosshall LB, 2005, CURR BIOL, V15, pR255, DOI 10.1016/j.cub.2005.03.027; Wang ZS, 2006, J NEUROSCI, V26, P7375, DOI 10.1523/JNEUROSCI.1967-06.2006; Witt M, 2002, HISTOCHEM CELL BIOL, V117, P493, DOI 10.1007/s00418-002-0407-1; Wysocki CJ, 2004, ANAT REC PART A, V281A, P1201, DOI 10.1002/ar.a.20125; Zhang JZ, 2003, P NATL ACAD SCI USA, V100, P8337, DOI 10.1073/pnas.1331721100; Zhang XM, 2004, GENOMICS, V83, P802, DOI 10.1016/j.ygeno.2003.10.009; Zufall F, 2005, Naunyn Schmiedebergs Arch Pharmacol, V371, P245, DOI 10.1007/s00210-005-1028-8	41	31	31	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1416	1425		10.1096/fj.07-9233com	http://dx.doi.org/10.1096/fj.07-9233com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18096815				2022-12-28	WOS:000255898700014
J	Nakamura, Y; Ichinohe, M; Hirata, M; Matsuura, H; Fujiwara, T; Igarashi, T; Nakahara, M; Yamaguchi, H; Yasugi, S; Takenawa, T; Fukami, K				Nakamura, Yoshikazu; Ichinohe, Manabu; Hirata, Masayuki; Matsuura, Hirokazu; Fujiwara, Takashi; Igarashi, Takahiro; Nakahara, Masamichi; Yamaguchi, Hideki; Yasugi, Sadao; Takenawa, Tadaomi; Fukami, Kiyoko			Phospholipase C-delta 1 is an essential molecule downstream of Foxn1, the gene responsible for the nude mutation, in normal hair development	FASEB JOURNAL			English	Article						phosphoinositide; nude mice; hair follicle; hair keratin	C ISOZYMES; DIFFERENTIATION; FOLLICLE; EXPRESSION; MOUSE; PROTEIN; WHN; KERATINOCYTES; PHENOTYPE; HOXC13	Nude mice exhibit athymia and hairlessness by a loss-of-function mutation in the transcription factor Foxn1 gene. Although the immunological functions of Foxn1 have been studied intensively, there have been relatively few studies of its functions in skin. Foxn1 regulates expression of hair keratins, which is essential for normal hair structure; however, how Foxn1 regulates hair keratin expression and hair formation is largely unknown. In the present study, we found that mice lacking phospholipase C (PLC)-delta 1, a key molecule in the phosphoinositide signaling pathway, and nude mice show similar hair abnormalities, such as lack of cuticle and bending. We also found that expression of hair keratins was remarkably decreased in skin of PLC-delta 1 knockout mice. Furthermore, expression of PLC-delta 1 was induced in Foxn1-transfected U2OS cells. In addition, we showed that PLC-delta 1 expression was remarkably decreased in skin of nude mice. In skin and keratinocytes of nude mice as well as PLC-delta 1 KO mice, activation of PLC downstream effectors, such as PKC and nuclear factor of activated T cells, was impaired. These results indicate that PLC-delta 1 is an essential molecule downstream of Foxn1 in normal hair formation, and strongly suggest that hairlessness in nude mice is caused by insufficient expression of PLC-delta 1.	[Nakamura, Yoshikazu; Ichinohe, Manabu; Hirata, Masayuki; Matsuura, Hirokazu; Igarashi, Takahiro; Nakahara, Masamichi; Yamaguchi, Hideki; Fukami, Kiyoko] Tokyo Univ Pharm & Life Sci, Lab Genome & Biosignal, Tokyo 1920392, Japan; [Fujiwara, Takashi] Ehime Univ, Integrated Ctr Sci, Dept Biol Resources, Toon City, Ehime, Japan; [Yasugi, Sadao] Tokyo Metropolitan Univ, Grad Sch Sci, Dept Biol Sci, Tokyo 158, Japan; [Takenawa, Tadaomi] Kobe Univ, Grad Sch Med, Dept Lipid Biochem, Kobe, Hyogo 657, Japan	Tokyo University of Pharmacy & Life Sciences; Ehime University; Tokyo Metropolitan University; Kobe University	Fukami, K (corresponding author), Tokyo Univ Pharm & Life Sci, Lab Genome & Biosignal, 1432-1 Horinouchi, Tokyo 1920392, Japan.	kfukami@ls.toyaku.ac.jp	Yamaguchi, Hideki/AAP-1767-2021	Yamaguchi, Hideki/0000-0003-2125-9655; Nakamura, Yoshikazu/0000-0001-8355-1091				Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Botchkarev VA, 1999, NAT CELL BIOL, V1, P158, DOI 10.1038/11078; Brissette JL, 1996, GENE DEV, V10, P2212, DOI 10.1101/gad.10.17.2212; Bunce MW, 2006, BBA-MOL CELL BIOL L, V1761, P560, DOI 10.1016/j.bbalip.2006.03.002; DasGupta R, 1999, DEVELOPMENT, V126, P4557; FLANAGAN SP, 1966, GENET RES, V8, P295, DOI 10.1017/S0016672300010168; Frank J, 1999, NATURE, V398, P473, DOI 10.1038/18997; Fukami K, 2002, J BIOCHEM, V131, P293, DOI 10.1093/oxfordjournals.jbchem.a003102; Godwin AR, 1998, GENE DEV, V12, P11, DOI 10.1101/gad.12.1.11; Ishii Y, 1997, DEV GROWTH DIFFER, V39, P643; Janes SM, 2004, J CELL SCI, V117, P4157, DOI 10.1242/jcs.01302; Jave-Suarez LF, 2002, J BIOL CHEM, V277, P3718, DOI 10.1074/jbc.M101616200; Johns SA, 2005, DEV DYNAM, V232, P1062, DOI 10.1002/dvdy.20278; Kobielak K, 2003, J CELL BIOL, V163, P609, DOI 10.1083/jcb.200309042; Kulessa H, 2000, EMBO J, V19, P6664, DOI 10.1093/emboj/19.24.6664; LI J, 2007, DIFFERENTIATION; Meier N, 1999, MECH DEVELOP, V89, P215, DOI 10.1016/S0925-4773(99)00218-X; Nakamura Y, 2005, MOL CELL BIOL, V25, P10979, DOI 10.1128/MCB.25.24.10979-10988.2005; Nakamura Y, 2003, EMBO J, V22, P2981, DOI 10.1093/emboj/cdg302; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; Nishida T, 2006, BIOCHEM BIOPH RES CO, V345, P1536, DOI 10.1016/j.bbrc.2006.05.065; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Okada M, 2005, FEBS LETT, V579, P4949, DOI 10.1016/j.febslet.2005.07.082; PANTELOURIS EM, 1968, NATURE, V217, P370, DOI 10.1038/217370a0; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Sayama K, 2002, J BIOL CHEM, V277, P40390, DOI 10.1074/jbc.M112423200; Schlake T, 1997, P NATL ACAD SCI USA, V94, P3842, DOI 10.1073/pnas.94.8.3842; Schlake T, 2000, DEV DYNAM, V217, P368, DOI 10.1002/(SICI)1097-0177(200004)217:4<368::AID-DVDY4>3.0.CO;2-Z; Yuhki M, 2004, DEVELOPMENT, V131, P1825, DOI 10.1242/dev.01079	30	43	45	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2008	22	3					841	849		10.1096/fj.07-9239com	http://dx.doi.org/10.1096/fj.07-9239com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17938256				2022-12-28	WOS:000254143700022
J	Szczesna-Cordary, D; Jones, M; Moore, JR; Watt, J; Glenn, W; Kerrick, L; Xu, Y; Wang, Y; Wagg, C; Lopaschuk, GD				Szczesna-Cordary, Danuta; Jones, Michelle; Moore, Jeffrey R.; Watt, James; Glenn, W.; Kerrick, L.; Xu, Yuanyuan; Wang, Ying; Wagg, Cory; Lopaschuk, Gary D.			Myosin regulatory light chain E22K mutation results in decreased cardiac intracellular calcium and force transients	FASEB JOURNAL			English	Article						transgenic mice; Ca2+/Mg2+ binding to RLC; cardiac hypertrophy; in vitro motility assays; intact and skinned muscle fibers; energy metabolism	FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; HEAVY-MEROMYOSIN; CA2+ BINDING; NECK REGION; PPAR-ALPHA; FIBERS; DOMAIN; RLC; IDENTIFICATION; ACTIVATION	The glutamic acid to lysine mutation at the 22(nd) amino acid residue ( E22K) in the human cardiac myosin regulatory light chain ( RLC) gene causes familial hypertrophic cardiomyopathy ( FHC) with a phenotype of midventricular obstruction and septal hypertrophy. Our recent histopathology results have shown that the hearts of transgenic E22K mice ( Tg- E22K) resemble those of human patients, demonstrating enlarged interventricular septa and papillary muscles. In this study, we show no effect of the E22K mutation on the kinetics of mutated myosin in its ATP- powered interaction with fluorescently labeled single actin filaments compared to nontransgenic or transgenic wild- type ( Tg- WT) control mice. Likewise, no change in cross- bridge dissociation rates ( gapp) was observed in freshly skinned papillary muscle fibers. In contrast, maximal force and ATPase were decreased similar to 20% in Tg- E22K skinned papillary muscle fibers and intracellular [Ca2+] and force transients were significantly decreased in intact papillary muscle fibers from Tg- E22K compared to Tg- WT mice. Moreover, energy metabolism measured in isolated working Tg- E22K mouse hearts perfused under conditions of physiologically relevant levels of metabolic demand was similar in Tg- E22K and control hearts before and after 20 min of no- flow ischemia. Our results suggest that the pathological response observed in the E22K myocardium might be triggered by mutation induced changes in the properties of the RLC Ca2+- Mg2+ site, the state of the Ca2+/Mg2+ occupancy and consequently the Ca2+ buffering ability of the RLC. By decreasing the affinity of the RLC for Ca2+, the E22K mutation most likely promotes a Mg2+- saturated RLC producing less force and ATPase than the Ca2+-saturated RLC of WT fibers. Decreased Ca2+ binding may also lead to faster Ca2+ dissociation kinetics in Tg- E22K intact fibers resulting in decreased duration and amplitude of [Ca2+] and force transients. These changes when placed in vivo would result in higher workloads and consequently cardiac hypertrophy.	Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL USA; Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL USA; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02215 USA; Univ Alberta, Cardiovasc Res Grp, Edmonton, AB T6G 2M7, Canada	University of Miami; University of Miami; Boston University; University of Alberta	Szczesna-Cordary, D (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, PO Box 016189, 1600 NW 10th Ave Rm 6113, Miami, FL 33101 USA.	dszczesna@med.miami.edu		Moore, Jeffrey/0000-0001-7190-9332	NHLBI NIH HHS [R01 HL071778-04, R01 HL071778, HL077280, HL071778, R01 HL071778-01A1, R01 HL077280] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071778, R01HL077280] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen K, 2000, J APPL PHYSIOL, V88, P180, DOI 10.1152/jappl.2000.88.1.180; Baker JE, 1998, P NATL ACAD SCI USA, V95, P2944, DOI 10.1073/pnas.95.6.2944; Baylor SM, 2000, NEWS PHYSIOL SCI, V15, P19; Belke DD, 1999, AM J PHYSIOL-REG I, V277, pR1210, DOI 10.1152/ajpregu.1999.277.4.R1210; Campbell FM, 2002, J BIOL CHEM, V277, P4098, DOI 10.1074/jbc.M106054200; DASILVA ACR, 1992, EUR J BIOCHEM, V204, P85; DIFFEE GM, 1995, BIOPHYS J, V68, P1443, DOI 10.1016/S0006-3495(95)80317-6; Dumka D, 2006, AM J PHYSIOL-HEART C, V291, pH2098, DOI 10.1152/ajpheart.00396.2006; Flavigny J, 1998, J MOL MED-JMM, V76, P208, DOI 10.1007/s001090050210; GUTH K, 1986, PFLUG ARCH EUR J PHY, V407, P552, DOI 10.1007/BF00657515; HARRIS DE, 1993, J BIOL CHEM, V268, P14764; Heineke J, 2006, NAT REV MOL CELL BIO, V7, P589, DOI 10.1038/nrm1983; HOLROYDE MJ, 1979, J BIOL CHEM, V254, P6478; Hougs L, 2005, EUR J HUM GENET, V13, P161, DOI 10.1038/sj.ejhg.5201310; Kabaeva ZT, 2002, EUR J HUM GENET, V10, P741, DOI 10.1038/sj.ejhg.5200872; KABAEVA ZT, 2002, THESIS HUMBOLDT U BE; KENDRICKJONES J, 1991, J CELL SCI, P55; LANKFORD EB, 1995, J CLIN INVEST, V95, P1409, DOI 10.1172/JCI117795; Lips DJ, 2003, EUR HEART J, V24, P883, DOI 10.1016/S0195-668X(02)00829-1; Lowey S, 2002, TRENDS CARDIOVAS MED, V12, P348, DOI 10.1016/S1050-1738(02)00181-0; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; Maron BJ, 2000, CIRCULATION, V102, P858; MARON BJ, 2003, CARD ELECTROPHYSIOL, V6, P100; Mogensen J, 2001, J MED GENET, V38, P193, DOI 10.1136/jmg.38.3.193; Moore JR, 2004, J MUSCLE RES CELL M, V25, P29, DOI 10.1023/B:JURE.0000021394.48560.71; Moore JR, 2001, J CELL BIOL, V155, P625, DOI 10.1083/jcb.200103128; Morner S, 2003, J MOL CELL CARDIOL, V35, P841, DOI 10.1016/S0022-2828(03)00146-9; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; Reck-Peterson SL, 2001, J CELL BIOL, V153, P1121, DOI 10.1083/jcb.153.5.1121; REINACH FC, 1986, NATURE, V322, P80, DOI 10.1038/322080a0; Richard P, 2003, CIRCULATION, V107, P2227, DOI 10.1161/01.CIR.0000066323.15244.54; Sambandam N, 2006, AM J PHYSIOL-HEART C, V290, pH87, DOI 10.1152/ajpheart.00285.2005; Svensson C, 1997, J CELL BIOCHEM, V67, P241, DOI 10.1002/(SICI)1097-4644(19971101)67:2<241::AID-JCB9>3.0.CO;2-X; SZCZESNA D, 1987, FEBS LETT, V210, P177, DOI 10.1016/0014-5793(87)81332-7; Szczesna D, 2001, J BIOL CHEM, V276, P7086, DOI 10.1074/jbc.M009823200; Szczesna-Cordary D, 2005, J CELL SCI, V118, P3675, DOI 10.1242/jcs.02492; Szczesna-Cordary D, 2004, J BIOL CHEM, V279, P3535, DOI 10.1074/jbc.M307092200; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; WAGG C, 2006, BIOPH J, pA274; Wang Y, 1999, J MUSCLE RES CELL M, V20, P645, DOI 10.1023/A:1005559613516; Wang Y, 2006, J MOL BIOL, V361, P286, DOI 10.1016/j.jmb.2006.06.018; Wang YC, 2007, FASEB J, V21, P2205, DOI 10.1096/fj.06-7538com; Warshaw DM, 2000, J BIOL CHEM, V275, P37167, DOI 10.1074/jbc.M006438200	43	34	35	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3974	3985		10.1096/fj.07-8630com	http://dx.doi.org/10.1096/fj.07-8630com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17606808				2022-12-28	WOS:000251283500022
J	Ehrchen, J; Helming, L; Varga, G; Pasche, B; Loser, K; Gunzer, M; Sunderkotter, C; Sorg, C; Roth, J; Lengeling, A				Ehrchen, Jan; Helming, Laura; Varga, Georg; Pasche, Bastian; Loser, Karin; Gunzer, Matthias; Sunderkoetter, Cord; Sorg, Clemens; Roth, Johannes; Lengeling, Andreas			Vitamin D receptor signaling contributes to susceptibility to infection with Leishmania major	FASEB JOURNAL			English	Article						interferon-gamma; host resistance; macrophage; knockout mice; parasite	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NITRIC-OXIDE SYNTHASE; MACROPHAGE ACTIVATION; IN-VIVO; 1,25-DIHYDROXYVITAMIN D-3; DENDRITIC CELLS; T-CELLS; REACTIVE NITROGEN; IMMUNE-RESPONSES; MANNOSE RECEPTOR	We have previously reported that 1 alpha, 25-dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) can selectively suppress key functions of interferon-gamma (IFN-gamma) activated macrophages. To further explore this mechanism for its relevance in vivo, we investigated an infection model that crucially depends on the function of IFN-gamma activated macrophages, the infection with the intracellular protozoan Leishmania major. 1 alpha, 25(OH)(2)D-3 treatment of L. major infected macrophages demonstrated a vitamin D receptor (Vdr) dependent inhibition of macrophage killing activity. Further analysis showed that this was a result of decreased production of nitric oxide by 1 alpha,25(OH)(2)D-3-treated macrophages due to Vdr-dependent up-regulation of arginase 1 expression, which overrides NO production by Nos2. When analyzing the course of infection in vivo, we found that Vdr-knockout (Vdr-KO) mice were more resistant to L. major infection than their wild-type littermates. This result is in agreement with an inhibitory influence of 1 alpha, 25(OH)(2)D-3 on the macrophage mediated host defense. Further investigation showed that Vdr-KO mice developed an unaltered T helper cell type 1 (Th1) response on infection as indicated by normal production of IFN-gamma by CD4+ and CD8+ T cells. Therefore, we propose that the absence of 1 alpha, 25(OH)(2)D-3-mediated inhibition of macrophage microbicidal activity in Vdr-KO mice results in increased resistance to Leishmania infection.	Helmholtz Ctr Infect Res, Dept Expt Mouse Genet, Res Grp Infect Genet, D-38124 Braunschweig, Germany; Helmholtz Ctr Infect Res, Junior Res Grp Immunodynam, D-38124 Braunschweig, Germany; Univ Munster, Inst Expt Dermatol, D-4400 Munster, Germany; Univ Munster, Dept Dermatol, D-4400 Munster, Germany	Helmholtz Association; Helmholtz-Center for Infection Research; Helmholtz Association; Helmholtz-Center for Infection Research; University of Munster; University of Munster	Ehrchen, J (corresponding author), Helmholtz Ctr Infect Res, Dept Expt Mouse Genet, Res Grp Infect Genet, Inhoffenstr 7, D-38124 Braunschweig, Germany.		Gunzer, Matthias/AAW-7026-2021	Gunzer, Matthias/0000-0002-5534-6055; Sunderkotter, Cord/0000-0002-2929-145X				Adorini L, 2005, CELL IMMUNOL, V233, P115, DOI 10.1016/j.cellimm.2005.04.013; Ashcroft DM, 2000, BMJ-BRIT MED J, V320, P963, DOI 10.1136/bmj.320.7240.963; Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Cantorna MT, 2000, J NUTR, V130, P2648, DOI 10.1093/jn/130.11.2648; Cantorna MT, 1996, P NATL ACAD SCI USA, V93, P7861, DOI 10.1073/pnas.93.15.7861; Cantorna MT, 1998, J NUTR, V128, P68, DOI 10.1093/jn/128.1.68; CLOHISY DR, 1987, J BIOL CHEM, V262, P15922; Deluca HF, 2001, FASEB J, V15, P2579, DOI 10.1096/fj.01-0433rev; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; Diefenbach A, 1999, SCIENCE, V284, P951, DOI 10.1126/science.284.5416.951; DING AH, 1988, J IMMUNOL, V141, P2407; Ehrchen J, 2004, INFECT IMMUN, V72, P5106, DOI 10.1128/IAI.72.9.5106-5114.2004; Erben RG, 2002, MOL ENDOCRINOL, V16, P1524, DOI 10.1210/me.16.7.1524; Froicu M, 2003, MOL ENDOCRINOL, V17, P2386, DOI 10.1210/me.2003-0281; Gauzzi MC, 2005, J IMMUNOL, V174, P270, DOI 10.4049/jimmunol.174.1.270; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Handman E, 2002, TRENDS PARASITOL, V18, P332, DOI 10.1016/S1471-4922(02)02352-8; Helming L, 2005, BLOOD, V106, P4351, DOI 10.1182/blood-2005-03-1029; Holscher C, 2006, J IMMUNOL, V176, P1115, DOI 10.4049/jimmunol.176.2.1115; Iniesta V, 2005, INFECT IMMUN, V73, P6085, DOI 10.1128/IAI.73.9.6085-6090.2005; Iniesta V, 2001, J EXP MED, V193, P777, DOI 10.1084/jem.193.6.777; Kang S, 1998, BRIT J DERMATOL, V138, P77; KOEFFLER HP, 1985, BIOCHEM BIOPH RES CO, V127, P596; Kropf P, 2005, FASEB J, V19, P1000, DOI 10.1096/fj.04-3416fje; Lehmann B, 2004, EXP DERMATOL, V13, P11, DOI 10.1111/j.1600-0625.2004.00257.x; LEMIRE JM, 1992, AUTOIMMUNITY, V12, P143, DOI 10.3109/08916939209150321; LEMIRE JM, 1991, J CLIN INVEST, V87, P1103, DOI 10.1172/JCI115072; LEMIRE JM, 1985, J IMMUNOL, V134, P3032; LEMIRE JM, 1992, J CELL BIOCHEM, V49, P26, DOI 10.1002/jcb.240490106; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Loke H, 2002, AM J TROP MED HYG, V67, P102, DOI 10.4269/ajtmh.2002.67.102; Loke P'ng, 2002, BMC Immunol, V3, P7, DOI 10.1186/1471-2172-3-7; Mahon BD, 2003, J CELL BIOCHEM, V89, P922, DOI 10.1002/jcb.10580; Meehan TF, 2002, P NATL ACAD SCI USA, V99, P5557, DOI 10.1073/pnas.082100699; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Munder M, 1998, J IMMUNOL, V160, P5347; Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741; Nagpal S, 2005, ENDOCR REV, V26, P662, DOI 10.1210/er.2004-0002; O'Kelly J, 2002, J CLIN INVEST, V109, P1091, DOI 10.1172/JCI200212392; Penna G, 2000, J IMMUNOL, V164, P2405, DOI 10.4049/jimmunol.164.5.2405; Piemonti L, 2000, J IMMUNOL, V164, P4443, DOI 10.4049/jimmunol.164.9.4443; PROVVEDINI DM, 1983, SCIENCE, V221, P1181, DOI 10.1126/science.6310748; REICHEL H, 1987, J BIOL CHEM, V262, P10931; Roth DE, 2004, J INFECT DIS, V190, P920, DOI 10.1086/423212; Roy S, 1999, J INFECT DIS, V179, P187, DOI 10.1086/314536; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Sacks D, 2002, NAT IMMUNOL, V3, P1041, DOI 10.1038/ni1102-1041; Schonlau F, 2003, J LEUKOCYTE BIOL, V73, P564, DOI 10.1189/jlb.12011003; Schonlau F, 2000, EUR J IMMUNOL, V30, P2729, DOI 10.1002/1521-4141(200009)30:9&lt;2729::AID-IMMU2729&gt;3.0.CO;2-3; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; SUNDERKOTTER C, 1993, J IMMUNOL, V151, P4891; TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x; Veldman CM, 2000, ARCH BIOCHEM BIOPHYS, V374, P334, DOI 10.1006/abbi.1999.1605; WANG ZE, 1994, J EXP MED, V179, P1367, DOI 10.1084/jem.179.4.1367; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; Wilkinson RJ, 2000, LANCET, V355, P618, DOI 10.1016/S0140-6736(99)02301-6; Wittke A, 2004, J IMMUNOL, V173, P3432, DOI 10.4049/jimmunol.173.5.3432; Zella JB, 2003, ARCH BIOCHEM BIOPHYS, V417, P77, DOI 10.1016/S0003-9861(03)00338-2	60	69	70	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3208	3218		10.1096/fj.06-7261com	http://dx.doi.org/10.1096/fj.06-7261com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17551101				2022-12-28	WOS:000249781600021
J	Rennemeier, C; Hammerschmidt, S; Niemann, S; Inamura, S; Zahringer, U; Kehrel, BE				Rennemeier, Claudia; Hammerschmidt, Sven; Niemann, Silke; Inamura, Seiichi; Zaehringer, Ulrich; Kehrel, Beate E.			Thrombospondin-1 promotes cellular adherence of Gram-positive pathogens via recognition of peptidoglycan	FASEB JOURNAL			English	Article						colonization; platelet lectin; pneumococci; staphylococci; host tissue cells	STREPTOCOCCUS-PNEUMONIAE; STAPHYLOCOCCUS-AUREUS; LIPOTEICHOIC ACID; MENINGEAL INFLAMMATION; VITRONECTIN RECEPTOR; WALL COMPONENTS; SURFACE PROTEIN; VIRULENCE GENES; CELLS; BINDING	Thrombospondin-1 (TSP1) is a matricellular glycoprotein that has key roles in interactions between human cells and components of the extracellular matrix. Here we report a novel role for the lectin TSP1 in pathogen-host interactions. Binding assays and flow cytometric analysis demonstrate that Streptococcus pneumoniae and other Gram-positive pathogens including S. pyogenes, Staphylococcus aureus, and Listeria monocytogenes interact specifically with human TSP1. We also show for the first time that host cell-bound TSP1 promotes adherence of Gram-positive pathogens to human epithelial and endothelial cell lines. Pretreatment of bacteria with sodium periodate but not Pronase E substantially reduced TSP1-mediated bacterial adherence to host cells, suggesting that a glycoconjugate on the bacterial cell surface functions as the receptor for TSP1. Lipoteichoic acids did not affect TSP1-mediated adherence of S. pneumoniae to host cells. In contrast, attachment of S. pneumoniae and other Gram-positive pathogens to host cells via TSP1 was blocked by soluble peptidoglycan, indicating recognition of bacterial peptidoglycan by TSP1. In conclusion, our results demonstrate that recognition of Gram-positive pathogens by TSP1 promotes bacterial colonization of host tissue cells. In this scenario, peptidoglycan functions as adhesin and TSP1 acts as a molecular bridge linking Gram-positive bacteria with receptors on the host cell.	Univ Wurzburg, Res Ctr Infect Dis, Wurzburg, Germany; Univ Hosp Muenster, Dept Anaesthesiol & Intens Care, Munster, Germany; Res Ctr Borstel, Leibniz Ctr Med & Biosci, Borstel, Germany	University of Wurzburg; University of Munster; Forschungszentrum Borstel	Hammerschmidt, S (corresponding author), Univ Munich, Max Von Pettenkofer Inst Hyg & Microbiol, Pettenkoferstr 9A, D-80336 Munich, Germany.	hammerschmidt@mvp.uni-muenchen.de	Hammerschmidt, Sven/G-2598-2010	Hammerschmidt, Sven/0000-0002-6382-6681				Adams J, 2004, INT J BIOCHEM CELL B, V36, P960, DOI 10.1016/j.biocel.2004.02.009; Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; AGBANYO FR, 1993, J CLIN INVEST, V92, P288, DOI 10.1172/JCI116563; Armstrong LC, 2003, MATRIX BIOL, V22, P63, DOI 10.1016/S0945-053X(03)00005-2; BERGER H, 1982, J BACTERIOL, V152, P1241; Bergmann S, 2003, MOL MICROBIOL, V49, P411, DOI 10.1046/j.1365-2958.2003.03557.x; Boneca IG, 2005, CURR OPIN MICROBIOL, V8, P46, DOI 10.1016/j.mib.2004.12.008; Bubert A, 1999, MOL GEN GENET, V261, P323, DOI 10.1007/s004380050973; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; CHUGH TD, 1990, INFECT IMMUN, V58, P315, DOI 10.1128/IAI.58.2.315-319.1990; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Draing C, 2006, J BIOL CHEM, V281, P33849, DOI 10.1074/jbc.M602676200; Dziarski R, 2005, INFECT IMMUN, V73, P5212, DOI 10.1128/IAI.73.8.5212-5216.2005; Dziarski R, 2006, CELL MICROBIOL, V8, P1059, DOI 10.1111/j.1462-5822.2006.00726.x; Elzie CA, 2004, INT J BIOCHEM CELL B, V36, P1090, DOI 10.1016/j.biocel.2003.12.012; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Grimbert P, 2006, J IMMUNOL, V177, P3534, DOI 10.4049/jimmunol.177.6.3534; Hammerschmidt S, 2006, CURR OPIN MICROBIOL, V9, P12, DOI 10.1016/j.mib.2005.11.001; Hammerschmidt S, 2005, INFECT IMMUN, V73, P4653, DOI 10.1128/IAI.73.8.4653-4667.2005; Hammerschmidt S, 1997, MOL MICROBIOL, V25, P1113, DOI 10.1046/j.1365-2958.1997.5391899.x; Hermans PWM, 2006, J BIOL CHEM, V281, P968, DOI 10.1074/jbc.M510014200; HERRMANN M, 1991, INFECT IMMUN, V59, P279, DOI 10.1128/IAI.59.1.279-288.1991; Hughes J, 1997, J IMMUNOL, V158, P4389; Inamura S, 2006, ORG BIOMOL CHEM, V4, P232, DOI 10.1039/b511866b; Isenberg JS, 2006, J BIOL CHEM, V281, P26069, DOI 10.1074/jbc.M605040200; JAFFE EA, 1982, NATURE, V295, P246, DOI 10.1038/295246a0; Jansen WTM, 1998, CLIN DIAGN LAB IMMUN, V5, P703, DOI 10.1128/CDLI.5.5.703-710.1998; JEPRAS RI, 1985, J HYG-CAMBRIDGE, V95, P29, DOI 10.1017/S0022172400062252; Jurk K, 2003, FASEB J, V17, P1490, DOI 10.1096/fj.02-0830fje; KEHREL B, 1991, BIOCHEM BIOPH RES CO, V179, P985, DOI 10.1016/0006-291X(91)91915-Y; Kolberg J, 2006, MICROBIOL-SGM, V152, P1307, DOI 10.1099/mic.0.28747-0; Lau GW, 2001, MOL MICROBIOL, V40, P555, DOI 10.1046/j.1365-2958.2001.02335.x; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; McNicol A, 2006, THROMB HAEMOSTASIS, V95, P288, DOI 10.1160/TH05-07-0491; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Molinari G, 1998, J INFECT DIS, V177, P1600, DOI 10.1086/515310; Nadesalingam J, 2005, J IMMUNOL, V175, P1785, DOI 10.4049/jimmunol.175.3.1785; Narizhneva NV, 2005, FASEB J, V19, P1158, DOI 10.1096/fj.04-3310fje; Niemann S, 2004, CIRCULATION, V110, P193, DOI 10.1161/01.CIR.0000134486.93030.E7; Orr AW, 2004, J BIOL CHEM, V279, P48983, DOI 10.1074/jbc.M404881200; Pearce BJ, 2002, RES MICROBIOL, V153, P243, DOI 10.1016/S0923-2508(02)01312-8; Polissi A, 1998, INFECT IMMUN, V66, P5620, DOI 10.1128/IAI.66.12.5620-5629.1998; Pracht D, 2005, INFECT IMMUN, V73, P2680, DOI 10.1128/IAI.73.5.2680-2689.2005; RAUGI GJ, 1987, J INVEST DERMATOL, V89, P551, DOI 10.1111/1523-1747.ep12461198; Rietschel ET, 1998, MICROB DRUG RESIST, V4, P37, DOI 10.1089/mdr.1998.4.37; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SCHELD WM, 1978, J CLIN INVEST, V61, P1394, DOI 10.1172/JCI109057; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Sjobring U, 2002, BLOOD, V100, P4470, DOI 10.1182/blood-2002-01-0069; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Talay Susanne R., 2005, V12, P90, DOI 10.1159/000081691; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; Travassos LH, 2005, J BIOL CHEM, V280, P36714, DOI 10.1074/jbc.M501649200; TUOMANEN E, 1985, J INFECT DIS, V151, P859, DOI 10.1093/infdis/151.5.859; Unkmeir A, 2002, MOL MICROBIOL, V46, P933, DOI 10.1046/j.1365-2958.2002.03222.x; Vollmer W, 2000, J BIOL CHEM, V275, P20496, DOI 10.1074/jbc.M910189199; Weber JR, 1995, J NEUROIMMUNOL, V63, P63; Weber JR, 2003, IMMUNITY, V19, P269, DOI 10.1016/S1074-7613(03)00205-X; Weidenmaier C, 2004, NAT MED, V10, P243, DOI 10.1038/nm991; WILCOX KW, 1975, J BACTERIOL, V122, P443, DOI 10.1128/JB.122.2.443-453.1975; Yoshimura A, 2000, J ENDOTOXIN RES, V6, P407, DOI 10.1177/09680519000060050201; Yoshimura A, 1999, J IMMUNOL, V163, P1	64	69	70	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3118	3132		10.1096/fj.06-7992com	http://dx.doi.org/10.1096/fj.06-7992com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17507668				2022-12-28	WOS:000249781600013
J	Evron, T; Geyer, BC; Cherni, I; Muralidharan, M; Kilbourne, J; Fletcher, SP; Soreq, H; Mor, TS				Evron, Tama; Geyer, Brian C.; Cherni, Irene; Muralidharan, Mrinalini; Kilbourne, Jacquelyn; Fletcher, Samuel P.; Soreq, Hermona; Mor, Tsafrir S.			Plant-derived human acetylcholinesterase-R provides protection from lethal organophosphate poisoning and its chronic aftermath	FASEB JOURNAL			English	Article						paraoxon intoxication; neuromuscular junction; transgenic plants; long-term protection; bioscavenger	RECOMBINANT HUMAN ACETYLCHOLINESTERASE; HUMAN BUTYRYLCHOLINESTERASE; READTHROUGH ACETYLCHOLINESTERASE; EXPRESSION; PURIFICATION; ANTIDOTE; PYRIDOSTIGMINE; TRANSCRIPTS; REVEALS; PROTEIN	Therapeutically valuable proteins are often rare and/or unstable in their natural context, calling for production solutions in heterologous systems. A relevant example is that of the stress-induced, normally rare, and naturally unstable "read-through" human acetylcholinesterase variant, AChE-R. AChE-R shares its active site with the synaptic AChE-S variant, which is the target of poisonous organophosphate anticholinesterase insecticides such as the parathion metabolite paraoxon. Inherent AChE-R overproduction under organophosphate intoxication confers both short-term protection ( as a bioscavenger) and long-term neuromuscular damages ( as a regulator). Here we report the purification, characterization, and testing of human, endoplasmic reticulumretained AChE-RER produced from plant-optimized cDNA in Nicotiana benthamiana plants. AChE-RER purified to homogeneity showed indistinguishable biochemical properties, with IC50 = 10(-7) M for the organophosphate paraoxon, similar to mammalian cell culture-derived AChE. In vivo titration showed dose-dependent protection by intravenously injected AChE-RER of FVB/N male mice challenged with a lethal dose of paraoxon, with complete elimination of short-term clinical symptoms at near molar equivalence. By 10 days postexposure, AChE-R prophylaxis markedly limited postexposure increases in plasma murine AChE-R levels while minimizing the organophosphate-induced neuromuscular junction dismorphology. Our findings present plant-produced AChE-RER as a bimodal agent, conferring both short- and long- term protection from organophosphate intoxication.-Evron, T., Geyer, B. C., Cherni, I., Muralidharan, M., Kilbourne, J., Fletcher, S. P., Soreq, H., Mor, T. S. Plant- derived human acetylcholinesterase- R provides protection from lethal organophosphate poisoning and its chronic aftermath.	Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA; Arizona State Univ, Biodesign Inst, Tempe, AZ 85287 USA; Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Hebrew University of Jerusalem	Soreq, H (corresponding author), Arizona State Univ, Sch Life Sci, POB 874501, Tempe, AZ 85287 USA.	soreq@cc.huji.ac.il; tsafrir.mor@asu.edu	mor, tsafrir/E-9422-2013	Soreq, Hermona/0000-0002-0955-526X	NINDS NIH HHS [U54 NS058183-010005] Funding Source: Medline; PHS HHS [U54N5058183-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U54NS058183] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashani Y, 2000, DRUG DEVELOP RES, V50, P298, DOI 10.1002/1098-2299(200007/08)50:3/4<298::AID-DDR13>3.3.CO;2-O; Birikh KR, 2003, P NATL ACAD SCI USA, V100, P283, DOI 10.1073/pnas.0135647100; Brenner T, 2003, FASEB J, V17, P214, DOI 10.1096/fj.02-0609com; Cerasoli DM, 2005, CHEM-BIOL INTERACT, V157, P363, DOI 10.1016/j.cbi.2005.10.052; Chan RYY, 1998, J BIOL CHEM, V273, P9727, DOI 10.1074/jbc.273.16.9727; Cohen O, 2004, BIOCHEM J, V378, P117, DOI 10.1042/BJ20031305; Cohen O, 2003, J MOL NEUROSCI, V21, P199, DOI 10.1385/JMN:21:3:199; Darreh-Shori T, 2004, J NEUROCHEM, V88, P1102, DOI 10.1046/j.1471-4159.2003.02230.x; Dharmani Chandrabhan, 2005, Reviews on Environmental Health, V20, P215; Doctor BP, 2005, CHEM-BIOL INTERACT, V157, P167, DOI 10.1016/j.cbi.2005.10.024; Farchi N, 2003, J PHYSIOL-LONDON, V546, P165, DOI 10.1113/jphysiol.2002.030841; Fletcher SP, 2004, PLANT MOL BIOL, V55, P33, DOI 10.1007/s11103-004-0394-9; Friedman A, 1996, NAT MED, V2, P1382, DOI 10.1038/nm1296-1382; Galili U, 2005, IMMUNOL CELL BIOL, V83, P674, DOI 10.1111/j.1440-1711.2005.01366.x; Geyer BC, 2005, CHEM-BIOL INTERACT, V157, P331, DOI 10.1016/j.cbi.2005.10.097; Giddings G, 2000, NAT BIOTECHNOL, V18, P1151, DOI 10.1038/81132; Gomord V, 2004, CURR OPIN PLANT BIOL, V7, P171, DOI 10.1016/j.pbi.2004.01.015; Greenfield RA, 2002, AM J MED SCI, V323, P326, DOI 10.1097/00000441-200206000-00005; Grisaru D, 2006, J IMMUNOL, V176, P27, DOI 10.4049/jimmunol.176.1.27; Grunwald J, 1997, J BIOCHEM BIOPH METH, V34, P123, DOI 10.1016/S0165-022X(97)01208-6; Jurgens G, 2004, ANNU REV CELL DEV BI, V20, P481, DOI 10.1146/annurev.cellbio.20.082503.103057; Kaplan D, 2001, BIOCHEMISTRY-US, V40, P7433, DOI 10.1021/bi010181x; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; Kronman C, 2000, J BIOL CHEM, V275, P29488, DOI 10.1074/jbc.M004298200; Kronvang B, 2005, WATER SCI TECHNOL, V51, P55, DOI 10.2166/wst.2005.0575; Lee EC, 2003, JAMA-J AM MED ASSOC, V290, P659, DOI 10.1001/jama.290.5.659; Lenz DE, 2005, CHEM-BIOL INTERACT, V157, P205, DOI 10.1016/j.cbi.2005.10.025; Lev-Lehman E, 2000, J MOL NEUROSCI, V14, P93, DOI 10.1385/JMN:14:1-2:093; London L, 2005, AM J IND MED, V47, P308, DOI 10.1002/ajim.20147; Marchot P, 1996, PROTEIN SCI, V5, P672; MAXWELL DM, 1993, J PHARMACOL EXP THER, V264, P1085; Meshorer E, 2004, J BIOL CHEM, V279, P29740, DOI 10.1074/jbc.M402752200; Meshorer E, 2002, SCIENCE, V295, P508, DOI 10.1126/science.1066752; Mor TS, 2001, BIOTECHNOL BIOENG, V75, P259, DOI 10.1002/bit.10012; Nijholt I, 2004, MOL PSYCHIATR, V9, P174, DOI 10.1038/sj.mp.4001446; Pick M, 2006, BLOOD, V107, P3397, DOI 10.1182/blood-2005-08-3240; RAVEH L, 1993, BIOCHEM PHARMACOL, V45, P2465, DOI 10.1016/0006-2952(93)90228-O; Saxena A, 1998, MOL PHARMACOL, V53, P112, DOI 10.1124/mol.53.1.112; SEIDMAN S, 1995, MOL CELL BIOL, V15, P2993; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; Shohami E, 2000, J MOL MED-JMM, V78, P228, DOI 10.1007/s001090000104; Sklan EH, 2004, P NATL ACAD SCI USA, V101, P5512, DOI 10.1073/pnas.0307659101; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Sternfeld M, 2000, P NATL ACAD SCI USA, V97, P8647, DOI 10.1073/pnas.140004597; Sternfeld M, 1998, J NEUROSCI, V18, P1240; Taylor P., 1996, GOODMAN GILMANS PHAR, P161; Yamasue H, 2003, P NATL ACAD SCI USA, V100, P9039, DOI 10.1073/pnas.1530467100	49	29	31	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2961	2969		10.1096/fj.07-8112com	http://dx.doi.org/10.1096/fj.07-8112com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17475919	Green Accepted			2022-12-28	WOS:000249237500036
J	Joshi, MS; Mineo, C; Shaul, PW; Bauer, JA				Joshi, Mandar S.; Mineo, Chieko; Shaul, Philip W.; Bauer, John Anthony			Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear	FASEB JOURNAL			English	Article						caveolin-1; endothelial nitric oxide synthase; functional genomics; gene polymorphism; protein-protein interactions	NITRIC-OXIDE SYNTHASE; CORONARY-ARTERY-DISEASE; GENE POLYMORPHISM; PHOSPHORYLATION; HYPERTENSION; CELLS; EXPRESSION; MECHANISM; PROTEINS; CLEAVAGE	Human endothelial nitric oxide synthase ( NOS3) gene polymorphism at Exon 7 ( Glu298Asp) has been linked to vascular endothelial dysfunction, but the mechanisms are not defined. Shear is a key modulator of NOS3 function in vivo and association with caveolae is important for the control of NOS3 protein activity. Here we tested the hypothesis that altered enrichment of NOS3 in the caveolar membrane defines Glu298Asp genotype- specific responses and NOS3 activity. Basal caveolar membrane enrichment was carried out to quantitate the NOS3 enrichment in caveolae. Cells were subjected to shear and NOS3 protein levels, phosphorylation, enzyme function were investigated. Variant genotypes had lower NOx production pre- and post- shear, but no genotype- dependent alterations in pNOS3 were observed. Asp variants had significantly lower NOS3 enrichment in the caveolar membrane fraction. Further, immunoprecipitation studies demonstrated that Asp variants had substantially less NOS3/ Cav- 1 association ( similar to 40%) during static conditions. Furthermore, acute shear causes impaired NOS3/ Cav- 1 dissociation in Asp variants. The results from immunoprecipitation studies were in complete agreement with caveolar membrane preparation findings. Collectively, these data demonstrate functional consequences of the Glu298Asp NOS3 variation and further define disruption of NOS3 caveolar localization and shear- induced mobilization as the primary mechanism responsible for these differences. - Joshi, M. S., Mineo, C., Shaul, P. W., Bauer, J. A. Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear.	Columbus Childrens Res Inst, Ctr Cardiovasc Med, Columbus, OH 43205 USA; Univ Texas, SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75235 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bauer, JA (corresponding author), Columbus Childrens Res Inst, Ctr Cardiovasc Med, 700 Childrens Dr, Columbus, OH 43205 USA.	bauerj@ccri.net			NHLBI NIH HHS [R01 HL063067, HL63067, R01 HL058888, HL58888] Funding Source: Medline; NIDDK NIH HHS [DK55053, R01 DK055053] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063067, R01HL058888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055053] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aird WC, 2004, CRIT CARE MED, V32, pS271, DOI 10.1097/01.CCM.0000129669.21649.40; Andrews Karen L, 2002, Heart Fail Rev, V7, P423, DOI 10.1023/A:1020702215520; Andrews KL, 2005, EXPERT OPIN THER TAR, V9, P101, DOI 10.1517/14728222.9.1.101; Angus JA, 1996, CLIN EXP PHARMACOL P, V23, pS16, DOI 10.1111/j.1440-1681.1996.tb03036.x; Arnal JF, 1999, CELL MOL LIFE SCI, V55, P1078, DOI 10.1007/s000180050358; AWOLESI MA, 1994, SURGERY, V116, P439; Ballermann BJ, 1998, KIDNEY INT, V54, pS100, DOI 10.1046/j.1523-1755.1998.06720.x; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; Boo YC, 2006, FREE RADICAL BIO MED, V41, P144, DOI 10.1016/j.freeradbiomed.2006.03.024; BUSSE R, 1995, ANN MED, V27, P331, DOI 10.3109/07853899509002586; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Fairchild TA, 2001, J BIOL CHEM, V276, P26674, DOI 10.1074/jbc.M103647200; Fike CD, 2004, AM J PHYSIOL-LUNG C, V286, pL1244, DOI 10.1152/ajplung.00345.2003; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Govers R, 2001, AM J PHYSIOL-RENAL, V280, pF193, DOI 10.1152/ajprenal.2001.280.2.F193; Hibi K, 1998, HYPERTENSION, V32, P521, DOI 10.1161/01.HYP.32.3.521; Hingorani AD, 2003, CURR HYPERTENS REP, V5, P19, DOI 10.1007/s11906-003-0006-0; Hingorani AD, 1999, CIRCULATION, V100, P1515, DOI 10.1161/01.CIR.100.14.1515; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; Lin MI, 2003, J BIOL CHEM, V278, P44719, DOI 10.1074/jbc.M302836200; Maniatis NA, 2006, CIRC RES, V99, P870, DOI 10.1161/01.RES.0000245187.08026.47; Markus HS, 1998, STROKE, V29, P1908, DOI 10.1161/01.STR.29.9.1908; Mihm MJ, 2003, BIOCHEM PHARMACOL, V65, P1189, DOI 10.1016/S0006-2952(03)00012-1; Minshall RD, 2003, AM J PHYSIOL-LUNG C, V285, pL1179, DOI 10.1152/ajplung.00242.2003; Murata T, 2002, J BIOL CHEM, V277, P44085, DOI 10.1074/jbc.M205934200; Raij L, 1998, HYPERTENSION, V31, P189, DOI 10.1161/01.HYP.31.1.189; Searles CD, 2006, AM J PHYSIOL-CELL PH, V291, pC803, DOI 10.1152/ajpcell.00457.2005; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Tesauro M, 2000, P NATL ACAD SCI USA, V97, P2832, DOI 10.1073/pnas.97.6.2832; Wang XL, 2000, FEBS LETT, V471, P45, DOI 10.1016/S0014-5793(00)01356-9; Wang XL, 1996, NAT MED, V2, P41, DOI 10.1038/nm0196-41; Wattanapitayakul SK, 2001, TRENDS PHARMACOL SCI, V22, P361, DOI 10.1016/S0165-6147(00)01692-8; ZWIETERING MH, 1990, APPL ENVIRON MICROB, V56, P1875	35	99	100	2	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2655	2663		10.1096/fj.06-7088com	http://dx.doi.org/10.1096/fj.06-7088com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17449720	Green Accepted			2022-12-28	WOS:000249237500007
J	Mathews, CK; Song, SW				Mathews, Christopher K.; Song, Shiwei			Maintaining precursor pools for mitochondrial DNA replication	FASEB JOURNAL			English	Review						mitochondria; DNA precursors; deoxyribonucleotides; nucleotide pools	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MOUSE L-CELLS; DEOXYNUCLEOTIDE CARRIER; THYMIDINE PHOSPHORYLASE; NUCLEOSIDE ANALOGS; POLYMERASE-GAMMA; NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT; RIBONUCLEOTIDE REDUCTASE; COMPUTATIONAL MODEL	Among the human diseases that result from abnormalities in mitochondrial genome stability or maintenance are several that result from mutations affecting enzymes of deoxyribonucleoside triphosphate ( dNTP) metabolism. In addition, it is evident that the toxicity of antiviral nucleoside analogs is determined in part by the extent to which their intracellular conversion to dNTP analogs occurs within the mitochondrion. Finally, recent work from this laboratory has shown considerable variation among different mammalian tissues with respect to mitochondrial dNTP pool sizes and has suggested that natural asymmetries in mitochondrial dNTP concentrations may contribute to the high rates at which the mitochondrial genome undergoes mutation. These factors suggest that much more information is needed about maintenance and regulation of dNTP pools within mammalian mitochondria. This review summarizes our current understanding and suggests directions for future research.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Mathews, CK (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 Agr & Life Sci Bldg, Corvallis, OR 97331 USA.	mathewsc@onid.orst.edu						ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219; BESTWICK RK, 1982, J BIOL CHEM, V257, P9305; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938; Bradshaw PC, 2005, BIOCHEM J, V392, P363, DOI 10.1042/BJ20050749; Bradshaw PC, 2005, AM J PHYSIOL-CELL PH, V288, pC989, DOI 10.1152/ajpcell.00530.2004; Bridges EG, 1999, J BIOL CHEM, V274, P4620, DOI 10.1074/jbc.274.8.4620; Desler C, 2006, NUCLEOS NUCLEOT NUCL, V25, P1171, DOI 10.1080/15257770600894501; Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998; ENRIQUEZ JA, 1994, NUCLEIC ACIDS RES, V22, P1861, DOI 10.1093/nar/22.10.1861; Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200; Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103; Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279; Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; KAROL MH, 1968, SCIENCE, V162, P470, DOI 10.1126/science.162.3852.470; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; Kumagai Y, 2006, INTERNAL MED, V45, P443, DOI 10.2169/internalmedicine.45.1371; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; Ladner RD, 1997, J BIOL CHEM, V272, P19072, DOI 10.1074/jbc.272.30.19072; Lam W, 2005, MOL PHARMACOL, V67, P408, DOI 10.1124/mol.104.007120; Lara MC, 2006, NEUROLOGY, V67, P1461, DOI 10.1212/01.wnl.0000239824.95411.52; Lee H, 2003, BIOCHEMISTRY-US, V42, P14711, DOI 10.1021/bi035596s; LEEDS JM, 1987, MOL CELL BIOL, V7, P532, DOI 10.1128/MCB.7.1.532; Lewis W, 2005, LAB INVEST, V85, P972, DOI 10.1038/labinvest.3700301; Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4; Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200; Lindhurst MJ, 2006, P NATL ACAD SCI USA, V103, P15927, DOI 10.1073/pnas.0607661103; Lynx MD, 2006, BIOCHEM PHARMACOL, V72, P239, DOI 10.1016/j.bcp.2006.04.004; Lynx MD, 2006, BIOCHEM PHARMACOL, V71, P1342, DOI 10.1016/j.bcp.2006.01.003; Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746; Marcelino LA, 1999, MUTAT RES-DNA REPAIR, V434, P177, DOI 10.1016/S0921-8777(99)00028-2; Mathews CK, 2006, FASEB J, V20, P1300, DOI 10.1096/fj.06-5730rev; MATHEWS CK, 1986, EXP CELL RES, V162, P285, DOI 10.1016/0014-4827(86)90335-6; McKee Edward E, 2004, Cardiovasc Toxicol, V4, P155, DOI 10.1385/CT:4:2:155; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; PARKER WB, 1994, J NIH RES, V6, P57; Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200; Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100; Pontarin G, 2006, J BIOL CHEM, V281, P22720, DOI 10.1074/jbc.M604498200; Rampazzo C, 2004, J BIOL CHEM, V279, P17019, DOI 10.1074/jbc.M313957200; Rampazzo C, 2000, P NATL ACAD SCI USA, V97, P8239, DOI 10.1073/pnas.97.15.8239; Rosenberg MJ, 2002, NAT GENET, V32, P175, DOI 10.1038/ng948; Saada A, 2003, BIOCHEM BIOPH RES CO, V310, P963, DOI 10.1016/j.bbrc.2003.09.104; Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751; Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8; Song SW, 2005, P NATL ACAD SCI USA, V102, P4990, DOI 10.1073/pnas.0500253102; Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200; Suh JH, 2003, FREE RADICAL BIO MED, V35, P1064, DOI 10.1016/S0891-5849(03)00468-4; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Wang LY, 2003, FEBS LETT, V554, P319, DOI 10.1016/S0014-5793(03)01181-5; Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200; YOUNG P, 1994, BIOCHEM BIOPH RES CO, V203, P46, DOI 10.1006/bbrc.1994.2146	62	29	29	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2294	2303		10.1096/fj.06-7977rev	http://dx.doi.org/10.1096/fj.06-7977rev			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17403938				2022-12-28	WOS:000248454400004
J	Mouri, A; Noda, Y; Hara, H; Mizoguchi, H; Tabira, T; Nabeshima, T				Mouri, Akihiro; Noda, Yukihiro; Hara, Hideo; Mizoguchi, Hiroyuki; Tabira, Takeshi; Nabeshima, Toshitaka			Oral vaccination with a viral vector containing A beta cDNA attenuates age-related A beta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model	FASEB JOURNAL			English	Article						A beta-peptide; cognitive dysfunction	ADENOASSOCIATED VIRUS VECTOR; AMYLOID PRECURSOR PROTEIN; NITRIC-OXIDE SYNTHASE; TRANSGENIC MICE; DISEASE; IMMUNIZATION; PEPTIDE; IMPAIRMENT; GENE; MICROGLIA	Immunotherapy with A beta is expected to bring great improvement for Alzheimer disease (AD). However, clinical trials have been suspended because of meningoencephalitics, which accompanied lymphocytic infiltration. We have developed an oral vaccine for AD with a recombinant adeno-associated viral vector carrying A beta cDNA (AAV/A beta). The vaccine reduces the amount of A beta deposited without lymphocytic infiltration in APP transgenic (Tg2576) mice. In the present study, Tg2576 mice showed progressive cognitive impairments in the novel object recognition test, Y-maze test, water maze test, and contextual conditioned fear learning test. A single oral administration of AAV/A beta to Tg2576 mice at the age of 10 months alleviated progressive cognitive impairment with decreased A beta deposition, insoluble A beta, soluble A beta oligomer (A beta*56), microglial attraction, and synaptic degeneration induced in the brain regions at the age of 13 months. A histological analysis with hematoxylin and eosin and an immunohistochemical analysis with antibodies against CD3, CD4, CD8, and CD19 suggested there was no lymphocytic infiltration or microhemorrhage in the brain of AAV/A beta-vaccinated Tg2576 mice at 13 months of age. Taken together, these results suggest that immunotherapy with AAV/A beta is a safe and effective treatment for AD.	Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Showa Ku, Nagoya, Aichi 4668560, Japan; Meijo Univ, Fac Pharm, Div Clin Sci & Neuropsychopharmacol, Nagoya, Aichi 468, Japan; Natl Ctr Geriatr & Gerontol, Natl Inst Longev Sci, Dept Vasc Dementia Res, Morioka, Obu, Japan	Nagoya University; Meijo University; National Center for Geriatrics & Gerontology	Nabeshima, T (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668560, Japan.	tnabeshi@med.nagoya-u.ac.jp						Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Berns K I, 1979, Adv Virus Res, V25, P407, DOI 10.1016/S0065-3527(08)60574-6; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Combs CK, 2001, J NEUROSCI, V21, P1179; DICKSON DW, 1988, AM J PATHOL, V132, P86; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; During MJ, 1998, NAT MED, V4, P1131, DOI 10.1038/2625; Enomoto T, 2005, MOL PHARMACOL, V68, P1765, DOI 10.1124/mol.105.011304; Faria AMC, 1999, ADV IMMUNOL, V73, P153, DOI 10.1016/S0065-2776(08)60787-7; Furlan R, 2003, BRAIN, V126, P285, DOI 10.1093/brain/awg031; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Hara H, 2004, J ALZHEIMERS DIS, V6, P483; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kensil C R, 1995, Pharm Biotechnol, V6, P525; Kobayashi K, 2000, J NEUROSCI, V20, P2418; Lazarov O, 2002, J NEUROSCI, V22, P9785; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Mamiya T, 2000, NEUROPHARMACOLOGY, V39, P2391, DOI 10.1016/S0028-3908(00)00078-2; Manabe T, 1998, NATURE, V394, P577, DOI 10.1038/29073; Matsubara E, 2003, J NEUROCHEM, V85, P1101, DOI 10.1046/j.1471-4159.2003.01654.x; Maurice T, 1999, BRIT J PHARMACOL, V127, P335, DOI 10.1038/sj.bjp.0702553; Monsonego A, 2006, P NATL ACAD SCI USA, V103, P5048, DOI 10.1073/pnas.0506209103; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nagai T, 2002, FASEB J, V16, P50, DOI 10.1096/fj.02-0448fje; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Pfeifer M, 2002, SCIENCE, V298, P1379, DOI 10.1126/science.1078259; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Racke MM, 2005, J NEUROSCI, V25, P629, DOI 10.1523/JNEUROSCI.4337-04.2005; Rampon C, 2000, NAT NEUROSCI, V3, P238, DOI 10.1038/72945; Ribaut-Barassin C, 2003, NEUROSCIENCE, V120, P405, DOI 10.1016/S0306-4522(03)00332-4; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Wilcock DM, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-24; Winters BD, 2005, J NEUROSCI, V25, P4243, DOI 10.1523/JNEUROSCI.0480-05.2005; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Xie Z, 2002, J NEUROSCI, V22, P3484; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	48	126	142	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2135	2148		10.1096/fj.06-7685com	http://dx.doi.org/10.1096/fj.06-7685com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17341681				2022-12-28	WOS:000247500300023
J	Pelosi, L; Giacinti, C; Nardis, C; Borsellino, G; Rizzuto, E; Nicoletti, C; Wannenes, F; Battistini, L; Rosenthal, N; Molinaro, M; Musaro, A				Pelosi, Laura; Giacinti, Cristina; Nardis, Chiara; Borsellino, Giovanna; Rizzuto, Emanuele; Nicoletti, Carmine; Wannenes, Francesca; Battistini, Luca; Rosenthal, Nadia; Molinaro, Mario; Musaro, Antonio			Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines	FASEB JOURNAL			English	Article						fibrosis; inflammatory response; injury	GROWTH-FACTOR-I; SKELETAL-MUSCLE; TRANSGENE EXPRESSION; PROTEIN; PROLIFERATION; INHIBITION; INJURIES; ISOFORM; CELLS	Muscle regeneration following injury is characterized by myonecrosis accompanied by local inflammation, activation of satellite cells, and repair of injured fibers. The resolution of the inflammatory response is necessary to proceed toward muscle repair, since persistence of inflammation often renders the damaged muscle incapable of sustaining efficient muscle regeneration. Here, we show that local expression of a muscle-restricted insulin-like growth factor (IGF)-1 (mIGF-1) transgene accelerates the regenerative process of injured skeletal muscle, modulating the inflammatory response, and limiting fibrosis. At the molecular level, mIGF-1 expression significantly down-regulated proinflammatory cytokines, such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta, and modulated the expression of CC chemokines involved in the recruitment of monocytes/ macrophages. Analysis of the underlying molecular mechanisms revealed that mIGF-1 expression modulated key players of inflammatory response, such as macrophage migration inhibitory factor ( MIF), high mobility group protein-1 ( HMGB1), and transcription NF-kappa B. The rapid restoration of injured mIGF-1 transgenic muscle was also associated with connective tissue remodeling and a rapid recovery of functional properties. By modulating the inflammatory response and reducing fibrosis, supplemental mIGF-1 creates a qualitatively different environment for sustaining more efficient muscle regeneration and repair.	Univ Roma La Sapienza, Dept Histol & Med Embryol, CE BEMM, I-00161 Rome, Italy; Univ Roma La Sapienza, Interuniv Inst Myol, I-00161 Rome, Italy; Santa Lucia Fdn Sci Inst, Neuroimmunol Unit, Rome, Italy; IRCCS San Raffaele, Rome, Italy; EMBL Mouse Biol Program, Monterotondo, Italy; Imperial Coll Sch Med, Natl Heart & Lung Inst, Harefield Heart Sci Ctr, London, England; Edith Cowan Univ, Perth, WA, Australia	Sapienza University Rome; Sapienza University Rome; IRCCS Santa Lucia; IRCCS San Raffaele Pisana; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; European Molecular Biology Laboratory (EMBL); Imperial College London; Edith Cowan University	Musaro, A (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, CE BEMM, Via A Scarpa 14, I-00161 Rome, Italy.	antonio.musaro@uniroma1.it	Battistini, Luca/D-6920-2014; Rizzuto, Emanuele/K-9437-2016; Musaro, Antonio/P-2953-2019; Musarò, Antonio/K-9598-2016; Borsellino, Giovanna/K-3074-2016; Rosenthal, Nadia/O-7009-2015; Battistini, luca/ABE-1882-2021	Battistini, Luca/0000-0002-6488-4891; Rizzuto, Emanuele/0000-0003-2314-6128; Musaro, Antonio/0000-0002-2944-9739; Musarò, Antonio/0000-0002-2944-9739; Borsellino, Giovanna/0000-0002-4227-6481; Rosenthal, Nadia/0000-0002-7599-7365; GIACINTI, Cristina/0000-0002-5596-6967; NICOLETTI, Carmine/0000-0001-5896-2040	Telethon [GSP030543] Funding Source: Medline	Telethon(Fondazione Telethon)		Baker W, 2004, J LEUKOCYTE BIOL, V76, P352, DOI 10.1189/jlb.1102528; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Barton PJR, 2005, CIRCULATION, V112, pI46, DOI 10.1161/01.CIRCULATIONAHA.105.525873; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Cannon JG, 1998, MOL CELL BIOCHEM, V179, P159, DOI 10.1023/A:1006828425418; CANTINI M, 1994, BIOCHEM BIOPH RES CO, V202, P1688, DOI 10.1006/bbrc.1994.2129; CANTINI M, 1995, J NEUROPATH EXP NEUR, V54, P121, DOI 10.1097/00005072-199501000-00014; CHANG MS, 1994, J BIOL CHEM, V269, P25277; Dobrowolny G, 2005, J CELL BIOL, V168, P193, DOI 10.1083/jcb.200407021; DOUGLAS MR, 2002, EXPERT REV MOL MED, P1; Frangogiannis NG, 2003, AM J PHYSIOL-HEART C, V285, pH483, DOI 10.1152/ajpheart.01016.2002; Fraser CC, 2006, CELL CYCLE, V5, P1160, DOI 10.4161/cc.5.11.2773; Hirata A, 2003, AM J PATHOL, V163, P203, DOI 10.1016/S0002-9440(10)63644-9; Hogaboam CM, 1998, KIDNEY INT, V54, P2152, DOI 10.1046/j.1523-1755.1998.00176.x; Huang RP, 2001, J IMMUNOL METHODS, V255, P1, DOI 10.1016/S0022-1759(01)00394-5; Huard J, 2002, J BONE JOINT SURG AM, V84A, P822, DOI 10.2106/00004623-200205000-00022; Jarvinen TAHJ, 2005, AM J SPORT MED, V33, P745, DOI 10.1177/0363546505274714; Konig B, 1999, ANTICANCER RES, V19, P1519; Lescaudron L, 1997, J MUSCLE RES CELL M, V18, P631, DOI 10.1023/A:1018679722112; Merly F, 1999, MUSCLE NERVE, V22, P724, DOI 10.1002/(SICI)1097-4598(199906)22:6<724::AID-MUS9>3.0.CO;2-O; Muller S, 2004, J INTERN MED, V255, P332, DOI 10.1111/j.1365-2796.2003.01296.x; Musaro A, 1999, MOL CELL BIOL, V19, P3115; Musaro A, 2004, P NATL ACAD SCI USA, V101, P1206, DOI 10.1073/pnas.0303792101; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Palumbo R, 2004, BIOCHEM PHARMACOL, V68, P1165, DOI 10.1016/j.bcp.2004.03.048; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Sanz S, 2005, GUT, V54, P134, DOI 10.1136/gut.2003.024505; Sato K, 2003, MUSCLE NERVE, V28, P365, DOI 10.1002/mus.10436; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; Summan M, 2003, J INTERF CYTOK RES, V23, P237, DOI 10.1089/107999003321829953; Tidball JG, 2005, AM J PHYSIOL-REG I, V288, pR345, DOI 10.1152/ajpregu.00454.2004; TIDBALL JG, 1995, MED SCI SPORT EXER, V27, P1022, DOI 10.1249/00005768-199507000-00011	35	203	211	2	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1393	1402		10.1096/fj.06-7690com	http://dx.doi.org/10.1096/fj.06-7690com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264161				2022-12-28	WOS:000246117000015
J	Pederson, T				Pederson, Thoru			COUNTERPOINT: Statistical analysis in NIH peer review - identifying innovation	FASEB JOURNAL			English	Editorial Material									Univ Massachusetts, Sch Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Pederson, T (corresponding author), Univ Massachusetts, Sch Med, 377 Plantat St, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu							0	0	0	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2007	21	2					309	310		10.1096/fj.07-0205ufm	http://dx.doi.org/10.1096/fj.07-0205ufm			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17267384				2022-12-28	WOS:000244686300003
J	Chang, YM; Stockinger, MP; Tashiro, H; Lin, CLG				Chang, Yueming; Stockinger, Michael P.; Tashiro, Hirofumi; Lin, Chien-Liang Glenn			A novel noncoding RNA rescues mutant SOD1-mediated cell death	FASEB JOURNAL			English	Article						ALS; neurodegeneration; rRNA	CU/ZN SUPEROXIDE-DISMUTASE; TRANSGENIC-MOUSE MODEL; MOTOR-NEURON DISEASE; ALZHEIMERS-DISEASE; EXTEND SURVIVAL; GENE; EXPRESSION; ALS; MICE; SUPEROXIDE-DISMUTASE-1	Transgenic mice expressing mutant Cu2+/Zn2+ superoxide dismutase SOD1 (G93A) develop similar clinical and pathological phenotypes to amyotrophic lateral sclerosis (ALS) patients. Here, we utilize representational difference analysis to identify the transcripts that are up-regulated in the presymptomatic stage of SOD1 (G93A) mice. Unexpectedly, three predominant clones were 18S or 28S ribosomal RNA (rRNA) segments. One of these clones corresponded to a capped and polyadenylated transcript containing a large portion of 18S rRNA, named MSUR1 (mutant SOD1-up-regulated RNA 1). In vitro expression experiments show that MSUR1 is able to rescue SOD1 (G93A)mediated cell death. Expression of MSUR1 significantly reduces SOD1 (G93A)-induced free radical levels and oxidative damage. Further, MSUR1 can reduce hydrogen peroxide-mediated cytotoxicity. MSUR1 does not encode a protein, suggesting its role as a functional noncoding RNA. It is widely expressed in various tissues. Searching the database of GenBank revealed that a large number of expressed sequence tag (EST) clones contain large portions of rRNA sequence, potentially indicating a heretofore overlooked class of mRNAs with functional significance.	[Chang, Yueming; Stockinger, Michael P.; Tashiro, Hirofumi; Lin, Chien-Liang Glenn] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; [Chang, Yueming; Lin, Chien-Liang Glenn] Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA	Ohio State University; Ohio State University	Lin, CLG (corresponding author), Ohio State Univ, Dept Neurosci, 4198 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	lin.492@osu.edu	Lin, Chien-liang G/E-3513-2011		NIA NIH HHS [AG-17317] Funding Source: Medline; NIMH NIH HHS [MH-059805] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG017317] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andrus PK, 1998, J NEUROCHEM, V71, P2041; Beers DR, 2006, P NATL ACAD SCI USA, V103, P16021, DOI 10.1073/pnas.0607423103; Boillee S, 2006, SCIENCE, V312, P1389, DOI 10.1126/science.1123511; Boillee S, 2006, NEURON, V52, P39, DOI 10.1016/j.neuron.2006.09.018; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Bruijn LI, 1996, NEUROPATH APPL NEURO, V22, P373, DOI 10.1111/j.1365-2990.1996.tb00907.x; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Butchbach MER, 2002, GENE, V292, P81, DOI 10.1016/S0378-1119(02)00669-8; Caricasole A, 2002, FASEB J, V16, P1331, DOI 10.1096/fj.02-0018fje; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Costa FF, 2007, GENE, V386, P1, DOI 10.1016/j.gene.2006.09.028; Costa FF, 2005, GENE, V357, P83, DOI 10.1016/j.gene.2005.06.019; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; DURHAM HD, 1993, NEUROTOXICOLOGY, V14, P387; Gong YH, 2000, J NEUROSCI, V20, P660, DOI 10.1523/JNEUROSCI.20-02-00660.2000; Guo H, 2002, MOL CELL NEUROSCI, V21, P546, DOI 10.1006/mcne.2002.1198; GURNEY ME, 1994, NEW ENGL J MED, V331, P1721, DOI 10.1056/NEJM199412223312516; Hall ED, 1998, J NEUROSCI RES, V53, P66, DOI 10.1002/(SICI)1097-4547(19980701)53:1<66::AID-JNR7>3.3.CO;2-K; Halliwell B, 2000, IUBMB LIFE, V50, P251, DOI 10.1080/15216540051080930; Hashimoto Y, 2001, J NEUROSCI, V21, P9235, DOI 10.1523/JNEUROSCI.21-23-09235.2001; Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046; Mauro VP, 1997, P NATL ACAD SCI USA, V94, P422, DOI 10.1073/pnas.94.2.422; Maximov V, 2002, MED HYPOTHESES, V59, P670, DOI 10.1016/S0306-9877(02)00223-2; Menzies FM, 2002, BRAIN, V125, P1522, DOI 10.1093/brain/awf167; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; Pramatarova A, 2001, J NEUROSCI, V21, P3369, DOI 10.1523/JNEUROSCI.21-10-03369.2001; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Shamovsky I, 2006, NATURE, V440, P556, DOI 10.1038/nature04518; Sokolova T, 2001, NEUROSCI LETT, V297, P129, DOI 10.1016/S0304-3940(00)01689-X; Supattapone S, 2004, J MOL MED, V82, P348, DOI 10.1007/s00109-004-0534-3; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7	38	6	7	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					691	702		10.1096/fj.07-9532com	http://dx.doi.org/10.1096/fj.07-9532com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17957031				2022-12-28	WOS:000254143700008
J	Kostiuk, MA; Corvi, MM; Keller, BO; Plummer, G; Prescher, JA; Hangauer, MJ; Bertozzi, CR; Rajaiah, G; Falck, JR; Berthiaume, LG				Kostiuk, Morris A.; Corvi, Maria M.; Keller, Bernd O.; Plummer, Greg; Prescher, Jennifer A.; Hangauer, Matthew J.; Bertozzi, Carolyn R.; Rajaiah, Gurram; Falck, John R.; Berthiaume, Luc G.			Identification of palmitoylated mitochondrial proteins using a bio-orthogonal azido-palmitate analogue	FASEB JOURNAL			English	Article						azido-fatty acid; carbamoyl phosphate synthetase 1; Staudinger ligation; 3-hydroxy-3-methylglutaryl CoA synthase	COENZYME-A DEHYDROGENASE; ACID BETA-OXIDATION; ELECTRON-TRANSFER FLAVOPROTEIN; ACYL-COA DEHYDROGENASES; RAT-LIVER MITOCHONDRIA; IRON-SULFUR FLAVOPROTEIN; SITE FATTY ACYLATION; GLUTAMATE-DEHYDROGENASE; CATALYTIC-PROPERTIES; IN-VITRO	Increased levels of circulating saturated free fatty acids, such as palmitate, have been implicated in the etiology of type II diabetes and cancer. In addition to being a constituent of glycerolipids and a source of energy, palmitate also covalently attaches to numerous cellular proteins via a process named palmitoylation. Recognized for its roles in membrane tethering, cellular signaling, and protein trafficking, palmitoylation is also emerging as a potential regulator of metabolism. Indeed, we showed previously that the acylation of two mitochondrial proteins at their active site cysteine residues result in their inhibition. Herein, we sought to identify other palmitoylated proteins in mitochondria using a nonradioactive bio-orthogonal azido-palmitate analog that can be selectively derivatized with various tagged triarylphosphines. Our results show that, like palmitate, incorporation of azido-palmitate occurred on mitochondrial proteins via thioester bonds at sites that could be competed out by palmitoyl-CoA. Using this method, we identified 21 putative palmitoylated proteins in the rat liver mitochondrial matrix, a compartment not recognized for its content in palmitoylated proteins, and confirmed the palmitoylation of newly identified mitochondrial 3-hydroxy 3-methylglutaryl-CoA synthase. We postulate that covalent modification and perhaps inhibition of various mitochondrial enzymes by palmitoyl-CoA could lead to the metabolic impairments found in obesity-related diseases.	[Kostiuk, Morris A.; Corvi, Maria M.; Plummer, Greg; Berthiaume, Luc G.] Univ Alberta, Fac Med & Dent, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; [Keller, Bernd O.] Univ British Columbia, Child & Family Res Inst, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; [Prescher, Jennifer A.; Hangauer, Matthew J.; Bertozzi, Carolyn R.] Univ Calif Berkeley, Dept Chem & Mol Cell Biol, Berkeley, CA 94720 USA; [Prescher, Jennifer A.; Hangauer, Matthew J.; Bertozzi, Carolyn R.] Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; [Prescher, Jennifer A.; Hangauer, Matthew J.; Bertozzi, Carolyn R.] Lawrence Berkeley Natl Lab, Div Mat Sci, Berkeley, CA USA; [Rajaiah, Gurram; Falck, John R.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA	University of Alberta; Child & Family Research Institute; University of British Columbia; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of Texas System; University of Texas Southwestern Medical Center Dallas	Berthiaume, LG (corresponding author), Univ Alberta, Fac Med & Dent, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada.	luc.berthiaume@ualberta.ca	Falck, John R/B-3030-2011	Falck, John R/0000-0002-9219-7845; Corvi, Maria/0000-0002-6192-5029; Berthiaume, Luc/0000-0003-0926-059X; Keller, Bernd/0000-0002-6154-5173	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058867, R37GM058867, R01GM031278] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [GM58867, R37 GM058867, R01 GM058867, R01 GM031278] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agnihotri G, 2003, BIOORGAN MED CHEM, V11, P9, DOI 10.1016/S0968-0896(02)00333-4; Bano MC, 1998, BIOCHEM J, V330, P723, DOI 10.1042/bj3300723; BECKMANN JD, 1985, BIOCHEMISTRY-US, V24, P3913, DOI 10.1021/bi00336a016; BECKMANN JD, 1985, BIOCHEMISTRY-US, V24, P3922, DOI 10.1021/bi00336a017; BERTHIAUME L, 1994, J BIOL CHEM, V269, P6498; BERTHIAUME L, 1995, METHOD ENZYMOL, V250, P454; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Bizzozero OA, 2001, BBA-PROTEIN STRUCT M, V1545, P278, DOI 10.1016/S0167-4838(00)00291-0; Corvi MM, 2001, J BIOL CHEM, V276, P45704, DOI 10.1074/jbc.M102766200; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DEICHAITE I, 1993, J BIOL CHEM, V268, P13738; DEVADAS B, 1992, J BIOL CHEM, V267, P7224; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Eder M, 1997, EUR J BIOCHEM, V245, P600, DOI 10.1111/j.1432-1033.1997.00600.x; Faergeman NJ, 1997, BIOCHEM J, V323, P1; FAHIEN LA, 1983, ARCH BIOCHEM BIOPHYS, V220, P386, DOI 10.1016/0003-9861(83)90428-9; FAHIEN LA, 1979, ARCH BIOCHEM BIOPHYS, V192, P33, DOI 10.1016/0003-9861(79)90069-9; FAHIEN LA, 1989, J BIOL CHEM, V264, P12303; FRISELL WR, 1962, J BIOL CHEM, V237, P94; Fukata M, 2004, NEURON, V44, P987, DOI 10.1016/j.neuron.2004.12.005; Ghisla S, 2004, EUR J BIOCHEM, V271, P494, DOI 10.1046/j.1432-1033.2003.03946.x; GILBERT HF, 1981, J BIOL CHEM, V256, P7371; HALL CL, 1980, J BIOL CHEM, V255, P3591; Hang HC, 2007, J AM CHEM SOC, V129, P2744, DOI 10.1021/ja0685001; He XY, 1996, BIOCHEMISTRY-US, V35, P9625, DOI 10.1021/bi960374y; Hegardt FG, 1999, BIOCHEM J, V338, P569, DOI 10.1042/0264-6021:3380569; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; IKEDA Y, 1983, J BIOL CHEM, V258, P1077; IZAI K, 1992, J BIOL CHEM, V267, P1027; Kho Y, 2004, P NATL ACAD SCI USA, V101, P12479, DOI 10.1073/pnas.0403413101; KISPAL G, 1986, J BIOL CHEM, V261, P14209; Lam TKT, 2003, AM J PHYSIOL-ENDOC M, V284, pE863, DOI 10.1152/ajpendo.00033.2003; Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201; Linder ME, 2007, NAT REV MOL CELL BIO, V8, P74, DOI 10.1038/nrm2084; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; LOWE DM, 1985, BIOCHEM J, V227, P591, DOI 10.1042/bj2270591; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; Meertens LM, 1998, EMBO J, V17, P6972, DOI 10.1093/emboj/17.23.6972; Prescher JA, 2004, NATURE, V430, P873, DOI 10.1038/nature02791; REED WD, 1975, J BIOL CHEM, V250, P3117; Resh MD, 2006, METHODS, V40, P191, DOI 10.1016/j.ymeth.2006.04.013; Resh MD, 2006, NAT CHEM BIOL, V2, P584, DOI 10.1038/nchembio834; RESH MD, 2006, SCI STKE, pRE14, DOI DOI 10.1126/STKE.3592006RE14; ROSS NW, 1988, J NEUROSCI RES, V21, P35, DOI 10.1002/jnr.490210106; RUZICKA FJ, 1975, BIOCHEM BIOPH RES CO, V66, P622, DOI 10.1016/0006-291X(75)90555-0; RUZICKA FJ, 1977, J BIOL CHEM, V252, P8440; Saxon E, 2002, J AM CHEM SOC, V124, P14893, DOI 10.1021/ja027748x; Saxon E, 2000, SCIENCE, V287, P2007, DOI 10.1126/science.287.5460.2007; SCHMIDT MFG, 1985, J GEN VIROL, V66, P2635, DOI 10.1099/0022-1317-66-12-2635; Speers AE, 2004, CHEM BIOL, V11, P535, DOI 10.1016/j.chembiol.2004.03.012; STUCKI JW, 1989, J BIOL CHEM, V264, P6376; SUMEGI B, 1984, J BIOL CHEM, V259, P8748; SUMEGI B, 1991, BIOCHIM BIOPHYS ACTA, V1081, P121, DOI 10.1016/0005-2760(91)90016-B; SUMEGI B, 1984, J BIOL CHEM, V259, P5040; Susin SA, 2000, METHOD ENZYMOL, V322, P205; Swarthout JT, 2005, J BIOL CHEM, V280, P31141, DOI 10.1074/jbc.M504113200; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Utsumi T, 2003, FEBS LETT, V539, P37, DOI 10.1016/S0014-5793(03)00180-7; Veit M, 2000, BIOCHEM J, V345, P145, DOI 10.1042/0264-6021:3450145; Vilas GL, 2006, P NATL ACAD SCI USA, V103, P6542, DOI 10.1073/pnas.0600824103; Warden SM, 2001, BIOCHEM J, V354, P275, DOI 10.1042/0264-6021:3540275; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978; WILLIAMSON G, 1984, BIOCHEM J, V218, P521, DOI 10.1042/bj2180521; Yang JY, 2005, BIOCHEMISTRY-US, V44, P11903, DOI 10.1021/bi0508082; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhao LH, 2002, J BIOL CHEM, V277, P49352, DOI 10.1074/jbc.M209760200	66	101	104	1	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2008	22	3					721	732		10.1096/fj.07-9199com	http://dx.doi.org/10.1096/fj.07-9199com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17971398	Green Accepted			2022-12-28	WOS:000254143700011
J	Nakatani, M; Takehara, Y; Sugino, H; Matsumoto, M; Hashimoto, O; Hasegawa, Y; Murakami, T; Uezumi, A; Takeda, S; Noji, S; Sunada, Y; Tsuchida, K				Nakatani, Masashi; Takehara, Yuka; Sugino, Hiromu; Matsumoto, Mitsuru; Hashimoto, Osamu; Hasegawa, Yoshihisa; Murakami, Tatsuya; Uezumi, Akiyoshi; Takeda, Shin'ichi; Noji, Sumihare; Sunada, Yoshihide; Tsuchida, Kunihiro			Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice	FASEB JOURNAL			English	Article						Duchenne muscular dystrophy; activin; therapy; myostatin blockade	MUSCULAR-DYSTROPHY; BINDING-PROTEIN; ACTIVIN; HYPERTROPHY; RECEPTOR; GROWTH; DIFFERENTIATION; HYPERPLASIA; MUTATIONS; SEVERITY	Myostatin is a potent negative regulator of skeletal muscle growth. Therefore, myostatin inhibition offers a novel therapeutic strategy for muscular dystrophy by restoring skeletal muscle mass and suppressing the progression of muscle degeneration. The known myostatin inhibitors include myostatin propeptide, follistatin, follistatin-related proteins, and myostatin antibodies. Although follistatin shows potent myostatin-inhibiting activities, it also acts as an efficient inhibitor of activins. Because activins are involved in multiple functions in various organs, their blockade by follistatin would affect multiple tissues other than skeletal muscles. In the present study, we report the characterization of a myostatin inhibitor derived from follistatin, which does not affect activin signaling. The dissociation constants (K-d) of follistatin to activin and myostatin are 1.72 nM and 12.3 nM, respectively. By contrast, the dissociation constants (K-d) of a follistatin-derived myostatin inhibitor, designated FS I-I, to activin and myostatin are 64.3 mu M and 46.8 nM, respectively. Transgenic mice expressing FS I-I, under the control of a skeletal muscle-specific promoter showed increased skeletal muscle mass and strength. Hyperplasia and hypertrophy were both observed. We crossed FS I-I transgenic mice with mdx mice, a model for Duchenne muscular dystrophy. Notably, the skeletal muscles in the mdx/FS I-I mice showed enlargement and reduced cell infiltration. Muscle strength is also recovered in the mdx/FS I-I mice. These results indicate that myostatin blockade by FS I-I has a therapeutic potential for muscular dystrophy.	[Nakatani, Masashi; Murakami, Tatsuya; Uezumi, Akiyoshi; Tsuchida, Kunihiro] Fujita Hlth Univ, Inst Comprehens Med Sci, Div Therapies Against Intractable Dis, Toyoake, Aichi 4701192, Japan; [Nakatani, Masashi; Takehara, Yuka; Sugino, Hiromu; Matsumoto, Mitsuru] Univ Tokushima, Inst Enzyme Res, Tokushima 770, Japan; [Hashimoto, Osamu; Hasegawa, Yoshihisa] Kitasato Univ, Sch Vet Med & Anim Sci, Lab Expt Anim Sci, Towada, Aomori 034, Japan; [Takeda, Shin'ichi; Sunada, Yoshihide] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mol Therapy, Tokyo, Japan; [Noji, Sumihare] Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, Tokushima 770, Japan; [Takeda, Shin'ichi; Sunada, Yoshihide] Kawasaki Med Sch, Dept Internal Med, Div Neurol, Okayama, Japan	Fujita Health University; Tokushima University; Kitasato University; National Center for Neurology & Psychiatry - Japan; Tokushima University; Kawasaki Medical School	Tsuchida, K (corresponding author), Fujita Hlth Univ, Inst Comprehens Med Sci, Div Therapies Against Intractable Dis, Toyoake, Aichi 4701192, Japan.	tsuchida@fujita-hu.ac.jp	Noji, Sumihare/E-3047-2010; Uezumi, Akiyoshi/ABF-7359-2020; Tsuchida, Kunihiro/A-4501-2012	Uezumi, Akiyoshi/0000-0003-4294-0116; Tsuchida, Kunihiro/0000-0002-3983-5756				Amthor H, 2007, P NATL ACAD SCI USA, V104, P1835, DOI 10.1073/pnas.0604893104; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bartoli M, 2007, GENE THER, V14, P733, DOI 10.1038/sj.gt.3302928; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Bogdanovich S, 2005, FASEB J, V19, P543, DOI 10.1096/fj.04-2796com; Clop A, 2006, NAT GENET, V38, P813, DOI 10.1038/ng1810; DONOGHUE MJ, 1991, P NATL ACAD SCI USA, V88, P5847, DOI 10.1073/pnas.88.13.5847; Engvall E, 2003, FASEB J, V17, P1579, DOI 10.1096/fj.02-1215rev; Grobet L, 2003, GENESIS, V35, P227, DOI 10.1002/gene.10188; Guo QX, 1998, MOL ENDOCRINOL, V12, P96, DOI 10.1210/mend.12.1.0053; Harrington AE, 2006, EMBO J, V25, P1035, DOI 10.1038/sj.emboj.7601000; Hashimoto O, 2000, CELL SIGNAL, V12, P565, DOI 10.1016/S0898-6568(00)00099-1; Hill JJ, 2002, J BIOL CHEM, V277, P40735, DOI 10.1074/jbc.M206379200; Hill JJ, 2003, MOL ENDOCRINOL, V17, P1144, DOI 10.1210/me.2002-0366; Holzbaur ELF, 2006, NEUROBIOL DIS, V23, P697, DOI 10.1016/j.nbd.2006.05.009; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; Khurana TS, 2003, NAT REV DRUG DISCOV, V2, P379, DOI 10.1038/nrd1085; Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Li ZF, 2005, AM J PATHOL, V166, P491, DOI 10.1016/S0002-9440(10)62271-7; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Liu ZH, 2006, J ENDOCRINOL, V189, P409, DOI 10.1677/joe.1.06420; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; NAKAMURA T, 1992, J BIOL CHEM, V267, P16385; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nishi M, 2002, BIOCHEM BIOPH RES CO, V293, P247, DOI 10.1016/S0006-291X(02)00209-7; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohsawa Y, 2006, J CLIN INVEST, V116, P2924, DOI 10.1172/JCI28520; Parsons SA, 2006, AM J PATHOL, V168, P1975, DOI 10.2353/ajpath.2006.051316; Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; Sugino Hiromu, 2000, P251; Thompson TB, 2005, DEV CELL, V9, P535, DOI 10.1016/j.devcel.2005.09.008; Tsuchida K, 2006, EXPERT OPIN BIOL TH, V6, P147, DOI 10.1517/14712598.6.2.147; Tsuchida K, 2000, J BIOL CHEM, V275, P40788, DOI 10.1074/jbc.M006114200; Tsuchida Kunihiro, 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P157, DOI 10.2174/1568008043339901; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; Whittemore LA, 2003, BIOCHEM BIOPH RES CO, V300, P965, DOI 10.1016/S0006-291X(02)02953-4; Yamakawa N, 2002, EMBO J, V21, P1684, DOI 10.1093/emboj/21.7.1684; Yang JZ, 2001, MOL REPROD DEV, V60, P351, DOI 10.1002/mrd.1097; Zhu XL, 2000, FEBS LETT, V474, P71, DOI 10.1016/S0014-5793(00)01570-2	45	142	163	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					477	487		10.1096/fj.07-8673com	http://dx.doi.org/10.1096/fj.07-8673com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17893249				2022-12-28	WOS:000252822600018
J	Sedding, DG; Homann, M; Seay, U; Tillmanns, H; Preissner, KT; Braun-Dullaeus, RC				Sedding, Daniel G.; Homann, Matthias; Seay, Ulrike; Tillmanns, Harald; Preissner, Klaus T.; Braun-Dullaeus, Ruediger C.			Calpain counteracts mechanosensitive apoptosis of vascular smooth muscle cells in vitro and in vivo	FASEB JOURNAL			English	Article						signal transduction; remodeling; p53; restenosis	P53-DEPENDENT APOPTOSIS; HUMAN ATHEROSCLEROSIS; BALLOON ANGIOPLASTY; PROTEASE CALPAIN; PROLIFERATION; P53; EXPRESSION; CELLULARITY; RESTENOSIS; INHIBITOR	Mechanical forces contribute to vascular remodeling processes. Elevated mechanical stress causes apoptosis of vascular smooth muscle cells (VSMCs) within the media. This study examined the role of the cystein protease calpain in force-induced vascular cell apoptosis and its effect on injury-induced vascular remodeling processes. VSMCs were exposed to cyclic tensile force in vitro, which resulted in increased p53 protein expression and transcriptional activity as well as a significant increase of apoptotic VSMCs. Apoptosis was prevented by the p53 inhibitor pifithrin and by p53 antisense oligonucleotides, indicating dependency of force-induced apoptosis on p53. Simultaneously, calpain activity increased by mechanical stress. Prevention of calpain activation by calpeptin or antisense oligonucleotides augmented strain-induced p53 expression and transcriptional activity, resulting in a further increase of apoptotic rate. p53 protein was directly disintegrated by activated calpain. The in vivo relevance of the findings was tested: pharmacologic inhibition of initial calpain activation augmented early apoptosis of medial VSMCs 24 h after balloon injury in a p53-dependent manner but resulted in a marked increase in late neointima formation. We conclude that calpain counteracts mechanically induced excessive VSMC apoptosis through its p53-degrading properties, which identifies calpain as a key regulator of mechanosensitive remodeling processes of the vascular wall.	[Braun-Dullaeus, Ruediger C.] Tech Univ Dresden, Dept Internal Med Cardiol, D-01307 Dresden, Germany; [Homann, Matthias; Preissner, Klaus T.] Univ Giessen, Dept Biochem, Giessen, Germany; [Sedding, Daniel G.; Seay, Ulrike; Tillmanns, Harald] Univ Giessen, Dept Internal Med Cardiol, Giessen, Germany	Technische Universitat Dresden; Justus Liebig University Giessen; Justus Liebig University Giessen	Braun-Dullaeus, RC (corresponding author), Tech Univ Dresden, Dept Internal Med Cardiol, Fetscherstr 76, D-01307 Dresden, Germany.	r.braun-dullaeus@mailbox.tu-dresden.de	Braun-Dullaeus, Ruediger C/G-1844-2013	Braun-Dullaeus, Ruediger C/0000-0003-3888-6532				Ariyoshi H, 1998, ARTERIOSCL THROM VAS, V18, P493, DOI 10.1161/01.ATV.18.3.493; Atencio IA, 2000, CELL GROWTH DIFFER, V11, P247; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Beohar N, 2004, CIRCULATION, V109, P108, DOI 10.1161/01.CIR.0000105724.30980.CD; Best PJM, 1999, ARTERIOSCL THROM VAS, V19, P14, DOI 10.1161/01.ATV.19.1.14; BOCHATONPIALLAT ML, 1995, AM J PATHOL, V146, P1059; Braun-Dullaeus RC, 1999, J CLIN INVEST, V104, P815, DOI 10.1172/JCI5339; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Del Bello B, 2007, ONCOGENE, V26, P2717, DOI 10.1038/sj.onc.1210079; Durand E, 2002, J AM COLL CARDIOL, V39, P1680, DOI 10.1016/S0735-1097(02)01831-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; Guevara NV, 1999, NAT MED, V5, P335, DOI 10.1038/6585; HAN DKM, 1995, AM J PATHOL, V147, P267; HANKE H, 1990, CIRC RES, V67, P651, DOI 10.1161/01.RES.67.3.651; Ihling C, 1998, J PATHOL, V185, P303; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; Kamenz J, 2000, CARDIOVASC RES, V45, P766, DOI 10.1016/S0008-6363(99)00355-7; Kollum M, 1997, ARTERIOSCL THROM VAS, V17, P2383, DOI 10.1161/01.ATV.17.11.2383; Lauth M, 2000, HYPERTENSION, V35, P648, DOI 10.1161/01.HYP.35.2.648; Malik N, 1998, CIRCULATION, V98, P1657, DOI 10.1161/01.CIR.98.16.1657; Mayr M, 2002, FASEB J, V16, P1423, DOI 10.1096/fj.02-0042fje; Mayr M, 2000, FASEB J, V14, P261, DOI 10.1096/fasebj.14.2.261; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Mnjoyan ZH, 2003, CIRCULATION, V108, P464, DOI 10.1161/01.CIR.0000080339.49212.49; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Perlman H, 1997, CIRCULATION, V95, P981; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; ROSSER BG, 1993, J BIOL CHEM, V268, P23593; Sato K, 2001, BIOL CHEM, V382, P743, DOI 10.1515/BC.2001.090; Sedding DG, 2003, CIRCULATION, V108, P616, DOI 10.1161/01.CIR.0000079102.08464.E2; Sotoudeh M, 2002, AM J PHYSIOL-HEART C, V282, pH1709, DOI 10.1152/ajpheart.00744.2001; Walsh K, 2000, CIRC RES, V87, P184, DOI 10.1161/01.RES.87.3.184; Wernig F, 2003, HYPERTENSION, V41, P903, DOI 10.1161/01.HYP.0000062882.42265.88; Yonemitsu Y, 1998, CIRC RES, V82, P147	41	13	16	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					579	589		10.1096/fj.07-8853com	http://dx.doi.org/10.1096/fj.07-8853com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17846083				2022-12-28	WOS:000252822600028
J	Band, M; Shams, I; Joel, A; Avivi, A				Band, Mark; Shams, Imad; Joel, Alma; Avivi, Aaron			Cloning and in vivo expression of vascular endothelial growth factor receptor 2 (Flk1) in the naturally hypoxia-tolerant subterranean mole rat	FASEB JOURNAL			English	Article						Spalax ehrenbergi; VEGF-R2	ENDOTHELIAL GROWTH-FACTOR; SPALAX-EHRENBERGI; FACTOR RECEPTOR-2; UP-REGULATION; BLOOD-FLOW; GLUCOSE-TRANSPORTER; MESSENGER-RNA; RESPONSES; VEGF; ERYTHROPOIETIN	Vascular endothelial growth factor receptor (VEGF) plays a critical role in blood vessel formation and affects nerve growth and survival. VEGF receptor 2 (Flk1) functions as the major signal transducer of angiogenesis, mediating VEGF induction of endothelial tubulogenesis. We have cloned and analyzed expression of Flk1 in the blind subterranean mole rat Spalax ehrenbergi. Spalax experience abrupt and sharp changes in oxygen supply in their sealed underground niche and, hence, are genetically adapted to hypoxia and serve as a unique, natural mammalian model organism for hypoxia tolerance. Spalax Flk1 is relatively conserved at the nucleic acid and amino acid level compared to human, mouse, and rat orthologs. Reverse transcription-quantitative polymerase chain reaction was used to analyze Flk1 expression in muscle and brain of animals exposed to ambient or variant hypoxic oxygen levels at multiple stages of development. Transcript levels were compared with those obtained from Rattus, a primary model for human physiology. Our findings demonstrate that under normoxic conditions Flk1 patterns of expression correlate well with our previous investigations of VEGF expression. Exposure to hypoxic conditions resulted in divergent patterns of Flk1 expression between Spalax and Rattus and between muscle and brain. It appears that the regulatory mechanisms differentiating expression between the species and between tissues are most likely unique, suggesting that Flk1 expression may be regulated by multiple processes, including both angiogenesis and neurogenesis.-Band, M., Shams, I., Joel, A., Avivi, A. Cloning and in vivo expression of vascular endothelial growth factor receptor 2 (Flk1) in the naturally hypoxia-tolerant subterranean mole rat.	[Shams, Imad; Joel, Alma; Avivi, Aaron] Univ Haifa, Inst Evolut, Lab Anim Mol Evolut, IL-31905 Haifa, Israel; [Band, Mark] Univ Illinois, W M Keck Ctr Comparat & Fuct Genom, Urbana, IL 61801 USA	University of Haifa; University of Illinois System; University of Illinois Urbana-Champaign	Avivi, A (corresponding author), Univ Haifa, Inst Evolut, Lab Anim Mol Evolut, Mt Carmel, IL-31905 Haifa, Israel.	aaron@research.haifa.ac.il		Shams, Imad/0000-0001-6496-2928				Andresen J, 2006, J APPL PHYSIOL, V100, P318, DOI 10.1152/japplphysiol.00937.2005; AR A, 1977, RESP PHYSIOL, V30, P201, DOI 10.1016/0034-5687(77)90031-7; ARIELI R, 1991, COMP BIOCHEM PHYS A, V100, P543, DOI 10.1016/0300-9629(91)90367-L; ARIELI R, 1984, EXPERIENTIA, V40, P512, DOI 10.1007/BF01952413; ARIELI R, 1986, EXPERIENTIA, V42, P441, DOI 10.1007/BF02118650; ARIELI R, 1986, EXPERIENTIA, V42, P131, DOI 10.1007/BF01952430; ARIELI R, 1977, PHYSIOL ZOOL, V50, P61, DOI 10.1086/physzool.50.1.30155716; Ashur-Fabian C, 2004, P NATL ACAD SCI USA, V101, P12236, DOI 10.1073/pnas.0404998101; Avivi A, 2007, ONCOGENE, V26, P2507, DOI 10.1038/sj.onc.1210045; Avivi A, 2005, FASEB J, V19, P1314, DOI 10.1096/fj.04-3414fje; Avivi A, 1999, FEBS LETT, V452, P133, DOI 10.1016/S0014-5793(99)00584-0; Avivi A, 2006, PHYSIOL GENOMICS, V27, P54, DOI 10.1152/physiolgenomics.00001.2006; BURLINGTON RF, 1968, NATURE, V219, P1370, DOI 10.1038/2191370a0; Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023; Choi J, 2007, DEV BIOL, V304, P735, DOI 10.1016/j.ydbio.2007.01.023; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Gilbert RD, 2003, HIGH ALT MED BIOL, V4, P203, DOI 10.1089/152702903322022802; GURNETT AM, 1984, J PROTEIN CHEM, V3, P445, DOI 10.1007/BF01025063; Hankeln T, 2005, J INORG BIOCHEM, V99, P110, DOI 10.1016/j.jinorgbio.2004.11.009; Hare Gregory M T, 2004, Curr Opin Anaesthesiol, V17, P363, DOI 10.1097/00001503-200410000-00003; Harik N, 1996, BRAIN RES, V737, P335, DOI 10.1016/0006-8993(96)00965-1; Jensen A, 1999, EUR J OBSTET GYN R B, V84, P155, DOI 10.1016/S0301-2115(98)00325-X; Kappel A, 2000, BLOOD, V96, P3078; KEREM D, 1973, COMP BIOCHEM PHYSIOL, V45, P731, DOI 10.1016/0300-9629(73)90076-5; KLEINSCHMIDT T, 1984, H-S Z PHYSIOL CHEM, V365, P531, DOI 10.1515/bchm2.1984.365.1.531; Kremer C, 1997, CANCER RES, V57, P3852; Laudenbach V, 2007, NEUROBIOL DIS, V26, P243, DOI 10.1016/j.nbd.2006.12.020; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LOU HC, 1987, ANN NEUROL, V22, P289, DOI 10.1002/ana.410220302; Nevo, 1999, MOSAIC EVOLUTION SUB; NEVO E, 1989, HEREDITY, V62, P85, DOI 10.1038/hdy.1989.11; Nevo E., 1961, Mammalia Paris, V25, P127, DOI 10.1515/mamm.1961.25.2.127; Nevo E., 2001, ADAPTIVE RAD BLIND S; Rissanen TT, 2002, AM J PATHOL, V160, P1393, DOI 10.1016/S0002-9440(10)62566-7; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shams I, 2005, FASEB J, V19, P1749, DOI 10.1096/fj.05-3975fje; Shams I, 2005, COMP BIOCHEM PHYS A, V142, P376, DOI 10.1016/j.cbpa.2005.09.003; Shams I, 2004, P NATL ACAD SCI USA, V101, P9698, DOI 10.1073/pnas.0403540101; Shams Imad, 2005, FASEB J, V19, P307; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Shiote M, 2005, NEUROSCIENCE, V132, P175, DOI 10.1016/j.neuroscience.2004.12.031; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Soderstrom V, 1999, J EXP BIOL, V202, P829; Soderstrom V, 1999, NEUROSCI LETT, V267, P1, DOI 10.1016/S0304-3940(99)00269-4; Wang YM, 2007, J NEUROSCI RES, V85, P740, DOI 10.1002/jnr.21169; Widmer HR, 1997, P NATL ACAD SCI USA, V94, P2062, DOI 10.1073/pnas.94.5.2062; Wiener CM, 1996, BIOCHEM BIOPH RES CO, V225, P485, DOI 10.1006/bbrc.1996.1199; Xiao ZF, 2007, CELL RES, V17, P73, DOI 10.1038/sj.cr.7310126; Yang SY, 2001, ARTERIOSCL THROM VAS, V21, P1934, DOI 10.1161/hq1201.099432; Zeller K, 1996, DEV BRAIN RES, V91, P200, DOI 10.1016/0165-3806(95)00177-8	52	10	11	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					105	112		10.1096/fj.07-8892com	http://dx.doi.org/10.1096/fj.07-8892com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17726089				2022-12-28	WOS:000252309900014
J	Liu, K; Mori, S; Takahashi, HK; Tomono, Y; Wake, H; Kanke, T; Sato, Y; Hiraga, N; Adachi, N; Yoshino, T; Nishibori, M				Liu, Keyue; Mori, Shuji; Takahashi, Hideo K.; Tomono, Yasuko; Wake, Hidenori; Kanke, Toru; Sato, Yasuharu; Hiraga, Norihito; Adachi, Naoto; Yoshino, Tadashi; Nishibori, Masahiro			Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats	FASEB JOURNAL			English	Article						target therapy; inflammation; blood-brain barrier; matrix metalloproteinase; inducible nitric oxide synthase	CEREBRAL-ARTERY OCCLUSION; TISSUE-PLASMINOGEN-ACTIVATOR; EMBOLIC FOCAL ISCHEMIA; TUMOR-NECROSIS-FACTOR; NEURITE OUTGROWTH; MATRIX-METALLOPROTEINASE; RHEUMATOID-ARTHRITIS; PROTEIN; RECEPTOR; AMPHOTERIN	The high mobility group box-1 (HMGB1), originally identified as an architectural nuclear protein, exhibits an inflammatory cytokine- like activity in the extracellular space. Here we show that treatment with neutralizing anti- HMGB1 monoclonal antibody ( mAb; 200 mu g, twice) remarkably ameliorated brain infarction induced by 2- h occlusion of the middle cerebral artery in rats, even when the mAb was administered after the start of reperfusion. Consistent with the 90% reduction in infarct size, the accompanying neurological deficits in locomotor function were significantly improved. Anti- HMGB1 mAb inhibited the increased permeability of the blood- brain barrier, the activation of microglia, the expression of TNF-alpha and iNOS, and suppressed the activity of MMP- 9, whereas it had little effect on blood flow. Intracerebroventricular injection of HMGB1 increased the severity of infarction. Immunohistochemical study revealed that HMGB1 immunoreactivity in the cell nuclei decreased or disappeared in the affected areas, suggesting the release of HMGB1 into the extracellular space. These results indicate that HMGB1 plays a critical role in the development of brain infarction through the amplification of plural inflammatory responses in the ischemic region and could be an outstandingly suitable target for the treatment. Intravenous injection of neutralizing anti- HMGB1 mAb provides a novel therapeutic strategy for ischemic stroke.	Okayama Univ, Grad Sch Med, Dept Pharmacol, Dent Pharmaceut Sci, Okayama 7008530, Japan; Shigei Med Inst, Okayama, Japan; Ehime Univ, Dept Anesthesiol & Resuscitol, Matsuyama, Ehime 790, Japan	Okayama University; Ehime University	Nishibori, M (corresponding author), Okayama Univ, Grad Sch Med, Dept Pharmacol, Dent Pharmaceut Sci, Okayama 7008530, Japan.	mbori@md.okayama-u.ac.jp		Takahashi, Hideo/0000-0001-9444-9746				Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Aoki T, 2002, STROKE, V33, P2711, DOI 10.1161/01.STR.0000033932.34467.97; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Becker K, 2001, STROKE, V32, P206, DOI 10.1161/01.STR.32.1.206; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Danton GH, 2004, AM J NEURORADIOL, V25, P181; Dumitriu IE, 2005, TRENDS IMMUNOL, V26, P381, DOI 10.1016/j.it.2005.04.009; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; Harris M, 2004, LANCET ONCOL, V5, P292, DOI 10.1016/S1470-2045(04)01467-6; Hiraga N, 2007, EUR J PHARMACOL, V557, P236, DOI 10.1016/j.ejphar.2006.11.020; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286, DOI 10.1152/ajpregu.1995.268.1.R286; Kaur J, 2004, J CEREBR BLOOD F MET, V24, P945, DOI 10.1097/01.WCB.0000137868.50767.E8; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Kokkola R, 2003, ARTHRITIS RHEUM, V48, P2052, DOI 10.1002/art.11161; Lindsberg PJ, 2003, CURR OPIN NEUROL, V16, P73, DOI 10.1097/00019052-200302000-00010; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Maeda M, 2002, J CEREBR BLOOD F MET, V22, P1205, DOI 10.1097/01.wcb.0000037993.34930.72; Matsuo Y, 2001, STROKE, V32, P2143, DOI 10.1161/hs0901.94259; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; NISHI H, 1989, STROKE, V20, P1236, DOI 10.1161/01.STR.20.9.1236; Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; Pedrazzi M, 2006, J NEUROCHEM, V99, P827, DOI 10.1111/j.1471-4159.2006.04120.x; Phillips JB, 2000, STROKE, V31, P1686, DOI 10.1161/01.STR.31.7.1686; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; Ren D, 2006, INFLAMM RES, V55, P207, DOI 10.1007/s00011-006-0072-2; Rouhiainen A, 2004, BLOOD, V104, P1174, DOI 10.1182/blood-2003-10-3536; ROUSSEL S, 1992, HYPERTENSION, V19, P40, DOI 10.1161/01.HYP.19.1.40; Sado Y, 1996, CELL BIOL INT, V20, P7, DOI 10.1006/cbir.1996.0003; Shimazu T, 2005, STROKE, V36, P353, DOI 10.1161/01.STR.0000152271.21943.a2; Singh R, 2005, CURR OPIN RHEUMATOL, V17, P274; Slevin M, 2005, J CELL MOL MED, V9, P85, DOI 10.1111/j.1582-4934.2005.tb00339.x; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; Taniguchi N, 2003, ARTHRITIS RHEUM, V48, P971, DOI 10.1002/art.10859; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; Ueno H, 2004, AM J RESP CRIT CARE, V170, P1310, DOI 10.1164/rccm.200402-188OC; Ulloa L, 2005, TRENDS MOL MED, V11, P56, DOI 10.1016/j.molmed.2004.12.007; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Yang H, 2005, J LEUKOCYTE BIOL, V78, P1, DOI 10.1189/jlb.1104648; Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82; Zhao BQ, 2004, BLOOD, V103, P2610, DOI 10.1182/blood-2003-03-0835	50	279	299	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3904	3916		10.1096/fj.07-8770com	http://dx.doi.org/10.1096/fj.07-8770com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17628015				2022-12-28	WOS:000251283500016
J	Zhu, W; Xie, W; Pan, T; Xu, PG; Fridkin, M; Zheng, H; Jankovic, J; Youdim, MBH; Le, WD				Zhu, Wen; Xie, Wenjie; Pan, Tianhong; Xu, Pingyi; Fridkin, Mati; Zheng, Hailin; Jankovic, Joseph; Youdim, Moussa B. H.; Le, Weidong			Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators	FASEB JOURNAL			English	Article						ubiquitin-proteaome system; Parkinson's disease; VK-28; M30	PARKINSONS-DISEASE; PROTEASOME INHIBITION; SUBSTANTIA-NIGRA; OXIDATIVE STRESS; ALPHA-SYNUCLEIN; NEURODEGENERATIVE DISEASES; CELL-DEATH; UBIQUITIN-PROTEASOME; REGULATORY PROTEINS; INCREASES IRON	Dysfunction of the ubiquitin- proteasome system ( UPS) and accumulation of iron in substantia nigra ( SN) are implicated in the pathogenesis of Parkinson's disease ( PD). UPS dysfunction and iron misregulation may reinforce each other's contribution to the degeneration of dopamine ( DA) neurons. In the present study, we use a new brain- permeable iron chelator, VK- 28 [ 5-( 4-( 2- hydroxyethyl) piperazin- 1- yl ( methyl)- 8- hydroxyquinoline], and its derivative M30 [ 5-( N- methyl- N- propargyaminomethyl)- 8- hydroxyquinoline] in vivo to test their neuroprotective and neurorestorative properties against proteasome inhibitor ( lactacystin) - induced nigrostriatal degeneration. Bilateral microinjections of lactacystin ( 1.25 mu g/side) into the mouse medial forebrain bundle were performed. Administration of VK- 28 ( 5 mg/ kg, once a day) or M30 ( 5 mg/ kg, once a day) was applied intraperitoneally 7 days before or after the lactacystin microinjection until the mice were sacrificed 28 days after microinjection. We found that VK- 28 and M30 both significantly improved behavioral performances and attenuated lacta-cystin-induced DA neuron loss, proteasomal inhibition, iron accumulation, and microglial activation in SN. In addition, M30 restored the Bcl-2 level, which was suppressed after lactacystin injection. These findings suggest that brain- permeable iron chelators can improve DA neuron survival under UPS impairment. Furthermore, M30, a derivative of VK- 28 and neuroprotective agent rasagiline, may serve as a better neuroprotective therapy for PD.	Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; Tech Rapport Family, Fac Med, IL-31096 Haifa, Israel; Sun Yat Sen Univ, First Affilliated Hosp, Dept Neurol, Guangzhou, Peoples R China; Weizmann Inst Sci, Dept Chem, Rehovot, Israel	Baylor College of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Sun Yat Sen University; Weizmann Institute of Science	Youdim, MBH (corresponding author), Baylor Coll Med, Dept Neurol, NB 205, Houston, TX 77030 USA.	youdim@tx.technion.ac.il; weidongl@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043567] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 043567] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Avramovich-Tirosh Y, 2007, J NEUROCHEM, V100, P490, DOI 10.1111/j.1471-4159.2006.04258.x; Bar-Am O, 2005, FASEB J, V19, P1899, DOI 10.1096/fj.05-3794fje; Ben Shachar D, 2004, NEUROPHARMACOLOGY, V46, P254, DOI 10.1016/j.neuropharm.2003.09.005; Berg D, 2002, NEUROTOX RES, V4, P637, DOI 10.1080/1029842021000045444; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bove J, 2006, ANN NEUROL, V60, P260, DOI 10.1002/ana.20937; Cairo G, 2000, BIOCHEM J, V352, P241, DOI 10.1042/0264-6021:3520241; Del Rio MJ, 2004, ARCH MED RES, V35, P185, DOI 10.1016/j.arcmed.2004.01.001; Fornai F, 2003, J NEUROSCI, V23, P8955; Friedlich AL, 2007, MOL PSYCHIATR, V12, P222, DOI 10.1038/sj.mp.4001937; Gaeta A, 2005, BRIT J PHARMACOL, V146, P1041, DOI 10.1038/sj.bjp.0706416; Gal S, 2005, J NEUROCHEM, V95, P79, DOI 10.1111/j.1471-4159.2005.03341.x; Gerlach M, 2006, J NEURAL TRANSM-SUPP, P133; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Goswami A, 2006, BIOCHEM BIOPH RES CO, V342, P184, DOI 10.1016/j.bbrc.2006.01.136; Gotz ME, 2004, ANN NY ACAD SCI, V1012, P193, DOI 10.1196/annals.1306.017; Grunblatt E, 2004, J NEURAL TRANSM, V111, P1543, DOI 10.1007/s00702-004-0212-1; Grunblatt E, 2001, J NEUROCHEM, V77, P146, DOI 10.1046/j.1471-4159.2001.t01-1-00227.x; GUTTERIDGE JMC, 1992, ANN NEUROL, V32, pS16, DOI 10.1002/ana.410320705; HALLGREN B, 1958, J NEUROCHEM, V3, P41, DOI 10.1111/j.1471-4159.1958.tb12607.x; He Y, 2001, BRAIN RES, V909, P187, DOI 10.1016/S0006-8993(01)02681-6; Hirsch EC, 1999, MOVEMENT DISORD, V14, P383, DOI 10.1002/1531-8257(199903)14:2<383::AID-MDS1037>3.0.CO;2-F; Jellinger KA, 2001, ADV NEUROL, V86, P55; Kaur D, 2004, AGEING RES REV, V3, P327, DOI 10.1016/j.arr.2004.01.003; Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0; Ke ZJ, 2004, NEUROCHEM INT, V45, P361, DOI 10.1016/j.neuint.2003.09.008; Kordower JH, 2006, ANN NEUROL, V60, P264, DOI 10.1002/ana.20935; Le WD, 1997, NEUROSCI LETT, V224, P197, DOI 10.1016/S0304-3940(97)00170-5; Lee M, 2001, FREE RADICAL BIO MED, V31, P1550, DOI 10.1016/S0891-5849(01)00633-5; Lotharius J, 2005, J NEUROSCI, V25, P6329, DOI 10.1523/JNEUROSCI.1746-05.2005; Mandel S, 2004, J MOL NEUROSCI, V24, P401, DOI 10.1385/JMN:24:3:401; Mandel S, 2004, J NEUROCHEM, V88, P1555, DOI 10.1046/j.1471-4159.2003.02291.x; Manning-Bog AB, 2006, ANN NEUROL, V60, P256, DOI 10.1002/ana.20938; Maruyama W, 2006, J NEURAL TRANSM-SUPP, P125; McNaught KS, 2006, ANN NEUROL, V60, P243, DOI 10.1002/ana.20936; McNaught KS, 2002, NEUROREPORT, V13, P1437, DOI 10.1097/00001756-200208070-00018; McNaught KSP, 2004, ANN NEUROL, V56, P149, DOI 10.1002/ana.20186; McNaught KSP, 2006, NEUROBIOL AGING, V27, P530, DOI 10.1016/j.neurobiolaging.2005.08.012; Morrish PK, 1998, J NEUROL NEUROSUR PS, V64, P314, DOI 10.1136/jnnp.64.3.314; Nair VD, 2006, J BIOL CHEM, V281, P39550, DOI 10.1074/jbc.M603950200; OESTREICHER E, 1994, BRAIN RES, V660, P8, DOI 10.1016/0006-8993(94)90833-8; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Sagi Y, 2007, NEUROBIOL DIS, V25, P35, DOI 10.1016/j.nbd.2006.07.020; Shamoto-Nagai M, 2006, J NEURAL TRANSM, V113, P633, DOI 10.1007/s00702-005-0410-5; Siderowf A, 2003, ANN INTERN MED, V138, P651, DOI 10.7326/0003-4819-138-8-200304150-00013; SOFIC E, 1988, J NEURAL TRANSM, V74, P199, DOI 10.1007/BF01244786; Tatton WG, 1999, BBA-BIOENERGETICS, V1410, P195, DOI 10.1016/S0005-2728(98)00167-4; Theil EC, 2000, J BIOL CHEM, V275, P40659, DOI 10.1074/jbc.R000019200; Turnbull S, 2001, FREE RADICAL BIO MED, V30, P1163, DOI 10.1016/S0891-5849(01)00513-5; Wang J, 2007, MOL CELL BIOL, V27, P2423, DOI 10.1128/MCB.01111-06; Youdim MBH, 2003, BIOCHEM PHARMACOL, V66, P1635, DOI 10.1016/S0006-2952(03)00535-5; Zhang X, 2005, BIOCHEM BIOPH RES CO, V333, P544, DOI 10.1016/j.bbrc.2005.05.150; Zheng HL, 2005, BIOORGAN MED CHEM, V13, P773, DOI 10.1016/j.bmc.2004.10.037	53	111	113	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3835	3844		10.1096/fj.07-8386com	http://dx.doi.org/10.1096/fj.07-8386com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17690154				2022-12-28	WOS:000251283500008
J	Castaldi, L; Serra, C; Moretti, F; Messina, G; Paoletti, R; Sampaolesi, M; Torgovnick, A; Baiocchi, M; Padula, F; Pisaniello, A; Molinaro, M; Cossu, G; Levrero, M; Bouche, M				Castaldi, L.; Serra, C.; Moretti, F.; Messina, G.; Paoletti, R.; Sampaolesi, M.; Torgovnick, A.; Baiocchi, M.; Padula, F.; Pisaniello, A.; Molinaro, M.; Cossu, G.; Levrero, M.; Bouche, M.			Bisperoxovanadium, a phospho-tyrosine phosphatase inhibitor, reprograms myogenic cells to acquire a pluripotent, circulating phenotype	FASEB JOURNAL			English	Article						satellite cells; gene reprogramming; muscle deseases; cell therapy	NF-KAPPA-B; SKELETAL-MUSCLE; STEM-CELLS; SATELLITE CELLS; DIFFERENTIATION; ALPHA; MICE; REGENERATION; ACTIVATION; PRECURSORS	Satellite cells are the main source of myogenic progenitors in postnatal skeletal muscle, but their use in cell therapy for muscle disorders is limited because these cells cannot be delivered through circulation and they are rapidly exhausted in severe myopathies. The search for alternative donor cells is ongoing, but none of the candidates so far show all the features required for successful colonization and repair of diseased muscle. In this study, we show that bisperoxovanadium, a phospho-tyrosine phosphatase inhibitor, induces myogenic cells to acquire a gene expression profile and a differentiation potential consistent with the phenotype of a circulating precursors, while maintaining their myogenic potential. These effects are mediated, at least in part, by NF-kappa B activation through the Tyr42-I kappa B-alpha phosphorylation, as shown by the expression of the dominant negative mutant form of the p50 NF-kappa B subunit. Moreover, when bisperoxovanadium-treated cells are injected into the femoral artery of alpha-sarcoglican null dystrophic mice, they are able to circulate and to reach muscle tissue; importantly, they contribute to muscle regeneration, as shown by the expression of alpha-sarcoglican in some fibers. Our observations indicate that bisperoxovanadium, or similar compounds, may prove very valuable to obtain and to expand, from committed cells, multipotent cell populations suitable for gene-cell therapy applications and may help to understand the molecular basis of genome reprogramming and "stem-ness".	Univ Roma La Sapienza, Dept Histol & Med Embryol, CE BEMM, I-00161 Rome, Italy; Univ Roma La Sapienza, Interuniv Inst Myol, I-00161 Rome, Italy; Fdn A Cesalpino, CRS Regina Elena Canc Inst, Milan, Italy; Dibit H San Raffaele, Stem Cell Res Inst, Milan, Italy; Ist Super Sanita, Hematol Lab, I-00161 Rome, Italy; San Raffaele Biomed Sci Pk, Inst Cell Biol & Tissue Engn, Rome, Italy; Univ Roma La Sapienza, Dept Internal Med, Rome, Italy	Sapienza University Rome; Sapienza University Rome; Istituto Superiore di Sanita (ISS); Sapienza University Rome	Bouche, M (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, CE BEMM, Via A Scarpa 14, I-00161 Rome, Italy.	marina.bouche@uniroma1.it	Sampaolesi, Maurilio/H-6509-2013; Messina, Graziella/A-1469-2014; Levrero, Massimo/G-5680-2016	Sampaolesi, Maurilio/0000-0002-2422-3757; Messina, Graziella/0000-0001-8189-0727; Levrero, Massimo/0000-0002-4978-0875; Baiocchi, Marta/0000-0003-0976-0690; Bouche, Marina/0000-0002-0938-5360				Barat C, 2003, J BIOL CHEM, V278, P6992, DOI 10.1074/jbc.M212433200; Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Bonci D, 2003, GENE THER, V10, P630, DOI 10.1038/sj.gt.3301936; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; D'Andrea M, 2006, J CELL PHYSIOL, V207, P379, DOI 10.1002/jcp.20585; Delaisse JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374; Dellavalle A, 2007, NAT CELL BIOL, V9, P255, DOI 10.1038/ncb1542; Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Galvez BG, 2006, J CELL BIOL, V174, P231, DOI 10.1083/jcb.200512085; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hakelien AM, 2002, NAT BIOTECHNOL, V20, P460, DOI 10.1038/nbt0502-460; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Israeli D, 2004, J CELL PHYSIOL, V201, P409, DOI 10.1002/jcp.20088; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Latella L, 2000, CELL DEATH DIFFER, V7, P145, DOI 10.1038/sj.cdd.4400592; Lehtinen SK, 1996, BIOCHEM BIOPH RES CO, V229, P36, DOI 10.1006/bbrc.1996.1754; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; Luchin A, 2001, J BIOL CHEM, V276, P36703, DOI 10.1074/jbc.M106418200; Miyamoto T, 2002, DEV CELL, V3, P137, DOI 10.1016/S1534-5807(02)00201-0; Montarras D, 2005, SCIENCE, V309, P2064, DOI 10.1126/science.1114758; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; Odelberg SJ, 2000, CELL, V103, P1099, DOI 10.1016/S0092-8674(00)00212-9; Ouellet M, 2003, BIOCHEMISTRY-US, V42, P8260, DOI 10.1021/bi034013b; Palacios D, 2006, J CELL PHYSIOL, V207, P1, DOI 10.1002/jcp.20489; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pisaniello A, 2003, J CELL SCI, V116, P1589, DOI 10.1242/jcs.00358; Pomerantz J, 2004, NAT CELL BIOL, V6, P810, DOI 10.1038/ncb0904-810; Qu-Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150; Sacco A, 2005, J CELL BIOL, V171, P483, DOI 10.1083/jcb.200506123; Sampaolesi M, 2003, SCIENCE, V301, P487, DOI 10.1126/science.1082254; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021; Taranger CK, 2005, MOL BIOL CELL, V16, P5719, DOI 10.1091/mbc.e05-06-0572; Torrente Y, 2001, J CELL BIOL, V152, P335, DOI 10.1083/jcb.152.2.335; Waris G, 2003, J BIOL CHEM, V278, P40778, DOI 10.1074/jbc.M303248200; Watanabe Y, 2004, GENE DEV, V18, P889, DOI 10.1101/gad.1179004; Zhou LZH, 2001, FREE RADICAL BIO MED, V31, P1405, DOI 10.1016/S0891-5849(01)00719-5	45	17	19	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3573	3583		10.1096/fj.06-7454com	http://dx.doi.org/10.1096/fj.06-7454com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17601985	Green Accepted			2022-12-28	WOS:000250517800020
J	Reif, R; Sales, S; Hettwer, S; Dreier, B; Gisler, C; Wolfel, J; Luscher, D; Zurlinden, A; Stephan, A; Ahmed, S; Baici, A; Ledermann, B; Kunz, B; Sonderegger, P				Reif, Raymond; Sales, Susanne; Hettwer, Stefan; Dreier, Birgit; Gisler, Claudio; Woelfel, Jens; Luescher, Daniel; Zurlinden, Andreas; Stephan, Alexander; Ahmed, Shaheen; Baici, Antonio; Ledermann, Birgit; Kunz, Beat; Sonderegger, Peter			Specific cleavage of agrin by neurotrypsin, a synaptic protease linked to mental retardation	FASEB JOURNAL			English	Article						serine peptidase; extracellular matrix; cognitive function; nervous system	PRO-ARG CHLOROMETHYLKETONE; HUMAN ALPHA-THROMBIN; CRYSTAL-STRUCTURE; ACTIVE-SITE; SUBSTRATE-SPECIFICITY; DENDRITIC SPINES; GROWTH; COAGULATION; MECHANISMS; FILOPODIA	The synaptic serine protease neurotrypsin is thought to be important for adaptive synaptic processes required for cognitive functions, because humans deficient in neurotrypsin suffer from severe mental retardation. In the present study, we describe the biochemical characterization of neurotrypsin and its so far unique substrate agrin. In cell culture experiment as well as in neurotrypsin-deficient mice, we showed that agrin cleavage depends on neurotrypsin and occurs at two conserved sites. Neurotrypsin and agrin were expressed recombinantly,purified, and assayed in vitro. A catalytic efficiency of 1.3 x 10(4) M-1 s(-1) was determined. Neurotrypsin activity was shown to depend on calcium with an optimal activity in the pH range of 7-8.5. Mutagenesis analysis of the amino acids flanking the scissile bonds showed that cleavage is highly specific due to the unique substrate recognition pocket of neurotrypsin at the active site. The C-terminal agrin fragment released after cleavage has recently been identified as an inactivating ligand of the Na+ / K+-ATPase at CNS synapses, and its binding has been demonstrated to regulate presynaptic excitability. Therefore, dysregulation of agrin processing is a good candidate for a pathogenetic mechanism underlying mental retardation. In turn, these results may also shed light on mechanisms involved in cognitive functions.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Lab Anim Res, CH-8057 Zurich, Switzerland; Neurotune AG, Schlieren, Switzerland	University of Zurich; University of Zurich	Sonderegger, P (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	peter.sonderegger@bioc.uzh.ch		Baici, Antonio/0000-0002-2980-0541				ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Annies M, 2006, MOL CELL NEUROSCI, V31, P515, DOI 10.1016/j.mcn.2005.11.005; Baldi L, 2005, BIOTECHNOL PROGR, V21, P148, DOI 10.1021/bp049830x; Bezakova G, 2003, NAT REV MOL CELL BIO, V4, P295, DOI 10.1038/nrm1074; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; Bode W, 2006, SEMIN THROMB HEMOST, V32, P16, DOI 10.1055/s-2006-939551; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Chelly J, 2001, NAT REV GENET, V2, P669, DOI 10.1038/35088558; Coombs GS, 1996, J BIOL CHEM, V271, P4461; DeLano W.L, PYMOL MOL GRAPHICS S; Ethell IM, 2005, PROG NEUROBIOL, V75, P161, DOI 10.1016/j.pneurobio.2005.02.003; Fiala JC, 2002, BRAIN RES REV, V39, P29, DOI 10.1016/S0165-0173(02)00158-3; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; Gschwend TP, 1997, MOL CELL NEUROSCI, V9, P207, DOI 10.1006/mcne.1997.0616; Hilgenberg LGW, 2006, CELL, V125, P359, DOI 10.1016/j.cell.2006.01.052; Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613; Kardos J, 1999, BIOCHEMISTRY-US, V38, P12248, DOI 10.1021/bi990764v; Knott GW, 2006, NAT NEUROSCI, V9, P1117, DOI 10.1038/nn1747; Krishnaswamy S, 2005, J THROMB HAEMOST, V3, P54, DOI 10.1111/j.1538-7836.2004.01021.x; Kummer TT, 2006, CURR OPIN NEUROBIOL, V16, P74, DOI 10.1016/j.conb.2005.12.003; Lin YR, 2005, CRYST GROWTH DES, V5, P579, DOI 10.1021/cg049747h; Matus A, 2005, CURR OPIN NEUROBIOL, V15, P67, DOI 10.1016/j.conb.2005.01.015; McCroskery S, 2006, MOL CELL NEUROSCI, V33, P15, DOI 10.1016/j.mcn.2006.06.004; Misgeld T, 2005, P NATL ACAD SCI USA, V102, P11088, DOI 10.1073/pnas.0504806102; Molinari F, 2002, SCIENCE, V298, P1779, DOI 10.1126/science.1076521; Nimchinsky EA, 2002, ANNU REV PHYSIOL, V64, P313, DOI 10.1146/annurev.physiol.64.081501.160008; Proba K, 1998, BBA-GENE STRUCT EXPR, V1396, P143, DOI 10.1016/S0167-4781(97)00205-4; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; Ropers HH, 2006, CURR OPIN GENET DEV, V16, P260, DOI 10.1016/j.gde.2006.04.017; Ropers HH, 2005, NAT REV GENET, V6, P46, DOI 10.1038/nrg1501; RUHLMANN A, 1973, J MOL BIOL, V77, P417, DOI 10.1016/0022-2836(73)90448-8; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6	35	77	85	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3468	3478		10.1096/fj.07-8800com	http://dx.doi.org/10.1096/fj.07-8800com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17586728				2022-12-28	WOS:000250517800010
J	Cantero, AV; Portero-Otin, M; Ayala, V; Auge, N; Sanson, M; Elbaz, M; Thiers, JC; Pamplona, R; Salvayre, R; Negre-Salvayre, A				Cantero, Anne-Valerie; Portero-Otin, Manuel; Ayala, Victoria; Auge, Nathalie; Sanson, Marie; Elbaz, Meyer; Thiers, Jean-Claude; Pamplona, Reinald; Salvayre, Robert; Negre-Salvayre, Anne			Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-beta: implications for diabetic atherosclerosis	FASEB JOURNAL			English	Article						oxidative stress; growth arrest; MGO; wound healing; apoptosis	GROWTH-FACTOR; CARDIOVASCULAR-DISEASE; ACCELERATED ATHEROSCLEROSIS; MAILLARD REACTION; MESANGIAL CELLS; PROTEINS; COMPLICATIONS; ACTIVATION; N-EPSILON-(CARBOXYMETHYL)LYSINE; GLYCOXIDATION	Purpose: Low molecular weight carbonyl compounds, such as the alpha-ketoaldehydes methylglyoxal (MGO) and glyoxal (GO), are formed under hyperglycemic conditions and behave as advanced glycation end product (AGE) precursors. They form adducts on proteins, thereby inducing cellular dysfunctions involved in chronic complications of diabetes. Methods and main findings: Nontoxic concentrations of GO or MGO altered the PDGF-induced PDGFR beta-phosphorylation, ERK1/ 2-activation, and nuclear translocation, and the subsequent proliferation of mesenchymal cells (smooth muscle cells and skin fibroblasts). This resulted mainly from inhibition of the intrinsic tyrosine kinase of PDGFR beta and in part from altered PDGF-BB binding to PDGFR beta. Concomitantly, the formation of AGE adducts (N-epsilon carboxymethyl-ly-sine and N-epsilon carboxyethyl-lysine) was observed on immunoprecipitated PDGFR beta. Arginine and aminoguanidine, used as carbonyl scavengers, reversed the inhibitory effect and the formation of AGE adducts on PDGFR beta. AGE-PDGFR beta adducts were also detected by anti-AGE antibodies in PDGFR beta immunopurified from aortas of diabetic (streptozotocin-treated) compared to nondiabetic apolipoprotein E-null mice. Mass spectrometry analysis of aortas demonstrated increased AGE formation in diabetic specimens. Conclusions: these data indicate that MGO and GO induce desensitization of PDGFR beta that helps to reduce mesenchymal cell proliferation.	Univ Toulouse 3, CHU Rangueil, IFR 31, INSERM,U466, F-31059 Toulouse 9, France; Univ Toulouse 3, CHU Rangueil, IFR 31, Dept Biochem, F-31059 Toulouse 9, France; Univ Lleida, Dept Basic Med Sci, Metab Pathophysiol Res Grp, Lleida, Spain	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universitat de Lleida	Negre-Salvayre, A (corresponding author), Univ Toulouse 3, CHU Rangueil, IFR 31, INSERM,U466, F-31059 Toulouse 9, France.	salvayre@toulouse.inserm.fr	Ayala, Maria Victoria/A-7391-2010; Pamplona, Reinald/A-7359-2010; Portero-Otin, Manuel/B-7122-2009	Ayala, Maria Victoria/0000-0002-1496-966X; Pamplona, Reinald/0000-0003-4337-6107; Portero-Otin, Manuel/0000-0002-1823-0299; Auge, Nathalie/0000-0003-2088-7211; ELBAZ, Meyer/0000-0002-3520-7883; Negre-Salvayre, Anne/0000-0003-2136-5706				Askari B, 2002, HISTOL HISTOPATHOL, V17, P1317, DOI 10.14670/HH-17.1317; Baynes JW, 2000, FREE RADICAL BIO MED, V28, P1708, DOI 10.1016/S0891-5849(00)00228-8; Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; Betsholtz C, 2004, CURR OPIN NEPHROL HY, V13, P45, DOI 10.1097/00041552-200401000-00007; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Bucciarelli LG, 2002, CIRCULATION, V106, P2827, DOI 10.1161/01.CIR.0000039325.03698.36; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Escargueil-Blanc I, 2001, CIRCULATION, V104, P1814, DOI 10.1161/hc4001.097179; Ferreira AEN, 2003, BIOCHEM J, V376, P109, DOI 10.1042/BJ20030496; Forbes JM, 2004, DIABETES, V53, P1813, DOI 10.2337/diabetes.53.7.1813; Hedin U, 2004, CURR OPIN LIPIDOL, V15, P559, DOI 10.1097/00041433-200410000-00010; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Jia XM, 2006, FASEB J, V20, P1555, DOI 10.1096/fj.05-5478fje; Kalapos MP, 1999, TOXICOL LETT, V110, P145, DOI 10.1016/S0378-4274(99)00160-5; KANNEL WB, 1979, CIRCULATION, V59, P8, DOI 10.1161/01.CIR.59.1.8; Kolodgie FD, 2001, CURR OPIN CARDIOL, V16, P285, DOI 10.1097/00001573-200109000-00006; Koveker GB, 2000, INT J CLIN PRACT, V54, P590; Laakso M, 1999, PRIMARY CARE, V26, P829, DOI 10.1016/S0095-4543(05)70133-0; Lapolla A, 2005, MOL NUTR FOOD RES, V49, P685, DOI 10.1002/mnfr.200400093; Lieuw-A-Fa MLM, 2004, NEPHROL DIAL TRANSPL, V19, P631, DOI 10.1093/ndt/gfg619; Liu BF, 2003, KIDNEY INT, V63, P947, DOI 10.1046/j.1523-1755.2003.00829.x; Lu CY, 2004, P NATL ACAD SCI USA, V101, P11767, DOI 10.1073/pnas.0401588101; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Margolis DJ, 2005, WOUND REPAIR REGEN, V13, P531, DOI 10.1111/j.1524-475X.2005.00074.x; Metz TO, 2003, J BIOL CHEM, V278, P42012, DOI 10.1074/jbc.M304292200; Morgan PE, 2002, ARCH BIOCHEM BIOPHYS, V403, P259, DOI 10.1016/S0003-9861(02)00222-9; Pamplona R, 2005, J BIOL CHEM, V280, P21522, DOI 10.1074/jbc.M502255200; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Passarelli M, 2005, DIABETES, V54, P2198, DOI 10.2337/diabetes.54.7.2198; Portero-Otin M, 2002, DIABETES, V51, P1535, DOI 10.2337/diabetes.51.5.1535; Raines EW, 2004, CYTOKINE GROWTH F R, V15, P237, DOI 10.1016/j.cytogfr.2004.03.004; Randell E. W., 2005, Journal of Pharmacological and Toxicological Methods, V51, P153, DOI 10.1016/j.vascn.2004.08.005; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; Requena JR, 2001, P NATL ACAD SCI USA, V98, P69, DOI 10.1073/pnas.011526698; Riboulet-Chavey A, 2006, DIABETES, V55, P1289, DOI 10.2337/db05-0857; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sakamoto H, 2002, J BIOL CHEM, V277, P45770, DOI 10.1074/jbc.M207485200; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Seki N, 2003, METABOLISM, V52, P1558, DOI 10.1016/j.metabol.2003.07.010; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; Thomas MC, 2005, CURR DRUG TARGETS, V6, P453, DOI 10.2174/1389450054021873; Thornalley PJ, 1996, GEN PHARMACOL-VASC S, V27, P565, DOI 10.1016/0306-3623(95)02054-3; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; Thorpe SR, 2003, AMINO ACIDS, V25, P275, DOI 10.1007/s00726-003-0017-9; Vindis C, 2006, CIRC RES, V98, P785, DOI 10.1161/01.RES.0000216288.93234.c3; Watson RT, 2004, ENDOCR REV, V25, P177, DOI 10.1210/er.2003-0011; Yan SF, 2003, CIRC RES, V93, P1159, DOI 10.1161/01.RES.0000103862.26506.3D; Yao DC, 2006, CELL, V124, P275, DOI 10.1016/j.cell.2005.11.024	49	102	107	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3096	3106		10.1096/fj.06-7536com	http://dx.doi.org/10.1096/fj.06-7536com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17504976				2022-12-28	WOS:000249781600011
J	Jacquelin, B; Mayau, V; Brysbaert, G; Regnault, B; Diop, OM; Arenzana-Seisdedos, F; Rogge, L; Coppee, JY; Barre-Sinoussi, F; Benecke, A; Muller-Trutwin, MC				Jacquelin, Beatrice; Mayau, Veronique; Brysbaert, Guillaume; Regnault, Beatrice; Diop, Ousmane M.; Arenzana-Seisdedos, Fernando; Rogge, Lars; Coppee, Jean-Yves; Barre-Sinoussi, Francoise; Benecke, Arndt; Mueller-Trutwin, Michaela C.			Long oligonucleotide microarrays for African green monkey gene expression profile analysis	FASEB JOURNAL			English	Article						nonhuman primate; macaque; CD4(+) T cell; brain; tonsil	IMMUNODEFICIENCY VIRUS SIVAGM; NONHUMAN-PRIMATES; VERVET MONKEYS; LYMPH-NODES; CELLS; TRANSCRIPTOME; INFECTION; BLOOD; REPLICATION; INFORMATION	Nonhuman primates, including African green monkey (AGM), are important models for biomedical research. The information on monkey genomes is still limited and no versatile gene expression screening tool is available. We tested human whole genome microarrays for cross-species reactivity with AGM transcripts using both long oligonucleotide arrays (60-mer probes) and short oligonucleotide arrays (25-mer). Using the long oligonucleotide arrays, we detected 4-fold more AGM transcripts than with the short oligonucleotide technology. The number of detected transcripts was comparable to that detected using human RNA, with 87% of the detected genes being shared between both species. The specificity of the signals obtained with the long oligonucleotide arrays was determined by analyzing the transcriptome of concanavalin A-activated CD4(+) T cells vs. nonactivated T cells of two monkey species AGM and macaque. For both species, the genes showing the most significant changes in expression, such as IL-2R, were those known to be regulated in human CD4(+) T cell activation. Finally, tissue specificity of the signals was established by comparing the transcription profiles of AGM brain and tonsil cells. In conclusion, the ABI human microarray platform provides a highly valuable tool for the assessment of AGM gene expression profiles.	Inst Pasteur, Unite Regulat Infect Retrovirales, F-75724 Paris 15, France; Inst Pasteur, Plateforme Puces ADN Genopole, F-75724 Paris 15, France; Inst Pasteur, Lab Pathol Virale Mol, F-75724 Paris 15, France; Inst Pasteur, Grp Ans Immunoregulat 5, F-75724 Paris 15, France; Inst Pasteur, Lab Retrovirol, Dakar, Senegal; Inst Rech Interdisciplinaire, CNRS, Bures Sur Yvette, France; Inst Hautes Etud Sci, F-91440 Bures Sur Yvette, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Dakar; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Muller-Trutwin, MC (corresponding author), Inst Pasteur, Unite Regulat Infect Retrovirales, 25 Rue Dr Roux, F-75724 Paris 15, France.	mmuller@pasteur.fr	Barre-Sinoussi, Françoise/G-8355-2011; Benecke, Arndt G./T-1079-2019; Arenzana-Seisdedos, Fernando/E-5835-2016; Rogge, Lars/GYJ-6142-2022	Muller-Trutwin, Michaela/0000-0002-3854-2396; Brysbaert, Guillaume/0000-0002-6807-6621; Rogge, Lars/0000-0003-1262-9204; JACQUELIN, Beatrice/0000-0002-1896-5092; REGNAULT, Beatrice/0000-0002-3914-1914				Ali-Seyed M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-54; AlvarezThull L, 1996, BIOTHERAPY, V9, P55, DOI 10.1007/BF02628657; Bammler T, 2005, NAT METHODS, V2, P351, DOI 10.1038/nmeth0605-477a; Barrett JC, 2003, DRUG DISCOV TODAY, V8, P134, DOI 10.1016/S1359-6446(02)02578-3; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; Chen HF, 2000, TRANSPLANTATION, V69, P1555; Chismar JD, 2002, BIOTECHNIQUES, V33, P516, DOI 10.2144/02333st01_11836a; Cobb JP, 2005, P NATL ACAD SCI USA, V102, P4801, DOI 10.1073/pnas.0409768102; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Deinard A, 2001, J HUM EVOL, V41, P45, DOI 10.1006/jhev.2001.0480; Dillman JF, 2005, TOXICOL SCI, V87, P306, DOI 10.1093/toxsci/kfi243; Eady JJ, 2005, PHYSIOL GENOMICS, V22, P402, DOI 10.1152/physiolgenomics.00080.2005; Fujiyama A, 2002, SCIENCE, V295, P131, DOI 10.1126/science.1065199; George MD, 2006, J MED PRIMATOL, V35, P261, DOI 10.1111/j.1600-0684.2006.00180.x; George MD, 2003, VIROLOGY, V312, P84, DOI 10.1016/S0042-6822(03)00207-1; Gibbs RA, 2007, SCIENCE, V316, P222, DOI 10.1126/science.1139247; GICHUKI CW, 1994, TROP MED PARASITOL, V45, P237; GITHURE JI, 1987, EXP PARASITOL, V64, P438, DOI 10.1016/0014-4894(87)90058-0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Gueye A, 2004, J MED PRIMATOL, V33, P83, DOI 10.1111/j.1600-0684.2004.00057.x; Irizarry RA, 2005, NAT METHODS, V2, P345, DOI 10.1038/nmeth756; Jentsch JD, 1997, SCIENCE, V277, P953, DOI 10.1126/science.277.5328.953; Kryworuchko M, 2006, VITAM HORM, V74, P531, DOI 10.1016/S0083-6729(06)74021-3; Kuhmann SE, 2001, J VIROL, V75, P8449, DOI 10.1128/JVI.75.18.8449-8460.2001; Kuo WP, 2006, NAT BIOTECHNOL, V24, P832, DOI 10.1038/nbt1217; Lachance PED, 2004, J NEUROCHEM, V88, P1455, DOI 10.1046/j.1471-4159.2003.02274.x; Lafont BAP, 2000, CYTOMETRY, V41, P193, DOI 10.1002/1097-0320(20001101)41:3<193::AID-CYTO6>3.0.CO;2-G; Lee AM, 2006, NEUROPHARMACOLOGY, V50, P441, DOI 10.1016/j.neuropharm.2005.10.003; Lee AM, 2006, EUR J PHARMACOL, V552, P151, DOI 10.1016/j.ejphar.2006.09.006; Liew FY, 2002, NAT REV IMMUNOL, V2, P55, DOI 10.1038/nri705; Liu Jun O, 2005, Sci STKE, V2005, pre1; Magness CL, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-r60; Marvanova M, 2003, FASEB J, V17, P929, DOI 10.1096/fj.02-0681fje; Morris G, 2005, PROG BRAIN RES, V147, P285, DOI 10.1016/S0079-6123(04)47021-6; Muller MC, 2003, FRONT BIOSCI-LANDMRK, V8, pD1170, DOI 10.2741/1130; Muller-Trutwin M, 2005, IMMUNOL CELL BIOL, V83, P578, DOI 10.1111/j.1440-1711.2005.01394.x; Muller-Trutwin MC, 1999, AIDS RES HUM RETROV, V15, P931, DOI 10.1089/088922299310647; Noth S, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-307; Noth Sebastian, 2006, Genomics Proteomics & Bioinformatics, V4, P90, DOI 10.1016/S1672-0229(06)60021-1; Noth Sebastian, 2006, Genomics Proteomics & Bioinformatics, V4, P212, DOI 10.1016/S1672-0229(07)60002-3; Pandrea I, 2005, J VIROL, V79, P6249, DOI 10.1128/JVI.79.10.6249-6259.2005; Pandrea I, 2006, J VIROL, V80, P4858, DOI 10.1128/JVI.80.10.4858-4867.2006; Penn SG, 2000, NAT GENET, V26, P315, DOI 10.1038/81613; Petersen D, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-63; Ploquin MJY, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-37; Ploquin MJY, 2004, J VIROL, V78, P798, DOI 10.1128/JVI.78.2.798-810.2004; Radtke C, 2003, FASEB J, V17, P335, DOI 10.1096/fj.03-0214fje; Regan CP, 2006, J PHARMACOL EXP THER, V316, P727, DOI 10.1124/jpet.105.094839; RHIM JS, 1967, P SOC EXP BIOL MED, V125, P602, DOI 10.3181/00379727-125-32157; RUDEL LL, 1995, AM J CLIN NUTR, V62, p463S, DOI 10.1093/ajcn/62.2.463S; Schindler H, 2005, ANAL BIOCHEM, V344, P92, DOI 10.1016/j.ab.2005.06.006; Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239; Sibal L R, 2001, ILAR J, V42, P74; Spindel ER, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-160; Stears RL, 2003, NAT MED, V9, P140, DOI 10.1038/nm0103-140; Stefano GB, 2005, MED SCI MONITOR, V11, pMS35; Taylor JR, 1997, NEUROSCIENCE, V81, P745, DOI 10.1016/S0306-4522(97)00214-5; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Walker SJ, 2006, J NEUROSCI METH, V152, P179, DOI 10.1016/j.jneumeth.2005.09.007; Wang ZN, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-165; Windpassinger C, 2002, GENE, V292, P25, DOI 10.1016/S0378-1119(02)00649-2; YALCIN S, 1992, J GEN VIROL, V73, P1673, DOI 10.1099/0022-1317-73-7-1673; Zeng ZZ, 2003, J CHEM NEUROANAT, V25, P269, DOI 10.1016/S0891-0618(03)00038-3; Zhang LD, 2006, BMC GENOMICS, V7, DOI [10.1186/1471-2164-7-323, 10.1186/1471-2164-7-153]; 2004, NATURE REV GENET, V5, P229	65	11	12	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3262	3271		10.1096/fj.07-8271com	http://dx.doi.org/10.1096/fj.07-8271com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17507667				2022-12-28	WOS:000249781600026
J	Meplan, C; Crosley, LK; Nicol, F; Beckett, GJ; Howie, AF; Hill, KE; Horgan, G; Mathers, JC; Arthur, JR; Hesketh, JE				Meplan, Catherine; Crosley, Lynne K.; Nicol, Fergus; Beckett, Geoffrey J.; Howie, Alexander F.; Hill, Kristina E.; Horgan, Graham; Mathers, John C.; Arthur, John R.; Hesketh, John E.			Genetic polymorphisms in the human selenoprotein P gene determine the response of selenoprotein markers to selenium supplementation in a gender-specific manner (the SELGEN study)	FASEB JOURNAL			English	Article						nutrient-gene interaction; 3 ' untranslated region; BMI	GLUTATHIONE-PEROXIDASE; CANCER PREVENTION; OXIDATIVE DAMAGE; EXPRESSION; HEALTH; DEFICIENCY; MORTALITY; DELETION; TISSUES; MOUSE	Selenium (Se), a micronutrient essential for human health, is incorporated into at least 25 selenoproteins including selenoprotein P (SePP), which transports Se within the body. This research identified two single nucleotide polymorphisms (SNPs) in the SePP gene, one in the coding region (position 24731, causing an Ala to Thr change) and one in the 3 ' untranslated region (position 25191). Their frequency was similar in Caucasian, Chinese, and South Asian populations. Prospectively genotyped volunteers were supplemented for 6 wk with 100 mu g sodium selenite/ day. Blood samples were analyzed for plasma Se and selenoprotein biomarkers at baseline, after supplementation, and during a washout period. Plasma Se, SePP, and glutathione peroxidase 3 (GPx3) levels increased with supplementation. Baseline plasma Se content depended on both SePP genotypes and body mass index. Pre-supplementation SePP concentration was associated with gender and genotype at SNP 24731 and post-supplementation concentration with SNP 25191. Both SNPs and gender were associated with differences in GPx3 activity, plasma, and erythrocyte thioredoxin reductase 1 concentrations and lymphocyte glutathione peroxidase 1 and 4 activities and concentrations. In conclusion, the data reveal two common functional SNPs within the human SePP gene that may predict behavior of biomarkers of Se status and response to supplementation and thus susceptibility to disease.	Univ Newcastle, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle, Sch Med, Human Nutr Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle, Sch Med, Sch Clin Med Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Edinburgh, Dept Clin Biochem, Edinburgh, Midlothian, Scotland; Vanderbilt Univ, Sch Med, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37212 USA; BioSS, Aberdeen, Scotland; Rowett Res Inst, Aberdeen, Scotland	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; University of Edinburgh; Vanderbilt University; James Hutton Institute; University of Aberdeen	Hesketh, JE (corresponding author), Univ Newcastle, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	j.e.hesketh@ncl.ac.uk	Horgan, Graham/J-3738-2013	Mathers, John/0000-0003-3406-3002	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058763] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK-58763] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akbaraly NT, 2005, CLIN CHEM, V51, P2117, DOI 10.1373/clinchem.2005.055301; Al-Taie OH, 2004, NUTR CANCER, V48, P6, DOI 10.1207/s15327914nc4801_2; Allan CB, 1999, ANNU REV NUTR, V19, P1, DOI 10.1146/annurev.nutr.19.1.1; Beckett GJ, 2005, J ENDOCRINOL, V184, P455, DOI 10.1677/joe.1.05971; BERMANO G, 1995, BIOCHEM J, V311, P425, DOI 10.1042/bj3110425; Bhopal R, 1999, BRIT MED J, V319, P215, DOI 10.1136/bmj.319.7204.215; Broome CS, 2004, AM J CLIN NUTR, V80, P154; Brown KM, 2000, CLIN SCI, V98, P593, DOI 10.1042/CS19990276; Burk RF, 2005, ANNU REV NUTR, V25, P215, DOI 10.1146/annurev.nutr.24.012003.132120; Burk RF, 2006, CANCER EPIDEM BIOMAR, V15, P804, DOI 10.1158/1055-9965.EPI-05-0950; Combs GF, 2005, J NUTR, V135, P343, DOI 10.1093/jn/135.2.343; Fischbacher C M, 2002, J Epidemiol Community Health, V56, P79, DOI 10.1136/jech.56.1.79; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; Hill KE, 2004, J NUTR, V134, P157, DOI 10.1093/jn/134.1.157; Hirashima M, 2003, BIOL PHARM BULL, V26, P794; Maehara S, 2004, INT J CANCER, V112, P184, DOI 10.1002/ijc.20304; Meplan C., 2006, Nutritional genomics: impact on health and disease, P132, DOI 10.1002/3527608109.ch8; Miller S, 2001, CLIN SCI, V100, P543, DOI 10.1042/CS20000299; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Ray AL, 2006, J NUTR, V136, P172, DOI 10.1093/jn/136.1.172; Rayman MP, 2004, BRIT J NUTR, V92, P557, DOI 10.1079/BJN20041251; Rayman MP, 2005, P NUTR SOC, V64, P527, DOI 10.1079/PNS2005467; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; Riese C, 2006, ENDOCRINOLOGY, V147, P5883, DOI 10.1210/en.2006-0689; Saito Y, 2004, BIOCHEM J, V381, P841, DOI 10.1042/BJ20040328; Schomburg L, 2003, BIOCHEM J, V370, P397, DOI 10.1042/BJ20021853; Schweizer U, 2004, BRAIN RES REV, V45, P164, DOI 10.1016/j.brainresrev.2004.03.004; Schweizer U, 2005, BIOCHEM J, V386, P221, DOI 10.1042/BJ20041973; Small-Howard AL, 2005, BIOCHEM SOC T, V33, P1493, DOI 10.1042/BST0331493; STADTMAN TC, 1990, ANNU REV BIOCHEM, V59, P111, DOI 10.1146/annurev.bi.59.070190.000551; Steinbrenner H, 2006, FREE RADICAL BIO MED, V40, P1513, DOI 10.1016/j.freeradbiomed.2005.12.022; Weiss SL, 1996, J NUTR, V126, P2260, DOI 10.1093/jn/126.9.2260; WEITZEL F, 1990, BIOCHIM BIOPHYS ACTA, V1036, P88, DOI 10.1016/0304-4165(90)90018-R; Whanger PD, 2004, BRIT J NUTR, V91, P11, DOI 10.1079/BJN20031015; Wolters M, 2006, EUR J CLIN NUTR, V60, P85, DOI 10.1038/sj.ejcn.1602271; Xia YM, 2005, AM J CLIN NUTR, V81, P829, DOI 10.1093/ajcn/81.4.829	36	168	174	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3063	3074		10.1096/fj.07-8166com	http://dx.doi.org/10.1096/fj.07-8166com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17536041				2022-12-28	WOS:000249781600008
J	Goldberg, A; Parolini, M; Chin, BY; Czismadia, E; Otterbein, LE; Bach, FH; Wang, HJ				Goldberg, Alyssa; Parolini, Margherita; Chin, Beek Y.; Czismadia, Eva; Otterbein, Leo E.; Bach, Fritz H.; Wang, Hongjun			Toll-like receptor 4 suppression leads to islet allograft survival	FASEB JOURNAL			English	Article						islet transplantation; carbon monoxide; inflammation; type 1 diabetes	HEME OXYGENASE-1 GENE; CARBON-MONOXIDE PRODUCTION; NECROSIS-FACTOR-ALPHA; ENDOTHELIAL-CELLS; NITRIC-OXIDE; KAPPA-B; EXPRESSION; APOPTOSIS; MICE; ACTIVATION	Carbon monoxide ( CO) exposure of an islet donor frequently leads to islet allograft long- term survival and tolerance in recipients. We show here that CO confers its protective effects at least in part by suppressing Toll- like receptor 4 ( TLR4) up- regulation in pancreatic beta cells. TLR4 is normally up- regulated in islets during the isolation procedure; donor treatment with CO suppresses TLR4 expression in isolated islets as well as in transplanted grafts. TLR4 up- regulation allows initiation of inflammation, which leads to islet allograft rejection; islet grafts from TLR4- deficient mice survive indefinitely in BALB/ c recipients and show significantly less inflammation at various days after transplantation compared with grafts from a control donor. Isolated islets preinfected with a TLR4 dominant negative virus before transplantation demonstrated prolonged survival in recipients. Despite the salutary effects of TLR4 suppression, HO- 1 expression is still needed in the recipient for islet survival: TLR4deficient islets were rejected promptly after being transplanted into recipients in which HO- 1 activity was blocked. In addition, incubation of an insulinoma cell line, beta TC3, with an anti- TLR4 antibody protects those cells from cytokine- induced apoptosis. Our data suggest that TLR4 induction in beta cells is involved in beta cell death and graft rejection after transplantation. CO exposure protects islets from rejection by blocking TLR4 up- regulation.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg, Boston, MA 02215 USA; Univ Milan, Milan, Italy	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Milan	Wang, HJ (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg, 99 Brookline Ave, Boston, MA 02215 USA.	hwang3@bidmc.harvard.edu	Wang, Hongjun/AAA-1319-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077721] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL077721] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alcaraz MJ, 2003, CURR PHARM DESIGN, V9, P2541, DOI 10.2174/1381612033453749; Amersi F, 1999, J CLIN INVEST, V104, P1631, DOI 10.1172/JCI7903; Appelberg R, 2000, INFECT IMMUN, V68, P19, DOI 10.1128/IAI.68.1.19-23.2000; AUAUJO JA, 2003, J IMMUNOL, V171, P1572; Bellocchio S, 2004, J IMMUNOL, V173, P7406, DOI 10.4049/jimmunol.173.12.7406; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; CAMPBELL IL, 1988, J IMMUNOL, V141, P2325; CHOI SY, 1996, J PARODONTOL IMPLANT, V15, P19; Davalli AM, 1996, DIABETES, V45, P1161, DOI 10.2337/diabetes.45.9.1161; Dunzendorfer S, 2004, FASEB J, V18, P1117, DOI 10.1096/fj.03-1263fje; Durante W, 1997, AM J PHYSIOL-HEART C, V273, pH317, DOI 10.1152/ajpheart.1997.273.1.H317; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; Flodstrom M, 1997, ENDOCRINOLOGY, V138, P2747, DOI 10.1210/en.138.7.2747; Foresti R, 1997, J BIOL CHEM, V272, P18411, DOI 10.1074/jbc.272.29.18411; Goldstein DR, 2003, J CLIN INVEST, V111, P1571, DOI 10.1172/JCI200317573; Grey ST, 1999, J EXP MED, V190, P1135, DOI 10.1084/jem.190.8.1135; Gunther L, 2002, DIABETES, V51, P994, DOI 10.2337/diabetes.51.4.994; Hohmeier HE, 2003, INT J OBESITY, V27, pS12, DOI 10.1038/sj.ijo.0802493; Hollestelle SCG, 2004, CIRCULATION, V109, P393, DOI 10.1161/01.CIR.0000109140.51366.72; Johansson U, 2003, BIOCHEM BIOPH RES CO, V308, P474, DOI 10.1016/S0006-291X(03)01392-5; Katori M, 2002, TRANSPLANTATION, V74, P905, DOI 10.1097/00007890-200210150-00001; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kumagai N, 2002, TRANSPLANTATION, V74, P1223, DOI 10.1097/00007890-200211150-00005; Kushida T, 2002, BIOCHEM BIOPH RES CO, V291, P68, DOI 10.1006/bbrc.2002.6403; Lamhamedi-Cherradi SE, 2003, DIABETES, V52, P2274, DOI 10.2337/diabetes.52.9.2274; Li XW, 2003, INFECT IMMUN, V71, P4414, DOI 10.1128/IAI.71.8.4414-4420.2003; MAINES MD, 1986, J BIOL CHEM, V261, P411; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Methe H, 2004, TRANSPLANTATION, V78, P1324, DOI 10.1097/01.TP.0000137930.40597.03; Molano RD, 2003, DIABETES, V52, P957, DOI 10.2337/diabetes.52.4.957; O'Brien GC, 2005, J IMMUNOL, V174, P1020, DOI 10.4049/jimmunol.174.2.1020; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Otterbein L, 1997, AM J PHYSIOL-LUNG C, V272, pL268; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Oyama J, 2004, CIRCULATION, V109, P784, DOI 10.1161/01.CIR.0000112575.66565.84; Palmer SM, 2006, CLIN TRANSPLANT, V20, P30, DOI 10.1111/j.1399-0012.2005.00436.x; Pileggi A, 2001, DIABETES, V50, P1983, DOI 10.2337/diabetes.50.9.1983; Pileggi A, 2005, CELL TRANSPLANT, V14, P85, DOI 10.3727/000000005783983160; Poltorak A, 2001, J IMMUNOL, V167, P2106, DOI 10.4049/jimmunol.167.4.2106; Qureshi ST, 1999, TRENDS GENET, V15, P291, DOI 10.1016/S0168-9525(99)01782-5; RICORDI C, 1990, ACTA DIABETOL LAT, V27, P185, DOI 10.1007/BF02581331; ROTENBERG MO, 1990, J BIOL CHEM, V265, P7501; Satoh M, 2004, LAB INVEST, V84, P173, DOI 10.1038/labinvest.3700031; Terry CM, 1998, AM J PHYSIOL-HEART C, V274, pH883, DOI 10.1152/ajpheart.1998.274.3.H883; Thornley TB, 2006, J IMMUNOL, V176, P1561, DOI 10.4049/jimmunol.176.3.1561; Vaidya SA, 2003, CURR OPIN IMMUNOL, V15, P402, DOI 10.1016/S0952-7915(03)00070-0; Vives-Pi M, 2003, CLIN EXP IMMUNOL, V133, P208, DOI 10.1046/j.1365-2249.2003.02211.x; Wang HJ, 2006, ENDOCRINOLOGY, V147, P762, DOI 10.1210/en.2005-0632; Wang HJ, 2005, DIABETES, V54, P1400, DOI 10.2337/diabetes.54.5.1400; Wassef A, 2004, HISTOL HISTOPATHOL, V19, P1201, DOI 10.14670/HH-19.1201; Weatherill AR, 2005, J IMMUNOL, V174, P5390, DOI 10.4049/jimmunol.174.9.5390; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Woo J, 2000, TRANSPLANTATION, V69, P623, DOI 10.1097/00007890-200002270-00026; Yang LM, 1999, AM J PHYSIOL-LUNG C, V277, pL127, DOI 10.1152/ajplung.1999.277.1.L127; Yet SF, 1997, J BIOL CHEM, V272, P4295, DOI 10.1074/jbc.272.7.4295; Zhai Y, 2004, J IMMUNOL, V173, P7115, DOI 10.4049/jimmunol.173.12.7115; Zhou CG, 2005, J HIGH ENERGY PHYS	60	55	61	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2840	2848		10.1096/fj.06-7910com	http://dx.doi.org/10.1096/fj.06-7910com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17475921				2022-12-28	WOS:000249237500025
J	Grenz, A; Zhang, H; Hermes, M; Eckle, T; Klingel, K; Huang, DY; Muller, CE; Robson, SC; Osswald, H; Eltzschig, HK				Grenz, Almut; Zhang, Hua; Hermes, Marina; Eckle, Tobias; Klingel, Karin; Huang, Dan Yang; Mueller, Christa E.; Robson, Simon C.; Osswald, Hartmut; Eltzschig, Holger K.			Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury	FASEB JOURNAL			English	Article						acute renal failure; kidney; preconditioning; NTPDase	TUBULOGLOMERULAR FEEDBACK; ADENOSINE RECEPTORS; ECTO-5'-NUCLEOTIDASE CD73; ENDOTHELIAL-CELLS; EXTRACELLULAR ATP; MICE LACKING; TRIPHOSPHATE; HYPOXIA; RELEASE; INFLAMMATION	Previous studies showed increased extracellular nucleotides during renal ischemia- reperfusion. While nucleotides represent the main source for extracellular adenosine and adenosine signaling contributes to renal protection from ischemia, we hypothesized a role for ecto- nucleoside- triphosphate- diphosphohydrolases ( E- NTPDases) in renal protection. We used a model of murine ischemia- reperfusion and in situ ischemic preconditioning ( IP) via a hanging weight system for atraumatic renal artery occlusion. Initial studies with a nonspecific inhibitor of E- NTPDases ( POM- 1) revealed inhibition of renal protection by IP. We next pursued transcriptional responses of E- NTPDases ( ENTPDase1 - 3, and 8) to renal IP, and found a robust and selective induction of E- NTPDase1/ CD39 transcript and protein. Moreover, based on clearance studies, plasma electrolytes, and renal tubular histology, IP protection was abolished in gene- targeted mice for cd39 whereas increased renal adenosine content with IP was attenuated. Furthermore, administration of apyrase reconstituted renal protection by IP in cd39 -/ - mice. Finally, apyrase treatment of wild- type mice resulted in increased renal adenosine concentrations and a similar degree of renal protection from ischemia as IP treatment. Taken together, these data identify CD39- dependent nucleotide phosphohydrolysis in renal protection. Moreover, the present studies suggest apyrase treatment as a novel pharmacological approach to renal diseases precipitated by limited oxygen availability.	Univ Tubingen Hosp, Dept Anesthesiol & Intens Care Med, D-72072 Tubingen, Germany; Univ Tubingen Hosp, Dept Pharmacol & Toxicol, Tubingen, Germany; Univ Tubingen Hosp, Dept Pathol, Tubingen, Germany; Univ Bonn, Inst Pharmaceut, D-5300 Bonn, Germany; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Liver & Transplant Ctr, Boston, MA USA	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Bonn; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Eltzschig, HK (corresponding author), Univ Tubingen Hosp, Dept Anesthesiol & Intens Care Med, Waldhornle Str 22, D-72072 Tubingen, Germany.	hartmut.osswald@uni-tuebingen.de; heltzschig@partners.org	Robson, Simon C./AAA-8537-2021; Müller, Christa Elisabeth/C-7748-2014; Eckle, Tobias/AAE-6705-2020	Müller, Christa Elisabeth/0000-0002-0013-6624; Eckle, Tobias/0000-0002-6065-4669	NHLBI NIH HHS [R01 HL063972, R01 HL063972-04, R01 HL063972-03, 1P01 HL 076540, R01 HL063972-05] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL076540, R01HL063972] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bigonnesse F, 2004, BIOCHEMISTRY-US, V43, P5511, DOI 10.1021/bi0362222; Bodin P, 1998, INFLAMM RES, V47, P351, DOI 10.1007/s000110050341; Bodin P, 2001, J CARDIOVASC PHARM, V38, P900, DOI 10.1097/00005344-200112000-00012; Candinas D, 1996, THROMB HAEMOSTASIS, V76, P807; Castrop H, 2004, J CLIN INVEST, V114, P634, DOI 10.1172/JCI200421851; Day YJ, 2003, J CLIN INVEST, V112, P883, DOI 10.1172/JCI200315483; Day YJ, 2006, J IMMUNOL, V176, P3108, DOI 10.4049/jimmunol.176.5.3108; Eckle T, 2006, AM J PHYSIOL-HEART C, V291, pH2533, DOI 10.1152/ajpheart.00472.2006; Eltzschig HK, 2004, BLOOD, V104, P3986, DOI 10.1182/blood-2004-06-2066; Eltzschig HK, 2004, BRIT MED BULL, V70, P71, DOI 10.1093/bmb/ldh025; Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891; Eltzschig HK, 2006, CIRC RES, V99, P1100, DOI 10.1161/01.RES.0000250174.31269.70; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Grenz A, 2007, J AM SOC NEPHROL, V18, P833, DOI 10.1681/ASN.2006101141; Grenz A, 2007, AM J PHYSIOL-RENAL, V292, pF475, DOI 10.1152/ajprenal.00275.2006; Huang DY, 2006, AM J PHYSIOL-RENAL, V291, pF1264, DOI 10.1152/ajprenal.00299.2005; Huang DY, 2006, AM J PHYSIOL-RENAL, V291, pF282, DOI 10.1152/ajprenal.00113.2005; JABLONSKI P, 1983, TRANSPLANTATION, V35, P198, DOI 10.1097/00007890-198303000-00002; Kadereit B, 2005, J AM SOC NEPHROL, V16, P3507, DOI 10.1681/ASN.2005010108; Lee HT, 2004, AM J PHYSIOL-RENAL, V286, pF298, DOI 10.1152/ajprenal.00185.2003; Lee YJ, 2005, J CELL PHYSIOL, V204, P792, DOI 10.1002/jcp.20342; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; Luippold G, 1999, J CHROMATOGR B, V724, P231, DOI 10.1016/S0378-4347(98)00580-5; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; Muller CE, 2006, BIOORG MED CHEM LETT, V16, P5943, DOI 10.1016/j.bmcl.2006.09.003; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Okusa MD, 2001, KIDNEY INT, V59, P2114, DOI 10.1046/j.1523-1755.2001.0590062114.x; Pinsky DJ, 2002, J CLIN INVEST, V109, P1031, DOI 10.1172/JCI200210649; Robson SC, 2005, SEMIN THROMB HEMOST, V31, P217, DOI 10.1055/s-2005-869527; Roos A, 2006, J AM SOC NEPHROL, V17, P1724, DOI 10.1681/ASN.2005090923; Sitkovsky M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; Suadicani SO, 2006, J NEUROSCI, V26, P1378, DOI 10.1523/JNEUROSCI.3902-05.2006; Sun DQ, 2001, P NATL ACAD SCI USA, V98, P9983, DOI 10.1073/pnas.171317998; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; Thomson S, 2000, J CLIN INVEST, V106, P289, DOI 10.1172/JCI8761; Vallon V, 2003, NEWS PHYSIOL SCI, V18, P169, DOI 10.1152/nips.01442.2003; Vallon V, 2006, PHYSIOL REV, V86, P901, DOI 10.1152/physrev.00031.2005; Weissmuller Thomas, 2005, Purinergic Signal, V1, P229, DOI 10.1007/s11302-005-6323-9; Zhou WD, 2000, J CLIN INVEST, V105, P1363, DOI 10.1172/JCI8621	43	130	133	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2863	2873		10.1096/fj.06-7947com	http://dx.doi.org/10.1096/fj.06-7947com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17442731				2022-12-28	WOS:000249237500027
J	Neumann, M; Naumann, M				Neumann, Manfred; Naumann, Michael			Beyond I kappa Bs: alternative regulation of NF-kappa B activity	FASEB JOURNAL			English	Review						RelA phosphorylation; RelA acetylation; GR/NF-kappa B cross-talk; nucleolar sequestration; dimer exchange	GLUCOCORTICOID-RECEPTOR; C-REL; DEPENDENT TRANSCRIPTION; NUCLEOLAR LOCALIZATION; TRANSACTIVATION DOMAIN; MEDIATED PHOSPHORYLATION; HISTONE DEACETYLASE; NUCLEAR RECEPTORS; NEMO/IKK-GAMMA; P65 SUBUNIT	The transcription factor nuclear factor-kappa B ( NF- kappa B) is a crucial regulator of many physiological and patho- physiological processes, including control of the adaptive and innate immune responses, inflammation, proliferation, tumorigenesis, and apoptosis. Thus, the tight regulation of NF- kappa B activity within a cell is extremely important. The central mechanism of NF- kappa B regulation is the signal- induced proteolytic degradation of a family of cytoplasmic inhibitors of NF- kappa B, the I kappa Bs. However, with the discovery of an I kappa B- independent noncanonical or '' alternative '' pathway of NF- kappa B activation, the importance of other regulatory mechanisms responsible for the fine- tuning of NF- kappa B became clear. Post- translational modification, especially phosphorylation, of the Rel proteins, of which dimeric NF- kappa B is composed, are such alternative regulatory mechanisms. The best analyzed example is RelA phosphorylation, which takes place at specific amino acids resulting in distinct functional changes of this gene regulatory protein. The interaction of NF- kappa B with other proteins such as glucocorticoid receptors is very important for the regulation of NF- kappa B activity. Recently, exciting new concepts of I kappa B- independent NF- kappa B control like dimer exchange and nucleolar sequestration of RelA have been described, indicating that many aspects of NF- kappa B control are waiting to be discovered. - Neumann, M., Naumann, M. Beyond I kappa Bs: alternative regulation of NF- kappa B activity.	Otto Von Guericke Univ, Fac Med, Inst Expt Internal Med, D-39120 Magdeburg, Germany	Otto von Guericke University	Neumann, M (corresponding author), Otto Von Guericke Univ, Fac Med, Inst Expt Internal Med, Leipziger Str 44, D-39120 Magdeburg, Germany.	docmn@web.de	Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313				Adcock Ian M, 2004, Proc Am Thorac Soc, V1, P247, DOI 10.1513/pats.200402-001MS; Adli M, 2006, J BIOL CHEM, V281, P26976, DOI 10.1074/jbc.M603133200; Bae JS, 2003, BIOCHEM BIOPH RES CO, V305, P1094, DOI 10.1016/S0006-291X(03)00869-6; Birbach A, 2004, J CELL SCI, V117, P3615, DOI 10.1242/jcs.01224; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Bournat JC, 2000, J NEUROSCI RES, V61, P21, DOI 10.1002/1097-4547(20000701)61:1<21::AID-JNR3>3.0.CO;2-7; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200; Campbell KJ, 2006, CANCER RES, V66, P929, DOI 10.1158/0008-5472.CAN-05-2234; Chen F, 2006, CELL DEATH DIFFER, V13, P1835, DOI 10.1038/sj.cdd.4402014; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; Datta A, 2004, J BIOL CHEM, V279, P36698, DOI 10.1074/jbc.M312305200; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; De Bosscher K, 2006, ONCOGENE, V25, P6868, DOI 10.1038/sj.onc.1209935; Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200; DRUKER BJ, 1994, J BIOL CHEM, V269, P5387; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Fognani C, 2000, ONCOGENE, V19, P2224, DOI 10.1038/sj.onc.1203543; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Gao F, 2006, NAT CELL BIOL, V8, P1171, DOI 10.1038/ncb1483; Gao M, 2005, MOL CELL, V19, P581, DOI 10.1016/j.molcel.2005.08.017; Garside H, 2004, J BIOL CHEM, V279, P50050, DOI 10.1074/jbc.M407309200; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Guan HC, 2005, J BIOL CHEM, V280, P9957, DOI 10.1074/jbc.M412180200; Harris J, 2006, J IMMUNOL, V177, P2527, DOI 10.4049/jimmunol.177.4.2527; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heyninck K, 2005, TRENDS BIOCHEM SCI, V30, P1, DOI 10.1016/j.tibs.2004.11.001; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Huang DB, 2005, STRUCTURE, V13, P1365, DOI 10.1016/j.str.2005.06.018; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Jacque E, 2005, P NATL ACAD SCI USA, V102, P14635, DOI 10.1073/pnas.0507342102; Janssens S, 2006, CELL DEATH DIFFER, V13, P773, DOI 10.1038/sj.cdd.4401843; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kato T, 2003, MOL CELL, V12, P829, DOI 10.1016/S1097-2765(03)00358-7; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Liden J, 2000, BIOCHEM BIOPH RES CO, V273, P1008, DOI 10.1006/bbrc.2000.3079; Liu Y, 2006, J BIOL CHEM, V281, P31359, DOI 10.1074/jbc.M604478200; Luecke HF, 2005, GENE DEV, V19, P1116, DOI 10.1101/gad.1297105; Mabb AM, 2006, NAT CELL BIOL, V8, P986, DOI 10.1038/ncb1458; Maier HJ, 2003, J BIOL CHEM, V278, P39242, DOI 10.1074/jbc.M301521200; Maine GN, 2007, EMBO J, V26, P436, DOI 10.1038/sj.emboj.7601489; Marienfeld R, 2001, ONCOGENE, V20, P8142, DOI 10.1038/sj.onc.1204884; Martens C, 2005, MOL ENDOCRINOL, V19, P885, DOI 10.1210/me.2004-0333; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; Mattioli I, 2006, J BIOL CHEM, V281, P6175, DOI 10.1074/jbc.M508045200; Mauro C, 2006, J BIOL CHEM, V281, P18482, DOI 10.1074/jbc.M601502200; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; Niedick I, 2004, J CELL SCI, V117, P3447, DOI 10.1242/jcs.01129; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; O'Mahony AM, 2004, J BIOL CHEM, V279, P18137, DOI 10.1074/jbc.M401397200; Park GY, 2006, J BIOL CHEM, V281, P18684, DOI 10.1074/jbc.M600733200; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Qin CH, 2002, MOL ENDOCRINOL, V16, P1793, DOI 10.1210/me.2002-0006; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sanchez JF, 2003, MOL CELL BIOL, V23, P4649, DOI 10.1128/MCB.23.13.4649-4662.2003; Sanchez-Valdepenas C, 2006, J IMMUNOL, V176, P4666, DOI 10.4049/jimmunol.176.8.4666; Sasaki CY, 2005, J BIOL CHEM, V280, P34538, DOI 10.1074/jbc.M504943200; Schwabe RF, 2005, FASEB J, V19, P1758, DOI 10.1096/fj.05-3736fje; Starczynowski DT, 2005, ONCOGENE, V24, P7355, DOI 10.1038/sj.onc.1208902; STARCZYNOWSKI DT, 2006, IN PRESS ONCOGENE; Stark LA, 2005, MOL CELL BIOL, V25, P5985, DOI 10.1128/MCB.25.14.5985-6004.2005; Strober W, 2006, NAT REV IMMUNOL, V6, P9, DOI 10.1038/nri1747; Sweet T, 2003, J CELL BIOCHEM, V90, P884, DOI 10.1002/jcb.10701; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Wuerzberger-Davis SM, 2007, ONCOGENE, V26, P641, DOI 10.1038/sj.onc.1209815; Yeh PY, 2004, J BIOL CHEM, V279, P26143, DOI 10.1074/jbc.M402362200; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yu SH, 2004, J MOL MED, V82, P621, DOI 10.1007/s00109-004-0559-7; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zwergal A, 2006, J IMMUNOL, V177, P665, DOI 10.4049/jimmunol.177.1.665	97	205	217	1	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2642	2654		10.1096/fj.06-7615rev	http://dx.doi.org/10.1096/fj.06-7615rev			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17431096				2022-12-28	WOS:000249237500006
J	Herzog, EL; Van Arnam, J; Hu, BQ; Zhang, J; Chen, QS; Haberman, AM; Krause, DS				Herzog, Erica L.; Van Arnam, John; Hu, Buqu; Zhang, Jason; Chen, Qingsheng; Haberman, Ann M.; Krause, Diane S.			Lung-specific nuclear reprogramming is accompanied by heterokaryon formation and Y chromosome loss following bone marrow transplantation and secondary inflammation	FASEB JOURNAL			English	Article						plasticity; fusion	PURKINJE NEURONS; STEM-CELLS; IN-VIVO; SKELETAL-MUSCLE; MURINE LUNG; FUSION; INJURY; EPITHELIUM; EMPHYSEMA; CARDIOMYOCYTES	Cell fusion is one mechanism by which bone marrow-derived cells (BMDCs) take on the gene expression pattern of nonhematopoietic cells. This process occurs in a number of organs with posten-graftment injury but has never been found in the lung. We performed bone marrow (BM) transplant in a murine model of lung inflammation to test whether transplanted BMDCs develop lung-specific gene expression by fusing with diseased pneumocytes. Mice lacking the lung-specific protein surfactant protein C (Sp-C) were lethally irradiated, transplanted with sex mismatched wild-type marrow, and sacrificed 6 months later. Nineteen/38 recipients exhibited Sp-C mRNA (RT-PCR) and/or protein (mean 0.95 +/- 1.18 Sp-C+ cells per 1000 type II pneumocytes by confocal microscopy). In male recipients of female BM, 65% of Sp-C + cells contained the Y chromosome, indicating their origin from fusion. Only 28% of Sp-C + cells in female recipients of male BMDCs contained the Y chromosome, suggesting that 72% of Sp-C-expressing cells lost the Y chromosome. In the setting of post-transplant inflammation, pneumocyte-specific reprogramming of transplanted BMDCs predominantly derives from heterokaryon formation. This process does not reverse inflammation caused by Sp-C deficiency; nevertheless, further investigation may identify phenotypes benefiting from such an approach.	Yale Univ, Sch Med, Internal Med Pulm & Crit Care Div, Dept Internal Med, New Haven, CT 06511 USA; Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06511 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06511 USA	Yale University; Yale University; Yale University	Herzog, EL (corresponding author), Yale Univ, Sch Med, Internal Med Pulm & Crit Care Div, Dept Internal Med, 333 Cedar St,TAC 441-S, New Haven, CT 06511 USA.	erica.herzog@yale.edu			NHLBI NIH HHS [1K08HL079066, HL073742] Funding Source: Medline; NIDDK NIH HHS [R01 DK061846, DK61846] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073742, K08HL079066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061846] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Andrade J, 2005, CARDIOVASC RES, V68, P387, DOI 10.1016/j.cardiores.2005.09.016; Bourbon JR, 2001, COMP BIOCHEM PHYS A, V129, P151, DOI 10.1016/S1095-6433(01)00312-9; Chang JC, 2005, AM J RESP CELL MOL, V33, P335, DOI 10.1165/rcmb.2005-0129OC; Di A, 2006, NAT CELL BIOL, V8, P933, DOI 10.1038/ncb1456; Glasser SW, 2003, J BIOL CHEM, V278, P14291, DOI 10.1074/jbc.M210909200; Gomperts BN, 2006, J IMMUNOL, V176, P1916, DOI 10.4049/jimmunol.176.3.1916; Harris RG, 2004, SCIENCE, V305, P90, DOI 10.1126/science.1098925; Held PK, 2006, MOL THER, V13, P49, DOI 10.1016/j.ymthe.2005.09.004; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Herzog EL, 2006, STEM CELLS, V24, P1986, DOI 10.1634/stemcells.2005-0579; Jentsch I, 2001, CHROMOSOME RES, V9, P211, DOI 10.1023/A:1016696303479; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kotton DN, 2005, AM J RESP CELL MOL, V33, P328, DOI 10.1165/rcmb.2005-0175RC; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lee Chun Geun, 2006, Proc Am Thorac Soc, V3, P476; Loi R, 2006, AM J RESP CRIT CARE, V173, P171, DOI 10.1164/rccm.200502-309OC; MacPherson H, 2005, J CELL SCI, V118, P2441, DOI 10.1242/jcs.02375; Nogee LM, 2001, NEW ENGL J MED, V344, P573, DOI 10.1056/NEJM200102223440805; Palermo AT, 2005, DEV BIOL, V279, P336, DOI 10.1016/j.ydbio.2004.12.024; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103; Sacco A, 2005, J CELL BIOL, V171, P483, DOI 10.1083/jcb.200506123; Summer R, 2004, AM J PHYSIOL-LUNG C, V287, pL477, DOI 10.1152/ajplung.00020.2004; THEISE ND, 2002, J EXP HEM; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wang ZD, 2000, J EXP MED, V192, P1587, DOI 10.1084/jem.192.11.1587; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Yamada M, 2004, J IMMUNOL, V172, P1266, DOI 10.4049/jimmunol.172.2.1266	31	23	23	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2592	2601		10.1096/fj.06-7861com	http://dx.doi.org/10.1096/fj.06-7861com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17449722				2022-12-28	WOS:000248454400032
J	Habib, A; Shamseddeen, I; Nasrallah, MS; Antoun, TA; Nemer, G; Bertoglio, J; Badreddine, R; Badr, KF				Habib, Aida; Shamseddeen, Ishraq; Nasrallah, Mona S.; Antoun, Tania Abi; Nemer, Georges; Bertoglio, Jacques; Badreddine, Rami; Badr, Kamal F.			Modulation of COX-2 expression by statins in human monocytic cells	FASEB JOURNAL			English	Article						inflammation; prenylation; prostaglandin; Rac GTPase; NF-kappa B	SMOOTH-MUSCLE-CELLS; PROTEIN HEME OXYGENASE-1; PROSTACYCLIN RECEPTOR; ENDOTHELIAL-CELLS; TRANSCRIPTIONAL ACTIVATION; ATHEROSCLEROTIC PLAQUES; PROSTAGLANDIN E-2; THROMBOXANE A(2); RHO GTPASE; CYCLOOXYGENASE-2	Macrophage cyclooxygenase- 2 ( COX- 2) plays an important role in prostaglandin E-2 and thromboxane A(2) production. Statins are inhibitors of HMG CoA (3-Hydroxy-3-methylglutaryl coenzyme A) reductases and cholesterol synthesis, which block the expression of several inflammatory proteins independent of their capacity to lower endogenous cholesterol. In the present study, we investigated the effect of simvastatin and mevastatin on COX- 2 induction in human monocytic cell line U937 and analyzed the underlying mechanisms. Pretreatment of U937 cells with simvastatin or mevastatin for 24 h resulted in a significant reduction in the lipopolysaccharide (LPS)-dependent induction of prostaglandin E2, thromboxane A2 synthesis, and COX- 2 expression. Mevalonate, the direct metabolite of HMG CoA reductase, and farnesyl pyrophosphate and geranylgeranyl-pyrophosphate, intermediates of the mevalonate pathway, significantly reversed the inhibitory effect of statins on COX-2. An inhibitor of geranylgeranyl transferases, GGTI-286 mimicked the effect of statins on COX- 2 expression. Cytonecrotic factor-1 increased LPS-dependent expression of COX- 2. Treatment of cells with NSC 23766, an inhibitor of Rac, which we demonstrated to block Rac 2 activation, resulted in an inhibition of the LPS-dependent expression of COX- 2. Whereas no effect was obtained with RhoA/C blocker, C3 exoenzyme. Gel retardation experiments and NF kappa B-p65 transcription factor assay showed that simvastatin and NSC 23766 decrease significantly NF-kappa B complex formation. In macrophages, the antiinflammatory effects of statins are mediated in part through the inhibition of COX- 2 and prostanoids. Rac GTPase protein is identified as one of the targets of statins in this regulation.-Habib, A., Shamseddeen, I., Nasrallah, M. S., Antoun, T. A., Nemer, G., Bertoglio, J. Badreddine, R., Badr, K. F. Modulation of COX- 2 expression by statins in human monocytic cells.	Amer Univ Beirut, Dept Biochem, Beirut, Lebanon; Amer Univ Beirut, Dept Internal Med, Beirut, Lebanon; Fac Pharm Chatenay Malabry, INSERM U749, F-92290 Chatenay Malabry, France	American University of Beirut; American University of Beirut; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Habib, A (corresponding author), Amer Univ Beirut, Dept Biochem, POB 11-236, Beirut, Lebanon.	ah31@aub.edu.lb	Nemer, Georges/ABB-5117-2020; Habib, Aida/H-8647-2019; Nemer, Georges/H-7801-2014	Nemer, Georges/0000-0003-2157-5279; Habib, Aida/0000-0001-6027-0043; 				Barbieri SS, 2003, CARDIOVASC RES, V60, P187, DOI 10.1016/S0008-6363(03)00365-1; Barry OP, 1999, J BIOL CHEM, V274, P7545, DOI 10.1074/jbc.274.11.7545; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bishop-Bailey D, 1998, BIOCHEM BIOPH RES CO, V249, P44, DOI 10.1006/bbrc.1998.8966; Bocan Thomas M A, 2002, Curr Opin Investig Drugs, V3, P1312; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; Cayatte AJ, 2000, ARTERIOSCL THROM VAS, V20, P1724, DOI 10.1161/01.ATV.20.7.1724; Chen JC, 2004, EXP CELL RES, V301, P305, DOI 10.1016/j.yexcr.2004.05.039; Cheng Y, 2006, J CLIN INVEST, V116, P1391, DOI 10.1172/JCI27540; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Cipollone F, 2004, ARTERIOSCL THROM VAS, V24, P1259, DOI 10.1161/01.ATV.0000133192.39901.be; Cipollone F, 2003, CIRCULATION, V107, P1479, DOI 10.1161/01.CIR.0000056530.03783.81; Cipollone F, 2001, CIRCULATION, V104, P921, DOI 10.1161/hc3401.093152; Corsini Alberto, 2000, Journal of Cardiovascular Pharmacology and Therapeutics, V5, P161, DOI 10.1177/107424840000500304; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P333, DOI 10.1016/0005-2760(94)00196-6; Degraeve F, 2001, J BIOL CHEM, V276, P46849, DOI 10.1074/jbc.M104197200; Demasi M, 2003, J BIOL CHEM, V278, P38607, DOI 10.1074/jbc.M305944200; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; Egan KM, 2004, SCIENCE, V306, P1954, DOI 10.1126/science.1103333; Egan KM, 2005, CIRCULATION, V111, P334, DOI 10.1161/01.CIR.0000153386.95356.78; Fabre JE, 2001, J CLIN INVEST, V107, P603, DOI 10.1172/JCI10881; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; FitzGerald GA, 2001, CLIN EXP RHEUMATOL, V19, pS31; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; FitzGerald GA, 2000, ANN MED, V32, P21; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gomez-Hernandez A, 2006, J CARDIOVASC PHARM, V47, P60; Gotto AM, 2003, CLIN CARDIOL, V26, pI21; Grosser N, 2004, FREE RADICAL BIO MED, V37, P2064, DOI 10.1016/j.freeradbiomed.2004.09.009; Grosser N, 2004, BIOCHEM BIOPH RES CO, V325, P871, DOI 10.1016/j.bbrc.2004.10.123; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; HABIB A, 1993, J BIOL CHEM, V268, P23448; Hernandez-Presa MA, 2002, ATHEROSCLEROSIS, V160, P49, DOI 10.1016/S0021-9150(01)00547-0; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; JONES DA, 1993, J BIOL CHEM, V268, P9049; Kothapalli D, 2004, J CLIN INVEST, V113, P609, DOI 10.1172/JCI200419097; Laufer S, 2003, CURR OPIN RHEUMATOL, V15, P623, DOI 10.1097/00002281-200309000-00017; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Liao JK, 2004, INT J CLIN PRACT, V58, P41, DOI 10.1111/j.1368-504X.2004.00375.x; Liao JK, 2002, INT J CARDIOL, V86, P5, DOI 10.1016/S0167-5273(02)00195-X; Martel-Pelletier J, 2003, SEMIN ARTHRITIS RHEU, V33, P155, DOI 10.1016/S0049-0172(03)00134-3; Martin-Ventura JL, 2005, STROKE, V36, P1796, DOI 10.1161/01.STR.0000174289.34110.b0; Miggin SM, 2003, J BIOL CHEM, V278, P6947, DOI 10.1074/jbc.M210637200; Moreau V, 2003, MOL CELL BIOL, V23, P6809, DOI 10.1128/MCB.23.19.6809-6822.2003; Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016/S0012-1606(02)00026-X; O'Meara SJ, 2005, BIOCHEM J, V386, P177, DOI 10.1042/BJ20041290; O'Meara SJ, 2004, BRIT J PHARMACOL, V143, P318, DOI 10.1038/sj.bjp.0705956; O'Meara SJ, 2004, BRIT J PHARMACOL, V143, P292, DOI 10.1038/sj.bjp.0705947; Ongini E, 2004, P NATL ACAD SCI USA, V101, P8497, DOI 10.1073/pnas.0401996101; Paramo J. A., 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P303, DOI 10.2174/1568006054553381; Penglis PS, 2000, J IMMUNOL, V165, P1605, DOI 10.4049/jimmunol.165.3.1605; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Shovman O, 2002, IMMUNOL RES, V25, P271, DOI 10.1385/IR:25:3:271; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; ZHANG SZ, 1990, CELL BIOL TOXICOL, V6, P219	58	39	42	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1665	1674		10.1096/fj.06-6766com	http://dx.doi.org/10.1096/fj.06-6766com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17317725				2022-12-28	WOS:000246866500008
J	Kashkevich, K; Humeny, A; Ziegler, U; Groschup, MH; Nicken, P; Leeb, T; Fischer, C; Becker, CM; Schiebel, K				Kashkevich, Kseniya; Humeny, Andreas; Ziegler, Ute; Groschup, Martin H.; Nicken, Petra; Leeb, Tosso; Fischer, Christine; Becker, Cord-Michael; Schiebel, Katrin			Functional relevance of DNA polymorphisms within the promoter region of the prion protein gene and their association to BSE infection	FASEB JOURNAL			English	Article						PRNP; German bovine breeds; haplotype; expression; single nucleotide polymorphism	BOVINE SPONGIFORM ENCEPHALOPATHY; GERMAN CATTLE BREEDS; HAPLOTYPE RECONSTRUCTION; SEQUENCE VARIATION; NATURAL SCRAPIE; PRNP GENES; PRP GENE; SHEEP; SUSCEPTIBILITY; EXPRESSION	Transmissible spongiform encephalopathies ( TSEs) are a group of neurodegenerative diseases that can occur spontaneously or can be caused by infection or mutations within the prion protein gene PRNP. Nonsynonymous DNA polymorphisms within the PRNP gene have been shown to influence susceptibility/ resistance to infection in sheep and humans. Analysis of DNA polymorphisms within the core promoter region of the PRNP gene in four major German bovine breeds resulted in the identification of both SNPs and insertion/ deletion ( indel) polymorphisms. Comparative genotyping of both controls and animals that tested positive for bovine spongiform encephalopathy ( BSE) revealed a significantly different distribution of two indel polymorphisms and two SNPs within Braunvieh animals, suggesting an association of these polymorphisms with BSE susceptibility. The functional relevance of these polymorphisms was analyzed using reporter gene constructs in neuronal cells. A specific haplotype near exon 1 was identified that exhibited a significantly lower expression level. Genotyping of nine polymorphisms within the promoter region and haplotype calculation revealed that the haplotype associated with the lowest expression level was underrepresented in the BSE group of all breeds compared to control animals, indicating a correlation of reduced PRNP expression and increased resistance to BSE.	Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, D-91054 Erlangen, Germany; Friedrich Loeffler Inst, Inst Novel & Emerging Infect Dis, Insel Riems, Germany; Univ Vet Med, Inst Anim Breeding & Genet, Hannover, Germany; Univ Heidelberg, Inst Human Genet, Heidelberg, Germany	University of Erlangen Nuremberg; Friedrich Loeffler Institute; University of Veterinary Medicine Hannover, Foundation; Ruprecht Karls University Heidelberg	Schiebel, K (corresponding author), Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, Fahrstr 17, D-91054 Erlangen, Germany.	katrin.schiebel@biochem.uni-erlangen.de	Leeb, Tosso/G-3187-2014	Leeb, Tosso/0000-0003-0553-4880; Nicken, Petra/0000-0002-8535-1453				Balbus N, 2005, MAMM GENOME, V16, P884, DOI 10.1007/s00335-005-0052-9; BELT PBGM, 1995, J GEN VIROL, V76, P509, DOI 10.1099/0022-1317-76-3-509; Bonk T, 2002, CLIN BIOCHEM, V35, P87, DOI 10.1016/S0009-9120(02)00279-5; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Geldermann H, 2006, ANIM GENET, V37, P469, DOI 10.1111/j.1365-2052.2006.01519.x; Geldermann H, 2003, ANIM GENET, V34, P283, DOI 10.1046/j.1365-2052.2003.01006.x; Heaton MP, 2003, MAMM GENOME, V14, P765, DOI 10.1007/s00335-003-2283-y; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; Herkert M, 1998, EUR J NEUROSCI, V10, P1553, DOI 10.1046/j.1460-9568.1998.00164.x; Hills D, 2003, ANIM GENET, V34, P183, DOI 10.1046/j.1365-2052.2003.00977.x; Humeny A, 2002, NEUROGENETICS, V4, P59, DOI 10.1007/s10048-001-0126-0; Hunter N, 1996, ARCH VIROL, V141, P809, DOI 10.1007/BF01718157; Inoue S, 1997, J VET MED SCI, V59, P175, DOI 10.1292/jvms.59.175; Johnson RT, 1998, NEW ENGL J MED, V339, P1994, DOI 10.1056/NEJM199812313392707; Juling K, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-33; KLEBE RJ, 1969, J CELL BIOL, V43, P69; Kretzschmar HA, 1999, EUR ARCH PSY CLIN N, V249, P56; MANSON JC, 1994, NEURODEGENERATION, V3, P331; NEIBERGS HL, 1994, ANIM GENET, V25, P313, DOI 10.1111/j.1365-2052.1994.tb00364.x; Peirano RI, 2000, NUCLEIC ACIDS RES, V28, P3047, DOI 10.1093/nar/28.16.3047; Sander P, 2005, J BIOL CHEM, V280, P37408, DOI 10.1074/jbc.M506361200; Sander P, 2004, NEUROGENETICS, V5, P19, DOI 10.1007/s10048-003-0171-y; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Tranulis MA, 2002, APMIS, V110, P33, DOI 10.1034/j.1600-0463.2002.100105.x; WESTAWAY D, 1991, NEURON, V7, P59, DOI 10.1016/0896-6273(91)90074-A; Windl O, 1999, HUM GENET, V105, P244, DOI 10.1007/s004390051096; Zhang C, 2004, GENETICS, V167, P1863, DOI 10.1534/genetics.104.026401	29	34	35	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1547	1555		10.1096/fj.06-7522com	http://dx.doi.org/10.1096/fj.06-7522com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17255470				2022-12-28	WOS:000246117000029
J	Rodrigues, AJ; Coppola, G; Santos, C; Costa, MD; Ailion, M; Sequeiros, J; Geschwind, DH; Maciel, P				Rodrigues, Ana-Joao; Coppola, Giovanni; Santos, Claudia; Costa, Maria do Carmo; Ailion, Michael; Sequeiros, Jorge; Geschwind, Daniel H.; Maciel, Patricia			Functional genomics and biochemical characterization of the C-elegans orthologue of the Machado-Joseph disease protein ataxin-3	FASEB JOURNAL			English	Article						polyglutamine disorders; ubiquitin-proteasome pathway; microarray; ataxia; knockout	VALOSIN-CONTAINING PROTEIN; CAENORHABDITIS-ELEGANS; NEUROLOGICAL DISEASE; RNA INTERFERENCE; AZORES ISLANDS; GENE-PRODUCT; F-BOX; EXPRESSION; LOCALIZATION; PROTEOLYSIS	Machado-Joseph disease (MJD) is the most common dominant spinocerebellar ataxia. MJD is caused by a CAG trinucleotide expansion in the ATXN3 gene, which encodes a protein named ataxin-3. Ataxin-3 has been proposed to act as a deubiquitinating enzyme in the ubiquitin-proteasome pathway and to be involved in transcriptional repression; nevertheless, its precise biological function(s) remains unknown. To gain further insight into the function of ataxin-3, we have identified the Caenorhabditis elegans orthologue of the ATXN3 gene and characterized its pattern of expression, developmental regulation, and subcellular localization. We demonstrate that, analogous to its human orthologue, C. elegans ataxin-3 has deubiquitinating activity in vitro against polyubiquitin chains with four or more ubiquitins, the minimum ubiquitin length for proteasomal targeting. To further evaluate C. elegans ataxin-3, we characterized the first known knockout animal models both phenotypically and biochemically, and found that the two C. elegans strains were viable and displayed no gross phenotype. To identify a molecular phenotype, we performed a large-scale microarray analysis of gene expression in both knockout strains. The data revealed a significant deregulation of core sets of genes involved in the ubiquitin-proteasome pathway, structure/motility, and signal transduction. This gene identification provides important clues that can help elucidate the specific biological role of ataxin-3 and unveil some of the physiological effects caused by its absence or diminished function.	Univ Minho, Life & Hlth Sci Res Inst, Hlth Sci Sch, P-4710057 Braga, Portugal; Univ Calif Los Angeles, Program Neurogenet, Dept Neurol, David Geffen Sch Med, Los Angeles, CA USA; UnIGENe, Inst Mol & Cell Biol, Oporto, Portugal; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	Universidade do Minho; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Universidade do Porto; Utah System of Higher Education; University of Utah	Maciel, P (corresponding author), Univ Minho, Life & Hlth Sci Res Inst, Hlth Sci Sch, Campus Gualtar, P-4710057 Braga, Portugal.	pmaciel@ecsaude.uminho.pt	Maciel, Patricia/AAH-2102-2020; Rodrigues, Ana/GYQ-6273-2022; Maciel, Patrícia/B-5989-2009; Ailion, Michael/ABE-6210-2021; Rodrigues, Ana João/D-3782-2012	Maciel, Patricia/0000-0002-0920-6350; Maciel, Patrícia/0000-0002-0920-6350; Ailion, Michael/0000-0002-8070-1362; Rodrigues, Ana João/0000-0003-1968-7968; Sequeiros, Jorge/0000-0002-9846-1037; Pereira da Costa, Maria do Carmo/0000-0001-8466-4864	Fundação para a Ciência e a Tecnologia [POCI/SAU-MMO/60412/2004] Funding Source: FCT	Fundação para a Ciência e a Tecnologia		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Berke SJS, 2005, J BIOL CHEM, V280, P32026, DOI 10.1074/jbc.M506084200; Boeddrich A, 2006, EMBO J, V25, P1547, DOI 10.1038/sj.emboj.7601043; BRENNER S, 1974, GENETICS, V77, P71; Burnett B, 2003, HUM MOL GENET, V12, P3195, DOI 10.1093/hmg/ddg344; Chai YH, 2004, J BIOL CHEM, V279, P3605, DOI 10.1074/jbc.M310939200; Cope Gregory A., 2006, BMC Biochemistry, V7, DOI 10.1186/1471-2091-7-1; COUTINHO P, 1978, NEUROLOGY, V28, P703, DOI 10.1212/WNL.28.7.703; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; Davidson BL, 2004, LANCET NEUROL, V3, P145, DOI 10.1016/S1474-4422(04)00678-7; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; DOCARMO CM, 2004, GENOMICS, V84, P361; Doss-Pepe EW, 2003, MOL CELL BIOL, V23, P6469, DOI 10.1128/MCB.23.18.6469-6483.2003; Evert BO, 2003, J NEUROPATH EXP NEUR, V62, P1006, DOI 10.1093/jnen/62.10.1006; Gales L, 2005, J MOL BIOL, V353, P642, DOI 10.1016/j.jmb.2005.08.061; Gusella JF, 2000, NAT REV NEUROSCI, V1, P109, DOI 10.1038/35039051; Hulo N, 2006, NUCLEIC ACIDS RES, V34, pD227, DOI 10.1093/nar/gkj063; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Inoue T, 2005, P NATL ACAD SCI USA, V102, P4972, DOI 10.1073/pnas.0408122102; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; La Spada AR, 2003, NEURON, V38, P681, DOI 10.1016/S0896-6273(03)00328-3; LANG AE, 1994, ANN NEUROL, V36, P443, DOI 10.1002/ana.410360318; LASPADA AR, 1994, ANN NEUROL, V36, P814, DOI 10.1002/ana.410360604; Lee J, 2001, GENES CELLS, V6, P899, DOI 10.1046/j.1365-2443.2001.00471.x; Lerer I, 1996, EUR J HUM GENET, V4, P3; Li FS, 2002, J BIOL CHEM, V277, P45004, DOI 10.1074/jbc.M205259200; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miller MA, 2001, SCIENCE, V291, P2144, DOI 10.1126/science.1057586; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Piekny AJ, 2003, DEVELOPMENT, V130, P5695, DOI 10.1242/dev.00807; Reinke V, 2004, DEVELOPMENT, V131, P311, DOI 10.1242/dev.00914; Restituito S, 2000, J NEUROSCI, V20, P6394, DOI 10.1523/JNEUROSCI.20-17-06394.2000; Rosenberg R N, 1978, Adv Neurol, V21, P33; Schuberth C, 2004, EMBO REP, V5, P818, DOI 10.1038/sj.embor.7400203; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Tait D, 1998, HUM MOL GENET, V7, P991, DOI 10.1093/hmg/7.6.991; Takeyama K, 2002, NEURON, V35, P855, DOI 10.1016/S0896-6273(02)00875-9; TAKIYAMA Y, 1993, NAT GENET, V4, P300, DOI 10.1038/ng0793-300; Tops BBJ, 2005, NUCLEIC ACIDS RES, V33, P347, DOI 10.1093/nar/gki183; Trottier Y, 1998, NEUROBIOL DIS, V5, P335, DOI 10.1006/nbdi.1998.0208; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Zhong WW, 2006, SCIENCE, V311, P1481, DOI 10.1126/science.1123287; Zhong XY, 2006, HUM MOL GENET, V15, P2409, DOI 10.1093/hmg/ddl164; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217; Zoghbi HY, 1999, CURR OPIN NEUROBIOL, V9, P566, DOI 10.1016/S0959-4388(99)00013-6	55	52	54	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1126	1136		10.1096/fj.06-7002com	http://dx.doi.org/10.1096/fj.06-7002com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17234717				2022-12-28	WOS:000245650400017
J	Williamson, R; Usardi, A; Hanger, DP; Anderton, BH				Williamson, Ritchie; Usardi, Alessia; Hanger, Diane P.; Anderton, Brian H.			Membrane-bound beta-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism	FASEB JOURNAL			English	Article						Alzheimer's disease; ADDLs; protein aggregation; tau	ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; COMMON MECHANISM; TAU; PEPTIDE; TOXICITY; KINASE; BRAIN; NEURONS; NEURODEGENERATION	Recently published research indicates that soluble oligomers of beta-amyloid (AD) may be the key neurotoxic species associated with the progression of Alzheimer's disease (AD) and that the process of AD aggregation may drive this event. Furthermore, soluble oligomers of AD and tau accumulate in the lipid rafts of brains from AD patients through an as yet unknown mechanism. Using cell culture models we report a novel action of AD on neuronal plasma membranes where exogenously applied AD in the form of ADDLs can be trafficked on the neuronal membrane and accumulate in lipid rafts. ADDI-induced dynamic alterations in lipid raft protein composition were found to facilitate this movement. We show clear associations between AD accumulation and redistribution on the neuronal membrane and alterations in the protein composition of lipid rafts. In addition, our data from fyn(-/-) transgenic mice show that accumulation of AD on the neuronal surface was not sufficient to cause cell death but that fyn is required for both the redistribution of AD and subsequent cell death. These results identify fyn-dependent AD redistribution and accumulation in lipid rafts as being key to ADDL-induced cell death and defines a mechanism by which oligomers of AD and tau accumulate in lipid rafts.	[Williamson, Ritchie; Usardi, Alessia; Hanger, Diane P.; Anderton, Brian H.] Kings Coll London, Inst Psychiat, Dept Neurosci Box 037, MRC Ctr Neurodegenerat Res, London SE5 8AF, England	University of London; King's College London	Williamson, R (corresponding author), Kings Coll London, Inst Psychiat, Dept Neurosci Box 037, MRC Ctr Neurodegenerat Res, Crespigny Pk, London SE5 8AF, England.	ritchie.williamson@iop.kcl.ac.uk	Williamson, Ritchie/E-1522-2012; Hanger, Diane/C-5697-2009	Williamson, Ritchie/0000-0003-4278-0909; Hanger, Diane/0000-0002-3044-9816	MRC [G0400050] Funding Source: UKRI; Medical Research Council [G0400050] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arispe N, 2002, FASEB J, V16, P1526, DOI 10.1096/fj.02-0829com; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Cecchi C, 2005, J CELL SCI, V118, P3459, DOI 10.1242/jcs.02473; Chin J, 2004, J NEUROSCI, V24, P4692, DOI 10.1523/JNEUROSCI.0277-04.2004; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Fulga TA, 2007, NAT CELL BIOL, V9, P139, DOI 10.1038/ncb1528; Gellermann GP, 2005, P NATL ACAD SCI USA, V102, P6297, DOI 10.1073/pnas.0407035102; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Hayashi H, 2004, J NEUROSCI, V24, P4894, DOI 10.1523/JNEUROSCI.0861-04.2004; Heredia L, 2006, J NEUROSCI, V26, P6533, DOI 10.1523/JNEUROSCI.5567-05.2006; Hering H, 2003, J NEUROSCI, V23, P3262; Kakio A, 2003, BIOCHEM BIOPH RES CO, V303, P514, DOI 10.1016/S0006-291X(03)00386-3; Kawarabayashi T, 2004, J NEUROSCI, V24, P3801, DOI 10.1523/JNEUROSCI.5543-03.2004; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kelly BL, 2006, J BIOL CHEM, V281, P28079, DOI 10.1074/jbc.M605081200; Kim SI, 2006, J CELL BIOCHEM, V99, P878, DOI 10.1002/jcb.20978; Klein C, 2002, J NEUROSCI, V22, P698, DOI 10.1523/JNEUROSCI.22-03-00698.2002; Klein WL, 2002, NEUROCHEM INT, V41, P345, DOI 10.1016/S0197-0186(02)00050-5; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Liu TB, 2004, J NEUROCHEM, V88, P554, DOI 10.1046/j.1471-4159.2003.02196.x; Maloney MT, 2005, J NEUROSCI, V25, P11313, DOI 10.1523/JNEUROSCI.3711-05.2005; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; Morrow IC, 2005, TRAFFIC, V6, P725, DOI 10.1111/j.1600-0854.2005.00318.x; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Oshima N, 2001, AM J PATHOL, V158, P2209, DOI 10.1016/S0002-9440(10)64693-7; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Roselli F, 2005, J NEUROSCI, V25, P11061, DOI 10.1523/JNEUROSCI.3034-05.2005; Sharma VM, 2007, J CELL SCI, V120, P748, DOI 10.1242/jcs.03378; Williamson R, 2002, J NEUROSCI, V22, P10, DOI 10.1523/JNEUROSCI.22-01-00010.2002; Wogulis M, 2005, J NEUROSCI, V25, P1071, DOI 10.1523/JNEUROSCI.2381-04.2005; Yamamoto N, 2007, J BIOL CHEM, V282, P2646, DOI 10.1074/jbc.M606202200; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; Yip CM, 2001, J MOL BIOL, V311, P723, DOI 10.1006/jmbi.2001.4881	40	99	102	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1552	1559		10.1096/fj.07-9766com	http://dx.doi.org/10.1096/fj.07-9766com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18096814				2022-12-28	WOS:000255898700027
J	Summermatter, S; Mainieri, D; Russell, AP; Seydoux, J; Montani, JP; Buchala, A; Solinas, G; Dulloo, AG				Summermatter, S.; Mainieri, D.; Russell, A. P.; Seydoux, J.; Montani, J. P.; Buchala, A.; Solinas, G.; Dulloo, A. G.			Thrifty metabolism that favors fat storage after caloric restriction: a role for skeletal muscle phosphatidylinositol-3-kinase activity and AMP-activated protein kinase	FASEB JOURNAL			English	Article						thermogenesis; weight cycling; catch-up growth; obesity; diabetes	STEAROYL-COA DESATURASE-1; CATCH-UP FAT; DE-NOVO LIPOGENESIS; DIRECTLY STIMULATES THERMOGENESIS; LIPID OXIDATION; WEIGHT-LOSS; UNCOUPLING PROTEIN-3; ENERGY-METABOLISM; ADIPOSE-TISSUE; BODY-WEIGHT	Energy conservation directed at accelerating body fat recovery (or catch-up fat) contributes to obesity relapse after slimming and to excess fat gain during catch-up growth after malnutrition. To investigate the mechanisms underlying such thrifty metabolism for catch-up fat, we tested whether during refeeding after caloric restriction rats exhibiting catch-up fat driven by suppressed thermogenesis have diminished skeletal muscle phosphatidylinositol-3-kinase (PI3K) activity or AMP-activated protein kinase (AMPK) signaling-two pathways required for hormone-induced thermogenesis in ex vivo muscle preparations. The results show that during isocaloric refeeding with a low-fat diet, at time points when body fat, circulating free fatty acids, and intramyocellular lipids in refed animals do not exceed those of controls, muscle insulin receptor substrate 1-associated PI3K activity (basal and in vivo insulin-stimulated) is lower than that in controls. Isocaloric refeeding with a high-fat diet, which exacerbates the suppression of thermogenesis, results in further reductions in muscle PI3K activity and in impaired AMPK phosphorylation (basal and in vivo leptin-stimulated). It is proposed that reduced skeletal muscle PI3K/AMPK signaling and suppressed thermogenesis are interdependent. Defective PI3K or AMPK signaling will reduce the rate of substrate cycling between de novo lipogenesis and lipid oxidation, leading to suppressed thermogenesis, which accelerates body fat recovery and furthermore sensitizes skeletal muscle to dietary fat-induced impairments in PI3K/AMPK signaling.	[Summermatter, S.; Mainieri, D.; Montani, J. P.; Solinas, G.; Dulloo, A. G.] Univ Fribourg, Dept Med, Div Physiol, CH-1700 Fribourg, Switzerland; [Buchala, A.] Univ Fribourg, Dept Biol, CH-1700 Fribourg, Switzerland; [Russell, A. P.] Deakin Univ, Sch Exercise & Nutr Sci, Ctr Phys Act & Nutr, Melbourne, Vic, Australia; [Seydoux, J.] Univ Geneva, Fac Med, Dept Basic Neurosci, Geneva, Switzerland	University of Fribourg; University of Fribourg; Deakin University; University of Geneva	Dulloo, AG (corresponding author), Univ Fribourg, Dept Med, Div Physiol, Rue Musee 5, CH-1700 Fribourg, Switzerland.	abdul.dulloo@unifr.ch	Buchala, Antony/A-2656-2012; Solinas, Giovanni/P-6596-2017; Solinas, Giovanni/R-4777-2019	Solinas, Giovanni/0000-0002-0140-2621; Solinas, Giovanni/0000-0002-0140-2621; Russell, Aaron/0000-0002-7323-9501; Summermatter, Serge/0000-0003-4870-0148; DULLOO, Abdul/0000-0003-3877-6149; MAINIERI, DAVIDE/0000-0003-0797-5794				Aguilar V, 2007, CELL METAB, V5, P476, DOI 10.1016/j.cmet.2007.05.006; ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; Barnes BR, 2002, DIABETES, V51, P2703, DOI 10.2337/diabetes.51.9.2703; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; BOYLE PC, 1978, PHYSIOL BEHAV, V21, P261, DOI 10.1016/0031-9384(78)90050-1; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; Cannon B, 2006, BBA-BIOENERGETICS, V1757, P449, DOI 10.1016/j.bbabio.2006.05.016; Cettour-Rose P, 2005, DIABETES, V54, P751, DOI 10.2337/diabetes.54.3.751; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Crescenzo R, 2003, FEBS LETT, V544, P138, DOI 10.1016/S0014-5793(03)00491-5; Crescenzo R, 2003, DIABETES, V52, P1090, DOI 10.2337/diabetes.52.5.1090; Crescenzo R, 2006, DIABETES, V55, P2286, DOI 10.2337/db06-0312; Dobrzyn A, 2005, AM J PHYSIOL-ENDOC M, V288, pE599, DOI 10.1152/ajpendo.00439.2004; Dulloo AG, 1998, AM J CLIN NUTR, V68, P599, DOI 10.1093/ajcn/68.3.599; Dulloo AG, 2004, PHYSIOL BEHAV, V83, P587, DOI 10.1016/j.physbeh.2004.07.028; Dulloo AG, 2004, INT J OBESITY, V28, pS29, DOI 10.1038/sj.ijo.0802861; DULLOO AG, 1990, AM J CLIN NUTR, V52, P415, DOI 10.1093/ajcn/52.3.415; Dulloo AG, 2001, INT J OBESITY, V25, pS22, DOI 10.1038/sj.ijo.0801907; Dulloo AG, 2002, INT J OBESITY, V26, pS46, DOI 10.1038/sj.ijo.0802127; Dulloo AG, 2002, FEBS LETT, V515, P109, DOI 10.1016/S0014-5793(02)02449-3; DULLOO AG, 1995, AM J PHYSIOL-REG I, V269, pR365, DOI 10.1152/ajpregu.1995.269.2.R365; ENTENMAN C, 1957, METHOD ENZYMOL, V3, P299, DOI 10.1016/S0076-6879(57)03395-9; Evans SA, 2005, AM J PHYSIOL-REG I, V288, pR1468, DOI 10.1152/ajpregu.00602.2004; Harper ME, 2001, BIOCHEM SOC T, V29, P768, DOI 10.1042/bst0290768; HARRIS RBS, 1984, J NUTR, V114, P1143, DOI 10.1093/jn/114.6.1143; HILL JO, 1984, AM J PHYSIOL, V247, pR318, DOI 10.1152/ajpregu.1984.247.2.R318; Hood DA, 2001, J APPL PHYSIOL, V90, P1137, DOI 10.1152/jappl.2001.90.3.1137; Hutchinson DS, 2006, DIABETES, V55, P682, DOI 10.2337/diabetes.55.03.06.db05-0901; Keys A, 1950, BIOL HUMAN STARVATIO; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Liu Y, 2006, BIOCHEM BIOPH RES CO, V339, P701, DOI 10.1016/j.bbrc.2005.11.068; MacLean PS, 2004, AM J PHYSIOL-REG I, V287, pR1306, DOI 10.1152/ajpregu.00463.2004; Mainieri D, 2006, FASEB J, V20, P1751, DOI 10.1096/fj.06-5934fje; MILLER DS, 1959, BRIT J NUTR, V13, P501, DOI 10.1079/BJN19590064; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Park SH, 2002, J APPL PHYSIOL, V93, P2081, DOI 10.1152/japplphysiol.00504.2002; Pirola L, 2001, J BIOL CHEM, V276, P21544, DOI 10.1074/jbc.M011330200; Rahman SM, 2003, P NATL ACAD SCI USA, V100, P11110, DOI 10.1073/pnas.1934571100; Russell AP, 2003, FEBS LETT, V551, P104, DOI 10.1016/S0014-5793(03)00875-5; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Slawik M, 2006, AGEING RES REV, V5, P144, DOI 10.1016/j.arr.2006.03.004; Solinas G, 2006, ENDOCRINOLOGY, V147, P31, DOI 10.1210/en.2005-1033; Solinas G, 2004, FEBS LETT, V577, P539, DOI 10.1016/j.febslet.2004.10.066; Sriwijitkamol A, 2006, AM J PHYSIOL-ENDOC M, V290, pE925, DOI 10.1152/ajpendo.00429.2005; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Weyer C, 2000, AM J CLIN NUTR, V72, P946; Yang YA, 2003, EXP CELL RES, V282, P132, DOI 10.1016/S0014-4827(02)00023-X	49	41	41	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2008	22	3					774	785		10.1096/fj.07-8972com	http://dx.doi.org/10.1096/fj.07-8972com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17928359	Green Submitted			2022-12-28	WOS:000254143700016
J	Yona, S; Lin, HH; Dri, P; Davies, JQ; Hayhoe, RPG; Lewis, SM; Heinsbroek, SEM; Brown, KA; Perretti, M; Hamann, J; Treacher, DF; Gordon, S; Stacey, M				Yona, Simon; Lin, Hsi-Hsien; Dri, Pietro; Davies, John Q.; Hayhoe, Richard P. G.; Lewis, Sion M.; Heinsbroek, Sigrid E. M.; Brown, K. Alun; Perretti, Mauro; Hamann, Joerg; Treacher, David F.; Gordon, Siamon; Stacey, Martin			Ligation of the adhesion-GPCR EMR2 regulates human neutrophil function	FASEB JOURNAL			English	Article						inflammation; migration; sepsis	ACTIVATION ANTIGEN CD97; EGF-TM7 RECEPTOR CD97; LIGAND CD55; CHONDROITIN SULFATE; MYELOID CELLS-1; CELLULAR LIGAND; FAMILY; EXPRESSION; MOLECULE; MEMBER	At present, similar to 150 different members of the adhesion-G protein-coupled receptor (GPCR) family have been identified in metazoans. Surprisingly, very little is known about their function, although they all possess large extracellular domains coupled to a seven-transmembrane domain, suggesting a potential role in cell adhesion and signaling. Here, we demonstrate how the human-restricted adhesion-GPCR, EMR2 (epidermal growth factor-like module-containing mucin-like hormone receptor), regulates neutrophil responses by potentiating the effects of a number of proinflammatory mediators and show that the transmembrane region is critical for adhesion-GPCR function. Using an anti-EMR2 antibody, ligation of EMR2 increases neutrophil adhesion and migration, and augments superoxide production and proteolytic enzyme degranulation. On neutrophil activation, EMR2 is rapidly translocated to membrane ruffles and the leading edge of the cell. Further supporting the role in neutrophil, activation, EMR2 expression on circulating neutrophils is significantly increased in patients with systemic inflammation. These data illustrate a definitive function for a human adhesion-GPCR within the innate immune system and suggest an important role in potentiating the inflammatory response. Ligation of the adhesion-GPCR EMR2 regulates human neutrophil function.	[Yona, Simon; Davies, John Q.; Heinsbroek, Sigrid E. M.; Gordon, Siamon; Stacey, Martin] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; [Lin, Hsi-Hsien] Chang Gung Univ, Dept Microbiol & Immunol, Tao Yuan, Taiwan; [Dri, Pietro] Univ Trieste, Dept Physiol & Pathol, Trieste, Italy; [Hayhoe, Richard P. G.; Perretti, Mauro] Univ London, William Harvey Res Inst, London, England; [Lewis, Sion M.; Brown, K. Alun; Treacher, David F.] Kings Coll London, St Thomas Hosp, London WC2R 2LS, England; [Hamann, Joerg] Univ Amsterdam, Dept Expt Immunol, Amsterdam, Holland, Netherlands	University of Oxford; Chang Gung University; University of Trieste; University of London; Queen Mary University London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Amsterdam	Gordon, S (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	siamon.gordon@path.ox.ac.uk; martin.stacey@path.ox.ac.uk	LIN, Hsi-Hsien/N-1488-2015; lewis, Sion/C-2258-2009; Yona, Simon/ABE-6572-2020	Hamann, Jorg/0000-0002-9448-1727; Yona, Simon/0000-0002-3984-2008; Hayhoe, Richard/0000-0002-7335-2715	Medical Research Council [G0500623] Funding Source: Medline; MRC [G0500623] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alonso-Lebrero JL, 2000, BLOOD, V95, P2413, DOI 10.1182/blood.V95.7.2413.007k17_2413_2419; BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; Bjarnadottir TK, 2004, GENOMICS, V84, P23, DOI 10.1016/j.ygeno.2003.12.004; Bokoch GM, 2005, TRENDS CELL BIOL, V15, P163, DOI 10.1016/j.tcb.2005.01.002; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Brown KA, 2006, LANCET, V368, P157, DOI 10.1016/S0140-6736(06)69005-3; Brzostowski JA, 2001, TRENDS BIOCHEM SCI, V26, P291, DOI 10.1016/S0968-0004(01)01804-7; Chang GW, 2007, BIOCHEM BIOPH RES CO, V353, P133, DOI 10.1016/j.bbrc.2006.11.148; Chiang N, 2003, BRIT J PHARMACOL, V139, P89, DOI 10.1038/sj.bjp.0705220; DEWALD B, 1988, J BIOL CHEM, V263, P16179; Fagerholm SC, 2006, BLOOD, V108, P3379, DOI 10.1182/blood-2006-03-013557; Galle J, 2006, AM J PATHOL, V169, P1802, DOI 10.2353/ajpath.2006.060006; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; Hamann J, 1999, ARTHRITIS RHEUM-US, V42, P650, DOI 10.1002/1529-0131(199904)42:4<650::AID-ANR7>3.0.CO;2-S; HAMANN J, 1995, J IMMUNOL, V155, P1942; Hamann J, 1996, J EXP MED, V184, P1185, DOI 10.1084/jem.184.3.1185; Hayhoe RPG, 2006, BLOOD, V107, P2123, DOI 10.1182/blood-2005-08-3099; Heyworth PG, 2003, CURR OPIN IMMUNOL, V15, P578, DOI 10.1016/S0952-7915(03)00109-2; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697; Kop EN, 2005, ARTHRITIS RHEUM-US, V52, P442, DOI 10.1002/art.20788; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Kwakkenbos MJ, 2005, J LEUKOCYTE BIOL, V77, P112, DOI 10.1189/jlb.0704402; Kwakkenbos MJ, 2004, IMMUNOGENETICS, V55, P655, DOI 10.1007/s00251-003-0625-2; Kwakkenbos MJ, 2002, J LEUKOCYTE BIOL, V71, P854; Lattin J, 2007, J LEUKOCYTE BIOL, V82, P16, DOI 10.1189/jlb.0107051; Leemans JC, 2004, J IMMUNOL, V172, P1125, DOI 10.4049/jimmunol.172.2.1125; Lin HH, 2004, J BIOL CHEM, V279, P31823, DOI 10.1074/jbc.M402974200; Lin HH, 1997, GENOMICS, V41, P301, DOI 10.1006/geno.1997.4674; Lin HH, 2005, J EXP MED, V201, P1615, DOI 10.1084/jem.20042307; Lin HH, 2000, GENOMICS, V67, P188, DOI 10.1006/geno.2000.6238; Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275; Luttrell LM, 2002, J CELL SCI, V115, P455; MCPHAIL LC, 1984, J BIOL CHEM, V259, P5768; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Muller WA, 2003, TRENDS IMMUNOL, V24, P327, DOI 10.1016/S1471-4906(03)00117-0; Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785; Nechiporuk T, 2001, J BIOL CHEM, V276, P4150, DOI 10.1074/jbc.M004814200; Netea MG, 2006, J LEUKOCYTE BIOL, V80, P1454, DOI 10.1189/jlb.1205758; Olson TS, 2002, AM J PHYSIOL-REG I, V283, pR7, DOI 10.1152/ajpregu.00738.2001; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Phillipson M, 2006, J EXP MED, V203, P2569, DOI 10.1084/jem.20060925; Piao XH, 2004, SCIENCE, V303, P2033, DOI 10.1126/science.1092780; Qian F, 2002, P NATL ACAD SCI USA, V99, P16981, DOI 10.1073/pnas.252484899; Qureshi SS, 2001, CLIN EXP IMMUNOL, V125, P258, DOI 10.1046/j.1365-2249.2001.01596.x; Radsak MP, 2004, J IMMUNOL, V172, P4956, DOI 10.4049/jimmunol.172.8.4956; Schioth HB, 2005, GEN COMP ENDOCR, V142, P94, DOI 10.1016/j.ygcen.2004.12.018; Schoenberg MH, 1998, LANGENBECK ARCH SURG, V383, P44, DOI 10.1007/s004230050090; Stacey M, 2003, BLOOD, V102, P2916, DOI 10.1182/blood-2002-11-3540; Stacey M, 2002, J BIOL CHEM, V277, P29283, DOI 10.1074/jbc.M204306200; Stacey M, 2001, J BIOL CHEM, V276, P18863, DOI 10.1074/jbc.M101147200; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2; Visser L, 2002, J NEUROIMMUNOL, V132, P156, DOI 10.1016/S0165-5728(02)00306-5; WADDELL TK, 1994, J BIOL CHEM, V269, P18485; Wang T, 2005, BLOOD, V105, P2836, DOI 10.1182/blood-2004-07-2878; Weston MD, 2004, AM J HUM GENET, V74, P357, DOI 10.1086/381685; Whittaker CA, 2006, DEV BIOL, V300, P252, DOI 10.1016/j.ydbio.2006.07.044	58	72	74	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					741	751		10.1096/fj.07-9435com	http://dx.doi.org/10.1096/fj.07-9435com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17928360				2022-12-28	WOS:000254143700013
J	Garcia, GE; Truong, LD; Li, P; Zhang, P; Du, J; Chen, JF; Feng, LL				Garcia, Gabriela E.; Truong, Luan D.; Li, Ping; Zhang, Ping; Du, Jie; Chen, Jiang-Fan; Feng, Lili			Adenosine A(2A) receptor activation and macrophage-mediated experimental glomerulonephritis	FASEB JOURNAL			English	Article						chemokines; anti-inflammatory cytokines; tissue injury protection	EXPERIMENTAL CRESCENTIC GLOMERULONEPHRITIS; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; MESANGIAL CELL-PROLIFERATION; MARROW-DERIVED CELLS; TNF-ALPHA; WKY RATS; BLOOD-PRESSURE; NITRIC-OXIDE; MAJOR SOURCE; IN-VIVO	In immune-induced inflammation, leukocytes are key mediators of tissue damage. Since A(2A) adenosine receptors (A(2A)Rs) are endogenous suppressors of inflammation, we examined cellular and molecular mechanisms of kidney damage to determine if selective activation of A(2A)R would suppress inflammation in a rat model of glomerulonephritis. Activation of A(2A)R reduced the degree of kidney injury in both the acute inflammatory phase and the progressive phase of glomerulonephritis. This protection against acute and chronic inflammation was associated with suppression of the glomerular expression of the MDC/CCL22 chemokine and down-regulation of MIP-1 alpha/CCL3, RANTES/CCL5, MIP-1 beta/CCL4, and MCP-1/CCL2 chemokines. The expression of anti-inflammatory cytokines, interluekin (IL)-4 and IL-10, also increased. The mechanism for these anti-inflammatory responses to the A(2A)R agonist was suppression of macrophages function. A(2A)R expression was increased in macrophages, macrophage-derived chemokines were reduced in response to the A(2A)R agonist, and chemokines not expressed in macrophages did not respond to A(2A)R activation. Thus, activation of the A(2A)R on macrophages inhibits immune-associated inflammation. In glomerulonephritis, A(2A)R activation modulates inflammation and tissue damage even in the progressive phase of glomerulonephritis. Accordingly, pharmacological activation of A(2A)R could be developed into a novel treatment for glomerulonephritis and other macrophage-related inflammatory diseases.	[Garcia, Gabriela E.; Li, Ping; Zhang, Ping; Du, Jie; Feng, Lili] Baylor Coll Med, Dept Med, Nephrol Sect, Houston, TX 77030 USA; [Truong, Luan D.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Truong, Luan D.] Methodist Hosp, Houston, TX 77030 USA; [Chen, Jiang-Fan] Boston Univ, Sch Med, Dept Neurol, Mol Neuropharmacol Lab, Boston, MA 02118 USA	Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Boston University	Garcia, GE (corresponding author), Baylor Coll Med, Dept Med, Nephrol Sect, Alkek N520,1 Baylor Plaza, Houston, TX 77030 USA.	geg@bcm.tmc.edu		Chen, Jiang-Fan/0000-0002-0446-3956	NIDDK NIH HHS [P50 DK064233-010005, P50 DK064233, P50 DK064233-050010] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK064233] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXOPOULOS E, 1990, KIDNEY INT, V37, P100, DOI 10.1038/ki.1990.14; Anders HJ, 2003, KIDNEY INT, V63, P401, DOI 10.1046/j.1523-1755.2003.00750.x; Armstrong JM, 2001, BIOCHEM J, V354, P123, DOI 10.1042/0264-6021:3540123; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bariety J, 2005, KIDNEY INT, V68, P1109, DOI 10.1111/j.1523-1755.2005.00503.x; BULLOUGH DA, 1995, J IMMUNOL, V155, P2579; CASATI C, 1994, J PHARMACOL EXP THER, V268, P1506; Chen SH, 1998, J EXP MED, V188, P193, DOI 10.1084/jem.188.1.193; Cheng P, 1999, J POROUS MEDIA, V2, P19, DOI 10.1615/JPorMedia.v2.i1.20; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colasanti M, 2000, BRAIN RES BULL, V52, P155, DOI 10.1016/S0361-9230(00)00262-8; Conti A, 1997, PHARMACOL RES, V35, P123, DOI 10.1006/phrs.1996.0125; Cook HT, 1999, KIDNEY INT, V55, P1319, DOI 10.1046/j.1523-1755.1999.00354.x; CRONSTEIN BN, 1985, J IMMUNOL, V135, P1366; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; Day YJ, 2005, J IMMUNOL, V174, P5040, DOI 10.4049/jimmunol.174.8.5040; Day YJ, 2003, J CLIN INVEST, V112, P883, DOI 10.1172/JCI200315483; El-Shemi AGA, 2004, KIDNEY INT, V65, P1280, DOI 10.1111/j.1523-1755.2004.00536.x; Feng LL, 2000, J CLIN INVEST, V105, P341, DOI 10.1172/JCI2869; FENG LL, 1995, J CLIN INVEST, V95, P1009, DOI 10.1172/JCI117745; Feng LL, 1999, KIDNEY INT, V56, P612, DOI 10.1046/j.1523-1755.1999.00604.x; Fredholm BB, 1996, N-S ARCH PHARMACOL, V354, P262, DOI 10.1007/BF00171056; Garcia GE, 2000, J LEUKOCYTE BIOL, V67, P577, DOI 10.1002/jlb.67.4.577; Garcia GE, 2003, AM J PATHOL, V162, P1061, DOI 10.1016/S0002-9440(10)63903-X; Garcia GE, 2003, KIDNEY INT, V64, P160, DOI 10.1046/j.1523-1755.2003.00077.x; Gessi S, 2000, BRIT J PHARMACOL, V129, P2, DOI 10.1038/sj.bjp.0703045; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; Hasko G, 1996, J IMMUNOL, V157, P4634; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; HOLDSWORTH SR, 1981, J CLIN INVEST, V68, P686, DOI 10.1172/JCI110304; Huang S, 1997, BLOOD, V90, P1600, DOI 10.1182/blood.V90.4.1600.1600_1600_1610; Ikezumi Y, 2003, KIDNEY INT, V63, P83, DOI 10.1046/j.1523-1755.2003.00717.x; Isome M, 2004, NEPHROL DIAL TRANSPL, V19, P2997, DOI 10.1093/ndt/gfh558; Javaid B, 2005, KIDNEY INT, V67, P1692, DOI 10.1111/j.1523-1755.2005.00266.x; JOHNSON RJ, 1991, J CLIN INVEST, V87, P847, DOI 10.1172/JCI115089; Kanellis J, 2004, AM J PATHOL, V165, P341, DOI 10.1016/S0002-9440(10)63301-9; KAWASAKI K, 1993, J IMMUNOL, V150, P1074; KAWASAKI K, 1992, KIDNEY INT, V41, P1517, DOI 10.1038/ki.1992.221; Khoa ND, 2003, J IMMUNOL, V171, P3991, DOI 10.4049/jimmunol.171.8.3991; Khoa ND, 2001, J IMMUNOL, V167, P4026, DOI 10.4049/jimmunol.167.7.4026; Kobashi C, 2005, CIRC RES, V97, P1245, DOI 10.1161/01.RES.0000194328.57164.36; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; Le Hir M, 2001, J AM SOC NEPHROL, V12, P2060, DOI 10.1681/ASN.V12102060; Ledent C, 1997, NATURE, V388, P674, DOI 10.1038/41771; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; Moeller MJ, 2004, J AM SOC NEPHROL, V15, P61, DOI 10.1097/01.ASN.0000102468.37809.C6; Niemir ZI, 1997, KIDNEY INT, V52, P393, DOI 10.1038/ki.1997.346; NIKOLICPATERSON DJ, 1994, KIDNEY INT, V45, pS79; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; RAMKUMAR V, 1991, MOL PHARMACOL, V40, P639; RICHTER J, 1992, J LEUKOCYTE BIOL, V51, P270, DOI 10.1002/jlb.51.3.270; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SCHREINER GF, 1978, J EXP MED, V147, P369, DOI 10.1084/jem.147.2.369; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; THIEL M, 1995, J LAB CLIN MED, V126, P275; Thiel M, 1996, J LEUKOCYTE BIOL, V59, P671, DOI 10.1002/jlb.59.5.671; Timoshanko JR, 2003, J AM SOC NEPHROL, V14, P1785, DOI 10.1097/01.ASN.0000073902.38428.33; Trincavelli ML, 2002, BIOCHEM PHARMACOL, V64, P625, DOI 10.1016/S0006-2952(02)01222-4; UNANUE ER, 1965, J EXP MED, V121, P697, DOI 10.1084/jem.121.5.697; Wada T, 1996, FASEB J, V10, P1418, DOI 10.1096/fasebj.10.12.8903512; WEBB RL, 1993, J PHARMACOL EXP THER, V267, P287; Willets JM, 1999, J NEUROCHEM, V73, P1781, DOI 10.1046/j.1471-4159.1999.0731781.x; Wu XB, 1997, J IMMUNOL, V158, P3917; Xia YY, 1997, AM J PATHOL, V151, P375; XIA YY, 1993, AM J PHYSIOL, V264, pF774, DOI 10.1152/ajprenal.1993.264.5.F774; Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103	67	35	46	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					445	454		10.1096/fj.07-8430com	http://dx.doi.org/10.1096/fj.07-8430com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17898087	Green Accepted			2022-12-28	WOS:000252822600015
J	Crook, MF; Olive, M; Xue, HH; Langenickel, TH; Boehm, M; Leonard, WJ; Nabel, EG				Crook, Martin F.; Olive, Michelle; Xue, Hai-Hui; Langenickel, Thomas H.; Boehm, Manfred; Leonard, Warren J.; Nabel, Elizabeth G.			GA-binding protein regulates KIS gene expression, cell migration, and cell cycle progression	FASEB JOURNAL			English	Article						kinase interacting strathmin; p27(Kip1); vascular smooth muscle cells; vascular biology	TRANSCRIPTION FACTOR GABP; DEPENDENT KINASE INHIBITORS; ETS-DOMAIN; COOPERATIVE INTERACTIONS; VASCULAR-DISEASE; FACTOR FAMILY; RB GENE; P27(KIP1); PROMOTER; DNA	The cyclin-dependent kinase inhibitor p27(Kip1) arrests cell cycle progression through G1/S phases and is regulated by phosphorylation of serine/threonine residues. Recently, we identified the serine/threonine kinase, KIS, which phosphorylates p27(Kip1) on serine 10 leading to nuclear export of p27(Kip1) and protein degradation. However, the molecular mechanisms of transcriptional activation of the human KIS gene and its biological activity are not known. We mapped the transcription initiation site similar to 116 bp 5' to the translation start site, and sequences extending to -141 were sufficient for maximal promoter activity. Mutation in either of two Ets-binding sites in this region resulted in an approximately 75-80% decrease in promoter activity. These sites form at least 3 specific complexes, which contained GA-binding protein (GABP). Knocking down GABP alpha by siRNA in vascular smooth muscle cells (VSMCs) diminished KIS gene expression and reduced cell migration. Correspondingly, in serum stimulated GABP alpha-deficient mouse embryonic fibroblasts (MEFs), KIS gene expression was also significantly reduced, which was associated with an increase in p27(Kip1) protein levels and a decreased percentage of cells in S-phase. Consistent with these findings, following vascular injury in vivo, GABP alpha-heterozygous mice demonstrated reduced KIS gene expression within arterial lesions and these lesions were significantly smaller compared to GABP(+/+) mice. In summary, serum-responsive GABP binding to Ets-binding sites activates the KIS promoter, leading to KIS gene expression, cell migration, and cell cycle progression. -Crook, M. F., Olive, M., Xue, H.-H., Langenickel, T. H., Boehm, M., Leonard, W. J., Nabel, E. G. GA-binding protein regulates KIS gene expression, cell migration, and cell cycle progression.	[Crook, Martin F.; Olive, Michelle; Langenickel, Thomas H.; Boehm, Manfred; Nabel, Elizabeth G.] NHLBI, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA; [Xue, Hai-Hui; Leonard, Warren J.] NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Nabel, EG (corresponding author), NHLBI, Cardiovasc Branch, NIH, Bldg 31-Rm 5A48,31 Ctr Dr, Bethesda, MD 20892 USA.	nabele@nih.gov	Leonard, Warren/AAA-1397-2022	Xue, Hai-Hui/0000-0002-9163-7669	Intramural NIH HHS Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL005066, Z01HL005410, Z01HL005066] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG200334, Z01HG200334] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Avots A, 1997, MOL CELL BIOL, V17, P4381, DOI 10.1128/MCB.17.8.4381; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Boehm M, 2004, J CLIN INVEST, V114, P419, DOI 10.1172/jci200420176; Boussiotis VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144; Carlini LE, 2002, J BIOL CHEM, V277, P8682, DOI 10.1074/jbc.M109754200; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chinenov Y, 2000, J BIOL CHEM, V275, P7749, DOI 10.1074/jbc.275.11.7749; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Flory E, 1996, J VIROL, V70, P2260, DOI 10.1128/JVI.70.4.2260-2268.1996; Hashiya N, 2004, CIRCULATION, V109, P3035, DOI 10.1161/01.CIR.0000130643.41587.DB; Imaki H, 2003, CANCER RES, V63, P4607; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Izumi M, 2000, BBA-GENE STRUCT EXPR, V1492, P341, DOI 10.1016/S0167-4781(00)00117-2; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; Lie-Venema H, 2003, CIRC RES, V92, P749, DOI 10.1161/01.RES.0000066662.70010.DB; Maucuer A, 2000, EUR J BIOCHEM, V267, P4456, DOI 10.1046/j.1432-1327.2000.01493.x; Nabel EG, 2002, NAT REV DRUG DISCOV, V1, P587, DOI 10.1038/nrd869; Ophascharoensuk V, 1998, NAT MED, V4, P575, DOI 10.1038/nm0598-575; Pagano M, 2004, MOL CELL, V14, P414, DOI 10.1016/S1097-2765(04)00268-0; Ristevski S, 2004, MOL CELL BIOL, V24, P5844, DOI 10.1128/MCB.24.13.5844-5849.2004; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Rosmarin  AG, 2004, BLOOD CELL MOL DIS, V32, P143, DOI 10.1016/j.bcmd.2003.09.005; Rudge TL, 2002, EXP CELL RES, V274, P45, DOI 10.1006/excr.2001.5451; Santiago FS, 2004, CIRC RES, V95, P479, DOI 10.1161/01.RES.0000141135.36279.67; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; Schweppe RE, 2003, J BIOL CHEM, V278, P16863, DOI 10.1074/jbc.M213063200; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sowa Y, 1997, CANCER RES, V57, P3145; Tanner FC, 2000, CIRCULATION, V101, P2022, DOI 10.1161/01.CIR.101.17.2022; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Xue HH, 2004, NAT IMMUNOL, V5, P1036, DOI 10.1038/ni1117; Yamasaki L, 2004, CURR OPIN CELL BIOL, V16, P623, DOI 10.1016/j.ceb.2004.08.005; Yang ZF, 2007, NAT CELL BIOL, V9, P339, DOI 10.1038/ncb1548	44	17	17	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2008	22	1					225	235		10.1096/fj.07-8573com	http://dx.doi.org/10.1096/fj.07-8573com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17726090				2022-12-28	WOS:000252309900025
J	Kirsch, M; Kemp-Harper, B; Weissmann, N; Grimminger, F; Schmidt, HHHW				Kirsch, Mark; Kemp-Harper, Barbara; Weissmann, Norbert; Grimminger, Friedrich; Schmidt, Harald H. H. W.			Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling	FASEB JOURNAL			English	Article						vascular disease; PH; lung perfusate	NITRIC-OXIDE SYNTHASE; SOLUBLE GUANYLATE-CYCLASE; VASODILATOR-STIMULATED PHOSPHOPROTEIN; VASCULAR SMOOTH-MUSCLE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; ENDOTHELIUM-DEPENDENT RELAXATION; RAT LUNG; ARTERIAL-HYPERTENSION; GENE-EXPRESSION; RELAXING FACTOR	The availability of inhibitors of cGMP-specific phosphodiesterase 5 (PDE 5), such as sildenafil, has revolutionized the treatment of pulmonary hypertension (PH). Sildenafil may exert its protective effects in a mechanism-based fashion by targeting a pathophysiologically attenuated NO-cGMP signaling pathway. To elucidate this, we analyzed changes in the pulmonary expression and activity of key enzymes of NO-cGMP signaling as well as the functional pulmonary responses to sildenafil in the 5 or 21 day hypoxia mouse model of PH. Surprisingly, we found doubled NO synthase ( NOS) II and III levels, no evidence for attenuated NO bioaviability as evidenced by the nitro-sative/oxidative stress marker protein nitro tyrosine, and no changes in the expression and activity of the NO receptor, soluble guanylyl cyclase (sGC). PDE 5 was either unchanged at day 5 or, after 21 days of hypoxia, even significantly decreased along with unchanged activity. Biochemically, these changes were mirrored by increased cGMP spillover into the lung perfusate and cGMP-dependent phosphorylation of the vasodilator-stimulated phosphoprotein, VASP. Sildenafil further augmented cGMP and phospho-VASP levels in lungs of mice exposed for 5 or 21 days and decreased pulmonary arterial pressure in mice after 5 days but not 21 days of hypoxia. In conclusion, NO-cGMP signaling is compensatorily up-regulated in the hypoxic mouse model of PH, and sildenafil further augments this pathway to functionally alleviate pulmonary vasoconstriction. -Kirsch, M., Kemp-Harper, B., Weissmann, N., Grimminger, F., Schmidt, H. H. H. W. Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO- cGMP signaling.	[Kemp-Harper, Barbara; Schmidt, Harald H. H. W.] Monash Univ, Dept Pharmacol, Melbourne, Vic 3800, Australia; [Kemp-Harper, Barbara; Schmidt, Harald H. H. W.] Monash Univ, Ctr Vasc Hlth, Melbourne, Vic 3800, Australia; [Kirsch, Mark] Univ Giessen, Rudolf Buchheim Inst Pharmacol, Giessen, Germany; [Weissmann, Norbert; Grimminger, Friedrich] Univ Giessen, Lung Ctr, Med Clin 2 5, Giessen, Germany	Monash University; Monash University; Justus Liebig University Giessen; Justus Liebig University Giessen	Schmidt, HHHW (corresponding author), Monash Univ, Dept Pharmacol, Wellington Rd,Bldg 13E,Rm 116, Melbourne, Vic 3800, Australia.	harald.schmidt@med.monash.edu.au	Schmidt, Harald HHW/B-1549-2008; Kemp-Harper, Barbara K/A-7882-2008	Schmidt, Harald HHW/0000-0003-0419-5549; Grimminger, Friedrich/0000-0001-8725-6276; Weissmann, Norbert/0000-0003-2675-3871				ADNOT S, 1991, J CLIN INVEST, V87, P155, DOI 10.1172/JCI114965; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BHARANI A, 2003, INDIAN HEART J, V55, P285; Cohen AH, 1996, J CLIN INVEST, V97, P172, DOI 10.1172/JCI118386; CRAWLEY DE, 1992, AM J PHYSIOL, V263, pL325, DOI 10.1152/ajplung.1992.263.3.L325; Demiryurek MR, 2000, PULM PHARMACOL THER, V13, P157, DOI 10.1006/pupt.2000.0238; Dumitrascu R, 2006, CIRCULATION, V113, P286, DOI 10.1161/CIRCULATIONAHA.105.581405; Evgenov OV, 2004, CIRCULATION, V110, P2253, DOI 10.1161/01.CIR.0000144469.01521.8A; Fagan KA, 1999, AM J PHYSIOL-LUNG C, V277, pL472, DOI 10.1152/ajplung.1999.277.3.L472; Feil R, 2006, EMBO REP, V7, P149, DOI 10.1038/sj.embor.7400627; Feil R, 2002, CIRC RES, V90, P1080, DOI 10.1161/01.RES.0000019586.95768.40; Frank DU, 1998, J APPL PHYSIOL, V85, P1070, DOI 10.1152/jappl.1998.85.3.1070; Fukumoto Y, 2007, TOHOKU J EXP MED, V211, P309, DOI 10.1620/tjem.211.309; Galle J, 1999, BRIT J PHARMACOL, V127, P195, DOI 10.1038/sj.bjp.0702495; Ghofrani HA, 2002, LANCET, V360, P895, DOI 10.1016/S0140-6736(02)11024-5; Goyal P, 2004, FREE RADICAL BIO MED, V36, P1279, DOI 10.1016/j.freeradbiomed.2004.02.071; GRIMMINGER F, 1995, J APPL PHYSIOL, V78, P1509, DOI 10.1152/jappl.1995.78.4.1509; Hanasato N, 1999, AM J PHYSIOL-LUNG C, V277, pL225, DOI 10.1152/ajplung.1999.277.2.L225; HERVE P, 1995, AM J MED, V99, P249, DOI 10.1016/S0002-9343(99)80156-9; Ibarra-Alvarado C, 2002, MOL PHARMACOL, V61, P312, DOI 10.1124/mol.61.2.312; IGNARRO LJ, 1988, J PHARMACOL EXP THER, V244, P181; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; ISAACSON TC, 1994, J APPL PHYSIOL, V76, P933, DOI 10.1152/jappl.1994.76.2.933; Jernigan NL, 2003, AM J PHYSIOL-LUNG C, V285, pL634, DOI 10.1152/ajplung.00328.2002; Jernigan NL, 2002, AM J PHYSIOL-LUNG C, V282, pL1366, DOI 10.1152/ajplung.00273.2001; JOHNS RA, 1989, CIRC RES, V65, P1508, DOI 10.1161/01.RES.65.6.1508; Kahl KG, 2003, J NEUROSCI RES, V73, P198, DOI 10.1002/jnr.10649; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; Kotera J, 2000, J HISTOCHEM CYTOCHEM, V48, P685, DOI 10.1177/002215540004800512; Krick S, 2005, FASEB J, V19, P857, DOI 10.1096/fj.04-2890fje; LeCras TD, 1996, AM J PHYSIOL-LUNG C, V270, pL164, DOI 10.1152/ajplung.1996.270.1.L164; Li DC, 1999, AM J PHYSIOL-LUNG C, V277, pL841, DOI 10.1152/ajplung.1999.277.4.L841; Li DC, 2001, AM J PHYSIOL-LUNG C, V281, pL369, DOI 10.1152/ajplung.2001.281.2.L369; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lugnier C, 1999, J PHYSIOL PHARMACOL, V50, P639; MacLean MR, 1997, J PHARMACOL EXP THER, V283, P619; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Martyn KD, 2006, CELL SIGNAL, V18, P69, DOI 10.1016/j.cellsig.2005.03.023; Muramatsu M, 1996, J APPL PHYSIOL, V80, P1336, DOI 10.1152/jappl.1996.80.4.1336; Murata T, 2002, J BIOL CHEM, V277, P44085, DOI 10.1074/jbc.M205934200; Murray F, 2002, BRIT J PHARMACOL, V137, P1187, DOI 10.1038/sj.bjp.0704984; Murray F, 2007, AM J PHYSIOL-LUNG C, V292, pL294, DOI 10.1152/ajplung.00190.2006; Muzaffar S, 2005, THORAX, V60, P305, DOI 10.1136/thx.2003.018796; Oelze M, 2000, CIRC RES, V87, P999, DOI 10.1161/01.RES.87.11.999; Pauvert O, 2004, AM J PHYSIOL-LUNG C, V287, pL577, DOI 10.1152/ajplung.00449.2003; Petkov V, 2003, J CLIN INVEST, V111, P1339, DOI 10.1172/JCI200317500; Phillips PG, 2005, AM J PHYSIOL-LUNG C, V288, pL103, DOI 10.1152/ajplung.00095.2004; Polson JB, 1996, ANNU REV PHARMACOL, V36, P403, DOI 10.1146/annurev.pa.36.040196.002155; Preston IR, 2004, EXP BIOL MED, V229, P920, DOI 10.1177/153537020422900908; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; RODMAN DM, 1990, AM J PHYSIOL, V258, pL207, DOI 10.1152/ajplung.1990.258.4.L207; Rubin LJ, 2002, NEW ENGL J MED, V346, P896, DOI 10.1056/NEJMoa012212; Sauzeau V, 2003, CIRC RES, V93, P630, DOI 10.1161/01.RES.0000093220.90027.D9; Schermuly RT, 2007, CIRCULATION, V115, P2331, DOI 10.1161/CIRCULATIONAHA.106.676809; Schermuly RT, 2005, J CLIN INVEST, V115, P2811, DOI 10.1172/JCI24838; Sebkhi A, 2003, CIRCULATION, V107, P3230, DOI 10.1161/01.CIR.0000074226.20466.B1; SHAUL PW, 1995, AM J RESP CELL MOL, V13, P167, DOI 10.1165/ajrcmb.13.2.7542896; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Turley JE, 2003, AM J PHYSIOL-LUNG C, V284, pL489, DOI 10.1152/ajplung.00246.2002; Valencia A, 2006, FREE RADICAL BIO MED, V41, P1704, DOI 10.1016/j.freeradbiomed.2006.09.006; WARNHOLTZ A, 2007, IN PRESS ARTHERSCLER; Weissmann N, 2005, THROMB HAEMOSTASIS, V94, P630, DOI 10.1160/TH05-02-0104; Weissmann N, 2004, RESP PHYSIOL NEUROBI, V139, P191, DOI 10.1016/j.resp.2003.10.003; Weissmann N, 2003, AM J PHYSIOL-HEART C, V284, pH931, DOI 10.1152/ajpheart.00376.2002; Weissmann N, 2006, P NATL ACAD SCI USA, V103, P19093, DOI 10.1073/pnas.0606728103; Wingler M, 2001, FREE RADICAL BIO MED, V31, P1456, DOI 10.1016/S0891-5849(01)00727-4; XIA XD, 2003, NEI KE ZA ZHI, V42, P628; Xue C, 1996, HYPERTENSION, V28, P743, DOI 10.1161/01.HYP.28.5.743; XUE C, 1994, AM J PHYSIOL-LUNG C, V267, pL667, DOI 10.1152/ajplung.1994.267.6.L667; ZABEL U, 1998, BIOCHEM J, V127, P195; Zhao L, 2003, CIRCULATION, V107, P234, DOI 10.1161/01.CIR.0000050653.10758.6B; Zhao L, 2001, CIRCULATION, V104, P424, DOI 10.1161/hc2901.093117	72	32	34	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					30	40		10.1096/fj.06-7526com	http://dx.doi.org/10.1096/fj.06-7526com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17679609				2022-12-28	WOS:000252309900006
J	Kutuzov, MA; Andreeva, AV; Voyno-Yasenetskaya, TA				Kutuzov, Mikhail A.; Andreeva, Alexandra V.; Voyno-Yasenetskaya, Tatyana A.			Regulation of apoptosis signal-regulating kinase 1 degradation by G alpha 13	FASEB JOURNAL			English	Article						signal transduction; MAP kinases; heterotrimeric G proteins	NITRIC-OXIDE-SYNTHASE; INDUCED CELL-DEATH; DEPENDENT REGULATION; ASK1 UBIQUITINATION; CARDIOMYOCYTE DEATH; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; OXIDATIVE STRESS; INNATE IMMUNITY; PC12 CELLS	Apoptosis signal-regulating kinase (ASK1) is a mitogen-activated protein kinase (MAPK) that transduces apoptotic signals from a variety of stresses. We have shown previously that alpha subunits of heterotrimeric G12 and G13 proteins stimulate ASK1 kinase activity and ASK1-dependent apoptosis (1). Here, we report a novel mechanism of G-protein-dependent regulation of ASK1. We demonstrated that G alpha 13 forms a complex with ASK1 in an activation-independent manner. Both N-and C-terminal regulatory domains of ASK1 were essential for the efficient interaction, while its kinase domain was not required. Formation of the G alpha 13-ASK1 complex was enhanced by JNK-interacting leucine zipper protein, JLP. Constitutively activated G alpha 13Q226L increased ASK1 expression. Short-term activation of a serotonin 5-HT4 receptor that is coupled to G alpha 13 also increased ASK1 expression. Importantly, prolonged activation of 5-HT4 receptor in COS-7 cells or prolonged treatment of human umbilical vein endothelial cells with thrombin concomitantly down-regulated both G alpha 13 and ASK1. Data showed that G alpha 13Q226L reduced the rate of ASK1 degradation, decreased ASK1 ubiquitination, and reduced association of ASK1 with an E3 ubiquitin ligase CHIP, previously shown to mediate ASK1 degradation. Our findings indicate that ASK1 expression levels can be regulated by G alpha 13, at least in part via control of ASK1 ubiquitination and degradation.	Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Voyno-Yasenetskaya, TA (corresponding author), Univ Illinois, Dept Pharmacol, MC 868,909 S Wolcott Ave, Chicago, IL 60612 USA.	tvy@uic.edu		Kutuzov, Mikhail/0000-0003-3386-4350	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM056159, R01GM065160, R01GM056159] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-06078] Funding Source: Medline; NIGMS NIH HHS [GM-65160, GM-56159] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adarichev VA, 2003, AM J PHYSIOL-CELL PH, V285, pC922, DOI 10.1152/ajpcell.00115.2003; Andreeva AV, 2006, MOL PHARMACOL, V69, P975, DOI 10.1124/mol.105.018846; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Bilodeau ML, 2006, MOL PHARMACOL, V69, P677, DOI 10.1124/mol.105.022038; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; Gu JL, 2002, P NATL ACAD SCI USA, V99, P9352, DOI 10.1073/pnas.102291599; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hayakawa T, 2006, MICROBES INFECT, V8, P1098, DOI 10.1016/j.micinf.2005.12.001; He Y, 2006, J BIOL CHEM, V281, P5559, DOI 10.1074/jbc.M512338200; Hershko T, 2006, J BIOL CHEM, V281, P31309, DOI 10.1074/jbc.M601758200; Hwang JR, 2005, CELL STRESS CHAPERON, V10, P147, DOI 10.1379/CSC-90R.1; Izumiya Y, 2003, CIRC RES, V93, P874, DOI 10.1161/01.RES.0000100665.67510.F5; Jiang JH, 2003, J BIOL CHEM, V278, P49332, DOI 10.1074/jbc.M304738200; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kashef K, 2005, BIOCHEMISTRY-US, V44, P14090, DOI 10.1021/bi050604l; Kelkar N, 2005, MOL CELL BIOL, V25, P2733, DOI 10.1128/MCB.25.7.2733-2743.2005; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Kutuzov MA, 2005, J BIOL CHEM, V280, P25388, DOI 10.1074/jbc.M413202200; Liu JF, 2001, J SUPERCOND, V14, P3, DOI 10.1023/A:1007867802653; Liu QH, 2006, MOL CELL BIOL, V26, P3785, DOI 10.1128/MCB.26.10.3785-3797.2006; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Matsukawa J, 2004, J BIOCHEM, V136, P261, DOI 10.1093/jb/mvh134; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; Matsuzawa A, 2005, ANTIOXID REDOX SIGN, V7, P472, DOI 10.1089/ars.2005.7.472; Matsuzawa A, 2002, ANTIOXID REDOX SIGN, V4, P415, DOI 10.1089/15230860260196218; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Nishida K, 2006, ANTIOXID REDOX SIGN, V8, P1729, DOI 10.1089/ars.2006.8.1729; Noguchi T, 2005, J BIOL CHEM, V280, P37033, DOI 10.1074/jbc.M506771200; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Ponimaskin EG, 2002, J BIOL CHEM, V277, P20812, DOI 10.1074/jbc.M112216200; Riobo NA, 2005, TRENDS PHARMACOL SCI, V26, P146, DOI 10.1016/j.tips.2005.01.007; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Sayama K, 1998, J INVEST DERMATOL, V110, P541; Sayama K, 2005, EUR J IMMUNOL, V35, P1886, DOI 10.1002/eji.200425827; Soh YJ, 2000, MOL PHARMACOL, V58, P535, DOI 10.1124/mol.58.3.535; Takeda K, 2000, J BIOL CHEM, V275, P9805, DOI 10.1074/jbc.275.13.9805; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Vaiskunaite R, 2001, J BIOL CHEM, V276, P46088, DOI 10.1074/jbc.M108711200; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Watanabe T, 2005, BIOCHEM BIOPH RES CO, V333, P562, DOI 10.1016/j.bbrc.2005.05.151; Yamawaki H, 2005, J CLIN INVEST, V115, P733, DOI 10.1172/JCI200523001; Zhao YG, 2007, J BIOL CHEM, V282, P7777, DOI 10.1074/jbc.M609146200	44	8	9	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3727	3736		10.1096/fj.06-8029com	http://dx.doi.org/10.1096/fj.06-8029com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17595347				2022-12-28	WOS:000250517800034
J	Chang, WP; Downs, D; Huang, XP; Da, H; Fung, KM; Tang, J				Chang, Wan-Pin; Downs, Deborah; Huang, Xiang-Ping; Da, Huining; Fung, Kar-Ming; Tang, Jordan			Amyloid-beta reduction by memapsin 2 (beta-secretase) immunization	FASEB JOURNAL			English	Article						immunotherapy; Alzheimer's disease; BACE1	ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; MOUSE MODEL; KNOCKOUT MICE; BACE1; BRAIN; GENERATION; INHIBITORS; THERAPEUTICS; PEPTIDES	Memapsin 2 (beta-secretase, BACE1) is the protease that initiates cleavage of beta-amyloid precursor protein leading to the production of amyloid-beta (A beta) and the onset of Alzheimer's disease (AD). Reducing A beta by targeting memapsin 2 is a major strategy in developing new AD therapy. Here, in a proof-of-concept study, we show that immunization of transgenic AD mice (Tg2576) with memapsin 2 resulted in A beta reduction and cognitive improvement. To study the basis of this therapy, we demonstrated that anti-memapsin 2 (anti-M2) antibodies were rapidly internalized and reduced A beta production in cultured cells. These antibodies also effectively crossed the blood-brain barrier to reach the brain. Two-and 10-month Tg2576 mice were immunized and monitored over 10 and 6 months, respectively. We observed a significant decrease of plasma and brain A beta(40) and A beta(42) (similar to 35%) in the immunized mice as compared to controls. Immunized mice also showed better cognitive performance than controls in both cohorts. Brain histological analyses found no evidence of T cell/microglia/astrocyte activation in the immunized mice, suggesting the absence of inflammatory responses. These results suggest that memapsin 2 immunization in Tg2576 was effective in reducing A beta production and improving cognitive function and that the current approach warrants further investigation as a therapy for AD.	Oklahoma Med Res Fdn, Prot Studies Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Chang, WP (corresponding author), Oklahoma Med Res Fdn, Prot Studies Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	wanpin-chang@omrf.ouhsc.edu			NCRR NIH HHS [P20 RR 15577-07] Funding Source: Medline; NIA NIH HHS [AG-18933] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018933] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arbel M, 2005, P NATL ACAD SCI USA, V102, P7718, DOI 10.1073/pnas.0502427102; Barten Donna M, 2006, Drugs R D, V7, P87, DOI 10.2165/00126839-200607020-00003; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Chang WP, 2004, J NEUROCHEM, V89, P1409, DOI 10.1111/j.1471-4159.2004.02452.x; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; Dominguez D, 2005, J BIOL CHEM, V280, P30797, DOI 10.1074/jbc.M505249200; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P16263, DOI 10.1021/bi005122i; Ghosh AK, 2005, CURR TOP MED CHEM, V5, P1609, DOI 10.2174/156802605775009711; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harrison SM, 2003, MOL CELL NEUROSCI, V24, P646, DOI 10.1016/S1044-7431(03)00227-6; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Hoe HS, 2005, MOL CELL BIOL, V25, P9259, DOI 10.1128/MCB.25.21.9259-9268.2005; Huang XP, 2004, J BIOL CHEM, V279, P37886, DOI 10.1074/jbc.M402130200; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; John V, 2006, CURR TOP MED CHEM, V6, P569, DOI 10.2174/156802606776743084; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kawooya JK, 2003, ANAL BIOCHEM, V323, P103, DOI 10.1016/j.ab.2003.08.027; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lee EB, 2005, FEBS LETT, V579, P2564, DOI 10.1016/j.febslet.2005.03.070; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; LIN XL, 1994, METHOD ENZYMOL, V241, P195; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Masliah E, 2005, NEURON, V46, P857, DOI 10.1016/j.neuron.2005.05.010; Monsonego A, 2003, SCIENCE, V302, P834, DOI 10.1126/science.1088469; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Rogaeva E, 2007, NAT GENET, V39, P168, DOI 10.1038/ng1943; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Seyfert S, 2004, J NEUROL, V251, P355, DOI 10.1007/s00415-004-0334-2; Shen J, 2007, P NATL ACAD SCI USA, V104, P403, DOI 10.1073/pnas.0608332104; Sidor MM, 2005, J NEUROIMMUNOL, V165, P104, DOI 10.1016/j.jneuroim.2005.04.022; Siemers ER, 2006, NEUROLOGY, V66, P602, DOI 10.1212/01.WNL.0000198762.41312.E1; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sun AY, 2002, EXP NEUROL, V175, P10, DOI 10.1006/exnr.2002.7875; TRIGUERO D, 1989, P NATL ACAD SCI USA, V86, P4761, DOI 10.1073/pnas.86.12.4761; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Wilcock DM, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-24; Willem M, 2006, SCIENCE, V314, P664, DOI 10.1126/science.1132341; Wiltfang J, 2001, J BIOL CHEM, V276, P42645, DOI 10.1074/jbc.M102790200; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200	51	34	42	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3184	3196		10.1096/fj.06-7993com	http://dx.doi.org/10.1096/fj.06-7993com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17494994				2022-12-28	WOS:000249781600019
J	Frosch, WA				Frosch, William A.			"Taking the waters" - springs, wells, and spas	FASEB JOURNAL			English	Editorial Material									Weill Cornell Med Coll, Dept Psychiat, New York, NY 10021 USA	Cornell University	Frosch, WA (corresponding author), Weill Cornell Med Coll, Dept Psychiat, 525 E 68th St, New York, NY 10021 USA.	wafrosc@med.cornell.edu						CROUTIER AL, 1992, TAKING WATERS SPIRIT, P110; CUNLIFFE B, 1987, CITY BATH, P104; PORTER R, 1990, MED HIST S, V10, pR7	3	15	15	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					1948	1950		10.1096/fj.07-0702ufm	http://dx.doi.org/10.1096/fj.07-0702ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17592155				2022-12-28	WOS:000247500300002
J	Baroni, M; Pizzirani, C; Pinotti, M; Ferrari, D; Adinolfi, E; Calzavarini, S; Caruso, P; Bernardi, F; Di Virgilio, F				Baroni, Marcello; Pizzirani, Cinzia; Pinotti, Mirko; Ferrari, Davide; Adinolfi, Elena; Calzavarini, Sara; Caruso, Pierpaolo; Bernardi, Francesco; Di Virgilio, Francesco			Stimulation of P2 (P2X(7)) receptors in human dendritic cells induces the release of tissue factor-bearing microparticles	FASEB JOURNAL			English	Article						coagulation; inflammation; extracellular ATP; purinergic receptors	SHED MEMBRANE MICROPARTICLES; EXTRACELLULAR ATP; ACTIVATION; BLOOD; NUCLEOTIDES; IDENTIFICATION; INFLAMMATION; COAGULATION; THROMBOSIS; EXPRESSION	Receptors for extracellular nucleotides are the focus of increasing attention for their ability to cause release of plasma membrane vesicles ( microparticles, MPs). Here, we show that monocyte-derived human dendritic cells (DCs) stimulated with a P2X(7) receptor (P2X(7)R) agonist undergo a large release of MPs endowed with procoagulant activity. Functional and Western blot studies revealed that MPs contain the membrane-bound form of tissue factor (TF), a glycoprotein acting as essential cofactor of activated factor VII and triggering blood coagulation. Quiescent DCs express the membrane-bound (full length), as well as truncated alternatively spliced TF forms. DC reactivity to anti- TF Abs disappeared almost completely on stimulation with ATP or benzoyl ATP ( BzATP), as shown by immunoblot and confocal microscopy analysis. Concurrently, TF reactivity and activity appeared in the vesicular fraction, indicating that MPs are important carriers for the dissemination of full-length TF form. Activity of MP-bound TF, comparable to that of relipidated recombinant TF, was dose dependently inhibited by the addition of a specific anti- human TF antibody. We infer that a large fraction of this protein, and its procoagulant potential, are "deliverable" after physiological or pathological stimuli. These findings might have implications for triggering and propagating coagulation in healthy and atherosclerotic vessels.-Marcello Baroni, Cinzia Pizzirani, Mirko Pinotti, Davide Ferrari, Elena Adinolfi, Sara Calzavarini, Pierpaolo Caruso, Francesco Bernardi, and Francesco Di Virgilio. Stimulation of P2 ( P2X7) receptors in human dendritic cells induces the release of tissue factor-bearing microparticles.	Univ Ferrara, Interdisciplinary Ctr Study Inflammat, Ferrara, Italy; Univ Ferrara, Dept Biochem, Ferrara, Italy; Univ Ferrara, Dept Expt & Diagnost Med, Ferrara, Italy	University of Ferrara; University of Ferrara; University of Ferrara	Di Virgilio, F (corresponding author), Sect Gen Pathol, Dept Expt & Diagnost Med, Via Borsari 46, I-44100 Ferrara, Italy.	fdv@unife.it	bernardi, francesco/F-5443-2013; Di Virgilio, Francesco/J-3754-2018; Ferrari, Davide/F-5644-2015; Adinolfi, Elena/F-9169-2010; DI VIRGILIO, Francesco/O-4634-2019; Calzavarini, Sara/AAU-9368-2020	Di Virgilio, Francesco/0000-0003-3566-1362; Ferrari, Davide/0000-0002-5727-9204; Adinolfi, Elena/0000-0001-8129-9929; DI VIRGILIO, Francesco/0000-0003-3566-1362; Calzavarini, Sara/0000-0002-7494-2995; Pinotti, Mirko/0000-0002-4114-7055	Telethon [GGP06070] Funding Source: Medline	Telethon(Fondazione Telethon)		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04-11-1025; Ahamed J, 2006, P NATL ACAD SCI USA, V103, P13932, DOI 10.1073/pnas.0606411103; Andrei C, 2004, P NATL ACAD SCI USA, V101, P9745, DOI 10.1073/pnas.0308558101; Atkinson B, 2006, BLOOD CELL MOL DIS, V36, P217, DOI 10.1016/j.bcmd.2005.12.025; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bianco F, 2005, J IMMUNOL, V174, P7268, DOI 10.4049/jimmunol.174.11.7268; Biro E, 2003, J THROMB HAEMOST, V1, P2561, DOI 10.1046/j.1538-7836.2003.00456.x; Bogdanov VY, 2003, NAT MED, V9, P458, DOI 10.1038/nm841; Boulanger CM, 2006, HYPERTENSION, V48, P180, DOI 10.1161/01.HYP.0000231507.00962.b5; Burnstock G, 2006, PHARMACOL REV, V58, P58, DOI 10.1124/pr.58.1.5; Campo G, 2006, ARTERIOSCL THROM VAS, V26, P2800, DOI 10.1161/01.ATV.0000247249.82030.94; Carta S, 2006, BLOOD, V108, P1618, DOI 10.1182/blood-2006-03-014126; Cirillo P, 2004, CIRCULATION, V109, P2911, DOI 10.1161/01.CIR.0000129312.43547.08; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Dinarello CA, 2005, J EXP MED, V201, P1355, DOI 10.1084/jem.20050640; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Elssner A, 2004, J IMMUNOL, V172, P4987, DOI 10.4049/jimmunol.172.8.4987; Ferrari D, 2000, FASEB J, V14, P2466, DOI 10.1096/fj.00-0031com; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Fortin JP, 2005, AM J PHYSIOL-HEART C, V288, pH2192, DOI 10.1152/ajpheart.01135.2004; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Hathcock J, 2004, SEMIN HEMATOL, V41, P30, DOI 10.1053/j.seminhematol.2003.11.007; Idzko M, 2002, BLOOD, V100, P925, DOI 10.1182/blood.V100.3.925; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; la Sala A, 2002, BLOOD, V99, P1715, DOI 10.1182/blood.V99.5.1715; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; Mallat Z, 2000, CIRCULATION, V101, P841, DOI 10.1161/01.CIR.101.8.841; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Morel O, 2006, PATHOPHYSIOL HAEMO T, V35, P15, DOI 10.1159/000093538; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; PIZZIRANI C, 2006, IN PRESS BLOOD; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rao LVM, 2005, ARTERIOSCL THROM VAS, V25, P47, DOI 10.1161/01.ATV.0000151624.45775.13; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schnurr M, 2003, BLOOD, V102, P613, DOI 10.1182/blood-2002-12-3745; Schnurr M, 2000, J IMMUNOL, V165, P4704, DOI 10.4049/jimmunol.165.8.4704; Shet AS, 2003, BLOOD, V102, P2678, DOI 10.1182/blood-2003-03-0693; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; Wilkin F, 2002, EUR J IMMUNOL, V32, P2409, DOI 10.1002/1521-4141(200209)32:9<2409::AID-IMMU2409>3.0.CO;2-H; Wong CW, 2006, NAT MED, V12, P950, DOI 10.1038/nm1441; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	48	75	77	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1926	1933		10.1096/fj.06-7238com	http://dx.doi.org/10.1096/fj.06-7238com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314141				2022-12-28	WOS:000246866500033
J	Lehner, F; Kulik, U; Klempnauer, J; Borlak, J				Lehner, F.; Kulik, U.; Klempnauer, J.; Borlak, J.			The hepatocyte nuclear factor 6 (HNF6) and FOXA2 are key regulators in colorectal liver metastases	FASEB JOURNAL			English	Article						liver-enriched transcription factors; colon cancer; human liver; hepatocellular carcinoma	ENRICHED TRANSCRIPTION FACTORS; HEPATOCYTE NUCLEAR FACTOR-6; BINDING PROTEIN; DNA-BINDING; EXPRESSION; DIFFERENTIATION; RECRUITMENT; GENETICS; CBP	The molecular causes leading to secondary liver malignancies are unknown. Here we report regulation of major hepatic nuclear factors in human colorectal liver metastases and primary colonic cancer. Notably, the genes coding for HNF6, HNF1 beta, and C/EBP gamma were selectively regulated in liver metastases. We therefore studied protein expression of regulated transcription factors and found unacetylated HNF6 to be a hallmark of colorectal liver metastases. For its known interaction with HNF6, we investigated expression of FOXA2, which we found to be specifically induced in colorectal liver metastases. By electromobility shift assay, we examined DNA binding of disease regulated transcription factors. Essentially, no HNF6 DNA binding was observed. We also searched for sequence variations in the DNA binding domains of HNF6, but did not identify any mutation. Furthermore, we probed for expression of 28 genes targeted by HNF6. Mostly transcript expression was repressed except for tumor growth. In conclusion, we show HNF6 protein expression to be driven by the hepatic environment. Its expression is not observed in healthy colon or primary colonic cancer. HNF6 DNA binding is selectively abrogated through lack of post- translational modification and interaction with FOXA2. Targeting of FOXA2 and HNF6 may therefore enable mechanismbased therapy for colorectal liver metastases.	Fraunhofer Inst Toxicol & Expt Med, D-30625 Hannover, Germany; Hannover Med Sch, Dept Gen Visceral & Transplantat Surg, D-3000 Hannover, Germany	Fraunhofer Gesellschaft; Hannover Medical School	Borlak, J (corresponding author), Fraunhofer Inst Toxicol & Expt Med, Nikolai Fuchs Str 1, D-30625 Hannover, Germany.	borlak@item.fraunhofer.de						Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Baglioni S, 2004, AM J MED GENET C, V129C, P35, DOI 10.1002/ajmg.c.30023; Briancon N, 2004, J BIOL CHEM, V279, P33398, DOI 10.1074/jbc.M405312200; Clotman F, 2002, DEVELOPMENT, V129, P1819; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Hayashi Y, 1999, J CLIN PATHOL-MOL PA, V52, P19; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Jain S, 2005, HEPATO-GASTROENTEROL, V52, P1567; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jenny M, 2002, EMBO J, V21, P6338, DOI 10.1093/emboj/cdf649; Jo WS, 2005, SEMIN ONCOL, V32, P11, DOI 10.1053/j.seminoncol.2004.09.034; Kishimoto T, 1998, CELL GROWTH DIFFER, V9, P337; Lannoy VJ, 2000, J BIOL CHEM, V275, P22098, DOI 10.1074/jbc.M000855200; Lannoy VJ, 1998, J BIOL CHEM, V273, P13552, DOI 10.1074/jbc.273.22.13552; Lazarevich N, 2004, HEPATOLOGY, V39, P1038, DOI 10.1002/hep.20155; Lee CS, 2005, NATURE, V435, P944, DOI 10.1038/nature03649; Lemaigre F, 2004, CURR OPIN GENET DEV, V14, P582, DOI 10.1016/j.gde.2004.08.004; Niehof M, 2001, J BIOL CHEM, V276, P9016, DOI 10.1074/jbc.M009284200; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Rausa FM, 2004, J BIOL CHEM, V279, P43070, DOI 10.1074/jbc.M407472200; Rausa FM, 2003, MOL CELL BIOL, V23, P437, DOI 10.1128/MCB.23.2.437-449.2003; Rubins NE, 2005, MOL CELL BIOL, V25, P7069, DOI 10.1128/MCB.25.16.7069-7077.2005; Schrem H, 2004, PHARMACOL REV, V56, P291, DOI 10.1124/pr.56.2.5; Schrem H, 2002, PHARMACOL REV, V54, P129, DOI 10.1124/pr.54.1.129; van de Velde CJH, 2005, ANN ONCOL, V16, P144, DOI 10.1093/annonc/mdi702; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Xu L, 2001, CANCER RES, V61, P3176; Yoshida Y, 2006, HEPATOLOGY, V43, P276, DOI 10.1002/hep.21044	29	26	28	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1445	1462		10.1096/fj.06-6575com	http://dx.doi.org/10.1096/fj.06-6575com			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17283222				2022-12-28	WOS:000246117000020
J	Lehman, N; Ledford, B; Di Fulvio, M; Frondorf, K; McPhail, LC; Gomez-Cambronero, J				Lehman, Nicholas; Ledford, Bill; Di Fulvio, Mauricio; Frondorf, Kathleen; McPhail, Linda C.; Gomez-Cambronero, Julian			Phospholipase D2-derived phosphatidic acid binds to and activates ribosomal p70 S6 kinase independently of mTOR	FASEB JOURNAL			English	Article						signal transduction; network phospholipases and kinases; small interfering RNA; protein/lipid binding; immunofluorescence colocalization	MAMMALIAN TARGET; HUMAN NEUTROPHILS; NADPH OXIDASE; IN-VIVO; SUPEROXIDE GENERATION; SIGNALING PATHWAY; PROTEIN-SYNTHESIS; PLASMA-MEMBRANE; PHOSPHORYLATION; RAPAMYCIN	The product of phospholipase D (PLD) enzymatic action in cell membranes, phosphatidic acid (PA), regulates kinases implicated in NADPH oxidase activation, as well as the mammalian target of rapamycin ( mTOR) kinase. However, other protein targets for this lipid second messenger must exist in order to explain other key PA-mediated cellular functions. In this study, PA was found to specifically and saturably bind to and activate recombinant and immunoprecipitated endogenous ribosomal S6 kinase (S6K) with a stoichiometry of 94:1 lipid/protein. Polyphosphoinositides PI4-P and PI4,5P(2) and cardiolipin could also bind to and activate S6K, albeit with different kinetics. Conversely, PA with at least one acyl side chain saturated ( 10: 0) was ineffective in binding or activating the enzyme. Transfection of COS-7 cells with a wild-type myc-(pcDNA)-PLD2 construct resulted in high PLD activity, concomitantly with an increase in ribosomal p70S6K enzyme activity and phosphorylation in T-389 and T-421/S-424 as well as phosphorylation of p70S6K's natural substrate S6 protein in S-235/S-236. Overexpression of a lipase inactive mutant (K758R), however, failed to induce an increase in both PLD and S6K activity or phosphorylation, indicating that the enzymatic activity of PLD2 (i.e., synthesis of PA) must be present to affect S6K. Neither inhibiting mTOR kinase activity with rapamycin nor silencing mTOR gene expression altered the augmentative effect of PLD2 exerted on p70S6K activity. This finding indicates that PA binds to and activates p70S6K, even in the absence of mTOR. Lastly, COS-7 transfection with PLD2 changed the pattern of subcellular expression, and a colocalization of S6K and PLD2 was observed by immunofluorescence microscopy. These results show for the first time a direct (mTOR-independent) participation of PLD in the p70S6K pathway and implicate PA as a nexus that brings together cell phospholipases and kinases.	Wright State Univ, Sch Med, Dept Neurosci Cell Biol & Physiol, Dayton, OH 45435 USA; Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27109 USA	University System of Ohio; Wright State University Dayton; Wake Forest University	Gomez-Cambronero, J (corresponding author), Wright State Univ, Sch Med, Dept Neurosci Cell Biol & Physiol, 3640 Colonel Glenn Hwy, Dayton, OH 45435 USA.	julian.cambronero@wright.edu	McPhail, Linda C/D-9505-2013	McPhail, Linda C/0000-0002-8670-306X; Gomez-Cambronero, Julian/0000-0002-7581-9227	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL056653, R01HL056653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022564] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL056653] Funding Source: Medline; NIAID NIH HHS [AI22564, R01 AI022564] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Al-Shami R, 2005, J CELL BIOCHEM, V94, P1218, DOI 10.1002/jcb.20379; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Ballou LM, 2003, FEBS LETT, V550, P51, DOI 10.1016/S0014-5793(03)00816-0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; Bannister P, 2001, TREE PHYSIOL SER, V1, P3; Banno Y, 2001, J BIOL CHEM, V276, P35622, DOI 10.1074/jbc.M105673200; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; Berven LA, 2004, EXP CELL RES, V296, P183, DOI 10.1016/j.yexer.2003.12.032; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; Buchsbaum RJ, 2003, J BIOL CHEM, V278, P18833, DOI 10.1074/jbc.M207876200; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chen J, 2002, BIOCHEM PHARMACOL, V64, P1071, DOI 10.1016/S0006-2952(02)01263-7; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Cho DH, 2006, AM J PHYSIOL-CELL PH, V291, pC317, DOI 10.1152/ajpcell.00491.2005; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Delon C, 2004, J BIOL CHEM, V279, P44763, DOI 10.1074/jbc.M405771200; Di Fulvio M, 2006, ONCOGENE, V25, P3032, DOI 10.1038/sj.onc.1209340; DING JB, 1994, FEBS LETT, V348, P149, DOI 10.1016/0014-5793(94)00593-1; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Eliasson J, 2006, AM J PHYSIOL-ENDOC M, V291, pE1197, DOI 10.1152/ajpendo.00141.2006; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Frank C, 1999, BIOCHEMISTRY-US, V38, P11993, DOI 10.1021/bi982586w; Freyberg Z, 2002, MOL BIOL CELL, V13, P3930, DOI 10.1091/mbc.02-04-0059; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Gomez-Cambronero J, 2003, J IMMUNOL, V171, P6846, DOI 10.4049/jimmunol.171.12.6846; Gomez-Cambronero J, 2003, FEBS LETT, V550, P94, DOI 10.1016/S0014-5793(03)00828-7; Grange M, 2000, J BIOL CHEM, V275, P33379, DOI 10.1074/jbc.M006329200; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Horn JM, 2001, BBA-MOL CELL BIOL L, V1530, P97, DOI 10.1016/S1388-1981(00)00172-4; Hui L, 2004, MOL CELL BIOL, V24, P5677, DOI 10.1128/MCB.24.13.5677-5686.2004; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jones JA, 2005, BIOCHEMISTRY-US, V44, P13235, DOI 10.1021/bi0505159; Jones JA, 2002, J BIOL CHEM, V277, P15530, DOI 10.1074/jbc.M111555200; Joseph T, 2002, ONCOGENE, V21, P3651, DOI 10.1038/sj.onc.1205380; Kam Y, 2004, FASEB J, V18, P311, DOI 10.1096/fj.03-0731com; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; Kusner DJ, 2002, J BIOL CHEM, V277, P50683, DOI 10.1074/jbc.M209221200; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Lehman JA, 2003, J BIOL CHEM, V278, P28130, DOI 10.1074/jbc.M300376200; Lehman N, 2006, BLOOD, V108, P3564, DOI 10.1182/blood-2006-02-005959; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MCPHAIL LC, 1995, P NATL ACAD SCI USA, V92, P7931, DOI 10.1073/pnas.92.17.7931; Miles DJC, 2003, DIS AQUAT ORGAN, V55, P77, DOI 10.3354/dao055077; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; NEMENOFF RA, 1988, J BIOL CHEM, V263, P19455; OLSON SC, 1990, FEBS LETT, V272, P19, DOI 10.1016/0014-5793(90)80439-P; Picq M, 2002, J MED CHEM, V45, P1678, DOI 10.1021/jm011032f; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rebholz H, 2006, FEBS J, V273, P2023, DOI 10.1111/j.1742-4658.2006.05219.x; Riemenschneider MJ, 2006, CANCER RES, V66, P5618, DOI 10.1158/0008-5472.CAN-06-0364; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; Sekulic A, 2000, CANCER RES, V60, P3504; Sergeant S, 2001, J BIOL CHEM, V276, P4737, DOI 10.1074/jbc.M006571200; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; Stace CL, 2006, BBA-MOL CELL BIOL L, V1761, P913, DOI 10.1016/j.bbalip.2006.03.006; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Talvas J, 2006, J NUTR, V136, P1466, DOI 10.1093/jn/136.6.1466; TORTORELLA D, 1993, BIOCHEMISTRY-US, V32, P9181, DOI 10.1021/bi00086a025; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Yan LJ, 2006, J BIOL CHEM, V281, P19793, DOI 10.1074/jbc.C600028200; Zheng XJ, 2003, MOL CELL ENDOCRINOL, V206, P113, DOI 10.1016/S0303-7207(03)00211-9	77	87	91	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1075	1087		10.1096/fj.06-6652com	http://dx.doi.org/10.1096/fj.06-6652com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17242159				2022-12-28	WOS:000245650400012
J	Perotti, MA; Allen, JM; Reed, DL; Braig, HR				Perotti, M. Alejandra; Allen, Julie M.; Reed, David L.; Braig, Henk R.			Host-symbiont interactions of the primary endosymbiont of human head and body lice	FASEB JOURNAL			English	Article						host-pathogen interaction; host-symbiont evolution; organ-forming bacteria; immune evasion; bacteriotome	PLEBEJUS FALL HOMOPTERA; PEDICULUS-HUMANUS; PHYLOGENETIC ANALYSIS; HORIZONTAL TRANSFER; EMBRYONIC MYCETOME; RATIO DISTORTION; FINE-STRUCTURE; RIBOSOMAL-RNA; LOUSE; ARSENOPHONUS	The first mycetome was discovered more than 340 yr ago in the human louse. Despite the remarkable biology and medical and social importance of human lice, its primary endosymbiont has eluded identification and characterization. Here, we report the host-symbiont interaction of the mycetomic bacterium of the head louse Pediculus humanus capitis and the body louse P. h. humanus. The endosymbiont represents a new bacterial lineage in the gamma-Proteobacteria. Its closest sequenced relative is Arsenophonus nasoniae, from which it differs by more than 10%. A. nasoniae is a male-killing endosymbiont of jewel wasps. Using microdissection and multiphoton confocal microscopy, we show the remarkable interaction of this bacterium with its host. This endosymbiont is unique because it occupies sequentially four different mycetomes during the development of its host, undergoes three cycles of proliferation, changes in length from 2-4 mu m to more than 100 mu m, and has two extracellular migrations, during one of which the endosymbionts have to outrun its host's immune cells. The host and its symbiont have evolved one of the most complex interactions: two provisional or transitory mycetomes, a main mycetome and a paired filial mycetome. Despite the close relatedness of body and head lice, differences are present in the mycetomic provisioning and the immunological response.	Univ Coll N Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales; Univ Florida, Florida Museum Nat Hist, Gainesville, FL USA; Univ Florida, Dept Zool, Gainesville, FL 32611 USA	Bangor University; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Braig, HR (corresponding author), Univ Coll N Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales.	h.braig@bangor.ac.uk	Braig, Henk/I-5477-2013; Reed, David/A-6296-2008	Braig, Henk/0000-0001-9592-1141; 				Aschner M., 1933, Zeitschrift fuer Morphologie und Oekologie der Tiere Berlin, V26, P529, DOI 10.1007/BF00446386; ASCHNER MANFRED, 1934, PARASITOLOGY, V26, P309, DOI 10.1017/S0031182000023611; Batut J, 2004, NAT REV MICROBIOL, V2, P933, DOI 10.1038/nrmicro1044; Baudisch K., 1958, Zeitschrift fuer Morphologie und Oekologie der Tiere Berlin, V47, P436, DOI 10.1007/BF00411810; Braendle C, 2003, PLOS BIOL, V1, P70, DOI 10.1371/journal.pbio.0000021; Buchner P., 1965, ENDOSYMBIOSIS ANIMAL; Burgess IE, 2004, ANNU REV ENTOMOL, V49, P457, DOI 10.1146/annurev.ento.49.061802.123253; Dale C, 2006, APPL ENVIRON MICROB, V72, P2997, DOI 10.1128/AEM.72.4.2997-3004.2006; Drancourt M, 2005, NAT REV MICROBIOL, V3, P23, DOI 10.1038/nrmicro1063; EBERLE MW, 1983, CAN J MICROBIOL, V29, P755, DOI 10.1139/m83-123; EBERLE MW, 1982, J INSECT PHYSIOL, V28, P417, DOI 10.1016/0022-1910(82)90068-3; Foucault C, 2006, J INFECT DIS, V193, P474, DOI 10.1086/499279; GHERNA RL, 1991, INT J SYST BACTERIOL, V41, P563, DOI 10.1099/00207713-41-4-563; Grimaldi D, 2006, P ROY SOC B-BIOL SCI, V273, P625, DOI 10.1098/rspb.2005.3337; Grindle N, 2003, J INVERTEBR PATHOL, V83, P264, DOI 10.1016/S0022-2011(03)00080-6; Heddi A, 2005, CELL MICROBIOL, V7, P293, DOI 10.1111/j.1462-5822.2004.00461.x; Hinton H.E., 1981, BIOL INSECT EGGS, VI; Hooke Robert, 1665, MICROGRAPHIA SOME PH; Houhamdi L, 2006, AM J TROP MED HYG, V74, P521, DOI 10.4269/ajtmh.2006.74.521; Hurst GDD, 2000, EMERG INFECT DIS, V6, P329, DOI 10.3201/eid0604.000402; Hypsa V, 1997, INT J SYST BACTERIOL, V47, P1140, DOI 10.1099/00207713-47-4-1140; Johnson KP, 2004, P ROY SOC B-BIOL SCI, V271, P1771, DOI 10.1098/rspb.2004.2798; Kittler R, 2004, CURR BIOL, V14, P2309, DOI 10.1016/j.cub.2004.12.024; Kittler R, 2003, CURR BIOL, V13, P1414, DOI 10.1016/S0960-9822(03)00507-4; KORNER HK, 1974, Z PARASITENKD, V44, P149, DOI 10.1007/BF02433467; KORNER HK, 1972, Z PARASITENKD, V40, P203; Kyei-Poku GK, 2005, MOL ECOL, V14, P285, DOI 10.1111/j.1365-294X.2004.02409.x; Leo NP, 2005, PARASITOL RES, V98, P44, DOI 10.1007/s00436-005-0013-y; Leo NP, 2005, HEREDITY, V95, P34, DOI 10.1038/sj.hdy.6800663; Leo NP, 2002, INSECT MOL BIOL, V11, P651, DOI 10.1046/j.1365-2583.2002.00367.x; Leo NP, 2002, J MED ENTOMOL, V39, P662, DOI 10.1603/0022-2585-39.4.662; LEVENE H, 1959, AM NAT, V93, P347, DOI 10.1086/282094; Marchesi JR, 1998, APPL ENVIRON MICROB, V64, P795; McMeniman CJ, 2006, HEREDITY, V96, P63, DOI 10.1038/sj.hdy.6800760; Murrell A, 2005, PARASITOL RES, V97, P274, DOI 10.1007/s00436-005-1413-8; Perotti MA, 2006, FASEB J, V20, P2372, DOI 10.1096/fj.06-5870fje; Perotti MA, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-10; Puchta O., 1955, Zeitschrift fuer Parasitenkunde, V17, P1; Raoult D, 2006, J INFECT DIS, V193, P112, DOI 10.1086/498534; Reed DL, 2004, PLOS BIOL, V2, P1972, DOI 10.1371/journal.pbio.0020340; Ries E., 1931, Zeitschrift fuer Morphologie und Oekologie der Tiere Berlin, V20, P233, DOI 10.1007/BF00444101; Russell JA, 2005, APPL ENVIRON MICROB, V71, P7987, DOI 10.1128/AEM.71.12.7987-7994.2005; Russell JA, 2003, MOL ECOL, V12, P1061, DOI 10.1046/j.1365-294X.2003.01780.x; Spaulding AW, 2001, INSECT MOL BIOL, V10, P57, DOI 10.1046/j.1365-2583.2001.00231.x; SWAMMERDAM J, 1737, BYBEL NATUURE HIST I, V2; Thao ML, 2000, CURR MICROBIOL, V41, P300, DOI 10.1007/s002840010138; Thao MLL, 2004, CURR MICROBIOL, V48, P140, DOI 10.1007/s00284-003-4157-7; Trowbridge RE, 2006, J INVERTEBR PATHOL, V91, P64, DOI 10.1016/j.jip.2005.08.009; Veneti Z, 2005, SCIENCE, V307, P1461, DOI 10.1126/science.1107182; Yong Z, 2003, CR BIOL, V326, P565, DOI 10.1016/S1631-0691(03)00153-7; YOSHIZAWA K, 2006, ZOOL J LINN SOC, V146; Zawadzka M, 1997, TISSUE CELL, V29, P665, DOI 10.1016/S0040-8166(97)80042-0; Zinsser Hans., 1935, RATS LICE HIST	53	71	73	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					1058	1066		10.1096/fj.06-6808com	http://dx.doi.org/10.1096/fj.06-6808com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17227954				2022-12-28	WOS:000245650400010
J	Kalinina, E; Biswas, R; Berezniuk, I; Hermoso, A; Aviles, FX; Fricker, LD				Kalinina, Elena; Biswas, Reeta; Berezniuk, Iryna; Hermoso, Antoni; Aviles, Francesc X.; Fricker, Lloyd D.			A novel subfamily of mouse cytosolic carboxypeptidases	FASEB JOURNAL			English	Article						posttranslational processing; Nna1; Purkinje cell degeneration; CCP	PURKINJE-CELL DEGENERATION; TUBULIN-TYROSINE-LIGASE; METALLOCARBOXYPEPTIDASE GENE FAMILY; CEREBELLAR MUTANT MOUSE; RETINAL DEGENERATION; PROTEIN STRUCTURES; PCD; IDENTIFICATION; NNA1; DIFFERENTIATION	Nna1 is a recently described gene product that has sequence similarity with metallocarboxypeptidases. In the present study, five additional Nna1-like genes were identified in the mouse genome and named cytosolic carboxypeptidase (CCP) 2 through 6. Modeling suggests that the carboxypeptidase domain folds into a structure that resembles metallocarboxypeptidases of the M14 family, with all necessary residues for catalytic activity and broad substrate specificity. All CCPs are abundant in testis and also expressed in brain, pituitary, eye, and other mouse tissues. In brain, Nna1/CCP1, CCP5, and CCP6 are broadly distributed, whereas CCP2 and 3 exhibit restricted patterns of expression. Nna1/CCP1, CCP2, CCP5, and CCP6 were found to exhibit a cytosolic distribution, with a slight accumulation of CCP5 in the nucleus. Based on the above results, we hypothesized that Nna1/CCP1 and CCP2-6 function in the processing of cytosolic proteins such as alpha-tubulin, which is known to be modified by the removal of a C-terminal tyrosine. Analysis of the forms of alpha tubulin in the olfactory bulb of mice lacking Nna1/CCP1 showed the absence of the detyrosinylated form in the mitral cells. Taken together, these results are consistent with a role for Nna1/CCP1 and the related CCPs in the processing of tubulin.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Autonomous Univ Barcelona, Inst Biotecnol I Biomed, Bellaterra, Barcelona, Spain; Autonomous Univ Barcelona, Dept Bioquim & Biol Mol, Bellaterra, Barcelona, Spain	Yeshiva University; Albert Einstein College of Medicine; Autonomous University of Barcelona; Autonomous University of Barcelona	Fricker, LD (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	fricker@aecom.yu.edu	Aviles, Francesc Xavier/F-3482-2019; Kalinina, Elena/D-9252-2012; Avilés, Francesc Xavier/A-2664-2015; Pulido, Toni Hermoso/K-3701-2015	Aviles, Francesc Xavier/0000-0002-1399-6789; Kalinina, Elena/0000-0003-0180-090X; Avilés, Francesc Xavier/0000-0002-1399-6789; Pulido, Toni Hermoso/0000-0003-2016-6465	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004494] Funding Source: NIH RePORTER; NCI NIH HHS [CA13330] Funding Source: Medline; NIDA NIH HHS [DA-04494] Funding Source: Medline; NIDDK NIH HHS [DK-051271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AROLAS JL, 2006, IN PRESS CURR PHARM; AULD DS, 2004, HDB PROTEOLYTIC ENZY, P821; AULD DS, 2004, HDB PROTEOLYTIC ENZY, P812; AVILES FX, 2004, HDB PROTEOLYTIC ENZY, P831; BARRA HS, 1988, MOL NEUROBIOL, V2, P133, DOI 10.1007/BF02935343; Barrett A.J., 1998, HDB PROTEOLYTIC ENZY, P1318; BLANKS JC, 1982, J COMP NEUROL, V212, P231, DOI 10.1002/cne.902120303; Chakrabarti L, 2006, MAMM GENOME, V17, P103, DOI 10.1007/s00335-005-0096-x; DeLano W.L, PYMOL MOL GRAPHICS S; DELAVEGA R, 2007, IN PRESS FASEB J; Dong W, 1999, NEUROSCIENCE, V89, P1301, DOI 10.1016/S0306-4522(98)00381-9; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Erck C, 2005, P NATL ACAD SCI USA, V102, P7853, DOI 10.1073/pnas.0409626102; ERSFELD K, 1993, J CELL BIOL, V120, P725, DOI 10.1083/jcb.120.3.725; Estebanez-Perpina E, 2001, J MOL BIOL, V313, P629, DOI 10.1006/jmbi.2001.5076; Fernandez-Gonzalez A, 2002, SCIENCE, V295, P1904, DOI 10.1126/science.1068912; Fiser A, 2003, BIOINFORMATICS, V19, P2500, DOI 10.1093/bioinformatics/btg362; Fontenele-Neto JD, 2005, MOL BRAIN RES, V137, P132, DOI 10.1016/j.molbrainres.2005.02.026; FRICKER LD, 2004, HDB PROTEOLYTIC ENZY, P844; Fricker LD, 2004, HDB PROTEOLYTIC ENZY, V1, P848, DOI 10.1016/B978-0-12-079611-3.50259-7; Fricker LD, 2004, HDB PROTEOLYTIC ENZY, V8, P840; GREER CA, 1982, BRAIN RES, V235, P156, DOI 10.1016/0006-8993(82)90206-2; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harris A, 2000, MOL CELL NEUROSCI, V16, P578, DOI 10.1006/mcne.2000.0900; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; HENDRIKS DF, 2004, HDB PROTEOLYTIC ENZY, P825; Huang HJ, 1999, CANCER RES, V59, P2981; Janke C, 2005, SCIENCE, V308, P1758, DOI 10.1126/science.1113010; Kato C, 2004, INT J CANCER, V112, P365, DOI 10.1002/ijc.20431; Lafanechere L, 1998, J CELL SCI, V111, P171; LANDIS SC, 1978, J COMP NEUROL, V177, P125, DOI 10.1002/cne.901770109; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LAVAIL MM, 1982, J COMP NEUROL, V212, P217, DOI 10.1002/cne.902120302; Layne MD, 1998, J BIOL CHEM, V273, P15654, DOI 10.1074/jbc.273.25.15654; Lei YH, 1999, DNA CELL BIOL, V18, P175, DOI 10.1089/104454999315565; Mizuguchi K, 1998, BIOINFORMATICS, V14, P617, DOI 10.1093/bioinformatics/14.7.617; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; Reznik SE, 2001, CELL MOL LIFE SCI, V58, P1790, DOI 10.1007/PL00000819; Rong YQ, 2004, MOL BRAIN RES, V132, P128, DOI 10.1016/j.molbrainres.2004.10.015; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; SKIDGEL RA, 2004, HDB PROTEOLYTIC ENZY, P851; SKIDGEL RA, 2004, HDB PROTEOLYTIC ENZY, P837; Springman EB, 2004, HDB PROTEOLYTIC ENZY, P828; Wang TY, 2006, MOL CELL NEUROSCI, V33, P200, DOI 10.1016/j.mcn.2006.07.009; WEBSTER DR, 2004, HDB PROTEOLYTIC ENZY, P2111; Wei SW, 2002, J BIOL CHEM, V277, P14954, DOI 10.1074/jbc.M112254200; Xin XN, 1998, DNA CELL BIOL, V17, P897, DOI 10.1089/dna.1998.17.897	48	94	102	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					836	850		10.1096/fj.06-7329com	http://dx.doi.org/10.1096/fj.06-7329com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17244818				2022-12-28	WOS:000244686400021
J	McCann, JC; Ames, BN				McCann, Joyce C.; Ames, Bruce N.			Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction?	FASEB JOURNAL			English	Review						calcitriol; cognition; depression; memory; brain development; cytokine theory	CALCIUM-BINDING PROTEINS; INFLAMMATORY-BOWEL-DISEASE; CENTRAL-NERVOUS-SYSTEM; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR IMMUNOREACTIVITY; NUTRITION EXAMINATION SURVEY; RANDOMIZED CONTROLLED-TRIAL; MULTIPLE-SCLEROSIS; MICE LACKING; ADULT-RAT; COGNITIVE DYSFUNCTION	Vitamin D insufficiency is common in the United States; the elderly and African-Americans are at particularly high risk of deficiency. This review, written for a broad scientific readership, presents a critical overview of scientific evidence relevant to a possible causal relationship between vitamin D deficiency and adverse cognitive or behavioral effects. Topics discussed are 1) biological functions of vitamin D relevant to cognition and behavior; 2) studies in humans and rodents that directly examine effects of vitamin D inadequacy on cognition or behavior; and 3) immunomodulatory activity of vitamin D relative to the proinflammatory cytokine theory of cognitive/behavioral dysfunction. We conclude there is ample biological evidence to suggest an important role for vitamin D in brain development and function. However, direct effects of vitamin D inadequacy on cognition/behavior in human or rodent systems appear to be subtle, and in our opinion, the current experimental evidence base does not yet fully satisfy causal criteria. Possible explanations for the apparent inconsistency between results of biological and cognitive/behavioral experiments, as well as suggested areas for further research are discussed. Despite residual uncertainty, recommendations for vitamin D supplementation of at-risk groups, including nursing infants, the elderly, and African-Americans appear warranted to ensure adequacy.	[McCann, Joyce C.; Ames, Bruce N.] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	McCann, JC (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	jmccann@chori.org; bames@chori.org						Adorini L, 2005, CELL IMMUNOL, V233, P115, DOI 10.1016/j.cellimm.2005.04.013; Adorini L, 2004, J STEROID BIOCHEM, V89-90, P437, DOI 10.1016/j.jsbmb.2004.03.013; Adorini L, 2007, J STEROID BIOCHEM, V103, P689, DOI 10.1016/j.jsbmb.2006.12.065; Airaksinen MS, 1997, P NATL ACAD SCI USA, V94, P1488, DOI 10.1073/pnas.94.4.1488; Alexianu ME, 1998, J NEUROSCI RES, V51, P58, DOI 10.1002/(SICI)1097-4547(19980101)51:1<58::AID-JNR6>3.0.CO;2-K; AlfahelKakunda A, 1997, DEV BRAIN RES, V103, P9, DOI 10.1016/S0165-3806(97)00101-6; Almeras L, 2007, PROTEOMICS, V7, P769, DOI 10.1002/pmic.200600392; ALTEMUS KL, 1987, PHYSIOL BEHAV, V39, P435, DOI 10.1016/0031-9384(87)90369-6; Amato MP, 2006, J NEUROL SCI, V245, P41, DOI 10.1016/j.jns.2005.08.019; Ames BN, 2005, EMBO REP, V6, pS20, DOI 10.1038/sj.embor.7400426; Ames BN, 2006, P NATL ACAD SCI USA, V103, P17589, DOI 10.1073/pnas.0608757103; Ames Bruce N., 2005, Molecular Aspects of Medicine, V26, P363, DOI 10.1016/j.mam.2005.07.007; Anisman H, 2005, CURR PHARM DESIGN, V11, P963, DOI 10.2174/1381612053381701; Armstrong DJ, 2007, CLIN RHEUMATOL, V26, P551, DOI 10.1007/s10067-006-0348-5; Arnett PA, 2006, J NEUROL NEUROSUR PS, V77, P606, DOI 10.1136/jnnp.2004.047712; Baas D, 2000, GLIA, V31, P59, DOI 10.1002/(SICI)1098-1136(200007)31:1<59::AID-GLIA60>3.0.CO;2-Y; Baeke F, 2007, NUTR RES REV, V20, P106, DOI 10.1017/S0954422407742713; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; Barker RA, 2006, LANCET NEUROL, V5, P285, DOI 10.1016/S1474-4422(06)70386-6; Barnard KD, 2006, DIABETIC MED, V23, P445, DOI 10.1111/j.1464-5491.2006.01814.x; Barski JJ, 2003, J NEUROSCI, V23, P3469; Becker A, 2006, BEHAV BRAIN RES, V166, P177, DOI 10.1016/j.bbr.2005.07.010; Becker A, 2005, BEHAV BRAIN RES, V161, P306, DOI 10.1016/j.bbr.2005.02.015; Beer TM, 2004, MOL CANCER THER, V3, P373; Benton D, 2001, NEUROSCI BIOBEHAV R, V25, P297, DOI 10.1016/S0149-7634(01)00015-X; Berggard T, 2002, J BIOL CHEM, V277, P16662, DOI 10.1074/jbc.M200415200; Bergh JJ, 2006, AM J PHYSIOL-CELL PH, V290, pC822, DOI 10.1152/ajpcell.00403.2005; Berridge MJ, 2006, CELL CALCIUM, V40, P405, DOI 10.1016/j.ceca.2006.09.002; Berridge MJ, 2004, BBA-MOL CELL RES, V1742, P3, DOI 10.1016/j.bbamcr.2004.08.012; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Bierhaus A, 2003, P NATL ACAD SCI USA, V100, P1920, DOI 10.1073/pnas.0438019100; Bikle DD, 2004, J CELL BIOCHEM, V92, P436, DOI 10.1002/jcb.20095; Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P18, DOI 10.1093/ajcn/84.1.18; Black PH, 2006, MED HYPOTHESES, V67, P879, DOI 10.1016/j.mehy.2006.04.008; Bodnar LM, 2007, J NUTR, V137, P447, DOI 10.1093/jn/137.2.447; Boyan BD, 2006, STEROIDS, V71, P286, DOI 10.1016/j.steroids.2005.09.018; Brands AMA, 2007, J INT NEUROPSYCH SOC, V13, P288, DOI 10.1017/S1355617707070312; Brands AMA, 2006, DIABETES, V55, P1800, DOI 10.2337/db05-1226; Brewer LD, 2006, CELL CALCIUM, V40, P277, DOI 10.1016/j.ceca.2006.04.001; Brewer LD, 2001, J NEUROSCI, V21, P98, DOI 10.1523/JNEUROSCI.21-01-00098.2001; Brown J, 2003, NEUROSCI LETT, V343, P139, DOI 10.1016/S0304-3940(03)00303-3; Bryan J, 2004, NUTR REV, V62, P295, DOI 10.1301/nr.2004.aug.295-306; Bula CM, 2005, ENDOCRINOLOGY, V146, P5581, DOI 10.1210/en.2005-0806; Buller KM, 2001, CLIN EXP PHARMACOL P, V28, P581, DOI 10.1046/j.1440-1681.2001.03490.x; Burket R, 2003, NEUROSCI RES COMMUN, V33, P63, DOI 10.1002/nrc.10081; Burne THJ, 2006, BRAIN RES BULL, V69, P74, DOI 10.1016/j.brainresbull.2005.10.014; Burne THJ, 2005, BEHAV BRAIN RES, V157, P299, DOI 10.1016/j.bbr.2004.07.008; Burne THJ, 2004, BEHAV BRAIN RES, V154, P549, DOI 10.1016/j.bbr.2004.03.023; Burne THJ, 2004, PHYSIOL BEHAV, V81, P651, DOI 10.1016/j.physbeh.2004.03.004; Cannell JJ, 2006, EPIDEMIOL INFECT, V134, P1129, DOI 10.1017/S0950268806007175; Cantorna MT, 2006, PROG BIOPHYS MOL BIO, V92, P60, DOI 10.1016/j.pbiomolbio.2006.02.020; CHARD PS, 1995, P NATL ACAD SCI USA, V92, P5144, DOI 10.1073/pnas.92.11.5144; Cheatham CL, 2006, AM J CLIN NUTR, V83, p1458S, DOI 10.1093/ajcn/83.6.1458S; Chia R, 2005, NAT GENET, V37, P1181, DOI 10.1038/ng1665; Choi WS, 2001, BIOCHEM BIOPH RES CO, V287, P656, DOI 10.1006/bbrc.2001.5649; Christophersen NS, 2007, EXP NEUROL, V204, P791, DOI 10.1016/j.expneurol.2007.01.014; Cianferotti L, 2007, P NATL ACAD SCI USA, V104, P9428, DOI 10.1073/pnas.0702884104; Cornet A, 1998, J NEUROSCI RES, V53, P742, DOI 10.1002/(SICI)1097-4547(19980915)53:6<742::AID-JNR11>3.0.CO;2-#; Cruess DG, 2005, AM J PSYCHIAT, V162, P2125, DOI 10.1176/appi.ajp.162.11.2125; Cui XY, 2007, INT J DEV NEUROSCI, V25, P227, DOI 10.1016/j.ijdevneu.2007.03.006; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; Danilenko K V, 1994, Arctic Med Res, V53, P137; Dantzer R, 2006, NEUROL CLIN, V24, P441, DOI 10.1016/j.ncl.2006.03.003; Dardenne O, 2001, ENDOCRINOLOGY, V142, P3135, DOI 10.1210/en.142.7.3135; Davies G, 2003, SCHIZOPHRENIA BULL, V29, P587, DOI 10.1093/oxfordjournals.schbul.a007030; Dawson-Hughes B, 2005, OSTEOPOROSIS INT, V16, P713, DOI 10.1007/s00198-005-1867-7; de Beaurepaire R, 2002, BRAIN BEHAV IMMUN, V16, P610, DOI 10.1016/S0889-1591(02)00005-3; DEBOLAND AR, 1988, CALCIFIED TISSUE INT, V43, P370, DOI 10.1007/BF02553281; Deluca HF, 2001, FASEB J, V15, P2579, DOI 10.1096/fj.01-0433rev; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; DEVIRAGH PA, 1989, P NATL ACAD SCI USA, V86, P3887, DOI 10.1073/pnas.86.10.3887; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; Dixon LB, 2001, J NUTR, V131, P1232, DOI 10.1093/jn/131.4.1232; Do Thi NA, 2007, GENE THER, V14, P441, DOI 10.1038/sj.gt.3302844; Dumas TC, 2004, HIPPOCAMPUS, V14, P701, DOI 10.1002/hipo.10210; Dumville JC, 2006, J NUTR HEALTH AGING, V10, P151; Dunn AJ, 2005, NEUROSCI BIOBEHAV R, V29, P891, DOI 10.1016/j.neubiorev.2005.03.023; Duque G, 2005, AM J PHYSIOL-ENDOC M, V288, pE723, DOI 10.1152/ajpendo.00180.2004; Dusso AS, 2005, AM J PHYSIOL-RENAL, V289, pF8, DOI 10.1152/ajprenal.00336.2004; Ebert R, 2006, MOL CELL ENDOCRINOL, V248, P149, DOI 10.1016/j.mce.2005.11.039; Elliott ME, 2003, PHARMACOTHERAPY, V23, P702, DOI 10.1592/phco.23.6.702.32182; Equils O, 2006, CLIN EXP IMMUNOL, V143, P58, DOI 10.1111/j.1365-2249.2005.02961.x; Erben RG, 2002, MOL ENDOCRINOL, V16, P1524, DOI 10.1210/me.16.7.1524; Eyles D, 2007, J STEROID BIOCHEM, V103, P538, DOI 10.1016/j.jsbmb.2006.12.096; Eyles D, 2003, NEUROSCIENCE, V118, P641, DOI 10.1016/S0306-4522(03)00040-X; Eyles DW, 2006, PSYCHONEUROENDOCRINO, V31, P958, DOI 10.1016/j.psyneuen.2006.05.006; Eyles DW, 2005, J CHEM NEUROANAT, V29, P21, DOI 10.1016/j.jchemneu.2004.08.006; Ferguson Robert J, 2003, Curr Neurol Neurosci Rep, V3, P215, DOI 10.1007/s11910-003-0081-2; Feron F, 2005, BRAIN RES BULL, V65, P141, DOI 10.1016/j.brainresbull.2004.12.007; Fierro L, 1996, J PHYSIOL-LONDON, V496, P617, DOI 10.1113/jphysiol.1996.sp021713; Filipovic BR, 2007, WORLD J GASTROENTERO, V13, P438, DOI 10.3748/wjg.v13.i3.438; Froicu M, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-5; Fuller-Thomson E, 2006, INFLAMM BOWEL DIS, V12, P697, DOI 10.1097/00054725-200608000-00005; Garcia-Martinez JM, 2006, J NEUROSCI RES, V83, P68, DOI 10.1002/jnr.20713; Garcion E, 1999, J NEUROCHEM, V73, P859, DOI 10.1046/j.1471-4159.1999.0730859.x; Garcion E, 2002, TRENDS ENDOCRIN MET, V13, P100, DOI 10.1016/S1043-2760(01)00547-1; Garland CF, 2007, J STEROID BIOCHEM, V103, P708, DOI 10.1016/j.jsbmb.2006.12.007; Gezen-Ak D, 2007, TOHOKU J EXP MED, V212, P275, DOI 10.1620/tjem.212.275; Gill SS, 2006, NAT MED, V12, P479, DOI 10.1038/nm0406-479; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Giovannucci E, 2006, JNCI-J NATL CANCER I, V98, P451, DOI 10.1093/jnci/djj101; Gloth F M 3rd, 1999, J Nutr Health Aging, V3, P5; Gnegy ME, 2000, CRIT REV NEUROBIOL, V14, P91; GNEGY ME, 1993, ANNU REV PHARMACOL, V33, P45, DOI 10.1146/annurev.pa.33.040193.000401; Gold Deborah T, 2006, Curr Osteoporos Rep, V4, P134, DOI 10.1007/BF02686959; Gold SM, 2006, NEUROL CLIN, V24, P507, DOI 10.1016/j.ncl.2006.03.007; Gombart AF, 2005, FASEB J, V19, P1067, DOI 10.1096/fj.04-3284com; GOPLEN DP, 1994, PEDIATR HEMAT ONCOL, V11, P173; Grant WB, 2006, PROG BIOPHYS MOL BIO, V92, P65, DOI 10.1016/j.pbiomolbio.2006.02.013; Griffin MD, 2003, ANNU REV NUTR, V23, P117, DOI 10.1146/annurev.nutr.23.011702.073114; Grondin R, 2002, BRAIN, V125, P2191, DOI 10.1093/brain/awf234; Gunstad J, 2006, J CLIN NEUROSCI, V13, P540, DOI 10.1016/j.jocn.2005.08.010; Gurlek A, 2002, ENDOCR REV, V23, P763, DOI 10.1210/er.2001-0044; Hagg T, 2005, TRENDS NEUROSCI, V28, P589, DOI 10.1016/j.tins.2005.08.009; Halling Anders, 2006, Eur J Gen Pract, V12, P114, DOI 10.1080/13814780600881128; Handoko H, 2006, AM J HUM BIOL, V18, P415, DOI 10.1002/ajhb.20504; HANNAH SS, 1994, NUTR REV, V52, P376, DOI 10.1111/j.1753-4887.1994.tb01368.x; HARRIS RA, 1981, J NEUROCHEM, V36, P460, DOI 10.1111/j.1471-4159.1981.tb01615.x; Harris SS, 2006, J NUTR, V136, P1126, DOI 10.1093/jn/136.4.1126; Harrison PJ, 1999, BRAIN, V122, P593, DOI 10.1093/brain/122.4.593; Hauwel M, 2005, BRAIN RES REV, V48, P220, DOI 10.1016/j.brainresrev.2004.12.012; Heaney RP, 1999, AM J CLIN NUTR, V69, P825; Heflin LH, 2005, JNCI-J NATL CANCER I, V97, P854, DOI 10.1093/jnci/dji137; HEIZMANN CW, 1992, TRENDS NEUROSCI, V15, P259, DOI 10.1016/0166-2236(92)90067-I; Hendy GN, 2005, CURR OPIN NEPHROL HY, V14, P350, DOI 10.1097/01.mnh.0000172721.44875.24; Heo M, 2006, INT J OBESITY, V30, P513, DOI 10.1038/sj.ijo.0803122; Herva A, 2006, INT J OBESITY, V30, P520, DOI 10.1038/sj.ijo.0803174; Hill A.B., 1971, PRINCIPLES MED STAT; Holick MF, 2005, J NUTR, V135, p2739S, DOI 10.1093/jn/135.11.2739S; Holick MF, 2003, J CELL BIOCHEM, V88, P296, DOI 10.1002/jcb.10338; Holick MF, 2006, J CLIN INVEST, V116, P2062, DOI 10.1172/JCI29449; Houghton LA, 2006, AM J CLIN NUTR, V84, P694, DOI 10.1093/ajcn/84.4.694; Hughes PJ, 2006, J CELL BIOCHEM, V98, P590, DOI 10.1002/jcb.20787; Hypponen E, 2007, AM J CLIN NUTR, V85, P860, DOI 10.1093/ajcn/85.3.860; Iaboni A, 2006, J RHEUMATOL, V33, P2453; Insel TR, 2001, NAT REV NEUROSCI, V2, P129, DOI 10.1038/35053579; Isik A, 2007, CLIN RHEUMATOL, V26, P872, DOI 10.1007/s10067-006-0407-y; Jia ZH, 1999, STEROIDS, V64, P541, DOI 10.1016/S0039-128X(99)00030-6; Johnson JA, 1996, DEV BRAIN RES, V92, P120, DOI 10.1016/0165-3806(95)00204-9; Jonsson A, 2006, J NEUROL SCI, V245, P77, DOI 10.1016/j.jns.2005.09.016; Jouvenceau A, 2002, NEUROPHARMACOLOGY, V42, P444, DOI 10.1016/S0028-3908(01)00202-7; Junge HJ, 2004, CELL, V118, P389, DOI 10.1016/j.cell.2004.06.029; Kalueff A, 2006, NEUROREPORT, V17, P717, DOI 10.1097/01.wnr.0000215770.79281.e4; Kalueff A. V., 2006, CNS & Neurological Disorders-Drug Targets, V5, P363, DOI 10.2174/187152706777452209; Kalueff AV, 2007, CURR OPIN CLIN NUTR, V10, P12, DOI 10.1097/MCO.0b013e328010ca18; Kalueff AV, 2006, NEUROSCI RES, V54, P254, DOI 10.1016/j.neures.2005.12.008; Kalueff AV, 2005, BRAIN RES BULL, V67, P156, DOI 10.1016/j.brainresbull.2005.06.022; Kalueff AV, 2005, J NEUROGENET, V19, P1, DOI 10.1080/01677060590949683; Kalueff AV, 2004, NEUROREPORT, V15, P1271, DOI 10.1097/01.wnr.0000129370.04248.92; Kalueff AV, 2004, PHYSIOL BEHAV, V82, P405, DOI 10.1016/j.physbeh.2004.04.010; Kalueff AV, 2004, BIOCHEMISTRY-MOSCOW+, V69, P738, DOI 10.1023/B:BIRY.0000040196.65686.2f; Kalueff AV, 2004, BRAIN RES BULL, V64, P25, DOI 10.1016/j.brainresbull.2004.04.015; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kantarci O, 2006, CURR OPIN NEUROL, V19, P248, DOI 10.1097/01.wco.0000227033.47458.82; Keisala T, 2007, J STEROID BIOCHEM, V104, P269, DOI 10.1016/j.jsbmb.2007.03.031; Kesby JP, 2006, BIOL PSYCHIAT, V60, P591, DOI 10.1016/j.biopsych.2006.02.033; Kim JH, 2005, FASEB J, V19, P109, DOI 10.1096/fj.05-4826fje; Kim JS, 2005, J KOREAN MED SCI, V20, P495, DOI 10.3346/jkms.2005.20.3.495; Kim YS, 2006, EXP MOL MED, V38, P333, DOI 10.1038/emm.2006.40; Kishimoto J, 1998, NEUROBIOL AGING, V19, P77, DOI 10.1016/S0197-4580(97)00166-8; Ko P, 2004, DEV BRAIN RES, V153, P61, DOI 10.1016/j.devbrainres.2004.07.013; Komuro H, 1996, NEURON, V17, P275, DOI 10.1016/S0896-6273(00)80159-2; Kong J, 2006, J IMMUNOL, V176, P3780, DOI 10.4049/jimmunol.176.6.3780; Korzbauer PT, 2006, ANN NEUROL, V59, P444, DOI 10.1002/ana.20794; Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701; Koutkia P, 2001, GASTROENTEROLOGY, V121, P1485, DOI 10.1053/gast.2001.29686; Kozora E, 2006, ARTHRIT RHEUM-ARTHR, V55, P628, DOI 10.1002/art.22101; Kress AM, 2006, J PSYCHOSOM RES, V60, P263, DOI 10.1016/j.jpsychores.2005.08.011; KUNINGAS M, 2007, IN PRESS NEUROBIOL A; Landfield PW, 1998, NEUROBIOL AGING, V19, P469, DOI 10.1016/S0197-4580(98)00079-7; Lang AE, 2006, ANN NEUROL, V59, P459, DOI 10.1002/ana.20737; Langub MC, 2001, NEUROSCIENCE, V104, P49, DOI 10.1016/S0306-4522(01)00049-5; Lansdowne ATG, 1998, PSYCHOPHARMACOLOGY, V135, P319, DOI 10.1007/s002130050517; Leclerc C, 2006, BBA-MOL CELL RES, V1763, P1184, DOI 10.1016/j.bbamcr.2006.08.005; Ledda F, 2007, NAT NEUROSCI, V10, P293, DOI 10.1038/nn1855; Lee JS, 2001, J NUTR, V131, P1503, DOI 10.1093/jn/131.5.1503; LEFEBVRE DC, 2003, J NEUROSCI RES, V71, P575, DOI DOI 10.1002/JNR.10491; Lewy AJ, 2006, P NATL ACAD SCI USA, V103, P7414, DOI 10.1073/pnas.0602425103; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Li YC, 1998, ENDOCRINOLOGY, V139, P4391, DOI 10.1210/en.139.10.4391; Lin R, 2004, BIOESSAYS, V26, P21, DOI 10.1002/bies.10368; Lips P, 2006, J INTERN MED, V260, P245, DOI 10.1111/j.1365-2796.2006.01685.x; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Liu CZ, 2006, EXP NEUROL, V201, P452, DOI 10.1016/j.expneurol.2006.04.025; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; Looker AC, 2002, BONE, V30, P771, DOI 10.1016/S8756-3282(02)00692-0; LUINE V N, 1987, Steroids, V49, P133, DOI 10.1016/0039-128X(87)90082-1; Luong KVQ, 2006, CURR MED CHEM, V13, P2443; Mackay-Sim A, 2004, INT REV NEUROBIOL, V59, P351; Mackner LM, 2006, INFLAMM BOWEL DIS, V12, P239, DOI 10.1097/01.MIB.0000217769.83142.c6; Madrigal JLM, 2002, NEUROPSYCHOPHARMACOL, V26, P155, DOI 10.1016/S0893-133X(01)00292-5; Maier SF, 2003, BRAIN BEHAV IMMUN, V17, P69, DOI 10.1016/S0889-1591(03)00032-1; Martineau AR, 2007, AM J RESP CRIT CARE, V176, P208, DOI 10.1164/rccm.200701-007OC; Martini LA, 2006, NUTR REV, V64, P479, DOI 10.1111/j.1753-4887.2006.tb00180.x; Mathieu C, 2005, TRENDS ENDOCRIN MET, V16, P261, DOI 10.1016/j.tem.2005.06.004; Mathieu C, 2005, DIABETOLOGIA, V48, P1247, DOI 10.1007/s00125-005-1802-7; Mathieu C, 2002, TRENDS MOL MED, V8, P174, DOI 10.1016/S1471-4914(02)02294-3; Matsumoto Y, 2004, NEUROPHARMACOLOGY, V46, P1195, DOI 10.1016/j.neuropharm.2004.02.012; Matsumoto Y, 2001, EUR J PHARMACOL, V430, P283, DOI 10.1016/S0014-2999(01)01374-7; McCann JC, 2005, AM J CLIN NUTR, V82, P281, DOI 10.1093/ajcn/82.2.281; McCann JC, 2007, AM J CLIN NUTR, V85, P931, DOI 10.1093/ajcn/85.4.931; McCann JC, 2006, NEUROSCI BIOBEHAV R, V30, P696, DOI 10.1016/j.neubiorev.2005.12.003; McGrath J, 2004, SCHIZOPHR RES, V67, P237, DOI 10.1016/j.schres.2003.08.005; McGrath J, 2003, SCHIZOPHR RES, V63, P73, DOI 10.1016/S0920-9964(02)00435-8; McGrath J, 2001, MED HYPOTHESES, V56, P367, DOI 10.1054/mehy.2000.1226; McGrath J, 2001, TRENDS NEUROSCI, V24, P570, DOI 10.1016/S0166-2236(00)01949-4; McGrath J, 1999, SCHIZOPHR RES, V40, P173, DOI 10.1016/S0920-9964(99)00052-3; McGrath JJ, 2006, SCHIZOPHR RES, V81, P91, DOI 10.1016/j.schres.2005.07.017; McGrath JJ, 2004, J STEROID BIOCHEM, V89-90, P557, DOI 10.1016/j.jsbmb.2004.03.070; Mikocka-Walus AA, 2007, INFLAMM BOWEL DIS, V13, P225, DOI 10.1002/ibd.20062; Miller DB, 2005, METABOLISM, V54, P33, DOI 10.1016/j.metabol.2005.01.011; Miller Ellen H, 2006, Clin Cornerstone, V8 Suppl 3, pS14, DOI 10.1016/S1098-3597(06)80019-0; Miller WL, 2000, TRENDS ENDOCRIN MET, V11, P315, DOI 10.1016/S1043-2760(00)00287-3; Minasyan A, 2007, J STEROID BIOCHEM, V104, P274, DOI 10.1016/j.jsbmb.2007.03.032; Mizuno K, 2007, NEUROSCIENCE, V145, P393, DOI 10.1016/j.neuroscience.2006.11.056; Molinari S, 1996, P NATL ACAD SCI USA, V93, P8028, DOI 10.1073/pnas.93.15.8028; Moore ME, 2005, BIOCHEM SOC T, V33, P573, DOI 10.1042/BST0330573; Moore TB, 1996, CLIN EXP METASTAS, V14, P239; MULLER K, 1992, CYTOKINE, V4, P506, DOI 10.1016/1043-4666(92)90012-G; Munger KL, 2006, JAMA-J AM MED ASSOC, V296, P2832, DOI 10.1001/jama.296.23.2832; MUSIOL IM, 1992, NEUROSCIENCE, V48, P841, DOI 10.1016/0306-4522(92)90272-4; MYERS P, 2004, RATTUS NORVEGICUS; Nadjar A, 2005, NEUROPSYCHOPHARMACOL, V30, P1492, DOI 10.1038/sj.npp.1300755; Nagpal S, 2005, ENDOCR REV, V26, P662, DOI 10.1210/er.2004-0002; Nagpal S, 2001, CURR MED CHEM, V8, P1661, DOI 10.2174/0929867013371950; *NAS DRI, 1997, DIET REF INT CALC PH; NAVEILHAN P, 1994, J NEUROSCI RES, V37, P271, DOI 10.1002/jnr.490370212; Naveilhan P, 1996, NEUROREPORT, V7, P2171, DOI 10.1097/00001756-199609020-00023; Nehring JA, 2007, P NATL ACAD SCI USA, V104, P10006, DOI 10.1073/pnas.0703512104; Nesby-O'Dell S, 2002, AM J CLIN NUTR, V76, P187, DOI 10.1093/ajcn/76.1.187; NEVEU I, 1994, J NEUROSCI RES, V38, P214, DOI 10.1002/jnr.490380212; NEVEU I, 1994, MOL BRAIN RES, V24, P70, DOI 10.1016/0169-328X(94)90119-8; NEVEU I, 1994, NEUROREPORT, V6, P124, DOI 10.1097/00001756-199412300-00032; Newmark HL, 2007, MOVEMENT DISORD, V22, P461, DOI 10.1002/mds.21317; Norman AW, 2006, ENDOCRINOLOGY, V147, P5542, DOI 10.1210/en.2006-0946; Norman PE, 2005, ARTERIOSCL THROM VAS, V25, P39, DOI 10.1161/01.ATV.0000148450.56697.4a; O'Connor JC, 2006, NEUROL CLIN, V24, P539, DOI 10.1016/j.ncl.2006.03.001; O'Loan J, 2007, PSYCHONEUROENDOCRINO, V32, P227, DOI 10.1016/j.psyneuen.2006.12.006; O'Shea JJ, 2002, NAT REV IMMUNOL, V2, P37, DOI 10.1038/nri702; Obradovic D, 2006, J NEUROCHEM, V96, P500, DOI 10.1111/j.1471-4159.2005.03579.x; OHSHIMA T, 1991, J NEUROL, V238, P320, DOI 10.1007/BF00315329; OKANO T, 1977, J NUTR SCI VITAMINOL, V23, P165; Ozer S, 2004, PROG NEURO-PSYCHOPH, V28, P255, DOI 10.1016/j.pnpbp.2003.10.002; Palin K, 2004, BRAIN BEHAV IMMUN, V18, P223, DOI 10.1016/j.bbi.2003.09.002; Panda DK, 2001, P NATL ACAD SCI USA, V98, P7498, DOI 10.1073/pnas.131029498; Pappa HM, 2006, PEDIATRICS, V118, P1950, DOI 10.1542/peds.2006-0841; Pauls TL, 1996, BBA-GENE STRUCT EXPR, V1306, P39, DOI 10.1016/0167-4781(95)00221-9; Pittas AG, 2007, J CLIN ENDOCR METAB, V92, P2017, DOI 10.1210/jc.2007-0298; Poulsen DJ, 2007, J NEUROSCI RES, V85, P735, DOI 10.1002/jnr.21163; Prufer K, 1999, J CHEM NEUROANAT, V16, P135, DOI 10.1016/S0891-0618(99)00002-2; Prufer K, 1997, CELL MOL BIOL, V43, P543; Przybelski RJ, 2007, ARCH BIOCHEM BIOPHYS, V460, P202, DOI 10.1016/j.abb.2006.12.018; Pucak ML, 2006, INT REV PSYCHIATR, V17, P477, DOI 10.1080/02646830500381757; Purves D., 2001, NEUROSCIENCE; Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006; Raiten DJ, 2004, AM J CLIN NUTR, V80, p1673S, DOI 10.1093/ajcn/80.6.1673S; Rohe B, 2005, STEROIDS, V70, P458, DOI 10.1016/j.steroids.2005.02.016; Rose CR, 2003, NATURE, V426, P74, DOI 10.1038/nature01983; Ryan CM, 2006, PEDIATR DIABETES, V7, P289, DOI 10.1111/j.1399-5448.2006.00206.x; Saarma M, 1999, MICROSC RES TECHNIQ, V45, P292, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<292::AID-JEMT13>3.0.CO;2-8; Saha S, 2006, ACTA PSYCHIAT SCAND, V114, P36, DOI 10.1111/j.1600-0447.2005.00742.x; Sajadi A, 2006, NEUROBIOL DIS, V22, P119, DOI 10.1016/j.nbd.2005.10.006; Sanchez B, 2002, MOL BRAIN RES, V108, P143, DOI 10.1016/S0169-328X(02)00545-4; SAPORITO MS, 1994, BRAIN RES, V633, P189, DOI 10.1016/0006-8993(94)91539-3; Sato Y, 2005, J BONE MINER RES, V20, P1327, DOI 10.1359/JBMR.050402; Sato Y, 1998, BONE, V23, P555, DOI 10.1016/S8756-3282(98)00134-3; Savli H, 2002, BRIT J HAEMATOL, V118, P1065, DOI 10.1046/j.1365-2141.2002.03734.x; Saykin Andrew J, 2003, Semin Clin Neuropsychiatry, V8, P201; Schaller B, 2005, BRAIN RES, V1036, P163, DOI 10.1016/j.brainres.2004.12.054; Schiepers OJG, 2005, PROG NEURO-PSYCHOPH, V29, P201, DOI 10.1016/j.pnpbp.2004.11.003; Schierle GS, 1997, CEREB CORTEX, V7, P130, DOI 10.1093/cercor/7.2.130; Schleithoff SS, 2006, AM J CLIN NUTR, V83, P754, DOI 10.1093/ajcn/83.4.754; Schmidt H, 2005, P NATL ACAD SCI USA, V102, P5850, DOI 10.1073/pnas.0407855102; Schwaller Beat, 2002, Cerebellum, V1, P241, DOI 10.1080/147342202320883551; Segaert S, 1998, Curr Opin Clin Nutr Metab Care, V1, P347, DOI 10.1097/00075197-199807000-00006; Sheehy C, 2006, RHEUMATOLOGY, V45, P1325, DOI 10.1093/rheumatology/kel231; SIEGARIZ AM, 2001, J AM MED WOMEN ASSOC, V72, P44; SIEGARIZ AM, 2001, J AM MED WOMEN ASSOC, V56, P72; Smith MP, 2007, NEUROSCI LETT, V412, P259, DOI 10.1016/j.neulet.2006.11.017; Smith MP, 2006, NEUROCHEM RES, V31, P533, DOI 10.1007/s11064-006-9048-4; SMITH RS, 1991, MED HYPOTHESES, V35, P298, DOI 10.1016/0306-9877(91)90272-Z; SONNENBERG J, 1986, ENDOCRINOLOGY, V118, P1433, DOI 10.1210/endo-118-4-1433; Srinivasan V, 2006, WORLD J BIOL PSYCHIA, V7, P138, DOI 10.1080/15622970600571822; St-Arnaud R, 1999, BONE, V25, P127, DOI 10.1016/S8756-3282(99)00118-0; Stanford JA, 2007, NEUROBIOL AGING, V28, P156, DOI 10.1016/j.neurobiolaging.2005.10.015; Stio M, 2005, INT IMMUNOPHARMACOL, V5, P649, DOI 10.1016/j.intimp.2004.11.002; STIO M, 1993, J NEUROSCI RES, V35, P559, DOI 10.1002/jnr.490350512; Stio M, 2001, J STEROID BIOCHEM, V77, P213, DOI 10.1016/S0960-0760(01)00059-0; Stumpf Walter E., 2005, Journal of Pharmacological and Toxicological Methods, V51, P25, DOI 10.1016/j.vascn.2004.09.001; STUMPF WE, 1989, PSYCHOPHARMACOLOGY, V97, P285, DOI 10.1007/BF00439440; Sun J, 2006, AM J PHYSIOL-ENDOC M, V291, pE315, DOI 10.1152/ajpendo.00590.2005; Takeuchi K, 1996, J BIOL CHEM, V271, P33335, DOI 10.1074/jbc.271.52.33335; Taniura H, 2006, J NEUROSCI RES, V83, P1179, DOI 10.1002/jnr.20824; Taupin P, 2002, J NEUROSCI RES, V69, P745, DOI 10.1002/jnr.10378; Timms PM, 2002, QJM-INT J MED, V95, P787, DOI 10.1093/qjmed/95.12.787; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Toutenhoofd SL, 2000, CELL CALCIUM, V28, P83, DOI 10.1054/ceca.2000.0136; Tuzcu M, 2006, EUR J PHARMACOL, V537, P106, DOI 10.1016/j.ejphar.2006.03.024; Ulfig N, 2002, ADV ANAT EMBRYOL CEL, V165, P1; van den Berg E, 2006, DRUG TODAY, V42, P741, DOI 10.1358/dot.2006.42.11.1003542; van Driel M, 2004, CURR PHARM DESIGN, V10, P2535; Van Houdenhove B, 2006, ACTA NEUROL BELG, V106, P149; Vazquez G, 2000, J BIOL CHEM, V275, P16134, DOI 10.1074/jbc.C901008199; Veenstra TD, 1997, BIOCHEM BIOPH RES CO, V235, P15, DOI 10.1006/bbrc.1997.6718; Veenstra TD, 1997, DEV BRAIN RES, V99, P53, DOI 10.1016/S0165-3806(96)00196-4; Veenstra TD, 1998, BRAIN RES, V804, P193, DOI 10.1016/S0006-8993(98)00565-4; VIETH R, 1995, NUTR RES, V15, P725, DOI 10.1016/0271-5317(95)00039-L; Vieth R, 2000, J NUTR, V130, P578, DOI 10.1093/jn/130.3.578; Vieth R, 2007, AM J CLIN NUTR, V85, P649, DOI 10.1093/ajcn/85.3.649; Vieth R, 2006, PROG BIOPHYS MOL BIO, V92, P26, DOI 10.1016/j.pbiomolbio.2006.02.003; Vieth R, 2004, NUTR J, V3, DOI 10.1186/1475-2891-3-8; Wainwright PE, 2006, AM J CLIN NUTR, V84, P961, DOI 10.1093/ajcn/84.5.961; Walbert T, 2001, HORM METAB RES, V33, P525, DOI 10.1055/s-2001-17210; Wallin MT, 2006, J REHABIL RES DEV, V43, P63, DOI 10.1682/JRRD.2004.09.0120; Wang JY, 2001, BRAIN RES, V904, P67, DOI 10.1016/S0006-8993(01)02450-7; Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005-0106; Wang Y, 2000, NEUROPHARMACOLOGY, V39, P873, DOI 10.1016/S0028-3908(99)00255-5; Watkins LR, 2005, J INTERN MED, V257, P139, DOI 10.1111/j.1365-2796.2004.01443.x; Watts C, 2005, J ANAT, V207, P197, DOI 10.1111/j.1469-7580.2005.00448.x; Westerink RHS, 2006, J NEUROCHEM, V99, P628, DOI 10.1111/j.1471-4159.2006.04099.x; Wilkins CH, 2006, AM J GERIAT PSYCHIAT, V14, P1032, DOI 10.1097/01.JGP.0000240986.74642.7c; Wilson CJ, 2002, J AM GERIATR SOC, V50, P2041, DOI 10.1046/j.1532-5415.2002.50619.x; Winkler Dietmar, 2006, Expert Rev Neurother, V6, P1039, DOI 10.1586/14737175.6.7.1039; Woo NH, 2006, NEUROSCIENTIST, V12, P43, DOI 10.1177/1073858405284360; Wortsman J, 2000, AM J CLIN NUTR, V72, P690, DOI 10.1093/ajcn/72.3.690; Yamauchi T, 2005, BIOL PHARM BULL, V28, P1342, DOI 10.1248/bpb.28.1342; Yan J, 2005, NEUROSCI LETT, V380, P37, DOI 10.1016/j.neulet.2005.01.018; Ying KY, 2005, MINI-REV MED CHEM, V5, P761, DOI 10.2174/1389557054553785; Yirmiya R, 2006, P NATL ACAD SCI USA, V103, P16876, DOI 10.1073/pnas.0604234103; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; Yudkoff M., 1999, BASIC NEUROCHEMISTRY, Vsixth; Zehnder D, 2001, J CLIN ENDOCR METAB, V86, P888, DOI 10.1210/jc.86.2.888; Zhu Y, 2005, EUR J IMMUNOL, V35, P217, DOI 10.1002/eji.200425491; Zittermann A, 2003, BRIT J NUTR, V89, P552, DOI 10.1079/BJN2003837; Zittermann A, 2004, PEDIAT ALLERG IMM-UK, V15, P242, DOI 10.1111/j.1399-3038.2004.00140.x; Zittermann A, 2006, PROG BIOPHYS MOL BIO, V92, P39, DOI 10.1016/j.pbiomolbio.2006.02.001	338	289	298	0	46	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					982	1001		10.1096/fj.07-9326rev	http://dx.doi.org/10.1096/fj.07-9326rev			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	18056830				2022-12-28	WOS:000254581000005
J	Redondo, C; Vouropoulou, M; Evans, J; Findlay, JBC				Redondo, Clara; Vouropoulou, Maria; Evans, Jonathan; Findlay, John B. C.			Identification of the retinol-binding protein (RBP) interaction site and functional state of RBPs for the membrane receptor	FASEB JOURNAL			English	Article						apo; holo; surface plasmon resonance; mouse urinary protein; lipocalin	MAJOR URINARY PROTEIN; PLASMA; RAT; TRANSTHYRETIN; ACID; EXPRESSION; MICE	This laboratory has advanced a model whereby retinol is transported around the body bound to retinol-binding protein (RBP), is transferred across the membrane of cells by a specific receptor/transporter, and is picked up from the membrane by an intracellular homolog, cellular retinol-binding protein (CRBP). This process involves a number of protein-protein interactions, and we hypothesized that conformational changes were an integral part of the retinol transfer mechanism. Previously we identified the potential interaction site on RBP for its membrane receptor. Here we confirm by the analysis of chimera containing a grafted CD loop from RBP that this is indeed the receptor interaction site and go on to demonstrate that the conformational changes that occur to this region on the apo to holo transition in RBP also take place in a chimera binding a quite different ligand, thus establishing the concept. We have also gone on to support the hypothesis that CRBP may also bind to a receptor in the membrane. Previous evidence has indicated that one such receptor might be lecithin:retinol acyltransferase, an enzyme that catalyzes retinol esterification. Here we provide the first evidence that the plasma membrane receptor for RBP could be the same as that for CRBP. This observation offers support for the intracellular phase of the uptake process for retinol, providing an efficient and highly unique mechanism in eukaryotic biology.	[Redondo, Clara; Vouropoulou, Maria; Evans, Jonathan; Findlay, John B. C.] Univ Leeds, Fac Biol Sci, Inst Membrane & Syst Biol, LIGHT Labs, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Findlay, JBC (corresponding author), Univ Leeds, Fac Biol Sci, Inst Membrane & Syst Biol, LIGHT Labs, Clarendon Way, Leeds LS2 9JT, W Yorkshire, England.	j.b.c.findlay@bmb.leeds.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barratt E, 2005, J AM CHEM SOC, V127, P11827, DOI 10.1021/ja0527525; BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; BAVIK CO, 1993, J BIOL CHEM, V268, P20540; Bingham RJ, 2004, J AM CHEM SOC, V126, P1675, DOI 10.1021/ja038461i; BLANER WS, 1987, EUR J BIOCHEM, V164, P301, DOI 10.1111/j.1432-1033.1987.tb11058.x; BLOMHOFF R, 1985, J BIOL CHEM, V260, P3571; Boudjelal M, 1996, BIOCHEM J, V317, P23, DOI 10.1042/bj3170023; BURKE BJ, 2005, LIPOCALINS; CAVAGGIONI A, 1990, COMP BIOCHEM PHYS B, V96, P513, DOI 10.1016/0305-0491(90)90049-Y; CHEN CC, 1977, J BIOL CHEM, V252, P5216; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; DAVIS JT, 1992, BIOL REPROD, V47, P528, DOI 10.1095/biolreprod47.4.528; DAVIS JT, 1995, BIOL REPROD, V52, P356, DOI 10.1095/biolreprod52.2.356; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Kawaguchi R, 2007, SCIENCE, V315, P820, DOI 10.1126/science.1136244; MELHUS H, 1995, BIOCHEM BIOPH RES CO, V210, P105, DOI 10.1006/bbrc.1995.1633; Moise AR, 2007, BIOCHEMISTRY-US, V46, P4449, DOI 10.1021/bi7003069; Naylor HM, 1999, BIOCHEMISTRY-US, V38, P2647, DOI 10.1021/bi982291i; Newcomer ME, 2000, BBA-PROTEIN STRUCT M, V1482, P57, DOI 10.1016/S0167-4838(00)00150-3; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; Perazzolo C, 2005, J BIOMOL NMR, V33, P233, DOI 10.1007/s10858-005-3355-y; Perazzolo C, 2007, J BIOMOL NMR, V38, P3, DOI 10.1007/s10858-006-9110-1; Quadro L, 1999, EMBO J, V18, P4633, DOI 10.1093/emboj/18.17.4633; Quadro L, 2004, J LIPID RES, V45, P1975, DOI 10.1194/jlr.M400137-JLR200; Quadro L, 2002, J BIOL CHEM, V277, P30191, DOI 10.1074/jbc.M205046200; Redondo C, 2006, HORM METAB RES, V38, P269, DOI 10.1055/s-2006-925349; SIVAPRASADARAO A, 1993, BIOCHEM SOC T, V21, P619, DOI 10.1042/bst0210619; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P571; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; SIVAPRASADARAO A, 1994, BIOCHEM J, V300, P437, DOI 10.1042/bj3000437; Sivaprasadarao A, 1998, METH MOL B, V89, P155; Sundaram M, 1998, METH MOL B, V89, P141; Sundaram M, 1998, J BIOL CHEM, V273, P3336, DOI 10.1074/jbc.273.6.3336; Sundaram M, 2002, BIOCHEM J, V362, P265, DOI 10.1042/0264-6021:3620265; Timm DE, 2001, PROTEIN SCI, V10, P997, DOI 10.1110/ps.52201; Turnbull WB, 2003, J AM CHEM SOC, V125, P14859, DOI 10.1021/ja036166s; vanAalten DMF, 1995, PROTEIN ENG, V8, P1129; Vogel S, 2002, BIOCHEMISTRY-US, V41, P15360, DOI 10.1021/bi0268551; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yamamoto M, 1998, EUR J BIOCHEM, V257, P344, DOI 10.1046/j.1432-1327.1998.2570344.x; Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711; Zanotti G, 1998, ACTA CRYSTALLOGR D, V54, P1049, DOI 10.1107/S0907444998002303; ZANOTTI G, 1993, J BIOL CHEM, V268, P10728	46	24	24	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1043	1054		10.1096/fj.07-8939com	http://dx.doi.org/10.1096/fj.07-8939com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	17991731				2022-12-28	WOS:000254581000010
J	Atamna, H; Nguyen, A; Schultz, C; Boyle, K; Newberry, J; Kato, H; Ames, BN				Atamna, Hani; Nguyen, Andy; Schultz, Carla; Boyle, Kathleen; Newberry, Justin; Kato, Hiroyuki; Ames, Bruce N.			Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways	FASEB JOURNAL			English	Article						aging; complex TV; heme; cytochrome c	T-BUTYL HYDROXYLAMINE; IFOSFAMIDE-INDUCED ENCEPHALOPATHY; NO-SYNTHASE INHIBITOR; CYTOCHROME-C; IN-VITRO; MEMORY RETENTION; NITRIC-OXIDE; REDUCTION; RATS; SUPEROXIDE	Methylene blue (MB) has been used clinically for about a century to treat numerous ailments. We show that MB and other diaminophenothiazines extend the life span of human IMR90 fibroblasts in tissue culture by >20 population doubling (PDLs). MB delays senescence at nM levels in IMR90 by enhancing mitochondrial function. MB increases mitochondrial complex IV by 30%, enhances cellular oxygen consumption by 37-70%, increases heme synthesis, and reverses premature senescence caused by H2O2 or cadmium. MB also induces phase-2 antioxidant enzymes in hepG2 cells. Flavin-dependent enzymes are known to use NAD(P)H to reduce MB to leucomethylene blue (MBH2), whereas cytochrome c reoxidizes MBH2 to MB. Experiments on lysates from rat liver mitochondria suggest the ratio MB/cytochrome c is important for the protective actions of MB. We propose that the cellular senescence delay caused by MB is due to cycling between MB and MBH2 in mitochondria, which may partly explain the increase in specific mitochondrial activities. Cycling of MB between oxidized and reduced forms may block oxidant production by mitochondria. Mitochondrial dysfunction and oxidative stress are thought to be key aberrations that lead to cellular senescence and aging. MB may be useful to delay mitochondrial dysfunction with aging and the decrease in complex IV in Alzheimer disease.	[Atamna, Hani] Childrens Hosp Oakland, Res Inst, Nutr Metab Ctr, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Atamna, H (corresponding author), Childrens Hosp Oakland, Res Inst, Nutr Metab Ctr, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	hatamna@chori.org						Atamna H, 2006, P NATL ACAD SCI USA, V103, P3381, DOI 10.1073/pnas.0600134103; Atamna H, 2000, J BIOL CHEM, V275, P6741, DOI 10.1074/jbc.275.10.6741; Atamna H, 2001, FASEB J, V15, P2196, DOI 10.1096/fj.01-0134com; Atamna H, 1996, BIOCHEM PHARMACOL, V51, P693, DOI 10.1016/S0006-2952(95)02258-9; BONGARD RD, 1995, AM J PHYSIOL-LUNG C, V269, pL78, DOI 10.1152/ajplung.1995.269.1.L78; Boon EM, 2003, BIOCONJUGATE CHEM, V14, P1140, DOI 10.1021/bc034139l; BRISTOL DW, 2006, TOXICOLOGY CARCINOGE; Callaway NL, 2004, PHARMACOL BIOCHEM BE, V77, P175, DOI 10.1016/j.pbb.2003.10.007; Callaway NL, 2002, NEUROSCI LETT, V332, P83, DOI 10.1016/S0304-3940(02)00827-3; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Chandler JE, 2000, THERIOGENOLOGY, V54, P261, DOI 10.1016/S0093-691X(00)00346-0; Clifton Jack 2nd, 2003, Am J Ther, V10, P289; de-Oliveira RW, 1999, BRAZ J MED BIOL RES, V32, P1529, DOI 10.1590/S0100-879X1999001200012; DEGUCHI T, 1978, BIOCHIM BIOPHYS ACTA, V544, P8, DOI 10.1016/0304-4165(78)90204-0; Demirbilek S, 2006, EUR SURG RES, V38, P35, DOI 10.1159/000091525; Dierks EA, 1998, ARCH BIOCHEM BIOPHYS, V351, P1, DOI 10.1006/abbi.1997.0408; Dorta DJ, 2003, J INORG BIOCHEM, V97, P251, DOI 10.1016/S0162-0134(03)00314-3; Fujisawa H, 1999, J GERONTOL A-BIOL, V54, pB276, DOI 10.1093/gerona/54.7.B276; Furian AF, 2007, NEUROCHEM INT, V50, P164, DOI 10.1016/j.neuint.2006.07.012; Gabrielli D, 2004, PHOTOCHEM PHOTOBIOL, V79, P227, DOI 10.1562/BE-03-27.1; Grivennikova VG, 2006, BBA-BIOENERGETICS, V1757, P553, DOI 10.1016/j.bbabio.2006.03.013; GRUETTER CA, 1981, J PHARMACOL EXP THER, V219, P181; Haluzik M, 1999, ENDOCR RES, V25, P163, DOI 10.1080/07435809909066138; Haluzik M, 1998, PHYSIOL RES, V47, P337; HAYFLICK L, 1992, EXP GERONTOL, V27, P363, DOI 10.1016/0531-5565(92)90066-9; Hintze KJ, 2003, J NUTR, V133, P2721, DOI 10.1093/jn/133.9.2721; Hipkiss AR, 2001, MECH AGEING DEV, V122, P169, DOI 10.1016/S0047-6374(00)00231-1; HRUSHESKY WJM, 1985, LANCET, V1, P565; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; KAMAT PV, 1987, J PHYS CHEM-US, V91, P396, DOI 10.1021/j100286a029; KELNER MJ, 1985, J BIOL CHEM, V260, P5168; KELNER MJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P422, DOI 10.1016/0003-9861(88)90393-1; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Kwok Edmund S H, 2006, J Intensive Care Med, V21, P359, DOI 10.1177/0885066606290671; LAGERCRANTZ C, 1991, FREE RADICAL RES COM, V14, P395, DOI 10.3109/10715769109093428; Lamond Scott, 2003, Reprod Biomed Online, V7, P407; Lee JH, 2004, CARCINOGENESIS, V25, P1435, DOI 10.1093/carcin/bgh139; MARTINEZ JL, 1978, PHYSIOL PSYCHOL, V6, P387; MAYER B, 1993, BIOCHEM PHARMACOL, V45, P367, DOI 10.1016/0006-2952(93)90072-5; MCCORD JM, 1970, J BIOL CHEM, V245, P1374; MCFARLAND GA, 1994, EXP CELL RES, V212, P167, DOI 10.1006/excr.1994.1132; Mellish KJ, 2002, PHOTOCHEM PHOTOBIOL, V75, P392, DOI 10.1562/0031-8655(2002)075<0392:IVPAOA>2.0.CO;2; Merker MP, 1997, AM J PHYSIOL-LUNG C, V272, pL673, DOI 10.1152/ajplung.1997.272.4.L673; Patel PN, 2006, ANN PHARMACOTHER, V40, P299, DOI 10.1345/aph.1G114; Pelgrims J, 2000, BRIT J CANCER, V82, P291, DOI 10.1054/bjoc.1999.0917; Rezzani R, 2001, NEPHRON, V89, P329, DOI 10.1159/000046094; Rice Lesley, 1998, Biochemical Society Transactions, V26, pS319; Riedel W, 2003, MOL CELL BIOCHEM, V247, P83, DOI 10.1023/A:1024142400835; SALARIS SC, 1991, BIOCHEM PHARMACOL, V42, P499, DOI 10.1016/0006-2952(91)90311-R; SILLS MR, 1994, ARCH PEDIAT ADOL MED, V148, P306, DOI 10.1001/archpedi.1994.02170030076017; Sweet G, 2007, J AM COLL SURGEONS, V204, P454, DOI 10.1016/j.jamcollsurg.2006.12.030; TEICHER BA, 1990, RADIAT RES, V121, P187, DOI 10.2307/3577503; Visarius TM, 1999, J PHARMACOL EXP THER, V289, P820; Wagner G, 2006, CURR DRUG TARGETS, V7, P1531; Wagner SJ, 1998, PHOTOCHEM PHOTOBIOL, V67, P343, DOI 10.1562/0031-8655(1998)067<0343:FAVPBA>2.3.CO;2; WAGNER SJ, 1995, TRANSFUSION, V35, P407, DOI 10.1046/j.1537-2995.1995.35595259151.x; Wariishi H, 2000, J BIOL CHEM, V275, P32919, DOI 10.1074/jbc.M004223200; Zhao YG, 2003, J BIOL CHEM, V278, P2356, DOI 10.1074/jbc.M209681200	58	211	226	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					703	712		10.1096/fj.07-9610com	http://dx.doi.org/10.1096/fj.07-9610com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17928358				2022-12-28	WOS:000254143700009
J	Parvez, S; Beck, A; Peinelt, C; Soboloff, J; Lis, A; Monteilh-Zoller, M; Gill, DL; Fleig, A; Penner, R				Parvez, Suhel; Beck, Andreas; Peinelt, Christine; Soboloff, Jonathan; Lis, Annette; Monteilh-Zoller, Mahealani; Gill, Donald. L.; Fleig, Andrea; Penner, Reinhold			STIM2 protein mediates distinct store-dependent and store-independent modes of CRAC channel activation	FASEB JOURNAL			English	Article						STIM1; calmodulin; store-operated calcium entry	INOSITOL TRISPHOSPHATE RECEPTORS; OPERATED CA2+ ENTRY; PLASMA-MEMBRANE; 2-AMINOETHOXYDIPHENYL BORATE; CALCIUM INFLUX; RELEASE; ORAI1; CALMODULIN; DEPLETION; SENSOR	STIM1 and CRACM1 (or Orail) are essential molecular components mediating store-operated Ca2+ entry (SOCE) and Ca2+ release-activated Ca2+ (CRAC) currents. Although STIM1 acts as a luminal Ca2+ sensor in the endoplasmic reticulum (ER), the function of STIM2 remains unclear. Here we reveal that STIM2 has two distinct modes of activating CRAC channels: a store-operated mode that is activated through depletion of ER Ca2+ stores by inositol 1,4,5-trisphosphate (InsP(3)) and store-independent activation that is mediated by cell dialysis during whole-cell perfusion. Both modes are regulated by calmodulin (CaM). The store-operated mode is transient in intact cells, possibly reflecting recruitment of CaM, whereas loss of CaM in perfused cells accounts for the persistence of the store-independent mode. The inhibition by CaM can be reversed by 2-aminoethoxydiphenyl borate (2-APB), resulting in rapid, store-independent activation of CRAC channels. The aminoglycoside antibiotic G418 is a highly specific and potent inhibitor of STIM2-dependent CRAC channel activation. The results reveal a novel bimodal control of CRAC channels by STIM2, the store dependence and CaM regulation, which indicates that the STIM2/CRACM1 complex may be under the control of both luminal and cytoplasmic Ca2+ levels.	[Parvez, Suhel; Beck, Andreas; Peinelt, Christine; Lis, Annette; Monteilh-Zoller, Mahealani; Fleig, Andrea; Penner, Reinhold] Univ Hawaii, Queens Med Ctr, Ctr Biomed Res, Honolulu, HI 96813 USA; [Parvez, Suhel; Beck, Andreas; Peinelt, Christine; Lis, Annette; Monteilh-Zoller, Mahealani; Fleig, Andrea; Penner, Reinhold] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA; [Soboloff, Jonathan; Gill, Donald. L.] Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19122 USA	The Queen's Medical Center; University of Hawaii System; University of Hawaii System; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Penner, R (corresponding author), Univ Hawaii, Queens Med Ctr, Ctr Biomed Res, 1301 Punchbowl St,UHT 8, Honolulu, HI 96813 USA.	rpenner@hawaii.edu	Parvez, Suhel/E-6778-2010; Peinelt, Christine/ABH-5292-2020; Soboloff, Jonathan/I-6995-2012	Parvez, Suhel/0000-0002-6318-6506; Soboloff, Jonathan/0000-0001-5192-1297; Fleig, Andrea/0000-0001-8396-7249; Penner, Reinhold/0000-0002-5366-1537; Peinelt, Christine/0000-0002-3474-6893	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058173, R01AI050200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040927] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI058173, R01-AI050200, R01 AI050200, AI058173] Funding Source: Medline; NINDS NIH HHS [R01-NS040927, R01 NS040927] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adkins CE, 2000, BIOCHEM J, V345, P357, DOI 10.1042/0264-6021:3450357; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Gwack Y, 2007, J BIOL CHEM, V282, P16232, DOI 10.1074/jbc.M609630200; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; LI S, 2007, CURR BIOL, V17, P794; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; Moreau B, 2005, J BIOL CHEM, V280, P8776, DOI 10.1074/jbc.M409619200; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Soboloff J, 2006, CURR BIOL, V16, P1465, DOI 10.1016/j.cub.2006.05.051; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; Vaca L, 1996, FEBS LETT, V390, P289, DOI 10.1016/0014-5793(96)00675-8; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Williams RT, 2001, BIOCHEM J, V357, P673, DOI 10.1042/0264-6021:3570673; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	33	127	134	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2008	22	3					752	761		10.1096/fj.07-9449com	http://dx.doi.org/10.1096/fj.07-9449com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17905723	Green Accepted			2022-12-28	WOS:000254143700014
J	Hinz, B; Cheremina, O; Brune, K				Hinz, Burkhard; Cheremina, Olga; Brune, Kay			Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man	FASEB JOURNAL			English	Article						cyclooxygenase isoenzymes; COX-2 selectivity; human whole blood assay; pharmacokinetics	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; EXPRESSION; ASPIRIN; INFLAMMATION; MECHANISM; COX-3; DETERMINANTS; SYNTHASES; ARTHRITIS; THERAPY	For more than three decades, acetaminophen ( INN, paracetamol) has been claimed to be devoid of significant inhibition of peripheral prostanoids. Meanwhile, attempts to explain its action by inhibition of a central cyclooxygenase (COX)-3 have been rejected. The fact that acetaminophen acts functionally as a selective COX-2 inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade. Ex vivo COX inhibition and pharmacokinetics of acetaminophen were assessed in 5 volunteers receiving single 1000 mg doses orally. Coagulation-induced thromboxane B-2 and lipopolysaccharideinduced prostaglandin E-2 were measured ex vivo and in vitro in human whole blood as indices of COX-1 and COX-2 activity. In vitro, acetaminophen elicited a 4.4-fold selectivity toward COX-2 inhibition (IC50 = 113.7 mu mol/L for COX-1; IC50 = 25.8 mu mol/L for COX-2). Following oral administration of the drug, maximal ex vivo inhibitions were 56% (COX-1) and 83% (COX-2). Acetaminophen plasma concentrations remained above the in vitro IC50 for COX-2 for at least 5 h postadministration. Ex vivo IC50 values ( COX-1: 105.2 mu mol/L; COX-2: 26.3 mu mol/L) of acetaminophen compared favorably with its in vitro IC50 values. In contrast to previous concepts, acetaminophen inhibited COX-2 by more than 80%, i.e., to a degree comparable to nonsteroidal antiinflammatory drugs ( NSAIDs) and selective COX-2 inhibitors. However, a > 95% COX-1 blockade relevant for suppression of platelet function was not achieved. Our data may explain acetaminophen's analgesic and antiinflammatory action as well as its superior overall gastrointestinal safety profile compared with NSAIDs. In view of its substantial COX-2 inhibition, recently defined cardiovascular warnings for use of COX-2 inhibitors should also be considered for acetaminophen.	[Hinz, Burkhard] Univ Rostock, Inst Pharmacol & Toxicol, D-18057 Rostock, Germany; [Cheremina, Olga; Brune, Kay] Univ Erlangen Nurnberg, Inst Expt & Clin Pharmacol & Toxicol, Erlangen, Germany	University of Rostock; University of Erlangen Nuremberg	Hinz, B (corresponding author), Univ Rostock, Inst Pharmacol & Toxicol, Schillingallee 70, D-18057 Rostock, Germany.	burkhard.hinz@med.uni-rostock.de						Abramson SB, 2002, ARTHRITIS RHEUM, V46, P2831, DOI 10.1002/art.10609; Bannwarth Bernard, 2004, Expert Opin Drug Saf, V3, P269, DOI 10.1517/14740338.3.4.269; Birmingham PK, 2001, ANESTHESIOLOGY, V94, P385; Bjornsson GA, 2003, BRIT J CLIN PHARMACO, V55, P405, DOI 10.1046/j.1365-2125.2003.01779.x; BOARDMAN PL, 1967, BMJ-BRIT MED J, V4, P264, DOI 10.1136/bmj.4.5574.264; Botting RM, 2000, CLIN INFECT DIS, V31, pS202, DOI 10.1086/317520; Boutaud O, 2002, P NATL ACAD SCI USA, V99, P7130, DOI 10.1073/pnas.102588199; Cannon CP, 2006, LANCET, V368, P1771, DOI 10.1016/S0140-6736(06)69666-9; Catella-Lawson F, 2001, NEW ENGL J MED, V345, P1809, DOI 10.1056/NEJMoa003199; Chan AT, 2006, CIRCULATION, V113, P1578, DOI 10.1161/CIRCULATIONAHA.105.595793; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Dinchuk JE, 2003, IMMUNOL LETT, V86, P121, DOI 10.1016/S0165-2478(02)00268-7; FERREIRA SH, 1978, POL J PHARMACOL PHAR, V30, P133; FLOWER RJ, 1972, NATURE, V240, P410, DOI 10.1038/240410a0; Forman JP, 2005, HYPERTENSION, V46, P500, DOI 10.1161/01.HYP.0000177437.07240.70; Graham Garry G, 2005, Am J Ther, V12, P46, DOI 10.1097/00045391-200501000-00008; Graham GG, 2005, DRUG SAFETY, V28, P227, DOI 10.2165/00002018-200528030-00004; HALLIWELL B, 1990, ARCH BIOCHEM BIOPHYS, V280, P1, DOI 10.1016/0003-9861(90)90510-6; Hinz B, 2000, BIOCHEM BIOPH RES CO, V278, P790, DOI 10.1006/bbrc.2000.3885; Hinz B, 2006, ARTHRITIS RHEUM-US, V54, P282, DOI 10.1002/art.21540; Honore P, 1995, PAIN, V63, P365, DOI 10.1016/0304-3959(95)00065-8; Jenkins C, 2004, BMJ-BRIT MED J, V328, P434, DOI 10.1136/bmj.328.7437.434; Kang KB, 2006, TRANSL RES, V148, P289, DOI 10.1016/j.trsl.2006.06.004; Kis B, 2005, J PHARMACOL EXP THER, V315, P1, DOI 10.1124/jpet.105.085431; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LANZ R, 1986, EUR J PHARMACOL, V130, P105, DOI 10.1016/0014-2999(86)90188-3; LAU GSN, 1994, J PHARMACEUT BIOMED, V12, P1563, DOI 10.1016/0731-7085(94)00859-0; Mantzke US, 2002, ANAESTHESIST, V51, P735, DOI 10.1007/s00101-002-0359-9; MCCORMACK K, 1987, ARCH TOXICOL, V60, P261, DOI 10.1007/BF01234664; MIELKE CH, 1981, ARCH INTERN MED, V141, P305, DOI 10.1001/archinte.141.3.305; MINERS JO, 1983, BRIT J CLIN PHARMACO, V16, P503, DOI 10.1111/j.1365-2125.1983.tb02207.x; Munsterhjelm E, 2005, ANESTHESIOLOGY, V103, P712, DOI 10.1097/00000542-200510000-00009; Niemi TT, 2000, ACTA ANAESTH SCAND, V44, P69, DOI 10.1034/j.1399-6576.2000.440113.x; Ouellet M, 2001, ARCH BIOCHEM BIOPHYS, V387, P273, DOI 10.1006/abbi.2000.2232; PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705; Qin N, 2005, J PHARMACOL EXP THER, V315, P1298, DOI 10.1124/jpet.105.090944; Rahme E, 2002, ARTHRITIS RHEUM-US, V46, P3046, DOI 10.1002/art.10604; REILLY IAG, 1987, BLOOD, V69, P180; RING EFJ, 1974, ANN RHEUM DIS, V33, P353, DOI 10.1136/ard.33.4.353; Rodriguez LAG, 2001, EPIDEMIOLOGY, V12, P570; RUMACK BH, 1978, PEDIATRICS, V62, P943; Schnitzer TJ, 2002, J PAIN SYMPTOM MANAG, V23, pS24, DOI 10.1016/S0885-3924(02)00372-X; Schwab JM, 2003, FASEB J, V17, P2174, DOI 10.1096/fj.03-0595lte; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; SKJELBRED P, 1979, EUR J CLIN PHARMACOL, V15, P27, DOI 10.1007/BF00563555; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Somasundaram S, 1997, GUT, V41, P344, DOI 10.1136/gut.41.3.344; Swierkosz Tomasz A, 2002, Med Sci Monit, V8, pBR496; TRIGGS EJ, 1975, J PHARMACOKINET BIOP, V3, P387, DOI 10.1007/BF01059473; Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264; Warner TD, 2004, J PHARMACOL EXP THER, V310, P642, DOI 10.1124/jpet.103.063875	51	294	305	0	43	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					383	390		10.1096/fj.07-8506com	http://dx.doi.org/10.1096/fj.07-8506com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17884974				2022-12-28	WOS:000252822600008
J	Pinz, I; Robbins, J; Rajasekaran, NS; Benjamin, IJ; Ingwall, JS				Pinz, Ilka; Robbins, Jeffrey; Rajasekaran, Namakkal S.; Benjamin, Ivor J.; Ingwall, Joanne S.			Unmasking different mechanical and energetic roles for the small heat shock proteins CryAB and HSPB2 using genetically modified mouse hearts	FASEB JOURNAL			English	Article						transgenesis; cardiac function	ALPHA-B-CRYSTALLIN; CARDIAC TITIN; ISCHEMIA; MUSCLE; ASSOCIATION; MYOCARDIUM; FAMILY; MEMBER; DAMAGE; GENE	CryAB and HSPB2 are small heat shock proteins constitutively expressed in the heart. CryAB protects cytoskeletal organization and intermediate filament assembly; the functions of HSPB2 are unknown. The promoters of CryAB and HSPB2 share regulatory elements, making identifying their separate functions difficult. Here, using a genetic approach, we report distinct roles for these sHSPs, with CryAB protecting mechanical properties and HSPB2 protecting energy reserve. Isolated hearts of wild type mice (WT), mice lacking both sHSPs (DKO), WT mice overexpressing mouse CryAB protein (mCryAB(Tg)), and mice with no HSPB2 made by crossing DKO with mCryABTg (DKO/ mCryAB(Tg)) were stressed with either ischemia/reperfusion or inotropic stimulation. Contractile performance and energetics were measured using P-31 NMR spectroscopy. Ischemia/reperfusion caused severe diastolic dysfunction in DKO hearts. Recovery of [ATP] and [PCr] during reperfusion was impaired only in DKO/ mCryAB(Tg). During inotropic stimulation, DKO/ mCryABTg showed blunted systolic and diastolic function and revealed massive energy wasting on acute stress: vertical bar Delta G(similar to ATP)vertical bar similar to decreased in DKO by 6.4 +/- 0.7 and in DKO/mCryAB(Tg) by 5.5 +/- 0.8 kJ/mol compared with only similar to 3.3 kJ/mol in WT and mCryAB(Tg). Thus, CryAB and HSPB2 proteins play nonredundant roles in the heart, CryAB in structural remodeling and HSPB2 in maintaining energetic balance.-Pinz, I., Robbins, J., Rajasekaran, N. S., Benjamin, I. J., Ingwall, J. S. Unmasking different mechanical and energetic roles for the small heat shock proteins CryAB and HSPB2 using genetically modified mouse hearts.	[Pinz, Ilka; Ingwall, Joanne S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Physiol Chem Lab, Boston, MA 02115 USA; [Rajasekaran, Namakkal S.; Benjamin, Ivor J.] Univ Utah, Hlth Sci Ctr, Ctr Cardiovasc Translat Biomed, Div Cardiol, Salt Lake City, UT 84132 USA; [Robbins, Jeffrey] Childrens Hosp, Cincinnati, OH 45229 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Utah System of Higher Education; University of Utah; Cincinnati Children's Hospital Medical Center	Ingwall, JS (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Physiol Chem Lab, 221 Longwood Ave,Rm 247, Boston, MA 02115 USA.	ivor.benjamin@hsc.utah.edu; jingwall@rics.bwh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052320, R01HL063834, R01HL063985] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL63834, R01-HL63985, HL52320] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barbato R, 1996, CIRC RES, V78, P821, DOI 10.1161/01.RES.78.5.821; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Bullard B, 2004, J BIOL CHEM, V279, P7917, DOI 10.1074/jbc.M307473200; Cazorla O, 2000, CIRC RES, V86, P59, DOI 10.1161/01.RES.86.1.59; CHU G, 1996, CIRC RES, V9, P1064; Golenhofen N, 2006, PFLUG ARCH EUR J PHY, V451, P518, DOI 10.1007/s00424-005-1488-1; Golenhofen N, 1999, J MOL CELL CARDIOL, V31, P569, DOI 10.1006/jmcc.1998.0892; Golenhofen N, 2002, J MOL CELL CARDIOL, V34, P309, DOI 10.1006/jmcc.2001.1513; Golenhofen N, 1998, AM J PHYSIOL-HEART C, V274, pH1457, DOI 10.1152/ajpheart.1998.274.5.H1457; Iwaki A, 1997, GENOMICS, V45, P386, DOI 10.1006/geno.1997.4956; Kadono T, 2006, J MOL CELL CARDIOL, V40, P783, DOI 10.1016/j.yjmcc.2006.03.003; KAMMERME.H, 1973, ANAL BIOCHEM, V56, P341, DOI 10.1016/0003-2697(73)90199-1; Kappe G, 2003, CELL STRESS CHAPERON, V8, P53, DOI 10.1379/1466-1268(2003)8<53:THGECS>2.0.CO;2; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; Lutsch G, 1997, CIRCULATION, V96, P3466; Morrison LE, 2004, AM J PHYSIOL-HEART C, V286, pH847, DOI 10.1152/ajpheart.00715.2003; Nakagawa M, 2001, EXP CELL RES, V271, P161, DOI 10.1006/excr.2001.5362; Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com; Saupe KW, 1998, CIRC RES, V82, P898; SHAMA KM, 1999, CELL STRUCT FUNCT, V1, P1; Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095; Suzuki A, 1998, J CELL BIOL, V140, P1113, DOI 10.1083/jcb.140.5.1113; Taylor RP, 2005, J MOL CELL CARDIOL, V38, P433, DOI 10.1016/j.yjmcc.2004.12.014; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wang XJ, 2001, CIRC RES, V89, P84, DOI 10.1161/hh1301.092688; Yan LJ, 2002, EMBO J, V21, P5164, DOI 10.1093/emboj/cdf528	26	36	37	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2008	22	1					84	92		10.1096/fj.07-8130com	http://dx.doi.org/10.1096/fj.07-8130com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17846079				2022-12-28	WOS:000252309900012
J	Sher, D; Fishman, Y; Melamed-Book, N; Zhang, ML; Zlotkin, E				Sher, Daniel; Fishman, Yelena; Melamed-Book, Naomi; Zhang, Mingliang; Zlotkin, Eliahu			Osmotically driven prey disintegration in the gastrovascular cavity of the green hydra by a pore-forming protein	FASEB JOURNAL			English	Article						chemical ecology; toxin; digestion; cnidaria	SEA-ANEMONES; CHIRONEX-FLECKERI; NEMATOCYST VENOM; GLAND-CELLS; TOXINS; POLYPEPTIDES; TENTACLES; MEMBRANE; CNIDARIA; EXTRACT	Pore-forming proteins (PFPs) are watersoluble proteins able to integrate into target membranes to form transmembrane pores. They are common determinants of bacterial pathogenicity and are often found in animal venoms. We recently isolated and characterized Hydralysins (Hlns), paralytic PFPs from the venomous green hydra Chlorohydra viridissima that are not found within the nematocytes, suggesting they are not involved in prey capture. The present study aimed to decipher the biological role of Hlns. Using in situ hybridization and immunohistochemistry, we show that Hlns are expressed by digestive cells surrounding the gastrovascular cavity (GVC) of Chlorohydra and secreted onto the prey during feeding. At biologically relevant concentrations, Hlns bind prey membranes and form pores, lysing the cells and disintegrating the prey tissue. Hlns are unable to bind Chlorohydra membranes, thus protecting the producing animal from the destructive effect of its own cytolytic protein. We suggest that osmotic disintegration of the prey within the GVC by Hlns, followed by phagocytosis and intracellular digestion, allows the soft-bodied green hydra to feed on hard, cuticle-covered prey while lacking the physical means to mechanically disintegrate it. Our results extend the biological significance of PFPs beyond the commonly expected offensive or defensive roles. -Sher, D., Fishman, Y., Melamed-Book, N., Zhang, M., Zlotkin, E. Osmotically driven prey disintegration in the gastrovascular cavity of the green hydra by a pore-forming protein.	[Sher, Daniel; Fishman, Yelena; Zhang, Mingliang; Zlotkin, Eliahu] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Cell & Anim Biol, IL-91904 Jerusalem, Israel; [Melamed-Book, Naomi] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Confocal Microscopy Unit, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Sher, D (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Cell & Anim Biol, IL-91904 Jerusalem, Israel.	dsher@pob.huji.ac.il						Amimoto Y, 2006, MECH DEVELOP, V123, P352, DOI 10.1016/j.mod.2006.03.002; Anderluh G, 2002, TOXICON, V40, P111, DOI 10.1016/S0041-0101(01)00191-X; Antignani A, 2006, CURR OPIN CELL BIOL, V18, P685, DOI 10.1016/j.ceb.2006.10.004; Bassler BL, 2006, CELL, V125, P237, DOI 10.1016/j.cell.2006.04.001; Basulto A, 2006, J EXP ZOOL PART A, V305A, P253, DOI 10.1002/jez.a.256; BENOS DJ, 1977, TISSUE CELL, V9, P11, DOI 10.1016/0040-8166(77)90045-3; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; BODE HR, 1987, DEV BIOL, V122, P577, DOI 10.1016/0012-1606(87)90321-6; Bosch TCG, 2007, DEV BIOL, V303, P421, DOI 10.1016/j.ydbio.2006.12.012; CASTE JD, 2004, CURRENT PROTOCOLS PR; Cole DS, 2003, CLIN SCI, V104, P455, DOI 10.1042/CS20020362; Cromer BA, 2002, EUR BIOPHYS J BIOPHY, V31, P356, DOI 10.1007/s00249-002-0219-1; Don TA, 2004, INT J PARASITOL, V34, P1029, DOI 10.1016/j.ijpara.2004.04.013; Edwards L, 2000, TOXICON, V38, P1015, DOI 10.1016/S0041-0101(99)00213-5; ENDEAN R, 1971, TOXICON, V9, P255, DOI 10.1016/0041-0101(71)90078-X; GORDON D, 1982, BIOCHIM BIOPHYS ACTA, V688, P229, DOI 10.1016/0005-2736(82)90598-3; HAYNES J. F., 1973, BIOL HYDRA; Hermo L, 2002, MOL REPROD DEV, V63, P394, DOI 10.1002/mrd.90023; HOLSTEIN TW, 1992, FEBS LETT, V309, P288, DOI 10.1016/0014-5793(92)80791-E; Honma T, 2003, BBA-PROTEINS PROTEOM, V1652, P103, DOI 10.1016/j.bbapap.2003.08.007; Horibata Y, 2004, J BIOL CHEM, V279, P33379, DOI 10.1074/jbc.M401460200; Kanaev LI, 1952, HYDRA; Lee JY, 2002, BIOCHEM BIOPH RES CO, V296, P1238, DOI 10.1016/S0006-291X(02)02062-4; Leippe M, 2004, J EUKARYOT MICROBIOL, V51, P516, DOI 10.1111/j.1550-7408.2004.tb00286.x; Lenhoff H.M., 1983, P29; LENTZ T, 1966, CELL BIOL HYDRA; LOTAN A, 1995, NATURE, V375, P456, DOI 10.1038/375456a0; Martinez DE, 1997, DEV BIOL, V192, P523, DOI 10.1006/dbio.1997.8715; MCNEIL PL, 1981, J CELL SCI, V49, P311; MEINARDI E, 1994, COMP BIOCHEM PHYS B, V109, P153, DOI 10.1016/0305-0491(94)90152-X; Miller DJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r59; Nagai H, 2002, BIOSCI BIOTECH BIOCH, V66, P2621, DOI 10.1271/bbb.66.2621; Nagai H, 2000, BIOCHEM BIOPH RES CO, V275, P589, DOI 10.1006/bbrc.2000.3352; Nagai H, 2000, BIOCHEM BIOPH RES CO, V275, P582, DOI 10.1006/bbrc.2000.3353; PARDY RL, 1983, HYDRA RES METHODS; Parker MW, 2005, PROG BIOPHYS MOL BIO, V88, P91, DOI 10.1016/j.pbiomolbio.2004.01.009; Purves W. K., 2004, LIFE SCI BIOL; Ramasamy S, 2005, TOXICOL LETT, V155, P219, DOI 10.1016/j.toxlet.2004.09.018; Ramasamy S, 2005, TOXICOL LETT, V155, P135, DOI 10.1016/j.toxlet.2004.09.004; Ruppert EE, 1994, INVERTEBRATE ZOOLOGY; SCHMIDT T, 1986, J CELL SCI, V85, P197; Sher D, 2005, TOXICON, V45, P865, DOI 10.1016/j.toxicon.2005.02.004; Sher D, 2005, J BIOL CHEM, V280, P22847, DOI 10.1074/jbc.M503242200; Shimizu H, 2004, J COMP PHYSIOL A, V190, P623, DOI 10.1007/s00359-004-0518-3; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; THOMAS RG, 1979, TOXICON, V17, P221, DOI 10.1016/0041-0101(79)90211-3; VANPRAET M, 1985, ADV MAR BIOL, V22, P65, DOI 10.1016/S0065-2881(08)60050-4; Weber J., 1988, P427; Zhang ML, 2003, BIOCHEMISTRY-US, V42, P8939, DOI 10.1021/bi0343929	49	29	29	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2008	22	1					207	214		10.1096/fj.07-9133com	http://dx.doi.org/10.1096/fj.07-9133com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17679608				2022-12-28	WOS:000252309900023
J	Baron-Menguy, C; Bocquet, A; Guihot, AL; Chappard, D; Amiot, MJ; Andriantsitohaina, R; Loufrani, L; Henrion, D				Baron-Menguy, Celine; Bocquet, Arnaud; Guihot, Anne-Laure; Chappard, Daniel; Amiot, Marie-Joseph; Andriantsitohaina, Ramaroson; Loufrani, Laurent; Henrion, Daniel			Effects of red wine polyphenols on postischemic neovascularization model in rats: low doses are proangiogenic, high doses anti-angiogenic	FASEB JOURNAL			English	Article						VEGF; remodeling; nitric oxide; blood flow	ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; PORCINE CORONARY-ARTERIES; EDHF-MEDIATED RELAXATIONS; NITRIC-OXIDE PRODUCTION; DEPENDENT VASORELAXATION; FACTOR EXPRESSION; ACTIVATION; INHIBITION; THROMBIN	Polyphenols, present in green tea, grapes, or red wine, have paradoxical properties: they protect against cardiac and cerebral ischemia but inhibit angiogenesis in vitro. So we investigated the effects of polyphenols in vivo on postischemic neovascularization. Rats treated with low (0.2 mg . kg(-1) . day(-1)) or high (20 mg . kg(-1) . day(-1)) doses of red wine polyphenolic compounds (RWPC) were submitted to femoral artery ligature on the left leg. Two wks after ligature, high doses of RWPC (i.e., 7 glasses of red wine) reduced arterial, arteriolar, and capillary densities and blood flow in association with an inhibition of a PI3 kinase-Akt-endothelial NO synthase (eNOS) pathway, decreased VEGF expression, and lower metalloproteinase (MMP) activation. Low doses of RWPC ( i. e., 1/10th glass of red wine) increased the left/right (L/R) leg ratio to control level in association with an increased blood flow and microvascular density. This angiogenic effect was associated with an overexpression of PI3 kinase-Akt-eNOS pathway and an increased VEGF production without effect on MMP activation. Thus, low and high doses RWPC have respectively pro- and anti-angiogenic properties on postischemic neovascularization in vivo. This unique dual effect of RWPC offers important perspectives for the treatment and prevention of ischemic diseases ( low dose) or cancer growth ( high dose).	Fac Med, CNRS, UMR 6214, INSERM,Dept Neurovasc Integrated Biol, F-49045 Angers, France; Univ Angers, UFR Med, Angers, France; INSERM, EMI 0335, Angers, France; INRA 1260, INSERM, UMR 476, Marseille, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Universite d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Henrion, D (corresponding author), Fac Med, CNRS, UMR 6214, INSERM,Dept Neurovasc Integrated Biol, F-49045 Angers, France.	daniel.henrion@univ-angers.fr	Henrion, Daniel/N-7023-2015; Daniel, chappard/AFK-4857-2022; AMIOT, MARIE JOSEPHE/N-8894-2019; Amiot, Marie Josephe/M-1203-2017; Henrion, Daniel/J-8141-2015; ANDRIANTSITOHAINA, Ramaroson/H-5286-2018; Amiot, Marie Josephe/C-4457-2015; Henrion, Daniel/AAK-1995-2021; Daniel, chappard/AAG-3528-2022	Henrion, Daniel/0000-0003-1094-0285; AMIOT, MARIE JOSEPHE/0000-0003-4563-4587; Amiot, Marie Josephe/0000-0003-4563-4587; Henrion, Daniel/0000-0003-1094-0285; Henrion, Daniel/0000-0003-1094-0285; andriantsitohaina, ramaroson/0000-0002-4770-3585				Albini A, 2005, FASEB J, V19, P527, DOI 10.1096/fj.05-5128fje; Andriambeloson E, 1997, BRIT J PHARMACOL, V120, P1053, DOI 10.1038/sj.bjp.0701011; Andriambeloson E, 1998, J NUTR, V128, P2324, DOI 10.1093/jn/128.12.2324; Barthomeuf C, 2006, FREE RADICAL BIO MED, V40, P581, DOI 10.1016/j.freeradbiomed.2005.09.015; Bassus S, 2001, ARTERIOSCL THROM VAS, V21, P1550, DOI 10.1161/hq0901.095148; Bernatova I, 2002, AM J PHYSIOL-HEART C, V282, pH942, DOI 10.1152/ajpheart.00724.2001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLVILLENASH PR, 1992, ANN RHEUM DIS, V51, P919, DOI 10.1136/ard.51.7.919; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Cordova AC, 2005, J AM COLL SURGEONS, V200, P428, DOI 10.1016/j.jamcollsurg.2004.10.030; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Curin Y, 2005, PHARMACOL REP, V57, P97; Deindl E, 2001, CIRC RES, V89, P779, DOI 10.1161/hh2101.098613; Diebolt M, 2001, HYPERTENSION, V38, P159, DOI 10.1161/01.HYP.38.2.159; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Favot L, 2003, CARDIOVASC RES, V59, P479, DOI 10.1016/S0008-6363(03)00433-4; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Iijima K, 2002, CIRCULATION, V105, P2404, DOI 10.1161/01.CIR.0000016349.36385.FB; Labrecque L, 2005, CARCINOGENESIS, V26, P821, DOI 10.1093/carcin/bgi024; Loufrani L, 2001, CIRCULATION, V103, P864, DOI 10.1161/01.CIR.103.6.864; Martin S, 2003, BIOCHEM PHARMACOL, V65, P669, DOI 10.1016/S0006-2952(02)01568-X; Martin S, 2002, BRIT J PHARMACOL, V135, P1579, DOI 10.1038/sj.bjp.0704603; Ndiaye M, 2004, BRIT J PHARMACOL, V142, P1131, DOI 10.1038/sj.bjp.0705774; Ndiaye M, 2003, BIOCHEM BIOPH RES CO, V310, P371, DOI 10.1016/j.bbrc.2003.09.028; Oak MH, 2004, CIRCULATION, V110, P1861, DOI 10.1161/01.CIR.0000142617.52881.F4; Oak MH, 2003, ARTERIOSCL THROM VAS, V23, P1001, DOI 10.1161/01.ATV.0000070101.70534.38; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Pechanova O, 2004, J HYPERTENS, V22, P1551, DOI 10.1097/01.hjh.0000133734.32125.c7; Perez-Vizcaino F, 2006, BIOCHEM BIOPH RES CO, V346, P919, DOI 10.1016/j.bbrc.2006.05.198; Pfosser A, 2005, CARDIOVASC RES, V65, P728, DOI 10.1016/j.cardiores.2004.10.019; Ranaivo HR, 2004, BRIT J PHARMACOL, V142, P671, DOI 10.1038/sj.bjp.0705833; Schaper W, 2003, ARTERIOSCL THROM VAS, V23, P1143, DOI 10.1161/01.ATV.0000069625.11230.96; Siddiqui IA, 2004, J CELL BIOCHEM, V91, P232, DOI 10.1002/jcb.10737; Szmitko PE, 2005, AM J PHYSIOL-HEART C, V288, pH2023, DOI 10.1152/ajpheart.00868.2004; Tamarat R, 2002, HYPERTENSION, V39, P830, DOI 10.1161/hy0302.104671; Wallerath T, 2003, J AM COLL CARDIOL, V41, P471, DOI 10.1016/S0735-1097(02)02826-7; Zenebe W, 2003, PHYSIOL RES, V52, P425	38	64	68	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3511	3521		10.1096/fj.06-7782com	http://dx.doi.org/10.1096/fj.06-7782com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17595348				2022-12-28	WOS:000250517800014
J	Hooper, SB; Kitchen, MJ; Wallace, MJ; Yagi, N; Uesugi, K; Morgan, MJ; Hall, C; Siu, KKW; Williams, IM; Siew, M; Irvine, SC; Pavlov, K; Lewis, RA				Hooper, Stuart B.; Kitchen, Marcus J.; Wallace, Megan J.; Yagi, Naoto; Uesugi, Kentaro; Morgan, Michael J.; Hall, Chris; Siu, Karen K. W.; Williams, Ivan M.; Siew, Melissa; Irvine, Sarah C.; Pavlov, Konstantin; Lewis, Robert A.			Imaging lung aeration and lung liquid clearance at birth	FASEB JOURNAL			English	Article						phase contrast X-ray imaging; fetus; neonate; airways	RAY PHASE-CONTRAST; NEWBORN RABBITS; FETAL SHEEP; SYNCHROTRON-RADIATION; EXPANSION; PRESSURE; FLUID; LAMBS; LABOR	Aeration of the lung and the transition to air-breathing at birth is fundamental to mammalian life and initiates major changes in cardiopulmonary physiology. However, the dynamics of this process and the factors involved are largely unknown, because it has not been possible to observe or measure lung aeration on a breath-by-breath basis. We have used the high contrast and spatial resolution of phase contrast X-ray imaging to study lung aeration at birth in spontaneously breathing neonatal rabbits. As the liquid-filled fetal lungs provide little absorption or phase contrast, they are not visible and only become visible as they aerate, allowing a detailed examination of this process. Pups were imaged live from birth to determine the timing and spatial pattern of lung aeration, and relative levels of lung aeration were measured from the images using a power spectral analysis. We report the first detailed observations and measurements of lung aeration, demonstrating its dependence on inspiratory activity and body position; dependent regions aerated at much slower rates. The air/liquid interface moved toward the distal airways only during inspiration, with little proximal movement during expiration, indicating that transpulmonary pressures play an important role in airway liquid clearance at birth. Using these imaging techniques, the dynamics of lung aeration and the critical role it plays in regulating the physiological changes at birth can be fully explored. - Hooper, S. B., Kitchen, M. J., Wallace, M. J., Yagi, N., Uesugi, K., Morgan, M. J., Hall, C., Siu, K. K. W., Williams, I. M., Siew, M., Irvine, S. C., Pavlov, K., Lewis, R. A. Imaging lung aeration and lung liquid clearance at birth.	Monash Univ, Dept Physiol, Melbourne, Vic 3800, Australia; Monash Univ, Sch Phys, Melbourne, Vic 3800, Australia; Monash Univ, Monash Ctr Synchrotron Sci, Melbourne, Vic 3800, Australia; Monash Univ, Dept Med Imaging & Radiat Sci, Melbourne, Vic 3800, Australia; JASRI, SPring 8, Sayo, Japan	Monash University; Monash University; Monash University; Monash University	Hooper, SB (corresponding author), Monash Univ, Dept Physiol, Melbourne, Vic 3800, Australia.	stuart.hooper@med.monash.edu.au	Pavlov, Konstantin M/A-3802-2008; Irvine, Sarah/J-4411-2013; Kitchen, Marcus/A-1355-2008; Siu, Karen K W/C-1472-2008	Pavlov, Konstantin M/0000-0002-1756-4406; Kitchen, Marcus/0000-0002-0029-6660; Siew, Melissa/0000-0003-3014-2379; Hooper, Stuart/0000-0003-1676-4825; Wallace, Megan/0000-0001-5785-5120				Barker PM, 2002, J APPL PHYSIOL, V93, P1542, DOI 10.1152/japplphysiol.00092.2002; BLAND RD, 1979, AM J OBSTET GYNECOL, V135, P364, DOI 10.1016/0002-9378(79)90706-3; BLAND RD, 1980, J APPL PHYSIOL, V49, P171, DOI 10.1152/jappl.1980.49.2.171; Bland RD, 2001, AM J PHYSIOL-LUNG C, V280, pL602, DOI 10.1152/ajplung.2001.280.4.L602; Davey MG, 1998, RESP PHYSIOL, V113, P83, DOI 10.1016/S0034-5687(98)00036-X; Dawes GS, 1968, FETAL NEONATAL PHYSL; FAWCITT J, 1960, Acta Paediatr Suppl, V49(Suppl 123), P5, DOI 10.1111/j.1651-2227.1960.tb05965.x; Goto S, 2001, NUCL INSTRUM METH A, V467, P682, DOI 10.1016/S0168-9002(01)00445-4; Harding R, 1996, REPROD FERT DEVELOP, V8, P117, DOI 10.1071/RD9960117; Harding R, 1996, J APPL PHYSIOL, V81, P209, DOI 10.1152/jappl.1996.81.1.209; HIRVONEN L, 1975, ANN CHIR GYNAECOL FE, V64, P170; Hooper SB, 2005, CURR RESPIR MED REV, V1, P185, DOI 10.2174/1573398054023037; Joyce BJ, 2003, AM J PHYSIOL-LUNG C, V284, pL643, DOI 10.1152/ajplung.00090.2002; Kitchen MJ, 2005, BRIT J RADIOL, V78, P1018, DOI 10.1259/bjr/13024611; Kitchen MJ, 2004, PHYS MED BIOL, V49, P4335, DOI 10.1088/0031-9155/49/18/010; Kovar J, 2002, J APPL PHYSIOL, V93, P629, DOI 10.1152/japplphysiol.01044.2001; Lewis RA, 2005, PHYS MED BIOL, V50, P5031, DOI 10.1088/0031-9155/50/21/006; MISEROCCHI G, 1994, J APPL PHYSIOL, V77, P2260, DOI 10.1152/jappl.1994.77.5.2260; Nardo L, 2000, EXP LUNG RES, V26, P105, DOI 10.1080/019021400269907; Olver RE, 2004, ANNU REV PHYSIOL, V66, P77, DOI 10.1146/annurev.physiol.66.071702.145229; RAJ JU, 1986, AM REV RESPIR DIS, V134, P305; RIMMER S, 1982, ARCH DIS CHILD, V57, P63; RUDOLPH AM, 1985, CIRC RES, V57, P811, DOI 10.1161/01.RES.57.6.811; Snigirev A, 1995, REV SCI INSTRUM, V66, P5486, DOI 10.1063/1.1146073; Stocks J, 1999, Monaldi Arch Chest Dis, V54, P358; SUKI B, 1994, NATURE, V368, P615, DOI 10.1038/368615a0; Suzuki Y, 2002, J SYNCHROTRON RADIAT, V9, P160, DOI 10.1107/S090904950200554X; Yagi N, 1999, MED PHYS, V26, P2190, DOI 10.1118/1.598735	28	144	146	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3329	3337		10.1096/fj.07-8208com	http://dx.doi.org/10.1096/fj.07-8208com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17536040				2022-12-28	WOS:000249781600033
J	Steensberg, A; Keller, C; Hillig, T; Frosig, C; Wojtaszewski, JFP; Pedersen, BK; Pilegaard, H; Sander, M				Steensberg, Adam; Keller, Charlotte; Hillig, Thore; Frosig, Christian; Wojtaszewski, Jorgen F. P.; Pedersen, Bente Klarlund; Pilegaard, Henriette; Sander, Mikael			Nitric oxide production is a proximal signaling event controlling exercise-induced mRNA expression in human skeletal muscle	FASEB JOURNAL			English	Article						interleukin; NO; AMP-activated kinase; nuclear factor kappa B	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; ALPHA-ADRENERGIC VASOCONSTRICTION; HUMAN ENDOTHELIAL-CELLS; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; INTERLEUKIN-6 RELEASE; EXHAUSTIVE EXERCISE; CYTOKINE RESPONSE; GLUCOSE-INGESTION	Previous studies have described the magnitude and time course by which several genes are regulated within exercising skeletal muscle. These include interleukin- 6 ( IL- 6), interleukin- 8 ( IL- 8), heme oxygenase1 ( HO- 1), and heat shock protein- 72 ( HSP72), which are involved in secondary signaling and preservation of intracellular environment. However, the primary signaling mechanisms coupling contraction to transcription are unknown. We hypothesized that exercise- induced nitric oxide ( NO) production is an important signaling event for IL- 6, IL- 8, HO- 1, and HSP72 expression in muscle. Twenty healthy males participated in the study. By realtime PCR, mRNA levels for 11 genes were determined in thigh muscle biopsies obtained 1) before and after 2 h knee extensor exercise without ( control) and with concomitant NO synthase inhibition ( nitro- L- arginine methyl ester, L- NAME, 5 mg center dot kg (-1)); or 2) before and after 2 h femoral artery infusion of the NO donor nitroglycerin ( NTG, 1.5 mu g center dot kg(-1) center dot min (-1)). L- NAME caused marked reductions in exercise- induced expression of 4 of 11 mRNAs including IL- 6, IL- 8, and HO- 1. IL- 6 protein release from the study leg to the circulation increased in the control but not in the L- NAME trial. NTG infusion significantly augmented expression of the mRNAs attenuated by L- NAME. These findings advance the novel concept that NO production contributes to regulation of gene expression in muscle during exercise. Subsequently, we sought evidence for involvement of AMP- activated kinase or nuclear factor kappa B, but found none.	Natl Hosp, Dept Cardiol, Copenhagen Muscle Res Ctr & Aviat Med, Dept Infect Dis,Ctr Inflammat & Metab, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Dept Mol Biol, Copenhagen, Denmark; Univ Copenhagen, Dept Exercise & Sport Sci, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen	Sander, M (corresponding author), Natl Hosp, Dept Cardiol, Copenhagen Muscle Res Ctr & Aviat Med, Dept Infect Dis,Ctr Inflammat & Metab, Sect 7522,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	sanders@dadlnet.dk	Wojtaszewski, Jørgen FP/P-6583-2014; Frøsig, Christian/A-3750-2015; Pilegaard, Henriette/M-2315-2014; Pedersen, Bente Klarlund/AGR-3217-2022	Wojtaszewski, Jørgen FP/0000-0001-9785-6830; Frøsig, Christian/0000-0001-9302-9328; Pilegaard, Henriette/0000-0002-1071-0327; Pedersen, Bente Klarlund/0000-0001-6508-6288; wojtaszewski, jorgen/0000-0001-8185-3408; Hillig, Thore/0000-0002-2085-5183				Akerstrom T, 2005, J PHYSIOL-LONDON, V563, P507, DOI 10.1113/jphysiol.2004.077610; ANDERSEN P, 1985, J APPL PHYSIOL, V59, P1647, DOI 10.1152/jappl.1985.59.5.1647; Baeza-Raja B, 2004, MOL BIOL CELL, V15, P2013, DOI 10.1091/mbc.E03-08-0585; BALON TW, 1994, J APPL PHYSIOL, V77, P2519, DOI 10.1152/jappl.1994.77.6.2519; Birk JB, 2006, J PHYSIOL-LONDON, V577, P1021, DOI 10.1113/jphysiol.2006.120972; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; Chan MHS, 2004, FASEB J, V18, P1785, DOI 10.1096/fj.03-1039fje; Civitarese AE, 2005, AM J PHYSIOL-ENDOC M, V289, pE1023, DOI 10.1152/ajpendo.00193.2005; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; Dinenno FA, 2003, J PHYSIOL-LONDON, V553, P281, DOI 10.1113/jphysiol.2003.049940; Du JH, 2005, BIOCHEM BIOPH RES CO, V337, P1139, DOI 10.1016/j.bbrc.2005.09.174; Febbraio MA, 2003, J PHYSIOL-LONDON, V549, P607, DOI 10.1113/jphysiol.2003.042374; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; Febbraio MA, 2004, DIABETES, V53, P1643, DOI 10.2337/diabetes.53.7.1643; Febbraio MA, 2000, J APPL PHYSIOL, V89, P1055, DOI 10.1152/jappl.2000.89.3.1055; Frandsen U, 2001, J PHYSIOL-LONDON, V531, P257, DOI 10.1111/j.1469-7793.2001.0257j.x; Frandsen U, 1996, BIOCHEM BIOPH RES CO, V227, P88, DOI 10.1006/bbrc.1996.1472; Grange RW, 2001, PHYSIOL GENOMICS, V5, P35, DOI 10.1152/physiolgenomics.2001.5.1.35; Haapanen N, 1997, INT J EPIDEMIOL, V26, P739, DOI 10.1093/ije/26.4.739; Hemish J, 2003, J BIOL CHEM, V278, P42321, DOI 10.1074/jbc.M308192200; Higaki Y, 2001, DIABETES, V50, P241, DOI 10.2337/diabetes.50.2.241; Hiscock N, 2004, FASEB J, V18, P992, DOI 10.1096/fj.03-1259fje; Hiscock N, 2003, AM J PHYSIOL-HEART C, V285, pH1759, DOI 10.1152/ajpheart.00150.2003; Ho RC, 2005, AM J PHYSIOL-CELL PH, V289, pC794, DOI 10.1152/ajpcell.00632.2004; Jensen L, 2004, AM J PHYSIOL-REG I, V287, pR397, DOI 10.1152/ajpregu.00071.2004; Ji LL, 2004, FASEB J, V18, P1499, DOI 10.1096/fj.04-1846com; Jorgensen SB, 2006, J PHYSIOL-LONDON, V574, P17, DOI 10.1113/jphysiol.2006.109942; Jung JE, 2004, NEUROSCI LETT, V354, P197, DOI 10.1016/j.neulet.2003.10.012; Kalra D, 2000, CIRCULATION, V102, P1302, DOI 10.1161/01.CIR.102.11.1302; Keller C, 2001, FASEB J, V15, P2748, DOI 10.1096/fj.01-0507fje; Koulmann N, 2006, PFLUG ARCH EUR J PHY, V452, P125, DOI 10.1007/s00424-005-0030-9; Lau KS, 1998, FEBS LETT, V431, P71, DOI 10.1016/S0014-5793(98)00728-5; Lau KS, 2000, PHYSIOL GENOMICS, V2, P21, DOI 10.1152/physiolgenomics.2000.2.1.21; Lei BA, 2005, P NATL ACAD SCI USA, V102, P6966, DOI 10.1073/pnas.0500768102; Lundby C, 2006, EUR J APPL PHYSIOL, V96, P363, DOI 10.1007/s00421-005-0085-5; Lundby C, 2003, TOXICOLOGY, V192, P229, DOI 10.1016/S0300-483X(03)00328-7; Maass DL, 2005, CRIT CARE MED, V33, P2794, DOI 10.1097/01.CCM.0000189747.97541.59; MacDonald C, 2003, J APPL PHYSIOL, V95, P2273, DOI 10.1152/japplphysiol.00242.2003; MALYSHEV IY, 1995, FEBS LETT, V370, P159, DOI 10.1016/0014-5793(95)00801-F; Miki C, 1999, CYTOKINE, V11, P244, DOI 10.1006/cyto.1998.0419; Nieman DC, 2005, MED SCI SPORT EXER, V37, P1283, DOI 10.1249/01.mss.0000175054.99588.b1; Nieman DC, 1998, MED SCI SPORT EXER, V30, P671, DOI 10.1097/00005768-199805000-00005; NORTHOFF H, 1991, INT J SPORTS MED S1, V12, P9; Ostrowski K, 1998, J PHYSIOL-LONDON, V513, P889, DOI 10.1111/j.1469-7793.1998.889ba.x; Pae HO, 2005, ENDOCRINOLOGY, V146, P2229, DOI 10.1210/en.2004-1431; PEDERSEN BK, 2000, SCAND J MED SCI S S1, V16, P3; Penkowa M, 2003, FASEB J, V17, DOI 10.1096/fj.03-0311fje; Pilegaard H, 2004, P NUTR SOC, V63, P221, DOI 10.1079/PNS2004345; Pilegaard H, 2003, DIABETES, V52, P657, DOI 10.2337/diabetes.52.3.657; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Pilz RB, 2005, FRONT BIOSCI-LANDMRK, V10, P1239, DOI 10.2741/1616; Plomgaard P, 2005, EXERC IMMUNOL REV, V11, P53; Radegran G, 1999, AM J PHYSIOL-HEART C, V276, pH1951, DOI 10.1152/ajpheart.1999.276.6.H1951; Roberts CK, 1999, AM J PHYSIOL-ENDOC M, V277, pE390, DOI 10.1152/ajpendo.1999.277.2.E390; Sander M, 2000, P NATL ACAD SCI USA, V97, P13818, DOI 10.1073/pnas.250379497; Sander M, 1999, HYPERTENSION, V33, P937, DOI 10.1161/01.HYP.33.4.937; Silveira LR, 2003, FREE RADICAL BIO MED, V35, P455, DOI 10.1016/S0891-5849(03)00271-5; Smolka MB, 2000, AM J PHYSIOL-REG I, V279, pR1539, DOI 10.1152/ajpregu.2000.279.5.R1539; Starkie R, 2003, FASEB J, V17, P884, DOI 10.1096/fj.02-0670fje; Steensberg A, 2001, J PHYSIOL-LONDON, V537, P633, DOI 10.1111/j.1469-7793.2001.00633.x; Steensberg A, 2003, AM J PHYSIOL-ENDOC M, V285, pE433, DOI 10.1152/ajpendo.00074.2003; Steensberg A, 2000, J PHYSIOL-LONDON, V529, P237, DOI 10.1111/j.1469-7793.2000.00237.x; Stoppani J, 2002, AM J PHYSIOL-ENDOC M, V283, pE1239, DOI 10.1152/ajpendo.00278.2002; Suzuki K, 2002, EXERC IMMUNOL REV, V8, P6; Thomas GD, 1998, P NATL ACAD SCI USA, V95, P15090, DOI 10.1073/pnas.95.25.15090; Tuyt LML, 1999, J IMMUNOL, V162, P4893; Umansky V, 1998, EUR J IMMUNOL, V28, P2276, DOI 10.1002/(SICI)1521-4141(199808)28:08<2276::AID-IMMU2276>3.0.CO;2-H; van Hall G, 2003, J CLIN ENDOCR METAB, V88, P3005, DOI 10.1210/jc.2002-021687; Vesely MJJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1087, DOI 10.1152/ajpcell.1998.275.4.C1087; VILLARETE LH, 1995, BIOCHEM BIOPH RES CO, V211, P671, DOI 10.1006/bbrc.1995.1864; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; Wojtaszewski JFP, 1997, DIABETES, V46, P1775, DOI 10.2337/diabetes.46.11.1775; Wray DW, 2004, J PHYSIOL-LONDON, V555, P545, DOI 10.1113/jphysiol.2003.054650; Zou MH, 2004, J BIOL CHEM, V279, P43940, DOI 10.1074/jbc.M404421200; Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200	75	63	65	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2683	2694		10.1096/fj.06-7477com	http://dx.doi.org/10.1096/fj.06-7477com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17470570				2022-12-28	WOS:000249237500010
J	Watterson, KR; Berg, KM; Kapitonov, D; Payne, SG; Miner, AS; Bittman, R; Milstien, S; Ratz, PH; Spiegel, S				Watterson, Kenneth R.; Berg, Krystina M.; Kapitonov, Dmitri; Payne, Shawn G.; Miner, Amy S.; Bittman, Robert; Milstien, Sheldon; Ratz, Paul H.; Spiegel, Sarah			Sphingosine-1-phosphate and the immunosuppressant, FTY720-phosphate, regulate detrusor muscle tone	FASEB JOURNAL			English	Article						sphingolipid metabolite; calcium channels	2-AMINOETHOXYDIPHENYL BORATE 2-APB; SMOOTH-MUSCLE; CALCIUM-CHANNEL; SPHINGOSINE 1-PHOSPHATE; DEPENDENT REGULATION; RECEPTOR; ACTIVATION; ENTRY; CONTRACTION; SENSITIVITY	Overactive bladder syndrome ( OBS) results from disturbances of bladder function. Bladder smooth muscle ( detrusor) exhibits spontaneous rhythmic activity ( tone) independent of neurogenic control, which is enhanced in patients with OBS. We have now uncovered a prominent role for the bioactive sphingolipid metabolite, sphingosine- 1- phosphate ( S1P), in regulating rabbit detrusor smooth muscle tone and contraction. S1P- induced contraction of detrusor muscle was dependent on stretch and intracellular calcium. Although detrusor expresses the S1P receptors S1P1 and S1P2, only S1P2 appeared to be involved in S1Pinduced contraction, since SEW2871 ( S1P1 agonist) and dihydro- S1P ( potent agonist for all S1P receptors except S1P2) were poor contractile agents. In agreement, the S1P2 antagonist JTE013 inhibited S1P- induced contraction. The fast, transient muscle contraction ( phasic) mediated by S1P was dependent on phospholipase C ( PLC) whereas the slower, sustained contraction ( tonic) was not. Surprisingly, the immunosuppressant FTY720phosphate, an agonist for all S1P receptors except S1P2, had distinct contractile properties and also induced slow, sustained contraction. Thus, FTY720- phosphate and/ or S1P may regulate calcium channels in an S1P receptor- independent manner. Collectively, our results demonstrate that S1P may regulate detrusor smooth muscle tone and suggest that dysregulation of complex S1P signaling might contribute to OBS.	Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Richmond, VA 23298 USA; NIMH, NIH, Bethesda, MD 20892 USA; CUNY, Queens Coll, Dept Chem & Biochem, Flushing, NY USA	Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); City University of New York (CUNY) System; Queens College NY (CUNY)	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, 1101 E Marshall St,2011 Sanger Hall, Richmond, VA 23298 USA.	sspiegel@vcu.edu		Kapitonov, Dmitri/0000-0001-9177-5239	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH001039] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIDDK NIH HHS [R01DK059620] Funding Source: Medline; NIGMS NIH HHS [R37 GM043880] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON KE, 1986, ACTA PHARMACOL TOX, V58, P193; Andersson KE, 2004, PHYSIOL REV, V84, P935, DOI 10.1152/physrev.00038.2003; Arikawa K, 2003, J BIOL CHEM, V278, P32841, DOI 10.1074/jbc.M305024200; Bai DL, 2006, J PHARMACOL EXP THER, V319, P1452, DOI 10.1124/jpet.106.112045; Bischoff A, 2000, BRIT J PHARMACOL, V130, P1871, DOI 10.1038/sj.bjp.0703515; Bjorklund S, 2005, MOL CELL ENDOCRINOL, V231, P65, DOI 10.1016/j.mce.2004.12.001; Bolz SS, 2003, CIRCULATION, V108, P342, DOI 10.1161/01.CIR.0000080324.12530.0D; Bootman MD, 2002, CURR BIOL, V12, pR563, DOI 10.1016/S0960-9822(02)01055-2; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; Coussin F, 2002, CIRC RES, V91, P151, DOI 10.1161/01.RES.0000028150.51130.36; Dobryndeva Y, 2001, MOL PHARMACOL, V60, P541; Gregory RB, 2001, BIOCHEM J, V354, P285, DOI 10.1042/0264-6021:3540285; Heringdorf DMZ, 2004, J CELL BIOCHEM, V92, P937, DOI 10.1002/jcb.20107; Hsiao SH, 2005, TOXICOL SCI, V86, P194, DOI 10.1093/toxsci/kfi167; Hu W, 2006, BIOCHEM BIOPH RES CO, V343, P1038, DOI 10.1016/j.bbrc.2006.03.079; HU W, 2006, AM J PHYSIOL, V343, pG605; Igarashi J, 2001, J BIOL CHEM, V276, P36281, DOI 10.1074/jbc.M105628200; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Iwasaki H, 2001, RECEPTOR CHANNEL, V7, P429; Jezior JR, 2001, BRIT J PHARMACOL, V134, P78, DOI 10.1038/sj.bjp.0704241; Kajioka S, 2004, AM J PHYSIOL-RENAL, V286, pF77, DOI 10.1152/ajprenal.00355.2002; KIM MY, 2005, AM J PHYSIOL, V290, pC100; KONO M, 2007, IN PRESS J BIOL CHEM; Koyrakh L, 2005, AM J TRANSPLANT, V5, P529, DOI 10.1111/j.1600-6143.2005.00754.x; LORENZ JN, 2006, AM J PHYSIOL, V292, pR440; Lu XQ, 2006, TETRAHEDRON LETT, V47, P825, DOI 10.1016/j.tetlet.2005.11.092; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Mehta D, 2005, J BIOL CHEM, V280, P17320, DOI 10.1074/jbc.M411674200; Moosmang S, 2006, CIRC RES, V98, P105, DOI 10.1161/01.RES.0000197851.11031.9c; Moosmang S, 2003, EMBO J, V22, P6027, DOI 10.1093/emboj/cdg583; Nofer JR, 2004, J CLIN INVEST, V113, P569, DOI 10.1172/JCI200418004; Ohmori T, 2004, J THROMB HAEMOST, V2, P203, DOI 10.1111/j.1538-7836.2004.0562h.x; Osada M, 2002, BIOCHEM BIOPH RES CO, V299, P483, DOI 10.1016/S0006-291X(02)02671-2; Pfaff M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-48; Poburko D, 2004, EUR J PHARMACOL, V505, P19, DOI 10.1016/j.ejphar.2004.09.060; Ratz PH, 2005, AM J PHYSIOL-CELL PH, V288, pC769, DOI 10.1152/ajpcell.00529.2004; Ratz PH, 2003, AM J PHYSIOL-REG I, V284, pR1063, DOI 10.1152/ajpregu.00596.2002; Rosenfeldt HM, 2003, FASEB J, V17, P1789, DOI 10.1096/fj.02-0836com; Salomone S, 2003, EUR J PHARMACOL, V469, P125, DOI 10.1016/S0014-2999(03)01731-X; Shenfeld OZ, 1999, UROL RES, V27, P386, DOI 10.1007/s002400050168; SJOGREN C, 1982, J UROLOGY, V128, P1368, DOI 10.1016/S0022-5347(17)53509-0; SMITH DJ, 1994, NEUROUROL URODYNAM, V34, P14; Song HJ, 2006, MOL CELLS, V21, P42; Speich JE, 2005, AM J PHYSIOL-CELL PH, V289, pC12, DOI 10.1152/ajpcell.00418.2004; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; VANBREEMEN C, 1995, TRENDS PHARMACOL SCI, V16, P98, DOI 10.1016/S0165-6147(00)88990-7; Watterson KR, 2005, CELL SIGNAL, V17, P289, DOI 10.1016/j.cellsig.2004.09.013; Wegener JW, 2004, FASEB J, V18, P1159, DOI 10.1096/fj.04-1516fje; Xu SZ, 2006, CIRC RES, V98, P1381, DOI 10.1161/01.RES.0000225284.36490.a2; Xu SZ, 2005, BRIT J PHARMACOL, V145, P405, DOI 10.1038/sj.bjp.0706197; Zhou HP, 2004, AM J PHYSIOL-CELL PH, V286, pC1130, DOI 10.1152/ajpcell.00429.2003	54	17	17	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2818	2828		10.1096/fj.06-7326com	http://dx.doi.org/10.1096/fj.06-7326com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17449719				2022-12-28	WOS:000249237500023
J	Mellott, TJ; Follettie, MT; Diesl, V; Hill, AA; Lopez-Coviella, I; Blusztajn, JK				Mellott, Tiffany J.; Follettie, Maximillian T.; Diesl, Veronica; Hill, Andrew A.; Lopez-Coviella, Ignacio; Krzysztof Blusztajn, Jan			Prenatal choline availability modulates hippocampal and cerebral cortical gene expression	FASEB JOURNAL			English	Article						microarray; memory; nutrition; development; pregnancy	LONG-TERM POTENTIATION; II MUTANT MICE; PROTEIN-KINASE-II; CALMODULIN-DEPENDENT KINASE; GROWTH-FACTOR-I; DNA METHYLATION; SPLICE VARIANTS; MESSENGER-RNA; RAT-BRAIN; ACETYLCHOLINE-RELEASE	An increased supply of the essential nutrient choline during fetal development [ embryonic day ( E) 11 - 17] in rats causes life-long improvements in memory performance, whereas choline deficiency during this time impairs certain aspects of memory. We analyzed mRNA expression in brains of prenatally choline- deficient, choline- supplemented, or control rats of various ages [ postnatal days ( P) 1 to 34 for hippocampus and E16 to P34 for cortex] using oligonucleotide microarrays and found alterations in gene expression levels evoked by prenatal choline intake that were, in most cases, transient occurring during the P15- P34 period. We selected a subset of genes, encoding signaling proteins, and verified the microarray data by reverse transcriptase- polymerase chain reaction analyses. Prenatally choline- supplemented rats had the highest expression of calcium/ calmodulin ( CaM)- dependent protein kinase ( CaMK) I and insulin- like growth factor ( IGF) II ( Igf2) in the cortex and of the transcription factor Zif268/ EGR1 in the cortex and hippocampus. Prenatally choline deficient rats had the highest expression of CaMKII beta, protein kinase C beta 2, and GABA(B) receptor 1 isoforms c and d in the hippocampus. Similar changes in the expression of the proteins encoded by these genes were observed using immunoblot analyses. These data show that the prenatal supply of choline causes multiple modifications in the developmental patterns of expression of genes known to influence learning and memory and provide molecular correlates for the cognitive changes evoked by altered availability of choline in utero.	Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; Wyeth Ayerst Res, Biol Technol, Cambridge, MA USA	Boston University; Boston University; Pfizer	Blusztajn, JK (corresponding author), Boston Univ, Sch Med, Dept Pathol & Lab Med, 715 Albany St,Rm L804, Boston, MA 02118 USA.	jbluszta@bu.edu		Mellott, Tiffany/0000-0003-3287-9374; /0000-0001-8438-3122	NIA NIH HHS [AG-009525] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albright CD, 1999, DEV BRAIN RES, V115, P123, DOI 10.1016/S0165-3806(99)00057-7; Albright CD, 2003, NUTR NEUROSCI, V6, P129, DOI 10.1080/1028415031000084418; Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; Amir-Ahmady B, 2001, J BIOL CHEM, V276, P10514, DOI 10.1074/jbc.M010535200; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BIERI JG, 1977, J NUTR, V107, P1394; Bieri JG., 1980, J NUTR, V110, P1726, DOI [10.1093/jn/110.8.1726, DOI 10.1093/JN/110.8.1726]; Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; Bozon B, 2003, NEURON, V40, P695, DOI 10.1016/S0896-6273(03)00674-3; BYRNE MC, 2000, CURRENT PROTOCOLS MO; CARDELL M, 1993, J NEUROCHEM, V61, P1308, DOI 10.1111/j.1471-4159.1993.tb13623.x; Cermak JM, 1998, FASEB J, V12, P349, DOI 10.1096/fasebj.12.3.349; CHAPMAN PF, 1995, NEURON, V14, P591, DOI 10.1016/0896-6273(95)90315-1; Charles KJ, 2001, NEUROSCIENCE, V106, P447, DOI 10.1016/S0306-4522(01)00296-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark SE, 2001, NEUROSCIENCE, V104, P441, DOI 10.1016/S0306-4522(01)00087-2; Craciunescu CN, 2003, J NUTR, V133, P3614, DOI 10.1093/jn/133.11.3614; Davis S, 1998, CR ACAD SCI III-VIE, V321, P97, DOI 10.1016/S0764-4469(97)89808-3; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; Eden S, 2001, EMBO J, V20, P3518, DOI 10.1093/emboj/20.13.3518; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; FAZELI MS, 1993, J NEUROSCI, V13, P1346; Feil R, 2006, MUTAT RES-FUND MOL M, V600, P46, DOI 10.1016/j.mrfmmm.2006.05.029; FIBIGER HC, 1991, TRENDS NEUROSCI, V14, P220, DOI 10.1016/0166-2236(91)90117-D; Fink CC, 2003, NEURON, V39, P283, DOI 10.1016/S0896-6273(03)00428-8; FNB (Food and Nutrition Board) IOM (Institute of Medicine), 1998, DIET REF INT THIAM R; Fritschy JM, 1999, EUR J NEUROSCI, V11, P761, DOI 10.1046/j.1460-9568.1999.00481.x; GARNER SC, 1995, J NUTR, V125, P2851; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Glazewski S, 1996, SCIENCE, V272, P421, DOI 10.1126/science.272.5260.421; GOLDENRING JR, 1983, J BIOL CHEM, V258, P2632; GOLDENRING JR, 1986, ANN NY ACAD SCI, V466, P457, DOI 10.1111/j.1749-6632.1986.tb38423.x; Gonzalez-Parra S, 2002, HORM RES, V57, P10, DOI 10.1159/000057940; Gordon JA, 1996, NEURON, V17, P491, DOI 10.1016/S0896-6273(00)80181-6; Hall J, 2000, NAT NEUROSCI, V3, P533, DOI 10.1038/75698; He XB, 2001, BIOCHEM BIOPH RES CO, V283, P243, DOI 10.1006/bbrc.2001.4732; Hill AA, 2001, GENOME BIOL, V2; Holley SJ, 2002, DEV BIOL, V244, P319, DOI 10.1006/dbio.2002.0608; Honse Y, 2003, NEUROSCIENCE, V122, P689, DOI 10.1016/S0306-4522(03)00603-1; Ikarashi Y, 1999, BRAIN RES, V816, P238, DOI 10.1016/S0006-8993(98)01163-9; Isomoto S, 1998, BIOCHEM BIOPH RES CO, V253, P10, DOI 10.1006/bbrc.1998.9706; Jones JP, 1999, DEV BRAIN RES, V118, P159, DOI 10.1016/S0165-3806(99)00103-0; Jones MW, 2001, NAT NEUROSCI, V4, P289, DOI 10.1038/85138; Kar S, 1997, P NATL ACAD SCI USA, V94, P14054, DOI 10.1073/pnas.94.25.14054; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; KONISHI Y, 1994, BRAIN RES, V649, P53, DOI 10.1016/0006-8993(94)91048-0; Kumari M, 2001, J BIOL CHEM, V276, P29764, DOI 10.1074/jbc.M100317200; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; LOCKER J, 1986, CARCINOGENESIS, V7, P1309, DOI 10.1093/carcin/7.8.1309; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; McCann JC, 2006, NEUROSCI BIOBEHAV R, V30, P696, DOI 10.1016/j.neubiorev.2005.12.003; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1999, DEV BRAIN RES, V118, P51, DOI 10.1016/S0165-3806(99)00105-4; Mellott TJ, 2004, FASEB J, V18, P545, DOI 10.1096/fj.03-0877fje; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MILLER LG, 1989, J PHARMACOL EXP THER, V248, P1; Miyashita Y, 1998, NEUROBIOL LEARN MEM, V70, P197, DOI 10.1006/nlme.1998.3848; Mohler H, 2001, LIFE SCI, V68, P2297, DOI 10.1016/S0024-3205(01)01018-9; Montoya D, 2000, NEUROSCI LETT, V296, P85, DOI 10.1016/S0304-3940(00)01660-8; Murrell A, 2001, EMBO REP, V2, P1101, DOI 10.1093/embo-reports/kve248; Nava F, 2001, EUR J PHARMACOL, V430, P261, DOI 10.1016/S0014-2999(01)01163-3; Niculescu MD, 2006, FASEB J, V20, P43, DOI 10.1096/fj.05-4707com; Niculescu MD, 2005, MOL BRAIN RES, V134, P309, DOI 10.1016/j.molbrainres.2004.11.001; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; OCHIISHI T, 1994, BRAIN RES, V659, P179, DOI 10.1016/0006-8993(94)90877-X; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; Oomizu S, 2003, ALCOHOL CLIN EXP RES, V27, P975, DOI 10.1097/01.ALC.0000071743.57855.BE; Paola D, 2000, BIOCHEM BIOPH RES CO, V268, P642, DOI 10.1006/bbrc.2000.2164; Paulsen M, 2001, J PATHOL, V195, P97, DOI 10.1002/path.890; Petrie J, 2001, ALCOHOL CLIN EXP RES, V25, P819, DOI 10.1097/00000374-200106000-00005; Pfaff T, 1999, EUR J NEUROSCI, V11, P2874, DOI 10.1046/j.1460-9568.1999.00704.x; Pyapali GK, 1998, J NEUROPHYSIOL, V79, P1790, DOI 10.1152/jn.1998.79.4.1790; RAPPOLEE DA, 1992, GENE DEV, V6, P939, DOI 10.1101/gad.6.6.939; Reinhart B, 2002, MOL CELL BIOL, V22, P2089, DOI 10.1128/MCB.22.7.2089-2098.2002; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Schmitt JM, 2005, J NEUROSCI, V25, P1281, DOI 10.1523/JNEUROSCI.4086-04.2005; Schwarz DA, 2000, J BIOL CHEM, V275, P32174, DOI 10.1074/jbc.M005333200; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SILVA AJ, 1992, COLD SPRING HARB SYM, V57, P527, DOI 10.1101/SQB.1992.057.01.058; Tsujiuchi T, 1999, JPN J CANCER RES, V90, P909, DOI 10.1111/j.1349-7006.1999.tb00834.x; Tucker KL, 2001, NEURON, V30, P649, DOI 10.1016/S0896-6273(01)00325-7; WAINFAN E, 1989, CANCER RES, V49, P4094; Wayman GA, 2004, J NEUROSCI, V24, P3786, DOI 10.1523/JNEUROSCI.3294-03.2004; Weeber EJ, 2000, J NEUROSCI, V20, P5906, DOI 10.1523/JNEUROSCI.20-16-05906.2000; Wei KR, 2001, NEUROREPORT, V12, P833, DOI 10.1097/00001756-200103260-00042; Wei KR, 2001, MOL BRAIN RES, V89, P103, DOI 10.1016/S0169-328X(01)00068-7; Williams CL, 1998, BRAIN RES, V794, P225, DOI 10.1016/S0006-8993(98)00229-7; Zeisel SH, 2004, J AM COLL NUTR, V23, p621S, DOI 10.1080/07315724.2004.10719433; ZEISEL SH, 1995, J NUTR, V125, P3049; Zeisel SH, 2006, ANNU REV NUTR, V26, P229, DOI 10.1146/annurev.nutr.26.061505.111156; Zhang JH, 1998, ENDOCRINOLOGY, V139, P4523, DOI 10.1210/en.139.11.4523	97	35	40	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1311	1323		10.1096/fj.06-6597com	http://dx.doi.org/10.1096/fj.06-6597com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264169				2022-12-28	WOS:000246117000007
J	Ke, PY; Hu, CM; Chang, YC; Chang, ZF				Ke, Po-Yuan; Hu, Chun-Mei; Chang, Yi-Chang; Chang, Zee-Fen			Hiding human thymidine kinase 1 from APC/C-mediated destruction by thymidine binding	FASEB JOURNAL			English	Article						cell cycle; proteolysis; ubiquitination; dTTP synthesis	MOUSE RIBONUCLEOTIDE REDUCTASE; SERUM-STIMULATED CELLS; MESSENGER-RNA; MITOTIC PHOSPHORYLATION; SUBSTRATE-BINDING; MAMMALIAN-CELLS; GENE-EXPRESSION; TUMOR-MARKER; HELA-CELLS; DEGRADATION	Thymidine kinase 1 (TK1) is a key cytosolic enzyme in the salvage pathway for dTTP synthesis. In mitotic exit, human TK1 (hTK1) is degraded via the anaphase-promoting complex/cyclosome (APC/C)-Cdh1 pathway to limit dTTP production. In this study, we show that thymidine binding stabilizes hTK1 during growth arrest. By in vitro degradation, ubiquitination, and Cdh1 binding analyses, we provide direct evidence that thymidine binding protects wild-type hTK1 protein from APC/C-Cdh1-mediated destruction. In contrast, mutant-type hTK1 protein defective in thymidine binding ability could still be polyubiquitinated by APC/CCdh1 in the presence of thymidine. These results suggest that the status of thymidine binding to hTK1 protein determines its susceptibility to degradation due to APC/C targeting. Our in vivo experimental data also demonstrated that thymidine treatment abolished Cdh1/proteasome-responsive suppression of hTK1 expression. Moreover, exposure of mitotic-arrested K562 cells to thymidine (100 mu M) stabilized endogenous TK1, causing nucleotide imbalance in the early G(1) phase and an increase of S phase accumulation. In conclusion, thymidine is not only a substrate of TK1 but also acts as its expression regulator by modulating its proteolytic control during mitotic exit, conferring a feed-forward regulation of dTTP formation.	Natl Taiwan Univ, Grad Inst Biochem & Mol Biol, Coll Med, Taipei, Taiwan	National Taiwan University	Chang, ZF (corresponding author), Natl Taiwan Univ, Grad Inst Biochem & Mol Biol, Coll Med, 1,Sect 1,Jen Ai Rd, Taipei, Taiwan.	zfchang@ha.mc.ntu.edu.tw	Ke, Po-Yuan/AAQ-6324-2021	Ke, Po-Yuan/0000-0002-0471-0806				Berenstein D, 2000, J BIOL CHEM, V275, P32187, DOI 10.1074/jbc.M005325200; Bolderson E, 2004, HUM MOL GENET, V13, P2937, DOI 10.1093/hmg/ddh316; BRADLEY MO, 1978, NATURE, V274, P607, DOI 10.1038/274607a0; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; CHANG ZF, 1990, BIOCHEM BIOPH RES CO, V169, P780, DOI 10.1016/0006-291X(90)90399-8; CHANG ZF, 1994, J BIOL CHEM, V269, P21249; Chang ZF, 1998, J BIOL CHEM, V273, P12095, DOI 10.1074/jbc.273.20.12095; CHANG ZF, 1995, J BIOL CHEM, V270, P27374, DOI 10.1074/jbc.270.45.27374; Chimploy K, 2001, J BIOL CHEM, V276, P7093, DOI 10.1074/jbc.M006232200; Chou WL, 2001, BBA-GENE STRUCT EXPR, V1519, P209, DOI 10.1016/S0167-4781(01)00241-X; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Gilles SI, 2003, INT J BIOL MARKER, V18, P1; HALLEK M, 1992, ANN HEMATOL, V65, P1, DOI 10.1007/BF01715117; He QM, 2004, INT J ONCOL, V25, P945; HENGSTSCHLAGER M, 1994, J BIOL CHEM, V269, P13836; ITO M, 1990, J BIOL CHEM, V265, P6954; JI JP, 1991, J BIOL CHEM, V266, P16289; Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; Ke PY, 2005, GENE DEV, V19, P1920, DOI 10.1101/gad.1322905; Ke PY, 2004, MOL CELL BIOL, V24, P514, DOI 10.1128/MCB.24.2.514-526.2004; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; Li CL, 2004, BIOCHEM BIOPH RES CO, V313, P587, DOI 10.1016/j.bbrc.2003.11.147; LIEBERMAN HB, 1988, MOL CELL BIOL, V8, P5280, DOI 10.1128/MCB.8.12.5280; Mathews CK, 2006, FASEB J, V20, P1300, DOI 10.1096/fj.06-5730rev; MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6; MUNCHPETERSEN B, 1993, J BIOL CHEM, V268, P15621; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100; Posch M, 2000, J MOL BIOL, V300, P493, DOI 10.1006/jmbi.2000.3876; Rahman L, 2004, CANCER CELL, V5, P341, DOI 10.1016/S1535-6108(04)00080-7; Reichard P, 2000, J BIOL CHEM, V275, P33021, DOI 10.1074/jbc.M005337200; Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751; SHERLEY JL, 1988, J BIOL CHEM, V263, P375; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; STUART P, 1985, MOL CELL BIOL, V5, P1490, DOI 10.1128/MCB.5.6.1490; Sutterluety H, 1997, J MOL BIOL, V265, P153, DOI 10.1006/jmbi.1996.0721; Sutterluety H, 1996, J MOL BIOL, V259, P383, DOI 10.1006/jmbi.1996.0327; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6; Welin M, 2004, P NATL ACAD SCI USA, V101, P17970, DOI 10.1073/pnas.0406332102; Wintersberger E, 1997, BIOCHEM SOC T, V25, P303, DOI 10.1042/bst0250303	43	11	13	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					1276	1284		10.1096/fj.06-7272com	http://dx.doi.org/10.1096/fj.06-7272com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17227951	Green Submitted			2022-12-28	WOS:000245650400032
J	Chang, KC; Unsinger, J; Davis, CG; Schwulst, SJ; Muenzer, JT; Strasser, A; Hotchkiss, RS				Chang, Katherine C.; Unsinger, Jacqueline; Davis, Christopher G.; Schwulst, Steven J.; Muenzer, Jared T.; Strasser, Andreas; Hotchkiss, Richard S.			Multiple triggers of cell death in sepsis: death receptor and mitochondrial-mediated apoptosis	FASEB JOURNAL			English	Article						endotoxin; necrosis; cytokines	BH3-ONLY PROTEINS PUMA; IMPROVES SURVIVAL; LYMPHOCYTE APOPTOSIS; FAS LIGAND; BCL-2; INHIBITION; DEPLETION; MICE; BIM; PATHOPHYSIOLOGY	Lymphocyte apoptosis plays a central role in the pathophysiology of sepsis. Lymphocyte apoptosis was examined in mice with defective death receptor pathways due to transgenic expression of a dominant negative mutant of Fas-associated death domain (FADD-DN) or Bid(-/-) and in mice with defective mitochondrial-mediated pathways due to loss of Bim(-/-), Puma(-/-), or Noxa(-/-). FADD-DN transgenic and Bid(-/-) mice had significant albeit incomplete protection, and this protection was associated with increased survival. Surprisingly, splenic B cells were also protected in FADD-DN mice although transgene expression was confined to T cells, providing evidence for an indirect protective mechanism. Bim(-/-) provided virtually complete protection against lymphocyte apoptosis whereas Puma(-/-) and Noxa(-/-) mice had modest or no protection, respectively. Bim(-/-) mice had improved survival, and adoptive transfer of splenocytes from Bim(-/-) mice into Rag 1(-/-) mice demonstrated that this was a lymphocyte intrinsic effect. The improved survival was associated with decreased interleukin (IL) -10 and IL-6 cytokines. Collectively, these data indicate that numerous death stimuli are generated during sepsis, and it therefore appears unlikely that blocking a single "trigger" can inhibit apoptosis. If siRNA becomes practical therapeutically, proapoptotic proteins would be potential targets.	Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Walter & Eliza Hall Inst Med Res, Dept Immunol, Melbourne, Vic 3050, Australia	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Walter & Eliza Hall Institute	Hotchkiss, RS (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, 660 S Euclid, St Louis, MO 63110 USA.	hotchkir@msnotes.wustl.edu	Strasser, Andreas/C-7581-2013	Strasser, Andreas/0000-0002-5020-4891	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055194, R01GM044118, R37GM044118] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55194, GM44118] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Chen SH, 2005, NEW GENERAT COMPUT, V23, P3, DOI 10.1007/BF03037645; Chung CS, 2003, J LEUKOCYTE BIOL, V74, P344, DOI 10.1189/jlb.0102006; Chung CS, 1998, ARCH SURG-CHICAGO, V133, P1213, DOI 10.1001/archsurg.133.11.1213; Chung CS, 2001, SURGERY, V130, P339, DOI 10.1067/msy.2001.116540; Coopersmith CM, 2002, JAMA-J AM MED ASSOC, V287, P1716, DOI 10.1001/jama.287.13.1716; Creagh EM, 2001, BIOCHEM SOC T, V29, P696, DOI 10.1042/0300-5127:0290696; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Erlacher M, 2005, BLOOD, V106, P4131, DOI 10.1182/blood-2005-04-1595; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Felmet KA, 2005, J IMMUNOL, V174, P3765, DOI 10.4049/jimmunol.174.6.3765; Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JCI26321; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Green DR, 2000, NATURE, V405, P28, DOI 10.1038/35011175; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hildeman DA, 2002, IMMUNITY, V16, P759, DOI 10.1016/S1074-7613(02)00322-9; Hiramatsu M, 1997, SHOCK, V7, P247, DOI 10.1097/00024382-199704000-00002; Hotchkiss RS, 2006, J IMMUNOL, V176, P5471, DOI 10.4049/jimmunol.176.9.5471; Hotchkiss RS, 2005, J IMMUNOL, V174, P5110, DOI 10.4049/jimmunol.174.8.5110; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741; Hotchkiss RS, 1999, J IMMUNOL, V162, P4148; Hotchkiss RS, 1999, P NATL ACAD SCI USA, V96, P14541, DOI 10.1073/pnas.96.25.14541; Hotchkiss RS, 2003, SCAND J INFECT DIS, V35, P585, DOI 10.1080/00365540310015692; Hotchkiss RS, 2000, J IMMUNOL, V164, P3675, DOI 10.4049/jimmunol.164.7.3675; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Hotchkiss RS, 2002, J IMMUNOL, V168, P2493, DOI 10.4049/jimmunol.168.5.2493; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Iwata A, 2003, J IMMUNOL, V171, P3136, DOI 10.4049/jimmunol.171.6.3136; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; Le Tulzo Y, 2002, SHOCK, V18, P487, DOI 10.1097/00024382-200212000-00001; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; Murphy SL, 1998, NATL VITAL STAT REP, V48, P1; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Oberholzer A, 2005, SHOCK, V23, P488, DOI 10.1097/01.shk.0000163802.46355.59; Oberholzer C, 2001, FASEB J, V15, P879, DOI 10.1096/fj.00-058rev; Oberholzer C, 2001, P NATL ACAD SCI USA, V98, P11503, DOI 10.1073/pnas.181338198; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Pellegrini M, 2003, P NATL ACAD SCI USA, V100, P14175, DOI 10.1073/pnas.2336198100; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Rathmell JC, 1998, IMMUNOL CELL BIOL, V76, P387, DOI 10.1046/j.1440-1711.1998.00774.x; Remick DG, 2002, SHOCK, V17, P463, DOI 10.1097/00024382-200206000-00004; Roy S, 2000, J EXP MED, V192, pF21, DOI 10.1084/jem.192.8.F21; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Su X, 1998, J IMMUNOL, V160, P5288; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Toti P, 2004, AM J CLIN PATHOL, V122, P765, DOI 10.1309/RV6E9BMC9954A2WU; van Dissel JT, 1998, LANCET, V351, P950, DOI 10.1016/S0140-6736(05)60606-X; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Weaver JGR, 2004, FASEB J, V18, P1185, DOI 10.1096/fj.03-1230com; Wei QQ, 2006, AM J PHYSIOL-RENAL, V290, pF35, DOI 10.1152/ajprenal.00184.2005; Wesche DE, 2005, J LEUKOCYTE BIOL, V78, P325, DOI 10.1189/jlb.0105017; Wesche-Soldato DE, 2005, BLOOD, V106, P2295, DOI 10.1182/blood-2004-10-4086; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	60	122	132	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					708	719		10.1096/fj.06-6805com	http://dx.doi.org/10.1096/fj.06-6805com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17307841				2022-12-28	WOS:000244686400010
J	Benayoun, B; Baghdiguian, S; Lajmanovich, A; Bartoli, M; Daniele, N; Gicquel, E; Bourg, N; Raynaud, F; Pasquier, MA; Suel, L; Lochmuller, H; Lefranc, G; Richard, I				Benayoun, Beatrice; Baghdiguian, Stephen; Lajmanovich, Alicia; Bartoli, Marc; Daniele, Nathalie; Gicquel, Evelyne; Bourg, Nathalie; Raynaud, Fabrice; Pasquier, Marie-Anne; Suel, Laurence; Lochmuller, Hanns; Lefranc, Gerard; Richard, Isabelle			NF-kappa B-dependent expression of the antiapoptotic factor c-FLIP is regulated by calpain 3, the protein involved in limb-girdle muscular dystrophy type 2A	FASEB JOURNAL			English	Article						muscle; apoptosis; FLICE; inhibitary protein; lgmd2A	SKELETAL-MUSCLE ATROPHY; SIGNALING MODULE; MESSENGER-RNA; CELL-DEATH; APOPTOSIS; ACTIVATION; PATHWAY; ALPHA; INSIGHTS; DETERMINANTS	Limb-girdle muscular dystrophy type 2A (LGMD2A) is a recessive genetic disorder caused by mutations in the cysteine protease calpain 3 (CAPN3) that leads to selective muscle wasting. We previously showed that CAPN3 deficiency is associated with a profound perturbation of the NF-kappa B/I kappa B alpha survival pathway. In this study, the consequences of altered NF-kappa B/I kappa B alpha pathway were investigated using biological materials from LGMD2A patients. We first show that die antiapoptotic factor cellular-FUCE inhibitory protein (c-FLIP), which is dependent on the NF-kappa B pathway in normal muscle cells, is down-regulated in LGMD2A biopsies. In muscle cells isolated from LGMD2A patients, NF-kappa B is readily activated on cytokine induction as shown by an increase in its DNA binding activity. However, we observed discrepant transcriptional responses depending on the NF-kappa B target genes. I kappa B alpha is expressed following NF-kappa B activation independent of the CAPN3 status, whereas expression of c-FLIP is obtained only when CAPN3 is present. These data lead us to postulate that CAPN3 intervenes in the regulation of the expression of NF-kappa B-dependent survival genes to prevent apoptosis in skeletal muscle. Deregulations in the NF-kappa B pathway could be part of the mechanism responsible for the muscle wasting resulting from CAPN3 deficiency.	[Benayoun, Beatrice; Bartoli, Marc; Daniele, Nathalie; Gicquel, Evelyne; Bourg, Nathalie; Suel, Laurence; Richard, Isabelle] CNRS, Genethon FRE 3018, F-91000 Evry, France; [Baghdiguian, Stephen; Lefranc, Gerard] Univ Montpellier 2, CNRS, UMR 5554, Montpellier, France; [Lajmanovich, Alicia; Pasquier, Marie-Anne] INSERM, Albert Bonniot Inst, EMI 353, Res Grp Lymphoma, La Tronche, France; [Raynaud, Fabrice] IGF, UMR 5203, Dept Neurosci, Montpellier, France; [Lochmuller, Hanns] Univ Munich, Friedrich Baur Inst, Munich, Germany; [Lochmuller, Hanns] Univ Munich, Dept Neurol, D-8000 Munich, Germany; [Lefranc, Gerard] CNRS, UPR 1142, Inst Genet Humaine, Lab Immunol Mol, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; University of Munich; University of Munich; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Richard, I (corresponding author), CNRS, Genethon FRE 3018, 1 Rue Int, F-91000 Evry, France.	richard@genethon.fr	Bartoli, Marc/O-8893-2016; Danièle, Nathalie/J-7432-2013; Bartoli, Marc/Q-5979-2017; Richard, isabelle/J-8298-2013	Bartoli, Marc/0000-0003-3339-9858; Bartoli, Marc/0000-0003-3339-9858; Daniele, Nathalie/0000-0002-7985-2788; Raynaud, Fabrice/0000-0003-3055-0524; Lochmuller, Hanns/0000-0003-2324-8001; Baghdiguian, Stephen/0000-0002-2992-9708	Medical Research Council [G0601943B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Baghdiguian S, 2001, J MOL MED, V79, P254, DOI 10.1007/s001090100225; Baghdiguian S, 1999, NAT MED, V5, P503, DOI 10.1038/8385; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bullani RR, 2001, J INVEST DERMATOL, V117, P360, DOI 10.1046/j.0022-202x.2001.01418.x; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Campbell KJ, 2006, CANCER RES, V66, P929, DOI 10.1158/0008-5472.CAN-05-2234; Chae J, 2001, NEUROMUSCULAR DISORD, V11, P547, DOI 10.1016/S0960-8966(01)00197-3; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Fardeau M, 1996, NEUROMUSCULAR DISORD, V6, P447, DOI 10.1016/S0960-8966(96)00387-2; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; Ho RC, 2005, AM J PHYSIOL-CELL PH, V289, pC794, DOI 10.1152/ajpcell.00632.2004; Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Hunter RB, 2004, J CLIN INVEST, V114, P1504, DOI 10.1172/JCI200421696; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jovanovic M, 2006, ONCOGENE, V25, P6176, DOI 10.1038/sj.onc.1209912; Judge AR, 2007, AM J PHYSIOL-CELL PH, V292, pC372, DOI 10.1152/ajpcell.00293.2006; Kataoka T, 2005, CRIT REV IMMUNOL, V25, P31, DOI 10.1615/CritRevImmunol.v25.i1.30; Kramerova I, 2004, HUM MOL GENET, V13, P1373, DOI 10.1093/hmg/ddh153; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Luo GJ, 2003, AM J PHYSIOL-REG I, V284, pR1249, DOI 10.1152/ajpregu.00490.2002; Marcilhac A, 2006, INT J BIOCHEM CELL B, V38, P2128, DOI 10.1016/j.biocel.2006.06.005; Martin M, 1997, MOL BIOL CELL, V8, P1543, DOI 10.1091/mbc.8.8.1543; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mourkioti F, 2006, J CLIN INVEST, V116, P2945, DOI 10.1172/JCI28721; Nagaraju K, 2000, J IMMUNOL, V164, P5459, DOI 10.4049/jimmunol.164.10.5459; Oda A, 2002, BLOOD, V99, P1850, DOI 10.1182/blood.V99.5.1850; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Phillips T, 2005, FASEB J, V19, P668, DOI 10.1096/fj.04-2870fje; PONS F, 1993, NEUROMUSCULAR DISORD, V3, P507, DOI 10.1016/0960-8966(93)90106-T; Ricci MS, 2004, MOL CELL BIOL, V24, P8541, DOI 10.1128/MCB.24.19.8541-8555.2004; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; Turco MC, 2004, LEUKEMIA, V18, P11, DOI 10.1038/sj.leu.2403171; Valnet-Rabier MB, 2005, BRIT J HAEMATOL, V128, P767, DOI 10.1111/j.1365-2141.2005.05378.x; VAN AD, 1996, SCIENCE, V274, P787; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Welm AL, 2002, J BIOL CHEM, V277, P33848, DOI 10.1074/jbc.M204096200; Zhou XD, 2004, CLIN SCI, V106, P397, DOI 10.1042/CS20030238	44	44	45	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1521	1529		10.1096/fj.07-8701com	http://dx.doi.org/10.1096/fj.07-8701com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18073330				2022-12-28	WOS:000255898700024
J	Hudson, BI; Carter, AM; Harja, E; Kalea, AZ; Arriero, M; Yang, HJ; Grant, PJ; Schmidt, AM				Hudson, Barry I.; Carter, Angela M.; Harja, Evis; Kalea, Anastasia Z.; Arriero, Maria; Yang, Hojin; Grant, Peter J.; Schmidt, Ann Marie			Identification, classification, and expression of RAGE gene splice variants	FASEB JOURNAL			English	Article						RNA splicing; DNA cloning	GLYCATION END-PRODUCTS; TYPE-1 DIABETIC-PATIENTS; CORONARY-ARTERY-DISEASE; CELL-SURFACE RECEPTOR; SOLUBLE RECEPTOR; PLASMA-LEVELS; HUMAN BRAIN; PROTEIN; ATHEROSCLEROSIS; ENDPRODUCTS	The receptor for advanced glycation end-products (RAGE) is a single-transmembrane, multiligand receptor of the immunoglobulin superfamily. RAGE up-regulation is implicated in numerous pathological states including vascular disease, diabetes, cancer, and neurodegeneration. The understanding of the regulation of RAGE is important in both disease pathogenesis and normal homeostasis. Here, we demonstrate the characterization and identification of human RAGE splice variants by analysis of RAGE cDNA from tissue and cells. We identified a vast range of splice forms that lead to changes in the protein coding region of RAGE, which we have classified according to the Human Gene Nomenclature Committee (HGNC). These resulted in protein changes in the ligand-binding domain of RAGE or the removal of the transmembrane domain and cytosolic tail. Analysis of splice variants for premature termination codons reveals similar to 50% of identified variants are targeted to the nonsense-mediated mRNA decay pathway. Expression analysis revealed the RAGE_v1 variant to be the primary secreted soluble isoform of RAGE. Taken together, identification of functional splice variants of RAGE underscores the biological diversity of the RAGE gene and will aid in the understanding of the gene in the normal and pathological state.	[Hudson, Barry I.; Harja, Evis; Kalea, Anastasia Z.; Arriero, Maria; Yang, Hojin; Schmidt, Ann Marie] Columbia Univ, Coll Phys & Surg, Div Surg Sci, Dept Surg, New York, NY 10032 USA; [Carter, Angela M.; Grant, Peter J.] Univ Leeds, Leeds Inst Genet Hlth & Therapeut, Acad Unit Mol Vasc Med, Leeds, W Yorkshire, England	Columbia University; University of Leeds	Hudson, BI (corresponding author), Columbia Univ, Coll Phys & Surg, Div Surg Sci, Dept Surg, 630 W 168th St,PS 17-401, New York, NY 10032 USA.	bh202l@columbia.edu	Hudson, Barry/B-3122-2009; Grant, Peter/HIR-3733-2022; Kalea, Anastasia Z./G-4053-2010	Hudson, Barry/0000-0001-7647-8121; Kalea, Anastasia Z./0000-0001-5775-3984				Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BARTOLAZZI A, 1995, J CELL SCI, V108, P1723; Basta G, 2006, J CLIN ENDOCR METAB, V91, P4628, DOI 10.1210/jc.2005-2559; Ding QX, 2005, NEUROSCI LETT, V373, P67, DOI 10.1016/j.neulet.2004.09.059; Emanuele E, 2005, ARCH NEUROL-CHICAGO, V62, P1734, DOI 10.1001/archneur.62.11.1734; Falcone C, 2005, ARTERIOSCL THROM VAS, V25, P1032, DOI 10.1161/01.ATV.0000160342.20342.00; Geroldi D, 2005, J HYPERTENS, V23, P1725, DOI 10.1097/01.hjh.0000177535.45785.64; Geroldi D, 2006, CURR MED CHEM, V13, P1971, DOI 10.2174/092986706777585013; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hudson BI, 2005, ARTERIOSCL THROM VAS, V25, P879, DOI 10.1161/01.ATV.0000164804.05324.8b; Hudson BI, 2004, PHARM RES-DORDR, V21, P1079, DOI 10.1023/B:PHAM.0000032992.75423.9b; Jang JH, 2002, BLOOD CELL MOL DIS, V29, P133, DOI 10.1006/bcmd.2002.0548; Katakami N, 2005, DIABETES CARE, V28, P2716, DOI 10.2337/diacare.28.11.2716; KISSLINGER, 1999, J BIOL CHEM, V274, P31740; Koyama H, 2005, ARTERIOSCL THROM VAS, V25, P2587, DOI 10.1161/01.ATV.0000190660.32863.cd; Koyama H, 2007, MOL MED, V13, P625, DOI 10.2119/2007-00087.Koyama; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; Malherbe P, 1999, MOL BRAIN RES, V71, P159, DOI 10.1016/S0169-328X(99)00174-6; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Park IH, 2004, MOL IMMUNOL, V40, P1203, DOI 10.1016/j.molimm.2003.11.027; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Sakurai S, 2006, DIABETES RES CLIN PR, V73, P158, DOI 10.1016/j.diabres.2005.12.013; Schlueter C, 2003, BBA-GENE STRUCT EXPR, V1630, P1, DOI 10.1016/j.bbaexp.2003.08.008; SUGAYA K, 1994, GENOMICS, V23, P408, DOI 10.1006/geno.1994.1517; Wain HM, 2002, GENOMICS, V79, P464, DOI 10.1006/geno.2002.6748; Wendt TM, 2003, AM J PATHOL, V162, P1123, DOI 10.1016/S0002-9440(10)63909-0; Yonekura H, 2003, BIOCHEM J, V370, P1097, DOI 10.1042/BJ20021371	29	271	281	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1572	1580		10.1096/fj.07-9909com	http://dx.doi.org/10.1096/fj.07-9909com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18089847				2022-12-28	WOS:000255898700029
J	Rottmann, S; Speckgens, S; Luscher-Firzlaff, J; Luscher, B				Rottmann, Sabine; Speckgens, Stefanie; Luescher-Firzlaff, Juliane; Luescher, Bernhard			Inhibition of apoptosis by MAD1 is mediated lay repression of the PTEN tumor suppression gene	FASEB JOURNAL			English	Article						AKT; MYC; PI3K; transcription	NF-KAPPA-B; MYC ANTAGONIST MAD1; TRANSCRIPTIONAL REPRESSOR; MYC/MAX/MAD NETWORK; CELL-GROWTH; MAX NETWORK; CYCLIN D2; E-BOX; PROTEIN; EXPRESSION	The MYC/MAX/MAD network of transcriptional regulators controls distinct aspects of cell physiology, including cell proliferation and apoptosis. Within the network MAD proteins antagonize the functions of MYC oncoproteins, and the latter are deregulated in the majority of human cancers. While MYC sensitizes cells to proapoptotic signals, the transcriptional repressor MAD1 inhibits apoptosis in response to a broad range of stimuli, including oncoproteins. The molecular targets of MAD1 that mediate inhibition of apoptosis are not known. Here we describe the phosphatase and tensin homologue deleted on chromosome ten (PTEN) tumor suppressor gene as a target of MAD1. By binding to the proximal promoter region, MAD I downregulated PTEN expression. PTEN functions as a lipid phosphatase that regulates the phosphatidylinositol 3-kinase/AKT pathway. Indeed MAD1-dependent repression of PTEN led to activation of AKT and subsequent stimulation of the antiapoptotic NF-kappa B pathway. Interfering with AKT function affected the control of Fas-induced apoptosis by MAD1. In addition, knockdown of PTEN using small interfering RNA (siRNA) or the lack of PTEN rendered cells insensitive to inhibition of apoptosis by MAD1. These findings identify the PTEN gene as a target of the MYC-antagonist MAD1 and provide a molecular framework critical for the ability of MAD1 to inhibit apoptosis.	[Rottmann, Sabine; Speckgens, Stefanie; Luescher-Firzlaff, Juliane; Luescher, Bernhard] Rhein Westfal TH Aachen, Univ Klinikum, Inst Biochem, Abt Biochem & Molekularbiol, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Luscher, B (corresponding author), Rhein Westfal TH Aachen, Univ Klinikum, Inst Biochem, Abt Biochem & Molekularbiol, Pauwelsstr 30, D-52074 Aachen, Germany.	luescher@rwth-aachen.de	Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709				AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; Bejarano MT, 2000, EXP CELL RES, V260, P61, DOI 10.1006/excr.2000.4996; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; CERNI C, 1995, ONCOGENE, V11, P587; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Gehring S, 2000, J BIOL CHEM, V275, P10413, DOI 10.1074/jbc.275.14.10413; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Hettinger K, 2007, CELL DEATH DIFFER, V14, P218, DOI 10.1038/sj.cdd.4401946; Holzel M, 2001, EMBO REP, V2, P1125, DOI 10.1093/embo-reports/kve251; Hurlin PJ, 2003, EMBO J, V22, P4584, DOI 10.1093/emboj/cdg442; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Iritani BM, 2002, EMBO J, V21, P4820, DOI 10.1093/emboj/cdf492; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nilsson JA, 2004, MOL CELL BIOL, V24, P1560, DOI 10.1128/MCB.24.4.1560-1569.2004; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Pezzolesi MG, 2007, HUM MOL GENET, V16, P1058, DOI 10.1093/hmg/ddm053; Queva C, 1999, CELL GROWTH DIFFER, V10, P785; Queva C, 2001, MOL CELL BIOL, V21, P703, DOI 10.1128/MCB.21.3.703-712.2001; Rohn JL, 1998, ONCOGENE, V17, P2811, DOI 10.1038/sj.onc.1202393; Rottmann S, 2006, CURR TOP MICROBIOL, V302, P63; ROTTMANN S, 2003, THESIS U HANNOVER GE; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Strutt H, 1999, METH MOL B, V119, P455; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Whelan JT, 2007, CELL CYCLE, V6, P80, DOI 10.4161/cc.6.1.3648; Zbuk KM, 2007, NAT REV CANCER, V7, P35, DOI 10.1038/nrc2037; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhou XP, 2003, AM J HUM GENET, V73, P404, DOI 10.1086/377109; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	55	6	7	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2008	22	4					1124	1134		10.1096/fj.07-9627com	http://dx.doi.org/10.1096/fj.07-9627com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	17998413				2022-12-28	WOS:000254581000018
J	Autio, KJ; Kastaniotis, AJ; Pospiech, H; Miinalainen, IJ; Schonauer, MS; Dieckmann, CL; Hiltunen, JK				Autio, Kaija J.; Kastaniotis, Alexander J.; Pospiech, Helmut; Miinalainen, Ilkka J.; Schonauer, Melissa S.; Dieckmann, Carol L.; Hiltunen, J. Kalervo			An ancient genetic link between vertebrate mitochondrial fatty acid synthesis and RNA processing	FASEB JOURNAL			English	Article						HsHTD2; RNase P	ACYL CARRIER PROTEIN; PEROXISOMAL MULTIFUNCTIONAL ENZYME; CELLULAR MESSENGER-RNA; HUMAN RIBONUCLEASE-P; SACCHAROMYCES-CEREVISIAE; INTERNAL INITIATION; ESCHERICHIA-COLI; YEAST; SUBUNITS; BIOSYNTHESIS	In bacteria, functionally related gene products are often encoded by a common transcript. Such polycistronic transcripts are rare in eukaryotes. Here we isolated several clones from human cDNA libraries, which rescued the respiratory-deficient phenotype of a yeast mitochondrial 3-hydroxyacyl thioester dehydratase 2 (htd2) mutant strain. All complementing cDNAs were derived from the RPP14 transcript previously described to encode the RPP14 subunit of the human ribonuclease P (RNase P) complex. We identified a second, 3' open reading frame (ORF) on the RPP14 transcript encoding a protein showing similarity to known dehydratases and hydratase 2 enzymes. The protein was localized in mitochondria, and the recombinant enzyme exhibited (3R)-specific hydratase 2 activity. Based on our results, we named the protein human 3-hydroxyacyl-thioester dehydratase 2 (HsHTD2), which is involved in mitochondrial fatty acid synthesis. The bicistronic arrangement of RPP14 and HsHTD2, as well as the general exon structure of the gene, is conserved in vertebrates from fish to humans, indicating a genetic link conserved for 400 million years between RNA processing and mitochondrial fatty acid synthesis.	[Autio, Kaija J.; Kastaniotis, Alexander J.; Pospiech, Helmut; Miinalainen, Ilkka J.; Hiltunen, J. Kalervo] Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland; [Autio, Kaija J.; Kastaniotis, Alexander J.; Pospiech, Helmut; Miinalainen, Ilkka J.; Hiltunen, J. Kalervo] Univ Oulu, Bioctr, Oulu, Finland; [Schonauer, Melissa S.; Dieckmann, Carol L.] Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ USA; [Schonauer, Melissa S.; Dieckmann, Carol L.] Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA	Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; University of Arizona; University of Arizona	Hiltunen, JK (corresponding author), Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland.	kalervo.hiltunen@oulu.fi	Pospiech, Helmut/J-8598-2015	Autio, Kaija/0000-0001-9398-7649; Miinalainen, Ilkka/0000-0002-3922-3442; Kastaniotis, Alexander/0000-0003-3624-9214; Hiltunen, Kalervo/0000-0002-3073-9602				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Blumenthal Thomas, 2004, Briefings in Functional Genomics & Proteomics, V3, P199, DOI 10.1093/bfgp/3.3.199; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Davis RE, 1997, MOL BIOCHEM PARASIT, V89, P25, DOI 10.1016/S0166-6851(97)00097-2; Felsenstein J, 2006, MOL BIOL EVOL, V23, P691, DOI 10.1093/molbev/msj079; FILPPULA SA, 1995, J BIOL CHEM, V270, P27453, DOI 10.1074/jbc.270.46.27453; FITCH WALTER M., 1967, BIOCHEM GENET, V1, P65, DOI 10.1007/BF00487738; Fukui T, 1997, J BACTERIOL, V179, P4821, DOI 10.1128/jb.179.15.4821-4830.1997; Ganot P, 2004, MOL CELL BIOL, V24, P7795, DOI 10.1128/MCB.24.17.7795-7805.2004; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Gray TA, 1999, P NATL ACAD SCI USA, V96, P5616, DOI 10.1073/pnas.96.10.5616; Hampsey M, 2006, NAT STRUCT MOL BIOL, V13, P564, DOI 10.1038/nsmb0706-564; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; Hiltunen JK, 2005, BIOCHEM SOC T, V33, P1162, DOI 10.1042/BST0331162; HILTUNEN JK, 1989, J BIOL CHEM, V264, P13536; Hinnebusch AG, 2005, ANNU REV MICROBIOL, V59, P407, DOI 10.1146/annurev.micro.59.031805.133833; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Jarrous N, 1999, J CELL BIOL, V146, P559, DOI 10.1083/jcb.146.3.559; Jarrous N, 2002, RNA, V8, P1, DOI 10.1017/S1355838202011184; Jarrous N, 1999, RNA, V5, P153, DOI 10.1017/S135583829800185X; Kastaniotis AJ, 2004, MOL MICROBIOL, V53, P1407, DOI 10.1111/j.1365-2958.2004.04191.x; Koski MK, 2004, J BIOL CHEM, V279, P24666, DOI 10.1074/jbc.M400293200; Kozak M, 2005, NUCLEIC ACIDS RES, V33, P6593, DOI 10.1093/nar/gki958; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Miinalainen IJ, 2003, J BIOL CHEM, V278, P20154, DOI 10.1074/jbc.M302851200; Park SJ, 2003, J BACTERIOL, V185, P5391, DOI 10.1128/JB.185.18.5391-5397.2003; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Porras P, 2006, J BIOL CHEM, V281, P16551, DOI 10.1074/jbc.M600790200; Puranam RS, 2001, MOL CELL BIOL, V21, P548, DOI 10.1128/MCB.21.2.548-561.2001; Qin YM, 1999, J BIOL CHEM, V274, P28619, DOI 10.1074/jbc.274.40.28619; Qin YM, 2000, J BIOL CHEM, V275, P4965, DOI 10.1074/jbc.275.7.4965; Reiss J, 1999, AM J HUM GENET, V64, P706, DOI 10.1086/302296; Rosenblad MA, 2006, NUCLEIC ACIDS RES, V34, P5145, DOI 10.1093/nar/gkl626; ROSSMANITH W, 1995, J BIOL CHEM, V270, P12885, DOI 10.1074/jbc.270.21.12885; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; Stuible HP, 1998, J BIOL CHEM, V273, P22334, DOI 10.1074/jbc.273.35.22334; SUGINO H, 1992, J BACTERIOL, V174, P2485, DOI 10.1128/jb.174.8.2485-2492.1992; SULO P, 1993, J BIOL CHEM, V268, P17634; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wada H, 1997, P NATL ACAD SCI USA, V94, P1591, DOI 10.1073/pnas.94.4.1591; Xiao SH, 2002, ANNU REV BIOCHEM, V71, P165, DOI 10.1146/annurev.biochem.71.110601.135352; Zhang L, 2005, J BIOL CHEM, V280, P12422, DOI 10.1074/jbc.M413686200; Zhang L, 2003, J BIOL CHEM, V278, P40067, DOI 10.1074/jbc.M306121200; Zhang NS, 2003, GENE, V303, P121, DOI 10.1016/S0378-1119(02)01142-3	48	43	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2008	22	2					569	578		10.1096/fj.07-8986	http://dx.doi.org/10.1096/fj.07-8986			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17898086				2022-12-28	WOS:000252822600027
J	Zou, L; Yang, RX; Chai, JJ; Pei, G				Zou, Lin; Yang, Rongxi; Chai, Jingjing; Pei, Gang			Rapid xenograft tumor progression in beta-arrestin1 transgenic mice due to enhanced tumor angiogenesis	FASEB JOURNAL			English	Article						matrix metalloproteinase 9; MMP9; vascular endothelial growth factor; VEGF; phosphatidylinositol 3-kinase; PI3K	ARRESTIN-DEPENDENT ENDOCYTOSIS; PROTEASE-ACTIVATED RECEPTOR-2; GROWTH-FACTOR VEGF; BETA-ARRESTIN; MATRIX METALLOPROTEINASES; PHOSPHATIDYLINOSITOL 3-KINASE; OVARIAN-CARCINOMA; CANCER-THERAPY; GELATINASE-B; CELL-LINE	beta-arrestins (beta-Arrs) are known to be associated with tumor signaling pathways such as transforming growth factor-beta 1 (TGF-beta 1), P53/Murine double minute (MDM2) and NF-kappa B. To investigate the role of beta-Arr in tumor progression in vivo, we generated beta-Arr transgenic mice by subcutaneously inoculating tumor cells in them. We found that the xenograft tumor initiated earlier and grew more rapidly in beta-Arr1 transgenic mice than in both the beta-Arr2 transgenic and wild-type mice after inoculating murine liver cancer Hepa1-6 cells or lymphoma EL4 cells. Moreover, matrix metalloproteinase 9 (MMP9) activity, vascular endothelial growth factor ( VEGF) concentration in plasma and new small blood vessel formation in tumor tissues were enhanced in beta-Arr1 transgenic mice compared with those in control mice. In addition, injection of MMP9 inhibitors in beta-Arr1 transgenic mice abrogated all these effects and suppressed rapid tumor progression. Similar results were observed in human microvascular endothelial cells, where overexpressed beta-Arr1 did increase MMP9 activity and small blood vessel formation. Furthermore, phosphatidylinositol 3-kinase (PI3K) inhibitors could suppress beta-Arr1-enhanced MMP9 activity and the C-terminal 181-418 amino acids (aa) of beta-Arr1 was largely responsible for this effect. Our data reveal a functional role for beta-arrestin1 in tumor progression in vivo, in which overexpression of beta-Arr1 promotes MMP9 activity and tumor angiogenesis by providing a suitable microenvironment for tumor progression.	[Zou, Lin; Yang, Rongxi; Chai, Jingjing; Pei, Gang] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China; [Yang, Rongxi] Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China; [Zou, Lin] Chongqing Univ Med Sci, Childrens Hosp, Clin Mol Med Ctr, Chongqing, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Chongqing Medical University	Pei, G (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China.	gpei@sibs.ac.cn	Xiao, Yang/B-5668-2012					ABECASSIS I, 2003, EXP CELL ERS, V291, P393; Belotti D, 2003, CANCER RES, V63, P5224; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Bryja V, 2007, P NATL ACAD SCI USA, V104, P6690, DOI 10.1073/pnas.0611356104; Buchanan FG, 2006, P NATL ACAD SCI USA, V103, P1492, DOI 10.1073/pnas.0510562103; Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x; Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Choi JH, 2006, CANCER RES, V66, P3912, DOI 10.1158/0008-5472.CAN-05-1785; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FIDLER IJ, 1995, J NATL CANCER I, V87, P1588, DOI 10.1093/jnci/87.21.1588; Fridman R, 2003, CANCER METAST REV, V22, P153, DOI 10.1023/A:1023091214123; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Girnita L, 2007, J BIOL CHEM, V282, P11329, DOI 10.1074/jbc.M611526200; Grimm CF, 2000, GASTROENTEROLOGY, V119, P1104, DOI 10.1053/gast.2000.18157; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayward SW, 1998, INT J ONCOL, V13, P35; Huang SY, 2002, J NATL CANCER I, V94, P1134; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Klein G, 2004, CRIT REV ONCOL HEMAT, V50, P87, DOI 10.1016/j.critevonc.2003.09.001; Ko HM, 2005, FEBS LETT, V579, P6451, DOI 10.1016/j.febslet.2005.10.027; Kroger A, 2001, CANCER RES, V61, P2609; Lefkowitz RJ, 2004, CURR OPIN CELL BIOL, V16, P162, DOI 10.1016/j.ceb.2004.01.001; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Ma YH, 2000, CELL RES, V10, P303, DOI 10.1038/sj.cr.7290057; Morris DR, 2006, CANCER RES, V66, P307, DOI 10.1158/0008-5472.CAN-05-1735; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; PAGET S, 1989, CANCER METAST REV, V8, P98; POVISC TJ, 2003, J BIOL CHEM, V278, P51334; Revankar CM, 2004, J BIOL CHEM, V279, P24578, DOI 10.1074/jbc.M402121200; Shenoy S.K., 2005, SCI STKE, V2005, pcm10; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; Wang P, 2003, J BIOL CHEM, V278, P6363, DOI 10.1074/jbc.M210350200; Wang P, 2006, BIOCHEMISTRY-US, V45, P9374, DOI 10.1021/bi0602617; Wang YY, 2006, NAT IMMUNOL, V7, P139, DOI 10.1038/ni1294	45	35	42	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					355	364		10.1096/fj.07-9046com	http://dx.doi.org/10.1096/fj.07-9046com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17890288				2022-12-28	WOS:000252822600005
J	Tam, J; Trembovler, V; Di Marzo, V; Petrosino, S; Leo, G; Alexandrovich, A; Regev, E; Casap, N; Shteyer, A; Ledent, C; Karsak, M; Zimmer, A; Mechoulam, R; Yirmiya, R; Shohami, E; Bab, I				Tam, Joseph; Trembovler, Victoria; Di Marzo, Vincenzo; Petrosino, Stefania; Leo, Gabriella; Alexandrovich, Alex; Regev, Eran; Casap, Nardy; Shteyer, Arie; Ledent, Catherine; Karsak, Meliha; Zimmer, Andreas; Mechoulam, Raphael; Yirmiya, Raz; Shohami, Esther; Bab, Itai			The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling	FASEB JOURNAL			English	Article						2-arachidonoylglycerol; norepinephrine; sympathetic nervous system; traumatic brain injury	SYMPATHETIC-NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; NORADRENALINE RELEASE; MEDIATED INHIBITION; VAS-DEFERENS; ANANDAMIDE; MICE; PATHOGENESIS; PROTEIN	We have recently reported that in bone the cannabinoid CB1 receptor is present in sympathetic terminals. Here we show that traumatic brain injury (TBI), which in humans enhances peripheral osteogenesis and fracture healing, acutely stimulates bone formation in a distant skeletal site. At this site we demonstrate i) a high level of the main endocannabinoid, 2-arachidonoylglycerol (2-AG), and expression of diacylglycerol lipases, enzymes essential for 2-AG synthesis; ii) that the TBI-induced increase in bone formation is preceded by elevation of the 2-AG and a decrease in norepinephrine (NE) levels. The TBI stimulation of bone formation was absent in CB1-null mice. In wild-type animals it could be mimicked, including the suppression of NE levels, by 2-AG administration. The TBI- and 2-AG-induced stimulation of osteogenesis was restrained by the beta-adrenergic receptor agonist isoproterenol. NE from sympathetic terminals is known to tonically inhibit bone formation by activating osteoblastic beta 2- adrenergic receptors. The present findings further demonstrate that the sympathetic control of bone formation is regulated through 2-AG activation of prejunctional CB1. Elevation of bone 2-AG apparently suppresses NE release from bone sympathetic terminals, thus alleviating the inhibition of bone formation. The involvement of osteoblastic CB2 signaling in this process is minimal, if any.	[Tam, Joseph; Bab, Itai] Hebrew Univ Jerusalem, Bone Lab, IL-91120 Jerusalem, Israel; [Trembovler, Victoria; Alexandrovich, Alex] Hebrew Univ Jerusalem, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Regev, Eran; Casap, Nardy; Shteyer, Arie] Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Dept Oral & Maxillofacial Surg, IL-91120 Jerusalem, Israel; [Mechoulam, Raphael] Hebrew Univ Jerusalem, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel; [Yirmiya, Raz] Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; [Di Marzo, Vincenzo; Petrosino, Stefania; Leo, Gabriella] Inst Biomol Chem, Consiglio Nazl Ric, Endocannabinoid Res Grp, Pozzilli, Italy; [Petrosino, Stefania] Univ Salerno, Dipartimento Sci Farmaceut, Fisciano, Italy; [Ledent, Catherine] Univ Libre Bruxelles, Inst Rech Interdisciplinaire & Biol Humaine & Mol, Brussels, Belgium; [Karsak, Meliha; Zimmer, Andreas] Univ Bonn, Inst Mol Psychiat, D-5300 Bonn, Germany	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Consiglio Nazionale delle Ricerche (CNR); University of Salerno; Universite Libre de Bruxelles; University of Bonn	Bab, I (corresponding author), Hebrew Univ Jerusalem, Bone Lab, IL-91120 Jerusalem, Israel.	babi@cc.huji.ac.il	Yirmiya, Raz/D-1090-2014; Di Marzo, Vincenzo/AAD-7742-2019; Zimmer, Andreas/B-8357-2009	Yirmiya, Raz/0000-0002-4009-7316; Di Marzo, Vincenzo/0000-0002-1490-3070; Tam, Joseph/0000-0002-0948-0093; Karsak, Meliha/0000-0001-6612-6317				Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Bisogno T, 2003, J CELL BIOL, V163, P463, DOI 10.1083/jcb.200305129; Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Contractor A, 2003, J NEUROSCI, V23, P422, DOI 10.1523/JNEUROSCI.23-02-00422.2003; Deutsch DG, 1997, J CLIN INVEST, V100, P1538, DOI 10.1172/JCI119677; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398; FRIED A, 1993, J CELL PHYSIOL, V155, P472, DOI 10.1002/jcp.1041550306; Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028; Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255; Ishac EJN, 1996, BRIT J PHARMACOL, V118, P2023, DOI 10.1111/j.1476-5381.1996.tb15639.x; Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050; Karsak M, 2005, HUM MOL GENET, V14, P3389, DOI 10.1093/hmg/ddi370; Klein BY, 1999, CALCIFIED TISSUE INT, V65, P217, DOI 10.1007/s002239900686; Kondo H, 2005, J BIOL CHEM, V280, P30192, DOI 10.1074/jbc.M504179200; KURER MHJ, 1992, PARAPLEGIA, V30, P165, DOI 10.1038/sc.1992.48; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Malinowska B, 1997, N-S ARCH PHARMACOL, V356, P197, DOI 10.1007/PL00005041; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 2002, Sci STKE, V2002, pre5, DOI 10.1126/stke.2002.129.re5; Melamed E, 2002, AM J PHYS MED REHAB, V81, P670, DOI 10.1097/00002060-200209000-00006; Monteleone P, 2005, NEUROPSYCHOPHARMACOL, V30, P1216, DOI 10.1038/sj.npp.1300695; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Niederhoffer N, 2003, N-S ARCH PHARMACOL, V367, P434, DOI 10.1007/s00210-003-0755-y; Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PERTWEE RG, 1992, BRIT J PHARMACOL, V105, P980, DOI 10.1111/j.1476-5381.1992.tb09088.x; RENFREE KJ, 1994, SPINE, V19, P740, DOI 10.1097/00007632-199404000-00002; Rhee MH, 1997, J MED CHEM, V40, P3228, DOI 10.1021/jm970126f; Rigaux P, 2005, JOINT BONE SPINE, V72, P146, DOI 10.1016/j.jbspin.2004.05.012; Rouzer CA, 2002, CHEM PHYS LIPIDS, V119, P69, DOI 10.1016/S0009-3084(02)00068-3; Schlicker E, 2003, BRIT J PHARMACOL, V140, P323, DOI 10.1038/sj.bjp.0705449; Steffens S, 2005, NATURE, V434, P782, DOI 10.1038/nature03389; Stella N, 2001, EUR J PHARMACOL, V425, P189, DOI 10.1016/S0014-2999(01)01182-7; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 2000, CHEM PHYS LIPIDS, V108, P89, DOI 10.1016/S0009-3084(00)00189-4; Szabo B, 2005, HANDB EXP PHARMACOL, V168, P327; Szabo B, 2001, J PHARMACOL EXP THER, V297, P819; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Tam J, 2006, MOL PHARMACOL, V70, P786, DOI 10.1124/mol.106.026435; Vizi ES, 2001, EUR J PHARMACOL, V431, P237, DOI 10.1016/S0014-2999(01)01413-3; Wildburger R, 2001, WIEN KLIN WOCHENSCHR, V113, P119; WILDBURGER R, 1994, BONE MINER, V27, P183, DOI 10.1016/S0169-6009(08)80192-4; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; Yao M., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P319; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780	57	138	148	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					285	294		10.1096/fj.06-7957com	http://dx.doi.org/10.1096/fj.06-7957com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17704191				2022-12-28	WOS:000252309900030
J	Lefevre, J; Michaud, SE; Haddad, P; Dussault, S; Menard, C; Groleau, J; Turgeon, J; Rivard, A				Lefevre, Jonas; Michaud, Sophie-Elise; Haddad, Paola; Dussault, Sylvie; Menard, Catherine; Groleau, Jessika; Turgeon, Julie; Rivard, Alain			Moderate consumption of red wine (cabernet sauvignon) improves ischemia-induced neovascularization in ApoE-deficient mice: effect on endothelial progenitor cells and nitric oxide	FASEB JOURNAL			English	Article						hypercholesterolemia; resveratrol	CIGARETTE-SMOKE EXPOSURE; GROWTH-FACTOR; MOUSE MODEL; RESVERATROL; ANGIOGENESIS; IMPAIRMENT; EXPRESSION; MIGRATION; VEGF; VASCULOGENESIS	Moderate consumption of red wine is associated with a decreased incidence of cardiovascular diseases in populations with relatively high amount of fat in the diet. However, the mechanisms involved in this protective effect are not completely understood. Here we show that moderate consumption of red wine ( equivalent to 2 glasses/ day in humans) but not ethanol only, improves blood flow recovery by 32% after hindlimb ischemia in hypercholesterolemic ApoE- deficient mice. In ischemic tissues, red wine consumption reduces oxidative stress and increases capillary density by 46%. Endothelial progenitor cells ( EPCs) have been shown to have an important role in postnatal neovascularization. We found that the number of EPCs is increased by 60% in ApoE mice exposed to red wine. Moreover, the migratory capacity of EPCs is significantly improved in red wine- drinking mice. The wine used in our study is a cabernet sauvignon from Langue-doc-Roussillon, France, which contains a relatively high concentration ( 4 - 6 mg/ L) of the polyphenolic antioxidant resveratrol. We demonstrate that resveratrol can rescue oxidized low- density lipoprotein ( oxLDL)- induced impairment of in vitro angiogenic activities in human umbilical vein endothelial cells ( HUVECs). Resveratrol exposure is also associated with increased activation of Akt/ eNOS together with a restoration of nitric oxide production in HUVECs exposed to oxLDL. Our study suggests that moderate consumption of red wine improves ischemia- induced neovascularization in high- cholesterol conditions by increasing the number and the functional activities of EPCs and by restoring the Akt- eNOS- NO pathway.	Univ Montreal, Ctr Hosp, Dept Cardiovasc Res, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Rivard, A (corresponding author), Univ Montreal, Ctr Hosp, 1560 Sherbrooke Est, Montreal, PQ H2L 4MI, Canada.	rivardal@total.net						Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Bohm M, 2004, NEPHROL DIAL TRANSPL, V19, P11, DOI 10.1093/ndt/gfg340; Chen JZ, 2004, CLIN SCI, V107, P273, DOI 10.1042/CS20030389; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Couffinhal T, 1999, CIRCULATION, V99, P3188, DOI 10.1161/01.CIR.99.24.3188; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; DEMROW HS, 1995, CIRCULATION, V91, P1182, DOI 10.1161/01.CIR.91.4.1182; Dernbach E, 2004, BLOOD, V104, P3591, DOI 10.1182/blood-2003-12-4103; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FITZPATRICK DF, 1993, AM J PHYSIOL, V265, pH774; FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6; FUHRMAN B, 1995, AM J CLIN NUTR, V61, P549, DOI 10.1093/ajcn/61.3.549; GOLDBERG DM, 1995, AM J ENOL VITICULT, V46, P159; GRONBECK M, 1995, BRIT MED J, V310, P1169; Iijima K, 2000, CIRCULATION, V101, P805, DOI 10.1161/01.CIR.101.7.805; Iijima K, 2002, CIRCULATION, V105, P2404, DOI 10.1161/01.CIR.0000016349.36385.FB; Kunsch C, 1999, CIRC RES, V85, P753, DOI 10.1161/01.RES.85.8.753; Lekakis J, 2005, EUR J CARDIOV PREV R, V12, P596, DOI 10.1097/00149831-200512000-00013; Michaud SE, 2003, FASEB J, V17, P1150, DOI 10.1096/fj.02-0172fje; Michaud SE, 2006, ATHEROSCLEROSIS, V187, P423, DOI 10.1016/j.atherosclerosis.2005.10.009; Michaud SE, 2006, J MOL CELL CARDIOL, V41, P275, DOI 10.1016/j.yjmcc.2006.05.004; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Ndiaye M, 2004, FASEB J, V18, DOI 10.1096/fj.04-2146fje; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Olas B, 2001, MICROBIOS, V105, P7; Orsini F, 1997, J NAT PROD, V60, P1082, DOI 10.1021/np970069t; Ou HC, 2006, CLIN CHIM ACTA, V364, P196, DOI 10.1016/j.cccn.2005.06.018; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03-0168rev; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Rivard A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0; Rivard A, 1998, MOL MED, V4, P429, DOI 10.1007/BF03401749; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Thum T, 2007, ARTERIOSCL THROM VAS, V27, P748, DOI 10.1161/01.ATV.0000258787.18982.73; Urbich C, 2002, CIRCULATION, V106, P981, DOI 10.1161/01.CIR.0000027107.54614.1A; Urpi-Sarda M, 2005, ANAL CHEM, V77, P3149, DOI 10.1021/ac0484272; VanBelle E, 1997, CIRCULATION, V96, P2667, DOI 10.1161/01.CIR.96.8.2667; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Wang J, 2006, FASEB J, V20, P2313, DOI 10.1096/fj.06-6281com	41	67	68	2	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3845	3852		10.1096/fj.06-7491com	http://dx.doi.org/10.1096/fj.06-7491com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17641150				2022-12-28	WOS:000251283500009
J	Rottner, M; Kunzelmann, C; Mergey, M; Freyssinet, JM; Martinez, MC				Rottner, Mathilde; Kunzelmann, Corinne; Mergey, Martine; Freyssinet, Jean-Marie; Martinez, Maria Carmen			Exaggerated apoptosis and NF-kappa B activation in pancreatic and tracheal cystic fibrosis cells	FASEB JOURNAL			English	Article						CFTR; phosphatidylserine; inflammation; cytokines	TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL-CELLS; PHOSPHATIDYLSERINE; INFLAMMATION; EXPRESSION; SECRETION; INFANTS; DISEASE; FLUID; FAS	The pathophysiologic mechanisms causing inflammation in cystic fibrosis (CF) remain obscure. The effects of proapoptotic agents on pancreatic and tracheal cell lines expressing wild-type CFTR (PANC-1 and NT-1, respectively) or the homozygous CFTR Delta F508 mutation (CFPAC-1 and CFT-2, respectively) were assessed. An increased susceptibility to apoptosis was observed in CFPAC-1 and CFT-2 cells. Apoptosis was reduced by treatment with a pan-caspase inhibitor and by incubation at 27 degrees C, allowing recruitment of CFTR Delta F508 at the plasma membrane. Inhibition of CFTR function in wild-type cells induced an increase of apoptosis. Apoptosis in CFPAC-1, but not in CFT- 2 cells, was associated with overexpression of the proinflammatory mediators interleukin-6 and interleukin-8. In CF cells, apoptosis was linked to NF-kappa B pathway activation. Conditioned medium from actinomycin D-treated CFPAC-1 cells produced an increase in apoptosis of wild-type cells, suggesting that proinflammatory mediators secreted by mutant cells promote apoptosis. This was confirmed through the induction of apoptosis in wild-type cells by exogenous interleukin-6 and interleukin-8. These results suggest that CFTR Delta F508 mutation, apoptosis, and activation of the NF-kappa B pathway contribute to the self-perpetuating inflammatory cycle, at least in pancreatic cells, and provide evidence that excessive apoptosis may account for the exaggerated proinflammatory response observed in CF patients.-Rottner, R., Kunzelmann, C., Mergey, M., Freyssinet, J- M., Marti nez, M. C. Exaggerated apoptosis and NF-kappa B activation in pancreatic and tracheal cystic fibrosis cells.	CNRS, INSERM U 771, UMR 6214, Fac Med, F-49045 Angers, France; INSERM, U770, F-94275 Le Kremlin Bicetre, France; Univ Paris Sud, Hop Bicetre, Fac Med, F-94275 Le Kremlin Bicetre, France; Univ Strasbourg, Fac Med, Inst Hematol & Immunol, Strasbourg, France; INSERM, U680, Paris, France; Univ Paris 06, Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Martinez, MC (corresponding author), CNRS, INSERM U 771, UMR 6214, Fac Med, Rue Haute Reculee, F-49045 Angers, France.	carmen.martinez@univ-angers.fr	Freyssinet, Jean-Marie/G-2719-2013					Akabas MH, 2000, J BIOL CHEM, V275, P3729, DOI 10.1074/jbc.275.6.3729; Amsellem C, 2002, RESP MED, V96, P244, DOI 10.1053/rmed.2001.1257; ASHCROFT FM, 2000, ION CHANNELS DIS, V12, P211; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Becker MN, 2004, AM J RESP CRIT CARE, V169, P645, DOI 10.1164/rccm.200207-765OC; Cannon CL, 2003, AM J RESP CELL MOL, V29, P188, DOI 10.1165/rcmb.4898; Courtney J M, 2004, J Cyst Fibros, V3, P223, DOI 10.1016/j.jcf.2004.06.006; Dakin CJ, 2002, AM J RESP CRIT CARE, V165, P904, DOI 10.1164/ajrccm.165.7.2010139; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Durieu I, 1999, THORAX, V54, P1093, DOI 10.1136/thx.54.12.1093; Gidon-Jeangirard C, 1999, BIOCHEM BIOPH RES CO, V265, P709, DOI 10.1006/bbrc.1999.1752; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P3587, DOI 10.1073/pnas.93.8.3587; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; LEMNAOUAR M, 1993, EUR J CLIN INVEST, V23, P151, DOI 10.1111/j.1365-2362.1993.tb00754.x; Lim M, 2001, Paediatr Respir Rev, V2, P159, DOI 10.1053/prrv.2000.0124; Maiuri L, 1997, FEBS LETT, V408, P225, DOI 10.1016/S0014-5793(97)00347-5; Muhlebach MS, 1999, AM J RESP CRIT CARE, V160, P186, DOI 10.1164/ajrccm.160.1.9808096; Puchelle Edith, 2002, Paediatr Respir Rev, V3, P115, DOI 10.1016/S1526-0550(02)00005-7; Ratjen F, 2002, THORAX, V57, P930, DOI 10.1136/thorax.57.11.930; Schwiebert LM, 1999, AM J PHYSIOL-CELL PH, V276, pC700, DOI 10.1152/ajpcell.1999.276.3.C700; TAYLOR CJ, 2002, PAEDIATR RESPIR REV, V1, P77; Thiagarajah JR, 2004, FASEB J, V18, P875, DOI 10.1096/fj.03-1248fje; Vandivier RW, 2002, J CLIN INVEST, V109, P661, DOI 10.1172/JCI200213572; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Vilela RM, 2006, INT IMMUNOPHARMACOL, V6, P1651, DOI 10.1016/j.intimp.2006.06.012; Weber AJ, 2001, AM J PHYSIOL-LUNG C, V281, pL71, DOI 10.1152/ajplung.2001.281.1.L71; Zaman MM, 2004, CLIN DIAGN LAB IMMUN, V11, P819, DOI 10.1128/CDLI.11.5.819-824.2004; Zwaal RFA, 2005, CELL MOL LIFE SCI, V62, P971, DOI 10.1007/s00018-005-4527-3	28	45	45	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2939	2948		10.1096/fj.06-7614com	http://dx.doi.org/10.1096/fj.06-7614com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17442732				2022-12-28	WOS:000249237500034
J	Sexton, A; McDonald, M; Cayla, C; Thiemermann, C; Ahluwalia, A				Sexton, Alison; McDonald, Michelle; Cayla, Cecile; Thiemermann, Chris; Ahluwalia, Amrita			12-Lipoxygenase-derived eicosanoids protect against myocardial ischemia/reperfusion injury via activation of neuronal TRPV1	FASEB JOURNAL			English	Article						coronary vasodilation; channel activation; capsaicin receptor	GENE-RELATED PEPTIDE; IMPAIRS POSTISCHEMIC RECOVERY; ISOLATED RAT HEARTS; ARACHIDONIC-ACID; VANILLOID RECEPTOR; CORONARY VASODILATION; CAPSAICIN RECEPTORS; REPERFUSION INJURY; SENSORY NEURONS; PAIN PATHWAY	Recent evidence implicates the neuronal transient receptor potential vanilloid receptor 1 ( TRPV1), expressed on sensory C- fibers, as playing an important endogenous protective role in limiting the damaging effects of myocardial I/ R injury. In neurons the 12- lipoxygenase ( 12- LOX) arachidonic acid ( AA) metabolite, 12( S)- HpETE, has been proposed as the endogenous ligand for TRPV1. However, whether 12( S)- HpETE underlies TRPV1 channel activation during I/ R is unknown. Treatment of isolated Langendorff rat hearts with a 12- LOX/ AA cocktail significantly attenuated I/ R injury ( similar to 40% inhibition of infarct size), an effect reversed by the 12- LOX inhibitor baicalein or after chemical desensitization of local sensory C- fiber afferents using capsaicin. Both 12( S)- HpETE and AA caused dose- dependent coronary vasodilatation ( similar to EC50s of 6 X 10 - 19 and 1 X 10 - 7, respectively) that was profoundly suppressed by the TRPV1 antagonist capsazepine, in hearts of TRPV1 knockout mice compared with wild- type mice, or by treatment with a CGRP antagonist. In addition, I/ R itself stimulates up- regulation of TRPV1 expression in both the cell bodies located within the dorsal root ganglia and locally within the myocardium. Together, our data identify a novel 12- LOX/ AA/ TRPV1 pathway activated and up- regulated during I/ R injury, providing an endogenous damage- limiting mechanism whose targeting may prove useful in treating myocardial infarction.	Queen Mary Univ London, Barts & London Med Sch, William Harvey Res Inst, London EC1M 6BQ, England	University of London; Queen Mary University London	Ahluwalia, A (corresponding author), Queen Mary Univ London, Barts & London Med Sch, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	a.ahluwalia@qmul.ac.uk		AHLUWALIA, Amrita/0000-0001-7626-6399; Goddard, Alison/0000-0003-1916-4737; Thiemermann, Christoph/0000-0003-4228-9722				Amaya F, 2003, BRAIN RES, V963, P190, DOI 10.1016/S0006-8993(02)03972-0; BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x; Biro T, 2006, J INVEST DERMATOL, V126, P1909, DOI 10.1038/sj.jid.5700321; Carlton SM, 2001, NEUROSCI LETT, V310, P53, DOI 10.1016/S0304-3940(01)02093-6; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chai WX, 2006, EUR J PHARMACOL, V531, P246, DOI 10.1016/j.ejphar.2005.12.039; Chang YZ, 2000, J PHARMACOL EXP THER, V294, P147; Chen W, 1999, AM J PHYSIOL-HEART C, V276, pH2094, DOI 10.1152/ajpheart.1999.276.6.H2094; CHIBA T, 1989, AM J PHYSIOL, V256, pE331, DOI 10.1152/ajpendo.1989.256.2.E331; Cortright DN, 2004, EUR J BIOCHEM, V271, P1814, DOI 10.1111/j.1432-1033.2004.04082.x; EMONDSALT X, 1993, EUR J PHARMACOL, V250, P403, DOI 10.1016/0014-2999(93)90027-F; Faraci FM, 2001, AM J PHYSIOL-REG I, V281, pR246, DOI 10.1152/ajpregu.2001.281.1.R246; Gabel SA, 2001, AM J PHYSIOL-HEART C, V280, pH1963, DOI 10.1152/ajpheart.2001.280.5.H1963; GAMSE R, 1982, N-S ARCH PHARMACOL, V320, P205, DOI 10.1007/BF00510129; GRYGLEWSKI R, 1972, BRIT J PHARMACOL, V46, P449, DOI 10.1111/j.1476-5381.1972.tb08142.x; HOLZER P, 1991, PHARMACOL REV, V43, P143; Hoover DB, 2000, JPN J PHARMACOL, V84, P367, DOI 10.1254/jjp.84.367; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896-6273(02)00908-X; Kallner G, 1998, J CARDIOVASC PHARM, V32, P500, DOI 10.1097/00005344-199809000-00023; Kaplan BB, 2004, ANN NY ACAD SCI, V1018, P244, DOI 10.1196/annals.1296.029; Koenig E, 2000, J NEUROSCI, V20, P8390, DOI 10.1523/JNEUROSCI.20-22-08390.2000; Li YJ, 1996, EUR J PHARMACOL, V311, P163, DOI 10.1016/0014-2999(96)00426-8; MAGGI CA, 1995, PROG NEUROBIOL, V45, P1, DOI 10.1016/0301-0082(94)E0017-B; MAGGI CA, 1988, NEUROSCIENCE, V26, P233, DOI 10.1016/0306-4522(88)90140-6; McLean PG, 2002, CIRC RES, V90, P465, DOI 10.1161/hh0402.105372; McLean PG, 1999, BRIT J PHARMACOL, V128, P275, DOI 10.1038/sj.bjp.0702743; Miller AW, 2003, J PHARMACOL EXP THER, V304, P139, DOI 10.1124/jpet.102.041780; Moens AL, 2005, INT J CARDIOL, V100, P179, DOI 10.1016/j.ijcard.2004.04.013; MURPHY E, 1995, CIRC RES, V76, P457, DOI 10.1161/01.RES.76.3.457; Nishiyama M, 1998, EUR J PHARMACOL, V341, P57, DOI 10.1016/S0014-2999(97)01353-8; PREIBISZ JJ, 1993, AM J HYPERTENS, V6, P434, DOI 10.1093/ajh/6.5.434; Rubino A, 1996, CARDIOVASC RES, V31, P467; Schicho R, 2004, EUR J NEUROSCI, V19, P1811, DOI 10.1111/j.1460-9568.2004.03290.x; Shin J, 2002, P NATL ACAD SCI USA, V99, P10150, DOI 10.1073/pnas.152002699; Starkopf J, 1998, CARDIOVASC RES, V37, P66, DOI 10.1016/S0008-6363(97)00240-X; Strecker T, 2005, CARDIOVASC RES, V65, P405, DOI 10.1016/j.cardiores.2004.10.013; Tohda C, 2001, J NEUROCHEM, V76, P1628, DOI 10.1046/j.1471-4159.2001.00193.x; USTINOVA EE, 1995, CARDIOVASC RES, V30, P55, DOI 10.1016/0008-6363(95)00010-0; Verma S, 2002, CIRCULATION, V105, P2332, DOI 10.1161/01.CIR.0000016602.96363.36; Wang DH, 2005, ACTA PHARMACOL SIN, V26, P286, DOI 10.1111/j.1745-7254.2005.00057.x; Wang LH, 2005, CIRCULATION, V112, P3617, DOI 10.1161/CIRCULATIONAHA.105.556274; Webb A, 2004, P NATL ACAD SCI USA, V101, P13683, DOI 10.1073/pnas.0402927101; Wolfrum S, 2005, REGUL PEPTIDES, V127, P217, DOI 10.1016/j.regpep.2004.12.008; Yellon DM, 2000, HEART, V83, P381, DOI 10.1136/heart.83.4.381; Zink MH, 2001, AM J PHYSIOL-HEART C, V280, pH693, DOI 10.1152/ajpheart.2001.280.2.H693	47	57	63	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2695	2703		10.1096/fj.06-7828com	http://dx.doi.org/10.1096/fj.06-7828com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17470568				2022-12-28	WOS:000249237500011
J	Hashimoto, T; Hussien, R; Oommen, S; Gohil, K; Brooks, GA				Hashimoto, Takeshi; Hussien, Rajaa; Oommen, Saji; Gohil, Kishorchandra; Brooks, George A.			Lactate sensitive transcription factor network in L6 cells: activation of MCT1 and mitochondrial biogenesis	FASEB JOURNAL			English	Article						muscle; lactate shuttle; lactate oxidation complex; exercise; cell signaling	HUMAN SKELETAL-MUSCLE; MONOCARBOXYLATE TRANSPORTER; GENE-EXPRESSION; EXERCISE; PGC-1-ALPHA; MEMBRANE; CD147; LDH; INCREASES; OXIDATION	We hypothesized that in addition to serving as a fuel source and gluconeogenic precursor, lactate anion (La-) is a signaling molecule. Therefore, we screened genome-wide responses of L6 cells to elevated ( 10 and 20 mM) sodium-La- added to buffered, high-glucose media. Lactate increased reactive oxygen species (ROS) production and up-regulated 673 genes, many known to be responsive to ROS and Ca2+ . The induction of genes encoding for components of the mitochondrial lactate oxidation complex was confirmed by independent methods (PCR and EMSA). Specifically, lactate increased monocarboxylate transporter-1 (MCT1) mRNA and protein expression within 1 h and cytochrome c oxidase ( COX) mRNA and protein expression in 6 h. Increases in COX coincided with increases in peroxisome proliferator activated-receptor gamma coactivator-1 alpha (PGC1 alpha) expression and the DNA binding activity of nuclear respiratory factor (NRF)-2. We conclude that the lactate signaling cascade involves ROS production and converges on transcription factors affecting mitochondrial biogenesis.	Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Univ Calif Davis, Ctr Comparat Resp Biol & Med, Davis, CA 95616 USA	University of California System; University of California Berkeley; University of California System; University of California Davis	Brooks, GA (corresponding author), Univ Calif Berkeley, Dept Integrat Biol, 5101 VLSB, Berkeley, CA 94720 USA.	gbrooks@berkeley.edu		Brooks, George A./0000-0002-1389-1629	NIAMS NIH HHS [R01 AR050459] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050459] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker SK, 1998, J APPL PHYSIOL, V84, P987, DOI 10.1152/jappl.1998.84.3.987; Bergman BC, 1999, J APPL PHYSIOL, V87, P1684, DOI 10.1152/jappl.1999.87.5.1684; BLAKE DA, 1989, ANAL BIOCHEM, V177, P156, DOI 10.1016/0003-2697(89)90031-6; Bonen A, 2000, AM J PHYSIOL-ENDOC M, V279, pE1131, DOI 10.1152/ajpendo.2000.279.5.E1131; Brooks G. A., 2003, EXERCISE PHYSL PEOPL, P322; Brooks GA, 1998, COMP BIOCHEM PHYS B, V120, P89, DOI 10.1016/S0305-0491(98)00025-X; Brooks GA, 2002, BIOCHEM SOC T, V30, P258, DOI 10.1042/bst0300258; Brooks GA, 1999, P NATL ACAD SCI USA, V96, P1129, DOI 10.1073/pnas.96.3.1129; Brooks GA, 1999, J APPL PHYSIOL, V87, P1713, DOI 10.1152/jappl.1999.87.5.1713; Butz CE, 2004, J APPL PHYSIOL, V97, P1059, DOI 10.1152/japplphysiol.00009.2004; Chabi B, 2005, MED SCI SPORT EXER, V37, P2102, DOI 10.1249/01.mss.0000177426.68149.83; CHEETHAM ME, 1986, J APPL PHYSIOL, V61, P54, DOI 10.1152/jappl.1986.61.1.54; Coles L, 2004, J PHYSIOL-LONDON, V561, P253, DOI 10.1113/jphysiol.2004.073478; Cuff MA, 2002, J PHYSIOL-LONDON, V539, P361, DOI 10.1113/jphysiol.2001.014241; Dubouchaud H, 2000, AM J PHYSIOL-ENDOC M, V278, pE571, DOI 10.1152/ajpendo.2000.278.4.E571; Fasanaro P, 2006, FASEB J, V20, P1242, DOI 10.1096/fj.05-4695fje; Fletcher WM, 1907, J PHYSIOL-LONDON, V35, P247; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; Garcia-Roves PM, 2006, AM J PHYSIOL-ENDOC M, V290, pE1172, DOI 10.1152/ajpendo.00633.2005; Giudice A, 2006, BIOESSAYS, V28, P169, DOI 10.1002/bies.20359; Gutmann I., 1974, METHODS ENZYMATIC AN, P1464; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Hashimoto T, 2005, J PHYSIOL-LONDON, V567, P121, DOI 10.1113/jphysiol.2005.087411; Hashimoto T, 2006, AM J PHYSIOL-ENDOC M, V290, pE1237, DOI 10.1152/ajpendo.00594.2005; Hill AV, 1920, J PHYSIOL-LONDON, V54, P84; Hood DA, 2001, J APPL PHYSIOL, V90, P1137, DOI 10.1152/jappl.2001.90.3.1137; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Koulmann N, 2006, PFLUG ARCH EUR J PHY, V452, P125, DOI 10.1007/s00424-005-0030-9; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Mahoney DJ, 2005, FASEB J, V19, P1498, DOI 10.1096/fj.04-3149fje; McClelland GB, 2003, BIOCHEM BIOPH RES CO, V304, P130, DOI 10.1016/S0006-291X(03)00550-3; McClelland GB, 2002, J APPL PHYSIOL, V92, P1573, DOI 10.1152/japplphysiol.01069.2001; Miller BF, 2005, J APPL PHYSIOL, V98, P856, DOI 10.1152/japplphysiol.00753.2004; MOHAZZAB HKM, 1999, AM J PHYSIOL, V276, pH235; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Moyes CD, 2005, J EXP BIOL, V208, P1601, DOI 10.1242/jeb.01502; Nethery D, 2000, J APPL PHYSIOL, V89, P72, DOI 10.1152/jappl.2000.89.1.72; OHKUWA T, 1984, EUR J APPL PHYSIOL O, V53, P213, DOI 10.1007/BF00776592; Ojuka EO, 2004, P NUTR SOC, V63, P275, DOI 10.1079/PNS2004339; Ongwijitwat S, 2005, GENE, V360, P65, DOI 10.1016/j.gene.2005.06.015; Philp NJ, 2003, INVEST OPHTH VIS SCI, V44, P1305, DOI 10.1167/iovs.02-0552; Richardson RS, 1998, J APPL PHYSIOL, V85, P627, DOI 10.1152/jappl.1998.85.2.627; ROTH DA, 1990, ARCH BIOCHEM BIOPHYS, V279, P386, DOI 10.1016/0003-9861(90)90506-T; ROTH DA, 1990, ARCH BIOCHEM BIOPHYS, V279, P377, DOI 10.1016/0003-9861(90)90505-S; Silveira LR, 2006, BBA-MOL CELL RES, V1763, P969, DOI 10.1016/j.bbamcr.2006.06.010; Smith MA, 2006, RESP PHYSIOL NEUROBI, V151, P229, DOI 10.1016/j.resp.2005.12.011; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Surh YJ, 2005, J NUTR, V135, p2993S, DOI 10.1093/jn/135.12.2993S; TAKIZAWA M, 2006, TOXICOL IN VITRO, DOI DOI 10.1016/J.TIV.2006.1009.1003; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Terada S, 2004, AM J PHYSIOL-ENDOC M, V286, pE208, DOI 10.1152/ajpendo.00051.2003; Wilson MC, 2002, J BIOL CHEM, V277, P3666, DOI 10.1074/jbc.M109658200; Wright DC, 2007, J BIOL CHEM, V282, P194, DOI 10.1074/jbc.M606116200	53	267	278	1	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2602	2612		10.1096/fj.07-8174com	http://dx.doi.org/10.1096/fj.07-8174com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17395833				2022-12-28	WOS:000248454400033
J	Li, JX; Zhang, C; Xu, XQ; Wang, J; Yu, HN; Lai, R; Gong, WM				Li, Jianxu; Zhang, Cheng; Xu, Xueqing; Wang, Jie; Yu, Haining; Lai, Ren; Gong, Weimin			Trypsin inhibitory loop is an excellent lead structure to design serine protease inhibitors and antimicrobial peptides	FASEB JOURNAL			English	Article						trypsin resistance	PROTEINASE-INHIBITOR; MOLECULAR-CLONING; SKIN SECRETIONS; SUNFLOWER SEEDS; BACTERIA	The disulfide-bridged hendecapeptide ( CWTKSIPPKPC) loop, derived from an amphibian skin peptide, is found to have strong trypsin inhibitory capability. This loop, called the trypsin inhibitory loop ( TIL), appears to be the smallest serine protease inhibitor known. A series of synthetic peptides derived from this loop also exhibits trypsin inhibitory activity; some peptides even exhibit both antimicrobial and trypsin inhibitory activities. Antimicrobial peptides are attractive candidates for producing novel antibiotics, but their sensitivity to trypsin-like proteases appreciably limits their application. Bifunctional peptides with both antimicrobial and trypsin inhibitory activities could be ideal candidates for clinical antibiotics, since these reported synthetic peptides have shown resistance against trypsin. The crystal structure of a complex of trypsin with one TIL derivative is solved. The concept of TIL is introduced in this paper. Novel trypsin inhibitors or antimicrobial peptides can be designed readily on the basis of the TIL. Furthermore, functional analysis and a precursor comparison suggest that serine protease inhibitors may have a common ancestor with antimicrobial peptides.	Chinese Acad Sci, Kunming Inst Zool, Biotoxin Unit, Key Lab Anim Models & Human Dis, Kunming 650223, Peoples R China; Chinese Acad Sci, Inst Biophys, Beijing, Peoples R China; Nanjing Agr Univ, Life Sci Coll, Minist Agr, Key Lab Microbiol Engn Agr Environm, Nanjing, Peoples R China; Heibei Normal Univ, Coll Life Sci, Hebei, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; Institute of Biophysics, CAS; Ministry of Agriculture & Rural Affairs; Nanjing Agricultural University; Hebei Normal University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Lai, R (corresponding author), Chinese Acad Sci, Kunming Inst Zool, Biotoxin Unit, Key Lab Anim Models & Human Dis, Kunming 650223, Peoples R China.	rlai@mail.kiz.ac.cn; wgong@ibp.ac.cn	Zhang, Cheng/O-4372-2015; Li, Jianxu/I-5723-2013	Zhang, Cheng/0000-0001-9042-4007; 				BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Christeller JT, 2005, FEBS J, V272, P5710, DOI 10.1111/j.1742-4658.2005.04975.x; Conlon JM, 2004, BBA-PROTEINS PROTEOM, V1696, P1, DOI 10.1016/j.bbapap.2003.09.004; DARVEAU RP, 1991, ANTIMICROB AGENTS CH, V35, P153; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Friedrich CL, 2000, ANTIMICROB AGENTS CH, V44, P2086, DOI 10.1128/AAC.44.8.2086-2092.2000; Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756; Korsinczky MLJ, 2001, J MOL BIOL, V311, P579, DOI 10.1006/jmbi.2001.4887; Lai R, 2002, PEPTIDES, V23, P427, DOI 10.1016/S0196-9781(01)00641-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Luckett S, 1999, J MOL BIOL, V290, P525, DOI 10.1006/jmbi.1999.2891; Mulvenna JP, 2005, J BIOL CHEM, V280, P32245, DOI 10.1074/jbc.M506060200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Prakash B, 1996, J MOL EVOL, V42, P560, DOI 10.1007/BF02352286; Qi RF, 2005, ACTA BIOCH BIOPH SIN, V37, P283, DOI 10.1111/j.1745-7270.2005.00048.x; SIMMACO M, 1994, J BIOL CHEM, V269, P11956; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; ZHANG Y, 1995, J BIOL CHEM, V270, P10246, DOI 10.1074/jbc.270.17.10246	21	57	64	1	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2466	2473		10.1096/fj.06-7966com	http://dx.doi.org/10.1096/fj.06-7966com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17384140				2022-12-28	WOS:000248454400021
J	Noguchi, M; Ropars, V; Roumestand, C; Suizu, F				Noguchi, Masayuki; Ropars, Virginie; Roumestand, Christian; Suizu, Futoshi			Proto-oncogene TCL1: more than just a coactivator for Akt	FASEB JOURNAL			English	Review						protein kinase B; T cell leukemia 1; Akt-PH domain; isoform	PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAIN; ETHER LIPID ANALOGS; T-CELL LEUKEMIA; BACKBONE DYNAMICS; CRYSTAL-STRUCTURE; NGFI-B; SERINE/THREONINE KINASE; TRANSCRIPTION FACTOR; MOLECULAR-BASIS	Serine threonine kinase Akt, also called PKB ( protein kinase B), plays a central role in regulating intracellular survival. Deregulation of this Akt signaling pathway underlies various human neoplastic diseases. Recently, the proto-oncogene TCL1 ( T cell leukemia 1), with a previously unknown physiological function, was shown to interact with the Akt pleckstrin homology domain, enhancing Akt kinase activity; hence, it functions as an Akt kinase coactivator. In contrast to pathological conditions in which the TCL1 gene is highly activated in various human neoplasmic diseases, the physiological expression of TCL1 is tightly limited to early developmental cells as well as various developmental stages of immune cells. The NBRE ( nerve growth factor-responsive element) of the proximal TCL1 promoter sequences can regulate the restricted physiological expression of TCL1 in a negative feedback mechanism. Further, based on the NMR structural studies of Akt-TCL1 protein complexes, an inhibitory peptide, "Akt-in," consisting of the beta A strand of TCL1, has been identified and has therapeutic potential. This review article summarizes and discusses recent advances in the understanding of TCL1-Akt functional interaction in order to clarify the biological action of the proto-oncogene TCL1 family and the development avenues for a suppressive drug specific for Akt, a core intracellular survival regulator. -Noguchi, M., Ropars, V., Roumestand, C., Suizu, F. Protooncogene TCL1: more than just a coactivator for Akt.	Hokkaido Univ, Div Canc Biol, Inst Genet Med, Kita Ku, Sapporo, Hokkaido 0600815, Japan; CNRS, Ctr Biochim Struct, UMR 5048, F-34090 Montpellier, France; Univ Montpellier I, F-34090 Montpellier, France; Univ Montpellier 2, F-34090 Montpellier, France; INSERM, U554, Montpellier, France	Hokkaido University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Noguchi, M (corresponding author), Hokkaido Univ, Div Canc Biol, Inst Genet Med, Kita Ku, N15 W7, Sapporo, Hokkaido 0600815, Japan.	m_noguch@igm.hokudai.ac.jp	Suizu, Futoshi/G-3530-2019	Suizu, Futoshi/0000-0003-0206-4289; Ropars, Virginie/0000-0002-3372-6030; ROUMESTAND, Christian/0000-0002-4082-3293				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Auguin D, 2004, J BIOL CHEM, V279, P35890, DOI 10.1074/jbc.M400364200; Auguin D, 2004, J BIOMOL NMR, V28, P137, DOI 10.1023/B:JNMR.0000013836.62154.c2; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Barr RK, 2004, J BIOL CHEM, V279, P36327, DOI 10.1074/jbc.M402181200; Barthe P, 1999, J BIOMOL NMR, V15, P271, DOI 10.1023/A:1008336418418; Bartkowski JPB, 1997, PHYTOCHEM ANALYSIS, V8, P1, DOI 10.1002/(SICI)1099-1565(199701)8:1<1::AID-PCA328>3.0.CO;2-H; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Castillo SS, 2004, CANCER RES, V64, P2782, DOI 10.1158/0008-5472.CAN-03-1530; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Collins BJ, 2003, EMBO J, V22, P4202, DOI 10.1093/emboj/cdg407; Datta K, 2001, CANCER RES, V61, P1768; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Du KY, 2005, ONCOGENE, V24, P7401, DOI 10.1038/sj.onc.1209099; Dummler B, 2006, MOL CELL BIOL, V26, P8042, DOI 10.1128/MCB.00722-06; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; French SW, 2003, J BIOL CHEM, V278, P948, DOI 10.1074/jbc.M207166200; French SW, 2002, BIOCHEMISTRY-US, V41, P6376, DOI 10.1021/bi016068o; Fu ZQ, 1998, P NATL ACAD SCI USA, V95, P3413, DOI 10.1073/pnas.95.7.3413; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Gills JJ, 2004, EXPERT OPIN INV DRUG, V13, P787, DOI 10.1517/13543784.13.7.787; Gritti C, 1998, BLOOD, V92, P368, DOI 10.1182/blood.V92.2.368.414k39_368_373; Guignard L, 2000, J BIOMOL NMR, V17, P215, DOI 10.1023/A:1008386110930; Hallas C, 1999, P NATL ACAD SCI USA, V96, P14418, DOI 10.1073/pnas.96.25.14418; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hiromura M, 2004, J BIOL CHEM, V279, P53407, DOI 10.1074/jbc.M403775200; Hiromura M, 2006, J BIOL CHEM, V281, P27753, DOI 10.1074/jbc.M602420200; Hoh F, 1998, STRUCTURE, V6, P147, DOI 10.1016/S0969-2126(98)00017-3; Hoyer KK, 2005, J IMMUNOL, V175, P864, DOI 10.4049/jimmunol.175.2.864; Hoyer KK, 2002, P NATL ACAD SCI USA, V99, P14392, DOI 10.1073/pnas.212410199; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; Kang SM, 2005, BLOOD, V105, P1288, DOI 10.1182/blood-2004-04-1453; Kitahara R, 2002, J MOL BIOL, V320, P609, DOI 10.1016/S0022-2836(02)00516-8; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kumar CC, 2005, ONCOGENE, V24, P7493, DOI 10.1038/sj.onc.1209087; Kunstle G, 2002, MOL CELL BIOL, V22, P1513, DOI 10.1128/MCB.22.5.1513-1525.2002; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Laine J, 2002, J BIOL CHEM, V277, P3743, DOI 10.1074/jbc.M107069200; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; MADANI A, 1995, ONCOGENE, V10, P2259; Maruyama K, 1998, INT J ONCOL, V12, P1237; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Meinke G, 1999, NAT STRUCT BIOL, V6, P471; Meuillet EJ, 2003, MOL CANCER THER, V2, P389; MURZIN AG, 1994, J MOL BIOL, V236, P1382, DOI 10.1016/0022-2836(94)90065-5; Narducci MG, 2000, CANCER RES, V60, P2095; Niv MY, 2004, J BIOL CHEM, V279, P1242, DOI 10.1074/jbc.M306723200; Okram B, 2006, CHEM BIOL, V13, P779, DOI 10.1016/j.chembiol.2006.05.015; Ozes ON, 1999, NATURE, V401, P82; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 1999, P NATL ACAD SCI USA, V96, P2949, DOI 10.1073/pnas.96.6.2949; Pekarsky Y, 2001, ONCOGENE, V20, P5638, DOI 10.1038/sj.onc.1204596; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; Pekarsky Y, 2001, JAMA-J AM MED ASSOC, V286, P2308, DOI 10.1001/jama.286.18.2308; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Reuveni H, 2002, BIOCHEMISTRY-US, V41, P10304, DOI 10.1021/bi0202530; Roumestand C, 2001, J MOL BIOL, V312, P247, DOI 10.1006/jmbi.2001.4928; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SOULIER J, 1994, ONCOGENE, V9, P3565; Stambolic V, 2006, TRENDS CELL BIOL, V16, P461, DOI 10.1016/j.tcb.2006.07.001; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; STERN MH, 1993, ONCOGENE, V8, P2475; Teague TK, 1999, P NATL ACAD SCI USA, V96, P12691, DOI 10.1073/pnas.96.22.12691; Teitell M, 1999, P NATL ACAD SCI USA, V96, P9809, DOI 10.1073/pnas.96.17.9809; Teitell MA, 2005, NAT REV CANCER, V5, P640, DOI 10.1038/nrc1672; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Thompson JE, 2004, J CLIN ONCOL, V22, P4217, DOI 10.1200/jco.2004.01.103; Toker A, 2006, CANCER RES, V66, P3963, DOI 10.1158/0008-5472.CAN-06-0743; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Virgilio L, 1998, P NATL ACAD SCI USA, V95, P3885, DOI 10.1073/pnas.95.7.3885; Wanzel M, 2005, NAT CELL BIOL, V7, P30, DOI 10.1038/ncb1202; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yang YS, 1998, J BIOMOL NMR, V11, P337, DOI 10.1023/A:1008279616063; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Zanesi N, 2006, CANCER RES, V66, P915, DOI 10.1158/0008-5472.CAN-05-3426	100	54	56	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2273	2284		10.1096/fj.06-7684com	http://dx.doi.org/10.1096/fj.06-7684com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17360849	Green Submitted			2022-12-28	WOS:000248454400002
J	Konig, S; Mosblech, A; Heilmann, I				Koenig, Sabine; Mosblech, Alina; Heilmann, Ingo			Stress-inducible and constitutive phosphoinositide pools have distinctive fatty acid patterns in Arabidopsis thaliana	FASEB JOURNAL			English	Article						hyperosmotic stress; plant; PtdIns (4,5) P-2 pools; signal transduction	PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; HYPEROSMOTIC STRESS; PHOSPHOLIPASE-C; INOSITOL 1,4,5-TRISPHOSPHATE; RAPID ACCUMULATION; PHOSPHATIDIC-ACID; METABOLISM; PROTEIN; KINASE; GROWTH	Function and development of eukaryotic cells require tight control of diverse physiological processes. Numerous cellular processes are regulated by polyphosphoinositides, which interact with protein partners or mediate release of the second messenger, inositol 1,4,5-trisphosphate (InsP3). Emerging evidence suggests that different regulatory or signaling functions of polyphosphoinositides may be orchestrated by the establishment of distinct subcellular pools; the principles underlying pool-formation are, however, not understood. Arabidopsis plants exhibit transient increases in polyphosphoinositides with hyperosmotic stress, providing a model for comparing constitutive and stress-inducible polyphosphoinositide pools. Using a combination of thin-layer-chromatography and gaschromatography, phospholipids from stressed and nonstressed Arabidopsis plants were analyzed for their associated fatty acids. Under nonstress conditions structural phospholipids and phosphatidylinositol contained 50-70 mol% polyunsaturated fatty acids (PUFA), whereas polyphosphoinositides were more saturated (10-20 mol% PUFA). With hyperosmotic stress polyphosphoinositides with up to 70 mol% PUFA were formed that differed from constitutive species and coincided with a transient loss in unsaturated phosphatidylinositol. The patterns indicate inducible turnover of an unsaturated phosphatidylinositol pool, which accumulates under standard conditions and is primed for phosphorylation on stimulation. Metabolic analysis of wild-type and transgenic plants disturbed in phosphoinositide metabolism suggests that, in contrast to saturated species, unsaturated polyphosphoinositides are channeled toward InsP3-production.	Univ Gottingen, Dept Plant Biochem, Albrecht Haller Inst Plant Sci, D-37077 Gottingen, Germany	University of Gottingen	Heilmann, I (corresponding author), Univ Gottingen, Dept Plant Biochem, Albrecht Haller Inst Plant Sci, Justus Liebig Weg 11, D-37077 Gottingen, Germany.	iheilma@uni-goettingen.de						Balla T, 2006, J ENDOCRINOL, V188, P135, DOI 10.1677/joe.1.06595; Balla T, 2005, J CELL SCI, V118, P2093, DOI 10.1242/jcs.02387; Balla Tamas, 2002, Sci STKE, V2002, ppl3, DOI 10.1126/stke.2002.125.pl3; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; Bonangelino CJ, 2002, J CELL BIOL, V156, P1015, DOI 10.1083/jcb.200201002; Bunney TD, 2000, PLANT CELL, V12, P1679, DOI 10.1105/tpc.12.9.1679; Carricaburu V, 2001, EUR J BIOCHEM, V268, P1238, DOI 10.1046/j.1432-1327.2001.01984.x; CHILVERS ER, 1991, BIOCHEM J, V275, P373, DOI 10.1042/bj2750373; CHO MH, 1992, LC GC-MAG SEP SCI, V10, P464; CHO MH, 1993, PLANT PHYSIOL, V103, P637, DOI 10.1104/pp.103.2.637; CHRISTIE WW, 2003, LIPID ANAL, V15, P142; Collin S, 1999, EUR J BIOCHEM, V262, P652, DOI 10.1046/j.1432-1327.1999.00378.x; Cooke IR, 2006, BIOPHYS J, V91, P487, DOI 10.1529/biophysj.105.078683; Cote G G, 1996, Subcell Biochem, V26, P317; DeWald DB, 2001, PLANT PHYSIOL, V126, P759, DOI 10.1104/pp.126.2.759; Doughman RL, 2003, J MEMBRANE BIOL, V194, P77, DOI 10.1007/s00232-003-2027-7; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Drobak BK, 2000, FEBS LETT, V481, P240, DOI 10.1016/S0014-5793(00)01941-4; DROBAK BK, 1994, PLANT J, V6, P389, DOI 10.1046/j.1365-313X.1994.06030389.x; Guan XL, 2006, YEAST, V23, P465, DOI 10.1002/yea.1362; Hartel H, 2000, P NATL ACAD SCI USA, V97, P10649, DOI 10.1073/pnas.180320497; Heilmann I, 1999, PLANT PHYSIOL, V119, P1331, DOI 10.1104/pp.119.4.1331; Heilmann I, 2001, PLANT PHYSIOL, V126, P1507, DOI 10.1104/pp.126.4.1507; HIRAYAMA T, 1995, P NATL ACAD SCI USA, V92, P3903, DOI 10.1073/pnas.92.9.3903; Hornung E, 2002, EUR J BIOCHEM, V269, P4852, DOI 10.1046/j.1432-1033.2002.03184.x; Janmey PA, 2006, TRENDS CELL BIOL, V16, P538, DOI 10.1016/j.tcb.2006.08.009; Justin AM, 2003, BBA-MOL CELL BIOL L, V1634, P52, DOI 10.1016/j.bbalip.2003.08.006; Justin AM, 2002, EUR J BIOCHEM, V269, P2347, DOI 10.1046/j.1432-1033.2002.02893.x; KING CE, 1987, BIOCHEM J, V244, P209, DOI 10.1042/bj2440209; Kinnunen PKJ, 2000, CELL PHYSIOL BIOCHEM, V10, P243, DOI 10.1159/000016360; Kost B, 1999, J CELL BIOL, V145, P317, DOI 10.1083/jcb.145.2.317; Laloi M, 2007, PLANT PHYSIOL, V143, P461, DOI 10.1104/pp.106.091496; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Liu YM, 1998, BIOCHEM BIOPH RES CO, V245, P684, DOI 10.1006/bbrc.1998.8329; Meijer HJG, 1999, PLANTA, V208, P294; Meijer HJG, 2003, ANNU REV PLANT BIOL, V54, P265, DOI 10.1146/annurev.arplant.54.031902.134748; Milne SB, 2005, J LIPID RES, V46, P1796, DOI 10.1194/jlr.D500010-JLR200; Mueller-Roeber B, 2002, PLANT PHYSIOL, V130, P22, DOI 10.1104/pp.004770; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; Munnik T, 2000, PLANT J, V22, P147, DOI 10.1046/j.1365-313x.2000.00725.x; Munnik T, 2001, TRENDS PLANT SCI, V6, P227, DOI 10.1016/S1360-1385(01)01918-5; Perera IY, 1999, P NATL ACAD SCI USA, V96, P5838, DOI 10.1073/pnas.96.10.5838; Perera IY, 2006, PLANT PHYSIOL, V140, P746, DOI 10.1104/pp.105.075119; Perera IY, 2005, FEBS LETT, V579, P3427, DOI 10.1016/j.febslet.2005.05.018; Perera IY, 2002, PLANT PHYSIOL, V129, P1795, DOI 10.1104/pp.003426; Pettitt TR, 2006, J LIPID RES, V47, P1588, DOI 10.1194/jlr.D600004-JLR200; Phillips SE, 2006, CRIT REV BIOCHEM MOL, V41, P21, DOI 10.1080/10409230500519573; Pical C, 1999, J BIOL CHEM, V274, P38232, DOI 10.1074/jbc.274.53.38232; RANDALL PJ, 1973, PLANT PHYSIOL, V52, P229, DOI 10.1104/pp.52.3.229; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Roy A, 2004, J BIOL CHEM, V279, P44683, DOI 10.1074/jbc.M401583200; Santarius M, 2006, BIOCHEM J, V398, P1, DOI 10.1042/BJ20060565; Schmid AC, 2004, FEBS LETT, V576, P9, DOI 10.1016/j.febslet.2004.08.052; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Stevenson JM, 2000, TRENDS PLANT SCI, V5, P252, DOI 10.1016/S1360-1385(00)01652-6; Suh BC, 2005, CURR OPIN NEUROBIOL, V15, P370, DOI 10.1016/j.conb.2005.05.005; van Meer G, 2005, EMBO J, V24, P3159, DOI 10.1038/sj.emboj.7600798; Vincent P, 2005, J CELL BIOL, V168, P801, DOI 10.1083/jcb.200412074; Wang XM, 2002, CURR OPIN PLANT BIOL, V5, P408, DOI 10.1016/S1369-5266(02)00283-2; Wasteneys GO, 2003, ANNU REV PLANT BIOL, V54, P691, DOI 10.1146/annurev.arplant.54.031902.134818; Welti R, 2004, CURR OPIN PLANT BIOL, V7, P337, DOI 10.1016/j.pbi.2004.03.011; Welti R, 2002, J BIOL CHEM, V277, P31994, DOI 10.1074/jbc.M205375200; Wenk MR, 2004, P NATL ACAD SCI USA, V101, P8262, DOI 10.1073/pnas.0401874101	67	64	67	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					1958	1967		10.1096/fj.06-7887com	http://dx.doi.org/10.1096/fj.06-7887com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17327357				2022-12-28	WOS:000247500300006
J	Offer, T; Ames, BN; Bailey, SW; Sabens, EA; Nozawa, M; Ayling, JE				Offer, Tal; Ames, Bruce N.; Bailey, Steven W.; Sabens, Elizabeth A.; Nozawa, Mamoru; Ayling, June E.			5-Methyltetrahydrofolate inhibits photosensitization reactions and strand breaks in DNA	FASEB JOURNAL			English	Article						folate; folic acid; ultraviolet radiation; singlet oxygen; supercoiled DNA	FOLIC-ACID; MOLECULAR-OXYGEN; ULTRAVIOLET; FOLATE; PHOTOLYSIS; RADIATION; DAMAGE; SKIN; PHOTOOXIDATION; GENERATION	The known functions of folate are to support one-carbon metabolism and to serve as photoreceptors for cryptochromes and photolyases. We demonstrate that 5-methyltetrahydrofolate (5-MTHF, the predominant folate in plasma) is also a potent, near diffusion limited, scavenger of singlet oxygen and quencher of excited photosensitizers. Both pathways result in decomposition of 5-MTHF, although ascorbate can protect against this loss. In the absence of photosensitizers, 5-MTHF is directly decomposed only very slowly by UVA or UVB. Although synthetic folic acid can promote DNA damage by UVA, submicromolar 5-MTHF inhibits photosensitization-induced strand breaks. These observations suggest a new role for reduced folate in protection from ultraviolet damage and have bearing on the hypothesis that folate photodegradation influenced the evolution of human skin color.	Univ S Alabama, Dept Pharmacol, Mobile, AL 36688 USA; CHORI, Nutr & Metab Ctr, Oakland, CA USA	University of South Alabama; Children's Hospital Oakland Research Institute	Ayling, JE (corresponding author), Univ S Alabama, Dept Pharmacol, Rm 3370,MSB,307 N Univ Blvd, Mobile, AL 36688 USA.	jayling@jaguar1.usouthal.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K05AT001323] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068165] Funding Source: NIH RePORTER; NCCIH NIH HHS [K05 AT001323] Funding Source: Medline; NHLBI NIH HHS [HL068165] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ames BN, 2002, NAT REV CANCER, V2, P694, DOI 10.1038/nrc886; BLAZEK ER, 1989, PHOTOCHEM PHOTOBIOL, V49, P607, DOI 10.1111/j.1751-1097.1989.tb08431.x; BRANDA RF, 1978, SCIENCE, V201, P625, DOI 10.1126/science.675247; BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x; CABRERIZO FM, 2007, IN PRESS PHOTOCHEM P; CHOU PT, 1983, BIOCHEM BIOPH RES CO, V115, P932, DOI 10.1016/S0006-291X(83)80024-2; DEVASAGAYAM TPA, 1991, BIOCHEMISTRY-US, V30, P6283, DOI 10.1021/bi00239a029; Fenech M, 2001, MUTAT RES-FUND MOL M, V475, P57, DOI 10.1016/S0027-5107(01)00079-3; FIEL RJ, 1981, CANCER RES, V41, P3543; FIEL RJ, 1982, BIOCHEM BIOPH RES CO, V107, P1067, DOI 10.1016/0006-291X(82)90630-1; Gregory JF, 2001, J NUTR, V131, P1928, DOI 10.1093/jn/131.7.1928; Higgins JR, 2000, BRIT J OBSTET GYNAEC, V107, P1149, DOI 10.1111/j.1471-0528.2000.tb11115.x; Hirakawa K, 2003, ARCH BIOCHEM BIOPHYS, V410, P261, DOI 10.1016/S0003-9861(02)00722-1; Hughes MC, 2006, INT J CANCER, V119, P1953, DOI 10.1002/ijc.22061; Huovinen P, 2006, PHOTOCHEM PHOTOBIOL, V82, P515, DOI 10.1562/2005-07-05-RA-601; Ito K, 1997, BIOL CHEM, V378, P1307; Jablonski NG, 2000, J HUM EVOL, V39, P57, DOI 10.1006/jhev.2000.0403; Kelly P, 1997, AM J CLIN NUTR, V65, P1790, DOI 10.1093/ajcn/65.6.1790; Kift R, 2006, PHOTOCHEM PHOTOBIOL, V82, P579, DOI 10.1562/2005-04-20-RA-494; LEE PCC, 1987, PHOTOCHEM PHOTOBIOL, V45, P79, DOI 10.1111/j.1751-1097.1987.tb08407.x; LIPMAN RSA, 1995, BIOCHEMISTRY-US, V34, P11217, DOI 10.1021/bi00035a030; LOWRY OH, 1949, J BIOL CHEM, V180, P389; Mahns A, 2003, FREE RADICAL RES, V37, P391, DOI 10.1080/1071576031000064702; MISKOSKI S, 1993, PHOTOCHEM PHOTOBIOL, V57, P447, DOI 10.1111/j.1751-1097.1993.tb02317.x; Morrison HI, 1996, JAMA-J AM MED ASSOC, V275, P1893, DOI 10.1001/jama.275.24.1893; Off MK, 2005, J PHOTOCH PHOTOBIO B, V80, P47, DOI 10.1016/j.jphotobiol.2005.03.001; Partch CL, 2005, METHOD ENZYMOL, V393, P726, DOI 10.1016/S0076-6879(05)93038-3; Ravanat JL, 2000, J BIOL CHEM, V275, P40601, DOI 10.1074/jbc.M006681200; Ravanat JL, 2001, J PHOTOCH PHOTOBIO B, V63, P88, DOI 10.1016/S1011-1344(01)00206-8; Stover PJ, 2004, NUTR REV, V62, pS3, DOI 10.1111/j.1753-4887.2004.tb00070.x; STUDER SL, 1989, J AM CHEM SOC, V111, P7643, DOI 10.1021/ja00201a071; Thomas AH, 2000, J PHOTOCH PHOTOBIO A, V135, P147, DOI 10.1016/S1010-6030(00)00304-X; Thomas AH, 2003, PHOTOCH PHOTOBIO SCI, V2, P245, DOI 10.1039/b209993d; Tucker KL, 2005, AM J CLIN NUTR, V82, P627; Vorobey P, 2006, PHOTOCHEM PHOTOBIOL, V82, P817, DOI 10.1562/2005-11-23-RA-739; Wright A, 2003, FREE RADICAL BIO MED, V34, P637, DOI 10.1016/S0891-5849(02)01361-8	36	39	39	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2101	2107		10.1096/fj.06-7513com	http://dx.doi.org/10.1096/fj.06-7513com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17341682				2022-12-28	WOS:000247500300019
J	Sudo, H; Maru, Y				Sudo, Haruka; Maru, Yoshiro			LAPSER1 is a putative cytokinetic tumor suppressor that shows the same centrosome and midbody subcellular localization pattern as p80 katanin	FASEB JOURNAL			English	Article						tetraploid; central spindle; microtubule; Fps; MKLP1	TYROSINE KINASE; SPINDLE POLE; BCR-ABL; PROTEIN; CANCER; CELLS; GROWTH; INTERACTS; MITOSIS; PHOSPHORYLATION	Prostate cancer is one of the most common cancers in men, with more than 500,000 new worldwide cases reported annually, resulting in 200,000 deaths of mainly older men in developed countries. Existing treatments have not proved very effective in managing prostate cancer, and continuing efforts therefore are ongoing to explore novel targets and strategies for future therapies. LAPSER1 has been identified as a candidate tumor suppressor gene in prostate cancer, but its true functions remain unknown. We report here that LAPSER1 colocalizes to the centrosomes and midbodies in mitotic cells with gamma-tubulin, MKLP1, and p80 katanin, and is involved in cytokinesis. Moreover, RNAi-mediated disruption of LAPSER1, which is accompanied by the mislocalization of p80 katanin, results in malformation of the central spindle. Significantly, the enhanced expression of LAPSER1 induces binucleation and renders the cells resistant to oncogenic transformation. In cells transformed by the v-Fps oncogene, overexpressed LAPSER1 induces abortive cytokinesis, followed by mitotic catastrophe in a p80 katanin-dependent manner. Cells that are rescued from this apoptotic pathway with Z-VAD-fmk display karyokinesis. These results suggest that LAPSER1 participates in cytokinesis by interacting with p80 katanin, the disruption of which may potentially cause genetic instability and cancer.	Tokyo Womens Med Univ, Dept Pharmacol, Shinjuku Ku, Tokyo 1628666, Japan	Tokyo Women's Medical University	Maru, Y (corresponding author), Tokyo Womens Med Univ, Dept Pharmacol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	ymaru@research.twmu.ac.jp	Sudo, Haruka/GWC-9919-2022					ARIIZUMI K, 1985, J VIROL, V55, P660, DOI 10.1128/JVI.55.3.660-669.1985; Buster D, 2002, J CELL SCI, V115, P1083; Cabeza-Arvelaiz Y, 2001, ONCOGENE, V20, P6707, DOI 10.1038/sj.onc.1204866; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Errico A, 2004, HUM MOL GENET, V13, P2121, DOI 10.1093/hmg/ddh223; Fabbro M, 2005, DEV CELL, V9, P477, DOI 10.1016/j.devcel.2005.09.003; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Gromley A, 2005, CELL, V123, P75, DOI 10.1016/j.cell.2005.07.027; Hartman JJ, 1998, CELL, V93, P277, DOI 10.1016/S0092-8674(00)81578-0; Ishii H, 2001, P NATL ACAD SCI USA, V98, P10374, DOI 10.1073/pnas.181222898; Karabay A, 2004, J NEUROSCI, V24, P5778, DOI 10.1523/JNEUROSCI.1382-04.2004; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Konno D, 2002, J CELL SCI, V115, P4695, DOI 10.1242/jcs.00127; Kuriyama R, 2002, J CELL BIOL, V156, P783, DOI 10.1083/jcb.200109090; Laurent CE, 2004, MOL CELL BIOL, V24, P9351, DOI 10.1128/MCB.24.21.9351-9358.2004; Margolis RL, 2005, CANCER CELL, V8, P353, DOI 10.1016/j.ccr.2005.10.017; McNally KP, 2000, J CELL SCI, V113, P1623; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; Rajaraman R, 2005, CELL BIOL INT, V29, P1084, DOI 10.1016/j.cellbi.2005.10.003; Reagan-Shaw S, 2005, FASEB J, V19, P611, DOI 10.1096/fj.04-2910fje; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Takahashi S, 2003, J BIOL CHEM, V278, P49129, DOI 10.1074/jbc.C300289200; Takeda N, 1999, P NATL ACAD SCI USA, V96, P203, DOI 10.1073/pnas.96.1.203; Vinogradov AE, 2001, GENOME, V44, P350, DOI 10.1139/gen-44-3-350; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140; Yu WQ, 2005, J NEUROSCI, V25, P5573, DOI 10.1523/JNEUROSCI.0834-05.2005	31	31	34	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					2086	2100		10.1096/fj.06-7254com	http://dx.doi.org/10.1096/fj.06-7254com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17351128				2022-12-28	WOS:000247500300018
J	Batkai, S; Osei-Hyiaman, D; Pan, H; El-Assal, O; Rajesh, M; Mukhopadhyay, P; Hong, F; Harvey-White, J; Jafri, A; Hasko, G; Huffman, JW; Gao, B; Kunos, G; Pacher, P				Batkai, Sandor; Osei-Hyiaman, Douglas; Pan, Hao; El-Assal, Osama; Rajesh, Mohanraj; Mukhopadhyay, Partha; Hong, Feng; Harvey-White, Judith; Jafri, Anjum; Hasko, Gyorgy; Huffman, John W.; Gao, Bin; Kunos, George; Pacher, Pal			Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury	FASEB JOURNAL			English	Article						endocannabinoids; anandamide; 2-arachidonoylglycerol; peroxynitrite; oxidative stress	ENDOCANNABINOID SYSTEM; CB2 RECEPTOR; REPERFUSION INJURY; ISCHEMIA-REPERFUSION; N-ACYLETHANOLAMINES; HEMODYNAMIC PROFILE; ADHESION MOLECULES; LIVER-INJURY; ANANDAMIDE; ACTIVATION	Hepatic ischemia-reperfusion (I/R) injury continues to be a fatal complication that can follow liver surgery or transplantation. We have investigated the involvement of the endocannabinoid system in hepatic I/R injury using an in vivo mouse model. Here we report that I/R triggers several-fold increases in the hepatic levels of the endocannabinoids anandamide and 2-arachidonoylglycerol, which originate from hepatocytes, Kupffer, and endothelial cells. The I/R-induced increased tissue endocannabinoid levels positively correlate with the degree of hepatic damage and serum TNF- alpha, MIP- 1 alpha, and MIP- 2 levels. Furthermore, a brief exposure of hepatocytes to various oxidants (H2O2 and peroxynitrite) or inflammatory stimuli (endotoxin and TNF-alpha) also increases endocannabinoid levels. Activation of CB2 cannabinoid receptors by JWH133 protects against I/R damage by decreasing inflammatory cell infiltration, tissue and serum TNF-alpha, MIP-1 alpha and MIP- 2 levels, tissue lipid peroxidation, and expression of adhesion molecule ICAM- 1 in vivo. JWH133 also attenuates the TNF-alpha-induced ICAM-1 and VCAM- 1 expression in human liver sinusoidal endothelial cells (HLSECs) and the adhesion of human neutrophils to HLSECs in vitro. Consistent with the protective role of CB2 receptor activation, CB2-/- mice develop increased I/R-induced tissue damage and proinflammatory phenotype. These findings suggest that oxidative/nitrosative stress and inflammatory stimuli may trigger endocannabinoid production, and indicate that targeting CB2 cannabinoid receptors may represent a novel protective strategy against I/R injury. We also demonstrate that CB2-/- mice have a normal hemodynamic profile.-Batkai, S., Osei-Hyiaman, D., Pan, H., El-Assal, O., Rajesh, M., Mukhopadhyay, P., Hong, F., Harvey-White, J., Jafri, A., Hasko, G., Huffman, J. W., Gao, B., Kunos, G., Pacher, P. Cannabinoid-2 receptor mediates protection against hepatic ischemia/ reperfusion injury.	NIAAA, Sect Oxidat Stress & Tissue Injury, Lab Physiol Studies, NIH, Bethesda, MD 20892 USA; Univ Med & Dent New Jersey, Dept Surg, New Jersey Med Sch, Newark, NJ 07103 USA; Clemson Univ, Howard L Hunter Chem Lab, Clemson, SC 29631 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Rutgers State University New Brunswick; Rutgers State University Medical Center; Clemson University	Pacher, P (corresponding author), NIAAA, Sect Oxidat Stress & Tissue Injury, Lab Physiol Studies, NIH, 5625 Fishers Lane,MSC-9413, Bethesda, MD 20892 USA.	pacher@mail.nih.gov	MUKHOPADHYAY, PARTHA/G-3890-2010; Mohanraj, Rajesh/L-1798-2019; Batkai, Sandor/G-3889-2010; Batkai, Sandor/H-7983-2014; Pacher, Pal/B-6378-2008	MUKHOPADHYAY, PARTHA/0000-0002-1178-1274; Pacher, Pal/0000-0001-7036-8108; Mohanraj, Rajesh/0000-0003-2660-2184; Osei-Hyiaman, Douglas/0000-0002-2725-5519; Pan, Hao/0000-0001-9925-0752	Intramural NIH HHS [Z01 AA000375-02] Funding Source: Medline; NIDA NIH HHS [R01 DA003590, DA03590] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000369, Z01AA000351, Z01AA000368, Z01AA000375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003590] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Arai T, 1998, CIRC RES, V82, P540, DOI 10.1161/01.RES.82.5.540; Batkai S, 2004, CIRCULATION, V110, P1996, DOI 10.1161/01.CIR.0000143230.23252.D2; Batkai S, 2004, AM J PHYSIOL-HEART C, V287, pH595, DOI 10.1152/ajpheart.00184.2004; Batkai S, 2001, NAT MED, V7, P827, DOI 10.1038/89953; Berger C, 2004, J NEUROCHEM, V88, P1159, DOI 10.1046/j.1471-4159.2003.02244.x; Bhunia AK, 1998, J BIOL CHEM, V273, P34349, DOI 10.1074/jbc.273.51.34349; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; CARLOS TM, 1994, BLOOD, V84, P2068; Di Filippo C, 2004, J LEUKOCYTE BIOL, V75, P453, DOI 10.1189/jlb.0703303; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Elmes SJR, 2005, PAIN, V118, P327, DOI 10.1016/j.pain.2005.09.005; Elmes SJR, 2004, EUR J NEUROSCI, V20, P2311, DOI 10.1111/j.1460-9568.2004.03690.x; Engeli S, 2005, DIABETES, V54, P2838, DOI 10.2337/diabetes.54.10.2838; Fan CG, 1999, J MOL MED, V77, P577, DOI 10.1007/s001099900029; Gabbay E, 2005, LIVER INT, V25, P921, DOI 10.1111/j.1478-3231.2005.01180.x; Gebremedhin D, 1999, AM J PHYSIOL-HEART C, V276, pH2085, DOI 10.1152/ajpheart.1999.276.6.H2085; Hayakawa K, 2004, NEUROREPORT, V15, P2381, DOI 10.1097/00001756-200410250-00016; Huffman JW, 2005, MINI-REV MED CHEM, V5, P641, DOI 10.2174/1389557054368844; Huffman JW, 1999, BIOORGAN MED CHEM, V7, P2905, DOI 10.1016/S0968-0896(99)00219-9; Husted Thomas L, 2005, Curr Opin Investig Drugs, V6, P508; Jaeschke H, 2003, GASTROENTEROLOGY, V125, P1246, DOI 10.1016/S0016-5085(03)01209-5; Jaeschke H, 1996, TOXICOL APPL PHARM, V139, P213, DOI 10.1006/taap.1996.0160; Jaeschke H, 1997, AM J PHYSIOL-GASTR L, V273, pG602, DOI 10.1152/ajpgi.1997.273.3.G602; Jaeschke H, 2006, AM J PHYSIOL-GASTR L, V290, pG1083, DOI 10.1152/ajpgi.00568.2005; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050; Kimball ES, 2006, AM J PHYSIOL-GASTR L, V291, pG364, DOI 10.1152/ajpgi.00407.2005; Klein TW, 2005, NAT REV IMMUNOL, V5, P400, DOI 10.1038/nri1602; Kunos G, 2006, NAT MED, V12, P607, DOI 10.1038/nm0606-608; Kupiec-Weglinski JW, 2005, TRANSPL P, V37, P1653, DOI 10.1016/j.transproceed.2005.03.134; Lamontagne D, 2006, ARCH MAL COEUR VAISS, V99, P242; Leker RR, 2003, STROKE, V34, P2000, DOI 10.1161/01.STR.0000079817.68944.1E; Liaudet L, 2002, INFECT IMMUN, V70, P192, DOI 10.1128/IAI.70.1.192-198.2002; Liu J, 2000, BIOCHEM J, V346, P835, DOI 10.1042/0264-6021:3460835; Louw DF, 2000, BRAIN RES, V857, P183, DOI 10.1016/S0006-8993(99)02422-1; Mallat A, 2006, J Endocrinol Invest, V29, P58; Maresz K, 2005, J NEUROCHEM, V95, P437, DOI 10.1111/j.1471-4159.2005.03380.x; Massa F, 2005, J MOL MED, V83, P944, DOI 10.1007/s00109-005-0698-5; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Mauler F, 2002, J PHARMACOL EXP THER, V302, P359, DOI 10.1124/jpet.302.1.359; Milman G, 2006, P NATL ACAD SCI USA, V103, P2428, DOI 10.1073/pnas.0510676103; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Muthian S, 2004, NEUROSCIENCE, V129, P743, DOI 10.1016/j.neuroscience.2004.08.044; Nagayama T, 1999, J NEUROSCI, V19, P2987; Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103; Ohkohchi N, 1999, TRANSPLANT P, V31, P1055, DOI 10.1016/S0041-1345(98)01902-2; Osei-Hyiaman D, 2005, J CLIN INVEST, V115, P1298, DOI 10.1172/JCI200523057; Pacher P, 2005, HANDB EXP PHARMACOL, V168, P599; Pacher P, 2006, PHARMACOL REV, V58, P87, DOI 10.1124/pr.58.1.6; Pacher P, 2005, BRIT J PHARMACOL, V146, P313, DOI 10.1038/sj.bjp.0706332; Pacher P, 2005, NEUROPHARMACOLOGY, V48, P1130, DOI 10.1016/j.neuropharm.2004.12.005; Pacher P, 2005, AM J PHYSIOL-HEART C, V289, pH533, DOI 10.1152/ajpheart.00107.2005; Pacher P, 2004, J PHYSIOL-LONDON, V558, P647, DOI 10.1113/jphysiol.2004.064824; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Parmentier-Batteur S, 2002, J NEUROSCI, V22, P9771, DOI 10.1523/jneurosci.22-22-09771.2002; Pertwee RG, 2005, HANDB EXP PHARMACOL, V168, P1; Schabitz WR, 2002, STROKE, V33, P2112, DOI 10.1161/01.STR.0000023491.63693.18; SCHMID PC, 1995, FEBS LETT, V375, P117, DOI 10.1016/0014-5793(95)01194-J; Siegmund SV, 2006, J BIOL CHEM, V281, P10431, DOI 10.1074/jbc.M509706200; Siegmund SV, 2005, HEPATOLOGY, V41, P1085, DOI 10.1002/hep.20667; Sinor AD, 2000, NEUROSCI LETT, V278, P157, DOI 10.1016/S0304-3940(99)00922-2; Szabo Gabor, 2005, Current Vascular Pharmacology, V3, P215, DOI 10.2174/1570161054368599; Teixeira-Clerc F, 2006, NAT MED, V12, P671, DOI 10.1038/nm1421; Walter L, 2004, BRIT J PHARMACOL, V141, P775, DOI 10.1038/sj.bjp.0705667; Wang L, 2003, P NATL ACAD SCI USA, V100, P1393, DOI 10.1073/pnas.0336351100; Zamora-Valdes Daniel, 2005, Ann Hepatol, V4, P248	67	194	219	2	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1788	1800		10.1096/fj.06-7451com	http://dx.doi.org/10.1096/fj.06-7451com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17327359	Green Accepted			2022-12-28	WOS:000246866500021
J	Cayla, C; Todiras, M; Iliescu, R; Saul, VV; Gross, V; Pilz, B; Chai, GX; Merino, VF; Pesquero, JB; Baltatu, OC; Bader, M				Cayla, Cecile; Todiras, Mihail; Iliescu, Radu; Saul, Vera V.; Gross, Volkmar; Pilz, Bernhard; Chai, Guixuan; Merino, Vanessa F.; Pesquero, Joao B.; Baltatu, Ovidiu C.; Bader, Michael			Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension	FASEB JOURNAL			English	Article						bradykinin; blood pressure; endotoxemia	BRADYKININ B-2 RECEPTOR; NITRIC-OXIDE SYNTHASE; NORMAL BLOOD-PRESSURE; AORTIC ENDOTHELIAL-CELLS; KNOCKOUT MICE; CONVERTING-ENZYME; SEPTIC SHOCK; ESCHERICHIA-COLI; ANIMAL-MODELS; B2 RECEPTORS	Kinins play a central role in the modulation of cardiovascular function and in the pathophysiology of inflammation. These peptides mediate their effects by binding to two specific G-protein coupled receptors named B1 and B2. To evaluate the full functional relevance of the kallikrein- kinin system, we generated mice lacking both kinin receptors (B1B2-/-). Because of the close chromosomal position of both kinin receptor genes, B1B2-/- mice could not be obtained by simple breeding of the single knockout lines. Therefore, we inactivated the B1 receptor gene by homologous recombination in embryonic stem cells derived from B2-deficient animals. The B1B2-/- mice exhibited undetectable levels of mRNAs for both receptors and a lack of response to bradykinin (B2 agonist) and des-Arg(9)-bradykinin (B1 agonist), as attested by contractility studies with isolated smooth muscle tissues. B1B2-/- mice are healthy and fertile, and no sign of cardiac abnormality was detected. They are normotensive but exhibit a lower heart rate than controls. Furthermore, kinin receptor deficiency affects the pathogenesis of endotoxin- induced hypotension. While blood pressure decreased markedly in wild-type mice and B2-/- and moderately in B1-/- mice after bacterial lipopolysaccharide ( LPS) injection, blood pressure remained unchanged in B1B2-/- mice. These results clearly demonstrate a pivotal role of kinins and their receptors in hypotension induced by endotoxemia in mice.-Cayla, C., Todiras, M., Iliescu, R., Saul, V. V., Gross, V., Pilz, B., Chai, G., Merino, V. F., Pesquero, J. B., Baltatu, O. C., Bader, M. Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; HELIOS Klin, Franz Volhard Clin, D-13092 Berlin, Germany; Univ Fed Sao Paulo, Escola Paulista Med, Dept Biophys, BR-04023062 Sao Paulo, Brazil	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Franz-Volhard Clinical Research Center; Helios Kliniken; Universidade Federal de Sao Paulo (UNIFESP)	Bader, M (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	mbader@mdc-berlin.de	Todiras, Mihail/AAT-4426-2020; Pesquero, Joao/C-1470-2012; Bader, Michael/K-2124-2013; Baltatu, Ovidiu Constantin/E-5890-2011; Iliescu, Radu/C-5116-2011	Todiras, Mihail/0000-0002-9373-4753; Pesquero, Joao/0000-0002-4507-632X; Baltatu, Ovidiu Constantin/0000-0001-9732-6039; Iliescu, Radu/0000-0002-9124-577X; Bader, Michael/0000-0003-4780-4164				Bae SW, 2003, BIOCHEM BIOPH RES CO, V306, P981, DOI 10.1016/S0006-291X(03)01086-6; BAO G, 1992, HYPERTENSION, V20, P74, DOI 10.1161/01.HYP.20.1.74; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BORKOWSKI JA, 1995, J BIOL CHEM, V270, P13706, DOI 10.1074/jbc.270.23.13706; Cardoso CC, 2004, BIOL CHEM, V385, P295, DOI 10.1515/BC.2004.025; Cecile CA, 2002, INT IMMUNOPHARMACOL, V2, P1721, DOI 10.1016/S1567-5769(02)00175-3; CHULAK C, 1995, BRIT J PHARMACOL, V115, P330, DOI 10.1111/j.1476-5381.1995.tb15881.x; DAMAS J, 1979, BIOMED EXPRESS, V31, P249; DORLEANSJUSTE P, 1989, BRIT J PHARMACOL, V96, P920, DOI 10.1111/j.1476-5381.1989.tb11903.x; Duka A, 2006, AM J PHYSIOL-ENDOC M, V291, pE268, DOI 10.1152/ajpendo.00382.2005; Duka I, 2001, CIRC RES, V88, P275, DOI 10.1161/01.RES.88.3.275; Emanueli C, 1999, CIRCULATION, V100, P2359, DOI 10.1161/01.CIR.100.23.2359; Fein AM, 1997, JAMA-J AM MED ASSOC, V277, P482, DOI 10.1001/jama.277.6.482; Feletou M, 1996, J CARDIOVASC PHARM, V27, P500, DOI 10.1097/00005344-199604000-00008; Figueroa CD, 2001, BIOL REPROD, V64, P1590, DOI 10.1095/biolreprod64.6.1590; FLEMING I, 1992, J CARDIOVASC PHARM, V20, pS135, DOI 10.1097/00005344-199204002-00038; HAYASHI I, 1985, THROMB RES, V39, P313, DOI 10.1016/0049-3848(85)90227-0; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; Ignjatovic T, 2004, MOL PHARMACOL, V66, P1310, DOI 10.1124/mol.104.001990; KALTER ES, 1983, J INFECT DIS, V148, P682, DOI 10.1093/infdis/148.4.682; KATORI M, 1989, BRIT J PHARMACOL, V98, P1383, DOI 10.1111/j.1476-5381.1989.tb12688.x; Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6; LORTIE M, 1992, AM J PHYSIOL, V262, pR72, DOI 10.1152/ajpregu.1992.262.1.R72; Lu JL, 1996, BIOCHEM BIOPH RES CO, V225, P1, DOI 10.1006/bbrc.1996.1121; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Madeddu P, 1997, CIRCULATION, V96, P3570; Maestri R, 2003, HYPERTENSION, V41, P1151, DOI 10.1161/01.HYP.0000064180.55222.DF; MAJIMA M, 1993, HYPERTENSION, V22, P705, DOI 10.1161/01.HYP.22.5.705; Marceau F, 1998, PHARMACOL REV, V50, P357; McLean PG, 2000, CARDIOVASC RES, V48, P194, DOI 10.1016/S0008-6363(00)00184-X; McLean PG, 1999, BRIT J PHARMACOL, V128, P275, DOI 10.1038/sj.bjp.0702743; Meneton P, 2001, P NATL ACAD SCI USA, V98, P2634, DOI 10.1073/pnas.051619598; Milia AF, 2001, HYPERTENSION, V37, P1473, DOI 10.1161/01.HYP.37.6.1473; MINSHALL RD, 1994, CIRC RES, V74, P441, DOI 10.1161/01.RES.74.3.441; Monsees TK, 2002, BIOL REPROD, V67, P1832, DOI 10.1095/biolreprod.102.005207; Morinelli TA, 2001, J PHARMACOL EXP THER, V296, P71; NIES AS, 1968, CIRC RES, V22, P155, DOI 10.1161/01.RES.22.2.155; OTTERBEIN L, 1993, AGENTS ACTIONS, V39, pC125, DOI 10.1007/BF01972742; Pesquero JB, 2006, BIOL CHEM, V387, P119, DOI 10.1515/BC.2006.017; Pesquero JB, 2000, P NATL ACAD SCI USA, V97, P8140, DOI 10.1073/pnas.120035997; Qadri F, 1999, J HYPERTENS, V17, P1265, DOI 10.1097/00004872-199917090-00005; REGOLI D, 1980, PHARMACOL REV, V32, P1; Rhaleb NE, 1999, HYPERTENSION, V33, P329, DOI 10.1161/01.HYP.33.1.329; Robertson E J, 1997, Methods Mol Biol, V75, P173; SALVEMINI D, 1990, P NATL ACAD SCI USA, V87, P2593, DOI 10.1073/pnas.87.7.2593; Schanstra JP, 2003, AM J PHYSIOL-HEART C, V284, pH1904, DOI 10.1152/ajpheart.01150.2002; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; Trabold F, 2002, HYPERTENSION, V40, P90, DOI 10.1161/01.HYP.0000021747.43346.95; UENO A, 1995, BRIT J PHARMACOL, V114, P1250, DOI 10.1111/j.1476-5381.1995.tb13340.x; Venema RC, 2002, INT IMMUNOPHARMACOL, V2, P1755, DOI 10.1016/S1567-5769(02)00185-6; Vincent JL, 2000, AM J RESP CRIT CARE, V161, P1781, DOI 10.1164/ajrccm.161.6.9812004; WHALLEY ET, 1992, AGENT ACTION SUPPL, V38, P413; Yang XP, 1997, HYPERTENSION, V30, P735, DOI 10.1161/01.HYP.30.3.735; Yang XP, 2001, CIRC RES, V88, P1072, DOI 10.1161/hh1001.090759	56	80	82	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1689	1698		10.1096/fj.06-7175com	http://dx.doi.org/10.1096/fj.06-7175com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17289925				2022-12-28	WOS:000246866500010
J	Lorand, L				Lorand, Laszlo			Crosslinks in blood: transglutaminase and beyond	FASEB JOURNAL			English	Biographical-Item									Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Lorand, L (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Ward Bldg,Room 7-334,303 E Chicago Ave, Chicago, IL 60611 USA.	l-lorand@northwestern.edu							0	18	20	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2007	21	8					1627	1632		10.1096/fj.07-0602ufm	http://dx.doi.org/10.1096/fj.07-0602ufm			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17538029				2022-12-28	WOS:000246866500002
J	Roda-Navarro, P; Reyburn, HT				Roda-Navarro, Pedro; Reyburn, Hugh T.			Intercellular protein transfer at the NK cell immune synapse: mechanisms and physiological significance	FASEB JOURNAL			English	Review						membrane connective structure/nanotube	NATURAL-KILLER-CELLS; ANTIGEN-PRESENTING CELLS; CLASS-I MOLECULES; COMPLEX CLASS-I; T-CELLS; CUTTING EDGE; TARGET-CELLS; IMMUNOLOGICAL SYNAPSE; DENDRITIC CELLS; TUMOR-CELLS	Immune synapses ( IS) are supramolecular clusters providing intercellular communication among cells of the immune system. While the physiological role and consequences of IS formation are beginning to be understood, these studies have given rise to a new research topic in the biology of lymphocyte interactions: synaptic transfer of proteins between lymphocytes. During natural killer ( NK) cell immunosurveillance, clustering and transfer of receptor and ligand molecules have been observed at both the inhibitory and cytotoxic NK cell immune synapse ( NK-IS). The transfer of activating receptors seems to be associated with receptor distribution to thin membrane connective structures ( MCS)/ nanotubes that communicate effector and susceptible target cells. Strikingly, bidirectional transfer of the activating receptor NKG2D and its cellular ligand MICB correlates with a reduction in NK cell cytotoxic function. In this regard, synaptic uptake of MICB may represent a novel strategy of tumor immune evasion. Finally, synaptic acquisition of receptors by NK cells may also favor the spread of pathogens. In this review we discuss possible mechanisms of synaptic protein transfer and propose different testable hypotheses about the physiological and pathological significance of this process for NK cell function.-Roda-Navarro, P., Reyburn, H. T. Intercellular protein transfer at the NK cell immune synapse: mechanisms and physiological significance.	Univ Cambridge, Dept Pathol, Cambridge CB2 1TN, England	University of Cambridge	Roda-Navarro, P (corresponding author), Tennis Court Rd, Cambridge CB2 1QP, England.	pr284@cam.ac.uk; ht20@hermes.cam.ac.uk	Reyburn, Hugh T/B-4338-2009	Reyburn, Hugh T/0000-0003-2855-1595	Medical Research Council [G9800943] Funding Source: Medline; MRC [G9800943] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arnold PY, 1999, EUR J IMMUNOL, V29, P1363, DOI 10.1002/(SICI)1521-4141(199904)29:04<1363::AID-IMMU1363>3.0.CO;2-0; Arnon TI, 2004, BLOOD, V103, P664, DOI 10.1182/blood-2003-05-1716; Barcia C, 2006, J EXP MED, V203, P2095, DOI 10.1084/jem.20060420; Batista FD, 2001, NATURE, V411, P489, DOI 10.1038/35078099; BECKER JC, 1991, J IMMUNOL, V147, P4398; Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747; Biassoni R, 2001, IMMUNOL REV, V181, P203, DOI 10.1034/j.1600-065X.2001.1810117.x; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Black P H, 1980, Adv Cancer Res, V32, P75, DOI 10.1016/S0065-230X(08)60361-9; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Carlin LM, 2001, J EXP MED, V194, P1507, DOI 10.1084/jem.194.10.1507; Carrasco YR, 2004, IMMUNITY, V20, P589, DOI 10.1016/S1074-7613(04)00105-0; Carretero M, 1997, EUR J IMMUNOL, V27, P563, DOI 10.1002/eji.1830270230; Clayton A, 2005, BLOOD CELL MOL DIS, V34, P206, DOI 10.1016/j.bcmd.2005.03.003; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000; Coudert JD, 2005, BLOOD, V106, P1711, DOI 10.1182/blood-2005-03-0918; DAI JW, 1995, BIOPHYS J, V68, P988, DOI 10.1016/S0006-3495(95)80274-2; Davis DM, 1999, P NATL ACAD SCI USA, V96, P15062, DOI 10.1073/pnas.96.26.15062; Doucey MA, 2004, NAT IMMUNOL, V5, P328, DOI 10.1038/ni1043; Eisele G, 2006, BRAIN, V129, P2416, DOI 10.1093/brain/awl205; Eleme K, 2004, J EXP MED, V199, P1005, DOI 10.1084/jem.20032194; Eriksson M, 1999, J EXP MED, V190, P1005, DOI 10.1084/jem.190.7.1005; Fassett MS, 2001, P NATL ACAD SCI USA, V98, P14547, DOI 10.1073/pnas.211563598; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; Fuchs A, 2004, J IMMUNOL, V172, P3994, DOI 10.4049/jimmunol.172.7.3994; Gonzalez S, 2006, CURR TOP MICROBIOL, V298, P121; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Hanna J, 2004, J CLIN INVEST, V114, P1612, DOI 10.1172/JCI200422787; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; Huang JF, 1999, SCIENCE, V286, P952, DOI 10.1126/science.286.5441.952; Hudrisier D, 2005, EUR J IMMUNOL, V35, P2284, DOI 10.1002/eji.200526266; Hudrisier D, 2001, J IMMUNOL, V166, P3645, DOI 10.4049/jimmunol.166.6.3645; Hudrisier D, 2002, FASEB J, V16, P477, DOI 10.1096/fj.01-0933rev; Hwang I, 2000, J EXP MED, V191, P1137, DOI 10.1084/jem.191.7.1137; Hwang IY, 2003, P NATL ACAD SCI USA, V100, P6670, DOI 10.1073/pnas.1131852100; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; Joly E, 2003, NAT IMMUNOL, V4, P815, DOI 10.1038/ni0903-815; Jones SA, 2002, BBA-MOL CELL RES, V1592, P251, DOI 10.1016/S0167-4889(02)00319-1; Kopcow HD, 2005, P NATL ACAD SCI USA, V102, P15563, DOI 10.1073/pnas.0507835102; Kovar M, 2006, P NATL ACAD SCI USA, V103, P11671, DOI 10.1073/pnas.0603466103; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Long EO, 2001, IMMUNOL REV, V181, P223, DOI 10.1034/j.1600-065X.2001.1810119.x; Lopez-Botet M, 2004, TISSUE ANTIGENS, V63, P195, DOI 10.1111/j.1399-0039.2004.00210.x; Matala E, 2001, J IMMUNOL, V167, P1617, DOI 10.4049/jimmunol.167.3.1617; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Moretta A, 2002, NAT REV IMMUNOL, V2, P957, DOI 10.1038/nri956; Moretta A, 2005, CURR OPIN IMMUNOL, V17, P306, DOI 10.1016/j.coi.2005.03.004; Moretta L, 2004, EMBO J, V23, P255, DOI 10.1038/sj.emboj.7600019; MOSTBOCK S, 2006, BLOOD; Nakajima H, 2000, HUM IMMUNOL, V61, P39, DOI 10.1016/S0198-8859(99)00170-6; O'Keefe JP, 2004, P NATL ACAD SCI USA, V101, P9351, DOI 10.1073/pnas.0305965101; Onfelt B, 2004, J IMMUNOL, V173, P1511, DOI 10.4049/jimmunol.173.3.1511; Oppenheim DE, 2005, NAT IMMUNOL, V6, P928, DOI 10.1038/ni1239; Orange JS, 2003, P NATL ACAD SCI USA, V100, P14151, DOI 10.1073/pnas.1835830100; PETERS PJ, 1990, IMMUNOL TODAY, V11, P28; PETERS PJ, 1989, EUR J IMMUNOL, V19, P1469, DOI 10.1002/eji.1830190819; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Raucher D, 2000, J CELL BIOL, V148, P127, DOI 10.1083/jcb.148.1.127; Roda-Navarro P, 2004, J IMMUNOL, V173, P3640, DOI 10.4049/jimmunol.173.6.3640; Roda-Navarro P, 2006, P NATL ACAD SCI USA, V103, P11258, DOI 10.1073/pnas.0600721103; Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133; Salih HR, 2006, HUM IMMUNOL, V67, P188, DOI 10.1016/j.humimm.2006.02.008; Salih HR, 2003, BLOOD, V102, P1389, DOI 10.1182/blood-2003-01-0019; Salih HR, 2002, J IMMUNOL, V169, P4098, DOI 10.4049/jimmunol.169.8.4098; San Jose E, 1999, J BIOL CHEM, V274, P33740, DOI 10.1074/jbc.274.47.33740; Sancho D, 2000, J CELL BIOL, V149, P1249, DOI 10.1083/jcb.149.6.1249; Sanni TB, 2004, MOL BIOL CELL, V15, P3210, DOI 10.1091/mbc.E03-11-0779; Sentman C L, 1995, Semin Immunol, V7, P109, DOI 10.1006/smim.1995.0015; Sheetz MP, 2001, NAT REV MOL CELL BIO, V2, P392, DOI 10.1038/35073095; Shi M, 2001, J IMMUNOL, V167, P123, DOI 10.4049/jimmunol.167.1.123; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sjostrom A, 2001, J EXP MED, V194, P1519, DOI 10.1084/jem.194.10.1519; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; Suzuki T, 2001, J IMMUNOL, V166, P5567, DOI 10.4049/jimmunol.166.9.5567; Tabiasco J, 2003, J IMMUNOL, V170, P5993, DOI 10.4049/jimmunol.170.12.5993; Tabiasco J, 2002, EUR J IMMUNOL, V32, P1502, DOI 10.1002/1521-4141(200205)32:5<1502::AID-IMMU1502>3.0.CO;2-Y; Tangye SG, 1999, J IMMUNOL, V162, P6981; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; Togo T, 2000, MOL BIOL CELL, V11, P4339, DOI 10.1091/mbc.11.12.4339; Treanor B, 2006, J CELL BIOL, V174, P153, DOI 10.1083/jcb.200601108; Upshaw JL, 2006, NAT IMMUNOL, V7, P524, DOI 10.1038/ni1325; Vanherberghen B, 2004, P NATL ACAD SCI USA, V101, P16873, DOI 10.1073/pnas.0406240101; Vilen BJ, 1999, IMMUNITY, V10, P239, DOI 10.1016/S1074-7613(00)80024-2; Vyas YM, 2002, IMMUNOL REV, V189, P161, DOI 10.1034/j.1600-065X.2002.18914.x; Vyas YM, 2002, J IMMUNOL, V168, P3150, DOI 10.4049/jimmunol.168.7.3150; Vyas YM, 2001, J IMMUNOL, V167, P4358, DOI 10.4049/jimmunol.167.8.4358; Waldhauer I, 2006, CANCER RES, V66, P2520, DOI 10.1158/0008-5472.CAN-05-2520; Wu JD, 2004, J CLIN INVEST, V114, P560, DOI 10.1172/JCI200422206; Zavazava N, 1996, NAT MED, V2, P1005, DOI 10.1038/nm0996-1005; Zimmer J, 2001, J EXP MED, V194, P1531, DOI 10.1084/jem.194.10.1531	91	32	32	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1636	1646		10.1096/fj.06-7488rev	http://dx.doi.org/10.1096/fj.06-7488rev			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314139				2022-12-28	WOS:000246866500005
J	Thamilselvan, V; Craig, DH; Basson, MD				Thamilselvan, Vijayalakshmi; Craig, David H.; Basson, Marc D.			FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway	FASEB JOURNAL			English	Article						integrin affinity; membrane translocation; p85 subunit; Akt isoforms; physical forces; mechanotransduction	PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; PHOSPHOINOSITIDE 3-KINASE; KINASE-B; INDEPENDENT ACTIVATION; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; PI3 KINASE; IN-VITRO; INTEGRIN	Cancer cell adhesion is traditionally viewed as random, occurring if the cell's receptors match the substrate. Cancer cells are subjected to pressure and shear during growth against a constraining stroma, surgical manipulation, and passage through the venous and lymphatic system. Cells shed into a cavity such as the abdomen postoperatively also experience increased pressure from postoperative edema. Increased extracellular pressure stimulates integrin-mediated cancer cell adhesion via FAK and Src. PI 3- kinase ( PI3K) inhibitors ( LY294002 or wortmannin), Akt inhibitors, or Akt1 siRNA blocked adhesion stimulated by 15 mmHg pressure in SW620 or primary human malignant colonocytes. Pressure activated PI3K, tyrosine-phosphorylated and membrane- translocated the p85 subunit, and phosphorylated Akt. PI3K inhibitor ( LY294002) prevented pressure-stimulated Akt Ser473 and FAK Tyr397, but not FAK576 or Src416 phosphorylation. PP2 inhibited PI3K activity and Akt phosphorylation. FAK siRNA did not affect pressure- induced PI3K activation but blocked Akt phosphorylation. Pressure also stimulated FAK or FAKY397F mutant translocation to the membrane. Akt inhibitor IV blocked pressure- induced Akt and FAK translocation. Pressure activated Src- and PI3K- dependently induced p85 interaction with FAK, and FAK with beta 1 integrin. These results delineate a novel force-activated inside-out Src/ PI3K/FAK/Akt pathway by which cancer cells regulate their own adhesion. These signals may be potential targets for inhibition of metastatic adhesion.-Thamilselvan V., Craig D. H., Basson M. D. FAK association with multiple signal proteins mediates pressure- induced colon cancer cell adhesion via a Src- dependent PI3K/ Akt pathway.	John D Dingell VA Med Ctr, Dept Surg, Detroit, MI 48201 USA; Wayne State Univ, Detroit, MI 48202 USA	Wayne State University	Basson, MD (corresponding author), John D Dingell VA Med Ctr, Dept Surg, 4646 John R St, Detroit, MI 48201 USA.	marc.basson@va.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060771] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK60771] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Akagi T, 2002, MOL CELL BIOL, V22, P7015, DOI 10.1128/MCB.22.20.7015-7023.2002; Balasubramanian S, 2003, J BIOL CHEM, V278, P42214, DOI 10.1074/jbc.M303428200; Barry FA, 2002, J BIOL CHEM, V277, P12874, DOI 10.1074/jbc.M200482200; Basson MD, 2000, J CELL BIOCHEM, V78, P47, DOI 10.1002/(SICI)1097-4644(20000701)78:1<47::AID-JCB5>3.0.CO;2-M; Bongiorno-Borbone L, 2002, J NEUROCHEM, V81, P1212, DOI 10.1046/j.1471-4159.2002.00906.x; Brancaccio M, 2006, CARDIOVASC RES, V70, P422, DOI 10.1016/j.cardiores.2005.12.015; Chan ASH, 1997, J IMMUNOL, V159, P934; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Coffey JC, 2005, J BIOL CHEM, V280, P20968, DOI 10.1074/jbc.M414696200; Conway WC, 2006, J CELL BIOCHEM, V98, P1507, DOI 10.1002/jcb.20819; Cooper CR, 2002, NEOPLASIA, V4, P191, DOI 10.1038/sj.neo.7900224; Cospedal R, 1999, CARDIOVASC RES, V41, P708, DOI 10.1016/S0008-6363(98)00232-6; Crossthwaite AJ, 2004, J NEUROCHEM, V88, P1127, DOI 10.1046/j.1471-4159.2004.02257.x; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Franchini KG, 2000, CIRC RES, V87, P558, DOI 10.1161/01.RES.87.7.558; Gerszten RE, 2001, J BIOL CHEM, V276, P26846, DOI 10.1074/jbc.M011235200; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Gorin Y, 2001, FASEB J, V15, P1909, DOI 10.1096/fj..01-0165com; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; Hunger-Glaser I, 2004, J CELL PHYSIOL, V200, P213, DOI 10.1002/jcp.20018; Itoh N, 2002, CANCER, V94, P3127, DOI 10.1002/cncr.10591; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; Kang I, 1998, EXP MOL MED, V30, P263, DOI 10.1038/emm.1998.39; Kermorgant S, 2001, CARCINOGENESIS, V22, P1035, DOI 10.1093/carcin/22.7.1035; Kim RD, 2001, J SURG RES, V100, P176, DOI 10.1006/jsre.2001.6225; Kinashi T, 1999, J IMMUNOL, V162, P2850; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Koshida R, 2005, ARTERIOSCL THROM VAS, V25, P2548, DOI 10.1161/01.ATV.0000188511.84138.9b; Lezama R, 2005, J NEUROCHEM, V93, P1189, DOI 10.1111/j.1471-4159.2005.03110.x; Ling LX, 1999, J CELL BIOCHEM, V73, P533; Lymn JS, 1999, ARTERIOSCL THROM VAS, V19, P2133, DOI 10.1161/01.ATV.19.9.2133; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Miao H, 2002, BIOCHEM BIOPH RES CO, V292, P892, DOI 10.1006/bbrc.2002.6750; Mohri T, 1999, EXP CELL RES, V253, P533, DOI 10.1006/excr.1999.4720; Morel JCM, 2002, J BIOL CHEM, V277, P34679, DOI 10.1074/jbc.M206337200; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Nguyen KT, 2000, ONCOGENE, V19, P5385, DOI 10.1038/sj.onc.1203911; Ortiz PA, 2004, AM J PHYSIOL-RENAL, V287, pF281, DOI 10.1152/ajprenal.00383.2003; Papakonstanti EA, 2003, MOL ENDOCRINOL, V17, P870, DOI 10.1210/me.2002-0253; Pavalko FM, 2003, J CELL PHYSIOL, V194, P194, DOI 10.1002/jcp.10221; Phillips WA, 1998, CANCER, V83, P41, DOI 10.1002/(SICI)1097-0142(19980701)83:1<41::AID-CNCR6>3.0.CO;2-H; Qin SF, 2003, BIOCHEMISTRY-US, V42, P2995, DOI 10.1021/bi0205911; Resendiz JC, 2003, MOL PHARMACOL, V63, P639, DOI 10.1124/mol.63.3.639; Sasamoto A, 2005, AM J PHYSIOL-CELL PH, V288, pC1012, DOI 10.1152/ajpcell.00314.2004; Sawai H, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-37; Sawhney RS, 2004, J BIOL CHEM, V279, P47379, DOI 10.1074/jbc.M402031200; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shen TL, 2001, FEBS LETT, V499, P176, DOI 10.1016/S0014-5793(01)02545-5; Shimizu Y, 1996, IMMUNOL TODAY, V17, P565, DOI 10.1016/S0167-5699(96)10061-X; Siu MKY, 2005, J BIOL CHEM, V280, P25029, DOI 10.1074/jbc.M501049200; Skaletz-Rorowski A, 2003, CARDIOVASC RES, V57, P253, DOI 10.1016/S0008-6363(02)00618-1; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; Takahashi N, 1999, CIRC RES, V84, P1194, DOI 10.1161/01.RES.84.10.1194; Tapia JA, 1999, BBA-MOL CELL RES, V1448, P486, DOI 10.1016/S0167-4889(98)00157-8; Thamilselvan V, 2004, GASTROENTEROLOGY, V126, P8, DOI 10.1053/j.gastro.2003.10.078; Thamilselvan V, 2005, CARCINOGENESIS, V26, P1687, DOI 10.1093/carcin/bgi135; Trusolino L, 2000, FASEB J, V14, P1629, DOI 10.1096/fj.14.11.1629; van Zyp JV, 2006, CANCER BIOL THER, V5, P1169; van Zyp JV, 2004, AM J SURG, V188, P467, DOI 10.1016/j.amjsurg.2004.07.005; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; von Willebrand M, 1998, J BIOL CHEM, V273, P3994, DOI 10.1074/jbc.273.7.3994; Walsh MF, 2003, CELL PHYSIOL BIOCHEM, V13, P135, DOI 10.1159/000071864; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135; Wojciak-Stothard B, 2003, J CELL BIOL, V161, P429, DOI 10.1083/jcb.200210135; Wu X, 2004, BJU INT, V93, P143, DOI 10.1111/j.1464-410X.2004.04574.x; Yap CL, 2002, BLOOD, V99, P151, DOI 10.1182/blood.V99.1.151; Zell T, 1996, J IMMUNOL, V156, P883	76	134	140	3	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1730	1741		10.1096/fj.06-6545com	http://dx.doi.org/10.1096/fj.06-6545com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17317726				2022-12-28	WOS:000246866500015
J	Eliyahu, E; Park, JH; Shtraizent, N; He, X; Schuchman, EH				Eliyahu, Efrat; Park, Jae-Ho; Shtraizent, Nataly; He, Xingxuan; Schuchman, Edward H.			Acid ceramidase is a novel factor required for early embryo survival	FASEB JOURNAL			English	Article						apoptosis; oocytes; ceramide	FARBER-DISEASE; MOUSE OOCYTES; SPHINGOLIPIDS; BIOSYNTHESIS; HYDROLYSIS; ACTIVATION; TRANSITION; APOPTOSIS; CLONING; DEATH	Recent studies suggest that the lipid, ceramide, induces the default apoptosis process in eggs. Yet, it is obscure how newly formed embryos overcome this fate. Acid ceramidase ( AC) is a key regulatory enzyme involved in ceramide metabolism, and mutations in the AC gene ( Asah1) result in Farber Lipogranulomatosis, a fatal human genetic disorder. Our previous studies revealed that AC knockout ( Asah1-/-) mice had a lethal phenotype, and herein we reveal the mechanism underlying this observation. A single- cell, polymerase chain reaction ( PCR) genotyping method was developed to analyze individual embryos from Asah1 +/- intercrosses. Combined with Annexin V staining, this genotype analysis demonstrated that Asah1-/- embryos could not survive beyond the 2- cell stage, and underwent apoptotic death. Notably, sphingosine-1-phosphate ( S1P) treatment of early 2- cell embryos from the Asah1 +/- intercrosses rescued Asah1-/- embryos, and enabled their progression from the 2- cell to 4 - 8- cell stage. Quantitative PCR also revealed that expression of the Asah1 gene in healthy embryos was initiated at the 2- cell stage, coincident with embryonic genome activation ( EGA). AC activity and Western blot analyses further demonstrated high expression and activity of the enzyme in normal, unfertilized eggs, which likely provide the protein to newly formed embryos prior to EGA. Based on these observations, we suggest that AC is an essential factor required for embryo survival that functions by removing ceramide from the newly formed embryos, thus inhibiting the default apoptosis pathway.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Schuchman, EH (corresponding author), Mt Sinai Sch Med, Dept Human Genet, 1425 Madison Ave, New York, NY 10029 USA.	edward.schuchman@mssm.edu			NIDDK NIH HHS [R01 DK54830] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054830] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; Chan A, 1998, HISTOCHEM CELL BIOL, V110, P553, DOI 10.1007/s004180050317; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Eliyahu E, 2002, BIOL REPROD, V67, P189, DOI 10.1095/biolreprod67.1.189; FLACH G, 1982, EMBO J, V1, P681, DOI 10.1002/j.1460-2075.1982.tb01230.x; GATT S, 1963, J BIOL CHEM, V238, P3131; GATT S, 1966, J BIOL CHEM, V241, P3724; Gordo AC, 2002, BIOL REPROD, V66, P1828, DOI 10.1095/biolreprod66.6.1828; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HASSLER DF, 1993, ADV LIPID RES, V26, P49; Kattner E, 1997, EUR J PEDIATR, V156, P292, DOI 10.1007/s004310050603; Kerr J. F. R., 1994, CELL BIOL LAB HDB, P319; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Li CM, 1999, GENOMICS, V62, P223, DOI 10.1006/geno.1999.5940; Li CM, 2002, GENOMICS, V79, P218, DOI 10.1006/geno.2002.6686; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; Linke, 2001, METABOLIC MOL BASES, P3573; MARSTON JH, 1964, J EXP ZOOL, V155, P237, DOI 10.1002/jez.1401550211; Miao YL, 2005, BIOL REPROD, V73, P1025, DOI 10.1095/biolreprod.105.043703; Ohanian J, 2001, CELL MOL LIFE SCI, V58, P2053, DOI 10.1007/PL00000836; Perez GI, 2005, FASEB J, V19, P860, DOI 10.1096/fj.04-2903fje; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Tarin JJ, 1999, BIOL REPROD, V61, P1347, DOI 10.1095/biolreprod61.5.1347; TELFORD NA, 1990, MOL REPROD DEV, V26, P90, DOI 10.1002/mrd.1080260113; van Lijnschoten G, 2000, PEDIATR DEVEL PATHOL, V3, P597, DOI 10.1007/s100240010107	27	72	84	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1403	1409		10.1096/fj.06-7016com	http://dx.doi.org/10.1096/fj.06-7016com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264167				2022-12-28	WOS:000246117000016
J	Levy, V; Lindon, C; Zheng, Y; Harfe, BD; Morgan, BA				Levy, Vered; Lindon, Catherine; Zheng, Ying; Harfe, Brian D.; Morgan, Bruce A.			Epidermal stem cells arise from the hair follicle after wounding	FASEB JOURNAL			English	Article						infundibulum; epidermis; follicular bulge; wound healing	LABEL-RETAINING CELLS; MOUSE EPIDERMIS; PROLIFERATIVE UNIT; SKIN; IDENTIFICATION; EPITHELIA; KINETICS; BEHAVIOR; HEDGEHOG	During normal development, the epidermis and hair follicle are distinct lineage compartments maintained by independent stem cell populations. Both epidermal and follicular keratinocytes are recruited to participate in epidermal repair in response to injury. However, it is generally thought that follicular cells contribute to the wound epidermis only transiently and are ultimately replaced by the progeny of stem cells derived from the original epidermal compartment prior to wounding. Here we use inducible and constitutive cre recombinase expressed from the Sonic hedgehog locus ( Shh) for in vivo lineage tracing. This analysis confirms that follicular cells participate in the initial resurfacing of the wound but also reveals that their progeny persist in wound epidermis for months after the wound is healed. It further demonstrates that Shh is not induced in keratinocytes during the wound healing process. We conclude that follicular cells can undergo reprogramming to become long-term repopulating epidermal progenitors following wounding.	Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA USA; Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32611 USA	Harvard University; Massachusetts General Hospital; Harvard University; State University System of Florida; University of Florida	Morgan, BA (corresponding author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, 149 13th St, Charlestown, MA 02129 USA.	bruce.morgan@cbrc2.mgh.harvard.edu						ALLEN TD, 1974, J CELL SCI, V15, P291; ARGYRIS TS, 1977, AM J PATHOL, V88, P575; BICKENBACH JR, 1981, J DENT RES, V60, P1611, DOI 10.1177/002203458106000311011; Bickenbach JR, 1998, EXP CELL RES, V244, P184, DOI 10.1006/excr.1998.4163; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Braun KM, 2003, DEVELOPMENT, V130, P5241, DOI 10.1242/dev.00703; Coulombe PA, 1997, BIOCHEM BIOPH RES CO, V236, P231, DOI 10.1006/bbrc.1997.6945; Gambardella L, 2003, CURR OPIN CELL BIOL, V15, P771, DOI 10.1016/j.ceb.2003.10.011; Ghazizadeh S, 2001, EMBO J, V20, P1215, DOI 10.1093/emboj/20.6.1215; Harfe BD, 2004, CELL, V118, P517, DOI 10.1016/j.cell.2004.07.024; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Kaur P, 2006, J INVEST DERMATOL, V126, P1450, DOI 10.1038/sj.jid.5700184; Levy V, 2005, DEV CELL, V9, P855, DOI 10.1016/j.devcel.2005.11.003; MACKENZIE IC, 1985, CELL TISSUE RES, V242, P551; MACKENZIE IC, 1970, NATURE, V226, P653, DOI 10.1038/226653a0; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; MORRIS RJ, 1994, CELL PROLIFERAT, V27, P279, DOI 10.1111/j.1365-2184.1994.tb01425.x; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; MORRIS RJ, 1986, CANCER RES, V46, P3061; Oro AE, 2003, DEV BIOL, V255, P238, DOI 10.1016/S0012-1606(02)00042-8; POTTEN CS, 1975, J CELL SCI, V17, P413; POTTEN CS, 1988, J CELL SCI, P45; POTTEN CS, 1974, CELL TISSUE KINET, V7, P77, DOI 10.1111/j.1365-2184.1974.tb00401.x; Schneider TE, 2003, P NATL ACAD SCI USA, V100, P11412, DOI 10.1073/pnas.2034935100; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Tudor D, 2004, J INVEST DERM SYMP P, V9, P208, DOI 10.1111/j.1087-0024.2004.09310.x; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436	28	290	307	1	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1358	1366		10.1096/fj.06-6926com	http://dx.doi.org/10.1096/fj.06-6926com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17255473				2022-12-28	WOS:000246117000011
J	Schnitzler, MMY; Waring, J; Gudermann, T; Chubanov, V				Schnitzler, Michael Mederos y; Waering, Janine; Gudermann, Thomas; Chubanov, Vladimir			Evolutionary determinants of divergent calcium selectivity of TRPM channels	FASEB JOURNAL			English	Article						transient receptor potential; TRPM2; TRPM7; TRPM8; nudix	CATION CHANNEL; ION-CHANNEL; ADP-RIBOSE; FUNCTIONAL-CHARACTERIZATION; MOLECULAR DETERMINANTS; SECONDARY HYPOCALCEMIA; CRYSTAL-STRUCTURE; KINASE DOMAIN; PROTEIN; IDENTIFICATION	The mammalian TRPM gene family can be subdivided into distinct categories of cation channels that are either highly permeable for Ca(2+) (TRPM3/6/7), nonselective (TRPM2/8), or even Ca(2+) impermeable (TRPM4/5). TRPM6/7 are fused to alpha-kinase domains, whereas TRPM2 is linked to an ADPribose phosphohydrolase (Nudix domain). At a molecular level, the evolutionary steps that gave rise to the structural and functional TRPM channel diversity remain elusive. Here, we provide phylogenetic evidence that Nudix-linked channels represent an ancestral type of TRPMs that is present in various phyla, ranging from protists to humans. Surprisingly, the pore-forming segments of invertebrate TRPM2-like proteins display high sequence similarity to those of Ca(2+)-selective TRPMs, while human TPPM2 is characterized by a loss of several conserved residues. Using the patch-clamp technique, Ca(2+) imaging, and site-directed mutagenesis, we demonstrate that restoration of only two "ancient" pore residues in human TRPM2 (Q981E/P983Y) significantly increased (similar to 4-fold) its permeability for Ca(2+) Conversely, introduction of a "modern" sequence motif into mouse TRPM7 (EI047Q/YI049P) resulted in the loss of Ca(2+) permeation and a linear TRPM2-like current-voltage relationship. Overall, our findings provide an integrative view on the evolution of the domain architecture and the structural basis of the distinct ion permeation profiles of TRPM channels.	[Schnitzler, Michael Mederos y; Waering, Janine; Gudermann, Thomas; Chubanov, Vladimir] Univ Marburg, Inst Pharmakol & Toxikol, D-35043 Marburg, Germany	Philipps University Marburg	Chubanov, V (corresponding author), Univ Marburg, Inst Pharmakol & Toxikol, Karl Von Frisch Str 1, D-35043 Marburg, Germany.	chubanov@staff.uni-marburg.de						Baubet V, 2000, P NATL ACAD SCI USA, V97, P7260, DOI 10.1073/pnas.97.13.7260; Chubanov V, 2005, N-S ARCH PHARMACOL, V371, P334, DOI 10.1007/s00210-005-1056-4; Chubanov V, 2004, P NATL ACAD SCI USA, V101, P2894, DOI 10.1073/pnas.0305252101; Chubanov V, 2007, J BIOL CHEM, V282, P7656, DOI 10.1074/jbc.M611117200; Demeuse P, 2006, J GEN PHYSIOL, V127, P421, DOI 10.1085/jgp.200509410; Estevez AY, 2003, J GEN PHYSIOL, V122, P207, DOI 10.1085/jgp.200308804; Garcia-Martinez C, 2000, J BIOL CHEM, V275, P32552, DOI 10.1074/jbc.M002391200; Grimm C, 2003, J BIOL CHEM, V278, P21493, DOI 10.1074/jbc.M300945200; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; Hofmann T, 2003, CURR BIOL, V13, P1153, DOI 10.1016/S0960-9822(03)00431-7; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jung S, 2003, J BIOL CHEM, V278, P3562, DOI 10.1074/jbc.M211484200; Kaske S, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-49; Kozak JA, 2005, J GEN PHYSIOL, V126, P499, DOI 10.1085/jgp.200509324; Kozak JA, 2003, BIOPHYS J, V84, P922, DOI 10.1016/S0006-3495(03)74909-1; KUHN FJ, 2007, J BIOL CHEM, V277, P23150; Kuhn FJP, 2004, J BIOL CHEM, V279, P46431, DOI 10.1074/jbc.M407263200; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; Li M, 2006, J GEN PHYSIOL, V127, P525, DOI 10.1085/jgp.200609502; Li MJ, 2007, J BIOL CHEM, V282, P25817, DOI 10.1074/jbc.M608972200; Liu CH, 2007, J NEUROSCI, V27, P604, DOI 10.1523/JNEUROSCI.4099-06.2007; Liu D, 2003, P NATL ACAD SCI USA, V100, P15160, DOI 10.1073/pnas.2334159100; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; Nilius B, 2007, BBA-MOL BASIS DIS, V1772, P805, DOI 10.1016/j.bbadis.2007.02.002; Oberwinkler J, 2005, J BIOL CHEM, V280, P22540, DOI 10.1074/jbc.M503092200; Owsianik G, 2006, ANNU REV PHYSIOL, V68, P685, DOI 10.1146/annurev.physiol.68.040204.101406; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Perraud AL, 2005, J BIOL CHEM, V280, P6138, DOI 10.1074/jbc.M411446200; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pieper U, 2006, NUCLEIC ACIDS RES, V34, pD291, DOI 10.1093/nar/gkj059; Poelwijk FJ, 2007, NATURE, V445, P383, DOI 10.1038/nature05451; Prawitt D, 2003, P NATL ACAD SCI USA, V100, P15166, DOI 10.1073/pnas.2334624100; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Saito S, 2006, PHYSIOL GENOMICS, V27, P219, DOI 10.1152/physiolgenomics.00322.2005; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Shen BW, 2003, J MOL BIOL, V332, P385, DOI 10.1016/S0022-2836(03)00954-9; Shi N, 2006, NATURE, V440, P570, DOI 10.1038/nature04508; Teramoto T, 2005, CELL METAB, V1, P343, DOI 10.1016/j.cmet.2005.04.007; Topala CN, 2007, CELL CALCIUM, V41, P513, DOI 10.1016/j.ceca.2006.10.003; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; Voets T, 2004, J BIOL CHEM, V279, P19, DOI 10.1074/jbc.M311201200; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200; Vriens J, 2004, PFLUG ARCH EUR J PHY, V449, P213, DOI 10.1007/s00424-004-1314-1; West RJ, 2001, GENE, V266, P103, DOI 10.1016/S0378-1119(01)00373-0; Wilding M, 1998, AM J PHYSIOL-CELL PH, V275, pC1277, DOI 10.1152/ajpcell.1998.275.5.C1277; Yamaguchi H, 2001, MOL CELL, V7, P1047, DOI 10.1016/S1097-2765(01)00256-8	56	55	55	2	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2008	22	5					1540	1551		10.1096/fj.07-9694com	http://dx.doi.org/10.1096/fj.07-9694com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18073331				2022-12-28	WOS:000255898700026
J	Avignolo, C; Bagnasco, L; Biasotti, B; Melchiori, A; Tomati, V; Bauer, I; Salis, A; Chiossone, L; Mingari, MC; Orecchia, P; Carnemolla, B; Neri, D; Zardi, L; Parodi, S				Avignolo, C.; Bagnasco, L.; Biasotti, B.; Melchiori, A.; Tomati, V.; Bauer, I.; Salis, A.; Chiossone, L.; Mingari, M. C.; Orecchia, P.; Carnemolla, B.; Neri, D.; Zardi, L.; Parodi, S.			Internalization via Antennapedia protein transduction domain of an scFv antibody toward c-Myc protein	FASEB JOURNAL			English	Article						intracellular delivery; PTD; miniantibody; fluorescence labeling; oncoprotein targeting	CELL; PEPTIDES; INHIBITORS; MEMBRANE; DELIVERY; HELIX-1; POTENT	We constructed a single-chain variable fragment miniantibody (G11-scFv) directed toward the transactivation. domain of c-Myc, which is fused with the internalization domain Int of Antennapedia at its carboxyl terminus (a cargo-carrier construct). In ELISA experiments, an EC50 for binding saturation was achieved at concentrations of G11-scFv-Int(-) of similar to 10(-8) M. Internalization of a fluoresceinated Fl-G11-scFv-Int(+) construct was observed in intact human cultured cells with confocal microscopy. After 5 h of incubation in medium containing 1 mu M Fl-G11-scFv-Int(+) or Fl-G11-scFv-Int(-), fluorescence intensity was determined in individual cells, both for cytoplasmic and nuclear compartments: concentration levels of Fl-G11-scFv-Int(+), relative to the extracellular culture medium concentration, were 4-5 times higher in the cytoplasm, 7-8 times higher in the nucleus, and 10 times higher in the nucleoli. In the same experimental conditions, the Fl-G11-scFv-Int(-) construct was 3-4 times more concentrated outside of the cells than inside. Cell membranes kept their integrity after 5 h of incubation. The antiproliferative activity of our miniantibody was studied on HCT116 cells. Incubation with 4 mu M G11-scFv-Int(+) for 4 days induced very significant statistical and biological growth inhibition, whereas Int alone was completely inactive. Miniantibodies capable of penetrating cell membranes dramatically broaden the potential for innovative therapeutic agents and attack of new targets.	[Avignolo, C.; Bagnasco, L.; Biasotti, B.; Tomati, V.; Bauer, I.; Parodi, S.] Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy; [Salis, A.] Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy; [Salis, A.; Mingari, M. C.] Univ Genoa, Dept Expt Med, I-16132 Genoa, Italy; [Avignolo, C.; Bagnasco, L.; Biasotti, B.; Melchiori, A.; Parodi, S.] Natl Canc Inst IST, Expt Oncol Lab, Genoa, Italy; [Chiossone, L.; Mingari, M. C.; Carnemolla, B.] Natl Canc Inst IST, Immunol Lab, Genoa, Italy; [Bagnasco, L.; Biasotti, B.; Parodi, S.] ISO, Genoa, Italy; [Orecchia, P.] Inst Giannina Gaslini, Genoa, Italy; [Neri, D.] Swiss Fed Inst Technol, Inst Pharmaceut Sci, Dept Chem & Appl Biosci, Zurich, Switzerland; [Zardi, L.] Adv Biotechnol Ctr, Lab Innovat Therapies, Genoa, Italy	University of Genoa; University of Genoa; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini; Swiss Federal Institutes of Technology Domain; ETH Zurich	Bagnasco, L (corresponding author), Univ Genoa, Dept Oncol Biol & Genet, L Go R Benzi 10, I-16132 Genoa, Italy.	luca.bagnasco@unige.it	Neri, Dario/P-4368-2016; orecchia, paola/AAH-3509-2019; Mingari, Maria Cristina/AAB-1315-2019; Tomati, Valeria/AAB-4543-2021; Chiossone, Laura/D-3062-2011; Salis, Annalisa/R-9241-2018	Neri, Dario/0000-0001-5234-7370; Tomati, Valeria/0000-0003-3761-1916; Chiossone, Laura/0000-0002-9097-5869; orecchia, paola/0000-0003-0556-9784; Salis, Annalisa/0000-0002-3082-2908				Albrecht H, 2006, CANCER BIOTHER RADIO, V21, P285, DOI 10.1089/cbr.2006.21.285; Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833; Bagnasco L, 2007, FASEB J, V21, P1256, DOI 10.1096/fj.06-7082com; BRINKLEY M, 1992, BIOCONJUGATE CHEM, V3, P2, DOI 10.1021/bc00013a001; Carnemolla B, 1996, INT J CANCER, V68, P397, DOI 10.1002/(SICI)1097-0215(19961104)68:3<397::AID-IJC20>3.3.CO;2-D; Cohen-Saidon C, 2003, BLOOD, V102, P2506, DOI 10.1182/blood-2002-12-3921; Colby DW, 2004, P NATL ACAD SCI USA, V101, P17616, DOI 10.1073/pnas.0408134101; Corey DR, 2007, NAT CHEM BIOL, V3, P8, DOI 10.1038/nchembio0107-8; CREIGHTON TE, 1984, PROTEINS STRUCTURE A, P6; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; Hanes J, 2000, NAT BIOTECHNOL, V18, P1287, DOI 10.1038/82407; HAZLETT T, 2004, PRINCIPLES FLUORESCE, V2004, P14; Heng BC, 2005, MED HYPOTHESES, V64, P1105, DOI 10.1016/j.mehy.2005.01.011; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hermeking H, 2003, CURR CANCER DRUG TAR, V3, P163, DOI 10.2174/1568009033481949; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; LAMB NJ, 1996, FRONT BIOSCI, V1, P19; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6; McCormick F, 2000, CURR OPIN BIOTECH, V11, P593, DOI 10.1016/S0958-1669(00)00149-X; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Neri D, 1996, NAT BIOTECHNOL, V14, P485, DOI 10.1038/nbt0496-485; Nieddu E, 2005, FASEB J, V19, P632, DOI 10.1096/fj.04-2369fje; Olofsson J, 2003, CURR OPIN BIOTECH, V14, P29, DOI 10.1007/s00216-010-3744-2; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Perez Norma, 2004, Genet Vaccines Ther, V2, P2, DOI 10.1186/1479-0556-2-2; Pescarolo MP, 2001, FASEB J, V15, P31; Reff Mitchell E, 2002, Cancer Control, V9, P152; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; UCHIDA T, 1988, EXP CELL RES, V178, P1, DOI 10.1016/0014-4827(88)90372-2; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WILLIAMS SC, 1993, EUR J IMMUNOL, V23, P1456, DOI 10.1002/eji.1830230709	37	19	22	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1237	1245		10.1096/fj.07-8865com	http://dx.doi.org/10.1096/fj.07-8865com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	18048579				2022-12-28	WOS:000254581000028
J	Chien, MP; Jiang, SB; Chang, DK				Chien, Miao-Ping; Jiang, Shibo; Chang, Ding-Kwo			The function of coreceptor as a basis for the kinetic dissection of HIV type 1 envelope protein-mediated cell fusion	FASEB JOURNAL			English	Article						gp120 shedding; NC-1 sensitive conformation; lipid and content mixing; recruitment; fusion peptide	IMMUNODEFICIENCY-VIRUS TYPE-1; MEMBRANE-FUSION; SOLUBLE CD4; CONFORMATIONAL-CHANGES; RECEPTOR-BINDING; TRANSMEMBRANE GLYCOPROTEIN; NEUTRALIZATION RESISTANCE; ACTIVE CONFORMATION; SYNTHETIC PEPTIDE; ATOMIC-STRUCTURE	The function of HIV-1 HXB2 envelope (Env) glycoprotein (gp) was investigated by surface plasmon resonance and fluorescence imaging techniques. Strikingly, it was found that gp120 shedding requires the presence of the X4 coreceptor. A similar coreceptor requirement was observed for the membrane mixing and the Env recruitment on the cell surface. However, exposure and membrane penetration of the fusion peptide do not require X4 and occur within the first minute after incubation of Env with CD4 and/or X4. Analogously X4 was not required but enhanced binding of the fusion inhibitor. In contrast, bundle formation of the gp41 ectodomain, as monitored by NC-1, was accelerated by the presence of X4. The kinetics of these key post-Env binding events as determined in real time by fluorescence microscopic imaging, coupled with the differential coreceptor requirement, led to the proposition that gp120 shedding, which takes place from 1 to 10 min after engagement of receptor and coreceptor to Env, is a primary function of the coreceptor. The shedding of the surface subunits is needed for the subsequent processes including hemifusion, full fusion, and Env recruitment. The temporal order of these fusogenic steps allows construction of a refined model on the Env-mediated cell fusion event.	[Chien, Miao-Ping; Chang, Ding-Kwo] Acad Sinica, Inst Chem, Taipei 11529, Taiwan; [Jiang, Shibo] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA	Academia Sinica - Taiwan; New York Blood Center	Chang, DK (corresponding author), Acad Sinica, Inst Chem, Taipei 11529, Taiwan.	dkc@chem.sinica.edu.tw	Jiang, Shibo/L-4500-2014; Chang, Ding-Kwo/E-7079-2015	Jiang, Shibo/0000-0001-8283-7135; Chien, Miao-Ping/0000-0002-6087-4688				ALOIA RC, 1993, P NATL ACAD SCI USA, V90, P5181, DOI 10.1073/pnas.90.11.5181; Berger EA, 1997, AIDS, V11, pS3; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103; Buzon V, 2005, BIOCHEMISTRY-US, V44, P13354, DOI 10.1021/bi050382r; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; Center RJ, 2002, J VIROL, V76, P7863, DOI 10.1128/JVI.76.15.7863-7867.2002; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; de Rosny E, 2004, J VIROL, V78, P2627, DOI 10.1128/JVI.78.5.2627-2631.2004; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; Dimitrov AS, 2005, BIOCHEMISTRY-US, V44, P12471, DOI 10.1021/bi051092d; Dimitrov AS, 2003, BIOCHEMISTRY-US, V42, P14150, DOI 10.1021/bi035154g; Doms RW, 2000, VIROLOGY, V276, P229, DOI 10.1006/viro.2000.0612; Dumonceaux J, 1998, J VIROL, V72, P512, DOI 10.1128/JVI.72.1.512-519.1998; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Finnegan CM, 2001, J VIROL, V75, P11096, DOI 10.1128/JVI.75.22.11096-11105.2001; FU YK, 1993, J VIROL, V67, P3818, DOI 10.1128/JVI.67.7.3818-3825.1993; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Gallo SA, 2001, BIOCHEMISTRY-US, V40, P12231, DOI 10.1021/bi0155596; GREWE C, 1990, J ACQ IMMUN DEF SYND, V3, P965; Haque ME, 2005, BIOPHYS J, V89, P3183, DOI 10.1529/biophysj.105.063032; Hoffman T L, 1998, AIDS, V12 Suppl A, pS17; Iyengar S, 2000, J VIROL, V74, P6720, DOI 10.1128/JVI.74.15.6720-6724.2000; Jiang S, 1998, J VIROL, V72, P10213, DOI 10.1128/JVI.72.12.10213-10217.1998; Jolly C, 2005, J VIROL, V79, P12088, DOI 10.1128/JVI.79.18.12088-12094.2005; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; Korazim O, 2006, J MOL BIOL, V364, P1103, DOI 10.1016/j.jmb.2006.08.091; KORTE T, 1994, EUR BIOPHYS J BIOPHY, V23, P105; Kuhmann SE, 2000, J VIROL, V74, P7005, DOI 10.1128/JVI.74.15.7005-7015.2000; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; Leavitt M, 2003, J VIROL, V77, P560, DOI 10.1128/JVI.77.1.560-570.2003; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Markosyan RM, 2003, MOL BIOL CELL, V14, P926, DOI 10.1091/mbc.E02-09-0573; Markosyan RM, 2005, MOL BIOL CELL, V16, P5502, DOI 10.1091/mbc.E05-06-0496; MATTHEWS TJ, 1994, IMMUNOL REV, V140, P93, DOI 10.1111/j.1600-065X.1994.tb00866.x; McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; Mkrtchyan SR, 2005, J VIROL, V79, P11161, DOI 10.1128/JVI.79.17.11161-11169.2005; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; Nagasawa T, 1996, P NATL ACAD SCI USA, V93, P14726, DOI 10.1073/pnas.93.25.14726; NEURATH AR, 1992, VIROLOGY, V188, P1, DOI 10.1016/0042-6822(92)90729-9; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; Park EJ, 2000, J VIROL, V74, P4183, DOI 10.1128/JVI.74.9.4183-4191.2000; Reeves JD, 1997, J VIROL, V71, P1453, DOI 10.1128/JVI.71.2.1453-1465.1997; Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Sackett K, 2006, J BIOL CHEM, V281, P21755, DOI 10.1074/jbc.M603135200; Salzwedel K, 2000, P NATL ACAD SCI USA, V97, P12794, DOI 10.1073/pnas.230438497; Salzwedel K, 2000, J VIROL, V74, P326, DOI 10.1128/JVI.74.1.326-333.2000; SATTENTAU QJ, 1993, PHILOS T R SOC B, V342, P59, DOI 10.1098/rstb.1993.0136; SCHNITTMAN SM, 1988, J IMMUNOL, V141, P4181; Sullivan N, 1998, J VIROL, V72, P6332, DOI 10.1128/JVI.72.8.6332-6338.1998; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; THALI M, 1992, J VIROL, V66, P5516, DOI 10.1128/JVI.66.9.5516-5524.1992; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weng YK, 1998, J VIROL, V72, P9676, DOI 10.1128/JVI.72.12.9676-9682.1998; WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILLEY RL, 1994, J VIROL, V68, P1029, DOI 10.1128/JVI.68.2.1029-1039.1994; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Yang XZ, 2002, J VIROL, V76, P4634, DOI 10.1128/JVI.76.9.4634-4642.2002; Yang XZ, 2000, J VIROL, V74, P5716, DOI 10.1128/JVI.74.12.5716-5725.2000	74	15	15	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1179	1192		10.1096/fj.07-9576com	http://dx.doi.org/10.1096/fj.07-9576com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	18032634				2022-12-28	WOS:000254581000023
J	Collet, C; Schiltz, C; Geoffroy, V; Maroteaux, L; Launay, JM; de Vernejoul, MC				Collet, C.; Schiltz, C.; Geoffroy, V.; Maroteaux, L.; Launay, J. -M.; de Vernejoul, M. -C.			The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation	FASEB JOURNAL			English	Article						osteoporosis; aging; neurotransmitter	NECROSIS-FACTOR-ALPHA; ACCELERATED SENESCENCE; RETINOIC ACID; CELL-FUNCTION; MURINE MODEL; 2B RECEPTOR; IN-VIVO; DIFFERENTIATION; 5-HYDROXYTRYPTAMINE; OSTEOPOROSIS	The monoamine serotonin (5-HT), a well-known neurotransmitter, is also important in peripheral tissues. Several studies have suggested that 5-HT is involved in bone metabolism. Starting from our original observation of increased 5-HT2B receptor (5HT(2B)R) expression during in vitro osteoblast differentiation, we investigated a putative bone phenotype in vivo in 5-HT2BR knockout mice. Of interest, 5-HT2BR mutant female mice displayed reduced bone density that was significant from age 4 months and had intensified by 12 and 18 months. This histomorphometrically confirmed osteopenia seems to be due to reduced bone formation because 1) the alkaline phosphatase-positive colony-forming unit capacity of bone marrow precursors was markedly reduced in the 5-HT2BR mutant mice from 4 to 12 months of age, 2) ex vivo primary osteoblasts from mutant mice exhibited reduced proliferation and delayed differentiation, and 3) calcium incorporation was markedly reduced in osteoblasts after 5-HT2BR depletion (produced genetically or by pharmacological inactivation). These findings support the hypothesis that the 5-HT2BR receptor facilitates osteoblast recruitment and proliferation and that its absence leads to osteopenia that worsens with age. We show here, for the first time, that the 5-HT2BR receptor is a physiological mediator of 5-HT in bone formation and, potentially, in the onset of osteoporosis in aging women.	[Schiltz, C.; Geoffroy, V.; de Vernejoul, M. -C.] Hop Lariboisiere, INSERM, U606, F-75475 Paris 10, France; [Collet, C.; Launay, J. -M.] Hop Lariboisiere, Serv Biochim, F-75475 Paris, France; [Maroteaux, L.] Inst Fer Moulin, INSERM, U839, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	de Vernejoul, MC (corresponding author), Hop Lariboisiere, INSERM, U606, 2 Rue Ambroise Pare, F-75475 Paris 10, France.	christine.devernejoul@lrb.aphp.fr	Geoffroy, Valerie/P-1521-2014; Maroteaux, Luc/H-4585-2019	Geoffroy, Valerie/0000-0003-3920-7482; Maroteaux, Luc/0000-0002-9499-8603; collet, corinne/0000-0001-6990-863X				Battaglino R, 2004, J BONE MINER RES, V19, P1420, DOI 10.1359/JBMR.040606; Bhasin N, 2004, ANAT EMBRYOL, V208, P135, DOI 10.1007/s00429-004-0380-7; Bhasin N, 2004, DEV DYNAM, V230, P201, DOI 10.1002/dvdy.20038; Bliziotes M, 2006, BONE, V39, P1313, DOI 10.1016/j.bone.2006.06.009; Bliziotes MM, 2001, BONE, V29, P477, DOI 10.1016/S8756-3282(01)00593-2; Bonyadi M, 2003, P NATL ACAD SCI USA, V100, P5840, DOI 10.1073/pnas.1036475100; Callebert J, 2006, J PHARMACOL EXP THER, V317, P724, DOI 10.1124/jpet.105.098269; Chen TL, 2004, BONE, V35, P83, DOI 10.1016/j.bone.2004.03.019; Cheng SL, 2000, J BONE MINER RES, V15, P2362, DOI 10.1359/jbmr.2000.15.12.2362; Choi DS, 1997, DEVELOPMENT, V124, P1745; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398; Franchimont N, 2005, BONE, V37, P601, DOI 10.1016/j.bone.2005.06.002; Geoffroy V, 2004, J BONE MINER RES, V19, P811, DOI 10.1359/JBMR.040119; Gustafsson BI, 2006, J CELL BIOCHEM, V98, P139, DOI 10.1002/jcb.20734; Hoyer D, 2002, PHARMACOL BIOCHEM BE, V71, P533, DOI 10.1016/S0091-3057(01)00746-8; Jaffre F, 2004, CIRCULATION, V110, P969, DOI 10.1161/01.CIR.0000139856.20505.57; Jilka RL, 1996, J CLIN INVEST, V97, P1732, DOI 10.1172/JCI118600; Kajkenova O, 1997, J BONE MINER RES, V12, P1772, DOI 10.1359/jbmr.1997.12.11.1772; Kellermann O, 1996, BRIT J PHARMACOL, V118, P1161, DOI 10.1111/j.1476-5381.1996.tb15519.x; Kubera M, 2005, PSYCHIAT RES, V134, P251, DOI 10.1016/j.psychres.2004.01.014; Launay JM, 2006, FASEB J, V20, P1843, DOI 10.1096/fj.06-5724com; Launay JM, 1996, J BIOL CHEM, V271, P3141, DOI 10.1074/jbc.271.6.3141; Lerner U. H., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P87; Lesurtel M, 2006, SCIENCE, V312, P104, DOI 10.1126/science.1123842; Locker M, 2006, CELL SIGNAL, V18, P628, DOI 10.1016/j.cellsig.2005.06.006; Lundberg P, 2001, ENDOCRINOLOGY, V142, P339, DOI 10.1210/en.142.1.339; Merciris D, 2007, AM J PATHOL, V170, P1676, DOI 10.2353/ajpath.2007.061069; MEUNIER P, 1971, CLIN ORTHOP RELAT R, V80, P147, DOI DOI 10.1097/00003086-197110000-00021; Moiseiwitsch JRD, 2000, CRIT REV ORAL BIOL M, V11, P230, DOI 10.1177/10454411000110020601; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P9508, DOI 10.1073/pnas.97.17.9508; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P2591, DOI 10.1073/pnas.050282397; PARFITT AM, 1995, J BONE MINER RES, V10, P466; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071; Ruddell RG, 2006, AM J PATHOL, V169, P861, DOI 10.2353/ajpath.2006.050767; SANDERSBUSH E, 2007, GOODMAN GILMANS PHAR, P297; Shin CS, 2000, J CELL BIOCHEM, V78, P566, DOI 10.1002/1097-4644(20000915)78:4<566::AID-JCB6>3.0.CO;2-K; SHUEY DL, 1992, TERATOLOGY, V46, P367, DOI 10.1002/tera.1420460407; Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005; Suzuki A, 1998, BONE, V23, P197, DOI 10.1016/S8756-3282(98)00099-4; Taylor A. F., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P285; Warden SJ, 2005, MOL CELL ENDOCRINOL, V242, P1, DOI 10.1016/j.mce.2005.06.005; Warden SJ, 2005, ENDOCRINOLOGY, V146, P685, DOI 10.1210/en.2004-1259; Watts SW, 2004, J PHARMACOL EXP THER, V309, P165, DOI 10.1124/jpet.103.062562; Westbroek I, 2001, J BIOL CHEM, V276, P28961, DOI 10.1074/jbc.M101824200	46	85	98	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2008	22	2					418	427		10.1096/fj.07-9209com	http://dx.doi.org/10.1096/fj.07-9209com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17846081	Green Submitted, Green Published, Green Accepted			2022-12-28	WOS:000252822600012
J	von Degenfeld, G; Wehrman, TS; Hammer, MM; Blau, HM				von Degenfeld, Georges; Wehrman, Tom S.; Hammer, Mark M.; Blau, Helen M.			A universal technology for monitoring G-protein-coupled receptor activation in vitro and noninvasively in live animals	FASEB JOURNAL			English	Article						luminescent in vivo imaging; in vivo pharmacology; GPCRs	BETA-GALACTOSIDASE; DRUG; TRAFFICKING; ARRESTINS; SYSTEM; ASSAYS	G-protein coupled receptors ( GPCRs) are a versatile and ubiquitous family of membrane receptors that transmit extracellular signals to mammalian cells and constitute the most important class of drug targets. Yet, sensitive and specific methods are lacking that would allow quantitative comparisons of pharmacologic properties of these receptors in physiological or pathological settings in live animals. We sought to overcome these limitations by employing low affinity, reversible beta-galactosidase complementation to quantify GPCR activation via interaction with beta-arrestin. A panel of cell lines was engineered expressing different GPCRs together with the reporter system. In vitro evaluation revealed highly sensitive, dynamic, and specific assessment of GPCR agonists and antagonists. Following implantation of the cells into mice, it was possible for the first time to monitor pharmacological GPCR activation and inhibition in their physiological context by noninvasive bioluminescence imaging in living animals. This technology has unique advantages that enable novel applications in the functional investigation of GPCR modulation in live animals in biological research and drug discovery.	Baxter Lab, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Baxter Lab Genet Pharmacol, Stanford, CA 94305 USA	Stanford University	Blau, HM (corresponding author), Bayer HealthCare, Cardiovasc Res, Wuppertal, Germany.	hblau@stanford.edu	Hammer, Mark/AAR-9625-2020	Hammer, Mark/0000-0002-1700-7984	NIA NIH HHS [AG020961, AG024987, T32 AG0259, AG009521] Funding Source: Medline; NIBIB NIH HHS [EB005011] Funding Source: Medline; NICHD NIH HHS [HD018179] Funding Source: Medline; NIGMS NIH HHS [T32 GM08412] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB005011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG009521, T32AG000259, R01AG024987, R01AG020961, R01AG009521] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; Drake MT, 2006, CIRC RES, V99, P570, DOI 10.1161/01.RES.0000242563.47507.ce; Eglen RM, 2005, COMB CHEM HIGH T SCR, V8, P311, DOI 10.2174/1386207054020813; GEIGER R, 1992, BIOL CHEM H-S, V373, P1187, DOI 10.1515/bchm3.1992.373.2.1187; HAMMER MM, 2007, FASEB J, V21, DOI DOI 10.1096/FJ.07.8777COM; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Jacoby E, 2006, CHEMMEDCHEM, V1, P760, DOI 10.1002/cmdc.200600134; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Lipworth BJ, 1997, BRIT J CLIN PHARMACO, V43, P9, DOI 10.1111/j.1365-2125.1997.tb00025.x; Lundstrom K, 2006, CURR PROTEIN PEPT SC, V7, P465, DOI 10.2174/138920306778559403; Moore CAC, 2007, ANNU REV PHYSIOL, V69, P451, DOI 10.1146/annurev.physiol.69.022405.154712; Newman SP, 1999, PHARM SCI TECHNOL TO, V2, P181, DOI 10.1016/S1461-5347(99)00152-2; Oakley RH, 2002, ASSAY DRUG DEV TECHN, V1, P21, DOI 10.1089/154065802761001275; Sadikot Ruxana T, 2005, Proc Am Thorac Soc, V2, P537, DOI 10.1513/pats.200507-067DS; Schlyer S, 2006, DRUG DISCOV TODAY, V11, P481, DOI 10.1016/j.drudis.2006.04.008; Shenoy Sudha K, 2005, Sci STKE, V2005, pcm10, DOI 10.1126/stke.2005/308/cm10; Thomsen W, 2005, CURR OPIN BIOTECH, V16, P655, DOI 10.1016/j.copbio.2005.10.008; Wakefield ID, 2002, FUND CLIN PHARMACOL, V16, P209, DOI 10.1046/j.1472-8206.2002.00099.x; Weber MA, 2005, AM J HYPERTENS, V18, p169S, DOI 10.1016/j.amjhyper.2005.09.009; Wehrman TS, 2006, P NATL ACAD SCI USA, V103, P19063, DOI 10.1073/pnas.0605218103; Wehrman T, 2007, NEURON, V53, P25, DOI 10.1016/j.neuron.2006.09.034; Wehrman TS, 2006, NAT METHODS, V3, P295, DOI 10.1038/NMETH868; Wehrman TS, 2005, NAT METHODS, V2, P521, DOI 10.1038/NMETH771; Yan YX, 2002, J BIOMOL SCREEN, V7, P451, DOI 10.1177/108705702237677	25	25	25	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3819	3826		10.1096/fj.07-9597com	http://dx.doi.org/10.1096/fj.07-9597com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17942828				2022-12-28	WOS:000251283500006
J	Rajagopalan, N; Pung, YF; Zhu, YZ; Wong, PTH; Kumar, PP; Kini, RM				Rajagopalan, Nandhakishore; Pung, Yuh Fen; Zhu, Yi Zhun; Wong, Peter Tsun Hon; Kumar, Prakash P.; Kini, R. Manjunatha			beta-Cardiotoxin: a new three-finger toxin from Ophiophagus hannah (king cobra) venom with beta-blocker activity	FASEB JOURNAL			English	Article						heart rate; bradycardia; adrenergic receptors; GPCR ligands; beta-blocker peptide	HEMOLYTIC-ACTIVITY; ALPHA-NEUROTOXINS; SNAKE; PROTEIN; INHIBITION; ANTAGONIST; TIROFIBAN; OHANIN; CHAIN	Snake venoms have provided a number of novel ligands with therapeutic potential. We have constructed a partial cDNA library from the mRNA of Ophiophagus hannah (king cobra) venom gland tissue and identified five new genes encoding proteins belonging to the three-finger toxin family of snake venom proteins. We have isolated and characterized one of these beta-sheet containing proteins with a mass of 7012.43 +/- 0.91 Da from the venom. The protein was nonlethal up to a dose of 10 mg/kg when injected intraperitoneally into Swiss albino mice. However, it induces labored breathing and death at a dose of 100 mg/kg. It does not show any hemolytic or anticoagulant activity. It caused a dose-dependent decrease of heart rate in vivo (anesthetized Sprague-Dawley rats) and also ex vivo (Langendorff isolated rat heart). This is in contrast to classical cardiotoxins from snake venom that increase the heart rate in animals. Radioligand displacement studies showed that this protein targets beta-adrenergic receptors with a binding affinity (K-i) of 5.3 and 2.3 mu M toward beta(1) and beta(2) subtypes, respectively, to bring about its effect, and hence, it was named as beta-cardiotoxin. This is the first report of a natural exogenous beta-blocker.	Natl Univ Singapore, Prot Sci Lab, Dept Biol Sci, Fac Sci, Singapore 117543, Singapore; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117548, Singapore; Natl Univ Singapore, Temasek Life Sci Lab, Singapore 117548, Singapore; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA	National University of Singapore; National University of Singapore; National University of Singapore; Virginia Commonwealth University	Kini, RM (corresponding author), Natl Univ Singapore, Prot Sci Lab, Dept Biol Sci, Fac Sci, Sci Dr 4, Singapore 117543, Singapore.	dbskumar@nus.edu.sg; dbskinim@nus.edu.sg	Kumar, Prakash P/A-6236-2009; Pung, Yuh Fen/E-8959-2016; Kini, Manjunatha/H-8029-2012; Zhu, Yi Zhun/ABG-8449-2021	Kumar, Prakash P/0000-0002-0963-1664; Pung, Yuh Fen/0000-0001-6195-3970; Zhu, Yi Zhun/0000-0001-7700-8041; Kini, Manjunatha/0000-0002-6100-3251				Arlock P, 2005, SCAND CARDIOVASC J, V39, P250, DOI 10.1080/14017430510035952; Banerjee Y, 2005, J BIOL CHEM, V280, P42601, DOI 10.1074/jbc.M508987200; BOFFA MC, 1983, THROMB RES, V32, P635, DOI 10.1016/0049-3848(83)90066-X; CASTRO VROE, 1989, TOXICON, V27, P511, DOI 10.1016/0041-0101(89)90112-8; Cerra MC, 2006, BASIC RES CARDIOL, V101, P43, DOI 10.1007/s00395-005-0547-2; Chang CC, 1999, J BIOMED SCI, V6, P368, DOI 10.1159/000025412; Chen DS, 1997, BIOCHEM J, V325, P685, DOI 10.1042/bj3250685; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; ENDO T, 1987, PHARMACOL THERAPEUT, V34, P403, DOI 10.1016/0163-7258(87)90002-7; Fry BG, 2003, J MOL EVOL, V57, P110, DOI 10.1007/s00239-003-2461-2; GATINEAU E, 1987, BIOCHEMISTRY-US, V26, P8046, DOI 10.1021/bi00399a004; Gress TW, 2000, NEW ENGL J MED, V342, P905, DOI 10.1056/NEJM200003303421301; Griffith R. K, 2003, BURGERS MED CHEM DRU, V6, P1, DOI 10.1002/0471266949.bmc093; GROGNET JM, 1988, EUR J BIOCHEM, V172, P383, DOI 10.1111/j.1432-1033.1988.tb13898.x; Harrison PM, 1996, J MOL BIOL, V264, P603, DOI 10.1006/jmbi.1996.0664; He YY, 2004, TOXICON, V44, P295, DOI 10.1016/j.toxicon.2004.06.003; Hider R.C., 1991, P1; HIDER RC, 1982, TOXICON, V20, P175, DOI 10.1016/0041-0101(82)90188-X; Higuchi S, 1999, IMMUNOPHARMACOLOGY, V44, P129, DOI 10.1016/S0162-3109(99)00119-8; Hollenberg NK, 2005, AM J HYPERTENS, V18, p165S, DOI 10.1016/j.amjhyper.2005.09.010; Huang Fengyang, 2004, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V2, P187, DOI 10.2174/1568016043356309; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; Kini RM, 2002, CLIN EXP PHARMACOL P, V29, P815, DOI 10.1046/j.1440-1681.2002.03725.x; Kondo K, 2002, CLIN PHARMACOKINET, V41, P187, DOI 10.2165/00003088-200241030-00003; Kumar TKS, 1997, J BIOMOL STRUCT DYN, V15, P431, DOI 10.1080/07391102.1997.10508957; Li J, 2006, BIOCHEM J, V398, P233, DOI 10.1042/BJ20060004; LOUW AI, 1978, BIOCHIM BIOPHYS ACTA, V512, P163, DOI 10.1016/0005-2736(78)90227-4; Marcinkiewicz C, 2005, CURR PHARM DESIGN, V11, P815, DOI 10.2174/1381612053381765; McClellan KJ, 1998, DRUGS, V56, P1067, DOI 10.2165/00003495-199856060-00017; MCDOWELL RS, 1992, BIOCHEMISTRY-US, V31, P4766, DOI 10.1021/bi00135a004; Nirthanan S, 2003, TOXICON, V41, P397, DOI 10.1016/S0041-0101(02)00388-4; O'Shea J Conor, 2002, Expert Opin Pharmacother, V3, P1199; Plosker GL, 2003, PHARMACOECONOMICS, V21, P885, DOI 10.2165/00019053-200321120-00005; Potter LT, 2001, LIFE SCI, V68, P2541, DOI 10.1016/S0024-3205(01)01050-5; Pung YF, 2006, GENE, V371, P246, DOI 10.1016/j.gene.2005.12.002; Pung YF, 2005, J BIOL CHEM, V280, P13137, DOI 10.1074/jbc.M414137200; ROUMESTAND C, 1994, J MOL BIOL, V243, P719, DOI 10.1016/0022-2836(94)90043-4; Sharpe IA, 2001, NAT NEUROSCI, V4, P902, DOI 10.1038/nn0901-902; Sherman David G, 2002, Curr Med Res Opin, V18 Suppl 2, ps48; SUN JJ, 1986, TOXICON, V24, P233, DOI 10.1016/0041-0101(86)90149-2; Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600; Tsetlin V, 1999, EUR J BIOCHEM, V264, P281, DOI 10.1046/j.1432-1327.1999.00623.x; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; Wu PL, 2006, J BIOL CHEM, V281, P7937, DOI 10.1074/jbc.M513035200; Xiang Y, 2003, SCIENCE, V300, P1530, DOI 10.1126/science.1079206; Yasuda Osamu, 1994, Artery, V21, P287; [No title captured]	47	74	82	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3685	3695		10.1096/fj.07-8658com	http://dx.doi.org/10.1096/fj.07-8658com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17616557				2022-12-28	WOS:000250517800030
J	Herrmann, A; Fleischer, K; Czajkowska, H; Muller-Newen, G; Becker, W				Herrmann, Andreas; Fleischer, Katrin; Czajkowska, Hanna; Mueller-Newen, Gerhard; Becker, Walter			Characterization of cyclin L1 as an immobile component of the splicing factor compartment	FASEB JOURNAL			English	Article						nuclear speckles; photobleaching; arginineserine-rich domain; mobility	SR PROTEINS; RS DOMAIN; SUBNUCLEAR LOCALIZATION; NUCLEAR SPECKLES; RNA; KINASE; PHOSPHORYLATION; TRANSCRIPTION; ORGANIZATION; EXPRESSION	Cyclin L1 and cyclin L2 are two closely related members of the cyclin family that contain C-terminal arginine-and serine-rich (RS) domains and are localized in the splicing factor compartment (nuclear speckles). Here we applied photobleaching techniques to show that a green fluorescent protein (GFP) fusion protein of cyclin L1, in contrast to cyclin L2, was not mobile within the nucleus of living COS7 cells. The objectives of this study were to 1) characterize the intranuclear localization and mobility properties of cyclin L1 in different cellular states, and 2) dissect the structural elements required for immobilization of cyclin L1. Transcriptional arrest by actinomycin D caused accumulation of GFP-cyclin L2 in rounded and enlarged nuclear speckles but did not affect the sub-nuclear pattern of distribution of GFP-cyclin L1. Although immobile in most phases of the cell cycle, GFP-cyclin L1 was diffusely distributed and highly mobile in the cytoplasm of metaphase cells. By analysis of a series of chimeras, deletion constructs, and a point mutant, a segment within the RS domain of cyclin L1 was identified to be necessary for the immobility of the protein in nuclear speckles. This study provides the first characterization of an immobile component of nuclear speckles.	Univ Aachen, Fak Med, Rhein Westfal TH Aachen, Inst Biochem, D-52074 Aachen, Germany	RWTH Aachen University	Becker, W (corresponding author), Univ Aachen, Fak Med, Inst Pharmakol & Toxikol, Rhein Westfal TH Aachen, Wendlingweg 2, D-52074 Aachen, Germany.	wbecker@ukaachen.de	Becker, Walter/B-8889-2008	Becker, Walter/0000-0002-0347-4768				Berke JD, 2001, NEURON, V32, P277, DOI 10.1016/S0896-6273(01)00465-2; Blencowe BJ, 1999, BIOCHEM CELL BIOL, V77, P277, DOI 10.1139/bcb-77-4-277; Boucher L, 2001, RNA, V7, P1693; Bubulya PA, 2004, EXP CELL RES, V296, P4, DOI 10.1016/j.yexcr.2004.03.018; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Cazalla D, 2002, MOL CELL BIOL, V22, P6871, DOI 10.1128/MCB.22.19.6871-6882.2002; Chen HH, 2006, MOL CELL BIOL, V26, P2736, DOI 10.1128/MCB.26.7.2736-2745.2006; Cmarko D, 1999, MOL BIOL CELL, V10, P211, DOI 10.1091/mbc.10.1.211; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; de Graaf K, 2004, J BIOL CHEM, V279, P4612, DOI 10.1074/jbc.M310794200; Dickinson LA, 2002, J BIOL CHEM, V277, P25465, DOI 10.1074/jbc.M202266200; Duncan PI, 1998, EXP CELL RES, V241, P300, DOI 10.1006/excr.1998.4083; Fang YD, 2004, MOL BIOL CELL, V15, P2664, DOI 10.1091/mbc.E04-02-0100; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; Kataoka N, 1999, J CELL BIOL, V145, P1145, DOI 10.1083/jcb.145.6.1145; Ko TK, 2001, J CELL SCI, V114, P2591; Kruhlak MJ, 2000, J CELL BIOL, V150, P41, DOI 10.1083/jcb.150.1.41; Lai MC, 2003, BIOCHEM J, V371, P937, DOI 10.1042/BJ20021827; Lai MC, 2001, P NATL ACAD SCI USA, V98, P10154, DOI 10.1073/pnas.181354098; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; Loyer P, 2005, CELL SIGNAL, V17, P1033, DOI 10.1016/j.cellsig.2005.02.005; Maris C, 2005, FEBS J, V272, P2118, DOI 10.1111/j.1742-4658.2005.04653.x; Martin RM, 2005, CYTOM PART A, V67A, P45, DOI 10.1002/cyto.a.20172; Misteli T, 2001, J CELL BIOL, V155, P181, DOI 10.1083/jcb.200108110; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Politz JCR, 2006, MOL BIOL CELL, V17, P1239, DOI 10.1091/mbc.E05-10-0952; Prasanth KV, 2003, MOL BIOL CELL, V14, P1043, DOI 10.1091/mbc.E02-10-0669; Rabut G., 2005, LIVE CELL IMAGING LA, P101; Sacco-Bubulya P, 2002, J CELL BIOL, V156, P425, DOI 10.1083/jcb.200107017; Shin C, 2005, MOL CELL BIOL, V25, P8334, DOI 10.1128/MCB.25.18.8334-8343.2005; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Yang LJ, 2004, J BIOL CHEM, V279, P11639, DOI 10.1074/jbc.M312895200; Yeakley JM, 1999, J CELL BIOL, V145, P447, DOI 10.1083/jcb.145.3.447; ZHANG GH, 1994, NATURE, V372, P809; Zhu J, 2000, GENE DEV, V14, P3166, DOI 10.1101/gad.189500	43	15	16	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3142	3152		10.1096/fj.07-8377com	http://dx.doi.org/10.1096/fj.07-8377com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17494991				2022-12-28	WOS:000249781600015
J	Yuan, HT; Venkatesha, S; Chan, B; Deutsch, U; Mammoto, T; Sukhatme, VP; Woolf, AS; Karumanchi, SA				Yuan, Hai Tao; Venkatesha, Shivalingappa; Chan, Barden; Deutsch, Urban; Mammoto, Tadanori; Sukhatme, Vikas P.; Woolf, Adrian S.; Karumanchi, S. Ananth			Activation of the orphan endothelial receptor Tie1 modifies Tie2-mediated intracellular signaling and cell survival	FASEB JOURNAL			English	Article						angiopoietin; apoptosis; embryo; endothelial cells; tie receptors	GROWTH-FACTOR RECEPTOR-1; TYROSINE KINASES TIE-1; PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOPOIETIN-1; ANGIOGENESIS; EXPRESSION; INTEGRITY; RELEASE; LIGANDS; FLT-1	A critical role for Tie1, an orphan endothelial receptor, in blood vessel morphogenesis has emerged from mutant mouse studies. Moreover, it was recently demonstrated that certain angiopoietin (Ang) family members can activate Tie1. We report here that Ang1 induces Tie1 phosphorylation in endothelial cells. Tie1 phosphorylation was, however, Tie2 dependent because 1) Ang1 failed to induce Tie1 phosphorylation when Tie2 was down-regulated in endothelial cells; 2) Tie1 phosphorylation was induced in the absence of Ang1 by either a constitutively active form of Tie2 or a Tie2 agonistic antibody; 3) in HEK 293 cells Ang1 phosphorylated a form of Tie1 without kinase activity when coexpressed with Tie2, and Ang1 failed to phosphorylate Tie1 when coexpressed with kinase-defective Tie2. Ang1-mediated AKT and 42/44MAPK phosphorylation is predominantly Tie2 mediated, and Tie1 down-regulates this pathway. Finally, based on a battery of in vitro and in vivo data, we show that a main role for Tie1 is to modulate blood vessel morphogenesis by virtue of its ability to down-regulate Tie2-driven signaling and endothelial survival. Our new observations help to explain why Tie1 null embryos have increased capillary densities in several organ systems. The experiments also constitute a paradigm for how endothelial integrity is fine-tuned by the interplay between closely related receptors by a single growth factor.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Mol & Vasc Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Renal Div, Boston, MA 02215 USA; Univ Bern, Theodor Kocher Inst, Bern, Switzerland; UCL Inst Child Hlth, Nephrourol Unit, London, England	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Bern; University of London; University College London	Yuan, HT (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Mol & Vasc Med, 330 Brookline Ave,RW663, Boston, MA 02215 USA.	hyuan@bidmc.harvard.edu	Karumanchi, Subbian Ananth/AAI-1694-2021; Sukhatme, Vikas/W-2776-2019; Woolf, Adrian S./AAZ-1075-2020	Woolf, Adrian S./0000-0001-5541-1358; Deutsch, Urban/0000-0003-4265-6262				Ahmed A, 1997, LAB INVEST, V76, P779; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Daly C, 2006, P NATL ACAD SCI USA, V103, P15491, DOI 10.1073/pnas.0607538103; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Dunk C, 2001, AM J PATHOL, V158, P265, DOI 10.1016/S0002-9440(10)63965-X; Eklund L, 2006, EXP CELL RES, V312, P630, DOI 10.1016/j.yexcr.2005.09.002; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Goede V, 1998, LAB INVEST, V78, P1385; Harfouche R, 2003, FASEB J, V17, P1523, DOI 10.1096/fj.02-0698fje; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Kearney JB, 2002, BLOOD, V99, P2397, DOI 10.1182/blood.V99.7.2397; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Koblizek TI, 1997, EUR J BIOCHEM, V244, P774, DOI 10.1111/j.1432-1033.1997.00774.x; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kontos CD, 2002, MOL CELL BIOL, V22, P1704, DOI 10.1128/MCB.22.6.1704-1713.2002; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Lee HJ, 2004, FASEB J, V18, P1200, DOI 10.1096/fj.03-1466com; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Marron MB, 2000, J BIOL CHEM, V275, P39741, DOI 10.1074/jbc.M007189200; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; McCarthy MJ, 1998, FEBS LETT, V423, P334, DOI 10.1016/S0014-5793(98)00122-7; Niu Q, 2004, CANCER BIOL THER, V3, P402, DOI 10.4161/cbt.3.4.735; Patan S, 1998, MICROVASC RES, V56, P1, DOI 10.1006/mvre.1998.2081; Peters KG, 2004, RECENT PROG HORM RES, V59, P51, DOI 10.1210/rp.59.1.51; Porat RM, 2004, CIRC RES, V94, P394, DOI 10.1161/01.RES.0000111803.92923.D6; Puri MC, 1999, DEVELOPMENT, V126, P4569; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Rodewald HR, 1996, ONCOGENE, V12, P397; Saharinen P, 2005, J CELL BIOL, V169, P239, DOI 10.1083/jcb.200411105; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takahashi A, 1999, BIOCHEM BIOPH RES CO, V257, P855, DOI 10.1006/bbrc.1999.0465; Teichert-Kuliszewska K, 2001, CARDIOVASC RES, V49, P659, DOI 10.1016/S0008-6363(00)00231-5; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Yabkowitz R, 1997, BLOOD, V90, P706, DOI 10.1182/blood.V90.2.706.706_706_715; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yuan HT, 1999, J AM SOC NEPHROL, V10, P1722; Yuan HT, 2002, KIDNEY INT, V61, P2078, DOI 10.1046/j.1523-1755.2002.00381.x	45	79	84	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3171	3183		10.1096/fj.07-8487com	http://dx.doi.org/10.1096/fj.07-8487com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17504972				2022-12-28	WOS:000249781600018
J	Zhang, M; Mal, N; Kiedrowski, M; Chacko, M; Askari, AT; Popovic, ZB; Koc, ON; Penn, MS				Zhang, Ming; Mal, Niladri; Kiedrowski, Matthew; Chacko, Matthews; Askari, Arman T.; Popovic, Zoran B.; Koc, Omer N.; Penn, Marc S.			SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction	FASEB JOURNAL			English	Article						HSC; cardiac regeneration; transplantation; SDF-1-based therapy	BONE-MARROW; VENTRICULAR-FUNCTION; MIGRATION; HEART; GROWTH; CXCR4; NEOVASCULARIZATION; TRANSPLANTATION; REGENERATION; PROGENITORS	Stem cell transplantation at the time of acute myocardial infarction (AMI) improves cardiac function. Whether the improved cardiac function results from regeneration of cardiac myocytes, modulation of remodeling, or preservation of injured tissue through paracrine mechanisms is actively debated. Because no specific stem cell population has been shown to be optimal, we investigated whether the benefit of stem cell transplantation could be attributed to a trophic effect on injured myocardium. Mesenchymal stem cells secrete SDF-1 and the interaction of SDF-1 with its receptor, CXCR4, increases survival of progenitor cells. Therefore, we compared the effects of MSC and MSC engineered to overexpress SDF-1 on cardiac function after AMI. Tail vein infusion of syngeneic MSC and MSC: SDF-1 1 day after AMI in the Lewis rat led to improved cardiac function by echocardiography by 70.7% and 238.8%, respectively, compared with saline controls 5 wk later. The beneficial effects of MSC and MSC: SDF-1 transplantation were mediated primarily through preservation, not regeneration of cardiac myocytes within the infarct zone. The direct effect of SDF-1 on cardiac myocytes was due to the observation that, between 24 and 48 h after AMI, SDF-1-expressing MSC increased cardiac myocyte survival, vascular density (18.2 +/- 4.0 vs. 7.6 +/- 2.3 vessels/mm(2), P<0.01; SDF-1: MSC vs. MSC), and cardiac myosin-positive area (MSC: 49.5%; mSC: SDF-1: 162.1%) within the infarct zone. There was no evidence of cardiac regeneration by the infused MSC or endogenous cardiac stem cells based on lack of evidence for cardiac myocytes being derived from replicating cells. These results indicate that stem cell transplantation may have significant beneficial effects on injured organ function independent of tissue regeneration and identify SDF-1: CXCR4 binding as a novel target for myocardial preservation.	Cleveland Clin Fdn, Dept Cardiovasc Med, Bakken Heart Brain Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Div Hematol & Oncol, Cleveland, OH 44106 USA; Ctr Stem Cell & Regenerat Med, Cleveland, OH USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University	Penn, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, Bakken Heart Brain Inst, 9500 Euclid Ave,NC10,NE30, Cleveland, OH 44195 USA.	pennm@ccf.org	Mordwinkin, Nicholas M/A-4347-2010	popovic, zoran/0000-0001-5692-2299	PHS HHS [1R01-74400] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abbott JD, 2004, CIRCULATION, V110, P3300, DOI 10.1161/01.CIR.0000147780.30124.CF; Askari A, 2004, J AM COLL CARDIOL, V43, P1908, DOI 10.1016/j.jacc.2003.12.045; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Broxmeyer HE, 2003, J IMMUNOL, V170, P421, DOI 10.4049/jimmunol.170.1.421; Damas JK, 2000, CARDIOVASC RES, V47, P778, DOI 10.1016/S0008-6363(00)00142-5; Hodgson DM, 2004, AM J PHYSIOL-HEART C, V287, pH471, DOI 10.1152/ajpheart.01247.2003; Itescu S, 2003, J MOL MED, V81, P288, DOI 10.1007/s00109-003-0432-0; Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22-3-415; Kahn J, 2004, BLOOD, V103, P2942, DOI 10.1182/blood-2003-07-2607; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Kayali AG, 2003, J CELL BIOL, V163, P859, DOI 10.1083/jcb.200304153; Koc ON, 2002, BONE MARROW TRANSPL, V30, P215, DOI 10.1038/sj.bmt.1703650; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood-2004-11-4349; Lee RJ, 2000, CIRCULATION, V102, P898; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; MILLS WR, 2006, IN PRESS J MOL CELL; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; NAGAYA, 2004, AM J PHYSIOL, V287, pH2670; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Ratajczak MZ, 2003, STEM CELLS, V21, P363, DOI 10.1634/stemcells.21-3-363; Rota M, 2005, CIRC RES, V97, P1332, DOI 10.1161/01.RES.0000196568.11624.ae; Schenk S, 2007, STEM CELLS, V25, P245, DOI 10.1634/stemcells.2006-0293; Shake JG, 2002, ANN THORAC SURG, V73, P1919, DOI 10.1016/S0003-4975(02)03517-8; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Suzuki K, 2001, CIRCULATION, V104, pI207; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; von Degenfeld G, 2003, BRIT J PHARMACOL, V140, P620, DOI 10.1038/sj.bjp.0705492; Vulliet PR, 2004, LANCET, V363, P783, DOI 10.1016/S0140-6736(04)15695-X; Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood-2004-02-0526; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22	36	360	394	1	32	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3197	3207		10.1096/fj.06-6558com	http://dx.doi.org/10.1096/fj.06-6558com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17496162				2022-12-28	WOS:000249781600020
J	Agouni, A; Mostefai, HA; Porro, C; Carusio, N; Favre, J; Richard, V; Henrion, D; Martinez, MC; Andriantsitohaina, R				Agouni, Abdelali; Mostefai, H. Ahmed; Porro, Chiarra; Carusio, Nunzia; Favre, Julie; Richard, Vincent; Henrion, Daniel; Martinez, M. Carmen; Andriantsitohaina, Ramaroson			Sonic hedgehog carried by microparticles corrects endothelial injury through nitric oxide release	FASEB JOURNAL			English	Article						microvesicles; NO-synthase; MPs; PI3-kinase inhibitor	SHED MEMBRANE MICROPARTICLES; GENE-THERAPY; CELLS; PROLIFERATION; MICROVESICLES; DYSFUNCTION; ADHESION	Microparticles ( MPs) are small fragments generated from the plasma membrane after cell stimulation. Among the candidate proteins harbored by MPs, we recently showed that sonic hedgehog ( Shh) is present in MPs generated from activated/ apoptotic human T lymphocytes [ Martinez et al., Blood ( 2006) vol. 108, 3012 - 3020]. We show here that Shh carried by MPs induces nitric oxide ( NO) release from endothelial cells, triggers changes in the expression and phosphorylation of enzymes related to the NO pathway, and decreases production of reactive oxygen species. When PI3- kinase and ERK signaling were specifically inhibited, the effects of MPs were reversed. In vivo injection of MPs in mice was also able to improve endothelial function by increasing NO release, and it reversed endothelial dysfunction after ischemia/ reperfusion. Silencing the effects of Shh with cyclopamine, a specific inhibitor of Shh, or siRNA, an inhibitor of the Shh receptor Patched, strongly reduced production of NO elicited by MPs. Taken together, we propose that the biological message carried by MPs harboring Shh may represent a new therapeutic approach against endothelial dysfunction during acute severe endothelial injury.	Univ Angers, Fac Med, INSERM, CNRS,UMR 6214,U771, F-49045 Angers, France; Univ Rouen, INSERM, UFR Med Pharmacie, U644, Rouen, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie	Andriantsitohaina, R (corresponding author), Univ Angers, Fac Med, INSERM, CNRS,UMR 6214,U771, Rue Haute Reculee, F-49045 Angers, France.	ramaroson.andriantsitohaina@univ-angers.fr	Henrion, Daniel/AAK-1995-2021; Agouni, Abdelali/AAP-5298-2020; PORRO, CHIARA/G-7849-2018; Richard, Vincent/B-1059-2014	Henrion, Daniel/0000-0003-1094-0285; Agouni, Abdelali/0000-0002-8363-1582; PORRO, CHIARA/0000-0002-7526-6968; Richard, Vincent/0000-0003-0590-0158; andriantsitohaina, ramaroson/0000-0002-4770-3585				Asai J, 2006, CIRCULATION, V113, P2413, DOI 10.1161/CIRCULATIONAHA.105.603167; Baj-Krzyworzeka M, 2002, EXP HEMATOL, V30, P450, DOI 10.1016/S0301-472X(02)00791-9; Barry OP, 1998, J CLIN INVEST, V102, P136, DOI 10.1172/JCI2592; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Martinez MC, 2006, BLOOD, V108, P3012, DOI 10.1182/blood-2006-04-019109; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Hugel B, 2005, PHYSIOLOGY, V20, P22, DOI 10.1152/physiol.00029.2004; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jimenez JJ, 2003, BRIT J HAEMATOL, V123, P896, DOI 10.1046/j.1365-2141.2003.04716.x; Kaeffer N, 1997, CIRCULATION, V96, P2311; Kanda S, 2003, J BIOL CHEM, V278, P8244, DOI 10.1074/jbc.M210635200; Kayed H, 2006, PANCREAS, V32, P119, DOI 10.1097/01.mpa.0000202937.55460.0c; Kusano KF, 2005, NAT MED, V11, P1197, DOI 10.1038/nm1313; Mallat Z, 2000, CIRCULATION, V101, P841, DOI 10.1161/01.CIR.101.8.841; Martin S, 2004, CIRCULATION, V109, P1653, DOI 10.1161/01.CIR.0000124065.31211.6E; Martinez MC, 2005, AM J PHYSIOL-HEART C, V288, pH1004, DOI 10.1152/ajpheart.00842.2004; Mezentsev A, 2005, AM J PHYSIOL-HEART C, V289, pH1106, DOI 10.1152/ajpheart.00265.2005; Moens AL, 2005, INT J CARDIOL, V100, P179, DOI 10.1016/j.ijcard.2004.04.013; Nomura S, 2001, ATHEROSCLEROSIS, V158, P277, DOI 10.1016/S0021-9150(01)00433-6; Podlasek CA, 2005, CURR PHARM DESIGN, V11, P4011, DOI 10.2174/138161205774913408; Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083; Ratajczak J, 2006, LEUKEMIA, V20, P1487, DOI 10.1038/sj.leu.2404296; RICHARD V, 1994, CIRCULATION, V89, P1254, DOI 10.1161/01.CIR.89.3.1254; RIOBO NA, 2006, J BIOL CHEM, V103, P4505; Sabatier F, 2002, DIABETES, V51, P2840, DOI 10.2337/diabetes.51.9.2840; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Tesse A, 2005, ARTERIOSCL THROM VAS, V25, P2522, DOI 10.1161/01.ATV.0000189298.62240.5d; Vokes SA, 2004, DEVELOPMENT, V131, P4371, DOI 10.1242/dev.01304; Yang HY, 2007, MOL IMMUNOL, V44, P1577, DOI 10.1016/j.molimm.2006.08.017	30	111	120	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2735	2741		10.1096/fj.07-8079com	http://dx.doi.org/10.1096/fj.07-8079com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17428963	Green Submitted			2022-12-28	WOS:000249237500015
J	Hubert, P; Herman, L; Maillard, C; Caberg, JH; Nikkels, A; Pierard, G; Foidart, JM; Noel, A; Boniver, J; Delvenne, P				Hubert, Pascale; Herman, Ludivine; Maillard, Catherine; Caberg, Jean-Hubert; Nikkels, Arjen; Pierard, Gerald; Foidart, Jean-Marie; Noel, Agnes; Boniver, Jacques; Delvenne, Philippe			Defensins induce the recruitment of dendritic cells in cervical human papillomavirus-associated (pre) neoplastic lesions formed in vitro and transplanted in vivo	FASEB JOURNAL			English	Article						alpha and beta defensins; antigen presenting cells; HPV; cervical lesions; migration	SQUAMOUS INTRAEPITHELIAL LESIONS; HUMAN NEUTROPHIL PEPTIDE-1; COLONY-STIMULATING FACTOR; LANGERHANS CELLS; ALPHA-DEFENSINS; UTERINE CERVIX; HUMAN SKIN; TRANSFORMED KERATINOCYTES; (PRE)NEOPLASTIC LESIONS; PRENEOPLASTIC LESIONS	In addition to their direct antimicrobial activity, defensins might also influence adaptive immunity by attracting immature dendritic cells ( DC). As these cells have been shown to be deficient in uterine cervix carcinogenesis, we evaluated the ability of alpha- defensin ( HNP- 2, human neutrophil defensin 2) and alpha- defensin ( H beta D2, human beta defensin 2) to stimulate their migration in human papillomavirus ( HPV)associated ( pre) cancers. We first observed, using RTPCR and immunohistology, that H beta D2 is absent in HPV- transformed keratinocytes and that it is weakly expressed in cervical ( pre) neoplastic lesions in comparison with normal keratinocytes. We next demonstrated that defensins exert a chemotactic activity for DC in a Boyden Chamber assay and stimulate their infiltration in an in vitro- formed ( pre) neoplastic epithelium ( organotypic culture of HPV- transformed keratinocytes). To evaluate the ability of defensins also to recruit DC in vivo, we developed a model of immunodeficient mice grafted with organotypic cultures of HPV + keratinocytes, which form an epithelium similar to a high- grade neoplastic lesion, with tumoral invasion and neovascularization. Intravenously injected human DC were able to infiltrate grafts of HPV + keratinocytes after administration of HNP- 2 in the transplantation chamber. Taken together, these results suggest that defensins could reverse a frequent immune alteration observed in cancer development.	CHU Sart Tilman, Univ Hosp Liege, Dept Pathol, B-4000 Liege, Belgium; CHU Sart Tilman, Univ Hosp Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; CHU Sart Tilman, Univ Hosp Liege, Dept Dermatol, B-4000 Liege, Belgium	University of Liege; University of Liege; University of Liege	Hubert, P (corresponding author), Univ Liege, Dept Pathol B35, CHU Sart Tilman, B-4000 Liege, Belgium.	P.hubert@ulg.ac.be		Noel, Agnes/0000-0002-7670-6179; Nikkels, Arjen/0000-0001-5240-4806				Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Al-Saleh W, 1998, J PATHOL, V184, P283, DOI 10.1002/(SICI)1096-9896(199803)184:3<283::AID-PATH25>3.0.CO;2-K; Ali RS, 2001, J INVEST DERMATOL, V117, P106; Andrade W, 1996, J IMMUNOL METHODS, V194, P181, DOI 10.1016/0022-1759(96)00083-X; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Bosch FX, 2002, VIRUS RES, V89, P183, DOI 10.1016/S0168-1702(02)00187-9; Buck CB, 2006, P NATL ACAD SCI USA, V103, P1516, DOI 10.1073/pnas.0508033103; Calore EE, 2001, GYNECOL OBSTET INVES, V51, P51, DOI 10.1159/000052891; Chadebech P, 2003, CELL BIOL TOXICOL, V19, P313, DOI 10.1023/B:CBTO.0000004975.36521.c8; Charbonnier AS, 1999, J EXP MED, V190, P1755, DOI 10.1084/jem.190.12.1755; Chavakis T, 2004, FASEB J, V18, P1306, DOI 10.1096/fj.03-1009fje; Chen HQ, 2006, PEPTIDES, V27, P931, DOI 10.1016/j.peptides.2005.08.018; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; Conejo-Garcia JR, 2004, NAT MED, V10, P950, DOI 10.1038/nm1097; DELVENNE P, 1995, AM J PATHOL, V146, P589; Duits LA, 2002, IMMUNOLOGY, V106, P517, DOI 10.1046/j.1365-2567.2002.01430.x; Economopoulou M, 2005, BLOOD, V106, P3831, DOI 10.1182/blood-2005-03-0889; FRIEDL F, 1970, P SOC EXP BIOL MED, V135, P543; Giannini SL, 1998, CLIN EXP IMMUNOL, V113, P183; Giannini SL, 2002, INT J CANCER, V97, P654, DOI 10.1002/ijc.10084; Grutkoski PS, 2003, ANTIMICROB AGENTS CH, V47, P2666, DOI 10.1128/AAC.47.8.2666-2668.2003; Havard L, 2005, VIROLOGY, V331, P357, DOI 10.1016/j.virol.2004.10.030; Hubert P, 2005, J PATHOL, V206, P346, DOI 10.1002/path.1771; Hubert P, 2005, EXP DERMATOL, V14, P469, DOI 10.1111/j.0906-6705.2005.00299.x; Hubert P, 2001, FASEB J, V15, P2521, DOI 10.1096/fj.00-0872fje; Hubert P, 1999, AM J PATHOL, V154, P775, DOI 10.1016/S0002-9440(10)65324-2; Hubert P, 1998, CANCER IMMUNOL IMMUN, V47, P81, DOI 10.1007/s002620050507; HUGHES RG, 1988, J CLIN PATHOL, V41, P253, DOI 10.1136/jcp.41.3.253; Josien R, 1997, J EXP MED, V186, P467, DOI 10.1084/jem.186.3.467; KAPLAN G, 1992, J EXP MED, V175, P1717, DOI 10.1084/jem.175.6.1717; Lillard JW, 1999, P NATL ACAD SCI USA, V96, P651, DOI 10.1073/pnas.96.2.651; Lundy FT, 2004, ORAL ONCOL, V40, P139, DOI 10.1016/S1368-8375(03)00142-8; Mallow EB, 1996, J BIOL CHEM, V271, P4038; Masson V, 2004, FASEB J, V18, P234, DOI 10.1096/fj.04-2140fje; Matthews K, 2003, J VIROL, V77, P8378, DOI 10.1128/JVI.77.15.8378-8385.2003; McKeown STW, 2006, ORAL ONCOL, V42, P685, DOI 10.1016/j.oraloncology.2005.11.005; MEMAR OM, 1995, J INVEST DERMATOL, V105, pS99, DOI 10.1111/1523-1747.ep12316241; Mizukawa N, 2000, ANTICANCER RES, V20, P1125; Muller CA, 2002, AM J PATHOL, V160, P1311, DOI 10.1016/S0002-9440(10)62558-8; Noel A, 2004, J CLIN PATHOL, V57, P577, DOI 10.1136/jcp.2003.014472; Papo N, 2005, CELL MOL LIFE SCI, V62, P784, DOI 10.1007/s00018-005-4560-2; PATER MM, 1985, VIROLOGY, V145, P313, DOI 10.1016/0042-6822(85)90164-3; Renard I, 2002, AM J PATHOL, V160, P113, DOI 10.1016/S0002-9440(10)64355-6; Sorensen OE, 2005, J IMMUNOL, V174, P4870, DOI 10.4049/jimmunol.174.8.4870; THIVOLET J, 1982, INT J DERMATOL, V21, P94, DOI 10.1111/j.1365-4362.1982.tb00510.x; van Wetering S, 2002, INFLAMM RES, V51, P8, DOI 10.1007/PL00000282; Wang W, 2004, J IMMUNOL, V173, P515, DOI 10.4049/jimmunol.173.1.515; Weinberg A, 2006, Adv Dent Res, V19, P42; Yang D, 2000, J LEUKOCYTE BIOL, V68, P9; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525	51	58	63	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2765	2775		10.1096/fj.06-7646com	http://dx.doi.org/10.1096/fj.06-7646com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17470569				2022-12-28	WOS:000249237500018
J	Vernace, VA; Arnaud, L; Schmidt-Glenewinkel, T; Figueiredo-Pereira, ME				Vernace, Vita A.; Arnaud, Lisette; Schmidt-Glenewinkel, Thomas; Figueiredo-Pereira, Maria E.			Aging perturbs 26S proteasome assembly in Drosophila melanogaster	FASEB JOURNAL			English	Article						ubiquitin; protein degradation; 26S/20S proteasomes; ATP depletion; fly aging	MULTICATALYTIC PROTEINASE COMPLEX; 26S PROTEASOME; SKELETAL-MUSCLE; ATP HYDROLYSIS; SACCHAROMYCES-CEREVISIAE; 20S PROTEASOME; DEGRADATION; UBIQUITIN; RESTRICTION; COMPARTMENTATION	Aging is associated with loss of quality control in protein turnover. The ubiquitin- proteasome pathway is critical to this quality control process as it degrades mutated and damaged proteins. We identified a unique aging- dependent mechanism that contributes to proteasome dysfunction in Drosophila melanogaster. Our studies are the first to show that the major proteasome form in old ( 43 - 47 days old) female and male flies is the weakly active 20S core particle, while in younger ( 1 - 32 days old) flies highly active 26S proteasomes are preponderant. Old ( 43 - 47 days) flies of both genders also exhibit a decline ( similar to 50%) in ATP levels, which is relevant to 26S proteasomes, as their assembly is ATP- dependent. The steep declines in 26S proteasome and ATP levels were observed at an age ( 43 - 47 days) when the flies exhibited a marked drop in locomotor performance, attesting that these are " old age" events. Remarkably, treatment with a proteasome inhibitor increases ubiquitinated protein levels and shortens the life span of old but not young flies. In conclusion, our data reveal a previously unknown mechanism that perturbs proteasome activity in " old- age" female and male Drosophila most likely depriving them of the ability to effectively cope with proteotoxic damages caused by environmental and/ or genetic factors.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Schmidt-Glenewinkel, T (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	thomas@genectr.hunter.cuny.edu; pereira@genectr.hunter.cuny.edu			NCRR NIH HHS [G12 RR003037, RR03037] Funding Source: Medline; NIA NIH HHS [R01 AG028847] Funding Source: Medline; NIGMS NIH HHS [GM60654, S06 GM060654] Funding Source: Medline; NINDS NIH HHS [NS41073, U54 NS041073] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U54NS041073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG028847] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aigaki T, 2002, MECH AGEING DEV, V123, P1531, DOI 10.1016/S0047-6374(02)00089-1; Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; Ashburner M., 1989, DROSOPHILA LAB HDB; Babbitt SE, 2005, CELL, V121, P553, DOI 10.1016/j.cell.2005.03.028; Bajorek M, 2003, CURR BIOL, V13, P1140, DOI 10.1016/S0960-9822(03)00417-2; Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; Bua EA, 2004, FASEB J, V18, P582, DOI 10.1096/fj.03-0668fje; Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132; Bulteau AL, 2001, J BIOL CHEM, V276, P45662, DOI 10.1074/jbc.M105374200; CALLEJA M, 1993, J BIOL CHEM, V268, P18891; Carrard G, 2002, INT J BIOCHEM CELL B, V34, P1461, DOI 10.1016/S1357-2725(02)00085-7; Chondrogianni N, 2005, EXP GERONTOL, V40, P931, DOI 10.1016/j.exger.2005.09.004; Elsasser S, 2005, METHOD ENZYMOL, V398, P353, DOI 10.1016/S0076-6879(05)98029-4; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; Forster A, 2003, TRENDS CELL BIOL, V13, P550, DOI 10.1016/j.tcb.2003.09.001; Gaczynska M, 2001, MECH AGEING DEV, V122, P235, DOI 10.1016/S0047-6374(00)00246-3; Gajewski CD, 2003, MOL BIOL CELL, V14, P3628, DOI 10.1091/mbc.E02-12-0796; Girardot F, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-69; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; GRAY DA, 2003, SCI AGING KNOWLEDGE, pRE6; Groll M, 1999, P NATL ACAD SCI USA, V96, P10976, DOI 10.1073/pnas.96.20.10976; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Hipkiss AR, 2006, MECH AGEING DEV, V127, P8, DOI 10.1016/j.mad.2005.09.006; Hoffman L, 1997, MOL BIOL REP, V24, P13, DOI 10.1023/A:1006892220996; Imai J, 2003, EMBO J, V22, P3557, DOI 10.1093/emboj/cdg349; ISHIDA Y, 1994, MOL CELL BIOCHEM, V133, P39, DOI 10.1007/BF01267946; Keller JN, 2002, AGEING RES REV, V1, P279, DOI 10.1016/S1568-1637(01)00006-X; Kisselev AF, 2002, J BIOL CHEM, V277, P22260, DOI 10.1074/jbc.M112360200; Kurucz E, 2002, BIOCHEM J, V365, P527, DOI 10.1042/BJ20011520; Lee CM, 1997, FREE RADICAL BIO MED, V22, P1259, DOI 10.1016/S0891-5849(96)00546-1; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Liu CW, 2006, MOL CELL, V24, P39, DOI 10.1016/j.molcel.2006.08.025; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; LONGO VD, 2004, SCI AGING KNOWLEDGE, pE6; LOWE J, 1988, J PATHOL, V155, P9, DOI 10.1002/path.1711550105; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Orso G, 2005, J CLIN INVEST, V115, P3026, DOI 10.1172/JCI24694; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; Sanchez-Blanco A, 2006, GENETICS, V172, P1699, DOI 10.1534/genetics.105.053389; SASAKI T, 1984, J BIOL CHEM, V259, P2489; Schwarze SR, 1998, FREE RADICAL BIO MED, V25, P740, DOI 10.1016/S0891-5849(98)00153-1; Schwarze SR, 1998, MUTAT RES-GENOMICS, V382, P99, DOI 10.1016/S1383-5726(97)00013-7; Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102; Stein RL, 1996, BIOCHEMISTRY-US, V35, P3899, DOI 10.1021/bi952262x; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x	48	116	116	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2672	2682		10.1096/fj.06-6751com	http://dx.doi.org/10.1096/fj.06-6751com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17413001	Green Accepted			2022-12-28	WOS:000249237500009
J	Althaus, M; Bogdan, R; Clauss, WG; Fronius, M				Althaus, Mike; Bogdan, Roman; Clauss, Wolfgang G.; Fronius, Martin			Mechano-sensitivity of epithelial sodium channels (ENaCs): laminar shear stress increases ion channel open probability	FASEB JOURNAL			English	Article						DEG/ENaC family; patch-clamp; outside-out; Xenopus oocyte	VASCULAR ENDOTHELIAL-CELLS; CORTICAL COLLECTING TUBULE; NA+ CHANNEL; XENOPUS OOCYTES; CAENORHABDITIS-ELEGANS; FROG-SKIN; MEMBRANE; FLOW; MECHANOTRANSDUCTION; STIMULATION	Epithelial cells are exposed to a variety of mechanical forces, but little is known about the impact of these forces on epithelial ion channels. Here we show that mechanical activation of epithelial sodium channels ( ENaCs), which are essential for electrolyte and water balance, occurs via an increased ion channel open probability. ENaC activity of heterologously expressed rat ( rENaC) and Xenopus ( xENaC) orthologs was measured by whole-cell as well as single-channel recordings. Laminar shear stress ( LSS), producing shear forces in physiologically relevant ranges, was used to mechanically stimulate ENaCs and was able to activate ENaC currents in whole-cell recordings. Preceding pharmacological activation of rENaC with Zn2+ and xENaC with gadolinium and glibenclamide largely prevented LSS-activated currents. In contrast, proteolytic cleavage with trypsin potentiated the LSS effect on rENaC whereas the LSS effect on xENaC was reversed ( inhibition of xENaC current). Further, we found that exposure of excised outside-out patches to LSS led to an increased ion channel open probability without affecting the number of active channels. We suggest that mechano-sensitivity of ENaC may represent a ubiquitous feature for the physiology of epithelia, providing a putative mechanism for coupling transepithelial Na+ reabsorption to luminal transport.	Univ Giessen, Inst Anim Physiol, D-35392 Giessen, Germany	Justus Liebig University Giessen	Fronius, M (corresponding author), Univ Giessen, Inst Anim Physiol, Wartweg 95, D-35392 Giessen, Germany.	martin.fronius@bio.uni-giessen.de	Fronius, Martin/K-4118-2013	Althaus, Mike/0000-0002-3554-7538				Anantharam A, 2006, J PHYSIOL-LONDON, V574, P333, DOI 10.1113/jphysiol.2006.109173; Awayda MS, 1998, J GEN PHYSIOL, V112, P97, DOI 10.1085/jgp.112.2.97; AWAYDA MS, 1995, AM J PHYSIOL-CELL PH, V268, pC1450, DOI 10.1152/ajpcell.1995.268.6.C1450; Barakat AI, 1999, CIRC RES, V85, P820, DOI 10.1161/01.RES.85.9.820; Brakemeier S, 2003, CARDIOVASC RES, V60, P488, DOI 10.1016/j.cardiores.2003.09.010; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Carattino MD, 2004, J BIOL CHEM, V279, P4120, DOI 10.1074/jbc.M311783200; Chraibi A, 1998, J GEN PHYSIOL, V111, P127, DOI 10.1085/jgp.111.1.127; Chraibi A, 1999, J PHARMACOL EXP THER, V290, P341; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; Diakov A, 2004, J BIOL CHEM, V279, P38134, DOI 10.1074/jbc.M403260200; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Drummond HA, 2000, BRAIN RES, V884, P1, DOI 10.1016/S0006-8993(00)02831-6; Drummond HA, 2004, HYPERTENSION, V44, P643, DOI 10.1161/01.HYP.0000144465.56360.ad; Drummond HA, 2001, ANN NY ACAD SCI, V940, P42; Ernstrom GG, 2002, ANNU REV GENET, V36, P411, DOI 10.1146/annurev.genet.36.061802.101708; Friis S, 2001, J MEMBRANE BIOL, V184, P291, DOI 10.1007/s00232-001-0100-7; Fronius M, 2003, J MEMBRANE BIOL, V195, P43, DOI 10.1007/s00232-003-2043-7; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hoger JH, 2002, P NATL ACAD SCI USA, V99, P7780, DOI 10.1073/pnas.102184999; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Jernigan NL, 2005, AM J PHYSIOL-RENAL, V289, pF891, DOI 10.1152/ajprenal.00019.2005; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; Kellenberger S, 2002, J PHYSIOL-LONDON, V543, P413, DOI 10.1113/jphysiol.2002.022020; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Knight KK, 2006, P NATL ACAD SCI USA, V103, P2805, DOI 10.1073/pnas.0511184103; KOEFOEDJOHNSEN V, 1958, ACTA PHYSIOL SCAND, V42, P298, DOI 10.1111/j.1748-1716.1958.tb01563.x; Lieu DK, 2004, AM J PHYSIOL-CELL PH, V286, pC1367, DOI 10.1152/ajpcell.00243.2003; Liu W, 2003, AM J PHYSIOL-RENAL, V285, pF998, DOI 10.1152/ajprenal.00067.2003; Mano I, 1999, BIOESSAYS, V21, P568, DOI 10.1002/(SICI)1521-1878(199907)21:7&lt;568::AID-BIES5&gt;3.0.CO;2-L; Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002; MCNAUGHTON KJ, 1966, J FLUID MECH, V25, P367, DOI 10.1017/S0022112066001708; Morimoto T, 2006, AM J PHYSIOL-RENAL, V291, pF663, DOI 10.1152/ajprenal.00514.2005; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; Palmer LG, 1996, J GEN PHYSIOL, V107, P35, DOI 10.1085/jgp.107.1.35; PALMER LG, 1986, P NATL ACAD SCI USA, V83, P2767, DOI 10.1073/pnas.83.8.2767; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; Rossier BC, 2002, J GEN PHYSIOL, V120, P67, DOI 10.1085/jgp.20028638; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Rossier BC, 1998, J GEN PHYSIOL, V112, P95, DOI 10.1085/jgp.112.2.95; Rossier Bernard C, 2004, Proc Am Thorac Soc, V1, P4, DOI 10.1513/pats.2306007; Satlin LM, 2001, AM J PHYSIOL-RENAL, V280, pF1010, DOI 10.1152/ajprenal.2001.280.6.F1010; Schnizler M, 2003, BBA-BIOMEMBRANES, V1609, P170, DOI 10.1016/S0005-2736(02)00684-3; Sheng SH, 2004, J BIOL CHEM, V279, P31687, DOI 10.1074/jbc.M405224200; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Tarran R, 2005, J BIOL CHEM, V280, P35751, DOI 10.1074/jbc.M505832200; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; Tavernarakis N, 2001, ANN NY ACAD SCI, V940, P28; TURNHEIM K, 1991, PHYSIOL REV, V71, P429, DOI 10.1152/physrev.1991.71.2.429; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329	52	84	86	2	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2389	2399		10.1096/fj.06-7694com	http://dx.doi.org/10.1096/fj.06-7694com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17426066				2022-12-28	WOS:000248454400014
J	Yaka, R; Biegon, A; Grigoriadis, N; Simeonidou, C; Grigoriadis, S; Alexandrovich, AG; Matzner, H; Schumann, J; Trembovler, V; Tsenter, J; Shohami, E				Yaka, Rami; Biegon, Anat; Grigoriadis, Nikolaos; Simeonidou, Constantina; Grigoriadis, Savvas; Alexandrovich, Alexander G.; Matzner, Henri; Schumann, Johanna; Trembovler, Victoria; Tsenter, Jeanna; Shohami, Esther			D-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury	FASEB JOURNAL			English	Article						traumatic brain injury; NMDA receptors; synaptic plasticity; BDNF	TRAUMATIC BRAIN-INJURY; FLUID-PERCUSSION INJURY; PERIPHERAL BENZODIAZEPINE-RECEPTORS; FOCAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; NEUROTROPHIC FACTOR; INTRACEREBRAL MICRODIALYSIS; HIPPOCAMPAL-NEURONS; NMDA RECEPTORS; RAT-BRAIN	Traumatic brain injury triggers a massive glutamate efflux, activation of NMDA receptor channels, and cell death. Recently, we reported that NMDA receptors in mice are down-regulated from hours to days following closed head injury (CHI), and treatment with NMDA improved recovery of motor and cognitive functions up to 14 d post-injury. Here we show that a single injection of a low dose of D-cycloserine (DCS), a partial NMDA receptor agonist, in CHI mice 24 h post-injury, resulted in a faster and greater recovery of motor and memory functions as assessed by neurological severity score and object recognition tests, respectively. Moreover, DCS treatment of CHI mice led to a significant improvement of hippocampal long-term potentiation (LTP) in the CA1 region that was completely blunted in CHI control mice. However, DCS did not improve CHI-induced impairment in synaptic glutamate release measured by paired pulse facilitation (PPF) ratio in hippocampal CA1 region. Finally, CHI-induced reduction of brain-derived neurotrophic factor (BDNF) was fully restored following DCS treatment. Since DCS is in clinical use for other indications, the present study offers a novel approach to treat human brain injury.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Brookhaven Natl Lab, Upton, NY 11973 USA; Aristotle Univ Thessaloniki, Fac Med, Dept Physiol, Thessaloniki, Greece; Hadassah Univ Hosp, Dept Neurosurg, IL-91120 Jerusalem, Israel; Hadassah Med Ctr, Dept Rehabil, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; United States Department of Energy (DOE); Brookhaven National Laboratory; Aristotle University of Thessaloniki; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center	Yaka, R (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, POB 12065, IL-91120 Jerusalem, Israel.	yaka@md.huji.ac.il			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050285] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 050285-01 A2] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Albensi BC, 2000, J NEUROSCI RES, V62, P177, DOI 10.1002/1097-4547(20001015)62:2&lt;177::AID-JNR3&gt;3.0.CO;2-D; Andersen JM, 2002, BEHAV BRAIN RES, V129, P211, DOI 10.1016/S0166-4328(01)00318-7; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Biegon A, 2002, J NEUROCHEM, V82, P924, DOI 10.1046/j.1471-4159.2002.01050.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Cao R, 2006, NEUROSCI LETT, V401, P136, DOI 10.1016/j.neulet.2006.03.005; CHEN M, 1991, ANN NEUROL, V30, P62, DOI 10.1002/ana.410300112; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Davalos A, 1997, STROKE, V28, P708, DOI 10.1161/01.STR.28.4.708; Di X, 1996, J NEUROSURG, V85, P655, DOI 10.3171/jns.1996.85.4.0655; Duncan EJ, 2004, SCHIZOPHR RES, V71, P239, DOI 10.1016/j.schres.2004.03.013; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; FRIEDMAN C, 2001, BIOINFORMATICS, V1, P1; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; Grossman R, 2003, NEUROIMAGE, V20, P1971, DOI 10.1016/j.neuroimage.2003.06.003; Heresco-Levy U, 2002, INT J NEUROPSYCHOPH, V5, P301, DOI 10.1017/S1461145702003061; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Korte M, 1996, J PHYSIOLOGY-PARIS, V90, P157, DOI 10.1016/S0928-4257(97)81415-5; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; LAAKE K, 2002, COCHRANE DB SYST REV; Lelong V, 2001, NEUROPHARMACOLOGY, V41, P517, DOI 10.1016/S0028-3908(01)00085-5; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nitsche MA, 2004, NEUROPSYCHOPHARMACOL, V29, P1573, DOI 10.1038/sj.npp.1300517; Owens J, 2000, NUCL MED BIOL, V27, P557, DOI 10.1016/S0969-8051(00)00102-5; Paxinos G, 2000, MOUSE BRAIN STEREOTA; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schneider JS, 2000, BRAIN RES, V860, P190, DOI 10.1016/S0006-8993(00)02036-9; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P329; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Simic G, 2000, EXP NEUROL, V165, P12, DOI 10.1006/exnr.2000.7448; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7; THIEL G, 1993, BRAIN PATHOL, V3, P87, DOI 10.1111/j.1750-3639.1993.tb00729.x; WALLACE MC, 1992, J NEUROSURG, V76, P127, DOI 10.3171/jns.1992.76.1.0127; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Yaka R, 2003, J BIOL CHEM, V278, P9630, DOI 10.1074/jbc.M209141200; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037; ZAFRA F, 1992, J NEUROSCI, V12, P4793	53	75	78	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2033	2041		10.1096/fj.06-7856com	http://dx.doi.org/10.1096/fj.06-7856com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17351125				2022-12-28	WOS:000247500300013
J	Amit, T; Avramovich-Tirosh, Y; Youdim, MBH; Mandel, S				Amit, Tamar; Avramovich-Tirosh, Yael; Youdim, Moussa B. H.; Mandel, Silvia			Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators	FASEB JOURNAL			English	Review						cell cycle; neurodegenerative diseases; APP mRNA; multifunctional drugs	AMYLOID PRECURSOR PROTEIN; GREEN TEA POLYPHENOL; PROLYL ISOMERASE PIN1; MONOAMINE-OXIDASE INHIBITION; INDUCED NEURONAL APOPTOSIS; CELL-CYCLE; OXIDATIVE STRESS; 5'-UNTRANSLATED REGION; NEURODEGENERATIVE DISEASES; DNA-REPLICATION	Dysregulation of brain iron homeostasis is central to early neuropathological events in Alzheimer's disease (AD), including oxidative stress, inflammatory processes, amyloid deposition, tau phosphorylation, and neuronal cell cycle regulatory failure, leading to apoptosis. Also, there is a direct link between iron metabolism and AD pathogenesis, demonstrated by the presence of an iron-responsive element in the 5' UTR of the amyloid precursor protein transcript. As a consequence of these findings, a new paradigm is emerging that includes the development of iron-chelating neuroprotective-neurorescue drugs with multimodal functions, acting at various pathological brain targets. This concept is challenging the widely held assumption that "silver bullet" agents are superior to "dirty drugs" in drug therapy for neurodegenerative diseases. At best, the so-called magic bullets exhibit moderate symptomatic activity without modifying the course of disease progression. The present review elaborates on conventional and novel therapeutic targets of various multifunctional iron-chelating drugs (e.g., chemically designed compounds; natural polyphenols) that address multiple central nervous system etiologies in AD, aimed at preventing or slowing disease evolution. A similar approach in drug design is being investigated for treatment of cancer, AIDS, cardiovascular diseases, and depression.	[Amit, Tamar; Avramovich-Tirosh, Yael; Youdim, Moussa B. H.; Mandel, Silvia] Technion Israel Inst Technol, Dept Pharmacol, Fac Med, Eve Topf Ctr Excellence Neurodegenerat Dis Res, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Dept Pharmacol, Fac Med, Eve Topf Ctr Excellence Neurodegenerat Dis Res, POB 9697, IL-31096 Haifa, Israel.	youdim@tx.technion.ac.il						Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Arendt T, 2007, BBA-MOL BASIS DIS, V1772, P413, DOI 10.1016/j.bbadis.2006.12.005; Atwood CS, 2003, BRAIN RES REV, V43, P1, DOI 10.1016/S0165-0173(03)00174-7; Avramovich-Tirosh Y, 2007, CURR ALZHEIMER RES, V4, P403, DOI 10.2174/156720507781788927; Avramovich-Tirosh Y, 2007, J NEUROCHEM, V100, P490, DOI 10.1111/j.1471-4159.2006.04258.x; Bandyopadhyay S, 2006, J BIOMOL SCREEN, V11, P469, DOI 10.1177/1087057106287271; Ben Shachar D, 2004, NEUROPHARMACOLOGY, V46, P254, DOI 10.1016/j.neuropharm.2003.09.005; Biswas SC, 2007, J NEUROSCI, V27, P893, DOI 10.1523/JNEUROSCI.3524-06.2007; Bowser R, 2002, J ALZHEIMERS DIS, V4, P249, DOI 10.3233/JAD-2002-4316; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; CASDORPH HR, 1983, NEW ZEAL MED J, V96, P66; Castellani RJ, 2007, NEUROCHEM RES, V32, P1640, DOI 10.1007/s11064-007-9360-7; Chen ZP, 1998, CANCER LETT, V129, P173, DOI 10.1016/S0304-3835(98)00108-6; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Copani A, 2002, FASEB J, V16, P2006, DOI 10.1096/fj.02-0422fje; Copani A, 1999, FASEB J, V13, P2225, DOI 10.1096/fasebj.13.15.2225; Copani A, 2002, NEUROCHEM RES, V27, P173, DOI 10.1023/A:1014879311761; Copani A, 2002, J NEUROSCI, V22, P3963, DOI 10.1523/JNEUROSCI.22-10-03963.2002; Copani A, 2007, BBA-MOL BASIS DIS, V1772, P409, DOI 10.1016/j.bbadis.2006.10.016; Dedeoglu A, 2004, EXP GERONTOL, V39, P1641, DOI 10.1016/j.exger.2004.08.016; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Evans Teresa A, 2007, Int J Med Sci, V4, P140; Fischer PM, 2003, CHEM BIOL, V10, P1144, DOI 10.1016/j.chembiol.2003.12.009; Fu D, 2007, BLOOD, V110, P752, DOI 10.1182/blood-2007-03-076737; Gal S, 2005, J NEUROCHEM, V95, P79, DOI 10.1111/j.1471-4159.2005.03341.x; GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310; Gupta S, 2003, ARCH BIOCHEM BIOPHYS, V410, P177, DOI 10.1016/S0003-9861(02)00668-9; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Herrup K, 2007, NAT REV NEUROSCI, V8, P368, DOI 10.1038/nrn2124; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; House E, 2004, J ALZHEIMERS DIS, V6, P291; Kalinowski DS, 2005, PHARMACOL REV, V57, P547, DOI 10.1124/pr.57.4.2; Khan N, 2006, CANCER RES, V66, P2500, DOI 10.1158/0008-5472.CAN-05-3636; Kim CH, 2005, ARCH BIOCHEM BIOPHYS, V435, P264, DOI 10.1016/j.abb.2004.12.022; Klein JA, 2003, J CLIN INVEST, V111, P785, DOI 10.1172/JCI200318182; Korhonen L, 2003, J NEUROSCI RES, V71, P769, DOI 10.1002/jnr.10546; Kuriyama S, 2006, AM J CLIN NUTR, V83, P355; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Levites Y, 2003, FASEB J, V17, P952, DOI 10.1096/fj.02-0881fje; Levites Y, 2001, J NEUROCHEM, V78, P1073, DOI 10.1046/j.1471-4159.2001.00490.x; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Liu Q, 2007, FASEB J, V21, P61, DOI 10.1096/fj.06-5841com; Lovejoy DB, 2003, CURR MED CHEM, V10, P1035, DOI 10.2174/0929867033457557; Lu PJ, 1999, NATURE, V399, P784; Mandel S, 2006, MOL NUTR FOOD RES, V50, P229, DOI 10.1002/mnfr.200500156; Mandel SA, 2005, NEUROSIGNALS, V14, P46, DOI 10.1159/000085385; Mandel S, 2007, PROG NEUROBIOL, V82, P348, DOI 10.1016/j.pneurobio.2007.06.001; Mazanetz MP, 2007, NAT REV DRUG DISCOV, V6, P464, DOI 10.1038/nrd2111; MCLACHLAN DRC, 1991, LANCET, V337, P1304, DOI 10.1016/0140-6736(91)92978-B; Moreira PI, 2005, J NEURAL TRANSM, V112, P921, DOI 10.1007/s00702-004-0242-8; Mosch B, 2007, J NEUROSCI, V27, P6859, DOI 10.1523/JNEUROSCI.0379-07.2007; Nagy Z, 2005, J CELL MOL MED, V9, P531, DOI 10.1111/j.1582-4934.2005.tb00485.x; Nurtjahja-Tjendraputra E, 2007, BLOOD, V109, P4045, DOI 10.1182/blood-2006-10-047753; Ono K, 2003, J NEUROCHEM, V87, P172, DOI 10.1046/j.1471-4159.2003.01976.x; Pahl PMB, 2007, J EXP THER ONCOL, V6, P193; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; Park KHJ, 2007, J NEUROSCI, V27, P2969, DOI 10.1523/JNEUROSCI.0186-07.2007; Pastorino L, 2006, NATURE, V440, P528, DOI 10.1038/nature04543; Payton S, 2003, J MOL NEUROSCI, V20, P267, DOI 10.1385/JMN:20:3:267; Rezai-Zadeh K, 2005, J NEUROSCI, V25, P8807, DOI 10.1523/JNEUROSCI.1521-05.2005; Reznichenko L, 2005, J NEUROCHEM, V93, P1157, DOI 10.1111/j.1471-4159.2005.03085.x; Reznichenko L, 2006, J NEUROCHEM, V97, P527, DOI 10.1111/j.1471-4159.2006.03770.x; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; Ritchie K, 2002, LANCET, V360, P1759, DOI 10.1016/S0140-6736(02)11667-9; Rogers JT, 2004, CURR DRUG TARGETS, V5, P535, DOI 10.2174/1389450043345272; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Rogers JT, 1999, J BIOL CHEM, V274, P6421, DOI 10.1074/jbc.274.10.6421; Shin RW, 2003, BRAIN RES, V961, P139, DOI 10.1016/S0006-8993(02)03893-3; Siddiq A, 2005, J BIOL CHEM, V280, P41732, DOI 10.1074/jbc.M504963200; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; Sortino MA, 2004, NEUROPHARMACOLOGY, V47, P1198, DOI 10.1016/j.neuropharm.2004.08.011; Verdaguer E, 2002, NEUROREPORT, V13, P413, DOI 10.1097/00001756-200203250-00010; Webber KM, 2005, MECH AGEING DEV, V126, P1019, DOI 10.1016/j.mad.2005.03.024; Whitnall Megan, 2006, Semin Pediatr Neurol, V13, P186, DOI 10.1016/j.spen.2006.08.008; Woods J, 2007, BBA-MOL BASIS DIS, V1772, P503, DOI 10.1016/j.bbadis.2006.12.004; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Yang Y, 2006, J NEUROSCI, V26, P775, DOI 10.1523/JNEUROSCI.3707-05.2006; Yang Y, 2001, J NEUROSCI, V21, P2661, DOI 10.1523/JNEUROSCI.21-08-02661.2001; Zaman K, 1999, J NEUROSCI, V19, P9821; Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537; Zheng H, 2005, J NEUROCHEM, V95, P68, DOI 10.1111/j.1471-4159.2005.03340.x; Zheng HL, 2005, BIOORGAN MED CHEM, V13, P773, DOI 10.1016/j.bmc.2004.10.037; ZHU W, 2007, FASEB J; ZHU X, 2007, BIOCHIM BIOPHYS ACTA, V1772, P402; Zhu XW, 2000, J NEUROPATH EXP NEUR, V59, P880, DOI 10.1093/jnen/59.10.880	86	101	105	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2008	22	5					1296	1305		10.1096/fj.07-8627rev	http://dx.doi.org/10.1096/fj.07-8627rev			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18048580				2022-12-28	WOS:000255898700003
J	Chen, YH; Harvey, BK; Hoffman, AF; Wang, Y; Chiang, YH; Lupica, CR				Chen, Yuan-Hao; Harvey, Brandon K.; Hoffman, Alexander F.; Wang, Yun; Chiang, Yung-Hsiao; Lupica, Carl R.			MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector	FASEB JOURNAL			English	Article						cyclic voltammetry; gene therapy; LTD; LTP; Parkinson's disease	METABOTROPIC GLUTAMATE RECEPTORS; LONG-TERM POTENTIATION; RAT NUCLEUS-ACCUMBENS; PARKINSONS-DISEASE; IN-VIVO; CAUDATE-PUTAMEN; 6-HYDROXYDOPAMINE LESION; CORTICOSTRIATAL SYNAPSES; DOPAMINE DENERVATION; NIGROSTRIATAL SYSTEM	This study determined the consequences of dopamine denervation of the striatum on synaptic plasticity and prevention of these changes with gene therapy using an adeno-associated viral vector (AAV) expressing glial cell line-derived neurotrophic factor (GDNF). C57BL6/J mice were injected with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP); long-term depression (LTD) or potentiation (LTP) were measured in vitro. Fast-scan cyclic voltammetry measured electrically released dopamine from a functionally relevant pool in these same striatal slices. After MPTP, dopamine release and uptake were greatly diminished, and LTP and LTD were blocked in the striatal slices. The loss of plasticity resulted directly from the loss of dopamine since its application rescued synaptic plasticity. Striatal GDNF expression via AAV, before MPTP, significantly protected against the loss of dopamine and prevented the blockade of corticostriatal LTP. These data demonstrate that dopamine plays a role in supporting several forms of striatal plasticity and that GDNF expression via AAV prevents the loss of dopamine and striatal plasticity caused by MPTP. We propose that impairment of striatal plasticity after dopamine denervation plays a role in the symptomology of Parkinson's disease and that AAV expression of neurotrophic factors represents a tenable approach to protecting against or slowing these neurobiological deficits.	[Chen, Yuan-Hao; Chiang, Yung-Hsiao] Triserv Gen Hosp, Dept Neurol Surg, Taipei 114, Taiwan; [Chen, Yuan-Hao; Chiang, Yung-Hsiao] Natl Def Med Ctr, Grad Inst Med Sci, Program Clin Med, Taipei, Taiwan; [Chen, Yuan-Hao; Harvey, Brandon K.; Hoffman, Alexander F.; Wang, Yun; Lupica, Carl R.] Natl Inst Drug Abuse, Natl Inst Hlth, Intramural Res Program, Dept Hlth & Human Serv, Baltimore, MD USA	Tri-Service General Hospital; National Defense Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Chiang, YH (corresponding author), Triserv Gen Hosp, Dept Neurol Surg, 325 Sect 2,Cheng Kung Rd,Neihu Dist, Taipei 114, Taiwan.	ychiang@mac.com; clupica@intra.nida.nih.gov	Harvey, Brandon Keith/AAY-4080-2021; Harvey, Brandon K/A-5559-2010; Hoffman, Alex/AIF-4544-2022; Lupica, Carl/AAY-3193-2021; Hoffman, Alex/H-3035-2012	Harvey, Brandon Keith/0000-0002-4036-1383; Hoffman, Alex/0000-0002-2676-0628; Lupica, Carl/0000-0002-5375-3263; Hoffman, Alex/0000-0002-2676-0628	NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000516, Z01DA000443, ZIADA000443, Z01DA000516, ZIADA000429, Z01DA000429, ZIADA000461, Z01DA000461] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abarca J, 1999, NEUROCHEM INT, V35, P19, DOI 10.1016/S0197-0186(99)00029-7; Araki T, 2000, EUR NEUROPSYCHOPHARM, V10, P365, DOI 10.1016/S0924-977X(00)00094-8; Arbuthnott GW, 2000, J ANAT, V196, P587, DOI 10.1046/j.1469-7580.2000.19640587.x; Barnes TD, 2005, NATURE, V437, P1158, DOI 10.1038/nature04053; Bensadoun JC, 2000, EXP NEUROL, V164, P15, DOI 10.1006/exnr.2000.7409; Cahill PS, 1996, ANAL CHEM, V68, P3180, DOI 10.1021/ac960347d; CALABRESI P, 1992, NEUROSCI LETT, V142, P95, DOI 10.1016/0304-3940(92)90628-K; CALABRESI P, 1992, EUR J NEUROSCI, V4, P929, DOI 10.1111/j.1460-9568.1992.tb00119.x; Calabresi P, 2007, TRENDS NEUROSCI, V30, P211, DOI 10.1016/j.tins.2007.03.001; Capozzo A, 1997, EXP NEUROL, V146, P142, DOI 10.1006/exnr.1997.6494; Centonze D, 1999, J NEUROPHYSIOL, V82, P3575, DOI 10.1152/jn.1999.82.6.3575; Cheng FC, 1998, NEUROSCI LETT, V252, P87, DOI 10.1016/S0304-3940(98)00554-0; ChoiLundberg DL, 1997, SCIENCE, V275, P838, DOI 10.1126/science.275.5301.838; Ciliax BJ, 1999, J COMP NEUROL, V409, P38, DOI 10.1002/(SICI)1096-9861(19990621)409:1<38::AID-CNE4>3.0.CO;2-1; COLWELL CS, 1995, J NEUROSCI, V15, P1704, DOI 10.1523/JNEUROSCI.15-03-01704.1995; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Eslamboli A, 2005, J NEUROSCI, V25, P769, DOI 10.1523/JNEUROSCI.4421-04.2005; FLORIO T, 1993, BRAIN RES, V619, P180, DOI 10.1016/0006-8993(93)91610-5; Ganguly A, 2001, NEUROSCIENCE, V103, P405, DOI 10.1016/S0306-4522(01)00005-7; Gasmi M, 2007, NEUROBIOL DIS, V27, P67, DOI 10.1016/j.nbd.2007.04.003; Geiger JRP, 2000, NEURON, V28, P927, DOI 10.1016/S0896-6273(00)00164-1; Gerdeman GL, 2003, TRENDS NEUROSCI, V26, P184, DOI 10.1016/S0166-2236(03)00065-1; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Graybiel AM, 1998, NEUROBIOL LEARN MEM, V70, P119, DOI 10.1006/nlme.1998.3843; Gubellini P, 2004, PROG NEUROBIOL, V74, P271, DOI 10.1016/j.pneurobio.2004.09.005; Heien MLAV, 2004, ANAL CHEM, V76, P5697, DOI 10.1021/ac0491509; HOFFER BJ, 1994, NEUROSCI LETT, V182, P107, DOI 10.1016/0304-3940(94)90218-6; Hoffman AF, 2003, J NEUROSCI, V23, P4815; Ingham CA, 1998, J NEUROSCI, V18, P4732; JONES SR, 1995, J PHARMACOL EXP THER, V274, P396; KEARNS CM, 1995, BRAIN RES, V672, P104, DOI 10.1016/0006-8993(94)01366-P; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; Kerr JND, 2001, J NEUROPHYSIOL, V85, P117, DOI 10.1152/jn.2001.85.1.117; Kirik D, 2004, NAT NEUROSCI, V7, P105, DOI 10.1038/nn1175; Kirik D, 2000, J NEUROSCI, V20, P4686, DOI 10.1523/JNEUROSCI.20-12-04686.2000; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; Kurosaki R, 2004, PHARMACOL BIOCHEM BE, V78, P143, DOI 10.1016/j.pbb.2004.03.006; Lai SK, 2003, NEUROCHEM INT, V43, P639, DOI 10.1016/S0197-0186(03)00080-9; LINDEFORS N, 1990, NEUROSCI LETT, V115, P248, DOI 10.1016/0304-3940(90)90463-J; LOVINGER DM, 1995, J NEUROPHYSIOL, V73, P1076, DOI 10.1152/jn.1995.73.3.1076; Mahon S, 2004, TRENDS NEUROSCI, V27, P460, DOI 10.1016/j.tins.2004.06.010; Meshul CK, 2000, EXP NEUROL, V165, P191, DOI 10.1006/exnr.2000.7467; Meshul CK, 1999, NEUROSCIENCE, V88, P1, DOI 10.1016/S0306-4522(98)00189-4; PARENT A, 1990, TRENDS NEUROSCI, V13, P254, DOI 10.1016/0166-2236(90)90105-J; Partridge JG, 2000, J NEUROPHYSIOL, V84, P1422, DOI 10.1152/jn.2000.84.3.1422; PENNARTZ CMA, 1990, BRAIN RES, V529, P30, DOI 10.1016/0006-8993(90)90808-O; PENNARTZ CMA, 1993, EUR J NEUROSCI, V5, P107, DOI 10.1111/j.1460-9568.1993.tb00475.x; Picconi B, 2005, NEUROTOXICOLOGY, V26, P779, DOI 10.1016/j.neuro.2005.02.002; Price CJ, 1999, J NEUROCHEM, V73, P2441, DOI 10.1046/j.1471-4159.1999.0732441.x; Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002; Sabeti J, 2002, J NEUROSCI METH, V121, P41, DOI 10.1016/S0165-0270(02)00229-7; Stephens B, 2005, NEUROSCIENCE, V132, P741, DOI 10.1016/j.neuroscience.2005.01.007; Tang KC, 2001, P NATL ACAD SCI USA, V98, P1255, DOI 10.1073/pnas.031374698; Tarazi FI, 2000, BRAIN RES, V881, P69, DOI 10.1016/S0006-8993(00)02812-2; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; WALSH JP, 1993, BRAIN RES, V608, P123, DOI 10.1016/0006-8993(93)90782-I; Wang Z, 2003, GENE THER, V10, P2105, DOI 10.1038/sj.gt.3302133; Wickens JR, 1996, NEUROSCIENCE, V70, P1, DOI 10.1016/0306-4522(95)00436-M; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Zhang H, 2003, J NEUROSCI, V23, P10585	60	42	44	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2008	22	1					261	275		10.1096/fj.07-8797com	http://dx.doi.org/10.1096/fj.07-8797com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17690153				2022-12-28	WOS:000252309900028
J	Deng, YQ; Li, B; Liu, F; Iqbal, K; Grundke-Iqbal, I; Brandt, R; Gong, CX				Deng, Yanqiu; Li, Bin; Liu, Fei; Iqbal, Khalid; Grundke-Iqbal, Inge; Brandt, Roland; Gong, Cheng-Xin			Regulation between O-GlcNAcylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer disease	FASEB JOURNAL			English	Article						glycosylation; cytoskeleton; glucose metabolism	CYCLIN-DEPENDENT KINASE-5; PROTEIN PHOSPHATASE 2A; RAT BRAIN-SLICES; N-ACETYLGLUCOSAMINE; NEUROFIBRILLARY DEGENERATION; MAMMALIAN NEUROFILAMENTS; GLUCOSE-METABOLISM; DYNAMIC INTERPLAY; TAIL DOMAIN; IN-VIVO	The medium subunit of neurofilament (NF-M) is extensively modified by phosphate and O-linked beta-N-acetylglucosamine (O-GlcNAc). Phosphorylation of NF-M plays a critical role in regulating its translocation, filament formation, and function. However, the regulation of NF-M phosphorylation and the role of NF-M O-GlcNAcylation (a modification by which GlcNAc is attached to the serine/threonine residues of a protein via an O-linked glycosidic bond) are largely unknown. Here, we demonstrate that O-GlcNAcylation and phosphorylation of NF-M regulate each other reciprocally in cultured neuroblastoma cells and in metabolically active rat brain slices. In animal models of fasting rats, which mimicked the decreased glucose uptake/metabolism observed in brains of individuals with Alzheimer disease (AD), we found a decrease in O-GlcNAcylation and increase in phosphorylation of NF-M. We also observed decreased O-GlcNAcylation and an increased phosphorylation of NF-M in AD brain. These results suggest that O-GlcNAcylation and phosphorylation of NF-M are regulated reciprocally and that the hyperphosphorylation and accumulation of NF-M in AD brain might be caused by impaired brain glucose uptake/metabolism via down-regulation of NF-M O-GlcNAcylation. -Deng, Y., Li, B., Liu, F., Iqbal, K., Grundke-Iqbal, I., Brandt, R., Gong, C.-X. Regulation between O-GlcNAcylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer disease.	[Deng, Yanqiu; Li, Bin; Liu, Fei; Iqbal, Khalid; Grundke-Iqbal, Inge; Gong, Cheng-Xin] New York State Inst Basic Res Dev Disabil, Dept Neurochem, Staten Isl, NY 10314 USA; [Brandt, Roland] Univ Osnabruck, Dept Neurobiol, Osnabruck, Germany	Institute for Basic Research in Developmental Disabilities; University Osnabruck	Gong, CX (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Neurochem, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	cxgong@mail.csi.cuny.edu		Brandt, Roland/0000-0003-0101-1257	NATIONAL INSTITUTE ON AGING [R01AG019158, P30AG019610, R01AG027429] Funding Source: NIH RePORTER; NIA NIH HHS [AG027429, P30 AG019610, P30 AG19610, AG019158, R01 AG019158, R01 AG027429-01, R01 AG027429, R01 AG027429-02] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alexander GE, 2002, AM J PSYCHIAT, V159, P738, DOI 10.1176/appi.ajp.159.5.738; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; Dong DLY, 1996, J BIOL CHEM, V271, P20845, DOI 10.1074/jbc.271.34.20845; DONG DLY, 1993, J BIOL CHEM, V268, P16679; Elder GA, 1998, J CELL BIOL, V141, P727, DOI 10.1083/jcb.141.3.727; Elder GA, 1999, J NEUROSCI RES, V57, P23, DOI 10.1002/(SICI)1097-4547(19990701)57:1<23::AID-JNR3>3.3.CO;2-1; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; Garcia ML, 2003, J CELL BIOL, V163, P1011, DOI 10.1083/jcb.200308159; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P149, DOI 10.1016/0165-5728(87)90049-X; Gong CX, 2006, J ALZHEIMERS DIS, V9, P1; Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535; Gong CX, 2003, NEUROSCI LETT, V340, P107, DOI 10.1016/S0304-3940(03)00096-X; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; Gong CX, 2001, BRAIN RES PROTOC, V6, P134, DOI 10.1016/S1385-299X(00)00046-5; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Hoyer S, 2004, ADV EXP MED BIOL, V541, P135; Hoyer S, 2000, EXP GERONTOL, V35, P1363, DOI 10.1016/S0531-5565(00)00156-X; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; Kamemura K, 2003, PROG NUCLEIC ACID RE, V73, P107, DOI 10.1016/S0079-6603(03)01004-3; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kesavapany S, 2003, NEUROSIGNALS, V12, P252, DOI 10.1159/000074627; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P7384, DOI 10.1073/pnas.85.19.7384; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; Li BS, 2001, J NEUROCHEM, V76, P703, DOI 10.1046/j.1471-4159.2001.00064.x; Li BS, 2000, J NEUROSCI, V20, P6055, DOI 10.1523/JNEUROSCI.20-16-06055.2000; Li X, 2006, EUR J NEUROSCI, V23, P2078, DOI 10.1111/j.1460-9568.2006.04735.x; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Liu F, 2004, P NATL ACAD SCI USA, V101, P10804, DOI 10.1073/pnas.0400348101; Liu Q, 2004, CELL MOL LIFE SCI, V61, P3057, DOI 10.1007/s00018-004-4268-8; Ludemann N, 2005, J BIOL CHEM, V280, P31648, DOI 10.1074/jbc.M504395200; MCLEAN WG, 1992, MOL NEUROBIOL, V6, P225, DOI 10.1007/BF02780555; PERRY G, 1985, P NATL ACAD SCI USA, V82, P3916, DOI 10.1073/pnas.82.11.3916; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Reiman EM, 2001, P NATL ACAD SCI USA, V98, P3334, DOI 10.1073/pnas.061509598; Roos MD, 1998, P ASSOC AM PHYSICIAN, V110, P422; Sanchez I, 2000, J CELL BIOL, V151, P1013, DOI 10.1083/jcb.151.5.1013; Schechter R, 2005, BIOCHEM BIOPH RES CO, V334, P979, DOI 10.1016/j.bbrc.2005.07.001; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; STERNBERGER NH, 1985, P NATL ACAD SCI USA, V82, P4274, DOI 10.1073/pnas.82.12.4274; Trimpin S, 2004, BIOCHEMISTRY-US, V43, P2091, DOI 10.1021/bi030196q; Veeranna, 1998, J NEUROSCI, V18, P4008; VEERANNA, 1995, J NEUROCHEM, V64, P2681; Wang JZ, 2001, FEBS LETT, V507, P81, DOI 10.1016/S0014-5793(01)02944-1; XU ZS, 1992, J BIOL CHEM, V267, P4467	49	68	89	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					138	145		10.1096/fj.07-8309com	http://dx.doi.org/10.1096/fj.07-8309com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17687114	Green Accepted			2022-12-28	WOS:000252309900017
J	Zanardi, A; Ferrari, R; Leo, G; Maskos, U; Changeux, JP; Zoli, M				Zanardi, Alessio; Ferrari, Rosaria; Leo, Giuseppina; Maskos, Uwe; Changeux, Jean-Pierre; Zoli, Michele			Loss of high-affinity nicotinic receptors increases the vulnerability to excitotoxic lesion and decreases the positive effects of an enriched environment	FASEB JOURNAL			English	Article						nicotinic subunit knockout mice; quinolinic acid; Morris water maze; fear conditioning; hippocampus	ACETYLCHOLINE-RECEPTORS; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; MOLECULAR-MECHANISMS; BETA-2 SUBUNIT; MICE LACKING; RISK-FACTORS; NEURODEGENERATION; DEMENTIA; STIMULATION	Pharmacological activation of nicotinic acetylcholine receptors (nAChRs) exerts neuroprotective effects in cultured neurons and the intact animal. Much less is known about a physiological protective role of nAChRs. To understand whether endogenous activation of beta 2* nAChRs contributes to the maintenance of the functional and morphological integrity of neural tissue, adult beta 2 -/- mice were subjected to in vivo challenges that cause neurodegeneration and cognitive impairment (intrahippocampal injection of the excitotoxin quinolinic acid), or neuroprotection and cognitive potentiation (2-month exposure to an enriched environment). The excitotoxic insult caused an increased deficit in the Morris water maze learning curve and increased loss of hippocampal pyramidal cells in beta 2 -/- mice. Exposure to an enriched environment improved performance in contextual and cued fear conditioning and object recognition tests in beta 2 +/+, whereas the improvement was absent in beta 2 -/- mice. In addition, beta 2 +/+, but not beta 2 -/-, mice exposed to an enriched environment showed a significant hypertrophy of the CA1/3 regions. Thus, lack of beta 2* nAChRs increased susceptibility to an excitotoxic insult and diminished the positive effects of an enriched environment. These results may be relevant to understanding the pathophysiological consequences of the marked decrease in nAChRs that occurs in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. -Zanardi, A., Ferrari, R., Leo, G., Maskos, U., Changeux, J.-P., Zoli, M. Loss of high affinity nicotinic receptors increases the vulnerability to excitotoxic lesion and decreases the positive effects of an enriched environment.	Univ Modena & Reggio Emilia, Interuniv Ctr Study Aging, Dept Biomed Sci, Physiol Sect, Modena, Italy; Inst Pasteur, CNRS, UA 2182 Recepteurs Cognit, F-75724 Paris, France	Universita di Modena e Reggio Emilia; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Zoli, M (corresponding author), Univ Modena & Reggio Emilia, Dept Biomed Sci, Physiol Sect, Via Campi 287, I-41100 Modena, Italy.	mzoli@unimo.it	Zoli, Michele/C-8899-2016	Zoli, Michele/0000-0002-8034-2849; leo, giuseppina/0000-0001-5972-2268	Telethon [D.105] Funding Source: Medline	Telethon(Fondazione Telethon)		Almeida OP, 2002, ADDICTION, V97, P15, DOI 10.1046/j.1360-0443.2002.00016.x; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bancroft J.D., 1996, THEORY PRACTICE HIST, VVolume 6; Caldarone BJ, 2000, NEUROPHARMACOLOGY, V39, P2779, DOI 10.1016/S0028-3908(00)00137-4; Champtiaux N, 2003, J NEUROSCI, V23, P7820; Court J, 2001, BIOL PSYCHIAT, V49, P175, DOI 10.1016/S0006-3223(00)01116-1; Court JA, 2005, NEUROPATH APPL NEURO, V31, P522, DOI 10.1111/j.1365-2990.2005.00674.x; Dajas-Bailador F, 2004, TRENDS PHARMACOL SCI, V25, P317, DOI 10.1016/j.tips.2004.04.006; Degroot A, 2005, NEUROREPORT, V16, P63, DOI 10.1097/00001756-200501190-00015; FANSELOW MS, 1984, BEHAV NEUROSCI, V98, P79, DOI 10.1037/0735-7044.98.1.79; Fujikawa DG, 2005, EPILEPSY BEHAV, V7, pS3, DOI 10.1016/j.yebeh.2005.08.003; Glatt SL, 1996, NEUROEPIDEMIOLOGY, V15, P20, DOI 10.1159/000109885; Gotti C, 2006, NEUROBIOL DIS, V23, P481, DOI 10.1016/j.nbd.2006.04.005; Hayashi Takeshi, 2006, Current Alzheimer Research, V3, P351, DOI 10.2174/156720506778249498; Hellstrom-Lindahl E, 2004, NEUROBIOL DIS, V15, P351, DOI 10.1016/j.nbd.2003.11.024; Hellstrom-Lindahl E, 2000, BEHAV BRAIN RES, V113, P159, DOI 10.1016/S0166-4328(00)00210-2; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Jankowsky JL, 2005, J NEUROSCI, V25, P5217, DOI 10.1523/JNEUROSCI.5080-04.2005; JANSON AM, 1993, NEUROSCIENCE, V97, P15; Kaneko S, 1997, BRAIN RES, V765, P135, DOI 10.1016/S0006-8993(97)00556-8; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kihara T, 1997, ANN NEUROL, V42, P159, DOI 10.1002/ana.410420205; Kihara T, 1998, BRAIN RES, V792, P331, DOI 10.1016/S0006-8993(98)00138-3; King SL, 2003, J NEUROSCI, V23, P3837; Klink R, 2001, J NEUROSCI, V21, P1452, DOI 10.1523/JNEUROSCI.21-05-01452.2001; Kramer AF, 2004, J GERONTOL A-BIOL, V59, P940; Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015; Letenneur L, 2004, BIOMED PHARMACOTHER, V58, P95, DOI 10.1016/j.biopha.2003.12.004; Levin ED, 2002, J NEUROBIOL, V53, P633, DOI 10.1002/neu.10151; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; Martin-Ruiz CM, 1999, J NEUROCHEM, V73, P1635, DOI 10.1046/j.1471-4159.1999.0731635.x; Maskos U, 2005, NATURE, V436, P103, DOI 10.1038/nature03694; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; Nanri M, 1998, JPN J PHARMACOL, V78, P463, DOI 10.1254/jjp.78.463; O'Neill AB, 1998, NEUROBIOL LEARN MEM, V69, P46, DOI 10.1006/nlme.1997.3803; O'Neill MJ, 2002, CNS NEUROL DISORD-DR, V1, P399, DOI 10.2174/1568007023339166; Olney JW, 1997, ARCH NEUROL-CHICAGO, V54, P1234, DOI 10.1001/archneur.1997.00550220042012; PARK GAS, 1992, NEUROSCI LETT, V143, P259, DOI 10.1016/0304-3940(92)90278-F; Paxinos G, 2001, MOUSE BRAIN SETEREOT; PAYLOR R, 1994, BEHAV NEUROSCI, V108, P810, DOI 10.1037/0735-7044.108.4.810; PERRY EK, 1995, NEUROSCIENCE, V64, P385, DOI 10.1016/0306-4522(94)00410-7; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; Picciotto MR, 2002, J NEUROBIOL, V53, P641, DOI 10.1002/neu.10102; Prendergast MA, 2001, NEUROSCIENCE, V102, P75, DOI 10.1016/S0306-4522(00)00450-4; Quik M, 2006, J PHARMACOL EXP THER, V316, P481, DOI 10.1124/jpet.105.094375; Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880; Rossi FM, 2001, P NATL ACAD SCI USA, V98, P6453, DOI 10.1073/pnas.101120998; SARTER M, 1988, PSYCHOPHARMACOLOGY, V94, P491, DOI 10.1007/BF00212843; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; Tees RC, 1999, BEHAV BRAIN RES, V105, P173, DOI 10.1016/S0166-4328(99)00074-1; Vaucher E, 2002, NEUROBIOL AGING, V23, P87, DOI 10.1016/S0197-4580(01)00250-0; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449; ZOLI M, 1992, MICROSC RES TECHNIQ, V21, P315, DOI 10.1002/jemt.1070210408; Zoli M, 1998, J NEUROSCI, V18, P4461; Zoli M, 1999, EMBO J, V18, P1235, DOI 10.1093/emboj/18.5.1235	55	16	18	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4028	4037		10.1096/fj.07-8260com	http://dx.doi.org/10.1096/fj.07-8260com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17622669				2022-12-28	WOS:000251283500027
J	Messina, S; Mazzeo, A; Bitto, A; Aguennouz, M; Migliorato, A; De Pasquale, MG; Minutoli, L; Altavilla, D; Zentilin, L; Giacca, M; Squadrito, F; Vita, G				Messina, Sonia; Mazzeo, Anna; Bitto, Alessandra; Aguennouz, M'hammed; Migliorato, Alba; De Pasquale, Maria G.; Minutoli, Letteria; Altavilla, Domenica; Zentilin, Lorena; Giacca, Mauro; Squadrito, Francesco; Vita, Giuseppe			VEGF overexpression via adeno-associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice	FASEB JOURNAL			English	Article						dystrophin gene; muscle necrosis; rAAV; Duchenne muscular dystrophy	ENDOTHELIAL GROWTH-FACTOR; MUSCULAR-DYSTROPHY; BONE-MARROW; SIGNAL-TRANSDUCTION; SATELLITE CELLS; STEM-CELLS; MOUSE; EXPRESSION; NEOVASCULARIZATION; AKT	Vascular endothelial growth factor (VEGF) is a major regulator of physiological and pathological angiogenesis. Recently it was reported that the delivery of VEGF using recombinant adeno-associated virus (rAAV) vectors reduces muscle damage and promotes muscle regeneration in different experimental models of muscle necrosis. We demonstrate that intramuscular administration of rAAV-VEGF improved pathophysiology of the mdx mouse, a model of Duchenne muscular dystrophy (DMD). One month after injection, rAAV-VEGF-treated muscles showed augmented expression of VEGF and immunolocalization of its receptor, VEGFR-2. VEGF-treated mdx mice showed increased forelimb strength and strength normalized to weight. Treatment reduced necrotic fibers area and increased regenerating fibers area with an augmented number of myogenin-positive satellite cells and myonuclei, and of developmental myosin heavy chain-positive fibers. Only the regenerating area showed increased capillary density. This study provides novel evidence of a VEGF beneficial effect in mdx mice that is exerted mainly by a proregenerative and angiogenic effect. It opens new therapeutic prospectives in DMD and other types of muscular disorders.	Univ Messina, Dept Neurosci Psychiat & Anaesthesiol, Unit Clin Neurobiol & Neuromuscular Dis, AOU Policlin G Martino, I-98125 Messina, Italy; Univ Messina, Dept Expt Med & Pharmacol, Messina, Italy; ICGEB, Mol Med Lab, Trieste, Italy; Univ Trieste, Fac Med, Dept Clin & Biomed Sci, I-34127 Trieste, Italy	AOU Policlinico Gaetano Martino; University of Messina; University of Messina; International Center for Genetic Engineering & Biotechnology (ICGEB); University of Trieste	Vita, G (corresponding author), Univ Messina, Dept Neurosci Psychiat & Anaesthesiol, Unit Clin Neurobiol & Neuromuscular Dis, AOU Policlin G Martino, I-98125 Messina, Italy.	giuseppe.vita@unime.it	Aguennouz, M'hammed/O-9520-2019; Giacca, Mauro/J-9287-2016	Aguennouz, M'hammed/0000-0003-0440-0354; Giacca, Mauro/0000-0003-2927-7225; Vita, Giuseppe/0000-0002-5204-7826; MAZZEO, Anna/0000-0003-1914-6184; MIGLIORATO, Alba/0000-0002-9256-6524; Messina, Sonia/0000-0001-7994-3391				Abadie J, 2002, GENE THER, V9, P1037, DOI 10.1038/sj.gt.3301773; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Arsic N, 2004, MOL THER, V10, P844, DOI 10.1016/j.ymthe.2004.08.007; Arsic N, 2003, MOL THER, V7, P450, DOI 10.1016/S1525-0016(03)00034-0; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; CARNWATH JW, 1987, J NEUROL SCI, V80, P39, DOI 10.1016/0022-510X(87)90219-X; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Connolly AM, 2001, NEUROMUSCULAR DISORD, V11, P703, DOI 10.1016/S0960-8966(01)00232-2; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; De Angelis L, 1999, J CELL BIOL, V147, P869, DOI 10.1083/jcb.147.4.869; Deodato B, 2002, GENE THER, V9, P777, DOI 10.1038/sj.gt.3301697; Dubowitz V., 1995, MUSCLE DISORDERS CHI; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Germani A, 2003, AM J PATHOL, V163, P1417, DOI 10.1016/S0002-9440(10)63499-2; Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367; Granchelli JA, 2000, NEUROMUSCULAR DISORD, V10, P235, DOI 10.1016/S0960-8966(99)00126-1; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Inagaki K, 2006, MOL THER, V14, P45, DOI 10.1016/j.ymthe.2006.03.014; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lescaudron L, 1999, NEUROMUSCULAR DISORD, V9, P72, DOI 10.1016/S0960-8966(98)00111-4; Matecki S, 2004, AM J PHYSIOL-REG I, V287, pR961, DOI 10.1152/ajpregu.00146.2004; MCARDLE A, 1995, NEUROMUSCULAR DISORD, V5, P445, DOI 10.1016/0960-8966(95)00001-4; Merly F, 1999, MUSCLE NERVE, V22, P724, DOI 10.1002/(SICI)1097-4598(199906)22:6<724::AID-MUS9>3.0.CO;2-O; Messina S, 2006, AM J PATHOL, V168, P918, DOI 10.2353/ajpath.2006.050673; Rissanen TT, 2002, AM J PATHOL, V160, P1393, DOI 10.1016/S0002-9440(10)62566-7; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; SCHMALBRUCH H, 1977, ANAT REC, V189, P169, DOI 10.1002/ar.1091890204; Shavlakadze T, 2004, MOL THER, V10, P829, DOI 10.1016/j.ymthe.2004.07.026; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Stupka N, 2006, NEUROMUSCULAR DISORD, V16, P337, DOI 10.1016/j.nmd.2006.03.003; Takahashi A, 2002, MOL CELL BIOL, V22, P4803, DOI 10.1128/MCB.22.13.4803-4814.2002; Tuomisto TT, 2004, ATHEROSCLEROSIS, V174, P111, DOI 10.1016/j.atherosclerosis.2004.01.015; Wagatsuma A, 2006, PHYSIOL RES, V55, P633, DOI 10.33549/physiolres.930811; ZACCHIGNA S, 2007, IN PRESS HUM GENE TH; Zentilin L, 2006, BLOOD, V107, P3546, DOI 10.1182/blood-2005-08-3215	44	73	82	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3737	3746		10.1096/fj.07-8459com	http://dx.doi.org/10.1096/fj.07-8459com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17575261				2022-12-28	WOS:000250517800035
J	Morales, ME; Mann, VH; Kines, KJ; Gobert, GN; Fraser, MJ; Kalinna, BH; Correnti, JM; Pearce, EJ; Brindley, PJ				Morales, Maria E.; Mann, Victoria H.; Kines, Kristine J.; Gobert, Geoffrey N.; Fraser, Malcolm J., Jr.; Kalinna, Bernd H.; Correnti, Jason M.; Pearce, Edward J.; Brindley, Paul J.			piggyBac transposon mediated transgenesis of the human blood fluke, Schistosoma mansoni	FASEB JOURNAL			English	Article						schistosome; gene manipulation; electroporation; parasitic helminth; functional genomics; reverse genetics	SOIL-TRANSMITTED HELMINTHIASIS; RNA INTERFERENCE; PARTICLE BOMBARDMENT; BACULOVIRUS GENOME; MAMMALIAN-CELLS; SLEEPING-BEAUTY; IN-VITRO; DNA; EXPRESSION; TRANSFORMATION	The transposon piggyBac from the genome of the cabbage looper moth Trichoplusia ni has been observed in the laboratory to jump into the genomes of key model and pathogenic eukaryote organisms including mosquitoes, planarians, human and other mammalian cells, and the malaria parasite Plasmodium falciparum. Introduction of exogenous transposons into schistosomes has not been reported but transposon-mediated transgenesis of schistosomes might supersede current methods for functional genomics of this important human pathogen. In the present study we examined whether the piggyBac transposon could deliver reporter transgenes into the genome of Schistosoma mansoni parasites. A piggyBac donor plasmid modified to encode firefly luciferase under control of schistosome gene promoters was introduced along with 7-methylguanosine capped RNAs encoding piggyBac transposase into cultured schistosomula by square wave electroporation. The activity of the helper transposase mRNA was confirmed by Southern hybridization analysis of genomic DNA from the transformed schistosomes, and hybridization signals indicated that the piggyBac transposon had integrated into numerous sites within the parasite chromosomes. piggyBac integrations were recovered by retrotransposon-anchored PCR, revealing characteristic piggyBac TTAA footprints in the vicinity of the endogenous schistosome retrotransposons Boudicca, SR1, and SR2. This is the first report of chromosomal integration of a transgene and somatic transgenesis of this important human pathogen, in this instance accomplished by mobilization of the piggyBac transposon.	Tulane Univ, Hlth Sci Ctr, Dept Trop Med, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Program Biomed Sci, New Orleans, LA 70112 USA; Queensland Inst Med Res, Div Infect Dis & Immunol, Brisbane, Qld 4006, Australia; Univ Notre Dame, Dept Biol Sci, South Bend, IN USA; Univ Melbourne, Fac Vet Sci, Ctr Anim Biotechnol, Parkville, Vic 3052, Australia; Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	Tulane University; Tulane University; QIMR Berghofer Medical Research Institute; University of Notre Dame; University of Melbourne; University of Pennsylvania	Brindley, PJ (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Trop Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.	paul.brindley@tulane.edu	Fraser, Malcolm J/C-9100-2009; Gobert, Geoffrey/A-1468-2011; Gobert, Geoffrey/V-2985-2019	Gobert, Geoffrey/0000-0001-5884-6453; Brindley, Paul J./0000-0003-1765-0002	PHS HHS [N0155270] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Balu B, 2005, P NATL ACAD SCI USA, V102, P16391, DOI 10.1073/pnas.0504679102; BASCH PF, 1981, J PARASITOL, V67, P179, DOI 10.2307/3280632; Brindley PJ, 2007, INT J PARASITOL, V37, P465, DOI 10.1016/j.ijpara.2006.12.012; Brindley PJ, 2005, TRENDS PARASITOL, V21, P533, DOI 10.1016/j.pt.2005.08.015; Brindley PJ, 2003, TRENDS PARASITOL, V19, P79, DOI 10.1016/S1471-4922(02)00061-2; CARY LC, 1989, VIROLOGY, V172, P156, DOI 10.1016/0042-6822(89)90117-7; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Copeland CS, 2003, J VIROL, V77, P6153, DOI 10.1128/JVI.77.11.6153-6166.2003; Correnti JA, 2005, MOL BIOCHEM PARASIT, V143, P209, DOI 10.1016/j.molbiopara.2005.06.007; Correnti JM, 2004, MOL BIOCHEM PARASIT, V137, P75, DOI 10.1016/j.molbiopara.2004.04.015; CORRENTI JM, 2007, IN PRESS INT J PARAS; Crabb BS, 2007, TRENDS MICROBIOL, V15, P3, DOI 10.1016/j.tim.2006.11.006; Davis RE, 1999, P NATL ACAD SCI USA, V96, P8687, DOI 10.1073/pnas.96.15.8687; DeMarco R, 2005, BIOCHEM BIOPH RES CO, V333, P230, DOI 10.1016/j.bbrc.2005.05.080; Ding S, 2005, CELL, V122, P473, DOI 10.1016/j.cell.2005.07.013; Dinguirard N, 2006, MOL BIOCHEM PARASIT, V146, P219, DOI 10.1016/j.molbiopara.2005.12.010; Drew AC, 1999, MOL BIOL EVOL, V16, P1256, DOI 10.1093/oxfordjournals.molbev.a026216; Drew AC, 1997, MOL BIOL EVOL, V14, P602, DOI 10.1093/oxfordjournals.molbev.a025799; Dupuy AJ, 2002, P NATL ACAD SCI USA, V99, P4495, DOI 10.1073/pnas.062630599; Elick TA, 1996, GENETICA, V97, P127, DOI 10.1007/BF00054620; Elick TA, 1996, GENETICA, V98, P33, DOI 10.1007/BF00120216; Franz AWE, 2006, P NATL ACAD SCI USA, V103, P4198, DOI 10.1073/pnas.0600479103; FRASER MJ, 1995, VIROLOGY, V211, P397, DOI 10.1006/viro.1995.1422; Fraser MJ, 1996, INSECT MOL BIOL, V5, P141, DOI 10.1111/j.1365-2583.1996.tb00048.x; Gonzalez-Estevez C, 2003, P NATL ACAD SCI USA, V100, P14046, DOI 10.1073/pnas.2335980100; Grevelding CG, 2006, PARASITIC FLATWORMS: MOLECULAR BIOLOGY, BIOCHEMISTRY, IMMUNOLOGY AND PHYSIOLOGY, P149, DOI 10.1079/9780851990279.0149; Handler AM, 2002, INSECT BIOCHEM MOLEC, V32, P1211, DOI 10.1016/S0965-1748(02)00084-X; Hedges DJ, 2005, PLOS COMPUT BIOL, V1, P333, DOI 10.1371/journal.pcbi.0010044; Heyers O, 2003, EXP PARASITOL, V105, P174, DOI 10.1016/j.exppara.2003.11.001; Hirai H, 2000, INT J PARASITOL, V30, P441, DOI 10.1016/S0020-7519(99)00186-1; Hotez PJ, 2006, PLOS MED, V3, P576, DOI 10.1371/journal.pmed.0030102; Hu W, 2003, NAT GENET, V35, P139, DOI 10.1038/ng1236; Kines KJ, 2006, EXP PARASITOL, V112, P209, DOI 10.1016/j.exppara.2006.02.003; King CH, 2005, LANCET, V365, P1561, DOI 10.1016/S0140-6736(05)66457-4; Korswagen HC, 1996, P NATL ACAD SCI USA, V93, P14680, DOI 10.1073/pnas.93.25.14680; Laha T, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-154; Laha T, 2004, INT J PARASITOL, V34, P1365, DOI 10.1016/j.ijpara.2004.08.007; LAZDINS JK, 1982, EXP PARASITOL, V53, P39, DOI 10.1016/0014-4894(82)90090-X; Li X, 2005, INSECT MOL BIOL, V14, P17, DOI 10.1111/j.1365-2583.2004.00525.x; Liu F, 2006, PLOS PATHOG, V2, P268, DOI 10.1371/journal.ppat.0020029; Maragathavally KJ, 2006, FASEB J, V20, P1880, DOI 10.1096/fj.05-5485fje; McCarthy E, 2004, INT J PARASITOL, V34, P703, DOI 10.1016/j.ijpara.2004.01.008; MCLAREN DJ, 1977, NATURE, V269, P147, DOI 10.1038/269147a0; Nabekura T, 2006, MOL THER, V13, P301, DOI 10.1016/j.ymthe.2005.09.021; Osman A, 2006, PLOS PATHOG, V2, P536, DOI 10.1371/journal.ppat.0020054; Pritham EJ, 2005, MOL BIOL EVOL, V22, P1751, DOI 10.1093/molbev/msi169; Sarkar A, 2003, MOL GENET GENOMICS, V270, P173, DOI 10.1007/s00438-003-0909-0; Savioli L, 2004, PARASITOL INT, V53, P103, DOI 10.1016/j.parint.2004.01.001; Shinmyo Y, 2004, DEV GROWTH DIFFER, V46, P343, DOI 10.1111/j.1440-169x.2004.00751.x; Skelly PJ, 2003, INT J PARASITOL, V33, P363, DOI 10.1016/S0020-7519(03)00030-4; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPOTILA LD, 1989, CHROMOSOMA, V97, P421, DOI 10.1007/BF00295025; Utzinger J, 2004, EXPERT OPIN PHARMACO, V5, P263, DOI 10.1517/eoph.5.2.263.26469; Verjovski-Almeida S, 2003, NAT GENET, V35, P148, DOI 10.1038/ng1237; Wang PC, 2001, J VIROL METHODS, V92, P83, DOI 10.1016/S0166-0934(00)00278-0; Wilber A, 2006, MOL THER, V13, P625, DOI 10.1016/j.ymthe.2005.10.014; Wilson MH, 2007, MOL THER, V15, P139, DOI 10.1038/sj.mt.6300028; Wilson RA, 2007, TRENDS PARASITOL, V23, P14, DOI 10.1016/j.pt.2006.10.002; Wippersteg V, 2005, INT J PARASITOL, V35, P583, DOI 10.1016/j.ijpara.2005.02.002; Wu P, 1998, J VIROL, V72, P5919, DOI 10.1128/JVI.72.7.5919-5926.1998; Wu SCY, 2006, P NATL ACAD SCI USA, V103, P15008, DOI 10.1073/pnas.0606979103; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Ziegler K, 2004, J VIROL METHODS, V122, P123, DOI 10.1016/j.jviromet.2004.08.012	63	74	80	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3479	3489		10.1096/fj.07-8726com	http://dx.doi.org/10.1096/fj.07-8726com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17586730				2022-12-28	WOS:000250517800011
J	Coutinho, EL; Andrade, LNDS; Chammas, R; Morganti, L; Schor, N; Bellini, MH				Coutinho, Enia Lucia; Andrade, Luciana Nogueira de Sousa; Chammas, Roger; Morganti, Ligia; Schor, Nestor; Bellini, Maria Helena			Anti-tumor effect of endostatin mediated by retroviral gene transfer in mice bearing renal cell carcinoma	FASEB JOURNAL			English	Article						gene therapy; cancer; bioassay; antiangiogenesis	ENDOTHELIAL GROWTH-FACTOR; TUMOR-GROWTH; IN-VITRO; ANGIOGENESIS; CANCER; THERAPY; EXPRESSION; INHIBITION; GALECTIN-3; ANTIANGIOGENESIS	We investigated whether transfer of the gene encoding the angiogenesis inhibitor endostatin into the NIH/3T3 fibroblast cell line could inhibit renal tumor growth in vivo. NIH/3T3 cells were transduced with retroviral vectors containing the murine endostatin (ES) gene. SCID mice bearing CaKi-1 derived tumors were given a subcutaneous injection of either ES-transduced cells or control cells and were monitored for tumor growth. At the end of the in vivo experiment, the mean tumor volume of treated mice was 51.6 +/- 2.4 mm(3), while the tumor volume of control was 234.5 +/- 14.8 mm(3). Microvascular density was significantly decreased on treatment (control 9.79 vs. ES 2.53%, < 0.001) accompanied by a 23-fold increase in intraturmoral necrotic area and a 2.94-fold increase in the apoptotic index, determined by immunohistochemistry with anti- activated caspase-3. Apoptotic cells were found in foci enriched in infiltrating leukocytes. In conclusion, retroviral endostatin gene transfer led to secretion of functional endostatin that was sufficiently active to inhibit tumor angiogenesis and tumor growth. A second mechanism may also be implied in endostatin-dependent tumor regression, associated with tumor infiltration of leukocytes. Besides its antiangiogenic properties, endostatin may be a promising adjuvant to immunotherapy.	IPEN CNEN SP, BR-05508900 Sao Paulo, Brazil; Univ Fed Sao Paulo, Dept Med, Div Nephrol, Sao Paulo, Brazil; CEPID FAPESP, Ctr Terapia Celular, Sao Paulo, Brazil; Univ Sao Paulo, Fac Med, Dept Radiol, Expt Oncol Lab, Sao Paulo, Brazil	Comissao Nacional de Energia Nuclear (CNEN); Instituto de Pesquisas Energeticas e Nucleares (IPEN); Universidade Federal de Sao Paulo (UNIFESP); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Universidade de Sao Paulo	Bellini, MH (corresponding author), IPEN CNEN SP, Cidade Univ IPEN-CNEN-SP,Av Lineu Prestes 2242, BR-05508900 Sao Paulo, Brazil.	mhmarumo@terra.com.br	Schor, Nestor/K-4364-2013; Morganti, Ligia/K-4352-2014; Chammas, Roger/A-8004-2011; Andrade, Luciana/P-4604-2017; Batista, Marcelo/K-4305-2013	Morganti, Ligia/0000-0002-7870-1793; Chammas, Roger/0000-0003-0342-8726; Andrade, Luciana/0000-0002-5481-4355; Andrade, Luciana/0000-0003-2735-1217				Bellini MH, 2003, FASEB J, V17, P2322, DOI 10.1096/fj.03-0018fje; Brammer RD, 2005, BRIT J CANCER, V93, P1024, DOI 10.1038/sj.bjc.6602835; BROWN LF, 1993, AM J PATHOL, V143, P1255; Chow WH, 1999, JAMA-J AM MED ASSOC, V281, P1628, DOI 10.1001/jama.281.17.1628; Cristofanilli M, 2002, NAT REV DRUG DISCOV, V1, P415, DOI 10.1038/nrd819; Dhanabal M, 1999, CANCER RES, V59, P189; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; DHANABAL M, 1999, BIOCHEM BIOPH RES CO, V258, P260; Ding I, 2001, CANCER RES, V61, P526; Dirix LY, 1997, BRIT J CANCER, V76, P238, DOI 10.1038/bjc.1997.368; Dirkx AEM, 2006, FASEB J, V20, P621, DOI 10.1096/fj.05-4493com; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Feldman AL, 2002, CANCER-AM CANCER SOC, V95, P1637, DOI 10.1002/cncr.10845; Feldman AL, 2001, J NATL CANCER I, V93, P1014, DOI 10.1093/jnci/93.13.1014; Feldman AL, 2000, CLIN CANCER RES, V6, P4628; Figlin RA, 1999, J UROLOGY, V161, P381, DOI 10.1016/S0022-5347(01)61897-4; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1998, P NATL ACAD SCI USA, V95, P9064, DOI 10.1073/pnas.95.16.9064; Folkman J., 2006, SCI STKE, V354, P35; Fukushi J, 2004, MOL BIOL CELL, V15, P3580, DOI 10.1091/mbc.E04-03-0236; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; Gleave ME, 1998, NEW ENGL J MED, V338, P1265, DOI 10.1056/NEJM199804303381804; Gordower L, 1999, NEUROPATH APPL NEURO, V25, P319; Jacobsen J, 2000, J UROLOGY, V163, P343, DOI 10.1016/S0022-5347(05)68049-4; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kleinman HK, 2001, JNCI-J NATL CANCER I, V93, P965, DOI 10.1093/jnci/93.13.965; Kurdow R, 2003, LANGENBECK ARCH SURG, V388, P401, DOI 10.1007/s00423-003-0400-8; Lao YH, 2001, INT J BIOCHEM CELL B, V33, P357, DOI 10.1016/S1357-2725(01)00023-1; MacDonald NJ, 2001, J BIOL CHEM, V276, P25190, DOI 10.1074/jbc.M100743200; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; Mulders P, 2003, UROL CLIN N AM, V30, P455, DOI 10.1016/S0094-0143(03)00024-7; Nangia-Makker P, 2000, AM J PATHOL, V156, P899, DOI 10.1016/S0002-9440(10)64959-0; Negrier S, 1998, NEW ENGL J MED, V338, P1272, DOI 10.1056/NEJM199804303381805; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Parkkila S, 2000, P NATL ACAD SCI USA, V97, P2220, DOI 10.1073/pnas.040554897; Pulkkanen KJ, 2002, CANCER GENE THER, V9, P908, DOI 10.1038/sj.cgt.7700519; Sabo E, 2001, CLIN CANCER RES, V7, P533; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; Sauter BV, 2000, P NATL ACAD SCI USA, V97, P4802, DOI 10.1073/pnas.090065597; Scappaticci FA, 2001, MOL THER, V3, P186, DOI 10.1006/mthe.2000.0243; STREIT M, 2004, CANCER RES, V62, P2004; Szary J, 2001, INT J CANCER, V91, P835, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1123>3.3.CO;2-K; TAKAHASHI A, 1994, CANCER RES, V54, P4233; Tomisawa M, 1999, EUR J CANCER, V35, P133, DOI 10.1016/S0959-8049(98)00278-0; TOMOHARU F, 2002, UROLOGY, V59, P973; TOMOHARU F, 2002, UROLOGY, V59, P6; van Wijngaarden J, 2004, LAB INVEST, V84, P1472, DOI 10.1038/labinvest.3700157; Wen W, 1999, CANCER RES, V59, P6052; WILFRED TV, 1994, BLOOD, V84, P780; YAGODA A, 1989, UROL INT, V44, P338, DOI 10.1159/000281537; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Yamanaka R, 2001, CANCER GENE THER, V8, P796, DOI 10.1038/sj.cgt.7700367; Yokoyama Y, 2000, CANCER RES, V60, P2190; Young RC, 1998, NEW ENGL J MED, V338, P1305, DOI 10.1056/NEJM199804303381811	54	21	23	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3153	3161		10.1096/fj.07-8412com	http://dx.doi.org/10.1096/fj.07-8412com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17513560				2022-12-28	WOS:000249781600016
J	Egozi, D; Shapira, M; Paor, G; Ben-Izhak, O; Skorecki, K; Hershko, DD				Egozi, Dana; Shapira, Maanit; Paor, Galit; Ben-Izhak, Ofer; Skorecki, Karl; Hershko, Dan D.			Regulation of the cell cycle inhibitor p27 and its ubiquitin ligase Skp2 in differentiation of human embryonic stem cells	FASEB JOURNAL			English	Article						tumorigenesis; cyclin-dependent kinase; hESc differentiation; F-box protein; ubiquitin system	DEPENDENT KINASE INHIBITORS; HUMAN PROSTATE-CANCER; SUBUNIT SKP2; HUMAN BREAST; P27(KIP1); DEGRADATION; EXPRESSION; PROTEIN; GROWTH; TRANSCRIPTION	Embryonic stem cells combine the features of robust proliferation with precise differentiation capacity. p27 is a cell cycle inhibitor that is involved in the regulation of proliferation and differentiation in many developing tissues. Recent studies in murine embryonic stem cells have suggested that p27 is involved in the progression of normal differentiation programs in these cells. However, the expression and regulation of p27 and its role in the differentiation of human embryonic stem cells ( hESc) has not been previously explored. Herein we show that p27 expression was low in undifferentiated hESc, but increased markedly in differentiated cells. The expression of Skp2, the ubiquitin ligase that targets p27 for degradation, was inversely related to p27 expression. Moreover, embryoid bodies ( EBs) with low p27 expression and high Skp2/ p27 ratio showed poorer differentiation than those with high p27 expression. Modulation of Skp2 expression is mainly regulated by its rate of degradation. In contrast to somatic cells, which have high levels of Skp2 mainly in S and G2/ M, in undifferentiated hESc Skp2 levels were also high in G1. These results point to a potentially important role for p27 regulation in hESc.	Technion Israel Inst Technol, Rambam Med Ctr, Dept Surg, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Dept Plast Surg, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Dept Nephrol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rambam Med Ctr, Dept Pathol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Res Inst, IL-31096 Haifa, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology	Hershko, DD (corresponding author), Technion Israel Inst Technol, Rambam Med Ctr, Dept Surg, IL-31096 Haifa, Israel.	d_hershko@rambam.health.gov.il						Amit M, 2004, BIOL REPROD, V70, P837, DOI 10.1095/biolreprod.103.021147; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Bryja V, 2005, STEM CELLS, V23, P965, DOI 10.1634/stemcells.2004-0174; Bryja V, 2004, CELL MOL LIFE SCI, V61, P1384, DOI 10.1007/s00018-004-4081-4; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Faast R, 2004, ONCOGENE, V23, P491, DOI 10.1038/sj.onc.1207133; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Fujii-Yamamoto H, 2005, J BIOL CHEM, V280, P12976, DOI 10.1074/jbc.M412224200; GRANA X, 1995, ONCOGENE, V11, P211; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Guo YP, 1997, CLIN CANCER RES, V3, P2269; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H; Hershko DD, 2006, CANCER-AM CANCER SOC, V107, P668, DOI 10.1002/cncr.22073; Imaki H, 2003, CANCER RES, V63, P4607; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Nakano T, 1996, SYST COMPUT JPN, V27, P1, DOI 10.1002/scj.4690270601; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REED M, 1994, SPILL SCI TECHNOL B, V1, P69, DOI 10.1016/1353-2561(94)90009-4; SALVATIER P, 1994, ONCOGENE, V9, P809; Sarmento LM, 2005, J EXP MED, V202, P157, DOI 10.1084/jem.20050559; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shapiro S, 2005, J NEUROSURG-SPINE, V2, P1; Sherr C. J., 1993, CELL, V48, P981; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Tzukerman M, 2003, P NATL ACAD SCI USA, V100, P13507, DOI 10.1073/pnas.2235551100; Tzukerman M, 2000, MOL BIOL CELL, V11, P4381, DOI 10.1091/mbc.11.12.4381; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; White J, 2005, MOL BIOL CELL, V16, P2018, DOI 10.1091/mbc.e04-12-1056; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Yang G, 2002, CLIN CANCER RES, V8, P3419; ZHANG J, 1995, FINITE ELEM ANAL DES, V19, P45, DOI 10.1016/0168-874X(94)00056-L	47	52	59	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2807	2817		10.1096/fj.06-7758com	http://dx.doi.org/10.1096/fj.06-7758com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17475922				2022-12-28	WOS:000249237500022
J	Resseguie, M; Song, JN; Niculescu, MD; da Costa, KA; Randall, TA; Zeisel, SH				Resseguie, Mary; Song, Jiannan; Niculescu, Mihai D.; da Costa, Kerry-Ann; Randall, Thomas A.; Zeisel, Steven H.			Phosphatidylethanolamine N-methyltransferase (PEMT) gene expression is induced by estrogen in human and mouse primary hepatocytes	FASEB JOURNAL			English	Article						choline; 17-beta-estradiol; bioinformatics; ERE; evolutionarily conserved gene motifs	CHOLINE AVAILABILITY ALTERS; RESPONSE ELEMENTS; RECEPTOR BINDING; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; VERTEBRATE GENOMES; SPATIAL MEMORY; RAT PITUITARY; HIGH-DENSITY; LIVER; HIPPOCAMPUS	Choline is an essential nutrient for humans, though some of the requirement can be met by endogenous synthesis catalyzed by phosphatidylethanolamine N-methyltransferase ( PEMT). Premenopausal women are relatively resistant to choline deficiency compared with postmenopausal women and men. Studies in animals suggest that estrogen treatment can increase PEMT activity. In this study we investigated whether the PEMT gene is regulated by estrogen. PEMT transcription was increased in a dose-dependent manner when primary mouse and human hepatocytes were treated with 17-beta-estradiol for 24 h. This increased message was associated with an increase in protein expression and enzyme activity. In addition, we report a region that contains a perfect estrogen response element (ERE) similar to 7.5 kb from the transcription start site corresponding to transcript variants NM_007169 and NM-008819 of the human and murine PEMT genes, respectively, three imperfect EREs in evolutionarily conserved regions and multiple imperfect EREs in nonconserved regions in the putative promoter regions. We predict that both the mouse and human PEMT genes have three unique transcription start sites, which are indicative of either multiple promoters and/or alternative splicing. This study is the first to explore the underlying mechanism of why dietary requirements for choline vary with estrogen status in humans.	Univ N Carolina, Sch Publ Hlth, Inst Nutr Res, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Ctr Bioinformat, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zeisel, SH (corresponding author), Univ N Carolina, Sch Publ Hlth, Inst Nutr Res, Dept Nutr, CB 7461, Chapel Hill, NC 27599 USA.	steven_zeisel@unc.edu		Randall, Thomas/0000-0002-4605-7606	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056350, R01DK055865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG009525, P01 AG009525-160005, AG09525] Funding Source: Medline; NIDDK NIH HHS [R01 DK055865-07, DK55865, DK56350, P30 DK056350, R01 DK055865, P30 DK056350-08] Funding Source: Medline; NIEHS NIH HHS [ES10126, P30 ES010126-089008, P30 ES010126] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agarwal A, 2002, MOL HUM REPROD, V8, P167, DOI 10.1093/molehr/8.2.167; Albright CD, 1999, DEV BRAIN RES, V115, P123, DOI 10.1016/S0165-3806(99)00057-7; Albright CD, 2005, DEV BRAIN RES, V159, P149, DOI 10.1016/j.devbrainres.2005.07.002; Albright CD, 2003, NUTR NEUROSCI, V6, P129, DOI 10.1080/1028415031000084418; Albright CD, 1998, NEUROCHEM RES, V23, P751, DOI 10.1023/A:1022411510636; Albright CD, 2001, DEV NEUROSCI-BASEL, V23, P100, DOI 10.1159/000048701; Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; AUDUBERT F, 1983, J BIOL CHEM, V258, P695; Bajic VB, 2003, NUCLEIC ACIDS RES, V31, P3605, DOI 10.1093/nar/gkg517; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441; BREMER J, 1961, BIOCHIM BIOPHYS ACTA, V46, P205, DOI 10.1016/0006-3002(61)90745-4; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Craciunescu CN, 2003, J NUTR, V133, P3614, DOI 10.1093/jn/133.11.3614; da Costa KA, 2005, AM J CLIN NUTR, V81, P440; da Costa KA, 2004, AM J CLIN NUTR, V80, P163; da Costa KA, 2006, FASEB J, V20, P1336, DOI 10.1096/fj.06-5734com; Driscoll MD, 1998, J BIOL CHEM, V273, P29321, DOI 10.1074/jbc.273.45.29321; DROUVA SV, 1986, ENDOCRINOLOGY, V119, P2611, DOI 10.1210/endo-119-6-2611; DROUVA SV, 1987, ENDOCRINOLOGY, V121, P569, DOI 10.1210/endo-121-2-569; Elnitski L, 2003, GENOME RES, V13, P64, DOI 10.1101/gr.817703; FISCHER L, 2007, IN PRESS AM J CLIN N; Fischer LM, 2005, J NUTR, V135, P826, DOI 10.1093/jn/135.4.826; Fisher MC, 2001, TERATOLOGY, V64, P114, DOI 10.1002/tera.1053; Guba SC, 1996, AM J CLIN PATHOL, V106, P709; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; HolmesMcNary MQ, 1996, AM J CLIN NUTR, V64, P572, DOI 10.1093/ajcn/64.4.572; Institute of Medicine, 1998, DIET REF INT THIAM R, P390, DOI [DOI 10.17226/6015, 10.17226/6015]; Kanamori H, 2000, J BIOL CHEM, V275, P5867, DOI 10.1074/jbc.275.8.5867; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; LeCluyse Edward L, 2005, Methods Mol Biol, V290, P207; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez D, 2002, ENDOCRINOLOGY, V143, P2155, DOI 10.1210/en.143.6.2155; LOY R, 1991, ADV EXP MED BIOL, V295, P373; MCMAHON KE, 1985, CLIN CHIM ACTA, V149, P1, DOI 10.1016/0009-8981(85)90267-0; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 1997, NEUROREPORT, V8, P3053, DOI 10.1097/00001756-199709290-00010; Meck WH, 2003, NEUROSCI BIOBEHAV R, V27, P385, DOI 10.1016/S0149-7634(03)00069-1; Mellott TJ, 2004, FASEB J, V18, P545, DOI 10.1096/fj.03-0877fje; MORITA M, 1995, HEPATOLOGY, V21, P1585, DOI 10.1016/0270-9139(95)90463-8; Niculescu MD, 2006, FASEB J, V20, P43, DOI 10.1096/fj.05-4707com; Noga AA, 2003, J BIOL CHEM, V278, P21851, DOI 10.1074/jbc.M301982200; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Ovcharenko I, 2004, NUCLEIC ACIDS RES, V32, pW280, DOI 10.1093/nar/gkh355; Peck JD, 2002, CANCER EPIDEM BIOMAR, V11, P361; Pyapali GK, 1998, J NEUROPHYSIOL, V79, P1790, DOI 10.1152/jn.1998.79.4.1790; Sathya G, 1997, MOL ENDOCRINOL, V11, P1994, DOI 10.1210/me.11.13.1994; Shaw GM, 2006, EPIDEMIOLOGY, V17, P285, DOI 10.1097/01.ede.0000208348.30012.35; Shaw GM, 2004, AM J EPIDEMIOL, V160, P102, DOI 10.1093/aje/kwh187; Shields DJ, 2001, BBA-MOL CELL BIOL L, V1532, P105, DOI 10.1016/S1388-1981(01)00122-6; Shiraki T, 2003, P NATL ACAD SCI USA, V100, P15776, DOI 10.1073/pnas.2136655100; SOTO AM, 1985, J STEROID BIOCHEM, V23, P87, DOI 10.1016/0022-4731(85)90265-1; SWEIRY JH, 1986, J DEV PHYSIOL, V8, P435; SWEIRY JH, 1985, J PHYSIOL-LONDON, V366, P251, DOI 10.1113/jphysiol.1985.sp015795; Tang SS, 2004, NUCLEIC ACIDS RES, V32, P6212, DOI 10.1093/nar/gkh943; TESSITORE L, 1995, INT J EXP PATHOL, V76, P125; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; Vance DE, 1998, BIOCHEM SOC T, V26, P337, DOI 10.1042/bst0260337; Vigo C, 1981, Biochem Soc Trans, V9, P98; VIGO C, 1981, BIOCHIM BIOPHYS ACTA, V665, P546, DOI 10.1016/0005-2760(81)90269-1; VIGO C, 1981, BIOCHEM J, V200, P321, DOI 10.1042/bj2000321; Walkey CJ, 1996, J LIPID RES, V37, P2341; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; Xie T, 1999, MOL PHARMACOL, V56, P31, DOI 10.1124/mol.56.1.31; YOUNG DL, 1971, J LIPID RES, V12, P590; Zeisel SH, 2003, J NUTR, V133, P1302; ZEISEL SH, 1995, J NUTR, V125, P3049; Zeisel SH, 2006, ANNU REV NUTR, V26, P229, DOI 10.1146/annurev.nutr.26.061505.111156	69	152	155	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2622	2632		10.1096/fj.07-8227com	http://dx.doi.org/10.1096/fj.07-8227com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17456783	Green Accepted, Green Submitted			2022-12-28	WOS:000248454400035
J	Davey, RE; Onishi, K; Mahdavi, A; Zandstra, PW				Davey, Ryan E.; Onishi, Kento; Mahdavi, Alborz; Zandstra, Peter W.			LIF-mediated control of embryonic stem cell self-renewal emerges due to an autoregulatory loop	FASEB JOURNAL			English	Article						positive feedback; cell signaling; Jak-STAT; threshold; systems biology	RESPONSIVE ELEMENT-BINDING; EARLY MOUSE EMBRYOGENESIS; ES CELLS; SIGNALING PATHWAYS; STAT3; DIFFERENTIATION; EXPRESSION; PLURIPOTENCY; INDUCTION; PROTEINS	Stem cells convert graded stimuli into all-or-nothing cell-fate responses. We investigated how embryonic stem cells (ESCs) convert leukemia inhibitory factor (LIF) concentration into an all-or-nothing cell-fate decision (self-renewal). Using a combined experimental/computational approach we demonstrate unexpected switch-like (on/off) signaling in response to LIF. This behavior emerges over time due to a positive feedback loop controlling transcriptional expression of LIF signaling pathway components. The autoregulatory loop maintains robust pathway responsiveness ("on") at sufficient concentrations of exogenous LIF, while autocrine signaling and low concentrations of exogenous LIF cause ESCs to adopt the weakly responsive ("off") state of differentiated cells. We demonstrate that loss of ligand responsiveness is reversible and precedes loss of the ESC transcription factors Oct4 and Nanog, suggesting an early step in the hierarchical control of differentiation. While endogenously produced ligands were insufficient to sustain the "on" state, they buffer it, influencing the timing of differentiation. These results demonstrate a novel switch-like behavior, which establishes the LIF threshold for ESC self-renewal.	Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada; Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON, Canada	University of Toronto; University of Toronto	Zandstra, PW (corresponding author), Univ Toronto, Terrence Donnelly Ctr Cellular & Biomol Res, 160 Coll St,11th Floor, Toronto, ON M5S 3E1, Canada.	peter.zandstra@utoronto.ca						Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Bader A, 2000, CIRC RES, V86, P787, DOI 10.1161/01.RES.86.7.787; Bagowski CP, 2001, CURR BIOL, V11, P1176, DOI 10.1016/S0960-9822(01)00330-X; Blanchard F, 2002, ONCOGENE, V21, P6264, DOI 10.1038/sj.onc.1205777; Boeuf H, 2001, J BIOL CHEM, V276, P46204, DOI 10.1074/jbc.M106718200; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chang KH, 2004, BIOTECHNOL BIOENG, V88, P287, DOI 10.1002/bit.20242; Dani C, 1998, DEV BIOL, V203, P149, DOI 10.1006/dbio.1998.9026; Davey RE, 2006, STEM CELLS, V24, P2538, DOI 10.1634/stemcells.2006-0216; Ebong S, 2004, INVEST OPHTH VIS SCI, V45, P872, DOI 10.1167/iovs.03-0311; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Gadue P, 2005, EXP HEMATOL, V33, P955, DOI 10.1016/j.exphem.2005.06.009; GOLDBETER A, 1982, Q REV BIOPHYS, V15, P555, DOI 10.1017/S0033583500003449; Guo Y, 2006, STEM CELLS, V24, P850, DOI 10.1634/stemcells.2005-0457; Hao J, 2006, DEV BIOL, V290, P81, DOI 10.1016/j.ydbio.2005.11.011; He F, 2005, NAT NEUROSCI, V8, P616, DOI 10.1038/nn1440; HICKARMANE V, 2006, PLOS COMPUT BIOL, V2, pE123; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Kamimura D, 2004, REV PHYSIOL BIOCH P, V149, P1, DOI 10.1007/s10254-003-0012-2; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Ko SY, 2006, CELL STRUCT FUNCT, V31, P53, DOI 10.1247/csf.31.53; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mikkers H, 2005, EMBO J, V24, P2715, DOI 10.1038/sj.emboj.7600749; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nashta AAF, 2004, J ENDOCRINOL, V181, P477, DOI 10.1677/joe.0.1810477; Nichols J, 1996, MECH DEVELOP, V57, P123, DOI 10.1016/0925-4773(96)00531-X; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; OBrien CA, 1997, J BIOL CHEM, V272, P15003, DOI 10.1074/jbc.272.23.15003; Ogawa K, 2006, BIOCHEM BIOPH RES CO, V343, P159, DOI 10.1016/j.bbrc.2006.02.127; Prudhomme W, 2004, P NATL ACAD SCI USA, V101, P2900, DOI 10.1073/pnas.0308768101; RATHJEN PD, 1990, GENE DEV, V4, P2308, DOI 10.1101/gad.4.12b.2308; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; SAITO M, 1992, J IMMUNOL, V148, P4066; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; Viswanathan S, 2005, BIOTECHNOL APPL BIOC, V42, P119, DOI 10.1042/BA20040207; Viswanathan S, 2002, STEM CELLS, V20, P119, DOI 10.1634/stemcells.20-2-119; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Zhan M, 2005, CELL BIOCHEM BIOPHYS, V43, P379, DOI 10.1385/CBB:43:3:379	46	58	62	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					2020	2032		10.1096/fj.06-7852com	http://dx.doi.org/10.1096/fj.06-7852com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17356004				2022-12-28	WOS:000247500300012
J	Liberman, AC; Refojo, D; Druker, J; Toscano, M; Rein, T; Holsboer, F; Arzt, E				Liberman, Ana C.; Refojo, Damian; Druker, Jimena; Toscano, Marta; Rein, Theo; Holsboer, Florian; Arzt, Eduardo			The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction	FASEB JOURNAL			English	Article						transrepression; T helper inhibition; immunosupression	NF-KAPPA-B; IFN-GAMMA; INTERFERON-GAMMA; DNA-BINDING; ANTIINFLAMMATORY ACTION; TH1 DEVELOPMENT; NUCLEAR-FACTOR; ZINC-FINGER; CROSS-TALK; IN-VITRO	Glucocorticoids (GCs) immunosuppression acts via regulation of several transcription factors (TF), including activating protein (AP)-1, NF-kappa B, and NFAT. GCs inhibit Th1 cytokines and promote a shift toward Th2 differentiation. Th1 phenotype depends on TF T-bet. In this study, we examined GC regulation of T-bet. We found that GCs inhibit T-bet transcriptional activity. We show that glucocorticoid receptor (GR) physically interacts with T-bet both in transfected cell lines and in primary splenocyte cultures with endogenous GR and T-bet. This interaction also blocks GR-dependent transcription. We show both in vitro and in vivo at endogenous binding sites that the mechanism underlying T-bet inhibition further involves reduction of T-bet binding to DNA. Using specific mutations of GR, we demonstrate that the first zinc finger region of GR is required for T-bet inhibition. GCs additionally inhibit T-bet both at mRNA and protein expression levels, revealing another layer of GR action on T-bet. Finally, we examined the functional consequences of GR/T-bet interaction on IFN-gamma, showing that GCs inhibit transcriptional activity of T-bet on its promoter. In view of the crucial role of T-bet in T cell differentiation and inflammation, we propose that GR inhibitory interaction with T-bet may be an important mechanism underlying the immunosuppressive properties of GCs.	Univ Buenos Aires, Lab Fisiol & Biol Mol, FCEN, Dept Fisiol & Biol Mol & Celular, RA-1428 Buenos Aires, DF, Argentina; IFIBYNE CONICET, Buenos Aires, DF, Argentina; Max Planck Inst Psychiat, D-80804 Munich, Germany; Univ Buenos Aires, Hosp Clin Jose De San Martin, Fac Med, Div Immunogenet, Buenos Aires, DF, Argentina	University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Max Planck Society; University of Buenos Aires	Arzt, E (corresponding author), Univ Buenos Aires, Lab Fisiol & Biol Mol, FCEN, Dept Fisiol & Biol Mol & Celular, Ciudad Univ, RA-1428 Buenos Aires, DF, Argentina.	earzt@fbmc.fcen.uba.ar		Rein, Theo/0000-0003-2850-4289; Refojo, Damian/0000-0002-9798-6413				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Adcock IM, 2001, PULM PHARMACOL THER, V14, P211, DOI 10.1006/pupt.2001.0283; Afkarian M, 2002, NAT IMMUNOL, V3, P549, DOI 10.1038/ni794; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Biola A, 2000, FEBS LETT, V487, P229, DOI 10.1016/S0014-5793(00)02297-3; Blotta MH, 1997, J IMMUNOL, V158, P5589; BOUMPAS DT, 1993, ANN INTERN MED, V119, P1198, DOI 10.7326/0003-4819-119-12-199312150-00007; BOUMPAS DT, 1991, CLIN EXP RHEUMATOL, V9, P413; Braun CM, 1997, J ALLERGY CLIN IMMUN, V100, P400, DOI 10.1016/S0091-6749(97)70255-0; BRINKMANN V, 1995, J IMMUNOL, V155, P3322; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Cho JY, 2003, INT IMMUNOL, V15, P1149, DOI 10.1093/intimm/dxg113; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; CIPPITELLI M, 1995, J BIOL CHEM, V270, P12548, DOI 10.1074/jbc.270.21.12548; Costas M, 1996, J CLIN INVEST, V98, P1409, DOI 10.1172/JCI118928; CUPPS TR, 1982, IMMUNOL REV, V65, P133, DOI 10.1111/j.1600-065X.1982.tb00431.x; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; De Bosscher K, 2000, J NEUROIMMUNOL, V109, P16, DOI 10.1016/S0165-5728(00)00297-6; FOX HS, 1991, J IMMUNOL, V146, P4362; Franchimont D, 2000, J IMMUNOL, V164, P1768, DOI 10.4049/jimmunol.164.4.1768; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hu XY, 2003, J IMMUNOL, V170, P4833, DOI 10.4049/jimmunol.170.9.4833; Hwang ES, 2005, SCIENCE, V307, P430, DOI 10.1126/science.1103336; Hwang ES, 2002, J IMMUNOL, V169, P248, DOI 10.4049/jimmunol.169.1.248; Hwang ES, 2005, J EXP MED, V202, P1289, DOI 10.1084/jem.20051044; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Klein-Hessling S, 2003, J IMMUNOL, V170, P2956, DOI 10.4049/jimmunol.170.6.2956; Kovalovsky D, 1998, EUR J IMMUNOL, V28, P2075; LAUE L, 1988, J STEROID BIOCHEM, V29, P591, DOI 10.1016/0022-4731(88)90156-2; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; Lighvani AA, 2001, P NATL ACAD SCI USA, V98, P15137, DOI 10.1073/pnas.261570598; MCKEAN DJ, 1995, INT IMMUNOL, V7, P9, DOI 10.1093/intimm/7.1.9; Miyaura H, 2002, J IMMUNOL, V168, P1087, DOI 10.4049/jimmunol.168.3.1087; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Mullen AC, 2001, SCIENCE, V292, P1907, DOI 10.1126/science.1059835; Neurath MF, 2002, J EXP MED, V195, P1129, DOI 10.1084/jem.20011956; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Novac N, 2006, FASEB J, V20, P1074, DOI 10.1096/fj.05-5457com; O'Shea JJ, 2005, CURR OPIN RHEUMATOL, V17, P305, DOI 10.1097/01.bor.0000160781.07174.db; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Paez-Pereda M, 2003, P NATL ACAD SCI USA, V100, P1034, DOI 10.1073/pnas.0237312100; RAIDEN S, 1995, J CLIN IMMUNOL, V15, P242, DOI 10.1007/BF01540881; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; Robinson DS, 2002, IMMUNITY, V16, P755, DOI 10.1016/S1074-7613(02)00331-X; RUPPRECHT R, 1993, MOL ENDOCRINOL, V7, P597, DOI 10.1210/me.7.4.597; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Tao YX, 2001, J BIOL CHEM, V276, P2329, DOI 10.1074/jbc.C000526200; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Visser J, 1998, BLOOD, V91, P4255, DOI 10.1182/blood.V91.11.4255.411a03_4255_4264; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Yin ZN, 2002, J IMMUNOL, V168, P1566, DOI 10.4049/jimmunol.168.4.1566; YOUNG HA, 1990, PHARMACOL THERAPEUT, V45, P137, DOI 10.1016/0163-7258(90)90012-Q; Yudt MR, 2003, MOL CELL BIOL, V23, P4319, DOI 10.1128/MCB.23.12.4319-4330.2003	66	76	85	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1177	1188		10.1096/fj.06-7452com	http://dx.doi.org/10.1096/fj.06-7452com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17215482				2022-12-28	WOS:000245650400022
J	Buttigieg, J; Brown, S; Zhang, M; Lowe, M; Holloway, AC; Nurse, CA				Buttigieg, Josef; Brown, Stephen; Zhang, Min; Lowe, Michael; Holloway, Alison C.; Nurse, Colin A.			Chronic nicotine in utero selectively suppresses hypoxic sensitivity in neonatal rat adrenal chromaffin cells	FASEB JOURNAL			English	Article						catecholamine; nAChR; SIDS; fetus; asphyxia	INFANT-DEATH-SYNDROME; CATECHOLAMINE SECRETION; EXPOSURE; FETAL; CHANNELS; INCREASE; MEDULLA; RELEASE; NEWBORN; STRESS	Nicotine in cigarette smoke has been linked to several deleterious side effects on the offspring of smoking mothers, including impaired development of the sympathoadrenal system, abnormal arousal reflexes, and sudden infant death syndrome. Catecholamine (CA) release from adrenomedullary chromaffin cells (AMCs) in response to asphyxial stressors, e.g., low O-2 (hypoxia) and elevated CO2 (hypercapnia), is critical for adaptation to extrauterine life and occurs before splanchnic innervation. Here, we investigated the effects of prenatal nicotine bitartrate exposure on the ability of neonatal (PO) rat AMCs to respond appropriately to asphyxial stressors. Control AMCs isolated from pups born to saline-treated dams displayed typical responses to hypoxia and hypercapnia, including inhibition of outward K+ current, membrane depolarization, increased cytosolic calcium, and CA secretion. In contrast, PO AMCs from pups born to nicotine-treated dams showed a marked suppression or loss of hypoxic sensitivity, although hypercapnic sensitivity and the expression of CO2 markers (i.e., carbonic anhydrase I and II) appeared normal. Moreover, isolated saline-treated PO AMCs lost their hypoxic sensitivity when grown in culture for similar to 1 wk in the presence of a subsaturating concentration of nicotine base (50 mu M), and this effect was abolished by the nicotinic acetylcholine receptor (nAChR) blocker mecamylamine (100 mu M). Taken together, these data suggest that the adverse effects of maternal smoking on sympathoadrenal function in the offspring are due in part to a loss or suppression of acute hypoxic sensitivity in adrenal chromaffin cells, triggered by the direct action of nicotine on endogenous nicotinic acetylcholine receptors.	[Buttigieg, Josef; Brown, Stephen; Zhang, Min; Lowe, Michael; Nurse, Colin A.] McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; [Holloway, Alison C.] McMaster Univ, Dept Obstet & Gynecol, Hamilton, ON L8S 4K1, Canada	McMaster University; McMaster University	Nurse, CA (corresponding author), McMaster Univ, Dept Biol, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.	nursec@mcmaster.ca						Bournaud R, 2007, PFLUG ARCH EUR J PHY, V454, P83, DOI 10.1007/s00424-006-0185-z; Cohen G, 2005, P NATL ACAD SCI USA, V102, P3817, DOI 10.1073/pnas.0409782102; Garcia-Fernandez M, 2007, PFLUG ARCH EUR J PHY, V454, P93, DOI 10.1007/s00424-006-0186-y; GIEGERICH R, 1996, P INT C INT SYST MOL, V4, P58; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAGLUND B, 1990, AM J PUBLIC HEALTH, V80, P29, DOI 10.2105/AJPH.80.1.29; Holloway AC, 2005, DIABETOLOGIA, V48, P2661, DOI 10.1007/s00125-005-0022-5; Keating DJ, 2001, AM J PHYSIOL-CELL PH, V281, pC1434, DOI 10.1152/ajpcell.2001.281.5.C1434; LAGERCRANTZ H, 1986, SCI AM, V254, P100, DOI 10.1038/scientificamerican0486-100; Matta SG, 2007, PSYCHOPHARMACOLOGY, V190, P269, DOI 10.1007/s00213-006-0441-0; MochizukiOda N, 1997, J NEUROCHEM, V69, P377; Mojet MH, 1997, J PHYSIOL-LONDON, V504, P175, DOI 10.1111/j.1469-7793.1997.175bf.x; Munoz-Cabello AM, 2005, J NEUROSCI, V25, P6631, DOI 10.1523/JNEUROSCI.1139-05.2005; Rico AJ, 2005, AM J PHYSIOL-CELL PH, V289, pC1417, DOI 10.1152/ajpcell.00023.2005; SEIDLER FJ, 1985, J PHYSL, V385, P1; Slotkin TA, 1998, J PHARMACOL EXP THER, V285, P931; SLOTKIN TA, 1988, J DEV PHYSIOL, V10, P1; SLOTKIN TA, 1995, BRAIN RES BULL, V38, P69, DOI 10.1016/0361-9230(95)00073-N; Thompson RJ, 2007, NEUROSCIENCE, V145, P130, DOI 10.1016/j.neuroscience.2006.11.040; Thompson RJ, 1997, J PHYSIOL-LONDON, V498, P503, DOI 10.1113/jphysiol.1997.sp021876; Thompson RJ, 1998, J PHYSIOL-LONDON, V512, P421, DOI 10.1111/j.1469-7793.1998.421be.x; Thompson RJ, 2002, PFLUG ARCH EUR J PHY, V444, P539, DOI 10.1007/s00424-002-0853-6; Zhang M, 2000, J PHYSIOL-LONDON, V525, P143, DOI 10.1111/j.1469-7793.2000.t01-1-00143.x	24	29	31	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2008	22	5					1317	1326		10.1096/fj.07-9194com	http://dx.doi.org/10.1096/fj.07-9194com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18070822				2022-12-28	WOS:000255898700005
J	Shimazoe, T; Morita, M; Ogiwara, S; Kojiya, T; Goto, J; Kamakura, M; Moriya, T; Shinohara, K; Takiguchi, S; Kono, A; Miyasaka, K; Funakoshi, A; Ikeda, M				Shimazoe, Takao; Morita, Mitsutaka; Ogiwara, Shinichiro; Kojiya, Tomoyoshi; Goto, Junpei; Kamakura, Masaki; Moriya, Takahiro; Shinohara, Kazuyuki; Takiguchi, Soichi; Kono, Akira; Miyasaka, Kyoko; Funakoshi, Akihiro; Ikeda, Masayuki			Cholecystokinin-A receptors regulate photic input pathways to the circadian clock	FASEB JOURNAL			English	Article						cholecystokinin-A receptor mutant mice; glycinergic amacrine cells; melanopsin retinal ganglion cells; suprachiasmatic nucleus neurons	RETINAL GANGLION-CELLS; AMACRINE CELLS; SUPRACHIASMATIC NUCLEUS; GENE-EXPRESSION; RAT RETINA; MELANOPSIN; RHYTHMS; NEUROTRANSMITTERS; IMMUNOREACTIVITY; LOCALIZATION	Daily behaviors are strongly dominated by internally generated circadian rhythms, but the underlying mechanisms remain unclear. In mammals, photoentrainment of behaviors to light-dark cycles involves signaling from both intrinsically photosensitive retinal ganglion cells and classic photoreceptor pathways to the suprachiasmatic nucleus (SCN). How classic photoreceptor pathways work with the photosensitive ganglion cells, however, is not fully understood. Although cholecystokinin (CCK) peptide has been shown to be present in a variety of vertebrate retinas, its function at a systems level is also unknown. In the present study we examined a possible role of CCK-A receptors in photoentrainment using CCK-A receptor knockout mice. The lacZ reporter gene within a gene-knockout cassette revealed precise localization of CCK-A receptors in the circadian clock system. We demonstrated that CCK-A receptors were located predominately on glycinergic amacrine cells but were rarely found on SCN neurons. Moreover, Ca2+ imaging analysis demonstrated that the CCK-A agonist, CCK-8 sulfate (CCK-8s), mobilized intracellular Ca2+ in amacrine cells but not glutamate-receptive SCN neurons. Furthermore, light pulse-induced mPer1/mPer2 gene expression in SCN, behavioral phase shifts, and the pupillary reflex were significantly reduced in CCK-A receptor knockout mice. These data indicate a novel function of CCK-A receptors in the nonimage-forming photoreception presumably via amacrine cell-mediated signal transduction pathways.	[Ogiwara, Shinichiro; Kojiya, Tomoyoshi; Goto, Junpei; Ikeda, Masayuki] Toyama Univ, Fac Sci, Dept Biol, Grad Sch Sci & Engn, Toyama 9308555, Japan; [Shimazoe, Takao; Morita, Mitsutaka] Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka, Japan; [Kamakura, Masaki] Toyama Prefectural Univ, Fac Engn, Biotechnol Res Ctr, Toyama, Japan; [Moriya, Takahiro; Shinohara, Kazuyuki] Nagasaki Univ, Grad Sch Biomed Sci, Course Med & Dent Sci, Dept Translat Med Sci, Nagasaki, Japan; [Takiguchi, Soichi; Kono, Akira; Funakoshi, Akihiro] Kyushu Natl Canc Ctr, Fukuoka, Japan; [Miyasaka, Kyoko] Tokyo Metropolitan Inst Gerontol, Dept Translat Med Sci, Tokyo, Japan; [Ikeda, Masayuki] Waseda Univ, Adv Inst Biol Sci, Tokyo, Japan	University of Toyama; Kyushu University; Toyama Prefectural University; Nagasaki University; Tokyo Metropolitan Institute of Gerontology; Waseda University	Ikeda, M (corresponding author), Toyama Univ, Fac Sci, Dept Biol, Grad Sch Sci & Engn, Rm B214,3190 Gofuku, Toyama 9308555, Japan.	msikeda@sci.u-toyama.ac.jp	Kamakura, Masaki/E-7954-2011	Ikeda, Masayuki/0000-0002-6833-9495				Belenky MA, 2003, J COMP NEUROL, V460, P380, DOI 10.1002/cne.10652; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Bi S, 2004, ENDOCRINOLOGY, V145, P3873, DOI 10.1210/en.2004-0284; Bragado MJ, 2003, NEUROPEPTIDES, V37, P374, DOI 10.1016/j.npep.2003.10.004; Correia SS, 2003, J BIOL CHEM, V278, P6307, DOI 10.1074/jbc.M205587200; DAVIDOWA H, 1995, BRAIN RES BULL, V36, P533, DOI 10.1016/0361-9230(94)00238-V; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; Dkhissi-Benyahya O, 2007, NEURON, V53, P677, DOI 10.1016/j.neuron.2007.02.005; Dumitrescu ON, 2006, VISUAL NEUROSCI, V23, P79, DOI 10.1017/S0952523806231079; ESKAY RL, 1982, BRAIN RES, V246, P315, DOI 10.1016/0006-8993(82)91183-0; Firth SI, 2002, VISUAL NEUROSCI, V19, P531, DOI 10.1017/S0952523802194156; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; Fry M, 2007, EXP BIOL MED, V232, P14; FUNAKOSHI A, 1995, BIOCHEM BIOPH RES CO, V210, P787, DOI 10.1006/bbrc.1995.1728; Gabriel R, 2004, CELL TISSUE RES, V315, P181, DOI 10.1007/s00441-003-0785-2; Gooley JJ, 2001, NAT NEUROSCI, V4, P1165, DOI 10.1038/nn768; Hannibal J, 2002, CELL TISSUE RES, V309, P73, DOI 10.1007/s00441-002-0574-3; Hatakeyama J, 2002, METHODS, V28, P387, DOI 10.1016/S1046-2023(02)00257-8; Herness S, 2002, J NEUROSCI, V22, P10018; Ikeda M, 2004, NEUROSCIENTIST, V10, P315, DOI 10.1177/10738584031262149; Ikeda M, 2003, NEURON, V38, P253, DOI 10.1016/S0896-6273(03)00164-8; Jobst EE, 2004, TRENDS ENDOCRIN MET, V15, P488, DOI 10.1016/j.tem.2004.10.007; Kopin AS, 1999, J CLIN INVEST, V103, P383, DOI 10.1172/JCI4901; Lagnado L, 1998, CURR BIOL, V8, pR598, DOI 10.1016/S0960-9822(98)70385-9; Lesauter J, 2002, NEUROSCIENCE, V111, P575, DOI 10.1016/S0306-4522(01)00604-2; Lucas RJ, 2003, SCIENCE, V299, P245, DOI 10.1126/science.1077293; MacNeil MA, 1998, NEURON, V20, P971, DOI 10.1016/S0896-6273(00)80478-X; MARSHAK DW, 1990, J NEUROSCI, V10, P3045; Moldavan MG, 2006, J NEUROPHYSIOL, V95, P3727, DOI 10.1152/jn.00909.2005; MOORE RY, 1972, BRAIN RES, V42, P201, DOI 10.1016/0006-8993(72)90054-6; Morin LP, 2006, BRAIN RES REV, V51, P1, DOI 10.1016/j.brainresrev.2005.08.003; Muramatsu Y, 2005, BIOCHEM BIOPH RES CO, V331, P1270, DOI 10.1016/j.bbrc.2005.04.040; Ogino T, 2000, GENOMICS, V70, P19, DOI 10.1006/geno.2000.6349; OSBORNE NN, 1981, NEUROSCI LETT, V26, P31, DOI 10.1016/0304-3940(81)90421-3; OSBORNE NN, 1982, EXP EYE RES, V34, P639, DOI 10.1016/0014-4835(82)90038-0; Panda S, 2003, SCIENCE, V301, P525, DOI 10.1126/science.1086179; Pickard GE, 1999, J NEUROSCI, V19, P4034; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shimazoe T, 1999, JPN J PHARMACOL, V80, P85, DOI 10.1254/jjp.80.85; Silver R, 1999, NEUROREPORT, V10, P3165, DOI 10.1097/00001756-199910190-00008; Simasko SM, 2002, AM J PHYSIOL-REG I, V283, pR1303, DOI 10.1152/ajpregu.00050.2002; STEPHAN FK, 1972, P NATL ACAD SCI USA, V69, P1583, DOI 10.1073/pnas.69.6.1583; Takiguchi S, 2002, PANCREAS, V24, P276, DOI 10.1097/00006676-200204000-00011; Takiguchi S, 1997, GENE, V197, P169, DOI 10.1016/S0378-1119(97)00259-X; VANDENPOL AN, 1985, NEUROSCIENCE, V15, P1049, DOI 10.1016/0306-4522(85)90254-4; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; Williams JA, 2001, ANNU REV PHYSIOL, V63, P77, DOI 10.1146/annurev.physiol.63.1.77; Yamanouchi S, 1997, NEUROSCI LETT, V227, P103, DOI 10.1016/S0304-3940(97)00324-8; Zhang DQ, 2005, BRAIN RES, V1050, P101, DOI 10.1016/j.brainres.2005.05.042	50	14	14	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1479	1490		10.1096/fj.07-9372com	http://dx.doi.org/10.1096/fj.07-9372com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18073333				2022-12-28	WOS:000255898700020
J	Qiu, Y; Bevan, H; Weeraperuma, S; Wratting, D; Murphy, D; Neal, CR; Bates, DO; Harper, SJ				Qiu, Yan; Bevan, Heather; Weeraperuma, Sudath; Wratting, Daniel; Murphy, David; Neal, Christopher R.; Bates, David O.; Harper, Steven J.			Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF(165)b	FASEB JOURNAL			English	Article						angiogenesis; splicing; transgenic	INCREASES HYDRAULIC CONDUCTIVITY; RAT SKELETAL-MUSCLE; SPLICE VARIANT; IN-VIVO; VASCULAR-PERMEABILITY; FACTOR FAMILY; VEGF; GLAND; ANGIOGENESIS; EXPRESSION	Extensive tissue remodeling occurs in breast tissue during pregnancy, resulting in growth and development of the mammary gland associated with extensive vascular remodeling, which is thought to be dependent on vascular endothelial growth factor (VEGF). We show here that the endogenous antiangiogenic splice isoform of VEGF, VEGF(165)b, is normally expressed in nonlactating human and mouse breast, and is down-regulated in WT mice during lactation. To demonstrate the physiological role of VEGF165b in mammary tissue, we generated transgenic (TG) mice expressing VEGF165b, under the control of the mouse mammary tumor virus (MMTV) enhancer/promoter. These mice increase expression of VEGF165b in mammary tissue during mammary development. The offspring of TG mothers, but not TG fathers, die shortly after birth. The female TG mice have fewer blood vessels, less blood in the mammary tissue, and impaired alveolar coverage of the fat pad, and do not produce sufficient milk for nourishment of their pups. These findings demonstrate that endogenous overexpression of VEGF165b in the mammary gland inhibits physiological angiogenesis and that the regulation of the balance of VEGF isoforms is a requirement for mammary alveolar development and milk production. This study provides the first evidence for the role of endogenous antiangiogenic VEGF isoforms in normal physiology - their down-regulation is required for effective milk production.	[Qiu, Yan; Bevan, Heather; Weeraperuma, Sudath; Wratting, Daniel; Neal, Christopher R.; Bates, David O.; Harper, Steven J.] Univ Bristol, Sch Vet Sci, Microvasc Res Labs, Bristol BS18 7DU, Avon, England; [Murphy, David] Univ Bristol, Henry Wellcome Labs Integrat Neurosci & Endocrino, Bristol BS18 7DU, Avon, England	University of Bristol; University of Bristol	Bates, DO (corresponding author), Univ Bristol, Preclin Vet Sch, Dept Physiol, Microvasc Res Labs, Southwell St, Bristol BS2 8EJ, Avon, England.	dave.bates@bris.ac.uk; s.harper@bris.ac.uk	Murphy, David/C-3967-2012	Murphy, David/0000-0003-2946-0353; Bates, David/0000-0003-4850-2360	British Heart Foundation [BB2000007] Funding Source: Medline; Wellcome Trust [69029, 058083] Funding Source: Medline	British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome TrustEuropean Commission)		Bates DO, 1996, AM J PHYSIOL-HEART C, V271, pH2520, DOI 10.1152/ajpheart.1996.271.6.H2520; Bates DO, 2006, CLIN SCI, V110, P575, DOI 10.1042/CS20050292; Bates DO, 2002, CANCER RES, V62, P4123; Benest AV, 2006, MICROCIRCULATION, V13, P423, DOI 10.1080/10739680600775940; Cao RH, 2001, P NATL ACAD SCI USA, V98, P6390, DOI 10.1073/pnas.101564798; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Djonov V, 2003, CELL TISSUE RES, V314, P107, DOI 10.1007/s00441-003-0784-3; Djonov V, 2001, MICROSC RES TECHNIQ, V52, P182, DOI 10.1002/1097-0029(20010115)52:2<182::AID-JEMT1004>3.3.CO;2-D; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P857; Fu BMM, 2004, MICROVASC RES, V68, P51, DOI 10.1016/j.mvr.2004.03.004; Glass CA, 2006, J PHYSIOL-LONDON, V572, P243, DOI 10.1113/jphysiol.2005.103127; Goldhar AS, 2005, MOL CELL ENDOCRINOL, V232, P9, DOI 10.1016/j.mce.2005.01.005; HansenSmith FM, 1996, CELL TISSUE RES, V286, P123, DOI 10.1007/s004410050681; HARALDSSON B, 1984, ACTA PHYSIOL SCAND, V122, P497, DOI 10.1111/j.1748-1716.1984.tb07538.x; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Jeffers KR, 1935, AM J ANAT, V56, P257, DOI 10.1002/aja.1000560204; Konopatskaya O, 2006, MOL VIS, V12, P626; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586; MATSUMOTO M, 1992, J VET MED SCI, V54, P937, DOI 10.1292/jvms.54.937; MATSUMOTO M, 1994, J VET MED SCI, V56, P65, DOI 10.1292/jvms.56.65; Pepper MS, 2000, DEV DYNAM, V218, P507, DOI 10.1002/1097-0177(200007)218:3<507::AID-DVDY1012>3.0.CO;2-5; Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8; Pritchard-Jones RO, 2007, BRIT J CANCER, V97, P223, DOI 10.1038/sj.bjc.6603839; Roberts WG, 1997, CANCER RES, V57, P765; Rossiter H, 2007, FASEB J, V21, P3994, DOI 10.1096/fj.07-8720com; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; SENGER DR, 1990, CANCER RES, V50, P1774; Suarez SC, 2006, CELL MOL LIFE SCI, V63, P2067, DOI 10.1007/s00018-006-6254-9; VAREY AHR, 2007, MICROCIRCULATION, V14, P637; Vuorela P, 2000, AM J CLIN NUTR, V72, P1196; Woolard J, 2006, FASEB J, V20, pA539; Zhou AL, 1998, CELL TISSUE RES, V293, P293, DOI 10.1007/s004410051121	36	50	56	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2008	22	4					1104	1112		10.1096/fj.07-9718com	http://dx.doi.org/10.1096/fj.07-9718com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	18032632				2022-12-28	WOS:000254581000016
J	Charrier-Hisamuddin, L; Laboisse, CL; Merlin, D				Charrier-Hisamuddin, Laetitia; Laboisse, Christian L.; Merlin, Didier			ADAM-15: a metalloprotease that mediates inflammation	FASEB JOURNAL			English	Review						metargidin (MDC-15); cell-cell interactions; cell-matrix interactions; inflammatory diseases; proteases	ENDOTHELIAL GROWTH-FACTOR; FUNCTION-ASSOCIATED ANTIGEN-1; NECROSIS-FACTOR-ALPHA; EPITHELIAL-CELL INTERACTIONS; ADHESION MOLECULE-1 ICAM-1; DISINTEGRIN-LIKE DOMAIN; SRC FAMILY PROTEINS; RHEUMATOID-ARTHRITIS; BOWEL-DISEASE; IN-VITRO	Cell-cell and cell-matrix interactions are of utmost importance in the pathogenesis of inflammatory diseases. For example, cell-cell and cell-matrix interactions are crucial for leukocyte homing and recruitment to inflammatory sites. The discovery of the disintegrin and metalloprotease (ADAM) proteins, which have both adhesive and proteolytic activities, raised the question of their involvement in inflammatory processes. More interestingly, the presence of the RGD integrin-binding sequence in the disintegrin domain of ADAM-15 (MDG15; metargidin) highlighted ADAM-15 as a protein particularly involved in cell-cell interactions. These findings therefore prompted authors to investigate the roles of ADAM-15 in inflammatory diseases. Because of the early description of ADAM-15 expression in endothelial cells, work first focused on the roles of ADAM-15 in vascular diseases, and ADAM-15 was found to be associated with atherosclerosis. Other studies also pointed at ADAM-15 as a mediator of rheumatoid arthritis and intestinal inflammation as well as inherent angiogenesis. The roles of ADAM-15 in these diseases appear to involve mechanisms as different as cell-cell interactions, cell-extracellular matrix (ECM) interactions, and shedding activity. Here we review and discuss these recent discoveries pointing to ADAM-15 as a mediator of mechanisms underlying inflammation and as a possible therapeutic target for prevention of inflammatory diseases.	[Charrier-Hisamuddin, Laetitia; Merlin, Didier] Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; [Laboisse, Christian L.] INSERM, U 539, Nantes, France	Emory University; Institut National de la Sante et de la Recherche Medicale (Inserm)	Charrier-Hisamuddin, L (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 615 Michael St, Atlanta, GA 30322 USA.	lcharri@emory.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399, R01DK071594, R01DK061941] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-061941, R01-DK-071594, R24-DK-064399] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agace WW, 2000, CURR OPIN CELL BIOL, V12, P563, DOI 10.1016/S0955-0674(00)00132-0; Al-Fakhri N, 2003, J CELL BIOCHEM, V89, P808, DOI 10.1002/jcb.10550; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Bohm BB, 2005, ARTHRITIS RHEUM-US, V52, P1100, DOI 10.1002/art.20974; Bohm BB, 2001, ARTHRITIS RHEUM-US, V44, P2046, DOI 10.1002/1529-0131(200109)44:9<2046::AID-ART354>3.0.CO;2-3; Bonnefoy JY, 1996, IMMUNOL TODAY, V17, P418, DOI 10.1016/0167-5699(96)10054-2; Booth V, 1998, J PERIODONTAL RES, V33, P491; Brand S, 2006, AM J PHYSIOL-GASTR L, V290, pG827, DOI 10.1152/ajpgi.00513.2005; Bunnett NW, 2006, SEMIN THROMB HEMOST, V32, P39, DOI 10.1055/s-2006-939553; Busso N, 2002, ARTHRITIS RHEUM, V46, P2268, DOI 10.1002/art.10498; Calixto JB, 2000, PAIN, V87, P1, DOI 10.1016/S0304-3959(00)00335-3; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Charrier L, 2005, AM J PHYSIOL-GASTR L, V288, pG346, DOI 10.1152/ajpgi.00262.2004; Charrier L, 2007, J BIOL CHEM, V282, P16948, DOI 10.1074/jbc.M700158200; CHOMARAT P, 1993, ARTHRITIS RHEUM-US, V36, P234, DOI 10.1002/art.1780360215; Coeshott C, 1999, P NATL ACAD SCI USA, V96, P6261, DOI 10.1073/pnas.96.11.6261; Couture R, 2001, EUR J PHARMACOL, V429, P161, DOI 10.1016/S0014-2999(01)01318-8; DELESPESSE G, 1992, IMMUNOL REV, V125, P77, DOI 10.1111/j.1600-065X.1992.tb00626.x; Di Girolamo N, 1998, EUR J IMMUNOL, V28, P1773, DOI 10.1002/(SICI)1521-4141(199806)28:06<1773::AID-IMMU1773>3.0.CO;2-B; Dignass AU, 1996, EXP CELL RES, V225, P422, DOI 10.1006/excr.1996.0193; DORING G, 1994, AM J RESP CRIT CARE, V150, pS114; Eliceiri BP, 2000, CANCER J, V6, pS245; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; Flannery CR, 2000, MATRIX BIOL, V19, P549, DOI 10.1016/S0945-053X(00)00111-6; Flannery CR, 1999, MATRIX BIOL, V18, P225, DOI 10.1016/S0945-053X(99)00024-4; FLEIT HB, 1992, BLOOD, V79, P2721; Fourie AM, 2003, J BIOL CHEM, V278, P30469, DOI 10.1074/jbc.M213157200; Garcia-Touchard A, 2005, ARTERIOSCL THROM VAS, V25, P1119, DOI 10.1161/01.ATV.0000164311.48592.da; Ham C, 2002, EXP CELL RES, V279, P239, DOI 10.1006/excr.2002.5606; Hehlgans S, 2007, BBA-REV CANCER, V1775, P163, DOI 10.1016/j.bbcan.2006.09.001; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; Henricks PAJ, 1998, EUR J PHARMACOL, V344, P1, DOI 10.1016/S0014-2999(98)00036-3; Herren B, 1997, FASEB J, V11, P173, DOI 10.1096/fasebj.11.2.9039960; Herren B, 2001, EXP CELL RES, V271, P152, DOI 10.1006/excr.2001.5353; Hommes DW, 1996, GUT, V38, P564, DOI 10.1136/gut.38.4.564; Horiuchi K, 2003, MOL CELL BIOL, V23, P5614, DOI 10.1128/MCB.23.16.5614-5624.2003; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; Ikari Y, 2000, THROMB HAEMOSTASIS, V84, P701; Ikeda M, 2000, J PATHOL, V191, P426; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526; Jeon OH, 2007, THROMB RES, V119, P609, DOI 10.1016/j.thromres.2006.04.010; KAISERLIAN D, 1991, EUR J IMMUNOL, V21, P2415, DOI 10.1002/eji.1830211018; Kallen KJ, 2002, BBA-MOL CELL RES, V1592, P323, DOI 10.1016/S0167-4889(02)00325-7; Kawamura-Kodama K, 1999, J INVEST DERMATOL, V112, P62, DOI 10.1046/j.1523-1747.1999.00479.x; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; KITSIS E, 1991, CLIN ORTHOP RELAT R, P63; Koch AE, 1998, ARTHRITIS RHEUM-US, V41, P951, DOI 10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D; Komiya K, 2005, ARTHRITIS RES THER, V7, pR1158, DOI 10.1186/ar1796; Koutroubakis IE, 2006, INFLAMM BOWEL DIS, V12, P515, DOI 10.1097/00054725-200606000-00012; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Langer H, 2005, THROMB HAEMOSTASIS, V94, P555, DOI 10.1160/TH04-12-0784; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Makagiansar IT, 2002, MOL CELL BIOCHEM, V233, P1, DOI 10.1023/A:1015556625038; MARTELPELLETIER J, 1991, J RHEUMATOL, V18, P80; Martin J, 2002, J BIOL CHEM, V277, P33683, DOI 10.1074/jbc.M200988200; Massberg S, 2002, J EXP MED, V196, P887, DOI 10.1084/jem.20012044; Matthews V, 2003, J BIOL CHEM, V278, P38829, DOI 10.1074/jbc.M210584200; May AE, 2002, CIRCULATION, V106, P2111, DOI 10.1161/01.CIR.0000033597.45947.0F; McKie N, 1997, BIOCHEM BIOPH RES CO, V230, P335, DOI 10.1006/bbrc.1996.5957; Moiseeva EP, 2001, CARDIOVASC RES, V52, P372, DOI 10.1016/S0008-6363(01)00399-6; Mosnier JF, 2006, LAB INVEST, V86, P1064, DOI 10.1038/labinvest.3700465; Naganuma M, 2002, AM J GASTROENTEROL, V97, P1741; Nakamura K, 2006, WORLD J GASTROENTERO, V12, P4628, DOI 10.3748/wjg.v12.i29.4628; Nath D, 2000, J CELL SCI, V113, P2319; Nath D, 1999, J CELL SCI, V112, P579; ODEKON LE, 1992, J CELL PHYSIOL, V150, P258, DOI 10.1002/jcp.1041500206; PANJA A, 1993, J EXP MED, V178, P1115, DOI 10.1084/jem.178.3.1115; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; Poghosyan Z, 2002, J BIOL CHEM, V277, P4999, DOI 10.1074/jbc.M107430200; RINALDI N, 1994, VIRCHOWS ARCH, V425, P171; Rinaldi N, 1997, ANN RHEUM DIS, V56, P729, DOI 10.1136/ard.56.12.729; ROBACHEGALLEA S, 1995, J BIOL CHEM, V270, P23688, DOI 10.1074/jbc.270.40.23688; ROBERTS NA, 1988, BAILLIERE CLIN RHEUM, V2, P211, DOI 10.1016/S0950-3579(88)80010-4; Ross R, 1999, AM HEART J, V138, pS419, DOI 10.1016/S0002-8703(99)70266-8; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; Sambrano GR, 2000, J BIOL CHEM, V275, P6819, DOI 10.1074/jbc.275.10.6819; Sanders DSA, 2005, J CLIN PATHOL, V58, P568, DOI 10.1136/jcp.2004.021840; Schonbeck U, 1998, J IMMUNOL, V161, P3340; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shimizu E, 2003, BIOCHEM BIOPH RES CO, V309, P779, DOI 10.1016/j.bbrc.2003.08.070; Syrovets T, 2004, CELL MOL LIFE SCI, V61, P873, DOI 10.1007/s00018-003-3348-5; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TOSI MF, 1988, J IMMUNOL, V141, P2097; Trochon-Joseph V, 2004, CANCER RES, V64, P2062, DOI 10.1158/0008-5472.CAN-03-3272; van Kempen LCL, 2006, EUR J CANCER, V42, P728, DOI 10.1016/j.ejca.2006.01.004; VANDEWINKEL JGJ, 1989, J IMMUNOL, V143, P571; Weissmann G, 2004, JCR-J CLIN RHEUMATOL, V10, pS26, DOI 10.1097/01.rhu.0000130687.75646.44; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; Weskamp G, 2006, NAT IMMUNOL, V7, P1293, DOI 10.1038/ni1399; Wheeler DJ, 1998, IMMUNOLOGY, V95, P105; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; Wu E, 1997, BIOCHEM BIOPH RES CO, V235, P437, DOI 10.1006/bbrc.1997.6714; Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013; Yasui A, 2004, PATHOBIOLOGY, V71, P185, DOI 10.1159/000078672; Yu Q, 2004, CLIN EXP METASTAS, V21, P235, DOI 10.1023/B:CLIN.0000037705.25256.d3; Yusuf-Makagiansar H, 2001, INFLAMMATION, V25, P203, DOI 10.1023/A:1011044616170; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	99	55	61	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					641	653		10.1096/fj.07-8876rev	http://dx.doi.org/10.1096/fj.07-8876rev			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17905725				2022-12-28	WOS:000254143700002
J	Selman, C; Lingard, S; Choudhury, AI; Batterham, RL; Claret, M; Clements, M; Ramadani, F; Okkenhaug, K; Schuster, E; Blanc, E; Piper, MD; Al-Qassab, H; Speakman, JR; Carmignac, D; Robinson, ICA; Thornton, JM; Gems, D; Partridge, L; Withers, DJ				Selman, Colin; Lingard, Steven; Choudhury, Agharul I.; Batterham, Rachel L.; Claret, Marc; Clements, Melanie; Ramadani, Faruk; Okkenhaug, Klaus; Schuster, Eugene; Blanc, Eric; Piper, Matthew D.; Al-Qassab, Hind; Speakman, John R.; Carmignac, Danielle; Robinson, Iain C. A.; Thornton, Janet M.; Gems, David; Partridge, Linda; Withers, Dominic J.			Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice	FASEB JOURNAL			English	Article						aging; longevity; insulin signaling	INSULIN-RECEPTOR GENE; CALORIC RESTRICTION; DWARF MICE; BODY-WEIGHT; EXPRESSION; IGF-1; LONGEVITY; INSIGHTS; MUTATION; DISRUPTION	Recent evidence suggests that alterations in insulin/insulin-like growth factor 1 (IGF1) signaling (IIS) can increase mammalian life span. For example, in several mouse mutants, impairment of the growth hormone (GH)/IGF1 axis increases life span and also insulin sensitivity. However, the intracellular signaling route to altered mammalian aging remains unclear. We therefore measured the life span of mice lacking either insulin receptor substrate (IRS) 1 or 2, the major intracellular effectors of the IIS receptors. Our provisional results indicate that female Irs1(-/-) mice are long-lived. Furthermore, they displayed resistance to a range of age-sensitive markers of aging including skin, bone, immune, and motor dysfunction. These improvements in health were seen despite mild, lifelong insulin resistance. Thus, enhanced insulin sensitivity is not a prerequisite for IIS mutant longevity. Irs1(-/-) female mice also displayed normal anterior pituitary function, distinguishing them from long-lived somatotrophic axis mutants. In contrast, Irs2(-/-) mice were short-lived, whereas Irs1(+/-) and Irs2(+/-) mice of both sexes showed normal life spans. Our results therefore suggest that IRS1 signaling is an evolutionarily conserved pathway regulating mammalian life span and may be a point of intervention for therapies with the potential to delay age-related processes.	[Selman, Colin; Lingard, Steven; Choudhury, Agharul I.; Batterham, Rachel L.; Claret, Marc; Clements, Melanie; Al-Qassab, Hind; Withers, Dominic J.] UCL, Rayne Inst, Ctr Diabet & Endocrinol, Dept Med, London, England; [Piper, Matthew D.; Gems, David; Partridge, Linda] UCL, Dept Biol, Ctr Res Ageing, London, England; [Ramadani, Faruk; Okkenhaug, Klaus] Babraham Inst, Lab Lymphocyte Signalling & Dev, Cambridge, England; [Schuster, Eugene; Blanc, Eric; Thornton, Janet M.] European Bioinformat Inst, Cambridge, England; [Speakman, John R.] Univ Aberdeen, Sch Biol Sci, ACERO, Aberdeen, Scotland; [Carmignac, Danielle; Robinson, Iain C. A.] Med Res Council Natl Inst Med Res, Div Mol Neuroendocrinol, London, England	University of London; King's College London; University College London; University of London; University College London; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; European Molecular Biology Laboratory (EMBL); University of Aberdeen; MRC National Institute for Medical Research	Withers, DJ (corresponding author), UCL, Rayne Inst, Ctr Diabet & Endocrinol, Dept Med, Univ St, London, England.	d.withers@ucl.ac.uk	Partridge, Linda/A-5501-2010; Speakman, John R./A-9494-2008; Blanc, Eric/C-5424-2009; Okkenhaug, Klaus/H-3154-2019; Okkenhaug, Klaus/D-5149-2012; Piper, Matthew/C-1714-2008; Withers, Dominic J/D-7671-2014; Partridge, Linda/E-7342-2015; Ramadani, Faruk/HHM-9664-2022	Speakman, John R./0000-0002-2457-1823; Okkenhaug, Klaus/0000-0002-9432-4051; Okkenhaug, Klaus/0000-0002-9432-4051; Piper, Matthew/0000-0003-3245-7219; Withers, Dominic J/0000-0002-8009-7521; Ramadani, Faruk/0000-0001-8228-4868; Thornton, Janet/0000-0003-0824-4096; Batterham, Rachel/0000-0002-5477-8585; Partridge, Linda/0000-0001-9615-0094; Selman, Colin/0000-0002-8727-0593; Gems, David/0000-0002-6653-4676; Claret, Marc/0000-0001-7766-9296; Schuster, Eugene/0000-0001-5076-2810	Biotechnology and Biological Sciences Research Council [BBS/E/B/0000M979, JF19128] Funding Source: Medline; Medical Research Council [MC_U117531708, G108/551, G0600866, G9900989, MC_U120097114] Funding Source: Medline; Wellcome Trust [066750] Funding Source: Medline; MRC [G0600866, MC_U117531708, G9900989, G108/551] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; Akbar AN, 2004, NAT REV IMMUNOL, V4, P737, DOI 10.1038/nri1440; Amador-Noguez D, 2004, AGING CELL, V3, P423, DOI 10.1111/j.1474-9728.2004.00125.x; Apweiler R, 2000, BIOINFORMATICS, V16, P1145, DOI 10.1093/bioinformatics/16.12.1145; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Ayyadevara S, 2005, AGING CELL, V4, P299, DOI 10.1111/j.1474-9726.2005.00172.x; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Barger JL, 2003, EXP GERONTOL, V38, P1343, DOI 10.1016/j.exger.2003.10.017; Bartke A, 2006, TRENDS ENDOCRIN MET, V17, P33, DOI 10.1016/j.tem.2006.01.002; Batterham RL, 2006, CELL METAB, V4, P223, DOI 10.1016/j.cmet.2006.08.001; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Breslin T, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-193; Breyer F, 2006, HEALTH POLICY, V75, P178, DOI 10.1016/j.healthpol.2005.03.011; Brown-Borg HM, 2000, EXP GERONTOL, V35, P199, DOI 10.1016/S0531-5565(00)00079-6; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Cao SX, 2001, P NATL ACAD SCI USA, V98, P10630, DOI 10.1073/pnas.191313598; CARMIGNAC DF, 1990, J ENDOCRINOL, V127, P69, DOI 10.1677/joe.0.1270069; Choudhury AI, 2005, J CLIN INVEST, V115, P940; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Conti B, 2006, SCIENCE, V314, P825, DOI 10.1126/science.1132191; Coschigano KT, 2000, ENDOCRINOLOGY, V141, P2608, DOI 10.1210/en.141.7.2608; Dhahbi JM, 2004, P NATL ACAD SCI USA, V101, P5524, DOI 10.1073/pnas.0305300101; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Flurkey K, 2002, MECH AGEING DEV, V123, P121, DOI 10.1016/S0047-6374(01)00339-6; Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016; Gazdag AC, 1999, DIABETES, V48, P1930, DOI 10.2337/diabetes.48.10.1930; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Halloran BP, 2002, J BONE MINER RES, V17, P1044, DOI 10.1359/jbmr.2002.17.6.1044; HARRISON DE, 1984, P NATL ACAD SCI-BIOL, V81, P1835, DOI 10.1073/pnas.81.6.1835; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Hubbard T, 2005, NUCLEIC ACIDS RES, V33, pD447, DOI 10.1093/nar/gki138; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; KROOK A, 1993, LANCET, V342, P277, DOI 10.1016/0140-6736(93)91820-C; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Liang HY, 2003, EXP GERONTOL, V38, P1353, DOI 10.1016/j.exger.2003.10.019; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Miller RA, 1997, FASEB J, V11, P775, DOI 10.1096/fasebj.11.10.9271362; Miller RA, 2001, J GERONTOL A-BIOL, V56, pB180, DOI 10.1093/gerona/56.4.B180; Ogata N, 2000, J CLIN INVEST, V105, P935, DOI 10.1172/JCI9017; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Piper M. D. W., 2005, DRUG DISCOV TODAY DI, V2, P249; Rincon M, 2004, MECH AGEING DEV, V125, P397, DOI 10.1016/j.mad.2004.03.006; Selman C, 2006, PHYSIOL GENOMICS, V27, P187, DOI 10.1152/physiolgenomics.00084.2006; Speakman JR, 2004, AGING CELL, V3, P87, DOI 10.1111/j.1474-9728.2004.00097.x; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Turturro A, 2002, J GERONTOL A-BIOL, V57, pB379, DOI 10.1093/gerona/57.11.B379; van der Pluijm I, 2007, PLOS BIOL, V5, P23, DOI 10.1371/journal.pbio.0050002; Vergara M, 2004, J GERONTOL A-BIOL, V59, P1244, DOI 10.1093/gerona/59.12.1244; Weindruch R., 1988, RETARDATION AGING DI; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116	60	381	392	0	39	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					807	818		10.1096/fj.07-9261com	http://dx.doi.org/10.1096/fj.07-9261com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17928362				2022-12-28	WOS:000254143700019
J	Liu, Y; Wang, Y; Rusinol, AE; Sinensky, MS; Liu, J; Shell, SM; Zou, Y				Liu, Yiyong; Wang, Youjie; Rusinol, Antonio E.; Sinensky, Michael S.; Liu, Ji; Shell, Steven M.; Zou, Yue			Involvement of xeroderma pigmentosum group A (XPA) in progeria arising from defective maturation of prelamin A	FASEB JOURNAL			English	Article						Hutchinson-Gilford progeria syndrome; lamin A; Zmpste24; DNA double strand breaks and repair; DNA damage	HUTCHINSON-GILFORD-PROGERIA; NUCLEOTIDE EXCISION-REPAIR; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; MUTANT LAMIN-A; MRE11/RAD50/NBS1 COMPLEX; INHIBITING FARNESYLATION; NUCLEAR ARCHITECTURE; REPLICATION FORKS; UV-IRRADIATION	Cellular accumulation of DNA damage has been widely implicated in cellular senescence, aging, and premature aging. In Hutchinson-Gilford progeria syndrome (HGPS) and restrictive dermopathy (RD), premature aging is linked to accumulation of DNA double-strand breaks (DSBs), which results in genome instability. However, how DSBs accumulate in cells despite the presence of intact DNA repair proteins remains unknown. Here we report that the recruitment of DSB repair factors Rad50 and Rad51 to the DSB sites, as marked by gamma-H2AX, was impaired in human HGPS and Zmpste24-deficient cells. Consistently, the progeria-associated DSBs appeared to be unrepairable although DSBs induced by camptothecin were efficiently removed in the progeroid cells. We also found that these progeroid cells exhibited nuclear foci of xeroderma pigmentosum group A (XPA), a unique nucleotide excision repair protein. Strikingly, these XPA foci colocalized with the DSB sites in the progeroid cells. This XPA-DSB association was further confirmed and found to be mediated by DNA, using a modified chromatin immunoprecipitation assay and coimmunoprecipitation. RNA interference (RNAi) knockdown of XPA in HGPS cells partially restored DSB repair as evidenced by Western blot analysis, immunofluorescence and comet assays. We propose that the uncharacteristic localization of XPA to or near DSBs inhibits DSB repair, thereby contributing to the premature aging phenotypes observed in progeria arising from genetic defects in prelamin A maturation.	[Liu, Yiyong; Wang, Youjie; Rusinol, Antonio E.; Sinensky, Michael S.; Liu, Ji; Shell, Steven M.; Zou, Yue] E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, Johnson City, TN 37614 USA; [Liu, Ji] Sichuan Univ, Dept Biochem & Mol Biol, Chengdu 610064, Peoples R China	East Tennessee State University; Sichuan University	Zou, Y (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, Johnson City, TN 37614 USA.	zouy@etsu.edu	Zou, Yue/ABA-8429-2020		NCI NIH HHS [R01 CA086927, R01 CA086927-05, CA-86927, R01 CA086927-04, R01 CA086927-06A2, R56 CA086927] Funding Source: Medline; NIA NIH HHS [R03 AG031503-01A1, R03 AG031503] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086927, R56CA086927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG031503] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Capell BC, 2005, P NATL ACAD SCI USA, V102, P12879, DOI 10.1073/pnas.0506001102; Corrigan DP, 2005, BIOCHEM J, V387, P129, DOI 10.1042/BJ20041359; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; D Bomgarden R, 2006, EMBO J, V25, P2605, DOI 10.1038/sj.emboj.7601123; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Fong LG, 2006, SCIENCE, V311, P1621, DOI 10.1126/science.1124875; Glynn MW, 2005, HUM MOL GENET, V14, P2959, DOI 10.1093/hmg/ddi326; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; Gorbunova V, 2005, MECH AGEING DEV, V126, P621, DOI 10.1016/j.mad.2005.02.008; Heller RC, 2006, NAT REV MOL CELL BIO, V7, P932, DOI 10.1038/nrm2058; Ichijima Y, 2005, BIOCHEM BIOPH RES CO, V336, P807, DOI 10.1016/j.bbrc.2005.08.164; Kirkwood TBL, 2005, CELL, V120, P437, DOI 10.1016/j.cell.2005.01.027; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lees-Miller SP, 2006, DNA REPAIR, V5, P286, DOI 10.1016/j.dnarep.2005.10.007; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Liu BH, 2005, NAT MED, V11, P780, DOI 10.1038/nm1266; Liu YY, 2006, J CELL SCI, V119, P4644, DOI 10.1242/jcs.03263; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; Mallampalli MP, 2005, P NATL ACAD SCI USA, V102, P14416, DOI 10.1073/pnas.0503712102; Manju K, 2006, J CELL SCI, V119, P2704, DOI 10.1242/jcs.03009; Mattout A, 2007, J CELL SCI, V120, P77, DOI 10.1242/jcs.03325; Mirkin EV, 2007, MICROBIOL MOL BIOL R, V71, P13, DOI 10.1128/MMBR.00030-06; Misteli T, 2005, NAT MED, V11, P718, DOI 10.1038/nm0705-718; Moir RD, 2000, J CELL BIOL, V149, P1179, DOI 10.1083/jcb.149.6.1179; Navarro CL, 2005, HUM MOL GENET, V14, P1503, DOI 10.1093/hmg/ddi159; Paull TT, 2005, CELL CYCLE, V4, P737, DOI 10.4161/cc.4.6.1715; Ricke RM, 2005, BIOL PROCED ONLINE, V7, P60, DOI 10.1251/bpo106; Riedl T, 2003, EMBO J, V22, P5293, DOI 10.1093/emboj/cdg489; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Scaffidi P, 2006, SCIENCE, V312, P1059, DOI 10.1126/science.1127168; Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095; SINENSKY M, 1994, CANCER RES, V54, P3229; Spann TP, 1997, J CELL BIOL, V136, P1201, DOI 10.1083/jcb.136.6.1201; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Toth JI, 2005, P NATL ACAD SCI USA, V102, P12873, DOI 10.1073/pnas.0505767102; Varela I, 2005, NATURE, V437, P564, DOI 10.1038/nature04019; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; von Zglinicki T, 2005, MECH AGEING DEV, V126, P111, DOI 10.1016/j.mad.2004.09.034; Wu X, 2007, ONCOGENE, V26, P757, DOI 10.1038/sj.onc.1209828; Wu XM, 2006, CANCER RES, V66, P2997, DOI 10.1158/0008-5472.CAN-05-3403; Yang ZG, 2006, BIOCHEMISTRY-US, V45, P15921, DOI 10.1021/bi061626q; Zou Y, 2006, J CELL PHYSIOL, V208, P267, DOI 10.1002/jcp.20622	46	76	78	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					603	611		10.1096/fj.07-8598com	http://dx.doi.org/10.1096/fj.07-8598com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17848622	Green Accepted			2022-12-28	WOS:000252822600030
J	Gauthier, BR; Duhamel, DL; Iezzi, M; Theander, S; Saltel, F; Fukuda, M; Wehrle-Haller, B; Wollheim, CB				Gauthier, Benoit R.; Duhamel, Dominique L.; Iezzi, Mariella; Theander, Sten; Saltel, Frederic; Fukuda, Mitsunori; Wehrle-Haller, Bernhard; Wollheim, Claes B.			Synaptotagmin VII splice variants alpha,beta, and delta are expressed in pancreatic beta-cells and regulate insulin exocytosis	FASEB JOURNAL			English	Article						islet beta-cells; calcium-induced exocytosis; INS-1E cells; membrane capacitance; RNAi	DENSE-CORE VESICLES; CALCIUM-DEPENDENT EXOCYTOSIS; SYNAPTIC-LIKE MICROVESICLES; PC12 CELLS; CA2+-DEPENDENT EXOCYTOSIS; C2 DOMAINS; SECRETION; MEMBRANE; PROTEIN; FUSION	Synaptotagmins (SYT) are calcium-binding proteins that participate in regulated exocytosis. Although SYTI to IX isoforms are expressed in insulin-producing cell lines, hitherto only SYTIX has been associated with native beta-cell insulin granules and implicated in exocytosis. SYTVII was also proposed to regulate insulin exocytosis, but its subcellular location and number of alternative splice variants produced remain controversial. Only transcripts of SYTVII alpha,beta, and a novel splice variant delta are expressed in beta-cells and INS-1E cells. Western blotting revealed that INS-1E cells predominantly produced SYTVII alpha and low levels of SYTVII beta, whereas SYTVII delta was undectable. The protein colocalized with insulin granules but not with synaptic-like microvesicles. Overexpression of SYTVII alpha resulted in decreased insulin granule content with a concomitant translocation of the variant to the plasma membrane, while SYTVII beta retained largely a granular pattern. Overexpressed SYTVII delta exhibited a distribution different to that of insulin granules and inhibited exocytosis when assessed by whole cell patch clamp capacitance recording. Silencing of SYTVII alpha by targeted RNA interference suppressed secretion, while repression of beta slightly increased release. Our results demonstrate that SYTVII is expressed on insulin granules and that only SYTVII alpha is implicated in exocytosis under physiological conditions. -Gauthier, B. R., Duhamel, D. L., Iezzi, M., Theander, S., Saltel, F., Fukuda, M., Wehrle-Haller, B., Wollheim. C. B. The synaptotagmin VII splice variants alpha, beta, and delta are expressed in pancreatic beta-cells and regulate insulin exocytosis.	[Gauthier, Benoit R.; Duhamel, Dominique L.; Iezzi, Mariella; Theander, Sten; Saltel, Frederic; Wehrle-Haller, Bernhard; Wollheim, Claes B.] Ctr Med Univ Geneva, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland; [Fukuda, Mitsunori] Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Aoba Ku, Sendai, Miyagi 980, Japan	University of Geneva; Tohoku University	Gauthier, BR (corresponding author), Ctr Med Univ Geneva, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland.	benoit.gauthier@medecine.unige.ch	Gauthier, Benoit R/C-3138-2017; Fukuda, MItsunori/I-1511-2015	Gauthier, Benoit R/0000-0001-8146-7486; Fukuda, MItsunori/0000-0002-8620-5853; saltel, frederic/0000-0002-0724-9680				Andrews NW, 2005, TRENDS CELL BIOL, V15, P626, DOI 10.1016/j.tcb.2005.09.001; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Bai JH, 2004, NEURON, V41, P929, DOI 10.1016/S0896-6273(04)00117-5; Barg S, 2001, J CELL SCI, V114, P2145; Black DL, 1998, NEURON, V20, P165, DOI 10.1016/S0896-6273(00)80444-4; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; Czibener C, 2006, J CELL BIOL, V174, P997, DOI 10.1083/jcb.200605004; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; Fukuda M, 2004, J BIOL CHEM, V279, P52677, DOI 10.1074/jbc.M409241200; Fukuda M, 2002, BIOCHEM J, V365, P173, DOI 10.1042/BJ20011877; Fukuda M, 2002, J BIOL CHEM, V277, P29315, DOI 10.1074/jbc.M201697200; Fukuda M, 2001, J BIOL CHEM, V276, P27670, DOI 10.1074/jbc.M100851200; Fukuda M, 2001, J NEUROCHEM, V77, P730, DOI 10.1046/j.1471-4159.2001.00266.x; FUKUDA M, 2003, RECENT RES DEV CHEM, V1, P15; Gao ZY, 2000, J BIOL CHEM, V275, P36079, DOI 10.1074/jbc.M004284200; Gauthier B, 1999, ATHEROSCLEROSIS, V142, P301, DOI 10.1016/S0021-9150(98)00245-7; Gauthier BR, 2004, J BIOL CHEM, V279, P31121, DOI 10.1074/jbc.M405030200; GEPPERT M, 1994, EMBO J, V13, P3720, DOI 10.1002/j.1460-2075.1994.tb06681.x; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Gut A, 2001, J CELL SCI, V114, P1709; Han WP, 2005, J BIOL CHEM, V280, P5089, DOI 10.1074/jbc.M408757200; Han WP, 2004, NEURON, V41, P85, DOI 10.1016/S0896-6273(03)00820-1; Hoy M, 2002, FEBS LETT, V531, P199, DOI 10.1016/S0014-5793(02)03500-7; Hui EF, 2005, P NATL ACAD SCI USA, V102, P5210, DOI 10.1073/pnas.0500941102; Iezzi M, 2000, FEBS LETT, V474, P66, DOI 10.1016/S0014-5793(00)01572-6; Iezzi M, 2005, FEBS LETT, V579, P5241, DOI 10.1016/j.febslet.2005.08.047; Iezzi M, 2004, J CELL SCI, V117, P3119, DOI 10.1242/jcs.01179; Jaiswal JK, 2002, J CELL BIOL, V159, P625, DOI 10.1083/jcb.200208154; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; Lezzi M, 2005, J CELL SCI, V118, P5647, DOI 10.1242/jcs.02658; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LI C, 1995, J BIOL CHEM, V270, P24898, DOI 10.1074/jbc.270.42.24898; MacDonald PE, 2005, DIABETES, V54, P736, DOI 10.2337/diabetes.54.3.736; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141; Meldolesi J, 2004, NAT CELL BIOL, V6, P476, DOI 10.1038/ncb0604-476; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; Missler M, 1998, J NEUROCHEM, V71, P1339; Modrek B, 2001, NUCLEIC ACIDS RES, V29, P2850, DOI 10.1093/nar/29.13.2850; Monterrat C, 2006, BBA-MOL CELL RES, V1763, P73, DOI 10.1016/j.bbamcr.2005.11.008; Monterrat C, 2007, HISTOCHEM CELL BIOL, V127, P625, DOI 10.1007/s00418-007-0271-0; Nicholson-Tomishima K, 2004, P NATL ACAD SCI USA, V101, P16648, DOI 10.1073/pnas.0406968101; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; Saegusa C, 2002, J BIOL CHEM, V277, P24499, DOI 10.1074/jbc.M202767200; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Sugita S, 2001, NEURON, V30, P459, DOI 10.1016/S0896-6273(01)00290-2; Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105; Tsuboi T, 2007, GENES CELLS, V12, P511, DOI 10.1111/j.1365-2443.2007.01070.x; Tucker WC, 2004, SCIENCE, V304, P435, DOI 10.1126/science.1097196; VALLEE BL, 1987, METALLOTHIONEIN, V2, P5; VANDEWINKEL M, 1983, BIOCHEM BIOPH RES CO, V114, P835, DOI 10.1016/0006-291X(83)90857-4; Virmani T, 2003, EMBO J, V22, P5347, DOI 10.1093/emboj/cdg514; Wang H, 2005, DIABETOLOGIA, V48, P720, DOI 10.1007/s00125-005-1692-8; Weller U, 1996, EUR J BIOCHEM, V236, P34, DOI 10.1111/j.1432-1033.1996.00034.x; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z; [No title captured]	61	40	40	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					194	206		10.1096/fj.07-8333com	http://dx.doi.org/10.1096/fj.07-8333com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17709608				2022-12-28	WOS:000252309900022
J	Levy, BD; Lukacs, NW; Berlin, AA; Schmidt, B; Guilford, WJ; Serhan, CN; Parkinson, JF				Levy, Bruce D.; Lukacs, Nicholas W.; Berlin, Aaron A.; Schmidt, Birgitta; Guilford, William J.; Serhan, Charles N.; Parkinson, John F.			Lipoxin A(4) stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism	FASEB JOURNAL			English	Article						resolution; lipid mediators; leukocytes	ASPIRIN-TRIGGERED LIPOXIN; ASTHMA; INFLAMMATION; RESOLUTION; B-4; 15-EPI-LXA(4); DESIGN; INJURY; CXCR4; CELLS	Cellular recruitment during inflammatory/ immune responses is tightly regulated. The ability to dampen inflammation is imperative for prevention of chronic immune responses, as in asthma. Here we investigated the ability of lipoxin A(4) (LXA(4)) stable analogs to regulate airway responses in two allergen-driven models of inflammation. A 15-epi-LXA(4) analog (ATLa) and a 3-oxa-15-epi-LXA(4) analog (ZK-994) prevented excessive eosinophil and T lymphocyte accumulation and activation after mice were sensitized and aerosol-challenged with ovalbumin. At < 0.5 mg/kg, these LXA4 analogs reduced leukocyte trafficking into the lung by > 50% and to a greater extent than equivalent doses of the CysLT1 receptor antagonist montelukast. Distinct from montelukast, ATLa treatment led to marked reductions in cysteinyl leukotrienes, interleukin-4 (IL-4), and IL-10, and both ATLa and ZK-994 inhibited levels of IL-13. In cockroach allergen- induced airway responses, both intraperitoneal and oral administration of ZK- 994 significantly reduced parameters of airway inflammation and hyper- responsiveness in a dose- dependent manner. ZK- 994 also significantly changed the balance of Th1/ Th2- specific cytokine levels. Thus, the ATLa/ LXA4 analog actions are distinct from CysLT1 antagonism and potently block both allergic airway inflammation and hyper- reactivity. Moreover, these results demonstrate these analogs' therapeutic potential as new agonists for the resolution of inflammation.	Bayer Hlthcare Pharmaceut, Appl Res US, Richmond, CA 94804 USA; Brigham & Womens Hosp, Harvard Med Sch, Dept Internal Med, Pulm & Crit Care Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Harvard Med Sch, Ctr Expt Therapeut & Referfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Univ Michigan, Med Ctr, Dept Pathol, Ann Arbor, MI 48109 USA; Berlex Biosci Richmond, Dept Med Chem, Dept Immunol, Richmond, CA USA	Bayer AG; Bayer Healthcare Pharmaceuticals; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Michigan System; University of Michigan	Levy, BD (corresponding author), Brigham & Womens Hosp, Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.	blevy@partners.org	Lukacs, Nicholas W/ABH-5583-2020		NHLBI NIH HHS [R01 HL068669-06A2, HL68669, R01 HL068669] Funding Source: Medline; NIAID NIH HHS [R01 AI068084, AI0608084, R01 AI068084-03] Funding Source: Medline; NIDCR NIH HHS [DE016191, P50 DE016191-02, P50 DE016191] Funding Source: Medline; NIGMS NIH HHS [GM38765, R01 GM038765, R37 GM038765-19, R37 GM038765] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068669] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038765, R01GM038765, R37GM038765] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ariel A, 2003, J IMMUNOL, V170, P6266, DOI 10.4049/jimmunol.170.12.6266; Bandeira-Melo C, 2000, J IMMUNOL, V164, P2267, DOI 10.4049/jimmunol.164.5.2267; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Barnes PJ, 2004, NAT REV DRUG DISCOV, V3, P831, DOI 10.1038/nrd1524; Berlin AA, 2005, AM J RESP CRIT CARE, V171, P35, DOI 10.1164/rccm.200403-385OC; Bonnans C, 2006, AM J PATHOL, V168, P1064, DOI 10.2353/ajpath.2006.051056; Bonnans C, 2002, AM J RESP CRIT CARE, V165, P1531, DOI 10.1164/rccm.200201-053OC; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Campbell EM, 1999, J IMMUNOL, V163, P2160; CHRISTIE PE, 1992, AM REV RESPIR DIS, V145, P1281, DOI 10.1164/ajrccm/145.6.1281; Clish CB, 2000, J BIOL CHEM, V275, P25372, DOI 10.1074/jbc.M002863200; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; Deng XY, 1999, BLOOD, V94, P1165, DOI 10.1182/blood.V94.4.1165.416k23_1165_1173; Fiorucci S, 2004, P NATL ACAD SCI USA, V101, P15736, DOI 10.1073/pnas.0404722101; Fukunaga K, 2005, J IMMUNOL, V174, P5033, DOI 10.4049/jimmunol.174.8.5033; Gronert K, 2001, AM J PATHOL, V158, P3, DOI 10.1016/S0002-9440(10)63937-5; Guilford WJ, 2005, PROSTAG LEUKOTR ESS, V73, P245, DOI 10.1016/j.plefa.2005.05.012; Guilford WJ, 2004, J MED CHEM, V47, P2157, DOI 10.1021/jm030569l; Hashimoto A, 2007, BIOMED PHARMACOTHER, V61, P81, DOI 10.1016/j.biopha.2006.06.023; Henderson WR, 2006, AM J RESP CRIT CARE, V173, P718, DOI 10.1164/rccm.200501-088OC; LEE TH, 1990, AM REV RESPIR DIS, V141, P1453, DOI 10.1164/ajrccm/141.6.1453; Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748; Levy BD, 2005, AM J RESP CRIT CARE, V172, P824, DOI 10.1164/rccm.200410-1413OC; Li BQ, 2001, BLOOD, V97, P2941, DOI 10.1182/blood.V97.10.2941; Machado FS, 2006, NAT MED, V12, P330, DOI 10.1038/nm1355; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Petasis NA, 2005, PROSTAG LEUKOTR ESS, V73, P301, DOI 10.1016/j.plefa.2005.05.020; Sanak M, 2000, EUR RESPIR J, V16, P44, DOI 10.1034/j.1399-3003.2000.16a08.x; SERHAN CN, 1995, BIOCHEMISTRY-US, V34, P14609, DOI 10.1021/bi00044a041; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Smit JJ, 2006, EUR J PHARMACOL, V533, P277, DOI 10.1016/j.ejphar.2005.12.064; Svensson CI, 2007, J EXP MED, V204, P245, DOI 10.1084/jem.20061826; Taube C, 2004, INT ARCH ALLERGY IMM, V135, P173, DOI 10.1159/000080899; Wenzel SE, 2006, AM J RESP CRIT CARE, V173, P698, DOI 10.1164/rccm.2601007	34	89	102	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2007	21	14					3877	3884		10.1096/fj.07-8653com	http://dx.doi.org/10.1096/fj.07-8653com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17625069	Green Accepted, Green Submitted			2022-12-28	WOS:000251283500013
J	Kumaran, J; Wei, L; Kotra, LP; Fish, EN				Kumaran, Jyothi; Wei, Lianhu; Kotra, Lakshmi P.; Fish, Eleanor N.			A structural basis for interferon-alpha-receptor interactions	FASEB JOURNAL			English	Article						interferon; interferon receptor; homology modeling; docking	CRYSTAL-STRUCTURE; BINDING; EXPRESSION; CLONING; BETA	Interferon (IFN)-alpha subtypes exhibit differences in biological potencies based on their affinity interactions with the IFN receptor subunits, IFNAR1 and IFNAR2. Using available three-dimensional structural information and computational biology, homology models of human IFN-alpha 1, human IFN-alpha 8, IFN alfacon-1, and murine IFN-alpha 4 were derived and docked with the extracellular region of human IFNAR2 to evaluate the behavior of potential interacting residue pairs and characterize the nature of the IFN-IFNAR2 binding interfaces. The data suggest that IFN afacon-1 has 9 optimal interactions with IFNAR2, comprising hydrophobic, electrostatic, and hydrogen bonding. Human IFN-alpha 2 exhibits 8 optimal interactions, human IFN-alpha 1, 7, and murine IFN-alpha 4 exhibits the least number of optimal interactions, at 5. A model of IFNAR1 was generated, taking into consideration the IFNAR1 extracellular domain interaction with cell surface glycosphingolipids, putative ligand interaction residues, and residues stabilizing the structural integrity of IFNAR. IFNAR1 was then docked with the various IFN-IFNAR2 complexes to describe the complete extracellular receptor pocket with bound IFN. These data provide insights into the species specificity of IFN-alpha s: residues in murine IFN-alpha 4 that preclude strong affinity interactions with human IFNAR because of steric crowding and residues in human IFN-alpha 8 that resemble a receptor interactive domain in murine IFN-alpha 4, are described.	Toronto Gen Res Inst, Univ Hlth Network, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Immunol, Toronto, ON, Canada; Univ Toronto, Dept Chem, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Pharmaceut Sci, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto; University of Toronto	Fish, EN (corresponding author), Toronto Gen Res Inst, Univ Hlth Network, Div Cell & Mol Biol, 67 Coll St,Rm 424, Toronto, ON M5G 2M1, Canada.	en.fish@utoronto.ca		Kotra, Lakshmi P./0000-0002-7071-4637				Blatt LM, 1996, J INTERF CYTOK RES, V16, P489, DOI 10.1089/jir.1996.16.489; Brierley MM, 2002, J INTERF CYTOK RES, V22, P835, DOI 10.1089/107999002760274845; Chill JH, 2002, BIOCHEMISTRY-US, V41, P3575, DOI 10.1021/bi011778f; Cutrone EC, 1997, FEBS LETT, V404, P197, DOI 10.1016/S0014-5793(97)00129-4; Cutrone EC, 2001, J BIOL CHEM, V276, P17140, DOI 10.1074/jbc.M009663200; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; EID P, 2005, EUR CYTOKINE NEWS EU, V11, P560; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; FISH EN, 1989, J INTERFERON RES, V9, P97, DOI 10.1089/jir.1989.9.97; GAJEANFEROLDI C, 2004, BIOCHEMISTRY-US, V43, P12498; Gavutis M, 2006, BIOPHYS J, V90, P3345, DOI 10.1529/biophysj.105.072546; GHISLAIN J, 1994, J IMMUNOL, V153, P3655; Gol'dshtein V, 1998, COMBUST THEOR MODEL, V2, P1; Karpusas M, 1997, P NATL ACAD SCI USA, V94, P11813, DOI 10.1073/pnas.94.22.11813; Klaus W, 1997, J MOL BIOL, V274, P661, DOI 10.1006/jmbi.1997.1396; Lamken P, 2004, J MOL BIOL, V341, P303, DOI 10.1016/j.jmb.2004.05.059; Mitsui Y, 1997, J INTERF CYTOK RES, V17, P319, DOI 10.1089/jir.1997.17.319; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Piehler J, 1999, J MOL BIOL, V289, P57, DOI 10.1006/jmbi.1999.2726; Piehler J, 2000, J BIOL CHEM, V275, P40425, DOI 10.1074/jbc.M006854200; Quadt-Akabayov SR, 2006, PROTEIN SCI, V15, P2656, DOI 10.1110/ps.062283006; Radhakrishnan R, 1996, STRUCTURE, V4, P1453, DOI 10.1016/S0969-2126(96)00152-9; Radhakrishnan R, 1999, J MOL BIOL, V286, P151, DOI 10.1006/jmbi.1998.2480; Roisman LC, 2001, P NATL ACAD SCI USA, V98, P13231, DOI 10.1073/pnas.221290398; SALI A, 2001, MODELLER; Slutzki M, 2006, J MOL BIOL, V360, P1019, DOI 10.1016/j.jmb.2006.05.069; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; *TRIP INC, SYBYL 7 0; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z	30	35	38	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3288	3296		10.1096/fj.07-8585com	http://dx.doi.org/10.1096/fj.07-8585com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17517919				2022-12-28	WOS:000249781600029
J	Marsche, G; Weigle, B; Sattler, W; Malle, E				Marsche, Gunther; Weigle, Bernd; Sattler, Wolfgang; Malle, Ernst			Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein	FASEB JOURNAL			English	Article						myeloperoxidase; inflammation; oxidized LDL; foam cells	GLYCATION END-PRODUCTS; MYELOPEROXIDASE-CATALYZED OXIDATION; HUMAN ATHEROSCLEROTIC LESIONS; FOAM CELL-FORMATION; E-NULL MICE; B TYPE-I; MODIFIED PROTEINS; OXIDIZED PHOSPHOLIPIDS; ENDOTHELIAL-CELLS; DIABETIC-NEPHROPATHY	Engagement of the receptor for advanced glycation end products (RAGE) by its signal transduction ligands evokes inflammatory cell infiltration and activation of the vessel wall. However, soluble RAGE (sRAGE), the truncated form spanning the extracellular binding domain of RAGE, has potent anti-inflammatory properties by acting as a decoy for RAGE ligands. We now show that sRAGE binds with high affinity to atherogenic low-density lipoprotein (LDL) modified by hypochlorous acid (HOCl), the major oxidant generated by the myeloperoxidase-H2O2-chloride system of phagocytes activated during inflammation. We further demonstrate that sRAGE can be co-precipitated with HOCl-LDL from spiked serum. To determine the functional significance of sRAGE binding to HOCl-LDL, cell association studies with macrophages were performed. sRAGE effectively inhibited cellular uptake of HOCl-LDL and subsequent lipid accumulation. Using Chinese hamster ovary cells over-expressing class B scavenger receptor CD36 or SR-BI, two preferential scavenger receptors for HOCl-LDL, we demonstrate that sRAGE only interferes with CD36-mediated uptake of HOCl-LDL. The present findings indicate that sRAGE acts as a sink for HOCl-LDL, which is abundantly present in human atherosclerotic lesions. We propose that sRAGE represents a physiological antagonist that interferes with scavenger receptor-mediated cholesterol accumulation and foam cell formation of macrophages.	Med Univ Graz, Ctr Mol Med, Inst Mol Biol & Biochem, A-8010 Graz, Austria; Eucodis GmbH, Vienna, Austria	Medical University of Graz	Malle, E (corresponding author), Med Univ Graz, Ctr Mol Med, Inst Mol Biol & Biochem, Harrachgasse 21, A-8010 Graz, Austria.	ernst.malle@meduni-graz.at	Malle, Ernst/D-3071-2013	Marsche, Gunther/0000-0002-2422-5381	Austrian Science Fund FWF [F 3007, P 17013, P 19074] Funding Source: Medline; Austrian Science Fund (FWF) [F 3007] Funding Source: researchfish	Austrian Science Fund FWF(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))		Artl A, 2000, ARTERIOSCL THROM VAS, V20, P763, DOI 10.1161/01.ATV.20.3.763; Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109-005-0688-7; Bucciarelli LG, 2002, CIRCULATION, V106, P2827, DOI 10.1161/01.CIR.0000039325.03698.36; Capeillere-Blandin C, 2004, BBA-MOL BASIS DIS, V1689, P91, DOI 10.1016/j.bbadis.2004.02.008; Carr AC, 2000, FEBS LETT, V487, P176, DOI 10.1016/S0014-5793(00)02227-4; Cipollone F, 2003, CIRCULATION, V108, P1070, DOI 10.1161/01.CIR.0000086014.80477.0D; Cuccurullo C, 2006, ARTERIOSCL THROM VAS, V26, P2716, DOI 10.1161/01.ATV.0000249630.02085.12; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Geroldi D, 2006, CURR MED CHEM, V13, P1971, DOI 10.2174/092986706777585013; Goova MT, 2001, AM J PATHOL, V159, P513, DOI 10.1016/S0002-9440(10)61723-3; Han JH, 1999, J LIPID RES, V40, P830; Hartwich J, 2002, PLATELETS, V13, P141, DOI 10.1080/09533710022149368; Hasegawa T, 2005, AM J PHYSIOL-GASTR L, V289, pG760, DOI 10.1152/ajpgi.00141.2005; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hirano K, 1999, CIRC RES, V85, P108; Hsieh HL, 2004, BIOCHEM BIOPH RES CO, V316, P949, DOI 10.1016/j.bbrc.2004.02.135; Huh HY, 1996, BLOOD, V87, P2020; Kislinger T, 2001, ARTERIOSCL THROM VAS, V21, P905, DOI 10.1161/01.ATV.21.6.905; Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Liu SX, 2006, ARTERIOSCL THROM VAS, V26, P1156, DOI 10.1161/01.ATV.0000214960.85469.68; Malle E, 2000, EUR J BIOCHEM, V267, P4495, DOI 10.1046/j.1432-1327.2000.01498.x; MALLE E, 1995, ARTERIOSCL THROM VAS, V15, P982, DOI 10.1161/01.ATV.15.7.982; Malle E, 2003, KIDNEY INT, V64, P1956, DOI 10.1046/j.1523-1755.2003.00336.x; Malle E, 2006, BBA-MOL CELL BIOL L, V1761, P392, DOI 10.1016/j.bbalip.2006.03.024; Marsche G, 2003, J BIOL CHEM, V278, P47562, DOI 10.1074/jbc.M308428200; Marsche G, 2007, FASEB J, V21, P1145, DOI 10.1096/fj.06-7439com; Naka Y, 2004, ARTERIOSCL THROM VAS, V24, P1342, DOI 10.1161/01.ATV.0000133191.71196.90; Opper C, 1998, PLATELETS, V9, P339, DOI 10.1080/09537109876582; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Rahaman SO, 2006, CELL METAB, V4, P211, DOI 10.1016/j.cmet.2006.06.007; Ramasamy R, 2005, TRENDS CARDIOVAS MED, V15, P237, DOI 10.1016/j.tcm.2005.08.003; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI200114002; TAKATA K, 1988, J BIOL CHEM, V263, P14819; Tiruppathi C, 2004, P NATL ACAD SCI USA, V101, P7699, DOI 10.1073/pnas.0401712101; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Wendt TM, 2003, AM J PATHOL, V162, P1123, DOI 10.1016/S0002-9440(10)63909-0; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; Yan SF, 2003, CIRC RES, V93, P1159, DOI 10.1161/01.RES.0000103862.26506.3D; Yonekura H, 2003, BIOCHEM J, V370, P1097, DOI 10.1042/BJ20021371; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	47	25	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3075	3082		10.1096/fj.07-8316com	http://dx.doi.org/10.1096/fj.07-8316com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17536039	Green Accepted			2022-12-28	WOS:000249781600009
J	Hwa, AJ; Fry, RC; Sivaraman, A; So, PT; Samson, LD; Stolz, DB; Griffith, LG				Hwa, Albert J.; Fry, Rebecca C.; Sivaraman, Anand; So, Peter T.; Samson, Leona D.; Stolz, Donna B.; Griffith, Linda G.			Rat liver sinusoidal endothelial cells survive without exogenous VEGF in 3D perfused co-cultures with hepatocytes	FASEB JOURNAL			English	Article						tissue engineering; liver; microvascular	DECAY-ACCELERATING FACTOR; GROWTH-FACTOR; IN-VITRO; NONPARENCHYMAL CELLS; EXPRESSION; INDUCTION; MORPHOGENESIS; LOCALIZATION; ANGIOGENESIS; GELSOLIN	Liver sinusoidal endothelial cells (SECs) are generally refractory to extended in vitro culture. In an attempt to recreate some features of the complex set of cues arising from the liver parenchyma, we cocultured adult rat liver SECs, identified by the expression of the marker SE-1, with primary adult rat hepatocytes in a 3D culture system that provides controlled microscale perfusion through the tissue mass. The culture was established in a medium containing serum and VEGF, and these factors were then removed to assess whether cells with the SE-1 phenotype could be supported by the local microenvironment in vitro. Rats expressing enhanced green fluorescent protein (EGFP) in all liver cells were used for isolation of the SE-1-positive cells added to cocultures. By the 13th day of culture, EGFP-expressing cells had largely disappeared from 2D control cultures but exhibited moderate proliferation in 3D perfused cultures. SE-1-positive cells were present in 3D cocultures after 13 days, and these cultures also contained Kupffer cells, stellate cells, and CD31-expressing endothelial cells. Global transcriptional profiling did not reveal profound changes between 2D and 3D cultures in expression of most canonical angiogenic factors but suggested changes in several pathways related to endothelial cell function.	MIT, Biol Engn Div, Dept Biol Engn, Cambridge, MA 02139 USA; MIT, Ctr Environm Hlth Sci, Cambridge, MA 02139 USA; MIT, Dept Mech Engn, Cambridge, MA 02139 USA; Univ Pittsburgh, Ctr Biol Imaging, Pittsburgh, PA USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Griffith, LG (corresponding author), MIT, Biol Engn Div, Dept Biol Engn, 16-429,77 Mass Ave, Cambridge, MA 02139 USA.	griff@mit.edu		Griffith, Linda/0000-0002-1801-5548; Fry, Rebecca/0000-0003-0899-9018	NCI NIH HHS [CA76541] Funding Source: Medline; NIEHS NIH HHS [U19ES011399-05S1, ES002109] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076541, R29CA076541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U19ES011399, P30ES002109] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arandjelovic S, 2003, BIOCHEMISTRY-US, V42, P6121, DOI 10.1021/bi0342158; ARIAS IM, 2001, LIVER BIOL PATHOBIOL; Block GD, 1996, J CELL BIOL, V132, P1133, DOI 10.1083/jcb.132.6.1133; Braet F, 1997, J MICROSC-OXFORD, V186, P84, DOI 10.1046/j.1365-2818.1997.1940755.x; BRAET F, 1994, LAB INVEST, V70, P944; Braet Filip, 2004, Comp Hepatol, V3, P7, DOI 10.1186/1476-5926-3-7; Braet Filip, 2002, Comp Hepatol, V1, P1, DOI 10.1186/1476-5926-1-1; Brun P, 2005, AM J PHYSIOL-GASTR L, V289, pG571, DOI 10.1152/ajpgi.00537.2004; Byrne G, 1997, TRANSPLANTATION, V63, P149, DOI 10.1097/00007890-199701150-00027; Carlevaro MF, 1997, J CELL BIOL, V136, P1375, DOI 10.1083/jcb.136.6.1375; Cogger VC, 2006, ATHEROSCLEROSIS, V189, P273, DOI 10.1016/j.atherosclerosis.2005.12.025; COUVELARD A, 1993, AM J PATHOL, V143, P738; de Haas RR, 1999, J HISTOCHEM CYTOCHEM, V47, P183, DOI 10.1177/002215549904700207; DeLeve LD, 2006, AM J PHYSIOL-GASTR L, V291, pG1187, DOI 10.1152/ajpgi.00229.2006; DeLeve LD, 2004, AM J PHYSIOL-GASTR L, V287, pG757, DOI 10.1152/ajpgi.00017.2004; DeLeve LD, 2002, SEMIN LIVER DIS, V22, P27, DOI 10.1055/s-2002-23204; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DOMANSKY K, 2005, P 9 INT C MIN SYST C, P853; DOMANSKY K, 2004, LAB ON CHIPS CELLOMI, P319; Donovan D., 2001, Angiogenesis, V4, P113, DOI 10.1023/A:1012218401036; Edwards S, 2005, HEPATOLOGY, V41, P451, DOI 10.1002/hep.20585; Endo D, 2004, J HEPATOL, V40, P399, DOI 10.1016/j.jhep.2003.11.019; Enomoto Katsuhiko, 2004, Medical Electron Microscopy, V37, P208, DOI 10.1007/s00795-004-0261-4; Eschbach E, 2005, J CELL BIOCHEM, V95, P243, DOI 10.1002/jcb.20360; GERLACH JC, 1994, INT J ARTIF ORGANS, V17, P301; Gomez-Lechon MJ, 1998, J CELL PHYSIOL, V177, P553, DOI 10.1002/(SICI)1097-4652(199812)177:4<553::AID-JCP6>3.0.CO;2-F; Goumans MJ, 2003, TRENDS CARDIOVAS MED, V13, P301, DOI 10.1016/S1050-1738(03)00142-7; Griffith LG, 2006, NAT REV MOL CELL BIO, V7, P211, DOI 10.1038/nrm1858; Harada K, 2003, J HEPATOL, V39, P716, DOI 10.1016/S0168-8278(03)00412-4; Hefferan TE, 2000, J BIOL CHEM, V275, P20255, DOI 10.1074/jbc.C000135200; Helm CLE, 2005, P NATL ACAD SCI USA, V102, P15779, DOI 10.1073/pnas.0503681102; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; ISOM H, 1987, J CELL BIOL, V105, P2877, DOI 10.1083/jcb.105.6.2877; Ito T, 2001, J AM SOC NEPHROL, V12, P2625, DOI 10.1681/ASN.V12122625; Iwatani H, 2004, KIDNEY INT, V65, P1604, DOI 10.1111/j.1523-1755.2004.00561.x; Krause P, 2000, J HEPATOL, V32, P718, DOI 10.1016/S0168-8278(00)80239-1; Lai WK, 2006, AM J PATHOL, V169, P200, DOI 10.2353/ajpath.2006.051191; Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Lee SH, 2004, BIOCHEM PHARMACOL, V68, P1391, DOI 10.1016/j.bcp.2004.06.009; Leifeld L, 2006, AM J PATHOL, V168, P778, DOI 10.2353/ajpath.2006.050323; Maharaj ASR, 2006, AM J PATHOL, V168, P639, DOI 10.2353/ajpath.2006.050834; MALICK LE, 1975, STAIN TECHNOL, V50, P265, DOI 10.3109/10520297509117069; Manganini M, 2000, ONCOGENE, V19, P124, DOI 10.1038/sj.onc.1203225; Maru Y, 2000, EUR J CELL BIOL, V79, P130, DOI 10.1078/S0171-9335(04)70015-1; Mason JC, 1999, BLOOD, V94, P1673, DOI 10.1182/blood.V94.5.1673.417a05_1673_1682; Mason JC, 2001, ARTHRITIS RHEUM, V44, P138, DOI 10.1002/1529-0131(200101)44:1<138::AID-ANR18>3.0.CO;2-G; Michalopoulos GK, 1999, HEPATOLOGY, V29, P90, DOI 10.1002/hep.510290149; Michalopoulos GK, 2001, AM J PATHOL, V159, P1877, DOI 10.1016/S0002-9440(10)63034-9; Mitaka T, 1999, HEPATOLOGY, V29, P111, DOI 10.1002/hep.510290103; Nahmias Y, 2006, TISSUE ENG, V12, P1627, DOI 10.1089/ten.2006.12.1627; Neubauer K, 2003, HISTOCHEM CELL BIOL, V120, P265, DOI 10.1007/s00418-003-0564-x; Oh SH, 2002, SEMIN CELL DEV BIOL, V13, P405, DOI 10.1016/S1084952102001271; Ohi N, 2006, AM J PATHOL, V168, P1097, DOI 10.2353/ajpath.2006.050462; OHMURA T, 1993, J HISTOCHEM CYTOCHEM, V41, P1253, DOI 10.1177/41.8.8331290; Pitt BR, 1997, AM J PHYSIOL-LUNG C, V273, pL856, DOI 10.1152/ajplung.1997.273.4.L856; POPPER H, 1978, AM J PATHOL, V92, P349; Powers MJ, 2002, BIOTECHNOL BIOENG, V78, P257, DOI 10.1002/bit.10143; Powers MJ, 2002, TISSUE ENG, V8, P499, DOI 10.1089/107632702760184745; Ranucci CS, 2000, BIOMATERIALS, V21, P783, DOI 10.1016/S0142-9612(99)00238-0; Ross MA, 2001, HEPATOLOGY, V34, P1135, DOI 10.1053/jhep.2001.29624; Semino CE, 2006, EXP CELL RES, V312, P289, DOI 10.1016/j.yexcr.2005.10.029; Semler EJ, 2005, BIOTECHNOL BIOENG, V89, P296, DOI 10.1002/bit.20328; SHAKADO S, 1995, HEPATOLOGY, V22, P969, DOI 10.1016/0270-9139(95)90322-4; Sivaraman A, 2005, CURR DRUG METAB, V6, P569, DOI 10.2174/138920005774832632; Suhler E, 1997, CRIT CARE MED, V25, P594, DOI 10.1097/00003246-199704000-00007; Tanikawa K., 1999, LIVER DIS HEPATIC SI; TOHYAMA C, 1993, HEPATOLOGY, V18, P1193; Tokairin T, 2002, J HEPATOL, V36, P725, DOI 10.1016/S0168-8278(02)00048-X; TSUJIKAWA K, 1994, EUR J CELL BIOL, V63, P240; Ueda A, 2004, AM J PHYSIOL-HEART C, V287, pH994, DOI 10.1152/ajpheart.00400.2003; VILLASCHI S, 1994, LAB INVEST, V71, P291; Wells RG, 2005, J CLIN GASTROENTEROL, V39, pS158, DOI 10.1097/01.mcg.0000155516.02468.0f; Wells RG, 2000, AM J PHYSIOL-GASTR L, V279, pG845, DOI 10.1152/ajpgi.2000.279.5.G845; Wu F J, 1995, Tissue Eng, V1, P29, DOI 10.1089/ten.1995.1.29; YU ZW, 1994, BIOSCIENCE REP, V14, P259, DOI 10.1007/BF01199051; Zeilinger K, 2004, TISSUE ENG, V10, P1113, DOI 10.1089/1076327041887899	77	91	91	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2564	2579		10.1096/fj.06-7473com	http://dx.doi.org/10.1096/fj.06-7473com			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17426068				2022-12-28	WOS:000248454400030
J	Kornyei, Z; Gocza, E; Ruhl, R; Orsolits, B; Voros, E; Szabo, B; Vagovits, B; Madarasz, E				Kornyei, Z.; Gocza, E.; Ruhl, R.; Orsolits, B.; Voros, E.; Szabo, B.; Vagovits, B.; Madarasz, E.			Astroglia-derived retinoic acid is a key factor in glia-induced neurogenesis	FASEB JOURNAL			English	Article						RA; astrocyte; stem cell; neuronal differentiation	EMBRYONIC STEM-CELLS; ADULT; ASTROCYTES; BRAIN; DIFFERENTIATION; EXPRESSION; INDUCTION; MICE; PROLIFERATION; SURVIVAL	Astroglial cells are essential components of the neurogenic niches within the central nervous system. Emerging evidence suggests that they are among the key regulators of postnatal neurogenesis. Although astrocytes have been demonstrated to possess the potential to instruct stem cells to adopt a neuronal fate, little is known about the nature of the glia-derived instructive signals. Here we propose that all-trans retinoic acid, one of the most powerful morphogenic molecules regulating neuronal cell fate commitment, may be one of the glia-derived factors directing astroglia-induced neurogenesis. According to data obtained from several complementary approaches, we show that cultured astrocytes express the key enzyme mRNAs of retinoic acid biosynthesis and actively produce all-trans retinoic acid. We show that blockage of retinoic acid signaling by the pan-RAR antagonist AGN193109 prevents glia-induced neuron formation by noncommitted stem cells. Therefore, we provide strong in vitro evidence for retinoic acid action in astroglia-induced neuronal differentiation.	Hungarian Acad Sci, Lab Cellular & Dev Neurobiol, Inst Expt Med, H-1083 Budapest, Hungary; Agr Biotechnol Ctr, Godollo, Hungary; Univ Debrecen, Dept Biochem & Mol Biol, Debrecen, Hungary; Eotvos Lorand Univ, Dept Biol Phys, Budapest, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; University of Debrecen; Eotvos Lorand University	Kornyei, Z (corresponding author), Hungarian Acad Sci, Lab Cellular & Dev Neurobiol, Inst Expt Med, H-1083 Budapest, Hungary.	kornyei@koki.hu	Gocza, Elen/C-9883-2014; Gocza, Elen/A-8838-2012	Gocza, Elen/0000-0001-7720-4720; Gocza, Elen/0000-0001-7720-4720				ALOISI F, 1994, J IMMUNOL, V152, P5022; Aouadi M, 2006, STEM CELLS, V24, P1399, DOI 10.1634/stemcells.2005-0398; Asson-Batres MA, 2006, J COMP NEUROL, V496, P149, DOI 10.1002/cne.20904; Castelo-Branco GA, 2006, MOL CELL NEUROSCI, V31, P251, DOI 10.1016/j.mcn.2005.09.014; Cedazo-Minguez A, 2001, NEUROSCIENCE, V105, P651, DOI 10.1016/S0306-4522(01)00224-X; Chadashvili T, 2006, J COMP NEUROL, V498, P1, DOI 10.1002/cne.21009; Chattopadhyay N, 2001, MOL BRAIN RES, V92, P172, DOI 10.1016/S0169-328X(01)00155-3; Chen Y, 2005, EXP NEUROL, V196, P87, DOI 10.1016/j.expneurol.2005.07.010; Choi WH, 2005, BIOCHEM BIOPH RES CO, V329, P125, DOI 10.1016/j.bbrc.2005.01.110; Crandall J, 2004, P NATL ACAD SCI USA, V101, P5111, DOI 10.1073/pnas.0306336101; Demeter K, 2004, EXP NEUROL, V188, P254, DOI 10.1016/j.expneurol.2004.04.011; Denisenko-Nehrbass NI, 2000, NEURON, V27, P359, DOI 10.1016/S0896-6273(00)00043-X; ESFANDIARI A, 1994, GLIA, V11, P255, DOI 10.1002/glia.440110306; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Hall AC, 2003, GLIA, V43, P47, DOI 10.1002/glia.10229; Haskell GT, 2005, J NEUROSCI, V25, P7636, DOI 10.1523/JNEUROSCI.0485-05.2005; Jacobs S, 2006, P NATL ACAD SCI USA, V103, P3902, DOI 10.1073/pnas.0511294103; JOHNSON AT, 1995, J MED CHEM, V38, P4764, DOI 10.1021/jm00024a003; Kane MA, 2005, BIOCHEM J, V388, P363, DOI 10.1042/BJ20041867; Keegan BR, 2005, SCIENCE, V307, P247, DOI 10.1126/science.1101573; Kornyei Z, 2005, GLIA, V49, P430, DOI 10.1002/glia.20123; Lane MA, 2005, PROG NEUROBIOL, V75, P275, DOI 10.1016/j.pneurobio.2005.03.002; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Lim DA, 1999, P NATL ACAD SCI USA, V96, P7526, DOI 10.1073/pnas.96.13.7526; Luo TL, 2004, J COMP NEUROL, V470, P297, DOI 10.1002/cne.20013; Ma DK, 2005, CURR OPIN NEUROBIOL, V15, P514, DOI 10.1016/j.conb.2005.08.003; McCaffery P, 2006, J NEUROBIOL, V66, P780, DOI 10.1002/neu.20237; McCaffery P, 2004, DEV BRAIN RES, V153, P233, DOI 10.1016/j.devbrainres.2004.09.003; Mey J, 2004, NEUROSCIENTIST, V10, P409, DOI 10.1177/1073858404263520; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A, 2003, MANIPULATING MOUSE E, P453; Nakayama T, 2003, NEUROSCI RES, V46, P241, DOI 10.1016/S0168-0102(03)00063-4; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; Nicole O, 2001, J NEUROSCI, V21, P3024, DOI 10.1523/JNEUROSCI.21-09-03024.2001; Nolte C, 2001, GLIA, V33, P72; Romand R, 2006, J COMP NEUROL, V496, P643, DOI 10.1002/cne.20936; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; Ruhl R, 2006, RAPID COMMUN MASS SP, V20, P2497, DOI 10.1002/rcm.2621; Schlett K, 2000, J NEUROSCI RES, V60, P184; Schlett K, 1997, J NEUROSCI RES, V47, P405; Schmidt CK, 2003, ANAL BIOCHEM, V315, P36, DOI 10.1016/S0003-2697(02)00662-0; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Sonneveld E, 1999, EXP CELL RES, V250, P284, DOI 10.1006/excr.1999.4513; Tarnok K, 2002, EUR J CELL BIOL, V81, P403, DOI 10.1078/0171-9335-00262; Ueki T, 2003, J NEUROSCI, V23, P11732; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862; Wang TW, 2005, DEVELOPMENT, V132, P2721, DOI 10.1242/dev.01867; Wobus AM, 2005, PHYSIOL REV, V85, P635, DOI 10.1152/physrev.00054.2003; WUARIN L, 1990, INT J DEV NEUROSCI, V8, P317, DOI 10.1016/0736-5748(90)90038-4	50	54	56	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2496	2509		10.1096/fj.06-7756com	http://dx.doi.org/10.1096/fj.06-7756com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17438145				2022-12-28	WOS:000248454400024
J	Rozenfeld, R; Devi, LA				Rozenfeld, Raphael; Devi, Lakshmi A.			Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers	FASEB JOURNAL			English	Article						G-protein-coupled receptors; morphine; oligomerization; 7TM receptors; enkephalin; narcotic addiction	BETA-ARRESTIN; MORPHINE-TOLERANCE; REGULATED KINASES; PROTEIN-KINASE; CELLS; ANALGESIA; MICE; OPIATE; PHOSPHORYLATION; DEPENDENCE	Opiates are analgesics of choice in the treatment of chronic pain, but their long-term use leads to the development of physiological tolerance. Thus, understanding the mechanisms modulating the response of their receptor, the mu opioid receptor (mu OR), is of great clinical relevance. Here we show that heterodimerization of mu OR with delta opioid receptors (delta OR) leads to a constitutive recruitment of beta-arrestin2 to the receptor complex resulting in changes in the spatiotemporal regulation of ERK1/2 signaling. The involvement of beta-arrestin2 is further supported by studies using beta-arrestin2 siRNA in cells endogenously expressing the heterodimers. The association of beta-rrestin2 with the heterodimer can be altered by treatment with a combination of mu OR agonist (DAMGO) and delta OR antagonist (Tipp psi), and this leads to a shift in the pattern of ERK1/2 phosphorylation to the pattern observed with mu OR alone. These data indicate that, in the naive state, mu OR- delta OR heterodimers are in a conformation conducive to beta-arrestin-mediated signaling. Destabilization of this conformation by cotreatment with mu OR and delta OR ligands leads to a switch to a non-beta-arrestin- mediated signaling. Taken together, these results show for the first time that mu OR- delta OR heterodimers, by differentially recruiting beta-arrestin, modulate the spatio-temporal dynamics of opioid receptor signaling.	Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Devi, LA (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, 19-84 Anenberg Bldg,1 Gustave L Levy Pl, New York, NY 10029 USA.	lakshmi.devi@mssm.edu	Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776	NATIONAL CANCER INSTITUTE [R24CA095823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R56DA008863, R37DA008863, R01DA008863, K05DA019521] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA095823] Funding Source: Medline; NIDA NIH HHS [K05 DA019521-08, R56 DA008863, R01 DA008863-17, R37 DA008863, R01 DA008863, DA08863, K05 DA019521, DA019521] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ABDELHAMID EE, 1991, J PHARMACOL EXP THER, V258, P299; Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Belcheva MM, 2005, J BIOL CHEM, V280, P27662, DOI 10.1074/jbc.M502593200; Bilecki W, 2005, CELL MOL LIFE SCI, V62, P2369, DOI 10.1007/s00018-005-5277-y; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Charles AC, 2003, MOL PHARMACOL, V63, P89, DOI 10.1124/mol.63.1.89; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Dai Y, 2002, J NEUROSCI, V22, P7737; Fan T, 2005, J BIOL CHEM, V280, P38478, DOI 10.1074/jbc.M505644200; Fukuda K, 1996, J NEUROCHEM, V67, P1309; Gesty-Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200; Gomes I, 2004, P NATL ACAD SCI USA, V101, P5135, DOI 10.1073/pnas.0307601101; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Guan JS, 2005, CELL, V122, P619, DOI 10.1016/j.cell.2005.06.010; Herz A., 1993, OPIOIDS; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Morinville A, 2003, J NEUROSCI, V23, P4888; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; Riba P, 2002, J PHARMACOL EXP THER, V300, P265, DOI 10.1124/jpet.300.1.265; Shenoy S.K., 2005, SCI STKE, V2005, pcm10; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Smith ER, 2004, J CELL BIOL, V164, P689, DOI 10.1083/jcb.200312028; TRAYNOR JR, 1993, TRENDS PHARMACOL SCI, V14, P84, DOI 10.1016/0165-6147(93)90068-U; Wang DX, 2005, MOL PHARMACOL, V67, P2173, DOI 10.1124/mol.104.010272; Wei HJ, 2004, J BIOL CHEM, V279, P48255, DOI 10.1074/jbc.M406205200; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yuen JWF, 2004, NEUROREPORT, V15, P1431, DOI 10.1097/01.wnr.0000130433.90962.6e; Zhu YX, 1999, NEURON, V24, P243, DOI 10.1016/S0896-6273(00)80836-3	33	165	172	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2455	2465		10.1096/fj.06-7793com	http://dx.doi.org/10.1096/fj.06-7793com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17384143	Green Accepted			2022-12-28	WOS:000248454400020
J	Sun, S; Liu, YM; Lipsky, S; Cho, M				Sun, Shan; Liu, Yaoming; Lipsky, Samantha; Cho, Michael			Physical manipulation of calcium oscillations facilitates osteodifferentiation of human mesenchymal stem cells	FASEB JOURNAL			English	Article						Ca2+; oscillation; hMSCs; electrical stimulation	NONINVASIVE ELECTRICAL STIMULUS; 3-DIMENSIONAL COLLAGEN GEL; HUMAN FIBROBLAST MIGRATION; CA2+ SIGNALING PATHWAYS; GENE-EXPRESSION; STIMULATION; RESPONSES; DIFFERENTIATION; ORGANIZATION; ACTIVATION	The role of cytosolic calcium oscillation has long been recognized in the regulation of cellular and molecular interactions. Information embedded in calcium oscillation can provide molecular cues for cell behavior such as cell differentiation. Although calcium dynamics are versatile and likely to depend on the cell type, the calcium dynamics in human mesenchymal stem cells ( hMSCs) and its role in differentiation are yet to be fully elucidated. In the present study we characterized the calcium oscillation profiles in hMSCs before and after subjecting the cells to the osteoinductive factors. Our findings indicate that the calcium spikes decreased rapidly with osteodifferentiation to a level observed in terminally differentiated human osteoblasts. In addition, the calcium oscillations appear to serve as a bidirectional signal during hMSC differentiation. While an altered calcium oscillation pattern may be an indicator for hMSC differentiation, it is also likely to be involved in directing hMSC differentiation. Treatment of hMSCs with a noninvasive electrical stimulation, for example, not only altered the calcium oscillations but also facilitated osteodifferentiation. Regulation of calcium oscillation by external physical stimulation could amplify hMSC differentiation into a tissue- specific lineage and may offer an alternate biotechnology to harness the unique properties of stem cells.	Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA; Univ Illinois, Dept Chem, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, M (corresponding author), Univ Illinois, Dept Bioengn, 851 S Morgan St,M-C 063, Chicago, IL 60607 USA.	mcho@uic.edu		Cho, Myoung Rae/0000-0002-8191-8045	NIBIB NIH HHS [EB006067] Funding Source: Medline; NIGMS NIH HHS [GM060741] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB006067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060741] Funding Source: NIH RePORTER	NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aaron RK, 1996, J ORTHOP RES, V14, P582, DOI 10.1002/jor.1100140412; Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001; Blum JS, 2001, J CELL BIOCHEM, V80, P532, DOI 10.1002/1097-4644(20010315)80:4<532::AID-JCB1007>3.0.CO;2-B; Chawla S, 2002, EUR J PHARMACOL, V447, P131, DOI 10.1016/S0014-2999(02)01837-X; Cho MR, 2002, IEEE T PLASMA SCI, V30, P1504, DOI 10.1109/TPS.2002.804200; Cho MR, 1999, FASEB J, V13, P677, DOI 10.1096/fasebj.13.6.677; CHO MR, 2002, FRONTIERS BIOSCI, V7, P1; D'Souza SJA, 2001, J BIOL CHEM, V276, P23531, DOI 10.1074/jbc.M100780200; den Dekker E, 2001, THROMB HAEMOSTASIS, V86, P1106; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Ducibella T, 2002, DEV BIOL, V250, P280, DOI 10.1006/dbio.2002.0788; Dupont G, 2000, BBA-MOL CELL RES, V1498, P134, DOI 10.1016/S0167-4889(00)00090-2; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HARBERD N, 2002, MOL BIOL CELL, P862; Jones J E, 1998, Eur J Dent Educ, V2, P42, DOI 10.1111/j.1600-0579.1998.tb00035.x; Kawano S, 2003, CELL CALCIUM, V34, P145, DOI 10.1016/S0143-4160(03)00069-1; Kawano S, 2002, CELL CALCIUM, V32, P165, DOI 10.1016/S0143416002001240; Khatib L, 2004, FASEB J, V18, P1903, DOI 10.1096/fj.04-1814fje; Kimura K, 1998, J BIOTECHNOL, V63, P55, DOI 10.1016/S0168-1656(98)00075-3; Lehmann U, 2001, METHODS, V25, P409, DOI 10.1006/meth.2001.1263; Li YJ, 2004, J ORTHOP RES, V22, P1283, DOI 10.1016/j.orthres.2004.04.002; LIU Y, 2005, ANN M BIOM ENG SOC B; Luttrell LM, 2002, CAN J PHYSIOL PHARM, V80, P375, DOI 10.1139/Y02-045; Marhl M, 2000, BIOSYSTEMS, V57, P75, DOI 10.1016/S0303-2647(00)00090-3; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; ROBINSON KR, 1985, J CELL BIOL, V101, P2023, DOI 10.1083/jcb.101.6.2023; Rodriguez JP, 2004, J CELL BIOCHEM, V93, P721, DOI 10.1002/jcb.20234; RONDE P, 2000, BIOCHIM BIOPHYS ACTA, V1498, P272; Salasznyk RM, 2004, J BIOMED BIOTECHNOL, P24, DOI 10.1155/S1110724304306017; Sauer H, 1999, J CELL BIOCHEM, V75, P710, DOI 10.1002/(SICI)1097-4644(19991215)75:4<710::AID-JCB16>3.0.CO;2-Z; SAVIOGALIMBERTI E, 2005, AM J PHYSIOL, V290, pH613; Short B, 2003, ARCH MED RES, V34, P565, DOI 10.1016/j.arcmed.2003.09.007; Sun S, 2004, TISSUE ENG, V10, P1558, DOI 10.1089/ten.2004.10.1558; Sun S, 2004, TISSUE ENG, V10, P1548, DOI 10.1089/1076327042500193; Sun S, 2006, BIOELECTROCHEMISTRY, V69, P133, DOI 10.1016/j.bioelechem.2005.11.007; Takeda K, 2004, EMBO REP, V5, P161, DOI 10.1038/sj.embor.7400072; TAYLOR DL, 1975, BIOL BULL, V149, P448; Torihashi S, 2002, J BIOL CHEM, V277, P19191, DOI 10.1074/jbc.M201728200; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Yanagida E, 2004, CELL CALCIUM, V36, P135, DOI 10.1016/j.ceca.2004.01.022; Zhao M, 2004, J CELL SCI, V117, P397, DOI 10.1242/jcs.00868; Zhuang HM, 1997, BIOCHEM BIOPH RES CO, V237, P225, DOI 10.1006/bbrc.1997.7118	44	147	156	0	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1472	1480		10.1096/fj.06-7153com	http://dx.doi.org/10.1096/fj.06-7153com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264165				2022-12-28	WOS:000246117000022
J	Bagnasco, L; Tortolina, L; Biasotti, B; Castagnino, N; Ponassi, R; Tomati, V; Nieddu, E; Stier, G; Malacarne, D; Parodi, S				Bagnasco, L.; Tortolina, L.; Biasotti, B.; Castagnino, N.; Ponassi, R.; Tomati, V.; Nieddu, E.; Stier, G.; Malacarne, D.; Parodi, S.			Inhibition of a protein-protein interaction between INI1 and c-Myc by small peptidomimetic molecules inspired by Helix-1 of c-Myc: identification of a new target of potential antineoplastic interest	FASEB JOURNAL			English	Article						inhibitors	MYC/MAX DIMERIZATION; CELL-GROWTH; DNA-BINDING; SEQUENCE; MAX; TRANSFORMATION; TRANSCRIPTION; APOPTOSIS	c-Myc is a transcription modulator protooncogene. When overexpressed, it becomes an important contributor to the multi-hit process of malignant transformation. In two earlier papers in this journal (see refs. 19, 20) we reported that retro-inverso peptidomimetic molecules inspired by the Helix-1 of c-Myc motif could be sequence-specific antiproliferative agents active in the low micromolar range. We also found that our peptides were not opening the four-alpha-helix Myc:Max bundle. Their antiproliferative activity in cancer cell lines needs the presence of side chains projecting outside of the bundle in the corresponding native H1 motif. This observation suggested interference with an external partner. In this study we investigated the INI1:Myc interaction. INI1 is a subunit of the SWI/SNF complex (component of the enhanceosome surrounding Myc:Max heterodimer). The INI1:Myc interaction was confirmed via pull down, ELISA, and fluorescence anisotropy assays. According to the length of INI1 fragments used, we calculated K(d)s ranging between 1.3 x 10(-6) and 4.8 x 10(-7) M. The three different techniques applied showed that the INI1:Myc interaction was also the target of our retro-inverso peptidomimetic molecules, which seem to bind specifically at INI1. A Myc binding, 21aa INI1 fragment (minimum interacting sequence), could inspire the synthesis of a new class of more selective c-Myc inhibitors.	Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy; Natl Canc Inst, Expt Oncol Lab, IST, Genoa, Italy; ISO, Genoa, Italy; Univ Genoa, Dept Pharmaceut Sci, Genoa, Italy; EMBL Heidelberg, Struct & Computat Biol Unit, Heidelberg, Germany	University of Genoa; University of Genoa; European Molecular Biology Laboratory (EMBL)	Bagnasco, L (corresponding author), Univ Genoa, Dept Oncol Biol & Genet, L go R Benzi 10, I-16132 Genoa, Italy.	luca.bagnasco@unige.it	Tomati, Valeria/AAB-4543-2021	Tomati, Valeria/0000-0003-3761-1916				Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Dang CV, 1999, MOL CELL BIOL, V19, P1; Giorello L, 1998, CANCER RES, V58, P3654; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765; HENRIKSSON M, 1996, CANCER RES, V68, P109; Kiessling A, 2006, CHEM BIOL, V13, P745, DOI 10.1016/j.chembiol.2006.05.011; KOHN KW, 2003, ENCY HUMAN GENOME, P457; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Mo H, 2006, P NATL ACAD SCI USA, V103, P6344, DOI 10.1073/pnas.0601418103; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Nieddu E, 2005, FASEB J, V19, P632, DOI 10.1096/fj.04-2369fje; Oskarsson T, 2005, NAT CELL BIOL, V7, P215, DOI 10.1038/ncb0305-215; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Pescarolo MP, 2001, FASEB J, V15, P31; Ponzielli R, 2005, EUR J CANCER, V41, P2485, DOI 10.1016/j.ejca.2005.08.017; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Xu Y, 2006, BIOORGAN MED CHEM, V14, P2660, DOI 10.1016/j.bmc.2005.11.052; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641	23	23	25	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					1256	1263		10.1096/fj.06-7082com	http://dx.doi.org/10.1096/fj.06-7082com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17215484				2022-12-28	WOS:000245650400029
J	Ma, ZY; Janmey, PA; Finkel, TH				Ma, Zhengyu; Janmey, Paul A.; Finkel, Terri H.			The receptor deformation model of TCR triggering	FASEB JOURNAL			English	Article						T cell receptor; signaling; TCR signal initiation; cytoskeleton; mechanical force	T-CELL-ACTIVATION; ANTIGEN PRESENTATION; DENDRITIC CELLS; MULTIVALENT ENGAGEMENT; IMMUNOLOGICAL SYNAPSE; CONFORMATIONAL-CHANGE; SIGNAL-TRANSDUCTION; LYMPH-NODES; MHC LIGANDS; PEPTIDE	Through T cell receptors (TCRs), T cells can detect and respond to very small numbers of foreign peptides among a huge number of self-peptides presented by major histocompatibility complexes (pMHCs) on the surface of antigen-presenting cells (APCs). How T cells achieve such remarkable sensitivity and specificity through pMHC-TCR binding is an intensively pursued issue in immunology today; the key question is how pMHC-TCR binding initiates, or triggers, a signal from TCRs. Multiple competing models have been proposed, none of which fully explains the sensitivity and specificity of TCR triggering. What has been omitted from existing theories is that the pMHC-TCR interaction at the T cell/APC interface must be under constant mechanical stress, due to the dynamic nature of cell-cell interaction. Taking this condition into consideration, we propose the receptor deformation model of TCR triggering. In this model, TCR signaling is initiated by conformational changes of the TCR/CD3 complex, induced by a pulling force originating from the cytoskeleton and transmitted through pMHC-TCR binding interactions with enough strength to resist rupture. By introducing mechanical force into a model of T cell signal initiation, the receptor deformation model provides potential mechanistic solutions to the sensitivity and specificity of TCR triggering.	[Ma, Zhengyu; Finkel, Terri H.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; [Janmey, Paul A.] Univ Penn, Sch Med, Inst Med & Engn, Dept Bioengn, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine	Ma, ZY (corresponding author), 1104G Abramson Res Bldg,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	maz@email.chop.edu; finkelt@email.chop.edu			NIAID NIH HHS [R21 AI078387, R21 AI078387-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI078387] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altan-Bonnet G, 2005, PLOS BIOL, V3, P1925, DOI 10.1371/journal.pbio.0030356; Barisas BG, 1999, MOL IMMUNOL, V36, P701, DOI 10.1016/S0161-5890(99)00091-7; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; Brossard C, 2005, EUR J IMMUNOL, V35, P1741, DOI 10.1002/eji.200425857; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; Casares S, 1999, J EXP MED, V190, P543, DOI 10.1084/jem.190.4.543; Cebecauer M, 2005, J IMMUNOL, V174, P6809, DOI 10.4049/jimmunol.174.11.6809; Cemerski S, 2006, CURR OPIN IMMUNOL, V18, P298, DOI 10.1016/j.coi.2006.03.011; Choudhuri K, 2005, NATURE, V436, P578, DOI 10.1038/nature03843; Cochran JR, 2000, IMMUNITY, V12, P241, DOI 10.1016/S1074-7613(00)80177-6; Davis SJ, 2006, NAT IMMUNOL, V7, P803, DOI 10.1038/ni1369; DONNADIEU E, 1994, CURR BIOL, V4, P584, DOI 10.1016/S0960-9822(00)00130-5; Dustin ML, 1997, P NATL ACAD SCI USA, V94, P3909, DOI 10.1073/pnas.94.8.3909; Dustin ML, 2001, ANNU REV CELL DEV BI, V17, P133, DOI 10.1146/annurev.cellbio.17.1.133; Gil D, 2005, J EXP MED, V201, P517, DOI 10.1084/jem.20042036; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; GRAY LS, 1988, J IMMUNOL, V141, P2424; Gunzer M, 2000, IMMUNITY, V13, P323, DOI 10.1016/S1074-7613(00)00032-7; INABA K, 1986, J EXP MED, V163, P247, DOI 10.1084/jem.163.2.247; Irvine DJ, 2002, NATURE, V419, P845, DOI 10.1038/nature01076; Jacobelli J, 2004, NAT IMMUNOL, V5, P531, DOI 10.1038/ni1065; Krogsgaard M, 2005, NATURE, V434, P238, DOI 10.1038/nature03391; Krogsgaard M, 2005, NAT IMMUNOL, V6, P239, DOI 10.1038/ni1173; Krogsgaard M, 2003, MOL CELL, V12, P1367, DOI 10.1016/S1097-2765(03)00474-X; Kuhns MS, 2006, IMMUNITY, V24, P133, DOI 10.1016/j.immuni.2006.01.006; La Gruta NL, 2004, J IMMUNOL, V172, P3662, DOI 10.4049/jimmunol.172.6.3662; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Levin SE, 2005, J EXP MED, V201, P489, DOI 10.1084/jem.20050179; LOCKSLEY RM, 1993, SCIENCE, V261, P1448, DOI 10.1126/science.8367726; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Miller MJ, 2004, J EXP MED, V200, P847, DOI 10.1084/jem.20041236; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Munnelly HM, 2000, INT IMMUNOL, V12, P1319, DOI 10.1093/intimm/12.9.1319; OIWA K, 1990, P NATL ACAD SCI USA, V87, P7893, DOI 10.1073/pnas.87.20.7893; Rudolph MG, 2006, ANNU REV IMMUNOL, V24, P419, DOI 10.1146/annurev.immunol.23.021704.115658; SCHILHAM MW, 1993, EUR J IMMUNOL, V23, P1299, DOI 10.1002/eji.1830230617; Schwesinger F, 2000, P NATL ACAD SCI USA, V97, P9972, DOI 10.1073/pnas.97.18.9972; Sporri R, 2002, EUR J IMMUNOL, V32, P3161, DOI 10.1002/1521-4141(200211)32:11<3161::AID-IMMU3161>3.0.CO;2-6; Stones JD, 2006, J IMMUNOL, V176, P1498, DOI 10.4049/jimmunol.176.3.1498; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; Tskvitaria-Fuller I, 2003, J IMMUNOL, V171, P2287, DOI 10.4049/jimmunol.171.5.2287; Underhill DM, 1999, J EXP MED, V190, P1909, DOI 10.1084/jem.190.12.1909; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; van der Merwe PA, 2000, SEMIN IMMUNOL, V12, P5, DOI 10.1006/smim.2000.0203; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; Vicente-Manzanares M, 2004, NAT REV IMMUNOL, V4, P110, DOI 10.1038/nri1268; Wiedemann A, 2005, IMMUNOL LETT, V98, P57, DOI 10.1016/j.imlet.2004.10.014; Yokosuka T, 2005, NAT IMMUNOL, V6, P1253, DOI 10.1038/ni1272	51	60	60	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2008	22	4					1002	1008		10.1096/fj.07-9331hyp	http://dx.doi.org/10.1096/fj.07-9331hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	17984179	Green Accepted			2022-12-28	WOS:000254581000006
J	Scobioala, S; Klocke, R; Kuhlmann, M; Tian, W; Hasib, L; Milting, H; Koenig, S; Stelljes, M; El-Banayosy, A; Tenderich, G; Michel, G; Breithardt, G; Nikol, S				Scobioala, Sergiu; Klocke, Rainer; Kuhlmann, Michael; Tian, Wen; Hasib, Lekbira; Milting, Hendrik; Koenig, Simone; Stelljes, Matthias; El-Banayosy, Aly; Tenderich, Gero; Michel, Guenter; Breithardt, Guenter; Nikol, Sigrid			Up-regulation of nestin in the infarcted myocardium potentially indicates differentiation of resident cardiac stem cells into various lineages including cardiomyocytes	FASEB JOURNAL			English	Article						cardiac regeneration; myocardial infarction; heart failure; progenitor cells; proteomics; intermediate filament	INTERMEDIATE-FILAMENT NESTIN; BONE-MARROW; PROGENITOR CELLS; PROTEIN NESTIN; EXPRESSION; HEART; RAT; ORGANIZATION; FIBROBLASTS; MULTIPOTENT	To identify proteins involved in cardiac regeneration, a proteomics approach was applied. A total of 26 proteins, which displayed aberrant expression in mouse hearts infarcted through ligation of the left anterior descending coronary artery, were identified. These included the intermediate filament protein nestin, which was up-regulated in the infarct border zone. Corresponding changes were observed for its mRNA. Nestin mRNA was also up-regulated in hearts from 17 of 19 patients with end-stage heart failure, including 4 with acute myocardial infarction in comparison with 8 donor hearts. Immunofluorescence confocal laser scanning microscopy revealed that nestin is expressed, on the one hand, in small proportions of cardiomyocytes, endothelial cells, smooth muscle cells, neuronal cells, and fibroblasts. On the other hand, it was found to be coexpressed with the stem cell markers c-kit, Sca-1, Mdr-1, and Abcg2 in small interstitial cells. In infarcted hearts from chimeric mice transplanted with bone marrow from enhanced green fluorescent protein (EGFP) transgenic mice, less than 1% of nestin-positive cells coexpressed EGFP, although EGFP-positive cells were abundant in these. Consequently, enhanced expression of nestin in the injured myocardium might reflect spontaneous regenerative processes supposedly based on the differentiation of resident cardiac stem cells into diverse cardiac cell types.	Univ Munster, IZKF, D-48149 Munster, Germany; [Stelljes, Matthias] Univ Hosp, Dept Haematol & Med Oncol, Munster, Germany; [Scobioala, Sergiu; Hasib, Lekbira; Koenig, Simone; Nikol, Sigrid] Univ Munster, IZKF, D-48149 Munster, Germany; [Milting, Hendrik; El-Banayosy, Aly; Tenderich, Gero] Ruhr Univ Bochum, Heart & Diabet Ctr NRW, Erich & Hanna Klessman Inst Cardiovasc Res & Dev, Bad Oeynhausen, Germany; [Scobioala, Sergiu; Klocke, Rainer; Kuhlmann, Michael; Tian, Wen; Hasib, Lekbira; Michel, Guenter; Breithardt, Guenter; Nikol, Sigrid] Univ Hosp, Dept Cardiol & Angiol, Munster, Germany	University of Munster; University of Munster; University of Munster; Ruhr University Bochum; University of Munster	Nikol, S (corresponding author), Univ Munster, IZKF, Albert Schweitzer Str 33, D-48149 Munster, Germany.	nikol@uni-muenster.de	König, Simone/B-6504-2008; Tenderich, Gero/AHA-6720-2022	König, Simone/0000-0003-0672-7246; Tian, wen/0000-0001-8257-6350				Anversa P, 2006, CIRCULATION, V113, P1451, DOI 10.1161/CIRCULATIONAHA.105.595181; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Buervenich S, 2001, MOL BRAIN RES, V94, P204, DOI 10.1016/S0169-328X(01)00166-8; CARVER W, 1993, ANAT RECORD, V236, P511, DOI 10.1002/ar.1092360311; Chimenti Stefano, 2004, Methods Mol Med, V98, P217; Diaz-Araya G, 2003, CELL COMMUN ADHES, V10, P155, DOI 10.1080/15419060390262598; Drapeau J, 2005, J CELL PHYSIOL, V204, P51, DOI 10.1002/jcp.20264; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; El-Banayosy A, 2005, ANN THORAC SURG, V80, P548, DOI 10.1016/j.athoracsur.2005.02.084; El-Helou V, 2005, HYPERTENSION, V46, P1219, DOI 10.1161/01.HYP.0000187888.39665.d9; FLORENES VA, 1994, CANCER RES, V54, P354; Frojdman K, 1997, DIFFERENTIATION, V61, P243, DOI 10.1046/j.1432-0436.1997.6140243.x; Fukuhara S, 2005, J HEART LUNG TRANSPL, V24, P67, DOI 10.1016/j.healun.2003.09.032; Goldsmith EC, 2004, DEV DYNAM, V230, P787, DOI 10.1002/dvdy.20095; Helisch A, 2003, MICROCIRCULATION, V10, P83, DOI 10.1038/sj.mn.7800173; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; Holley JE, 2003, NEUROPATH APPL NEURO, V29, P434, DOI 10.1046/j.1365-2990.2003.00491.x; KACHINSKY AM, 1995, J HISTOCHEM CYTOCHEM, V43, P843, DOI 10.1177/43.8.7542682; Kucia M, 2004, CIRC RES, V95, P1191, DOI 10.1161/01.RES.0000150856.47324.5b; Kuhlmann MT, 2006, J EXP MED, V203, P87, DOI 10.1084/jem.20051151; Lardon J, 2002, HISTOCHEM CELL BIOL, V117, P535, DOI 10.1007/s00418-002-0412-4; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; Linke A, 2005, P NATL ACAD SCI USA, V102, P8966, DOI 10.1073/pnas.0502678102; Lu Dong-feng, 2006, Nan Fang Yi Ke Da Xue Xue Bao, V26, P1629; Matsuura K, 2004, J BIOL CHEM, V279, P11384, DOI 10.1074/jbc.M310822200; Messina E, 2004, CIRC RES, V95, P911, DOI 10.1161/01.RES.0000147315.71699.51; Michael LH, 1995, AM J PHYSIOL-HEART C, V269, pH2147, DOI 10.1152/ajpheart.1995.269.6.H2147; Michalczyk K, 2005, HISTOL HISTOPATHOL, V20, P665, DOI 10.14670/HH-20.665; Mouquet F, 2005, CIRC RES, V97, P1090, DOI 10.1161/01.RES.0000194330.66545.f5; NelissenVrancken HJMG, 1996, CIRCULATION, V93, P349; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; QUANINI F, 2004, INT J CARDIOL, V95, P26; Raab S, 2004, THROMB HAEMOSTASIS, V91, P595, DOI 10.1160/TH03-09-0582; Rotondo F, 2006, ACTA NEUROPATHOL, V111, P272, DOI 10.1007/s00401-006-0031-6; Sahlgren CM, 2003, MOL CELL BIOL, V23, P5090, DOI 10.1128/MCB.23.14.5090-5106.2003; Sahlgren CM, 2001, J BIOL CHEM, V276, P16456, DOI 10.1074/jbc.M009669200; Scobioala S, 2004, CURR MED CHEM, V11, P3203, DOI 10.2174/0929867043363767; Smith RS, 1997, AM J PATHOL, V151, P317; Spinale FG, 2002, CIRC RES, V90, P520, DOI 10.1161/01.RES.0000013290.12884.A3; Terling C, 1995, INT J DEV BIOL, V39, P947; Urbanek K, 2006, P NATL ACAD SCI USA, V103, P9226, DOI 10.1073/pnas.0600635103; Wiese C, 2004, CELL MOL LIFE SCI, V61, P2510, DOI 10.1007/s00018-004-4144-6; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Woodahl EL, 2004, CURR DRUG METAB, V5, P11, DOI 10.2174/1389200043489108; Yang J, 1997, Sheng Li Xue Bao, V49, P657; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	49	41	42	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1021	1031		10.1096/fj.07-8252com	http://dx.doi.org/10.1096/fj.07-8252com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	17984177				2022-12-28	WOS:000254581000008
J	Intemann, KK; de Melo-Martin, I				Intemann, Kristen K.; de Melo-Martin, Inmaculada			Regulating scientific research: should scientists be left alone?	FASEB JOURNAL			English	Article						stem cell research; regulations; scientific autonomy; ethical values	EMBRYONIC STEM-CELLS; SCIENCE; BIOETHICS; POLITICS; LINES	In our current political climate, decisions about whether to fund research on new stem cell fines or do chimera experiments seem to arbitrarily depend on the religious and economic interests of the administration. Not unreasonably, many scientists believe that science should be left to its own devices in determining research priorities and conducting research. When nonscientific considerations constrain research, it is claimed that values are inappropriately dictating scientific decisions. This assumes, however, that all ethical and social values are irrelevant to such decisions. Using the case of embryonic stem cell research to illustrate the debate, we argue here that this position is untenable for several reasons. First, the aims of science, particularly in the case of the biomedical sciences, cannot be completely extricated from ethical and social aims. Hence, value judgments will be necessary to assess research priorities and methodologies. Second, maintaining this position is inconsistent with actual scientific practices. Scientists already recognize that there are some ethical values that appropriately constrain research, such as in human subject experimentation. Therefore, the problem cannot be that ethical values are brought to bear on science per se but that those values are highly questionable or are imposed by those who often lack the scientific expertise necessary to understand how ethical concerns may relate to the research. Finally, we argue that to the extent value judgments must be made, consensus about such values should be reached by a diverse group of stakeholders, including scientists, community members, policymakers, and ethicists.	[de Melo-Martin, Inmaculada] Weill Cornell Med Coll, Dept Publ Hlth, Div Med Eth, New York, NY 10021 USA; [Intemann, Kristen K.] Montana State Univ, Dept Hist & Philosophy, Bozeman, MT 59717 USA	Cornell University; Montana State University System; Montana State University Bozeman	Intemann, KK (corresponding author), Weill Cornell Med Coll, Dept Publ Hlth, Div Med Eth, 411 E 69th St, New York, NY 10021 USA.	imd2001@med.cornell.edu	de Melo-Martin, Inmaculada/AEE-1312-2022	de Melo-Martin, Inmaculada/0000-0001-8656-8497				Allegrucci C, 2007, HUM REPROD UPDATE, V13, P103, DOI 10.1093/humupd/dml041; Baltimore D, 2004, SCIENCE, V305, P1873, DOI 10.1126/science.305.5692.1873; Blackburn E, 2004, NEW ENGL J MED, V350, P1379, DOI 10.1056/NEJMp048072; Brown P, 2006, INT J HEALTH SERV, V36, P417, DOI 10.2190/0WMQ-VEYT-E11H-UY47; Brumfiel G, 2004, NATURE, V427, P663, DOI [10.1038/427663a, 10.1038/427663b]; Caplan A. L., 1992, MED WENT MAD; Daley GQ, 2003, NEW ENGL J MED, V349, P211, DOI 10.1056/NEJMp030088; Haack S., 1998, MANIFESTO PASSIONATE; Habermas J., 1996, FACTS NORMS CONTRIBU; Jain T, 2005, FERTIL STERIL, V84, P221, DOI 10.1016/j.fertnstert.2005.01.118; Jones JH, 1981, BAD BLOOD TUSKEGEE S; Joravsky D., 1970, LYSENKO AFFAIR; Kincaid H., 2007, VALUE FREE SCI; Kitcher Philip, 2001, SCI TRUTH DEMOCRACY; Lacey H., 1999, IS SCI VALUE FREE VA; McKee M, 2003, EUR J PUBLIC HEALTH, V13, P289, DOI 10.1093/eurpub/13.4.289; MEDVEDEV Z, 1969, RISE FALL LYSENKO; Raikwar SP, 2006, PHYSIOLOGY, V21, P19, DOI 10.1152/physiol.00034.2005; Rawls J., 1971, THEORY JUSTICE; Roll-Hansen N, 2005, ENDEAVOUR, V29, P143, DOI 10.1016/j.endeavour.2005.10.003; Scott CT, 2006, NAT BIOTECHNOL, V24, P487, DOI 10.1038/nbt0506-487; Taylor CJ, 2005, LANCET, V366, P2019, DOI 10.1016/S0140-6736(05)67813-0; Turner L, 2004, NAT BIOTECHNOL, V22, P509, DOI 10.1038/nbt0504-509; Watson JD, 1997, J MOL MED-JMM, V75, P624, DOI 10.1007/s001099770001; Wobus AM, 2005, PHYSIOL REV, V85, P635, DOI 10.1152/physrev.00054.2003; Wolpert L, 1999, NATURE, V398, P281, DOI 10.1038/18543	26	8	8	1	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					654	658		10.1096/fj.07-9077LSF	http://dx.doi.org/10.1096/fj.07-9077LSF			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17928363				2022-12-28	WOS:000254143700003
J	Sakashita, T; Hamada, N; Ikeda, DD; Yanase, S; Suzuki, M; Ishii, N; Kobayashi, Y				Sakashita, Tetsuya; Hamada, Nobuyuki; Ikeda, Daisuke D.; Yanase, Sumino; Suzuki, Michiyo; Ishii, Naoaki; Kobayashi, Yasuhiko			Modulatory effect of ionizing radiation on food-NaCl associative learning: the role of gamma subunit of G protein in Caenorhabditis elegans	FASEB JOURNAL			English	Article						learning behavior; irradiation; nematode; GPC-1	C-ELEGANS; PLASTICITY; NEUROGENESIS; CHEMOTAXIS; IRRADIATION; ADAPTATION; NEURONS; PATHWAY	Ionizing radiation (IR) is known to impair learning by suppressing adult neurogenesis in the hippocampus. However, in a mature nervous system, IR-induced functional alterations that are independent of neurogenesis remain largely unknown. In the present study, we analyzed the effects of IR on a food-NaCl associative learning paradigm of adult Caenorhabditis elegans that does not undergo neurogenesis. We observed that a decrease in chemotaxis toward NaCl occurs only after combined starvation and exposure to NaCl. Exposure to IR induced an additional decrease in chemotaxis immediately after an acute dose in the transition stage of the food-NaCl associative learning. Strikingly, chronic irradiation induced negative chemotaxis in the exposed animals, i.e., the primary avoidance response. IR-induced additional decreases in chemotaxis after acute and chronic irradiation were significantly suppressed in the gpc-1 mutant, which was defective in GPC-1 (one of the two gamma subunits of the heterotrimeric G-protein). Chemotaxis to cAMP, but not to lysine and benzaldehyde, was influenced by IR during the food-NaCl associative learning. Our novel findings suggest that IR behaves as a modulator in the food-NaCl associative learning via C elegans GPC-1 and a specific neuronal network and may shed light on the modulatory effect of IR on learning.	[Sakashita, Tetsuya; Hamada, Nobuyuki; Suzuki, Michiyo; Kobayashi, Yasuhiko] Japan Atom Energy Agcy, Quantum Beam Sci Directorate, Microbeam Radiat Biol Grp, Takasaki, Gunma 3701292, Japan; [Hamada, Nobuyuki; Kobayashi, Yasuhiko] Gunma Univ, Grad Sch Med, Dept Quantum Biol, Maebashi, Gunma 371, Japan; [Ikeda, Daisuke D.] Univ Tokyo, Grad Sch Sci, Mol Genet Res Lab, Tokyo 113, Japan; [Ikeda, Daisuke D.] Univ Tokyo, Grad Sch Sci, Grad Program Biophys & Biochem, Tokyo 113, Japan; [Yanase, Sumino] Daito Bunka Univ, Sch Sports & Hlth Sci, Higashi Matsuyama, Saitama, Japan; [Ishii, Naoaki] Tokai Univ, Sch Med, Dept Mol & Life Sci, Isehara, Kanagawa 25911, Japan	Japan Atomic Energy Agency; Gunma University; University of Tokyo; University of Tokyo; Tokai University	Sakashita, T (corresponding author), Japan Atom Energy Agcy, Quantum Beam Sci Directorate, Microbeam Radiat Biol Grp, 1233 Watanuki Machi, Takasaki, Gunma 3701292, Japan.	sakashita.tetsuya@jaea.go.jp		Hamada, Nobuyuki/0000-0003-2518-6131				BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BRENNER S, 1974, GENETICS, V77, P71; CASARETT AP, 1973, RADIAT RES, V53, P455, DOI 10.2307/3573778; COLBERT HA, 1995, NEURON, V14, P803, DOI 10.1016/0896-6273(95)90224-4; Czurko A, 1997, P NATL ACAD SCI USA, V94, P2766, DOI 10.1073/pnas.94.6.2766; Fan Y, 2007, EUR J NEUROSCI, V25, P38, DOI 10.1111/j.1460-9568.2006.05269.x; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; Hilliard MA, 2005, EMBO J, V24, P63, DOI 10.1038/sj.emboj.7600493; Hobert O, 2003, J NEUROBIOL, V54, P203, DOI 10.1002/neu.10168; Hukema RK, 2006, EMBO J, V25, P312, DOI 10.1038/sj.emboj.7600940; ISHII N, 1990, INT J RADIAT BIOL, V58, P827, DOI 10.1080/09553009014552201; Jansen G, 2002, EMBO J, V21, P986, DOI 10.1093/emboj/21.5.986; KOJIMA T, 1989, APPL RADIAT ISOTOPES, V40, P851, DOI 10.1016/0883-2889(89)90006-3; Matsumoto H, 2007, J RADIAT RES, V48, P97, DOI 10.1269/jrr.06090; Meshi D, 2006, NAT NEUROSCI, V9, P729, DOI 10.1038/nn1696; Mohri A, 2005, GENETICS, V169, P1437, DOI 10.1534/genetics.104.036111; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; Narici L, 2004, ADV SPACE RES-SERIES, V33, P1352, DOI 10.1016/j.asr.2003.09.052; Nuttley WM, 2002, P NATL ACAD SCI USA, V99, P12449, DOI 10.1073/pnas.192101699; Raber J, 2004, RADIAT RES, V162, P39, DOI 10.1667/RR3206; RABIN BM, 1989, RADIAT RES, V119, P113, DOI 10.2307/3577371; Saeki S, 2001, J EXP BIOL, V204, P1757; Sawin ER, 2000, NEURON, V26, P619, DOI 10.1016/S0896-6273(00)81199-X; Scotto-Lomassese S, 2003, J NEUROSCI, V23, P9289; SPARROW AH, 1967, RADIAT RES, V32, P915, DOI 10.2307/3572296; Spitz DR, 2004, CANCER METAST REV, V23, P311, DOI 10.1023/B:CANC.0000031769.14728.bc; Tomioka M, 2006, NEURON, V51, P613, DOI 10.1016/j.neuron.2006.07.024; Wong CS, 2004, MOL INTERV, V4, P273, DOI 10.1124/mi.4.5.7	28	10	13	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					713	720		10.1096/fj.07-9259com	http://dx.doi.org/10.1096/fj.07-9259com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17947388				2022-12-28	WOS:000254143700010
J	Choi, HS; Kim, CS; Hwang, CK; Song, KY; Law, PY; Wei, LN; Loh, HH				Choi, Hack Sun; Kim, Chun Sung; Hwang, Cheol Kyu; Song, Kyu Young; Law, Ping-Yee; Wei, Li-Na; Loh, Horace H.			Novel function of the poly(C)-binding protein alpha CP3 as a transcriptional repressor of the mu opioid receptor gene	FASEB JOURNAL			English	Article						double-stranded poly(C) element; MOR transcription	RNA-BINDING PROTEINS; SINGLE-STRANDED-DNA; NUCLEAR RIBONUCLEOPROTEIN-K; SPLICE VARIANTS; ERYTHROID-DIFFERENTIATION; DISTAL PROMOTER; NEURONAL CELLS; POLIOVIRUS RNA; HNRNP-K; IDENTIFICATION	The alpha-complex proteins (alpha CP) are generally known as RNA- binding proteins that interact in a sequence- specific fashion with single- stranded poly(C). These proteins are mainly involved in various post- transcriptional regulations ( e. g., mRNA stabilization or translational activation/ silencing). Here we report a novel function of alpha CP3, a member of the alpha CP family. alpha CP3 bound to the double- stranded poly(C) element essential for the mu opioid receptor ( MOR) promoter and repressed the promoter activity at the transcriptional level. We identified alpha CP3 using affinity column chromatography containing the double-stranded poly( C) element and matrix-assisted laser desorption ionization time- of- flight ( MALDI- TOF) mass spectrometry. alpha CP3 binding to the poly(C) sequence of the MOR gene was sequence specific, as confirmed by the supershift assay. In cotransfection studies, alpha CP3 repressed the MOR promoter only when the poly( C) sequence was intact. Ectopic expression of alpha CP3 led to repression of the endogenous MOR transcripts in NS20Y cells. When alpha CP3 was disrupted using small interfering RNA ( siRNA) in NS20Y cells, the transcription of the endogenous target MOR gene was increased significantly. Our data suggest that alpha CP3 can function as a repressor of MOR transcription dependent on the MOR poly( C) sequence. We demonstrate for the first time a role of alpha CP3 as a transcriptional repressor in MOR gene regulation.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Choi, HS (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall, 321 Church St, Minneapolis, MN 55455 USA.	choix074@umn.edu		Song, Kyu Young/0000-0001-7313-514X	NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806, R01DA011190, R01DA001583, K02DA013926, R56DA000564, R01DA000564, R37DA001583] Funding Source: NIH RePORTER; NIDA NIH HHS [DA00564, DA11806, DA11190, K02-DA13926, K05-DA00153, DA01583] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; Chkheidze AN, 2003, MOL CELL BIOL, V23, P8405, DOI 10.1128/MCB.23.23.8405-8415.2003; Choe CY, 1998, J BIOL CHEM, V273, P34926, DOI 10.1074/jbc.273.52.34926; Choi HS, 2006, BIOCHEM BIOPH RES CO, V343, P1132, DOI 10.1016/j.bbrc.2006.03.084; Choi HS, 2005, MOL PHARMACOL, V67, P1674, DOI 10.1124/mol.104.008284; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; GAILLARD C, 1994, NUCLEIC ACIDS RES, V22, P4183, DOI 10.1093/nar/22.20.4183; Gamarnik AV, 1998, GENE DEV, V12, P2293, DOI 10.1101/gad.12.15.2293; Gamarnik AV, 1997, RNA, V3, P882; Hwang CK, 2004, J BIOL CHEM, V279, P19764, DOI 10.1074/jbc.M400755200; Hwang CK, 2003, J BIOL CHEM, V278, P3742, DOI 10.1074/jbc.M208780200; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Kim CS, 2004, J BIOL CHEM, V279, P46464, DOI 10.1074/jbc.M403633200; Ko JL, 2003, MOL BRAIN RES, V112, P153, DOI 10.1016/S0169-328X(03)00086-X; Ko JL, 2002, MOL BRAIN RES, V104, P184, DOI 10.1016/S0169-328X(02)00357-1; Ko JL, 2001, J BIOL CHEM, V276, P788, DOI 10.1074/jbc.M004279200; Ko JL, 1997, BIOCHEM BIOPH RES CO, V234, P351, DOI 10.1006/bbrc.1997.6640; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; Lau JS, 2000, J CELL BIOCHEM, V79, P395, DOI 10.1002/1097-4644(20001201)79:3<395::AID-JCB50>3.0.CO;2-M; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; Makeyev AV, 2002, RNA, V8, P265, DOI 10.1017/S1355838202024627; Makeyev AV, 1999, J BIOL CHEM, V274, P24849, DOI 10.1074/jbc.274.35.24849; Makeyev AV, 2000, GENOMICS, V67, P301, DOI 10.1006/geno.2000.6244; Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MIN BH, 1994, P NATL ACAD SCI USA, V91, P9081, DOI 10.1073/pnas.91.19.9081; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; Ogata H, 1998, J BIOL CHEM, V273, P3060, DOI 10.1074/jbc.273.5.3060; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Pan YX, 2001, P NATL ACAD SCI USA, V98, P14084, DOI 10.1073/pnas.241296098; Pan YX, 2002, GENE, V295, P97, DOI 10.1016/S0378-1119(02)00825-9; PATTERSON SD, 1995, ELECTROPHORESIS, V16, P1791, DOI 10.1002/elps.11501601299; Ritchie SA, 2003, NUCLEIC ACIDS RES, V31, P1502, DOI 10.1093/nar/gkg246; Thakur S, 2003, MOL CELL BIOL, V23, P3774, DOI 10.1128/MCB.23.11.3774-3787.2003; Tommerup N, 1996, GENOMICS, V33, P149, DOI 10.1006/geno.1996.0176; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; Wei LN, 2002, CURR OPIN PHARMACOL, V2, P69, DOI 10.1016/S1471-4892(01)00123-0; WEISS IM, 1995, MOL CELL BIOL, V15, P2457; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000	45	23	23	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3963	3973		10.1096/fj.07-8561com	http://dx.doi.org/10.1096/fj.07-8561com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17625070				2022-12-28	WOS:000251283500021
J	Jones, GW; Nielsen-Leroux, C; Yang, Y; Yuan, Z; Dumas, VF; Monnerat, RG; Berry, C				Jones, Gareth W.; Nielsen-Leroux, Christina; Yang, Yankun; Yuan, Zhiming; Dumas, Vinicius Fiuza; Monnerat, Rose Gomes; Berry, Colin			A new Cry toxin with a unique two-component dependency from Bacillus sphaericus	FASEB JOURNAL			English	Article						insecticidal toxin; toxin evolution; toxin interactions	THURINGIENSIS SUBSP ISRAELENSIS; CULEX-PIPIENS DIPTERA; WESTERN CORN-ROOTWORM; MOSQUITOCIDAL TOXIN; BINARY TOXIN; LABORATORY CULTURE; CROSS-RESISTANCE; PLASMID TRANSFER; CRYSTAL TOXIN; STRAINS	Highly pathogenic strains of Bacillus sphaericus produce the mosquitocidal Bin proteins, but resistance to this toxin can be produced under laboratory and field conditions. Analysis of strains able to overcome this resistance revealed the presence of a previously undescribed type of two-component toxin. One subunit, Cry48Aa1, is related to the 3-domain crystal toxins of Bacillus thuringiensis. Uniquely for this type of protein, insect toxicity is only achieved in the presence of a second, accessory protein, Cry49Aa1. This protein is itself related to both the binary toxin of B. sphaericus and to Cry35 and Cry36 of B. thuringiensis, none of which require interaction with Cry48Aa1-like proteins for their activity. The necessity for both Cry48Aa1 and Cry49Aa1 components for pathogenicity, therefore, indicates an unprecedented interaction to generate toxicity. Despite high potency for purified Cry48Aa1/Cry49Aa1 proteins (LC50 for third instar Culex quinquefasciatus larvae: 15.9 ng/ml and 6.3 ng/ml respectively), bacteria producing them show suboptimal mosquitocidal activity due to low-level Cry48Aa1 production. This new toxin combination may indicate a fortuitous combination of members of the gene families that encode 3-domain Cry toxins and Binary-like toxins, permitting the "mix-and-match" evolution of a new component in the mosquitocidal armoury. -Jones, G. W., Nielsen-Leroux, C., Yang, Y., Yuan, Z., Dumas, V. F., Monnerat, R. G., Colin Berry, C. A new Cry toxin with a unique two-component dependency from Bacillus sphaericus.	Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, Wales; Inst Pasteur, Dept Microbiol, Paris, France; Chinese Acad Sci, Wuhan Inst Virol, Wuhan, Peoples R China; Parque Estacao Biol, Embrapa Recursos Genet & Biotecnol, Brasilia, DF, Brazil	Cardiff University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Chinese Academy of Sciences; Wuhan Institute of Virology, CAS; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA)	Berry, C (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Museum Ave, Cardiff CF10 3US, Wales.	berry@cf.ac.uk	Berry, Colin/A-4338-2010; Yang, Yankun/AAJ-3032-2020	Berry, Colin/0000-0002-9943-548X; Yang, Yankun/0000-0003-4815-6832; Plummer, Beverley/0000-0002-6559-7237; Jones, Gareth/0000-0002-0125-4841				Agaisse H, 1996, MOL MICROBIOL, V20, P633, DOI 10.1046/j.1365-2958.1996.5401046.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; [Anonymous], 1971, PROBIT ANAL STAT TRE; ARANTES O, 1991, GENE, V108, P115, DOI 10.1016/0378-1119(91)90495-W; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; Baum JA, 2004, APPL ENVIRON MICROB, V70, P4889, DOI 10.1128/AEM.70.8.4889-4898.2004; BAUMANN L, 1988, J BACTERIOL, V170, P2045, DOI 10.1128/jb.170.5.2045-2050.1988; Bocs S, 2003, NUCLEIC ACIDS RES, V31, P3723, DOI 10.1093/nar/gkg590; BROADWELL AH, 1986, APPL ENVIRON MICROB, V52, P758, DOI 10.1128/AEM.52.4.758-764.1986; Charles JF, 1997, FEMS MICROBIOL LETT, V156, P153, DOI 10.1016/S0378-1097(97)00419-9; CLARK MA, 1990, J BACTERIOL, V172, P6759, DOI 10.1128/jb.172.12.6759-6763.1990; Cokmus C, 1997, J INVERTEBR PATHOL, V69, P197, DOI 10.1006/jipa.1997.4660; DAVIDSON EW, 1990, CAN J MICROBIOL, V36, P870, DOI 10.1139/m90-151; de Maagd RA, 2003, ANNU REV GENET, V37, P409, DOI 10.1146/annurev.genet.37.110801.143042; Ellis RT, 2002, APPL ENVIRON MICROB, V68, P1137, DOI 10.1128/AEM.68.3.1137-1145.2002; Gammon K, 2006, APPL ENVIRON MICROB, V72, P1766, DOI 10.1128/AEM.72.3.1766-1770.2006; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; Helgason E, 2000, APPL ENVIRON MICROB, V66, P2627, DOI 10.1128/AEM.66.6.2627-2630.2000; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JW, 1996, APPL ENVIRON MICROB, V62, P2174, DOI 10.1128/AEM.62.6.2174-2176.1996; MAHILLON J, 1994, GENETICA, V93, P13, DOI 10.1007/BF01435236; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; Marchler-Bauer A, 2004, NUCLEIC ACIDS RES, V32, pW327, DOI 10.1093/nar/gkh454; Masson L, 2004, BIOCHEMISTRY-US, V43, P12349, DOI 10.1021/bi048946z; Monnerat RG, 2007, BIOL CONTROL, V41, P291, DOI 10.1016/j.biocontrol.2006.11.008; NICOLAS L, 1993, FEMS MICROBIOL LETT, V106, P275, DOI 10.1111/j.1574-6968.1993.tb05976.x; Nielsen-LeRoux C, 2001, APPL ENVIRON MICROB, V67, P5049, DOI 10.1128/AEM.67.11.5049-5054.2001; OEI C, 1992, J GEN MICROBIOL, V138, P1515, DOI 10.1099/00221287-138-7-1515; OEI C, 1990, FEMS MICROBIOL LETT, V72, P265, DOI 10.1111/j.1574-6968.1990.tb03900.x; Park HW, 1999, FEMS MICROBIOL LETT, V181, P319, DOI 10.1111/j.1574-6968.1999.tb08862.x; Park HW, 2005, AM J TROP MED HYG, V72, P732, DOI 10.4269/ajtmh.2005.72.732; Pei GF, 2002, APPL ENVIRON MICROB, V68, P3003, DOI 10.1128/AEM.68.6.3003-3009.2002; RUPAR MJ, 2003, NUCL ACIDS ENCODING; Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944; Schwartz JL, 2001, J MEMBRANE BIOL, V184, P171, DOI 10.1007/s00232-001-0086-1; Silva MHNL, 2004, FEMS MICROBIOL LETT, V241, P185, DOI 10.1016/j.femsle.2004.10.018; Silva-Filha MH, 1999, INSECT BIOCHEM MOLEC, V29, P711, DOI 10.1016/S0965-1748(99)00047-8; SILVAFILHA MH, 1995, J ECON ENTOMOL, V88, P525, DOI 10.1093/jee/88.3.525; SINEGRE G, 1994, 8 EUR M SOC VECT EC, P17; Smith AW, 2005, J INVERTEBR PATHOL, V88, P27, DOI 10.1016/j.jip.2004.10.005; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THANABALU T, 1991, J BACTERIOL, V173, P2776, DOI 10.1128/JB.173.9.2776-2785.1991; Thanabalu T, 1996, GENE, V170, P85, DOI 10.1016/0378-1119(95)00836-5; Thomas DJI, 2000, APPL ENVIRON MICROB, V66, P118, DOI 10.1128/AEM.66.1.118-124.2000; Thomas DJI, 2001, APPL ENVIRON MICROB, V67, P330, DOI 10.1128/AEM.67.1.330-338.2001; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tran LB, 2001, APPL ENVIRON MICROB, V67, P4488, DOI 10.1128/AEM.67.10.4488-4494.2001; Wirth MC, 2004, J MED ENTOMOL, V41, P935, DOI 10.1603/0022-2585-41.5.935; Yuan ZM, 2003, MED VET ENTOMOL, V17, P251, DOI 10.1046/j.1365-2915.2003.00429.x; Yuan ZM, 2000, BIOCONTROL SCI TECHN, V10, P41, DOI 10.1080/09583150029378	50	54	60	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4112	4120		10.1096/fj.07-8913com	http://dx.doi.org/10.1096/fj.07-8913com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17646596				2022-12-28	WOS:000251283500036
J	Sakamoto, K; Honda, T; Yokoya, S; Waguri, S; Kimura, J				Sakamoto, Kazuho; Honda, Takashi; Yokoya, Sachihiko; Waguri, Satoshi; Kimura, Junko			Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers	FASEB JOURNAL			English	Article						HMG-CoA reductase inhibitors; isoprenylation; myopathy; rhabdomyolysis; skeletal muscle	COA REDUCTASE INHIBITORS; COENZYME Q(10); CELL-DEATH; MUSCLE; LOVASTATIN; MYOPATHY; PHARMACOKINETICS; CYCLOSPORINE; APOPTOSIS; LYSOPHOSPHATIDYLCHOLINE	Three-hydroxy-3-methyl-glutaryl-CoA (HMGCoA) reductase inhibitors, known as statins, induce skeletal muscle injury including myalgia, myositis, and rhabdo-myolysis. The mechanism of this myotoxicity remains unknown. This study examined the effect of statins on single skeletal myofibers enzymatically isolated from the rat flexor digitorum brevis muscles. Fluvastatin and pravastatin induced the formation of numerous vacuoles in the myofibers after 72 h of treatment. This effect progressed in a time- and concentration-dependent manner and, consequently, cell death occurred after 120 h. Electron micrographs revealed craters along the sarcolemma and swelling of the sarcoplasmic reticula and mitochondria, in addition to intracellular vacuoles. When caffeine was added after 72 h of fluvastatin treatment, contractile shortening of statin-treated myofibers was significantly attenuated and blebs formed on the surface of the myofibers. The coapplication of geranylgeranylpyro-phosphate (GGPP) with fluvastatin prevented the morphological changes, while that of farnesylpyrophosphate (FPP) was ineffective. Furthermore, perillyl alcohol, an inhibitor of Rab geranylgeranyl transferase and geranylgeranyl transferase-I (GGTase-I), mimicked the effect of statins, while a specific GGTase-I inhibitor (GGTI-298) or a farnesyl transferase inhibitor (FTI-277) failed to do so. These results suggest that the inactivation of Rab GTPase, which involved in intracellular membrane transport, is a crucial factor in statin-induced-morphological abnormality in skeletal muscle fibers.-Sakamoto, K., Honda, T., Yokoya, S., Waguri, S., Kimura, J. Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers.	Fukushima Med Univ, Sch Med, Dept Pharmacol, Fukushima 9601295, Japan; Fukushima Med Univ, Sch Med, Dept Cell Sci, Fukushima 9601295, Japan; Fukushima Med Univ, Sch Med, Dept Anat & Histol, Fukushima 9601295, Japan; Fukushima Med Univ, Sch Nursing, Dept Human Life Sci, Fukushima, Japan	Fukushima Medical University; Fukushima Medical University; Fukushima Medical University; Fukushima Medical University	Sakamoto, K (corresponding author), Fukushima Med Univ, Sch Med, Dept Pharmacol, Hikarigaoka 1, Fukushima 9601295, Japan.	kazuho@fmu.ac.jp						Alsheikh-Ali AA, 2005, CIRCULATION, V111, P3051, DOI 10.1161/CIRCULATIONAHA.105.555482; BEKOFF A, 1977, J PHYSIOL-LONDON, V271, P25, DOI 10.1113/jphysiol.1977.sp011988; Bergman M, 2003, J MUSCLE RES CELL M, V24, P417, DOI 10.1023/A:1027367022415; CARLSEN RC, 1985, CAN J PHYSIOL PHARM, V63, P958, DOI 10.1139/y85-158; CHUCRALLAH A, 1992, EUR NEUROL, V32, P293, DOI 10.1159/000116845; Cooper AA, 2006, SCIENCE, V313, P324, DOI 10.1126/science.1129462; Di Giovanni S, 2001, NEUROLOGY, V57, P515, DOI 10.1212/WNL.57.3.515; Dirks AJ, 2006, AM J PHYSIOL-CELL PH, V291, pC1208, DOI 10.1152/ajpcell.00226.2006; ENDO A, 1992, J LIPID RES, V33, P1569; Farmer JA, 2001, LANCET, V358, P1383, DOI 10.1016/S0140-6736(01)06489-3; FOLKERS K, 1990, P NATL ACAD SCI USA, V87, P8931, DOI 10.1073/pnas.87.22.8931; Goalstone ML, 1999, J BIOL CHEM, V274, P2880, DOI 10.1074/jbc.274.5.2880; GREENSPAN MD, 1988, DRUG METAB DISPOS, V16, P678; Grosshans BL, 2006, P NATL ACAD SCI USA, V103, P11821, DOI 10.1073/pnas.0601617103; Hargreaves IP, 2005, DRUG SAFETY, V28, P659, DOI 10.2165/00002018-200528080-00002; Holdaas H, 2006, INT J CLIN PHARM TH, V44, P163; Ichihara K, 2002, LANCET, V359, P2195, DOI 10.1016/S0140-6736(02)09098-0; Ivessa NE, 1997, J BIOL CHEM, V272, P20828, DOI 10.1074/jbc.272.33.20828; Kaufmann P, 2006, CELL MOL LIFE SCI, V63, P2415, DOI 10.1007/s00018-006-6235-z; Kivisto KT, 1998, BRIT J CLIN PHARMACO, V46, P49, DOI 10.1046/j.1365-2125.1998.00034.x; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kyrklund C, 2004, BRIT J CLIN PHARMACO, V57, P181, DOI 10.1046/j.1365-2125.2003.01972.x; LAAKSONEN R, 1995, CLIN PHARMACOL THER, V57, P62, DOI 10.1016/0009-9236(95)90266-X; Lackner MR, 2005, CANCER CELL, V7, P325, DOI 10.1016/j.ccr.2005.03.024; Lane KT, 2006, J LIPID RES, V47, P681, DOI 10.1194/jlr.R600002-JLR200; Leung KF, 2006, J LIPID RES, V47, P467, DOI 10.1194/jlr.R500017-JLR200; Levy HB, 2006, ANN PHARMACOTHER, V40, P290, DOI 10.1345/aph.1G409; Li LB, 2002, MOL PHARMACOL, V62, P602, DOI 10.1124/mol.62.3.602; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Lindahl A, 1996, CLIN PHARMACOL THER, V60, P493, DOI 10.1016/S0009-9236(96)90145-9; Maeda S, 2005, MOL PHARMACOL, V68, P414, DOI 10.1124/mol.104.000786; Matsuyama K, 2002, BIOL PHARM BULL, V25, P346, DOI 10.1248/bpb.25.346; Matzno S, 2005, J PHARM PHARMACOL, V57, P1475, DOI 10.1211/jpp.57.11.0014; Matzno S, 1997, J LIPID RES, V38, P1639; Naba Hiroyasu, 2004, Drug Metab Pharmacokinet, V19, P339, DOI 10.2133/dmpk.19.339; Nakagawa H, 1998, FEBS LETT, V438, P289, DOI 10.1016/S0014-5793(98)01320-9; Nakahara K, 1998, TOXICOL APPL PHARM, V152, P99, DOI 10.1006/taap.1998.8491; NAKAHARA K, 1994, BIOCHEM BIOPH RES CO, V202, P1579, DOI 10.1006/bbrc.1994.2112; Nishimoto T, 2003, BIOCHEM PHARMACOL, V66, P2133, DOI 10.1016/j.bcp.2003.08.011; Ogata Y, 2002, J CARDIOVASC PHARM, V40, P907, DOI 10.1097/00005344-200212000-00012; Omar MA, 2002, ANN PHARMACOTHER, V36, P288, DOI 10.1345/aph.1A289; Park JW, 2002, INT J CLIN PHARM TH, V40, P439; Ren ZB, 1997, BIOCHEM PHARMACOL, V54, P113, DOI 10.1016/S0006-2952(97)00151-2; Rosenson RS, 2004, AM J MED, V116, P408, DOI 10.1016/j.amjmed.2003.10.033; Schaefer WH, 2004, TOXICOL APPL PHARM, V194, P10, DOI 10.1016/j.taap.2003.08.013; Seachrist JL, 2005, TOXICOL SCI, V88, P551, DOI 10.1093/toxsci/kfi305; SERAJUDDIN ATM, 1991, J PHARM SCI, V80, P830, DOI 10.1002/jps.2600800905; Shitara Y, 2006, PHARMACOL THERAPEUT, V112, P71, DOI 10.1016/j.pharmthera.2006.03.003; Smith CC, 2003, ARCH INTERN MED, V163, P688, DOI 10.1001/archinte.163.6.688; SMITH PF, 1991, J PHARMACOL EXP THER, V257, P1225; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Thompson PD, 1997, METABOLISM, V46, P1206, DOI 10.1016/S0026-0495(97)90218-3; Ucar M, 2000, DRUG SAFETY, V22, P441, DOI 10.2165/00002018-200022060-00003; WACLAWIK AJ, 1993, J NEUROPATH EXP NEUR, V52, P542, DOI 10.1097/00005072-199309000-00012; Westwood FR, 2005, TOXICOL PATHOL, V33, P246, DOI 10.1080/01926230590908213; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; Yokoyama K, 2002, CIRCULATION, V105, P962, DOI 10.1161/hc0802.104457	58	50	51	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4087	4094		10.1096/fj.07-8713com	http://dx.doi.org/10.1096/fj.07-8713com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17634390				2022-12-28	WOS:000251283500033
J	Wexler-Cohen, Y; Shai, Y				Wexler-Cohen, Yael; Shai, Yechiel			Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition	FASEB JOURNAL			English	Article						HIV-1 inhibition; lipopeptides; coiled coil; T-20; virus entry; envelope protein; heptad repeat; peptide-membrane interaction	VIRAL MEMBRANE-FUSION; VIRUS TYPE-1 GP41; CELL-CELL FUSION; IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; SYNTHETIC PEPTIDE; MECHANISM; ENTRY; SURFACE; ECTODOMAIN	The core complex is a structure involved in the fusion mechanism of many viruses, as well as in intracellular vesicle fusion. A powerful approach for studying the dynamic stages of HIV-1-cell fusion utilizes DP178, a core complex inhibitory peptide derived from the known sequence of the virus. Strikingly, we show that fatty acids can replace the entire C-terminal region of DP178, known to play a crucial role in the activity of the peptide. The inhibitory activity correlated with the length of the fatty acid, with the direction of fatty acid attachment (N-or C-terminus) and, as envisioned by a new triple staining assay, with the concentration of the peptides on cells. Our findings indicate, for the first time, the C-terminal boundary of the endogenous core structure in situ and establish that the C-terminal region of DP178 functions mainly as an anchor to the cell membrane. Apart from the mechanistic implications, such short lipopeptides provide new, promising fusion inhibitors. Because the fusion mechanism of HIV-1 is shared by other pathogen-enveloped viruses and by intracellular vesicle fusion, our results might influence the research and therapeutic efforts in these systems as well.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	yechiel.shai@weizmann.ac.il						Center RJ, 2002, J VIROL, V76, P7863, DOI 10.1128/JVI.76.15.7863-7867.2002; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Clapham PR, 2002, J GEN VIROL, V83, P1809, DOI 10.1099/0022-1317-83-8-1809; Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Gerber D, 2004, J BIOL CHEM, V279, P48224, DOI 10.1074/jbc.M403436200; Huerta L, 2002, CYTOMETRY, V47, P100, DOI 10.1002/cyto.10051; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Judice JK, 1997, P NATL ACAD SCI USA, V94, P13426, DOI 10.1073/pnas.94.25.13426; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; LaBranche CC, 2001, ANTIVIR RES, V50, P95, DOI 10.1016/S0166-3542(01)00130-9; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M411141200; Melikyan GB, 2006, J VIROL, V80, P3249, DOI 10.1128/JVI.80.7.3249-3258.2006; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Peisajovich SG, 2003, J BIOL CHEM, V278, P21012, DOI 10.1074/jbc.M212773200; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Ryu JR, 1999, BIOCHEM BIOPH RES CO, V265, P625, DOI 10.1006/bbrc.1999.1739; Sal-Man N, 2004, J MOL BIOL, V344, P855, DOI 10.1016/j.jmb.2004.09.066; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; Sollner TH, 2004, CURR OPIN CELL BIOL, V16, P429, DOI 10.1016/j.ceb.2004.06.015; Steger HK, 2006, J BIOL CHEM, V281, P25813, DOI 10.1074/jbc.M601457200; WEISS A, 1984, J IMMUNOL, V133, P123; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Wexler-Cohen Y, 2006, J BIOL CHEM, V281, P9005, DOI 10.1074/jbc.M512475200; WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Zanetti G, 2006, PLOS PATHOG, V2, DOI 10.1371/journal.ppat.0020083; Zhang CWH, 2001, J BIOL CHEM, V276, P39577, DOI 10.1074/jbc.M107147200; Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817	33	74	80	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3677	3684		10.1096/fj.07-8582com	http://dx.doi.org/10.1096/fj.07-8582com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17575260				2022-12-28	WOS:000250517800029
J	Liu, YL; Li, M; Warburton, RR; Hill, NS; Fanburg, BL				Liu, Yinglin; Li, Min; Warburton, Rod R.; Hill, Nicholas S.; Fanburg, Barry L.			The 5-HT transporter transactivates the PDGF beta receptor in pulmonary artery smooth muscle cells	FASEB JOURNAL			English	Article						serotonin; pulmonary hypertension	PROTEIN-TYROSINE PHOSPHATASES; GROWTH-FACTOR; SEROTONIN TRANSPORTER; SIGNALING PATHWAY; COUPLED RECEPTORS; MESANGIAL CELLS; IN-VITRO; HYPERTENSION; ACTIVATION; HYPERPLASIA	Serotonin ( 5- HT) stimulates smooth muscle cell growth through 5- HT receptors and the 5- HT transporter ( 5- HTT), and has been associated with pulmonary hypertension ( PH). Platelet- derived growth factor receptors ( PDGFR) have also been associated with PH. We present evidence for the first time that 5- HT transactivates PDGFR beta through the 5- HTT in pulmonary artery ( PA) SMCs. Inhibition of PDGFR kinase with imatinib or AG1296 blocks 5- HT- stimulated PDGFR beta phosphorylation. 5- HTT inhibitors and the Na +/ K +- ATPase inhibitor ouabain, but not 5- HT2 and 5- HT1B/ 1D receptor inhibitors, block PDGFR beta activation by 5- HT. Notably, 5- HTT binds the PDGFR beta upon 5- HT stimulation and the 5- HTT inhibitor fluoxetine blocks both the binding and PDGDR beta activation. Activation of PDGFR beta may occur through oxidation of a catalytic cysteine of tyrosine phosphatase. 5- HT- activated PDGFR beta phosphorylation is blocked by the antioxidant N- acetyl- L- cysteine and the NADPH oxidase inhibitor, DPI. Inhibition of PDGFR kinase with imatinib or AG1296 significantly inhibits SMC proliferation and migration induced by 5- HT in vitro. Infusion of 5- HT by miniosmotic pumps enhances PDGFR beta activation in mouse lung in vivo. In summary, these results demonstrate that 5- HT transactivates PDGFR beta in PASMCs leading to SMC proliferation and migration, and may be an important signaling pathway in the production of PH in vivo.	Tufts Univ, New England Med Ctr, Pulm Crit Care & Sleep Div, Tupper Res Inst, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Fanburg, BL (corresponding author), Tufts Univ, New England Med Ctr, Pulm Crit Care & Sleep Div, Tupper Res Inst, 750 Washington St,257, Boston, MA 02111 USA.	bfanburg@tufts-nemc.org			NHLBI NIH HHS [R01 HL32723] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032723] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balasubramaniam V, 2003, AM J PHYSIOL-LUNG C, V284, pL826, DOI 10.1152/ajplung.00199.2002; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BOSIN TR, 1990, BIOCHEM PHARMACOL, V40, P723, DOI 10.1016/0006-2952(90)90307-7; Buchdunger E, 2002, EUR J CANCER, V38, pS28, DOI 10.1016/S0959-8049(02)80600-1; Chen CH, 2006, MOL PHARMACOL, V69, P1347, DOI 10.1124/mol.105.017558; Choi MH, 2005, NATURE, V435, P347, DOI 10.1038/nature03587; Choudhury GG, 2006, CELL SIGNAL, V18, P1854, DOI 10.1016/j.cellsig.2006.02.003; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Day RM, 2006, BIOCHEM PHARMACOL, V71, P386, DOI 10.1016/j.bcp.2005.10.035; DeMali KA, 1999, J BIOL CHEM, V274, P19551, DOI 10.1074/jbc.274.28.19551; Eddahibi S, 1999, CIRC RES, V84, P329, DOI 10.1161/01.RES.84.3.329; Eddahibi S, 2003, CIRCULATION, V108, P1839, DOI 10.1161/01.CIR.0000091409.53101.E8; Eddahibi S, 2001, J CLIN INVEST, V108, P1141, DOI 10.1172/JCI12805; FANBURG BL, 1997, AM J PHYSIOL, V272, P795; Gooz M, 2006, J BIOL CHEM, V281, P21004, DOI 10.1074/jbc.M512096200; Groen A, 2005, J BIOL CHEM, V280, P10298, DOI 10.1074/jbc.M412424200; HERVE P, 1995, AM J MED, V99, P249, DOI 10.1016/S0002-9343(99)80156-9; Lampugnani MG, 1999, METH MOL B, V96, P177; LEE SL, 1991, CIRC RES, V68, P1362, DOI 10.1161/01.RES.68.5.1362; Lee SL, 1999, AM J PHYSIOL-LUNG C, V277, pL282, DOI 10.1152/ajplung.1999.277.2.L282; Lee SL, 1998, FREE RADICAL BIO MED, V24, P855, DOI 10.1016/S0891-5849(97)00359-6; Liu YL, 2006, AM J RESP CELL MOL, V34, P182, DOI 10.1165/rcmb.2005-0163OC; Liu YL, 2004, CIRC RES, V95, P579, DOI 10.1161/01.RES.0000141428.53262.a4; Long L, 2006, CIRC RES, V98, P818, DOI 10.1161/01.RES.0000215809.47923.fd; Lowes VL, 2002, NEUROSIGNALS, V11, P5, DOI 10.1159/000057317; Marcos E, 2004, CIRC RES, V94, P1263, DOI 10.1161/01.RES.0000126847.27660.69; Meng TC, 2005, METHODS, V35, P28, DOI 10.1016/j.ymeth.2004.07.005; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P2591, DOI 10.1073/pnas.050282397; Olivares-Reyes JA, 2005, MOL PHARMACOL, V68, P356, DOI 10.1124/mol.104.010637; Ormond J, 2004, NEURON, V44, P715, DOI 10.1016/j.neuron.2004.11.001; Popescu LM, 2006, EUR J PHARMACOL, V546, P177, DOI 10.1016/j.ejphar.2006.06.068; RAMMAOORTHY S, 1999, SCIENCE, V285, P763; Saito Y, 2001, J MOL CELL CARDIOL, V33, P3, DOI 10.1006/jmcc.2000.1272; Schermuly RT, 2005, J CLIN INVEST, V115, P2811, DOI 10.1172/JCI24838; Simon AR, 2005, CELL BIOCHEM BIOPHYS, V42, P263, DOI 10.1385/CBB:42:3:263; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Zanatta LM, 2001, BRAZ J MED BIOL RES, V34, P1265, DOI 10.1590/S0100-879X2001001000005	38	62	64	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2725	2734		10.1096/fj.06-8058com	http://dx.doi.org/10.1096/fj.06-8058com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17504974				2022-12-28	WOS:000249237500014
J	Nakanishi, K; Dohmae, N; Morishima, N				Nakanishi, Keiko; Dohmae, Naoshi; Morishima, Nobuhiro			Endoplasmic reticulum stress increases myofiber formation in vitro	FASEB JOURNAL			English	Article						apoptosis; Bcl-xL; caspase-12; IGF-II; myoblast	GROWTH-FACTOR-II; UNFOLDED PROTEIN RESPONSE; SKELETAL-MUSCLE; ER STRESS; INDUCED APOPTOSIS; STRIATED-MUSCLE; DNA-SYNTHESIS; CELL-DEATH; INSULIN; DIFFERENTIATION	Myoblast differentiation involves myoblast fusion followed by myofiber formation. We recently demonstrated that endoplasmic reticulum (ER) stress signaling occurs during myoblast differentiation in vivo. This signaling results in apoptosis in a subpopulation of myoblasts. In a cell culture model of myogenesis, inhibition of ER stress signaling blocked apoptosis and myoblast differentiation. To further examine the role of ER stress during myogenesis, we exposed cultured myoblasts to ER stress inducers during the transition from proliferation to differentiation. The stress inducers tunicamycin (an inhibitor of N-glycosylation in the ER) and thapsigargin (an inhibitor of ER-specific calcium ATPase) were used at doses that induce 40-50% apoptosis in myoblast cultures. Increased ER stress enhanced differentiation-associated apoptosis of myoblasts. It is likely that apoptosis induced by ER stress selectively eliminates vulnerable cells. We found that the surviving myoblast cells were even more resistant to apoptosis. Remarkably, the surviving cells efficiently differentiated into contracting myofibers that are rarely found in culture models of myogenesis. Our observations suggest that ER stress exerts a positive effect on myofiber formation, possibly mimicking the action of signals that drive apoptosis and differentiation in vivo. These results may provide important insight for developing therapies to improve myofiber formation.-Nakanishi, K., Dohmae, N., Morishima, N. Endoplasmic reticulum stress increases myofiber formation in vitro.	RIKEN, Biomol Characterizat Team, Wako, Saitama 3510198, Japan; RIKEN, Bioarchitect Res Grp, Wako, Saitama 3510198, Japan	RIKEN; RIKEN	Morishima, N (corresponding author), RIKEN, Biomol Characterizat Team, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	morishim@postman.riken.jp	Dohmae, Naoshi/C-2040-2011; Morishima, Nobuhiro/D-3946-2017; Nakanishi, Keiko/B-9963-2013	Dohmae, Naoshi/0000-0002-5242-9410; 				Bach AD, 2004, J CELL MOL MED, V8, P413, DOI 10.1111/j.1582-4934.2004.tb00466.x; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; COUSINS JC, 2000, PRINCIPLES TISSUE EN; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DELAGUILA LF, 1999, AM J PHYSIOL, V276, pE845; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; Friedman AD, 1996, CANCER RES, V56, P3250; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; HANEWINKEL H, 1987, J BIOL CHEM, V262, P12351; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Lawlor MA, 2000, J CELL BIOL, V151, P1131, DOI 10.1083/jcb.151.6.1131; Miller JB, 1999, CURR TOP DEV BIOL, V43, P191; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Morishima N, 2004, J BIOL CHEM, V279, P50375, DOI 10.1074/jbc.M408493200; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakanishi K, 2005, J CELL BIOL, V169, P555, DOI 10.1083/jcb.200412024; Neville C, 1997, METHOD CELL BIOL, V52, P85, DOI 10.1016/S0091-679X(08)60375-1; OKA Y, 1985, J BIOL CHEM, V260, P9435; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; ONTELL M, 1984, AM J ANAT, V171, P133, DOI 10.1002/aja.1001710202; Polesskaya A, 2002, DEV CELL, V3, P757, DOI 10.1016/S1534-5807(02)00372-6; Powell CA, 2002, AM J PHYSIOL-CELL PH, V283, pC1557, DOI 10.1152/ajpcell.00595.2001; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; ROSEN KM, 1993, ENDOCRINOLOGY, V133, P474, DOI 10.1210/en.133.2.474; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; STOCKDALE F, 1961, EXP CELL RES, V24, P508, DOI 10.1016/0014-4827(61)90450-5; STOCKDALE FE, 1992, DEV BIOL, V154, P284, DOI 10.1016/0012-1606(92)90068-R; Sultan KR, 2006, AM J PHYSIOL-CELL PH, V290, pC650, DOI 10.1152/ajpcell.00163.2005; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vandenburgh H, 1996, HUM GENE THER, V7, P2195, DOI 10.1089/hum.1996.7.17-2195; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	43	80	84	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2994	3003		10.1096/fj.06-6408com	http://dx.doi.org/10.1096/fj.06-6408com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17435177				2022-12-28	WOS:000249237500039
J	Omerovic, J; Santangelo, L; Puggioni, EMR; Marrocco, J; Dall'Armi, C; Palumbo, C; Belleudi, F; Di Marcotullio, L; Frati, L; Torrisi, MR; Cesareni, G; Gulino, A; Alimandi, M				Omerovic, Jasminka; Santangelo, Laura; Puggioni, Eleonora Maria-Rosaria; Marrocco, Jordan; Dall'Armi, Claudia; Palumbo, Camilla; Belleudi, Francesca; Di Marcotullio, Lucia; Frati, Luigi; Torrisi, Maria-Rosaria; Cesareni, Gianni; Gulino, Alberto; Alimandi, Maurizio			The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation	FASEB JOURNAL			English	Article						negative regulators; ubiquitin ligase; nuclear translocation	GROWTH-FACTOR RECEPTOR; WW DOMAIN; TYROSINE KINASES; PROTEIN LIGASE; ITCH; P73; UBIQUITYLATION; ENDOCYTOSIS; ISOFORM; GENE	The ErbB- 4 receptors are unique in the EGFR/ ErbB family for the ability to associate with WW domain- containing proteins. To identify new ligands of the cytoplasmic tail of ErbB- 4, we panned a brain cDNA phage library with ErbB- 4 peptides containing sequence motifs corresponding to putative docking sites for class- I WW domains. This approach led to identification of AIP4/ Itch, a member of the Nedd4- like family of E3 ubiquitin protein ligases, as a protein that specifically interacts with and ubiquitinates ErbB- 4 in vivo. Interaction with the ErbB- 4 receptors occurs via the WW domains of AIP4/ Itch. Functional analyses demonstrate that AIP4/ Itch is recruited to the ErbB- 4 receptor to promote its polyubiquitination and degradation, thereby regulating stability of the receptor and access of receptor intracellular domains to the nuclear compartment. These findings expand our understanding of the mechanisms contributing to the integrity of the ErbB signaling network and mechanistically link the cellular ubiquitination pathway of AIP4/ Itch to the ErbB- 4 receptor.	Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dept Biol, I-00173 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00173 Rome, Italy; Neuromed Inst, Isernia, Italy; Azienda Ospedaliera Sant Andrea, Rome, Italy; IRCCS, Ist Dermatol Sant Maria & San Gallicano, Rome, Italy; Ist Regina Elena, Ctr Ric Sperimentale, I-00161 Rome, Italy	Sapienza University Rome; University of Rome Tor Vergata; University of Rome Tor Vergata; IRCCS Neuromed; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Alimandi, M (corresponding author), Univ Roma La Sapienza, Dept Expt Med & Pathol, Viale Regina Elena 324, I-00161 Rome, Italy.	maurizio.alimandi@uniroma1.it	Omerovic, Jasminka/D-4998-2017; Cesareni, Gianni/AAW-1382-2020; Frati, Luigi/ABI-7437-2020; Alimandi, Maurizio/AAG-9246-2019	Alimandi, Maurizio/0000-0002-1409-6803; Marrocco, Jordan/0000-0001-8357-5288; DI MARCOTULLIO, LUCIA/0000-0003-0274-7178; Palumbo, Camilla/0000-0001-5087-7140				Angers A, 2004, J BIOL CHEM, V279, P11471, DOI 10.1074/jbc.M309934200; Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Baulida J, 1996, J BIOL CHEM, V271, P5251; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510; Diamonti AJ, 2002, P NATL ACAD SCI USA, V99, P2866, DOI 10.1073/pnas.052709799; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; Ferretti E, 2006, ONCOGENE, V25, P7267, DOI 10.1038/sj.onc.1209716; Gallagher E, 2006, P NATL ACAD SCI USA, V103, P1717, DOI 10.1073/pnas.0510664103; Gallo RM, 2006, BIOCHEM BIOPH RES CO, V349, P372, DOI 10.1016/j.bbrc.2006.08.055; Gilbertson R, 2001, GENE CHROMOSOME CANC, V31, P288, DOI 10.1002/gcc.1146; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hughes DPM, 2004, CANCER RES, V64, P2047, DOI 10.1158/0008-5472.CAN-03-3096; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Linggi B, 2006, ONCOGENE, V25, P160, DOI 10.1038/sj.onc.1209003; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Omerovic J, 2004, EXP CELL RES, V294, P469, DOI 10.1016/j.yexcr.2003.12.002; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Qiu XB, 2002, P NATL ACAD SCI USA, V99, P14843, DOI 10.1073/pnas.232580999; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Rubin C, 2005, CELL RES, V15, P66, DOI 10.1038/sj.cr.7290268; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155	39	62	62	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2849	2862		10.1096/fj.06-7925com	http://dx.doi.org/10.1096/fj.06-7925com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17463226				2022-12-28	WOS:000249237500026
J	Patel, HH; Zhang, S; Murray, F; Suda, RYS; Head, BP; Yokoyama, U; Swaney, JS; Niesman, IR; Schermuly, RT; Pullamsetti, SS; Thistlethwaite, PA; Miyanohara, A; Farquhar, MG; Yuan, JXJ; Insel, PA				Patel, Hemal H.; Zhang, Shen; Murray, Fiona; Suda, Ryan Y. S.; Head, Brian P.; Yokoyama, Utako; Swaney, James S.; Niesman, Ingrid R.; Schermuly, Ralph T.; Pullamsetti, Soni Savai; Thistlethwaite, Patricia A.; Miyanohara, Atsushi; Farquhar, Marilyn G.; Yuan, Jason X. -J.; Insel, Paul A.			Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension	FASEB JOURNAL			English	Article						statins; calcium; primary pulmonary hypertension; secondary pulmonary hypertension	NITRIC-OXIDE SYNTHASE; PROTEIN-COUPLED RECEPTOR; P42/44 MAP KINASE; PLASMA-MEMBRANE; CHOLESTEROL DEPLETION; SIGNAL-TRANSDUCTION; LIPID RAFTS; NULL MICE; IN-VIVO; DOMAIN	Vasoconstriction and vascular medial hypertrophy, resulting from increased intracellular [Ca2+] in pulmonary artery smooth muscle cells (PASMC), contribute to elevated vascular resistance in patients with idiopathic pulmonary arterial hypertension (IPAH). Caveolae, microdomains within the plasma membrane, contain the protein caveolin, which binds certain signaling molecules. We tested the hypothesis that PASMC from IPAH patients express more caveolin-1 (Cav-1) and caveolae, which contribute to increased capacitative Ca2+ entry (CCE) and DNA synthesis. Immunohistochemistry showed increased expression of Cav-1 in smooth muscle cells but not endothelial cells of pulmonary arteries from patients with IPAH. Subcellular fractionation and electron microscopy confirmed the increase in Cav-1 and caveolae expression in IPAH-PASMC. Treatment of IPAHPASMC with agents that deplete membrane cholesterol (methyl-beta-cyclodextrin or lovastatin) disrupted caveolae, attenuated CCE, and inhibited DNA synthesis of IPAH-PASMC. Increasing Cav-1 expression of normal PASMC with a Cav-1-encoding adenovirus increased caveolae formation, CCE, and DNA synthesis; treatment of IPAH-PASMC with siRNA targeted to Cav-1 produced the opposite effects. Treatments that down-regulate caveolin/caveolae expression, including cholesterol-lowering drugs, reversed the increased CCE and DNA synthesis in IPAH-PASMC. Increased caveolin and caveolae expression thus contribute to IPAHPASMC pathophysiology. The close relationship between caveolin/caveolae expression and altered cell physiology in IPAH contrast with previous results obtained in various animal models, including caveolin-knockout mice, thus emphasizing unique features of the human disease. The results imply that disruption of caveolae in PASMC may provide a novel therapeutic approach to attenuate disease manifestations of IPAH.-Patel, H. H., Zhang, S., Murray, F., Suda, R. Y. S., Head, B. P., Yokoyama, U., Swaney, J. S., Niesman, I. R., Schermuly, R. T., Savai Pullamsetti, S., Thistlethwaite, P. A., Miyanohara, A., Farquhar, M. G., Yuan, J. X.-J., Insel, P. A. Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Surg, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Gene Therapy Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Univ Giessen, Lung Ctr, Med Clin 2 5, Giessen, Germany	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Justus Liebig University Giessen	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr,BSB 3076, La Jolla, CA 92093 USA.	pinsel@ucsd.edu	Yokoyama, Utako/AAD-1404-2022; Patel, Hemal/C-7325-2019	Yokoyama, Utako/0000-0003-1803-0155; Schermuly, Ralph/0000-0002-5167-6970; Patel, Hemal/0000-0001-6722-9625; Murray, Fiona/0000-0002-5572-4810; Suda, Ryan/0000-0002-1115-4561; Niesman, Ingrid/0000-0001-9767-6629; Pullamsetti, Soni Savai/0000-0003-0440-8831	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066941, F32HL074625, R01HL066012, R01HL064945] Funding Source: NIH RePORTER; NCI NIH HHS [CA10076] Funding Source: Medline; NHLBI NIH HHS [R01 HL066012, HL66012, HL74625, HL66941, HL64945] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Achcar ROD, 2006, CHEST, V129, P696, DOI 10.1378/chest.129.3.696; Bayer-Garner I, 2002, MODERN PATHOL, V15, P1, DOI 10.1038/modpathol.3880481; Brazer SCW, 2003, J BIOL CHEM, V278, P27208, DOI 10.1074/jbc.M301118200; Campian ME, 2006, N-S ARCH PHARMACOL, V373, P391, DOI 10.1007/s00210-006-0087-9; Capozza F, 2005, AM J PHYSIOL-CELL PH, V288, pC677, DOI 10.1152/ajpcell.00232.2004; Christian AE, 1997, J LIPID RES, V38, P2264; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V284, pC457, DOI 10.1152/ajpcell.00380.2002; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; Deng ZM, 2000, AM J HUM GENET, V67, P737, DOI 10.1086/303059; Dudzinski DM, 2006, ANNU REV PHARMACOL, V46, P235, DOI 10.1146/annurev.pharmtox.44.101802.121844; Eddahibi S, 2002, EUR RESPIR J, V20, P1559, DOI 10.1183/09031936.02.00081302; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Farber HW, 2004, NEW ENGL J MED, V351, P1655, DOI 10.1056/NEJMra035488; Feron O, 2006, CARDIOVASC RES, V69, P788, DOI 10.1016/j.cardiores.2005.12.014; Feron O, 2001, CIRC RES, V88, P129; Feron O, 1998, J BIOL CHEM, V273, P30249, DOI 10.1074/jbc.273.46.30249; Fine SW, 2001, AM J CLIN PATHOL, V115, P719; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Gaine S, 2000, JAMA-J AM MED ASSOC, V284, P3160, DOI 10.1001/jama.284.24.3160; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Geraci MW, 2001, CIRC RES, V88, P555, DOI 10.1161/01.RES.88.6.555; Girgis RE, 2003, AM J PHYSIOL-HEART C, V285, pH938, DOI 10.1152/ajpheart.01097.2002; Gratton JP, 2004, CIRC RES, V94, P1408, DOI 10.1161/01.RES.0000129178.56294.17; Hardin CD, 2006, CARDIOVASC RES, V69, P808, DOI 10.1016/j.cardiores.2005.11.024; Head BP, 2005, J BIOL CHEM, V280, P31036, DOI 10.1074/jbc.M502540200; Humbert M, 2004, NEW ENGL J MED, V351, P1425, DOI 10.1056/NEJMra040291; Insel PA, 2007, BRIT J PHARMACOL, V150, P251, DOI 10.1038/sj.bjp.0706981; Jasmin JF, 2006, CIRCULATION, V114, P912, DOI 10.1161/CIRCULATIONAHA.106.634709; Jasmin JF, 2004, CARDIOVASC RES, V63, P747, DOI 10.1016/j.cardiores.2004.05.018; Jones KA, 2004, EXP CELL RES, V295, P512, DOI 10.1016/j.yexcr.2004.01.022; Kamoun WS, 2006, HEPATOLOGY, V43, P182, DOI 10.1002/hep.20940; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; Kato K, 2002, CANCER, V94, P929, DOI 10.1002/cncr.10329.abs; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Li LK, 2001, CANCER RES, V61, P4386; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Machado RD, 2001, AM J HUM GENET, V68, P92, DOI 10.1086/316947; Mathew R, 2004, CIRCULATION, V110, P1499, DOI 10.1161/01.CIR.0000141576.39579.23; McLaughlin VV, 2006, CIRCULATION, V114, P1417, DOI 10.1161/CIRCULATIONAHA.104.503540; McNally EM, 1998, HUM MOL GENET, V7, P871, DOI 10.1093/hmg/7.5.871; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; Nishimura T, 2003, CIRCULATION, V108, P1640, DOI 10.1161/01.CIR.0000087592.47401.37; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; Peng Y, 2004, MOL BIOL CELL, V15, P384, DOI 10.1091/mbc.e03-06-0445; Raikar LS, 2006, J CELL BIOCHEM, V98, P861, DOI 10.1002/jcb.20732; Rajjayabun PH, 2001, UROLOGY, V58, P811, DOI 10.1016/S0090-4295(01)01337-1; Ramos M, 2006, VASC PHARMACOL, V44, P50, DOI 10.1016/j.vph.2005.09.007; Razani B, 2001, J BIOL CHEM, V276, P38121; Rong JX, 2003, P NATL ACAD SCI USA, V100, P13531, DOI 10.1073/pnas.1735526100; Rubin LJ, 2002, AM J RESP CRIT CARE, V166, P1308, DOI 10.1164/rccm.2208008; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Timme TL, 2000, ONCOGENE, V19, P3256, DOI 10.1038/sj.onc.1203654; Williams TM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-214; Yang G, 2000, CLIN CANCER RES, V6, P3430; Yu Y, 2004, P NATL ACAD SCI USA, V101, P13861, DOI 10.1073/pnas.0405908101; Yu Y, 2003, AM J PHYSIOL-CELL PH, V284, pC316, DOI 10.1152/ajpcell.00125.2002; Zhao YY, 2002, P NATL ACAD SCI USA, V99, P11375, DOI 10.1073/pnas.172360799	66	94	101	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2970	2979		10.1096/fj.07-8424com	http://dx.doi.org/10.1096/fj.07-8424com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17470567				2022-12-28	WOS:000249237500037
J	Lee, WC; Tsoi, YK; Troendle, FJ; DeLucia, MW; Ahmed, Z; Dicky, CA; Dickson, DW; Eckman, CB				Lee, Wing C.; Tsoi, Yuen K.; Troendle, Frederick J.; DeLucia, Michael W.; Ahmed, Zeshan; Dicky, Chad A.; Dickson, Dennis W.; Eckman, Christopher B.			Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy	FASEB JOURNAL			English	Article						Krabbe disease; enzyme replacement therapy; psychosine; twitcher	TWITCHER MOUSE; PSYCHOSINE CYTOTOXICITY; PHORBOL ESTER; MURINE MODEL; GLIAL-CELLS; GALACTOSYLSPHINGOSINE; OLIGODENDROCYTES; TRANSPLANTATION; REPLACEMENT; EXPRESSION	Globoid cell leukodystrophy ( GLD), also known as Krabbe disease, is a devastating, degenerative neurological disorder. It is inherited as an autosomal recessive trait caused by loss-of-function mutations in the galactocerebrosidase ( GALC) gene. Previously, we have shown that peripheral injection of recombinant GALC, administered every other day, results in a substantial improvement in early clinical phenotype in the twitcher mouse model of GLD. While we did detect active enzyme in the brain following peripheral administration, most of the administered enzyme was localized to the periphery. Given the substantial central nervous system ( CNS) involvement in this disease, we were interested in determining whether or not a single-dose administration of the recombinant enzyme directly to the CNS, which could potentially be achieved clinically, would result in any substantial improvement. Following intracerebroventricular ( icv) administration of GALC we noted a significant, 16.5%, reduction in the GALC substrate psychosine, the abnormal accumulation of which is believed to play a pivotal role in the CNS pathology observed in this disease. Moreover, recombinant GALC was found not only in periventricular regions but also at sites distant to the injection such as the cerebral cortex and cerebellum. Most importantly, animals receiving a single icv dose of the enzyme at postnatal day 20 survived up to 51 days, which compares favorably to the control twitcher animals, which normally only live to postnatal day 40/42. These results indicate that even a single icv administration of the recombinant enzyme can have significant clinical impact and suggests that other lysosomal storage disorders with significant CNS involvement may similarly benefit.	Mayo Clin Jacksonville, Coll Med, Dept Pharmacol, Jacksonville, FL 32224 USA; Mayo Clin Jacksonville, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic	Eckman, CB (corresponding author), Mayo Clin Jacksonville, Coll Med, Dept Pharmacol, Birdsall Bldg Rm 327,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	eckman@mayo.edu	Ahmed, Zeshan/E-6225-2011	Lee, Chris/0000-0001-9068-5274; Dickson, Dennis W/0000-0001-7189-7917				Caniglia M, 2002, PEDIATR TRANSPLANT, V6, P427, DOI 10.1034/j.1399-3046.2002.02026.x; DUCHEN LW, 1980, BRAIN, V103, P695, DOI 10.1093/brain/103.3.695; Escolar ML, 2005, NEW ENGL J MED, V352, P2069, DOI 10.1056/NEJMoa042604; GAL AE, 1977, CLIN CHIM ACTA, V77, P53, DOI 10.1016/0009-8981(77)90401-6; Haq E, 2003, J NEUROCHEM, V86, P1428, DOI 10.1046/j.1471-4159.2003.01941.x; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; Jatana M, 2002, NEUROSCI LETT, V330, P183, DOI 10.1016/S0304-3940(02)00655-9; Kanazawa T, 2000, J CELL BIOL, V149, P943, DOI 10.1083/jcb.149.4.943; KOBAYASHI T, 1980, BRAIN RES, V202, P479, DOI 10.1016/0006-8993(80)90159-6; KOLODNY EH, 1996, HDB CLIN NEUROLOGY, V22, P187; Kondo Y, 2005, P NATL ACAD SCI USA, V102, P18670, DOI 10.1073/pnas.0506473102; Krivit W, 1998, NEW ENGL J MED, V338, P1119, DOI 10.1056/NEJM199804163381605; Lee WC, 2005, FASEB J, V19, P1549, DOI 10.1096/fj.05-3826fje; Lee WC, 2006, NEUROBIOL DIS, V23, P273, DOI 10.1016/j.nbd.2006.03.005; Luddi A, 2001, NEUROBIOL DIS, V8, P600, DOI 10.1006/nbdi.2001.0407; OLMSTEAD CE, 1987, BEHAV BRAIN RES, V25, P143, DOI 10.1016/0166-4328(87)90007-6; Rafi MA, 1996, BIOCHEM MOL MED, V58, P142, DOI 10.1006/bmme.1996.0042; Sakai N, 1996, J NEUROCHEM, V66, P1118, DOI 10.1046/j.1471-4159.1996.66031118.x; Scriver C.R., 2001, METABOLIC MOL BASES, P3669; SHAPIRO E, 1991, TREATMENT GENETIC DI, P223; Shen JS, 2002, J NEUROSCI RES, V68, P588, DOI 10.1002/jnr.10247; SUGAMA S, 1990, PEDIATR RES, V28, P473, DOI 10.1203/00006450-199011000-00011; SUGAMA S, 1991, BRAIN DEV-JPN, V13, P104, DOI 10.1016/S0387-7604(12)80116-1; SUZUKI K, 1989, METABOLIC BASIS INHE, P1699; TANAKA K, 1993, J NEUROPATH EXP NEUR, V52, P490, DOI 10.1097/00005072-199309000-00007; TANAKA K, 1989, BRAIN RES, V482, P347, DOI 10.1016/0006-8993(89)91198-0; Taniike M, 1999, J NEUROPATH EXP NEUR, V58, P644, DOI 10.1097/00005072-199906000-00009; Tohyama J, 2001, NEUROCHEM RES, V26, P667, DOI 10.1023/A:1010991420942; Wenger D.A., 1997, MOL GENETIC BASIS NE, P421; Wenger DA, 2000, MOL GENET METAB, V70, P1, DOI 10.1006/mgme.2000.2990; Zaka M, 2004, NEUROSCI LETT, V358, P205, DOI 10.1016/j.neulet.2003.12.126	31	76	86	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2520	2527		10.1096/fj.06-6169com	http://dx.doi.org/10.1096/fj.06-6169com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17403939				2022-12-28	WOS:000248454400026
J	Caprio, M; Feve, B; Claes, A; Viengchareun, S; Lombes, M; Zennaro, MC				Caprio, Massimiliano; Feve, Bruno; Claes, Aurelie; Viengchareun, Say; Lombes, Marc; Zennaro, Maria-Christina			Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis	FASEB JOURNAL			English	Article						adipocyte differentiation; aldosterone; glucocorticoids; nuclear receptors	ADIPOSE CONVERSION; GLUCOCORTICOID RECEPTOR; VISCERAL OBESITY; BROWN ADIPOCYTES; GENE-EXPRESSION; 3T3-L1 CELLS; DIFFERENTIATION; DEHYDROGENASE; ACTIVATION; COREPRESSOR	In addition to their role in controlling water and salt homeostasis, recent work suggests that aldosterone and mineralocorticoid receptors (MR) may be involved in adipocyte biology. This is of particular relevance given the role of MR as a high-affinity receptor for both mineralocorticoids and glucocorticoids. We have thus examined the effect of aldosterone and MR on white adipose cell differentiation. When cells are cultured in a steroid-free medium, aldosterone promotes acquisition of the adipose phenotype of 3T3-L1 and 3T3-F442A cells in a time-, dose-, and MR-dependent manner. In contrast, late and long-term exposure to dexamethasone inhibits adipocyte terminal maturation. The aldosterone effect on adipose maturation was accompanied by induction of PPAR gamma mRNA expression, which was blocked by the MR antagonist spironolactone. Under permissive culture conditions, specific MR down-regulation by siRNAs markedly inhibited 3T3-L1 differentiation by interfering with the transcriptional control of adipogenesis, an effect not mimicked by specific inactivation of the glucocorticoid receptor. These results demonstrate that MR represents an important proadipogenic transcription factor that may mediate both aldosterone and glucocorticoid effects on adipose tissue development. MR thus may be of pathophysiological relevance to the development of obesity and the metabolic syndrome.	Coll France, INSERM, U7721, F-75005 Paris, France; INSERM, U693, Fac Med Paris Sud, Le Kremlin Bicetre, France; Univ Paris 11, Orsay, France; Univ Roma Tor Vergata, Chair Endocrinol, Dept Internal Med, Rome, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; University of Rome Tor Vergata	Zennaro, MC (corresponding author), Coll France, INSERM, U7721, 11,Pl M Berthelot, F-75005 Paris, France.	maria-christina.zennaro@college-de-france.fr	Caprio, Massimiliano/J-3020-2012; Viengchareun, Say/GOV-6812-2022; Lombes, Marc/L-5933-2018; Zennaro, Maria-Christina/G-2841-2013; Viengchareun, Say/M-6612-2017	Caprio, Massimiliano/0000-0003-0722-7163; Lombes, Marc/0000-0003-3189-023X; Zennaro, Maria-Christina/0000-0001-5449-9191; Feve, Bruno/0000-0001-6577-9009; viengchareun, say/0000-0003-4280-3250				ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049; Bridgham JT, 2006, SCIENCE, V312, P97, DOI 10.1126/science.1123348; Ehrhart-Bornstein M, 2003, P NATL ACAD SCI USA, V100, P14211, DOI 10.1073/pnas.2336140100; Fallo F, 2006, J CLIN ENDOCR METAB, V91, P454, DOI 10.1210/jc.2005-1733; FEVE B, 1990, J BIOL CHEM, V265, P16343; FEVE B, 1989, MOL CELL ENDOCRINOL, V67, P17, DOI 10.1016/0303-7207(89)90226-8; Fu MG, 2005, MOL ENDOCRINOL, V19, P2437, DOI 10.1210/me.2004-0539; Funder JW, 2005, HEART FAIL REV, V10, P15, DOI 10.1007/s10741-005-2344-2; Gomez-Sanchez CE, 2006, ENDOCRINOLOGY, V147, P1343, DOI 10.1210/en.2005-0860; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; HAUNER H, 1989, J CLIN INVEST, V84, P1663, DOI 10.1172/JCI114345; Hellal-Levy C, 1999, FEBS LETT, V464, P9, DOI 10.1016/S0014-5793(99)01667-1; Hu X, 2006, MOL ENDOCRINOL, V20, P1471, DOI 10.1210/me.2005-0247; Kershaw EE, 2005, DIABETES, V54, P1023, DOI 10.2337/diabetes.54.4.1023; Kitagawa H, 2002, MOL CELL BIOL, V22, P3698, DOI 10.1128/MCB.22.11.3698-3706.2002; KOZAK LP, 1974, J BIOL CHEM, V249, P7775; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Morton NM, 2004, DIABETES, V53, P931, DOI 10.2337/diabetes.53.4.931; MOUSTAID N, 1990, J CELL BIOCHEM, V42, P243, DOI 10.1002/jcb.240420407; Newell-Price J, 2006, LANCET, V367, P1605, DOI 10.1016/S0140-6736(06)68699-6; PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138; Penfornis P, 2000, AM J PHYSIOL-ENDOC M, V279, pE386, DOI 10.1152/ajpendo.2000.279.2.E386; RONDINONE CM, 1993, ENDOCRINOLOGY, V132, P2421, DOI 10.1210/en.132.6.2421; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; Sohn YC, 2003, MOL ENDOCRINOL, V17, P366, DOI 10.1210/me.2002-0150; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Viengchareun S, 2001, AM J PHYSIOL-ENDOC M, V280, pE640, DOI 10.1152/ajpendo.2001.280.4.E640; Yang XY, 2006, CELL, V126, P801, DOI 10.1016/j.cell.2006.06.050; Zelcer N, 2006, J CLIN INVEST, V116, P607, DOI 10.1172/JCI27883; Zennaro MC, 1998, J CLIN INVEST, V101, P1254, DOI 10.1172/JCI1915; Zennaro MC, 2001, MOL ENDOCRINOL, V15, P1586, DOI 10.1210/me.15.9.1586	36	238	256	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					2185	2194		10.1096/fj.06-7970com	http://dx.doi.org/10.1096/fj.06-7970com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17384139				2022-12-28	WOS:000247500300027
J	Knobloch, J; Shaughnessy, JD; Ruther, U				Knobloch, Juergen; Shaughnessy, John D., Jr.; Ruether, Ulrich			Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway	FASEB JOURNAL			English	Article						limb truncations; microphthalmia; teratogenic mechanism; programmed cell death	APICAL ECTODERMAL RIDGE; PROGRAMMED CELL-DEATH; BETA-CATENIN; TERATOGENIC ACTIVITY; HEAD INDUCTION; CHICK EMBRYO; P53; DICKKOPF-1; MECHANISM; ACTIVATION	Thalidomide, a sedative originally used to treat morning sickness and now used to treat leprosy and multiple myeloma, is also a teratogen that induces birth defects in humans such as limb truncations and microphthalmia. However, the teratogenic mechanism of action of this drug remains obscure. Thalidomide induces limb and eye defects in the chicken embryo at an EC50 of 50 mu g/kg egg wt and apoptosis in primary human embryonic fibroblasts ( HEFs) at an EC50 of 8.9 mu M. Using these model systems, we demonstrate by semiquantitative reverse transcriptase- polymerase chain reaction and whole- mount in situ hybridization that thalidomide- induced oxidative stress enhances signaling through bone morphogenetic proteins ( Bmps). This leads to up- regulation of the Bmp target gene and Wnt antagonist Dickkopf1 ( Dkk1) with subsequent inhibition of canonical Wnt/beta-catenin signaling and increased cell death as shown by trypan blue and terminal deoxynucleotidyl transferase- mediated nick end labeling staining. Thalidomide- induced cell death was dramatically reduced in HEFs and in embryonic limb buds by the use of inhibitors against Bmps, Dkk1, and Gsk3 beta, a beta-catenin antagonist acting downstream of Dkk1 in the Wnt pathway. Most interestingly, blocking of Dkk1 or Gsk3 beta dramatically counteracts thalidomideinduced limb truncations and microphthalmia. From this, we conclude that perturbing of Bmp/ Dkk1/ Wnt signaling is central to the teratogenic effects of thalidomide.	Univ Dusseldorf, Inst Entwicklungs & Mol Biol Tiere, D-40225 Dusseldorf, Germany; Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Donna D & Donald M Lambert Lab Myeloma Genet, Little Rock, AR 72205 USA	Heinrich Heine University Dusseldorf; University of Arkansas System; University of Arkansas Medical Sciences	Knobloch, J (corresponding author), Univ Dusseldorf, Inst Entwicklungs & Mol Biol Tiere, Univ Str 1, D-40225 Dusseldorf, Germany.	ruether@uni-duesseldorf.de		Knobloch, Jurgen/0000-0001-6868-0055	NCI NIH HHS [CA-55819, CA-97513] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055819, R33CA097513] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn K, 2001, DEVELOPMENT, V128, P4449; Aslan M, 2003, ANTIOXID REDOX SIGN, V5, P781, DOI 10.1089/152308603770380089; Barthel A, 2005, BIOL CHEM, V386, P207, DOI 10.1515/BC.2005.026; Beck HN, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-12; BLASCHKE G, 1979, ARZNEIMITTEL-FORSCH, V29-2, P1640; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chiarugi P, 2005, FREE RADICAL RES, V39, P353, DOI 10.1080/10715760400027987; COILA S, 2007, IN PRESS BLOOD; DEBOCK CA, 1963, NATURE, V199, P1204, DOI 10.1038/1991204a0; FABRO S, 1964, LIFE SCI, V3, P987, DOI 10.1016/0024-3205(64)90109-2; FABRO S, 1965, NATURE, V208, P1208, DOI 10.1038/2081208a0; FABRO S, 1967, NATURE, V215, P296, DOI 10.1038/215296a0; Francis JM, 2000, J BIOL CHEM, V275, P39137, DOI 10.1074/jbc.M007212200; Franz Wolfgang, 2000, PERSPEKTIVEN WIRTSCH, V1, P53, DOI DOI 10.1111/1468-2516.00005; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966; Hagen T, 2004, BIOCHEM J, V379, P471, DOI 10.1042/BJ20031749; Hansen JM, 2004, ANTIOXID REDOX SIGN, V6, P1, DOI 10.1089/152308604771978291; KEMPER F, 1962, LANCET, V2, P836; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KNOCHE B, 1994, J CHROMATOGR A, V666, P235, DOI 10.1016/0021-9673(94)80385-4; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LENZ W, 1988, TERATOLOGY, V38, P203, DOI 10.1002/tera.1420380303; Maass M, 2000, HERZ, V25, P68, DOI 10.1007/PL00001953; Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; MELLIN GW, 1962, NEW ENGL J MED, V267, P1238, DOI 10.1056/NEJM196212132672407; Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534-5807(01)00041-7; NEWMAN LM, 1993, REPROD TOXICOL, V7, P359, DOI 10.1016/0890-6238(93)90025-3; Parman T, 1999, NAT MED, V5, P582, DOI 10.1038/8466; Pizette S, 1999, DEVELOPMENT, V126, P883; Qiang YW, 2003, ONCOGENE, V22, P1536, DOI 10.1038/sj.onc.1206239; SAUNDERS JW, 1972, ANN NY ACAD SCI, V193, P29, DOI 10.1111/j.1749-6632.1972.tb27821.x; Schardein J., 1993, CHEM INDUCED BIRTH D; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Shin SY, 2004, CANCER LETT, V212, P225, DOI 10.1016/j.canlet.2004.03.003; SMITHELLS RW, 1992, J MED GENET, V29, P716, DOI 10.1136/jmg.29.10.716; Stephens TD, 2000, BIOCHEM PHARMACOL, V59, P1489, DOI 10.1016/S0006-2952(99)00388-3; Trousse F, 2001, J NEUROSCI, V21, P1292; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Wells Peter G, 2005, Toxicol Appl Pharmacol, V207, P354, DOI 10.1016/j.taap.2005.01.061; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wolpert L, 2002, INT J DEV BIOL, V46, P869; WOLPERT L, 1979, J EMBRYOL EXP MORPH, V50, P175; Yamamoto M, 1996, CANCER-AM CANCER SOC, V77, P1628, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1628::AID-CNCR31>3.3.CO;2-Z; Yokouchi Y, 1996, DEVELOPMENT, V122, P3725; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191; Zuzarte-Luis V, 2004, DEV BIOL, V272, P39, DOI 10.1016/j.ydbio.2004.04.015; ZWILLING E, 1955, J EXP ZOOL, V128, P423, DOI 10.1002/jez.1401280304	50	95	97	0	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1410	1421		10.1096/fj.06-7603com	http://dx.doi.org/10.1096/fj.06-7603com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17283219				2022-12-28	WOS:000246117000017
J	Voskoboynik, A; Simon-Blecher, N; Soen, Y; Rinkevich, B; De Tomaso, AW; Ishizuka, KJ; Weissman, IL				Voskoboynik, Ayelet; Simon-Blecher, Noa; Soen, Yoav; Rinkevich, Baruch; De Tomaso, Anthony W.; Ishizuka, Katherine J.; Weissman, Irving L.			Striving for normality: whole body regeneration through a series of abnormal generations	FASEB JOURNAL			English	Article						vascular budding; blastogenesis; development; tunicate	ASCIDIAN BOTRYLLUS-SCHLOSSERI; BILATERAL ASYMMETRY; STEM-CELLS; BUDS; POLARITY; PALLEAL; DEATH	Embryogenesis and asexual reproduction are commonly considered to be coordinated developmental processes, which depend on accurate progression through a defined sequence of developmental stages. Here we report a peculiar developmental scenario in a simple chordate, Botryllus schlosseri, wherein a normal colony of individuals ( zooids and buds) is regenerated from the vasculature ( vascular budding) through a sequence of morphologically abnormal developmental stages. Vascular budding was induced by surgically removing buds and zooids from B. schlosseri colonies, leaving only the vasculature and the tunic that connects them. In vivo imaging and histological sections showed that the timing and morphology of developing structures during vascular budding deviated significantly from other asexual reproduction modes ( the regular asexual reproduction mode in this organism and vascular budding in other botryllid species). Subsequent asexual reproduction cycles exhibited gradual regaining of normal developmental patterns, eventually leading to regeneration of a normal colony. The conversion into a normal body form suggests the activation of an alternative pathway of asexual reproduction, which involves gradual regaining of normal positional information. It presents a powerful model for studying the specification of the same body plan by different developmental programs.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Hopkins Marine Stn, Dept Biol, Pacific Grove, CA USA; Natl Inst Oceanog Oceanog & Limnol Res, Haifa, Israel; Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Stanford University; Bar Ilan University; Stanford University	Voskoboynik, A (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.	ayeletv@stanford.edu	Palmer, Theo/GSI-6635-2022		NIDDK NIH HHS [R01 DK054762, R01-DK54762] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054762] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANCROFT FW, 1903, MARK ANNIVERSARY, V8, P147; Berrill N.J., 1975, P241; Berrill NJ, 1941, BIOL BULL-US, V80, P185, DOI 10.2307/1537596; Berrill NJ, 1941, BIOL BULL-US, V80, P169, DOI 10.2307/1537595; BERRILL NJ, 1950, TUNICATA ACCOUNT BRI, P1; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brien P., 1968, Advances in Morphogenesis, V7, P151; BURIGHEI P, 1976, Bollettino di Zoologia, V43, P293; Burighel P, 1997, MICROSCOPICAL ANATOM, V15, P221; Delsuc F, 2006, NATURE, V439, P965, DOI 10.1038/nature04336; DESANTO RS, 1969, J ULTRA MOL STRUCT R, V28, P259, DOI 10.1016/S0022-5320(69)90084-7; FREEMAN G, 1971, J EXP ZOOL, V178, P433, DOI 10.1002/jez.1401780403; FUJIMOTO H, 1976, J MORPHOL, V150, P607, DOI 10.1002/jmor.1051500302; FUKUMOTO M, 1971, DEV GROWTH DIFFER, V13, P73; GILBERT SF, 2000, DEV BIOL, P121; GRETCHEN LH, 1967, ANIMAL TISSUE TECHNI, P14; IZZARD CS, 1973, J MORPHOL, V139, P1, DOI 10.1002/jmor.1051390102; Laird DJ, 2005, CELL, V123, P1351, DOI 10.1016/j.cell.2005.10.026; LAUZON RJ, 1992, DEV DYNAM, V194, P71, DOI 10.1002/aja.1001940109; LAUZON RJ, 1993, CELL TISSUE RES, V272, P115, DOI 10.1007/BF00323577; Manni L, 2006, BIOESSAYS, V28, P902, DOI 10.1002/bies.20462; MILKMAN R, 1967, BIOL BULL, V132, P229, DOI 10.2307/1539891; MILKMAN R, 1961, BIOL BULL, V121, P376; MILLAR RH, 1971, ADV MAR BIOL, V9, P1, DOI 10.1016/S0065-2881(08)60341-7; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; MUKAI H, 1976, Science Reports of the Faculty of Education Gunma University, V25, P61; NAKAUCHI M, 1974, Reports of the Usa Marine Biological Station, V21, P29; NAKAUCHI M, 1974, Reports of the Usa Marine Biological Station, V21, P19; NAKAUCHI M, 1978, BIOL BULL, V154, P453, DOI 10.2307/1541071; Nakauchi M., 1990, Advances in Invertebrate Reproduction, V5, P49; NAKAUCHI M, 1986, ADV INVERTEBRATE REP, P49; OKA H, 1957, BIOL BULL, V112, P225, DOI 10.2307/1539200; OKA H, 1959, BIOL BULL, V117, P340, DOI 10.2307/1538913; Okuyama M, 2001, ZOOL SCI, V18, P261, DOI 10.2108/zsj.18.261; RINKEVICH B, 1995, P NATL ACAD SCI USA, V92, P7695, DOI 10.1073/pnas.92.17.7695; RINKEVICH B, 1987, BIOL BULL, V173, P474, DOI 10.2307/1541694; Rinkevich B., 1996, INVERTEBRATE CELL CU, P1; ROBERTSON EJ, 1987, TERATOCARCINOMAS EMB, P1; Rossi DJ, 2006, CELL, V125, P229, DOI 10.1016/j.cell.2006.04.006; SABBADIN A, 1982, AM ZOOL, V22, P765; Sabbadin A., 1956, Rendiconti Accad Lincei (8), V20, P659; SABBADIN A, 1975, DEV BIOL, V46, P79, DOI 10.1016/0012-1606(75)90088-3; SATOH N, 1994, DEV BIOL ASCIDIANS, P169; Tiozzo S, 2005, DEV DYNAM, V232, P468, DOI 10.1002/dvdy.20250; Watanabe H., 1953, SCI REP TOKYO BUNRIK, V7, P183; WATKINS MJ, 1958, BIOL BULL, V115, P147, DOI 10.2307/1539101; WOLPERT L, 2001, PRINCIPLES DEV	47	56	57	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1335	1344		10.1096/fj.06-7337com	http://dx.doi.org/10.1096/fj.06-7337com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17289924				2022-12-28	WOS:000246117000009
J	Costin, GE; Hearing, VJ				Costin, Gertrude-E.; Hearing, Vincent J.			Human skin pigmentation: melanocytes modulate skin color in response to stress	FASEB JOURNAL			English	Review						hyperpigmentation; UV radiation; aging; melanocyte photoprotection	ESTROGEN-RECEPTOR-BETA; CULTURED HUMAN MELANOCYTES; STEM-CELL FACTOR; PROOPIOMELANOCORTIN-DERIVED PEPTIDES; FIBROBLAST-GROWTH-FACTOR; ULTRAVIOLET-B RADIATION; HUMAN KERATINOCYTES; STIMULATING FACTOR; HUMAN EPIDERMIS; CYCLIC-AMP	All organisms, from simple invertebrates to complex human beings, exist in different colors and patterns, which arise from the unique distribution of pigments throughout the body. Pigmentation is highly heritable, being regulated by genetic, environmental, and endocrine factors that modulate the amount, type, and distribution of melanins in the skin, hair, and eyes. In addition to its roles in camouflage, heat regulation, and cosmetic variation, melanin protects against UV radiation and thus is an important defense system in human skin against harmful factors. Being the largest organ of the body that is always under the influence of internal and external factors, the skin often reacts to those agents by modifying the constitutive pigmentation pattern. The focus of this review is to provide an updated overview of important physiological and biological factors that increase pigmentation and the mechanisms by which they do so. We consider endocrine factors that induce temporary ( e. g., during pregnancy) or permanent ( e. g., during aging) changes in skin color, environmental factors ( e. g., UV), certain drugs, and chemical compounds, etc. Understanding the mechanisms by which different factors and compounds induce melanogenesis is of great interest pharmaceutically ( as therapy for pigmentary diseases) and cosmeceutically ( e. g., to design tanning products with potential to reduce skin cancer risk).	Avon Prod Inc, New Technol Dept, Global R&D, Suffern, NY 10901 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	Avon Products; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Costin, GE (corresponding author), Avon Prod Inc, New Technol Dept, Global R&D, 1 Avon Pl, Suffern, NY 10901 USA.	gertrude.costin@avon.com			Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC010784, ZIABC010786, Z01BC010784, Z01BC010786] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Malek Z, 2000, PIGM CELL RES, V13, P156, DOI 10.1034/j.1600-0749.13.s8.28.x; ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; [Anonymous], DERMATOL GENET MED; Ashcroft GS, 1999, AM J PATHOL, V155, P1137, DOI 10.1016/S0002-9440(10)65217-0; Barankin B, 2002, J CUTAN MED SURG, V6, P236, DOI 10.1007/s10227-001-0045-240; Basrur V, 2003, J PROTEOME RES, V2, P69, DOI 10.1021/pr025562r; Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; Boissy RE, 1997, PIGM CELL RES, V10, P12, DOI 10.1111/j.1600-0749.1997.tb00461.x; BOLOGNIA J, 1999, ADV DERMATOL, V15, P341; Bolognia J L, 1993, Clin Geriatr Med, V9, P209; BOLOGNIA JL, 1995, AM J MED, V98, pS99, DOI 10.1016/S0002-9343(99)80066-7; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; Branza-Nichita N, 1999, BIOCHEM BIOPH RES CO, V261, P720, DOI 10.1006/bbrc.1999.1030; Breyer MD, 1996, J AM SOC NEPHROL, V7, P8; Busca R, 1998, MOL BIOL CELL, V9, P1367, DOI 10.1091/mbc.9.6.1367; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Carrasco MP, 1996, J CLIN ENDOCR METAB, V81, P2104, DOI 10.1210/jc.81.6.2104; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; CHIBA S, 1990, J BIOL CHEM, V265, P19777; COLEMAN RA, 1995, ADV PROSTAG THROMB L, V23, P283; Commo S, 2004, PIGM CELL RES, V17, P488, DOI 10.1111/j.1600-0749.2004.00170.x; Cone RD, 1996, RECENT PROG HORM RES, V51, P287; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; Elias PM, 2005, J INVEST DERMATOL, V125, P183, DOI 10.1111/j.0022-202X.2005.23668.x; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; FITZPATRICK T B, 1963, Dermatol Wochenschr, V147, P481; FITZPATRICK TB, 1959, J INVEST DERMATOL, V32, P197, DOI 10.1038/jid.1959.37; FRIEDMANN PS, 1990, J CELL PHYSIOL, V142, P334, DOI 10.1002/jcp.1041420216; Funasaka Y, 1998, BRIT J DERMATOL, V139, P216; Garland C F, 1993, Ann Epidemiol, V3, P103; Garland CF, 2003, ANN EPIDEMIOL, V13, P395, DOI 10.1016/S1047-2797(02)00461-1; GILCHREST BA, 1979, J INVEST DERMATOL, V73, P141, DOI 10.1111/1523-1747.ep12581580; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; Goh C. L., 1999, SMJ, V40, P455; GORDON PR, 1989, J INVEST DERMATOL, V93, P700, DOI 10.1111/1523-1747.ep12319900; Grimes PE, 2005, AM J DERMATOPATH, V27, P96, DOI 10.1097/01.dad.0000154419.18653.2e; HAAKE AR, 1999, DERMATOLOGY GEN MED, P70; Hachiya A, 2001, J INVEST DERMATOL, V116, P578, DOI 10.1046/j.1523-1747.2001.01290.x; Haczynski J, 2002, INT J MOL MED, V10, P149; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HALABAN R, 1993, ANN NY ACAD SCI, V680, P290, DOI 10.1111/j.1749-6632.1993.tb19691.x; HANSON D, 1990, J INVEST DERMATOL, V95, P158, DOI 10.1111/1523-1747.ep12477928; HARA M, 1995, J INVEST DERMATOL, V105, P744, DOI 10.1111/1523-1747.ep12325522; Hattori H, 2004, J INVEST DERMATOL, V122, P1256, DOI 10.1111/j.0022-202X.2004.22503.x; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; Hearing VJ, 2000, PIGM CELL RES, V13, P23, DOI 10.1034/j.1600-0749.13.s8.7.x; HEARING VJ, 1997, IBC LIB SERIES; Hirobe T, 2005, PIGM CELL RES, V18, P2, DOI 10.1111/j.1600-0749.2004.00198.x; HIROBE T, 1992, J CELL PHYSIOL, V152, P337, DOI 10.1002/jcp.1041520215; Im S, 2002, J KOREAN MED SCI, V17, P58, DOI 10.3346/jkms.2002.17.1.58; Im SB, 1998, CANCER RES, V58, P47; Imokawa G, 1998, BIOCHEM J, V330, P1235, DOI 10.1042/bj3301235; Imokawa G, 2000, J BIOL CHEM, V275, P33321, DOI 10.1074/jbc.M004346200; Imokawa G, 2004, PIGM CELL RES, V17, P96, DOI 10.1111/j.1600-0749.2003.00126.x; Imokawa G, 1996, BIOCHEM J, V314, P305, DOI 10.1042/bj3140305; IMOKAWA G, 1995, J INVEST DERMATOL, V105, P32, DOI 10.1111/1523-1747.ep12312500; IMOKAWA G, 1992, J BIOL CHEM, V267, P24675; Imokawa G, 1996, BIOCHEM J, V313, P625, DOI 10.1042/bj3130625; INSEL PA, 1975, SCIENCE, V190, P896, DOI 10.1126/science.171770; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Ito S, 2000, PIGM CELL RES, V13, P103, DOI 10.1034/j.1600-0749.13.s8.19.x; JEE SH, 1994, BIOCHEM BIOPH RES CO, V199, P1407, DOI 10.1006/bbrc.1994.1387; JIMBOW K, 1976, J INVEST DERMATOL, V67, P72, DOI 10.1111/1523-1747.ep12512500; Kadono S, 2001, J INVEST DERMATOL, V116, P571, DOI 10.1046/j.1523-1747.2001.01296.x; Kanda N, 2004, J INVEST DERMATOL, V123, P329, DOI 10.1111/j.0022-202X.2004.23231.x; Kanda N, 2004, J INVEST DERMATOL, V123, P319, DOI 10.1111/j.0022-202X.2004.12645.x; Kang WH, 2002, BRIT J DERMATOL, V146, P228, DOI 10.1046/j.0007-0963.2001.04556.x; Kippenberger S, 1998, J INVEST DERMATOL, V110, P364; Kobayashi N, 1998, J INVEST DERMATOL, V110, P806, DOI 10.1046/j.1523-1747.1998.00178.x; Kochevar Irene E., 1995, P51; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kushimoto T, 2001, P NATL ACAD SCI USA, V98, P10698, DOI 10.1073/pnas.191184798; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; LEVANTINE A, 1973, BRIT J DERMATOL, V89, P549, DOI 10.1111/j.1365-2133.1973.tb03024.x; LEVY H, 1982, S AFR MED J, V62, P735; Li-Stiles B, 1998, J LIPID RES, V39, P569; Lindelof B, 1999, BRIT J DERMATOL, V141, P108; Mann A, 2001, J INVEST DERMATOL, V117, P1382, DOI 10.1046/j.0022-202x.2001.01600.x; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; MCLEOD SD, 1994, J STEROID BIOCHEM, V49, P9, DOI 10.1016/0960-0760(94)90295-X; MOLOKHIA MM, 1973, BRIT J DERMATOL, V89, P207; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NORDLUND J J, 1985, Journal of Dermatology (Tokyo), V12, P105; NORDLUND JJ, 1986, J INVEST DERMATOL, V86, P433, DOI 10.1111/1523-1747.ep12285717; OKUDA K, 1992, BLOOD, V79, P2880; ORTONNE JP, 2003, FITZPATRICKS DERMATO, P836; Parker F, 1981, TXB ENDOCRINOLOGY, P1088; Pathak MA, 1995, MELANIN: ITS ROLE IN HUMAN PHOTOPROTECTION, P125; PATHAK MA, 1968, ARCH BIOCHEM BIOPHYS, V123, P468, DOI 10.1016/0003-9861(68)90168-9; PEACOCKE M, 1988, P NATL ACAD SCI USA, V85, P5282, DOI 10.1073/pnas.85.14.5282; Pelletier G, 2004, HISTOL HISTOPATHOL, V19, P629, DOI 10.14670/HH-19.629; PENTLAND AP, 1990, J CLIN INVEST, V86, P566, DOI 10.1172/JCI114746; PENTLAND AP, 1987, BIOCHIM BIOPHYS ACTA, V919, P71, DOI 10.1016/0005-2760(87)90219-0; PENTLAND AP, 1990, J INVEST DERMATOL, V94, P43, DOI 10.1111/1523-1747.ep12873337; Pierce KL, 1999, J BIOL CHEM, V274, P35944, DOI 10.1074/jbc.274.50.35944; Prota G., 1992, MELANINS MELANOGENES, P1; Punnonen R, 1972, Acta Obstet Gynecol Scand Suppl, V21, P3; RANSON M, 1988, J INVEST DERMATOL, V91, P593, DOI 10.1111/1523-1747.ep12477126; ROBINS AH, 1972, BRIT J PSYCHIAT, V121, P613, DOI 10.1192/bjp.121.6.613; ROBINS AH, 1991, BIOL PERSPECTIVES HU, P1; Schadow A, 2001, J INVEST DERMATOL, V116, P31, DOI 10.1046/j.1523-1747.2001.00179.x; SCHAUER E, 1994, J CLIN INVEST, V93, P2258, DOI 10.1172/JCI117224; Scott G, 2002, PIGM CELL RES, V15, P322, DOI 10.1034/j.1600-0749.2002.02056.x; Scott G, 2005, EXP CELL RES, V304, P407, DOI 10.1016/j.yexcr.2004.11.016; Scott G, 2004, J INVEST DERMATOL, V122, P1214, DOI 10.1111/j.0022-202X.2004.22516.x; Scott G, 2003, PIGM CELL RES, V16, P139, DOI 10.1034/j.1600-0749.2003.00022.x; Scott GA, 2006, J INVEST DERMATOL, V126, P855, DOI 10.1038/sj.jid.5700180; SEIJI M, 1963, ANN NY ACAD SCI, V100, P497, DOI 10.1111/j.1749-6632.1963.tb42911.x; Sies H, 2004, ANNU REV NUTR, V24, P173, DOI 10.1146/annurev.nutr.24.012003.132320; Slominski A, 2000, J CLIN ENDOCR METAB, V85, P3582, DOI 10.1210/jc.85.10.3582; SMITH AG, 1977, J INVEST DERMATOL, V68, P169, DOI 10.1111/1523-1747.ep12492633; Stern RS, 2001, J AM ACAD DERMATOL, V44, P755, DOI 10.1067/mjd.2001.114576; Stern RS, 1997, NEW ENGL J MED, V336, P1041, DOI 10.1056/NEJM199704103361501; Sturm RA, 1998, BIOESSAYS, V20, P712, DOI 10.1002/(SICI)1521-1878(199809)20:9<712::AID-BIES4>3.0.CO;2-I; SWOPE VB, 1995, EXP CELL RES, V217, P453, DOI 10.1006/excr.1995.1109; Tachibana M, 2000, PIGM CELL RES, V13, P230, DOI 10.1034/j.1600-0749.2000.130404.x; Tada A, 1998, CELL GROWTH DIFFER, V9, P575; Tadokoro T, 2003, FASEB J, V17, P1177, DOI 10.1096/fj.02-0865fje; Tadokoro T, 2003, PIGM CELL RES, V16, P190, DOI 10.1034/j.1600-0749.2003.00019.x; Taylor AH, 2000, J MOL ENDOCRINOL, V24, P145, DOI 10.1677/jme.0.0240145; Thornton MJ, 2005, EXPERT OPIN THER TAR, V9, P617, DOI 10.1517/14728222.9.3.617; Thornton MJ, 2003, J INVEST DERM SYMP P, V8, P100, DOI 10.1046/j.1523-1747.2003.12181.x; Tobin DJ, 2006, CHEM SOC REV, V35, P52, DOI 10.1039/b505793k; TOBIN DJ, 2002, 9 ANN EUR HAIR RES S; TODA K, 1972, NATURE-NEW BIOL, V236, P143, DOI 10.1038/newbio236143a0; TOMITA Y, 1987, J INVEST DERMATOL, V89, P299, DOI 10.1111/1523-1747.ep12471536; Toyofuku K, 2001, FASEB J, V15, P2149, DOI 10.1096/fj.01-0216com; Unver N, 2006, BRIT J DERMATOL, V155, P119, DOI 10.1111/j.1365-2133.2006.07210.x; URABE K, 1994, BBA-MOL CELL RES, V1221, P272, DOI 10.1016/0167-4889(94)90250-X; URANO R, 1995, J DERMATOL SCI, V9, P176, DOI 10.1016/0923-1811(94)00375-O; Verdier-Sevain S, 2004, FASEB J, V18, P1252, DOI 10.1096/fj.03-1088fje; Verdier-Sevrain S, 2006, EXP DERMATOL, V15, P83, DOI 10.1111/j.1600-0625.2005.00377.x; Wakamatsu K, 1997, PIGM CELL RES, V10, P288, DOI 10.1111/j.1600-0749.1997.tb00688.x; Wang SQ, 2001, J AM ACAD DERMATOL, V44, P767, DOI 10.1067/mjd.2001.112384; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; Xiao Fan Wang, 2003, IEEE Circuits and Systems Magazine, V3, P6, DOI 10.1109/MCAS.2003.1228503; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821; Yamaguchi Y, 2004, J CELL BIOL, V165, P275, DOI 10.1083/jcb.200311122; YOHN JJ, 1993, J INVEST DERMATOL, V100, P23, DOI 10.1111/1523-1747.ep12349932; Zecca L, 1996, NEUROSCIENCE, V73, P407, DOI 10.1016/0306-4522(96)00047-4	146	587	634	6	152	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					976	994		10.1096/fj.06-6649rev	http://dx.doi.org/10.1096/fj.06-6649rev			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17242160				2022-12-28	WOS:000245650400003
J	John, CD; Sahni, V; Mehet, D; Morris, JF; Christian, HC; Perretti, M; Flower, RJ; Solito, E; Buckingham, JC				John, C. D.; Sahni, V.; Mehet, D.; Morris, J. F.; Christian, H. C.; Perretti, M.; Flower, R. J.; Solito, E.; Buckingham, J. C.			Formyl peptide receptors and the regulation of ACTH secretion: targets for annexin A1, lipoxins, and bacterial peptides	FASEB JOURNAL			English	Article						glucocorticoids; annexin 1; pituitary; HPA axis; formyl peptides	ANTERIOR-PITUITARY GLAND; N-FORMYLPEPTIDE RECEPTOR; METHIONYL-LEUCYL-PHENYLALANINE; RAT PANCREATIC-ISLETS; PROTEIN-KINASE-C; LIPOCORTIN 1; IN-VITRO; CORTICOTROPIN RELEASE; INSULIN-SECRETION; CELL-LINE	The N-formyl peptide receptors (FPRs) are a family of G-protein coupled receptors that respond to proinflammatory N-formylated bacterial peptides ( e. g., formyl-Met-Leu-Phe, fMLF) and, thus, contribute to the host response to bacterial infection. Paradoxically, a growing body of evidence suggests that some members of this receptor family may also be targets for certain anti-inflammatory molecules, including annexin A1 (ANXA1), which is an important mediator of glucocorticoid ( GC) action. To explore further the potential role of FPRs in mediating ANXA1 actions, we have focused on the pituitary gland, where ANXA1 has a well-defined role as a cell-cell mediator of the inhibitory effects of GCs on the secretion of corticotrophin ( ACTH), and used molecular, genetic, and pharmacological approaches to address the question in well-established rodent models. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis identified mRNAs for four FPR family members in the mouse anterior pituitary gland, Fpr-rs1, Fpr-rs2, Fpr-rs6, and Fpr-rs7. Functional studies confirmed that, like dexamethasone, ANXA1 and two ANXA1-derived peptides (ANXA1(1-188) and ANXA1(Ac2-26)) inhibit the evoked release of ACTH from rodent anterior pituitary tissue in vitro. Fpr1 gene deletion failed to modify the pituitary responses to dexamethasone or ANXA1(Ac2-26). However, lipoxin A4 (LXA4, 0.02-2 mu M, a lipid mediator with high affinity for Fpr-rs1) mimicked the inhibitory effects of ANXA1 on ACTH release as also did fMLF in high (1-100 mu M) but not lower (10-100 nM) concentrations. Additionally, a nonselective FPR antagonist (Boc1, 100 mu M) overcame the effects of dexamethasone, ANXA1(1-188), ANXA1(Ac2-26), fMLF, and LXA4 on ACTH release, although at a lower concentration ( 50 mu M), it was without effect. Together, the results suggest that the actions of ANXA1 in the pituitary gland are independent of Fpr1 but may involve other FPR family members, in particular, Fpr-rs1 or a closely related receptor. They thus provide the first evidence for a role of the FPR family in the regulation of neuroendocrine function.	Univ London Imperial Coll Sci Technol & Med, Div Neurosci & Mental Hlth, Dept Cell Biol & Neurosci, London W12 0NN, England; Univ Oxford, Dept Human Anat & Genet, Oxford OX1 2JD, England; St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Ctr Biochem Pharmacol, London, England	Imperial College London; University of Oxford; University of London; Queen Mary University London	Buckingham, JC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Neurosci & Mental Hlth, Dept Cell Biol & Neurosci, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	j.buckingham@imperial.ac.uk		Solito, Egle/0000-0001-5279-0049	BBSRC [BB/E52708X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E52708X/1] Funding Source: Medline; Wellcome Trust [040269] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		AGUILERA G, 1983, J BIOL CHEM, V258, P8039; Altamura AC, 1999, EUR NEUROPSYCHOPHARM, V10, P1, DOI 10.1016/S0924-977X(99)00017-6; Becker EL, 1998, CELL TISSUE RES, V292, P129, DOI 10.1007/s004410051042; BUCK T, 1997, IEEE T EVOLUTIONARY, V1, P3; BUCKINGHAM JC, 1978, J PHYSL, V286, P331; CASTELLINO F, 1992, P NATL ACAD SCI USA, V89, P3775, DOI 10.1073/pnas.89.9.3775; Chapman L, 2002, ENDOCRINOLOGY, V143, P4330, DOI 10.1210/en.2002-220529; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Christian HC, 1997, ENDOCRINOLOGY, V138, P5341, DOI 10.1210/en.138.12.5341; COWELL AM, 1991, J ENDOCRINOL, V130, P21, DOI 10.1677/joe.0.1300021; dePaulis A, 1996, J ALLERGY CLIN IMMUN, V98, P152, DOI 10.1016/S0091-6749(96)70237-3; Ernst S, 2004, J IMMUNOL, V172, P7669, DOI 10.4049/jimmunol.172.12.7669; Fu HM, 2006, J LEUKOCYTE BIOL, V79, P247, DOI 10.1189/jlb.0905498; Gao JL, 1998, GENOMICS, V51, P270, DOI 10.1006/geno.1998.5376; Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657; Gavins FNE, 2003, BLOOD, V101, P4140, DOI 10.1182/blood-2002-11-3411; Gavins FNE, 2004, FASEB J, V18, P100, DOI 10.1096/fj.04-2178fje; Hartt JK, 1999, J EXP MED, V190, P741, DOI 10.1084/jem.190.5.741; Hayhoe RPG, 2006, BLOOD, V107, P2123, DOI 10.1182/blood-2005-08-3099; He R, 2000, J IMMUNOL, V165, P4598, DOI 10.4049/jimmunol.165.8.4598; Hetland G, 1998, J CLIN PATHOL-MOL PA, V51, P143, DOI 10.1136/mp.51.3.143; Holsboer F, 1996, ENDOCR REV, V17, P187, DOI 10.1210/er.17.2.187; Hong SH, 2002, FEBS LETT, V532, P17, DOI 10.1016/S0014-5793(02)03613-X; Iribarren P, 2005, IMMUNOL RES, V31, P165, DOI 10.1385/IR:31:3:165; John C, 2002, ENDOCRINOLOGY, V143, P3060, DOI 10.1210/en.143.8.3060; John CD, 2004, TRENDS ENDOCRIN MET, V15, P103, DOI 10.1016/j.tem.2004.02.001; KIM SJ, 1989, ANN NY ACAD SCI, V559, P461; Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; LUINI A, 1990, J NEUROCHEM, V54, P30, DOI 10.1111/j.1471-4159.1990.tb13279.x; Maderna P, 2002, AM J PATHOL, V160, P2275, DOI 10.1016/S0002-9440(10)61175-3; MARASCO WA, 1984, J BIOL CHEM, V259, P5430; OHNISHI M, 1995, ENDOCRINOLOGY, V136, P2421, DOI 10.1210/en.136.6.2421; Panaro MA, 1999, IMMUNOPHARM IMMUNOT, V21, P397, DOI 10.3109/08923979909007117; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Perretti M, 2001, AM J PATHOL, V158, P1969, DOI 10.1016/S0002-9440(10)64667-6; Philip JG, 1997, NEUROREPORT, V8, P1871, DOI 10.1097/00001756-199705260-00016; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; Rabiet MJ, 2005, EUR J IMMUNOL, V35, P2486, DOI 10.1002/eji.200526338; REES LH, 1971, ENDOCRINOLOGY, V89, P254, DOI 10.1210/endo-89-1-254; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; SEHRAN NC, 2005, CURR OPIN CLIN NUTR, V8, P115; SMITH ME, 1993, J ARCHAEOL RES, V1, P5; Smith T., 1993, Molecular Neuropharmacology, V3, P45; Solito E, 2003, ENDOCRINOLOGY, V144, P1164, DOI 10.1210/en.2002-220592; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; TAYLOR AD, 1993, NEUROENDOCRINOLOGY, V58, P430, DOI 10.1159/000126572; THEOGARAJ E, 2005, PERINATAL DEXAMETHAS; Traverso V, 1999, ENDOCRINOLOGY, V140, P4311, DOI 10.1210/en.140.9.4311; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8; Wang ZG, 2002, GENE, V299, P57, DOI 10.1016/S0378-1119(02)01012-0	52	29	29	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1037	1046		10.1096/fj.06-7299com	http://dx.doi.org/10.1096/fj.06-7299com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17218541	Green Accepted			2022-12-28	WOS:000245650400008
J	Spees, JL; Whitney, MJ; Sullivan, DE; Lasky, JA; Laboy, M; Ylostalo, J; Prockop, DJ				Spees, Jeffrey L.; Whitney, Mandolin J.; Sullivan, Deborah E.; Lasky, Joseph A.; Laboy, Miguel; Ylostalo, Joni; Prockop, Darwin J.			Bone marrow progenitor cells contribute to repair and remodeling of the lung and heart in a rat model of progressive pulmonary hypertension	FASEB JOURNAL			English	Article						stem cell; monocrotaline; cardiac hypertrophy	GENE-THERAPY; STROMAL CELLS; STEM-CELLS; TRANSPLANTATION; CHIMERISM; CARDIOMYOCYTES; DIFFERENTIATE; PROLIFERATION; RESTORATION; ENGRAFTMENT	Infusion of bone marrow stem or progenitor cells may provide powerful therapies for injured tissues such as the lung and heart. We examined the potential of bone marrow-derived (BMD) progenitor cells to contribute to repair and remodeling of lung and heart in a rat monocrotaline (MCT) model of pulmonary hypertension. Bone marrow from green fluorescent protein (GFP)-transgenic male rats was transplanted into GFP-negative female rats. The chimeric animals were injected with MCT to produce pulmonary hypertension. Significant numbers of male GFP-positive BMD cells engrafted in the lungs of MCT-treated rats. Microarray analyses and double-immunohistochemistry demonstrated that many of the cells were interstitial fibroblasts or myofibroblasts, some of the cells were hematopoietic cells, and some were pulmonary epithelial cells (Clara cells), vascular endothelial cells, and smooth muscle cells. A few BMD cells fused with pulmonary cells from the host, but the frequency was low. In the hypertrophied hearts of MCT-treated rats, we found a significant increase in the relative numbers of BMD cells in the tight ventricle wall as compared with the left ventricle. Some of the BMD cells in the right ventricle were vascular cells and cardiomyocytes. We report BMD cardiomyocytes with a normal chromosome number, fusion of BMD cells with host cardiomyocytes, and, in some cases, nuclear fusion.	[Spees, Jeffrey L.] Univ Vermont, Cardiovasc Res Inst, Dept Med, Colchester, VT 05446 USA; [Spees, Jeffrey L.; Whitney, Mandolin J.; Ylostalo, Joni; Prockop, Darwin J.] Tulane Univ, Hlth Sci Ctr, Ctr Gene Therapy, Dept Med, New Orleans, LA 70118 USA; [Sullivan, Deborah E.; Lasky, Joseph A.; Laboy, Miguel] Tulane Univ, Hlth Sci Ctr, Sect Pulm Dis Crit Care & Environm Med, New Orleans, LA USA	University of Vermont; Tulane University; Tulane University	Spees, JL (corresponding author), Univ Vermont, Cardiovasc Res Inst, Dept Med, 208 South Pk Dr,Ste 2, Colchester, VT 05446 USA.	jeffrey.spees@uvm.edu	Ylostalo, Joni/AAH-9457-2019	Ylostalo, Joni/0000-0001-9746-1994	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL077570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048323, R21AR047796] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL077570-01] Funding Source: Medline; NIAMS NIH HHS [AR48323, AR47796] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Caplice NM, 2003, P NATL ACAD SCI USA, V100, P4754, DOI 10.1073/pnas.0730743100; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Deb A, 2003, CIRCULATION, V107, P1247, DOI 10.1161/01.CIR.0000061910.39145.F0; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fukuhara S, 2004, CELL TRANSPLANT, V13, P741, DOI 10.3727/000000004783983486; GHODSI F, 1981, AM J PHYSIOL, V240, pH149, DOI 10.1152/ajpheart.1981.240.2.H149; Hattan N, 2005, CARDIOVASC RES, V65, P334, DOI 10.1016/j.cardiores.2004.10.004; Hayashida K, 2005, CHEST, V127, P1793, DOI 10.1378/chest.127.5.1793; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Jiang SG, 2004, P NATL ACAD SCI USA, V101, P16891, DOI 10.1073/pnas.0404398101; Kajstura J, 2005, CIRC RES, V96, P127, DOI 10.1161/01.RES.0000151843.79801.60; Kotton DN, 2001, DEVELOPMENT, V128, P5181; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Loi R, 2006, AM J RESP CRIT CARE, V173, P171, DOI 10.1164/rccm.200502-309OC; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mengel M, 2004, AM J PATHOL, V165, P2079, DOI 10.1016/S0002-9440(10)63258-0; Mengel M, 2004, J AM SOC NEPHROL, V15, P978, DOI 10.1097/01.ASN.0000120369.92378.54; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Mouquet F, 2005, CIRC RES, V97, P1090, DOI 10.1161/01.RES.0000194330.66545.f5; Nagaya N, 2003, CIRCULATION, V108, P889, DOI 10.1161/01.CIR.0000079161.56080.22; Ortiz LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI 10.1073/pnas.1432929100; Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100; SPECS L, 2006, P NATL ACAD SCI USA, V103, P1283; Spyridonidis A, 2004, AM J PATHOL, V164, P1147, DOI 10.1016/S0002-9440(10)63203-8; Suratt BT, 2003, AM J RESP CRIT CARE, V168, P318, DOI 10.1164/rccm.200301-145OC; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Thiele J, 2004, TRANSPLANTATION, V77, P1902, DOI 10.1097/01.TP.0000127591.34203.8E; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Zhao YDD, 2005, CIRC RES, V96, P442, DOI 10.1161/01.RES.0000157672.70560.7b	36	103	112	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1226	1236		10.1096/fj.07-8076com	http://dx.doi.org/10.1096/fj.07-8076com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	18032636				2022-12-28	WOS:000254581000027
J	Fazel, SS; Chen, L; Angoulvant, D; Li, SH; Weisel, RD; Keating, A; Li, RK				Fazel, Shafie S.; Chen, Liwen; Angoulvant, Denis; Li, Shu-Hong; Weisel, Richard D.; Keating, Armand; Li, Ren-Ke			Activation of c-kit is necessary for mobilization of reparative bone marrow progenitor cells in response to cardiac injury	FASEB JOURNAL			English	Article						myocardial infarction; heart failure; stem cells; cell signaling	ACUTE MYOCARDIAL-INFARCTION; COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELLS; THERAPEUTIC ANGIOGENESIS; INFLAMMATORY RESPONSE; ENDOTHELIAL-CELLS; TISSUE INHIBITORS; CLINICAL-TRIAL; HEART-FAILURE; EXPRESSION	Cardiovascular disease is the number-one cause of mortality in the developed world. The aim of this study is to define the mechanisms by which bone marrow progenitor cells are mobilized in response to cardiac ischemic injury. We used a closed-chest model of murine cardiac infarction/reperfusion, which segregated the surgical thoracotomy from the induction of cardiac infarction, so that we could study isolated fluctuations in cytokines without the confounding impact of surgery. We show here that bone marrow activation of the c-kit tyrosine kinase receptor in response to released soluble KitL is necessary for bone marrow progenitor cell mobilization after ischemic cardiac injury. We also show that release of KitL and c-kit activation require the activity of matrix metalloproteinase-9 within the bone marrow compartment. Finally, we demonstrate that mice with c-kit dysfunction develop cardiac failure after myocardial infarction and that bone marrow transplantation rescues the failing cardiac phenotype. In light of the ongoing trials of progenitor cell therapy for heart disease, our study outlines the endogenous repair mechanisms that are invoked after cardiac injury. Amplification of this pathway may aid in restoration of cardiac function after myocardial infaretion.-Fazel, S. S., Chen, L., Angoulvant, D., Li, S. H., Weisel, R. D., Keating, A., Li, R. K. Activation of c-kit is necessary for mobilization of reparative bone marrow progenitor cells in response to cardiac injury.	[Fazel, Shafie S.; Chen, Liwen; Angoulvant, Denis; Li, Shu-Hong; Weisel, Richard D.; Li, Ren-Ke] Univ Toronto, Toronto Gen Hosp, MaRS Ctr,Dept Surg, Res Inst,Div Cardiac Surg, Toronto, ON M5G 1L7, Canada; [Keating, Armand] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Li, RK (corresponding author), Univ Toronto, Toronto Gen Hosp, MaRS Ctr,Dept Surg, Res Inst,Div Cardiac Surg, Toronto Med Discovery Tower,Rm 3-702,101 Coll St, Toronto, ON M5G 1L7, Canada.	renkeli@uhnres.utoronto.ca	angoulvant, denis/A-6239-2009; Angoulvant, Denis/Q-9743-2019	Angoulvant, Denis/0000-0003-0788-8092; Li, Ren-Ke/0000-0002-2584-060X				Aicher A, 2003, NAT MED, V9, P1370, DOI 10.1038/nm948; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Assmus B, 2006, NEW ENGL J MED, V355, P1222, DOI 10.1056/NEJMoa051779; Ayach BB, 2006, P NATL ACAD SCI USA, V103, P2304, DOI 10.1073/pnas.0510997103; Badorff C, 2003, CIRCULATION, V107, P1024, DOI 10.1161/01.CIR.0000051460.85800.BB; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Broudy VC, 1996, BLOOD, V88, P75; Bubnic SJ, 2002, BONE MARROW TRANSPL, V30, P867, DOI 10.1038/sj.bmt.1703761; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; De Falco E, 2004, BLOOD, V104, P3472, DOI 10.1182/blood-2003-12-4423; Dewald O, 2004, AM J PATHOL, V164, P665, DOI 10.1016/S0002-9440(10)63154-9; Dewald O, 2003, P NATL ACAD SCI USA, V100, P2700, DOI 10.1073/pnas.0438035100; Fazel S, 2005, ANN THORAC SURG, V79, pS2238, DOI 10.1016/j.athoracsur.2005.02.085; Fazel S, 2006, J CLIN INVEST, V116, P1865, DOI 10.1172/JCI27019; Frangogiannis NG, 1998, CIRCULATION, V98, P687, DOI 10.1161/01.CIR.98.7.687; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Heissig B, 2005, J EXP MED, V202, P739, DOI 10.1084/jem.20050959; Heissig B, 2003, THROMB HAEMOSTASIS, V90, P570, DOI 10.1160/TH03-03-0188; Irwin MW, 1999, CIRCULATION, V99, P1492, DOI 10.1161/01.CIR.99.11.1492; Jin DK, 2006, NAT MED, V12, P557, DOI 10.1038/nm1400; Kajstura J, 2005, CIRC RES, V96, P127, DOI 10.1161/01.RES.0000151843.79801.60; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Kuhlmann MT, 2006, J EXP MED, V203, P87, DOI 10.1084/jem.20051151; Lehrke S, 2006, CIRC RES, V99, P553, DOI 10.1161/01.RES.0000238375.88582.d8; Li TS, 2005, CARDIOVASC RES, V65, P64, DOI 10.1016/j.cardiores.2004.08.019; Li TS, 2003, AM J PHYSIOL-HEART C, V285, pH931, DOI 10.1152/ajpheart.01146.2002; Lunde K, 2006, NEW ENGL J MED, V355, P1199, DOI 10.1056/NEJMoa055706; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; Mann DL, 1999, CIRCULATION, V100, P999, DOI 10.1161/01.CIR.100.9.999; Massa M, 2005, BLOOD, V105, P199, DOI 10.1182/blood-2004-05-1831; Matsui J, 2004, J BIOL CHEM, V279, P18600, DOI 10.1074/jbc.M311643200; Michael LH, 1995, AM J PHYSIOL-HEART C, V269, pH2147, DOI 10.1152/ajpheart.1995.269.6.H2147; Miyamoto T, 1997, ATHEROSCLEROSIS, V129, P207, DOI 10.1016/S0021-9150(96)06043-1; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Pollick C, 1995, J Am Soc Echocardiogr, V8, P602, DOI 10.1016/S0894-7317(05)80373-6; Rafii S, 2002, SEMIN CELL DEV BIOL, V13, P61, DOI 10.1006/scdb.2001.0285; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Rouet-Benzineb P, 1999, EUR J HEART FAIL, V1, P337, DOI 10.1016/S1388-9842(99)00048-3; Schachinger V, 2006, NEW ENGL J MED, V355, P1210, DOI 10.1056/NEJMoa060186; Sheng T, 2005, CIRCULATION, V111, P2438, DOI 10.1161/01.CIR.0000167553.49133.81; Smith MA, 2001, BLOOD REV, V15, P191, DOI 10.1054/blre.2001.0167; Spinale FG, 1998, CIRC RES, V82, P482, DOI 10.1161/01.RES.82.4.482; Starckx S, 2002, LEUKEMIA LYMPHOMA, V43, P233, DOI 10.1080/10428190290005982; Virag JI, 2003, AM J PATHOL, V163, P2433, DOI 10.1016/S0002-9440(10)63598-5; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wollert KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140-6736(04)16626-9; Yang EV, 2006, CANCER RES, V66, P10357, DOI 10.1158/0008-5472.CAN-06-2496; Zhang H, 2005, AM J PHYSIOL-HEART C, V289, pH2089, DOI 10.1152/ajpheart.00019.2005; Ziegelhoeffer T, 2004, CIRC RES, V94, P230, DOI 10.1161/01.RES.0000110419.50982.1C	60	54	58	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					930	940		10.1096/fj.07-8636com	http://dx.doi.org/10.1096/fj.07-8636com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17967925				2022-12-28	WOS:000254143700031
J	Gorelik, S; Ligumsky, M; Kohen, R; Kanner, J				Gorelik, Shlomit; Ligumsky, Moshe; Kohen, Ron; Kanner, Joseph			A novel function of red wine polyphenols in humans: prevention of absorption of cytotoxic lipid peroxidation products	FASEB JOURNAL			English	Article						red muscle; malondialdehyde; human plasma; antioxidants	LOW-DENSITY-LIPOPROTEIN; OXIDATION-PRODUCTS; TRAPPING REACTIONS; GASTRIC FLUID; MALONDIALDEHYDE; DIET; IDENTIFICATION; MEAT; MICE; RICH	Current evidence supports a contribution of polyphenols to the prevention of cardiovascular disease, but their mechanisms of action are not understood. We investigated the impact of red wine polyphenols on postprandial cytotoxic lipid peroxidation products (MDA) levels in humans. In a randomized, crossover study, the effect of red wine polyphenols on postprandial levels of plasma and urine MDA was investigated. Three meals of 250 g turkey cutlets supplemented by water (A); soaked in red wine after heating plus 200 ml of red wine (B); or soaked in red wine prior to heating plus 200 ml of red wine (C) were administered to 10 healthy volunteers. Subject baseline plasma levels of MDA were 50 +/- 20 nM. After a meal of turkey meat cutlets, plasma MDA levels increased by 160 nM (P<0.0001); after (B) there was a 75% reduction in the absorption of MDA (P< 0.0001). However, after (C), the elevation of plasma MDA was completely prevented (P< 0.0001). Similar results were obtained for MDA accumulation in urine. Our study suggests that red wine polyphenols exert a beneficial effect by the novel new function, absorption inhibition of the lipo-toxin MDA. These findings explain the potentially harmful effects of oxidized fats found in foods and the important benefit of dietary polyphenols in the meal. Gorelik, S., Ligumsky, M., Kohen, R., Kanner, J. A novel function of red wine polyphenols in humans: prevention of absorption of cytotoxic lipid peroxidation products.	[Kanner, Joseph] ARO, Volcani Ctr, Dept Food Sci, Bet Dagan, Israel; [Gorelik, Shlomit; Kohen, Ron] Hebrew Univ Jerusalem, Sch Pharm, Davd R Bloom Ctr Pharm, Dept Pharmaceut, Jerusalem, Israel; [Ligumsky, Moshe] Hadassah Med Ctr, Div Internal Med, Gastrointestinal Unit, IL-91120 Jerusalem, Israel	VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center	Kanner, J (corresponding author), ARO, Volcani Ctr, Dept Food Sci, Bet Dagan, Israel.	vtkanner@agri.gov.il	Kohen, Ron/ABC-2281-2021	Kohen, Ron/0000-0001-7268-9845				ALDINI G, 2006, IN PRESS MED RES REV; Aviram M, 2002, DRUG EXP CLIN RES, V28, P49; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Bors W, 1987, Free Radic Res Commun, V2, P289, DOI 10.3109/10715768709065294; BROWN ED, 1995, LIPIDS, V30, P1053, DOI 10.1007/BF02536291; Carlsen H, 2003, J NUTR, V133, P2137, DOI 10.1093/jn/133.7.2137; Cohn JS, 2002, CURR OPIN LIPIDOL, V13, P19, DOI 10.1097/00041433-200202000-00004; Cuevas AM, 2000, LIPIDS, V35, P143, DOI 10.1007/BF02664763; Feng ZH, 2006, MUTAT RES-FUND MOL M, V601, P125, DOI 10.1016/j.mrfmmm.2006.06.003; Gee JM, 1998, FREE RADICAL BIO MED, V25, P19, DOI 10.1016/S0891-5849(98)00020-3; Giron-Calle J, 2002, J AGR FOOD CHEM, V50, P6194, DOI 10.1021/jf025681r; Goldberg T, 2004, J AM DIET ASSOC, V104, P1287, DOI 10.1016/j.jada.2004.05.214; Gopaul NK, 2000, FREE RADICAL RES, V33, P115, DOI 10.1080/10715760000300671; Gorelik S, 2005, J AGR FOOD CHEM, V53, P3397, DOI 10.1021/jf040401o; Gorelik S, 2007, ARCH BIOCHEM BIOPHYS, V458, P236, DOI 10.1016/j.abb.2006.12.006; HADLEY M, 1989, FREE RADICAL BIO MED, V6, P49, DOI 10.1016/0891-5849(89)90159-7; Halliwell B, 2000, FREE RADICAL RES, V33, P819, DOI 10.1080/10715760000301341; HOLVOET P, 1995, J CLIN INVEST, V95, P2611, DOI 10.1172/JCI117963; Hu FB, 2002, JAMA-J AM MED ASSOC, V288, P2569, DOI 10.1001/jama.288.20.2569; Ichinose T, 2004, FOOD CHEM TOXICOL, V42, P1795, DOI 10.1016/j.fct.2004.06.011; Kadiiska MB, 2005, FREE RADICAL BIO MED, V38, P698, DOI 10.1016/j.freeradbiomed.2004.09.017; Kandra L, 2004, BIOCHEM BIOPH RES CO, V319, P1265, DOI 10.1016/j.bbrc.2004.05.122; KANNER J, 1994, MEAT SCI, V36, P169, DOI 10.1016/0309-1740(94)90040-X; Kanner J, 2001, FREE RADICAL BIO MED, V31, P1388, DOI 10.1016/S0891-5849(01)00718-3; KANNER J, 1985, ARCH BIOCHEM BIOPHYS, V237, P314, DOI 10.1016/0003-9861(85)90282-6; KANNER J, 2007, IN PRESS MOL NUTR FO; KUBOW S, 1992, FREE RADICAL BIO MED, V12, P63, DOI 10.1016/0891-5849(92)90059-P; Kuhnau J, 1976, World Rev Nutr Diet, V24, P117; Lo CY, 2006, MOL NUTR FOOD RES, V50, P1118, DOI 10.1002/mnfr.200600094; Lotito SB, 2006, FREE RADICAL BIO MED, V41, P1727, DOI 10.1016/j.freeradbiomed.2006.04.033; McDougall GJ, 2005, BIOFACTORS, V23, P189, DOI 10.1002/biof.5520230403; Niedernhofer LJ, 2003, J BIOL CHEM, V278, P31426, DOI 10.1074/jbc.M212549200; Norat T, 2001, NUTR REV, V59, P37, DOI 10.1111/j.1753-4887.2001.tb06974.x; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PICHE LA, 1988, CARCINOGENESIS, V9, P473, DOI 10.1093/carcin/9.3.473; Plastaras JP, 2000, CHEM RES TOXICOL, V13, P1235, DOI 10.1021/tx0001631; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sies H, 2005, J NUTR, V135, P969, DOI 10.1093/jn/135.5.969; Staprans I, 2003, J LIPID RES, V44, P705, DOI 10.1194/jlr.M200266-JLR200; Staprans I, 1999, DIABETES CARE, V22, P300, DOI 10.2337/diacare.22.2.300; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Stocker R, 2005, J THROMB HAEMOST, V3, P1825, DOI 10.1111/j.1538-7836.2005.01370.x; Suomela JP, 2005, LIPIDS, V40, P437, DOI 10.1007/s11745-005-1402-4; Totlani VM, 2006, J AGR FOOD CHEM, V54, P7311, DOI 10.1021/jf061244r; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Ursini F, 1998, FREE RADICAL BIO MED, V25, P250, DOI 10.1016/S0891-5849(98)00044-6; Vlassara H, 2002, P NATL ACAD SCI USA, V99, P15596, DOI 10.1073/pnas.242407999; West JD, 2006, CHEM RES TOXICOL, V19, P173, DOI 10.1021/tx050321u; Williams MJA, 1999, J AM COLL CARDIOL, V33, P1050, DOI 10.1016/S0735-1097(98)00681-0; Williamson G, 2005, AM J CLIN NUTR, V81, p243S, DOI [10.1093/ajcn/81.1.230S, 10.1093/ajcn/81.1.243S]; Zhang QH, 2004, P NATL ACAD SCI USA, V101, P4752, DOI 10.1073/pnas.0400924101	51	144	146	2	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					41	46		10.1096/fj.07-9041com	http://dx.doi.org/10.1096/fj.07-9041com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17712060				2022-12-28	WOS:000252309900007
J	Bodo, E; Kromminga, A; Funk, W; Laugsch, M; Duske, U; Jelkmann, WG; Paus, R				Bodo, Eniko; Kromminga, Arno; Funk, Wolfgang; Laugsch, Magdalena; Duske, Ute; Jelkmann, Wolfgang; Paus, Ralf			Human hair follicles are an extrarenal source and a nonhematopoietic target of erythropoietin	FASEB JOURNAL			English	Article						anagen hair follicles; tissue protection; hemoglobin alpha-1; kinesin light chain 3; aminase oxidase; calmegin; RAS-like family 10	CORTICOTROPIN-RELEASING HORMONE; INDUCIBLE FACTOR-I; PROTECTS NEURONS; GROWTH-FACTOR; RECEPTOR; HYPOXIA; EXPRESSION; BIOLOGY; INVOLVEMENT; APOPTOSIS	Erythropoietin primarily serves as an essential growth factor for erythrocyte precursor cells. However, there is increasing evidence that erythropoietin ( EPO)/EPO receptor ( EPO-R) signaling operates as a potential tissue-protective system outside the bone marrow. Arguing that growing hair follicles ( HF) are among the most rapidly proliferating tissues, we have here explored whether human HFs are sources of EPO and targets of EPO-R-mediated signaling. Human scalp skin and microdissected HFs were assessed for EPO and EPO-R expression, and the effects of EPO on organ-cultured HFs were assessed in the presence/absence of a classical apoptosis-inducing chemotherapeutic agent. Here, we show that human scalp HFs express EPO on the mRNA and protein level in situ, up-regulate EPO transcription under hypoxic conditions, and express transcripts for EPO-R and the EPO-stimulatory transcriptional cofactor hypoxia-inducible factor-1 alpha. Although EPO does not significantly alter human hair growth in vitro, it significantly down-regulates chemotherapy-induced intrafollicular apoptosis and changes the gene expression program of the HFs. The current study points to intriguing targets of EPO beyond the erythropoietic system: human HFs are an extrarenal site of EPO production and an extrahematopoietic site of EPO-R expression. They may recruit EPO/EPO-R signaling e. g., for modulating HF apoptosis under conditions of hypoxia and chemotherapy-induced stress. - Bodo, E., Kromminga, A., Funk, W., Laugsch, M, Duske, U., Jelkmann, W., Paus, R. Human hair follicles are an extrarenal source and a non-hematopoietic target of erythropoietin.	Univ Lubeck, Dept Dermatol, Lubeck, Germany; Inst Immunol Clin Pathol Mol Med, Hamburg, Germany; Klin Dr Kozlowski, Munich, Germany; Univ Lubeck, Dept Physiol, Lubeck, Germany	University of Lubeck; University of Lubeck	Paus, R (corresponding author), Univ Lubeck, Univ Hosp Schleswig Holstein, Dept Dermatol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	ralf.paus@uk-sh.de	Laugsch, Magdalena/AAH-8170-2021; Paus, Ralf/F-6243-2011; Jelkmann, Wolfgang/AAF-8897-2019					Bodo E, 2005, AM J PATHOL, V166, P985, DOI 10.1016/S0002-9440(10)62320-6; BODO E, 2006, J INVEST DERMATOL SU, V126, pP126; Braun S, 2006, J CELL SCI, V119, P4841, DOI 10.1242/jcs.03259; Brines M, 2006, KIDNEY INT, V70, P246, DOI 10.1038/sj.ki.5001546; Bruegge K, 2007, CURR MED CHEM, V14, P1853; Carlini RG, 1999, KIDNEY INT, V55, P546, DOI 10.1046/j.1523-1755.1999.00266.x; Dame C, 2003, MIL DRUG TH, P35; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Elliott S, 2006, BLOOD, V107, P1892, DOI 10.1182/blood-2005-10-4066; Foitzik K, 2006, AM J PATHOL, V168, P748, DOI 10.2353/ajpath.2006.050468; Galeano M, 2006, CRIT CARE MED, V34, P1139, DOI 10.1097/01.CCM.0000206468.18653.EC; Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Hara M, 2000, J INVEST DERMATOL, V114, P438, DOI 10.1046/j.1523-1747.2000.00894.x; Hasselblatt M, 2006, J NEUROSURG ANESTH, V18, P132, DOI 10.1097/00008506-200604000-00007; Isogai R, 2006, ARCH DERMATOL RES, V297, P389, DOI 10.1007/s00403-005-0615-3; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Ito N, 2005, FASEB J, V19, P1332, DOI 10.1096/fj.04-1968fje; Ito T, 2004, AM J PATHOL, V164, P623, DOI 10.1016/S0002-9440(10)63151-3; Jahoda CAB, 2001, LANCET, V358, P1445, DOI 10.1016/S0140-6736(01)06532-1; Jelkmann W, 2004, INTERNAL MED, V43, P649, DOI 10.2169/internalmedicine.43.649; Juul SE, 1998, EARLY HUM DEV, V52, P235, DOI 10.1016/S0378-3782(98)00030-9; Kaushansky K, 2006, NEW ENGL J MED, V354, P2034, DOI 10.1056/NEJMra052706; Kobayashi H, 2005, FASEB J, V19, P1710, DOI 10.1096/fj.04-2293fje; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; Kumar SM, 2005, AM J PATHOL, V166, P823, DOI 10.1016/S0002-9440(10)62303-6; LeBaron MJ, 2007, ENDOCRINOLOGY, V148, P989, DOI 10.1210/en.2006-1219; Lindner G, 1997, AM J PATHOL, V151, P1601; Liu RQ, 2006, J NEUROCHEM, V96, P1101, DOI 10.1111/j.1471-4159.2005.03597.x; Liu T C, 1990, Gaoxiong Yi Xue Ke Xue Za Zhi, V6, P181; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; MASUDA S, 1993, J BIOL CHEM, V268, P11208; *NATL COMM CLIN LA, 1992, NCCLS DOCUM C28 P, V12, P1; Paus R, 2006, TRENDS IMMUNOL, V27, P32, DOI 10.1016/j.it.2005.10.002; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PHILPOTT MP, 1991, J INVEST DERMATOL, V96, P875, DOI 10.1111/1523-1747.ep12475232; PHILPOTT MP, 1990, J CELL SCI, V97, P463; Rossert J, 2005, NEPHROL DIAL TRANSPL, V20, P1025, DOI 10.1093/ndt/gfh800; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Savino R, 2004, CELL DEATH DIFFER, V11, pS2, DOI 10.1038/sj.cdd.4401469; Selzer E, 2000, MELANOMA RES, V10, P421, DOI 10.1097/00008390-200010000-00003; Sharpies EJ, 2006, SEMIN NEPHROL, V26, P325, DOI 10.1016/j.semnephrol.2006.05.010; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 2002, FASEB J, V16, P896, DOI 10.1096/fj.01-0952fje; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Slominski A, 2003, EUR J BIOCHEM, V270, P3335, DOI 10.1046/j.1432-1033.2003.03708.x; Slominski A, 2002, J INVEST DERMATOL, V119, P1449, DOI 10.1046/j.1523-1747.2002.19617.x; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2001, FASEB J, V15, P1678, DOI 10.1096/fj.00-0850rev; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Zou HF, 2006, BIOTECHNOL LETT, V28, P1901, DOI 10.1007/s10529-006-9176-6; Zouboulis CC, 2002, P NATL ACAD SCI USA, V99, P7148, DOI 10.1073/pnas.102180999	58	60	60	1	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3346	3354		10.1096/fj.07-8628com	http://dx.doi.org/10.1096/fj.07-8628com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17540710				2022-12-28	WOS:000249781600035
J	Evangelisti, C; Tazzari, PL; Riccio, M; Fiume, R; Hozumi, Y; Fala, F; Goto, K; Manzoli, L; Cocco, L; Martelli, AM				Evangelisti, Camilla; Tazzari, Pier Luigi; Riccio, Massimo; Fiume, Roberta; Hozumi, Yasukazu; Fala, Federica; Goto, Kaoru; Manzoli, Lucia; Cocco, Lucio; Martelli, Alberto M.			Nuclear diacylglycerol kinase-zeta is a negative regulator of cell cycle progression in C2C12 mouse myoblasts	FASEB JOURNAL			English	Article						nucleus; lipid-dependent signaling pathways; siRNA; phosphorylated pRB	RETINOBLASTOMA PROTEIN-PHOSPHORYLATION; SKELETAL-MUSCLE DIFFERENTIATION; C-ALPHA; PHOSPHATIDIC-ACID; SWISS 3T3-CELLS; PHOSPHOLIPASE-C; DNA-REPLICATION; SITES; PROLIFERATION; LOCALIZATION	The nucleus contains diacylglycerol kinases ( DGKs), i.e., the enzymes that, by converting diacylglycerol ( DG) into phosphatidic acid, terminate DG-dependent events. It has been demonstrated that nuclear DGK-zeta interferes with cell cycle progression. We previously reported that nuclear DGK-zeta expression increased during myogenic differentiation, whereas its down-regulation impaired differentiation. Here, we evaluated the possible involvement of nuclear DGK-zeta in cell cycle progression of C2C12 myoblasts. Overexpression of a wild-type DGK-zeta, which mainly localized to the nucleus ( but not of a kinase dead mutant or of a mutant that did not enter the nucleus), blocked the cells in the G(1) phase of the cell cycle, as demonstrated by in situ analysis of biotinylated-16-dUTP incorporated into newly synthesized DNA and by flow cytometry. In contrast, down-regulation of endogenous DGK-zeta by short interfering RNA ( siRNA) increased the number of cells in both the S and G(2)/M phases of the cell cycle. Cell cycle arrest of cells overexpressing wild-type DGK-zeta was accompanied by decreased levels of retinoblastoma protein phosphorylated on Ser-807/811. Down-regulation of endogenous DGK-zeta, using siRNA, prevented the cell cycle block characterizing C2C12 cell myogenic differentiation. Overall, our results identify nuclear DGK-zeta as a key determinant of cell cycle progression and differentiation of C2C12 cells. -Evangelisti, C., Tazzari, P. L., Riccio, M., Fiume, R., Hozumi, Y., Fala, F., Goto, K., Manzoli, L., Cocco, L., Martelli, A. M. Nuclear diacylglycerol kinase-zeta is a negative regulator of cell cycle progression in C2C12 mouse myoblasts.	Univ Bologna, Dipartimento Sci Anat Umane & Fisiopatol Apparato, Cell Signaling Lab, Sez Anat, I-40126 Bologna, Italy; Policlin S Orsola Malphigi, Serv Immunoematol & Trasfus, Bologna, Italy; Univ Modena & Reggio Emilia, Dipartimento Anat & Istol, Modena, Italy; Yamagata Univ, Sch Med, Dept Anat & Cell Biol, Yamagata 99023, Japan; IOR, CNR, IGM, Bologna, Italy	University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Universita di Modena e Reggio Emilia; Yamagata University; Consiglio Nazionale delle Ricerche (CNR)	Martelli, AM (corresponding author), Univ Bologna, Dipartimento Sci Anat Umane & Fisiopatol Apparato, Cell Signaling Lab, Sez Anat, Via Irnerio 48, I-40126 Bologna, Italy.	alberto.martelli@unibo.it	Hozumi, Yasukazu/AAO-6439-2020; TAZZARI, PIER LUIGI/HGC-8394-2022; Cocco, Lucio/AAI-2206-2020; Evangelisti, Camilla/C-6977-2019	TAZZARI, PIER LUIGI/0000-0002-8789-657X; Cocco, Lucio/0000-0002-9206-8277; Evangelisti, Camilla/0000-0003-3531-9540; Hozumi, Yasukazu/0000-0002-9102-5419; FIUME, ROBERTA/0000-0001-7757-4000				Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; Berezney R, 2005, ADV ENZYME REGUL, V45, P17, DOI 10.1016/j.advenzreg.2005.02.013; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; Brantey MA, 2000, CANCER RES, V60, P4320; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Cardenas C, 2004, J BIOL CHEM, V279, P39122, DOI 10.1074/jbc.M401044200; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; Drexler HCA, 2003, CELL CYCLE, V2, P438, DOI 10.4161/cc.2.5.461; Driscoll B, 1999, J BIOL CHEM, V274, P9463, DOI 10.1074/jbc.274.14.9463; Evangelisti C, 2006, EUR J HISTOCHEM, V50, P9; Evangelisti C, 2006, J CELL PHYSIOL, V209, P370, DOI 10.1002/jcp.20744; Faenza I, 2007, ENDOCRINOLOGY, V148, P1108, DOI 10.1210/en.2006-1003; Figueroa A, 2003, MOL CELL BIOL, V23, P4991, DOI 10.1128/MCB.23.14.4991-5004.2003; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Goto K, 2006, ADV ENZYME REGUL, V46, P192, DOI 10.1016/j.advenzreg.2006.01.005; Goto K, 2006, BBA-MOL CELL BIOL L, V1761, P535, DOI 10.1016/j.bbalip.2006.04.001; Grossel MJ, 2006, J CELL BIOCHEM, V97, P485, DOI 10.1002/jcb.20712; Hozumi Y, 2003, EUR J NEUROSCI, V18, P1448, DOI 10.1046/j.1460-9568.2003.02871.x; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; Jones JA, 2002, J BIOL CHEM, V277, P15530, DOI 10.1074/jbc.M111555200; Joulia D, 2003, EXP CELL RES, V286, P263, DOI 10.1016/S0014-4827(03)00074-0; Los AP, 2006, J BIOL CHEM, V281, P858, DOI 10.1074/jbc.M502693200; LOS AP, 2006, BIOCHIM BIOPHYS ACTA, V1773, P352; Ma H, 1998, J CELL BIOL, V143, P1415, DOI 10.1083/jcb.143.6.1415; Markiewicz E, 2005, J CELL SCI, V118, P409, DOI 10.1242/jcs.01630; Martelli AM, 2006, BBA-MOL CELL BIOL L, V1761, P542, DOI 10.1016/j.bbalip.2006.02.009; Martelli AM, 2004, CELL MOL LIFE SCI, V61, P1143, DOI 10.1007/s00018-004-3414-7; Martelli AM, 2005, J CELL BIOCHEM, V96, P285, DOI 10.1002/jcb.20527; Martelli AM, 2000, CANCER RES, V60, P815; Martelli AM, 2002, CELL MOL LIFE SCI, V59, P1129, DOI 10.1007/s00018-002-8492-9; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Neri LM, 1998, J BIOL CHEM, V273, P29738, DOI 10.1074/jbc.273.45.29738; Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499; Topham MK, 2006, J CELL BIOCHEM, V97, P474, DOI 10.1002/jcb.20704; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Trinkle-Mulcahy L, 2003, MOL BIOL CELL, V14, P107, DOI 10.1091/mbc.E02-07-0376; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; ZHOU W, 1993, J BIOL CHEM, V268, P23041	43	35	38	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3297	3307		10.1096/fj.07-8336com	http://dx.doi.org/10.1096/fj.07-8336com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17488950				2022-12-28	WOS:000249781600030
J	van Tuyn, J; Pijnappels, DA; de Vries, AAF; de Vries, I; Dijke, IVDVV; Knaan-Shanzer, S; van der Laarse, A; Schalij, MJ; Atsma, DE				van Tuyn, John; Pijnappels, Daniel A.; de Vries, Antoine A. F.; de Vries, Ingrid; Velde-van Dijke, Ietje van der; Knaaen-Shanzer, Shoshan; van der Laarse, Arnoud; Schalij, Martin J.; Atsma, Douwe E.			Fibroblasts from human postmyocardial infarction scars acquire properties of cardiomyocytes after transduction with a recombinant myocardin gene	FASEB JOURNAL			English	Article						conduction (block); fibrosis; gene transfer; heart infarction; myocytes	SMOOTH-MUSCLE; LIPOMATOUS METAPLASIA; STEM-CELLS; EXPRESSION; HEART; ACTIVATION; CONDUCTION	Myocardial scar formation impairs heart function by inducing cardiac remodeling, decreasing myocardial compliance, and compromising normal electrical conduction. Conversion of myocardial scar fibroblasts ( MSFs) into ( functional) cardiomyocytes may be an effective alternative treatment to limit loss of cardiac performance after myocardial injury. In this study, we investigated whether the phenotype of MSFs can be modified by gene transfer into cells with properties of cardiomyocytes. To this end, fibroblasts from postmyocardial infarction scars of human left ventricles were isolated and characterized by cell biological, immunological, and molecular biological assays. Cultured human MSFs express GATA4 and connexin 43 and display adipogenic differentiation potential. Infection of human MSFs with a lentivirus vector encoding the potent cardiogenic transcription factor myocardin renders them positive for a wide variety of cardiomyocyte-specific proteins, including sarcomeric components, transcription factors, and ion channels, and induces the expression of several smooth muscle marker genes. Forced myocardin expression also endowed human MSFs with the ability to transmit an action potential and to repair an artificially created conduction block in cardiomyocyte cultures. These finding indicate that in vivo myocardin gene transfer may potentially limit cardiomyocyte loss, myocardial fibrosis, and disturbances in electrical conduction caused by myocardial infarction. - van Tuyn, J., Pijnappels, D. A., de Vries, A. A. F., de Vries, I., van der Velde-van Dijke, I., Knaan-Shanzer, S., van der Laarse, A., Schalij, M. J., Atsma, D. E. Fibroblasts from human postmyocardial infarction scars acquire properties of cardiomyocytes after transduction with a recombinant myocardin gene.	Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Mol Cell Biol, Virus & Stem Cell Biol Lab, NL-2300 RC Leiden, Netherlands; Interuniv Cardiol Inst Netherlands, Utrecht, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Interuniversity Cardiology Institute of the Netherlands; Utrecht University	Atsma, DE (corresponding author), Leiden Univ, Med Ctr, Dept Cardiol, POB 9600, NL-2300 RC Leiden, Netherlands.	d.e.atsma@lumc.nl	de Vries, Antoine/ABG-5787-2021; van Tuyn, John/R-3939-2019; van Tuyn, John/D-1342-2009; Pijnappels, Daniël/AAA-2304-2022	van Tuyn, John/0000-0001-5989-5185; van Tuyn, John/0000-0001-5989-5185; Pijnappels, Daniël/0000-0001-6731-4125				Baroldi G, 1997, CAN J CARDIOL, V13, P65; Brown RD, 2005, ANNU REV PHARMACOL, V45, P657, DOI 10.1146/annurev.pharmtox.45.120403.095802; Camelliti P, 2006, ADV CARDIOL, V42, P132, DOI 10.1159/000092566; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; Chien KR, 2006, J CLIN INVEST, V116, P1838, DOI 10.1172/JCI29050; Creemers EE, 2006, MOL CELL, V23, P83, DOI 10.1016/j.molcel.2006.05.026; de Muinck ED, 2006, GENE THER, V13, P659, DOI 10.1038/sj.gt.3302680; Dimmeler S, 2005, J CLIN INVEST, V115, P572, DOI 10.1172/JCI200524283; Donello JE, 1998, J VIROL, V72, P5085, DOI 10.1128/JVI.72.6.5085-5092.1998; Dunwoodie SL, 2007, SEMIN CELL DEV BIOL, V18, P54, DOI 10.1016/j.semcdb.2006.12.003; Etzion S, 2002, CIRCULATION, V106, pI125, DOI 10.1161/01.cir.0000032888.55215.b8; Frangogiannis NG, 2006, ANTIOXID REDOX SIGN, V8, P1907, DOI 10.1089/ars.2006.8.1907; Fukushige T, 2006, GENE DEV, V20, P3395, DOI 10.1101/gad.1481706; Gaudesius G, 2003, CIRC RES, V93, P421, DOI 10.1161/01.RES.0000089258.40661.0C; GONZALEZSANCHEZ A, 1990, DEV BIOL, V139, P197, DOI 10.1016/0012-1606(90)90288-T; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Huang XP, 1999, CIRC RES, V84, P1; Jain MK, 1998, CIRC RES, V83, P980, DOI 10.1161/01.RES.83.10.980; Kizana E, 2006, GENE THER, V13, P1611, DOI 10.1038/sj.gt.3302813; Kizana E, 2005, CIRCULATION, V111, P394, DOI 10.1161/01.CIR.0000153812.64956.EF; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Miragoli M, 2006, CIRC RES, V98, P801, DOI 10.1161/01.RES.0000214537.44195.a3; Mitchell JA, 2004, AM J PHYSIOL-ENDOC M, V287, pE439, DOI 10.1152/ajpendo.00275.2003; Murry CE, 1996, J CLIN INVEST, V98, P2209, DOI 10.1172/JCI119030; Murry CE, 2006, J AM COLL CARDIOL, V47, P1777, DOI 10.1016/j.jacc.2006.02.002; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Parmacek MS, 2004, PROG CARDIOVASC DIS, V47, P159, DOI 10.1016/j.pcad.2004.07.003; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pijnappels DA, 2006, CARDIOVASC RES, V72, P282, DOI 10.1016/j.cardiores.2006.07.016; REISER PJ, 1994, AM J PHYSIOL-HEART C, V267, pH1589; Samaha FF, 1996, J BIOL CHEM, V271, P395, DOI 10.1074/jbc.271.1.395; Srivastava D, 2006, CELL, V126, P1037, DOI 10.1016/j.cell.2006.09.003; Sun Y, 2002, BASIC RES CARDIOL, V97, P343, DOI 10.1007/s00395-002-0365-8; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; Takemura H, 2005, CIRC J, V69, P1405, DOI 10.1253/circj.69.1405; van Tuyn J, 2005, CARDIOVASC RES, V67, P245, DOI 10.1016/j.cardiores.2005.04.013; van Tuyn J, 2007, STEM CELLS, V25, P271, DOI 10.1634/stemcells.2006-0366; Vellinga J, 2006, J GENE MED, V8, P147, DOI 10.1002/jgm.844; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Winer-Muram HT, 2004, J COMPUT ASSIST TOMO, V28, P455, DOI 10.1097/00004728-200407000-00004; Wu SM, 2006, CELL, V127, P1137, DOI 10.1016/j.cell.2006.10.028; Yasui K, 2001, CIRC RES, V88, P536, DOI 10.1161/01.RES.88.5.536	43	33	36	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3369	3379		10.1096/fj.07-8211com	http://dx.doi.org/10.1096/fj.07-8211com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17579192				2022-12-28	WOS:000249781600037
J	Paul, S; Singh, C; Mishra, S; Chaudhuri, TK				Paul, Subhankar; Singh, Chanpreet; Mishra, Saroj; Chaudhuri, Tapan K.			The 69 kDa Escherichia coli maltodextrin glucosidase does not get encapsulated underneath GroES and folds through trans mechanism during GroEL/GroES-assisted folding	FASEB JOURNAL			English	Article						in vivo and in vitro folding; large substrate protein; trans folding mechanism	BACTERIAL CHAPERONIN GROEL; MOLECULAR CHAPERONES; CRYSTAL-STRUCTURE; SINGLE-RING; IN-VITRO; PROTEIN; POLYPEPTIDE; INTERMEDIATE; ATP; COMPLEX	Escherichia coli chaperonin GroEL and GroES assist in folding of a wide variety of substrate proteins in the molecular mass range of similar to 50 kDa, using cis mechanism, but limited information is available on how they assist in folding of larger proteins. Considering that the central cavity of GroEL can accommodate a non- native protein of similar to 60 kDa, it is important to study the GroEL- GroES- assisted folding of substrate proteins that are large enough for cis encapsulation. In this study, we have reported the mechanism of GroEL/ GroES- assisted in vivo and in vitro folding of a 69 kDa monomeric E. coli protein maltodextrin glucosidase ( MalZ). Coexpression of GroEL and GroES in E. coli causes a 2- fold enhancement of exogenous MalZ activity in vivo. In vitro, GroEL and GroES in the presence of ATP give rise to a 7- fold enhancement in MalZ refolding. Neither GroEL nor single ring GroEL ( SR1) in the presence or absence of ATP could enhance the in vitro folding of MalZ. GroES could not encapsulate GroELbound MalZ. All these experimental findings suggested that GroEL/ GroES- assisted folding of MalZ followed trans mechanism, whereas denatured MalZ and GroES bound to the opposite rings of a GroEL molecule.	Indian Inst Technol, Dept Biochem Engn & Biotechnol, New Delhi 110016, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Delhi	Chaudhuri, TK (corresponding author), Indian Inst Technol, Dept Biochem Engn & Biotechnol, Haus Khas, New Delhi 110016, India.	tapan@dbeb.iitd.ac.in	Singh, Chanpreet/ABD-7407-2020	Singh, Chanpreet/0000-0002-2697-3033				Bhattacharyya AM, 2002, BIOCHEMISTRY-US, V41, P422, DOI 10.1021/bi011726q; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chaudhuri TK, 2001, CELL, V107, P235, DOI 10.1016/S0092-8674(01)00523-2; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Chuang JL, 1999, J BIOL CHEM, V274, P10395, DOI 10.1074/jbc.274.15.10395; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; Farr GW, 2003, EMBO J, V22, P3220, DOI 10.1093/emboj/cdg313; Farr GW, 2000, CELL, V100, P561, DOI 10.1016/S0092-8674(00)80692-3; Feltham JL, 2000, CELL, V100, P193, DOI 10.1016/S0092-8674(00)81557-3; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GORDON CL, 1994, J BIOL CHEM, V269, P27941; Grallert H, 1998, J BIOL CHEM, V273, P33305, DOI 10.1074/jbc.273.50.33305; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Horovitz A, 1998, CURR OPIN STRUC BIOL, V8, P93, DOI 10.1016/S0959-440X(98)80015-8; Horwich AL, 1998, METHOD ENZYMOL, V290, P141, DOI 10.1016/S0076-6879(98)90013-1; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Huang YS, 1999, J BIOL CHEM, V274, P10405, DOI 10.1074/jbc.274.15.10405; Ikura T, 2000, J MOL BIOL, V297, P791, DOI 10.1006/jmbi.2000.3580; Kerner MJ, 2005, CELL, V122, P209, DOI 10.1016/j.cell.2005.05.028; Lin Z, 2006, CRIT REV BIOCHEM MOL, V41, P211, DOI 10.1080/10409230600760382; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Motojima F, 2004, P NATL ACAD SCI USA, V101, P15005, DOI 10.1073/pnas.0406132101; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Song JL, 2000, J BIOL CHEM, V275, P22305, DOI 10.1074/jbc.M002038200; Song JL, 2003, J BIOL CHEM, V278, P2515, DOI 10.1074/jbc.M209705200; TAPIO S, 1991, J BIOL CHEM, V266, P19450; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	40	27	28	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2874	2885		10.1096/fj.06-7958com	http://dx.doi.org/10.1096/fj.06-7958com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17494995				2022-12-28	WOS:000249237500028
J	Wan, M; Sabirsh, A; Wetterholm, A; Agerberth, B; Haeggstrom, JZ				Wan, Min; Sabirsh, Alan; Wetterholm, Anders; Agerberth, Birgitta; Haeggstrom, Jesper Z.			Leukotriene B-4 triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses	FASEB JOURNAL			English	Article						phagocytosis; inflammation	HUMAN POLYMORPHONUCLEAR LEUKOCYTES; INVASIVE BACTERIAL-INFECTION; SRC FAMILY KINASES; ANTIMICROBIAL PEPTIDES; A(4) HYDROLASE; DEFICIENT MICE; 5-LIPOXYGENASE; RECEPTOR; ACTIVATION; PROTEIN	In humans, the antimicrobial peptide LL- 37 and the potent chemotactic lipid leukotriene B-4 ( LTB4) are important mediators of innate immunity and host defense. Here we show that LTB4, at very low ( 1 nM) concentrations, strongly promotes release of LL- 37 peptides from human neutrophils ( PMNs) in a time- and dose- dependent manner, as determined by Western blot, enzyme- linked immunoassay ( ELISA), and antibacterial activity. The LTB4- induced LL- 37 release is mediated by the BLT1 receptor, and protein phosphatase- 1 ( PP- 1) inhibits the release by suppressing the BLT1- mediated exocytosis of PMN granules. Conversely, LL- 37 elicits translocation of 5- lipoxygenase ( 5- LO) from the cytosol to the perinuclear membrane in PMNs and promotes the synthesis and release of LTB4, particularly from cells primed with LPS or GM- CSF. Furthermore, LL- 37 stimulates PMN phagocytosis of Escherichia coli particles, a functional response that is enhanced by LTB4, especially in GM- CSF pretreated cells. In these cells, LL- 37 also enhances LTB4- induced phagocytosis. Hence, in human PMNs, positive feedback circuits exist between LL- 37 and LTB4 that reciprocally stimulate the release of these mediators with the potential for synergistic bioactions and enhanced immune responses. Moreover, these novel lipid- peptide signaling pathways may offer new opportunities for pharmacological intervention and treatment of chronic inflammatory diseases.	Karolinska Inst, Div Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Karolinska Inst, Div Chem 2, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Haeggstrom, JZ (corresponding author), Karolinska Inst, Div Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	jesper.haeggstrom@ki.se		Sabirsh, Alan/0000-0001-5310-0281				Bailie MB, 1996, J IMMUNOL, V157, P5221; Borregaard N, 1997, ANN NY ACAD SCI, V832, P62, DOI 10.1111/j.1749-6632.1997.tb46237.x; Byrum RS, 1999, J IMMUNOL, V163, P6810; Chen M, 2006, J EXP MED, V203, P837, DOI 10.1084/jem.20052371; Chromek M, 2006, NAT MED, V12, P636, DOI 10.1038/nm1407; CSERNOK E, 1990, AM J PATHOL, V137, P1113; DIPERSIO JF, 1988, J IMMUNOL, V140, P4315; Edfeldt K, 2006, ARTERIOSCL THROM VAS, V26, P1551, DOI 10.1161/01.ATV.0000223901.08459.57; FEINMARK SJ, 1981, FEBS LETT, V136, P141, DOI 10.1016/0014-5793(81)81233-1; Flamand L, 2004, J INFECT DIS, V189, P2001, DOI 10.1086/386374; Funk CD, 2005, NAT REV DRUG DISCOV, V4, P664, DOI 10.1038/nrd1796; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GOLDMAN DW, 1982, J IMMUNOL, V129, P1600; GOLDMAN DW, 1984, J EXP MED, V159, P1027, DOI 10.1084/jem.159.4.1027; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; HAFSTROM I, 1981, FEBS LETT, V130, P146, DOI 10.1016/0014-5793(81)80684-9; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Iizuka Y, 2005, J BIOL CHEM, V280, P24816, DOI 10.1074/jbc.M413257200; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; MALAVIYA R, 1993, J BIOL CHEM, V268, P4939; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; Mocsai A, 1999, J IMMUNOL, V162, P1120; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Qiu H, 2006, P NATL ACAD SCI USA, V103, P8161, DOI 10.1073/pnas.0602414103; Raqib R, 2006, P NATL ACAD SCI USA, V103, P9178, DOI 10.1073/pnas.0602888103; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; Scott MG, 2000, J IMMUNOL, V164, P549, DOI 10.4049/jimmunol.164.2.549; Serezani CHC, 2005, BLOOD, V106, P1067, DOI 10.1182/blood-2004-08-3323; SERHAN CN, 1982, BIOCHEM BIOPH RES CO, V107, P1006, DOI 10.1016/0006-291X(82)90622-2; Sorensen OE, 2001, BLOOD, V97, P3951, DOI 10.1182/blood.V97.12.3951; Surette ME, 1998, FASEB J, V12, P1521, DOI 10.1096/fasebj.12.14.1521; Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970; Varoga D, 2005, ANN ANAT, V187, P499, DOI 10.1016/j.aanat.2005.03.004; Werz O, 2002, BLOOD, V99, P1044, DOI 10.1182/blood.V99.3.1044; WONG A, 1991, BIOCHEMISTRY-US, V30, P9346, DOI 10.1021/bi00102a030; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200; Yoshio H, 2003, PEDIATR RES, V53, P211, DOI 10.1203/01.PDR.0000047471.47777.B0; Zasloff M, 2002, LANCET, V360, P1116, DOI 10.1016/S0140-6736(02)11239-6; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	45	49	51	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2897	2905		10.1096/fj.06-7974com	http://dx.doi.org/10.1096/fj.06-7974com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17446260				2022-12-28	WOS:000249237500030
J	Li, YC; Boehning, DF; Qian, T; Popov, VL; Weinman, SA				Li, Yanchun; Boehning, Darren F.; Qian, Ting; Popov, Vsevolod L.; Weinman, Steven A.			Hepatitis C virus core protein increases mitochondrial ROS production by stimulation of Ca2+ uniporter activity	FASEB JOURNAL			English	Article						HCV core; mitochondria; cytosolic Ca2+; MAVS	ANTIVIRAL SIGNALING PROTEIN; OXIDATIVE STRESS; PERMEABILITY TRANSITION; ENDOPLASMIC-RETICULUM; SUBCELLULAR-LOCALIZATION; MOLECULAR DETERMINANTS; INNATE IMMUNITY; CALCIUM; MECHANISMS; EXPRESSION	Many viruses have evolved mechanisms to alter mitochondrial function. The hepatitis C virus (HCV) produces a viral core protein that targets to mitochondria and increases Ca2(+)- dependent ROS production. The aim of this study was to determine whether core's effects are mediated by changes in mitochondrial Ca2+ uptake. Core expression caused enhanced mitochondrial Ca2+ uptake in response to ER Ca2+ release induced by thapsigargin or ATP. It also increased mitochondrial superoxide production and mitochondrial permeability transition ( MPT). Incubating mouse liver mitochondria with an HCV core ( 100 ng/mg) in vitro increased Ca2+ entry rate by similar to 2-fold. Entry was entirely inhibited by the mitochondrial Ca2+ uniporter inhibitor, Ru-360, but not influenced by an Na+/ Ca2+ exchanger inhibitor or ROS scavengers. These results indicate that core directly increases mitochondrial Ca2+ uptake via a primary effect on the uniporter. This enhanced the ability of mitochondria to sequester Ca2+ in response to ER Ca2+ release, and increased mitochondrial ROS production and MPT. Thus, the mitochondrial Ca2+ uniporter is a newly identified target for viral modification of cell function.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Weinman, SA (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, 301 Univ Blvd, Galveston, TX 77555 USA.	sweinman@utmb.edu	Weinman, Steven/E-7012-2011; li, yan/GTI-4638-2022; Boehning, Darren/I-8539-2015	Boehning, Darren/0000-0001-7920-6922	NIAAA NIH HHS [AA12863] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012863] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aguilar HI, 1996, GASTROENTEROLOGY, V110, P558, DOI 10.1053/gast.1996.v110.pm8566604; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; Benali-Furet NL, 2005, ONCOGENE, V24, P4921, DOI 10.1038/sj.onc.1208673; Bergqvist A, 2003, J BIOL CHEM, V278, P18877, DOI 10.1074/jbc.M300185200; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bianchi K, 2004, BBA-MOL CELL RES, V1742, P119, DOI 10.1016/j.bbamcr.2004.09.015; Blattner JR, 2001, ANAL BIOCHEM, V295, P220, DOI 10.1006/abio.2001.5219; Camello-Almaraz C, 2006, AM J PHYSIOL-CELL PH, V291, pC1082, DOI 10.1152/ajpcell.00217.2006; Chinopoulos C, 2006, FEBS J, V273, P433, DOI 10.1111/j.1742-4658.2005.05103.x; Choi J, 2006, AM J PHYSIOL-GASTR L, V290, pG847, DOI 10.1152/ajpgi.00522.2005; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Chou AH, 2005, J IMMUNOL, V174, P2160, DOI 10.4049/jimmunol.174.4.2160; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Goldenthal MJ, 2004, MOL CELL BIOCHEM, V262, P1, DOI 10.1023/B:MCBI.0000038228.85494.3b; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Griffin S, 2005, J VIROL, V79, P15525, DOI 10.1128/JVI.79.24.15525-15536.2005; Gunter TE, 2000, CELL CALCIUM, V28, P285, DOI 10.1054/ceca.2000.0168; Hernandez-SanMiguel E, 2006, CELL CALCIUM, V40, P53, DOI 10.1016/j.ceca.2006.03.009; JOHONSON D, 1967, METHOD ENZYMOL, V10, P94; Julian D, 2005, J EXP BIOL, V208, P4109, DOI 10.1242/jeb.01867; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; KOIKE K, 2005, CLIN GASTROENTEROL H, V3, P132; Korenaga M, 2005, J BIOL CHEM, V280, P37481, DOI 10.1074/jbc.M506412200; Kowaltowski AJ, 1998, ARCH BIOCHEM BIOPHYS, V359, P77, DOI 10.1006/abbi.1998.0870; Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102; Meyer K, 2005, VIROLOGY, V336, P198, DOI 10.1016/j.virol.2005.03.016; Michelangeli F, 2005, CURR OPIN CELL BIOL, V17, P135, DOI 10.1016/j.ceb.2005.01.005; Moreau B, 2006, CURR BIOL, V16, P1672, DOI 10.1016/j.cub.2006.06.059; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Otani K, 2005, GASTROENTEROLOGY, V128, P96, DOI 10.1053/j.gastro.2004.10.045; OTT MT, 1989, J SURG RES, V47, P248, DOI 10.1016/0022-4804(89)90115-7; Piccoli C, 2006, BBA-BIOENERGETICS, V1757, P1429, DOI 10.1016/j.bbabio.2006.05.018; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Schwer B, 2004, J VIROL, V78, P7958, DOI 10.1128/JVI.78.15.7958-7968.2004; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Seth RB, 2006, CELL RES, V16, P141, DOI 10.1038/sj.cr.7310019; Shoshan-Barmatz V, 2004, BBA-BIOENERGETICS, V1657, P105, DOI 10.1016/j.bbabio.2004.02.009; Suzuki R, 2005, J VIROL, V79, P1271, DOI 10.1128/JVI.79.2.1271-1281.2005; Suzuki R, 1999, INTERVIROLOGY, V42, P145, DOI 10.1159/000024973; Szabadkai G, 2006, J CELL BIOL, V175, P901, DOI 10.1083/jcb.200608073; Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002; Tillmann HL, 2005, SEMIN LIVER DIS, V25, P84, DOI 10.1055/s-2005-864784; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Walter L, 2005, J BIOENERG BIOMEMBR, V37, P191, DOI 10.1007/s10863-005-6600-x; Wang D, 2006, IEEE AERO EL SYS MAG, V21, P3, DOI 10.1109/MAES.2006.1705163; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zheng Y, 2005, J MICROBIOL, V43, P529	48	129	133	2	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2474	2485		10.1096/fj.06-7345com	http://dx.doi.org/10.1096/fj.06-7345com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17392480				2022-12-28	WOS:000248454400022
J	Nemeth, ZH; Bleich, D; Csoka, B; Pacher, P; Mabley, JG; Himer, L; Vizi, ES; Deitch, EA; Szabo, C; Cronstein, BN; Hasko, G				Nemeth, Zoltan H.; Bleich, David; Csoka, Balazs; Pacher, Pal; Mabley, Jon G.; Himer, Leonora; Vizi, E. Sylvester; Deitch, Edwin A.; Szabo, Csaba; Cronstein, Bruce N.; Hasko, Gyorgy			Adenosine receptor activation ameliorates type 1 diabetes	FASEB JOURNAL			English	Article						immune; islet; inflammation	RAT PANCREATIC-ISLETS; IFN-GAMMA; INSULIN-SECRETION; A(2B) RECEPTORS; A(2A) RECEPTOR; CELL-LINE; TNF-ALPHA; T-CELLS; EXPRESSION; MACROPHAGES	Growing evidence indicates that adenosine receptors could be promising therapeutic targets in autoimmune diseases. Here we studied the role of adenosine receptors in controlling the course of type 1 diabetes. Diabetes in CD-1 mice was induced by multiple-low-dose-streptozotocin ( MLDS) treatment and in nonobese diabetic ( NOD) mice by cyclophosphamide injection. The nonselective adenosine receptor agonist 5'- N- ethylcarboxamidoadenosine ( NECA) prevented diabetes development in both MLDS-challenged mice and in cyclophosphamide-treated NOD mice. The effect of NECA was reversed by the selective A(2B) receptor antagonist N-( 4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetamide ( MRS 1754). The selective A(1) receptor agonist 2-chloro-N-6-cyclopentyladenosine ( CCPA) and A(3) receptor agonist N-6-( 3-iodobenzyl)-adenosine-5'-N-methyluronamide ( IB-MECA) were less efficacious in ameliorating the course of diabetes. NECA inhibited diabetes in A(2A) receptor KO mice and the selective A2A receptor agonist 2-p-(2-carboxyethyl)phenethyl-amino-5'-N-ethyl-carboxamidoadenosine ( CGS21680) had no effect in normal mice, indicating a lack of role of A2A receptors. NECA failed to prevent cytokine-induced beta-cell death in vitro, but NECA strongly suppressed expression of the proinflammatory cytokines TNF-alpha, MIP-1 alpha, IL-12, and IFN-gamma in pancreata, endotoxin, or anti-CD3-stimulated splenic cells, and T helper 1 lymphocytes, indicating that the beneficial effect of NECA was due to immunomodulation. These results demonstrate that adenosine receptor ligands are potential candidates for the treatment of type 1 diabetes.	UMDNJ, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA; UMDNJ, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA; Natl Inst Alcohol Abuse & Alcoholism, Lab Physiol Studies, Sect Oxidat Stress & Tissue Injury, NIH, Bethesda, MD USA; Univ Brighton, Sch Pharm & Biomol Sci, Brighton, E Sussex, England; Hungarian Acad Sci, Inst Expt Med, Dept Pharmacol, H-1051 Budapest, Hungary; NYU, Sch Med, Dept Med, Div Clin Pharmacol, New York, NY USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); University of Brighton; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; New York University	Hasko, G (corresponding author), UMDNJ, New Jersey Med Sch, Dept Surg, 185 S Orange Ave, Newark, NJ 07103 USA.	haskoge@umdnj.edu	Szabo, Csaba/D-1882-2013; Mabley, Jon G/D-2296-2010; Pacher, Pal/B-6378-2008; Cronstein, Bruce N/D-4678-2011; Szabo, Csaba/ABG-2644-2021	Pacher, Pal/0000-0001-7036-8108; Cronstein, Bruce N/0000-0002-4295-7383; Csoka, Balazs/0000-0002-7562-1130; Mabley, Jon/0000-0001-9423-6230	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000375] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AA000375-02] Funding Source: Medline; NIGMS NIH HHS [R01 GM66189, R01 GM066189-02, R01 GM066189, R01 GM066189-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cameron MJ, 2000, J IMMUNOL, V165, P1102, DOI 10.4049/jimmunol.165.2.1102; DEBRAYSACHS M, 1991, J AUTOIMMUN, V4, P237, DOI 10.1016/0896-8411(91)90021-4; Eiselein L, 2004, ILAR J, V45, P231, DOI 10.1093/ilar.45.3.231; Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891; Feoktistov I, 1997, PHARMACOL REV, V49, P381; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Gessi S, 2000, BRIT J PHARMACOL, V129, P2, DOI 10.1038/sj.bjp.0703045; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; Hasko G, 1996, J IMMUNOL, V157, P4634; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; HIGUCHI Y, 1992, J EXP MED, V176, P1719, DOI 10.1084/jem.176.6.1719; Khoa ND, 2001, J IMMUNOL, V167, P4026, DOI 10.4049/jimmunol.167.7.4026; Koshiba M, 1997, J BIOL CHEM, V272, P25881, DOI 10.1074/jbc.272.41.25881; Kreckler LM, 2006, J PHARMACOL EXP THER, V317, P172, DOI 10.1124/jpet.105.096016; Kukreja A, 1999, J CLIN ENDOCR METAB, V84, P4371, DOI 10.1210/jc.84.12.4371; Lai EY, 2007, DIABETES, V56, P107, DOI 10.2337/db06-0623; Lappas CM, 2005, J IMMUNOL, V174, P1073, DOI 10.4049/jimmunol.174.2.1073; Ledent C, 1997, NATURE, V388, P674, DOI 10.1038/41771; Mabley JG, 2003, MOL MED, V9, P96, DOI 10.2119/2003-00016.Mabley; Mirabet M, 1999, J CELL SCI, V112, P491; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Nemeth ZH, 2005, J IMMUNOL, V175, P8260, DOI 10.4049/jimmunol.175.12.8260; Nemeth ZH, 2006, J IMMUNOL, V176, P5616, DOI 10.4049/jimmunol.176.9.5616; NISHIDA Y, 1984, INT J IMMUNOPHARMACO, V6, P335, DOI 10.1016/0192-0561(84)90051-1; Odashima M, 2005, GASTROENTEROLOGY, V129, P26, DOI 10.1053/j.gastro.2005.05.032; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Olsson R, 2000, TRANSPLANTATION, V70, P280, DOI 10.1097/00007890-200007270-00007; Rabinovitch A, 1998, DIABETES METAB REV, V14, P129, DOI 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.3.CO;2-M; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; Ralevic V, 1998, PHARMACOL REV, V50, P413; SANDBERG G, 1983, INT J IMMUNOPHARMACO, V5, P259, DOI 10.1016/0192-0561(83)90027-9; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; Szabo C, 1998, BRIT J PHARMACOL, V125, P379, DOI 10.1038/sj.bjp.0702040; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; Verspohl EJ, 2002, CAN J PHYSIOL PHARM, V80, P562, DOI 10.1139/Y02-079; Xaus J, 1999, J IMMUNOL, V162, P3607; Yang D, 2006, J CLIN INVEST, V116, P1913, DOI 10.1172/JCI27933	38	85	94	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2379	2388		10.1096/fj.07-8213com	http://dx.doi.org/10.1096/fj.07-8213com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17405852	Green Accepted			2022-12-28	WOS:000248454400013
J	Yan, Y; Yamada, K; Niwa, M; Nagai, T; Nitta, A; Nabeshima, T				Yan, Yijin; Yamada, Kiyofumi; Niwa, Minae; Nagai, Taku; Nitta, Atsumi; Nabeshima, Toshitaka			Enduring vulnerability to reinstatement of methamphetamine-seeking behavior in glial cell line-derived neurotrophic factor mutant mice	FASEB JOURNAL			English	Article						GDNF mutant mice; METH self-administration; relapse	DELTA-FOSB; DRUG-ADDICTION; COCAINE; GDNF; ABUSE; ACQUISITION; EXTINCTION; RECEPTORS; DEGENERATION; STRIATUM	Genetic factors are considered to play an important role in drug dependence/addiction including the development of drug dependence and relapse. With the use of a model of drug self-administration in mutant mice, several specific genes and proteins have been identified as potentially important in the development of drug dependence. In contrast, little is known about the role of specific genes in enduring vulnerability to relapse, a clinical hallmark of drug addiction. Using a mouse model of reinstatement, which models relapse of drug-seeking behavior in addicts, we provide evidence that a partial reduction in the expression of the glial cell line-derived neurotrophic factor (GDNF) potentiates methamphetamine (METH) self-administration, enhances motivation to take METH, increases vulnerability to drug-primed reinstatement, and prolongs cue-induced reinstatement of extinguished METH-seeking behavior. In contrast, there was no significant difference in novelty responses, METH-stimulated hyperlocomotion and locomotor sensitization, food-reinforced operant behavior and motivation, or reinstatement of food-seeking behavior between GDNF heterozygous knockout mice and wild-type littermates. These findings suggest that GDNF may be associated with enduring vulnerability to reinstatement of METH-seeking behavior and a potential target in the development of therapies to control relapse.	Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Showa Ku, Nagoya, Aichi 4668560, Japan; Kanazawa Univ, Grad Sch Nat Sci & Technol, Lab Neuropsychopharmacol, Kanazawa, Ishikawa 920, Japan	Nagoya University; Kanazawa University	Nabeshima, T (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Showa Ku, Nagoya, Aichi 4668560, Japan.	tnabeshi@med.nagoya-u.ac.jp	Niwa, Minae/AAV-2639-2021; Sokabe, Masahiro/I-1565-2012; Nagai, Taku/I-7507-2014; Yan, Yijin/C-2733-2012; Yamada, Kiyofumi/I-7487-2014; Niwa, Minae/G-5469-2011; Nitta, Atsumi/AAF-4211-2019	Niwa, Minae/0000-0002-8784-7815; Nagai, Taku/0000-0001-5050-7748; Yamada, Kiyofumi/0000-0002-5280-5180; Niwa, Minae/0000-0002-8784-7815; 				Airavaara M, 2004, EUR J NEUROSCI, V20, P2336, DOI 10.1111/j.1460-9568.2004.03700.x; Caine SB, 2002, J NEUROSCI, V22, P2977, DOI 10.1523/JNEUROSCI.22-07-02977.2002; Chiamulera C, 2001, NAT NEUROSCI, V4, P873, DOI 10.1038/nn0901-873; ChoiLundberg DL, 1997, SCIENCE, V275, P838, DOI 10.1126/science.275.5301.838; Colby CR, 2003, J NEUROSCI, V23, P2488; Elmer GI, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0004.2002; Epstein DH, 2006, PSYCHOPHARMACOLOGY, V189, P1, DOI 10.1007/s00213-006-0529-6; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; Gerdeman GL, 2003, TRENDS NEUROSCI, V26, P184, DOI 10.1016/S0166-2236(03)00065-1; Gerlai R, 2001, EUR J NEUROSCI, V14, P1153, DOI 10.1046/j.0953-816x.2001.01724.x; Green-Sadan T, 2005, EXP NEUROL, V194, P97, DOI 10.1016/j.expneurol.2005.01.020; Green-Sadan T, 2003, EUR J NEUROSCI, V18, P2093, DOI 10.1046/j.1460-9568.2003.02943.x; Griffin WC, 2006, BRAIN RES, V1068, P257, DOI 10.1016/j.brainres.2005.10.080; He DY, 2005, J NEUROSCI, V25, P619, DOI 10.1523/JNEUROSCI.3959-04.2005; Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414; Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403; Kendler KS, 2003, AM J PSYCHIAT, V160, P687, DOI 10.1176/appi.ajp.160.4.687; Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583; Le AD, 2006, J NEUROSCI, V26, P1872, DOI 10.1523/JNEUROSCI.4895-05.2006; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Lu L, 2004, NEUROPHARMACOLOGY, V47, P214, DOI 10.1016/j.neuropharm.2004.06.027; Mandel RJ, 1997, P NATL ACAD SCI USA, V94, P14083, DOI 10.1073/pnas.94.25.14083; Messer CJ, 2000, NEURON, V26, P247, DOI 10.1016/S0896-6273(00)81154-X; Mizoguchi H, 2004, MOL PHARMACOL, V65, P1293, DOI 10.1124/mol.65.5.1293; Nagai T, 2004, P NATL ACAD SCI USA, V101, P10554, DOI 10.1073/pnas.0400417101; Nestler EJ, 2000, NAT GENET, V26, P277, DOI 10.1038/81570; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Nestler EJ, 2001, P NATL ACAD SCI USA, V98, P11042, DOI 10.1073/pnas.191352698; NIWA M, IN PRESS BIOL PSYCHI; PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Prescott CA, 1999, AM J PSYCHIAT, V156, P34, DOI 10.1176/ajp.156.1.34; ROBERTS DCS, 1993, PSYCHOPHARMACOLOGY, V111, P215, DOI 10.1007/BF02245526; Rocha BA, 1998, NATURE, V393, P175, DOI 10.1038/30259; Self DW, 2004, NEUROPHARMACOLOGY, V47, P242, DOI 10.1016/j.neuropharm.2004.07.005; Stuber GD, 2005, NEURON, V46, P661, DOI 10.1016/j.neuron.2005.04.036; Sutton MA, 2003, NATURE, V421, P70, DOI 10.1038/nature01249; Szumlinski KK, 2004, NEURON, V43, P401, DOI 10.1016/j.neuron.2004.07.019; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Tsuang MT, 1998, ARCH GEN PSYCHIAT, V55, P967, DOI 10.1001/archpsyc.55.11.967; Uhl GR, 2004, ARCH GEN PSYCHIAT, V61, P223, DOI 10.1001/archpsyc.61.3.223; Ulery PG, 2006, J NEUROSCI, V26, P5131, DOI 10.1523/JNEUROSCI.4970-05.2006; Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005; Volkow ND, 2004, NAT REV NEUROSCI, V5, P963, DOI 10.1038/nrn1539; Yan YJ, 2007, BEHAV BRAIN RES, V177, P261, DOI 10.1016/j.bbr.2006.11.033; Yan YJ, 2006, BEHAV BRAIN RES, V168, P137, DOI 10.1016/j.bbr.2005.11.030; Zavala AR, 2003, BRAIN RES, V990, P157, DOI 10.1016/S0006-8993(03)03452-8	49	44	65	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					1994	2004		10.1096/fj.06-7772com	http://dx.doi.org/10.1096/fj.06-7772com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17356005				2022-12-28	WOS:000247500300009
J	Hanel, P; Andreani, P; Graler, MH				Haenel, Petra; Andreani, Paul; Graeler, Markus H.			Erythrocytes store and release sphingosine 1-phosphate in blood	FASEB JOURNAL			English	Article						HPLC; plasma; sphingolipid; thrombocyte	PROTEIN-COUPLED RECEPTORS; LYMPHOCYTE EGRESS; T-CELLS; IN-VIVO; SPHINGOSINE-1-PHOSPHATE; FTY720; MODULATION; EXPRESSION; SPHINGOLIPIDS; EXTRACTION	The blood constituent sphingosine 1-phosphate (S1P) is a specific ligand for five G-protein-coupled receptors designated S1P(1-5). Expression of the S1P(1) receptor on lymphocytes is required for their exit from secondary lymphoid organs, suggesting that S1P serves as a stimulus for maintaining lymphocyte circulation in blood. Despite its potential role in immune surveillance, the regulatory system that controls blood S1P levels is not well understood. This report reveals that erythrocytes constitute a buffer system for S1P in blood. They efficiently incorporated and stored S1P, and protected it from cellular degradation. They also released S1P into plasma, but not into other serum-free media, indicating that S1P release was controlled by a plasma factor. Erythrocytes did not generate S1P since an increase in plasma S1P levels was always accompanied by a decrease in cellular S1P levels. Thrombocytes that were reported to generate and release S1P after activation did not contribute to the observed S1P release in blood. The amount of erythrocytes as well as the proportion of plasma in the medium determined the magnitude of S1P release. Adoptively transferred S1P-loaded and unloaded mouse erythrocytes displayed a normal life span and similar S1P levels 24 h after recovery, indicating that S1P incorporation and release are dynamically regulated in vivo.	Hannover Med Sch, Inst Immunol, D-30625 Hannover, Germany	Hannover Medical School	Graler, MH (corresponding author), Hannover Med Sch, Inst Immunol, Bldg K11,OE 9422,Carl Neuberg Str 1, D-30625 Hannover, Germany.	graeler.markus@mh-hannover.de	Gräler, Markus/ABH-1905-2021	Gräler, Markus/0000-0001-6650-7849				Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Andreani P, 2006, ANAL BIOCHEM, V358, P239, DOI 10.1016/j.ab.2006.08.027; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Butter JJ, 2005, J CHROMATOGR B, V824, P65, DOI 10.1016/j.jchromb.2005.06.040; Chiba K, 2006, CELL MOL IMMUNOL, V3, P11; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Deutschman DH, 2003, AM HEART J, V146, P62, DOI 10.1016/S0002-8703(03)00118-2; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; Jolly PS, 2005, BLOOD, V105, P4736, DOI 10.1182/blood-2004-12-4686; Karliner JS, 2004, J CELL BIOCHEM, V92, P1095, DOI 10.1002/jcb.20129; Kharel Y, 2005, J BIOL CHEM, V280, P36865, DOI 10.1074/jbc.M506293200; Kono M, 2006, J BIOL CHEM, V281, P7324, DOI 10.1074/jbc.M508382200; Lo CG, 2005, J EXP MED, V201, P291, DOI 10.1084/jem.20041509; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; McVerry BJ, 2005, CELL SIGNAL, V17, P131, DOI 10.1016/j.cellsig.2004.08.006; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Ruwisch L, 2001, N-S ARCH PHARMACOL, V363, P358, DOI 10.1007/s002100000365; Sanna MG, 2006, NAT CHEM BIOL, V2, P434, DOI 10.1038/nchembio804; Schwab SR, 2005, SCIENCE, V309, P1735, DOI 10.1126/science.1113640; Van Veldhoven PP, 2005, CHEM PHYS LIPIDS, V136, P164; Wei SH, 2005, NAT IMMUNOL, V6, P1228, DOI 10.1038/ni1269; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; Young N, 2006, THESCIENTIFICWORLDJO, V6, P946, DOI 10.1100/tsw.2006.182; Zemann B, 2006, BLOOD, V107, P1454, DOI 10.1182/blood-2005-07-2628	26	297	304	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					1202	1209		10.1096/fj.06-7433com	http://dx.doi.org/10.1096/fj.06-7433com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17215483				2022-12-28	WOS:000245650400024
J	Yamaguchi, Y; Passeron, T; Hoashi, T; Watabe, H; Rouzaud, F; Yasumoto, K; Hara, T; Tohyama, C; Katayama, I; Miki, T; Hearing, VJ				Yamaguchi, Yuji; Passeron, Thierry; Hoashi, Toshihiko; Watabe, Hidenori; Rouzaud, Franocois; Yasumoto, Ken-ichi; Hara, Takahiko; Tohyama, Chiharu; Katayama, Ichiro; Miki, Toru; Hearing, Vincent J.			Dickkopf 1 (DKK1) regulates skin pigmentation and thickness by affecting Wnt/beta-catenin signaling in keratinocytes	FASEB JOURNAL			English	Article						keratin 9; epithelial cell transforming sequence 2; protease-activated receptor 2; glucose synthase kinase; melanocyte	PROTEINASE-ACTIVATED RECEPTOR-2; MESENCHYMAL-EPITHELIAL INTERACTIONS; EXPOSING BONE-MARROW; ADULT STEM-CELLS; PALMOPLANTAR FIBROBLASTS; GENE-EXPRESSION; WNT; DIFFERENTIATION; PATHWAY; PHOSPHORYLATION	The epidermis (containing primarily keratinocytes and melanocytes) overlies the dermis (containing primarily fibroblasts) of human skin. We previously reported that dickkopf 1 (DKK1) secreted by fibroblasts in the dermis elicits the hypopigmented phenotype of palmoplantar skin due to suppression of melanocyte function and growth via the regulation of two important signaling factors, microphthalmia-associated transcription factor (MITF) and beta-catenin. We now report that treatment of keratinocytes with DKK1 increases their proliferation and decreases their uptake of melanin and that treatment of reconstructed skin with DKK1 induces a thicker and less pigmented epidermis. DNA microarray analysis revealed many genes regulated by DKK1, and several with critical expression patterns were validated by reverse transcriptase-polymerase chain reaction and Western blotting. DKK1 induced the expression of keratin 9 and a-Kelch-like ECT2 interacting protein (alpha KLEIP) but down-regulated the expression of beta-catenin, glycogen synthase kinase 3(3, protein kinase C, and proteinase-activated receptor-2 (PAR-2), which is consistent with the expression patterns of those proteins in human palmoplantar skin. Treatment of reconstructed skin with DKK1 reproduced the expression patterns of those key proteins observed in palmoplantar skin. These findings further elucidate why human skin is thicker and paler on the palms and soles than on the trunk through topographical and site-specific differences in the secretion of DKK1 by dermal fibroblasts that affects the overlying epidermis.	[Yamaguchi, Yuji] Nagoya City Univ, Grad Sch Med Sci, Dept Geriatr & Environm Dermatol, Mizuho Ku, Nagoya, Aichi 4678601, Japan; [Yamaguchi, Yuji; Passeron, Thierry; Hoashi, Toshihiko; Watabe, Hidenori; Rouzaud, Franocois; Yasumoto, Ken-ichi; Hara, Takahiko; Miki, Toru; Hearing, Vincent J.] NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; [Yamaguchi, Yuji; Tohyama, Chiharu; Katayama, Ichiro] Osaka Univ, Grad Sch Med, Dept Dermatol, Osaka, Japan	Nagoya City University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Osaka University	Yamaguchi, Y (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Geriatr & Environm Dermatol, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	jaijin@med.nagoya-cu.ac	Yamaguchi, Yuji/B-9312-2008; Yamaguchi, Yuji/X-6681-2019; Tohyama, Chiharu/AAI-5598-2020	Tohyama, Chiharu/0000-0003-1061-6872; Yasumoto, Ken-ichi/0000-0002-8090-1161; Passeron, Thierry/0000-0002-0797-6570; Yamaguchi, Yuji/0000-0003-4338-2662	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010785, ZIABC010785, ZIABC010786, Z01BC010786] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3; Babiarz-Magee L, 2004, PIGM CELL RES, V17, P241, DOI 10.1111/j.1600-0749.2004.00133.x; Brandner JM, 2004, J INVEST DERMATOL, V122, P1310, DOI 10.1111/j.0022-202X.2004.22529.x; Carroll K, 2004, NAT REV MOL CELL BIO, V5, P55, DOI 10.1038/nrm1278; Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Dasen JS, 2003, NATURE, V425, P926, DOI 10.1038/nature02051; Di WL, 2005, J CELL SCI, V118, P1505, DOI 10.1242/jcs.01733; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200; Gregory CA, 2005, J BIOL CHEM, V280, P2309, DOI 10.1074/jbc.M406275200; Hachem JP, 2006, J INVEST DERMATOL, V126, P2074, DOI 10.1038/sj.jid.5700351; Hara T, 2004, MOL BIOL CELL, V15, P1172, DOI 10.1091/mbc.E03-07-0531; Hoashi T, 2005, J BIOL CHEM, V280, P14006, DOI 10.1074/jbc.M413692200; Hofbauer KH, 2003, EUR J BIOCHEM, V270, P4515, DOI 10.1046/j.1432-1033.2003.03846.x; Ikeda A, 2002, J CELL SCI, V115, P9; Ikeda A, 2001, HUM MOL GENET, V10, P1325, DOI 10.1093/hmg/10.12.1325; Jarzab B, 2005, CANCER RES, V65, P1587, DOI 10.1158/0008-5472.CAN-04-3078; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kmita M, 2002, NATURE, V420, P145, DOI 10.1038/nature01189; KNAPP AC, 1986, J CELL BIOL, V103, P657, DOI 10.1083/jcb.103.2.657; Kobayashi S, 1996, FEBS LETT, V386, P149, DOI 10.1016/0014-5793(96)00393-6; Kushimoto T, 2001, P NATL ACAD SCI USA, V98, P10698, DOI 10.1073/pnas.191184798; Li W, 2004, J INVEST DERMATOL, V123, P622, DOI 10.1111/j.0022-202X.2004.23416.x; Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Papp H, 2003, EXP DERMATOL, V12, P811, DOI 10.1111/j.0906-6705.2003.00097.x; Pullar CE, 2006, FASEB J, V20, P76, DOI 10.1096/fj.05-4188com; Saito H, 2003, PIGM CELL RES, V16, P261, DOI 10.1034/j.1600-0749.2003.00039.x; Scott G, 2003, J INVEST DERMATOL, V121, P529, DOI 10.1046/j.1523-1747.2003.12427.x; Scott G, 2001, J INVEST DERMATOL, V117, P1412, DOI 10.1046/j.0022-202x.2001.01575.x; Seeliger S, 2003, FASEB J, V17, P1871, DOI 10.1096/fj.02-1112com; Seiberg M, 2000, EXP CELL RES, V254, P25, DOI 10.1006/excr.1999.4692; Sick S, 2006, SCIENCE, V314, P1447, DOI 10.1126/science.1130088; Steinhoff M, 1999, EXP DERMATOL, V8, P282; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Yamaguchi Y, 2001, J DERMATOL, V28, P521, DOI 10.1111/j.1346-8138.2001.tb00025.x; Yamaguchi Y, 2005, BRIT J DERMATOL, V152, P664, DOI 10.1111/j.1365-2133.2005.06401.x; Yamaguchi Y, 2004, J CELL BIOL, V165, P275, DOI 10.1083/jcb.200311122; Yamaguchi Y, 2004, BRIT J DERMATOL, V151, P1019, DOI 10.1111/j.1365-2133.2004.06170.x; Yamaguchi Y, 2001, ARCH DERMATOL, V137, P621; Yamaguchi Y, 2005, J DERMATOL SCI, V40, P1, DOI 10.1016/j.jdermsci.2005.04.006; Yamaguchi Y, 1999, J INVEST DERMATOL, V112, P483, DOI 10.1046/j.1523-1747.1999.00544.x; Yamaguchi Y, 2007, J INVEST DERMATOL, V127, P1217, DOI 10.1038/sj.jid.5700629; Yamaguchi Y, 2006, FASEB J, V20, P1486, DOI 10.1096/fj.06-5725fje; Zakany J, 2004, SCIENCE, V304, P1669, DOI 10.1126/science.1096049	53	100	109	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1009	1020		10.1096/fj.07-9475com	http://dx.doi.org/10.1096/fj.07-9475com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	17984176				2022-12-28	WOS:000254581000007
J	Araki, W; Takahashi-Sasaki, N; Chui, DH; Saito, S; Takeda, K; Shirotani, K; Takahashi, K; Murayama, KS; Kametani, F; Shiraishi, H; Komano, H; Tabira, T				Araki, Wataru; Takahashi-Sasaki, Noriko; Chui, De-Hua; Saito, Shinya; Takeda, Kazuya; Shirotani, Keiro; Takahashi, Keikichi; Murayama, Kiyoko S.; Kametani, Fuyuki; Shiraishi, Hirohisa; Komano, Hiroto; Tabira, Takeshi			A family of membrane proteins associated with presenilin expression and gamma-secretase function	FASEB JOURNAL			English	Article						Alzheimer's disease; beta-amyloid; nicastrin	AMYLOID-BETA-PEPTIDE; ALZHEIMERS-DISEASE; DIFFERENTIAL DISPLAY; PROTEOLYTIC RELEASE; TALKING POINT; MESSENGER-RNA; MUTATIONS; NICASTRIN; COMPLEX; TRAFFICKING	Presenilin 1 (PS1) forms the gamma-secretase complex with at least three components: nicastrin, APH-1, and PEN-2. This complex mediates intramembrane cleavage of amyloid precursor protein (APP) to generate beta-amyloid protein (A beta) as well as other type 1 transmembrane proteins. Although PS1 mutations linked to familial Alzheimer's disease influence these cleavages, their biological consequences have not been fully understood. In this study, we used mRNA differential display analysis to identify a gene, denoted adoplin-1/ORMDL-1, which displays significantly reduced expression in association with PS1 mutations. Adoplin-1 and two highly homologous genes (adoplin-2, -3) constitute a gene family that encodes transmembrane proteins. The mRNA and protein levels of adoplins (particularly adoplin-1, -2) were markedly elevated in PS-deficient fibroblasts, compared to wild-type cells. Moreover, knockdown of the three adoplins by RNA interference affected maturation of nicastrin and its association with PS1. Adoplin knockdown additionally resulted in elevated levels of APP C-terminal fragments and decreased A beta production, suggestive of reduced gamma-secretase activity. Our data collectively indicate that adoplins are unique molecules with PS-related expression and functions that may play important role(s) in the maturation and activity of the gamma-secretase complex.	[Araki, Wataru; Saito, Shinya; Murayama, Kiyoko S.] NCNP, Natl Inst Neurosci, Dept Demyelinating Dis & Aging, Tokyo 1878502, Japan; [Takahashi-Sasaki, Noriko] Tokyo Univ Agr & Technol, Katayanagi Adv Res Labs, Tokyo, Japan; [Chui, De-Hua] Peking Univ, Neurosci Res Inst, Beijing 100871, Peoples R China; [Takeda, Kazuya; Takahashi, Keikichi; Tabira, Takeshi] NCGG, Natl Inst Longev Sci, Aichi, Japan; [Shirotani, Keiro] Hokkaido Univ, Grad Sch Med Sci, Dept Biochem, Sapporo, Hokkaido, Japan; [Kametani, Fuyuki] Tokyo Metropolitan Org Med Res, Tokyo Inst Psychiat, Tokyo, Japan; [Shiraishi, Hirohisa; Komano, Hiroto] Iwate Med Univ, Fac Pharmaceut Sci, Iwate, Japan	National Center for Neurology & Psychiatry - Japan; Tokyo University of Agriculture & Technology; Peking University; Hokkaido University; Tokyo Institute of Psychiatry; Tokyo Metropolitan Institute of Medical Science; Iwate Medical University	Araki, W (corresponding author), NCNP, Natl Inst Neurosci, Dept Demyelinating Dis & Aging, Tokyo 1878502, Japan.	araki@ncnp.go.jp	Araki, Wataru/G-7913-2014; Kametani, Fuyuki/G-4752-2011	Araki, Wataru/0000-0001-8467-6937; Kametani, Fuyuki/0000-0001-9125-7001				Araki W, 2001, J NEUROCHEM, V79, P1161, DOI 10.1046/j.1471-4159.2001.00638.x; Bentahir M, 2006, J NEUROCHEM, V96, P732, DOI 10.1111/j.1471-4159.2005.03578.x; Chen FS, 2006, NATURE, V440, P1208, DOI 10.1038/nature04667; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Chui DH, 2001, J ALZHEIMERS DIS, V3, P231; De Strooper B, 2007, EMBO REP, V8, P141, DOI 10.1038/sj.embor.7400897; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; HJELMQVIST L, 2002, GENOME BIOL, V3; KAMETANI F, 1993, BIOCHEM BIOPH RES CO, V191, P392, DOI 10.1006/bbrc.1993.1230; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee RKK, 1997, P NATL ACAD SCI USA, V94, P5422, DOI 10.1073/pnas.94.10.5422; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Mirnics K, 2005, J NEUROSCI, V25, P1571, DOI 10.1523/JNEUROSCI.4145-04.2005; Saito S, 2005, BIOCHEM BIOPH RES CO, V327, P18, DOI 10.1016/j.bbrc.2004.11.130; Saito S, 2005, BIOCHEM BIOPH RES CO, V330, P1068, DOI 10.1016/j.bbrc.2005.03.096; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shirotani K, 1999, NEUROSCI LETT, V262, P37, DOI 10.1016/S0304-3940(99)00037-3; Shirotani K, 2000, J BIOL CHEM, V275, P3681, DOI 10.1074/jbc.275.5.3681; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Takeda K, 2004, EUR J NEUROSCI, V19, P258, DOI 10.1111/j.0953-816X.2003.03135.x; WANG XK, 1995, BIOTECHNIQUES, V18, P448; Wolfe MS, 2007, EMBO REP, V8, P136, DOI 10.1038/sj.embor.7400896; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang YW, 2005, J BIOL CHEM, V280, P17020, DOI 10.1074/jbc.M409467200; Zhou SX, 2005, P NATL ACAD SCI USA, V102, P7499, DOI 10.1073/pnas.0502768102	40	9	16	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2008	22	3					819	827		10.1096/fj.07-9072com	http://dx.doi.org/10.1096/fj.07-9072com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17928364				2022-12-28	WOS:000254143700020
J	Fainaru, O; Adini, A; Benny, O; Adini, I; Short, S; Bazinet, L; Nakai, K; Pravda, E; Hornstein, MD; D'Amato, RJ; Folkman, J				Fainaru, Ofer; Adini, Avner; Benny, Ofra; Adini, Irit; Short, Sarah; Bazinet, Lauren; Nakai, Kei; Pravda, Elke; Hornstein, Mark D.; D'Amato, Robert J.; Folkman, Judah			Dendritic cells support angiogenesis and promote lesion growth in a murine model of endometriosis	FASEB JOURNAL			English	Article						Lewis lung carcinoma; melanoma	PERITONEAL-FLUID; MIGRATION; IMMUNITY; ABSENCE; WOMEN; VEGF	Endometriosis affects 10-15% of women and is associated with pelvic pain and infertility. Angiogenesis plays an essential role in its pathogenesis. Dendritic cells (DCs) were recently implicated in supporting tumor angiogenesis. As both tumors and endometriosis lesions depend on angiogenesis, we investigated the possibility that DCs may also play a role in endometriosis. We induced endometriosis in 8-wk-old female C57BL/6 mice by implantation of autologous endometrium into the peritoneal cavity. We observed an abundance of CD11c(+) DCs infiltrating sites of angiogenesis in endometriosis lesions. We noticed a similar pattern of infiltrating DCs at sites of angiogenesis in the peritoneal Lewis lung carcinoma tumor model. These DCs were immature ( major histocompatability complex class IIlow) and expressed vascular endothelial growth factor receptor 2. Peritoneal implanted bone marrow-derived DCs (BMDCs) incorporated into both endometriosis lesions and into B16 melanoma tumors and enhanced their growth at 8 days compared with controls (5.1 +/- 2.5 vs. 1.5 +/- 0.5mm(2), n = 4 and 4, P<0.0001 for endometriosis; 67.6 +/- 15.1 vs. 22.7 +/- 14.6 mm(2), n = 5 and 7, P = 0.0004 for mouse melanoma). Finally, immature BMDCs but not mature BMDCs enhanced microvascular endothelial cell migration in vitro ( 219 +/- 51 vs. 93 +/- 32 cells, P = 0.02). Based on these findings, we suggest a novel role for DCs in supporting angiogenesis and promoting lesion growth both in endometriosis and in tumors.	[Fainaru, Ofer; Adini, Avner; Benny, Ofra; Adini, Irit; Short, Sarah; Bazinet, Lauren; Nakai, Kei; Pravda, Elke; D'Amato, Robert J.; Folkman, Judah] Harvard Univ, Sch Med, Childrens Hosp Boston, Vasc Biol Program,Dept Surg, Boston, MA 02115 USA; [Fainaru, Ofer; Hornstein, Mark D.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Fainaru, O (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, Vasc Biol Program,Dept Surg, 300 Longwood Ave, Boston, MA 02115 USA.	ofer.fainaru@childrens.harvard.edu	Benny, Ofra/AAB-3294-2021					Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Becker CM, 2006, AM J PATHOL, V168, P2074, DOI 10.2353/ajpath.2006.051133; Becker CM, 2006, FERTIL STERIL, V85, P71, DOI 10.1016/j.fertnstert.2005.07.1290; Becker CM, 2005, FERTIL STERIL, V84, P1144, DOI 10.1016/j.fertnstert.2005.04.040; Conejo-Garcia JR, 2004, NAT MED, V10, P950, DOI 10.1038/nm1097; Coukos G, 2005, BRIT J CANCER, V92, P1182, DOI 10.1038/sj.bjc.6602476; Cramer DW, 2002, ANN NY ACAD SCI, V955, P11, DOI 10.1111/j.1749-6632.2002.tb02761.x; CRAMER DW, 2002, ANN NY ACAD SCI, V955, P396; Dabrosin C, 2002, AM J PATHOL, V161, P909, DOI 10.1016/S0002-9440(10)64251-4; De Palma M, 2006, BBA-REV CANCER, V1766, P159, DOI 10.1016/j.bbcan.2006.06.003; DMOWSKI WP, 1981, AM J OBSTET GYNECOL, V141, P377, DOI 10.1016/0002-9378(81)90598-6; Donnez J, 1998, HUM REPROD, V13, P1686, DOI 10.1093/humrep/13.6.1686; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Efstathiou JA, 2005, FERTIL STERIL, V83, P171, DOI 10.1016/j.fertnstert.2004.06.058; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Folkman J, 2002, CANCER CELL, V1, P113, DOI 10.1016/S1535-6108(02)00038-7; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5; Hull ML, 2003, J CLIN ENDOCR METAB, V88, P2889, DOI 10.1210/jc.2002-021912; Iwasaki A, 2001, J IMMUNOL, V166, P4884, DOI 10.4049/jimmunol.166.8.4884; Labeur MS, 1999, J IMMUNOL, V162, P168; Lutz MB, 2000, EUR J IMMUNOL, V30, P1813, DOI 10.1002/1521-4141(200007)30:7<1813::AID-IMMU1813>3.0.CO;2-8; McLaren J, 1996, J CLIN INVEST, V98, P482, DOI 10.1172/JCI118815; Muller SM, 2005, P NATL ACAD SCI USA, V102, P10587, DOI 10.1073/pnas.0502752102; Nap AW, 2004, J CLIN ENDOCR METAB, V89, P1089, DOI 10.1210/jc.2003-031406; OOSTERLYNCK DJ, 1991, FERTIL STERIL, V56, P45; Pujol BF, 2001, EUR J CELL BIOL, V80, P99, DOI 10.1078/0171-9335-00136; SHOLLEY MM, 1984, LAB INVEST, V51, P624; Short SM, 2005, J CELL BIOL, V168, P643, DOI 10.1083/jcb.200407060; Suzumori N, 2004, FERTIL STERIL, V82, P93, DOI 10.1016/j.fertnstert.2003.11.043; Taylor RN, 2002, ANN NY ACAD SCI, V955, P89, DOI 10.1111/j.1749-6632.2002.tb02769.x; Webster B, 2006, J EXP MED, V203, P1903, DOI 10.1084/jem.20052272	32	83	90	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					522	529		10.1096/fj.07-9034com	http://dx.doi.org/10.1096/fj.07-9034com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17873101				2022-12-28	WOS:000252822600022
J	Gabet, AS; Accardi, R; Bellopede, A; Popp, S; Boukamp, P; Sylla, BS; Londono-Vallejo, JA; Tommasino, M				Gabet, Anne-Sophie; Accardi, Rosita; Bellopede, Angelica; Popp, Susanne; Boukamp, Petra; Sylla, Bakary S.; Londono-Vallejo, J. Arturo; Tommasino, Massimo			Impairment of the telomere/telomerase system and genomic instability are associated with keratinocyte immortalization induced by the skin human papillomavirus type 38	FASEB JOURNAL			English	Article						HPV38 E6 and E7; telomere dysfunctions; chromosomal abnormalities	REVERSE-TRANSCRIPTASE HTERT; SQUAMOUS-CELL CARCINOMAS; TELOMERE DYSFUNCTION; CHROMOSOMAL INSTABILITY; CANCER; E6; MICE; E7; CLASSIFICATION; ACTIVATION	The skin human papillomavirus (HPV) types belonging to the genus beta of the HPV phylogenetic tree appear to be associated with nonmelanoma skin cancer. We previously showed that the beta HPV type 38 E6 and E7 oncoproteins are able to inactivate the tumor suppressors p53 and retinoblastoma. Here, both viral proteins were expressed in primary human skin keratinocytes in order to study their effects on the telomere/telomerase system. We show that immortalization of skin keratinocytes induced by HPV38 E6/E7 is associated with hTERT gene overexpression. This event is, in part, explained by the accumulation of the p53-related protein, Delta Np73. Despite elevated levels of hTERT mRNA, the telomerase activity detected in HPV38 E6/E7 keratinocytes was lower than that observed in HPV16 E6/E7 keratinocytes. The low telomerase activation in highly proliferative HPV38 E6/E7 keratinocytes resulted in the presence of extremely short and unstable telomeres. In addition, we observed anaphase bridges, mitotic multipolarity, and dramatic genomic aberrations. Interestingly, the ectopic expression of hTERT prevents both telomere erosion and genomic instability. Thus, we showed that in HPV38 E6/E7 keratinocytes characterized by unscheduled proliferation, suboptimal activation of telomerase and subsequent extensive telomere shortening result in genomic instability facilitating cellular immortalization.	[Gabet, Anne-Sophie; Accardi, Rosita; Bellopede, Angelica; Sylla, Bakary S.; Tommasino, Massimo] Int Agcy Res Canc, WHO, Infect & Canc Biol Grp, F-69372 Lyon, France; [Popp, Susanne; Boukamp, Petra] Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany; [Londono-Vallejo, J. Arturo] UPMC, CNRS, Inst Curie, UMR7147, Paris, France	World Health Organization; International Agency for Research on Cancer (IARC); Helmholtz Association; German Cancer Research Center (DKFZ); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Tommasino, M (corresponding author), Int Agcy Res Canc, WHO, Infect & Canc Biol Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	tommasino@iarc.fr	Londono-Vallejo, Arturo/ABH-5555-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563				Accardi R, 2006, EMBO REP, V7, P334, DOI 10.1038/sj.embor.7400615; Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Beitzinger M, 2006, ONCOGENE, V25, P813, DOI 10.1038/sj.onc.1209125; Bickenbach JR, 1998, J INVEST DERMATOL, V111, P1045, DOI 10.1046/j.1523-1747.1998.00420.x; Boldrini L, 2003, INT J MOL MED, V11, P607; BOUKAMP P, 1982, JNCI-J NATL CANCER I, V68, P415; Boukamp P, 2005, CARCINOGENESIS, V26, P1657, DOI 10.1093/carcin/bgi123; Caldeira S, 2003, J VIROL, V77, P2195, DOI 10.1128/JVI.77.3.2195-2206.2003; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; der-Sarkissian H, 2004, ONCOGENE, V23, P1221, DOI 10.1038/sj.onc.1207152; Dong W, 2005, J VIROL, V79, P14899, DOI 10.1128/JVI.79.23.14899-14908.2005; Filatov L, 1998, ONCOGENE, V16, P1825, DOI 10.1038/sj.onc.1201711; Gewin L, 2004, GENE DEV, V18, P2269, DOI 10.1101/gad.1214704; Gisselsson D, 2002, BRIT J CANCER, V87, P202, DOI 10.1038/sj.bjc.6600438; Gomez D, 2003, J BIOL CHEM, V278, P50554, DOI 10.1074/jbc.M308440200; Jackson S, 2000, ONCOGENE, V19, P592, DOI 10.1038/sj.onc.1203339; James MA, 2006, INT J CANCER, V119, P1878, DOI 10.1002/ijc.22064; Jin YS, 1999, GENE CHROMOSOME CANC, V26, P295, DOI 10.1002/(SICI)1098-2264(199912)26:4<295::AID-GCC3>3.0.CO;2-W; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Murnane JP, 2004, BIOESSAYS, V26, P1164, DOI 10.1002/bies.20125; Pantic M, 2006, ONCOGENE, V25, P4413, DOI 10.1038/sj.onc.1209486; Parris CN, 1999, BRIT J CANCER, V79, P47, DOI 10.1038/sj.bjc.6690010; Pfister Herbert, 2003, J Natl Cancer Inst Monogr, P52; Plug-DeMaggio AW, 2004, ONCOGENE, V23, P3561, DOI 10.1038/sj.onc.1207388; Popp S, 2002, INT J CANCER, V99, P352, DOI 10.1002/ijc.10321; Racek T, 2005, J BIOL CHEM, V280, P40402, DOI 10.1074/jbc.C500193200; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Schaper ID, 2005, CANCER RES, V65, P1394, DOI 10.1158/0008-5472.CAN-04-3263; Shay JW, 2005, CARCINOGENESIS, V26, P867, DOI 10.1093/carcin/bgh296; Steenbergen RDM, 2005, J CLIN VIROL, V32, pS25, DOI 10.1016/j.jcv.2004.11.019; Stewenius Y, 2005, P NATL ACAD SCI USA, V102, P5541, DOI 10.1073/pnas.0408454102; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; Ulaner GA, 2000, INT J CANCER, V85, P330, DOI 10.1002/(SICI)1097-0215(20000201)85:3<330::AID-IJC6>3.0.CO;2-U; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Zhang AJ, 2004, ONCOGENE, V23, P7441, DOI 10.1038/sj.onc.1207527	40	50	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2008	22	2					622	632		10.1096/fj.07-8389com	http://dx.doi.org/10.1096/fj.07-8389com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17898088				2022-12-28	WOS:000252822600032
J	Kalsotra, A; Du, LP; Wang, Y; Ladd, PA; Kikuta, Y; Duvic, M; Boyd, AS; Keeney, DS; Strobel, HW				Kalsotra, Auinash; Du, Liping; Wang, Ying; Ladd, Patricia A.; Kikuta, Yasushi; Duvic, Madeleine; Boyd, Alan S.; Keeney, Diane S.; Strobel, Henry W.			Inflammation resolved by retinoid X receptor-mediated inactivation of leukotriene signaling pathways	FASEB JOURNAL			English	Article						cytochromes P4504F; epidermal inflammation; resolution signals	CYTOCHROME-P450 CYP GENES; CHAIN FATTY-ACIDS; HUMAN SKIN CELLS; OMEGA-HYDROXYLASES; PSORIATIC LESIONS; ARACHIDONIC-ACID; B-4 RECEPTOR; EXPRESSION; METABOLISM; KERATINOCYTES	Leukotrienes are implicated in the pathogenesis of diverse, inflammation-driven diseases. Metabolic inactivation of leukotriene signaling is an innate response to resolve inflammation, yet little is known of mechanisms regulating disposition of leukotrienes in peripheral tissues afflicted in common inflammatory diseases. We studied leukotriene hydroxylases (CYP4F gene products) in human skin, a common target of inflammation and adverse drug reactions. Epidermal keratinocytes express at least six CYP4F enzymes; the most highly expressed and highly regulated is CYP4F3A-the main neutrophil leukotriene hydroxylase. Differentiation-specific factors and retinoids are positive CYP4F regulators in vitro, effecting increased leukotriene B4 hydroxylation (inactivation). CYP4F expression is up-regulated in situ in hyperproliferative dermatoses-an innate mechanism to repair and restore epidermal barrier competency-and after retinoid therapy. Enhanced CYP4F-mediated inactivation of leukotriene signaling is a previously unrecognized antiinflammatory property of therapeutic retinoids mediated by preferential interactions between retinoid X receptors and CYP4F promoter elements in epidermal cells.	[Kalsotra, Auinash; Wang, Ying; Strobel, Henry W.] Univ Texas Houston, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Du, Liping; Keeney, Diane S.] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37212 USA; [Ladd, Patricia A.; Boyd, Alan S.; Keeney, Diane S.] Vanderbilt Univ, Sch Med, Dept Med Dermatol, Nashville, TN 37212 USA; [Kikuta, Yasushi] Fukuyama Univ, Dept Appl Biol Sci, Fukuyama, Hiroshima, Japan; [Duvic, Madeleine] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX USA	University of Texas System; University of Texas Health Science Center Houston; Vanderbilt University; Vanderbilt University; Fukuyama University; University of Texas System; UTMD Anderson Cancer Center	Strobel, HW (corresponding author), Univ Texas Houston, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, 6431 Fannin St,Med Sch Bldg 6,Room 200, Houston, TX 77030 USA.	henry.w.strobel@uth.tmc.edu		Kalsotra, Auinash/0000-0002-1011-0006	NATIONAL CANCER INSTITUTE [K24CA086815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045603, R01AR047357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH070054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044174] Funding Source: NIH RePORTER; NCI NIH HHS [K24-CA86815] Funding Source: Medline; NIAMS NIH HHS [AR47357, R01 AR45603] Funding Source: Medline; NIMH NIH HHS [R01 MH070054] Funding Source: Medline; NINDS NIH HHS [R01 NS044174] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmad N, 2004, J INVEST DERMATOL, V123, P417, DOI 10.1111/j.0022-202X.2004.23307.x; Arita M, 2005, BIOCHEM BIOPH RES CO, V338, P149, DOI 10.1016/j.bbrc.2005.07.181; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; BARKER JNWN, 1991, LANCET, V337, P211, DOI 10.1016/0140-6736(91)92168-2; Baron JM, 2005, J INVEST DERMATOL, V125, P143, DOI 10.1111/j.0022-202X.2005.23791.x; Berry KAZ, 2003, J BIOL CHEM, V278, P24449, DOI 10.1074/jbc.M300856200; Blomhoff R, 2006, J NEUROBIOL, V66, P606, DOI 10.1002/neu.20242; Christmas P, 2001, J BIOL CHEM, V276, P38166; Cui X, 2003, BBA-GEN SUBJECTS, V1619, P325, DOI 10.1016/S0304-4165(02)00491-9; Curley CR, 2006, EUR J HUM GENET, V14, P1215, DOI 10.1038/sj.ejhg.5201687; Du LP, 2006, J PHARMACOL EXP THER, V319, P1162, DOI 10.1124/jpet.106.111724; Du LP, 2006, TOXICOL APPL PHARM, V213, P135, DOI 10.1016/j.taap.2005.10.003; Du LP, 2006, J PHARMACOL EXP THER, V316, P371, DOI 10.1124/jpet.105.093922; DUVIC M, 1997, J AM ACAD DERMATOL, V37, P18; Fisher GJ, 1996, FASEB J, V10, P1002, DOI 10.1096/fasebj.10.9.8801161; Fogh K, 2000, PROSTAG OTH LIPID M, V63, P43, DOI 10.1016/S0090-6980(00)00096-4; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Heise R, 2006, J INVEST DERMATOL, V126, P2473, DOI 10.1038/sj.jid.5700432; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; Kalsotra A, 2004, TOXICOL APPL PHARM, V199, P295, DOI 10.1016/j.taap.2003.12.033; Kalsotra A, 2003, FEBS LETT, V555, P236, DOI 10.1016/S0014-5793(03)01240-7; Kalsotra A, 2007, ARCH BIOCHEM BIOPHYS, V461, P104, DOI 10.1016/j.abb.2007.02.027; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Kalsotra A, 2006, PHARMACOL THERAPEUT, V112, P589, DOI 10.1016/j.pharmthera.2006.03.008; Kikuta Y, 2004, BBA-MOL CELL BIOL L, V1683, P7, DOI 10.1016/j.bbalip.2004.03.007; Kikuta Y, 2002, PROSTAG OTH LIPID M, V68-9, P345, DOI 10.1016/S0090-6980(02)00039-4; Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310; KUPPER TS, 1990, J CLIN INVEST, V86, P1783, DOI 10.1172/JCI114907; Ladd PA, 2003, J BIOL CHEM, V278, P35184, DOI 10.1074/jbc.M301666200; Le Quere V, 2004, J LIPID RES, V45, P1446, DOI 10.1194/jlr.M300463-JLR200; Lefevre C, 2006, HUM MOL GENET, V15, P767, DOI 10.1093/hmg/ddi491; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Merk HF, 2004, TOXICOL APPL PHARM, V195, P267, DOI 10.1016/j.taap.2003.09.023; MUKHTAR H, 1989, J INVEST DERMATOL, V93, P231, DOI 10.1111/1523-1747.ep12277578; Murphy RC, 2007, BIOCHEM J, V405, P379, DOI 10.1042/BJ20070289; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Nelson DR, 2004, PHARMACOGENETICS, V14, P1, DOI 10.1097/00008571-200401000-00001; Nigam S, 2005, BIOCHEM BIOPH RES CO, V338, P161, DOI 10.1016/j.bbrc.2005.09.065; Peters-Golden M, 2005, J IMMUNOL, V174, P589, DOI 10.4049/jimmunol.174.2.589; Quack M, 2002, J CELL BIOCHEM, V86, P601, DOI 10.1002/jcb.10247; Rizzo WB, 2005, HUM MUTAT, V26, P1, DOI 10.1002/humu.20181; SALMON JK, 1994, WESTERN J MED, V160, P146; Sanders RJ, 2006, J BIOL CHEM, V281, P13180, DOI 10.1074/jbc.M513481200; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Smith KJ, 2002, J CUTAN MED SURG, V6, P241, DOI 10.1007/s10227-001-0047-4; SOBERMAN RJ, 1988, J BIOL CHEM, V263, P7996; Sontag TJ, 2002, J BIOL CHEM, V277, P25290, DOI 10.1074/jbc.M201466200; Stark K, 2006, PROSTAG OTH LIPID M, V79, P114, DOI 10.1016/j.prostaglandins.2005.12.003; Stark K, 2005, ARCH BIOCHEM BIOPHYS, V441, P174, DOI 10.1016/j.abb.2005.07.003; Stark K, 2004, BASIC CLIN PHARMACOL, V94, P177; Stark K, 2003, ARCH BIOCHEM BIOPHYS, V409, P188, DOI 10.1016/S0003-9861(02)00511-8; Steinhoff M, 2001, CURR OPIN ALLERGY CL, V1, P469, DOI 10.1097/00130832-200110000-00014; Talas U, 2000, J INVEST DERMATOL, V114, P165, DOI 10.1046/j.1523-1747.2000.00825.x; Thacher SM, 2000, CURR PHARM DESIGN, V6, P25, DOI 10.2174/1381612003401415; Wang SK, 2000, J BIOL CHEM, V275, P40686, DOI 10.1074/jbc.M004512200; WHEELAN P, 1993, J BIOL CHEM, V268, P25439; Wheelan P, 1999, J PHARMACOL EXP THER, V288, P326; Winterfield L, 2003, CLIN DERMATOL, V21, P447, DOI 10.1016/j.clindermatol.2003.08.011; Xu FY, 2006, J PHARMACOL EXP THER, V318, P835, DOI 10.1124/jpet.106.104976; Yokomizo T, 2001, ARCH BIOCHEM BIOPHYS, V385, P231, DOI 10.1006/abbi.2000.2168; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200; Zhang XL, 2000, BIOCHEM BIOPH RES CO, V279, P864, DOI 10.1006/bbrc.2000.4020; Zouboulis CC, 2001, SKIN PHARMACOL APPL, V14, P303, DOI 10.1159/000056361	64	8	9	2	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2008	22	2					538	547		10.1096/fj.07-9244com	http://dx.doi.org/10.1096/fj.07-9244com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17884973				2022-12-28	WOS:000252822600024
J	Xu, Z; Lam, LSM; Lam, LH; Chau, SF; Ng, TB; Au, SWN				Xu, Zheng; Lam, Levina Suk Mi; Lam, Lok Hei; Chau, So Fun; Ng, Tzi Bun; Au, Shannon Wing Ngor			Molecular basis of the redox regulation of SUMO proteases: a protective mechanism of intermolecular disulfide linkage against irreversible sulfhydryl oxidation	FASEB JOURNAL			English	Article						deconjugation; cysteine protease; oxidative stress	TRANSCRIPTION FACTOR FOXO3A; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PROTEIN SUMOYLATION; RESIDUES; COMPLEX; STRESS; GROWTH	Sumoylation has emerged as an indispensable post-translational modification that modulates the functions of a broad spectrum of proteins. Recent studies have demonstrated that reactive oxygen species influence the equilibrium of sumoylation-desumoylation. We show herein that H2O2 induces formation of an intermolecular disulfide linkage of human SUMO protease SENP1 via the active-site Cys 603 and a unique residue Cys 613. Such reversible modification confers a higher recovery of enzyme activity, which is also observed in yeast Ulp1, but not in human SENP2, suggesting its protective role against irreversible sulfhydryl oxidation. In vivo formation of a disulfide-linked dimer of SENP1 is also detected in cultured cells in response to oxidative stress. The modifications are further elucidated by the crystal structures of Ulp1 with the catalytic cysteine oxidized to sulfenic, sulfinic, and sulfonic acids. Our findings suggest that, in addition to SUMO conjugating enzymes, SUMO proteases may act as redox sensors and effectors modulating the desumoylation pathway and specific cellular responses to oxidative stress.-Xu, Z., Lam, L. S. M., Lam, L. H., Chau, S. F., Ng, T. B., Au, S. W. N. Molecular basis of the redox regulation of SUMO proteases: a protective mechanism of intermolecular disulfide linkage against irreversible sulfhydryl oxidation.	[Xu, Zheng; Lam, Levina Suk Mi; Lam, Lok Hei; Chau, So Fun; Ng, Tzi Bun; Au, Shannon Wing Ngor] Chinese Univ Hong Kong, Fac Sci, Ctr Prot Sci & Crystallog, Dept Biochem, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong	Au, SWN (corresponding author), Chinese Univ Hong Kong, Fac Sci, Ctr Prot Sci & Crystallog, Dept Biochem, Hong Kong, Hong Kong, Peoples R China.	shannon-au@cuhk.edu.hk						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barford D, 2004, CURR OPIN STRUC BIOL, V14, P679, DOI 10.1016/j.sbi.2004.09.012; Bergmann EM, 1997, J VIROL, V71, P2436, DOI 10.1128/JVI.71.3.2436-2448.1997; Bossis G, 2006, MOL CELL, V21, P349, DOI 10.1016/j.molcel.2005.12.019; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chevallet M, 2003, J BIOL CHEM, V278, P37146, DOI 10.1074/jbc.M305161200; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; DeLano W.L, PYMOL MOL GRAPHICS S; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Holm L, 1996, METHOD ENZYMOL, V266, P653; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Kamitani T, 1998, J BIOL CHEM, V273, P11349, DOI 10.1074/jbc.273.18.11349; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Kleywegt GJ, 1997, ACTA CRYSTALLOGR D, V53, P179, DOI 10.1107/S0907444996012279; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; LASKOWSKI RA, CURR OPIN STRUCT BIO, V8, P631; LESLIE A, 1995, MOSFLM USERS GUIDE; Mahadev K, 2001, J BIOL CHEM, V276, P48662, DOI 10.1074/jbc.M105061200; Manza LL, 2004, CHEM RES TOXICOL, V17, P1706, DOI 10.1021/tx049767l; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Reverter D, 2004, STRUCTURE, V12, P1519, DOI 10.1016/j.str.2004.05.023; Salmeen A, 2005, ANTIOXID REDOX SIGN, V7, P560, DOI 10.1089/ars.2005.7.560; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; Shen LN, 2006, BIOCHEM J, V397, P279, DOI 10.1042/BJ20052030; Tatham MH, 2003, BIOCHEMISTRY-US, V42, P3168, DOI 10.1021/bi026861x; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vijayalakshmi J, 2001, STRUCTURE, V9, P367, DOI 10.1016/S0969-2126(01)00597-4; Wood MJ, 2004, NATURE, V430, P917, DOI 10.1038/nature02790; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Xu Z, 2005, BIOCHEM J, V386, P325, DOI 10.1042/BJ20041210; Xu Z, 2006, BIOCHEM J, V398, P345, DOI 10.1042/BJ20060526; Zhou WD, 2004, J BIOL CHEM, V279, P32262, DOI 10.1074/jbc.M404173200	41	90	93	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					127	137		10.1096/fj.06-7871com	http://dx.doi.org/10.1096/fj.06-7871com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17704192				2022-12-28	WOS:000252309900016
J	Doufexis, M; Storr, HL; King, PJ; Clark, AJL				Doufexis, Marina; Storr, Helen L.; King, Peter J.; Clark, Adrian J. L.			Interaction of the melanocortin 2 receptor with nucleoporin 50: evidence for a novel pathway between a G-protein-coupled receptor and the nucleus	FASEB JOURNAL			English	Article						ACTH; GPCR	ADRENOCORTICAL TUMOR-CELLS; ACTH RECEPTOR; GLOMERULOSA CELLS; ADRENAL-CORTEX; EXPRESSION; RAT; KINASE; GENE; STEROIDOGENESIS; TRANSCRIPTION	The adrenocorticotropin (ACTH) receptor (melanocortin 2 receptor, or MC2R) is the smallest G-protein-coupled receptor that, when activated by the peptide hormone ACTH, stimulates cAMP production and adrenal steroidogenesis. Receptor expression is dependent on a specific membrane trafficking process involving an accessory protein (melanocortin 2 receptor accessory protein, or MRAP) and other unidentified components. In an attempt to discover novel receptor interacting proteins, the C-terminal tail of the MC2R was used to screen a mouse adrenal Y6 cell cDNA library using the bacterial two-hybrid system. This identified the nucleoporin Nup 50 (Npap60) as the major full-length interacting protein. Interaction was confirmed by a GST pulldown assay and by coimmunoprecipitation in human H295R cells (which express both proteins endogenously). Deletion analysis identified the region between residues 143 and 466 in Nup50 as being required for interaction with the MC2R. Stimulation of H295R cells with ACTH (10(-6) M) was followed by a gradual translocation of the Nup50-MC2R complex from the membrane to the nucleus after 30 min. This time course is most consistent with MC2R internalization dynamics and may suggest a novel role for Nup50.-Doufexis, M., Storr, H. L., King, P. J., Clark, A. J. L. Interaction of the melanocortin 2 receptor with nucleoporin 50: evidence for a novel pathway between a G-protein-coupled receptor and the nucleus.	Ctr Endocrinol, William Harvey Res Inst, London, England	University of London; Queen Mary University London	Clark, AJL (corresponding author), Univ London Queen Mary Coll, Ctr Endocrinol, William Harvey Res Inst, London EC1A 7BE, England.	a.j.clark@qmul.ac.uk		Storr, Helen/0000-0002-9963-1931				Baig AH, 2002, ENDOCR RES, V28, P281, DOI 10.1081/ERC-120016798; Bhattacharya M, 1998, P NATL ACAD SCI USA, V95, P15792, DOI 10.1073/pnas.95.26.15792; Boivin B, 2003, J BIOL CHEM, V278, P29153, DOI 10.1074/jbc.M301738200; Boston BA, 1996, ENDOCRINOLOGY, V137, P2043, DOI 10.1210/en.137.5.2043; Cammas FM, 1997, MOL ENDOCRINOL, V11, P867, DOI 10.1210/me.11.7.867; Chorvatova A, 2000, ENDOCRINOLOGY, V141, P684, DOI 10.1210/en.141.2.684; Cieslik K, 2001, J BIOL CHEM, V276, P1211, DOI 10.1074/jbc.M005305200; Dove Simon L, 2004, Methods Mol Biol, V261, P231; DURROUX T, 1991, ENDOCRINOLOGY, V129, P2139, DOI 10.1210/endo-129-4-2139; Enyeart JJ, 2005, VITAM HORM, V70, P265, DOI 10.1016/S0083-6729(05)70008-X; Faenza I, 2000, J BIOL CHEM, V275, P30520, DOI 10.1074/jbc.M004630200; Fan F, 1997, GENOMICS, V40, P444, DOI 10.1006/geno.1996.4557; Forti FL, 2002, BIOCHEMISTRY-US, V41, P10133, DOI 10.1021/bi0258086; Gobeil F, 2002, CIRC RES, V90, P682, DOI 10.1161/01.RES.0000013303.17964.7A; Guan TL, 2000, MOL CELL BIOL, V20, P5619, DOI 10.1128/MCB.20.15.5619-5630.2000; HALKERSTON IDK, 1975, ADV CYCLIC NUCLEOTID, V6, P100; Jo Y, 2004, ENDOCRINOLOGY, V145, P5629, DOI 10.1210/en.2004-0941; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Kobayashi H, 2006, J ENDOCRINOL, V189, P671, DOI 10.1677/joe.1.06419; KOJIMA I, 1985, J BIOL CHEM, V260, P4248; Le T, 2001, ENDOCRINOLOGY, V142, P4282, DOI 10.1210/en.142.10.4282; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Lindsay ME, 2002, CELL, V110, P349, DOI 10.1016/S0092-8674(02)00836-X; Matsuura Y, 2005, EMBO J, V24, P3681, DOI 10.1038/sj.emboj.7600843; Metherell LA, 2005, NAT GENET, V37, P166, DOI 10.1038/ng1501; Morris DG, 2003, J CLIN ENDOCR METAB, V88, P6080, DOI 10.1210/jc.2002-022048; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Nakano T, 1996, SYST COMPUT JPN, V27, P1, DOI 10.1002/scj.4690270601; Nankova BB, 2003, NEUROSCI LETT, V344, P149, DOI 10.1016/S0304-3940(03)00361-6; NAVILLE D, 1994, MOL CELL ENDOCRINOL, V106, P131, DOI 10.1016/0303-7207(94)90194-5; Noon LA, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740017; O'Malley KL, 2003, J BIOL CHEM, V278, P28210, DOI 10.1074/jbc.M300792200; SCHIMMER BP, 1995, J CELL PHYSIOL, V163, P164, DOI 10.1002/jcp.1041630119; Slominski A, 1996, J CLIN ENDOCR METAB, V81, P2746, DOI 10.1210/jc.81.7.2746; Smitherman M, 2000, MOL CELL BIOL, V20, P5631, DOI 10.1128/MCB.20.15.5631-5642.2000; Wang XJ, 2000, J BIOL CHEM, V275, P20204, DOI 10.1074/jbc.M003113200; Watanabe G, 1997, J BIOL CHEM, V272, P20063, DOI 10.1074/jbc.272.32.20063; Willard FS, 2000, IMMUNOL CELL BIOL, V78, P387, DOI 10.1046/j.1440-1711.2000.00927.x; Yamamoto S, 1998, MICROSC RES TECHNIQ, V40, P479, DOI 10.1002/(SICI)1097-0029(19980301)40:6<479::AID-JEMT8>3.0.CO;2-K; Yamazaki T, 1998, ENDOCRINOLOGY, V139, P4765, DOI 10.1210/en.139.12.4765	40	15	16	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2007	21	14					4095	4100		10.1096/fj.06-7927com	http://dx.doi.org/10.1096/fj.06-7927com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17625072	Green Accepted			2022-12-28	WOS:000251283500034
J	Perri, SR; Annabi, B; Galipeau, J				Perri, Sabrina R.; Annabi, Borhane; Galipeau, Jacques			Angiostatin inhibits monocyte/macrophage migration via disruption of actin cytoskeleton	FASEB JOURNAL			English	Article						TAMs; actin disruption; tissue remodeling	TUMOR-ASSOCIATED MACROPHAGES; ENDOTHELIAL-CELL GROWTH; BREAST-CANCER; CHEMOATTRACTANT PROTEIN-1; ANTICANCER THERAPIES; INDUCE APOPTOSIS; MESSENGER-RNA; NITRIC-OXIDE; PROGRESSION; ANGIOGENESIS	In light of the involvement of tumor-associated macrophages ( TAM) in the promotion of tumor growth and metastasis, strategies to prevent TAM recruitment within the tumor microenvironment are currently under investigation. The recent observation that angiostatin reduces macrophage infiltration in an atherosclerosis model prompted our laboratory to further explore the use of human plasminogen angiostatin ( hK1 - 3) protein as a macrophage modulatory agent. We demonstrate that hK1 - 3 blocks migration of murine peritoneal macrophages ( 91% decrease, P< 0.00005) and human monocytes ( 85% decrease, P< 0.05) in vitro. Cell viability of hK1 - 3- treated cells is not affected, as determined by fluorochrome- labeled inhibitors of caspase- propidium iodide ( FLICA/ PI) flow cytometry analysis. Furthermore, confocal microscopy of phalloidin- stained cells reveals that hK1 - 3 leads to disruption of actin filopodia/ lamellipodia in human monocytes and induces distinct podosome accumulation in mature differentiated macrophages. Paradoxically, we observed a 3.5- fold increase in secretion and a 3- to 5.5- fold increase in gelatinolytic activity of macrophage-produced matrix metalloproteinase- 9, which we suggest is a cellular response to compensate for the dominant static effect of hK1 - 3 on actin. We also demonstrate that hK1 - 3 induces the phosphorylation of extracellular signal- regulated kinase ( ERK1/ 2) in human monocytes. hK1 - 3- mediated macrophage immobilization has the potential to be exploited therapeutically in pathological conditions associated with cellular hypoxia, such as cancer and atherosclerosis.	McGill Univ, Lady Davis Inst Med Res, Div Expt Med, Montreal, PQ H3T 1E2, Canada; Univ Quebec, Dept Chem, Montreal, PQ, Canada; Jewish Gen Hosp, Dept Med, Div Hematol Oncol, Montreal, PQ, Canada	Lady Davis Institute; McGill University; University of Quebec; University of Quebec Montreal; McGill University	Galipeau, J (corresponding author), Lady Davis Inst Med Res, 3755 Cote-Ste-Catherine Rd, Montreal, PQ H3T 1E2, Canada.	jacques.galipeau@mcgill.ca	Galipeau, Jacques/R-9909-2019	Galipeau, Jacques/0000-0002-9374-1996				Akool ES, 2003, MOL CELL BIOL, V23, P4901, DOI 10.1128/MCB.23.14.4901-4916.2003; Annabi B, 2006, ANTI-CANCER DRUG, V17, P429, DOI 10.1097/01.cad.0000203388.68034.06; Azenshtein E, 2005, CANCER LETT, V217, P73, DOI 10.1016/j.canlet.2004.05.024; Babb SG, 1997, CELL MOTIL CYTOSKEL, V37, P308; Barbera-Guillem E, 2002, CANCER RES, V62, P7042; Benelli R, 2001, FASEB J, V15, P267, DOI 10.1096/fj.01-0651fje; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Bolat F, 2006, J EXP CLIN CANC RES, V25, P365; BOTTAZZI B, 1983, SCIENCE, V220, P210, DOI 10.1126/science.6828888; Bratt A, 2005, J BIOL CHEM, V280, P34859, DOI 10.1074/jbc.M503915200; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Dirkx AEM, 2006, J LEUKOCYTE BIOL, V80, P1183, DOI 10.1189/jlb.0905495; Dudani AK, 2005, BIOCHEM CELL BIOL, V83, P28, DOI 10.1139/O04-109; Dudani AK, 2007, MOL CELL BIOCHEM, V300, P197, DOI 10.1007/s11010-006-9384-3; Ernkvist M, 2006, FEBS J, V273, P2000, DOI 10.1111/j.1742-4658.2006.05216.x; Evans JG, 2006, EUR J CELL BIOL, V85, P145, DOI 10.1016/j.ejcb.2005.08.006; Evans JG, 2003, J CELL BIOL, V161, P697, DOI 10.1083/jcb.200212037; Genersch E, 2000, J CELL SCI, V113, P4319; Haghnegahdar H, 2000, J LEUKOCYTE BIOL, V67, P53, DOI 10.1002/jlb.67.1.53; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Huwiler A, 2003, J BIOL CHEM, V278, P51758, DOI 10.1074/jbc.M305722200; Ishigami S, 2003, ANTICANCER RES, V23, P4079; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Knowles Helen, 2004, Novartis Found Symp, V256, P189; Kolaczkowska E, 2006, IMMUNOBIOLOGY, V211, P137, DOI 10.1016/j.imbio.2005.08.004; Kusmartsev S, 2005, J IMMUNOL, V174, P4880, DOI 10.4049/jimmunol.174.8.4880; Leek RD, 2002, J MAMMARY GLAND BIOL, V7, P177, DOI 10.1023/A:1020304003704; Lewis C, 2005, AM J PATHOL, V167, P627, DOI 10.1016/S0002-9440(10)62038-X; Linder S, 2000, J CELL SCI, V113, P4165; Lu YB, 2005, J LEUKOCYTE BIOL, V78, P259, DOI 10.1189/jlb.0904498; Lucas R, 1998, BLOOD, V92, P4730; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Mantovani A, 2004, EUR J CANCER, V40, P1660, DOI 10.1016/j.ejca.2004.03.016; Mantovani A, 2006, BLOOD, V108, P408, DOI 10.1182/blood-2006-05-019430; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; Moulton KS, 2003, P NATL ACAD SCI USA, V100, P4736, DOI 10.1073/pnas.0730843100; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; NOONAN DM, 2006, RETROVIROLOGY S1, V3, pS80; Oosterling SJ, 2005, J PATHOL, V207, P147, DOI 10.1002/path.1830; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Payne AS, 2002, J INVEST DERMATOL, V118, P915, DOI 10.1046/j.1523-1747.2002.01725.x; Perri SR, 2007, MOL CANCER THER, V6, P441, DOI 10.1158/1535-7163.MCT-06-0434; Perri SR, 2005, CANCER RES, V65, P8359, DOI 10.1158/0008-5472.CAN-05-0508; Peyruchaud O, 2003, J BIOL CHEM, V278, P45826, DOI 10.1074/jbc.M309024200; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Saio M, 2001, J IMMUNOL, V167, P5583, DOI 10.4049/jimmunol.167.10.5583; Saji H, 2001, CANCER, V92, P1085, DOI 10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K; Shimura S, 2000, CANCER RES, V60, P5857; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Sinha P, 2005, J IMMUNOL, V174, P636, DOI 10.4049/jimmunol.174.2.636; Takanami I, 1999, ONCOLOGY-BASEL, V57, P138, DOI 10.1159/000012021; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; Ueno T, 2000, CLIN CANCER RES, V6, P3282; Wang H, 2006, CANCER RES, V66, P7211, DOI 10.1158/0008-5472.CAN-05-4331; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; YOSHIMURA T, 1989, J EXP MED, V169, P1449, DOI 10.1084/jem.169.4.1449; Zetter BR, 2001, J CELL BIOL, V152, pF35, DOI 10.1083/jcb.152.6.F35	60	26	31	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3928	3936		10.1096/fj.07-8158com	http://dx.doi.org/10.1096/fj.07-8158com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17622568				2022-12-28	WOS:000251283500018
J	Ost, A; Danielsson, A; Liden, M; Eriksson, U; Nystrom, FH; Stralfors, P				Ost, Anita; Danielsson, Anna; Liden, Martin; Eriksson, Ulf; Nystrom, Fredrik H.; Stralfors, Peter			Retinol-binding protein-4 attenuates insulin-induced phosphorylation of IRS1 and ERK1/2 in primary human adipocytes	FASEB JOURNAL			English	Article						insulin resistance; type 2 diabetes; adipokine; protein phosphorylation; MAP kinase	GLUCOSE-TRANSPORT; RECEPTOR SUBSTRATE-1; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; RESISTANCE; RETINOL-BINDING-PROTEIN-4; EXPRESSION; OBESITY; SERINE-307; METABOLISM	Reduced sensitivity to insulin in adipose, muscle, and liver tissues is a hallmark of type 2 diabetes. Animal models and patients with type 2 diabetes exhibit elevated levels of circulating retinol-binding protein (RBP4), and RBP4 can induce insulin resistance in mice. However, little is known about how RBP4 affects insulin signaling. We examined the mechanisms of action of RBP4 in primary human adipocytes. RBP4-treated adipocytes exhibited the same molecular defects in insulin signaling, via IRS1 to MAP kinase, as in adipocytes from patients with type 2 diabetes. Without affecting autophosphorylation of the insulin receptor, RBP4 blocked the insulin-stimulated phosphorylation of IRS1 at serine (307) [ corresponding to serine (302) in the murine sequence] and concomitantly increased the EC50 (from 0.5 to 2 nM) for insulin stimulation of IRS1 phosphorylation at tyrosine. The phosphorylation of IRS1 at serine (312) [ corresponding to serine (307) in the murine sequence] was not affected in cells from diabetic patients and was also not affected by RBP4. The EC50 for insulin stimulation of downstream phosphorylation of MAP kinase ERK1/2 was increased (from 0.2 to 0.8 nM) by RBP4. We show that ERK1/2 phosphorylation is similarly impaired in adipocytes from patients with type 2 diabetes. However, the sensitivity to insulin for downstream signaling to control of protein kinase B and glucose uptake was not affected by RBP4. When insulin-resistant adipocytes from patients with type 2 diabetes were incubated with antibodies against RBP4, insulin-induced phosphorylation of IRS1 at serine (307) was normalized and the EC50 for insulin stimulation of ERK1/2 phosphorylation was reduced. Endogenous levels of RBP4 were markedly reduced in adipocytes from obese or type 2 diabetic subjects, whereas expression levels of RBP4 mRNA were unaffected. These findings indicate that RBP4 may be released from diabetic adipocytes and act locally to inhibit phosphorylation of IRS1 at serine (307), a phosphorylation site that may integrate nutrient sensing with insulin signaling.	Linkoping Univ, Dept Cell Biol, SE-58185 Linkoping, Sweden; Linkoping Univ, Ctr Diabet Res, SE-58185 Linkoping, Sweden; Ludwig Inst Canc Res, S-10401 Stockholm, Sweden; Linkoping Univ, Dept Med & Care, Linkoping, Sweden	Linkoping University; Linkoping University; Ludwig Institute for Cancer Research; Linkoping University	Stralfors, P (corresponding author), Linkoping Univ, Dept Cell Biol, SE-58185 Linkoping, Sweden.	peter.stralfors@ibk.liu.se		Nystrom, Fredrik/0000-0002-1680-1000; Stralfors, Peter/0000-0002-1196-1806				Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Carvalho E, 1999, FASEB J, V13, P2173, DOI 10.1096/fasebj.13.15.2173; Daniels Norman, 2001, American Journal of Bioethics, V1, P2, DOI 10.1162/152651601300168834; Danielsson A, 2006, BIOCHEM BIOPH RES CO, V342, P1183, DOI 10.1016/j.bbrc.2006.02.075; Danielsson A, 2005, J BIOL CHEM, V280, P34389, DOI 10.1074/jbc.C500230200; FROST SC, 1987, J BIOL CHEM, V262, P9872; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; Graham TE, 2006, NEW ENGL J MED, V354, P2552, DOI 10.1056/NEJMoa054862; Gual P, 2005, BIOCHIMIE, V87, P99, DOI 10.1016/j.biochi.2004.10.019; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Janke J, 2006, DIABETES, V55, P2805, DOI 10.2337/db06-0616; Kim YB, 2003, DIABETES, V52, P1935, DOI 10.2337/diabetes.52.8.1935; Krook A, 2000, DIABETES, V49, P284, DOI 10.2337/diabetes.49.2.284; Liden M, 2005, EXP CELL RES, V310, P401, DOI 10.1016/j.yexcr.2005.08.002; MARINARI L, 1987, J LIPID RES, V28, P941; MELHUS H, 1995, BIOCHEM BIOPH RES CO, V210, P105, DOI 10.1006/bbrc.1995.1633; Pirola L, 2004, DIABETOLOGIA, V47, P170, DOI 10.1007/s00125-003-1313-3; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Stenkula KG, 2004, MOL CELL ENDOCRINOL, V221, P1, DOI 10.1016/j.mce.2004.04.011; STRALFORS P, 1989, EUR J BIOCHEM, V182, P379, DOI 10.1111/j.1432-1033.1989.tb14842.x; Thorn H, 2003, MOL BIOL CELL, V14, P3967, DOI 10.1091/mbc.E03-01-0050; Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711; Zick Y, 2004, BIOCHEM SOC T, V32, P812, DOI 10.1042/BST0320812	25	98	105	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3696	3704		10.1096/fj.07-8173com	http://dx.doi.org/10.1096/fj.07-8173com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17575262				2022-12-28	WOS:000250517800031
J	Bai, XY; Chen, XM; Sun, AQ; Feng, Z; Hou, K; Fu, B				Bai, Xue-Yuan; Chen, Xiangmei; Sun, An-Qiang; Feng, Zhe; Hou, Kai; Fu, Bo			Membrane topology structure of human high-affinity, sodium-dependent dicarboxylate transporter	FASEB JOURNAL			English	Article						Krebs cycle; immunofluorescence; SCAM; Flag; localization	TRANSMEMBRANE PROTEIN TOPOLOGY; NA+/DICARBOXYLATE COTRANSPORTER; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-PROPERTIES; EXPRESSION; PREDICTION; ACCESSIBILITY; CHANNEL; CLONING; CITRATE	High-affinity, sodium-dependent dicarboxylate transporter (NaDC3) is responsible for transport of Krebs cycle intermediates and may involve in regulation of aging and life span. Hydropathy analysis predicts that NaDC3 contains 11 or 12 hydrophobic transmembrane (TM)domains. However, the actual membrane topological structure of NaDC3 remains unknown. In this study, confocal immunofluorescence microscopy and membrane biotinylation of epitope-tagged N and C termini of NaDC3 provide evidence of an extracellular C terminus and an intracellular N terminus, indicating an odd number of transmembrane regions. The position of hydrophilic loops within NaDC3 was identified with antibodies against the loops domains combined with cysteine accessibility methods. A confocal image of membrane localization and transport activity assay of the cysteine insertion mutants show behavior similar to that of wild-type NaDC3 in transfected HEK293 cells, suggesting that these mutants retain a native protein configuration. We find that NaDC3 contains 11 transmembrane helices. The loops 1, 3, 5, 7, and 9 face the extracellular side, and loops 2, 4, 6, and 10 face the cytoplasmic side. A re-entrant loop-like structure between TM8 and TM9 may protrude into the membrane. Our results support the topography of 11 transmembrane domains with an extracellular C terminus and an intracellular N terminus of NaDC3, and for the first time provide experimental evidence for a novel topological model for NaDC3	Chinese Peoples Liberat Army Gen Hosp, Chinese PLA Inst Nephrol, Dept Biochem & Mol Biol, Beijing 100853, Peoples R China; Mil Med Postgrad Coll, Beijing 100853, Peoples R China; Mt Sinai Sch Med, Dept Pediat, New York, NY USA	Chinese People's Liberation Army General Hospital; Icahn School of Medicine at Mount Sinai	Bai, XY (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Chinese PLA Inst Nephrol, Dept Biochem & Mol Biol, 28 Fuxing Rd, Beijing 100853, Peoples R China.	baixy@301hospital.com.cn; xmchen@public.bta.net.cn						[白雪源 Bai Xueyuan], 2004, [中国生物化学与分子生物学报, Chinese Journal of Biochemistry and Molecular Biology], V20, P615; Bai XY, 2006, J CELL PHYSIOL, V206, P821, DOI 10.1002/jcp.20553; Bai XY, 2004, SCI CHINA SER C, V47, P530, DOI 10.1360/03yc0044; BLANKA R, 2000, SCIENCE, V290, P2137; Bogdanov M, 2005, METHODS, V36, P148, DOI 10.1016/j.ymeth.2004.11.002; CHEN WP, 1999, J CHEM SOC P1, V2, P103; Chen XM, 2005, J GERONTOL A-BIOL, V60, P709, DOI 10.1093/gerona/60.6.709; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Du GG, 2002, P NATL ACAD SCI USA, V99, P16725, DOI 10.1073/pnas.012688999; Fei YJ, 2003, J BIOL CHEM, V278, P6136, DOI 10.1074/jbc.M208763200; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Inoue K, 2002, J BIOL CHEM, V277, P39469, DOI 10.1074/jbc.M207072200; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; Kekuda R, 1999, J BIOL CHEM, V274, P3422, DOI 10.1074/jbc.274.6.3422; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Liu XY, 2002, BBA-BIOMEMBRANES, V1564, P333, DOI 10.1016/S0005-2736(02)00467-4; Markovich D, 2004, PFLUG ARCH EUR J PHY, V447, P594, DOI 10.1007/s00424-003-1128-6; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Oshiro N, 2005, AM J PHYSIOL-CELL PH, V289, pC1159, DOI 10.1152/ajpcell.00295.2004; Pajor AM, 2006, PFLUG ARCH EUR J PHY, V451, P597, DOI 10.1007/s00424-005-1487-2; Pajor AM, 2000, J MEMBRANE BIOL, V175, P1, DOI 10.1007/s002320001049; Pajor AM, 2001, AM J PHYSIOL-CELL PH, V280, pC1215, DOI 10.1152/ajpcell.2001.280.5.C1215; PAK CYC, 1987, MINER ELECTROL METAB, V13, P257; Saugstad JA, 2004, J BIOL CHEM, V279, P55514, DOI 10.1074/jbc.M411849200; Schrodt S, 2006, J BIOL CHEM, V281, P6455, DOI 10.1074/jbc.M509784200; Steffgen J, 1999, J BIOL CHEM, V274, P20191, DOI 10.1074/jbc.274.29.20191; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; Wang HP, 2000, AM J PHYSIOL-CELL PH, V278, pC1019, DOI 10.1152/ajpcell.2000.278.5.C1019; Zhang C, 2001, J POROUS MEDIA, V4, P89	35	13	16	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2409	2417		10.1096/fj.06-7652com	http://dx.doi.org/10.1096/fj.06-7652com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17426067				2022-12-28	WOS:000248454400016
J	Dagon, Y; Avraham, Y; Ilan, Y; Mechoulam, R; Berry, EM				Dagon, Yossi; Avraham, Yosefa; Ilan, Yaron; Mechoulam, Raphael; Berry, Elliot M.			Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase	FASEB JOURNAL			English	Article						liver disease; hepatic encephalopathy; AMPK; endocannabinoid receptor	HEPATIC-ENCEPHALOPATHY; SYNAPTIC PLASTICITY; MAGNETIC-RESONANCE; BRAIN CONSTITUENT; ENERGY-METABOLISM; FOOD-INTAKE; IN-VIVO; RECEPTOR; RATS; MICE	Hepatic encephalopathy (HE) is a neuropsychiatric disorder of complex pathogenesis caused by acute or chronic liver failure. We studied the etiology of cerebral dysfunction in a murine model of HE induced by either bile duct ligation or thioacetamide administration. We report that stimulation of cerebral AMP-activated protein kinase (AMPK), a major intracellular energy sensor, is a compensatory response to liver failure. This function of AMPK is regulated by endo-cannabinoids. The cannabinoid system controls systemic energy balance via the cannabinoid receptors CB-1 and CB-2. Under normal circumstances, AMPK activity is mediated by CB-1 while CB- 2 is barely detected. However, CB- 2 is strongly stimulated in response to liver failure. Administration of Delta 9-tetrahydrocannabinol( THC) augmented AMPK activity and restored brain function in WT mice but not in their CB- 2 KO littermates. These results suggest that HE is a disease of energy flux. CB- 2 signaling is a cerebral stress response mechanism and makes AMPK a promising target for its treatment by modulating the cannabinoid system.	Hebrew Univ Jerusalem, Hadassah Med Sch, Fac Med, Braun Sch Publ Hlth,Dept Human Nutr & Metab, Jerusalem, Israel; Hadassah Univ Hosp, Liver Unit, Jerusalem, Israel; Hebrew Univ Jerusalem, Fac Med, Dept Med Chem & Nat Prod, Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Berry, EM (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Fac Med, Braun Sch Publ Hlth,Dept Human Nutr & Metab, Jerusalem, Israel.	berry@md.huji.ac.il	Dagon, Yossi/AAI-5882-2020					Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; Avraham Y, 2006, NEUROBIOL DIS, V21, P237, DOI 10.1016/j.nbd.2005.07.008; Avraham Y, 1996, BRAIN RES, V732, P133, DOI 10.1016/0006-8993(96)00514-8; Baker D, 2003, LANCET NEUROL, V2, P291, DOI 10.1016/S1474-4422(03)00381-8; Barbiroli B, 2002, BRAIN RES BULL, V59, P75, DOI 10.1016/S0361-9230(02)00839-0; BERGOLD PJ, 1990, P NATL ACAD SCI USA, V87, P3788, DOI 10.1073/pnas.87.10.3788; BERNARD A, 1967, SCIENCE, V158, P1600; Berry EM, 2002, PHARMACOL THERAPEUT, V95, P185, DOI 10.1016/S0163-7258(02)00257-7; Bezuglov V, 2001, BIOORG MED CHEM LETT, V11, P447, DOI 10.1016/S0960-894X(00)00689-2; Bisogno T, 2000, BIOCHEM J, V351, P817, DOI 10.1042/0264-6021:3510817; BUTTERWORTH RF, 1987, NEUROCHEM PATHOL, V6, P1, DOI 10.1007/BF02833598; Campas C, 2003, BLOOD, V101, P3674, DOI 10.1182/blood-2002-07-2339; Cheer JF, 2004, J NEUROSCI, V24, P4393, DOI 10.1523/JNEUROSCI.0529-04.2004; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Costa-Mattioli M, 2005, NATURE, V436, P1166, DOI 10.1038/nature03897; Dagon Y, 2006, BIOCHEM BIOPH RES CO, V340, P43, DOI 10.1016/j.bbrc.2005.11.159; Dagon Y, 2005, J BIOL CHEM, V280, P42142, DOI 10.1074/jbc.M507607200; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Felipo V, 2002, PROG NEUROBIOL, V67, P259, DOI 10.1016/S0301-0082(02)00019-9; Ferenci P, 2002, HEPATOLOGY, V35, P716, DOI 10.1053/jhep.2002.31250; FITZHUGH OG, 1948, SCIENCE, V108, P626, DOI 10.1126/science.108.2814.626; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; Gerber T, 2000, DRUGS, V60, P1353, DOI 10.2165/00003495-200060060-00008; Gerdeman GL, 2003, TRENDS NEUROSCI, V26, P184, DOI 10.1016/S0166-2236(03)00065-1; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; HOYER S, 1993, ANN NY ACAD SCI, V695, P77, DOI 10.1111/j.1749-6632.1993.tb23032.x; IVERSEN LL, 2000, SCI MARIJUANA, P36; Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kola B, 2005, J BIOL CHEM, V280, P25196, DOI 10.1074/jbc.C500175200; Martin BR, 2005, LIFE SCI, V77, P1543, DOI 10.1016/j.lfs.2005.05.005; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Meisse D, 2002, FEBS LETT, V526, P38, DOI 10.1016/S0014-5793(02)03110-1; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Mishima K, 2001, JPN J PHARMACOL, V87, P297, DOI 10.1254/jjp.87.297; MIZUNO Y, 1995, BBA-MOL BASIS DIS, V1271, P265, DOI 10.1016/0925-4439(95)00038-6; Molina-Holgado F, 2005, MOL CELL NEUROSCI, V28, P189, DOI 10.1016/j.mcn.2004.09.004; OLTON DS, 1976, J EXP PSYCHOL-ANIM B, V2, P97, DOI 10.1037/0097-7403.2.2.97; Ott P, 2005, NEUROCHEM INT, V47, P13, DOI 10.1016/j.neuint.2005.04.002; Pagotto U, 2005, ANN MED, V37, P270, DOI 10.1080/07853890510037419; PICK CG, 1983, INT J NEUROSCI, V21, P63, DOI 10.3109/00207458308986121; Rose C, 2005, METAB BRAIN DIS, V20, P275, DOI 10.1007/s11011-005-7906-4; ROSS BD, 1989, M SOC MAGN RES MED A, P465; Sulcova E, 1998, PHARMACOL BIOCHEM BE, V59, P347, DOI 10.1016/S0091-3057(97)00422-X; SUMMERSKILL WHJ, 1956, Q J MED, V25, P245; Teixeira-Clerc F, 2006, NAT MED, V12, P671, DOI 10.1038/nm1421; Xiong Y, 2001, NEUROL RES, V23, P129, DOI 10.1179/016164101101198460; ZIMMERMANN C, 1989, HEPATOLOGY, V9, P594, DOI 10.1002/hep.1840090414; ZIMMERMANN T, 1992, HEPATOLOGY, V15, P467; Zwingmann C, 2003, HEPATOLOGY, V37, P420, DOI 10.1053/jhep.2003.50052	52	35	39	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2431	2441		10.1096/fj.06-7705com	http://dx.doi.org/10.1096/fj.06-7705com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17431095				2022-12-28	WOS:000248454400018
J	Huber, I; Itzhaki, I; Caspi, O; Arbel, G; Tzukerman, M; Gepstein, A; Habib, M; Yankelson, L; Kehat, I; Gepstein, L				Huber, Irit; Itzhaki, Ilanit; Caspi, Oren; Arbel, Gil; Tzukerman, Maty; Gepstein, Amira; Habib, Manhal; Yankelson, Lior; Kehat, Izhak; Gepstein, Lior			Identification and selection of cardiomyocytes during human embryonic stem cell differentiation	FASEB JOURNAL			English	Article						myogenesis; myosin light chain 2-V; promoter; selectable marker; embryoid body; cardiac differentiation	GREEN FLUORESCENT PROTEIN; CARDIAC PRECURSOR CELLS; IN-VITRO; HUMAN BLASTOCYSTS; EXPRESSION; HEART; ATRIAL; LINES; GENE; EXCITABILITY	Human embryonic stem cells (hESC) are pluripotent lines that can differentiate in vitro into cell derivatives of all three germ layers, including cardiomyocytes. Successful application of these unique cells in the areas of cardiovascular research and regenerative medicine has been hampered by difficulties in identifying and selecting specific cardiac progenitor cells from the mixed population of differentiating cells. We report the generation of stable transgenic hESC lines, using lentiviral vectors, and single-cell clones that express a reporter gene (eGFP) under the transcriptional control of a cardiac-specific promoter (the human myosin light chain-2V promoter). Our results demonstrate the appearance of eGFP-expressing cells during the differentiation of the hESC as embryoid bodies (EBs) that can be identified and sorted using FACS (purity > 95%, viability > 85%). The eGFP-expressing cells were stained positively for cardiac-specific proteins (> 93%), expressed cardiac-specific genes, displayed cardiac-specific action-potentials,and could form stable myocardial cell grafts following in vivo cell transplantation. The generation of these transgenic hESC lines may be used to identify and study early cardiac precursors for developmental studies, to robustly quantify the extent of cardiomyocyte differentiation, to label the cells for in vivo grafting, and to allow derivation of purified cell populations of cardiomyocytes for future myocardial cell therapy strategies.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Sohis Family Res Lab Regenerat Funct Myocardium, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Gepstein, L (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Sohis Family Res Lab Regenerat Funct Myocardium, 2 Efron St,POB 9649, IL-31096 Haifa, Israel.	mdlior@tx.technion.ac.il	Gepstein, Lior/H-9458-2012	kehat, izhak/0000-0002-4388-1579				Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; Andressen C, 2001, STEM CELLS, V19, P419, DOI 10.1634/stemcells.19-5-419; Assady S, 2001, DIABETES, V50, P1691, DOI 10.2337/diabetes.50.8.1691; Behfar A, 2002, FASEB J, V16, P1558, DOI 10.1096/fj.02-0072com; Christoffels VM, 2000, DEV BIOL, V223, P266, DOI 10.1006/dbio.2000.9753; Cohn JN, 1997, CIRCULATION, V95, P766; Dimmeler S, 2005, J CLIN INVEST, V115, P572, DOI 10.1172/JCI200524283; Feld Y, 2002, CIRCULATION, V105, P522, DOI 10.1161/hc0402.102661; Gassanov N, 2004, FASEB J, V18, P1710, DOI 10.1096/fj.04-1619fje; Gepstein L, 2002, CIRC RES, V91, P866, DOI 10.1161/01.RES.0000041435.95082.84; He JQ, 2003, CIRC RES, V93, P32, DOI 10.1161/01.RES.0000080317.92718.99; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; Hidaka K, 2003, FASEB J, V17, P740, DOI 10.1096/fj.02-0104fje; Houweling AC, 2005, CARDIOVASC RES, V67, P583, DOI 10.1016/j.cardiores.2005.06.013; Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776; Kaufman DS, 2001, P NATL ACAD SCI USA, V98, P10716, DOI 10.1073/pnas.191362598; Kehat I, 2002, CIRC RES, V91, P659, DOI 10.1161/01.RES.0000039084.30342.9B; Kehat I, 2004, NAT BIOTECHNOL, V22, P1282, DOI 10.1038/nbt1014; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; Kolossov E, 2005, FASEB J, V19, P577, DOI 10.1096/fj.03-1451fje; Kolossov E, 1998, J CELL BIOL, V143, P2045, DOI 10.1083/jcb.143.7.2045; Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117; Lang RJ, 2004, EUR J NEUROSCI, V20, P3209, DOI 10.1111/j.1460-9568.2004.03782.x; Levenberg S, 2002, P NATL ACAD SCI USA, V99, P4391, DOI 10.1073/pnas.032074999; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; Muller M, 2000, FASEB J, V14, P2540, DOI 10.1096/fj.00-0002com; Mummery C, 2003, CIRCULATION, V107, P2733, DOI 10.1161/01.CIR.0000068356.38592.68; Murry CE, 2005, CIRCULATION, V112, P3174, DOI 10.1161/CIRCULATIONAHA.105.546218; Odorico JS, 2001, STEM CELLS, V19, P193, DOI 10.1634/stemcells.19-3-193; Reinlib L, 2000, CIRCULATION, V101, pE182; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Satin J, 2004, J PHYSIOL-LONDON, V559, P479, DOI 10.1113/jphysiol.2004.068213; Soria B, 2000, DIABETES, V49, P157, DOI 10.2337/diabetes.49.2.157; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Xu CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91; Xue T, 2005, CIRCULATION, V111, P11, DOI 10.1161/01.CIR.0000151313.18547.A2; Zammit PS, 2000, DEV DYNAM, V217, P75, DOI 10.1002/(SICI)1097-0177(200001)217:1<75::AID-DVDY7>3.0.CO;2-L; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273; Zwaka TP, 2003, NAT BIOTECHNOL, V21, P319, DOI 10.1038/nbt788	42	207	218	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2551	2563		10.1096/fj.05-5711com	http://dx.doi.org/10.1096/fj.05-5711com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17435178				2022-12-28	WOS:000248454400029
J	Marzec, JM; Christie, JD; Reddy, SP; Jedlicka, AE; Vuong, H; Lanken, PN; Aplenc, R; Yamamoto, T; Yamamoto, M; Cho, HY; Kleeberger, SR				Marzec, Jacqui M.; Christie, Jason D.; Reddy, Sekhar P.; Jedlicka, Anne E.; Vuong, Hue; Lanken, Paul N.; Aplenc, Richard; Yamamoto, Tae; Yamamoto, Masayuki; Cho, Hye-Youn; Kleeberger, Steven R.			Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury	FASEB JOURNAL			English	Article						antioxidant; reactive oxygen species; ALI; acute respiratory distress syndrome; trauma; oxidative stress; translational	RESPIRATORY-DISTRESS-SYNDROME; GENE; MICE; SUSCEPTIBILITY; ASSOCIATION; EXPRESSION; PROTECTION; DISEASE; ARDS; DIFFERENTIATION	We recently used positional cloning to identify the transcription factor Nrf2 (NF-E2 related factor 2) as a susceptibility gene in a murine model of oxidant-induced acute lung injury (ALI). NRF2 binds to antioxidant response elements (ARE) and up-regulates protective detoxifying enzymes in response to oxidative stress. This led us to investigate NRF2 as a candidate susceptibility gene for risk of development of ALI in humans. We identified multiple single nucleotide polymorphisms ( SNPs) by resequencing NRF2 in ethnically diverse subjects, and one (-617 C/A) significantly (P < 0.001) diminished luciferase activity of promoter constructs containing the SNP and significantly decreased the binding affinity (P < 0.001) relative to the wild type at this locus (-617 CC). In a nested case-control study, patients with the -617 A SNP had a significantly higher risk for developing ALI after major trauma ( OR 6.44; 95% CI 1.34, 30.8; P=0.021) relative to patients with the wild type (-617 CC). This translational investigation provides novel insight into the molecular mechanisms of susceptibility to ALI and may help to identify patients who are predisposed to develop ALI under at risk conditions, such as trauma and sepsis. Furthermore, these findings may have important implications in other oxidative stress related illnesses.	Natl Inst Environm Hlth Sci, Lab Resp Biol, Dept Hlth & Human Serv, NIH, Res Triangle Pk, NC 27709 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol Biostat, Philadelphia, PA USA; Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; Univ Penn, Sch Med, Dept Med, Pulm Allergy & Crit Care Div, Philadelphia, PA USA; Childrens Hosp Philadelphia, Philadelphia, PA USA; Univ Tsukuba, Ctr TARA, Tsukuba, Ibaraki, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Pennsylvania; Pennsylvania Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Tsukuba	Kleeberger, SR (corresponding author), Natl Inst Environm Hlth Sci, Lab Resp Biol, Dept Hlth & Human Serv, NIH, 111 TW Alexander Dr Bldg 101,Rm D240, Res Triangle Pk, NC 27709 USA.	kleeber1@niehs.nih.gov	Yamamoto, Masayuki/A-4873-2010; Kleeberger, Steven R/F-1807-2019	Yamamoto, Masayuki/0000-0002-9073-9436; Kleeberger, Steven R/0000-0003-2948-8452	Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [P50 HL-60290-01, R01 HL-66109, K23 HL-04243] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004243, P50HL060290, R01HL066109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES100564, Z01ES100513] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; CHAN K, 1999, P NATL ACAD SCI USA, V93, P13943; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Cho HY, 2004, FASEB J, V18, P1258, DOI 10.1096/fj.03-1127fje; Cho HY, 2005, FREE RADICAL BIO MED, V38, P325, DOI 10.1016/j.freeradbiomed.2004.10.013; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Cho HY, 2002, AM J RESP CELL MOL, V26, P42, DOI 10.1165/ajrcmb.26.1.4536; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; Gadek JE, 1996, CHEST, V110, pS273, DOI 10.1378/chest.110.6_Supplement.273S; Goss CH, 2003, CRIT CARE MED, V31, P1607, DOI 10.1097/01.CCM.0000063475.65751.1D; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hou XY, 2002, J CLIN INVEST, V109, P533, DOI 10.1172/JC1200214099; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; Kanetsky PA, 2001, CANCER EPIDEM BIOMAR, V10, P509; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; Lam-Yuk-Tseung S, 2003, CELL MICROBIOL, V5, P299, DOI 10.1046/j.1462-5822.2003.00276.x; Lin Z, 2000, CLIN GENET, V58, P181, DOI 10.1034/j.1399-0004.2000.580305.x; Louie S, 1997, Adv Pharmacol, V38, P457; MANDER A, 2000, STATA TECHN B, V57, P5; Marshall RP, 2002, AM J RESP CRIT CARE, V166, P646, DOI 10.1164/rccm.2108086; Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS; Moss M, 1996, JAMA-J AM MED ASSOC, V275, P50, DOI 10.1001/jama.275.1.50; Moss M, 2000, CRIT CARE MED, V28, P2187, DOI 10.1097/00003246-200007000-00001; Olofsson P, 2003, NAT GENET, V33, P25, DOI 10.1038/ng1058; Patterson T, 2001, ONCOGENE, V20, P634, DOI 10.1038/sj.onc.1204134; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Rebbeck TR, 1999, CANCER EPIDEM BIOMAR, V8, P283; Reddy SPM, 2002, AM J PHYSIOL-LUNG C, V283, pL1161, DOI 10.1152/ajplung.00140.2002; REPINE JE, 1992, LANCET, V339, P466, DOI 10.1016/0140-6736(92)91067-I; Robertson KA, 1998, LEUKEMIA, V12, P690, DOI 10.1038/sj.leu.2401005; TERWILLIGER JD, 1994, HDB HUMAN GENETIC LI; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Wang YT, 2004, GENET EPIDEMIOL, V27, P14, DOI 10.1002/gepi.20003; Yamamoto T, 2004, BIOCHEM BIOPH RES CO, V321, P72, DOI 10.1016/j.bbrc.2004.06.112	45	264	280	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					2237	2246		10.1096/fj.06-7759com	http://dx.doi.org/10.1096/fj.06-7759com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17384144				2022-12-28	WOS:000247500300032
J	Marx, FP; Soehn, AS; Berg, D; Melle, C; Schiesling, C; Lang, M; Kautzmann, S; Strauss, KM; Franck, T; Engelender, S; Pahnke, J; Dawson, S; von Eggeling, F; Schulz, JB; Riess, O; Kruger, R				Marx, Frank P.; Soehn, Anne S.; Berg, Daniela; Melle, Christian; Schiesling, Carola; Lang, Mira; Kautzmann, Sabine; Strauss, Karsten M.; Franck, Thomas; Engelender, Simone; Pahnke, Jens; Dawson, Simon; von Eggeling, Ferdinand; Schulz, Joerg B.; Riess, Olaf; Krueger, Rejko			The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein - implications for Parkinson's disease	FASEB JOURNAL			English	Article						neurodegeneration; ubiquitin; alpha-synuclein; proteasome	LEWY-BODY FORMATION; ALPHA-SYNUCLEIN; AGGRESOMES; UBIQUITIN; BODIES; CHAINS; IDENTIFICATION; DEGRADATION; PROTEOLYSIS; INCLUSIONS	Synphilin-1 is linked to Parkinson's disease ( PD), based on its role as an alpha-synuclein (PARK1)-interacting protein and substrate of the ubiquitin E3 ligase Parkin (PARK2) and because of its presence in Lewy bodies ( LB) in brains of PD patients. We found that overexpression of synphilin-1 in cells leads to the formation of ubiquitinated cytoplasmic inclusions supporting a derangement of the ubiquitin-proteasome system in PD. We report here a novel specific interaction of synphilin- 1 with the regulatory proteasomal protein S6 ATPase ( tbp7). Functional characterization of this interaction on a cellular level revealed colocalization of S6 and synphilin- 1 in aggresome- like intracytoplasmic inclusions. Overexpression of synphilin- 1 and S6 in cells caused reduced proteasomal activity associated with a significant increase in inclusion formation compared to cells expressing synphilin-1 alone. Steady-state levels of synphilin-1 in cells were not altered after cotransfection of S6 and colocalization of synphilin-1-positive inclusions with lysosomal markers suggests the presence of an alternative lysosomal degradation pathway. Subsequent immunohistochemical studies in brains of PD patients identified S6 ATPase as a component of LB. This is the first study investigating the physiological role of synphilin- 1 in the ubiquitin proteasome system. Our data suggest a direct interaction of synphilin- 1 with the regulatory complex of the proteasome modulating proteasomal function.-Marx, F. P., Soehn, A. S., Berg, D., Melle, C., Schiesling, C., Lang, M., Kautzmann, S., Strauss, K. M., Franck, T., Engelender, S., Pahnke, J., Dawson, S., von Eggeling, F., Schulz, J. B., Riess, O., Kruger, R. The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein-implications for Parkinson's disease.	Univ Tubingen, Ctr Neurol, D-72076 Tubingen, Germany; Univ Tubingen, Hertie Inst Clin Brain Res, D-72076 Tubingen, Germany; Univ Tubingen, Dept Med Genet, D-72076 Tubingen, Germany; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel; Univ Jena, Inst Human Genet & Anthropol, Core Unit Chip Applicat, D-6900 Jena, Germany; Univ Zurich Hosp, Inst Neuropathol, Dept Pathol, CH-8091 Zurich, Switzerland; Univ Nottingham, Sch Biomed Sci, Nottingham NG7 2RD, England	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Friedrich Schiller University of Jena; University of Zurich; University Zurich Hospital; University of Nottingham	Kruger, R (corresponding author), Univ Tubingen, Ctr Neurol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	rejko.krueger@uni-tuebingen.de	von Eggeling, Ferdinand/A-1645-2008; Pahnke, Jens/G-1757-2010; von Eggeling, Ferdinand/AAC-8349-2022; Schulz, Jörg B/D-9786-2012; Berg, Daniela/A-8728-2019; von Eggeling, Ferdinand/B-4033-2014	Pahnke, Jens/0000-0001-7355-4213; von Eggeling, Ferdinand/0000-0002-8062-6999; Schulz, Jörg B/0000-0002-8903-0593; Berg, Daniela/0000-0001-5796-5442; von Eggeling, Ferdinand/0000-0002-8062-6999; Melle, Christian/0000-0002-1870-9419; Engelender, Simone/0000-0001-7401-6855				Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Dawson S, 2002, J BIOL CHEM, V277, P10893, DOI 10.1074/jbc.M107313200; Doss-Pepe EW, 2003, MOL CELL BIOL, V23, P6469, DOI 10.1128/MCB.23.18.6469-6483.2003; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Fortun J, 2003, J NEUROSCI, V23, P10672; Hazan J, 1999, NAT GENET, V23, P296, DOI 10.1038/15472; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Junn E, 2002, J BIOL CHEM, V277, P47870, DOI 10.1074/jbc.M203159200; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kruger R, 2002, TRENDS MOL MED, V8, P236, DOI 10.1016/S1471-4914(02)02333-X; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; Lee T., 2002, ACM T ASIAN LANGUAGE, V1, P83; Lehmann R, 2005, J PROTEOME RES, V4, P1717, DOI 10.1021/pr050163s; Lim KL, 2006, NEUROBIOL AGING, V27, P524, DOI 10.1016/j.neurobiolaging.2005.07.023; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Marx FP, 2003, HUM MOL GENET, V12, P1223, DOI 10.1093/hmg/ddg134; Matilla A, 2001, HUM MOL GENET, V10, P2821, DOI 10.1093/hmg/10.24.2821; Matsumoto M, 2004, EMBO J, V23, P659, DOI 10.1038/sj.emboj.7600081; McNaught KS, 2003, ANN NEUROL, V53, pS73, DOI 10.1002/ana.10512; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; O'Farrell C, 2001, MOL BRAIN RES, V97, P94, DOI 10.1016/S0169-328X(01)00292-3; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Ross CA, 2004, TRENDS CELL BIOL, V14, P703, DOI 10.1016/j.tcb.2004.10.006; Schulz JB, 1999, CURR OPIN NEUROL, V12, P433, DOI 10.1097/00019052-199908000-00010; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tanaka M, 2004, J BIOL CHEM, V279, P4625, DOI 10.1074/jbc.M310994200; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0	37	40	41	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1759	1767		10.1096/fj.06-6734com	http://dx.doi.org/10.1096/fj.06-6734com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17327361				2022-12-28	WOS:000246866500018
J	Matus, M; Lewin, G; Stumpel, F; Buchwalow, IB; Schneider, MD; Schutz, G; Schmitz, W; Muller, FU				Matus, Marek; Lewin, Geertje; Stuempel, Frank; Buchwalow, Igor B.; Schneider, Michael D.; Schuetz, Guenther; Schmitz, Wilhelm; Mueller, Frank U.			Cardiomyocyte-specific inactivation of transcription factor CREB in mice	FASEB JOURNAL			English	Article						Cre-loxP system; knockout mice; cAMP responsive element binding protein; heart	ELEMENT-BINDING PROTEIN; CONGESTIVE-HEART-FAILURE; RESPONSE ELEMENT; CYCLIC-AMP; CARDIAC MYOCYTES; NUCLEAR-PROTEIN; TRANSGENIC MICE; GENE-TRANSCRIPTION; SOMATOSTATIN GENE; TARGETED MUTATION	The transcription factor cAMP response element (CRE)-binding protein (CREB, Creb1) plays a critical role in regulating gene expression in response to activation of the cAMP-dependent signaling pathway, which is implicated in the pathophysiology of heart failure. Using the Cre-loxP system, we generated mice with a cardiomyocyte- specific inactivation of CREB and studied in this model whether CREB is critical for cardiac function. CREB-deficient mice were viable and displayed neither changes in cardiac morphology nor alterations of basal or isoproterenol-stimulated left ventricular function in vivo or of important cardiac regulatory proteins. Since CREB was proposed as a negative regulator of cardiomyocyte apoptosis by enhancing the expression of the antiapoptotic protein Bcl-2, we analyzed the fragmentation of DNA, the activity of caspases 3/7 and the expression of Bcl-2 and did not observe any differences between CREB-deficient and CREB- normal hearts. Our results suggest that the presence of CREB is not critical for normal cardiac function in mice.-Matus M., Lewin G., Stumpel F., Buchwalow I. B., Schneider M. D., Schutz G., Schmitz W., and Muller F. U. Cardiomyocyte-specific inactivation of transcription factor CREB in mice.	Univ Munster, Inst Pharmacol & Toxicol, D-48129 Munster, Germany; Univ Munster, Inst Pathol, D-48129 Munster, Germany; Baylor Coll Med, Ctr Cardiovasc Dev, Dept Med, Houston, TX USA; German Canc Res Ctr, Div Mol Biol Cell 1, Heidelberg, Germany	University of Munster; University of Munster; Baylor College of Medicine; Helmholtz Association; German Cancer Research Center (DKFZ)	Muller, FU (corresponding author), Univ Munster, Inst Pharmacol & Toxicol, Domagkstr 12, D-48129 Munster, Germany.	mullerf@uni-muenster.de		Schneider, Michael/0000-0001-9645-1938				Agah R, 1997, J CLIN INVEST, V100, P169, DOI 10.1172/JCI119509; Antos CL, 2003, J BIOL CHEM, V278, P28930, DOI 10.1074/jbc.M303113200; Backs J, 2006, CIRC RES, V98, P15, DOI 10.1161/01.RES.0000197782.21444.8f; Blendy JA, 1996, EMBO J, V15, P1098, DOI 10.1002/j.1460-2075.1996.tb00447.x; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Buchwalow IB, 2004, NITRIC OXIDE-BIOL CH, V10, P203, DOI 10.1016/j.niox.2004.04.004; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Colucci WS, 1997, AM J CARDIOL, V80, pL15, DOI 10.1016/S0002-9149(97)00845-X; Colucci WS., 1997, HEART DIS TXB CARDIO, P394; Felker GM, 2001, AM HEART J, V142, P932, DOI 10.1067/mhj.2001.119611; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; Freeland K, 2001, MOL BRAIN RES, V92, P98, DOI 10.1016/S0169-328X(01)00158-9; GOLDSPINK PH, 1994, CIRC RES, V74, P1042, DOI 10.1161/01.RES.74.6.1042; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gusterson RJ, 2003, J BIOL CHEM, V278, P6838, DOI 10.1074/jbc.M211762200; Hjalmarson A, 2000, JAMA-J AM MED ASSOC, V283, P1295, DOI 10.1001/jama.283.10.1295; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; Husse B, 2005, BIOCHEM BIOPH RES CO, V334, P1260, DOI 10.1016/j.bbrc.2005.06.206; Isoda T, 2003, FASEB J, V17, P144, DOI 10.1096/fj.01-0981com; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Mantamadiotis T, 1998, BIOTECHNIQUES, V25, P968, DOI 10.2144/98256bm07; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mehrhof FB, 2001, CIRCULATION, V104, P2088, DOI 10.1161/hc4201.097133; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MULLER FU, 1995, CIRCULATION, V92, P2041, DOI 10.1161/01.CIR.92.8.2041; Muller FU, 1998, FASEB J, V12, P1191; Muller FU, 2005, J BIOL CHEM, V280, P6906, DOI 10.1074/jbc.M407864200; Muller FU, 2004, CELL DEATH DIFFER, V11, P485, DOI 10.1038/sj.cdd.4401383; Muller FU, 2002, FASEB J, V16, P103, DOI 10.1096/fj.02-0486fje; Muller FU, 2001, CARDIOVASC RES, V52, P95, DOI 10.1016/S0008-6363(01)00361-3; OFIR R, 1991, GENE EXPRESSION, V1, P55; Oike Y, 1999, BLOOD, V93, P2771; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; Tanaka Y, 2000, MECH DEVELOP, V95, P133, DOI 10.1016/S0925-4773(00)00360-9; UNG AL, 2000, GENES REV, V14, P272; Yanazume T, 2003, MOL CELL BIOL, V23, P3593, DOI 10.1128/MCB.23.10.3593-3606.2003; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4	49	21	21	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1884	1892		10.1096/fj.06-7915com	http://dx.doi.org/10.1096/fj.06-7915com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17307839				2022-12-28	WOS:000246866500029
J	Kaufman, L; Yang, GZ; Hayashi, K; Ashby, JR; Huang, L; Ross, MJ; Klotman, ME; Klotman, PE				Kaufman, Lewis; Yang, Guozhe; Hayashi, Kayo; Ashby, James R.; Huang, Li; Ross, Michael J.; Klotman, Mary E.; Klotman, Paul E.			The homophilic adhesion molecule sidekick-1 contributes to augmented podocyte aggregation in HIV-associated nephropathy	FASEB JOURNAL			English	Article						HIVAN; pseudocrescent; collapsing glomerulopathy	GLOMERULAR SLIT DIAPHRAGM; IDIOPATHIC COLLAPSING GLOMERULOPATHY; TIGHT JUNCTION PROTEIN; CELL-CELL ADHESION; ACTIN CYTOSKELETON; PHENOTYPE; NEPHRIN; DEDIFFERENTIATION; SUSCEPTIBILITY; PROLIFERATION	The collapsing glomerulopathy of HIV-associated nephropathy (HIVAN) is characterized by podocyte dedifferentiation and proliferation. In affected glomeruli, proliferating podocytes adhere in aggregates to form glomerular pseudocrescents and fill an enlarged Bowman's space. Previously, we reported that sidekick-1 (sdk-1), an adhesion molecule of the immunoglobulin superfamily, was highly up-regulated in HIV-1 transgenic podocytes. In the current work, we explore how sdk-1 overexpression contributes to HIVAN pathogenesis. Murine podocytes infected with HIV-1 virus expressed significantly more sdk-1 than control-infected cells. Podocytes stably transfected with an sdk-1 expression construct grew in large aggregates with a simplified morphology characterized by a disorganized actin cytoskeleton, changes similar to podocytes in HIVAN. In contrast to controls, HIV-1 infected podocytes adhered to stably transfected sdk-1 podocyte aggregates in mixing studies. Furthermore, substrate-released cell sheets of wild-type podocytes were readily dissociated by mechanical stress, whereas HIV-1 podocytes remained in aggregates. The number of HIV-1 podocyte aggregates was significantly reduced in cells expressing a short hairpin RNA (shRNA) construct specific for sdk-1 compared with cells expressing control shRNA. Finally, in a HIVAN mouse model, sdk-1 protein was detected in podocytes in collapsed glomerular tufts and in glomerular pseudocrescents. These findings suggest that sdk-1 is an important mediator of cellular adhesion in HIV-infected podocytes and may contribute to podocyte clustering that is characteristic of pseudocrescent formation in HIVAN.	Mt Sinai Sch Med, Div Nephrol, New York, NY 10029 USA; Mt Sinai Sch Med, Div Infect Dis, New York, NY 10029 USA; Juntendo Univ, Sch Med, Div Nephrol, Tokyo 113, Japan	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Juntendo University	Kaufman, L (corresponding author), Mt Sinai Sch Med, Div Nephrol, Box 1243,1 Gustave L Levy Pl, New York, NY 10029 USA.	lewis.kaufman@mssm.edu	klotman, mary e/A-1921-2016		NIDDK NIH HHS [K08 DK070530, P01 DK056492] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK070530, P01DK056492] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bariety J, 2005, KIDNEY INT, V68, P1109, DOI 10.1111/j.1523-1755.2005.00503.x; Bariety J, 2003, J AM SOC NEPHROL, V14, pS42, DOI 10.1097/01.ASN.0000067651.34743.B0; Bariety J, 1998, KIDNEY INT, V53, P918, DOI 10.1111/j.1523-1755.1998.00845.x; Barisoni L, 2002, MICROSC RES TECHNIQ, V57, P254, DOI 10.1002/jemt.10084; Barisoni L, 1999, J AM SOC NEPHROL, V10, P51; Barisoni L, 2000, KIDNEY INT, V58, P137, DOI 10.1046/j.1523-1755.2000.00149.x; Barisoni L, 2000, KIDNEY INT, V58, P173, DOI 10.1046/j.1523-1755.2000.00152.x; Bruggeman LA, 2000, J AM SOC NEPHROL, V11, P2079, DOI 10.1681/ASN.V11112079; Bruggeman LA, 1997, J CLIN INVEST, V100, P84, DOI 10.1172/JCI119525; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Ciani L, 2003, MOL CELL BIOL, V23, P3575, DOI 10.1128/MCB.23.10.3575-3582.2003; Fedorova E, 2006, J GENE MED, V8, P414, DOI 10.1002/jgm.861; Fogo AB, 2003, SEMIN NEPHROL, V23, P161, DOI 10.1053/snep.2003.50015; Gharavi AG, 2004, P NATL ACAD SCI USA, V101, P2488, DOI 10.1073/pnas.0308649100; Hayashi K, 2005, FASEB J, V19, P614, DOI 10.1096/fj.04-2947fje; He JCJ, 2004, J CLIN INVEST, V114, P643, DOI 10.1172/JCI200421004; Hirabayashi S, 2005, LAB INVEST, V85, P1528, DOI 10.1038/labinvest.3700347; Hirabayashi S, 2003, MOL CELL BIOL, V23, P4267, DOI 10.1128/MCB.23.12.4267-4282.2003; Huber TB, 2003, J BIOL CHEM, V278, P13417, DOI 10.1074/jbc.C200678200; Huen AC, 2002, J CELL BIOL, V159, P1005, DOI 10.1083/jcb.200206098; Husain M, 2005, AIDS, V19, P1975, DOI 10.1097/01.aids.0000191918.42110.27; Husain M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000019642.55998.69; Jones N, 2006, NATURE, V440, P818, DOI 10.1038/nature04662; Kaufman L, 2004, J AM SOC NEPHROL, V15, P1721, DOI 10.1097/01.ASN.0000128975.28958.C2; Khoshnoodi J, 2003, AM J PATHOL, V163, P2337, DOI 10.1016/S0002-9440(10)63590-0; Kim JM, 2003, SCIENCE, V300, P1298, DOI 10.1126/science.1081068; Liu G, 2003, J CLIN INVEST, V112, P209, DOI 10.1172/JCI200318242; Marras D, 2002, NAT MED, V8, P522, DOI 10.1038/nm0502-522; Monahan M, 2001, SEMIN NEPHROL, V21, P394, DOI 10.1053/snep.2001.23771; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; Nguyen DNT, 1997, DEVELOPMENT, V124, P3303; Oh J, 2004, PEDIATR NEPHROL, V19, P130, DOI 10.1007/s00467-003-1367-y; Patek CE, 2003, HUM MOL GENET, V12, P2379, DOI 10.1093/hmg/ddg240; Patrie KM, 2002, J BIOL CHEM, V277, P30183, DOI 10.1074/jbc.M203072200; Reiser J, 2000, J AM SOC NEPHROL, V11, P1, DOI 10.1681/ASN.V1111; Ross MJ, 2006, J AM SOC NEPHROL, V17, P996, DOI 10.1681/ASN.2005070692; Ross MJ, 2002, J AM SOC NEPHROL, V13, P2997, DOI 10.1097/01.ASN.0000040750.40907.99; Schwartz EJ, 2001, J AM SOC NEPHROL, V12, P1677, DOI 10.1681/ASN.V1281677; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI12849; Silberberg M, 2005, AM J PHYSIOL-RENAL, V288, pF1153, DOI 10.1152/ajprenal.00008.2005; Yamagata M, 2002, CELL, V110, P649, DOI 10.1016/S0092-8674(02)00910-8; Yang Y, 2002, NEPHRON, V91, P416, DOI 10.1159/000064281; Zheng ZY, 2005, P NATL ACAD SCI USA, V102, P2502, DOI 10.1073/pnas.0409786102	43	25	26	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1367	1375		10.1096/fj.06-7191com	http://dx.doi.org/10.1096/fj.06-7191com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17307840				2022-12-28	WOS:000246117000012
J	Methe, H; Groothuis, A; Sayegh, MH; Edelman, ER				Methe, Heiko; Groothuis, Adam; Sayegh, Mohamed H.; Edelman, Elazer R.			Matrix adherence of endothelial cells attenuates immune reactivity: induction of hyporesponsiveness in allo- and xenogeneic models	FASEB JOURNAL			English	Article						three-dimensional collagen matrices; T cells; tolerance; suppression; anergy; rodent	CD8(+) T-CELLS; INTERFERON-GAMMA; CULTURE; ANTIGEN; ATHEROSCLEROSIS; TRANSPLANTATION; INFLAMMATION; STIMULATION; EXPRESSION; MOLECULES	Endothelial integrity regulates vascular tone, luminal patency, and the immune reactivity to tissue grafts. Endothelial dysfunction is the first marker and site of disease initiation and severity. It has long been known that endothelial biochemical function is density dependent, and we have recently shown that endothelial immunobiology is anchorage dependent. Matrix-embedded endothelial cells (EC) establish a controlled anchorage state and are not only immune protected but also induce a system immune protective state. We now define this aspect of vascular and immune biology in detail. The in vitro immune response of allogeneic splenocytes ( proliferation, lytic activity, and cytokine expression) on exposure to aortic EC was significantly reduced if EC were embedded within three-dimensional collagen matrices (3D- EC; P < 0.005) to an even greater extent than EC that had reached confluence as monolayers on tissue culture plates ( EC-TCPS). Splenocyte reactivity was enhanced with repeated exposure to EC-TCPS but minimally if preexposed to 3D- EC ( P < 0.002). 3D- EC induced significantly greater differentiation of splenocytes into CD4(+) CD25(+) Foxp3(+) regulatory T cells than EC-TCPS ( P < 0.02). The reduced response to 3D- EC and potential protective effect to subsequent exposure were confirmed in vivo. Repeated exposure of immunecompetent mice to injections of xenogeneic EC-TCPS induced vigorous host immunity. In contrast, prior implantation of 3D-EC induced hyporesponsiveness toward subsequent injection of EC- TCPS with reduced humoral response, decreased lytic activity, and lower frequency of effector splenocytes ( P < 0.001). EC interaction with its matrix determines phenotype, viability, and biosecretory potential. We now show that this microenvironmental interaction also influences endothelialmediated activation of allo- and xenogeneic immune cells. 3D matrix- embedding limits the ability of EC to initiate adaptive immunity, and initial exposure to 3D-EC confers hyporesponsiveness to subsequent exposure to immunogeneic EC. These effects transcended the traditional control that confluence imposes on EC and reflects perhaps even higher order control. Our findings might offer novel insights to endothelialmediated diseases and potential cell- based therapies. -	MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Brigham & Womens Hosp, Transplantat Res Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc, Boston, MA USA	Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Methe, H (corresponding author), MIT, Harvard Mit Div Hlth Sci & Technol, 77 Massachusetts Ave,Bldg 56-322, Cambridge, MA 02139 USA.	hmethe@mit.edu		Sayegh, Mohamed/0000-0002-2847-588X	NHLBI NIH HHS [HL-49039] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cappellesso S, 2002, TRANSPL IMMUNOL, V10, P293, DOI 10.1016/S0966-3274(02)00073-4; CENTRA M, 1992, FASEB J, V6, P3117, DOI 10.1096/fasebj.6.12.1521742; Choi J, 2004, ANNU REV IMMUNOL, V22, P683, DOI 10.1146/annurev.immunol.22.012703.104639; Cid Maria C, 2004, Curr Rheumatol Rep, V6, P184, DOI 10.1007/s11926-004-0067-3; Denton M D, 2000, Pediatr Transplant, V4, P252, DOI 10.1034/j.1399-3046.2000.00031.x; Edelman DB, 2005, EXP NEUROL, V192, P1, DOI 10.1016/j.expneurol.2004.10.005; Gould DS, 1999, IMMUNOL TODAY, V20, P77, DOI 10.1016/S0167-5699(98)01394-2; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Harada H, 2003, J CLIN INVEST, V112, P234, DOI 10.1172/JCI200317008; Kern A, 2001, J INVEST DERMATOL, V117, P112, DOI 10.1046/j.0022-202x.2001.01386.x; Koglin J, 2000, CIRCULATION, V101, P1034, DOI 10.1161/01.CIR.101.9.1034; Krupnick AS, 2005, J IMMUNOL, V175, P6265, DOI 10.4049/jimmunol.175.10.6265; LaGier AJ, 2006, HUM IMMUNOL, V67, P568, DOI 10.1016/j.humimm.2006.04.013; Lee DY, 2004, J BIOMAT SCI-POLYM E, V15, P753, DOI 10.1163/156856204774196144; Limmer A, 2000, NAT MED, V6, P1348, DOI 10.1038/82161; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Marelli-Berg FM, 2000, J IMMUNOL, V165, P4182, DOI 10.4049/jimmunol.165.8.4182; McMillan D E, 1997, Vasc Med, V2, P132; Methe H, 2005, CIRCULATION, V112, pI89, DOI 10.1161/01.CIRCULATIONAHA.105.524991; Methe H, 2005, J HEART LUNG TRANSPL, V24, P833, DOI 10.1016/j.healun.2004.05.014; NATHAN A, 1995, P NATL ACAD SCI USA, V92, P8130, DOI 10.1073/pnas.92.18.8130; Nugent HM, 1999, CIRC RES, V84, P384, DOI 10.1161/01.RES.84.4.384; Nugent HM, 2003, CIRC RES, V92, P1068, DOI 10.1161/01.RES.0000073844.41372.38; Nugent HM, 2001, J SURG RES, V99, P228, DOI 10.1006/jsre.2001.6198; NUGENT MA, 1993, CIRC RES, V73, P1051, DOI 10.1161/01.RES.73.6.1051; Papagianni A, 2003, NEPHROL DIAL TRANSPL, V18, P113, DOI 10.1093/ndt/18.1.113; Perez VL, 1998, CELL IMMUNOL, V189, P31, DOI 10.1006/cimm.1998.1362; Raines EW, 2000, INT J EXP PATHOL, V81, P173, DOI 10.1046/j.1365-2613.2000.00155.x; ROBSON SC, 1995, INT ARCH ALLERGY IMM, V106, P305, DOI 10.1159/000236861; Rosemblatt M, 2004, CURR PHARM DESIGN, V10, P109, DOI 10.2174/1381612043453487; Sasaki T, 2002, CYTOTHERAPY, V4, P285, DOI 10.1080/146532402320219808; Schleicher E, 1996, KIDNEY BLOOD PRESS R, V19, P305, DOI 10.1159/000174091; Siebers U, 1997, ANN NY ACAD SCI, V831, P304; Simeonovic CJ, 1999, CELL TRANSPLANT, V8, P365, DOI 10.1177/096368979900800404; Singh NP, 2003, TRANSPLANTATION, V75, P586, DOI 10.1097/01.TP.0000052594.83318.68; Stegemann JP, 2003, EXP CELL RES, V283, P146, DOI 10.1016/S0014-4827(02)00041-1; Turesson C, 2004, CURR PHARM DESIGN, V10, P129, DOI 10.2174/1381612043453414; Valujskikh A, 2003, CURR OPIN IMMUNOL, V15, P493, DOI 10.1016/S0952-7915(03)00110-9; Wang H, 2000, NAT MED, V6, P549, DOI 10.1038/75029; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; WREN SM, 1993, TRANSPLANTATION, V56, P905, DOI 10.1097/00007890-199310000-00025; Zhai Y, 2002, J IMMUNOL, V169, P1270, DOI 10.4049/jimmunol.169.3.1270	42	15	16	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1515	1526		10.1096/fj.06-7051com	http://dx.doi.org/10.1096/fj.06-7051com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264166				2022-12-28	WOS:000246117000026
J	Fuchs, J; Tichopad, A; Golub, Y; Munz, M; Schweitzer, KJ; Wolf, B; Berg, D; Mueller, JC; Gasser, T				Fuchs, Julia; Tichopad, Ales; Golub, Yulia; Munz, Marita; Schweitzer, Katherine J.; Wolf, Bjoern; Berg, Daniela; Mueller, Jakob C.; Gasser, Thomas			Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain	FASEB JOURNAL			English	Article						Parkinson's disease; SNP; NACP-Rep1; substantia nigra; gene expression; real-time RT-PCR; ELISA	FAMILIAL PARKINSONS-DISEASE; MESSENGER-RNA EXPRESSION; HUMAN PLASMA; LYMPHOCYTES; DUPLICATION; DOPAMINE; SUSCEPTIBILITY; TRIPLICATION; HAPLOTYPES; MUTATION	Genetic variability in the promoter and 3' region of the SNCA gene coding alpha-synuclein modulates the risk to develop sporadic Parkinson's disease (PD). Whether this is mediated by regulating alpha-synuclein expression levels remains unknown. Therefore, we analyzed levels of alpha-synuclein in blood and human post mortem brain tissue including the substantia nigra using quantitative real-time reverse transcriptase-polymerase chain reaction and enzyme linked immunosorbent assay in vivo. Single nucleotide polymorphism (SNP) rs356219, a tagging SNP for a disease-associated haplotype in the 3' region of the SNCA gene, has a significant effect on SNCA mRNA levels in the substantia nigra and the cerebellum. Further, the "protective" genotype 259/259 of the PD-associated promoter repeat NACP-Rep1 is associated with lower protein levels in blood than genotypes 261/261, 259/261, and 259/263. In conclusion, we provide evidence that alpha-synuclei levels are influenced by genetic variability in the promoter and 3' region of the SNCA gene in vivo.	[Fuchs, Julia; Golub, Yulia; Munz, Marita; Schweitzer, Katherine J.; Wolf, Bjoern; Berg, Daniela; Mueller, Jakob C.; Gasser, Thomas] Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurodegenerat Dis, D-72076 Tubingen, Germany; [Tichopad, Ales] Tech Univ Munich, Freising Weihenstephan, Germany; [Mueller, Jakob C.] Max Planck Inst Ornithol, Dept Behav Ecol & Evolut Genet, Seewiesen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Technical University of Munich; Max Planck Society	Gasser, T (corresponding author), Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurodegenerat Dis, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	thomas.gasser@med.uni-tuebingen.de	Fuchs, Julia/M-7529-2017; Gasser, Thomas/GNH-5293-2022	Fuchs, Julia/0000-0002-3045-0470; Gasser, Thomas/0000-0002-1069-1146	NATIONAL INSTITUTE OF MENTAL HEALTH [R24MH068855] Funding Source: NIH RePORTER; NIMH NIH HHS [R24 MH068855] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Barbanti P, 1999, MOVEMENT DISORD, V14, P764, DOI 10.1002/1531-8257(199909)14:5<764::AID-MDS1008>3.0.CO;2-W; Bengtsson M, 2005, GENOME RES, V15, P1388, DOI 10.1101/gr.3820805; Caronti B, 1999, NEUROREPORT, V10, P2907, DOI 10.1097/00001756-199909290-00006; Caronti B, 2001, J NEURAL TRANSM, V108, P803, DOI 10.1007/s007020170030; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Chiba-Falek O, 2001, HUM MOL GENET, V10, P3101, DOI 10.1093/hmg/10.26.3101; Chiba-Falek O, 2006, MOVEMENT DISORD, V21, P1703, DOI 10.1002/mds.21007; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; El-Agnaf OMA, 2006, FASEB J, V20, P419, DOI 10.1096/fj.03-1449com; Farrer M, 2004, ANN NEUROL, V55, P174, DOI 10.1002/ana.10846; Farrer M, 2001, HUM MOL GENET, V10, P1847, DOI 10.1093/hmg/10.17.1847; Fuchs J, 2007, NEUROLOGY, V68, P916, DOI 10.1212/01.wnl.0000254458.17630.c5; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; Kim S, 2004, FASEB J, V18, P1615, DOI 10.1096/fj.04-1917fje; Kingsbury AE, 2004, MOVEMENT DISORD, V19, P162, DOI 10.1002/mds.10683; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Maraganore DM, 2006, JAMA-J AM MED ASSOC, V296, P661, DOI 10.1001/jama.296.6.661; MCCuLLAGH P., 1989, GEN LINEAR MODELS, V37; Michell AW, 2005, NEUROSCI LETT, V381, P294, DOI 10.1016/j.neulet.2005.02.030; Mizuta I, 2006, HUM MOL GENET, V15, P1151, DOI 10.1093/hmg/ddl030; Mueller JC, 2005, ANN NEUROL, V57, P535, DOI 10.1002/ana.20438; Nagai Y, 1996, NEUROLOGY, V46, P791, DOI 10.1212/WNL.46.3.791; Neystat M, 1999, MOVEMENT DISORD, V14, P417, DOI 10.1002/1531-8257(199905)14:3<417::AID-MDS1005>3.0.CO;2-X; Nishioka K, 2006, ANN NEUROL, V59, P298, DOI 10.1002/ana.20753; Pals P, 2004, ANN NEUROL, V56, P591, DOI 10.1002/ana.20268; Petrozzi L, 2001, NEUROL SCI, V22, P83, DOI 10.1007/s100720170058; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tan EK, 2004, NEUROLOGY, V62, P128, DOI 10.1212/01.WNL.0000101721.25345.DC; Xia Y, 1996, ANN NEUROL, V40, P207, DOI 10.1002/ana.410400212	32	195	202	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2008	22	5					1327	1334		10.1096/fj.07-9348com	http://dx.doi.org/10.1096/fj.07-9348com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18162487				2022-12-28	WOS:000255898700006
J	Ricke, WA; McPherson, SJ; Bianco, JJ; Cunha, GR; Wang, Y; Risbridger, GP				Ricke, William A.; McPherson, Stephen J.; Bianco, Joseph J.; Cunha, Gerald R.; Wang, Yuzhuo; Risbridger, Gail P.			Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling	FASEB JOURNAL			English	Article						prostate cancer; hormone action; mouse models	MESENCHYMAL-EPITHELIAL INTERACTIONS; MESSENGER-RNA EXPRESSION; NOBLE RATS; INTRAEPITHELIAL NEOPLASIA; MICE; ANDROGEN; BETA; CANCER; MOUSE; GLAND	It was recently demonstrated that antiestrogens prevented prostate cancer (PRCA) in men. The source of estradiol (E2) that contributes to carcinogenesis, as well as the selected estrogen receptor (ER) signaling pathway, is unknown. To evaluate estrogen's effects in carcinogenesis, we developed a new model of PRCA utilizing testosterone and E2 to stimulate PRCA. To determine whether local in situ production of E2 affected incidence of PRCA, aromatase-knockout (ArKO) mice were evaluated. In contrast to the wildtype mice, ArKO mice had reduced incidences of PRCA, which implicates in situ production of E2 as an important determinant of PRCA. To determine whether E2-mediated responses were due to ER alpha or ER beta signaling, ER alpha-knockout (alpha ERKO) or ER beta-knock-out (beta ERKO) mice were used. Prostates from beta ERKO mice underwent biochemical and histological carcinogenesis similar to wild-type mice, whereas prostates from alpha ERKO mice remained free of pathology. These data suggest that effective prevention of carcinogenesis will require antagonism of ER alpha but not ER beta. This mouse model provides a means to examine genetic gain and loss of function and determine the efficacy of therapeutics on prostatic carcinogenesis.	[Ricke, William A.] Univ Rochester, Med Ctr, Dept Urol, James P Wilmot Canc Ctr, Rochester, NY 14642 USA; [Ricke, William A.] Univ Rochester, Med Ctr, Dept Pathol, James P Wilmot Canc Ctr, Rochester, NY 14642 USA; [Ricke, William A.] Univ Rochester, Med Ctr, Dept Lab Med, James P Wilmot Canc Ctr, Rochester, NY 14642 USA; [McPherson, Stephen J.; Bianco, Joseph J.; Risbridger, Gail P.] Monash Univ, Monash Inst Med Res, Ctr Urol Res, Clayton, Vic 3168, Australia; [Cunha, Gerald R.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; [Cunha, Gerald R.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA; [Wang, Yuzhuo] Univ British Columbia, British Columbia Canc Agcy, Dept Canc Endocrinol, Vancouver, BC V5Z 1M9, Canada; [Wang, Yuzhuo] Univ British Columbia, British Columbia Canc Agcy, Prostate Ctr, Vancouver, BC V5Z 1M9, Canada	University of Rochester; University of Rochester; University of Rochester; Monash University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; British Columbia Cancer Agency; University of British Columbia; British Columbia Cancer Agency; University of British Columbia	Ricke, WA (corresponding author), Univ Rochester, Med Ctr, Dept Urol, James P Wilmot Canc Ctr, 601 Elmwood Ave,Box 656, Rochester, NY 14642 USA.	william_ricke@urmc.rochester.edu	McPherson, Stephen/A-9490-2009; Risbridger, Gail P/B-8655-2008	Risbridger, Gail P/0000-0003-3089-4028; Wang, Yuzhuo/0000-0002-9749-8591; Bianco, Joseph/0000-0001-5403-348X; Ricke, William/0000-0002-9807-2090	NATIONAL CANCER INSTITUTE [R01CA123199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA123199] Funding Source: Medline; NIEHS NIH HHS [P30 ES01247] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BELANGER A, 1994, J CLIN ENDOCR METAB, V79, P1086; Carmichael PL, 2001, TOXICOL PATHOL, V29, P155, DOI 10.1080/019262301753178564; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Cunha GR, 1996, ACTA ANAT, V155, P63; CUNHA GR, 1992, J ANDROL, V13, P465; DONJACOUR AA, 1993, ENDOCRINOLOGY, V132, P2342, DOI 10.1210/en.132.6.2342; Dore M, 2005, VET PATHOL, V42, P100, DOI 10.1354/vp.42-1-100; Hayward SW, 1998, INT J ONCOL, V13, P35; Hayward SW, 1996, ANN NY ACAD SCI, V784, P50, DOI 10.1111/j.1749-6632.1996.tb16227.x; Hollmer M, 2006, NAT BIOTECHNOL, V24, P1455, DOI 10.1038/nbt1206-1455; ISAACS JT, 1994, SEMIN CANCER BIOL, V5, P391; Konac E, 2005, MOL CELL BIOCHEM, V276, P45, DOI 10.1007/s11010-005-2815-8; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lau KM, 1998, ENDOCRINOLOGY, V139, P424, DOI 10.1210/en.139.1.424; LEAV I, 1988, J NATL CANCER I, V80, P1045, DOI 10.1093/jnci/80.13.1045; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MAWHINNEY MG, 1979, INVEST UROL, V16, P409; McPherson SJ, 2001, ENDOCRINOLOGY, V142, P2458, DOI 10.1210/en.142.6.2458; McPherson SJ, 2007, ENDOCRINOLOGY, V148, P566, DOI 10.1210/en.2006-0906; NASLUND MJ, 1986, J UROLOGY, V136, P1136, DOI 10.1016/S0022-5347(17)45239-6; NEUBAUER B, 1981, INVEST UROL, V18, P229; NEVALAINEN MT, 1993, CANCER RES, V53, P5199; NOBLE RL, 1977, CANCER RES, V37, P1929; NOBLE RL, 1980, CANCER RES, V40, P3574; POLLARD M, 1987, PROSTATE, V10, P325, DOI 10.1002/pros.2990100406; Price D, 2006, J UROLOGY, V176, P965, DOI 10.1016/j.juro.2006.04.011; Prins G.S., 1997, PROSTATE BASIC CLIN, P245; Prins GS, 2001, CANCER RES, V61, P6089; Ricke WA, 2006, INT J CANCER, V118, P2123, DOI 10.1002/ijc.21614; Risbridger G, 2001, DEV BIOL, V229, P432, DOI 10.1006/dbio.2000.9994; Russo J, 2003, J STEROID BIOCHEM, V87, P1, DOI 10.1016/S0960-0760(03)00390-X; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Spearow JL, 1999, SCIENCE, V285, P1259, DOI 10.1126/science.285.5431.1259; Stanbrough M, 2001, P NATL ACAD SCI USA, V98, P10823, DOI 10.1073/pnas.191235898; THOMPSON SA, 1979, INVEST UROL, V17, P83; THOMPSON TC, 1993, MOL CARCINOGEN, V7, P165, DOI 10.1002/mc.2940070307; UMBAS R, 1992, CANCER RES, V52, P5104; vomSaal FS, 1997, P NATL ACAD SCI USA, V94, P2056; WALSH PC, 1976, J CLIN INVEST, V57, P1093, DOI 10.1172/JCI108353; Wang YH, 2000, CANCER RES, V60, P6008; Wang YZ, 2001, CANCER RES, V61, P6064; Weihua Zhang, 2001, Proceedings of the National Academy of Sciences of the United States of America, V98, P6330, DOI 10.1073/pnas.111150898; WILSON JD, 1980, AM J MED, V68, P745, DOI 10.1016/0002-9343(80)90267-3; YU M, 1993, LAB INVEST, V68, P33	46	167	175	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1512	1520		10.1096/fj.07-9526com	http://dx.doi.org/10.1096/fj.07-9526com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18055862				2022-12-28	WOS:000255898700023
J	Huet, E; Vallee, B; Szul, D; Verrecchia, F; Mourah, S; Jester, JV; Hoang-Xuan, T; Menashi, S; Gabison, EE				Huet, Eric; Vallee, Benoit; Szul, Dominika; Verrecchia, Franck; Mourah, Samia; Jester, James V.; Hoang-Xuan, Thanh; Menashi, Suzanne; Gabison, Eric E.			Extracellular matrix metalloprteinase inducer/CD147 promotes myofibroblast differentiation by inducing alpha-smooth muscle actin expression and collagen gel contraction: implications in tissue remodeling	FASEB JOURNAL			English	Article						epithelial-stromal interactions; wound healing; MMPs; TGh beta	GROWTH-FACTOR-BETA; TUMOR-STROMAL INTERACTIONS; BREAST-CANCER CELLS; METALLOPROTEINASE INDUCER; GENE-EXPRESSION; TGF-BETA; DERMAL FIBROBLASTS; EMMPRIN; INDUCTION; BASIGIN	Extracellular matrix metalloproteinase inducer (EMMPRIN) is a cell surface glycoprotein enriched on tumor cells and normal epithelia. It is mainly known for its ability to induce matrix metalloproteinase production in fibroblasts following epithelial-stromal interaction. We sought to examine whether EMMPRIN has a broader role promoting fibroblast-to-myofibroblast differentiation. Because alpha-smooth muscle actin (alpha SMA) is considered a marker of this differentiation process, we analyzed the effect of EMMPRIN on its expression in corneal and skin fibroblasts by Western blots, immunocytochemistry, and a functional assay of collagen lattice contraction. Increasing EMMPRIN expression by cDNA transfection or by treatment with exogenously added recombinant EMMPRIN resulted in an up-regulation of alpha SMA expression. EMMPRIN also increased the contractile properties of the treated fibroblasts as demonstrated by the immunohistochemical appearance of stress fibers and by the accelerated contraction of fibroblast-embedded collagen lattices. Blocking EMMPRIN expression by small interfering RNA inhibited alpha SMA and collagen gel contraction induced not only by EMMPRIN but also by transforming growth factor-beta, a major mediator of myofibroblast differentiation that also regulated EMMPRIN expression. These findings, combined with the fact that EMMPRIN and aSMA colocalized to the same cells in the stroma of pathological corneas, expand on the mechanism by which EMMPRIN remodels extracellular matrix during wound healing and cancer.	[Huet, Eric; Vallee, Benoit; Szul, Dominika; Menashi, Suzanne; Gabison, Eric E.] Univ Paris 12, CNRS, CRRET Lab, UMR 7149, F-94010 Creteil, France; [Verrecchia, Franck] Hop St Louis, INSERM, U697, Paris, France; [Mourah, Samia] Hop St Louis, INSERM, Pharmacol Lab, U716, Paris, France; [Jester, James V.] Univ Calif Irvine, Dept Ophthalmol, Irvine, CA USA; [Hoang-Xuan, Thanh; Gabison, Eric E.] Rothschild & Bichat Hosp, AP HP, Fdn Ophtalmol A, Dept Ophthalmol, Paris, France	Centre National de la Recherche Scientifique (CNRS); Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California Irvine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP	Menashi, S (corresponding author), Univ Paris 12, CNRS, CRRET Lab, UMR 7149, Av Gen Gaulle, F-94010 Creteil, France.	menashi@univ-paris12.fr	HUET, Eric/R-3178-2018; Verrecchia, Franck/G-5535-2018	HUET, Eric/0000-0002-5541-5954; Verrecchia, Franck/0000-0003-4920-2554; Jester, James/0000-0002-9246-0981				Berton A., 2000, Molecular Cell Biology Research Communications, V3, P173, DOI 10.1006/mcbr.2000.0210; Betsuyaku T, 2003, AM J RESP CELL MOL, V28, P600, DOI 10.1165/rcmb.2002-0059OC; Bisson C, 2003, INT J CANCER, V105, P7, DOI 10.1002/ijc.11012; Chen X, 2001, HISTOCHEM CELL BIOL, V115, P465; Curtin KD, 2005, J CELL SCI, V118, P2649, DOI 10.1242/jcs.02408; DeCastro R, 1996, J INVEST DERMATOL, V106, P1260, DOI 10.1111/1523-1747.ep12348959; Desmouliere A, 2004, INT J DEV BIOL, V48, P509, DOI 10.1387/ijdb.041802ad; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Fini ME, 2005, CORNEA, V24, pS2, DOI 10.1097/01.ico.0000178743.06340.2c; Gabison EE, 2005, AM J PATHOL, V166, P209, DOI 10.1016/S0002-9440(10)62245-6; Gabison EE, 2003, OPHTHALMOLOGY, V110, P1626, DOI 10.1016/S0161-6420(03)00486-X; Gabison EE, 2005, BIOCHIMIE, V87, P361, DOI 10.1016/j.biochi.2004.09.023; Guo HM, 1997, J BIOL CHEM, V272, P24; Hinz B, 2006, EUR J CELL BIOL, V85, P175, DOI 10.1016/j.ejcb.2005.09.004; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Jester JV, 1996, CORNEA, V15, P505; Jester JV, 2003, INVEST OPHTH VIS SCI, V44, P1850, DOI 10.1167/iovs.02-0973; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Karsdal MA, 2002, J BIOL CHEM, V277, P44061, DOI 10.1074/jbc.M207205200; KATAOKA H, 1993, CANCER RES, V53, P3154; Konttinen YT, 2000, ARTHRITIS RHEUM, V43, P275, DOI 10.1002/1529-0131(200002)43:2<275::AID-ANR6>3.0.CO;2-#; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Lin HC, 2001, INVEST OPHTH VIS SCI, V42, P2517; Marieb EA, 2004, CANCER RES, V64, P1229, DOI 10.1158/0008-5472.CAN-03-2832; Masur SK, 1996, P NATL ACAD SCI USA, V93, P4219, DOI 10.1073/pnas.93.9.4219; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Menashi S, 2003, CANCER RES, V63, P7575; Mio T, 1996, IN VITRO CELL DEV-AN, V32, P427; Nakamura T, 1997, CANCER RES, V57, P3305; Nielsen BS, 2001, CANCER RES, V61, P7091; Norgauer J, 2002, BRIT J DERMATOL, V147, P1180, DOI 10.1046/j.1365-2133.2002.05025.x; Petridou S, 2000, INVEST OPHTH VIS SCI, V41, P89; Philipp K, 2005, INT J MOL MED, V15, P299; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Shackel NA, 2002, AM J PATHOL, V160, P641, DOI 10.1016/S0002-9440(10)64884-5; Sidhu SS, 2004, ONCOGENE, V23, P956, DOI 10.1038/sj.onc.1207070; Stuelten CH, 2005, J CELL SCI, V118, P2143, DOI 10.1242/jcs.02334; Sun JX, 2001, CANCER RES, V61, P2276; Tang Y, 2005, CANCER RES, V65, P3193, DOI 10.1158/0008-5472.CAN-04-3605; Tang Y, 2004, MOL CANCER RES, V2, P73; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Toole BP, 2003, CURR TOP DEV BIOL, V54, P371, DOI 10.1016/S0070-2153(03)54015-7; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Verrecchia Franck, 2002, Curr Rheumatol Rep, V4, P143, DOI 10.1007/s11926-002-0010-4; Yan L, 2005, THROMB HAEMOSTASIS, V93, P199, DOI 10.1160/TH04-08-0536; Yu Q, 2000, GENE DEV, V14, P163; Yuan WH, 2001, J BIOL CHEM, V276, P38502, DOI 10.1074/jbc.M107081200; Yurchenko V, 2006, IMMUNOLOGY, V117, P301, DOI 10.1111/j.1365-2567.2005.02316.x; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	50	73	78	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1144	1154		10.1096/fj.07-8748com	http://dx.doi.org/10.1096/fj.07-8748com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	17965264				2022-12-28	WOS:000254581000020
J	Sato-Jin, K; Nishimura, EK; Akasaka, E; Huber, W; Nakano, H; Miller, A; Du, JY; Wu, M; Hanada, K; Sawamura, D; Fisher, DE; Imokawa, G				Sato-Jin, Kayo; Nishimura, Emi K.; Akasaka, Eijiro; Huber, Wade; Nakano, Hajime; Miller, Arlo; Du, Jinyan; Wu, Min; Hanada, Katsumi; Sawamura, Daisuke; Fisher, David E.; Imokawa, Genji			Epistatic connections between microphthalmia-associated transcription factor and endothelin signaling in Waardenburg syndrome and other pigmentary disorders	FASEB JOURNAL			English	Article						cAMP response element-binding protein; CREB; cyclin-dependent kinase 2; melanocyte; endothelin B receptor	B RECEPTOR GENE; GROWTH-FACTOR; SYNDROME TYPE-2; MELANOCYTE DEVELOPMENT; HUMAN KERATINOCYTES; HUMAN HOMOLOG; MITF; EXPRESSION; ACTIVATION; DIFFERENTIATION	Waardenburg syndrome (WS) is an inherited sensorineural deafness condition in humans caused by melanocyte deficiencies in the inner ear and forelock. Mutation of microphthalmia-associated transcription factor (MITF) is known to produce WS type IIA whereas mutations of either endothelin (EDN) or its receptor endothelin receptor B (EDNRB) produce WS type IV. However, a link between MITF haploinsufficiency and EDN signaling has not yet been established. Here we demonstrate mechanistic connections between EDN and MITF and their functional importance in melanocytes. Addition of EDN to cultured human melanocytes stimulated the phosphorylation of MITF in an EDNRB-dependent manner, which was completely abolished by mitogen-activated protein kinase kinase inhibition. The expression of melanocyte-specific MITF mRNA transcripts was markedly augmented after incubation with EDN1 and was followed by increased expression of MITF protein. Up-regulated expression of MITF was found to be mediated via both the mitogen-activated protein kinase-p90 ribosomal S6 kinase-cAMP response element-binding protein (CREB) and CAMP-protein kinase A-CREB pathways. In addition, EDNRB expression itself was seen to be dependent on MITE. The functional importance of these connections is illustrated by the ability of EDN to stimulate expression of melanocytic pigmentation and proliferation markers in an MITF-dependent fashion. Collectively these data provide mechanistic and epistatic links between MITF and EDN/EDNRB, critical melanocytic survival factors and WS genes.	[Imokawa, Genji] Tokyo Univ Technol, Sch Bion, Katayanagi Inst, Hachioji, Tokyo 1920982, Japan; [Sato-Jin, Kayo; Akasaka, Eijiro; Nakano, Hajime; Hanada, Katsumi; Sawamura, Daisuke; Imokawa, Genji] Hirosaki Univ, Grad Sch Med, Dept Dermatol, Hirosaki, Aomori, Japan; [Nishimura, Emi K.] Kanazawa Univ, Canc Res Inst, Dept Stem Cell Med, Kanazawa, Ishikawa 920, Japan; [Nishimura, Emi K.; Huber, Wade; Miller, Arlo; Du, Jinyan; Wu, Min; Fisher, David E.] Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat Hematol Oncol, Boston, MA 02115 USA; [Nishimura, Emi K.; Huber, Wade; Miller, Arlo; Du, Jinyan; Wu, Min; Fisher, David E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Melanoma Program, Boston, MA 02115 USA	Tokyo University of Technology; Hirosaki University; Kanazawa University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Imokawa, G (corresponding author), Tokyo Univ Technol, Sch Bion, Katayanagi Inst, W204,1404-1 Katakura, Hachioji, Tokyo 1920982, Japan.	imokawag@dream.ocn.ne.jp						BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Du JY, 2003, AM J PATHOL, V163, P333, DOI 10.1016/S0002-9440(10)63657-7; Edery P, 1996, NAT GENET, V12, P442, DOI 10.1038/ng0496-442; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Fuse N, 1996, BIOCHEM BIOPH RES CO, V219, P702, DOI 10.1006/bbrc.1996.0298; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; Halaban R., 2003, FITZPATRICKS DERMATO, V6th edn., P127; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hofstra RMW, 1996, NAT GENET, V12, P445, DOI 10.1038/ng0496-445; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; Huber WE, 2003, J BIOL CHEM, V278, P45224, DOI 10.1074/jbc.M309036200; HUGHES AE, 1994, NAT GENET, V7, P509, DOI 10.1038/ng0894-509; Imokawa G, 1998, BIOCHEM J, V330, P1235, DOI 10.1042/bj3301235; Imokawa G, 2000, J BIOL CHEM, V275, P33321, DOI 10.1074/jbc.M004346200; Imokawa G, 1997, PIGM CELL RES, V10, P218, DOI 10.1111/j.1600-0749.1997.tb00488.x; IMOKAWA G, 1995, J INVEST DERMATOL, V105, P32, DOI 10.1111/1523-1747.ep12312500; IMOKAWA G, 1992, J BIOL CHEM, V267, P24675; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Orlow SJ, 1998, CANCER RES, V58, P1521; PAVAN WJ, 1994, P NATL ACAD SCI USA, V91, P7159, DOI 10.1073/pnas.91.15.7159; Potterf SB, 2000, HUM GENET, V107, P1, DOI 10.1007/s004390050001; Price ER, 1998, J BIOL CHEM, V273, P33042, DOI 10.1074/jbc.273.49.33042; Price ER, 1998, J BIOL CHEM, V273, P17983, DOI 10.1074/jbc.273.29.17983; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; Reid K, 1996, DEVELOPMENT, V122, P3911; Shin MK, 1999, NATURE, V402, P496, DOI 10.1038/990040; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Verastegui C, 2000, J BIOL CHEM, V275, P30757, DOI 10.1074/jbc.C000445200; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; Widlund HR, 2002, J CELL BIOL, V158, P1079, DOI 10.1083/jcb.200202049; Wu M, 2000, GENE DEV, V14, P301; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAAR M, 1991, J INVEST DERMATOL, V97, P611, DOI 10.1111/1523-1747.ep12482985; YADA Y, 1991, J BIOL CHEM, V266, P18352; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YASUMOTO K, 1995, J BIOCHEM-TOKYO, V118, P874, DOI 10.1093/jb/118.5.874; YAVUZER U, 1995, ONCOGENE, V10, P123; Yoshida H, 1996, DEVELOPMENT, V122, P1207; ZAKUT R, 1993, ONCOGENE, V8, P2221	56	73	77	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1155	1168		10.1096/fj.07-9080com	http://dx.doi.org/10.1096/fj.07-9080com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	18039926				2022-12-28	WOS:000254581000021
J	Tsutsui, S; Vergote, D; Shariat, N; Warren, K; Ferguson, SSG; Power, C				Tsutsui, Shigeki; Vergote, David; Shariat, Neda; Warren, Kenneth; Ferguson, Stephen S. G.; Power, Christopher			Glucocorticoids regulate innate immunity in a model of multiple sclerosis: reciprocal interactions between the A1 adenosine receptor and beta-arrestin-1 in monocytoid cells	FASEB JOURNAL			English	Article						central nervous system; cytokines; experimental autoimmune encephalomyelitis; G protein-coupled receptor	PROTEIN-COUPLED RECEPTORS; BLOOD MONONUCLEAR-CELLS; MICROGLIAL CELLS; UP-REGULATION; INTRACEREBRAL HEMORRHAGE; GENE-EXPRESSION; NERVOUS-SYSTEM; BETA-ARRESTIN; ACTIVATION; BRAIN	Desensitization of seven transmembrane receptors (7TMRs), which are modulated by the beta-arrestins, leads to altered G protein activation. The A1 adenosine receptor (A1AR) is an antiinflammatory 7TMR exhibiting reduced expression and activity in both multiple sclerosis (MS) and the murine MS model, experimental autoimmune encephalomyelitis (EAE) in monocytoid cells. Herein, we report that beta-arrestin-1 expression was increased in brains of MS patients relative to non-MS brains, whereas A1AR expression was concomitantly reduced. This inverse relationship between beta-arrestin-1 and A1AR was confirmed in cultured monocytoid cells as beta-arrestin-1 overexpression resulted in a down-regulation of A1AR together with the internalization of the surface receptor. Moreover, a physical interaction between beta-arrestin-1 and A1AR was demonstrated in monocytoid cells. Proinflammatory cytokines regulated the A1AR/beta-arrestin-1 interactions, while A1AR activation also modulated proinflammatory cytokines expression. During EAE, beta-arrestin-1 and A1AR expression in the spinal cord displayed a similar pattern compared to that observed in MS brains. EAE-induced neuroinflammation and neurobehavioral deficits were suppressed by glucocorticoid treatments, accompanied by concurrent reduced beta-arrestin-1 and enhanced A1AR expression. Thus, the interplay between beta-arrestin-1 and A1AR in the central nervous system during neuroinflammation represents a reciprocal regulatory mechanism through which neuroprotective therapeutic strategies for neuroinflammatory diseases might be further developed.	[Vergote, David; Warren, Kenneth; Power, Christopher] Univ Alberta, Dept Med, Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada; [Tsutsui, Shigeki; Vergote, David; Shariat, Neda; Power, Christopher] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Ferguson, Stephen S. G.] Univ Western Ontario, Dept Physiol & Pharmacol, Cell Biol Res Grp, Robarts Res Inst, London, ON, Canada	University of Alberta; University of Calgary; Western University (University of Western Ontario)	Power, C (corresponding author), Univ Alberta, Dept Med, Heritage Med Res Ctr, Rm 611, Edmonton, AB T6G 2S2, Canada.	chris.power@ualberta.ca	Power, Christopher/C-7181-2013	Power, Christopher/0000-0002-5131-9711; Vergote, David/0000-0002-1298-3783				Bar-Or A, 1999, J NEUROIMMUNOL, V100, P252, DOI 10.1016/S0165-5728(99)00193-9; Barnett MH, 2004, ANN NEUROL, V55, P458, DOI 10.1002/ana.20016; Boven LA, 2003, J IMMUNOL, V170, P2638, DOI 10.4049/jimmunol.170.5.2638; Brundula V, 2002, BRAIN, V125, P1297, DOI 10.1093/brain/awf133; Brusaferri F, 2000, J NEUROL, V247, P435, DOI 10.1007/s004150070172; Burgoon MP, 2004, FRONT BIOSCI-LANDMRK, V9, P786, DOI 10.2741/1278; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Forooghian F, 2007, J CLIN IMMUNOL, V27, P388, DOI 10.1007/s10875-007-9091-1; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; GARLOW SJ, 1995, MOL BRAIN RES, V31, P201, DOI 10.1016/0169-328X(95)00043-R; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gelati M, 2002, ARCH NEUROL-CHICAGO, V59, P774, DOI 10.1001/archneur.59.5.774; GERWINS P, 1991, MOL PHARMACOL, V40, P149; Giorelli M, 2002, CELL SIGNAL, V14, P673, DOI 10.1016/S0898-6568(02)00011-6; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Hasko G, 1996, J IMMUNOL, V157, P4634; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Johnston JB, 2001, ANN NEUROL, V49, P650, DOI 10.1002/ana.1007; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Jones G, 2006, NEUROBIOL DIS, V21, P1, DOI 10.1016/j.nbd.2005.07.018; Kohno H, 2007, EXP EYE RES, V84, P569, DOI 10.1016/j.exer.2006.11.011; Lassmann H, 2001, CURR OPIN NEUROL, V14, P253, DOI 10.1097/00019052-200106000-00001; Lefkowitz RJ, 2004, CURR OPIN CELL BIOL, V16, P162, DOI 10.1016/j.ceb.2004.01.001; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Leussink VI, 2001, ARCH NEUROL-CHICAGO, V58, P91, DOI 10.1001/archneur.58.1.91; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Mayne M, 2001, STROKE, V32, P240, DOI 10.1161/01.STR.32.1.240; Mayne M, 1999, ANN NEUROL, V45, P633, DOI 10.1002/1531-8249(199905)45:5<633::AID-ANA12>3.0.CO;2-X; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; McQualter JL, 2001, J EXP MED, V194, P873, DOI 10.1084/jem.194.7.873; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Morrow SA, 2004, NEUROLOGY, V63, P1079, DOI 10.1212/01.WNL.0000138572.82125.F5; Navikas V, 1996, J NEUROSCI RES, V45, P322, DOI 10.1002/(SICI)1097-4547(19960815)45:4<322::AID-JNR1>3.0.CO;2-B; Nguyen MD, 2002, NAT REV NEUROSCI, V3, P216, DOI 10.1038/nrn752; Nie ZZ, 1997, MOL PHARMACOL, V52, P456, DOI 10.1124/mol.52.3.456; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; OHGURO H, 1993, P NATL ACAD SCI USA, V90, P3241, DOI 10.1073/pnas.90.8.3241; PARRUTI G, 1993, J BIOL CHEM, V268, P9753; Pender MP, 2002, INTERN MED J, V32, P554, DOI 10.1046/j.1445-5994.2002.00269.x; Pitzalis C, 2002, ANN NY ACAD SCI, V966, P108, DOI 10.1111/j.1749-6632.2002.tb04208.x; PLESS IB, 1993, PEDIATRICS, V91, P1131; Ponomarev ED, 2007, J IMMUNOL, V178, P39, DOI 10.4049/jimmunol.178.1.39; Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553; Ren HZ, 1999, MOL PHARMACOL, V55, P309, DOI 10.1124/mol.55.2.309; Rivkees SA, 1999, J BIOL CHEM, V274, P14204, DOI 10.1074/jbc.274.20.14204; Song XF, 2006, J BIOL CHEM, V281, P21491, DOI 10.1074/jbc.M603659200; Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150; Svenningsson P, 1997, J PHARMACOL EXP THER, V280, P1094; TEURICH S, 1995, CHEM SENSES, V20, P251, DOI 10.1093/chemse/20.2.251; Tsutsui S, 2005, ANN NEUROL, V57, P883, DOI 10.1002/ana.20502; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; ULVESTAD E, 1994, J NEUROPATH EXP NEUR, V53, P492, DOI 10.1097/00005072-199409000-00008; Vassilatis DK, 2003, P NATL ACAD SCI USA, V100, P4903, DOI 10.1073/pnas.0230374100; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Vroon A, 2003, J NEUROIMMUNOL, V137, P79, DOI 10.1016/S0165-5728(03)00050-X; Wandinger KP, 1998, ACTA NEUROL SCAND, V97, P359, DOI 10.1111/j.1600-0404.1998.tb05966.x; Wang JH, 2001, J BIOL CHEM, V276, P49236, DOI 10.1074/jbc.M108523200; Wardas J, 2002, POL J PHARMACOL, V54, P313; Wise A, 2004, ANNU REV PHARMACOL, V44, P43, DOI 10.1146/annurev.pharmtox.44.101802.121419; Yong VW, 2004, FRONT BIOSCI, V9, P864, DOI 10.2741/1276; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571	65	37	40	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					786	796		10.1096/fj.07-9002com	http://dx.doi.org/10.1096/fj.07-9002com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17965263				2022-12-28	WOS:000254143700017
J	Burmeister, C; Luersen, K; Heinick, A; Hussein, A; Domagalski, M; Walter, RD; Liebau, E				Burmeister, Cora; Lueersen, Kai; Heinick, Alexander; Hussein, Ayman; Domagalski, Marzena; Walter, Rolf D.; Liebau, Eva			Oxidative stress in Caenorhabditis elegans: protective effects of the Omega class glutathione transferase (GSTO-1)	FASEB JOURNAL			English	Article						antioxidant; RNA interference; GST	UBIQUITIN-CONJUGATING ENZYMES; AGE-AT-ONSET; S-TRANSFERASE; C-ELEGANS; FUNCTIONAL-ANALYSIS; CONFERS RESISTANCE; REDOX REGULATION; GENE-TRANSFER; GATA-FACTOR; IDENTIFICATION	To elucidate the function of Omega class glutathione transferases (GSTs) (EC 2.5.1.18) in multicellular organisms, the GSTO-1 from Caenorhabditis elegans (GSTO-1; C29E4.7) was investigated. Disc diffusion assays using Escherichia coli overexpressing GSTO-1 provided a test of resistance to long-term exposure under oxidative stress. After affinity purification, the recombinant GSTO-1 had minimal catalytic activity toward classic GST substrates but displayed significant thiol oxidoreductase and dehydroascorbate reductase activity. Microinjection of the GSTO-1-promoter green fluorescent protein construct and immunolocalization by electron microscopy localized the protein exclusively in the intestine of all postembryonic stages of C. elegans. Deletion analysis identified an similar to 300-nucleotide sequence upstream of the ATG start site necessary for GSTO-1 expression. Site-specific mutagenesis of a GATA transcription factor binding motif in the minimal promoter led to the loss of reporter expression. Similarly, RNA interference (RNAi) of Elt-2 indicated the involvement of this gut-specific transcription factor in GSTO-1 expression. Transcriptional upregulation under stress conditions of GSTO-1 was confirmed by analyzing promoter-reporter constructs in transgenic C. elegans strains. To investigate the function of GSTO-1 in vivo, transgenic animals overexpressing GSTO-1 were generated exhibiting an increased resistance to juglone-, paraquat-, and cumene hydroperoxide-induced oxidative stress. Specific silencing of the GSTO-1 by RNAi created worms with an increased sensitivity to several prooxidants, arsenite, and heat shock. We conclude that the stress-responsive GSTO-1 plays a key role in counteracting environmental stress.	[Burmeister, Cora; Lueersen, Kai; Heinick, Alexander; Liebau, Eva] Univ Munster, Inst Anim Physiol, D-48143 Munster, Germany; [Hussein, Ayman] An Najah Natl Univ, Fac Sci, Nablus, Israel; [Domagalski, Marzena; Walter, Rolf D.] Bernhard Nocht Inst Trop Med, Hamburg, Germany	University of Munster; An Najah National University; Bernhard Nocht Institut fur Tropenmedizin	Liebau, E (corresponding author), Univ Munster, Inst Anim Physiol, Hindenburgpl 55, D-48143 Munster, Germany.	liebaue@uni-muenster.de		Heinick, Alexander/0000-0002-3770-105X				Ayyadevara S, 2005, AGING CELL, V4, P257, DOI 10.1111/j.1474-9726.2005.00168.x; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Bossis G, 2006, MOL CELL, V21, P349, DOI 10.1016/j.molcel.2005.12.019; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caccuri AM, 2002, J BIOL CHEM, V277, P18777, DOI 10.1074/jbc.M201137200; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; Denton H, 2004, BIOCHEM J, V381, P405, DOI 10.1042/BJ20040283; Dixon DP, 2002, J BIOL CHEM, V277, P30859, DOI 10.1074/jbc.M202919200; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fukushige T, 1998, DEV BIOL, V198, P286, DOI 10.1016/S0012-1606(98)80006-7; Fukushige T, 2003, GENETICS, V165, P575; Fukushige T, 2005, DEV BIOL, V279, P446, DOI 10.1016/j.ydbio.2004.12.012; Garcera A, 2006, BIOCHEM J, V398, P187, DOI 10.1042/BJ20060034; Ghezzi P, 2005, FREE RADICAL RES, V39, P573, DOI 10.1080/10715760500072172; Giustarini D, 2004, J CELL MOL MED, V8, P201, DOI 10.1111/j.1582-4934.2004.tb00275.x; GRANATO M, 1994, NUCLEIC ACIDS RES, V22, P1762, DOI 10.1093/nar/22.9.1762; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kampkotter A, 2003, J MOL BIOL, V325, P25, DOI 10.1016/S0022-2836(02)01174-9; Kim J, 2006, BIOCHEM J, V398, P451, DOI 10.1042/BJ20060424; Kodym R, 1999, J BIOL CHEM, V274, P5131, DOI 10.1074/jbc.274.8.5131; Komatsu M, 2004, EMBO J, V23, P1977, DOI 10.1038/sj.emboj.7600205; Laliberte RE, 2003, J BIOL CHEM, V278, P16567, DOI 10.1074/jbc.M211596200; Leiers BR, 2003, FREE RADICAL BIO MED, V34, P1405, DOI 10.1016/S0891-5849(03)00102-3; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Li YJ, 2003, HUM MOL GENET, V12, P3259, DOI 10.1093/hmg/ddg357; Liao VHC, 2005, BIOMETALS, V18, P519, DOI 10.1007/s10534-005-2996-3; Liebau E, 1997, BIOCHEM J, V324, P659, DOI 10.1042/bj3240659; Liebau E, 2000, MOL BIOCHEM PARASIT, V109, P101, DOI 10.1016/S0166-6851(00)00232-2; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Murakami R, 2005, DEV GROWTH DIFFER, V47, P581; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Oskouian B, 2005, J BIOL CHEM, V280, P18403, DOI 10.1074/jbc.M410928200; Schmuck EM, 2005, PHARMACOGENET GENOM, V15, P493, DOI 10.1097/01.fpc.0000165725.81559.e3; Shi HL, 2004, MOL CELL BIOCHEM, V255, P67, DOI 10.1023/B:MCBI.0000007262.26044.e8; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940; WHITBREAD AK, 1940, METHOD ENZYMOL, V401, P78; Yin SP, 2005, J BIOL CHEM, V280, P34985, DOI 10.1074/jbc.M503522200; Yin ZL, 2001, J HISTOCHEM CYTOCHEM, V49, P983, DOI 10.1177/002215540104900806; Zakharyan RA, 2001, CHEM RES TOXICOL, V14, P1051, DOI 10.1021/tx010052h	42	94	101	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					343	354		10.1096/fj.06-7426com	http://dx.doi.org/10.1096/fj.06-7426com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17901115				2022-12-28	WOS:000252822600004
J	Quach, TT; Massicotte, G; Belin, MF; Honnorat, J; Glasper, ER; Devries, AC; Jakeman, LB; Baudry, M; Duchemin, AM; Kolattukudy, PE				Quach, Tam T.; Massicotte, Guy; Belin, Marie-Francoise; Honnorat, Jerome; Glasper, Erica R.; Devries, Anne C.; Jakeman, Lyn B.; Baudry, Michel; Duchemin, Anne-Marie; Kolattukudy, Pappachan E.			CRMP3 is required for hippocampal CA1 dendritic organization and plasticity	FASEB JOURNAL			English	Article						Golgi analysis; gene targeting; neurite outgrowth; LTP	RESPONSE MEDIATOR PROTEINS; LONG-TERM POTENTIATION; COLLAPSIN; ACTIN; PHOSPHORYLATION; INVOLVEMENT; EXTENSION; SYSTEM; FAMILY; CYPIN	In vitro studies have pointed to the collapsin response mediator proteins (CRMPs) as key regulators of neurite outgrowth and axonal differentiation. CRMP3 is expressed mostly in the nervous system during development but remains at high levels in the hippocampus of adults. To explore CRMP3 function in vivo, we generated mice with targeted disruption of the CRMP3 gene. Immunohistochemistry and Golgi staining of CA1 showed abnormal dendrite and spine morphogenesis in the hippocampus of CRMP3-deficient mice. Apical dendrites displayed an increase in undulation and a reduction in length and branching points. Basal dendrites also exhibited a reduction in length with an alteration in soma stem distribution and an increased number of thick dendrites localized in stratum oriens (SO). Long-term potentiation (LTP) was impaired in this area. These data indicate an important role for CRMP3 in dendrite arborization, guide-posts navigation, and neuronal plasticity.	[Quach, Tam T.; Belin, Marie-Francoise; Honnorat, Jerome] Univ Lyon 1, Fac Med Laennec, INSERM, U842, F-69372 Lyon, France; [Massicotte, Guy] Univ Quebec Trois Rivieres, Dept Chim Biol, Neurosci Res Grp, Trois Rivieres, PQ GA9 5H7, Canada; [Glasper, Erica R.; Devries, Anne C.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA; [Glasper, Erica R.; Devries, Anne C.] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; [Jakeman, Lyn B.] Ohio State Univ, Dept Cell Biol & Physiol, Columbus, OH 43210 USA; [Duchemin, Anne-Marie] Ohio State Univ, Dept Psychiat, Columbus, OH 43210 USA; [Baudry, Michel] Univ So Calif, Neurosci Program, Los Angeles, CA 90089 USA; [Kolattukudy, Pappachan E.] Univ Cent Florida, Burnett Coll Biomed Sci, Biomol Sci Ctr, Orlando, FL 32816 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Quebec; University of Quebec Trois Rivieres; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Southern California; State University System of Florida; University of Central Florida	Quach, TT (corresponding author), Univ Lyon 1, Fac Med Laennec, INSERM, U842, Rue Guillaume Paradin, F-69372 Lyon, France.	quach.1@lyon.inserm.fr	kolattukudy, pappachan e/A-1350-2012; GLASPER, ERICA/GOK-0082-2022; Honnorat, jerome/G-6394-2017; Jakeman, Lyn/A-5094-2009	GLASPER, ERICA/0000-0003-1938-2144; Honnorat, jerome/0000-0002-4721-5952; Jakeman, Lyn/0000-0002-1760-8819	NINDS NIH HHS [R01 NS043246-04, R01 NS043246] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043246] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akum BF, 2004, NAT NEUROSCI, V7, P145, DOI 10.1038/nn1179; Bretin S, 2006, J NEUROCHEM, V98, P1252, DOI 10.1111/j.1471-4159.2006.03969.x; Charrier E, 2003, MOL NEUROBIOL, V28, P51, DOI 10.1385/MN:28:1:51; Demyanenko GP, 1999, J NEUROSCI, V19, P4907; Firestein BL, 1999, NEURON, V24, P659, DOI 10.1016/S0896-6273(00)81120-4; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Honnorat J, 1999, EUR J NEUROSCI, V11, P4226, DOI 10.1046/j.1460-9568.1999.00864.x; Hotta A, 2005, MOL BIOL CELL, V16, P32, DOI 10.1091/mbc.E04-08-0679; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Knudsen A, 2007, CLIN EXP IMMUNOL, V149, P16, DOI 10.1111/j.1365-2249.2007.03379.x; Kramar EA, 2004, J NEUROSCI, V24, P5151, DOI 10.1523/JNEUROSCI.0800-04.2004; Kwon CH, 2006, NEURON, V50, P377, DOI 10.1016/j.neuron.2006.03.023; Lin B, 2005, J NEUROSCI, V25, P2062, DOI 10.1523/JNEUROSCI.4283-04.2005; OCONNOR TP, 1993, J CELL BIOL, V123, P935, DOI 10.1083/jcb.123.4.935; Ozer RS, 2000, MOL BIOL CELL, V11, P3573, DOI 10.1091/mbc.11.10.3573; Quach TT, 2000, GENE, V242, P175, DOI 10.1016/S0378-1119(99)00528-4; Quach TT, 2004, MOL CELL NEUROSCI, V25, P433, DOI 10.1016/j.mcn.2003.11.006; Quinn CC, 2003, J NEUROSCI, V23, P2815; Rosslenbroich V, 2005, EXP CELL RES, V310, P434, DOI 10.1016/j.yexcr.2005.08.005; Sasaki Y, 2002, NEURON, V35, P907, DOI 10.1016/S0896-6273(02)00857-7; Segal M, 2000, TRENDS NEUROSCI, V23, P53, DOI 10.1016/S0166-2236(99)01499-X; Su KY, 2007, J NEUROSCI, V27, P2513, DOI 10.1523/JNEUROSCI.4497-06.2007; Wang LH, 1996, J NEUROSCI, V16, P6197; Weitzdoerfer R, 2001, J NEURAL TRANSM-SUPP, P95; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012	26	55	56	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					401	409		10.1096/fj.07-9012com	http://dx.doi.org/10.1096/fj.07-9012com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17785607	Green Accepted			2022-12-28	WOS:000252822600010
J	Kramarova, TV; Shabalina, IG; Andersson, U; Westerberg, R; Carlberg, I; Houstek, J; Nedergaard, J; Cannon, B				Kramarova, Tatiana V.; Shabalina, Irina G.; Andersson, Ulf; Westerberg, Rolf; Carlberg, Inger; Houstek, Josef; Nedergaard, Jan; Cannon, Barbara			Mitochondrial ATP synthase levels in brown adipose tissue are governed by the c-Fo subunit P1 isoform	FASEB JOURNAL			English	Article						biogenesis; assembly; UCP1 promoter; transgenic mice	UNCOUPLING PROTEIN; EXPRESSION; GENE; ELECTROPHORESIS; PURIFICATION; SEQUENCES; F1-ATPASE; DOMAIN; UCP1; FAT	Despite the significance of mitochondrial ATP synthase for mammalian metabolism, the regulation of the amount of ATP synthase in mammalian systems is not understood. As brown adipose tissue mitochondria contain very low amounts of ATP synthase, relative to respiratory chain components, they constitute a physiological system that allows for examination of the control of ATP synthase assembly. To examine the role of the expression of the P1-isoform of the c-F-o subunit in the biogenesis of ATP synthase, we made transgenic mice that express the P1-c subunit isoform under the promoter of the brown adipose tissue-specific protein UCP1. In the resulting UCP1p1 transgenic mice, total P1-c subunit mRNA levels were increased; mRNA levels of other F1F(o)-ATPase subunits were unchanged. In isolated brown-fat mitochondria, protein levels of the total c-Fo subunit were increased. Remarkably, protein levels of ATP synthase subunits that are part of the F-1-ATPase complex were also increased, as was the entire Complex V. Increased ATPase and ATP synthase activities demonstrated an increased functional activity of the F1Fo-ATPase. Thus, the levels of the c-F-o subunit P1-isoform are crucial for defining the final content of the ATP synthase in brown adipose tissue. The level of c-F-o subunit may be a determining factor for F1Fo-ATPase assembly in all higher eukaryotes.-Kramarova, T. V., Shabalina, I. G., Andersson, U., Westerberg, R., Carlberg, I., Houstek, J., Nedergaard, J., Cannon, B. Mitochondrial ATP synthase levels in brown adipose tissue are governed by the c-F-o subunit P1 isoform.	[Kramarova, Tatiana V.; Shabalina, Irina G.; Andersson, Ulf; Westerberg, Rolf; Nedergaard, Jan; Cannon, Barbara] Stockholm Univ, Wenner Gren Inst, Arrhenius Lab, SE-10691 Stockholm, Sweden; [Carlberg, Inger] Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; [Houstek, Josef] Acad Sci Czech Republ, Inst Physiol, Dept Bioenerget, Prague, Czech Republic; [Houstek, Josef] Ctr Appl Genom, Prague, Czech Republic	Stockholm University; Stockholm University; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences	Cannon, B (corresponding author), Stockholm Univ, Wenner Gren Inst, Arrhenius Lab, SE-10691 Stockholm, Sweden.	barbara.cannon@wgi.su.se	Shabalina, Irina G/A-4225-2011; Andersson, Ulf/ABD-5162-2021; Shabalina, Irina/AAC-3720-2019; Nedergaard, Jan/A-1706-2010; Nedergaard, Jan/Q-8286-2019; Houstek, Josef/C-5019-2012; Cannon, Barbara/B-3089-2016	Shabalina, Irina G/0000-0002-2915-6450; Andersson, Ulf/0000-0003-0316-3860; Shabalina, Irina/0000-0002-2915-6450; Houstek, Josef/0000-0002-8413-4772; Cannon, Barbara/0000-0001-6594-2363; Nedergaard, Jan/0000-0003-2070-1587				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ackerman SH, 2005, PROG NUCLEIC ACID RE, V80, P95, DOI 10.1016/S0079-6603(05)80003-0; Andersson U, 1997, BIOCHEM J, V323, P379, DOI 10.1042/bj3230379; BOYER BB, 1991, MOL CELL BIOL, V11, P4147, DOI 10.1128/MCB.11.8.4147; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cannon B, 2000, METH MOL B, V155, P295; CANNON B, 1977, FEBS LETT, V76, P284, DOI 10.1016/0014-5793(77)80169-5; Carbajo RJ, 2005, J MOL BIOL, V351, P824, DOI 10.1016/j.jmb.2005.06.012; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; De Grassi A, 2006, GENE, V371, P224, DOI 10.1016/j.gene.2005.11.022; DYER MR, 1993, BIOCHEM J, V293, P51, DOI 10.1042/bj2930051; GAY NJ, 1985, EMBO J, V4, P3519, DOI 10.1002/j.1460-2075.1985.tb04111.x; Golozoubova V, 2006, AM J PHYSIOL-ENDOC M, V291, pE350, DOI 10.1152/ajpendo.00387.2005; HOUSTEK J, 1995, J BIOL CHEM, V270, P7689, DOI 10.1074/jbc.270.13.7689; HOUSTEK J, 1991, FEBS LETT, V294, P191, DOI 10.1016/0014-5793(91)80666-Q; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; LINDBERG O, 1967, J CELL BIOL, V34, P293, DOI 10.1083/jcb.34.1.293; PALMER DN, 1995, AM J MED GENET, V57, P260, DOI 10.1002/ajmg.1320570230; Sambrook J., 2001, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Shabalina IG, 2004, J BIOL CHEM, V279, P38236, DOI 10.1074/jbc.M402375200; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4	24	57	57	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					55	63		10.1096/fj.07-8581com	http://dx.doi.org/10.1096/fj.07-8581com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17666453				2022-12-28	WOS:000252309900009
J	Zhou, Y; Suram, A; Venugopal, C; Prakasam, A; Lin, SZ; Su, Y; Li, BL; Paul, SM; Sambamurti, K				Zhou, Yan; Suram, Anitha; Venugopal, Chitra; Prakasam, Annamalai; Lin, Suizhen; Su, Yuan; Li, Baolin; Paul, Steven M.; Sambamurti, Kumar			Geranylgeranyl pyrophosphate stimulates gamma-secretase to increase the generation of A beta and APP-CTF gamma	FASEB JOURNAL			English	Article						Alzheimer's disease; statins; mevalonic acid; amyloid precursor protein; AICD; isoprenoid	AMYLOID PRECURSOR PROTEIN; TRANSGENIC MOUSE MODEL; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; TYPE-4 ALLELE; CHOLESTEROL; PATHOLOGY; ASSOCIATION; SIMVASTATIN; STATINS	Cleavage of the amyloid precursor protein (APP) by beta- and gamma-secretases results in generation of the amyloid-beta protein (A beta), which is characteristically deposited in the brain of Alzheimer's disease patients. Inhibitors of 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase (the statins) reduce levels of cholesterol and isoprenoids such as geranylgeranyl pyrophosphate (GGPP). Previous studies have demonstrated that cholesterol increases and statins reduce A beta levels mostly by regulating gamma-secretase activity. In this study, we focused on the role of geranylgeranyl isoprenoids GGPP and geranylgeraniol (GGOH) in regulating A beta production. Our data show that the inhibition of GGPP synthesis by statins plays an important role in statin-mediated reduction of A beta secretion. Consistent with this finding, the geranylgeranyl isoprenoids preferentially increase the yield of A beta of 42 residues (A beta 42) in a dose-dependent manner. Our studies further demonstrated that geranylgeranyl isoprenoids increase the yield of APP-CTF gamma (a. k. a. AICD) as well as A beta by stimulating gamma-secretase-mediated cleavage of APP-CTF beta and APP-CTF beta in vitro. Furthermore, GGOH increases the levels of the active gamma-secretase complex in the detergent-insoluble membrane fraction along with its substrates, APP-CTF alpha and APP-CTF beta. Our results indicate that geranylgeranyl isoprenoids may be an important physiological facilitator of gamma-secretase activity that can foster production of the pathologically important A beta 42. -Zhou, Y., Suram, A., Venugopal, C., Prakasam, A., Lin, S., Su, Y., Li, B., Paul, S. M., Sambamurti, K. Geranylgeranyl pyrophosphate stimulates gamma-secretase to increase the generation of A beta and APP-CTF gamma.	[Zhou, Yan; Sambamurti, Kumar] Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Lin, Suizhen; Su, Yuan; Li, Baolin; Paul, Steven M.] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Zhou, Yan; Suram, Anitha; Venugopal, Chitra; Prakasam, Annamalai; Sambamurti, Kumar] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Eli Lilly; Medical University of South Carolina	Zhou, Y (corresponding author), Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, R4-331,1044 W Walnut, Indianapolis, IN 46202 USA.	Zhou2@iupui.edu; paul_steven_m@lilly.com; sambak@musc.edu	Paul, Steve/ABE-5400-2020; Sambamurti, Kumar/A-1620-2012	Sambamurti, Kumar/0000-0001-9507-9214	NIA NIH HHS [AG028544, R01 AG023055-02, AG023055, R01 AG023055-04, R01 AG023055, R03 AG028544, R01 AG023055-03, R01 AG023055-01A1] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG023055, R03AG028544] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BURKE JR, 1991, INT J NEUROL, V26, P41; Buxbaum JD, 2002, FRONT BIOSCI, V7, pA50, DOI 10.2741/buxbaum; Cole SL, 2005, J BIOL CHEM, V280, P18755, DOI 10.1074/jbc.M413895200; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Fagan AM, 2004, AM J PATHOL, V165, P1413, DOI 10.1016/S0002-9440(10)63399-8; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; George AJ, 2004, NEUROBIOL DIS, V16, P124, DOI 10.1016/j.nbd.2004.01.009; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; Hutter-Paier B, 2004, NEURON, V44, P227, DOI 10.1016/j.neuron.2004.08.043; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Kotti TJ, 2006, P NATL ACAD SCI USA, V103, P3869, DOI 10.1073/pnas.0600316103; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; Kuo YM, 1998, BIOCHEM BIOPH RES CO, V252, P711, DOI 10.1006/bbrc.1998.9652; Ohnuma S, 1996, J BIOCHEM-TOKYO, V119, P541; Ownby SE, 2003, LIPIDS, V38, P751, DOI 10.1007/s11745-003-1123-8; Parsons RB, 2006, BIOCHEM J, V399, P205, DOI 10.1042/BJ20060655; Parvathy S, 2004, J NEUROCHEM, V90, P1005, DOI 10.1111/j.1471-4159.2004.02521.x; Petanceska SS, 2002, J MOL NEUROSCI, V19, P155, DOI 10.1007/s12031-002-0026-2; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Refolo LM, 2001, NEUROBIOL DIS, V8, P890, DOI 10.1006/nbdi.2001.0422; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Sambamurti K, 2004, CURR DRUG TARGETS, V5, P517, DOI 10.2174/1389450043345335; Sambamurti K, 2002, NEUROMOL MED, V1, P1, DOI 10.1385/NMM:1:1:1; Sambamurti Kumar, 2006, Current Alzheimer Research, V3, P81, DOI 10.2174/156720506775697142; Simons M, 2002, ANN NEUROL, V52, P346, DOI 10.1002/ana.10292; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Sjogren M, 2003, DEMENT GERIATR COGN, V16, P25, DOI 10.1159/000069989; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; SPARKS DL, 1994, EXP NEUROL, V126, P88, DOI 10.1006/exnr.1994.1044; Sparks DL, 2000, ANN NY ACAD SCI, V903, P335, DOI 10.1111/j.1749-6632.2000.tb06384.x; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Urano Y, 2005, J LIPID RES, V46, P904, DOI 10.1194/jlr.M400333-JLR200; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Wada S, 2003, BIOCHEMISTRY-US, V42, P13977, DOI 10.1021/bi034904j; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Wolozin B, 2002, BIOCHEM SOC T, V30, P525, DOI 10.1042/bst0300525; Zamrini E, 2004, NEUROEPIDEMIOLOGY, V23, P94, DOI 10.1159/000073981; Zhou Y, 2003, SCIENCE, V302, P1215, DOI 10.1126/science.1090154	44	45	46	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					47	54		10.1096/fj.07-8175com	http://dx.doi.org/10.1096/fj.07-8175com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17666454	Green Accepted			2022-12-28	WOS:000252309900008
J	Basavapathruni, A; Anderson, KS				Basavapathruni, Aravind; Anderson, Karen S.			Reverse transcription of the HIV-1 pandemic	FASEB JOURNAL			English	Review						resistance; nucleoside; non-nucleoside; AIDS; NRTI; removal	IMMUNODEFICIENCY-VIRUS TYPE-1; DEPENDENT DNA-POLYMERASE; ACYCLIC NUCLEOSIDE PHOSPHONATES; T-LYMPHOTROPIC RETROVIRUS; HIGH-LEVEL RESISTANCE; ANTI-AIDS DRUGS; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT; NONNUCLEOSIDE INHIBITORS; MITOCHONDRIAL TOXICITY; ANTIVIRAL ACTIVITY	The HIV/AIDS pandemic has existed for > 25 years. Extensive work globally has provided avenues to combat viral infection, but the disease continues to rage on in the human population and infected similar to 4 million people in 2006 alone. In this review, we provide a brief history of HIV/AIDS, followed by analysis of one therapeutic target of HIV-1: its reverse transcriptase ( RT). We discuss the biochemical characterization of RT in order to place emphasis on possible avenues of inhibition, which now includes both nucleoside and non-nucleoside modalities. Therapies against RT remain a cornerstone of anti-HIV treatment, but the virus eventually resists inhibition through the selection of drug- resistant RT mutations. Current inhibitors and associated resistance are discussed, with the hopes that new therapeutics can be developed against RT.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Boston Univ, Beth Israel Med Ctr, Boston, MA 02215 USA	Yale University; Boston University; Harvard University; Beth Israel Deaconess Medical Center	Anderson, KS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, SHM B350B, 333 Cedar St, New Haven, CT 06520 USA.	karen.anderson@yale.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049551] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM049551, GM49551] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; ALTHAUS IW, 1993, J BIOL CHEM, V268, P6119; Anderson KS, 2002, BBA-MOL BASIS DIS, V1587, P296, DOI 10.1016/S0925-4439(02)00092-3; Anderson MT, 2001, CALC VAR PARTIAL DIF, V12, P1, DOI 10.1007/s005260000043; [Anonymous], 1981, MORBIDITY MORTALITY, V30, P250; Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; AUGUST EM, 1988, BIOCHEM PHARMACOL, V37, P4419, DOI 10.1016/0006-2952(88)90655-7; BABA M, 1987, BIOCHEM BIOPH RES CO, V142, P128, DOI 10.1016/0006-291X(87)90460-8; BABA M, 1989, BIOCHEM BIOPH RES CO, V165, P1375, DOI 10.1016/0006-291X(89)92756-3; Bacheler L, 2001, J VIROL, V75, P4999, DOI 10.1128/JVI.75.11.4999-5008.2001; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BALZARINI J, 1991, J BIOL CHEM, V266, P8686; Balzarini J, 2000, AIDS RES HUM RETROV, V16, P517, DOI 10.1089/088922200308936; Balzarini J, 1996, MOL PHARMACOL, V50, P394; BALZARINI J, 1987, MOL PHARMACOL, V32, P162; Balzarini J, 2004, CURR TOP MED CHEM, V4, P921, DOI 10.2174/1568026043388420; Barnard J, 1997, BIOCHEMISTRY-US, V36, P7786, DOI 10.1021/bi970140u; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Borkow G, 1999, ANTIMICROB AGENTS CH, V43, P259, DOI 10.1128/AAC.43.2.259; Bridges EG, 1999, J BIOL CHEM, V274, P4620, DOI 10.1074/jbc.274.8.4620; Brinkman K, 2000, CURR OPIN INFECT DIS, V13, P5, DOI 10.1097/00001432-200002000-00002; Brinkman K, 1998, AIDS, V12, P1735, DOI 10.1097/00002030-199814000-00004; Buchow H D, 1989, Haematol Blood Transfus, V32, P402; Camarasa MJ, 2004, CURR TOP MED CHEM, V4, P945, DOI 10.2174/1568026043388600; CAMMACK N, 1992, BIOCHEM PHARMACOL, V43, P2059, DOI 10.1016/0006-2952(92)90162-C; CARROLL SS, 1993, J BIOL CHEM, V268, P276; Centers for Disease Control (CDC), 1981, MMWR-MORBID MORTAL W, V30, P305; CHANG CN, 1992, J BIOL CHEM, V267, P13938; Coakley EP, 2000, AIDS, V14, pF9, DOI 10.1097/00002030-200001280-00002; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P202, DOI 10.1128/AAC.36.1.202; CURRAN JW, 1982, NEW ENGL J MED, V306, P248; Daluge SM, 1997, ANTIMICROB AGENTS CH, V41, P1082, DOI 10.1128/AAC.41.5.1082; Das K, 2005, PROG BIOPHYS MOL BIO, V88, P209, DOI 10.1016/j.pbiomolbio.2004.07.001; Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s; De Clercq E, 2005, NAT REV DRUG DISCOV, V4, P928, DOI 10.1038/nrd1877; De Clercq E, 2004, CHEM BIODIVERS, V1, P44, DOI 10.1002/cbdv.200490012; De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4; de Ronde A, 2000, AIDS, V14, P2632, DOI 10.1097/00002030-200011100-00038; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; Delaugerre C, 2001, J MED VIROL, V65, P445, DOI 10.1002/jmv.2055; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; DUEWEKE TJ, 1993, ANTIMICROB AGENTS CH, V37, P1127, DOI 10.1128/AAC.37.5.1127; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; Faletto MB, 1997, ANTIMICROB AGENTS CH, V41, P1099, DOI 10.1128/AAC.41.5.1099; FARMERIE WG, 1987, SCIENCE, V236, P305, DOI 10.1126/science.2436298; Feng JY, 2001, J BIOL CHEM, V276, P23832, DOI 10.1074/jbc.M101156200; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; FLETCHER RS, 1995, BIOCHEMISTRY-US, V34, P4346, DOI 10.1021/bi00013a025; FRANK KB, 1991, J BIOL CHEM, V266, P14232; Fu L, 1998, BIOCHEM PHARMACOL, V55, P1567, DOI 10.1016/S0006-2952(98)00050-1; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GALLO RC, 1983, SCIENCE, V220, P865, DOI 10.1126/science.6601823; GERARD GF, 1975, J VIROL, V15, P785, DOI 10.1128/JVI.15.4.785-797.1975; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; GOODY RS, 1991, FEBS LETT, V291, P1, DOI 10.1016/0014-5793(91)81089-Q; HAHN BH, 1984, NATURE, V312, P166, DOI 10.1038/312166a0; HANRAHAN JP, 1982, NEW ENGL J MED, V307, P498; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; HAO Z, 1988, MOL PHARMACOL, V34, P431; HEIDENREICH O, 1990, EUR J BIOCHEM, V192, P621, DOI 10.1111/j.1432-1033.1990.tb19268.x; HO HT, 1989, ANTIMICROB AGENTS CH, V33, P844, DOI 10.1128/AAC.33.6.844; Honkoop P, 1997, DRUG SAFETY, V17, P1, DOI 10.2165/00002018-199717010-00001; Honkoop P, 1997, LIVER, V17, P103; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang HF, 2000, CHEM BIOL, V7, P355, DOI 10.1016/S1074-5521(00)00113-7; Izopet J, 1999, J MED VIROL, V59, P507, DOI 10.1002/(SICI)1096-9071(199912)59:4&lt;507::AID-JMV14&gt;3.0.CO;2-C; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Jochmans D, 2006, J VIROL, V80, P12283, DOI 10.1128/JVI.00889-06; Johnson AA, 2001, J BIOL CHEM, V276, P38097; Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200; Johnson K. A, 1992, ENZYMES, VXX; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; Johnson Victoria A, 2005, Top HIV Med, V13, P125; KATI WM, 1992, J BIOL CHEM, V267, P25988; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862; KIM CH, 1987, J MED CHEM, V30, P862, DOI 10.1021/jm00388a020; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Kosalaraksa P, 1999, J VIROL, V73, P5356, DOI 10.1128/JVI.73.7.5356-5363.1999; LACEY SF, 1994, ANTIMICROB AGENTS CH, V38, P1428, DOI 10.1128/AAC.38.6.1428; LAFEMINA RL, 1992, J VIROL, V66, P7414, DOI 10.1128/JVI.66.12.7414-7419.1992; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Lennerstrand J, 2001, ANTIMICROB AGENTS CH, V45, P2144, DOI 10.1128/AAC.45.7.2144-2146.2001; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LIN PF, 1994, J INFECT DIS, V170, P1157, DOI 10.1093/infdis/170.5.1157; LIN TS, 1987, BIOCHEM PHARMACOL, V36, P2713; Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; Maeda Y, 1998, J INFECT DIS, V177, P1207, DOI 10.1086/515282; Maga G, 1997, J MOL BIOL, V274, P738, DOI 10.1006/jmbi.1997.1427; Maga G, 2000, ANTIMICROB AGENTS CH, V44, P1186, DOI 10.1128/AAC.44.5.1186-1194.2000; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MARTIN JL, 1994, ANTIMICROB AGENTS CH, V38, P2743, DOI 10.1128/AAC.38.12.2743; Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; MELLORS JW, 1992, MOL PHARMACOL, V41, P446; Meyer PR, 2002, ANTIMICROB AGENTS CH, V46, P1540, DOI 10.1128/AAC.46.5.1540-1545.2002; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 2000, ANTIMICROB AGENTS CH, V44, P3465, DOI 10.1128/AAC.44.12.3465-3472.2000; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; Miller MD, 2001, NUCLEOS NUCLEOT NUCL, V20, P1025, DOI 10.1081/NCN-100002483; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MIYASAKA T, 1989, J MED CHEM, V32, P2507, DOI 10.1021/jm00132a002; MOLLING K, 1971, NATURE-NEW BIOL, V234, P240, DOI 10.1038/newbio234240a0; MOUS J, 1988, J VIROL, V62, P1433, DOI 10.1128/JVI.62.4.1433-1436.1988; MULLER B, 1989, J BIOL CHEM, V264, P13975; Murakami E, 2004, ANTIVIR RES, V62, P57, DOI 10.1016/j.antiviral.2003.12.001; PARKER WB, 1994, J NIH RES, V6, P57; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; Pellegrin I, 1999, AIDS, V13, P1705, DOI 10.1097/00002030-199909100-00014; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Raju TNK, 1999, LANCET, V354, P1308, DOI 10.1016/S0140-6736(05)76086-4; Ray Adrian S., 2003, Antiviral Chemistry & Chemotherapy, V14, P115; Ren J, 2001, J MOL BIOL, V312, P795, DOI 10.1006/jmbi.2001.4988; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; RESTLE T, 1990, J BIOL CHEM, V265, P8986; REY MA, 1984, BIOCHEM BIOPH RES CO, V121, P126, DOI 10.1016/0006-291X(84)90696-X; RHO HM, 1981, VIROLOGY, V112, P355, DOI 10.1016/0042-6822(81)90642-5; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; RICHMAN DD, 2003, HUMAN IMMUNODEFICIEN; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; Robbins BL, 1998, ANTIMICROB AGENTS CH, V42, P612, DOI 10.1128/AAC.42.3.612; ROBBINS BL, 1995, ANTIMICROB AGENTS CH, V39, P2304, DOI 10.1128/AAC.39.10.2304; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; ROBEY WG, 1985, SCIENCE, V228, P593, DOI 10.1126/science.2984774; Sallie R, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-10; Sarafianos SG, 2002, EMBO J, V21, P6614, DOI 10.1093/emboj/cdf637; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P2423, DOI 10.1128/AAC.36.11.2423; SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P672, DOI 10.1128/AAC.36.3.672; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; Schneider B, 2000, MOL PHARMACOL, V57, P948; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; Sierra S, 2005, J CLIN VIROL, V34, P233, DOI 10.1016/j.jcv.2005.09.004; SKALSKI V, 1993, J BIOL CHEM, V268, P23234; Spence RA, 1996, BIOCHEMISTRY-US, V35, P1054, DOI 10.1021/bi952058+; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853; Stone A, 2002, NAT REV DRUG DISCOV, V1, P977, DOI 10.1038/nrd959; TAYLOR PB, 1994, J BIOL CHEM, V269, P6325; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; TRAMONTANO E, 1992, BIOCHEM PHARMACOL, V43, P1371; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Vaccaro JA, 1998, BIOCHEMISTRY-US, V37, P14189, DOI 10.1021/bi9810353; Vaccaro JA, 2000, ANTIMICROB AGENTS CH, V44, P217, DOI 10.1128/AAC.44.1.217-221.2000; VERMA IM, 1975, J VIROL, V15, P843, DOI 10.1128/JVI.15.4.843-854.1975; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; Wang DP, 2001, BIOORG MED CHEM LETT, V11, P2799, DOI 10.1016/S0960-894X(01)00510-8; YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602	163	39	41	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3795	3808		10.1096/fj.07-8697rev	http://dx.doi.org/10.1096/fj.07-8697rev			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17639073				2022-12-28	WOS:000251283500004
J	Garate, M; Campos, EI; Bush, JA; Xiao, H; Li, G				Garate, Marco; Campos, Eric I.; Bush, Jason A.; Xiao, Hao; Li, Gang			Phosphorylation of the tumor suppressor p33(ING1b) at Ser-126 influences its protein stability and proliferation of melanoma cells	FASEB JOURNAL			English	Article						protein half-life; cell proliferation	NUCLEOTIDE EXCISION-REPAIR; UV-DAMAGED DNA; INDUCED APOPTOSIS; HUMAN CHK1; P53; CHECKPOINT; IDENTIFICATION; INHIBITION; SUBSTRATE; PATHWAY	ING (inhibitor of growth) tumor suppressors regulate cell-cycle checkpoints, apoptosis, and ultimately tumor suppression. Among the ING family members, p33(ING1b) is the most intensively studied and plays an important role in the cellular stress response to DNA damage. Here we demonstrate that there is basal phosphorylation of p33(ING1b) at Ser-126 in normal physiological conditions and that this phosphorylation is increased on DNA damage. The mutation of Ser-126 to alanine dramatically shortened the half-life of p33(ING1b). Furthermore, we found that both Chk1 and Cdk1 can phosphorylate this residue. Interestingly, while Cdk1 can phosphorylate p33(ING1b) at Ser-126 in nonstress conditions, Chk1 predominantly phosphorylates this residue on DNA damage, which suggests that p33(ING1b) is a downstream target of the ATM/ATR response cascade to genotoxic stress. More importantly, our data indicate that the Ser-126 residue plays a key role in regulating the expression of cyclin B1 and proliferation of melanoma cells.	Univ British Columbia, Vancouver Coastal Hlth Res Inst, Dept Dermatol & Skin Sci, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Calif State Univ Fresno, Dept Biol, Fresno, CA 93740 USA; ImmuneChem Pharmaceut Inc, Burnaby, BC, Canada	University of British Columbia; Vancouver Coastal Health Research Institute; California State University System; California State University Fresno	Li, G (corresponding author), Univ British Columbia, Vancouver Coastal Hlth Res Inst, Dept Dermatol & Skin Sci, Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	gangli@interchange.ubc.ca	Li, Gang/A-8257-2011	Campos, Eric I./0000-0001-8152-3994				Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bean LJH, 2002, J BIOL CHEM, V277, P1864, DOI 10.1074/jbc.M108881200; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Brumbaugh KM, 2004, MOL CELL, V14, P585, DOI 10.1016/j.molcel.2004.05.005; BYERS HR, 1991, AM J PATHOL, V139, P423; Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; Campos EI, 2004, INT J ONCOL, V25, P73; Campos EI, 2004, J IMMUNOASS IMMUNOCH, V25, P71, DOI 10.1081/IAS-120027227; Cheung KJ, 2002, EXP CELL RES, V279, P291, DOI 10.1006/excr.2002.5610; Cheung KJ, 2001, CANCER RES, V61, P4974; Cheung KJJ, 2000, BRIT J CANCER, V83, P1468, DOI 10.1054/bjoc.2000.1464; Chin MY, 2005, EXP CELL RES, V304, P531, DOI 10.1016/j.yexcr.2004.11.023; Clifford B, 2003, CANCER RES, V63, P4074; Cuervo AM, 1998, MOL BIOL CELL, V9, P1995, DOI 10.1091/mbc.9.8.1995; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Gong W, 2006, MOL CELL BIOL, V26, P2947, DOI 10.1128/MCB.26.8.2947-2954.2006; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Helt CE, 2005, J BIOL CHEM, V280, P1186, DOI 10.1074/jbc.M410873200; Ho CC, 2005, EXP CELL RES, V304, P1, DOI 10.1016/j.yexcr.2004.10.016; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoffert JD, 2006, P NATL ACAD SCI USA, V103, P7159, DOI 10.1073/pnas.0600895103; JACK DB, 1995, MOL MED TODAY, V1, P2; KLEIN P, 1985, J BIOL CHEM, V260, P1757; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Leung KM, 2002, CANCER RES, V62, P4890; Li G, 1998, MELANOMA RES, V8, P17, DOI 10.1097/00008390-199802000-00004; Mone MJ, 2004, P NATL ACAD SCI USA, V101, P15933, DOI 10.1073/pnas.0403664101; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; Saito A, 2000, J HUM GENET, V45, P177, DOI 10.1007/s100380050206; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Scott M, 2001, J CELL SCI, V114, P3455; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Takahashi M, 2002, CANCER RES, V62, P2203; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; Tsang FC, 2003, FEBS LETT, V553, P277, DOI 10.1016/S0014-5793(03)01024-X; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; VEGESNA RVK, 1988, MOL PHARMACOL, V33, P537; Wang J, 2006, CANCER RES, V66, P1906, DOI 10.1158/0008-5472.CAN-05-3444; Wang YM, 2006, J BIOL CHEM, V281, P11887, DOI 10.1074/jbc.M511309200; Xu CF, 2005, MOL CELL PROTEOMICS, V4, P809, DOI 10.1074/mcp.T400019-MCP200; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757; ZHANG W, 1994, CANCER RES, V54, P4448; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	50	42	43	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3705	3716		10.1096/fj.07-8069com	http://dx.doi.org/10.1096/fj.07-8069com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17585055				2022-12-28	WOS:000250517800032
J	Davies, KJA; Ermak, G; Rothermel, BA; Pritchard, M; Heitman, J; Ahnn, J; Henrique-Silva, F; Crawford, D; Canaider, S; Strippoli, P; Carinci, P; Min, KT; Fox, DS; Cunningham, KW; Bassel-Duby, R; Olson, EN; Zhang, Z; Williams, RS; Gerber, HP; Perez-Riba, M; Seo, H; Cao, X; Klee, CB; Redondo, JM; Maltais, LJ; Bruford, EA; Povey, S; Molkentin, JD; McKeon, FD; Duh, EJ; Crabtree, GR; Cyert, MS; de la Luna, S; Estivill, X				Davies, Kelvin J. A.; Ermak, Gennady; Rothermel, Beverley A.; Pritchard, Melanie; Heitman, Joseph; Ahnn, Joohong; Henrique-Silva, Flavio; Crawford, Dana; Canaider, Silvia; Strippoli, Pierluigi; Carinci, Paolo; Min, Kyung-Tai; Fox, Deborah S.; Cunningham, Kyle W.; Bassel-Duby, Rhonda; Olson, Eric N.; Zhang, Zhuohua; Williams, R. Sanders; Gerber, Hans-Peter; Perez-Riba, Merce; Seo, Hisao; Cao, Xia; Klee, Claude B.; Redondo, Juan Miguel; Maltais, Lois J.; Bruford, Elspeth A.; Povey, Sue; Molkentin, Jeffery D.; McKeon, Frank D.; Duh, Elia J.; Crabtree, Gerald R.; Cyert, Martha S.; de la Luna, Susana; Estivill, Xavier			Renaming the DSCR1/Adapt78 gene family as RCAN: regulators of calcineurin	FASEB JOURNAL			English	Article						calcipressin; oxidative stress; Down syndrome; Alzheimer disease; MCIP; NFAT	SYNDROME CRITICAL REGION; DOWN-SYNDROME; DSCR1 ADAPT78; INHIBITS CALCINEURIN; ALZHEIMERS-DISEASE; IN-VIVO; PHOSPHATASE CALCINEURIN; CRYPTOCOCCUS-NEOFORMANS; INTERACTING PROTEIN-1; ENDOGENOUS INHIBITOR		Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Div Mol & Computat Biol, Los Angeles, CA 90089 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75230 USA; Monash Univ, Monash Inst Med Res, Ctr Funct Genom & Human Dis, Clayton, Vic 3168, Australia; Duke Univ, Med Ctr, Dept Mol Genet, Durham, NC USA; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA; Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju, South Korea; Univ Fed Sao Carlos, Dept Genet & Evolut, Sao Carlos, SP, Brazil; Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA; Univ Bologna, Dept Histol Embryol & Appl Biol, Bologna, Italy; NINDS, Neurogenet Branch, NIH, Bethesda, MD 20892 USA; Childrens Hosp, Res Inst Children, New Orleans, LA USA; Childrens Hosp, Louisiana State Hlth Sci Ctr, Dept Pediat, New Orleans, LA USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75230 USA; Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA; Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Inst Recerca Oncol, IDIBELL, Med & Mol Genet Ctr, Barcelona, Spain; Nagoya Univ, Environm Med Res Inst, Div Mol & Cellular Adaptat, Dept Endocrinol & Metab,Chikusa Ku, Nagoya, Aichi 464, Japan; NCI, Biochem Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; CNIC, Madrid, Spain; Jackson Lab, MGI, Mouse Genom Nomenclature Comm, Bar Harbor, ME 04609 USA; UCL, Dept Biol, Galton Lab, HUGO Gene Nomenclature Comm, London, England; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; ICREA, Barcelona, Spain; CRG, Genes & Dis Program, Gene Funct Grp, Barcelona, Spain; CRG, CeGen Barcelona Genotyping Node, Barcelona, Catalonia, Spain; Pompeu Fabra Univ, Dept Life Sci, Barcelona, Catalonia, Spain	University of Southern California; University of Southern California; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Monash University; Duke University; Duke University; Gwangju Institute of Science & Technology (GIST); Universidade Federal de Sao Carlos; Albany Medical College; University of Bologna; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Children's Hospital of New Orleans; Children's Hospital of New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Johns Hopkins University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Sanford Burnham Prebys Medical Discovery Institute; Duke University; Roche Holding; Genentech; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Nagoya University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centro Nacional de Investigaciones Cardiovasculares (CNIC); Jackson Laboratory; University of London; University College London; Cincinnati Children's Hospital Medical Center; Harvard University; Harvard Medical School; Johns Hopkins University; Stanford University; Stanford University; Stanford University; ICREA; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University	Davies, KJA (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA.	kelvin@usc.edu	Redondo, Juan Miguel/H-6351-2015; de la Luna, Susana/E-9553-2015; Henrique-Silva, Flavio/A-1937-2013; Bruford, Elspeth/AAU-4961-2020; Estivill, Xavier/E-2957-2012; Estivill, Xavier/A-3125-2013; Heitman, Joseph/ABC-6006-2021	Redondo, Juan Miguel/0000-0001-5779-9122; de la Luna, Susana/0000-0001-7765-916X; Bruford, Elspeth/0000-0002-8380-5247; Estivill, Xavier/0000-0002-0723-2256; Cyert, Martha/0000-0003-3825-7437; Perez-Riba, Merce/0000-0003-1604-4617; STRIPPOLI, PIERLUIGI/0000-0001-8769-8832; min, kyung-tai/0000-0003-0983-4258; Davies, Kelvin/0000-0001-7790-3003; Molkentin, Jeffery/0000-0002-3558-6529	ICREA Funding Source: Custom	ICREA(ICREA)		Abbasi S, 2006, J BIOL CHEM, V281, P7717, DOI 10.1074/jbc.M510775200; Arron JR, 2006, NATURE, V441, P595, DOI 10.1038/nature04678; Aubareda A, 2006, CELL SIGNAL, V18, P1430, DOI 10.1016/j.cellsig.2005.11.006; Canaider S, 2006, GENE, V372, P128, DOI 10.1016/j.gene.2005.12.029; Cano E, 2005, J BIOL CHEM, V280, P29435, DOI 10.1074/jbc.M506205200; Cao X, 2005, MOL ENDOCRINOL, V19, P102, DOI 10.1210/me.2004-0093; Cao X, 2002, BIOCHEM J, V367, P459, DOI 10.1042/BJ20011797; Casas C, 2001, MECH DEVELOP, V101, P289, DOI 10.1016/S0925-4773(00)00583-9; Chan B, 2005, P NATL ACAD SCI USA, V102, P13075, DOI 10.1073/pnas.0503846102; Chang KT, 2003, P NATL ACAD SCI USA, V100, P15794, DOI 10.1073/pnas.2536696100; Cook CN, 2005, J ALZHEIMERS DIS, V8, P63; Crawford DR, 1997, ARCH BIOCHEM BIOPHYS, V342, P6, DOI 10.1006/abbi.1997.0109; Ejima A, 2004, GENETICS, V168, P2077, DOI 10.1534/genetics.104.029934; Ermak G, 2002, FASEB J, V16, DOI 10.1096/fj.01-0846com; Ermak G, 2004, FASEB J, V18, P62, DOI 10.1096/fj.03-0451com; Ermak G, 2006, FEBS J, V273, P2100, DOI 10.1111/j.1742-4658.2006.05217.x; Ermak G, 2003, IUBMB LIFE, V55, P29, DOI 10.1080/1521654031000066820; Ermak G, 2001, J BIOL CHEM, V276, P38787, DOI 10.1074/jbc.M102829200; Fox DS, 2005, EUKARYOT CELL, V4, P1526, DOI 10.1128/EC.4.9.1526-1538.2005; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; Fuentes JJ, 1997, GENOMICS, V44, P358, DOI 10.1006/geno.1997.4866; Garbers C, 1996, EMBO J, V15, P2115, DOI 10.1002/j.1460-2075.1996.tb00565.x; Genesca L, 2003, BIOCHEM J, V374, P567, DOI 10.1042/BJ20030267; Gorlach J, 2000, EMBO J, V19, P3618, DOI 10.1093/emboj/19.14.3618; Harris CD, 2005, CELL MOL LIFE SCI, V62, P2477, DOI 10.1007/s00018-005-5085-4; HARRIS CD, 2007, IN PRESS FEBS J; Hesser BA, 2004, BLOOD, V104, P149, DOI 10.1182/blood-2004-01-0273; Hilioti Z, 2004, GENE DEV, V18, P35, DOI 10.1101/gad.1159204; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Kingsbury TJ, 2000, GENE DEV, V14, P1595; KORENBERG JR, 1994, P NATL ACAD SCI USA, V91, P4997, DOI 10.1073/pnas.91.11.4997; Leahy KP, 2000, ARCH BIOCHEM BIOPHYS, V379, P221, DOI 10.1006/abbi.2000.1897; Lee JI, 2003, J MOL BIOL, V328, P147, DOI 10.1016/S0022-2836(03)00237-7; Lin HY, 2003, FREE RADICAL BIO MED, V35, P528, DOI 10.1016/S0891-5849(03)00358-7; Mammucari C, 2005, DEV CELL, V8, P665, DOI 10.1016/j.devcel.2005.02.016; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; Miyazaki T, 1996, J BIOL CHEM, V271, P14567, DOI 10.1074/jbc.271.24.14567; MULERO C, 2007, IN PRESS CELL RES; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Rothermel BA, 2003, TRENDS CARDIOVAS MED, V13, P15, DOI 10.1016/S1050-1738(02)00188-3; Ryeom S, 2003, NAT IMMUNOL, V4, P874, DOI 10.1038/ni966; Sanna B, 2006, P NATL ACAD SCI USA, V103, P7327, DOI 10.1073/pnas.0509340103; SINET PM, 1994, BIOMED PHARMACOTHER, V48, P247, DOI 10.1016/0753-3322(94)90140-6; Strippoli P, 2000, GENE, V257, P223, DOI 10.1016/S0378-1119(00)00407-8; Strippoli P, 2000, GENOMICS, V64, P252, DOI 10.1006/geno.2000.6127; U M, 2004, LEUKEMIA, V18, P1850, DOI 10.1038/sj.leu.2403516; Vega RB, 2003, P NATL ACAD SCI USA, V100, P669, DOI 10.1073/pnas.0237225100; Vega RB, 2002, J BIOL CHEM, V277, P30401, DOI 10.1074/jbc.M200123200; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61	51	134	138	1	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3023	3028		10.1096/fj.06-7246com	http://dx.doi.org/10.1096/fj.06-7246com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17595344				2022-12-28	WOS:000249781600004
J	Aoki, H; Iwado, E; Eller, MS; Kondo, Y; Fujiwara, K; Li, GZ; Hess, KR; Siwak, DR; Sawaya, R; Mills, GB; Gilchrest, BA; Kondo, S				Aoki, Hiroshi; Iwado, Eiji; Eller, Mark S.; Kondo, Yasuko; Fujiwara, Keishi; Li, Guang-Zhi; Hess, Kenneth R.; Siwak, Doris R.; Sawaya, Raymond; Mills, Gordon B.; Gilchrest, Barbara A.; Kondo, Seiji			Telomere 3 ' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells	FASEB JOURNAL			English	Article						T-oligos; mTOR	PATHWAY; DEATH; APOPTOSIS; RADIATION; SURVIVAL; THERAPY; HOMOLOG; END; P53	Telomere 3' overhang-specific DNA oligonucleotides (T-oligos) induce cell death in cancer cells, presumably by mimicking telomere loop disruption. Therefore, T-oligos are considered an exciting new therapeutic strategy. The purpose of this study was to elucidate how T-oligos exert antitumor effects on human malignant glioma cells in vitro and in vivo. We demonstrated that T-oligos inhibited the proliferation of malignant glioma cells through induction of nonapoptotic cell death and mitochondria hyperpolarization, whereas normal astrocytes were resistant to T-oligos. Tumor cells treated with T-oligos developed features compatible with autophagy, with development of autophagic vacuoles and conversion of an autophagy-related protein, microtubule-associated protein 1 light chain 3 from type I ( cytoplasmic form) to type II ( membrane form of autophagic vacuoles). A reverse-phase protein microarray analysis and Western blotting revealed that treatment with T-oligos inhibited the mammalian target of the rapamycin ( mTOR) and the signal transducer and activator of transcription 3 (STAT3). Moreover, pretreatment with T-oligos significantly prolonged the survival time of mice inoculated intracranially with malignant glioma cells compared with that of untreated mice and those treated with control oligonucleotides ( P = 0.0065 and P = 0.043, respectively). These results indicate that T-oligos stimulate the induction of nonapoptotic autophagic also known as type II programmed cell death and are thus promising in the treatment of malignant glioma.-Aoki, H., Iwado, E., Eller, M. S., Kondo, Y., Fujiwara, K., Li, G.-Z., Hess, K. R., Siwak, D. R., Sawaya, R., Mills, G. B., Gilchrest, B. A., Kondo, S. Telomere 3' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; Boston University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System	Kondo, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, 1515 Holcombe Blvd, Houston, TX 77030 USA.	seikondo@mdanderson.org	Hess, Kenneth/K-6546-2019	Hess, Kenneth/0000-0003-1377-6070	NCI NIH HHS [CA-088936, CA-108558, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA088936, R01CA108558] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Daido S, 2005, CANCER RES, V65, P4368, DOI 10.1158/0008-5472.CAN-04-4202; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; Eller MS, 2006, P NATL ACAD SCI USA, V103, P15073, DOI 10.1073/pnas.0607332103; Eller MS, 2003, FASEB J, V17, P152, DOI 10.1096/fj.02-0197com; Eller MS, 2002, EXP CELL RES, V276, P185, DOI 10.1006/excr.2002.5531; Goukassian DA, 2004, P NATL ACAD SCI USA, V101, P3933, DOI 10.1073/pnas.0306389101; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Ito H, 2005, HUM GENE THER, V16, P685, DOI 10.1089/hum.2005.16.685; Ito H, 2006, JNCI-J NATL CANCER I, V98, P625, DOI 10.1093/jnci/djj161; Iwamaru A, 2007, ONCOGENE, V26, P1840, DOI 10.1038/sj.onc.1209992; IWAMARU A, 2006, ONCOGENE; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanzawa T, 2003, CANCER RES, V63, P2103; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Li GZ, 2004, EXP CELL RES, V301, P189, DOI 10.1016/j.yexcr.2004.08.019; Li GZ, 2003, P NATL ACAD SCI USA, V100, P527, DOI 10.1073/pnas.0235444100; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Marwaha V, 2005, J BIOL CHEM, V280, P32379, DOI 10.1074/jbc.M503245200; Mitchell P, 2005, LANCET NEUROL, V4, P413, DOI 10.1016/S1474-4422(05)70118-6; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Mukai S, 2000, CANCER RES, V60, P4461; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Paglin S, 2005, CANCER RES, V65, P11061, DOI 10.1158/0008-5472.CAN-05-1083; Paglin S, 2001, CANCER RES, V61, P439; Puri N, 2004, FASEB J, V18, P1373, DOI 10.1096/fj.04-1774com; Sheehan KM, 2005, MOL CELL PROTEOMICS, V4, P346, DOI 10.1074/mcp.T500003-MCP200; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Sonoda Y, 2001, CANCER RES, V61, P4956; Surawicz TS, 1998, J NEURO-ONCOL, V40, P151, DOI 10.1023/A:1006091608586; Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640; Terzis AJ, 1997, BRIT J CANCER, V75, P1744, DOI 10.1038/bjc.1997.298; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Yao KC, 2003, J NEUROSURG, V98, P378, DOI 10.3171/jns.2003.98.2.0378	48	53	54	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2918	2930		10.1096/fj.06-6941com	http://dx.doi.org/10.1096/fj.06-6941com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17449721				2022-12-28	WOS:000249237500032
J	Egger, M; Schgoer, W; Beer, AGE; Jeschke, J; Leierer, J; Theurl, M; Frauscher, S; Tepper, OM; Niederwanger, A; Ritsch, A; Kearney, M; Wanschitz, J; Gurtner, GC; Fischer-Colbrie, R; Weiss, G; Piza-Katzer, H; Losordo, DW; Patsch, JR; Schratzberger, P; Kirchmair, R				Egger, Margot; Schgoer, Wilfried; Beer, Arno G. E.; Jeschke, Johannes; Leierer, Johannes; Theurl, Markus; Frauscher, Silke; Tepper, Oren M.; Niederwanger, Andreas; Ritsch, Andreas; Kearney, Marianne; Wanschitz, Julia; Gurtner, Geoffrey C.; Fischer-Colbrie, Reiner; Weiss, Guenter; Piza-Katzer, Hildegunde; Losordo, Douglas W.; Patsch, Josef R.; Schratzberger, Peter; Kirchmair, Rudolf			Hypoxia up-regulates the angiogenic cytokine secretoneurin via an HIF-1 alpha- and basic FGF-dependent pathway in muscle cells	FASEB JOURNAL			English	Article						vascular biology; neuropeptides; ischemia	ENDOTHELIAL GROWTH-FACTOR; VEGF GENE-TRANSFER; SECRETOGRANIN-II; NEUROPEPTIDE SECRETONEURIN; PROHORMONE CONVERTASES; PERIPHERAL NEUROPATHY; INDUCIBLE FACTOR-1; CHROMOGRANIN-A; TUMOR-GROWTH; IN-VITRO	Expression of angiogenic cytokines like vascular endothelial growth factor is enhanced by hypoxia. We tested the hypothesis that decreased oxygen levels up-regulate the angiogenic factor secretoneurin. In vivo, muscle cells of mouse ischemic hind limbs showed increased secretoneurin expression, and inhibition of secretoneurin by a neutralizing antibody impaired the angiogenic response in this ischemia model. In a mouse soft tissue model of hypoxia, secretoneurin was increased in subcutaneous muscle fibers. In vitro, secretoneurin mRNA and protein were up-regulated in L6 myoblast cells after exposure to low oxygen levels. The hypoxia-dependent regulation of secretoneurin was tissue specific and was not observed in endothelial cells, vascular smooth muscle cells, or AtT20 pituitary tumor cells. The hypoxia-dependent induction of secretoneurin in L6 myoblasts is regulated by hypoxia-inducible factor-1 alpha, since inhibition of this factor using si-RNA inhibited up-regulation of secretoneurin. Induction of secretoneurin by hypoxia was dependent on basic fibroblast growth factor in vivo and in vitro, and inhibition of this regulation by heparinase suggests an involvement of low-affinity basic fibroblast growth factor binding sites. In summary, our data show that the angiogenic cytokine secretoneurin is up-regulated by hypoxia in muscle cells by hypoxia-inducible factor-1 alpha- and basic fibroblast growth factor-dependent mechanisms.-Egger, M., Schgoer, W., Beer, A. G. E., Jeschke, J., Leierer, J., Theurl, M., Frauscher, S., Tepper, O. M., Niederwanger, A., Ritsch, A., Kearney, M., Wanschitz, J., Gurtner, G. C., Fischer-Colbrie, R., Weiss, G., Piza-Katzer, H., Losordo, D. W., Patsch, J. R., Schratzberger, P., Kirchmair, R. Hypoxia up-regulates the angiogenic cytokine secretoneurin via an HIF-1 alpha- and basic FGF-dependent pathway in muscle cells.	Univ Innsbruck, Dept Internal Med, A-6020 Innsbruck, Austria; Med Univ Innsbruck, Gen Internal Med, Dept Internal Med, Innsbruck, Austria; Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria; Med Univ Innsbruck, Dept Plast Surg, Innsbruck, Austria; Med Univ Innsbruck, Dept Pharmacol, Innsbruck, Austria; NYU, Med Ctr, Lab Microvasc Res, New York, NY 10016 USA; NYU, Med Ctr, Vasc Tissue Engn, New York, NY 10016 USA; Tufts Univ, Sch Med, St Elizabeths Med Ctr, Div Cardiovasc Res, Boston, MA 02111 USA; Tufts Univ, Sch Med, St Elizabeths Med Ctr, Vasc Med, Boston, MA 02111 USA	University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; New York University; New York University; New York University Tandon School of Engineering; St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University	Kirchmair, R (corresponding author), Univ Innsbruck, Dept Internal Med, Anichstr 35, A-6020 Innsbruck, Austria.	rudolf.kirchmair@uibk.ac.at	Losordo, Douglas W/F-9782-2011	Losordo, Douglas/0000-0002-6857-7506; Ritsch, Andreas/0000-0002-0417-5161; Weiss, Guenter/0000-0003-0709-2158; Leierer, Johannes/0000-0002-7884-9827; Theurl, Markus/0000-0002-3609-9730				Bauer R, 2000, EUR J NEUROSCI, V12, P2746, DOI 10.1046/j.1460-9568.2000.00157.x; Calvani M, 2006, BLOOD, V107, P2705, DOI 10.1182/blood-2005-09-3541; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Emanueli C, 2002, CIRCULATION, V106, P2257, DOI 10.1161/01.CIR.0000033971.56802.C5; Fischer-Colbrie R, 2005, CURR PROTEIN PEPT SC, V6, P373, DOI 10.2174/1389203054546334; FISCHERCOLBRIE R, 1995, PROG NEUROBIOL, V46, P49, DOI 10.1016/0301-0082(94)00060-U; HOFLEHNER J, 1995, FEBS LETT, V360, P294, DOI 10.1016/0014-5793(95)00127-U; Iimuro S, 2004, CIRC RES, V95, P415, DOI 10.1161/01.RES.0000138018.61065.d1; Isner JM, 2000, J CLIN INVEST, V106, P615, DOI 10.1172/JCI10961; Jogi A, 2003, CANCER LETT, V197, P145, DOI 10.1016/S0304-3835(03)00095-8; Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B; Kirchmair R, 2005, CIRCULATION, V111, P2662, DOI 10.1161/CIRCULATIONAHA.104.470849; Kirchmair R, 2004, CIRCULATION, V110, P1121, DOI 10.1161/01.CIR.0000139884.81390.56; Kirchmair R, 2004, CIRCULATION, V109, P777, DOI 10.1161/01.CIR.0000112574.07422.C1; KIRCHMAIR R, 1993, NEUROSCIENCE, V53, P359, DOI 10.1016/0306-4522(93)90200-Y; Krishnamachary B, 2003, CANCER RES, V63, P1138; Laslop A, 1998, J NEUROCHEM, V70, P374; Lee EW, 2003, J CLIN INVEST, V111, P1853, DOI 10.1172/JCI200316929; Li J, 2002, J CELL SCI, V115, P1951; Marti E, 2001, ACTA NEUROPATHOL, V101, P159; Medhurst AD, 2001, NEUROSCIENCE, V105, P353, DOI 10.1016/S0306-4522(01)00190-7; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; Pruneri G, 1998, PROSTATE, V34, P113, DOI 10.1002/(SICI)1097-0045(19980201)34:2<113::AID-PROS5>3.0.CO;2-L; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Schratzberger P, 2001, J CLIN INVEST, V107, P1083, DOI 10.1172/JCI12188; Schratzberger P, 2000, NAT MED, V6, P405, DOI 10.1038/74664; Semenza GL, 2003, ANNU REV MED, V54, P17, DOI 10.1146/annurev.med.54.101601.152418; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Stockmann C, 2006, CLIN EXP PHARMACOL P, V33, P968, DOI 10.1111/j.1440-1681.2006.04474.x; Storkebaum E, 2004, J CLIN INVEST, V113, P14, DOI 10.1172/JCI200420682; Tepper OM, 2005, BLOOD, V105, P1068, DOI 10.1182/blood-2004-03-1051; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557; Zukowska-Grojec Z, 1998, CIRC RES, V83, P187, DOI 10.1161/01.RES.83.2.187	35	56	60	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2906	2917		10.1096/fj.06-7440com	http://dx.doi.org/10.1096/fj.06-7440com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17504977				2022-12-28	WOS:000249237500031
J	Lundberg, P; El-Andaloussi, S; Sutlu, T; Johansson, H; Langel, U				Lundberg, Pontus; El-Andaloussi, S.; Sutlu, T.; Johansson, H.; Langel, U.			Delivery of short interfering RNA using endosomolytic cell-penetrating peptides	FASEB JOURNAL			English	Article						CPP; gene silencing; siRNA; oligonucleotides; RNA interference	MAMMALIAN-CELLS; NUCLEIC-ACIDS; TAT; OLIGONUCLEOTIDES; MACROPINOCYTOSIS; PROTEINS; ENHANCE; CARRIER; ESCAPE; VECTOR	Cell- penetrating peptides ( CPPs) are peptides able to promote uptake of various cargos, including proteins and plasmids. Advances in recent years imply the uptake to be endocytic, where the current hurdle for efficient intracellular delivery is material being retained in the endosomes. In this study we wanted to compare the ability of various established CPPs to deliver siRNA and induce gene silencing of luciferase, with a novel designed penetratin analog having endosomolytic properties, using a noncovalent strategy. In principal, the penetratin analog EB1 will, upon protonation in the early- late endosomes, be able to form an amphipathic alpha helix resulting in permeabilization of the endosomal membrane. We demonstrate that even though all CPPs evaluated in this study can form complexes with siRNA, there is not a direct relationship between the complex formation ability and delivery efficacy. More important, although all CPPs significantly promote siRNA uptake, in some cases no gene silencing effect can be observed unless endosomal escape is induced. We find the designed endosomolytic peptide EB1 to be far more effective both in forming complexes and transporting biologically active siRNA than its parent peptide penetratin. We believe that developing CPPs with increased endosomolytical properties is a necessary step toward achieving biological effects at low concentrations for future in vivo applications.	Stockholm Univ, Dept Neurochem, S-10691 Stockholm, Sweden	Stockholm University	Lundberg, P (corresponding author), Stockholm Univ, Dept Neurochem, Svante Arrhenius Vag 21A, S-10691 Stockholm, Sweden.	pontus@neurochem.su.se	Johansson, Henrik J/O-3363-2014; Sutlu, Tolga/E-1190-2012	Johansson, Henrik J/0000-0003-4729-4205; Sutlu, Tolga/0000-0002-7813-8734; Langel, Ulo/0000-0001-6107-0844				Davidson BL, 2004, LANCET NEUROL, V3, P145, DOI 10.1016/S1474-4422(04)00678-7; Davidson TJ, 2004, J NEUROSCI, V24, P10040, DOI 10.1523/JNEUROSCI.3643-04.2004; El-Andaloussi S, 2005, J CONTROL RELEASE, V110, P189, DOI 10.1016/j.jconrel.2005.09.012; El-Andaloussi S, 2005, CURR PHARM DESIGN, V11, P3597, DOI 10.2174/138161205774580796; El-Andaloussi S, 2006, J GENE MED, V8, P1262, DOI 10.1002/jgm.950; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Goncalves C, 2004, MOL THER, V10, P373, DOI 10.1016/j.ymthe.2004.05.023; Kang SH, 1998, BIOCHEMISTRY-US, V37, P6235, DOI 10.1021/bi980300h; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630; Magzoub M, 2005, BIOCHEMISTRY-US, V44, P14890, DOI 10.1021/bi051356w; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Morris MC, 1999, NUCLEIC ACIDS RES, V27, P3510, DOI 10.1093/nar/27.17.3510; Petersen H, 2002, BIOMACROMOLECULES, V3, P926, DOI 10.1021/bm025539z; Shiraishi T, 2005, CHEM BIOL, V12, P923, DOI 10.1016/j.chembiol.2005.06.009; Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385; Turner JJ, 2005, NUCLEIC ACIDS RES, V33, P27, DOI 10.1093/nar/gki142; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996	20	246	283	1	70	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2664	2671		10.1096/fj.06-6502com	http://dx.doi.org/10.1096/fj.06-6502com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17463227				2022-12-28	WOS:000249237500008
J	Siegmund, SV; Qian, T; de Minicis, S; Harvey-White, J; Kunos, G; Vinod, KY; Hungund, B; Schwabe, RF				Siegmund, Soeren V.; Qian, Ting; de Minicis, Samuele; Harvey-White, Judith; Kunos, George; Vinod, K. Y.; Hungund, Basalingappa; Schwabe, Robert F.			The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species	FASEB JOURNAL			English	Article						ROS; 2-AG; HSC; hepatocyte; fibrosis	CANNABINOID-RECEPTOR; LIVER FIBROSIS; KAPPA-B; PERMEABILITY TRANSITION; NADPH OXIDASE; ANANDAMIDE; APOPTOSIS; PROLIFERATION; ACTIVATION; RESOLUTION	The endocannabinoid system is an important regulator of hepatic fibrogenesis. In this study, we determined the effects of 2- arachidonoyl glycerol ( 2- AG) on hepatic stellate cells ( HSCs), the main fibrogenic cell type in the liver. Culture- activated HSCs were highly susceptible to 2- AG- induced cell death with > 50% cell death at 10 mu M after 18 h of treatment. 2- AG- induced HSC death showed typical features of apoptosis such as PARP- and caspase 3- cleavage and depended on reactive oxygen species ( ROS) formation. Confocal microscopy revealed mitochondria as primary site of ROS production and demonstrated mitochondrial depolarization and increased mitochondrial permeability after 2- AG treatment. 2- AG- induced cell death was independent of cannabinoid receptors but required the presence of membrane cholesterol. Primary hepatocytes were resistant to 2- AG- induced ROS induction and cell death but became susceptible after GSH depletion suggesting antioxidant defenses as a critical determinant of 2- AG sensitivity. Hepatic levels of 2- AG were significantly elevated in two models of experimental fibrogenesis and reached concentrations that are sufficient to induce death in HSCs. These findings suggest that 2- AG may act as an antifibrogenic mediator in the liver by inducing cell death in activated HSCs but not hepatocytes.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Heidelberg Univ, Med Fac Mannheim, Dept Med 2, D-6800 Mannheim, Germany; Univ Texas, Med Branch, Dept Cell Biol & Neurosci, Galveston, TX 77550 USA; NIAAA, NIH, Bethesda, MD USA; Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA; Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA	Columbia University; Ruprecht Karls University Heidelberg; University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Nathan Kline Institute for Psychiatric Research; Columbia University	Schwabe, RF (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, Russ Berrie Pavill,Rm 415,1150 St Nicholas Ave, New York, NY 10032 USA.	rfs2102@columbia.edu	Schwabe, Robert/AAY-6506-2021					Bataller R, 2003, J CLIN INVEST, V112, P1383, DOI 10.1172/JCI200318212; Bataller R, 2001, SEMIN LIVER DIS, V21, P437, DOI 10.1055/s-2001-17558; Begg M, 2005, PHARMACOL THERAPEUT, V106, P133, DOI 10.1016/j.pharmthera.2004.11.005; Berdyshev EV, 2001, BIOCHEM J, V360, P67, DOI 10.1042/0264-6021:3600067; Biswas KK, 2003, HEPATOLOGY, V38, P1167, DOI 10.1053/jhep.2003.50459; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; De Minicis S, 2006, GASTROENTEROLOGY, V131, P272, DOI 10.1053/j.gastro.2006.05.048; De Petrocellis L, 2000, CHEM PHYS LIPIDS, V108, P191, DOI 10.1016/S0009-3084(00)00196-1; Derkinderen P, 2003, J NEUROSCI, V23, P2371; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Di Marzo V, 2005, NAT NEUROSCI, V8, P585, DOI 10.1038/nn1457; Dinh TP, 2002, P NATL ACAD SCI USA, V99, P10819, DOI 10.1073/pnas.152334899; Galli A, 2005, HEPATOLOGY, V41, P1074, DOI 10.1002/hep.20683; Gallop JR, 1995, CERN REPORT, V95, P1; Hammel P, 2001, NEW ENGL J MED, V344, P418, DOI 10.1056/NEJM200102083440604; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Issa R, 2004, GASTROENTEROLOGY, V126, P1795, DOI 10.1053/j.gastro.2004.03.009; Jacobsson SOP, 2001, J PHARMACOL EXP THER, V299, P951; Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Klein TW, 2005, NAT REV IMMUNOL, V5, P400, DOI 10.1038/nri1602; Kondo S, 1998, FEBS LETT, V429, P152, DOI 10.1016/S0014-5793(98)00581-X; Kweon YO, 2003, J HEPATOL, V39, P38, DOI 10.1016/S0168-8278(03)00178-8; Lang A, 2000, J HEPATOL, V33, P49, DOI 10.1016/S0168-8278(00)80159-2; Leist M, 1996, MOL MED, V2, P109, DOI 10.1007/BF03402207; Lemasters JJ, 1998, GASTROENTEROLOGY, V115, P783, DOI 10.1016/S0016-5085(98)70160-X; Maccarrone M, 2003, CELL DEATH DIFFER, V10, P946, DOI 10.1038/sj.cdd.4401284; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Magness ST, 2004, HEPATOLOGY, V40, P1151, DOI 10.1002/hep.20427; Makara JK, 2005, NAT NEUROSCI, V8, P1139, DOI 10.1038/nn1521; McCarron RM, 2003, ACTA NEUROCHIR SUPPL, V86, P271; Movsesyan VA, 2004, CELL DEATH DIFFER, V11, P1121, DOI 10.1038/sj.cdd.4401442; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; Oakley F, 2005, GASTROENTEROLOGY, V128, P108, DOI 10.1053/j.gastro.2004.10.003; Osei-Hyiaman D, 2005, J CLIN INVEST, V115, P1298, DOI 10.1172/JCI200523057; Rueda D, 2000, MOL PHARMACOL, V58, P814, DOI 10.1124/mol.58.4.814; Saile B, 1997, AM J PATHOL, V151, P1265; Sarker KP, 2003, J NEUROCHEM, V85, P50, DOI 10.1046/j.1471-4159.2003.01663.x; Sarker KP, 2003, CELL MOL LIFE SCI, V60, P1200, DOI 10.1007/s00018-003-3055-2; Schwabe RF, 2005, FASEB J, V19, P1758, DOI 10.1096/fj.05-3736fje; Schwabe RF, 2001, J IMMUNOL, V166, P6812, DOI 10.4049/jimmunol.166.11.6812; Siegmund SV, 2006, J BIOL CHEM, V281, P10431, DOI 10.1074/jbc.M509706200; Siegmund SV, 2005, HEPATOLOGY, V41, P1085, DOI 10.1002/hep.20667; Sobesky R, 1999, GASTROENTEROLOGY, V116, P378, DOI 10.1016/S0016-5085(99)70135-6; Teixeira-Clerc F, 2006, NAT MED, V12, P671, DOI 10.1038/nm1421; Tian XY, 2005, J BIOL CHEM, V280, P29788, DOI 10.1074/jbc.M502925200; Wang L, 2003, P NATL ACAD SCI USA, V100, P1393, DOI 10.1073/pnas.0336351100; Wright MC, 2001, GASTROENTEROLOGY, V121, P685, DOI 10.1053/gast.2001.27188; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	53	102	110	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2798	2806		10.1096/fj.06-7717com	http://dx.doi.org/10.1096/fj.06-7717com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17440119				2022-12-28	WOS:000249237500021
J	Yoshida, Y; Hachiya, A; Sriwiriyanont, P; Ohuchi, A; Kitahara, T; Takema, Y; Visscher, MO; Boissy, RE				Yoshida, Yasuko; Hachiya, Akira; Sriwiriyanont, Penkanok; Ohuchi, Atsushi; Kitahara, Takashi; Takema, Yoshinori; Visscher, Marty O.; Boissy, Raymond E.			Functional analysis of keratinocytes in skin color using a human skin substitute model composed of cells derived from different skin pigmentation types	FASEB JOURNAL			English	Article						race; melanocytes; melanization; complexion	HUMAN MELANOCYTES; EPIDERMAL HYPERPIGMENTATION; DISTRIBUTION PATTERNS; IN-VIVO; TYROSINASE; ENDOTHELIN-1; ACTIVATION; EXPRESSION; MELANOSOMES; INHIBITION	Skin color is one of the most distinct features in the human race. To assess the mechanisms of skin color variation, human skin substitutes ( HSS) were constructed by grafting mixtures of cultured keratinocytes and melanocytes from a combination of donor skin types, together with light skin derived fibroblasts, into chambers inserted onto the back skin of severe combined immunodeficient ( SCID) mice. The resulting complexion coloration of the HSS was relatively darker and lighter when dark and light skin derived keratinocytes, respectively, were combined with melanocytes derived from either light or dark skin. The melanin content in the epidermis and the maturation stage of melanosomes in basal keratinocytes were significantly increased in the HSS composed of dark compared to light skin derived keratinocytes. In addition, the ratio of individual/ clustered melanosomes in recipient keratinocytes was increased in the former as opposed to the latter HSS. The genetic expression of endothelin- 1, proopiomelanocortin, microphthalmia-associated transcription factor, tyrosinase, GP100, and MART1 were increased in HSS composed of dark vs. light skin derived keratinocytes. These data suggest that our HSS is a promising melanogenic model that demonstrates the role of the keratinocyte in regulating in part both melanogenesis and distribution of transferred melanosomes.	Univ Cincinnati, Coll Med, Dept Dermatol, Cincinnati, OH 45267 USA; Kao Biol Sci Labs, Haga, Tochigi, Japan; Tokyo Med Univ, Dept Dermatol, Shinjyuku Ku, Tokyo, Japan; Cincinnati Childrens Hosp, Res Fdn, Skin Sci Inst, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; Tokyo Medical University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Boissy, RE (corresponding author), Univ Cincinnati, Coll Med, Dept Dermatol, 231 Albert Sabin Way ML 592, Cincinnati, OH 45267 USA.	boissyre@ucmail.uc.edu						ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; Babiarz-Magee L, 2004, PIGM CELL RES, V17, P241, DOI 10.1111/j.1600-0749.2004.00133.x; BARTELT RN, 1984, Z HAUTKRANKHEITEN, V59, P1053; Bessou S, 1997, BRIT J DERMATOL, V137, P890, DOI 10.1046/j.1365-2133.1997.19822084.x; BIOSSY RE, 2006, PIGMENTARY SYSTEM, P155; Boissy RE, 2004, PIGM CELL RES, V17, P208, DOI 10.1111/j.1600-0749.2004.00130.x; Byers H.R, 2006, PIGMENTARY SYSTEM PH, P181; Cario-Andre M, 2006, PIGM CELL RES, V19, P434, DOI 10.1111/j.1600-0749.2006.00326.x; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; COOPER ML, 1991, J INVEST DERMATOL, V97, P649, DOI 10.1111/1523-1747.ep12483707; Diamond J, 2005, NATURE, V435, P283, DOI 10.1038/435283a; Evans RR, 1996, AM J CARDIOL, V78, P486, DOI 10.1016/S0002-9149(96)00344-X; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; Hachiya A, 2005, J INVEST DERMATOL, V125, P364, DOI 10.1111/j.0022-202X.2005.23832.x; Hachiya A, 2001, J INVEST DERMATOL, V116, P578, DOI 10.1046/j.1523-1747.2001.01290.x; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; Hedley SJ, 2002, PIGM CELL RES, V15, P49, DOI 10.1034/j.1600-0749.2002.00067.x; Hoath SB, 2003, J INVEST DERMATOL, V121, P1440, DOI 10.1046/j.1523-1747.2003.12606.x; HUNT G, 1994, PIGM CELL RES, V7, P217, DOI 10.1111/j.1600-0749.1994.tb00052.x; Im SB, 1998, CANCER RES, V58, P47; Imokawa G, 1997, PIGM CELL RES, V10, P218, DOI 10.1111/j.1600-0749.1997.tb00488.x; IMOKAWA G, 1995, J INVEST DERMATOL, V105, P32, DOI 10.1111/1523-1747.ep12312500; IOZUMI K, 1993, J INVEST DERMATOL, V100, P806, DOI 10.1111/1523-1747.ep12476630; IWATA M, 1990, J INVEST DERMATOL, V95, P9, DOI 10.1111/1523-1747.ep12872677; Jablonski NG, 2000, J HUM EVOL, V39, P57, DOI 10.1006/jhev.2000.0403; Kihira C, 1999, J DERMATOL SCI, V20, P72, DOI 10.1016/S0923-1811(98)00077-2; KONRAD K, 1973, ARCH DERMATOL, V107, P853; Maeda K, 1997, J DERMATOL SCI, V14, P199, DOI 10.1016/S0923-1811(96)00575-0; Minwalla L, 2001, J INVEST DERMATOL, V117, P341, DOI 10.1046/j.0022-202x.2001.01411.x; MONTAGNA W, 1991, J AM ACAD DERMATOL, V24, P929, DOI 10.1016/0190-9622(91)70148-U; Okazaki M, 2003, BRIT J DERMATOL, V148, P689, DOI 10.1046/j.1365-2133.2003.05283.x; ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291; Paine C, 2001, J INVEST DERMATOL, V116, P587, DOI 10.1046/j.1523-1747.2001.01291.x; Passeron T, 2005, J AUTOIMMUN, V25, P63, DOI 10.1016/j.jaut.2005.10.001; POMERANTZ SH, 1975, J CLIN INVEST, V55, P1127, DOI 10.1172/JCI108014; Quevedo WCJ, 2006, PIGMENTARY SYSTEM, P63; Scott G, 2001, J INVEST DERMATOL, V117, P1412, DOI 10.1046/j.0022-202x.2001.01575.x; Scott G.A, 2006, PIGMENTARY SYSTEM, P171; Seiberg M, 2000, J INVEST DERMATOL, V115, P162, DOI 10.1046/j.1523-1747.2000.00035.x; Seiberg M, 2000, EXP CELL RES, V254, P25, DOI 10.1006/excr.1999.4692; Seiberg M, 2001, PIGM CELL RES, V14, P236, DOI 10.1034/j.1600-0749.2001.140402.x; Sharlow ER, 2000, J CELL SCI, V113, P3093; Spritz RA, 2006, J DERMATOL SCI, V41, P3, DOI 10.1016/j.jdermsci.2005.10.001; SZABO G, 1969, NATURE, V222, P1082, DOI 10.1038/2221081a0; Tachibana M, 2000, PIGM CELL RES, V13, P230, DOI 10.1034/j.1600-0749.2000.130404.x; Thong HY, 2003, BRIT J DERMATOL, V149, P498, DOI 10.1046/j.1365-2133.2003.05473.x; Treiber FA, 2000, HYPERTENSION, V35, P722, DOI 10.1161/01.HYP.35.3.722; Yamamoto T, 1998, DERMATOLOGY, V197, P109, DOI 10.1159/000017979; Yang F, 2000, J INVEST DERMATOL, V114, P157, DOI 10.1046/j.1523-1747.2000.00836.x	49	50	54	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2829	2839		10.1096/fj.06-6845com	http://dx.doi.org/10.1096/fj.06-6845com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17475923				2022-12-28	WOS:000249237500024
J	Biteman, B; Hassan, IR; Walker, E; Leedom, AJ; Dunn, M; Seta, F; Laniado-Schwartzman, M; Gronert, K				Biteman, Benjamin; Hassan, Iram R.; Walker, Everald; Leedom, Alexander J.; Dunn, Michael; Seta, Francesca; Laniado-Schwartzman, Michal; Gronert, Karsten			Interdependence of lipoxin A(4) and heme-oxygenase in counter-regulating inflammation during corneal wound healing	FASEB JOURNAL			English	Article						lipid autacoids; resolution; neutrophil; 12/15-lipoxygenase	OCULAR IMMUNE PRIVILEGE; DOCOSAHEXAENOIC ACID; LIPID MEDIATORS; 12/15-LIPOXYGENASE; MACROPHAGES; RESOLUTION; MICE; 15-LIPOXYGENASE; PROTECTIN-D1; GENERATION	In the immune-privileged cornea, epithelial wounds heal rapidly with almost no scarring and, unlike in most other tissues, acute inflammation in the absence of infection is beneficial to healing. Molecular mechanisms, which account for this striking property, remain to be clearly defined, but they likely include autacoids that control leukocyte activation. Two prominent enzymes, 12/15-lipoxygenase (LOX), which generates antiinflammatory lipid autacoids, and heme-oxygenase (HO), which generates antioxidants and carbon monoxide, are highly expressed in human and mouse corneas. LXA(4), an endogenous 12/15-LOX product, proved to be a potent inhibitor of exacerbated inflammation and significantly increased re-epithelialization in corneal wounds. In vivo deletion of 12/15-LOX correlated with exacerbated inflammation and impaired wound healing in 12/15-LOX-/- mice, a phenotype that was rescued by treatment with LXA(4). More importantly, 12/15-LOX-/- mice demonstrated impaired induction of HO-1 in both acute and exacerbated inflammation. Topical LXA(4) restored HO-1 expression in 12/15-LOX-/- mice and amplified HO-1 gene expression in human corneal epithelial cells. HO-2(-/-) mice, which fail to induce HO-1, also demonstrated exacerbated inflammation in response to injury, a phenotype that, notably, correlated with a 50% reduction in endogenous LXA(4) formation. Collectively, results demonstrate a critical role for LXA(4) in inflammatory/ reparative responses and provide the first evidence that 12/15-LOX and HO systems function in concert to control inflammation.-Biteman, B., Hassan, I. R., Walker, E., Leedom, A. J., Dunn, M., Seta, F., Laniado-Schwartzman, M., Gronert, K. Interdependence of lipoxin A(4) and heme-oxygenase in counterregulating inflammation during corneal wound healing.	New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA	New York Medical College	Gronert, K (corresponding author), New York Med Coll, Dept Pharmacol, Basic Sci Bldg, Valhalla, NY 10595 USA.	karsten_gronert@nymc.edu	Seta, Francesca/ABB-1566-2020	Seta, Francesca/0000-0001-7985-5615	NATIONAL EYE INSTITUTE [R01EY016136, R01EY006513] Funding Source: NIH RePORTER; NEI NIH HHS [EY016136, EY06513, R01 EY016136-03, R01 EY016136] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abraham NG, 2006, CIRC RES, V99, P911, DOI 10.1161/01.RES.0000249616.10603.d6; Ariel A, 2005, J BIOL CHEM, V280, P43079, DOI 10.1074/jbc.M509796200; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Cao ZY, 2002, J BIOL CHEM, V277, P42299, DOI 10.1074/jbc.M200981200; Carlson EC, 2003, MOL VIS, V9, P615; Chang MS, 2005, INVEST OPHTH VIS SCI, V46, P849, DOI 10.1167/iovs.04-1166; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; Emerson MR, 2004, BRAIN RES, V1021, P140, DOI 10.1016/j.brainres.2004.06.045; Fleiszig Suzanne M J, 2002, Clin Exp Optom, V85, P271; Funk CD, 2002, PROSTAG OTH LIPID M, V68-9, P303, DOI 10.1016/S0090-6980(02)00036-9; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gan L, 1999, INVEST OPHTH VIS SCI, V40, P575; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; Gonzalez-Periz A, 2006, FASEB J, V20, P2537, DOI 10.1096/fj.06-6250fje; Gronert K, 2005, PROSTAG LEUKOTR ESS, V73, P221, DOI 10.1016/j.plefa.2005.05.009; Gronert K, 2005, J BIOL CHEM, V280, P15267, DOI 10.1074/jbc.M410638200; Gronert K, 1999, METH MOL B, V120, P119; Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923; Hanselmann C, 2001, BIOCHEM J, V353, P459, DOI 10.1042/0264-6021:3530459; Hazlett LD, 2005, OCUL IMMUNOL INFLAMM, V13, P133, DOI 10.1080/09273940490912362; Hegazi RAF, 2005, J EXP MED, V202, P1703, DOI 10.1084/jem.20051047; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Khatri S, 2002, INVEST OPHTH VIS SCI, V43, P2278; Klein RF, 2004, SCIENCE, V303, P229, DOI 10.1126/science.1090985; Kuhn H, 2006, PROG LIPID RES, V45, P334, DOI 10.1016/j.plipres.2006.02.003; Kumar V., 2004, ROBBINS COTRAN PATHO; LaniadoSchwartzman M, 1997, BIOCHEM PHARMACOL, V53, P1069, DOI 10.1016/S0006-2952(97)00080-4; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; LEVY BD, 1993, J CLIN INVEST, V92, P1572, DOI 10.1172/JCI116738; LEVY BD, 1993, LIPIDS, V28, P1047, DOI 10.1007/BF02537069; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Levy BD, 2007, J IMMUNOL, V178, P496, DOI 10.4049/jimmunol.178.1.496; Li ZJ, 2006, INVEST OPHTH VIS SCI, V47, P1947, DOI 10.1167/iovs.05-1193; LIMINGA M, 1994, BBA-LIPID LIPID MET, V1210, P288, DOI 10.1016/0005-2760(94)90231-3; Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420; Martin P, 2005, TRENDS CELL BIOL, V15, P599, DOI 10.1016/j.tcb.2005.09.002; McClellan SA, 2003, J IMMUNOL, V170, P5219, DOI 10.4049/jimmunol.170.10.5219; Nascimento-Silva V, 2005, AM J PHYSIOL-CELL PH, V289, pC557, DOI 10.1152/ajpcell.00045.2005; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; POSS KD, 1995, NEURON, V15, P867, DOI 10.1016/0896-6273(95)90177-9; Rogers B, 2003, FREE RADICAL BIO MED, V35, P872, DOI 10.1016/S0891-5849(03)00431-3; Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005; Serhan CN, 2006, J IMMUNOL, V176, P1848, DOI 10.4049/jimmunol.176.3.1848; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; SERHAN CN, 1989, FREE RADICAL RES COM, V7, P341, DOI 10.3109/10715768909087960; Seta F, 2006, AM J PATHOL, V169, P1612, DOI 10.2353/ajpath.2006.060555; Sharma GD, 2005, J BIOL CHEM, V280, P7917, DOI 10.1074/jbc.M408852200; Sodin-Semrl S, 2000, J IMMUNOL, V164, P2660, DOI 10.4049/jimmunol.164.5.2660; Streilein JW, 2003, J LEUKOCYTE BIOL, V74, P179, DOI 10.1189/jlb.1102574; Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224; Turkseven S, 2007, J CELL BIOCHEM, V100, P815, DOI 10.1002/jcb.21138; Ueno M, 2005, INVEST OPHTH VIS SCI, V46, P4097, DOI 10.1167/iovs.05-0548; Vij N, 2005, INVEST OPHTH VIS SCI, V46, P88, DOI 10.1167/iovs.04-0833	56	79	85	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2257	2266		10.1096/fj.06-7918com	http://dx.doi.org/10.1096/fj.06-7918com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17384141				2022-12-28	WOS:000247500300034
J	Liang, J; Pan, YL; Zhang, DX; Guo, CC; Shi, YQ; Wang, JB; Chen, Y; Wang, X; Liu, J; Guo, XG; Chen, Z; Qiao, TD; Fan, DM				Liang, Jie; Pan, Yanglin; Zhang, Dexin; Guo, Changcun; Shi, Yongquan; Wang, Jingbo; Chen, Yu; Wang, Xin; Liu, Jie; Guo, Xuegang; Chen, Zheng; Qiao, Taidong; Fan, Daiming			Cellular prion protein promotes proliferation and G1/S transition of human gastric cancer cells SGC7901 and AGS	FASEB JOURNAL			English	Article						PrPC proliferation; cyclinD1; PI3K/Akt; octa-peptide repeat region	TERMINAL SH3 DOMAIN; GASTROINTESTINAL-TRACT; SIGNAL-TRANSDUCTION; EXPRESSION; GENE; PHOSPHATIDYLINOSITOL; SURVIVAL; KINASE; LINE; PRPC	The function of cellular prion protein ( PrPC), the essential protein for the pathogenesis and transmission of prion diseases, is still largely unknown. The putative roles of PrPC are thought to be related to cell signaling, survival, and differentiation. In a previous study, we showed that PrPC was overexpressed in gastric cancer tissues. In the present report, we show that ectopic expression of PrPC could promote tumorigenesis, proliferation, and G1/S transition in gastric cancer cells. Furthermore, CyclinD1, a protein related to cell cycle, was shown to be significantly up-regulated by PrPC at both mRNA and protein levels. PI3K/Akt pathway mediated above PrPC signal since PrPC increased the expression of phosphorylated Akt, and the specific inhibitor of Akt, LY294002, could markedly suppress growth of SGC7901 and transactivation of CyclinD1 induced by PrPC. Octapeptide repeat region played a vital role in this function, as deletion of this region abolished or reduced these effects. Collectively, this study demonstrates that overexpression of PrPC might promote the tumorigenesis and proliferation of gastric cancer cells at least partially through activation of PI3K/ Akt pathway and subsequent transcriptional activation of CyclinD1 to regulate the G1/S phase transition, in which octapeptide repeat region might be an indispensable region.-Liang, J., Pan, Y., Zhang, D., Guo, C., Shi, Y., Wang, J., Chen, Y., Wang, X., Liu, J., Guo, X., Chen, Z., Qiao, T., Fan, D. Cellular prion protein promotes proliferation and G1/S transition of human gastric cancer cells SGC7901 and AGS.	Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Xian, Peoples R China	Air Force Military Medical University	Fan, DM (corresponding author), Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, 15 W Chang Le Rd, Xian, Peoples R China.	fandaim@fmmu.edu.cn	Shi, Yongquan/AAE-3954-2020	Guo, Changcun/0000-0002-9016-9699				Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Comincini S, 2004, ANTICANCER RES, V24, P1507; Couzin J, 2006, SCIENCE, V311, P1091, DOI 10.1126/science.311.5764.1091; Daggett V, 1998, CURR OPIN BIOTECH, V9, P359, DOI 10.1016/S0958-1669(98)80008-6; Diarra-Mehrpour M, 2004, CANCER RES, V64, P719, DOI 10.1158/0008-5472.CAN-03-1735; Du JP, 2005, INT J CANCER, V113, P213, DOI 10.1002/ijc.20570; Even Y, 2006, J CELL BIOCHEM, V99, P890, DOI 10.1002/jcb.20986; Ford MJ, 2002, NEUROSCIENCE, V113, P177, DOI 10.1016/S0306-4522(02)00155-0; Gougoumas DD, 2001, EXP CELL RES, V264, P408, DOI 10.1006/excr.2001.5151; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; Kikuchi Y, 2002, BIOL PHARM BULL, V25, P728, DOI 10.1248/bpb.25.728; Konturek PC, 2005, WORLD J GASTROENTERO, V11, P7651, DOI 10.3748/wjg.v11.i48.7651; Krebs B, 2006, BIOCHEM BIOPH RES CO, V340, P13, DOI 10.1016/j.bbrc.2005.11.158; Liang J, 2006, TUMOR BIOL, V27, P84, DOI 10.1159/000092488; Lysek DA, 2004, BIOCHEMISTRY-US, V43, P10393, DOI 10.1021/bi0494828; Mironov A, 2003, J NEUROSCI, V23, P7183, DOI 10.1523/JNEUROSCI.23-18-07183.2003; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Pammer J, 2000, VIRCHOWS ARCH, V436, P466, DOI 10.1007/s004280050474; Pammer J, 1999, LANCET, V354, P1702, DOI 10.1016/S0140-6736(99)02800-7; Pan YL, 2007, CANCER LETT, V246, P129, DOI 10.1016/j.canlet.2006.02.010; Pan YL, 2006, FASEB J, V20, P1886, DOI 10.1096/fj.06-6138fje; Roucou X, 2005, CELL DEATH DIFFER, V12, P783, DOI 10.1038/sj.cdd.4401629; Satoh J, 2000, AM J PATHOL, V157, P59, DOI 10.1016/S0002-9440(10)64517-8; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Steele AD, 2006, P NATL ACAD SCI USA, V103, P3416, DOI 10.1073/pnas.0511290103; Stuermer CAO, 2004, FASEB J, V18, P1731, DOI 10.1096/fj.04-2150fje; Tang X, 2007, CELL DEATH DIFFER, V14, P368, DOI 10.1038/sj.cdd.4402011; Tu YP, 2000, CANCER RES, V60, P6763; Vassallo N, 2005, BIOCHEM BIOPH RES CO, V332, P75, DOI 10.1016/j.bbrc.2005.04.099; Watt NT, 2005, J BIOL CHEM, V280, P35914, DOI 10.1074/jbc.M507327200; Wittekind M, 1997, J MOL BIOL, V267, P933, DOI 10.1006/jmbi.1996.0886; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831; Yin SM, 2006, J BIOL CHEM, V281, P10698, DOI 10.1074/jbc.M511819200; Yy, 2006, EXCLI J, V5, P11; Zhao YQ, 2002, CANCER LETT, V185, P211, DOI 10.1016/S0304-3835(02)00264-1	36	75	85	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2247	2256		10.1096/fj.06-7799com	http://dx.doi.org/10.1096/fj.06-7799com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17409275				2022-12-28	WOS:000247500300033
J	Malester, B; Tong, X; Ghiu, I; Kontogeorgis, A; Gutstein, DE; Xu, J; Hendricks-Munoz, KD; Coetzee, WA				Malester, Brian; Tong, XiaoYong; Ghiu, Ioana; Kontogeorgis, Andrianos; Gutstein, David E.; Xu, Jie; Hendricks-Munoz, Karen D.; Coetzee, William A.			Transgenic expression of a dominant negative K-ATP channel subunit in the mouse endothelium: effects on coronary flow and endothelin-1 secretion	FASEB JOURNAL			English	Article						potassium channels; coronary vasculature; transgenic mouse	SENSITIVE POTASSIUM CHANNELS; VASCULAR SMOOTH-MUSCLE; PANCREATIC BETA-CELLS; GUINEA-PIG HEART; INSULIN-SECRETION; ION CHANNELS; SULFONYLUREA RECEPTOR-1; CAMP SENSOR; MICE; RELEASE	K-ATP channels are involved in regulating coronary function, but the contribution of endothelial KATP channels remains largely uncharacterized. We generated a transgenic mouse model to specifically target endothelial KATP channels by expressing a dominant negative Kir6.1 subunit only in the endothelium. These animals had no obvious overt phenotype and no early mortality. Histologically, the coronary endothelium in these animals was preserved. There was no evidence of increased susceptibility to ergonovine-induced coronary vasospasm. However, isolated hearts from these animals had a substantially elevated basal coronary perfusion pressure. The KATP channel openers, adenosine and levcromakalim, decreased the perfusion pressure whereas the KATP channel blocker glibenclamide failed to produce a vasoconstrictive response. The inducible endothelial nitric oxide pathway was intact, as evidenced by vasodilation caused by bradykinin. In contrast, basal endothelin-1 release was significantly elevated in the coronary effluent from these hearts. Treatment of mice with bosentan (endothelin-1 receptor antagonist) normalized the coronary perfusion pressure, demonstrating that the elevated endothelin-1 release was sufficient to account for the increased coronary perfusion pressure. Pharmacological blockade of KATP channels led to elevated endothelin-1 levels in the coronary effluent of isolated mouse and rat hearts as well as enhanced endothelin-1 secretion from isolated human coronary endothelial cells. These data are consistent with a role for endothelial KATP channels to control the coronary blood flow by modulating the release of the vasoconstrictor, endothelin-1.	NYU, Sch Med, Dept Pediat, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Amer Cardiovasc Res Inst, Atlanta, GA USA	New York University; New York University; New York University; New York University; Boston University	Coetzee, WA (corresponding author), NYU, Sch Med, Dept Pediat, 560 1st Ave,TCH-521, New York, NY 10016 USA.	william.coetzee@med.nyu.edu	Tong, Xiaoyong/L-5791-2019	Coetzee, William/0000-0003-1522-8326	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081336, R01HL064838] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 081336, HL64838, R01 HL081336] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agah R, 1997, J CLIN INVEST, V100, P169, DOI 10.1172/JCI119509; AKAI K, 1995, J CARDIOVASC PHARM, V26, P541, DOI 10.1097/00005344-199510000-00006; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; BELLONI FL, 1991, AM J PHYSIOL, V261, pH720, DOI 10.1152/ajpheart.1991.261.3.H720; Bolad I, 2005, CURR OPIN CARDIOL, V20, P270, DOI 10.1097/01.hco.0000167719.37700.1d; Brayden JE, 2002, CLIN EXP PHARMACOL P, V29, P312, DOI 10.1046/j.1440-1681.2002.03650.x; Bugiardini R, 2004, CIRCULATION, V109, P2518, DOI 10.1161/01.CIR.0000128208.22378.E3; Chutkow WA, 2002, J CLIN INVEST, V110, P203, DOI 10.1172/JCI200215672; DAUT J, 1994, CARDIOVASC RES, V28, P811, DOI 10.1093/cvr/28.6.811; DAUT J, 1990, SCIENCE, V247, P1341, DOI 10.1126/science.2107575; Dorschner H, 1999, MOL PHARMACOL, V55, P1060; ECKMAN DM, 1992, BRIT J PHARMACOL, V106, P9, DOI 10.1111/j.1476-5381.1992.tb14285.x; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; Fisher TE, 2001, PROG BIOPHYS MOL BIO, V77, P269, DOI 10.1016/S0079-6107(01)00017-7; Geng XH, 2003, DIABETES, V52, P767, DOI 10.2337/diabetes.52.3.767; Ghiu IA, 2004, BIOPHYS J, V86, p441A; Heron-Milhavet L, 2004, MOL CELL NEUROSCI, V25, P585, DOI 10.1016/j.mcn.2003.10.012; HUTCHESON IR, 1994, AM J PHYSIOL, V266, pH590, DOI 10.1152/ajpheart.1994.266.2.H590; Ishizaka H, 1997, AM J PHYSIOL-HEART C, V273, pH104, DOI 10.1152/ajpheart.1997.273.1.H104; JACKSON WF, 1993, AM J PHYSIOL, V265, pH1797, DOI 10.1152/ajpheart.1993.265.5.H1797; Jackson WF, 1998, MICROCIRCULATION, V5, P85, DOI 10.1038/sj.mn.7300025; Kakkar R, 2006, CIRC RES, V98, P682, DOI 10.1161/01.RES.0000207498.40005.e7; Kang GX, 2006, J PHYSIOL-LONDON, V573, P595, DOI 10.1113/jphysiol.2006.107391; Katnik C, 1997, AM J PHYSIOL-HEART C, V272, pH2507, DOI 10.1152/ajpheart.1997.272.5.H2507; KLIEBER HG, 1994, CARDIOVASC RES, V28, P823, DOI 10.1093/cvr/28.6.823; KOMARU T, 1991, CIRC RES, V69, P1146, DOI 10.1161/01.RES.69.4.1146; Kunz L, 2006, J CLIN ENDOCR METAB, V91, P1950, DOI 10.1210/jc.2005-2269; KUO L, 1995, AM J PHYSIOL-HEART C, V269, pH541, DOI 10.1152/ajpheart.1995.269.2.H541; Miki T, 2002, NAT MED, V8, P466, DOI 10.1038/nm0502-466; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Morrissey Alison, 2005, BMC Physiol, V5, P1, DOI 10.1186/1472-6793-5-1; NAKASHIMA M, 1992, CIRC RES, V71, P859, DOI 10.1161/01.RES.71.4.859; Nenquin M, 2004, J BIOL CHEM, V279, P32316, DOI 10.1074/jbc.M402076200; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; NUSSDORFER GG, 1979, ANAT ANZEIGER, V145, P319; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Olsen HL, 2005, ENDOCRINOLOGY, V146, P4861, DOI 10.1210/en.2005-0800; ORourke ST, 1996, J CARDIOVASC PHARM, V27, P636, DOI 10.1097/00005344-199605000-00004; Pasyk EA, 2004, J BIOL CHEM, V279, P4234, DOI 10.1074/jbc.M309667200; QUAYLE JM, 1994, CARDIOVASC RES, V28, P797, DOI 10.1093/cvr/28.6.797; Quesada I, 2004, CURR MED CHEM, V11, P2707, DOI 10.2174/0929867043364379; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; Remedi MS, 2004, DIABETES, V53, P3159, DOI 10.2337/diabetes.53.12.3159; Russell FD, 1999, BRIT J PHARMACOL, V126, P391, DOI 10.1038/sj.bjp.0702315; SAMAHA FF, 1992, AM J PHYSIOL, V262, pC1220, DOI 10.1152/ajpcell.1992.262.5.C1220; Schnitzler MMY, 2000, J PHYSIOL-LONDON, V525, P307, DOI 10.1111/j.1469-7793.2000.t01-1-00307.x; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Seino S, 2003, PROG BIOPHYS MOL BIO, V81, P133, DOI 10.1016/S0079-6107(02)00053-6; Shibasaki T, 2004, J BIOL CHEM, V279, P7956, DOI 10.1074/jbc.M309068200; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; Theis JGW, 1997, CAN J PHYSIOL PHARM, V75, P1241, DOI 10.1139/cjpp-75-10-11-1241; Thevenod F, 2002, AM J PHYSIOL-CELL PH, V283, pC651, DOI 10.1152/ajpcell.00600.2001; Tong XY, 2006, AM J PHYSIOL-HEART C, V291, pH543, DOI 10.1152/ajpheart.00051.2006; Yoshida H, 2004, J MOL CELL CARDIOL, V37, P857, DOI 10.1016/j.yjmcc.2004.05.022	55	45	46	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					2162	2172		10.1096/fj.06-7821com	http://dx.doi.org/10.1096/fj.06-7821com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17341678				2022-12-28	WOS:000247500300025
J	Kristian, SA; Timmer, AM; Liu, GY; Lauth, X; Sal-Man, N; Rosenfeld, Y; Shai, Y; Gallo, RL; Nizet, V				Kristian, Sascha A.; Timmer, Anjuli M.; Liu, George Y.; Lauth, Xavier; Sal-Man, Neta; Rosenfeld, Yosef; Shai, Yechiel; Gallo, Richard L.; Nizet, Victor			Impairment of innate immune killing mechanisms by bacteriostatic antibiotics	FASEB JOURNAL			English	Article						antimicrobial peptides; cathelicidin; complement	PLATELET MICROBICIDAL PROTEIN; HUMAN ANTIMICROBIAL PEPTIDE; STAPHYLOCOCCUS-AUREUS; INFECTIONS; RESISTANCE; ORGANISMS; MEMBRANES; BACTERIA; DEFENSIN; OPERON	Antibiotics are designed to support host defense in controlling infection. Here we describe a paradoxical inhibitory effect of bacteriostatic antibiotics on key mediators of mammalian innate immunity. When growth of species including Escherichia coli and Staphylococcus aureus is suppressed by chloramphenicol or erythromycin, the susceptibility of the bacteria to cathelicidin antimicrobial peptides or serum complement was markedly diminished. Survival of the bacteria in human whole blood, human wound fluid, or a mouse wound infection model was in turn increased after antibiotic-induced bacteriostasis. These findings provide a further rationale against the indiscriminate use of antibiotics.	Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Vet Affairs San Diego Healthcare Syst, La Jolla, CA USA; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; Weizmann Institute of Science	Nizet, V (corresponding author), Univ Calif San Diego, Sch Med, Dept Pediat Cellular & Mol Med E1066, 9500 Gilman Dr, La Jolla, CA 92093 USA.	vnizet@ucsd.edu	Nizet, Victor/AAF-3190-2019; Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861; Sal-Man, Neta/0000-0002-1109-479X; Nizet, Victor/0000-0003-3847-0422	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI048176, R01AI048694] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-048694, AI-48176] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASMAR BI, 1983, PEDIATR INFECT DIS J, V2, P39, DOI 10.1097/00006454-198301000-00010; Barnes MG, 2002, INFECT IMMUN, V70, P403, DOI 10.1128/IAI.70.1.403-406.2002; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; Finberg RW, 2004, CLIN INFECT DIS, V39, P1314, DOI 10.1086/425009; Iimura M, 2005, J IMMUNOL, V174, P4901, DOI 10.4049/jimmunol.174.8.4901; Jeng A, 2003, J BACTERIOL, V185, P1208, DOI 10.1128/JB.185.4.1208-1217.2003; Koo SP, 1996, INFECT IMMUN, V64, P1070, DOI 10.1128/IAI.64.3.1070-1074.1996; Lauth X, 2002, J BIOL CHEM, V277, P5030, DOI 10.1074/jbc.M109173200; Mulligan M J, 1989, Infect Dis Clin North Am, V3, P389; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oren Z, 1999, BIOCHEM J, V341, P501, DOI 10.1042/0264-6021:3410501; Peschel A, 1999, J BIOL CHEM, V274, P8405, DOI 10.1074/jbc.274.13.8405; Proctor RA, 2006, NAT REV MICROBIOL, V4, P295, DOI 10.1038/nrmicro1384; SAHL HG, 1987, ARCH MICROBIOL, V149, P120, DOI 10.1007/BF00425076; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Silphaduang U, 2001, NATURE, V414, P268, DOI 10.1038/35104690; Stratton CW, 2003, EMERG INFECT DIS, V9, P10; von Eiff C, 2006, INJURY, V37, P26, DOI 10.1016/j.injury.2006.04.006; Wildman KAH, 2003, BIOCHEMISTRY-US, V42, P6545, DOI 10.1021/bi0273563; Xiong YQ, 1999, ANTIMICROB AGENTS CH, V43, P1111, DOI 10.1128/AAC.43.5.1111; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	23	35	36	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					1107	1116		10.1096/fj.06-6802com	http://dx.doi.org/10.1096/fj.06-6802com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17215486				2022-12-28	WOS:000245650400015
J	Paclet, MH; Berthier, S; Kuhn, L; Garin, J; Morel, F				Paclet, Marie-Helene; Berthier, Sylvie; Kuhn, Lauriane; Garin, Jerome; Morel, Francoise			Regulation of phagocyte NADPH oxidase activity: identification of two cytochrome b(558) activation states	FASEB JOURNAL			English	Article						NADPH oxidase complex; MRP; p67-phox	CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; DEPENDENT SUPEROXIDE PRODUCTION; IMMORTALIZED B-LYMPHOCYTES; SODIUM DODECYL-SULFATE; RESPIRATORY BURST; NEUTROPHILS; P47(PHOX); COMPONENTS; P67(PHOX)	Activation of the phagocyte NADPH oxidase (phox) requires the association of cytosolic proteins (p67-phox, p47-phox, p40-phox, and Rac1/2) with the membrane cytochrome b558, leading to a hemoprotein conformation change. To clarify this mechanism, the phagocyte NADPH oxidase complex was isolated through cytochrome b558 purification after three chromatographic steps. The purified neutrophil complex was constitutively active in the absence of an amphiphile agent with a maximum turnover (125 mol O-2(-) . s(-1) . mol heme b(-1)), indicating that cytochrome b558 has been activated by cytosolic proteins and is in an "open conformation," able to transfer a maximum rate of electrons. In contrast, the phox complex prepared with B lymphocyte cytosol shows a lower constitutive turnover (similar to 50 mol O-2(-) . s(-1) . mol heme b(-1)). Analysis of phox complex components by Western blot and mass spectrometry showed the presence of cytosolic factors (especially p67-phox) and structural proteins (moesin, ezrin). To investigate the difference in activity of phox complexes, we evaluated the effect of MRP8 and MRP14, specifically expressed in neutrophils, on the activity of the B lymphocyte complex. MRPs induce the switch between the partially and the fully "open" cytochrome b558 conformation. Moreover, their effect was independent of p67-phox. Data point out two potential cytochrome b558 activation states.	CHU Grenoble, GREPI EA 2938, Lab Enzymol, DBPC, F-38043 Grenoble 9, France; ERIT M CEA Grenoble, Lab Chim Prot, Grenoble, France	CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CEA	Paclet, MH (corresponding author), CHU Grenoble, GREPI EA 2938, Lab Enzymol, DBPC, BP 217, F-38043 Grenoble 9, France.	mhpaclet@chu-grenoble.fr	Paclet, Marie-Hélène/AAS-5029-2020	Kuhn, Lauriane/0000-0002-2637-1024				ABO A, 1992, J BIOL CHEM, V267, P16767; BATOT G, 1995, EUR J BIOCHEM, V234, P208, DOI 10.1111/j.1432-1033.1995.208_c.x; BELLAVITE P, 1984, BIOCHEM J, V223, P639, DOI 10.1042/bj2230639; Berthier S, 2003, J BIOL CHEM, V278, P25499, DOI 10.1074/jbc.M209755200; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; COHENTANUGI L, 1991, EUR J BIOCHEM, V202, P649, DOI 10.1111/j.1432-1033.1991.tb16419.x; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; DOUSSIERE J, 1985, BIOCHEMISTRY-US, V24, P7231, DOI 10.1021/bi00346a032; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Gorzalczany Y, 2002, J BIOL CHEM, V277, P18605, DOI 10.1074/jbc.M202114200; Grogan A, 1997, J CELL SCI, V110, P3071; Heyworth PG, 2003, CURR OPIN IMMUNOL, V15, P578, DOI 10.1016/S0952-7915(03)00109-2; Kerkhoff C, 2005, FASEB J, V19, P467, DOI 10.1096/fj.04-2377fje; KOBAYASHI S, 1995, J BIOCHEM, V117, P758, DOI 10.1093/oxfordjournals.jbchem.a124773; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALY FE, 1994, J BIOL CHEM, V269, P18743; MARKERT M, 1985, P NATL ACAD SCI USA, V82, P3144, DOI 10.1073/pnas.82.10.3144; Miyano K, 2001, BIOCHEMISTRY-US, V40, P14089, DOI 10.1021/bi010882u; MOREL F, 1993, BIOCHIM BIOPHYS ACTA, V1182, P101, DOI 10.1016/0925-4439(93)90159-X; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Paclet MH, 2001, EUR J BIOCHEM, V268, P5197, DOI 10.1046/j.0014-2956.2001.02455.x; Paclet MH, 2000, BIOCHEMISTRY-US, V39, P9302, DOI 10.1021/bi000483j; PAPAYANNOPOULOS IA, 1995, MASS SPECTROM REV, V14, P49, DOI 10.1002/mas.1280140104; REEVES EPL, 1999, BIOCHEM J, V15, P859; Sarfstein R, 2004, J BIOL CHEM, V279, P16007, DOI 10.1074/jbc.M312394200; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ugolev Y, 2006, J BIOL CHEM, V281, P19204, DOI 10.1074/jbc.M600042200; Vergnaud S, 2000, EUR J BIOCHEM, V267, P1059, DOI 10.1046/j.1432-1327.2000.01097.x; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Wientjes FB, 2001, BIOCHEM BIOPH RES CO, V289, P382, DOI 10.1006/bbrc.2001.5982; Zhan Y, 2002, J BIOL CHEM, V277, P4512, DOI 10.1074/jbc.M109520200	35	29	31	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1244	1255		10.1096/fj.06-6852com	http://dx.doi.org/10.1096/fj.06-6852com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17227953				2022-12-28	WOS:000245650400028
J	Spreafico, A; Schenone, S; Serchi, T; Orlandini, M; Angelucci, A; Magrini, D; Bernardini, G; Collodel, G; Di Stefano, A; Tintori, C; Bologna, M; Manetti, F; Botta, M; Santucci, A				Spreafico, Adriano; Schenone, Silvia; Serchi, Tommaso; Orlandini, Maurizio; Angelucci, Adriano; Magrini, David; Bernardini, Giulia; Collodel, Giulia; Di Stefano, Anna; Tintori, Cristina; Bologna, Mauro; Manetti, Fabrizio; Botta, Maurizio; Santucci, Annalisa			Antiproliferative and proapoptotic activities of new pyrazolo [3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells	FASEB JOURNAL			English	Article						bone cells; apoptosis; bone cancer; osteoblast; tyrosine kinase	FOCAL ADHESION KINASE; C-SRC; TYROSINE KINASE; IN-VITRO; OSTEOGENIC-SARCOMA; ESTROGEN-RECEPTOR; CARCINOMA-CELLS; DEFICIENT MICE; CANCER-CELLS; CODON 531	Osteosarcoma is the most frequent primitive malignant tumor of the skeletal system, characterized by an extremely aggressive clinical course that still lacks an effective treatment. Src kinase seems to be involved in the osteosarcoma malignant phenotype. We show that the treatment of human osteosarcoma cell lines with a new pyrazolo[3,4-d]pyrimidine derivative Src inhibitor, namely SI-83, impaired cell viability, with a half-maximal inhibitory concentration of 12 mu M in nonstarved cells and a kinetic different from that known for the Src inhibitor PP2. Analysis by terminal deoxynucleotidyl transferase-mediated nick end labeling, Hoechst, and flow cytometric assay showed that SI-83 induced apoptosis in SaOS-2 cells. Moreover, SI-83, by inhibiting Src phosphorylation, decreased in vivo osteosarcoma tumor mass in a mouse model. Finally, SI-83 showed selectivity for osteosarcoma, since it had a far lower effect in primary human osteoblasts. These results show that human osteosarcoma. had Src-dependent proliferation and that modulation of Src activity may be a therapeutic target of this new compound with low toxicity for nonneoplastic cells.	[Spreafico, Adriano; Serchi, Tommaso; Orlandini, Maurizio; Magrini, David; Bernardini, Giulia; Di Stefano, Anna; Santucci, Annalisa] Univ Siena, Dipartimento Biol Mol, I-53100 Siena, Italy; [Spreafico, Adriano] Univ Siena, Dipartimento Med Clin & Sci Immunol, Policlin Le Scotte, I-53100 Siena, Italy; [Tintori, Cristina; Manetti, Fabrizio; Botta, Maurizio] Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy; [Collodel, Giulia] Univ Siena, Dipartimento Chirurg Sez Biol Applicat, Policlin Le Scotte, I-53100 Siena, Italy; [Schenone, Silvia] Univ Genoa, Dipartimento Sci Farmaceut, Genoa, Italy; [Angelucci, Adriano; Bologna, Mauro] Univ Aquila, Dipartimento Biol Base & Applicata, Coppito, Italy	University of Siena; University of Siena; University of Siena; University of Siena; University of Genoa; University of L'Aquila	Santucci, A (corresponding author), Univ Siena, Dipartimento Biol Mol, Via Fiorienta 1, I-53100 Siena, Italy.	santucci@unisi.it; botta@unisi.it; santucci@unisi.it	Orlandini, Maurizio/AAF-8247-2020; Bernardini, Giulia/ABG-2209-2020; Manetti, Fabrizio/Q-9412-2019; spreafico, adriano/AAL-6492-2020; collodel, giulia/AAW-5217-2021; Santucci, Annalisa/K-1932-2018; Spreafico, Adriano/K-2397-2018; Angelucci, Adriano/B-7134-2013	Orlandini, Maurizio/0000-0002-6112-4889; Bernardini, Giulia/0000-0003-0016-0728; Manetti, Fabrizio/0000-0002-9598-2339; collodel, giulia/0000-0003-1587-0159; Santucci, Annalisa/0000-0001-6976-9086; Spreafico, Adriano/0000-0002-8047-8666; Angelucci, Adriano/0000-0002-8755-1889; Serchi, Tommaso/0000-0003-2386-3514; BOLOGNA, Mauro/0000-0002-6306-6897	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Amling M, 2000, BONE, V27, P603, DOI 10.1016/S8756-3282(00)00373-2; Angelucci A, 2006, EUR J CANCER, V42, P2838, DOI 10.1016/j.ejca.2006.06.024; Angers-Loustau A, 2004, MOL CANCER RES, V2, P595; Azuma K, 2005, ONCOGENE, V24, P4754, DOI 10.1038/sj.onc.1208654; Bacci G, 2000, J CLIN ONCOL, V18, P4016, DOI 10.1200/JCO.2000.18.24.4016; Bondavalli F, 2002, J MED CHEM, V45, P4875, DOI 10.1021/jm0209580; Boyd DD, 2004, CLIN CANCER RES, V10, P1545, DOI 10.1158/1078-0432.CCR-1565-02; Bruland OS, 1997, EUR J CANCER, V33, P1725, DOI 10.1016/S0959-8049(97)00252-9; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Carraro F, 2006, J MED CHEM, V49, P1549, DOI 10.1021/jm050603r; Carraro F, 2004, J MED CHEM, V47, P1595, DOI 10.1021/jm034257u; Casas-Ganem J, 2005, CURR OPIN RHEUMATOL, V17, P79, DOI 10.1097/01.bor.0000146608.03927.16; Contri A, 2005, J CLIN INVEST, V115, P369, DOI 10.1172/JC1200522094; Daigo Y, 1999, CANCER RES, V59, P4222; Dass CR, 2006, CLIN EXP METASTAS, V23, P367, DOI 10.1007/s10585-006-9046-6; Diaz-Montero CM, 2006, EUR J CANCER, V42, P1491, DOI 10.1016/j.ejca.2006.03.007; Donnini S, 2007, INT J CANCER, V120, P995, DOI 10.1002/ijc.22410; Frediani B, 2004, BONE, V35, P859, DOI 10.1016/j.bone.2004.06.001; Fuchs B, 2007, GENE, V399, P137, DOI 10.1016/j.gene.2007.05.003; Golubovskaya VM, 2003, MOL CANCER RES, V1, P755; Gorlick R, 2003, CLIN CANCER RES, V9, P5442; Grimer RJ, 2005, LANCET ONCOL, V6, P85, DOI 10.1016/S1470-2045(05)01734-1; Hayden JB, 2006, ORTHOP CLIN N AM, V37, P1, DOI 10.1016/j.ocl.2005.06.004; KAOLAN KB, 1995, GENE DEV, V9, P1505; Lee M, 2004, J CELL BIOCHEM, V93, P629, DOI 10.1002/jcb.20215; Liu ZJ, 2004, J CLIN ENDOCR METAB, V89, P3503, DOI 10.1210/jc.2003-031917; Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005; Longo M, 2004, BONE, V34, P100, DOI 10.1016/j.bone.2003.09.007; Longo M, 2006, J MOL ENDOCRINOL, V37, P489, DOI 10.1677/jme.1.02055; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585-005-0365-9; Manara MC, 2006, MOL BIOL CELL, V17, P1910, DOI 10.1091/mbc.E05-10-0971; Manetti F, 2007, CHEMMEDCHEM, V2, P343, DOI 10.1002/cmdc.200600214; Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9-4-422; Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311; MCALLISTER RM, 1971, CANCER-AM CANCER SOC, V27, P397, DOI 10.1002/1097-0142(197102)27:2<397::AID-CNCR2820270224>3.0.CO;2-X; Missbach M, 1999, BONE, V24, P437, DOI 10.1016/S8756-3282(99)00020-4; Moasser MM, 1999, CANCER RES, V59, P6145; Nam JS, 2002, CLIN CANCER RES, V8, P2430; Nilbert M, 2000, CANCER GENET CYTOGEN, V121, P94, DOI 10.1016/S0165-4608(00)00226-0; Orimo H, 2006, MOL CELL BIOCHEM, V282, P101, DOI 10.1007/s11010-006-1520-6; Perez M, 2001, EUR J CANCER, V37, P629, DOI 10.1016/S0959-8049(00)00436-6; Recchia I, 2004, BONE, V34, P65, DOI 10.1016/j.bone.2003.06.004; Ren S, 2003, BIOCHEM BIOPH RES CO, V308, P120, DOI 10.1016/S0006-291X(03)01309-3; Schenone S, 2004, EUR J MED CHEM, V39, P939, DOI 10.1016/j.ejmech.2004.07.010; Schenone S, 2004, EUR J MED CHEM, V39, P153, DOI 10.1016/j.ejmech.2003.11.007; Schenone S, 2004, BIOORG MED CHEM LETT, V14, P2511, DOI 10.1016/j.bmcl.2004.03.013; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Shor AC, 2007, CANCER RES, V67, P2800, DOI 10.1158/0008-5472.CAN-06-3469; Spreafico A, 2006, PROTEOMICS, V6, P3520, DOI 10.1002/pmic.200500858; Susa M, 2000, DRUG NEWS PERSPECT, V13, P169, DOI 10.1358/dnp.2000.13.3.566664; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073	53	59	60	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1560	1571		10.1096/fj.07-9873com	http://dx.doi.org/10.1096/fj.07-9873com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18171692				2022-12-28	WOS:000255898700028
J	Talavera, K; Yasumatsu, K; Yoshida, R; Margolskee, RF; Voets, T; Ninomiya, Y; Nilius, B				Talavera, Karel; Yasumatsu, Keiko; Yoshida, Ryusuke; Margolskee, Robert F.; Voets, Thomas; Ninomiya, Yuzo; Nilius, Bernd			The taste transduction channel TRPM5 is a locus for bitter-sweet taste interactions	FASEB JOURNAL			English	Article						quinine; quinidine; taste mixture; gustatory nerve; sensary interaction	NONSELECTIVE CATION CHANNEL; CHORDA TYMPANI NERVE; RECEPTOR-CELLS; MIXTURE INTERACTIONS; SIGNAL-TRANSDUCTION; ION-CHANNEL; RAPID ENTRY; RESPONSES; SUPPRESSION; STIMULI	Ordinary gustatory experiences, which are usually evoked by taste mixtures, are determined by multiple interactions between different taste stimuli. The most studied model for these gustatory interactions is the suppression of the responses to sweeteners by the prototype bitter compound quinine. Here we report that TRPM5, a cation channel involved in sweet taste transduction, is inhibited by quinine (EC50=50 mu M at -50 mV) owing to a decrease in the maximal whole-cell TRPM5 conductance and an acceleration of channel closure. Notably, quinine inhibits the gustatory responses of sweet-sensitive gustatory nerves in wildtype (EC50=similar to 1.6 mM) but not in Trpm5 knockout mice. Quinine induces a dose- and time-dependent inhibition of TRPM5-dependent responses of single sweet-sensitive fibers to sucrose, according to the restricted diffusion of the drug into the taste tissue. Quinidine, the stereoisomer of quinine, has similar effects on TRPM5 currents and on sweet-induced gustatory responses. In contrast, the chemically unrelated bitter compound denatonium benzoate has an similar to 100-fold weaker effect on TRPM5 currents and, accordingly, at 10 mM it does not alter gustatory responses to sucrose. The inhibition of TRPM5 by bitter compounds constitutes the molecular basis of a novel mechanism of taste interactions, whereby the bitter tastant inhibits directly the sweet transduction pathway.	[Talavera, Karel; Voets, Thomas; Nilius, Bernd] Katholieke Univ Leuven, Dept Mol Cell Biol, Lab Ion Channel Res, B-3000 Louvain, Belgium; [Yasumatsu, Keiko; Yoshida, Ryusuke; Ninomiya, Yuzo] Kyushu Univ, Grad Sch Dent Sci, Sect Oral Neurosci, Fukuoka 812, Japan; [Margolskee, Robert F.] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA	KU Leuven; Kyushu University; Icahn School of Medicine at Mount Sinai	Talavera, K (corresponding author), Katholieke Univ Leuven, Dept Mol Cell Biol, Lab Ion Channel Res, Herests 49,Campus Gasthuisberg,O&N1, B-3000 Louvain, Belgium.	karel.talavera@med.kuleuven.be	Voets, Thomas/AAD-4389-2019; Talavera, Karel/K-7990-2014; Voets, Thomas/E-2466-2012	Voets, Thomas/0000-0001-5526-5821; Talavera, Karel/0000-0002-3124-138X; Voets, Thomas/0000-0001-5526-5821; Margolskee, Robert/0000-0002-9572-2887				BARTOSHUK LM, 1975, PHYSIOL BEHAV, V14, P643, DOI 10.1016/0031-9384(75)90193-6; CALVINO AM, 1986, PHYSIOL BEHAV, V36, P1021, DOI 10.1016/0031-9384(86)90474-9; CALVINO AM, 1991, PERCEPT MOTOR SKILL, V73, P1216, DOI 10.2466/PMS.73.8.1216-1216; COOK DI, 1990, J MEMBRANE BIOL, V114, P37, DOI 10.1007/BF01869383; Damak S, 2006, CHEM SENSES, V31, P253, DOI 10.1093/chemse/bjj027; DeSimone JA, 2000, AM J PHYSIOL-CELL PH, V278, pC13, DOI 10.1152/ajpcell.2000.278.1.C13; Dinehart ME, 2006, PHYSIOL BEHAV, V87, P304, DOI 10.1016/j.physbeh.2005.10.018; Formaker BK, 1997, BRAIN RES, V772, P239, DOI 10.1016/S0006-8993(97)00845-7; Formaker BK, 1996, BRAIN RES, V727, P79; Frank ME, 2005, BRAIN RES BULL, V66, P70, DOI 10.1016/j.brainresbull.2005.04.004; Frank ME, 2003, BEHAV NEUROSCI, V117, P228, DOI 10.1037/0735-7044.117.2.228; Hofmann T, 2003, CURR BIOL, V13, P1153, DOI 10.1016/S0960-9822(03)00431-7; Huang YJ, 2007, P NATL ACAD SCI USA, V104, P6436, DOI 10.1073/pnas.0611280104; Kaske S, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-49; Kawai K, 2000, P NATL ACAD SCI USA, V97, P11044, DOI 10.1073/pnas.190066697; Keast RSJ, 2007, CHEM SENSES, V32, P245, DOI 10.1093/chemse/bjl052; LAWLESS H, 1982, PHYSIOL BEHAV, V29, P149, DOI 10.1016/0031-9384(82)90379-1; LAWLESS HT, 1979, J COMP PHYSIOL PSYCH, V93, P538, DOI 10.1037/h0077582; LAWLESS HT, 1977, SENS PROCESS, V1, P227; Liman E. R., 2007, V179, P287; Lin W, 2007, P NATL ACAD SCI USA, V104, P2471, DOI 10.1073/pnas.0610201104; Lindemann B, 2001, NATURE, V413, P219, DOI 10.1038/35093032; Liu D, 2003, P NATL ACAD SCI USA, V100, P15160, DOI 10.1073/pnas.2334159100; Liu D, 2005, J BIOL CHEM, V280, P20691, DOI 10.1074/jbc.M414072200; Malik VS, 2006, AM J CLIN NUTR, V84, P274; Margolskee RF, 2002, J BIOL CHEM, V277, P1, DOI 10.1074/jbc.R100054200; MOSKOWITZ HR, 1972, PERCEPT PSYCHOPHYS, V11, P257, DOI 10.3758/BF03210374; Nilius B, 2006, EMBO J, V25, P467, DOI 10.1038/sj.emboj.7600963; Nilius B, 2004, J PHYSIOL-LONDON, V560, P753, DOI 10.1113/jphysiol.2004.070839; Ogawa K, 1997, BRAIN RES, V769, P263, DOI 10.1016/S0006-8993(97)00729-4; OHRWALL H, 2006, SKAND ARCH PHYSL, V2, P1; Oike H, 2006, BBA-MOL CELL BIOL L, V1761, P1078, DOI 10.1016/j.bbalip.2006.07.005; Perez CA, 2002, NAT NEUROSCI, V5, P1169, DOI 10.1038/nn952; Peri I, 2000, AM J PHYSIOL-CELL PH, V278, pC17, DOI 10.1152/ajpcell.2000.278.1.C17; Prawitt D, 2003, P NATL ACAD SCI USA, V100, P15166, DOI 10.1073/pnas.2334624100; Prescott J, 2001, CHEM SENSES, V26, P993, DOI 10.1093/chemse/26.8.993; Romanov RA, 2007, EMBO J, V26, P657, DOI 10.1038/sj.emboj.7601526; Sanchez-Chapula JA, 2003, MOL PHARMACOL, V63, P1051, DOI 10.1124/mol.63.5.1051; SCHIFFERSTEIN HN, 2003, HDB OLFACTION GUSTAT; SCHLICHTER LC, 1992, CAN J PHYSIOL PHARM, V70, P247, DOI 10.1139/y92-031; Simon SA, 2006, NAT REV NEUROSCI, V7, P890, DOI 10.1038/nrn2006; SMITH DV, 1994, PHYSIOL BEHAV, V56, P1189, DOI 10.1016/0031-9384(94)90365-4; SPIELMAN AI, 1992, SOC GEN PHY, V47, P307; STEVENS JC, 1995, PERCEPT PSYCHOPHYS, V57, P18, DOI 10.3758/BF03211846; Stevens JC, 1996, CHEM SENSES, V21, P211, DOI 10.1093/chemse/21.2.211; STURGESS NC, 1987, PFLUG ARCH EUR J PHY, V409, P607, DOI 10.1007/BF00584661; Sugita M, 2006, CELL MOL LIFE SCI, V63, P2000, DOI 10.1007/s00018-006-6100-0; Talavera K, 2005, NATURE, V438, P1022, DOI 10.1038/nature04248; TRAVERS SP, 1984, J GEN PHYSIOL, V84, P221, DOI 10.1085/jgp.84.2.221; Ullrich ND, 2005, CELL CALCIUM, V37, P267, DOI 10.1016/j.ceca.2004.11.001; Vandenbeuch A, 2004, NEUROSCI LETT, V358, P137, DOI 10.1016/j.neulet.2004.01.013; VOGT MB, 1993, J NEUROPHYSIOL, V69, P658, DOI 10.1152/jn.1993.69.3.658; Zhang YF, 2003, CELL, V112, P293, DOI 10.1016/S0092-8674(03)00071-0; Zhang Z, 2007, J NEUROSCI, V27, P5777, DOI 10.1523/JNEUROSCI.4973-06.2007	54	65	66	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1343	1355		10.1096/fj.07-9591com	http://dx.doi.org/10.1096/fj.07-9591com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18070821	Green Accepted			2022-12-28	WOS:000255898700008
J	Limmon, GV; Arredouani, M; McCann, KL; Minor, RAC; Kobzik, L; Imani, F				Limmon, Gino V.; Arredouani, Mohamed; McCann, Kelly L.; Minor, Radiah A. Corn; Kobzik, Lester; Imani, Farhad			Scavenger receptor class-A is a novel cell surface receptor for double-stranded RNA	FASEB JOURNAL			English	Article						lung; epithelium; inflammation; virus infection	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; HUMAN EPITHELIAL-CELLS; DENSITY-LIPOPROTEIN; BINDING-SITE; LIPID UPTAKE; VIRAL-RNA; SR-AI/II; VIRUS; PKR	Double-stranded RNA (dsRNA) is a potent signal to the host immune system for the presence of an ongoing viral infection. The presence of dsRNA, intracellularly or extracellularly, leads to the induction of innate inflammatory cytokines in many cell types including epithelial cells. However, the cell surface receptor for recognition of extracellular dsRNA is not yet determined. Here, we report that extracellular dsRNA is recognized and internalized by scavenger receptor class-A (SR-A). Treatment of human epithelial cells with specific antagonists of SR-A or with an anti-SR-A antibody significantly inhibited dsRNA induction of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-8, and regulated on activation normal T-cell expressed and secreted (RANTES). Furthermore, intranasal dsRNA treatment of SR-A-deficient (SR-A(-/-)) mice showed a significant decrease in the expression of inflammatory cytokines and a corresponding decrease in the accumulation of polymorphonuclear leukocytes (PMNs) in lungs. These data provide direct evidence that SR-A is a novel cell surface receptor for dsRNA, and therefore, SR-A may play a role in antiviral immune responses.-Limmon, G. V., Arredouani, M., McCann, K. L., Corn Minor, R. A., Kobzik, L., Imani, L. Scavenger receptor class-A is a novel cell surface receptor for double-stranded RNA.	[Limmon, Gino V.; McCann, Kelly L.; Minor, Radiah A. Corn; Imani, Farhad] NIEHS, NIH, Lab Resp Biol, Durham, NC 27709 USA; [Arredouani, Mohamed; Kobzik, Lester] Harvard Univ, Dept Environm Hlth, Cambridge, MA 02138 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Harvard University	Imani, F (corresponding author), NIEHS, NIH, Lab Resp Biol, MD 2-01,111 T-W Alexander Dr, Durham, NC 27709 USA.	imani@niehs.nih.gov	Limmon, Gino/X-5913-2019; minor, radiah AC/B-6412-2012	Limmon, Gino/0000-0003-3030-7022; 	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101784, ZIAES101784] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arredouani MS, 2006, AM J RESP CELL MOL, V35, P474, DOI 10.1165/rcmb.2006-0128OC; Blair LA, 2002, J BIOL CHEM, V277, P359, DOI 10.1074/jbc.M109819200; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; DECKER T, 1992, J INTERFERON RES, V12, P445, DOI 10.1089/jir.1992.12.445; DECLERCQ E, 1969, NATURE, V222, P1148, DOI 10.1038/2221148a0; DOUKAS J, 1994, AM J PATHOL, V145, P137; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Genin P, 2000, J IMMUNOL, V164, P5352, DOI 10.4049/jimmunol.164.10.5352; Gern JE, 2003, AM J RESP CELL MOL, V28, P731, DOI 10.1165/rcmb.2002-0055OC; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Hiscott J, 2003, ANN NY ACAD SCI, V1010, P237, DOI 10.1196/annals.1299.042; IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Jiang Y, 2006, J BIOL CHEM, V281, P9058, DOI 10.1074/jbc.M507874200; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Jozefowski S, 2005, J IMMUNOL, V175, P8032, DOI 10.4049/jimmunol.175.12.8032; Jozefowski S, 2006, J LEUKOCYTE BIOL, V80, P870, DOI 10.1189/jlb.0705357; KOLIAIS SI, 1981, EXPERIENTIA, V37, P971, DOI 10.1007/BF01971785; Konno S, 2002, AM J RESP CELL MOL, V26, P594, DOI 10.1165/ajrcmb.26.5.4438; Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; LEE JY, 1994, VIROLOGY, V200, P307, DOI 10.1006/viro.1994.1192; Lin RT, 1999, MOL CELL BIOL, V19, P959; Liu B, 2002, J BIOL CHEM, V277, P34125, DOI 10.1074/jbc.M204265200; Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307; Majde JA, 1998, ARCH VIROL, V143, P2371, DOI 10.1007/s007050050467; Meusel TR, 2003, J IMMUNOL, V171, P3768, DOI 10.4049/jimmunol.171.7.3768; Meusel TR, 2002, J IMMUNOL, V168, P6429, DOI 10.4049/jimmunol.168.12.6429; Moore KJ, 2006, ARTERIOSCL THROM VAS, V26, P1702, DOI 10.1161/01.ATV.0000229218.97976.43; Murphy JE, 2005, ATHEROSCLEROSIS, V182, P1, DOI 10.1016/j.atherosclerosis.2005.03.036; Palecanda A, 1999, J EXP MED, V189, P1497, DOI 10.1084/jem.189.9.1497; Paludan SR, 2002, EUR CYTOKINE NETW, V13, P306; Peiser L, 2001, MICROBES INFECT, V3, P149, DOI 10.1016/S1286-4579(00)01362-9; Sen GC, 2005, CYTOKINE GROWTH F R, V16, P1, DOI 10.1016/j.cytogfr.2005.01.006; Stringer B, 1996, EXP LUNG RES, V22, P495, DOI 10.3109/01902149609046038; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Wyatt TA, 2005, ALCOHOL, V36, P31, DOI 10.1016/j.alcohol.2005.06.002; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zhou HR, 2003, TOXICOL SCI, V74, P335, DOI 10.1093/toxsci/kfg148	45	114	115	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					159	167		10.1096/fj.07-8348com	http://dx.doi.org/10.1096/fj.07-8348com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17709607				2022-12-28	WOS:000252309900019
J	Piontek, J; Winkler, L; Wolburg, H; Muller, SL; Zuleger, N; Piehl, C; Wiesner, B; Krause, G; Blasig, IE				Piontek, Joerg; Winkler, Lars; Wolburg, Hartwig; Mueller, Sebastian L.; Zuleger, Nikolaj; Piehl, Christian; Wiesner, Burkhard; Krause, Gerd; Blasig, Ingolf E.			Formation of tight junction: determinants of homophilic interaction between classic claudins	FASEB JOURNAL			English	Article						transmembrane protein; protein-protein interaction; cell-cell contacts; freeze-fracturing; FRET	BLOOD-BRAIN-BARRIER; PARACELLULAR CONDUCTANCE; SELECTIVE DECREASE; CHARGE SELECTIVITY; EXPRESSION; STRANDS; CATION; CONSTITUTES; MODULATION; OCCLUDIN	Claudins are the critical transmembrane proteins in tight junctions. Claudin-5, for instance, prevents paracellular permeation of small molecules. However, the molecular interaction mechanism is unknown. Hence, the claudin-claudin interaction and tight junction strand formation were investigated using systematic single mutations. Claudin-5 mutants transfected into tight junction-free cells demonstrated that the extracellular loop 2 is involved in strand formation via trans-interaction, but not via polymerization, along the plasma membrane of one cell. Three phenotypes were obtained: the tight junction type (wild-type-like trans-and cis-interaction; the disjunction type (blocked trans-interaction); the intracellular type (disturbed folding). Combining site-directed mutagenesis, live-cell imaging, electron microscopy-, and molecular modeling data led to an antiparallel homodimer homology model of the loop. These data for the first time explain how two claudins hold onto each other and constrict the paracellular space. The intermolecular interface includes aromatic (F147, Y148, Y158) and hydrophilic (Q156, E159) residues. The aromatic residues form a strong binding core between two loops from opposing cells. Since nearly all these residues are conserved in most claudins, our findings are of general relevance for all classical claudins. On the basis of the data we have established a novel molecular concept for tight junction formation. -Piontek, J., Winkler, L., Wolburg, H., Muller, S. L., Zuleger, N., Piehl, C., Wiesner, B., Krause, G., Blasig, I. E. Formation of tight junction: determinants of homophilic interaction between classic claudins.	[Piontek, Joerg; Winkler, Lars; Mueller, Sebastian L.; Zuleger, Nikolaj; Piehl, Christian; Wiesner, Burkhard; Krause, Gerd; Blasig, Ingolf E.] Leibniz Inst Mol Pharmacol, D-13125 Berlin, Germany; [Wolburg, Hartwig] Univ Tubingen, Inst Pathol, D-7400 Tubingen, Germany	Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP); Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Krause, G (corresponding author), Leibniz Inst Mol Pharmacol, Robert Rossle Str 10, D-13125 Berlin, Germany.	gkrause@fmp-berlin.de	Horstmann, Britta/C-2154-2008; Winkler, Lars/M-6134-2014; Piontek, Joerg/K-6305-2013; Piontek, Joerg/F-8549-2011; Winkler, Lars/D-1949-2012	Winkler, Lars/0000-0003-3350-1189; Piontek, Joerg/0000-0002-0880-8915; Piehl, Christian/0000-0002-1054-0081				Ahrens T, 2002, J BIOL CHEM, V277, P19455, DOI 10.1074/jbc.M200606200; Amasheh S, 2002, J CELL SCI, V115, P4969, DOI 10.1242/jcs.00165; Ben-Yosef T, 2003, HUM MOL GENET, V12, P2049, DOI 10.1093/hmg/ddg210; Blasig IE, 2006, CELL MOL LIFE SCI, V63, P505, DOI 10.1007/s00018-005-5472-x; Bross P, 1999, HUM MUTAT, V14, P186, DOI 10.1002/(SICI)1098-1004(1999)14:3<186::AID-HUMU2>3.0.CO;2-J; Colegio OR, 2003, AM J PHYSIOL-CELL PH, V284, pC1346, DOI 10.1152/ajpcell.00547.2002; Coyne CB, 2003, AM J PHYSIOL-LUNG C, V285, pL1166, DOI 10.1152/ajplung.00182.2003; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Deschenes SM, 1997, J NEUROSCI, V17, P9077; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Hou JH, 2005, J CELL SCI, V118, P5109, DOI 10.1242/jcs.02631; Ikenouchi J, 2005, J CELL BIOL, V171, P939, DOI 10.1083/jcb.200510043; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Kausalya PJ, 2006, J CLIN INVEST, V116, P878, DOI 10.1172/JCI26323; Liebner S, 2000, EUR J CELL BIOL, V79, P707, DOI 10.1078/0171-9335-00101; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; Mack AF, 2006, BRAIN RES, V1103, P25, DOI 10.1016/j.brainres.2006.04.135; Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Sasaki H, 2003, P NATL ACAD SCI USA, V100, P3971, DOI 10.1073/pnas.0630649100; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464; Van Itallie CM, 2003, AM J PHYSIOL-RENAL, V285, pF1078, DOI 10.1152/ajprenal.00116.2003; Van Itallie CM, 2004, PHYSIOLOGY, V19, P331, DOI 10.1152/physiol.00027.2004; Waters ML, 2004, BIOPOLYMERS, V76, P435, DOI 10.1002/bip.20144; Wen HJ, 2004, MOL CELL BIOL, V24, P8408, DOI 10.1128/MCB.24.19.8408-8417.2004; WOLBURG H, 1994, J CELL SCI, V107, P1347; Wu J, 2006, PROTEINS, V65, P808, DOI 10.1002/prot.21218; Wuller S, 2004, J BIOL CHEM, V279, P47254, DOI 10.1074/jbc.M408154200; Yon C, 2005, J BIOL CHEM, V280, P27412, DOI 10.1074/jbc.M501393200; Yu ASL, 2003, J BIOL CHEM, V278, P17350, DOI 10.1074/jbc.M213286200	37	291	298	0	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					146	158		10.1096/fj.07-8319com	http://dx.doi.org/10.1096/fj.07-8319com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17761522				2022-12-28	WOS:000252309900018
J	Hammer, MM; Wehrman, TS; Blau, HM				Hammer, Mark M.; Wehrman, Tom S.; Blau, Helen M.			A novel enzyme complementation-based assay for monitoring G-protein-coupled receptor internalization	FASEB JOURNAL			English	Article						GPCR signaling; ligand binding; high-throughput screening	CELLS; ENDOCYTOSIS; FUSION; SPECIFICITY; ACTIVATION; BINDING; SYSTEM; MUSCLE; GENE; RAT	G-protein-coupled receptor ( GPCR) signaling is involved in a wide range of physiological processes and diseases, and around one- half of currently used drugs target GPCRs. Assays for the signaling of GPCRs have suffered from drawbacks, including low signal- to- noise, temporally transient signals, and difficulty in applying a single assay to a wide range of GPCRs. We have developed a set of assays for G-protein-coupled receptor signaling based on beta-galactosidase enzyme complementation in live mammalian cells. We previously described an assay for GPCR activation by monitoring the binding of beta-arrestin to the receptor. Here we describe a second assay that monitors the internalization of GPCRs to endosomes, an event that follows receptor activation and is critical in desensitizing and resensitizing the receptor. We show that both assays display high signal- to- noise ratios with low variability and are quantitative for a wide range of GPCRs. EC(50)s obtained with these assays closely match results reported in the literature. Finally, we show that these assays are readily adapted to high- throughput chemical screens. Thus, these two assays for monitoring G- protein- coupled receptor activation and internalization should prove valuable in basic biological studies as well as in high- throughput screens.	DiscoverRx Corp, Fremont, CA USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Baxter Lab Genet Pharmacol, Stanford, CA USA	Stanford University	Blau, HM (corresponding author), Baxter Lab, CCSR 4215, 269 Campus Dr, Stanford, CA 94305 USA.	hblau@stanford.edu	Hammer, Mark/AAR-9625-2020	Hammer, Mark/0000-0002-1700-7984	NIA NIH HHS [AG024987, AG020961, AG009521, T32 AG0259] Funding Source: Medline; NICHD NIH HHS [HD018179] Funding Source: Medline; NIGMS NIH HHS [T32 GM08412] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG009521, R01AG020961, R01AG009521, T32AG000259, R01AG024987] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Blakely BT, 2000, NAT BIOTECHNOL, V18, P218, DOI 10.1038/72686; Blatner NR, 2004, J BIOL CHEM, V279, P53818, DOI 10.1074/jbc.M408408200; Borgland SL, 2003, J BIOL CHEM, V278, P18776, DOI 10.1074/jbc.M300525200; Charlton CA, 2000, DEV BIOL, V221, P112, DOI 10.1006/dbio.2000.9654; Charlton CA, 1997, J CELL BIOL, V138, P331, DOI 10.1083/jcb.138.2.331; Conchon S, 1997, J BIOL CHEM, V272, P25566, DOI 10.1074/jbc.272.41.25566; Davis P.B., 1990, AM J PHYSIOL, V258, P71; Evans NA, 2001, J NEUROCHEM, V77, P476, DOI 10.1046/j.1471-4159.2001.00269.x; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Haasen D, 2006, METHOD ENZYMOL, V414, P121, DOI 10.1016/S0076-6879(06)14008-2; Mohler WA, 1996, P NATL ACAD SCI USA, V93, P12423, DOI 10.1073/pnas.93.22.12423; Penn RB, 2001, J BIOL CHEM, V276, P32648, DOI 10.1074/jbc.M104143200; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; RAGGENBASS M, 1989, P NATL ACAD SCI USA, V86, P750, DOI 10.1073/pnas.86.2.750; Ridley SH, 2001, J CELL SCI, V114, P3991; Rossi F, 1997, P NATL ACAD SCI USA, V94, P8405, DOI 10.1073/pnas.94.16.8405; Seet LF, 2001, J BIOL CHEM, V276, P42445, DOI 10.1074/jbc.M105917200; ULLMANN A, 1967, J MOL BIOL, V24, P339, DOI 10.1016/0022-2836(67)90341-5; van Koppen CJ, 2004, MOL PHARMACOL, V66, P365, DOI 10.1124/mol.104.003822; VASILE E, 1983, J CELL BIOL, V96, P1677, DOI 10.1083/jcb.96.6.1677; VONDEGENFELD G, 2007, FASEB J, V21; Wangemann P, 1999, J MEMBRANE BIOL, V170, P67, DOI 10.1007/s002329900538; Wehrman TS, 2006, P NATL ACAD SCI USA, V103, P19063, DOI 10.1073/pnas.0605218103; Wehrman T, 2007, NEURON, V53, P25, DOI 10.1016/j.neuron.2006.09.034; Wehrman TS, 2005, NAT METHODS, V2, P521, DOI 10.1038/NMETH771; Wolkers WF, 2003, BBA-BIOMEMBRANES, V1612, P154, DOI 10.1016/S0005-2736(03)00114-7; Yan YX, 2002, J BIOMOL SCREEN, V7, P451, DOI 10.1177/108705702237677; Yang JT, 1996, J CELL BIOL, V135, P829, DOI 10.1083/jcb.135.3.829	28	26	27	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2007	21	14					3827	3834		10.1096/fj.07-8777com	http://dx.doi.org/10.1096/fj.07-8777com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17942829				2022-12-28	WOS:000251283500007
J	Li, WQ; Wu, G; Wan, Y				Li, Wenqi; Wu, George; Wan, Yong			The dual effects of Cdh1/APC in myogenesis	FASEB JOURNAL			English	Article						Skp2; Myf5; ubiquitylation and muscle differentiation	ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE WITHDRAWAL; SKELETAL-MUSCLE DIFFERENTIATION; UBIQUITIN LIGASE; DESTRUCTION BOX; MYOBLAST DIFFERENTIATION; PROLIFERATING MYOBLASTS; MAMMALIAN-CELLS; FACTOR MYF5; DNA-DAMAGE	Ubiquitin-dependent proteolysis plays an important role in regulating fundamental biological functions, including cell division and cellular differentiation. Previous studies implicate the ubiquitin-proteasome system ( UPS) in myogenic differentiation through regulating cell cycle progression and modulating myogenic factors such as MyoD and Myf5. Certain ubiquitin protein ligases, including the SCF complex and APC, have been suggested to govern terminal muscle differentiation. However, the underlying mechanism of regulation of both the cell cycle and myogenic factors by the UPS during this process remains unclear. We have dissected the role of the UPS in myogenic differentiation using an in vitro muscle differentiation system based on C2C12 cells. We demonstrate that Cdh1-APC regulates two critical proteins, Skp2 and Myf5, for proteolysis during muscle differentiation. The targeting of Skp2 by Cdh1-APC for destruction results in elevation of p21 and p27, which are crucial for coordinating cellular division and differentiation. Degradation of Myf5 by Cdh1-APC facilitates myogenic fusion. Knockdown of Cdh1 by siRNA significantly attenuates muscle differentiation. Taken together, Cdh1- APC is an important ubiquitin E3 ligase that modulates muscle differentiation through coordinating cell cycle progression and initiating the myogenic differentiation program.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wan, Y (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Ste 2-6C,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	yow4@pitt.edu			NCI NIH HHS [CA115943] Funding Source: Medline; NIGMS NIH HHS [GM070681] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA115943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM070681] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amack JD, 2001, HUM MOL GENET, V10, P1879, DOI 10.1093/hmg/10.18.1879; Ashe M, 2004, J BIOL CHEM, V279, P664, DOI 10.1074/jbc.M308810200; Ayad NG, 2003, CELL, V113, P101, DOI 10.1016/S0092-8674(03)00232-0; Bailey P, 2001, CURR OPIN CELL BIOL, V13, P679, DOI 10.1016/S0955-0674(00)00271-4; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Bowerman B, 2006, DEVELOPMENT, V133, P773, DOI 10.1242/dev.02276; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burton JL, 2005, MOL CELL, V18, P533, DOI 10.1016/j.molcel.2005.04.022; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen Z, 2006, MOL VIS, V12, P983; Delfini MC, 2000, DEVELOPMENT, V127, P5213; Delgado I, 2003, GENOMICS, V82, P109, DOI 10.1016/S0888-7543(03)00104-6; DeRenzo C, 2004, TRENDS CELL BIOL, V14, P420, DOI 10.1016/j.tcb.2004.07.005; Dyer MA, 2001, NAT REV NEUROSCI, V2, P333, DOI 10.1038/35072555; Epting CL, 2004, J CELL SCI, V117, P6185, DOI 10.1242/jcs.01548; Erbay E, 2001, J BIOL CHEM, V276, P36079, DOI 10.1074/jbc.C100406200; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Finley Daniel, 2004, Cell, VS116, pS29, DOI 10.1016/S0092-8674(03)00971-1; Gardrat F, 1997, MOL BIOL REP, V24, P77, DOI 10.1023/A:1006877214153; Gieffers C, 1999, P NATL ACAD SCI USA, V96, P11317, DOI 10.1073/pnas.96.20.11317; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Jackson PK, 2004, TRENDS CELL BIOL, V14, P331, DOI 10.1016/j.tcb.2004.05.005; Joazeiro CAP, 2006, CANCER RES, V66, P7840, DOI 10.1158/0008-5472.CAN-06-2033; Kitzmann M, 2001, CELL MOL LIFE SCI, V58, P571, DOI 10.1007/PL00000882; Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712; Kraft C, 2005, MOL CELL, V18, P543, DOI 10.1016/j.molcel.2005.04.023; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lindon C, 2000, MOL CELL BIOL, V20, P8923, DOI 10.1128/MCB.20.23.8923-8932.2000; Lindon C, 1998, J CELL BIOL, V140, P111, DOI 10.1083/jcb.140.1.111; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Nastasi T, 2004, DEV CELL, V6, P269, DOI 10.1016/S1534-5807(04)00020-6; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pownall ME, 2002, ANNU REV CELL DEV BI, V18, P747, DOI 10.1146/annurev.cellbio.18.012502.105758; Puente LG, 2006, MOL CELL PROTEOMICS, V5, P2244, DOI 10.1074/mcp.M600134-MCP200; Qi W, 2007, J BIOL CHEM, V282, P3672, DOI 10.1074/jbc.M609376200; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Sabourin LA, 1999, J CELL BIOL, V144, P631, DOI 10.1083/jcb.144.4.631; Schmidt A, 2005, GENE DEV, V19, P502, DOI 10.1101/gad.320705; Shen X, 2003, DEV DYNAM, V226, P128, DOI 10.1002/dvdy.10200; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Tamamori-Adachi M, 2004, J BIOL CHEM, V279, P50429, DOI 10.1074/jbc.M403084200; Tannu NS, 2004, MOL CELL PROTEOMICS, V3, P1065, DOI 10.1074/mcp.M400020-MCP200; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Vodermaier HC, 2004, CURR BIOL, V14, pR787, DOI 10.1016/j.cub.2004.09.020; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wan Y, 2001, P NATL ACAD SCI USA, V98, P13066, DOI 10.1073/pnas.231487598; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang W, 2005, BIOCHEMISTRY-US, V44, P14553, DOI 10.1021/bi051071j; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wirth KG, 2004, GENE DEV, V18, P88, DOI 10.1101/gad.285404; Yamano H, 2004, MOL CELL, V13, P137, DOI 10.1016/S1097-2765(03)00480-5; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	62	30	31	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3606	3617		10.1096/fj.07-8159com	http://dx.doi.org/10.1096/fj.07-8159com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17601983				2022-12-28	WOS:000250517800023
J	Scheele, C; Nielsen, AR; Walden, TB; Sewell, DA; Fischer, CP; Brogan, RJ; Petrovic, N; Larsson, O; Tesch, PA; Wennmalm, K; Hutchinson, DS; Cannon, B; Wahlestedt, C; Pedersen, BK; Timmons, JA				Scheele, Camilla; Nielsen, Anders Rinnov; Walden, Tomas B.; Sewell, Dean A.; Fischer, Christian P.; Brogan, Robert J.; Petrovic, Natasa; Larsson, Ola; Tesch, Per A.; Wennmalm, Kristian; Hutchinson, Dana S.; Cannon, Barbara; Wahlestedt, Claes; Pedersen, Bente K.; Timmons, James A.			Altered regulation of the PINK1 locus: a link between type 2 diabetes and neurodegeneration?	FASEB JOURNAL			English	Article						metabolism; inactivity; mitochondria; alteredgene regulation	GLYCATION END-PRODUCTS; SKELETAL-MUSCLE MASS; GENE-EXPRESSION; ADIPOSE-TISSUE; MITOCHONDRIAL DYSFUNCTION; INSULIN-RESISTANCE; PHYSICAL-ACTIVITY; IN-VIVO; DISEASE; RECEPTOR	Mutations in PINK1 cause the mitochondrial-related neurodegenerative disease Parkinson's. Here we investigate whether obesity, type 2 diabetes, or inactivity alters transcription from the PINK1 locus. We utilized a cDNA-array and quantitative real-time PCR for gene expression analysis of muscle from healthy volunteers following physical inactivity, and muscle and adipose tissue from nonobese or obese subjects with normal glucose tolerance or type 2 diabetes. Functional studies of PINK1 were performed utilizing RNA interference in cell culture models. Following inactivity, the PINK1 locus had an opposing regulation pattern ( PINK1 was down-regulated while natural antisense PINK1 was up-regulated). In type 2 diabetes skeletal muscle, all transcripts from the PINK1 locus were suppressed and gene expression correlated with diabetes status. RNA interference of PINK1 in human neuronal cell lines impaired basal glucose uptake. In adipose tissue, mitochondrial gene expression correlated with PINK1 expression although remained unaltered following siRNA knockdown of Pink1 in primary cultures of brown preadipocytes. In conclusion, regulation of the PINK1 locus, previously linked to neurodegenerative disease, is altered in obesity, type 2 diabetes and inactivity, while the combination of RNAi experiments and clinical data suggests a role for PINK1 in cell energetics rather than in mitochondrial biogenesis.	Karolinska Inst, Ctr Genom & Bioinformat, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; Univ Copenhagen, Rigshosp, Ctr Inflammat & Metab, DK-2100 Copenhagen, Denmark; Univ Stockholm, Wenner Gren Inst, Arrhenius Labs, S-11345 Stockholm, Sweden; Heriot Watt Univ, Sch Life Sci, Edinburgh, Midlothian, Scotland; Monash Univ, Dept Pharmacol, Clayton, Vic 3168, Australia; Scripps Res Inst, Dept Biochem, Jupiter, FL USA	Karolinska Institutet; Rigshospitalet; University of Copenhagen; Stockholm University; Heriot Watt University; Monash University; Scripps Research Institute	Timmons, JA (corresponding author), Karolinska Inst, Ctr Genom & Bioinformat, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden.	j.timmons@hw.ac.uk	Larsson, Ola/F-8151-2013; Timmons, James A/J-4698-2014; Scheele, Camilla/AAA-3599-2020; Wahlestedt, Claes/A-7039-2009; Pedersen, Bente Klarlund/AGR-3217-2022; Sewell, Dean A./C-3500-2009; Hutchinson, Dana/K-3795-2012; Timmons, James A/M-6350-2019; Cannon, Barbara/B-3089-2016	Timmons, James A/0000-0002-2255-1220; Scheele, Camilla/0000-0002-6055-9709; Pedersen, Bente Klarlund/0000-0001-6508-6288; Timmons, James A/0000-0002-2255-1220; Rinnov, Anders Rasmussen/0000-0003-3859-3289; Cannon, Barbara/0000-0001-6594-2363; Fischer, Christian/0000-0002-0657-9143; Hutchinson, Dana/0000-0001-9947-0106; Larsson, Ola/0000-0003-1412-1308				Abou-Sleiman PM, 2006, NAT REV NEUROSCI, V7, P207, DOI 10.1038/nrn1868; Asmann YW, 2006, DIABETES, V55, P3309, DOI 10.2337/db05-1230; Astrand PO, 2003, TXB WORK PHYSL PHYSL, V4th; Basta G, 2004, CARDIOVASC RES, V63, P582, DOI 10.1016/j.cardiores.2004.05.001; Beilina A, 2005, P NATL ACAD SCI USA, V102, P5703, DOI 10.1073/pnas.0500617102; BERG HE, 1993, CLIN PHYSIOL, V13, P337, DOI 10.1111/j.1475-097X.1993.tb00334.x; BERG HE, 1991, J APPL PHYSIOL, V70, P1882, DOI 10.1152/jappl.1991.70.4.1882; BERGSTROM J, 1966, SCAND J CLIN LAB INV, V18, P16, DOI 10.3109/00365516609065602; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Bucciarelli LG, 2002, CELL MOL LIFE SCI, V59, P1117, DOI 10.1007/s00018-002-8491-x; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Carey AL, 2006, DIABETOLOGIA, V49, P1000, DOI 10.1007/s00125-006-0178-7; Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779; FISCHER CP, 2006, SCAND J MED SCI SPOR, DOI DOI 10.1111/J.1066-0830.2006.00602.X; Gallagher D, 1997, J APPL PHYSIOL, V83, P229, DOI 10.1152/jappl.1997.83.1.229; Gandhi S, 2006, BRAIN, V129, P1720, DOI 10.1093/brain/awl114; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gesta S, 2006, P NATL ACAD SCI USA, V103, P6676, DOI 10.1073/pnas.0601752103; Gill JMR, 2006, CLIN SCI, V110, P409, DOI 10.1042/CS20050207; Haddad F, 2005, J APPL PHYSIOL, V98, P46, DOI 10.1152/japplphysiol.00553.2004; Hammarstedt A, 2003, BIOCHEM BIOPH RES CO, V301, P578, DOI 10.1016/S0006-291X(03)00014-7; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Harris TB, 2000, ANN NY ACAD SCI, V904, P462; Heilbronn LK, 2003, CURR PHARM DESIGN, V9, P1411, DOI 10.2174/1381612033454766; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Houstis N, 2006, NATURE, V440, P944, DOI 10.1038/nature04634; Howell SJ, 2000, CLIN ENDOCRINOL, V52, P609, DOI 10.1046/j.1365-2265.2000.00997.x; Irizarry RA, 2005, NAT METHODS, V2, P345, DOI 10.1038/nmeth756; Kemmer D, 2004, COMP FUNCT GENOM, V5, P584, DOI 10.1002/cfg.443; Kuroda Y, 2006, HUM MOL GENET, V15, P883, DOI 10.1093/hmg/ddl006; Larsson O, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-129; Levy JC, 1998, DIABETES CARE, V21, P2191, DOI 10.2337/diacare.21.12.2191; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lu CY, 2004, P NATL ACAD SCI USA, V101, P11767, DOI 10.1073/pnas.0401588101; Lu Q, 2006, AGEING RES REV, V5, P449, DOI 10.1016/j.arr.2006.07.001; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; NECHAD M, 1987, AM J PHYSIOL, V253, pC889, DOI 10.1152/ajpcell.1987.253.6.C889; PARISI MA, 1993, MOL CELL BIOL, V13, P1951, DOI 10.1128/MCB.13.3.1951; Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Pedersen M, 2003, MECH AGEING DEV, V124, P495, DOI 10.1016/S0047-6374(03)00027-7; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Petit A, 2005, J BIOL CHEM, V280, P34025, DOI 10.1074/jbc.M505143200; Ristow M, 2004, J MOL MED, V82, P510, DOI 10.1007/s00109-004-0552-1; Rolo AP, 2006, TOXICOL APPL PHARM, V212, P167, DOI 10.1016/j.taap.2006.01.003; SANDRI M, 2006, P NATL ACAD SCI US; Sasaki N, 1998, AM J PATHOL, V153, P1149, DOI 10.1016/S0002-9440(10)65659-3; Scheele C, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-74; Semple RK, 2004, INT J OBESITY, V28, P176, DOI 10.1038/sj.ijo.0802482; Silvestri L, 2005, HUM MOL GENET, V14, P3477, DOI 10.1093/hmg/ddi377; Sreekumar R, 2002, DIABETES, V51, P1913, DOI 10.2337/diabetes.51.6.1913; Steensberg A, 2003, J PHYSIOL-LONDON, V548, P631, DOI 10.1113/jphysiol.2002.032938; Stern DM, 2002, AGEING RES REV, V1, P1, DOI 10.1016/S0047-6374(01)00366-9; Tesch PA, 2004, J APPL PHYSIOL, V96, P1451, DOI 10.1152/japplphysiol.01051.2003; Timmons JA, 2006, GENOMICS, V87, P165, DOI 10.1016/j.ygeno.2005.09.007; Timmons JA, 2005, FASEB J, V19, P750, DOI 10.1096/fj.04-1980com; Timmons JA, 2007, P NATL ACAD SCI USA, V104, P4401, DOI 10.1073/pnas.0610615104; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Vlassara H, 2002, J INTERN MED, V251, P87, DOI 10.1046/j.1365-2796.2002.00932.x; Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487; Wang DF, 2006, P NATL ACAD SCI USA, V103, P13244, DOI 10.1073/pnas.0605551103; World Health Organization, 1999, DEF DIAGN CLASS DI 1; Wren JD, 2005, J BIOMED BIOTECHNOL, P104, DOI 10.1155/JBB.2005.104; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yang YF, 2006, P NATL ACAD SCI USA, V103, P10793, DOI 10.1073/pnas.0602493103; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999	67	75	81	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3653	3665		10.1096/fj.07-8520com	http://dx.doi.org/10.1096/fj.07-8520com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17567565				2022-12-28	WOS:000250517800027
J	Davies, WL; Cowing, JA; Carvalho, LS; Potter, IC; Trezise, AEO; Hunt, DM; Collin, SP				Davies, Wayne L.; Cowing, Jill A.; Carvalho, Livia S.; Potter, Ian C.; Trezise, Ann E. O.; Hunt, David M.; Collin, Shaun P.			Functional characterization, tuning, and regulation of visual pigment gene expression in an anadromous lamprey	FASEB JOURNAL			English	Article						color vision; lifecycle; recombinant protein	SOUTHERN-HEMISPHERE LAMPREY; COLOR-VISION; MOLECULAR EVOLUTION; RHODOPSIN; MORPHOLOGY; ACTIVATION; PHYLOGENY; KINASE; OPSIN	Lampreys are one of the two surviving groups of jawless vertebrates, whose ancestors arose more than 540 million years ago. Some species, such as Geotria australis, are anadromous, commencing life as ammocoetes in rivers, migrating downstream to the sea, and migrating back into rivers to spawn. Five photoreceptor types and five retinal cone opsin genes ( LWS, SWS1, SWS2, RhA, and RhB) have previously been identified in G. australis. This implies that the ancestral vertebrates possessed photopic or cone- based vision with the potential for pentachromacy. Changes in the morphology of photoreceptors and their spectral sensitivity are encountered during differing aquatic phases of the lamprey lifecycle. To understand the molecular basis for these changes, we characterized the visual pigments and measured the relative levels of opsin expression over two lifecycle phases that are accompanied by contrasting ambient light environments. By expressing recombinant opsins in vitro, we show that SWS1, SWS2, RhA, and RhB visual pigments possess lambda max values of 359, 439, 497, and 492 nm respectively. For the LWS visual pigment, we predict a lambda max value of 560 nm based on key spectral tuning sites in other vertebrate LWS opsins. Quantitative reverse transcriptasepolymerase chain reaction reveals that the retinal opsin genes of G. australis are differentially regulated such that the visual system switches from a broad sensitivity across a wide spectral range to a much narrower sensitivity centered around 490 - 500 nm on transition from marine to riverine conditions. These quantitative changes in visual pigment expression throughout the lifecycle may directly result from changes in the lighting conditions of the surrounding milieu.	Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; UCL Inst Ophthalmol, London, England; Murdoch Univ, Sch Biol Sci & Biotechnol, Murdoch, WA 6150, Australia	University of Queensland; University of London; University College London; Murdoch University	Collin, SP (corresponding author), Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia.	s.collin@uq.edu.au	Collin, Shaun/K-8827-2012; Hunt, David M/K-6024-2012; Davies, Wayne/I-1547-2014; Carvalho, Livia/B-4984-2013	Collin, Shaun/0000-0001-6236-0771; Hunt, David M/0000-0002-9264-3948; Davies, Wayne/0000-0003-0232-1812; Carvalho, Livia/0000-0002-3909-5778				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; Collin Shaun P, 2004, Clin Exp Optom, V87, P217; Collin SP, 2003, CURR BIOL, V13, pR864, DOI 10.1016/j.cub.2003.10.044; Collin SP, 2003, VISUAL NEUROSCI, V20, P119, DOI 10.1017/S0952523803202030; Collin SP, 1999, BRAIN BEHAV EVOLUT, V54, P96, DOI 10.1159/000006616; Cowing JA, 2002, BIOCHEM J, V367, P129, DOI 10.1042/BJ20020483; Davies WL, 2004, BIOCHEM BIOPH RES CO, V319, P410, DOI 10.1016/j.bbrc.2004.05.008; Davies WL, 2004, J BIOL CHEM, V279, P15877, DOI 10.1074/jbc.M313628200; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; Gill HS, 2003, COPEIA, P687, DOI 10.1643/IA02-085.1; Govardovskii VI, 2000, VISUAL NEUROSCI, V17, P509, DOI 10.1017/S0952523800174036; HAROSI FI, 1994, VISION RES, V34, P1359, DOI 10.1016/0042-6989(94)90134-1; HAROSI FI, 1993, VISUAL NEUROSCI, V10, P711, DOI 10.1017/S0952523800005411; Hisatomi O, 1997, PHOTOCHEM PHOTOBIOL, V66, P792, DOI 10.1111/j.1751-1097.1997.tb03226.x; Hunt DM, 2004, PHOTOCH PHOTOBIO SCI, V3, P713, DOI 10.1039/b314693f; Hunt DM, 2001, J EXP BIOL, V204, P3333; Hunt DM, 2001, CELL MOL LIFE SCI, V58, P1583, DOI 10.1007/PL00000798; Janz JM, 2001, BIOCHEMISTRY-US, V40, P7219, DOI 10.1021/bi002937i; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Lythgoe J.N., 1979, ECOLOGY VISION; McDowall R.M., 1988, DIADROMY FISHES; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P937, DOI 10.1021/bi00456a013; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; POTTER I C, 1979, Environmental Biology of Fishes, V4, P65, DOI 10.1007/BF00005929; POTTER IC, 1983, J ZOOL, V200, P1; POTTER IC, 1980, CAN J FISH AQUAT SCI, V37, P1595, DOI 10.1139/f80-207; POTTER IC, 1980, J ZOOL, V190, P405, DOI 10.1111/j.1469-7998.1980.tb01435.x; POTTER IC, 1987, J ZOOL, V212, P713, DOI 10.1111/j.1469-7998.1987.tb05966.x; Renaud CB, 1997, J APPL ICHTHYOL, V13, P143, DOI 10.1111/j.1439-0426.1997.tb00114.x; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SAKMAR TP, 1996, J CHEM, V35, P325; Shu DG, 2003, NATURE, V421, P526, DOI 10.1038/nature01264; Shu DG, 1999, NATURE, V402, P42, DOI 10.1038/46965; Takahashi Y, 2003, BIOCHEMISTRY-US, V42, P6025, DOI 10.1021/bi020629+; Wagner HJ, 2005, PROG RETIN EYE RES, V24, P521, DOI 10.1016/j.preteyeres.2005.01.002; WHITMORE AV, 1989, J COMP PHYSIOL A, V166, P103; Yokoyama S, 2000, PROG RETIN EYE RES, V19, P385, DOI 10.1016/S1350-9462(00)00002-1; Yokoyama S, 1999, P NATL ACAD SCI USA, V96, P6279, DOI 10.1073/pnas.96.11.6279; Yokoyama S, 2002, GENE, V300, P69, DOI 10.1016/S0378-1119(02)00845-4; Yokoyama S, 2003, GENE, V306, P91, DOI 10.1016/S0378-1119(03)00424-4; Yokoyama S, 2001, GENETICS, V158, P1697; YOUSON JH, 1980, CAN J FISH AQUAT SCI, V37, P1687, DOI 10.1139/f80-216; Zhao XY, 1997, VISUAL NEUROSCI, V14, P225, DOI 10.1017/S0952523800011366	51	62	63	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2713	2724		10.1096/fj.06-8057com	http://dx.doi.org/10.1096/fj.06-8057com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17463225				2022-12-28	WOS:000249237500013
J	Urayama, K; Guilini, C; Messaddeq, N; Hu, K; Steenman, M; Kurose, H; Ert, G; Nebigil, CG				Urayama, Kyoji; Guilini, Celia; Messaddeq, Nadia; Hu, Kai; Steenman, Marja; Kurose, Hitoshi; Ert, Georg; Nebigil, Canan G.			The prokineticin receptor-1 (GPR73) promotes cardiomyocyte survival and angiogenesis	FASEB JOURNAL			English	Article						PKR1; MI	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-COUPLED RECEPTORS; MOLECULAR-CLONING; HEART-FAILURE; MICE LACKING; IDENTIFICATION; EXPRESSION; CELLS; BV8; ACTIVATION	Prokineticins are potent angiogenic factors that bind to two G protein-coupled receptors to initiate their biological effects. We hypothesize that prokineticin receptor-1 (PKR1/GPR73) signaling may contribute to cardiomyocyte survival or repair in myocardial infarction. Since we showed that prokineticin-2 and PKR1 are expressed in adult mouse heart and cardiac cells, we investigated the role of prokineticin-2 on capillary endothelial cell and cardiomyocyte function. In cultured cardiac endothelial cells, prokineticin-2 or overexpression of PKR1 induces vessel-like formation without increasing VEGF levels. In cardiomyocytes and H9c2 cells, prokineticin-2 or overexpressing PKR1 activates Akt to protect cardiomyocytes against oxidative stress. The survival and angiogenesis promoting effects of prokineticin-2 in cardiac cells were completely reversed by siRNA-PKR1, indicating PKR1 involvement. We thus, further investigated whether intramyocardial gene transfer of DNA encoding PKR1 may rescue the myocardium against myocardial infarction in mouse model. Transient PKR1 gene transfer after coronary ligation reduces mortality and preserves left ventricular function by promoting neovascularization and protecting cardiomyocytes without altering VEGF levels. In human end-stage failing heart samples, reduced PKR1 and prokineticin-2 transcripts and protein levels implicate a more important role for prokineticin2/PKR1 signaling in heart. Our results suggest that PKR1 may represent a novel therapeutic target to limit myocardial injury following ischemic events. Urayama, K., Guilini, C., Messaddeq, N., Hu, K., Steenman, M., Kurose, H., Ert, G., Nebigil, C. G. The prokineticin receptor-1(GPR73) promotes cardiomyocyte survival and angiogenesis.	Univ Strasbourg 1, CNRS, UMR 7175, F-67412 Illkirch Graffenstaden, France; Inst Genet Biol Mol, Illkirch Graffenstaden, France; Univ Wurzburg, Ctr Cardiovasc Med, Wurzburg, Germany; INSERM U533, L Inst Thorax, Nantes, France; Kyushu Univ, Dept Pharmacol & Toxicol, Fukuoka 812, Japan	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Wurzburg; Institut National de la Sante et de la Recherche Medicale (Inserm); Kyushu University	Nebigil, CG (corresponding author), Univ Strasbourg 1, CNRS, UMR 7175, Bld Sebastien Brandt BP 10413, F-67412 Illkirch Graffenstaden, France.	nebigil@esbs.u-strasbg.fr	Steenman, Marja/D-3618-2015; Steenman, Marja/S-8433-2019; Nebigil, Canan/AAK-7162-2021	Steenman, Marja/0000-0003-4547-4448; Steenman, Marja/0000-0003-4547-4448; Nebigil, Canan/0000-0002-2035-5795				Abraham D, 2000, CIRC RES, V87, P644, DOI 10.1161/01.RES.87.8.644; Adams JW, 2001, ONCOGENE, V20, P1626, DOI 10.1038/sj.onc.1204275; Bellomo D, 2000, CIRC RES, V86, pE29, DOI 10.1161/01.RES.86.2.e29; Bullock CM, 2004, MOL PHARMACOL, V65, P582, DOI 10.1124/mol.65.3.582; Chen JC, 2005, MOL PHARMACOL, V67, P2070, DOI 10.1124/mol.105.011619; Cheng MY, 2002, NATURE, V417, P405, DOI 10.1038/417405a; Chotteau-Lelievre Anne, 2006, Methods Mol Biol, V326, P61; Dorsch M, 2005, J LEUKOCYTE BIOL, V78, P426, DOI 10.1189/jlb.0205061; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fujiyama S, 2001, CIRC RES, V88, P22, DOI 10.1161/01.RES.88.1.22; Giordano FJ, 2001, P NATL ACAD SCI USA, V98, P5780, DOI 10.1073/pnas.091415198; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Howes AL, 2006, J MOL CELL CARDIOL, V40, P597, DOI 10.1016/j.yjmcc.2005.12.003; Kan H, 2004, AM J PHYSIOL-CELL PH, V286, pC1, DOI 10.1152/ajpcell.00059.2003; Khurana R, 2005, CIRCULATION, V112, P1813, DOI 10.1161/CIRCULATIONAHA.105.535294; Kisliouk T, 2005, ENDOCRINOLOGY, V146, P3950, DOI 10.1210/en.2005-0297; Lamirault G, 2006, J MOL CELL CARDIOL, V40, P173, DOI 10.1016/j.yjmcc.2005.09.004; LeCouter J, 2004, P NATL ACAD SCI USA, V101, P16813, DOI 10.1073/pnas.0407697101; LeCouter J, 2003, P NATL ACAD SCI USA, V100, P2685, DOI 10.1073/pnas.0337667100; LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000; Li M, 2001, MOL PHARMACOL, V59, P692, DOI 10.1124/mol.59.4.692; Lin DCH, 2002, J BIOL CHEM, V277, P19276, DOI 10.1074/jbc.M202139200; Martucci C, 2006, BRIT J PHARMACOL, V147, P225, DOI 10.1038/sj.bjp.0706467; Masuda Y, 2002, BIOCHEM BIOPH RES CO, V293, P396, DOI 10.1016/S0006-291X(02)00239-5; McLaughlin JN, 2005, J BIOL CHEM, V280, P22172, DOI 10.1074/jbc.M500721200; Mialet-Perez J, 2006, ARCH MAL COEUR VAISS, V99, P616; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Nagoshi T, 2005, J CLIN INVEST, V115, P2128, DOI 10.1172/JCI23073; Nahrendorf M, 2006, CIRCULATION, V113, P1196, DOI 10.1161/CIRCULATIONAHA.105.602094; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P9508, DOI 10.1073/pnas.97.17.9508; Nebigil CG, 2003, CIRCULATION, V107, P3223, DOI 10.1161/01.CIR.0000074224.57016.01; Nebigil CG, 2003, FASEB J, V17, P1373, DOI 10.1096/fj.02-1122fje; Negri L, 2005, BRIT J PHARMACOL, V146, P625, DOI 10.1038/sj.bjp.0706376; Negri L, 2006, J NEUROSCI, V26, P6716, DOI 10.1523/JNEUROSCI.5403-05.2006; Ng KL, 2005, SCIENCE, V308, P1923, DOI 10.1126/science.1112103; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Okada H, 2005, CIRCULATION, V111, P2430, DOI 10.1161/01.CIR.0000165066.71481.8E; Parker R, 2000, BBA-GENE STRUCT EXPR, V1491, P369, DOI 10.1016/S0167-4781(00)00023-3; Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200; Richard DE, 2001, ONCOGENE, V20, P1556, DOI 10.1038/sj.onc.1204193; Soga T, 2002, BBA-GENE STRUCT EXPR, V1579, P173, DOI 10.1016/S0167-4781(02)00546-8; Tang CM, 2004, TRENDS CARDIOVAS MED, V14, P94, DOI 10.1016/j.tcm.2003.12.007; Yamaguchi O, 2003, P NATL ACAD SCI USA, V100, P15883, DOI 10.1073/pnas.2136717100	46	78	84	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2980	2993		10.1096/fj.07-8116com	http://dx.doi.org/10.1096/fj.07-8116com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17442730				2022-12-28	WOS:000249237500038
J	Leung, LY; Tian, D; Brangwynne, CP; Weitz, DA; Tschumperlin, DJ				Leung, Lester Y.; Tian, David; Brangwynne, Clifford P.; Weitz, David A.; Tschumperlin, Daniel J.			A new microrheometric approach reveals individual and cooperative roles for TGF-beta 1 and IL-1 beta in fibroblast-mediated stiffening of collagen gels	FASEB JOURNAL			English	Article						compliance; extracellular matrix; remodeling; myofibroblast; fibrosis	HUMAN LUNG FIBROBLASTS; MAGNETIC PARTICLE MOTIONS; KINASE-DEPENDENT PATHWAY; LIVING CELLS; MECHANICAL-PROPERTIES; EXTRACELLULAR-MATRIX; PULMONARY-FIBROSIS; TRACKING MICRORHEOLOGY; CONFINED COMPRESSION; SYNTHETIC PHENOTYPE	The stiffness of the extracellular matrix can profoundly influence cell and tissue behaviors. Thus there is an emerging emphasis on understanding how matrix mechanical environments are established, regulated, and modified. Here we develop a microrheometric assay to measure the mechanical properties of a model extracellular matrix (type I collagen gel) and use it to explore cytokine-induced, cell-mediated changes in matrix mechanical properties. The microrheometric assay uses micron-scale ferrimagnetic beads embedded within collagen gels during fibrillogenesis. The beads are magnetized, then subjected to a twisting field, with the aggregate rotation of the beads measured by a magnetometer. The degree of bead rotation reflects the stiffness of the surrounding matrix. We show that the microscale assay provides stiffness measures for collagen gels comparable to those obtained with standard macroscale rheometry. To demonstrate the utility of the assay for biological discovery, we measure stiffness changes in fibroblast-populated collagen gels exposed to three concentrations of six cytokines over 2 to 14 days. Among the cytokines tested, transforming growth factor-beta 1 and interleukin-1 beta enhanced matrix stiffness, and together exerted cooperative effects on cellular modulation of matrix mechanics. The microrheometry approach developed here should accelerate the discovery of biological pathways orchestrating cellular modulation of matrix mechanics.	Harvard Univ, Sch Publ Hlth, Program Mol & Integrat Physiol Sci, Dept Environm Hlth, Boston, MA 02115 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; Harvard Univ, Dept Phys, Cambridge, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University	Tschumperlin, DJ (corresponding author), Harvard Univ, Sch Publ Hlth, Program Mol & Integrat Physiol Sci, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.	dtschump@hsph.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM073628] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33009] Funding Source: Medline; NIGMS NIH HHS [GM73628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdollahi A, 2005, J EXP MED, V201, P925, DOI 10.1084/jem.20041393; Agoram B, 2001, J BIOMECH ENG-T ASME, V123, P362, DOI 10.1115/1.1385843; Atamas SP, 2003, CYTOKINE GROWTH F R, V14, P537, DOI 10.1016/S1359-6101(03)00060-1; Atamas SP, 2002, LIFE SCI, V72, P631, DOI 10.1016/S0024-3205(02)02299-3; Bausch AR, 1999, BIOPHYS J, V76, P573, DOI 10.1016/S0006-3495(99)77225-5; Chandran PL, 2006, J BIOMECH ENG-T ASME, V128, P259, DOI 10.1115/1.2165699; Chandran PL, 2004, J BIOMECH ENG-T ASME, V126, P152, DOI 10.1115/1.1688774; Chapman HA, 2004, J CLIN INVEST, V113, P148, DOI 10.1172/JCI200420729; Crocker JC, 2000, PHYS REV LETT, V85, P888, DOI 10.1103/PhysRevLett.85.888; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Diaz A, 1998, EXP CELL RES, V241, P222, DOI 10.1006/excr.1998.4050; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Dube J, 2000, INT J EXP PATHOL, V81, P429, DOI 10.1046/j.1365-2613.2000.00173.x; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Engler AJ, 2004, J CELL BIOL, V166, P877, DOI 10.1083/jcb.200405004; Fabry B, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.148102; Girton TS, 2000, J BIOMECH ENG-T ASME, V122, P216, DOI 10.1115/1.429652; GLOGAUER M, 1995, AM J PHYSIOL-CELL PH, V269, pC1093, DOI 10.1152/ajpcell.1995.269.5.C1093; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; Grinnell F, 2000, TRENDS CELL BIOL, V10, P362, DOI 10.1016/S0962-8924(00)01802-X; Grinnell F, 1999, J BIOL CHEM, V274, P918, DOI 10.1074/jbc.274.2.918; GUIDRY C, 1985, J CELL SCI, V79, P67; Hashimoto S, 2001, J ALLERGY CLIN IMMUN, V107, P1001, DOI 10.1067/mai.2001.114702; Hashimoto S, 2001, AM J RESP CRIT CARE, V163, P152, DOI 10.1164/ajrccm.163.1.2005069; HSU S, 1994, BIORHEOLOGY, V31, P21; Hubbell JA, 2003, CURR OPIN BIOTECH, V14, P551, DOI 10.1016/j.copbio.2003.09.004; IMAI Y, 1994, EUR J ENDOCRINOL, V131, P630, DOI 10.1530/eje.0.1310630; Ingram JL, 2004, FASEB J, V18, P1132, DOI 10.1096/fj.03-1492fje; Jinnin M, 2004, J BIOL CHEM, V279, P41783, DOI 10.1074/jbc.M406951200; Kaufman LJ, 2005, BIOPHYS J, V89, P635, DOI 10.1529/biophysj.105.061994; Kessler D, 2001, J BIOL CHEM, V276, P36575, DOI 10.1074/jbc.M101602200; Knapp DM, 1997, J RHEOL, V41, P971, DOI 10.1122/1.550817; Kolb M, 2001, J CLIN INVEST, V107, P1529, DOI 10.1172/JCI12568; KORDUCKI JM, 1992, INVEST OPHTH VIS SCI, V33, P2037; Lee PHA, 2004, J BIOL CHEM, V279, P48640, DOI 10.1074/jbc.M407241200; Lewis CC, 2005, J ALLERGY CLIN IMMUN, V115, P534, DOI 10.1016/j.jaci.2004.11.051; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maksym GN, 2000, J APPL PHYSIOL, V89, P1619, DOI 10.1152/jappl.2000.89.4.1619; Meshel AS, 2005, NAT CELL BIOL, V7, P157, DOI 10.1038/ncb1216; Mijailovich SM, 2002, J APPL PHYSIOL, V93, P1429, DOI 10.1152/japplphysiol.00255.2002; NAKAGAWA S, 1989, J INVEST DERMATOL, V93, P792, DOI 10.1111/1523-1747.ep12284425; Neidert MR, 2002, BIOMATERIALS, V23, P3717, DOI 10.1016/S0142-9612(02)00106-0; Ogle BM, 2002, J BIOMECH ENG-T ASME, V124, P724, DOI 10.1115/1.1519278; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Pawluczyk IZA, 1998, KIDNEY INT, V54, P62, DOI 10.1046/j.1523-1755.1998.00965.x; Pedersen JA, 2005, ANN BIOMED ENG, V33, P1469, DOI 10.1007/s10439-005-8159-4; Pizzo AM, 2005, J APPL PHYSIOL, V98, P1909, DOI 10.1152/japplphysiol.01137.2004; Qi J, 2006, TISSUE ENG, V12, P2913, DOI 10.1089/ten.2006.12.2913; Roeder BA, 2002, J BIOMECH ENG-T ASME, V124, P214, DOI 10.1115/1.1449904; Roy R, 1996, J CELL BIOCHEM, V62, P411, DOI 10.1002/(SICI)1097-4644(199609)62:3<411::AID-JCB11>3.0.CO;2-L; Sawhney RK, 2002, J CELL BIOL, V157, P1083, DOI 10.1083/jcb.200203069; Shreiber DI, 2001, EXP CELL RES, V266, P155, DOI 10.1006/excr.2001.5208; Storm C, 2005, NATURE, V435, P191, DOI 10.1038/nature03521; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Tschumperlin DJ, 2003, AM J RESP CELL MOL, V28, P142, DOI 10.1165/rcmb.2002-0121OC; Tseng Y, 2002, BIOPHYS J, V83, P3162, DOI 10.1016/S0006-3495(02)75319-8; VALBERG PA, 1987, BIOPHYS J, V52, P537, DOI 10.1016/S0006-3495(87)83243-5; VALBERG PA, 1987, BIOPHYS J, V52, P551, DOI 10.1016/S0006-3495(87)83244-7; Velegol D, 2001, BIOPHYS J, V81, P1786, DOI 10.1016/S0006-3495(01)75829-8; Wakatsuki T, 2000, BIOPHYS J, V79, P2353, DOI 10.1016/S0006-3495(00)76481-2; WANG N, 1994, BIOPHYS J, V66, P2181, DOI 10.1016/S0006-3495(94)81014-8; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Yamada S, 2000, BIOPHYS J, V78, P1736, DOI 10.1016/S0006-3495(00)76725-7; Zaman MH, 2006, P NATL ACAD SCI USA, V103, P10889, DOI 10.1073/pnas.0604460103; Zhang HY, 1997, J IMMUNOL, V158, P1392; Zhang HY, 1999, AM J RESP CELL MOL, V21, P658, DOI 10.1165/ajrcmb.21.6.3720; Zhou XX, 2005, AM J PHYSIOL-CELL PH, V288, pC435, DOI 10.1152/ajpcell.00035.2004; Zhu WB, 1996, J BIOMECH, V29, P773, DOI 10.1016/0021-9290(95)00136-0	69	46	46	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2064	2073		10.1096/fj.06-7510com	http://dx.doi.org/10.1096/fj.06-7510com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17341683				2022-12-28	WOS:000247500300016
J	Robinet, A; Millart, H; Oszust, F; Hornebeck, W; Bellon, G				Robinet, Arnaud; Millart, Herve; Oszust, Floriane; Hornebeck, William; Bellon, Georges			Binding of elastin peptides to S-Gal protects the heart against ischemia/reperfusion injury by triggering the RISK pathway	FASEB JOURNAL			English	Article						preconditioning; postconditioning; cardioprotection; aging	NITRIC-OXIDE SYNTHASE; MITOCHONDRIAL PERMEABILITY TRANSITION; SMOOTH-MUSCLE CELLS; UP-REGULATION; MATRIX METALLOPROTEINASE-1; MYOCARDIAL-INFARCTION; CHEMOTACTIC ACTIVITY; REPERFUSION INJURY; LAMININ RECEPTOR; VASCULAR WALL	Elastin peptides (EPs) generated by hydrolysis of elastic fibers by elastinolytic enzymes display a wide spectrum of biological activities. Here, we investigated their influence on rat heart ischemia-mediated injury using the Langendorff ex vivo model. EPs, i.e., kappa elastin, at 1.32- and 660-nM concentrations, when administered before the ischemia period, elicited a beneficial influence against ischemia by accelerating the recovery rate of heart contractile parameters and by decreasing significantly creatine kinase release and heart necrosis area when measured at the onset of the reperfusion. All effects were S-Gal-dependent, as being reproduced by (VGVAPG) 3 and as being inhibited by receptor antagonists, such as lactose and V14 peptide (VVGSPSAQDEASPL). EPs interaction with S-Gal triggered NO release and activation of PI3-kinase/Akt and ERK1/2 in human coronary endothelial cells (HCAECs) and rat neonatal cardiomyocytes (RCs). This signaling pathway, as designated as RISK, for reperfusion injury salvage kinase pathway, was shown to be responsible for the beneficial influence of EPs on ischemia/reperfusion injury on the basis of its inhibition by specific pharmacological inhibitors. EPs survival activity was attained at a concentration averaging that present into the blood circulation, supporting the contention that these matrikines might offer a natural protection against cardiac injury in young and adult individuals. Such protective effect might be lost with aging, since we found that hearts from 24-month-old rats did not respond to EPs.	Univ Reims, Fac Med, Lab Pharmacol Med, Reims, France; Univ Reims, Fac Med, Lab Biochim & Biol Mol, UMR 6198,CNRS, Reims, France	Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne	Hornebeck, W (corresponding author), Univ Reims, Biochim Lab, Fac Med, CNRS UMR 6 19, 51 Rue Cognacq Jay, F-51095 Reims, France.	william.hornebeck@univ-reims.fr	OSZUST, Floriane/B-7976-2012	OSZUST, Floriane/0000-0001-9742-3365				Adler A, 2004, AM J PHYSIOL-HEART C, V287, pH14, DOI 10.1152/ajpheart.01235.2003; Bizbiz L, 1997, ATHEROSCLEROSIS, V131, P73, DOI 10.1016/S0021-9150(97)06076-0; BLOOD CH, 1993, CANCER RES, V53, P2661; Bolli R, 1997, CIRC RES, V81, P42, DOI 10.1161/01.RES.81.1.42; Booms P, 2006, J MOL CELL CARDIOL, V40, P234, DOI 10.1016/j.yjmcc.2005.11.009; Boucher M, 2004, J CARDIOVASC PHARM, V43, P416, DOI 10.1097/00005344-200403000-00013; Brassart B, 2001, J BIOL CHEM, V276, P5222, DOI 10.1074/jbc.M003642200; Crisostomo PR, 2006, J AM COLL SURGEONS, V202, P797, DOI 10.1016/j.jamcollsurg.2005.12.002; Davidson SM, 2006, INT J BIOCHEM CELL B, V38, P414, DOI 10.1016/j.biocel.2005.09.017; Debret R, 2005, ARTERIOSCL THROM VAS, V25, P1353, DOI 10.1161/01.ATV.0000168412.50855.9f; Debret R, 2006, J INVEST DERMATOL, V126, P1860, DOI 10.1038/sj.jid.5700337; Duca L, 2005, MOL PHARMACOL, V67, P1315, DOI 10.1124/mol.104.002725; Faury G, 1997, MECH AGEING DEV, V95, P31, DOI 10.1016/S0047-6374(96)01842-8; FAURY G, 1995, J VASC RES, V32, P112, DOI 10.1159/000159084; Faury G, 2003, J CLIN INVEST, V112, P1419, DOI 10.1172/JCI200319028; Faury G, 2003, BIOMED PHARMACOTHER, V57, P216, DOI 10.1016/S0753-3322(03)00053-2; Floquet N, 2004, BIOPOLYMERS, V76, P266, DOI 10.1002/bip.20029; Fulop T, 2001, PATHOL BIOL, V49, P339, DOI 10.1016/S0369-8114(01)00143-2; GHUYSENITARD AF, 1992, CR ACAD SCI III-VIE, V315, P473; Guo Y, 2005, AM J PHYSIOL-HEART C, V289, pH2251, DOI 10.1152/ajpheart.00341.2005; Haendeler J, 2006, EUR J CLIN PHARMACOL, V62, P137, DOI 10.1007/s00228-005-0008-8; Hance KA, 2002, J VASC SURG, V35, P254, DOI 10.1067/mva.2002.120382; Hausenloy DJ, 2006, CARDIOVASC RES, V70, P240, DOI 10.1016/j.cardiores.2006.01.017; Hausenloy DJ, 2004, CARDIOVASC RES, V61, P448, DOI 10.1016/j.cardiores.2003.09.024; HINEK A, 1994, J CELL BIOL, V126, P563, DOI 10.1083/jcb.126.2.563; Hinek A, 1996, BIOL CHEM, V377, P471; Hornebeck W, 2005, ANTICANCER RES, V25, P2617; JACOB MP, 1987, P NATL ACAD SCI USA, V84, P995, DOI 10.1073/pnas.84.4.995; JOHNSON G, 1991, CRIT CARE MED, V19, P244, DOI 10.1097/00003246-199102000-00021; Jones SP, 2006, J MOL CELL CARDIOL, V40, P16, DOI 10.1016/j.yjmcc.2005.09.011; Liu YH, 2005, AM J PHYSIOL-HEART C, V289, pH2616, DOI 10.1152/ajpheart.00546.2005; Mizuno T, 2005, AM J PHYSIOL-HEART C, V288, pH2819, DOI 10.1152/ajpheart.00862.2004; MIZUNO T, 2005, J INVEST DERMATOL, V112, pI81; Mochizuki S, 2002, J BIOL CHEM, V277, P44854, DOI 10.1074/jbc.M205630200; Nackman GB, 1997, SURGERY, V122, P39, DOI 10.1016/S0039-6060(97)90262-2; Pezet Mylene, 2004, Journal de la Societe de Biologie, V198, P279; Qian HS, 2006, J CARDIOVASC PHARM, V47, P587, DOI 10.1097/01.fjc.0000211736.55583.5c; Razavi HM, 2005, PHARMACOL THERAPEUT, V106, P147, DOI 10.1016/j.pharmthera.2004.11.006; ROBERT L, 1989, PATHOL BIOL, V37, P736; Robert L, 2000, BIOGERONTOLOGY, V1, P123, DOI 10.1023/A:1010048014925; Robert L, 1996, ATHEROSCLEROSIS, V123, P169, DOI 10.1016/0021-9150(96)05804-2; Robinet A, 2005, J CELL SCI, V118, P343, DOI 10.1242/jcs.01613; Saito M, 2002, EXP GERONTOL, V37, P937, DOI 10.1016/S0531-5565(02)00021-9; SATO S, 1983, J MOL CELL CARDIOL, V15, P261, DOI 10.1016/0022-2828(83)90281-X; SENIOR RM, 1980, J CLIN INVEST, V66, P859, DOI 10.1172/JCI109926; SENIOR RM, 1984, J CELL BIOL, V99, P870, DOI 10.1083/jcb.99.3.870; Smith RS, 2005, LIFE SCI, V76, P2457, DOI 10.1016/j.lfs.2004.11.028; Strijdom H, 2006, FASEB J, V20, P314, DOI 10.1096/fj.05-4225fje; Tong HY, 2004, CIRC RES, V94, P1133, DOI 10.1161/01.RES.0000126048.32383.6B; Tsang A, 2004, CIRC RES, V95, P230, DOI 10.1161/01.RES.0000138303.76488.fe; Wang GW, 2005, AM J PHYSIOL-HEART C, V288, pH1290, DOI 10.1152/ajpheart.00796.2004; Wenzel D, 2006, CIRC RES, V98, P1203, DOI 10.1161/01.RES.0000219899.93384.ed	52	31	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					1968	1978		10.1096/fj.06-6477com	http://dx.doi.org/10.1096/fj.06-6477com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17341689				2022-12-28	WOS:000247500300007
J	Barbieri, SS; Weksler, BB				Barbieri, Silvia S.; Weksler, Babette B.			Tobacco smoke cooperates with interleukin-1 beta to alter beta-catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase-2 expression in vitro and in vivo	FASEB JOURNAL			English	Article						endothelial cells; inflammation; signal transduction	FACTOR-KAPPA-B; CIGARETTE-SMOKE; GENE-EXPRESSION; NITRIC-OXIDE; ACTIVATION; NICOTINE; KINASE; TARGET; CANCER; MACROPHAGES	Cigarette smoking affects all phases of atherosclerosis from endothelial dysfunction to acute occlusive clinical events. We explored activation by exposure to tobacco smoke of two genes, beta-catenin and COX-2, that play key roles in inflammation and vascular remodeling events. Using both in vivo and in vitro smoke exposure, we determined that tobacco smoke (TS) induced nuclear beta-catenin accumulation and COX-2 expression and activity and moreover interacted with IL-1 beta to enhance these effects. Exposure of cardiac endothelial cells to tobacco smoke plus IL-1 beta (TS/ IL-1 beta) enhanced permeability of endothelial monolayers and disrupted membrane VE-cadherin/beta-catenin complexes, decreased beta-catenin phosphorylation, and increased phosphorylation of GSK-3 beta, Akt, and EGFR. Transfection of endothelial cells with beta-catenin-directed small interferring RNA (siRNA) suppressed TS/ IL-1 beta-mediated effects on COX-2 modulation. Inhibitors of EGFR and phosphatidylinositol- 3-kinase also abolished both the TS/ IL-1 beta-mediated modulation of the Akt/GSK-3 beta/beta-catenin pathway and enhancement of COX-2 expression. Moreover, increased levels of Akt and GSK-3 beta phosphorylation, nuclear beta-catenin accumulation, COX-2 expression, and IL-1 beta were observed in cardiovascular tissue of ApoE(-/-) mice exposed to cigarette smoke daily for 2 wk. Our results suggest a novel mechanism by which cigarette smoking can induce proinflammatory and proatherosclerotic effects in vascular tissue.-Barbieri, S. S., Weksler, B. B. Tobacco smoke cooperates with interleukin-1 beta to alter beta- catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase- 2 expression in vitro and in vivo.	Cornell Univ, Weill Med Coll, Div Hematol Med Oncol, New York, NY 10021 USA; Univ Milan, Dept Pharmacol Sci, I-20122 Milan, Italy	Cornell University; University of Milan	Weksler, BB (corresponding author), Cornell Univ, Weill Med Coll, Div Hematol Med Oncol, 1300 York Ave, New York, NY 10021 USA.	babette@med.cornell.edu	Barbieri, Silvia Stella/K-2130-2018	Barbieri, Silvia Stella/0000-0002-7486-2637	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055627] Funding Source: NIH RePORTER; NHLBI NIH HHS [R0-1 HL-55627] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047; Araki Y, 2003, CANCER RES, V63, P728; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bernhard D, 2005, FASEB J, V19, P1096, DOI 10.1096/fj.04-3192com; Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572-1000(05)00007-4; Cipollone F, 2005, ARTERIOSCL THROM VAS, V25, P1925, DOI 10.1161/01.ATV.0000177814.41505.41; DelMaschio A, 1996, J CELL BIOL, V135, P497, DOI 10.1083/jcb.135.2.497; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Forster C, 2005, J PHYSIOL-LONDON, V565, P475, DOI 10.1113/jphysiol.2005.084038; George SJ, 2004, TRENDS CARDIOVAS MED, V14, P100, DOI 10.1016/j.tcm.2003.12.008; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; Inoue M, 1998, CIRCULATION, V98, P2108, DOI 10.1161/01.CIR.98.20.2108; Khan TA, 2005, CIRCULATION, V112, pI196, DOI 10.1161/CIRCULATIONAHA.104.526053; Kim SJ, 2002, BIOCHEM BIOPH RES CO, V296, P221, DOI 10.1016/S0006-291X(02)00824-0; Knight-Lozano CA, 2002, CIRCULATION, V105, P849, DOI 10.1161/hc0702.103977; Lau PP, 2006, ARTERIOSCL THROM VAS, V26, P143, DOI 10.1161/01.ATV.0000193510.19000.10; LODGE PA, 1992, TRANSPLANT P, V24, P2816; Marelli-Berg FM, 2000, J IMMUNOL METHODS, V244, P205, DOI 10.1016/S0022-1759(00)00258-1; Moncada S, 1997, ANN NY ACAD SCI, V811, P60, DOI 10.1111/j.1749-6632.1997.tb51989.x; Moraitis D, 2005, CANCER RES, V65, P664; Norvell SM, 2004, CALCIFIED TISSUE INT, V75, P396, DOI 10.1007/s00223-004-0213-y; Pichiule P, 2004, J BIOL CHEM, V279, P12171, DOI 10.1074/jbc.M305146200; PITTILO RM, 1990, INT J EXP PATHOL, V71, P573; Ryder MI, 2002, ORAL MICROBIOL IMMUN, V17, P331, DOI 10.1034/j.1399-302X.2002.170601.x; Sheu ML, 2004, MOL PHARMACOL, V66, P187, DOI 10.1124/mol.66.1.187; Shin VY, 2004, TOXICOL APPL PHARM, V195, P103, DOI 10.1016/j.taap.2003.10.009; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sigala F, 2003, EUR J VASC ENDOVASC, V26, P523, DOI 10.1016/S1078-5884(03)00342-3; Skurk C, 2005, CIRC RES, V96, P308, DOI 10.1161/01.RES.0000156273.30274.f7; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Stemme V, 2000, EUR J VASC ENDOVASC, V20, P146, DOI 10.1053/ejvs.2000.1145; Uruno A, 2004, HYPERTENS RES, V27, P887, DOI 10.1291/hypres.27.887; Wang YJ, 2004, INT IMMUNOPHARMACOL, V4, P1675, DOI 10.1016/j.intimp.2004.07.028; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Zennou V, 2001, NAT BIOTECHNOL, V19, P446, DOI 10.1038/88115	38	71	74	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1831	1843		10.1096/fj.06-7557com	http://dx.doi.org/10.1096/fj.06-7557com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17317723				2022-12-28	WOS:000246866500025
J	Chwatko, G; Boers, GHJ; Strauss, KA; Shih, DM; Jakubowski, H				Chwatko, Grazyna; Boers, Godfried H. J.; Strauss, Kevin A.; Shih, Diana M.; Jakubowski, Hieronim			Mutations in methylenetetrahydrofolate reductase or cystathionine beta-syntase gene, or a high-methionine diet, increase homocysteine thiolactone levels in humans and mice	FASEB JOURNAL			English	Article						genetic hyperhomocysteinemia; dietary hyperhomocysteinemia; atherosclerosis	PROGRAMMED CELL-DEATH; PROTEIN HOMOCYSTEINYLATION; PLASMA HOMOCYSTEINE; PATHOLOGICAL CONSEQUENCES; N-HOMOCYSTEINYLATION; SYNTHASE DEFICIENCY; POSSIBLE MECHANISM; ENDOTHELIAL-CELLS; ESCHERICHIA-COLI; MOLECULAR-BASIS	Genetic disorders of homocysteine (Hcy) metabolism or a high-methionine diet lead to elevations of plasma Hcy levels. In humans, severe genetic hyperhomocysteinemia results in premature death from vascular complications whereas dietary hyperhomocysteinemia is often used to induce atherosclerosis in animal models. Hcy is mistakenly selected in place of methionine by methionyl-tRNA synthetase during protein biosynthesis, which results in the formation of Hcy-thiolactone and initiates a pathophysiological pathway that has been implicated in human vascular disease. However, whether genetic deficiencies in Hcy metabolism or a high-methionine diet affect Hcy-thiolactone levels in mammals has been unknown. Here we show that plasma Hcy-thiolactone is elevated 59-fold and 72-fold in human patients with hyperhomocysteinemia secondary to mutations in methylenetetrahydrofolate reductase and cystathionine beta-synthase genes, respectively. We also show that mice, like humans, eliminate Hcy-thiolactone by urinary excretion; in contrast to humans, however, mice also eliminate significant amounts of plasma total Hcy (similar to 38%) by urinary excretion. In mice, hyperhomocysteinemia secondary to a high-methionine diet leads to 3.7-fold and 25-fold increases in plasma and urinary Hcy-thiolactone levels, respectively. Thus, we conclude that hyperhomocysteinemia leads to significant increases in the atherogenic metabolite Hcy-thiolactone in humans and mice. Chwatko, G., Boers, G. H. J., Strauss, K. A., Shih, D. M., Jakubowski, H. Mutations in methylenetetrahydrofolate reductase or cystathionine beta- syntase gene, or a high-methionine diet, increase homocysteine thiolactone levels in humans and mice.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, Newark, NJ 07101 USA; Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands; Clin Special Children, Strasburg, PA USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA; Polish Acad Sci, Inst Bioorgan Chem, PL-00901 Warsaw, Poland	Rutgers State University New Brunswick; Rutgers State University Medical Center; Radboud University Nijmegen; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Polish Academy of Sciences	Jakubowski, H (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, 225 Warren St, Newark, NJ 07101 USA.	jakubows@umdnj.edu	Jakubowski, Hieronim/AAA-6834-2019; Chwatko, Grażyna/R-8757-2016; Jakubowski, Hieronim/A-2510-2017	Jakubowski, Hieronim/0000-0001-5845-4409; Chwatko, Grazyna/0000-0001-9247-5131				BOSTOM A, 1995, ATHEROSCLEROSIS, V116, P59, DOI 10.1016/0021-9150(95)05522-X; Chwatko G, 2005, CLIN CHEM, V51, P408, DOI 10.1373/clinchem.2004.042531; Chwatko G, 2005, ANAL BIOCHEM, V337, P271, DOI 10.1016/j.ab.2004.11.035; de las Casas CM, 2003, BIRTH DEFECTS RES A, V67, P35, DOI 10.1002/bdra.10014; Den Heijer M, 2005, J THROMB HAEMOST, V3, P292, DOI 10.1111/j.1538-7836.2005.01141.x; Endo N, 2006, BRIT J NUTR, V95, P1088, DOI 10.1079/BJN20061764; Glowacki R, 2004, J BIOL CHEM, V279, P10864, DOI 10.1074/jbc.M313268200; Goyette P, 1996, AM J HUM GENET, V59, P1268; HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101; Hossain GS, 2003, J BIOL CHEM, V278, P30317, DOI 10.1074/jbc.M212897200; Jakubowski H, 2000, J BIOL CHEM, V275, P3957, DOI 10.1074/jbc.275.6.3957; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; Jakubowski H, 2005, CLIN CHEM LAB MED, V43, P1011, DOI 10.1515/CCLM.2005.177; Jakubowski H, 2004, CELL MOL LIFE SCI, V61, P470, DOI 10.1007/s00018-003-3204-7; Jakubowski H, 2002, ANAL BIOCHEM, V308, P112, DOI 10.1016/S0003-2697(02)00224-5; JAKUBOWSKI H, 1995, J BIOL CHEM, V270, P17672, DOI 10.1074/jbc.270.30.17672; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; Jakubowski H, 2006, CHEM-EUR J, V12, P8039, DOI 10.1002/chem.200600785; Jakubowski H, 2006, J NUTR, V136, p1741S, DOI 10.1093/jn/136.6.1741S; Jakubowsky H., 2005, AMINOACYL TRNA SYNTH, P384; Kluijtmans LAJ, 1999, AM J HUM GENET, V65, P59, DOI 10.1086/302439; Legendre C, 2002, BIOCHEM BIOPH RES CO, V295, P1052, DOI 10.1016/S0006-291X(02)00814-8; Lentz SR, 2005, J THROMB HAEMOST, V3, P1646, DOI 10.1111/j.1538-7836.2005.01364.x; Lonn E, 2006, NEW ENGL J MED, V354, P1567, DOI 10.1056/NEJMoa060900; Loscalzo J, 2006, NEW ENGL J MED, V354, P1629, DOI 10.1056/NEJMe068060; Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8; Perna AF, 2006, KIDNEY INT, V69, P869, DOI 10.1038/sj.ki.5000070; Roybal CN, 2004, J BIOL CHEM, V279, P14844, DOI 10.1074/jbc.M312948200; Sauls DL, 2006, BIOCHEMISTRY-US, V45, P2480, DOI 10.1021/bi052076j; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Spence JD, 2005, STROKE, V36, P2404, DOI 10.1161/01.STR.0000185929.38534.f3; Tuite NL, 2005, J BACTERIOL, V187, P4362, DOI 10.1128/JB.187.13.4362-4371.2005; Uji Y, 2002, CLIN CHEM, V48, P941; Undas A, 2005, THROMB HAEMOSTASIS, V93, P346, DOI 10.1160/TH04-08-0493; Undas A, 2004, STROKE, V35, P1299, DOI 10.1161/01.STR.0000128412.59768.6e; Undas A, 2006, THROMB HAEMOSTASIS, V96, P342, DOI 10.1160/TH06-04-0228; Undas A, 2006, ARTERIOSCL THROM VAS, V26, P1397, DOI 10.1161/01.ATV.0000219688.43572.75; van Guldener C, 1998, KIDNEY INT, V54, P166, DOI 10.1046/j.1523-1755.1998.00983.x; Yap S, 2001, ARTERIOSCL THROM VAS, V21, P2080, DOI 10.1161/hq1201.100225; Zhang C, 2001, J BIOL CHEM, V276, P35867, DOI 10.1074/jbc.M100747200; Zimny J, 2006, J BIOL CHEM, V281, P22485, DOI 10.1074/jbc.M603656200	43	90	90	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2007	21	8					1707	1713		10.1096/fj.06-7435com	http://dx.doi.org/10.1096/fj.06-7435com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17327360				2022-12-28	WOS:000246866500012
J	Lee, CK; Daniel, RM; Shepherd, C; Saul, D; Cary, SC; Danson, MJ; Eisenthal, R; Peterson, ME				Lee, Charles K.; Daniel, Roy M.; Shepherd, Charis; Saul, David; Cary, S. Craig; Danson, Michael J.; Eisenthal, Robert; Peterson, Michelle E.			Eurythermalism and the temperature dependence of enzyme activity	FASEB JOURNAL			English	Article						enzyme temperature optimum; Equilibrium Model; growth temperature; protein stability; temperature adaptation	ESCHERICHIA-COLI; THERMOTOGA-MARITIMA; PROTEIN THERMOSTABILITY; CATALASE; DENATURATION; ADAPTATION; RESISTANCE; FLEXIBILITY; DISRUPTION; STABILITY	The "Equilibrium Model" has provided new tools for describing and investigating enzyme thermal adaptation. It has been shown that the effect of temperature on enzyme activity is not only governed by Delta G double dagger(cat) and Delta G double dagger(inact) but also by two new intrinsic parameters, Delta H-eq and T-eq, which describe the enthalpy and midpoint, respectively, of a reversible equilibrium between active and inactive ( but not denatured) forms of enzyme. Twenty-one enzymes from organisms with a wide range of growth temperatures were characterized using the Equilibrium Model. Statistical analysis indicates that Teq is a better predictor of growth temperature than enzyme stability (Delta G double dagger(inact)). As expected from the Equilibrium Model, Delta H-eq correlates with catalytic temperature tolerance of enzymes and thus can be declared the first intrinsic and quantitative measure of enzyme eurythermalism. Other findings shed light on the evolution of psychrophilic and thermophilic enzymes. The findings suggest that the description of the Equilibrium Model of the effect of temperature on enzyme activity applies to all enzymes regardless of their temperature origins and that its associated parameters, Delta H-eq and T-eq, are intrinsic and necessary parameters for characterizing the thermal properties of enzymes and their temperature adaptation and evolution.-Lee, C. K., Daniel, R. M., Shepherd, C., Saul, D., Cary, S. C., Danson, M. J., Eisenthal, R., Peterson, M. E. Eurythermalism and the temperature dependence of enzyme activity.	Univ Waikato, Dept Sci Biol, Hamilton 3240, New Zealand; Univ Auckland, Sch Biol Sci, Auckland, New Zealand; Univ Delaware, Coll Marine & Earth Studies, Delaware, OH USA; Univ Bath, Dept Biol & Biochem, Bath, Avon, England; Univ Bath, Dept Biol & Biochem, Ctr Extremophile Res, Bath, Avon, England	University of Waikato; University of Auckland; University of Delaware; University of Bath; University of Bath	Daniel, RM (corresponding author), Univ Waikato, Dept Sci Biol, Hamilton 3240, New Zealand.	r.daniel@waikato.ac.nz	Lee, Charles/AAC-9417-2019; Peterson, Michelle E/C-2455-2009	Lee, Charles/0000-0002-6562-4733; Peterson, Michelle E/0000-0002-6413-322X; Cary, Stephen/0000-0002-2876-2387				Aguilar CF, 1997, J MOL BIOL, V271, P789, DOI 10.1006/jmbi.1997.1215; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calera JA, 2000, FEBS LETT, V475, P117, DOI 10.1016/S0014-5793(00)01637-9; D'Amico S, 2002, PHILOS T R SOC B, V357, P917, DOI 10.1098/rstb.2002.1105; DANIEL RM, 1982, BIOCHEM J, V207, P641, DOI 10.1042/bj2070641; Daniel RM, 2003, ANNU REV BIOPH BIOM, V32, P69, DOI 10.1146/annurev.biophys.32.110601.142445; Daniel RM, 1996, BIOCHEM J, V317, P1, DOI 10.1042/bj3170001; Daniel RM, 2001, TRENDS BIOCHEM SCI, V26, P223, DOI 10.1016/S0968-0004(01)01803-5; Diaz A, 2001, FREE RADICAL BIO MED, V31, P1323, DOI 10.1016/S0891-5849(01)00637-2; Eisenthal R, 2006, TRENDS BIOTECHNOL, V24, P289, DOI 10.1016/j.tibtech.2006.05.004; FLINT KP, 1987, J APPL BACTERIOL, V63, P261, DOI 10.1111/j.1365-2672.1987.tb04945.x; Georlette D, 2003, J BIOL CHEM, V278, P37015, DOI 10.1074/jbc.M305142200; Georlette D, 2004, FEMS MICROBIOL REV, V28, P25, DOI 10.1016/j.femsre.2003.07.003; Gerike U, 1997, EUR J BIOCHEM, V248, P49, DOI 10.1111/j.1432-1033.1997.00049.x; Gershenson A, 2000, BIOCHEMISTRY-US, V39, P4658, DOI 10.1021/bi992473s; HARTL DL, 1984, ANNU REV GENET, V18, P31, DOI 10.1146/annurev.ge.18.120184.000335; Ichikawa JK, 1998, ARCH BIOCHEM BIOPHYS, V358, P222, DOI 10.1006/abbi.1998.0830; Johns GC, 2004, MOL BIOL EVOL, V21, P314, DOI 10.1093/molbev/msh021; LOPEZMEDRANO R, 1995, INFECT IMMUN, V63, P4774; Merz A, 1999, J MOL BIOL, V288, P753, DOI 10.1006/jmbi.1999.2709; Miyazaki K, 2000, J MOL BIOL, V297, P1015, DOI 10.1006/jmbi.2000.3612; NODA L, 1957, J BIOL CHEM, V226, P541; Notomista E, 2000, BIOCHEMISTRY-US, V39, P8711, DOI 10.1021/bi000415x; OWUSU RK, 1989, ENZYME MICROB TECH, V11, P568, DOI 10.1016/0141-0229(89)90084-7; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Padmanabhan S, 2001, ARCH BIOCHEM BIOPHYS, V390, P42, DOI 10.1006/abbi.2001.2359; Pappenberger G, 1997, J MOL BIOL, V274, P676, DOI 10.1006/jmbi.1997.1421; Peterson ME, 2004, J BIOL CHEM, V279, P20717, DOI 10.1074/jbc.M309143200; PETERSON ME, 2005, THESIS U WAIKATO HAM; Peterson ME, 2007, BIOCHEM J, V402, P331, DOI 10.1042/BJ20061143; Schwartzman DW, 2004, BIOCHEM SOC T, V32, P168, DOI 10.1042/BST0320168; Statsoft Inc., 2005, STATISTICA VERS 7 1; Svingor A, 2001, J BIOL CHEM, V276, P28121, DOI 10.1074/jbc.M104432200; Switala J, 1999, BIOCHEMISTRY-US, V38, P3895, DOI 10.1021/bi982863z; Thomas TM, 1998, BIOCHEM J, V330, P1087; TSUBOI KK, 1975, J BIOL CHEM, V250, P132; Van den Burg B, 1998, P NATL ACAD SCI USA, V95, P2056, DOI 10.1073/pnas.95.5.2056; Wachtershauser G, 1998, THERMOPHILES KEYS MO, P47; WASSERMAN BP, 1981, ARCH BIOCHEM BIOPHYS, V212, P385, DOI 10.1016/0003-9861(81)90379-9; Xu Y, 2003, J BACTERIOL, V185, P5519, DOI 10.1128/JB.185.18.5519-5526.2003; Xu Y, 2003, INT J SYST EVOL MICR, V53, P533, DOI 10.1099/ijs.0.02228-0	41	27	27	18	95	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1934	1941		10.1096/fj.06-7265com	http://dx.doi.org/10.1096/fj.06-7265com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17341686				2022-12-28	WOS:000246866500034
J	Tan, DX; Manchester, LC; Di Mascio, P; Martinez, GR; Prado, FM; Reiter, RJ				Tan, Dun-Xian; Manchester, Lucien C.; Di Mascio, Paolo; Martinez, Glaucia R.; Prado, Fernanda M.; Reiter, Russel J.			Novel rhythms of N-1-acetyl-N-2-formyl-5-methoxykynuramine and its precursor melatonin in water hyacinth: importance for phytoremediation	FASEB JOURNAL			English	Article						plant; AFMK; circadian rhythm; antioxidant	EICHHORNIA-CRASSIPES; INDUSTRIAL EFFLUENTS; REACTIVE OXYGEN; EDIBLE PLANTS; ANTIOXIDANT; NITROGEN; PROTECTION; VITAMIN; ORGANS	N-1-acetyl- N-2-formyl-5-methoxykynuramine (AMFK) is a major metabolite of melatonin in mammals. To investigate whether AFMK exists in plants, an aquatic plant, water hyacinth, was used. To achieve this, LC/MS/MS with a deuterated standard was employed. AFMK was identified in any plant for the first time. Both it and its precursor, melatonin, were rhythmic with peaks during the late light phase. These novel rhythms indicate that these molecules do not serve as the chemical signal of darkness as in animals but may relate to processes of photosynthesis or photoprotection. These possibilities are supported by higher production of melatonin and AFMK in plants grown in sunlight (10,000-15,000 mu W/ cm(2)) compared to those grown under artificial light (400-450 mu W/ cm2). Melatonin and AFMK, as potent free radical scavengers, may assist plants in coping with harsh environmental insults, including soil and water pollutants. High levels of melatonin and AFMK in water hyacinth may explain why this plant more easily tolerates environmental pollutants, including toxic chemicals and heavy metals and is successfully used in phytoremediation. These novel findings could lead to improvements in the phytoremediative capacity of plants by either stimulating endogenous melatonin synthesis or by adding melatonin to water/soil in which they are grown.-Dun-Xian Tan, Lucien C. Manchester, Paolo Di Mascio, Glaucia R. Martinez, Fernanda M. Prado, and Russel J. Reiter. Novel rhythms of N-1-acetyl-N-2- formyl- 5- methoxykynuramine and its precursor melatonin in water hyacinth: importance for phytoremediation.	Univ Texas, Hlth Sci Ctr, Dept Struct & Cellular Biol, San Antonio, TX 78229 USA; St Marys Univ, Dept Biol Sci, San Antonio, TX USA; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508 Sao Paulo, Brazil	University of Texas System; University of Texas Health San Antonio; Universidade de Sao Paulo	Reiter, RJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Struct & Cellular Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	reiter@uthscsa.edu	Martinez, Glaucia Regina/I-3110-2016; Di Mascio, Paolo/D-1264-2014; tan, dun-xian/E-3610-2010; Tan, David/HIR-2214-2022	Martinez, Glaucia Regina/0000-0002-2628-4406; Di Mascio, Paolo/0000-0003-4125-8350; 				Afreen F, 2006, J PINEAL RES, V41, P108, DOI 10.1111/j.1600-079X.2006.00337.x; Arnao MB, 2007, J PINEAL RES, V42, P147, DOI 10.1111/j.1600-079X.2006.00396.x; Balzer I, 1996, BOT ACTA, V109, P180, DOI 10.1111/j.1438-8677.1996.tb00560.x; BEHRMANN G, 1997, BIOMETEOROLOGY, V14, P258; Chen GF, 2003, LIFE SCI, V73, P19, DOI 10.1016/S0024-3205(03)00252-2; Conti A, 2002, TREATISE ON PINEAL GLAND AND MELATONIN, P105; Cuzzocrea S, 1999, FASEB J, V13, P1930, DOI 10.1096/fasebj.13.14.1930; DUBBELS R, 1995, J PINEAL RES, V18, P28, DOI 10.1111/j.1600-079X.1995.tb00136.x; Hardeland R, 2005, ENDOCRINE, V27, P119, DOI 10.1385/ENDO:27:2:119; Hardeland R, 2004, RECENT ADV ENDOCRINO, P21; HATTORI A, 1995, BIOCHEM MOL BIOL INT, V35, P627; Hernandez-Ruiz J, 2005, J PINEAL RES, V39, P137, DOI 10.1111/j.1600-079X.2005.00226.x; Iriti M, 2006, MED HYPOTHESES, V67, P833, DOI 10.1016/j.mehy.2006.03.049; JAMIL K, 1987, J ENVIRON SCI HEAL B, V22, P103; Jayaweera MW, 2004, WATER SCI TECHNOL, V50, P217, DOI 10.2166/wst.2004.0379; Karbownik M, 2001, CELL BIOL TOXICOL, V17, P33, DOI 10.1023/A:1010903130693; Kim CY, 2000, TOHOKU J EXP MED, V191, P241, DOI 10.1620/tjem.191.241; Kolar J, 2005, J PINEAL RES, V39, P333, DOI 10.1111/j.1600-079X.2005.00276.x; Lei XY, 2004, J PINEAL RES, V36, P126, DOI 10.1046/j.1600-079X.2003.00106.x; Manchester LC, 2000, LIFE SCI, V67, P3023, DOI 10.1016/S0024-3205(00)00896-1; Mayo JC, 2005, J NEUROIMMUNOL, V165, P139, DOI 10.1016/j.jneuroim.2005.05.002; Misbahuddin M, 2002, ARCH ENVIRON HEALTH, V57, P516, DOI 10.1080/00039890209602082; MUELLER U, 2000, EUR J CELL BIOL S50, V79, P98; Mueller U., 1999, STUDIES ANTIOXIDANTS, P140; Murch SJ, 2000, PLANT CELL REP, V19, P698, DOI 10.1007/s002990000206; POEGGELER B, 1991, Naturwissenschaften, V78, P268; Qi WB, 2000, ENVIRON HEALTH PERSP, V108, P399, DOI 10.2307/3454379; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; Reiter RJ, 2001, CELL BIOCHEM BIOPHYS, V34, P237, DOI 10.1385/CBB:34:2:237; Reiter RJ, 2001, NUTR REV, V59, P286, DOI 10.1111/j.1753-4887.2001.tb07018.x; REITER RJ, 1991, MOL CELL ENDOCRINOL, V79, pC153, DOI 10.1016/0303-7207(91)90087-9; Riddle SG, 2002, ENVIRON SCI TECHNOL, V36, P1965, DOI 10.1021/es010603q; Semak I, 2005, BIOCHEMISTRY-US, V44, P9300, DOI 10.1021/bi050202d; Sener G, 2003, PHARMACOL TOXICOL, V93, P290, DOI 10.1111/j.1600-0773.2003.pto930607.x; Singhal V, 2003, BIORESOURCE TECHNOL, V86, P221, DOI 10.1016/S0960-8524(02)00178-5; Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Tan DX, 2001, FASEB J, V15, P2294, DOI 10.1096/fj.01-0309fje; Tan DX, 2003, J PINEAL RES, V34, P75, DOI 10.1034/j.1600-079X.2003.02111.x; Tan DX, 2003, J PINEAL RES, V34, P249, DOI 10.1034/j.1600-079X.2003.00037.x; Tan DX, 2000, BIOL SIGNAL RECEPT, V9, P137; Tan DX, 1993, ENDOCR J, V1, P57; Trivedy RK, 2002, WATER SCI TECHNOL, V45, P329, DOI 10.2166/wst.2002.0442; Van Tassel DL, 2001, J PINEAL RES, V31, P8, DOI 10.1034/j.1600-079X.2001.310102.x; Wolf K, 2001, J PLANT PHYSIOL, V158, P1491, DOI 10.1078/0176-1617-00561; Xia HL, 2006, BIORESOURCE TECHNOL, V97, P1050, DOI 10.1016/j.biortech.2005.04.039	46	165	175	5	67	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2007	21	8					1724	1729		10.1096/fj.06-7745com	http://dx.doi.org/10.1096/fj.06-7745com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314136				2022-12-28	WOS:000246866500014
J	Chiellini, G; Frascarelli, S; Ghelardoni, S; Carnicelli, V; Tobias, SC; DeBarber, A; Brogioni, S; Ronca-Testoni, S; Cerbai, E; Grandy, DK; Scanlan, TS; Zucchi, R				Chiellini, Grazia; Frascarelli, Sabina; Ghelardoni, Sandra; Carnicelli, Vittoria; Tobias, Sandra C.; DeBarber, Andrea; Brogioni, Simona; Ronca-Testoni, Simonetta; Cerbai, Elisabetta; Grandy, David K.; Scanlan, Thomas S.; Zucchi, Riccardo			Cardiac effects of 3-iodothyronamine: a new aminergic system modulating cardiac function	FASEB JOURNAL			English	Article						thyronamines; signal transduction; G protein-coupled receptors; myocardial function	PHOSPHOTYROSINE PHOSPHATASE; ACETYLCHOLINE CONCENTRATION; RAT; RECEPTOR; HEART; IDENTIFICATION; PROLIFERATION; ISCHEMIA; AGONISTS; TISSUES	3-iodothyronamine T(1)AM is a novel endogenous thyroid hormone derivative that activates the G protein-coupled receptor known as trace anime-associated receptor 1 (TAAR1). In the isolated working rat heart and in rat cardiomyocytes, T(1)AM produced a reversible, dose-dependent negative inotropic effect (e.g., 27 +/- 5, 51 +/- 3, and 65 +/- 2% decrease in cardiac output at 19, 25, and 38 mu M concentration, respectively). An independent negative chronotropic effect was also observed. The hemodynamic effects of T(1)AM were remarkably increased in the presence of the tyrosine kinase inhibitor genistein, whereas they were attenuated in the presence of the tyrosine phosphatase inhibitor vanadate. No effect was produced by inhibitors of protein kinase A, protein kinase C, calcium-calmodulin kinase II, phosphatidylinositol-3-kinase, or MAP kinases. Tissue cAMP levels were unchanged. In rat ventricular tissue, Western blot experiments with antiphosphotyrosine antibodies showed reduced phosphorylation of microsomal and cytosolic proteins after perfusion with synthetic T(1)AM; reverse transcriptase-polymerase chain reaction experiments revealed the presence of transcripts for at least 5 TAAR subtypes; specific and saturable binding of [I-125] T(1)AM was observed, with a dissociation constant in the low micromolar range ( 5 mu M); and endogenous T(1)AM was detectable by tandem mass spectrometry. In conclusion, our findings provide evidence for the existence of a novel aminergic system modulating cardiac function.	Univ Pisa, Dip Sci Uomo & Ambiente, I-56126 Pisa, Italy; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR USA; Univ Florence, Dipartimento Farmacol, Florence, Italy	University of Pisa; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Oregon Health & Science University; Oregon Health & Science University; University of Florence	Zucchi, R (corresponding author), Univ Pisa, Dip Sci Uomo & Ambiente, Via Roma 55, I-56126 Pisa, Italy.	r.zucchi@med.unipi.it	Cerbai, Elisabetta/J-2663-2013; Zucchi, Riccardo/AAC-8963-2022; Chiellini, Grazia/AAC-5877-2022	Cerbai, Elisabetta/0000-0001-7839-1361; ZUCCHI, RICCARDO/0000-0002-6450-3788	NIDDK NIH HHS [DK-52798] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK052798, R01DK052798] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bers DM, 2001, EXCITATION CONTRACTI; Bian JS, 1998, J MOL CELL CARDIOL, V30, P2103, DOI 10.1006/jmcc.1998.0774; Borowsky B, 2001, P NATL ACAD SCI USA, V98, P8966, DOI 10.1073/pnas.151105198; Bunzow JR, 2001, MOL PHARMACOL, V60, P1181, DOI 10.1124/mol.60.6.1181; CERBAI E, 1994, J PHYSIOL-LONDON, V481, P585, DOI 10.1113/jphysiol.1994.sp020465; COTE P, 1974, CARDIOVASC RES, V8, P721, DOI 10.1093/cvr/8.6.721; DEUSSEN A, 1988, CIRC RES, V63, P240, DOI 10.1161/01.RES.63.1.240; FORTIER PA, 1985, CAN J PHYSIOL PHARM, V63, P1429, DOI 10.1139/y85-235; FRANK JS, 1974, J CELL BIOL, V60, P586, DOI 10.1083/jcb.60.3.586; GANGULY PK, 1986, CIRC RES, V59, P684, DOI 10.1161/01.RES.59.6.684; GOTZSCHE LBH, 1994, EUR J ENDOCRINOL, V130, P281, DOI 10.1530/eje.0.1300281; GUENDKER C, 2001, ENDOCRINOLOGY, V142, P2369; Hart ME, 2006, J MED CHEM, V49, P1101, DOI 10.1021/jm0505718; Imai A, 1996, CANCER, V77, P132, DOI 10.1002/(SICI)1097-0142(19960101)77:1<132::AID-CNCR22>3.0.CO;2-5; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; Kubovcakova L, 2004, NEUROSCIENCE, V126, P375, DOI 10.1016/j.neuroscience.2004.04.005; Lindemann L, 2005, GENOMICS, V85, P372, DOI 10.1016/j.ygeno.2004.11.010; Lizotte E, 2005, ANAL BIOCHEM, V345, P47, DOI 10.1016/j.ab.2005.07.001; Massa A, 2004, ANN NY ACAD SCI, V1030, P264, DOI 10.1196/annals.1329.033; Micutkova L, 2004, ANN NY ACAD SCI, V1018, P424, DOI 10.1196/annals.1296.052; Milanes MV, 2000, N-S ARCH PHARMACOL, V361, P61, DOI 10.1007/s002109900165; Miyakawa M, 2006, SYNTHETIC COMMUN, V36, P891, DOI 10.1080/00397910500466074; NOMURA A, 1990, LIFE SCI, V47, P135, DOI 10.1016/0024-3205(90)90226-H; ODA RP, 1987, AM J PHYSIOL, V252, pH125, DOI 10.1152/ajpheart.1987.252.1.H125; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; PAGE E, 1978, AM J PHYSIOL, V235, pC147, DOI 10.1152/ajpcell.1978.235.5.C147; Petrone A, 2000, J CELL SCI, V113, P2345; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Scanlan TS, 2004, NAT MED, V10, P638, DOI 10.1038/nm1051; SCHRODERVANDERELST JP, 1990, ENDOCRINOLOGY, V127, P1656; Shah KR, 1995, INT J CARDIOL, V52, P101, DOI 10.1016/0167-5273(95)02457-8; Stangl V, 2002, CARDIOVASC RES, V53, P12, DOI 10.1016/S0008-6363(01)00420-5; Wassen FWJS, 2002, ENDOCRINOLOGY, V143, P2812, DOI 10.1210/en.143.7.2812; Younes A, 2005, AM J PHYSIOL-HEART C, V289, pH1652, DOI 10.1152/ajpheart.01110.2004; ZUCCHI R, 1994, CIRC RES, V74, P271, DOI 10.1161/01.RES.74.2.271; Zucchi R, 2002, FASEB J, V16, P1976, DOI 10.1096/fj.02-0402fje	37	99	102	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1597	1608		10.1096/fj.06-7474com	http://dx.doi.org/10.1096/fj.06-7474com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17284482				2022-12-28	WOS:000246117000034
J	Liu, M; Yang, YB; Gu, CF; Yue, YP; Wu, KK; Wu, JG; Zhu, Y				Liu, Mo; Yang, Yongbo; Gu, Chunfang; Yue, Yinpu; Wu, Kenneth K.; Wu, Jianguo; Zhu, Ying			Spike protein of SARS-CoV stimulates cyclooxygenase-2 expression via both calcium-dependent and calciumindependent protein kinase C pathways	FASEB JOURNAL			English	Article						COX; SARS-CoV; spike protein; transcriptional activation	NF-KAPPA-B; ENDOPLASMIC-RETICULUM STRESS; SIGNAL-TRANSDUCTION PATHWAY; VIRUS-INFECTION; SUBCELLULAR-LOCALIZATION; COX-2 EXPRESSION; NUCLEAR-FACTOR; ACTIVATION; CELLS; MAPK	We have previously shown that the nucleocapsid protein of SARS-associated coronavirus (SARS-CoV) activated cyclooxygenase-2 (COX-2) expression ( 1). In this study, we identified another viral protein, the spike of SARS-CoV, which played an important role in virus-stimulated COX-2 expression after screening all genes from the SARS-CoV genome. We found that an upstream calcium-dependent PKC isozyme PKC alpha that modulates the downstream ERK/ NF-kappa B pathway through an influx of extracellular Ca2+ is induced by the spike protein of SARS-CoV. The ERK/NF-kappa B was identified to be involved in the activation of COX-2 promoter and production of COX-2 protein in HEK293T cells. We also demonstrated that another unusual pathway, the calcium-independent PI3K/PKC epsilon/JNK/CREB pathway, functioned in cooperation with the calcium-dependent pathway to induce COX-2 expression upon stimulation by spike protein. This pathway can be blocked by PKC epsilon-specific, small interfering RNA, PI3K/JNK kinase-specific inhibitors as well as dominant negative JNK. PKC epsilon-specific siRNA also attenuated the phosphorylation of JNK. Our results provide evidence that helps us understand the function of SRAS-CoV spike protein in SARS pathogenesis.	Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China; Univ Texas, Hlth Sci Ctr, Vasc Biol Res Ctr, Inst Mol Med, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Div Hematol, Houston, TX USA	Wuhan University; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Zhu, Y (corresponding author), Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.	wu9988@vip.sina.com; yingzhu@whu.edu.cn	liu, mo/E-2087-2014; Wu, Jianguo/G-6267-2010; Wu, Kenneth Kun-Yu/B-1070-2010	Wu, Jianguo/0000-0002-1182-3024; Wu, Jianguo/0000-0002-8326-2895				Bosco D, 2001, DIABETES, V50, P1039, DOI 10.2337/diabetes.50.5.1039; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Choi SH, 2006, J BIOL CHEM, V281, P7468, DOI 10.1074/jbc.M512438200; Choudhury GG, 2004, J BIOL CHEM, V279, P27399, DOI 10.1074/jbc.M403530200; Corasaniti MT, 2003, TOXICOL LETT, V139, P213, DOI 10.1016/S0378-4274(02)00436-8; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Dolganiuc A, 2003, J IMMUNOL, V170, P5615, DOI 10.4049/jimmunol.170.11.5615; Eickmann M, 2003, SCIENCE, V302, P1504; Esteban V, 2005, CIRC RES, V96, P965, DOI 10.1161/01.RES.0000166326.91395.74; Hinz B, 2002, J PHARMACOL EXP THER, V300, P367, DOI 10.1124/jpet.300.2.367; Hung JH, 2004, J BIOL CHEM, V279, P46384, DOI 10.1074/jbc.M403568200; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Jijon HB, 2002, AM J PHYSIOL-CELL PH, V283, pC31, DOI 10.1152/ajpcell.00113.2001; Khoo S, 2003, J BIOL CHEM, V278, P32969, DOI 10.1074/jbc.M301198200; Kim H, 2005, J BIOL CHEM, V280, P21237, DOI 10.1074/jbc.M413842200; Lara-Pezzi E, 2002, J CLIN INVEST, V110, P1831, DOI 10.1172/JCI200215887; Lawrence A, 1999, BRIT DENT J, V1, P2; MARTIN JT, 2003, AM J RESP CRIT CARE, V169, P239; Murono S, 2001, P NATL ACAD SCI USA, V98, P6905, DOI 10.1073/pnas.121016998; Nal B, 2005, J GEN VIROL, V86, P1423, DOI 10.1099/vir.0.80671-0; Neurath MF, 1998, GUT, V43, P856, DOI 10.1136/gut.43.6.856; Nunez O, 2004, GUT, V53, P1665, DOI 10.1136/gut.2003.038364; Pavio N, 2003, J VIROL, V77, P3578, DOI 10.1128/JVI.77.6.3578-3585.2003; Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498; Pratt PF, 2003, J BIOL CHEM, V278, P51928, DOI 10.1074/jbc.M309256200; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Su HL, 2002, J VIROL, V76, P4162, DOI 10.1128/JVI.76.9.4162-4171.2002; Syeda F, 2006, J BIOL CHEM, V281, P11792, DOI 10.1074/jbc.M509292200; Wang HC, 2003, AM J PATHOL, V163, P2441, DOI 10.1016/S0002-9440(10)63599-7; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Yan XH, 2006, INT J BIOCHEM CELL B, V38, P1417, DOI 10.1016/j.biocel.2006.02.003; Yang TX, 2000, J BIOL CHEM, V275, P23281, DOI 10.1074/jbc.M910237199; Zhu JZ, 2005, J BIOL CHEM, V280, P8617, DOI 10.1074/jbc.M413539200; Zhu Y, 2005, VIRUS GENES, V30, P93, DOI 10.1007/s11262-004-4586-9; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	37	61	65	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1586	1596		10.1096/fj.06-6589com	http://dx.doi.org/10.1096/fj.06-6589com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17267381				2022-12-28	WOS:000246117000033
J	Novgorodov, AS; El-Alwani, M; Bielawski, J; Obeid, LM; Gudz, TI				Novgorodov, Alexander S.; El-Alwani, Mazen; Bielawski, Jacek; Obeid, Lina M.; Gudz, Tatyana I.			Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration	FASEB JOURNAL			English	Article						brain development; S1P2 receptor; FTY720; directional guidance cue	SPHINGOSINE 1-PHOSPHATE RECEPTOR; PROTEIN-COUPLED RECEPTORS; RHO FAMILY GTPASES; CELL-MIGRATION; GUIDANCE; FTY720; LYSOPHOSPHOLIPIDS; PROLIFERATION; MECHANISMS; INTEGRINS	Sphingosine-1-phosphate (S1P) acts as an extracellular ligand for a family of G-protein coupled receptors that are crucial in cell migration. S1P5 is exclusively expressed in oligodendrocytes and oligodendrocyte precursor cells (OPCs), which migrate considerable distances during brain development. The current studies suggest a physiological role for S1P and S1P5 in regulation of OPC migration. mRNA expression levels of S1P2 and S1P5 are comparable in OPCs, but S1P binding specifically to the S1P5 receptor blocked OPC migration (IC50 = 29 nM). Thus, knocking down S1P5 using siRNA prevented the S1P-induced decrease in OPC migration, whereas knocking down S1P2 did not have any effect. S1P-induced modulation of OPC migration was insensitive to pertussis toxin, suggesting that S1P5-initiated signaling is not mediated by the G alpha(i)-protein coupled pathway. Furthermore, S1P5 appears to engage the G alpha(12/13) protein coupled Rho/ROCK signaling pathway to impede OPC migration. To modulate OPC motility, extracellular S1P could be derived from the export of intracellular S1P generated in response to glutamate treatment of OPCs. These studies suggest that S1P could be a part of the neuron-oligodendroglial communication network regulating OPC migration and may provide directional guidance cues for migrating OPCs in the developing brain.	Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA; Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Gudz, TI (corresponding author), Med Univ S Carolina, Dept Neurosci, 114 Doughty St, Charleston, SC 29425 USA.	gudz@musc.edu	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; obeid, lina/0000-0002-0734-0847	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR 17677-04] Funding Source: Medline; NIGMS NIH HHS [GM062887] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JC, 2000, J CELL BIOL, V150, P807, DOI 10.1083/jcb.150.4.807; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Anelli V, 2005, J NEUROCHEM, V92, P1204, DOI 10.1111/j.1471-4159.2004.02955.x; Anliker B, 2004, SEMIN CELL DEV BIOL, V15, P457, DOI 10.1016/j.semcdb.2004.05.005; Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016; Barres BA, 1999, J CELL BIOL, V147, P1123, DOI 10.1083/jcb.147.6.1123; BARRES BA, 1993, NATURE, V361, P258, DOI 10.1038/361258a0; Bassi R, 2006, GLIA, V53, P621, DOI 10.1002/glia.20324; Behar TN, 1999, J NEUROSCI, V19, P4449; Behar TN, 1998, J NEUROSCI, V18, P6378; Belachew S, 1999, ACTA NEUROL BELG, V99, P21; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2004, YONSEI MED J, V45, P991, DOI 10.3349/ymj.2004.45.6.991; Brinkmann V, 2002, CURR OPIN IMMUNOL, V14, P569, DOI 10.1016/S0952-7915(02)00374-6; Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994; Cohen RI, 2005, CELL MOL LIFE SCI, V62, P505, DOI 10.1007/s00018-004-4485-1; Deng WB, 2006, J NEUROCHEM, V98, P213, DOI 10.1111/j.1471-4159.2006.03861.x; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795; Fujino M, 2003, J PHARMACOL EXP THER, V305, P70, DOI 10.1124/jpet.102.045658; Gallo V, 1996, J NEUROSCI, V16, P2659, DOI 10.1523/jneurosci.16-08-02659.1996; GEISER T, 1993, J BIOL CHEM, V268, P15419; Goetzl EJ, 2004, J CELL BIOCHEM, V92, P867, DOI 10.1002/jcb.20186; Goparaju SK, 2005, MOL CELL BIOL, V25, P4237, DOI 10.1128/MCB.25.10.4237-4249.2005; Gudz TI, 2006, J NEUROSCI, V26, P2458, DOI 10.1523/JNEUROSCI.4054-05.2006; Gudz TI, 2002, J NEUROSCI, V22, P7398; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Im DS, 2000, BIOCHEM BIOPH RES CO, V279, P139, DOI 10.1006/bbrc.2000.3933; Im DS, 2001, BIOCHEMISTRY-US, V40, P14053, DOI 10.1021/bi011606i; Jaillard C, 2005, J NEUROSCI, V25, P1459, DOI 10.1523/JNEUROSCI.4645-04.2005; Jarjour AA, 2004, NEUROSCIENTIST, V10, P99, DOI 10.1177/1073858403260751; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kawabata S, 2004, GENES CELLS, V9, P653, DOI 10.1111/j.1356-9597.2004.00749.x; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Le Stunff H, 2004, J CELL BIOCHEM, V92, P882, DOI 10.1002/h=jcb.20097; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lepley D, 2005, CANCER RES, V65, P3788, DOI 10.1158/0008-5472.CAN-04-2311; Malek RL, 2001, J BIOL CHEM, V276, P5692, DOI 10.1074/jbc.M003964200; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matute C, 2006, GLIA, V53, P212, DOI 10.1002/glia.20275; MILNER R, 1994, DEVELOPMENT, V120, P3497; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Novgorodov SA, 2005, J BIOL CHEM, V280, P16096, DOI 10.1074/jbc.M411707200; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Rosin C, 2004, J NEUROCHEM, V90, P1173, DOI 10.1111/j.1471-4159.2004.02584.x; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Siehler S, 2002, BBA-MOL CELL BIOL L, V1582, P94, DOI 10.1016/S1388-1981(02)00142-7; Spassky N, 2002, J NEUROSCI, V22, P5992; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Sugimoto Y, 2001, DEVELOPMENT, V128, P3321; Taha TA, 2004, BBA-MOL CELL BIOL L, V1682, P48, DOI 10.1016/S1388-1981(04)00023-X; Takuwa Y, 2002, J BIOCHEM, V131, P767, DOI 10.1093/oxfordjournals.jbchem.a003163; Terai K, 2003, NEUROSCIENCE, V116, P1053, DOI 10.1016/S0306-4522(02)00791-1; Tsai HH, 2002, TRENDS NEUROSCI, V25, P173, DOI 10.1016/S0166-2236(00)02096-8; Tsai HH, 2002, CELL, V110, P373, DOI 10.1016/S0092-8674(02)00838-3; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106; Yu NC, 2004, GLIA, V45, P17, DOI 10.1002/glia.10297	66	136	150	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1503	1514		10.1096/fj.06-7420com	http://dx.doi.org/10.1096/fj.06-7420com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17255471				2022-12-28	WOS:000246117000025
J	Vandeput, F; Combettes, L; Mills, SJ; Backers, K; Wohlkonig, A; Parys, JB; De Smedt, H; Missiaen, L; Dupont, G; Potter, BVL; Erneux, C				Vandeput, Fabrice; Combettes, Laurent; Mills, Stephen J.; Backers, Katrien; Wohlkonig, Alexandre; Parys, Jan B.; De Smedt, Humbert; Missiaen, Ludwig; Dupont, Genevieve; Potter, Barry V. L.; Erneux, Christophe			Biphenyl 2,3 ',4,5 ',6-pentakisphosphate, a novel inositol polyphosphate surrogate, modulates Ca2+ responses in rat hepatocytes	FASEB JOURNAL			English	Article						inositol 5-phosphatase; SHIP2; Ins(1,4,5) P-3 receptor; Ca2+ signaling; benzene polyphosphates	PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; 1,4,5-TRISPHOSPHATE 3-KINASE; 5-PHOSPHATASE ACTIVITY; METABOLIZING ENZYMES; SHIP2; OSCILLATIONS; CALCIUM; DOMAIN; BRAIN; CELLS	Benzene polyphosphates containing phosphate groups on one ring are Ins( 1,4,5) P-3 5-phosphatase inhibitors when evaluated against type-I Ins( 1,4,5) P-3 5- phosphatase. A novel biphenyl derivative, biphenyl 2,3', 4,5', 6- pentakisphosphate, with five phosphate groups on two rings was synthesized: It inhibited the activity of two inositol 5- phosphatases: type I and SHIP2 with Ins( 1,3,4,5) P-4 as substrate. The inhibition was competitive with respect to the substrate. IC50 value measured in rat hepatocytes, which contains the native Ins( 1,4,5) P-3 5- phosphatase, was in the micromolar range at 1.0 mu M Ins( 1,4,5) P-3 as substrate. Biphenyl 2,3', 4,5', 6- pentakisphosphate did not affect the activity of Ins( 1,4,5) P-3 3- kinase A in the 5 - 100 mu M range. Surprisingly, experimental evidence supports an effect of biphenyl 2,3', 4,5', 6- pentakisphosphate at the level of the Ins( 1,4,5) P-3 receptor. Finally, when injected into rat hepatocytes, the analog affected the frequency of Ca2+ oscillations in a positive or negative way depending on its concentration. At very high concentrations of the analog, Ca2+ oscillations were even suppressed. These data were interpreted as a dual effect of the biphenyl 2,3', 4,5', 6- pentakisphosphate on cytosolic [ Ca2+] increases: an activation effect through an increase in Ins( 1,4,5) P-3 level via Ins( 1,4,5) P-3 5- phosphatase inhibition and an inhibitory effect, which was exerted directly on the Ins( 1,4,5) P-3 receptor. Thus, our data show for the first time that the frequency of Ca2+ oscillations in response to a Ca2+- mobilizing agonist can be controlled by inhibitors of type-I Ins( 1,4,5) P-3 5- phosphatase.	Univ Libre Bruxelles, IRIBHM, B-1070 Brussels, Belgium; Univ Paris 11, INSERM UMR S757, Orsay, France; Univ Bath, Dept Pharm & Pharmacol, Wolfson Lab Med Chem, Bath BA2 7AY, Avon, England; Inst Biol, CNRS UMR8161, Lille, France; Katholieke Univ Leuven, Dept Mol Cell Biol, Fysiol Lab, Louvain, Belgium; Univ Libre Bruxelles, Fac Sci, Brussels, Belgium	Universite Libre de Bruxelles; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of Bath; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); KU Leuven; Universite Libre de Bruxelles	Erneux, C (corresponding author), Univ Libre Bruxelles, IRIBHM, Campus Erasme,Bldg C,808 Route Lennik, B-1070 Brussels, Belgium.	cerneux@ulb.ac.be	Potter, Barry VL/A-1845-2012; Potter, Barry/AAX-4781-2020; Combettes, Laurent/L-1842-2013	Combettes, Laurent/0000-0002-1376-4574; Wohlkonig, Alexandre/0000-0003-3103-5022; Parys, Jan/0000-0002-3591-4967	Wellcome Trust [060554] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Blero D, 2005, FEBS J, V272, P2512, DOI 10.1111/j.1742-4658.2005.04672.x; Blero D, 2001, BIOCHEM BIOPH RES CO, V282, P839, DOI 10.1006/bbrc.2001.4639; Bultynck G, 2004, BIOCHEM J, V381, P87, DOI 10.1042/BJ20040072; Chi YL, 2004, J BIOL CHEM, V279, P44987, DOI 10.1074/jbc.M406416200; Clair C, 2001, J CELL SCI, V114, P1999; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; DeSmedt F, 1997, J BIOL CHEM, V272, P17367, DOI 10.1074/jbc.272.28.17367; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; Dupont G, 2003, FEBS LETT, V534, P101, DOI 10.1016/S0014-5793(02)03789-4; Dupont G, 1997, CELL CALCIUM, V22, P321, DOI 10.1016/S0143-4160(97)90017-8; ERNEUX C, 1986, BIOCHEM BIOPH RES CO, V134, P351, DOI 10.1016/0006-291X(86)90570-X; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; ERNEUX C, 1985, MOL CELL ENDOCRINOL, V43, P123, DOI 10.1016/0303-7207(85)90075-9; ERNEUX C, 1991, TRENDS PHARMACOL SCI, V12, P174, DOI 10.1016/0165-6147(91)90539-5; Frederick JP, 2005, P NATL ACAD SCI USA, V102, P8454, DOI 10.1073/pnas.0503706102; Fujii M, 2005, J BIOL CHEM, V280, P1156, DOI 10.1074/jbc.M412006200; Hermosura MC, 2000, NATURE, V408, P735, DOI 10.1038/35047115; MAILLEUX P, 1991, J NEUROCHEM, V56, P345, DOI 10.1111/j.1471-4159.1991.tb02601.x; Miller GJ, 2004, MOL CELL, V15, P703, DOI 10.1016/j.molcel.2004.08.005; Mills SJ, 2006, CHEMBIOCHEM, V7, P1696, DOI 10.1002/cbic.200600125; Mitchell CA, 2002, IUBMB LIFE, V53, P25, DOI 10.1080/15216540210815; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Pesesse X, 1998, FEBS LETT, V437, P301, DOI 10.1016/S0014-5793(98)01255-1; Poinas A, 2005, CHEMBIOCHEM, V6, P1449, DOI 10.1002/cbic.200400443; POITRAS M, 1993, EUR J PHARM-MOLEC PH, V244, P203, DOI 10.1016/0922-4106(93)90145-Y; Riley AM, 1997, ANGEW CHEM INT EDIT, V36, P1472, DOI 10.1002/anie.199714721; Rowe T, 2006, ASSAY DRUG DEV TECHN, V4, P175, DOI 10.1089/adt.2006.4.175; Sleeman MW, 2005, NAT MED, V11, P199, DOI 10.1038/nm1178; Speed CJ, 1999, J CELL SCI, V112, P669; STOREY DJ, 1984, NATURE, V312, P374, DOI 10.1038/312374a0; TAKAZAWA K, 1988, BIOCHEM BIOPH RES CO, V153, P632, DOI 10.1016/S0006-291X(88)81142-2; Tordjmann T, 1997, EMBO J, V16, P5398, DOI 10.1093/emboj/16.17.5398; Vandeput F, 2006, CELL SIGNAL, V18, P2193, DOI 10.1016/j.cellsig.2006.05.010; Vanlingen S, 2001, BIOCHEM PHARMACOL, V61, P803, DOI 10.1016/S0006-2952(01)00540-8; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085	36	26	27	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1481	1491		10.1096/fj.06-7691com	http://dx.doi.org/10.1096/fj.06-7691com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264160				2022-12-28	WOS:000246117000023
J	Mascanfroni, I; Montesinos, MD; Susperreguy, S; Cervi, L; Ilarregui, JM; Ramseyer, VD; Masini-Repiso, AM; Targovnik, HM; Rabinovich, GA; Rellizas, CG				Mascanfroni, Ivan; del Mar Montesinos, Maria; Susperreguy, Sebastian; Cervi, Laura; Ilarregui, Juan M.; Ramseyer, Vanesa D.; Masini-Repiso, Ana M.; Targovnik, Heector M.; Rabinovich, Gabriel A.; Rellizas, Claudia G.			Control of dendritic cell maturation and function by triipdothyronine	FASEB JOURNAL			English	Article						adaptive immunity; thyroid hormones; antigen presentation	THYROID-HORMONE ACTION; COLONY-STIMULATING FACTOR; GROWTH-FACTOR-I; NF-KAPPA-B; IMMUNE-SYSTEM; BONE-MARROW; TRIIODOTHYRONINE RECEPTORS; ANTERIOR-PITUITARY; MEDIATED-IMMUNITY; NUCLEAR RECEPTOR	Accumulating evidence indicates a functional crosstalk between immune and endocrine mechanisms in the modulation of innate and adaptive immunity. However, the impact of thyroid hormones (THs) in the initiation of adaptive immune responses has not yet been examined. Here we investigated the presence of thyroid hormone receptors (TRs) and the impact of THs in the physiology of mouse dendritic cells (DCs), specialized antigen-presenting cells with the unique capacity to fully activate naive T cells and orchestrate adaptive immunity. Both immature and lipopolysaccharide-matured bone marrow-derived DCs expressed TRs at mRNA and protein levels, showing a preferential cytoplasmic localization. Remarkably, physiological levels of triiodothyronine (T3) stimulated the expression of DC maturation markers (major histocompatability complex II, CD80, CD86, and CD40), markedly increased the secretion of interleukin-12, and stimulated the ability of DCs to induce naive T cell proliferation and IFN-gamma production in allogeneic T cell cultures. Analysis of the mechanisms involved in these effects revealed the ability of T3 to influence the cytoplasmic-nuclear shuttling of nuclear factor-kappa B on primed DCs. Our study provides the first evidence for the presence of TRs on bone marrow-derived DCs and the ability of THs to regulate DC maturation and function. These results have profound implications in immunopathology, including cancer and autoimmune manifestations of the thyroid gland at the crossroads of the immune and endocrine systems.	[Mascanfroni, Ivan; del Mar Montesinos, Maria; Susperreguy, Sebastian; Cervi, Laura; Ramseyer, Vanesa D.; Masini-Repiso, Ana M.; Rellizas, Claudia G.] Univ Nacl Cordoba, Fac Ciencias Quim, CIBICI CONICET, Dept Bioquim Clin, RA-5000 Cordoba, Argentina; [Ilarregui, Juan M.; Rabinovich, Gabriel A.] Univ Buenos Aires, CONICET, IBYME, Buenos Aires, DF, Argentina; [Ilarregui, Juan M.; Rabinovich, Gabriel A.] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Buenos Aires, DF, Argentina; [Targovnik, Heector M.] Univ Buenos Aires, Fac Farm & Bioquim, Catedra Genet & Biol Mol, RA-1113 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; University of Buenos Aires; University of Buenos Aires; University of Buenos Aires	Rellizas, CG (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, CIBICI CONICET, Dept Bioquim Clin, Haya Torre Esq Medina Allende,Ciudad Univ, RA-5000 Cordoba, Argentina.	claudia@mail.fcq.unc.edu.ar		Ilarregui, Juan Martin/0000-0002-6871-6764; Ramseyer Payant, Vanesa/0000-0001-9368-0997				Alkemade A, 2005, J CLIN ENDOCR METAB, V90, P904, DOI 10.1210/jc.2004-0474; Ausubel LJ, 1996, P NATL ACAD SCI USA, V93, P15317, DOI 10.1073/pnas.93.26.15317; Bagriacik EU, 2000, J IMMUNOL, V164, P6158, DOI 10.4049/jimmunol.164.12.6158; BALAZS C, 1980, EUR J CLIN PHARMACOL, V17, P19, DOI 10.1007/BF00561672; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Barish GD, 2005, MOL ENDOCRINOL, V19, P2466, DOI 10.1210/me.2004-0529; Bassett JHD, 2003, MOL CELL ENDOCRINOL, V213, P1, DOI 10.1016/j.mce.2003.10.033; Baumann CT, 2001, J BIOL CHEM, V276, P11237, DOI 10.1074/jbc.M011112200; Bergh JJ, 2005, ENDOCRINOLOGY, V146, P2864, DOI 10.1210/en.2005-0102; Bonasio R, 2006, CURR OPIN IMMUNOL, V18, P503, DOI 10.1016/j.coi.2006.05.011; Bottero V, 2006, CELL DEATH DIFFER, V13, P785, DOI 10.1038/sj.cdd.4401888; CHATTERJEE S, 1983, ACTA ENDOCRINOL-COP, V103, P95, DOI 10.1530/acta.0.1030095; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CSABA G, 1977, HORM METAB RES, V9, P499, DOI 10.1055/s-0028-1093509; D'Arezzo S, 2004, ENDOCRINOLOGY, V145, P5694, DOI 10.1210/en.2004-0890; Davis PJ, 2005, TRENDS ENDOCRIN MET, V16, P429, DOI 10.1016/j.tem.2005.09.007; Delgado M, 2004, J LEUKOCYTE BIOL, V75, P1122, DOI 10.1189/jlb.1203626; Diekman MJM, 2001, J ENDOCRINOL, V168, P427, DOI 10.1677/joe.0.1680427; Dorshkind K, 2001, BIOESSAYS, V23, P288, DOI 10.1002/1521-1878(200103)23:3<288::AID-BIES1039>3.0.CO;2-P; Dorshkind K, 2000, ENDOCR REV, V21, P292, DOI 10.1210/er.21.3.292; Doulabi BZ, 2002, ENDOCRINOLOGY, V143, P979; FABRIS N, 1995, HORM RES, V43, P29, DOI 10.1159/000184234; Foster MP, 2000, CLIN IMMUNOL, V96, P140, DOI 10.1006/clim.2000.4889; Freeman L, 2005, BLOOD, V106, P2042, DOI 10.1182/blood-2005-01-0186; Gad M, 2003, APMIS, V111, P766, DOI 10.1034/j.1600-0463.2003.11107808.x; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Hager GL, 2000, J STEROID BIOCHEM, V74, P249, DOI 10.1016/S0960-0760(00)00100-X; Hagihara M, 2001, J IMMUNOL METHODS, V253, P45, DOI 10.1016/S0022-1759(01)00386-6; Hewison M, 2003, J IMMUNOL, V170, P5382, DOI 10.4049/jimmunol.170.11.5382; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jakobsen MA, 2006, SCAND J IMMUNOL, V63, P330, DOI 10.1111/j.1365-3083.2006.01745.x; Klecha AJ, 2006, J ENDOCRINOL, V189, P45, DOI 10.1677/joe.1.06137; Komi J, 2000, BLOOD, V95, P2875, DOI 10.1182/blood.V95.9.2875.009k12_2875_2882; Kreuzer KA, 1999, CLIN CHEM, V45, P297; Laderach D, 2003, J IMMUNOL, V171, P1750, DOI 10.4049/jimmunol.171.4.1750; Lipscomb MF, 2002, PHYSIOL REV, V82, P97, DOI 10.1152/physrev.00023.2001; Liu LX, 2003, ENDOCRINOLOGY, V144, P3836, DOI 10.1210/en.2003-0160; Maruvada P, 2003, J BIOL CHEM, V278, P12425, DOI 10.1074/jbc.M202752200; MeierHeusler S, 1995, J ENDOCRINOL INVEST, V18, P767, DOI 10.1007/BF03349809; Montesinos MM, 2006, LIFE SCI, V78, P2584, DOI 10.1016/j.lfs.2005.10.019; MOOIJ P, 1994, J ENDOCRINOL, V140, P503, DOI 10.1677/joe.0.1400503; Nahmod KA, 2003, FASEB J, V17, P491, DOI 10.1096/fj.02-0755fje; Nalbandian G, 2005, J IMMUNOL, V175, P2666, DOI 10.4049/jimmunol.175.4.2666; Roelen DL, 2003, TRANSPLANTATION, V76, P1608, DOI 10.1097/01.TP.0000086340.30817.BA; Rutella S, 2006, BLOOD, V108, P1435, DOI 10.1182/blood-2006-03-006403; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Siebler T, 2002, BONE, V30, P259, DOI 10.1016/S8756-3282(01)00631-7; Smithson G, 1998, J IMMUNOL, V161, P27; Storey NM, 2006, P NATL ACAD SCI USA, V103, P5197, DOI 10.1073/pnas.0600089103; Straw AD, 2003, J IMMUNOL, V170, P727, DOI 10.4049/jimmunol.170.2.727; Sundquist M, 2003, APMIS, V111, P715, DOI 10.1034/j.1600-0463.2003.11107804.x; Tamaru M, 1999, EUR J ENDOCRINOL, V141, P111, DOI 10.1530/eje.0.1410111; Tamaru M, 1999, EUR J ENDOCRINOL, V141, P625, DOI 10.1530/eje.0.1410625; Tao YH, 2006, FEMS IMMUNOL MED MIC, V47, P444, DOI 10.1111/j.1574-695X.2006.00108.x; VILLAVERDE DMS, 1992, ENDOCRINOLOGY, V131, P1313, DOI 10.1210/en.131.3.1313; Wang HC, 2001, CRIT REV IMMUNOL, V21, P323; Yamaguchi S, 1999, J MOL ENDOCRINOL, V22, P81, DOI 10.1677/jme.0.0220081; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Yen PM, 2006, MOL CELL ENDOCRINOL, V246, P121, DOI 10.1016/j.mce.2005.11.030; Zhu XG, 1998, J BIOL CHEM, V273, P27058, DOI 10.1074/jbc.273.42.27058	60	64	70	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1032	1042		10.1096/fj.07-8652com	http://dx.doi.org/10.1096/fj.07-8652com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	17991732				2022-12-28	WOS:000254581000009
J	Sadayappan, S; Finley, N; Howarth, JW; Osinska, H; Klevitsky, R; Lorenz, JN; Rosevear, PR; Robbins, J				Sadayappan, Sakthivel; Finley, Natosha; Howarth, Jack W.; Osinska, Hanna; Klevitsky, Raisa; Lorenz, John N.; Rosevear, Paul R.; Robbins, Jeffrey			Role of the acidic N ' region of cardiac troponin I in regulating myocardial function	FASEB JOURNAL			English	Article						muscle; transgenic mouse model; contractility; heart	KINASE-A PHOSPHORYLATION; HYPERTROPHIC CARDIOMYOPATHY; CONFORMATIONAL EXCHANGE; TERMINAL EXTENSION; INTERACTION SITES; HEART; DOMAIN; EXPRESSION; MUSCLE; STIMULATION	Cardiac troponin I (cTnI) phosphorylation modulates myocardial contractility and relaxation during beta-adrenergic stimulation. cTnI differs from the skeletal isoform in that it has a cardiac specific N' extension of 32 residues (N' extension). The role of the acidic N' region in modulating cardiac contractility has not been fully defined. To test the hypothesis that the acidic N' region of cTnI helps regulate myocardial function, we generated cardiac-specific transgenic mice in which residues 2-11 (cTnI(Delta 2-11)) were deleted. The hearts displayed significantly decreased contraction and relaxation under basal and P-adrenergic stress compared to nontransgenic hearts, with a reduction in maximal Ca2+-dependent force and maximal Ca2+- activated Mg2+-ATPase activity. However, Ca2+ sensitivity of force development and cTnI-Ser(23/24) phosphorylation were not affected. Chemical shift mapping shows that both cTnI and cTnI(Delta 2-11) interact with the N lobe of cardiac troponin C (cTnC) and that phosphorylation at Ser(23/24) weakens these interactions. These observations suggest that residues 2-11 of cTnI, comprising the acidic N' region, do not play a direct role in the calcium-induced transition in the cardiac regulatory or N lobe of cTnC. We hypothesized that phosphorylation at Ser(23/24) induces a large conformational change positioning the conserved acidic N region to compete with actin for the inhibitory region of cTnI. Consistent with this hypothesis, deletion of the conserved acidic N' region results in a decrease in myocardial contractility in the cTnI(Delta 2-11) mice demonstrating the importance of acidic N' region in regulating myocardial contractility and mediating the response of the heart to beta-AR stimulation.	[Sadayappan, Sakthivel; Osinska, Hanna; Klevitsky, Raisa; Robbins, Jeffrey] Childrens Hosp, Med Ctr, Dept Pediat, Div Mol Cardivasc Biol, Cincinnati, OH 45229 USA; [Lorenz, John N.] Univ Cincinnati, Dept Med, Cincinnati, OH 45221 USA	Cincinnati Children's Hospital Medical Center; University of Cincinnati	Robbins, J (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat, Div Mol Cardivasc Biol, MLC 7020,Burnet Ave, Cincinnati, OH 45229 USA.	jeff.robbins@cchmc.org		Sadayappan, Sakthivel/0000-0003-2006-7678	NHLBI NIH HHS [HL-83334, P50 HL052318, P50 HL074728-010004, P50 HL074728, HL-69799, P01 HL041496-090007, P01 HL022619-200019, P50 HL077101, P01 HL022619, P50 HL077101-010005, HL-52318, R01 HL061638-06, R01 HL061638, R01 HL056370, P01 HL069779-01, HL-56370, P01 HL069779, P01 HL069779-06A17077, R01 HL056370-04, HL-60546] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, R01HL061638, P50HL074728, P01HL069779, P50HL052318, R01HL060546, P01HL041496, R01HL083334, P50HL077101, R01HL056370] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott MB, 2000, J BIOL CHEM, V275, P20610, DOI 10.1074/jbc.M909252199; Abbott MB, 2000, FEBS LETT, V469, P168, DOI 10.1016/S0014-5793(00)01271-0; Abbott MB, 2001, BIOCHEMISTRY-US, V40, P5992, DOI 10.1021/bi0100642; Arad M, 2005, CIRCULATION, V112, P2805, DOI 10.1161/CIRCULATIONAHA.105.547448; Barbato JC, 2005, J BIOL CHEM, V280, P6602, DOI 10.1074/jbc.M408525200; Chandra M, 1997, BIOCHEMISTRY-US, V36, P13305, DOI 10.1021/bi9710129; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; El-Armouche A, 2006, CIRCULATION, V114, P670, DOI 10.1161/CIRCULATIONAHA.106.636845; FCNTZKC RC, 1999, J PHYSL, V517, P143; Fewell JG, 1998, J CLIN INVEST, V101, P2630, DOI 10.1172/JCI2825; Finley N, 1999, FEBS LETT, V453, P107, DOI 10.1016/S0014-5793(99)00693-6; Gaponenko V, 1999, J BIOL CHEM, V274, P16681, DOI 10.1074/jbc.274.24.16681; Haworth RS, 2004, CIRC RES, V95, P1091, DOI 10.1161/01.RES.0000149299.34793.3c; Holthauzen LMF, 2004, J BIOL CHEM, V279, P15204, DOI 10.1074/jbc.M308904200; Howarth JW, 2007, J MOL BIOL, V373, P706, DOI 10.1016/j.jmb.2007.08.035; James J, 2000, CIRC RES, V87, P805, DOI 10.1161/01.RES.87.9.805; Kentish JC, 2001, CIRC RES, V88, P1059, DOI 10.1161/hh1001.091640; KRANIAS EG, 1982, NATURE, V298, P182, DOI 10.1038/298182a0; Krenz M, 2004, J AM COLL CARDIOL, V44, P2390, DOI 10.1016/j.jacc.2004.09.044; Krenz M, 2007, J BIOL CHEM, V282, P24057, DOI 10.1074/jbc.M704574200; Layland J, 2004, J PHYSIOL-LONDON, V556, P835, DOI 10.1113/jphysiol.2004.061176; Murakami K, 2005, J MOL BIOL, V352, P178, DOI 10.1016/j.jmb.2005.06.067; MURPHY AM, 1991, BIOCHEMISTRY-US, V30, P707, DOI 10.1021/bi00217a018; Murphy RT, 2004, LANCET, V363, P371, DOI 10.1016/S0140-6736(04)15468-8; Sadayappan S, 2005, CIRC RES, V97, P1156, DOI 10.1161/01.RES.0000190605.79013.4d; SAGGIN L, 1989, J BIOL CHEM, V264, P16299; Sakthivel S, 2005, J BIOL CHEM, V280, P703, DOI 10.1074/jbc.M409513200; Sanbe A, 2005, CIRCULATION, V111, P2330, DOI 10.1161/01.CIR.0000164234.24957.75; SASSE S, 1993, CIRC RES, V72, P932, DOI 10.1161/01.RES.72.5.932; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Takimoto E, 2004, CIRC RES, V94, P496, DOI 10.1161/01.RES.0000117307.57798.F5; Turnbull L, 2002, J PHYSIOL-LONDON, V542, P911, DOI 10.1113/jphysiol.2002.022707; Ward DG, 2004, BIOCHEMISTRY-US, V43, P5772, DOI 10.1021/bi036310m; Ward DG, 2004, BIOCHEMISTRY-US, V43, P4020, DOI 10.1021/bi036128l; Ward DG, 2003, BIOCHEMISTRY-US, V42, P10324, DOI 10.1021/bi034495r; Ward DG, 2002, J BIOL CHEM, V277, P41795, DOI 10.1074/jbc.M206744200	36	22	23	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2008	22	4					1246	1257		10.1096/fj.07-9458com	http://dx.doi.org/10.1096/fj.07-9458com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	17984178	Green Accepted			2022-12-28	WOS:000254581000029
J	Endeward, V; Cartron, JP; Ripoche, P; Gros, G				Endeward, Volker; Cartron, Jean-Pierre; Ripoche, Pierre; Gros, Gerolf			RhAG protein of the Rhesus complex is a CO2 channel in the human red cell membrane	FASEB JOURNAL			English	Article						Rhesus-associated glycoprotein; membrane CO2; permeability; ammonia; aquaporin	CARBON-DIOXIDE PERMEABILITY; HUMAN-ERYTHROCYTES; AMMONIA TRANSPORT; GREEN-ALGA; BLOOD; AQUAPORIN-1; NULL; DIFFUSION; ANHYDRASE; NH3	We have determined CO2 permeabilities, P-CO2, of red cells of normal human blood and of blood deficient in various blood group proteins by a previously described mass spectrometric technique. While PCO2 of normal red cells is similar to 0.15 cm/s, we find in red blood cells (RBCs) lacking the Rh protein complex (Rh-null) a significantly reduced P-CO2 of 0.07 cm/s +/- 0.02 cm/s (P< 0.02). This value is similar to the value we have reported previously for RBCs lacking aquaporin-1 protein (AQP-1(null)), suggesting that each of the Rh and AQP-1 proteins is responsible for similar to 1/2 of the normal CO2 permeability of the RBC membrane. Four other blood group deficiencies tested lack diverse membrane proteins but exhibit normal CO2 permeability. The CO2 pathway constituted by Rh proteins was inhibitable at pH(e) = 7.4 by NH4Cl with an I-50 of similar to 10 mM corresponding to an I50 for NH3 of similar to 0.3 mM. The pathway independent of Rh proteins, presumably that constituted by AQP-1, was not inhibitable by NH4Cl/NH3. However, both pathways were strongly inhibited by DIDS, which accounts for the marked inhibitory effect of DIDS on normal PCO2, while in contrast another AE1 inhibitor, DiBAC, does not inhibit PCO2, although it markedly reduces PHCO3-. We conclude that Rh protein, presumably the Rh-associated glycoprotein RhAG, possesses a gas channel that allows passage of CO2 in addition to NH3.-Endeward, V., Cartron, J.-P., Ripoche, P., and Gros, G. RhAG protein of the Rhesus complex is a CO2 channel in the human red cell membrane.	[Endeward, Volker; Gros, Gerolf] Hannover Med Sch, Abt Vegetat Physiol, D-30623 Hannover, Germany; [Cartron, Jean-Pierre; Ripoche, Pierre] Inst Natl Sante & Rech Med, Paris, France; [Cartron, Jean-Pierre; Ripoche, Pierre] Inst Natl Transfus Sanguine, Hannover, Germany	Hannover Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm)	Gros, G (corresponding author), Hannover Med Sch, Abt Vegetat Physiol, D-30623 Hannover, Germany.	gros.gerolf@mh-hannover.de	Gros, Gerolf/K-8421-2012					Alberts B., 2008, MOL BIOL CEL, V5th ed.; BALLAS SK, 1984, BLOOD, V63, P1046; BLANK M, 1960, T FARADAY SOC, V56, P1832, DOI 10.1039/tf9605601832; Blank ME, 2003, J PHYSIOL-LONDON, V550, P419, DOI 10.1113/jphysiol.2003.040113; BRAHM J, 1982, J GEN PHYSIOL, V79, P791, DOI 10.1085/jgp.79.5.791; Bruce LJ, 2003, BLOOD, V101, P4180, DOI 10.1182/blood-2002-09-2824; Callebaut I, 2006, TRANSFUS CLIN BIOL, V13, P70, DOI 10.1016/j.tracli.2006.02.001; Cartron JP, 1999, BEST PRACT RES CL HA, V12, P655, DOI 10.1053/beha.1999.0047; Cartron JP, 2001, TRANSFUS CLIN BIOL, V8, P163, DOI 10.1016/S1246-7820(01)00142-2; Casey JR, 2004, J MED CHEM, V47, P2337, DOI 10.1021/jm031079w; Cho MR, 1999, BIOPHYS J, V76, P1136, DOI 10.1016/S0006-3495(99)77278-4; Cooper GJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1481, DOI 10.1152/ajpcell.1998.275.6.C1481; *CRC, 1977, CRC HDB CHEM PHYS; DENKER BM, 1988, J BIOL CHEM, V263, P15634; EDSALL JT, 1969, CO2 CHEM BIOCH PHYSL; Endeward V, 2006, FASEB J, V20, P1974, DOI 10.1096/fj.04-3300com; Endeward V, 2006, TRANSFUS CLIN BIOL, V13, P123, DOI 10.1016/j.tracli.2006.02.007; Endeward V, 2005, J PHYSIOL-LONDON, V567, P253, DOI 10.1113/jphysiol.2005.085761; Forster RE, 1998, P NATL ACAD SCI USA, V95, P15815, DOI 10.1073/pnas.95.26.15815; GROS G, 1971, PFLUG ARCH EUR J PHY, V324, P249, DOI 10.1007/BF00586422; GUTKNECHT J, 1977, J GEN PHYSIOL, V69, P779; Hill WG, 1999, J GEN PHYSIOL, V114, P405, DOI 10.1085/jgp.114.3.405; Hirschfelder J. O., 1954, MOL THEORY GASES LIQ; Huang CH, 2000, SEMIN HEMATOL, V37, P150, DOI 10.1016/S0037-1963(00)90040-4; ITADA N, 1977, J BIOL CHEM, V252, P3881; Khademi S, 2004, SCIENCE, V305, P1587, DOI 10.1126/science.1101952; KNAUF PA, 1995, AM J PHYSIOL-CELL PH, V269, pC1073, DOI 10.1152/ajpcell.1995.269.4.C1073; KUYPERS F, 1984, BIOCHEM J, V221, P931, DOI 10.1042/bj2210931; Le Van Kim C, 2006, BLOOD REV, V20, P93, DOI 10.1016/j.blre.2005.04.002; Marini AM, 2000, NAT GENET, V26, P341, DOI 10.1038/81656; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; MOORE WJ, 1962, PHYSL CHEM; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; Negrete HO, 1996, AM J PHYSIOL-RENAL, V271, pF886, DOI 10.1152/ajprenal.1996.271.4.F886; Nicolas V, 2003, J BIOL CHEM, V278, P25526, DOI 10.1074/jbc.M302816200; Prasad Ramjee, 1998, IEEE Communications Surveys & Tutorials, V1, P2, DOI 10.1109/COMST.1998.5340404; Reid ME, 2004, SEMIN HEMATOL, V41, P93, DOI 10.1053/j.seminhematol.2004.01.001; REINHART WH, 1986, BLOOD, V67, P1110; Ripoche P, 2006, TRANSFUS CLIN BIOL, V13, P117, DOI 10.1016/j.tracli.2006.03.004; Ripoche P, 2004, P NATL ACAD SCI USA, V101, P17222, DOI 10.1073/pnas.0403704101; SINGH SK, 1995, P NATL ACAD SCI USA, V92, P11573, DOI 10.1073/pnas.92.25.11573; SMITH BL, 1991, J BIOL CHEM, V266, P6407; Soupene E, 2004, P NATL ACAD SCI USA, V101, P7787, DOI 10.1073/pnas.0401809101; Soupene E, 2002, P NATL ACAD SCI USA, V99, P7769, DOI 10.1073/pnas.112225599; Soupene E, 2001, MOL CELL BIOL, V21, P5733, DOI 10.1128/MCB.21.17.5733-5741.2001; STURGEON P, 1970, BLOOD-J HEMATOL, V36, P310, DOI 10.1182/blood.V36.3.310.310; THULBORN KR, 1977, BLOOD, V50, P964; Uehlein N, 2003, NATURE, V425, P734, DOI 10.1038/nature02027; WAISBREN SJ, 1994, NATURE, V368, P332, DOI 10.1038/368332a0; Westhoff CM, 2002, J BIOL CHEM, V277, P12499, DOI 10.1074/jbc.C200060200; Yang BX, 2000, J BIOL CHEM, V275, P2686, DOI 10.1074/jbc.275.4.2686; Zheng L, 2004, P NATL ACAD SCI USA, V101, P17090, DOI 10.1073/pnas.0406475101	52	127	131	0	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					64	73		10.1096/fj.07-9097com	http://dx.doi.org/10.1096/fj.07-9097com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17712059				2022-12-28	WOS:000252309900010
J	Franceschini, S; Ilari, A; Verzili, D; Zamparelli, C; Antaramian, A; Rueda, A; Valdivia, HH; Chiancone, E; Colotti, G				Franceschini, Stefano; Ilari, Andrea; Verzili, Daniela; Zamparelli, Carlotta; Antaramian, Anaid; Rueda, Angelica; Valdivia, Hector H.; Chiancone, Emilia; Colotti, Gianni			Molecular basis for the impaired function of the natural F112L sorcin mutant: X-ray crystal structure, calcium affinity, and interaction with annexin VII and the ryanodine receptor	FASEB JOURNAL			English	Article						EF hand heart; PEF proteins channels; excitation-contraction coupling; calcium-induced channel release	HAND PROTEIN FAMILY; MISSENSE MUTATION; DOMAIN-VI; BINDING; HEART; MODULATION; CALPAIN; MUSCLE; DIFFRACTION; RELEASE	The penta-EF hand protein sorcin participates in the modulation of Ca2+-induced calcium-release in the heart through the interaction with several Ca2+ channels such as the ryanodine receptor. The modulating activity is impaired in the recently described natural F112L mutant. The F112 residue is located at the end of the D helix next to Asp113, one of the calcium ligands in the EF3 hand endowed with the highest affinity for the metal. The F112L-sorcin X-ray crystal structure at 2.5 angstrom resolution displays marked alterations in the EF3 hand, where the hydrogen bonding network established by Phe112 is disrupted, and in the EF1 region, which is tilted in both monomers that give rise to the dimer, the stable form of the molecule. In turn, the observed tilt is indicative of an increased flexibility of the N-terminal part of the molecule. The structural alterations result in a 6-fold decrease in calcium affinity with respect to the wild-type protein and to an even larger impairment of the interaction with annexin VII and of the ability of sorcin to interact with and inhibit ryanodine receptors. These results provide a plausible structural and functional framework that helps elucidate the phenotypic alterations of mice overexpressing F112L-sorcin.	[Franceschini, Stefano; Ilari, Andrea; Verzili, Daniela; Chiancone, Emilia; Colotti, Gianni] Univ Roma La Sapienza, CNR, Inst Mol Biol & Pathol, I-00185 Rome, Italy; [Zamparelli, Carlotta; Chiancone, Emilia] Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; [Antaramian, Anaid; Rueda, Angelica; Valdivia, Hector H.] Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Sapienza University Rome; University of Wisconsin System; University of Wisconsin Madison	Colotti, G (corresponding author), Univ Roma La Sapienza, CNR, Inst Mol Biol & Pathol, P Le A Moro 5, I-00185 Rome, Italy.	gianni.colotti@uniroma1.it	Colotti, Gianni/D-2015-2010; Ilari, Andrea/AAC-7670-2022; Rueda, Angelica/G-4055-2012; Rueda, Angelica/A-1394-2009; Colotti, Gianni/AAG-4918-2019; Rueda, Angelica/AAW-4621-2020; Ilari, Andrea/T-5501-2017	Colotti, Gianni/0000-0002-9913-0635; Ilari, Andrea/0000-0002-7754-399X; Rueda, Angelica/0000-0001-8749-8494; Rueda, Angelica/0000-0001-8749-8494; Ilari, Andrea/0000-0002-7754-399X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076826] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-76826] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andre I, 2002, ANAL BIOCHEM, V305, P195, DOI 10.1006/abio.2002.5661; BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; Blanchard H, 1996, PROTEIN SCI, V5, P535; Brookes AJ, 2000, NUCLEIC ACIDS RES, V28, P356, DOI 10.1093/nar/28.1.356; Brownawell AM, 1997, J BIOL CHEM, V272, P22182, DOI 10.1074/jbc.272.35.22182; Buetow KH, 1999, NAT GENET, V21, P323, DOI 10.1038/6851; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; Collis LP, 2007, FASEB J, V21, P475, DOI 10.1096/fj.06-6292com; Colotti G, 2006, BIOCHEMISTRY-US, V45, P12519, DOI 10.1021/bi060416a; DELANO WL, 2002, USERS MANUAL DELANO; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Farrell EF, 2003, J BIOL CHEM, V278, P34660, DOI 10.1074/jbc.M305931200; HARKINS AB, 1993, BIOPHYS J, V65, P865, DOI 10.1016/S0006-3495(93)81112-3; Ilari A, 2002, J MOL BIOL, V317, P447, DOI 10.1006/jmbi.2002.5417; Jia J, 2000, J MOL BIOL, V300, P1271, DOI 10.1006/jmbi.2000.3925; Jia J, 2001, STRUCTURE, V9, P267, DOI 10.1016/S0969-2126(01)00585-8; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; Lokuta AJ, 1997, J BIOL CHEM, V272, P25333, DOI 10.1074/jbc.272.40.25333; Matsumoto T, 2005, BASIC RES CARDIOL, V100, P250, DOI 10.1007/s00395-005-0518-7; Mella M, 2003, J BIOL CHEM, V278, P24921, DOI 10.1074/jbc.M213276200; Meyers MB, 2003, J BIOL CHEM, V278, P28865, DOI 10.1074/jbc.M302009200; Meyers MB, 1998, J BIOL CHEM, V273, P18930, DOI 10.1074/jbc.273.30.18930; MEYERS MB, 1995, FEBS LETT, V357, P230, DOI 10.1016/0014-5793(94)01338-2; Mohiddin SA, 2002, CIRCULATION, V106, P319; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rueda A, 2006, J PHYSIOL-LONDON, V576, P887, DOI 10.1113/jphysiol.2006.113951; Schuck P, 1997, CURR OPIN BIOTECH, V8, P498, DOI 10.1016/S0958-1669(97)80074-2; Seidler T, 2003, CIRC RES, V93, P132, DOI 10.1161/01.RES.0000081596.90205.E2; Smith Godfrey L, 2006, J Cardiovasc Electrophysiol, V17 Suppl 1, pS57, DOI 10.1111/j.1540-8167.2006.00384.x; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VANDERBLIEK AM, 1986, EMBO J, V5, P3201, DOI 10.1002/j.1460-2075.1986.tb04630.x; Xie XL, 2001, PROTEIN SCI, V10, P2419, DOI 10.1110/ps.ps.36701; YANG XR, 2005, AM J PHYSIOL, V289, pL337	35	27	29	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2008	22	1					295	306		10.1096/fj.07-8988com	http://dx.doi.org/10.1096/fj.07-8988com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17699613				2022-12-28	WOS:000252309900031
J	Boudreau, F; Lussier, CR; Mongrain, S; Darsigny, M; Drouin, JL; Doyon, G; Suh, ER; Beaulieu, JF; Rivard, N; Perreault, N				Boudreau, Francois; Lussier, Carine R.; Mongrain, Sebastien; Darsigny, Mathieu; Drouin, Julie L.; Doyon, Genevieve; Suh, Eun Ran; Beaulieu, Jean-Francois; Rivard, Nathalie; Perreault, Nathalie			Loss of cathepsin L activity promotes claudin-1 overexpression and intestinal neoplasia	FASEB JOURNAL			English	Article						tight junction; polarization; intestinal epithelium	ISOMALTASE GENE-EXPRESSION; CRYPT-VILLUS AXIS; CYSTEINE PROTEASES; TIGHT JUNCTIONS; UP-REGULATION; IN-VIVO; WNT; TRANSCRIPTION; DIFFERENTIATION; TRANSFORMATION	Intestinal epithelial integrity and polarity are maintained by cohesive interactions between cells via the formation of tight junctions. Irregularities in tight junctions have only recently been found to be associated with the initiation and progression of intestinal neoplasia. The claudin family of proteins is integral to the structure and function of the tight junction but little is known of the molecular events that regulate the expression of these components. The present report identifies cathepsin L, classically a lysosomal cysteine protease, as being induced during intestinal epithelial cell polarization and differentiation. Inhibition of intracellular cathepsin L activity results in the accumulation of disorganized cell layers and a decline in the expression of differentiation markers in cultured intestinal epithelial cells. This coincides with a rapid up-regulation of claudin- 1 protein accumulation. Mutant mice defective in cathepsin L activity ( furless) display an elevated level of intestinal claudin- 1 and claudin- 2 expression. Loss of cathepsin L activity leads to a marked increase in tumor multiplicity in the intestine of Apc(Min) mice. Given the traditionally viewed biological role of cathepsin L in the processing of lysosomal content as well as in pathological extracellular matrix remodeling, the results here demonstrate an as yet unsuspected intracellular role for this protease in normal intestinal epithelial polarization and initiation of neoplasia.	Fac Med Sci Sante, Dept Anat & Biol Cellulaire, Sherbrooke, PQ J1H 5N4, Canada; CIHR, Team Digest Epithelium, Sherbrooke, PQ, Canada; Univ Penn, Dept Med, GI Div, Philadelphia, PA 19104 USA	University of Pennsylvania	Boudreau, F (corresponding author), Fac Med Sci Sante, Dept Anat & Biol Cellulaire, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	francois.boudreau@usherbrooke.ca	Beaulieu, Jean-Francois/D-2054-2010					Amasheh S, 2002, J CELL SCI, V115, P4969, DOI 10.1242/jcs.00165; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Berchem G, 2002, ONCOGENE, V21, P5951, DOI 10.1038/sj.onc.1205745; Boucher MJ, 2004, AM J PHYSIOL-GASTR L, V286, pG736, DOI 10.1152/ajpgi.00453.2003; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; CHAUHAN SS, 1991, CANCER RES, V51, P1478; Clevers H, 2006, CANCER RES, V66, P2, DOI 10.1158/0008-5472.CAN-05-3849; Clevers H, 2004, CANCER CELL, V5, P5, DOI 10.1016/S1535-6108(03)00339-8; Collette J, 2004, INT REV CYTOL, V241, P1, DOI 10.1016/S0074-7696(04)41001-8; de Oliveira SS, 2005, FEBS LETT, V579, P6179, DOI 10.1016/j.febslet.2005.09.091; DeStafanis D, 1997, CELL TISSUE RES, V289, P109; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; GOTTESMAN MM, 1978, P NATL ACAD SCI USA, V75, P2767, DOI 10.1073/pnas.75.6.2767; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Herszenyi L, 1999, CANCER, V86, P1135, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1135::AID-CNCR6>3.0.CO;2-2; Hnatyszyn HJ, 2001, MOL CELL PROBE, V15, P169, DOI 10.1006/mcpr.2001.0355; Holmes JL, 2006, GENE EXPR PATTERNS, V6, P581, DOI 10.1016/j.modgep.2005.12.001; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; KOMINAMI E, 1988, FEBS LETT, V231, P225, DOI 10.1016/0014-5793(88)80736-1; Krueger S, 2001, CANCER GENE THER, V8, P522, DOI 10.1038/sj.cgt.7700341; Leotlela PD, 2007, ONCOGENE, V26, P3846, DOI 10.1038/sj.onc.1210155; Lipschutz JH, 2005, J BIOL CHEM, V280, P3780, DOI 10.1074/jbc.M408122200; MACIEWICZ RA, 1989, INT J CANCER, V43, P478, DOI 10.1002/ijc.2910430323; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; McGrath ME, 1999, ANNU REV BIOPH BIOM, V28, P181, DOI 10.1146/annurev.biophys.28.1.181; MENARD D, 1987, J PEDIATR GASTR NUTR, V6, P509, DOI 10.1097/00005176-198707000-00003; Menard D, 2006, CELL SIGNALING AND GROWTH FACTORS IN DEVELOPMENT: FROM MOLECULES TO ORGANOGENESIS, P755; Miwa N, 2001, ONCOL RES, V12, P469, DOI 10.3727/096504001108747477; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Oku N, 2006, CANCER RES, V66, P5251, DOI 10.1158/0008-5472.CAN-05-4478; Perreault N, 2005, GENE DEV, V19, P311, DOI 10.1101/gad.1260605; Perreault N, 2001, J BIOL CHEM, V276, P43328, DOI 10.1074/jbc.M104366200; Pinto D, 2005, EXP CELL RES, V306, P357, DOI 10.1016/j.yexcr.2005.02.022; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Sakaguchi T, 2002, J BIOL CHEM, V277, P21361, DOI 10.1074/jbc.M110261200; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; SHEAHAN K, 1989, CANCER RES, V49, P3809; Suh E, 1996, MOL CELL BIOL, V16, P619; Suh ER, 2001, AM J PHYSIOL-GASTR L, V280, pG149, DOI 10.1152/ajpgi.2001.280.1.G149; TRABER PG, 1990, BIOCHEM BIOPH RES CO, V173, P765, DOI 10.1016/S0006-291X(05)80853-8; TRABER PG, 1992, AM J PHYSIOL, V262, pG123, DOI 10.1152/ajpgi.1992.262.1.G123; Troy AM, 2004, EUR J CANCER, V40, P1610, DOI 10.1016/j.ejca.2004.03.011; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Urbich C, 2005, NAT MED, V11, P206, DOI 10.1038/nm1182; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van Itallie CM, 2006, ANNU REV PHYSIOL, V68, P403, DOI 10.1146/annurev.physiol.68.040104.131404; Wille A, 2004, BIOL CHEM, V385, P665, DOI 10.1515/BC.2004.082; Wright WW, 2003, BIOL REPROD, V68, P680, DOI 10.1095/biolreprod.102.006726	56	52	54	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3853	3865		10.1096/fj.07-8113com	http://dx.doi.org/10.1096/fj.07-8113com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17622569				2022-12-28	WOS:000251283500010
J	Bylund, DB				Bylund, David B.			Selecting selectivities and the neuropharmacology of antidepressant drug action - A commentary	FASEB JOURNAL			English	Editorial Material							REUPTAKE INHIBITORS; DEPRESSION; SYSTEMS; ADULTS; BRAIN		Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Bylund, DB (corresponding author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, 985800 Nebraska Med Ctr, Omaha, NE 68198 USA.	dbylund@unmc.edu	Bylund, David/A-9344-2009					Burke WJ, 2004, J CLIN PSYCHIAT, V65, P37; Bylund DB, 2007, NEUROCHEM INT, V51, P246, DOI 10.1016/j.neuint.2007.06.025; Kratochvil CJ, 2006, J CHILD ADOL PSYCHOP, V16, P11, DOI 10.1089/cap.2006.16.11; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Murrin LC, 2007, BIOCHEM PHARMACOL, V73, P1225, DOI 10.1016/j.bcp.2007.01.028; Pathak Sanjeev, 2005, Curr Psychiatry Rep, V7, P429, DOI 10.1007/s11920-005-0063-y; RICHELSON E, 1984, J PHARMACOL EXP THER, V230, P94; Shaw AM, 2007, EUR J PHARMACOL, V555, P30, DOI 10.1016/j.ejphar.2006.10.004; Williams M, 2005, BIOCHEM PHARMACOL, V70, P1707, DOI 10.1016/j.bcp.2005.08.019	9	0	0	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3417	3418		10.1096/fj.07-1102ufm-A	http://dx.doi.org/10.1096/fj.07-1102ufm-A			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17967928				2022-12-28	WOS:000250517800003
J	Aarabi, S; Bhatt, KA; Shi, Y; Paterno, J; Chang, EI; Loh, SA; Holmes, JW; Longaker, MT; Yee, H; Gurtner, GC				Aarabi, Shahram; Bhatt, Kirit A.; Shi, Yubin; Paterno, Josemaria; Chang, Edward I.; Loh, Shang A.; Holmes, Jeffrey W.; Longaker, Michael T.; Yee, Herman; Gurtner, Geoffrey C.			Mechanical load initiates hypertrophic scar formation through decreased cellular apoptosis	FASEB JOURNAL			English	Article						hypertrophic scar; wound healing; fibrosis; scarring	BCL-2 EXPRESSION; MANAGEMENT; AKT; FIBROBLASTS; ADHESION; PROTEIN; CELLS; MECHANOTRANSDUCTION; CONTRACTURES; VERSATILITY	Hypertrophic scars occur following cutaneous wounding and result in severe functional and esthetic defects. The pathophysiology of this process remains unknown. Here, we demonstrate for the first time that mechanical stress applied to a healing wound is sufficient to produce hypertrophic scars in mice. The resulting scars are histopathologically identical to human hypertrophic scars and persist for more than six months following a brief (one-week) period of augmented mechanical stress during the proliferative phase of wound healing. Resulting scars are structurally identical to human hypertrophic scars and showed dramatic increases in volume (20-fold) and cellular density (20-fold). The increased cellularity is accompanied by a four-fold decrease in cellular apoptosis and increased activation of the prosurvival marker Akt. To clarify the importance of apoptosis in hypertrophic scar formation, we examine the effects of mechanical loading on cutaneous wounds of animals with altered pathways of cellular apoptosis. In p53-null mice, with down-regulated cellular apoptosis, we observe significantly greater scar hypertrophy and cellular density. Conversely, scar hypertrophy and cellular density are significantly reduced in proapoptotic BclII-null mice. We conclude that mechanical loading early in the proliferative phase of wound healing produces hypertrophic scars by inhibiting cellular apoptosis through an Akt-dependent mechanism.	Stanford Univ, PSRL, Sch Med, Dept Surg, Stanford, CA 94305 USA; Columbia Univ, Dept Biomed Engn, New York, NY USA; NYU, Sch Med, Dept Pathol, New York, NY USA	Stanford University; Columbia University; New York University	Gurtner, GC (corresponding author), Stanford Univ, PSRL, Sch Med, Dept Surg, GK-210,257 Campus Dr, Stanford, CA 94305 USA.	ggurtner@stanford.edu		Holmes, Jeffrey/0000-0001-9125-7220	NHLBI NIH HHS [R01 HL-075639] Funding Source: Medline; NIA NIH HHS [R01 AG-021494] Funding Source: Medline; NIDDK NIH HHS [R01 DK067771] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK067771] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021494] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALENGHAT FJ, 2002, SCI STKE; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Bao G, 2003, NAT MATER, V2, P715, DOI 10.1038/nmat1001; Borer JS, 2002, CIRCULATION, V105, P1837, DOI 10.1161/01.CIR.0000014419.71706.85; Brissett A E, 2001, Facial Plast Surg, V17, P263, DOI 10.1055/s-2001-18827; Burke M, 1998, Aust Fam Physician, V27, P275; Clark JA, 1996, BURNS, V22, P443, DOI 10.1016/0305-4179(96)00038-1; Colwell AS, 2003, FRONT BIOSCI-LANDMRK, V8, pS1240, DOI 10.2741/1183; Costa AMA, 1999, AM J PATHOL, V155, P1671, DOI 10.1016/S0002-9440(10)65482-X; DEITCH EA, 1983, J TRAUMA, V23, P895, DOI 10.1097/00005373-198310000-00009; Edlich R F, 1998, J Emerg Med, V16, P759; EHRLICH HP, 1994, AM J PATHOL, V145, P105; Flusberg DA, 2001, MOL BIOL CELL, V12, P3087, DOI 10.1091/mbc.12.10.3087; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Greenhalgh DG, 1998, INT J BIOCHEM CELL B, V30, P1019, DOI 10.1016/S1357-2725(98)00058-2; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ingber DE, 2003, ANN MED, V35, P564, DOI 10.1080/07853890310016333; Lee JYY, 2004, AM J DERMATOPATH, V26, P379, DOI 10.1097/00000372-200410000-00006; LINARES HA, 1972, J INVEST DERMATOL, V59, P323, DOI 10.1111/1523-1747.ep12627386; Linge C, 2005, J INVEST DERMATOL, V125, P72, DOI 10.1111/j.0022-202X.2005.23771.x; LONGACRE JJ, 1976, SCAND J PLAST RECONS, V10, P113, DOI 10.3109/02844317609105199; Marneros AG, 2004, J INVEST DERMATOL, V122, P1126, DOI 10.1111/j.0022-202X.2004.22327.x; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Martin P, 2004, DEVELOPMENT, V131, P3021, DOI 10.1242/dev.01253; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Mustoe TA, 2002, PLAST RECONSTR SURG, V110, P560, DOI 10.1097/00006534-200208000-00031; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Qian Y, 2005, ONCOGENE, V24, P3154, DOI 10.1038/sj.onc.1208525; Reno F, 2003, WOUND REPAIR REGEN, V11, P331, DOI 10.1046/j.1524-475X.2003.11504.x; Riser BL, 2001, AM J PATHOL, V158, P11, DOI 10.1016/S0002-9440(10)63938-7; ROBSON MC, 1992, WORLD J SURG, V16, P87, DOI 10.1007/BF02067119; Santucci M, 2001, VIRCHOWS ARCH, V438, P457, DOI 10.1007/s004280000335; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Sheridan RL, 2000, INT ANESTHESIOL CLIN, V38, P129, DOI 10.1097/00004311-200007000-00009; Sheridan RL, 2004, J AM COLL SURGEONS, V198, P243, DOI 10.1016/j.jamcollsurg.2003.11.007; Sheridan RL, 2003, JAMA-J AM MED ASSOC, V290, P719, DOI 10.1001/jama.290.6.719; SHERRIS DA, 1995, OTOLARYNG CLIN N AM, V28, P1057; Singer AJ, 1997, NEW ENGL J MED, V337, P1142, DOI 10.1056/NEJM199710163371607; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Sugden PH, 2003, CIRC RES, V93, P1179, DOI 10.1161/01.RES.0000106132.04301.F5; Suzuki S, 1996, PLAST RECONSTR SURG, V98, P1016, DOI 10.1097/00006534-199611000-00014; Suzuki S, 1998, BRIT J PLAST SURG, V51, P363, DOI 10.1054/bjps.1997.0279; Tuan TL, 1998, MOL MED TODAY, V4, P19, DOI 10.1016/S1357-4310(97)80541-2; Umeda J, 2003, FASEB J, V17, P610, DOI 10.1096/fj.02-0597com; Varedi M, 2000, BIOCHEM CELL BIOL, V78, P427, DOI 10.1139/bcb-78-4-427; Vittal R, 2005, AM J PATHOL, V166, P367, DOI 10.1016/S0002-9440(10)62260-2; Wang JX, 2006, EXP CELL RES, V312, P205, DOI 10.1016/j.yexcr.2005.11.004; Wang Z, 2006, J CELL PHYSIOL, V206, P510, DOI 10.1002/jcp.20486; WHITE CR, 2004, TXB DERMATOPATHOLOGY; Wilson IF, 2000, PLAST RECONSTR SURG, V105, P27, DOI 10.1097/00006534-200001000-00005; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Zhan GD, 2003, NAT MATER, V2, P38, DOI 10.1038/nmat793	53	338	367	4	54	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3250	3261		10.1096/fj.07-8218com	http://dx.doi.org/10.1096/fj.07-8218com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17504973				2022-12-28	WOS:000249781600025
J	Waterland, RA; Travisano, M; Tahiliani, KG				Waterland, Robert A.; Travisano, Michael; Tahiliani, Kajal G.			Diet-induced hypermethylation at agouti viable yellow is not inherited transgenerationally through the female	FASEB JOURNAL			English	Article						transgenerational epigenetic inheritance; DNA; methylation; methyl supplementation; nutrition	EPIGENETIC INHERITANCE; GENE-EXPRESSION; DNA METHYLATION; MOUSE; MICE; MAMMALS; ALLELE; LOCUS	The effects of nonmutagenic environmental exposures can sometimes be transmitted for several generations, suggesting transgenerational inheritance of induced epigenetic variation. Methyl donor supplementation of female mice during pregnancy induces CpG hypermethylation at the agouti viable yellow ( A(vy)) allele in A(vy)/a offspring. Epigenetic inheritance occurs at A(vy); when passed through the female germ line, A(vy) epigenotype is not completely "reset." We therefore tested whether diet-induced epigenetic alterations at A(vy) are inherited transgenerationally. Female A(vy)/a mice were weaned onto either control ( n = 6) or a methyl-supplemented diet ( n = 5). These F0 dams were mated with a/a males. All F1 and F2 A(vy)/a females were weaned onto the same diet as their mothers, then mated with a/a males. F1, F2, and F3 A(vy)/a offspring were classified for coat color, an indicator of A(vy) methylation. In total, 62 F1, 98 F2, and 209 F3 A(vy)/a mice were studied. As expected, average A(vy)/a coat color was darker in the supplemented group ( P< 0.01). However, there was no cumulative effect of supplementation across successive generations. These results suggest that, in the female germ line, diet-induced A(vy) hypermethylation occurs in the absence of additional epigenetic modifications that normally confer transgenerational epigenetic inheritance at the locus. - Waterland, R. A., Travisano, M., Tahiliani, K. G. Diet-induced hypermethylation at agouti viable yellow is not inherited transgenerationally through the female.	Baylor Coll Med, Childrens Nutr Res Ctr, USDA, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Childrens Nutr Res Ctr, USDA, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Houston, Dept Biol & Biochem, Houston, TX USA; Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA	Baylor College of Medicine; United States Department of Agriculture (USDA); Baylor College of Medicine; United States Department of Agriculture (USDA); University of Houston System; University of Houston; University of Minnesota System; University of Minnesota Twin Cities	Waterland, RA (corresponding author), Baylor Coll Med, Childrens Nutr Res Ctr, USDA, Dept Pediat, Houston, TX 77030 USA.	waterland@bcm.edu	Travisano, Michael/AAI-4809-2020	Travisano, Michael/0000-0001-8168-0842	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK070007] Funding Source: NIH RePORTER; NIDDK NIH HHS [5K01DK070007] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Blewitt ME, 2006, PLOS GENET, V2, P399, DOI 10.1371/journal.pgen.0020049; Chong SY, 2004, CURR OPIN GENET DEV, V14, P692, DOI 10.1016/j.gde.2004.09.001; Cropley JE, 2006, P NATL ACAD SCI USA, V103, P17308, DOI 10.1073/pnas.0607090103; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Kaati G, 2002, EUR J HUM GENET, V10, P682, DOI 10.1038/sj.ejhg.5200859; Lane N, 2003, GENESIS, V35, P88, DOI 10.1002/gene.10168; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; Pembrey ME, 2006, EUR J HUM GENET, V14, P159, DOI 10.1038/sj.ejhg.5201538; Pembrey ME, 2002, EUR J HUM GENET, V10, P669, DOI 10.1038/sj.ejhg.5200901; Rakyan VK, 2006, CURR OPIN GENET DEV, V16, P573, DOI 10.1016/j.gde.2006.09.002; Rakyan VK, 2002, TRENDS GENET, V18, P348, DOI 10.1016/S0168-9525(02)02709-9; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; REIK W, 1993, DEVELOPMENT, V119, P933; Richards EJ, 2006, NAT REV GENET, V7, P395, DOI 10.1038/nrg1834; Roemer I, 1997, CURR BIOL, V7, P277, DOI 10.1016/S0960-9822(06)00124-2; SPERGEL G, 1971, METABOLISM, V20, P401, DOI 10.1016/0026-0495(71)90102-8; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Waterland RA, 2006, HUM MOL GENET, V15, P705, DOI 10.1093/hmg/ddi484; Waterland RA, 2006, GENESIS, V44, P401, DOI 10.1002/dvg.20230; Wolff GL, 1996, FUND APPL TOXICOL, V29, P176, DOI 10.1006/faat.1996.0019; Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949	23	140	146	2	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3380	3385		10.1096/fj.07-8229com	http://dx.doi.org/10.1096/fj.07-8229com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17551099				2022-12-28	WOS:000249781600038
J	Wooten-Blanks, LG; Song, PF; Senkal, CE; Ogretmen, B				Wooten-Blanks, Leslie G.; Song, Pengfei; Senkal, Can E.; Ogretmen, Besim			Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1	FASEB JOURNAL			English	Article						longevity assurance gene 1 ( LASS1); ceramide synthase; de novo ceramide generation; sphingolipids; lung cancer	LONGEVITY ASSURANCE GENE-1; ADENOCARCINOMA CELL-LINE; HTERT GENE; HUMAN HEAD; GROWTH; ACETYLATION; EXPRESSION; RNA; IDENTIFICATION; INHIBITION	In this study, distinct roles of de novo-generated endogenous ceramides and mechanisms by which deacetylated Sp3 regulates the hTERT promoter activity in response to ceramide signaling were explored. The generation of C-18-ceramide via the expression of ceramide synthase 1 ( CerS1), and not C-16-ceramide by CerS5 or CerS6 expression, resulted in repression of the hTERT promoter via deacetylation of Sp3 by histone deacetylase 1 ( HDAC1) in A549 human lung adenocarcinoma cells. Then roles and mechanisms of action of ceramide-mediated deacetylation of Sp3 in inhibiting the hTERT promoter were determined using constitutively deacetylated or acetylated Sp3 mutants at lysine ( K) 551. Expression of the deacetylated Sp3 mutant resulted in repression, whereas its acetylated mutant induced basal hTERT promoter activity in Drosophila S2 cells, which do not express any endogenous Sp3, and in A549 cells. Remarkably, chromatin immunoprecipitation data revealed that acetylated Sp3 mutant ( K551Q-Sp3) did not bind whereas deacetylated Sp3 ( K551R-Sp3) mutant bound strongly to the promoter DNA, resulting in the recruitment of histone deacetylase 1 ( HDAC1) and inhibition of the association of RNA polymerase II with the promoter. Mechanistically, increased generation of C-18-ceramide by hCerS1 expression, but not by its catalytically inactive mutant, mediated the association and recruitment of the deacetylated Sp3/HDAC1 complex to the hTERT promoter DNA, resulting in the local histone H3 deacetylation and repression of the promoter. - Wooten-Blanks, L. G., Song, P., Senkal, C. E., Ogretmen, B. Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Wooten-Blanks, LG (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	ogretmen@musc.edu			NCI NIH HHS [CA-88932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 2004, J BIOL CHEM, V279, P32620, DOI 10.1074/jbc.M402691200; Beyne-Rauzy O, 2005, BLOOD, V106, P3200, DOI 10.1182/blood-2005-04-1386; Bilsland AE, 2006, CANCER RES, V66, P1363, DOI 10.1158/0008-5472.CAN-05-1941; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Crowe DL, 2005, INT J ONCOL, V27, P847; Davis W, 2003, NUCLEIC ACIDS RES, V31, P1097, DOI 10.1093/nar/gkg192; Ellis DJP, 2006, GENE, V379, P68, DOI 10.1016/j.gene.2006.04.015; FOX TE, 2007, IN PRESS J BIOL CHEM; Fujimoto K, 2000, NUCLEIC ACIDS RES, V28, P2557, DOI 10.1093/nar/28.13.2557; Futerman AH, 2005, TRENDS CELL BIOL, V15, P312, DOI 10.1016/j.tcb.2005.04.006; Gomez-Munoz A, 2005, FEBS LETT, V579, P3744, DOI 10.1016/j.febslet.2005.05.067; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Horikawa I, 2003, CARCINOGENESIS, V24, P1167, DOI 10.1093/carcin/bgg085; Horikawa I, 1999, CANCER RES, V59, P826; Horikawa L, 2005, P NATL ACAD SCI USA, V102, P18437, DOI 10.1073/pnas.0508964102; Hou M, 2002, EXP CELL RES, V274, P25, DOI 10.1006/excr.2001.5462; Jiang JC, 1998, GENOME RES, V8, P1259, DOI 10.1101/gr.8.12.1259; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Koybasi S, 2004, J BIOL CHEM, V279, P44311, DOI 10.1074/jbc.M406920200; Li S, 2004, CANCER RES, V64, P4833, DOI 10.1158/0008-5472.CAN-04-0953; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Mitra P, 2007, FEBS LETT, V581, P735, DOI 10.1016/j.febslet.2007.01.041; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Ogretmen B, 1999, BIOCHEMISTRY-US, V38, P2189, DOI 10.1021/bi982236+; Ogretmen B, 2001, J BIOL CHEM, V276, P32506, DOI 10.1074/jbc.M101350200; Pelletier G, 2000, MOL CELL, V6, P1059, DOI 10.1016/S1097-2765(00)00104-0; Pewzner-Jung Y, 2006, J BIOL CHEM, V281, P25001, DOI 10.1074/jbc.R600010200; Senkal CE, 2007, MOL CANCER THER, V6, P712, DOI 10.1158/1535-7163.MCT-06-0558; Spassieva S, 2006, J BIOL CHEM, V281, P33931, DOI 10.1074/jbc.M608092200; Spengler ML, 2005, CELL SIGNAL, V17, P153, DOI 10.1016/j.cellsig.2004.06.007; Takakura M, 2005, MOL CELL BIOL, V25, P8037, DOI 10.1128/MCB.25.18.8037-8043.2005; Trapp S, 2006, J EXP MED, V203, P1307, DOI 10.1084/jem.20052240; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Wang SW, 2003, J BIOL CHEM, V278, P18842, DOI 10.1074/jbc.M209544200; Wang YH, 2003, J BIOL CHEM, V278, P25568, DOI 10.1074/jbc.M212574200; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wijesinghe DS, 2005, J LIPID RES, V46, P2706, DOI 10.1194/jlr.M500313-JLR200; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Wooten LG, 2005, J BIOL CHEM, V280, P28867, DOI 10.1074/jbc.M413444200	43	50	56	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3386	3397		10.1096/fj.07-8621com	http://dx.doi.org/10.1096/fj.07-8621com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17548428				2022-12-28	WOS:000249781600039
J	Zhang, M; Hu, PR; Krois, CR; Kane, MA; Napoli, JL				Zhang, Min; Hu, Peirong; Krois, Charles R.; Kane, Maureen A.; Napoli, Joseph L.			Altered vitamin A homeostasis and increased size and adiposity in the rdh1-null mouse	FASEB JOURNAL			English	Article						retinoic acid; retinol; short-chain dehydrogenase/reductase	RETINOL-BINDING-PROTEIN; ALL-TRANS-RETINOL; SHORT-CHAIN DEHYDROGENASE/REDUCTASE; ACID-METABOLIZING ENZYME; ALCOHOL-DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; CDNA CLONING; EXPRESSION; IDENTIFICATION; RAT	Rat RoDH performs efficiently ( V-m/ K-m) in a pathwayof all- trans- retinoic acid biosynthesis in cells and recognizes the physiological form of vitamin A, i. e., retinol bound with cellular retinol binding-protein, type I. Here we report that mouse embryo ( e7.5 to e18.5) and liver ( e12.5 to P2M) display inversely related mRNA expression of an Rodh ortholog, rdh1, and a major retinoic acid catabolic enzyme, cyp26a1, suggesting coordinate modulation of retinoic acid homeostasis. Rdh1 inactivation by homologous recombination produces mice with decreased liver cyp26a1 mRNA and protein and increased liver and kidney retinoid stores, when fed vitamin A- restricted diets. Thus, null mice autocompensate by down- regulating cyp26a1 and sparing retinoids, indicating that rdh1 metabolizes retinoids in vivo. Surprisingly, rdh1-null mice grow longer than wild type, with increased weight and adiposity, when restricted in vitamin A. Liver, kidney, and multiple fat pads increase in weight. Some differences reflect the larger sizes of rdh1- null mice, but mesentery, femoral, and inguinal fat pads grow disproportionately larger. These data reveal an unexpected contribution of Rdh1 to size and adiposity and provide the first genetic evidence of a candidate retinol dehydrogenase affecting either vitamin A- related homeostasis physiologically or vitamin A- related gene expression or biological function in vivo.	Univ Calif Berkeley, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Napoli, JL (corresponding author), Univ Calif Berkeley, 119 Morgan Hall,MC 3104, Berkeley, CA 94720 USA.	jna@berkeley.edu			NIDDK NIH HHS [DK-36970] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Abed S, 2001, GENE DEV, V15, P226, DOI 10.1101/gad.855001; Andreola F, 2004, J BIOL CHEM, V279, P3434, DOI 10.1074/jbc.M305832200; Berdanier CD, 2001, DIABETES RES CLIN PR, V54, pS11, DOI 10.1016/S0168-8227(01)00331-X; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BOERMAN MHEM, 1995, BIOCHEMISTRY-US, V34, P7027, DOI 10.1021/bi00021a014; Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; Chetyrkin SV, 2001, J BIOL CHEM, V276, P22278, DOI 10.1074/jbc.M102076200; Chiu S, 2004, OBES RES, V12, P1243, DOI 10.1038/oby.2004.158; Deltour L, 1999, J BIOL CHEM, V274, P16796, DOI 10.1074/jbc.274.24.16796; Dupe V, 2003, P NATL ACAD SCI USA, V100, P14036, DOI 10.1073/pnas.2336223100; E XP, 2002, J BIOL CHEM, V277, P36617, DOI 10.1074/jbc.M205519200; Fan XH, 2003, MOL CELL BIOL, V23, P4637, DOI 10.1128/MCB.23.13.4637-4648.2003; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; Ganji V, 2003, INT J FOOD SCI NUTR, V54, P485, DOI 10.1080/09637480310001622341; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; Gough WH, 1998, J BIOL CHEM, V273, P19778, DOI 10.1074/jbc.273.31.19778; Grun F, 2000, J BIOL CHEM, V275, P41210, DOI 10.1074/jbc.M007376200; Heise R, 2006, J INVEST DERMATOL, V126, P2473, DOI 10.1038/sj.jid.5700432; Hernandez RE, 2007, DEVELOPMENT, V134, P177, DOI 10.1242/dev.02706; Huang FJ, 2006, HUM REPROD, V21, P202, DOI 10.1093/humrep/dei286; Jian Z, 2004, REPROD TOXICOL, V19, P103, DOI 10.1016/j.reprotox.2004.06.012; Jurukovski V, 1999, MOL GENET METAB, V67, P62, DOI 10.1006/mgme.1999.2840; Kane MA, 2005, BIOCHEM J, V388, P363, DOI 10.1042/BJ20041867; Kedishvili NY, 1998, BIOCHEM BIOPH RES CO, V249, P191, DOI 10.1006/bbrc.1998.9105; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; Lin M, 2000, J BIOL CHEM, V275, P40106, DOI 10.1074/jbc.M008027200; MacLean G, 2001, MECH DEVELOP, V107, P195, DOI 10.1016/S0925-4773(01)00463-4; MADSEN M, 2001, PRO NUT SOC, V59, P65; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; Markova NG, 2003, MOL GENET METAB, V78, P119, DOI 10.1016/S1096-7192(02)00226-3; Martras S, 2004, EUR J BIOCHEM, V271, P1660, DOI 10.1111/j.1432-1033.2004.04058.x; Molotkov A, 2002, P NATL ACAD SCI USA, V99, P5337, DOI 10.1073/pnas.082093299; Muller O, 2005, CAN MED ASSOC J, V173, P279, DOI 10.1503/cmaj.050342; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; National Research Council, 1995, NUTR REQ LAB AN; Niederreither K, 2002, NAT GENET, V31, P84, DOI 10.1038/ng876; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; PARES X, 1990, METHOD ENZYMOL, V189, P436; Penzes P, 1997, GENE, V191, P167, DOI 10.1016/S0378-1119(97)00054-1; POSCH KC, 1992, J BIOL CHEM, V267, P19676; Ray WJ, 1997, J BIOL CHEM, V272, P18702, DOI 10.1074/jbc.272.30.18702; Reeves PG, 1997, J NUTR, V127, pS838; REINTJES S, 2004, DEV DYNAM, V230, P509; Rexer BN, 2002, BIOL REPROD, V67, P1555, DOI 10.1095/biolreprod.102.007021; Sakai Y, 2001, GENE DEV, V15, P213, DOI 10.1101/gad.851501; Su J, 1999, ENDOCRINOLOGY, V140, P5275, DOI 10.1210/endo.140.11.7137; Tahayato A, 2003, GENE EXPR PATTERNS, V3, P449, DOI 10.1016/S1567-133X(03)00066-8; Villarroya F, 1999, INT J OBESITY, V23, P1, DOI 10.1038/sj.ijo.0800799; Wang J, 2001, BIOCHEMISTRY-US, V40, P12533, DOI 10.1021/bi011396+; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; WOLF G, 1995, NUTR REV, V53, P230, DOI 10.1111/j.1753-4887.1995.tb01558.x; Wu BX, 2002, INVEST OPHTH VIS SCI, V43, P3365; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; Yashiro K, 2004, DEV CELL, V6, P411, DOI 10.1016/S1534-5807(04)00062-0; Zhang M, 2004, J BIOL CHEM, V279, P51482, DOI 10.1074/jbc.M409051200; Zhang M, 2003, GENE, V305, P121, DOI 10.1016/S0378-1119(02)01236-2; Zhang M, 2001, J BIOL CHEM, V276, P44083, DOI 10.1074/jbc.M105748200; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	60	69	69	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2886	2896		10.1096/fj.06-7964com	http://dx.doi.org/10.1096/fj.06-7964com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17435174				2022-12-28	WOS:000249237500029
J	Gong, YP; Zhang, RH; Zhang, JP; Xu, L; Zhang, F; Xu, W; Wang, Y; Chu, YW; Xiong, SD				Gong, Yanping; Zhang, Ruihua; Zhang, Jinping; Xu, Lin; Zhang, Feng; Xu, Wei; Wang, Ying; Chu, Yiwei; Xiong, Sidong			alpha-Dystroglycan is involved in positive selection of thymocytes by participating in immunological synapse formation	FASEB JOURNAL			English	Article						thymic development; fetal thymus organ culture; reaggregate thymus organ culture	T-CELL DEVELOPMENT; IMMATURE CD4(+)CD8(+) THYMOCYTES; DYSTROPHIN-GLYCOPROTEIN COMPLEX; THYMUS ORGAN-CULTURES; NEGATIVE SELECTION; BETA-DYSTROGLYCAN; IN-VITRO; TYROSINE PHOSPHORYLATION; NEUROMUSCULAR-JUNCTION; EXTRACELLULAR-MATRIX	alpha-Dystroglycan has been proved to be involved in lymphocyte activation by participating in inummological synapse (IS) formation. Considering the existence of IS formation in thymic development, we questioned whether alpha-dystroglycan was expressed in thymus and influenced thymic development. In this study, we demonstrated that alpha-dystroglycan was expressed on fetal thymocytes, especially on double-positive (DP, CD4(+)CD8(+)) cells. Blocking alpha-dystroglycan by treatment of fetal thymus organ culture (FTOC) with anti-alpha-dystroglycan antibody IIH6C4 decreased the number of DP cells compared with nontreated or isotype antibody controls. Down-regulation of alpha-dystroglycan by retroviruses carrying antisense cDNA of dystroglycan in reaggregate thymus organ culture (RTOC) further confirmed these results. Enhanced apoptosis of DP cells was observed after blocking alpha-dystroglycan. Interestingly, we found that blocking alpha-dystroglycan reduced IS formation between DP cells and thymic epithelial cells. Furthermore, blocking of-dystroglycan up-regulated CD95/CD95L expression and reduced Bcl-2 expression on DP cells in the developing thymus. Finally, the increase in the apoptosis of DP cells was associated with a consequent decrease in the positive selection, as indicated by the reduction of both ERK phosphorylation in DP cells and single-positive (SP, CD4(+) or CD8(+)) cell outcome. Altogether, these results indicated that alpha-dystroglycan was involved in positive selection of thymocytes by participating in the IS formation.	[Gong, Yanping; Zhang, Ruihua; Zhang, Jinping; Xu, Lin; Zhang, Feng; Xu, Wei; Wang, Ying; Chu, Yiwei] Fudan Univ, Shanghai Med Coll, Dept Immunol, Inst Immunobiol, Shanghai 200032, Peoples R China; [Xiong, Sidong] Shanghai Univ E Inst, Div Immunol, Shanghai, Peoples R China	Fudan University	Xiong, SD (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Immunol, Inst Immunobiol, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.	sdxiongfd@126.com						Amsen D, 1999, P NATL ACAD SCI USA, V96, P622, DOI 10.1073/pnas.96.2.622; ANDERSON G, 1995, J IMMUNOL, V154, P3636; Anderson G, 1996, ANNU REV IMMUNOL, V14, P73, DOI 10.1146/annurev.immunol.14.1.73; ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; Azzam HS, 2001, J IMMUNOL, V166, P5464, DOI 10.4049/jimmunol.166.9.5464; Bedossa P, 2002, LAB INVEST, V82, P1053, DOI 10.1097/01.LAB.0000024429.73158.DE; Bousso P, 2002, SCIENCE, V296, P1876, DOI 10.1126/science.1070945; Bowe MA, 2000, J CELL BIOL, V148, P801, DOI 10.1083/jcb.148.4.801; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; CHANG AC, 1995, J IMMUNOL, V154, P500; CHANG AC, 1993, J IMMUNOL, V151, P1789; Chen YJ, 2003, BIOCHEM J, V375, P329, DOI 10.1042/BJ20030808; Cifone MG, 1999, BLOOD, V93, P2282, DOI 10.1182/blood.V93.7.2282.407a23_2282_2296; DeLuca D, 2002, DEV COMP IMMUNOL, V26, P365, DOI 10.1016/S0145-305X(01)00085-4; DELUCA D, 1995, J IMMUNOL METHODS, V178, P13, DOI 10.1016/0022-1759(94)00236-P; DELUCA D, 1986, J IMMUNOL, V136, P430; DURBEEJ M, 1995, J CELL BIOL, V130, P79, DOI 10.1083/jcb.130.1.79; Durbeej M, 1998, J HISTOCHEM CYTOCHEM, V46, P449, DOI 10.1177/002215549804600404; Durbeej M, 2001, DIFFERENTIATION, V69, P121, DOI 10.1046/j.1432-0436.2001.690206.x; Durbeej M, 1998, CURR OPIN CELL BIOL, V10, P594, DOI 10.1016/S0955-0674(98)80034-3; Ebert PJR, 2000, J IMMUNOL, V165, P5435, DOI 10.4049/jimmunol.165.10.5435; Eichhorst ST, 2001, CANCER RES, V61, P243; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Ferreira A, 2002, MOL NEUROBIOL, V26, P69, DOI 10.1385/MN:26:1:069; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; Hailman E, 2002, IMMUNITY, V16, P839, DOI 10.1016/S1074-7613(02)00326-6; Hare KJ, 2003, J IMMUNOL, V171, P2825, DOI 10.4049/jimmunol.171.6.2825; Heaney DL, 2003, HEARING RES, V177, P12, DOI 10.1016/S0378-5955(02)00769-4; Heaney DL, 2002, HEARING RES, V174, P9, DOI 10.1016/S0378-5955(02)00611-1; Heathcote RD, 2000, DEV BIOL, V227, P595, DOI 10.1006/dbio.2000.9906; Henry MD, 2001, HUM PATHOL, V32, P791, DOI 10.1053/hupa.2001.26468; Hogquist KA, 2001, CURR OPIN IMMUNOL, V13, P225, DOI 10.1016/S0952-7915(00)00208-9; Hosokawa H, 2002, J CELL SCI, V115, P1487; Hozumi K, 2000, IMMUNOL LETT, V71, P61, DOI 10.1016/S0165-2478(99)00167-4; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Ilsley JL, 2001, CELL SIGNAL, V13, P625, DOI 10.1016/S0898-6568(01)00188-7; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; James M, 2000, J CELL SCI, V113, P1717; JENKINSON EJ, 1992, J EXP MED, V176, P845, DOI 10.1084/jem.176.3.845; Jiang FX, 2001, MOL MED, V7, P107, DOI 10.1007/BF03401944; Kahl J, 2003, J NEUROSCI, V23, P392, DOI 10.1523/JNEUROSCI.23-02-00392.2003; Keir ME, 2005, J IMMUNOL, V175, P7372, DOI 10.4049/jimmunol.175.11.7372; Kim MG, 2000, J IMMUNOL, V165, P192, DOI 10.4049/jimmunol.165.1.192; Kulms D, 2002, CELL DEATH DIFFER, V9, P598, DOI 10.1038/sj.cdd.4401002; Kurasawa K, 1999, CELL IMMUNOL, V194, P127, DOI 10.1006/cimm.1999.1502; Langenbach KJ, 2002, MUSCLE NERVE, V26, P644, DOI 10.1002/mus.10258; Lee LK, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-10; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Losasso C, 2000, FEBS LETT, V484, P194, DOI 10.1016/S0014-5793(00)02157-8; Lucas B, 2000, J IMMUNOL, V165, P1889, DOI 10.4049/jimmunol.165.4.1889; Magner W J, 2000, Dev Immunol, V7, P179, DOI 10.1155/2000/90943; Manole Emilia, 2000, J Cell Mol Med, V4, P289, DOI 10.1111/j.1582-4934.2000.tb00129.x; Mariathasan S, 2001, J IMMUNOL, V167, P4966, DOI 10.4049/jimmunol.167.9.4966; Masaki T, 2002, EXP NEUROL, V174, P109, DOI 10.1006/exnr.2001.7856; Middlebrook AJ, 2002, J IMMUNOL, V169, P2915, DOI 10.4049/jimmunol.169.6.2915; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Montanaro F, 2003, NEURON, V37, P193, DOI 10.1016/S0896-6273(03)00032-1; Montanaro F, 1999, J CELL BIOL, V145, P1325, DOI 10.1083/jcb.145.6.1325; Muschler J, 2002, CANCER RES, V62, P7102; NAKAYAMA T, 1990, SCIENCE, V249, P1558, DOI 10.1126/science.2120773; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NISHIMURA Y, 1995, J IMMUNOL, V154, P4395; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; Peng HB, 1998, CELL ADHES COMMUN, V5, P475, DOI 10.3109/15419069809005605; Plum J, 1996, BLOOD, V88, P4239; Priatel JJ, 2002, IMMUNITY, V17, P617, DOI 10.1016/S1074-7613(02)00451-X; PUNT JA, 1994, J EXP MED, V179, P709, DOI 10.1084/jem.179.2.709; Punt JA, 1997, J EXP MED, V186, P1911, DOI 10.1084/jem.186.11.1911; Richie LI, 2002, IMMUNITY, V16, P595, DOI 10.1016/S1074-7613(02)00299-6; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schmeissner PJ, 2001, J IMMUNOL, V167, P3715, DOI 10.4049/jimmunol.167.7.3715; Sciandra F, 2001, EUR J BIOCHEM, V268, P4590, DOI 10.1046/j.1432-1327.2001.02386.x; Sgambato A, 2003, AM J PATHOL, V162, P849, DOI 10.1016/S0002-9440(10)63881-3; Sotgia F, 2001, BIOCHEMISTRY-US, V40, P14585, DOI 10.1021/bi011247r; Spence HJ, 2004, EMBO REP, V5, P484, DOI 10.1038/sj.embor.7400140; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; van der Merwe PA, 2000, SEMIN IMMUNOL, V12, P5, DOI 10.1006/smim.2000.0203; Varas A, 1998, Dev Immunol, V6, P141, DOI 10.1155/1998/95861; Werlen G, 2003, SCIENCE, V299, P1859, DOI 10.1126/science.1067833; White SR, 2001, AM J RESP CELL MOL, V24, P179, DOI 10.1165/ajrcmb.24.2.3993; Williams O, 2001, EUR J IMMUNOL, V31, P1876, DOI 10.1002/1521-4141(200106)31:6<1876::AID-IMMU1876>3.0.CO;2-F; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; Yamada H, 1996, J BIOL CHEM, V271, P23418, DOI 10.1074/jbc.271.38.23418; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x; Zaccaria ML, 2001, NEUROSCIENCE, V104, P311, DOI 10.1016/S0306-4522(01)00092-6; Zhang JP, 2007, DNA CELL BIOL, V26, P19, DOI 10.1089/dna.2006.0525; Zhang JP, 2006, FASEB J, V20, P50, DOI 10.1096/fj.04-3303com	95	2	2	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1426	1439		10.1096/fj.07-9264com	http://dx.doi.org/10.1096/fj.07-9264com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18171694				2022-12-28	WOS:000255898700015
J	Junttila, MR; Li, SP; Westermarck, J				Junttila, Melissa R.; Li, Song-Ping; Westermarck, Jukka			Phosphatase-mediated crosstalk between MAPK signalling pathways in the regulation of cell survival	FASEB JOURNAL			English	Review						protein phosphatase; MKK; p38; ERK; transformation; cancer	ACTIVATED PROTEIN-KINASE; STRESS-INDUCED ACTIVATION; RECEPTOR TYROSINE KINASE; P38 MAPK; COLLAGENASE-1 MMP-1; C-JUN; DIFFERENTIAL REGULATION; UP-REGULATION; ERK; 2A	Mitogen-activated protein kinase (MAPK) pathways constitute a large modular network that regulates a variety of physiological processes, such as cell growth, differentiation, and apoptotic cell death. The function of the ERK pathway has been depicted as survival-promoting, in essence by opposing the proapoptotic activity of the stress-activated c-Jun NH2 terminal kinase (JNK)/p38 MAPK pathways. However, recently published work suggests that extracellular regulated kinase (ERK) pathway activity is suppressed by JNK/p38 kinases during apoptosis induction. In this review, we will summarize the current knowledge about JNK/p38-mediated mechanisms that negatively regulate the ERK pathway. In particular, we will focus on phosphatases (PP2A, MKPs) as inhibitors of ERK pathway activity in regulating apoptosis. A model proposed in this review places the negative regulation of the ERK pathway in a central position for the cellular decision-making process that determines whether cells will five or die in response to apoptosis-promoting signals. In addition, we will discuss the potential functional relevance of negative regulation of ERK pathway activity, for physiological and pathological conditions (e.g:, cellular transformation).	[Junttila, Melissa R.; Westermarck, Jukka] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; [Junttila, Melissa R.; Westermarck, Jukka] Abo Akad Univ, Turku, Finland; [Li, Song-Ping] Univ Helsinki, Inst Biomed, Helsinki, Finland; [Li, Song-Ping] Natl Publ Hlth Inst KTL, Helsinki, Finland; [Westermarck, Jukka] Univ Tampere, Inst Med Technol, Tampere 33250, Finland	University of Turku; Abo Akademi University; University of Helsinki; Tampere University	Westermarck, J (corresponding author), Univ Tampere, Inst Med Technol, Biokatu 6-8, Tampere 33250, Finland.	ltjuwe@uta.fi	Westermarck, Jukka/AAL-6464-2020	Westermarck, Jukka/0000-0001-7478-3018				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Ambrosino C, 2006, BIOCHEM J, V396, P163, DOI 10.1042/BJ20051502; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Ashwell JD, 2006, NAT REV IMMUNOL, V6, P532, DOI 10.1038/nri1865; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Black EJ, 2002, ONCOGENE, V21, P6540, DOI 10.1038/sj.onc.1205851; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Breitwieser W, 2007, GENE DEV, V21, P2069, DOI 10.1101/gad.430207; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dhanasekaran DN, 2007, ONCOGENE, V26, P3185, DOI 10.1038/sj.onc.1210411; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Dong Zigang, 2003, Mol Interv, V3, P306, DOI 10.1124/mi.3.6.306; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Dowd S, 1998, J CELL SCI, V111, P3389; Efimova T, 2004, MOL CELL BIOL, V24, P8167, DOI 10.1128/MCB.24.18.8167-8183.2004; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Friedman A, 2006, NATURE, V444, P230, DOI 10.1038/nature05280; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Gauthier ML, 2005, CANCER RES, V65, P1792, DOI 10.1158/0008-5472.CAN-04-3507; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Grbovic OM, 2006, P NATL ACAD SCI USA, V103, P57, DOI 10.1073/pnas.0609973103; Greenberg AK, 2002, AM J RESP CELL MOL, V26, P558, DOI 10.1165/ajrcmb.26.5.4689; Grethe S, 2006, CELL SIGNAL, V18, P531, DOI 10.1016/j.cellsig.2005.05.023; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Haj FG, 2003, J BIOL CHEM, V278, P739, DOI 10.1074/jbc.M210194200; Hanada M, 2001, J BIOL CHEM, V276, P5753, DOI 10.1074/jbc.M007773200; Hashigasako A, 2004, J BIOL CHEM, V279, P26445, DOI 10.1074/jbc.M314254200; Hayashi M, 2004, J MOL MED, V82, P800, DOI 10.1007/s00109-004-0602-8; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Hornberg JJ, 2005, FEBS J, V272, P244, DOI 10.1111/j.1432-1033.2004.04404.x; Hornberg JJ, 2005, ONCOGENE, V24, P5533, DOI 10.1038/sj.onc.1208817; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ikehara T, 2007, BIOCHEM BIOPH RES CO, V354, P1052, DOI 10.1016/j.bbrc.2007.01.085; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jiang Y, 1997, J BIOL CHEM, V272, P11096; Johansson N, 2000, J CELL SCI, V113, P227; Junttila MR, 2007, ONCOGENE, V26, P5267, DOI 10.1038/sj.onc.1210332; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; Kins S, 2003, AM J PATHOL, V163, P833, DOI 10.1016/S0002-9440(10)63444-X; Kogkopoulou O, 2006, J LEUKOCYTE BIOL, V79, P1052, DOI 10.1189/jlb.0705418; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kool J, 2003, ONCOGENE, V22, P4235, DOI 10.1038/sj.onc.1206611; Lee J, 2002, BIOCHEM BIOPH RES CO, V298, P765, DOI 10.1016/S0006-291X(02)02562-7; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Letourneux C, 2006, EMBO J, V25, P727, DOI 10.1038/sj.emboj.7600980; Li SP, 2003, CANCER RES, V63, P3473; Liu QH, 2004, AM J PHYSIOL-HEART C, V286, pH2204, DOI 10.1152/ajpheart.01050.2003; Liu QH, 2003, AM J PHYSIOL-HEART C, V285, pH97, DOI 10.1152/ajpheart.00956.2002; Longin S, 2007, J BIOL CHEM, V282, P26971, DOI 10.1074/jbc.M704059200; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Mattila E, 2005, NAT CELL BIOL, V7, P78, DOI 10.1038/ncb1209; McGuire TF, 2001, J BIOL CHEM, V276, P26365, DOI 10.1074/jbc.M010101200; McKay MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394; McNeil LK, 2005, P NATL ACAD SCI USA, V102, P13574, DOI 10.1073/pnas.0505110102; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; Noselli S, 2000, SCIENCE, V290, P68, DOI 10.1126/science.290.5489.68; Nyati MK, 2006, CANCER RES, V66, P11554, DOI 10.1158/0008-5472.CAN-06-1935; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Ossum CG, 2006, J EXP BIOL, V209, P1765, DOI 10.1242/jeb.02152; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Park ER, 2007, CELL SIGNAL, V19, P1488, DOI 10.1016/j.cellsig.2007.01.018; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; Prickett TD, 2007, MOL CELL BIOL, V27, P4217, DOI 10.1128/MCB.00067-07; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Remenyi A, 2005, MOL CELL, V20, P951, DOI 10.1016/j.molcel.2005.10.030; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Roy M, 2005, MOL CELL BIOL, V25, P7940, DOI 10.1128/MCB.25.18.7940-7952.2005; Rubinfeld H, 2005, MOL BIOTECHNOL, V31, P151, DOI 10.1385/MB:31:2:151; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shen YH, 2003, J BIOL CHEM, V278, P26715, DOI 10.1074/jbc.M303264200; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Strack S, 2002, J BIOL CHEM, V277, P41525, DOI 10.1074/jbc.M203767200; Suzuki K, 2001, J IMMUNOL, V166, P1185, DOI 10.4049/jimmunol.166.2.1185; Tanaka N, 2002, EMBO REP, V3, P785, DOI 10.1093/embo-reports/kvf153; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Toledano-Katchalski H, 2003, MOL CANCER RES, V1, P541; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; Van Kanegan MJ, 2005, J BIOL CHEM, V280, P36029, DOI 10.1074/jbc.M506986200; Waetzig V, 2005, MOL CELL NEUROSCI, V30, P67, DOI 10.1016/j.mcn.2005.06.001; Wang PY, 2003, EMBO J, V22, P2658, DOI 10.1093/emboj/cdg255; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Westermarck J, 1998, MATRIX BIOL, V17, P547, DOI 10.1016/S0945-053X(98)90107-X; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zebisch A, 2007, CURR MED CHEM, V14, P601, DOI 10.2174/092986707780059670; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	132	637	683	2	107	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					954	965		10.1096/fj.06-7859rev	http://dx.doi.org/10.1096/fj.06-7859rev			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	18039929				2022-12-28	WOS:000254581000003
J	Moehren, U; Papaioannou, M; Reeb, CA; Grassell, A; Nanni, S; Asim, M; Roell, D; Prade, I; Farsetti, A; Baniahmad, A				Moehren, Udo; Papaioannou, Maria; Reeb, Christina A.; Grassell, Annalisa; Nanni, Simona; Asim, Mohammad; Roell, Daniela; Prade, Ina; Farsetti, Antonella; Baniahmad, Aria			Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development	FASEB JOURNAL			English	Article						transrepression; gene silencing; agonist; antagonist; chromatin	HORMONE REPLACEMENT THERAPY; CELLS IN-VITRO; TRANSCRIPTIONAL REGULATION; PROTEIN-INTERACTION; TESTOSTERONE LEVELS; TARGET; GENE; GROWTH; ANTAGONIST; MODULATION	Androgens play a central role in prostate development and prostate cancer proliferation. Induction of telomerase is an early event in prostate carcinogenesis and is considered as a marker for both primary tumors and metastases. Interestingly, several reports suggest that telomerase activity is regulated by androgens in vivo. Here, we show that the wild-type (WT) human androgen receptor (AR) inhibits the expression of the human telomerase reverse transcriptase (hTERT) and telomerase activity via inhibition of hTERT promoter activity in the presence of androgen receptor agonists. However, pure androgen antagonists failed to repress hTERT transcription. The androgen-mediated repression of hTERT is abrogated in a human prostate cancer cell line exhibiting hormone-dependent growth, which expresses a mutant AR (T877A) frequently occurring in prostate cancer. We reveal that this single amino acid exchange is sufficient for the lack of transrepression. Interestingly, chromatin immunoprecipitation data suggest that, in contrast to the WT AR, the mutant AR is recruited less efficiently to the hTERT promoter in vivo, indicating that loss of transrepression results from reduced chromatin recruitment. Thus, our findings suggest that the WT AR inhibits expression of hTERT, which is indicative of a protective mechanism, whereas the T877A mutation of AR not only broadens the ligand spectrum of the receptor but abrogates this inhibitory mechanism in prostate cancer cells. This novel role of AR mutations in prostate cancer development suggests the benefit to a search for new AR antagonists that inhibit transactivation but allow transrepression.	[Baniahmad, Aria] Inst Human Genet & Anthropol, Fac Med, D-07743 Jena, Germany; [Moehren, Udo] Katholieke Univ Leuven, Div Biochem, Louvain, Belgium; [Grassell, Annalisa; Nanni, Simona; Farsetti, Antonella] Regina Elena Inst Canc Res, Dept Expt Oncol, Mol Oncogenesis Lab, Rome, Italy; [Farsetti, Antonella] CNR, Inst Neurobiol & Mol Med, Rome, Italy; [Baniahmad, Aria] Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland	KU Leuven; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Finland National Institute for Health & Welfare; University of Eastern Finland	Baniahmad, A (corresponding author), Inst Human Genet & Anthropol, Fac Med, Kollegiengasse 10, D-07743 Jena, Germany.	aban@mti.tini-jena.de	Papaioannou, Maria/AAI-3738-2021; Farsetti, Antonella/I-8710-2018	Papaioannou, Maria/0000-0003-3149-6523; Farsetti, Antonella/0000-0002-8603-7925; Prade, Ina/0000-0001-6951-151X	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Biroccio A, 2004, ENDOCR-RELAT CANCER, V11, P407, DOI 10.1677/erc.1.00764; Chatterjee B, 2003, MOL CELL BIOCHEM, V253, P89, DOI 10.1023/A:1026057402945; Comhaire FH, 2000, EUR UROL, V38, P655, DOI 10.1159/000020358; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; Culig Z, 2002, ENDOCR-RELAT CANCER, V9, P155, DOI 10.1677/erc.0.0090155; DAI WS, 1981, AM J EPIDEMIOL, V114, P804, DOI 10.1093/oxfordjournals.aje.a113251; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Fronsdal K, 2000, PROSTATE, V43, P111, DOI 10.1002/(SICI)1097-0045(20000501)43:2<111::AID-PROS5>3.0.CO;2-4; Fu MF, 2002, MOL CELL BIOL, V22, P3373, DOI 10.1128/MCB.22.10.3373-3388.2002; GAST A, 1995, MOL CELL ENDOCRINOL, V111, P93, DOI 10.1016/0303-7207(95)03554-K; Geserick C, 2006, ONCOGENE, V25, P4310, DOI 10.1038/sj.onc.1209465; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P3320, DOI 10.1073/pnas.94.7.3320; Guo CH, 2003, J UROLOGY, V170, P615, DOI 10.1097/01.ju.0000074653.22766.c8; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; Hoffman MA, 2000, J UROLOGY, V163, P824, DOI 10.1016/S0022-5347(05)67812-3; Janknecht R, 2004, FEBS LETT, V564, P9, DOI 10.1016/S0014-5793(04)00356-4; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Kim NW, 2001, UROLOGY, V57, P148, DOI 10.1016/S0090-4295(00)00962-6; Lichtsteiner SP, 1999, ANN NY ACAD SCI, V886, P1, DOI 10.1111/j.1749-6632.1999.tb09395.x; Meeker AK, 1996, ENDOCRINOLOGY, V137, P5743, DOI 10.1210/en.137.12.5743; Metivier R, 2006, EMBO REP, V7, P161, DOI 10.1038/sj.embor.7400626; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; Moehren U, 2007, MOL ENDOCRINOL, V21, P1039, DOI 10.1210/me.2006-0468; Morley JE, 1997, METABOLISM, V46, P410, DOI 10.1016/S0026-0495(97)90057-3; Nanni S, 2006, MOL CANCER RES, V4, P79, DOI 10.1158/1541-7786.MCR-05-0098; Prehn RT, 1999, CANCER RES, V59, P4161; Ravindranath N, 2001, PROSTATE, V49, P79, DOI 10.1002/pros.1120; Schatzl G, 2001, PROSTATE, V47, P52; Schindler A, 2001, INT J ONCOL, V19, P25; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Slater S, 2000, DRUG AGING, V17, P431, DOI 10.2165/00002512-200017060-00001; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Soda H, 2000, PROSTATE, V43, P161, DOI 10.1002/(SICI)1097-0045(20000515)43:3<161::AID-PROS1>3.0.CO;2-O; Sommerfeld HJ, 1996, CANCER RES, V56, P218; Taplin ME, 1999, CANCER RES, V59, P2511; Teske E, 2002, MOL CELL ENDOCRINOL, V197, P251, DOI 10.1016/S0303-7207(02)00261-7; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Zhang WB, 1998, CANCER RES, V58, P619	45	41	42	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1258	1267		10.1096/fj.07-9360com	http://dx.doi.org/10.1096/fj.07-9360com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	17991730				2022-12-28	WOS:000254581000030
J	Pacienza, N; Pozner, RG; Bianco, GA; D'Atri, LP; Croci, DO; Negrotto, S; Malaver, E; Gomez, RM; Rabinovich, GA; Schattner, M				Pacienza, Natalia; Pozner, Roberto G.; Bianco, German A.; D'Atri, Lina P.; Croci, Diego O.; Negrotto, Soledad; Malaver, Elisa; Gomez, Ricardo M.; Rabinovich, Gabriel A.; Schattner, Mirta			The immunoregulatory glycan-binding protein galectin-1 triggers human platelet activation	FASEB JOURNAL			English	Article						lectin; P-selectin; inflammation; hemostasis	CELL-ADHESION; P-SELECTIN; EXTRACELLULAR-MATRIX; MEMBRANE-VESICLES; DENDRITIC CELLS; TUMOR-CELLS; MICROPARTICLES; INHIBITION; EXPRESSION; SURFACE	Platelet activation is a critical process during inflammation, thrombosis, and cancer. Here, we show that galectin-1, an endogenous lectin with immunoregulatory properties, plays a key role in human platelet activation and function. Galectin-1 binds to human platelets in a carbohydrate-dependent manner and synergizes with ADP or thrombin to induce platelet aggregation and ATP release. Furthermore, galectin-1 induces F-actin polymerization, up-regulation of P-selectin, and GPIIIa expression; promotes shedding of microvesicles; and triggers conformational changes in GPIIb/IIIa. In addition, exposure to this lectin favors the generation of leukocyte-platelet aggregates. A further mechanistic analysis revealed the involvement of Ca2+ and cyclic nucleotide-dependent pathways in galectin-1-mediated control of platelet activation. Finally, expression of endogenous galectin-1 in human platelets contributes to ADP-induced aggregation. Our study reveals a novel unrecognized role for galectin-1 in the control of platelet physiology with potential implications in thrombosis, inflammation, and metastasis.	[Bianco, German A.; Croci, Diego O.; Rabinovich, Gabriel A.] Inst Biol & Med Expt, Natl Res Council, CONICET, RA-1428 Buenos Aires, DF, Argentina; [Pacienza, Natalia; Pozner, Roberto G.; Negrotto, Soledad; Malaver, Elisa; Schattner, Mirta] Natl Acad Med Buenos Aires, Hematol Res Inst, RA-1428 Buenos Aires, DF, Argentina; [Gomez, Ricardo M.] Natl Univ La Plata, Inst Biochem & Mol Biol, Dept Sci Biol, La Plata, Buenos Aires, Argentina; [Rabinovich, Gabriel A.] Univ Buenos Aires, Fac Exact & Nat Sci, Dept Biol Chem, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; Buenos Aires National Academy of Medicine; IIHEMA - Instituto de Investigaciones Hematologicas; National University of La Plata; University of Buenos Aires	Rabinovich, GA (corresponding author), Inst Biol & Med Expt, Natl Res Council, CONICET, Vuelta Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	gabyrabi@ciudad.com.ar; mschattner@hematologia.anm.edu.ar	Croci, Diego/AAJ-5709-2021; Gomez, Ricardo M/AAG-9555-2019	Croci, Diego/0000-0002-8623-0645; Gomez, Ricardo M/0000-0002-4001-519X; Pacienza, Natalia/0000-0002-6124-5269				ABRAMS CS, 1990, BLOOD, V75, P128; Afshar-Kharghan V, 2006, CURR OPIN HEMATOL, V13, P34, DOI 10.1097/01.moh.0000190107.54790.de; Amirkhosravi A, 2003, THROMB HAEMOSTASIS, V90, P549, DOI 10.1160/TH03-02-0102; Bakewell SJ, 2003, P NATL ACAD SCI USA, V100, P14205, DOI 10.1073/pnas.2234372100; Barrionuevo P, 2007, J IMMUNOL, V178, P436, DOI 10.4049/jimmunol.178.1.436; Biro E, 2005, J THROMB HAEMOST, V3, P2754, DOI 10.1111/j.1538-7836.2005.01646.x; BODE AP, 1985, THROMB RES, V39, P49, DOI 10.1016/0049-3848(85)90121-5; Brill A, 2005, CARDIOVASC RES, V67, P30, DOI 10.1016/j.cardiores.2005.04.007; Caine GJ, 2002, NEOPLASIA, V4, P465, DOI 10.1038/sj.neo.7900263; Camby I, 2002, J NEUROPATH EXP NEUR, V61, P585, DOI 10.1093/jnen/61.7.585; Camby I, 2006, GLYCOBIOLOGY, V16, p137R, DOI 10.1093/glycob/cwl025; Croce K, 2007, CURR OPIN HEMATOL, V14, P55, DOI 10.1097/00062752-200701000-00011; De Cicco M, 2004, CRIT REV ONCOL HEMAT, V50, P187, DOI 10.1016/j.critrevonc.2003.10.003; Falanga Anna, 2003, Clin Adv Hematol Oncol, V1, P673; Falati S, 2003, J EXP MED, V197, P1585, DOI 10.1084/jem.20021868; Fulcher JA, 2006, J IMMUNOL, V177, P216, DOI 10.4049/jimmunol.177.1.216; Garin MI, 2007, BLOOD, V109, P2058, DOI 10.1182/blood-2006-04-016451; Geng JG, 2004, CURR MED CHEM, V11, P2153, DOI 10.2174/0929867043364720; GU MJ, 1994, J CELL SCI, V107, P175; Hartwig JH, 2006, SEMIN HEMATOL, V43, pS94, DOI 10.1053/j.seminhematol.2005.11.004; He J, 2006, LAB INVEST, V86, P578, DOI 10.1038/labinvest.3700420; He JL, 2004, J BIOL CHEM, V279, P4705, DOI 10.1074/jbc.M311183200; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; Hirabayashi J, 2002, BBA-GEN SUBJECTS, V1572, P232, DOI 10.1016/S0304-4165(02)00311-2; Hu H, 2003, THROMB HAEMOSTASIS, V90, P679, DOI 10.1160/TH03-05-0274; Jain S, 2007, P NATL ACAD SCI USA, V104, P9024, DOI 10.1073/pnas.0700625104; Jurk K, 2005, SEMIN THROMB HEMOST, V31, P381, DOI 10.1055/s-2005-916671; La M, 2003, AM J PATHOL, V163, P1505, DOI 10.1016/S0002-9440(10)63507-9; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; MARCUS AJ, 1993, FASEB J, V7, P516, DOI 10.1096/fasebj.7.6.8472890; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; Merten M, 2000, CIRCULATION, V102, P1931, DOI 10.1161/01.CIR.102.16.1931; Merten M, 1999, CIRCULATION, V99, P2577, DOI 10.1161/01.CIR.99.19.2577; Moiseeva EP, 2003, BIOCHEM BIOPH RES CO, V310, P1010, DOI 10.1016/j.bbrc.2003.09.112; Palumbo JS, 2005, BLOOD, V105, P178, DOI 10.1182/blood-2004-06-2272; PEARLSTEIN E, 1984, CANCER RES, V44, P3884; Pereira J, 2006, THROMB HAEMOSTASIS, V95, P94, DOI 10.1160/TH05-05-0310; Perone MJ, 2006, J IMMUNOL, V177, P5278, DOI 10.4049/jimmunol.177.8.5278; Rabinovich G, 1999, J EXP MED, V190, P385, DOI 10.1084/jem.190.3.385; Rabinovich GA, 2002, CELL DEATH DIFFER, V9, P661, DOI 10.1038/sj.cdd.4401009; Rabinovich GA, 1998, J IMMUNOL, V160, P4831; Rabinovich GA, 2002, TRENDS IMMUNOL, V23, P313, DOI 10.1016/S1471-4906(02)02232-9; Rabinovich GA, 1999, IMMUNOLOGY, V97, P100; Rubinstein N, 2004, CANCER CELL, V5, P241, DOI 10.1016/S1535-6108(04)00024-8; Santucci L, 2003, GASTROENTEROLOGY, V124, P1381, DOI 10.1016/S0016-5085(03)00267-1; Saussez S, 2007, HEAD NECK-J SCI SPEC, V29, P874, DOI 10.1002/hed.20559; SCHATTNER M, 1993, BLOOD, V82, P3045; Schwarz UR, 2001, BIOCHEM PHARMACOL, V62, P1153, DOI 10.1016/S0006-2952(01)00760-2; Scott Ken, 2004, Glycoconjugate Journal, V19, P467; Shattil SJ, 2004, BLOOD, V104, P1606, DOI 10.1182/blood-2004-04-1257; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Silvestre MM, 2005, J RENIN-ANGIO-ALDO S, V6, pS1, DOI 10.1177/14703203050060010101; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; Stowell SR, 2007, BLOOD, V109, P219, DOI 10.1182/blood-2006-03-007153; Thijssen VLJL, 2006, P NATL ACAD SCI USA, V103, P15975, DOI 10.1073/pnas.0603883103; Timoshenko AV, 2003, MOL CELL BIOCHEM, V250, P139, DOI 10.1023/A:1024952727159; Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482; Toscano MA, 2007, CYTOKINE GROWTH F R, V18, P57, DOI 10.1016/j.cytogfr.2007.01.006; Toscano MA, 2006, J IMMUNOL, V176, P6323, DOI 10.4049/jimmunol.176.10.6323; van den Goor JM, 2003, J THORAC CARDIOV SUR, V126, P1101, DOI 10.1016/S0022-5223(03)01031-6; van der Leij J, 2007, MOL IMMUNOL, V44, P506, DOI 10.1016/j.molimm.2006.02.011; VANDENBRULE FA, 1995, BIOCHEM BIOPH RES CO, V209, P760, DOI 10.1006/bbrc.1995.1564; Vespa GNR, 1999, J IMMUNOL, V162, P799; Wagner DD, 2005, ARTERIOSCL THROM VAS, V25, P1321, DOI 10.1161/01.ATV.0000166521.90532.44; WIEDMER T, 1991, BLOOD, V78, P2880	66	56	57	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1113	1123		10.1096/fj.07-9524com	http://dx.doi.org/10.1096/fj.07-9524com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	17984174				2022-12-28	WOS:000254581000017
J	Levchenko, T; Veitonmaeki, N; Lundkvist, A; Gerhardt, H; Ming, Y; Berggren, K; Kvanta, A; Carlsson, R; Holmgren, L				Levchenko, Tetyana; Veitonmaeki, Niina; Lundkvist, Andrea; Gerhardt, Holger; Ming, Yue; Berggren, Kristina; Kvanta, Anders; Carlsson, Roland; Holmgren, Lars			Therapeutic antibodies targeting angiomotin inhibit angiogenesis in vivo	FASEB JOURNAL			English	Article						angiostatin; neoplasia; vascular/ocular disease; migration	ENDOTHELIAL-CELL MIGRATION; FIBROBLAST GROWTH-FACTOR; TRANSGENIC BALB/C MICE; ENDOGENOUS INHIBITORS; MACULAR DEGENERATION; ANGIOSTATIN; CANCER; PROTEIN; NEOVASCULARIZATION; PROGRESSION	We have previously shown that angiomotin (Amot) mediates angiostatin inhibition of endothelial migration and tube formation in vitro. A crucial role of angiomotin in regulating endothelial cell motility is indicated by the findings that knockdown of Amot in zebrafish reduces the number of filopodia of endothelial tip cells and severely impairs the migration of intersegmental vessels. In addition, targeting angiomotin using DNA vaccination inhibits angiogenesis and tumor growth in vivo. In this report, we have generated antibodies that, similar to angiostatin, bind to angiomotin on the endothelial cell surface. These antibodies inhibited FGF-2 and vascular endothelial growth factor (VEGF) -induced endothelial migration in the Boyden chamber assay. Furthermore, the anti-Amot B06 antibody significantly reduced the number of endothelial filopodia and inhibited vessel migration during retinal angiogenesis in vivo. We also show that systemic or local treatment with this antibody inhibits pathological blood vessel formation associated with tumor growth or laser-induced choroid neovascularization of the eye. These findings provide a rationale for using angiomotin antibodies for specifically targeting endothelial migration in angiogenesis-dependent diseases.-Levchenko, T., Veitonmaki, N, Lundkvist, A., Gerhardt, H., Ming, Y., Berggren, K, Kvanta, A., Carlsson, R., Hohngren, L. Therapeutic antibodies targeting angiomotin inhibit angiogenesis in vivo.	[Levchenko, Tetyana; Veitonmaeki, Niina; Holmgren, Lars] Karolinska Inst, St Eriks Eye Hosp, Canc Ctr Karolinska, Dept Pathol & Oncol, Stockholm, Sweden; [Ming, Yue; Kvanta, Anders] Karolinska Inst, St Eriks Eye Hosp, Dept Clin Neurosci, Sect Ophthalmol & Vis, Stockholm, Sweden; [Veitonmaeki, Niina; Berggren, Kristina; Carlsson, Roland] BioInvent Int AB, Lund, Sweden; [Lundkvist, Andrea; Gerhardt, Holger] Canc Res UK, Vasc Biol Lab, London, England	Karolinska Institutet; Karolinska Institutet; Cancer Research UK	Holmgren, L (corresponding author), Karolinska Inst, Dept Pathol & Oncol, Canc Ctr Karolinska, SE-17176 Stockholm, Sweden.	lars.holmgren@ki.se	Gerhardt, Holger/G-4610-2011; Gerhardt, Holger/G-4610-2011	Gerhardt, Holger/0000-0002-3030-0384; Tegnebratt, Tetyana/0000-0003-4298-2295; Gerhardt, Holger/0000-0001-9228-7472				Aase K, 2007, GENE DEV, V21, P2055, DOI 10.1101/gad.432007; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; Beerepoot LV, 2003, CLIN CANCER RES, V9, P4025; Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180; Bratt A, 2005, J BIOL CHEM, V280, P34859, DOI 10.1074/jbc.M503915200; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; Di Carlo E, 1999, LAB INVEST, V79, P1261; Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103; Ernkvist M, 2006, FEBS J, V273, P2000, DOI 10.1111/j.1742-4658.2006.05216.x; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gerhardt H, 2005, EXP SUPPL, V94, P3; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Greenwald RB, 2003, ADV DRUG DELIVER REV, V55, P217, DOI 10.1016/S0169-409X(02)00180-1; Holmgren L, 2006, P NATL ACAD SCI USA, V103, P9208, DOI 10.1073/pnas.0603110103; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; Kvanta A, 2006, ACTA OPHTHALMOL SCAN, V84, P282, DOI 10.1111/j.1600-0420.2006.00659.x; Levchenko T, 2004, ONCOGENE, V23, P1469, DOI 10.1038/sj.onc.1207264; Levchenko T, 2003, J CELL SCI, V116, P3803, DOI 10.1242/jcs.00694; Melani C, 2003, BLOOD, V102, P2138, DOI 10.1182/blood-2003-01-0190; Meneses PI, 2001, GENE THER, V8, P646, DOI 10.1038/sj.gt.3301423; Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294; Nyberg P, 2005, CANCER RES, V65, P3967, DOI 10.1158/0008-5472.CAN-04-2427; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; PASSANITI A, 1992, LAB INVEST, V67, P519; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Rovero S, 2000, J IMMUNOL, V165, P5133, DOI 10.4049/jimmunol.165.9.5133; Sato Y, 2006, ENDOTHELIUM-J ENDOTH, V13, P147, DOI 10.1080/1062332060069110; Soderlind E, 2000, NAT BIOTECHNOL, V18, P852, DOI 10.1038/78458; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; Veitonmaki N, 2003, FASEB J, V17, P764, DOI 10.1096/fj.02-0599-fje; Wahl ML, 2005, J CELL BIOCHEM, V96, P242, DOI 10.1002/jcb.20480; Wells CD, 2006, CELL, V125, P535, DOI 10.1016/j.cell.2006.02.045; Wood W, 2002, INT J BIOCHEM CELL B, V34, P726, DOI 10.1016/S1357-2725(01)00172-8	37	26	31	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2008	22	3					880	889		10.1096/fj.07-9509com	http://dx.doi.org/10.1096/fj.07-9509com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17984175				2022-12-28	WOS:000254143700026
J	Chen, N; Napoli, JL				Chen, Na; Napoli, Joseph L.			All-trans- retinoic acid stimulates translation and induces spine formation in hippocampal neurons through a membrane-associated RAR alpha	FASEB JOURNAL			English	Article						vitamin A; cytoskeleton remodeling; GluR; dendritic protein synthesis	LONG-TERM POTENTIATION; ACTIVITY-DEPENDENT REGULATION; LOCAL PROTEIN-SYNTHESIS; PHOSPHOINOSITIDE 3-KINASE-AKT-MAMMALIAN TARGET; RAPAMYCIN SIGNALING PATHWAY; RELATIONAL MEMORY DEFICIT; ESTROGEN-RECEPTOR-ALPHA; CENTRAL-NERVOUS-SYSTEM; VITAMIN-A-DEFICIENCY; SYNAPTIC PLASTICITY	Differentiation and patterning in the developing nervous system require the vitamin A metabolite all-trans-retinoic acid (atRA). Recent data suggest that higher cognitive functions, such as creation of hippocampal memory, also require atRA and its receptors, RAR, through affecting synaptic plasticity. Here we show that within 30 min atRA increased dendritic growth similar to 2- fold, and PSD-95 and synaptophysin puncta intensity similar to 3- fold, in cultured mouse hippocampal neurons, suggesting increased synapse formation. atRA (10 nM) increased ERK1/2 phosphorylation within 10 min. In synaptoneurosomes, atRA rapidly increased phosphorylation of ERK1/2, its target 4E-BP, and p70S6K, and its substrate, ribosome protein S6, indicating activation of MAPK and mammalian target of rapamycin (mTOR). Immunofluoresence revealed intense dendritic expression of RAR alpha in the mouse hippocampus and localization of RAR alpha on the surfaces of primary cultures of hippocampal neurons, with bright puncta along soma and neurites. Surface biotinylation confirmed the locus of RAR alpha expression. Knockdown of RAR alpha by shRNA impaired atRA-induced spine formation and abolished dendritic growth. Prolonged atRA stimulation reduced surface/total RAR alpha by 43%, suggesting internalization, whereas brain-derived nerve growth factor or bicuculline increased the ratio by similar to 1.8fold. atRA increased translation in the somatodendritic compartment, similar to brain-derived nerve growth factor. atRA specifically increased dendritic translation and surface expression of the alpha-amino-3-hydroxyl-5methyl-4-isoxazole propionate receptor (AMPAR) subunit 1 (GluR1), without affecting GluR2. These data provide mechanistic insight into atRA function in the hippocampus and identify a unique membrane-associated RAR alpha that mediates rapid induction of neuronal translation by atRA.	[Chen, Na; Napoli, Joseph L.] Univ Calif Berkeley, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Chen, N (corresponding author), Univ Calif Berkeley, 119 Morgan Hall,MC 3104, Berkeley, CA 94720 USA.	jna@berkeley.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013566] Funding Source: NIH RePORTER; NIA NIH HHS [AG13566] Funding Source: Medline; NIDDK NIH HHS [DK36870] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aggarwal S, 2006, MOL BIOL CELL, V17, P566, DOI 10.1091/mbc.E05-06-0519; Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; Akama KT, 2003, J NEUROSCI, V23, P2333; Banko JL, 2006, J NEUROSCI, V26, P2167, DOI 10.1523/JNEUROSCI.5196-05.2006; Boonyaratanakornkit V, 2007, MOL ENDOCRINOL, V21, P359, DOI 10.1210/me.2006-0337; Bouillet P, 1997, MECH DEVELOP, V63, P173, DOI 10.1016/S0925-4773(97)00039-7; Brandenberger R, 2004, NAT BIOTECHNOL, V22, P707, DOI 10.1038/nbt971; Canon E, 2004, MOL BIOL CELL, V15, P5583, DOI 10.1091/mbc.E04-05-0439; Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0; Chandrasekaran V, 2000, J NEUROBIOL, V42, P383, DOI 10.1002/(SICI)1097-4695(200003)42:4<383::AID-NEU1>3.0.CO;2-9; Chiang MY, 1998, NEURON, V21, P1353, DOI 10.1016/S0896-6273(00)80654-6; Chytil F, 2003, ANNU REV NUTR, V23, P1, DOI 10.1146/annurev.nutr.23.011702.073155; Cocco S, 2002, NEUROSCIENCE, V115, P475, DOI 10.1016/S0306-4522(02)00423-2; Costa-Mattioli M, 2005, NATURE, V436, P1166, DOI 10.1038/nature03897; Dai ZS, 1996, MOL CELL NEUROSCI, V7, P443, DOI 10.1006/mcne.1996.0032; Derkach VA, 2007, NAT REV NEUROSCI, V8, P101, DOI 10.1038/nrn2055; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Etchamendy N, 2003, BEHAV BRAIN RES, V145, P37, DOI 10.1016/S0166-4328(03)00099-8; Etchamendy N, 2001, J NEUROSCI, V21, P6423, DOI 10.1523/JNEUROSCI.21-16-06423.2001; Evans TRJ, 1999, BRIT J CANCER, V80, P1, DOI 10.1038/sj.bjc.6690312; Fiala JC, 1998, J NEUROSCI, V18, P8900; Fischer M, 2000, NAT NEUROSCI, V3, P887, DOI 10.1038/78791; FLETCHER TL, 1994, J NEUROSCI, V14, P6695; Fonseca R, 2006, NAT NEUROSCI, V9, P478, DOI 10.1038/nn1667; Friedman HV, 2000, NEURON, V27, P57, DOI 10.1016/S0896-6273(00)00009-X; Goldin M, 2001, J NEUROSCI, V21, P186, DOI 10.1523/JNEUROSCI.21-01-00186.2001; GRAY EG, 1959, J ANAT, V93, P420; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Groc L, 2004, NAT NEUROSCI, V7, P695, DOI 10.1038/nn1270; Grooms SY, 2006, J NEUROSCI, V26, P8339, DOI 10.1523/JNEUROSCI.0472-06.2006; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Heynen AJ, 2000, NEURON, V28, P527, DOI 10.1016/S0896-6273(00)00130-6; Hou LF, 2004, J NEUROSCI, V24, P6352, DOI 10.1523/JNEUROSCI.0995-04.2004; Huber KM, 2001, J NEUROPHYSIOL, V86, P321, DOI 10.1152/jn.2001.86.1.321; Huber KM, 2000, SCIENCE, V288, P1254, DOI 10.1126/science.288.5469.1254; Ivanova T, 2001, BRAIN RES, V889, P264, DOI 10.1016/S0006-8993(00)03149-8; Jacobs S, 2006, P NATL ACAD SCI USA, V103, P3902, DOI 10.1073/pnas.0511294103; Jontes JD, 2000, NAT NEUROSCI, V3, P231, DOI 10.1038/72936; Ju W, 2004, NAT NEUROSCI, V7, P244, DOI 10.1038/nn1189; Kane MA, 2005, BIOCHEM J, V388, P363, DOI 10.1042/BJ20041867; Kauer JA, 2006, NAT NEUROSCI, V9, P593, DOI 10.1038/nn0506-593; Kawaguchi R, 2007, SCIENCE, V315, P820, DOI 10.1126/science.1136244; Kelleher RJ, 2004, NEURON, V44, P59, DOI 10.1016/j.neuron.2004.09.013; Kelleher RJ, 2004, CELL, V116, P467, DOI 10.1016/S0092-8674(04)00115-1; Kelly MJ, 1999, STEROIDS, V64, P64, DOI 10.1016/S0039-128X(98)00095-6; Krezel W, 1999, NEUROSCIENCE, V89, P1291, DOI 10.1016/S0306-4522(98)00342-X; Lane MA, 2005, PROG NEUROBIOL, V75, P275, DOI 10.1016/j.pneurobio.2005.03.002; Lee CC, 2005, J BIOL CHEM, V280, P18543, DOI 10.1074/jbc.M414112200; Maden M, 2002, NAT REV NEUROSCI, V3, P843, DOI 10.1038/nrn963; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Mark M, 1999, P NUTR SOC, V58, P609, DOI 10.1017/S0029665199000798; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; McCaffery P, 2006, J NEUROBIOL, V66, P780, DOI 10.1002/neu.20237; McKinney RA, 1999, NAT NEUROSCI, V2, P44, DOI 10.1038/4548; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Misner DL, 2001, P NATL ACAD SCI USA, V98, P11714, DOI 10.1073/pnas.191369798; Muller D, 2000, HIPPOCAMPUS, V10, P596, DOI 10.1002/1098-1063(2000)10:5<596::AID-HIPO10>3.3.CO;2-P; Oh MC, 2006, J BIOL CHEM, V281, P752, DOI 10.1074/jbc.M509677200; Okabe S, 2001, J NEUROSCI, V21, P6105, DOI 10.1523/JNEUROSCI.21-16-06105.2001; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Scheetz AJ, 2000, NAT NEUROSCI, V3, P211, DOI 10.1038/72915; SCHEIBE RJ, 1991, J CELL BIOL, V113, P1173, DOI 10.1083/jcb.113.5.1173; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Simoncini T, 2002, STEROIDS, V67, P935, DOI 10.1016/S0039-128X(02)00040-5; Simoncini T, 2006, MOL ENDOCRINOL, V20, P1756, DOI 10.1210/me.2005-0259; Smith WB, 2005, NEURON, V45, P765, DOI 10.1016/j.neuron.2005.01.015; Sockanathan S, 1998, CELL, V94, P503, DOI 10.1016/S0092-8674(00)81591-3; Song RX, 2004, P NATL ACAD SCI USA, V101, P2076, DOI 10.1073/pnas.0308334100; Sutton MA, 2006, CELL, V125, P785, DOI 10.1016/j.cell.2006.03.040; Sweatt JD, 2004, CURR OPIN NEUROBIOL, V14, P311, DOI 10.1016/j.conb.2004.04.001; Takahashi J, 1999, J NEUROBIOL, V38, P65, DOI 10.1002/(SICI)1097-4695(199901)38:1<65::AID-NEU5>3.3.CO;2-H; Takahashi T, 2003, SCIENCE, V299, P1585, DOI 10.1126/science.1079886; Tardin C, 2003, EMBO J, V22, P4656, DOI 10.1093/emboj/cdg463; Toni N, 1999, NATURE, V402, P421, DOI 10.1038/46574; Vanderklish PW, 2002, P NATL ACAD SCI USA, V99, P1639, DOI 10.1073/pnas.032681099; Volterra A, 2004, GLIA, V47, P249, DOI 10.1002/glia.20080; Yuste R, 2004, NAT REV NEUROSCI, V5, P24, DOI 10.1038/nrn1300; Zhou Q, 2004, NEURON, V44, P749, DOI 10.1016/j.neuron.2004.11.011; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4	81	129	135	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					236	245		10.1096/fj.07-8739com	http://dx.doi.org/10.1096/fj.07-8739com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17712061				2022-12-28	WOS:000252309900026
J	Eirin-Lopez, JM; Ishibashi, T; Ausio, J				Eirin-Lopez, Jose Maria; Ishibashi, Toyotaka; Ausio, Juan			H2A.Bbd: a quickly evolving hypervariable mammalian histone that destabilizes nucleosomes in an acetylation-independent way	FASEB JOURNAL			English	Article						chromatin; evolution; sedimentation velocity	RAPID EVOLUTION; CORE PARTICLES; CHROMATIN; PROTEIN; H2A; TRANSCRIPTION; VARIANTS; VERTEBRATE; INCREASES; SELECTION	Molecular evolutionary analyses revealed that histone H2A.Bbd is a highly variable quickly evolving mammalian replacement histone variant, in striking contrast to all other histones. At the nucleotide level, this variability appears to be the result of a larger amount of nonsynonymous variation, which affects to a lesser extent, the structural domain of the protein comprising the histone fold. The resulting amino acid sequence diversity can be predicted to affect the internucleosomal and intranucleosomal histone interactions. Our phylogenetic analysis has allowed us to identify several of the residues involved. The biophysical characterization of nucleosomes reconstituted with recombinant mouse H2A.Bbd and their comparison to similar data obtained with human H2A.Bbd clearly support this notion. Despite the high interspecific amino acid sequence variability, all of the H2A.Bbd variants exert similar structural effects at the nucleosome level, which result in an unfolded highly unstable nucleoprotein complex. Such structure resembles that previously described for the highly dynamically acetylated nucleosomes associated with transcriptionally active regions of the genome. Nevertheless, the structure of nucleosome core particles reconstituted from H2A.Bbd is not affected by the presence of a hyperacetylated histone complement. This suggests that replacement by H2A.Bbd provides an alternative mechanism to unfold chromatin structure, possibly in euchromatic regions, in a way that is not dependent on acetylation.	[Eirin-Lopez, Jose Maria; Ishibashi, Toyotaka; Ausio, Juan] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; [Eirin-Lopez, Jose Maria] Univ A Coruna, Dept Biol Celular & Mol, Galicia, Spain	University of Victoria; Universidade da Coruna	Ausio, J (corresponding author), Univ Victoria, Dept Biochem & Microbiol, Petch Bldg 258A, Victoria, BC V8W 3P6, Canada.	jausio@uvic.ca	Ishibashi, Toyotaka/AAW-2687-2020; Eirin-Lopez, Jose Maria/A-5618-2008	Ishibashi, Toyotaka/0000-0001-8015-2319; Eirin-Lopez, Jose Maria/0000-0002-8041-9770				Angelov D, 2004, EMBO J, V23, P3815, DOI 10.1038/sj.emboj.7600400; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; Ausio J, 1998, METHODS, V15, P333, DOI 10.1006/meth.1998.0637; AUSIO J, 2004, CHROMATIN STRUCTURE, P241; Ausio Juan, 2006, Briefings in Functional Genomics & Proteomics, V5, P228, DOI 10.1093/bfgp/ell020; Bao YH, 2004, EMBO J, V23, P3314, DOI 10.1038/sj.emboj.7600316; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; Calestagne-Morelli A, 2006, BIOCHEM CELL BIOL, V84, P518, DOI 10.1139/O06-067; Chadwick BP, 2001, HUM MOL GENET, V10, P1101, DOI 10.1093/hmg/10.10.1101; Chadwick BP, 2001, J CELL BIOL, V152, P375, DOI 10.1083/jcb.152.2.375; Clayton AL, 2006, MOL CELL, V23, P289, DOI 10.1016/j.molcel.2006.06.017; Dorigo B, 2003, J MOL BIOL, V327, P85, DOI 10.1016/S0022-2836(03)00025-1; Doyen CM, 2006, EMBO J, V25, P4234, DOI 10.1038/sj.emboj.7601310; Eirin-Lopez JM, 2004, MOL BIOL EVOL, V21, P1992, DOI 10.1093/molbev/msh213; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Frehlick LJ, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-99; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Gautier T, 2004, EMBO REP, V5, P715, DOI 10.1038/sj.embor.7400182; Greaves IK, 2006, MOL CELL BIOL, V26, P5394, DOI 10.1128/MCB.00519-06; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; Imhof Axel, 2006, Briefings in Functional Genomics & Proteomics, V5, P222, DOI 10.1093/bfgp/ell030; ISENBERG I, 1978, HISTONES, V4; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levchenko V, 2004, BIOCHEMISTRY-US, V43, P2359, DOI 10.1021/bi035737q; Lewis JD, 2003, CHROMOSOMA, V111, P473, DOI 10.1007/s00412-002-0226-0; Li A, 2005, BIOCHEM CELL BIOL, V83, P505, DOI 10.1139/O05-114; Li A, 2005, BIOCHEMISTRY-US, V44, P2529, DOI 10.1021/bi048061n; Luger K, 1998, CURR OPIN STRUC BIOL, V8, P33, DOI 10.1016/S0959-440X(98)80007-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Malik HS, 2003, NAT STRUCT BIOL, V10, P882, DOI 10.1038/nsb996; Marino-Ramirez L, 2005, EXPERT REV PROTEOMIC, V2, P719, DOI 10.1586/14789450.2.5.719; Nei M., 2000, MOL EVOLUTION PHYLOG, P352; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; Okuwaki M, 2005, MOL CELL BIOL, V25, P10639, DOI 10.1128/MCB.25.23.10639-10651.2005; PEHRSON JR, 1992, SCIENCE, V257, P1398; Perez-Bercoff A, 2006, BIOINFORMATICS, V22, P112, DOI 10.1093/bioinformatics/bti761; PERRY M, 1982, J BIOL CHEM, V257, P7336; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; RETIEF JD, 1993, EUR J BIOCHEM, V218, P1095; Rooney AP, 1999, MOL BIOL EVOL, V16, P706, DOI 10.1093/oxfordjournals.molbev.a026153; RZHETSKY A, 1992, MOL BIOL EVOL, V9, P945; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Saperas N, 2006, FEBS J, V273, P4548, DOI 10.1111/j.1742-4658.2006.05461.x; Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979; SITNIKOVA T, 1995, MOL BIOL EVOL, V12, P319; Sitnikova T, 1996, MOL BIOL EVOL, V13, P605, DOI 10.1093/oxfordjournals.molbev.a025620; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TATCHELL K, 1979, BIOCHEMISTRY-US, V18, P2870, DOI 10.1021/bi00580a031; van Holde K.E., 1988, CHROMATIN; Wang XY, 2000, J BIOL CHEM, V275, P35013, DOI 10.1074/jbc.M004998200; Wyckoff GJ, 2000, NATURE, V403, P304, DOI 10.1038/35002070; YAGER TD, 1984, J BIOL CHEM, V259, P4212; Zhang JZ, 1998, P NATL ACAD SCI USA, V95, P3708, DOI 10.1073/pnas.95.7.3708	57	35	38	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					316	326		10.1096/fj.07-9255com	http://dx.doi.org/10.1096/fj.07-9255com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17726088				2022-12-28	WOS:000252309900033
J	Magzoub, M; Jin, S; Verkman, AS				Magzoub, Mazin; Jin, Songwan; Verkman, A. S.			Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin	FASEB JOURNAL			English	Article						FRAP; ECS; hyluronan	IN-VIVO; VOLUME FRACTION; FIBRILLAR COLLAGEN; SKIN FRAGILITY; SOLID TUMORS; TRANSPORT; INTERSTITIUM; MODULATION; EXPRESSION; MICROSCOPY	Drug access to tumors is limited by diffusion through the tumor interstitium. We used a micro-fiberoptic epifluorescence photobleaching method to determine the role of extracellular matrix (ECM) components in macromolecule diffusion deep in tumor tissue. In subcutaneous B16 tumors in living mice, translational diffusion of 10 kDa FITC-dextran was slowed 2- to 3- fold (compared with its diffusion in water) within a depth of 0.2 mm from the tumor surface, but >10-fold beyond a depth of 1 mm. Diffusion of larger macromolecules, FITC-albumin and 500 kDa FITC-dextran, was slowed by up to 40-fold at 0.5 mm and 300-fold at 2 mm. Intratumoral collagenase (to digest collagen) or cathespin C (to digest decorin) each increased diffusion of 10 kDa FITC-dextran by similar to 2-fold. However, these treatments dramatically increased diffusion (> 10-fold) of larger macromolecules, such as 500 kDa dextran, in deep tumor (2 mm depth). Intratumoral hyaluronidase, in contrast, slowed diffusion throughout the tumor. In vitro measurements in defined gel-like mixtures of collagen, hyaluronan, and decorin closely recapitulated results in tumors in vivo. Mathematical modeling quantified the roles of extracellular space volume fraction and dimensions, and indicated a substantial effect of cell density on diffusion in deep tumor. Our data define the determinants of diffusion in deep tumor and suggest collagen and decorin digestion to greatly facilitate macromolecule delivery.	[Magzoub, Mazin; Jin, Songwan; Verkman, A. S.] Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; [Magzoub, Mazin; Jin, Songwan; Verkman, A. S.] Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	alan.verkman@ucsf.edu			NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL73856, HL59198] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124, DK72517] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072517, R37DK035124, R01DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberts B., 1994, MOL BIOL CELL, P971; Alexandrakis G, 2004, NAT MED, V10, P203, DOI 10.1038/nm981; Banerjee RK, 2002, ANN BIOMED ENG, V30, P828, DOI 10.1114/1.1496087; BECKENLEHNER K, 1992, J CANCER RES CLIN, V118, P591, DOI 10.1007/BF01211802; Bittner K, 1996, BIOCHEM J, V314, P159, DOI 10.1042/bj3140159; Brown E, 2003, NAT MED, V9, P796, DOI 10.1038/nm879; Brown EB, 2004, MICROVASC RES, V67, P231, DOI 10.1016/j.mvr.2004.02.001; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; Buhling F, 2004, EUR RESPIR J, V23, P620, DOI 10.1183/09031936.04.00105304; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DiResta GR, 2000, ANN BIOMED ENG, V28, P543, DOI 10.1114/1.295; Douglas T, 2006, BIOMACROMOLECULES, V7, P2388, DOI 10.1021/bm0603746; ELKAREH AW, 1993, BIOPHYS J, V64, P1638, DOI 10.1016/S0006-3495(93)81532-7; Feder TJ, 1996, BIOPHYS J, V70, P2767, DOI 10.1016/S0006-3495(96)79846-6; Geng YQ, 2006, MATRIX BIOL, V25, P484, DOI 10.1016/j.matbio.2006.08.259; Graff BA, 2000, EUR J CANCER, V36, P1433, DOI 10.1016/S0959-8049(00)00120-9; Gribbon PM, 1998, WENN GR INT, V71, P95; HAHN RA, 1992, DEVELOPMENT, V115, P383; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; JAIN RK, 1987, CANCER RES, V47, P3039; JAKOBSEN I, 1995, MAGN RESON IMAGING, V2, P97; Koninger J, 2004, CLIN CANCER RES, V10, P4776, DOI 10.1158/1078-0432.CCR-1190-03; Krol A, 1999, CANCER RES, V59, P4136; Kuc IM, 1997, CONNECT TISSUE RES, V36, P287, DOI 10.3109/03008209709160228; Kuriyama N, 2001, CANCER RES, V61, P1805; Kyle AH, 1999, CANCER CHEMOTH PHARM, V43, P213, DOI 10.1007/s002800050886; LEVICK JR, 1987, Q J EXP PHYSIOL CMS, V72, P409, DOI 10.1113/expphysiol.1987.sp003085; Masuda A, 2001, J AM CHEM SOC, V123, P11468, DOI 10.1021/ja016401b; McKee TD, 2006, CANCER RES, V66, P2509, DOI 10.1158/0008-5472.CAN-05-2242; Nash MA, 2002, CLIN CANCER RES, V8, P1754; Netti PA, 2000, CANCER RES, V60, P2497; Netti PA, 1999, P NATL ACAD SCI USA, V96, P3137, DOI 10.1073/pnas.96.6.3137; Pluen A, 2001, P NATL ACAD SCI USA, V98, P4628, DOI 10.1073/pnas.081626898; POGANY G, 1994, ARCH BIOCHEM BIOPHYS, V313, P102, DOI 10.1006/abbi.1994.1365; Ramanujan S, 2002, BIOPHYS J, V83, P1650, DOI 10.1016/S0006-3495(02)73933-7; Ribatti D, 2007, CANCER LETT, V248, P18, DOI 10.1016/j.canlet.2006.06.007; Schomburg D, 1991, ENZYME HDB; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; Scott JE, 1998, EXP CELL RES, V243, P59, DOI 10.1006/excr.1998.4089; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; Shenoy V, 1995, MACROMOLECULES, V28, P8751, DOI 10.1021/ma00130a007; Smith KJ, 1997, J AM ACAD DERMATOL, V36, P239, DOI 10.1016/S0190-9622(97)70288-3; StCroix B, 1996, JNCI-J NATL CANCER I, V88, P1285, DOI 10.1093/jnci/88.18.1285; Stroh M, 2005, NAT MED, V11, P678, DOI 10.1038/nm1247; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; TANNOCK IF, 1989, CANCER RES, V49, P4373; Theocharis AD, 2003, INT J BIOCHEM CELL B, V35, P376, DOI 10.1016/S1357-2725(02)00264-9; Thiagarajah JR, 2006, NAT METHODS, V3, P275, DOI 10.1038/NMETH863; Yuan F, 2001, ANN BIOMED ENG, V29, P1150, DOI 10.1114/1.1424915	51	102	109	1	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					276	284		10.1096/fj.07-9150com	http://dx.doi.org/10.1096/fj.07-9150com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17761521				2022-12-28	WOS:000252309900029
J	Kumar, S; Ponnazhagan, S				Kumar, Sanjay; Ponnazhagan, Selvarangan			Bone homing of mesenchymal stem cells by ectopic alpha 4 integrin expression	FASEB JOURNAL			English	Article						tissue regeneration; cell therapy; bone targeting	ADHESION MOLECULE-1; ENGRAFTMENT; DIFFERENTIATION; MOBILIZATION; FIBRONECTIN; INHIBITION; DOMAIN-4; BINDING; VLA-4; STAGE	The pluripotent nature of mesenchymal stem cells ( MSC) widens their potential for tissue regeneration and as vehicles for cell therapy in molecular medicine. Although the MSC are relatively easier to obtain and propagate in culture, a major impediment remains in their engraftment to target tissues on autologous transfer. We report here that transient, ectopic expression of alpha 4 integrin (CD49d) on MSC greatly increases bone homing in an immunocompetent mouse model. Heterodimerization of the alpha 4 integrin with endogenous beta 1 integrin (CD29) was confirmed to influence this targeting. In addition to retaining their stem cell property, the engrafted MSC were also found to form osteoblasts and osteocytes in the growth plate of recipient mouse limb bones ( femur/ tibia) in vivo. These findings provide evidence for a novel strategy to achieve bone homing of genetically engineered MSC, which may broadly benefit in targeted therapies for osteopenic bone defects and cancer bone metastasis.	Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Ponnazhagan, S (corresponding author), Univ Alabama Birmingham, Dept Pathol, 701 19th St South, LHRB 513, Birmingham, AL 35294 USA.	pons@uab.edu			NATIONAL CANCER INSTITUTE [R01CA098817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050251] Funding Source: NIH RePORTER; NCI NIH HHS [CA-98817] Funding Source: Medline; NIAMS NIH HHS [AR-50251] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams GB, 2006, NATURE, V439, P599, DOI 10.1038/nature04247; Bergstrom DE, 1998, GENOMICS, V48, P304, DOI 10.1006/geno.1997.5176; Bonig H, 2006, BLOOD, V107, P79, DOI 10.1182/blood-2005-05-2023; Catalina MD, 1999, BLOOD, V93, P580, DOI 10.1182/blood.V93.2.580.402k16_580_589; Chateauvieux S, 2007, PHYSIOL GENOMICS, V29, P128, DOI 10.1152/physiolgenomics.00197.2006; Corey E, 2005, CANCER RES, V65, P1710, DOI 10.1158/0008-5472.CAN-04-2033; De Ugarte DA, 2003, IMMUNOL LETT, V89, P267, DOI 10.1016/S0165-2478(03)00108-1; Feeley BT, 2006, BONE, V38, P154, DOI 10.1016/j.bone.2005.07.015; Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jacobsen K, 1996, BLOOD, V87, P73; Jin H, 2006, J CLIN INVEST, V116, P652, DOI 10.1172/JCI24751; Kalajzic I, 2003, J CELL BIOCHEM, V88, P1168, DOI 10.1002/jcb.10459; KILGER G, 1995, J BIOL CHEM, V270, P5979, DOI 10.1074/jbc.270.11.5979; Koistinen P, 2002, J BIOL CHEM, V277, P24835, DOI 10.1074/jbc.M203149200; Kumar S, 2005, BBA-GENE STRUCT EXPR, V1731, P95, DOI 10.1016/j.bbaexp.2005.08.007; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MATSUSHIMA T, 1996, TRENDS CHEM PHYS, V4, P1; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; Pacary E, 2006, J CELL SCI, V119, P2667, DOI 10.1242/jcs.03004; PETERS SO, 1995, EXP HEMATOL, V23, P461; Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100; Prosper F, 1998, J CLIN INVEST, V101, P2456, DOI 10.1172/JCI188; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; SCHADENDORF D, 1993, J PATHOL, V170, P429, DOI 10.1002/path.1711700405; Schweitzer KM, 1996, AM J PATHOL, V148, P165; Stewart FM, 1998, BLOOD, V91, P3681; Woodside DG, 2006, J IMMUNOL, V176, P5041, DOI 10.4049/jimmunol.176.8.5041; Zanjani ED, 1999, BLOOD, V94, P2515, DOI 10.1182/blood.V94.7.2515.419k15_2515_2522; Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938	31	112	116	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3917	3927		10.1096/fj.07-8275com	http://dx.doi.org/10.1096/fj.07-8275com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17622670				2022-12-28	WOS:000251283500017
J	Glenn, JV; Beattie, JR; Barrett, L; Frizzell, N; Thorpe, SR; Boulton, ME; McGarvey, JJ; Stitt, AW				Glenn, Josephine V.; Beattie, J. Renwick; Barrett, Lindsay; Frizzell, Norma; Thorpe, Suzanne R.; Boulton, Mike E.; McGarvey, John J.; Stitt, Alan W.			Confocal Raman microscopy can quantify advanced glycation end product (AGE) modifications in Bruch's membrane leading to accurate, nondestructive prediction of ocular aging	FASEB JOURNAL			English	Article						RPE; Raman spectroscopy	MAILLARD REACTION-PRODUCTS; RETINAL-PIGMENT EPITHELIUM; HUMAN ARTICULAR-CARTILAGE; MACULAR DEGENERATION; SKIN COLLAGEN; DIABETIC-RETINOPATHY; LENS CRYSTALLINS; PROTEINS; ACCUMULATION; N-EPSILON-(CARBOXYMETHYL)LYSINE	The modification of proteins by nonenzymatic glycation leading to accumulation of advanced glycation end products ( AGEs) is a well-established phenomenon of aging. In the eyes of elderly patients, these adducts have been observed in retinal pigment epithelium (RPE), particularly within the underlying pentalaminar substrate known as Bruch's membrane. AGEs have also been localized to age-related subcellular deposits ( drusen and basal laminar deposits) and are thought to play a pathogenic role in progression of the major sight-threatening condition known as age-related macular degeneration (AMD). The current study has quantified AGEs in Bruch's membrane from postmortem eyes and established age-related correlations. In particular, we investigated the potential of confocal Raman microscopy to identify and quantify AGEs in Bruch's membrane in a nondestructive, analytical fashion. Bruch's membrane and the innermost layers of the underlying choroid (BM-Ch) were dissected from fresh postmortem eye-cups (n = 56). AGE adducts were quantified from homogenized tissue using reverse-phase HPLC and GC/MS in combination with immunohistochemistry. For parallel Raman analysis, BM-Ch was flat-mounted on slides and evaluated using a Raman confocal microscope and spectra analyzed by a range of statistical approaches. Quantitative analysis showed that the AGEs pentosidine, carboxymethyllysine (CML), and carboxyethyllysine (CEL) occurred at significantly higher levels in BM-Ch with age (P<0.05-0.01). Defined Raman spectral "fingerprints" were identified for various AGEs and these were observed in the clinical samples using confocal Raman microscopy. The Raman data set successfully modeled AGEs and not only provided quantitative data that compared with conventional analytical approaches, but also provided new and complementary information via a nondestructive approach with high spatial resolution. It was shown that the Raman approach could be used to predict chronological age of the clinical samples (P<0.001) and a difference in the Raman spectra between genders was highly significant (P<0.000001). With further development, this Raman-based approach has the potential for noninvasive examination of AGE adducts in living eyes and ultimately to assess their precise pathogenic role in age-related diseases.	Queens Univ Belfast, Fac Med & Hlth Sci, Sch Biomed Sci, Ctr Vis Sci, Belfast, Antrim, North Ireland; Queens Univ Belfast, Sch Chem & Chem Engn, Belfast, Antrim, North Ireland; Queens Univ Belfast, Ctr Clin Raman Microscopy, Belfast, Antrim, North Ireland; Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; Univ Texas, Med Branch, Dept Ophthalmol & Vis Sci, Galveston, TX 77550 USA	Queens University Belfast; Queens University Belfast; Queens University Belfast; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of Texas System; University of Texas Medical Branch Galveston	Stitt, AW (corresponding author), Queens Univ Belfast, Royal Victoria Hosp, Ctr Vis Sci, Sch Biomed Sci, Belfast BT12 6BA, Antrim, North Ireland.	a.stitt@qub.ac.uk	Stitt, Alan/A-9842-2009; Beattie, Renwick/B-7810-2008; Beattie, James Renwick/I-4506-2015	Stitt, Alan/0000-0002-8647-9918; Beattie, James Renwick/0000-0002-0205-717X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019971, R37DK019971] Funding Source: NIH RePORTER; MRC [G0600053] Funding Source: UKRI; Medical Research Council [G0600053] Funding Source: Medline; NIDDK NIH HHS [DK19971] Funding Source: Medline; Wellcome Trust [WT066193] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome Trust)		Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; [Anonymous], 2001, NEAR INFRARED TECHNO; Baynes JW, 2001, EXP GERONTOL, V36, P1527, DOI 10.1016/S0531-5565(01)00138-3; Beattie JR, 2005, MOL VIS, V11, P825; BEATTIE JR, 2007, IN PRESS MOL VISION; Bernstein PS, 2004, ARCH BIOCHEM BIOPHYS, V430, P163, DOI 10.1016/j.abb.2004.07.004; Cerami C, 1997, P NATL ACAD SCI USA, V94, P13915, DOI 10.1073/pnas.94.25.13915; COFFEY AJH, 1986, AM J OPHTHALMOL, V102, P164, DOI 10.1016/0002-9394(86)90138-8; Degenhardt TP, 1997, KIDNEY INT, V52, P1064, DOI 10.1038/ki.1997.429; Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; Farboud B, 1999, MOL VIS, V5, pU1; Furic K, 2005, J MOL STRUCT, V744, P169, DOI 10.1016/j.molstruc.2004.10.041; Genuth S, 2005, DIABETES, V54, P3103, DOI 10.2337/diabetes.54.11.3103; Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775; Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404; Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629; ISHIBASHI T, 1986, OPHTHALMOLOGICA, V192, P179, DOI 10.1159/000309639; KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944; Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003; LYONS TJ, 1991, DIABETES, V40, P1010, DOI 10.2337/diabetes.40.8.1010; Meerwaldt R, 2005, J AM SOC NEPHROL, V16, P3687, DOI 10.1681/ASN.2005020144; MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290; Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443; Pallikaris IG, 2005, INVEST OPHTH VIS SCI, V46, P409, DOI 10.1167/iovs.04-0162; PALLIKARIS IG, 2000, AM J OPTHALMOL, V141, P611; ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825; Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172; SCOTT WK, 2007, IN PRESS OPHTHALMOLO; SEBAG J, 1994, INVEST OPHTH VIS SCI, V35, P2976; Sell DR, 2005, ANN NY ACAD SCI, V1043, P118, DOI 10.1196/annals.1333.015; Sell DR, 2004, J BIOL CHEM, V279, P54173, DOI 10.1074/jbc.M408946200; Sell DR, 2000, FASEB J, V14, P145, DOI 10.1096/fasebj.14.1.145; SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47; Shih S, 2003, ARCH BIOCHEM BIOPHYS, V420, P79, DOI 10.1016/j.abb.2003.09.015; Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762; Stitt A, 2002, DIABETES, V51, P2826, DOI 10.2337/diabetes.51.9.2826; Stitt AW, 2005, DIABETES, V54, P785, DOI 10.2337/diabetes.54.3.785; Stitt AW, 1997, AM J PATHOL, V150, P523; Thomas MC, 2004, KIDNEY INT, V66, P1167, DOI 10.1111/j.1523-1755.2004.00868.x; Thornalley PJ, 1999, BIOCHEM J, V344, P109, DOI 10.1042/0264-6021:3440109; Thorpe SR, 2003, AMINO ACIDS, V25, P275, DOI 10.1007/s00726-003-0017-9; Verzijl N, 2000, BIOCHEM J, V350, P381, DOI 10.1042/0264-6021:3500381; Verzijl N, 2002, ARTHRITIS RHEUM, V46, P114, DOI 10.1002/1529-0131(200201)46:1<114::AID-ART10025>3.0.CO;2-P; Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200; WELLSKNECHT MC, 1995, BIOCHEMISTRY-US, V34, P15134, DOI 10.1021/bi00046a020; Wolffenbuttel BHR, 1998, P NATL ACAD SCI USA, V95, P4630, DOI 10.1073/pnas.95.8.4630; Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005; Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6; Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598	51	95	96	0	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3542	3552		10.1096/fj.06-7896com	http://dx.doi.org/10.1096/fj.06-7896com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17567569				2022-12-28	WOS:000250517800017
J	Sasser, AK; Sullivan, NJ; Studebaker, AW; Hendey, LF; Axel, AE; Hall, BM				Sasser, A. Kate; Sullivan, Nicholas J.; Studebaker, Adam W.; Hendey, Lindsay F.; Axel, Amy E.; Hall, Brett M.			Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer	FASEB JOURNAL			English	Article						tumor microenvironment; IL-6; metastasis; mesenchymal stem cells; ER-alpha; STAT3; MSC	MESENCHYMAL STEM-CELLS; TUMOR-MICROENVIRONMENT; BONE; FIBROBLASTS; CYTOKINE; ESTROGEN; STAT3; MICE; CARCINOMA; DIFFERENTIATION	Bone is the primary anatomical site of breast cancer metastasis, and bone metastasis is associated with increased morbidity and mortality. Mesenchymal stem cells (MSC) are a predominant fibroblast cell population within the bone marrow, and metastatic breast cancer cells that seed within bone would predictably encounter MSC or their soluble factors. Therefore, we examined the impact of primary human MSC on a panel of estrogen receptor-alpha (ER alpha)-positive (MCF-7, T47D, BT474, and ZR-75-1) and ER alpha-negative (MDA-MB-231 and MDA-MB-468) human breast tumor cell lines. All ER alpha-positive breast tumor cell lines displayed low basal activation of signal transducer and activator of transcription 3 (STAT3) until exposed to MSC, which induced chronic phosphorylation of STAT3 on tyrosine-705. Paracrine IL-6 was found to be the principal mediator of STAT3 phosphorylation in coculture studies, and MSC induction of STAT3 phosphorylation was lost when IL-6 was depleted from MSC conditioned media or the IL-6 receptor was blocked on tumor cells. Enhanced tumor cell growth rates were observed in the ER alpha-positive mammary tumor cell line MCF-7 after paracrine and autocrine IL-6 exposure, where MCF-7 growth rates were enhanced by > 2-fold when cocultured with MSC in vitro and even more pronounced in vivo with autocrine IL-6 production.	Childrens Res Inst, Ctr Childhood Canc, Columbus, OH 43205 USA; Ohio State Univ, Sch Med & Publ Hlth, Dept Pediat, Integrated Biomed Sci Grad Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University	Hall, BM (corresponding author), Childrens Res Inst, Ctr Childhood Canc, WA5015,700 Childrens Dr, Columbus, OH 43205 USA.	hallb@ccri.net						Anderson WF, 2005, BREAST CANCER RES TR, V90, P127, DOI 10.1007/s10549-004-3777-3; Bachelot T, 2003, BRIT J CANCER, V88, P1721, DOI 10.1038/sj.bjc.6600956; Bennermo M, 2004, CLIN CHEM, V50, P2136, DOI 10.1373/clinchem.2004.037531; Boyce BF, 1999, ENDOCR-RELAT CANCER, V6, P333, DOI 10.1677/erc.0.0060333; Cat B, 2006, J CELL SCI, V119, P2727, DOI 10.1242/jcs.03011; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Conze D, 2001, CANCER RES, V61, P8851; DeMichele A, 2003, CANCER RES, V63, P8051; Hall BM, 2004, LEUKEMIA LYMPHOMA, V45, P35, DOI 10.1080/1042819031000139620; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hess KR, 2003, BREAST CANCER RES TR, V78, P105, DOI 10.1023/A:1022166517963; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; James JJ, 2003, BRIT J CANCER, V89, P660, DOI 10.1038/sj.bjc.6601198; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; Kassem M, 1996, J CLIN ENDOCR METAB, V81, P513, DOI 10.1210/jc.81.2.513; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Kim DH, 2005, CYTOKINE, V31, P119, DOI 10.1016/j.cyto.2005.04.004; KUNPFER H, 2006, BREAST CANC RES TREA, V102, P129; Kurose K, 2001, HUM MOL GENET, V10, P1907, DOI 10.1093/hmg/10.18.1907; Ling XY, 2005, CANCER RES, V65, P2532, DOI 10.1158/0008-5472.CAN-04-2425; Moinfar F, 2000, CANCER RES, V60, P2562; NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453; OKADA K, 1994, J GASTROEN HEPATOL, V9, P462, DOI 10.1111/j.1440-1746.1994.tb01275.x; Okamoto M, 1997, CANCER RES, V57, P141; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Parr C, 2004, CLIN CANCER RES, V10, P202, DOI 10.1158/1078-0432.CCR-0553-3; Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood-2003-09-3070; Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Purohit A, 2002, BREAST CANCER RES, V4, P65, DOI 10.1186/bcr425; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; SASSER AK, 2007, IN PRESS CANC LETT; Selander KS, 2004, CANCER RES, V64, P6924, DOI 10.1158/0008-5472.CAN-03-2516; Studeny M, 2004, JNCI-J NATL CANCER I, V96, P1593, DOI 10.1093/jnci/djh299; VANDAM M, 1993, J BIOL CHEM, V268, P15285; Yasui Y, 1999, CANCER CAUSE CONTROL, V10, P431, DOI 10.1023/A:1008970121595; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995	39	166	174	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3763	3770		10.1096/fj.07-8832com	http://dx.doi.org/10.1096/fj.07-8832com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17586727				2022-12-28	WOS:000250517800038
J	Guha, M; Xu, ZG; Tung, D; Lanting, L; Natarajan, R				Guha, Mausumee; Xu, Zhong-Gao; Tung, David; Lanting, Linda; Natarajan, Rama			Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes	FASEB JOURNAL			English	Article						diabetic nephropathy; CTGF; glomerular mesangial cells; antisense oligonucleotide	HUMAN MESANGIAL CELLS; HIGH GLUCOSE; FACTOR-BETA; GENE-EXPRESSION; TGF-BETA; EXTRACELLULAR-MATRIX; AUTOCRINE ACTIVATION; MESSENGER-RNA; FACTOR CTGF; CCN FAMILY	Diabetic nephropathy ( DN) remains a major complication in both type 1 and type 2 diabetes. Systemic administration of antitransforming growth factor-beta ( TGF-beta) antibody has shown some promise in mouse models of DN. However, chronic blockade of the multifunctional TGB-beta could be problematic. Several downstream effects of TGF-beta are mediated by connective tissue growth factor ( CTGF), which is up-regulated in several renal cells and secreted in the urine in the diabetic state. Using murine models of DN ( type 1 and type 2) and a CTGF antisense oligonucleotide ( ASO) of novel chimeric chemistry, we evaluated the specific role of this target in DN. In the type 1 model of DN, C57BL6 mice were made diabetic using streptozotocin injections and hyperglycemic animals were treated with CTGF ASOs ( 20 mg/kg/2 qw) for 4 months. ASO, but not mismatch control oligonucleotide, -treated animals showed significant reduction in target CTGF expression in the kidney with a concomitant decrease in proteinuria and albuminuria. Treatment with the CTGF ASO for 8 wk reduced serum creatinine and attenuated urinary albuminuria and proteinuria in diabetic db/db mice, a model of type 2 DN. The ASO also reduced expression of genes involved in matrix expansion such as fibronectin and collagen ( I and IV) and an inhibitor of matrix degradation, PAI-1, in the renal cortex, contributing to significant reversal of mesangial expansion in both models of DN. Pathway analyses demonstrated that diabetes-induced phosphorylation of p38 MAPK and its downstream target CREB was also inhibited by the ASO. Our results strongly suggest that blocking CTGF using a chimeric ASO holds substantial promise for the treatment of DN. - Guha, M., Xu, Z-G., Tung, D., Lanting, L., Natarajan, R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes.	Kalypsys Inc, Dept Pharmacol, San Diego, CA 92121 USA; Beckman Inst City Hope, Dept Diabet, Duarte, CA USA; Pfizer Inc, St Louis, MO USA	City of Hope; Beckman Research Institute of City of Hope; Pfizer	Guha, M (corresponding author), Kalypsys Inc, Dept Pharmacol, 10420 Wateridge Circle, San Diego, CA 92121 USA.	mguha@kalypsys.com			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058191] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK58191, R01 DK058191] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Adler SG, 2001, KIDNEY INT, V60, P2330, DOI 10.1046/j.1523-1755.2001.00073.x; Blom IE, 2001, NEPHROL DIAL TRANSPL, V16, P1139, DOI 10.1093/ndt/16.6.1139; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Breyer MD, 2005, J AM SOC NEPHROL, V16, P27, DOI [10.1681/ASN.2009070721, 10.1681/ASN.2004080648]; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Crean JKG, 2002, J BIOL CHEM, V277, P44187, DOI 10.1074/jbc.M203715200; De Vriese A, 2001, J AM SOC NEPHROL, V12, P993, DOI 10.1681/ASN.V125993; Gilbert RE, 2003, DIABETES CARE, V26, P2632, DOI 10.2337/diacare.26.9.2632; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Han DC, 1999, J AM SOC NEPHROL, V10, P1891; Hoffman BB, 1998, KIDNEY INT, V54, P1107, DOI 10.1046/j.1523-1755.1998.00119.x; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Iglesias-de la Cruz MC, 2002, KIDNEY INT, V62, P901, DOI 10.1046/j.1523-1755.2002.00528.x; Kang SW, 2001, KIDNEY INT, V60, P543, DOI 10.1046/j.1523-1755.2001.060002543.x; Kim YS, 2005, J AM SOC NEPHROL, V16, P352, DOI 10.1681/ASN.2004070568; KREISBERG JI, 1993, KIDNEY INT, V43, P109, DOI 10.1038/ki.1993.18; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; McLennan SV, 2004, ENDOCRINOLOGY, V145, P5646, DOI 10.1210/en.2004-0436; MONIA BP, 1993, J BIOL CHEM, V268, P14514; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; Okada H, 2005, J AM SOC NEPHROL, V16, P133, DOI 10.1681/ASN.2004040339; Peng B, 2001, ANTISENSE NUCLEIC A, V11, P15, DOI 10.1089/108729001750072092; Reddy MA, 2002, AM J PHYSIOL-RENAL, V283, pF985, DOI 10.1152/ajprenal.00181.2002; Reeves WB, 2000, P NATL ACAD SCI USA, V97, P7667, DOI 10.1073/pnas.97.14.7667; Riser BL, 2003, KIDNEY INT, V64, P451, DOI 10.1046/j.1523-1755.2003.00130.x; Riser BL, 2000, J AM SOC NEPHROL, V11, P25, DOI 10.1681/ASN.V11125; Sakharova OV, 2001, CURR OPIN NEPHROL HY, V10, P727, DOI 10.1097/00041552-200111000-00001; Twigg SM, 2001, ENDOCRINOLOGY, V142, P1760, DOI 10.1210/endo.142.5.8141; Uchio K, 2004, WOUND REPAIR REGEN, V12, P60, DOI 10.1111/j.1067-1927.2004.012112.x-1; van Nieuwenhoven FA, 2005, NEPHROL DIAL TRANSPL, V20, P6, DOI 10.1093/ndt/gfh570; Wahab NA, 2002, J AM SOC NEPHROL, V13, P2437, DOI 10.1097/01.ASN.0000031828.58276.02; Wahab NA, 2001, BIOCHEM J, V359, P77, DOI 10.1042/0264-6021:3590077; Wang SN, 2001, KIDNEY INT, V60, P96, DOI 10.1046/j.1523-1755.2001.00776.x; Yokoi H, 2004, J AM SOC NEPHROL, V15, P1430, DOI 10.1097/01.ASN.0000130565.69170.85; Ziyadeh F N, 1997, Kidney Int Suppl, V60, pS7; ZIYADEH FN, 1994, J CLIN INVEST, V93, P536, DOI 10.1172/JCI117004; Ziyadeh FN, 2000, P NATL ACAD SCI USA, V97, P8015, DOI 10.1073/pnas.120055097	41	160	182	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3355	3368		10.1096/fj.06-6713com	http://dx.doi.org/10.1096/fj.06-6713com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17554073				2022-12-28	WOS:000249781600036
J	Lahdenranta, J; Sidman, RL; Pasqualini, R; Arap, W				Lahdenranta, Johanna; Sidman, Richard L.; Pasqualini, Renata; Arap, Wadih			Treatment of hypoxia-induced retinopathy with targeted proapoptotic peptidomimetic in a mouse model of disease	FASEB JOURNAL			English	Article						aminopeptidases; angiogenesis; peptide ligand; targeted therapy	ENDOTHELIAL GROWTH-FACTOR; IN-VIVO; PHAGE DISPLAY; HUMAN VASCULATURE; AMINOPEPTIDASE-A; TUMOR; PEPTIDES; ANGIOGENESIS; DELIVERY; RECEPTOR	We have previously identified ligands from combinatorial peptide libraries that target tumor vasculature after in vivo selection. These ligands bind to differentially expressed receptors in angiogenic vasculature such as alpha(v)beta(3)/alpha(v)beta(5) integrins, aminopeptidase N, and aminopeptidase A. We hypothesized that we can use these ligands to target angiogenic vasculature in retinopathies. Pathological retinal angiogenesis in conditions such as diabetic retinopathy, retinopathy of prematurity, and age-related macular degeneration is a major cause of blindness for which current treatments are inadequate. Here we tested whether known tumor vasculature targeting peptide ligands displayed on bacteriophage particles would home to the proliferating blood vessels of the retina in a standard mouse model of retinopathy of prematurity. We found that activated retinal blood vessels share many of the endothelial and periendothelial cell receptors expressed in tumor vasculature. Furthermore, these vascular receptors -alpha(v) integrins and aminopeptidases -are accessible through the circulation and mediate phage homing and internalization to endothelial and periendothelial cells. Treatment of mice with a peptide containing alpha(v)beta(3)/alpha(v)beta(5) integrin targeting domain fused to a proapoptotic domain significantly reduced oxygen-induced retinal angiogenesis by selectively inducing activated endothelial cell apoptosis. Targeted proapoptotic peptides may prove useful in the management of angiogenic retinal diseases.	Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Neurol, Harvard Inst Med, Boston, MA 02215 USA	University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Arap, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rpasqual@mdanderson.org						AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Arden GB, 2005, BRIT J OPHTHALMOL, V89, P764, DOI 10.1136/bjo.2004.062547; ASSMANN KJM, 1992, J EXP MED, V175, P623, DOI 10.1084/jem.175.3.623; AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; Brekken RA, 1998, CANCER RES, V58, P1952; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Burg MA, 1999, CANCER RES, V59, P2869; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; Curnis F, 2000, NAT BIOTECHNOL, V18, P1185, DOI 10.1038/81183; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Essler M, 2002, P NATL ACAD SCI USA, V99, P2252, DOI 10.1073/pnas.251687998; Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306; Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678; George AJT, 2003, TRENDS BIOTECHNOL, V21, P199, DOI 10.1016/S0167-7799(03)00079-9; Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834; Hoffman JA, 2003, CANCER CELL, V4, P383, DOI 10.1016/S1535-6108(03)00273-3; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Javadpour MM, 1996, J MED CHEM, V39, P3107, DOI 10.1021/jm9509410; Joyce JA, 2003, CANCER CELL, V4, P393, DOI 10.1016/S1535-6108(03)00271-X; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; Kolonin MG, 2004, NAT MED, V10, P625, DOI 10.1038/nm1048; Lahdenranta J, 2001, P NATL ACAD SCI USA, V98, P10368, DOI 10.1073/pnas.181329198; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Luttun A, 2004, CURR OPIN HEMATOL, V11, P262, DOI 10.1097/01.moh.0000126936.58889.95; Marchio S, 2004, CANCER CELL, V5, P151, DOI 10.1016/S1535-6108(04)00025-X; Moffatt S, 2005, HUM GENE THER, V16, P57, DOI 10.1089/hum.2005.16.57; Ozerdem Ugur, 2004, Angiogenesis, V7, P269, DOI 10.1007/s10456-004-4182-6; Pasqualini R, 2000, CANCER RES, V60, P722; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Pastorino F, 2003, CANCER RES, V63, P7400; PLATE KH, 1993, CANCER RES, V53, P5822; SCHRAPPE M, 1991, CANCER RES, V51, P4986; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; St Croix B, 2000, SCIENCE, V289, P1197; Trepel M, 2002, CURR OPIN CHEM BIOL, V6, P399, DOI 10.1016/S1367-5931(02)00336-8; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8	44	26	33	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3272	3278		10.1096/fj.07-8273com	http://dx.doi.org/10.1096/fj.07-8273com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17513561				2022-12-28	WOS:000249781600027
J	Serriere-Lanneau, V; Teixeira-Clerc, F; Li, LY; Schippers, M; de Wries, W; Julien, B; Tran-Van-Nhieu, J; Manin, S; Poelstra, K; Chun, J; Carpentier, S; Levade, T; Mallat, A; Lotersztajn, S				Serriere-Lanneau, Valerie; Teixeira-Clerc, Fatima; Li, Liying; Schippers, Marlies; de Wries, Willie; Julien, Boris; Tran-Van-Nhieu, Jeanne; Manin, Sylvie; Poelstra, Klaas; Chun, Jerold; Carpentier, Stephane; Levade, Thierry; Mallat, Ariane; Lotersztajn, Sophie			The sphingosine 1-phosphate receptor S1P(2) triggers hepatic wound healing	FASEB JOURNAL			English	Article						liver; hepatic myofibroblasts	PROTEIN-COUPLED RECEPTOR; LYSOPHOSPHOLIPID RECEPTORS; MEDIATED PATHWAY; SPHINGOSINE-1-PHOSPHATE; MYOFIBROBLASTS; KINASE; LIVER; APOPTOSIS; CELLS; ACTIVATION	Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid produced by sphingosine kinase (SphK1 and 2). We previously showed that S1P receptors (S1P(1), S1P(2), and S1P(3)) are expressed in hepatic myofibroblasts (hMF), a population of cells that triggers matrix remodeling during liver injury. Here we investigated the function of these receptors in the wound healing response to acute liver injury elicited by carbon tetrachloride, a process that associates hepatocyte proliferation and matrix remodeling. Acute liver injury was associated with the induction of S1P2, S1P3, SphK(1), and SphK(2) mRNAs and increased SphK activity, with no change in S1P1 expression. Necrosis, inflammation, and hepatocyte regeneration were similar in S1P(2) (-/-) and wild-type (WT) mice. However, compared with WT mice, S1P(2) (-/-) mice displayed reduced accumulation of hMF, as shown by lower induction of smooth muscle alpha-actin mRNA and lower induction of TIMP-1, TGF-beta 1, and PDGF-BB mRNAs, overall reflecting reduced activation of remodeling in response to liver injury. The wound healing response was similar in S1P(3) (-/-) and WT mice. In vitro, S1P enhanced proliferation of cultured WT hMF, and PDGF-BB further enhanced the mitogenic effect of S1P. In keeping with these findings, PDGF-BB up-regulated S1P(2) and SphK1 mRNAs, increased SphK activity, and S1P(2) induced PDGF-BB mRNA. These effects were blunted in S1P2 (-/-) cells, and S1P(2) (-/-) hMF exhibited reduced mitogenic and comitogenic responses to S1P. These results unravel a novel major role of S1P(2) in the wound healing response to acute liver injury by a mechanism involving enhanced proliferation of hMF.	IMRB, INSERM, U841, Creteil, France; Univ Paris 12, Fac Med, Creteil, France; Grp Hosp Henri Mondor Albert Chenevier, AP HP, Serv Hepatol & Gastroenterol, Creteil, France; Grp Hosp Henri Mondor Albert Chenevier, AP HP, Dept Pathol, Creteil, France; Univ Groningen, Dept Pharmacokinet & Drug Delivery, Groningen, Netherlands; Scripps Res Inst, Dept Mol Biol, Helen L Dorris Child & Adolescent Neuropsychiat D, La Jolla, CA USA; INSERM, IFR31, U858, Toulouse, France; Univ Toulouse 3, IFR31, F-31062 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; University of Groningen; Scripps Research Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Lotersztajn, S (corresponding author), Hop Henri Mondor, INSERM, U841, Inst Mondor Rech Biomed, F-94010 Creteil, France.	sophie.lotersztajn@creteil.inserm.fr	Lotersztajn, Sophie/K-9160-2017; Teixeira-Clerc, Fatima/AAB-5499-2021; VAN NHIEU, Jeanne TRAN/R-5235-2018; Chun, Jerold/Y-4670-2019; Julien, Boris/E-2374-2012; Teixeira-Clerc, Fatima/C-9884-2009; Levade, Thierry/O-8948-2014	Teixeira-Clerc, Fatima/0000-0003-1098-9222; lotersztajn, Sophie/0000-0002-0053-7807	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048478] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA019674] Funding Source: NIH RePORTER; NIDA NIH HHS [DA019674] Funding Source: Medline; NINDS NIH HHS [NS048478] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chae SS, 2004, J CLIN INVEST, V114, P1082, DOI 10.1172/JCI200422716; Davaille J, 2000, J BIOL CHEM, V275, P34628, DOI 10.1074/jbc.M006393200; Davaille J, 2002, J BIOL CHEM, V277, P37323, DOI 10.1074/jbc.M202798200; Donati C, 2004, FASEB J, V18, P449, DOI 10.1096/fj.04-1780fje; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Gon Y, 2005, P NATL ACAD SCI USA, V102, P9270, DOI 10.1073/pnas.0501997102; Goparaju SK, 2005, MOL CELL BIOL, V25, P4237, DOI 10.1128/MCB.25.10.4237-4249.2005; Hla T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI 10.1016/j.semcdb.2004.05.002; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Ikeda H, 2004, BIOCHEM BIOPH RES CO, V320, P754, DOI 10.1016/j.bbrc.2004.04.207; Ikeda H, 2003, GASTROENTEROLOGY, V124, P459, DOI 10.1053/gast.2003.50049; Im DS, 1997, AM J PHYSIOL-GASTR L, V272, pG1091, DOI 10.1152/ajpgi.1997.272.5.G1091; Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Li LY, 2003, GASTROENTEROLOGY, V125, P460, DOI 10.1016/S0016-5085(03)00906-5; Li LY, 2001, J BIOL CHEM, V276, P38152; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Lotersztajn S, 2005, ANNU REV PHARMACOL, V45, P605, DOI 10.1146/annurev.pharmtox.45.120403.095906; MALLAT A, 1995, J CLIN INVEST, V96, P42, DOI 10.1172/JCI118052; Mitra P, 2006, P NATL ACAD SCI USA, V103, P16394, DOI 10.1073/pnas.0603734103; Nofer JR, 2004, J CLIN INVEST, V113, P569, DOI 10.1172/JCI200418004; Olivera A, 2000, METHOD ENZYMOL, V311, P215; Osawa Y, 2005, HEPATOLOGY, V42, P1320, DOI 10.1002/hep.20967; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Taha TA, 2004, BBA-MOL CELL BIOL L, V1682, P48, DOI 10.1016/S1388-1981(04)00023-X; Teixeira-Clerc F, 2006, NAT MED, V12, P671, DOI 10.1038/nm1421; Wu WC, 2004, MOL CELL BIOL, V24, P7359, DOI 10.1128/MCB.24.17.7359-7369.2004; Yamanaka M, 2004, J BIOL CHEM, V279, P53994, DOI 10.1074/jbc.M410144200	37	70	72	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2005	2013		10.1096/fj.06-6889com	http://dx.doi.org/10.1096/fj.06-6889com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17341687				2022-12-28	WOS:000247500300010
J	Partlow, KC; Chen, JJ; Brant, JA; Neubauer, AM; Meyerrose, TE; Creer, MH; Nolta, JA; Caruthers, SD; Lanza, GM; Wickline, SA				Partlow, Kathryn C.; Chen, Junjie; Brant, Jason A.; Neubauer, Anne M.; Meyerrose, Todd E.; Creer, Michael H.; Nolta, Jan A.; Caruthers, Shelton D.; Lanza, Gregory M.; Wickline, Samuel A.			F-19 magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons	FASEB JOURNAL			English	Article						endothelial progenitor cells; nanoparticles; contrast agent	ENDOTHELIAL PROGENITOR CELLS; UMBILICAL-CORD BLOOD; MESENCHYMAL STEM-CELLS; IN-VITRO; NANOPARTICLES; TISSUE; DIFFERENTIATION; IDENTIFICATION; ANGIOGENESIS; DEPENDENCE	MRI has been employed to elucidate the migratory behavior of stem/progenitor cells noninvasively in vivo with traditional proton (H-1) imaging of iron oxide nanoparticle- labeled cells. Alternatively, we demonstrate that fluorine (F-19) MRI of cells labeled with different types of liquid perfluorocarbon ( PFC) nanoparticles produces unique and sensitive cell markers distinct from any tissue background signal. To define the utility for cell tracking, mononuclear cells harvested from human umbilical cord blood were grown under proendothelial conditions and labeled with nanoparticles composed of two distinct PFC cores ( perfluorooctylbromide and perfluoro-15-crown-5 ether). The sensitivity for detecting and imaging labeled cells was defined on 11.7T ( research) and 1.5T ( clinical) scanners. Stem/progenitor cells (CD34(+) CD133(+) CD31(+)) readily internalized PFC nanoparticles without aid of adjunctive labeling techniques, and cells remained functional in vivo. PFC-labeled cells exhibited distinct F-19 signals and were readily detected after both local and intravenous injection. PFC nanoparticles provide an unequivocal and unique signature for stem/progenitor cells, enable spatial cell localization with F-19 MRI, and permit quantification and detection of multiple fluorine signatures via F-19 MR spectroscopy. This method should facilitate longitudinal investigation of cellular events in vivo for multiple cell types simultaneously.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63103 USA; St Louis Univ, Sch Med, Dept Lab Med, St Louis, MO 63103 USA; Philips Med Syst, Andover, MA USA	Washington University (WUSTL); Saint Louis University; Saint Louis University; Philips; Philips Healthcare	Wickline, SA (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8215,660 S Euclid Ave, St Louis, MO 63110 USA.	saw@howdy.wustl.edu	Chen, Junjie/E-8095-2010; CHEN, JUNJIE/HHM-8428-2022	Partlow, Kathryn/0000-0002-3476-2527; Brant, Jason/0000-0002-3492-0679; Nolta, Jan/0000-0003-4576-8542	NCI NIH HHS [CO-37007, U54-CA-119342] Funding Source: Medline; NHLBI NIH HHS [HL-073646, HL-078631] Funding Source: Medline; NIDDK NIH HHS [R01 DK061848, R01 DK053041-08, R01 DK061848-06A1, R01 DK053041] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA119342] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053041, R01DK061848] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahrens ET, 2005, NAT BIOTECHNOL, V23, P983, DOI 10.1038/nbt1121; Aicher A, 2003, CIRCULATION, V107, P2134, DOI 10.1161/01.CIR.0000062649.63838.C9; Aoki M, 2004, STEM CELLS, V22, P994, DOI 10.1634/stemcells.22-6-994; Arbab AS, 2006, STEM CELLS, V24, P671, DOI 10.1634/stemcells.2005-0017; Arbab Ali Syed, 2004, Mol Imaging, V3, P24, DOI 10.1162/153535004773861697; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bulte JWM, 2004, CURR PHARM BIOTECHNO, V5, P567; Caruthers SD, 2006, INVEST RADIOL, V41, P305, DOI 10.1097/01.rli.0000199281.60135.6a; Coulombel L, 2004, ONCOGENE, V23, P7210, DOI 10.1038/sj.onc.1207941; Cunningham CH, 2005, MAGNET RESON MED, V53, P999, DOI 10.1002/mrm.20477; Daldrup-Link HE, 2005, EUR RADIOL, V15, P4, DOI 10.1007/s00330-004-2526-7; DARDZINSKI BJ, 1994, MAGNET RESON MED, V32, P88, DOI 10.1002/mrm.1910320112; Eggermann J, 2003, CARDIOVASC RES, V58, P478, DOI 10.1016/S0008-6363(03)00252-9; Fan CL, 2003, ACTA PHARMACOL SIN, V24, P212; Frank JA, 2003, RADIOLOGY, V228, P480, DOI 10.1148/radiol.2281020638; Gratama JW, 1998, CYTOMETRY, V34, P128, DOI 10.1002/(SICI)1097-0320(19980615)34:3<128::AID-CYTO3>3.0.CO;2-D; Hill JM, 2003, CIRCULATION, V108, P1009, DOI 10.1161/01.CIR.0000084537.66419.7A; Iwaguro H, 2005, METH MOLEC MED, V112, P239; Kim SW, 2006, STEM CELLS, V24, P1620, DOI 10.1634/stemcells.2005-0365; Kraitchman DL, 2003, CIRCULATION, V107, P2290, DOI 10.1161/01.CIR.0000070931.62772.4E; KRUGLUGER W, 1993, J PERIODONTAL RES, V28, P145, DOI 10.1111/j.1600-0765.1993.tb01062.x; Lanza GM, 1996, CIRCULATION, V94, P3334, DOI 10.1161/01.CIR.94.12.3334; Lanza GM, 2005, CURR TOP DEV BIOL, V70, P57, DOI 10.1016/S0070-2153(05)70003-X; Liu JW, 2006, STEM CELLS, V24, P199, DOI 10.1634/stemcells.2004-0364; Marsh JN, 2002, J ACOUST SOC AM, V112, P2858, DOI 10.1121/1.1517251; Mason RP, 1996, NMR BIOMED, V9, P125, DOI 10.1002/(SICI)1099-1492(199605)9:3<125::AID-NBM405>3.0.CO;2-F; Morawski AM, 2004, MAGN RESON MED, V52, P1255, DOI 10.1002/mrm.20287; Naruse K, 2005, DIABETES, V54, P1823, DOI 10.2337/diabetes.54.6.1823; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Stroh A, 2005, NEUROIMAGE, V24, P635, DOI 10.1016/j.neuroimage.2004.09.014; van den Bos EJ, 2003, CELL TRANSPLANT, V12, P743, DOI 10.3727/000000003108747352; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Walczak P, 2005, MAGN RESON MED, V54, P769, DOI 10.1002/mrm.20701	33	233	256	0	81	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1647	1654		10.1096/fj.06-6505com	http://dx.doi.org/10.1096/fj.06-6505com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17284484				2022-12-28	WOS:000246866500006
J	Ronkainen, VP; Ronkainen, JJ; Hannninen, SL; Leskinen, H; Ruas, JL; Pereira, T; Poellinger, L; Vuolteenaho, O; Tavi, P				Ronkainen, Veli-Pekka; Ronkainen, Jarkko J.; Hannninen, Sandra L.; Leskinen, Hanna; Ruas, Jorge L.; Pereira, Teresa; Poellinger, Lorenz; Vuolteenaho, Olli; Tavi, Pasi			Hypoxia inducible factor regulates the cardiac expression and secretion of apelin	FASEB JOURNAL			English	Article						hormones; infarction; ischemia; HIF	ADRENOMEDULLIN GENE-EXPRESSION; ORPHAN RECEPTOR APJ; PEPTIDE APELIN; IMMUNOCYTOCHEMICAL LOCALIZATION; MYOCARDIAL-INFARCTION; ENDOGENOUS LIGAND; BLOOD-PRESSURE; HIF-ALPHA; FACTOR-I; ACTIVATION	Apelin and its G-protein-coupled receptor APJ have various beneficial effects on cardiac function and blood pressure. The mechanisms that regulate apelin gene expression are not known. Because apelin gene expression has been shown to increase in cardiac ischemia, we investigated if apelin ( Apln) gene expression was sensitive to hypoxia. Here we show that hypoxia increases the apelin expression in rat myocardium and in cultured cardiomyocytes. Pharmacological activation of hypoxia inducible factor by desferrioxamine ( DFO) or expression of a constitutively active form of HIF-1 alpha increased apelin expression in cardiomyocyte cultures. The induction of apelin by hypoxia was abolished on transient expression of the HIF inhibitory PAS protein in cardiomyocytes. Increased apelin expression induced by hypoxia or DFO was accompanied by the processing of the cellular storage form proapelin into smaller apelin peptides and increased secretion of these biologically active forms of apelin. In a rat in vivo model, acute myocardial infarction ( 24 h) led to a transient increase in ventricular apelin mRNA levels. Our results indicate that apelin gene is regulated by hypoxia in cardiac myocytes via the HIF pathway, suggesting a role for apelin as a potential marker for acute cardiac hypoxia with a possible compensatory role in myocardial tissue suffering from oxygen deprivation.-Ronkainen, V.-P., Ronkainen, J. J., Hanninen, S. L., Leskinen, H., Ruas, J. L., Pereira, T., Poellinger, L., Vuolteenaho, O., Tavi, P. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin.	Oulu Univ, Dept Physiol, SF-90014 Oulu, Finland; Oulu Univ, Dept Pharmacol & Toxicol, SF-90014 Oulu, Finland; Bioctr Oulu, SF-90014 Oulu, Finland; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	University of Oulu; University of Oulu; University of Oulu; Karolinska Institutet	Tavi, P (corresponding author), Oulu Univ, Dept Physiol, POB 5000, SF-90014 Oulu, Finland.	pasi.tavi@oulu.fi	Ruas, Jorge/AAE-6094-2019; Pereira, Teresa/AAP-8197-2020	Ruas, Jorge/0000-0002-1110-2606; Pereira, Teresa/0000-0001-8654-2385				Ala-Kopsala M, 2004, CLIN CHEM, V50, P1576, DOI 10.1373/clinchem.2004.032490; Ashley EA, 2005, CARDIOVASC RES, V65, P73, DOI 10.1016/j.cardiores.2004.08.018; Berry MF, 2004, CIRCULATION, V110, pII187, DOI 10.1161/01.CIR.0000138382.57325.5c; Boucher J, 2005, ENDOCRINOLOGY, V146, P1764, DOI 10.1210/en.2004-1427; Boucher J, 2004, REGUL PEPTIDES, V122, P51; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chen MM, 2003, CIRCULATION, V108, P1432, DOI 10.1161/01.CIR.0000091235.94914.75; Chun YS, 2003, BIOCHEM J, V370, P149, DOI 10.1042/BJ20021087; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; De Mota N, 2004, P NATL ACAD SCI USA, V101, P10464, DOI 10.1073/pnas.0403518101; Foldes G, 2003, BIOCHEM BIOPH RES CO, V308, P480, DOI 10.1016/S0006-291X(03)01424-4; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ishida J, 2004, J BIOL CHEM, V279, P26274, DOI 10.1074/jbc.M404149200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kawamata Y, 2001, BBA-MOL CELL RES, V1538, P162, DOI 10.1016/S0167-4889(00)00143-9; Kido M, 2005, J AM COLL CARDIOL, V46, P2116, DOI 10.1016/j.jacc.2005.08.045; Kleinz MJ, 2005, REGUL PEPTIDES, V126, P233, DOI 10.1016/j.regpep.2004.10.019; Kleinz MJ, 2004, REGUL PEPTIDES, V118, P119, DOI 10.1016/j.regpep.2003.11.002; Kleinz MJ, 2005, PHARMACOL THERAPEUT, V107, P198, DOI 10.1016/j.pharmthera.2005.04.001; Lee DK, 2000, J NEUROCHEM, V74, P34, DOI 10.1046/j.1471-4159.2000.0740034.x; Leem CH, 1999, J PHYSIOL-LONDON, V517, P159, DOI 10.1111/j.1469-7793.1999.0159z.x; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; Masri B, 2005, CELL SIGNAL, V17, P415, DOI 10.1016/j.cellsig.2004.09.018; Nagaya N, 2000, AM J PHYSIOL-REG I, V278, pR1019, DOI 10.1152/ajpregu.2000.278.4.R1019; Nguyen SV, 1999, BIOCHEM BIOPH RES CO, V265, P382, DOI 10.1006/bbrc.1999.1674; O'Carroll AM, 2000, BBA-GENE STRUCT EXPR, V1492, P72, DOI 10.1016/S0167-4781(00)00072-5; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; Ruas JL, 2005, SEMIN CELL DEV BIOL, V16, P514, DOI 10.1016/j.semcdb.2005.04.001; Ruas JL, 2005, J CELL SCI, V118, P301, DOI 10.1242/jcs.01617; Ruas JL, 2002, J BIOL CHEM, V277, P38723, DOI 10.1074/jbc.M205051200; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Szokodi I, 2002, CIRC RES, V91, P434, DOI 10.1161/01.RES.0000033522.37861.69; Tatemoto K, 2001, REGUL PEPTIDES, V99, P87, DOI 10.1016/S0167-0115(01)00236-1; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Tavi P, 1998, CIRC RES, V83, P1165, DOI 10.1161/01.RES.83.11.1165; VUOLTEENAHO O, 1985, BIOCHEM BIOPH RES CO, V129, P82, DOI 10.1016/0006-291X(85)91406-8; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Winzell MS, 2005, REGUL PEPTIDES, V131, P12, DOI 10.1016/j.regpep.2005.05.004	43	129	134	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1821	1830		10.1096/fj.06-7294com	http://dx.doi.org/10.1096/fj.06-7294com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17341685				2022-12-28	WOS:000246866500024
J	Herzig, S; Khan, IFY; Grundemann, D; Matthes, J; Ludwig, A; Michels, G; Hoppe, UC; Chaudhuri, D; Schwartz, A; Yue, DT; Hullin, R				Herzig, Stefan; Khan, Ismail F. Y.; Gruendemann, Dirk; Matthes, Jan; Ludwig, Andreas; Michels, Guido; Hoppe, Uta C.; Chaudhuri, Dipayan; Schwartz, Arnold; Yue, David T.; Hullin, Roger			Mechanism of Ca(v)1.2 channel modulation by the amino terminus of cardiac beta(2)-subunits	FASEB JOURNAL			English	Article						cardiac electrophysiology; calcium channel subunit; dihydropyridine	SENSITIVE CALCIUM-CHANNEL; GATED CA2+ CHANNELS; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; HUMAN HEART; SUBCELLULAR-LOCALIZATION; SPLICE VARIANTS; DOMAIN; CLONING; BINDING	L- type calcium channels are composed of a pore, alpha(1c) ( Ca(v)1.2), and accessory beta- and alpha(2)delta-subunits. The beta(2)-subunit core structure was recently resolved at high resolution, providing important information on many functional aspects of channel modulation. In this study we reveal differential novel effects of five beta(2)-subunits isoforms expressed in human heart (beta(2a-e)) on the single L- type calcium channel current. These splice variants differ only by amino- terminal length and amino acid composition. Single- channel modulation by beta(2)-subunit isoforms was investigated in HEK293 cells expressing the recombinant L- type ion conducting pore. All beta(2)- subunits increased open probability, availability, and peak current with a highly consistent rank order (beta(2a) approximate to beta(2b) > beta(2e) approximate to beta(2c) > beta(2d)). We show graded modulation of some transition rates within and between deep- closed and inactivated states. The extent of modulation correlates strongly with the length of amino- terminal domains. Two mutant beta(2)-subunits that imitate the natural span related to length confirm this conclusion. The data show that the length of amino termini is a relevant physiological mechanism for channel closure and inactivation, and that natural alternative splicing exploits this principle for modulation of the gating properties of calcium channels.	Univ Cologne, Dept Pharmacol, D-50931 Cologne, Germany; Univ Cologne, Ctr Mol Med, Cologne, Germany; Univ Erlangen Nurnberg, Inst Expt & Clin Pharmacol & Toxicol, Erlangen, Germany; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Univ Cincinnati, Inst Mol Pharmacol & Biophys, Cincinnati, OH USA; Univ Hosp, Swiss Heart Ctr Bern, Dept Cardiol, Bern, Switzerland	University of Cologne; University of Cologne; University of Erlangen Nuremberg; Johns Hopkins University; University System of Ohio; University of Cincinnati; University of Bern; University Hospital of Bern	Herzig, S (corresponding author), Univ Cologne, Dept Pharmacol, Gleueler Str 24, D-50931 Cologne, Germany.	stefan.herzig@uni-koeln.de	Matthes, Jan/AAF-1229-2020; Gründemann, Dirk/AAD-2217-2022	Matthes, Jan/0000-0003-2754-1555; Herzig, Stefan/0000-0001-8107-5204; Chaudhuri, Dipayan/0000-0003-0605-7334	NHLBI NIH HHS [R01 HL079599-01, T32 HL07382-30] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079599, T32HL007382] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; CASTELLANO A, 1994, BIOCHEM SOC T, V22, P483, DOI 10.1042/bst0220483; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; Chien AJ, 1998, J BIOL CHEM, V273, P23590, DOI 10.1074/jbc.273.36.23590; Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515; DeWaard M, 1996, FEBS LETT, V380, P272, DOI 10.1016/0014-5793(96)00007-5; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Erhardt JA, 1998, J BIOL CHEM, V273, P35222, DOI 10.1074/jbc.273.52.35222; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Felix R, 1999, RECEPTOR CHANNEL, V6, P351; Foell JD, 2004, PHYSIOL GENOMICS, V17, P183, DOI 10.1152/physiolgenomics.00207.2003; Freise D, 1999, BIOL CHEM, V380, P897, DOI 10.1515/BC.1999.110; Groner F, 2004, BIOCHEM BIOPH RES CO, V314, P878, DOI 10.1016/j.bbrc.2003.12.174; Grundemann D, 1996, BIOTECHNIQUES, V21, P898; Grundemann D, 1997, J BIOL CHEM, V272, P10408; Haase H, 1996, J MOL MED-JMM, V74, P99; Harry JB, 2004, J BIOL CHEM, V279, P46367, DOI 10.1074/jbc.M409523200; HORN R, 1991, BIOPHYS J, V60, P433, DOI 10.1016/S0006-3495(91)82069-0; Hullin R, 2003, J BIOL CHEM, V278, P21623, DOI 10.1074/jbc.M211164200; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Hullin R, 1999, CIRCULATION, V100, P155, DOI 10.1161/01.CIR.100.2.155; Klugbauer N, 2000, FEBS LETT, V470, P189, DOI 10.1016/S0014-5793(00)01306-5; Ludwig A, 1997, J NEUROSCI, V17, P1339; Michels G, 2002, MOL PHARMACOL, V61, P682, DOI 10.1124/mol.61.3.682; MITTERDORFER J, 1994, FEBS LETT, V352, P141, DOI 10.1016/0014-5793(94)00938-4; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; Opatowsky Y, 2004, NEURON, V42, P387, DOI 10.1016/S0896-6273(04)00250-8; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 2002, MOL PHARMACOL, V62, P485, DOI 10.1124/mol.62.3.485; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Schroder F, 1998, CIRCULATION, V98, P969, DOI 10.1161/01.CIR.98.10.969; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; Splawski I, 2004, CELL, V119, P19, DOI 10.1016/j.cell.2004.09.011; SuhKim H, 1996, MOL PHARMACOL, V50, P1330; Takahashi SX, 2005, J GEN PHYSIOL, V126, P365, DOI 10.1085/jgp.200509354; Takahashi SX, 2003, BIOPHYS J, V84, P3007, DOI 10.1016/S0006-3495(03)70027-7; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; Vendel AC, 2006, J NEUROSCI, V26, P2635, DOI 10.1523/JNEUROSCI.0067-06.2006; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; Wei S, 2000, CIRC RES, V86, P175, DOI 10.1161/01.RES.86.2.175; Yue DT, 2004, NEURON, V42, P357, DOI 10.1016/S0896-6273(04)00259-4	46	29	29	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1527	1538		10.1096/fj.06-7377com	http://dx.doi.org/10.1096/fj.06-7377com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17289923				2022-12-28	WOS:000246117000027
J	Dou, GR; Wang, YC; Hu, XB; Hou, LH; Wang, CM; Xu, JF; Wang, YS; Liang, YM; Yao, LB; Yang, AG; Han, H				Dou, Guo-Rui; Wang, Yao-Chun; Hu, Xing-Bin; Hou, Li-Hong; Wang, Chun-Mei; Xu, Jian-Feng; Wang, Yu-Sheng; Liang, Ying-Min; Yao, Li-Bo; Yang, An-Gang; Han, Hua			RBPJ, the transcription factor downstream of Notch receptors, is essential for the maintenance of vascular homeostasis in adult mice	FASEB JOURNAL			English	Article						angiogenesis; Notch signaling; endothelial cells; choroidal neovascularization	ARTERIOVENOUS-MALFORMATIONS; ACTIVATED NOTCH4; PROGENITOR CELLS; TUMOR-GROWTH; EXPRESSION; PATHWAY; ANGIOGENESIS; INHIBITION; TARGET; GENES	In adults, angiogenic abnormalities are involved in not only tumor growth but several human inherited diseases as well. It is unclear, however, concerning how the normal vascular structure is maintained and how angiogenesis is initiated in normal adults. Using the Cre-LoxP-mediated conditional gene deletion, we show in the present study that in adult mice disruption of the transcription factor recombination signal-binding protein J kappa (RBP-J) in endothelial cells strikingly induced spontaneous angiogenesis in multiple tissues, including retina and cornea, as well as in internal organs, such as liver and lung. In a choroidal neovascularization model, which mimics the angiogenic process in tumor growth and age-related macular degeneration, RBP-J deficiency induced a more intensive angiogenic response to injury. This could be transmitted by bone marrow, indicating that RBP-J could modulate bone marrow-derived endothelial progenitor cells in adult angiogenesis. In addition, in the absence of RBP-J, proliferation of endothelial cells increased significantly, leading to accumulative vessel outgrowth. These findings suggest that in adults RBP-J-mediated Notch signaling may play an essential role in the maintenance of vascular homeostasis by repressing endothelial cell proliferation.	[Dou, Guo-Rui; Wang, Yao-Chun; Hu, Xing-Bin; Hou, Li-Hong; Wang, Chun-Mei; Liang, Ying-Min; Yao, Li-Bo; Yang, An-Gang; Han, Hua] Fourth Mil Med Univ, Dept Med Genet & Dev Biol, State Key Lab Canc Biol, Xian 710032, Peoples R China; [Dou, Guo-Rui; Xu, Jian-Feng; Wang, Yu-Sheng; Liang, Ying-Min] Fourth Mil Med Univ, Xijing Hosp, Dept Ophthalmol, Xian 710032, Peoples R China; [Han, Hua] Fourth Mil Med Univ, Tangdu Hosp, Dept Hematol, Xian 710032, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University	Han, H (corresponding author), Fourth Mil Med Univ, Dept Med Genet & Dev Biol, State Key Lab Canc Biol, Chang Le Xi St 17, Xian 710032, Peoples R China.	wangys@fmmu.edu.cn	Hu, XB/U-8501-2019					Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Carey KA, 2007, J GERONTOL A-BIOL, V62, P9, DOI 10.1093/gerona/62.1.9; Carlson TR, 2005, P NATL ACAD SCI USA, V102, P9884, DOI 10.1073/pnas.0504391102; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Duarte A, 2004, GENE DEV, V18, P2474, DOI 10.1101/gad.1239004; Fischer A, 2004, GENE DEV, V18, P901, DOI 10.1101/gad.291004; Gridley T, 2001, P NATL ACAD SCI USA, V98, P5377, DOI 10.1073/pnas.101138098; Gridley T, 2007, DEVELOPMENT, V134, P2709, DOI 10.1242/dev.004184; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; HANS EG, 2004, AM J OPHTHALMOL, V137, P496; HARRINGTON LS, 2007, MICROVASC RES; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200; Hou HY, 2006, CURR EYE RES, V31, P1051, DOI 10.1080/02713680601100459; Iso T, 2002, J BIOL CHEM, V277, P6598, DOI 10.1074/jbc.M110495200; Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Karsan A, 2005, CAN J PHYSIOL PHARM, V83, P14, DOI 10.1139/Y04-125; Kato H, 1997, DEVELOPMENT, V124, P4133; Kokubo H, 1999, BIOCHEM BIOPH RES CO, V260, P459, DOI 10.1006/bbrc.1999.0880; Krebs LT, 2000, GENE DEV, V14, P1343; Krebs LT, 2004, GENE DEV, V18, P2469, DOI 10.1101/gad.1239204; Lacombe P, 2005, STROKE, V36, P1053, DOI 10.1161/01.STR.0000163080.82766.eb; Lawson ND, 2002, DEV CELL, V3, P127, DOI 10.1016/S1534-5807(02)00198-3; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Leslie JD, 2007, DEVELOPMENT, V134, P839, DOI 10.1242/dev.003244; Liu ZJ, 2006, FASEB J, V20, P1009, DOI 10.1096/fj.05-4880fje; Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104; Nakajima M, 2003, MECH DEVELOP, V120, P657, DOI 10.1016/S0925-4773(03)00064-9; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Noseda M, 2004, MOL CELL BIOL, V24, P8813, DOI 10.1128/MCB.24.20.8813-8822.2004; Noseda M, 2006, CIRC RES, V98, P1468, DOI 10.1161/01.RES.0000229683.81357.26; Paris D, 2005, EUR J PHARMACOL, V514, P1, DOI 10.1016/j.ejphar.2005.02.050; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rao PK, 2000, EXP CELL RES, V260, P379, DOI 10.1006/excr.2000.5034; Rehman AO, 2006, TRENDS CELL BIOL, V16, P293, DOI 10.1016/j.tcb.2006.04.003; Roberts N, 2005, J CELL MOL MED, V9, P583, DOI 10.1111/j.1582-4934.2005.tb00490.x; Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001; Sainson RCA, 2005, FASEB J, V19, P1027, DOI 10.1096/fj.04-3172fje; Siekmann AF, 2007, NATURE, V445, P781, DOI 10.1038/nature05577; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Takahashi H, 2004, BIOCHEM BIOPH RES CO, V325, P461, DOI 10.1016/j.bbrc.2004.10.054; Taylor KL, 2002, MICROVASC RES, V64, P372, DOI 10.1006/mvre.2002.2443; Thurston G, 2007, NAT REV CANCER, V7, P327, DOI 10.1038/nrc2130; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Williams CK, 2006, BLOOD, V107, P931, DOI 10.1182/blood-2005-03-1000; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	54	86	95	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1606	1617		10.1096/fj.07-9998com	http://dx.doi.org/10.1096/fj.07-9998com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18096813				2022-12-28	WOS:000255898700032
J	Larouche, D; Tong, XM; Fradette, J; Coulombe, PA; Germain, L				Larouche, Danielle; Tong, Xuemei; Fradette, Julie; Coulombe, Pierre A.; Germain, Lucie			Vibrissa hair bulge houses two populations of skin epithelial stem cells distinct by their keratin profile	FASEB JOURNAL			English	Article						intermediate filaments; tissue engineering; transmission electron microscopy; rodent	ROOT SHEATH-CELLS; LABEL-RETAINING CELLS; IN-VITRO; MERKEL CELLS; MAMMALIAN-TISSUES; GENE-EXPRESSION; MOUSE SKIN; FOLLICLE; MICE; CYTOKERATINS	Defining the properties of postnatal stem cells is of interest given their relevance for tissue homeostasis and therapeutic applications, such as skin tissue engineering for burn patients. In hair follicles, the bulge region of the outer root sheath houses stem cells. We show that explants from the prominent bulge area, but not the bulb, in rodent vibrissa follicles can produce epidermis in a skin model of tissue engineering. Using morphological criteria and keratin expression, we typified epithelial stem cells of vibrissa bulge. Two types of slow-cycling cells (Bb, Bs1) featuring a high colony-forming capacity occur in the bulge. Bb cells are located in the outermost basal layer, express K5, K15, K17, and K19, and feature a loosely organized keratin network. Bs1 cells localize to the suprabasal layers proximal to Bb cells and express K5/K17, correlating with a network of densely bundled filaments. These prominent bundles are missing in K17-null mice, which lack vibrissa. Atypically, both the Bb and Bs1 keratinocytes lack K14 expression. These findings show heterogeneity within the hair follicle stem cell repository, establish that a subset of slow-cycling cells are suprabasal in location, and point to a special role for K5/K17 filaments in a newly defined subset of stem cells. Our results are discussed in the context of long-term survival of engineered tissues after grafting that requires the presence of stem cells.	[Larouche, Danielle; Fradette, Julie; Germain, Lucie] Hop St Sacrement CHA, Lab Organogenese Expt LEOX, Quebec City, PQ G1S 4L8, Canada; [Larouche, Danielle; Fradette, Julie; Germain, Lucie] Univ Laval, Dept Surg, Ste Foy, PQ G1K 7P4, Canada; [Tong, Xuemei; Coulombe, Pierre A.] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; [Tong, Xuemei; Coulombe, Pierre A.] Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA	Laval University; Laval University; Johns Hopkins University; Johns Hopkins University	Germain, L (corresponding author), Hop St Sacrement CHA, Lab Organogenese Expt LEOX, 1050 Chemin, Quebec City, PQ G1S 4L8, Canada.	lucic.germain@chg.ulaval.ca		Germain, Lucie/0000-0001-8883-6491; Fradette, Julie/0000-0002-1851-5112	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044232, R01AR042047, R55AR042047] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42047, AR44232] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Bernot KM, 2002, J INVEST DERMATOL, V119, P1137, DOI 10.1046/j.1523-1747.2002.19518.x; BICKENBACH JR, 1986, CELL TISSUE KINET, V19, P325, DOI 10.1111/j.1365-2184.1986.tb00684.x; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; BLESSING M, 1993, J CELL BIOL, V120, P743, DOI 10.1083/jcb.120.3.743; BYRNE C, 1994, DEVELOPMENT, V120, P2369; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; COULOMBE PA, 1989, J CELL BIOL, V109, P2295, DOI 10.1083/jcb.109.5.2295; Daniely Y, 2004, AM J PHYSIOL-CELL PH, V287, pC171, DOI 10.1152/ajpcell.00226.2003; Fradette J, 2003, J INVEST DERMATOL, V120, P313, DOI 10.1046/j.1523-1747.2003.12024.x; FRANKE WW, 1984, CELL, V36, P813, DOI 10.1016/0092-8674(84)90031-X; Fuchs E, 1995, ANNU REV CELL DEV BI, V11, P123, DOI 10.1146/annurev.cb.11.110195.001011; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HEID HW, 1988, DIFFERENTIATION, V37, P215, DOI 10.1111/j.1432-0436.1988.tb00724.x; IBRAHIM L, 1975, J EMBRYOL EXP MORPH, V33, P831; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; KOBAYASHI K, 1993, P NATL ACAD SCI USA, V90, P7391, DOI 10.1073/pnas.90.15.7391; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; Laplante AF, 2001, FASEB J, V15, P2377, DOI 10.1096/fj.01-0250com; LAROUCHE D, METHODS MOL MED; LENOIR MC, 1988, DEV BIOL, V130, P610, DOI 10.1016/0012-1606(88)90356-9; LIMAT A, 1991, EXP CELL RES, V194, P218, DOI 10.1016/0014-4827(91)90357-Z; Limat A, 2002, CELLS TISSUES ORGANS, V172, P79, DOI 10.1159/000065615; Lyle S, 1998, J CELL SCI, V111, P3179; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; Mazzalupo S, 2003, DEV DYNAM, V226, P356, DOI 10.1002/dvdy.10245; McGowan K, 1998, Subcell Biochem, V31, P173; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; McGowan KM, 2002, GENE DEV, V16, P1412, DOI 10.1101/gad.979502; Michel M, 1996, J CELL SCI, V109, P1017; Moll I, 1996, J INVEST DERMATOL, V106, P281, DOI 10.1111/1523-1747.ep12340714; MOLL R, 1984, DIFFERENTIATION, V28, P136, DOI 10.1111/j.1432-0436.1984.tb00277.x; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Morris RJ, 1999, J INVEST DERMATOL, V112, P470, DOI 10.1046/j.1523-1747.1999.00537.x; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; Paladini RD, 1996, J CELL BIOL, V132, P381, DOI 10.1083/jcb.132.3.381; Peters B, 2001, MOL BIOL CELL, V12, P1775, DOI 10.1091/mbc.12.6.1775; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; ROYAL I, 1995, EXP CELL RES, V220, P171, DOI 10.1006/excr.1995.1303; Schweizer J, 2006, J CELL BIOL, V174, P169, DOI 10.1083/jcb.200603161; STARK HJ, 1987, DIFFERENTIATION, V35, P236, DOI 10.1111/j.1432-0436.1987.tb00174.x; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; Tani H, 2000, P NATL ACAD SCI USA, V97, P10960, DOI 10.1073/pnas.97.20.10960; Tong XM, 2004, J INVEST DERMATOL, V122, P965, DOI 10.1111/j.0022-202X.2004.22422.x; Tong XM, 2006, GENE DEV, V20, P1353, DOI 10.1101/gad.1387406; Troy TC, 1999, J CELL PHYSIOL, V180, P409, DOI 10.1002/(SICI)1097-4652(199909)180:3<409::AID-JCP12>3.0.CO;2-V; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Wang ZL, 2003, J INVEST DERMATOL, V121, P1276, DOI 10.1111/j.1523-1747.2003.12644.x; Wawersik M, 1997, J BIOL CHEM, V272, P32557, DOI 10.1074/jbc.272.51.32557; WEINBERG WC, 1993, J INVEST DERMATOL, V100, P229, DOI 10.1111/1523-1747.ep12468971; Whitbread LA, 1998, EXP CELL RES, V244, P448, DOI 10.1006/excr.1998.4217	53	43	43	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2008	22	5					1404	1415		10.1096/fj.07-8109com	http://dx.doi.org/10.1096/fj.07-8109com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18162489				2022-12-28	WOS:000255898700013
J	Benny, O; Kim, SK; Gvili, K; Radzishevsky, IS; Mor, A; Verduzco, L; Menon, LG; Black, PM; Machluf, M; Carroll, RS				Benny, Ofra; Kim, Seung-Ki; Gvili, Koby; Radzishevsky, Inna S.; Mor, Amram; Verduzco, Luis; Menon, Lata G.; Black, Peter M.; Machluf, Marcelle; Carroll, Rona S.			In vivo fate and therapeutic efficacy of PF-4/CTF microspheres in an orthotopic human glioblastoma model	FASEB JOURNAL			English	Article						angiogenesis; brain tumor; PLGA; local delivery	BIODEGRADABLE MICROSPHERES; ENDOGENOUS INHIBITORS; LOADED MICROSPHERES; DRUG-DELIVERY; GROWTH-FACTOR; BRAIN-TUMORS; ANGIOGENESIS; RELEASE; PLATELET-FACTOR-4; BIOCOMPATIBILITY	The correlation between glioma grade and angiogenesis suggests that antiangiogenic therapies are potentially therapeutically effective for these tumors. However, to achieve tumor suppression, antiangiogenic therapies need to be administered daily using high systemic quantities. We designed a biodegradable polymeric device that overcomes those barriers by providing sustained local delivery of a C-terminal fragment of platelet factor 4 (PF-4/CTF), an antiangiogenic agent. Fluorescent-labeled microspheres composed of poly lactic-coglycolic acid (PLGA) were loaded with rhodamine-labeled PF-4/CTF and formulated to release their contents over time. Fluorescent labeling enabled the correlation between the in vitro to the in vivo kinetic and release studies. PF-4/CTF microspheres were injected into established intracranial human glioma tumors in nude mice. Noninvasive magnetic resonance imaging (MRI) was used to assess the therapeutic response. Tumor size, microvessel density, proliferation, and apoptosis rate were measured by histological analysis. Intracranially, the microspheres were located throughout the tumor bed and continuously released PF-4/CTF during the entire experimental period. MRI and histological studies showed that a single injection of microspheres containing PF-4/CTF caused a 65.2% and 72% reduction in tumor volume, respectively, with a significant decrease in angiogenesis and an increase in apoptosis. Our data demonstrate that polymeric microspheres are an effective therapeutic approach for delivering antiangiogenic agents that result in the inhibition of glioma tumor growth.	[Benny, Ofra; Gvili, Koby; Radzishevsky, Inna S.; Mor, Amram; Machluf, Marcelle; Carroll, Rona S.] Technion Israel Inst Technol, Dept Food Engn & Biotechnol, Fac Biotechnol & Food Engn, IL-32000 Haifa, Israel; [Kim, Seung-Ki; Verduzco, Luis; Menon, Lata G.; Black, Peter M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA; [Kim, Seung-Ki; Verduzco, Luis; Menon, Lata G.; Black, Peter M.] Harvard Univ, Childrens Hosp, Sch Med, Boston, MA 02115 USA; [Kim, Seung-Ki] Seoul Natl Univ Hosp, Dept Neurosurg, Seoul 110744, South Korea	Technion Israel Institute of Technology; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Seoul National University (SNU); Seoul National University Hospital	Carroll, RS (corresponding author), Technion Israel Inst Technol, Dept Food Engn & Biotechnol, Fac Biotechnol & Food Engn, IL-32000 Haifa, Israel.	machlufm@tx.technion.ac.il; rcarroll@rics.bwh.harvard.edu	Benny, Ofra/AAB-3294-2021; Kim, Seung-Ki/J-2742-2012	Radzishevsky, Inna/0000-0001-7748-7599				ARSHADY R, 1991, J CONTROL RELEASE, V17, P1, DOI 10.1016/0168-3659(91)90126-X; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Bello L, 2002, CLIN CANCER RES, V8, P3539; Benny O, 2005, CLIN CANCER RES, V11, P768; Bikfalvi A, 2004, SEMIN THROMB HEMOST, V30, P379, DOI 10.1055/s-2004-831051; Cadee JA, 2001, J BIOMED MATER RES, V56, P600, DOI 10.1002/1097-4636(20010915)56:4<600::AID-JBM1133>3.0.CO;2-I; Edlund U, 2002, ADV POLYM SCI, V157, P67; ELDRIDGE JH, 1991, MOL IMMUNOL, V28, P287, DOI 10.1016/0161-5890(91)90076-V; Etzler FM, 1997, PART PART SYST CHAR, V14, P278, DOI 10.1002/ppsc.19970140604; FRIESS W, J PHARM SCI, V91, P845; Gao P, 2006, CHEM PHARM BULL, V54, P89, DOI 10.1248/cpb.54.89; Gavini E, 2005, AAPS PHARMSCITECH, V6, DOI 10.1208/pt060117; Giussani C, 2003, CANCER RES, V63, P2499; Hagedorn M, 2002, CANCER RES, V62, P6884; Hagedorn M, 2001, FASEB J, V15, P550; Hyon SH, 2000, YONSEI MED J, V41, P720, DOI 10.3349/ymj.2000.41.6.720; Joki T, 2001, NAT BIOTECHNOL, V19, P35, DOI 10.1038/83481; Jouan V, 1999, BLOOD, V94, P984, DOI 10.1182/blood.V94.3.984.415k31_984_993; Lesniak MS, 2005, TECHNOL CANCER RES T, V4, P417, DOI 10.1177/153303460500400409; Li YH, 2003, CANCER BIOTHER RADIO, V18, P829, DOI 10.1089/108497803770418373; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MENEI P, 1993, BIOMATERIALS, V14, P470, DOI 10.1016/0142-9612(93)90151-Q; Menei P, 1996, NEUROSURGERY, V39, P117, DOI 10.1097/00006123-199607000-00023; NEUFELD G, 1988, J CELL PHYSIOL, V136, P537, DOI 10.1002/jcp.1041360321; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Patil Siddhesh D, 2004, Diabetes Technol Ther, V6, P887, DOI 10.1089/dia.2004.6.887; Prior S, 2004, J ANTIMICROB CHEMOTH, V53, P981, DOI 10.1093/jac/dkh227; Rege TA, 2005, NEURO-ONCOLOGY, V7, P106, DOI 10.1215/S115285170400119X; Rojas J, 1999, INT J PHARM, V183, P67, DOI 10.1016/S0378-5173(99)00046-0; RUCINSKI B, 1986, AM J PHYSIOL, V251, pH800, DOI 10.1152/ajpheart.1986.251.4.H800; RUIZ JM, 1990, PHARMACEUT RES, V7, P928, DOI 10.1023/A:1015945806917; Saini P, 1997, DRUG DELIV, V4, P129, DOI 10.3109/10717549709051884; Sales-Junior PA, 2005, VET IMMUNOL IMMUNOP, V107, P281, DOI 10.1016/j.vetimm.2005.05.004; Saltzman WM, 1999, PHARMACEUT RES, V16, P232, DOI 10.1023/A:1018824324275; Schmidt KF, 2004, J NEURO-ONCOL, V68, P207, DOI 10.1023/B:NEON.0000033364.43142.bf; Schmidt NO, 2004, CLIN CANCER RES, V10, P1255, DOI 10.1158/1078-0432.CCR-03-0052; Sun YP, 2004, MAGN RESON MED, V51, P893, DOI 10.1002/mrm.20029; Tanaka T, 1997, NAT MED, V3, P437, DOI 10.1038/nm0497-437; Tracy MA, 1999, BIOMATERIALS, V20, P1057, DOI 10.1016/S0142-9612(99)00002-2; Veziers J, 2001, J NEUROSURG, V95, P489, DOI 10.3171/jns.2001.95.3.0489	40	31	32	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					488	499		10.1096/fj.07-8801com	http://dx.doi.org/10.1096/fj.07-8801com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17873103				2022-12-28	WOS:000252822600019
J	Farmer, JL; Burghardt, RC; Jousan, FD; Hansen, PJ; Bazer, FW; Spencer, TE				Farmer, Jennifer L.; Burghardt, Robert C.; Jousan, F. Dean; Hansen, Peter J.; Bazer, Fuller W.; Spencer, Thomas E.			Galectin 15 (LGALS15) functions in trophectoderm migration and attachment	FASEB JOURNAL			English	Article						trophoblast; apoptosis	LEYDEN CRYSTAL PROTEIN; EXTRACELLULAR-MATRIX PROTEINS; OVINE UTERUS; ENDOGENOUS RETROVIRUSES; OSTEOPONTIN EXPRESSION; DOMESTIC-ANIMALS; EARLY-PREGNANCY; BOVINE EMBRYOS; CONCEPTUS; PROGESTERONE	Galectin 15 (LGALS15) is expressed specifically by the endometrial luminal epithelium ( LE) of the ovine uterus in concert with blastocyst growth, elongation, and implantation. LGALS15 contains a predicted carbohydrate recognition domain (CRD) as well as LDV and RGD recognition sequences for integrin binding. Studies tested the hypothesis that LGALS15 is a secreted regulator of blastocyst development, as well as growth, migration, adhesion, and apoptosis of trophoblast. Bovine embryos were produced in vitro by standard conditions, and putative zygotes were cultured in the presence of recombinant ovine LGALS15. Rates of embryo cleavage and blastocyst formation were not affected by LGALS15. LGALS15 moderately increased proliferation of ovine trophectoderm (oTr) cells. Staurosporine elicited apoptosis of oTr cells, which could be partially inhibited by LGALS15. Migration of oTr cells was stimulated by LGALS15 that was dependent on Jun N-terminal kinase (JNK). A dose-dependent increase in oTr cell attachment to LGALS15 was found that could be inhibited by cyclic GRGDS, but not GRADS, peptides. Mutation of the LDVRGD integrin binding sequence of LGALS15 to LADRAD decreased its ability to promote oTr cell attachment, whereas mutation of the CRD had little effect. LGALS15 induced formation of robust focal adhesions in oTr cells that was abolished by mutation of the LDVRGD sequence. Collectively, these results support the hypothesis that LGALS15 stimulates trophectoderm cell migration and attachment via integrin binding and activation which are critical to blastocyst elongation and implantation.	[Farmer, Jennifer L.; Bazer, Fuller W.; Spencer, Thomas E.] Texas A&M Univ, Ctr Anim Biotechnol & Genom, College Stn, TX 77843 USA; [Farmer, Jennifer L.; Bazer, Fuller W.; Spencer, Thomas E.] Texas A&M Univ, Dept Anim Sci, College Stn, TX 77843 USA; [Burghardt, Robert C.] Texas A&M Univ, Image Anal Lab, College Stn, TX 77843 USA; [Burghardt, Robert C.] Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX 77843 USA; [Jousan, F. Dean; Hansen, Peter J.] Univ Florida, Dept Anim Sci, Gainesville, FL 32611 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; State University System of Florida; University of Florida	Spencer, TE (corresponding author), Texas A&M Univ, Ctr Anim Biotechnol & Genom, 442 Kleberg Ctr,2471 TAMU, College Stn, TX 77843 USA.	tspencer@tamu.edu	Spencer, Thomas/AAD-6434-2020; Burghardt, Robert C./AAF-4847-2021; Bazer, Fuller/AAF-4317-2021; Hansen, Peter/AAI-4693-2021	Burghardt, Robert C./0000-0003-1021-8444; Bazer, Fuller/0000-0002-5823-5086; Hansen, Peter/0000-0003-3061-9333; Spencer, Thomas/0000-0003-2815-766X; Jousan, Frank Dean/0000-0002-2006-0612	NIEHS NIH HHS [P30 ES0910607] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aplin J D, 1997, Rev Reprod, V2, P84, DOI 10.1530/ror.0.0020084; Armant DR, 2005, DEV BIOL, V280, P260, DOI 10.1016/j.ydbio.2005.02.009; Arroyo J, 2004, PLACENTA, V25, P379, DOI 10.1016/j.placenta.2003.11.001; ASHWORTH CJ, 1989, BIOL REPROD, V40, P425, DOI 10.1095/biolreprod40.2.425; BAZER FW, 1975, J ANIM SCI, V41, P1376, DOI 10.2527/jas1975.4151376x; BAZER FW, 1992, P SOC EXP BIOL MED, V199, P373, DOI 10.3181/00379727-199-43371A; Bogoyevitch MA, 2006, MICROBIOL MOL BIOL R, V70, P1061, DOI 10.1128/MMBR.00025-06; BOHN H, 1983, ONCODEV BIOL MED, V4, P343; Burghardt RC, 2002, CELLS TISSUES ORGANS, V172, P202, DOI 10.1159/000066969; CARNEGIE JA, 1985, AM J ANAT, V174, P471, DOI 10.1002/aja.1001740409; Cooper DNW, 2002, BBA-GEN SUBJECTS, V1572, P209, DOI 10.1016/S0304-4165(02)00310-0; Dunlap KA, 2006, P NATL ACAD SCI USA, V103, P14390, DOI 10.1073/pnas.0603836103; Dunphy JL, 2000, J BIOL CHEM, V275, P32106, DOI 10.1074/jbc.M003739200; Dvorak AM, 1996, HISTOL HISTOPATHOL, V11, P711; Dyer KD, 1996, LIFE SCI, V58, P2073, DOI 10.1016/0024-3205(96)00201-9; FLECHON JE, 1986, REPROD NUTR DEV, V26, P1017, DOI 10.1051/rnd:19860609; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gray CA, 2006, BIOL REPROD, V74, P383, DOI 10.1095/biolreprod.105.046656; Gray CA, 2005, REPRODUCTION, V130, P231, DOI 10.1530/rep.1.00637; Gray CA, 2004, P NATL ACAD SCI USA, V101, P7982, DOI 10.1073/pnas.0402669101; Gray CA, 2002, REPRODUCTION, V124, P289, DOI 10.1530/rep.0.1240289; Gray CA, 2000, BIOL REPROD, V62, P448, DOI 10.1095/biolreprod62.2.448; Gray CA, 2001, BIOL REPROD, V64, P1608, DOI 10.1095/biolreprod64.6.1608; GUILLOMOT M, 1995, J REPROD FERTIL, P39; GUILLOMOT M, 1990, BIOL CELL, V68, P205, DOI 10.1016/0248-4900(90)90309-Q; GUILLOMOT M, 1981, PLACENTA, V2, P169, DOI 10.1016/S0143-4004(81)80021-5; Guillomot M, 1993, REPROD MAMMALS MAN, P387; Hayashi K, 2007, ENDOCRINOLOGY, V148, P3496, DOI 10.1210/en.2007-0283; Hirabayashi J, 2002, BBA-GEN SUBJECTS, V1572, P232, DOI 10.1016/S0304-4165(02)00311-2; HIRABAYASHI J, 1994, GLYCOCONJUGATE J, V11, P437, DOI 10.1007/BF00731280; Hughes RC, 2001, BIOCHIMIE, V83, P667; Johnson GA, 2003, BIOL REPROD, V69, P1458, DOI 10.1095/biolreprod.103.020651; Johnson GA, 2001, BIOL REPROD, V65, P820, DOI 10.1095/biolreprod65.3.820; Joyce MM, 2005, PLACENTA, V26, P160, DOI 10.1016/j.placenta.2004.05.009; Kabir J, 2002, BIOCHEM J, V367, P145, DOI 10.1042/BJ20020665; Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111; Lee VH, 1998, BIOL REPROD, V58, P1277, DOI 10.1095/biolreprod58.5.1277; LEWIS SK, IN PRESS BIOL REPROD; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Maddox-Hyttel P, 2003, REPRODUCTION, P103; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Nayal A, 2004, CURR OPIN CELL BIOL, V16, P94, DOI 10.1016/j.ceb.2003.11.007; Ochieng J, 1998, BIOCHEM BIOPH RES CO, V246, P788, DOI 10.1006/bbrc.1998.8708; ODA Y, 1993, J BIOL CHEM, V268, P5929; PARRISH JJ, 1986, THERIOGENOLOGY, V25, P591, DOI 10.1016/0093-691X(86)90143-3; Paula-Lopes FF, 1998, BIOL REPROD, V59, P1406, DOI 10.1095/biolreprod59.6.1406; Popovici RM, 2005, J CLIN ENDOCR METAB, V90, P6170, DOI 10.1210/jc.2004-2529; Raspotnig G, 1999, ANAL BIOCHEM, V275, P74, DOI 10.1006/abio.1999.4309; Rivera RM, 2001, REPRODUCTION, V121, P107, DOI 10.1530/rep.0.1210107; Roberts R M, 1987, Adv Exp Med Biol, V230, P137; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Satterfield MC, 2006, BIOL REPROD, V75, P289, DOI 10.1095/biolreprod.106.052944; Soto P, 2003, AM J REPROD IMMUNOL, V50, P380, DOI 10.1034/j.1600-0897.2003.00101.x; Spencer T E, 2004, J Anim Sci, V82 E-Suppl, pE4; Spencer TE, 2004, REPRODUCTION, V128, P657, DOI 10.1530/rep.1.00398; Spencer TE, 2004, ANIM REPROD SCI, V82-3, P537, DOI 10.1016/j.anireprosci.2004.04.014; Spencer TE, 2004, BIOL REPROD, V71, P2, DOI 10.1095/biolreprod.103.024133; Spencer TE, 2007, REPROD FERT DEVELOP, V19, P65, DOI 10.1071/RD06102; Swaminathan GJ, 1999, BIOCHEMISTRY-US, V38, P13837, DOI 10.1021/bi990756e; THATCHER WW, 1995, J REPROD FERTIL, P15; Vogel V, 2006, ANNU REV BIOPH BIOM, V35, P459, DOI 10.1146/annurev.biophys.35.040405.102013; von Wolff M, 2005, MOL HUM REPROD, V11, P189, DOI 10.1093/molehr/gah144; Wang JL, 2004, BBA-GEN SUBJECTS, V1673, P75, DOI 10.1016/j.bbagen.2004.03.013; WELLER PF, 1984, J BIOL CHEM, V259, P5100; Wolf E, 2003, REPROD DOMEST ANIM, V38, P276, DOI 10.1046/j.1439-0531.2003.00435.x; Yang RY, 2003, CELL MOL LIFE SCI, V60, P267, DOI 10.1007/s000180300022	68	58	60	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2008	22	2					548	560		10.1096/fj.07-9308com	http://dx.doi.org/10.1096/fj.07-9308com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17890287				2022-12-28	WOS:000252822600025
J	Gunnarsson, P; Levander, L; Pahlsson, P; Grenegard, M				Gunnarsson, Peter; Levander, Louise; Pahlsson, Peter; Grenegard, Magnus			The acute-phase protein alpha(1)-acid glycoprotein (AGP) induces rises in cytosolic Ca2+ in neutrophil granulocytes via sialic acid binding immunoglobulin-like lectins (Siglecs)	FASEB JOURNAL			English	Article						orosomucoid; plasma protein; calcium signaling; carbohydrate; L-selectin; phagocyte	HUMAN ALPHA-1-ACID GLYCOPROTEIN; L-SELECTIN; FUNCTIONAL-ACTIVITY; INHIBITORY MOTIF; ACTIVATION; EXPRESSION; MODULATION; RECEPTORS; SPECIFICITIES; STIMULATION	We studied whether the acute-phase protein alpha(1)-acid glycoprotein (AGP) induces rises in [Ca2+](i) in neutrophils and sought to identify the corresponding AGP receptor (or receptors). We found that AGP elicited a minimal rise in [Ca2+] i in Fura-2-loaded neutrophils, and this response was markedly enhanced by pretreatment with anti-L-selectin antibodies. (The EC50 value of the AGP-induced Ca2+ response was 9 mu g/ml.) Activation of phospholipase-C, Src tyrosine kinases, and PI3 kinases proved to be essential for the AGP-mediated increase in [Ca2+] i, whereas the p38 MAPK and SYK signaling pathways were not involved. Furthermore, antibodies against sialic acid binding, immunoglobulin-like lectin 5 (Siglec-5) and oligosaccharide 3 '- sialyl-lactose both antagonized the AGP-induced response and caused an immediate increase in [Ca2+] i in anti-L-selectin-treated neutrophils, which indicates a signaling capacity of Siglec-5. We used modified forms of AGP (treated with mild periodate or neuraminidase) to establish the importance of sialic acid residues. The modified forms of AGP caused a much smaller rise in [Ca2+] i than did unaltered AGP. Affinity chromatography confirmed that unchanged AGP, but not neuraminidase-treated AGP, bound to Siglec-5. Our report provides the first evidence for a signaling capacity by AGP through a defined receptor. Pre-engagement of L-selectin significantly enhanced this signaling capacity. -Gunnarsson, P., Levander, L., Pahlsson, P., Grenegard, M. The acute- phase protein alpha(1)- acid glycoprotein (AGP) induces rises in cytosolic Ca2+ in neutrophil granulocytes via sialic acid binding immunoglobulin- like lectins (Siglecs).	Linkoping Univ, Dept Med & Care, Div Pharmacol, S-58185 Linkoping, Sweden; Linkoping Univ, Dept Biomed & Surg, Div Cell Biol, Linkoping, Sweden	Linkoping University; Linkoping University	Gunnarsson, P (corresponding author), Linkoping Univ, Dept Med & Care, Div Pharmacol, S-58185 Linkoping, Sweden.	petgu@imv.liu.se						ABBASSI O, 1993, BLOOD CELLS, V19, P245; Angata T, 2006, FASEB J, V20, P1964, DOI 10.1096/fj.06-5800com; Avril T, 2004, J IMMUNOL, V173, P6841, DOI 10.4049/jimmunol.173.11.6841; Avril T, 2005, J BIOL CHEM, V280, P19843, DOI 10.1074/jbc.M502041200; BORIES PN, 1990, INFLAMMATION, V14, P315, DOI 10.1007/BF00915815; Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P7; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; Brenner B, 1997, IMMUNOLOGY, V92, P214, DOI 10.1046/j.1365-2567.1997.00336.x; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8625, DOI 10.1074/jbc.275.12.8625; BrinkmanVanderLinden ECM, 1996, GLYCOCONJUGATE J, V13, P27, DOI 10.1007/BF01049676; Burelout C, 2004, MOL PHARMACOL, V66, P293, DOI 10.1124/mol.66.2.293; Connolly NP, 2002, BRIT J HAEMATOL, V119, P221, DOI 10.1046/j.1365-2141.2002.03808.x; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; COSTELLO M, 1979, NATURE, V281, P677, DOI 10.1038/281677a0; CROCKETTTORABI E, 1995, J IMMUNOL, V154, P2291; CrockettTorabi E, 1997, AM J PHYSIOL-HEART C, V272, pH1302, DOI 10.1152/ajpheart.1997.272.3.H1302; Erickson-Miller CL, 2003, EXP HEMATOL, V31, P382, DOI 10.1016/S0301-472X(03)00046-8; Fournier T, 2000, BBA-PROTEIN STRUCT M, V1482, P157, DOI 10.1016/S0167-4838(00)00153-9; Fumagalli L, 2007, J IMMUNOL, V178, P3874, DOI 10.4049/jimmunol.178.6.3874; GAUDRY M, 1995, BLOOD, V86, P3567, DOI 10.1182/blood.V86.9.3567.bloodjournal8693567; Gergely J, 1999, IMMUNOL LETT, V68, P3, DOI 10.1016/S0165-2478(99)00024-3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Jorgensen HG, 1998, BIOMED CHROMATOGR, V12, P343, DOI 10.1002/(SICI)1099-0801(199811/12)12:6<343::AID-BMC760>3.0.CO;2-6; LAINE E, 1990, INFLAMMATION, V14, P1, DOI 10.1007/BF00914025; LAUDANNA C, 1994, J BIOL CHEM, V269, P4021; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; PAWLOWSKI T, 1989, ARTHRITIS RHEUM, V32, P347, DOI 10.1002/anr.1780320319; POS O, 1990, INFLAMMATION, V14, P133, DOI 10.1007/BF00917452; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; SAMELSON LE, 2005, ANNU REV IMMUNOL, V20, P371; Sjogren F, 2000, INFLAMMATION, V24, P21, DOI 10.1023/A:1006983824890; SMITH CD, 1987, J BIOL CHEM, V262, P6121; Smolen JE, 2000, J BIOL CHEM, V275, P15876, DOI 10.1074/jbc.M906232199; Theilgaard-Monch K, 2005, J LEUKOCYTE BIOL, V78, P462, DOI 10.1189/jlb.0105042; Timoshenko AV, 1998, BIOCHEMISTRY-MOSCOW+, V63, P546; VANOSS CJ, 1974, IMMUNOL COMMUN, V3, P321, DOI 10.3109/08820137409061112; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VASSON MP, 1994, CLIN CHIM ACTA, V224, P65, DOI 10.1016/0009-8981(94)90121-X; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WADDELL TK, 1994, J BIOL CHEM, V269, P18485; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Williams JP, 1997, AM J PHYSIOL-GASTR L, V273, pG1031, DOI 10.1152/ajpgi.1997.273.5.G1031; Zhang JQ, 2000, J BIOL CHEM, V275, P22121, DOI 10.1074/jbc.M002788200	46	41	44	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4059	4069		10.1096/fj.07-8534com	http://dx.doi.org/10.1096/fj.07-8534com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17675532				2022-12-28	WOS:000251283500030
J	Tosini, G; Davidson, AJ; Fukuhara, C; Kasamatsu, M; Castamon-Cervantes, O				Tosini, Gianluca; Davidson, Alec J.; Fukuhara, Chiaki; Kasamatsu, Manami; Castamon-Cervantes, Oscar			Localization of a circadian clock in mammalian photoreceptors	FASEB JOURNAL			English	Article						melatonin; circadian rhythms; clock genes; retina; rat	ACETYLTRANSFERASE MESSENGER-RNA; N-ACETYLTRANSFERASE; RAT RETINA; MOUSE RETINA; MELATONIN SYNTHESIS; DOPAMINE RELEASE; GENE-EXPRESSION; KAINIC ACID; RHYTHMS; PROTEIN	Several studies have demonstrated that the mammalian retina contains an autonomous circadian clock. Dopaminergic and other inner retinal neurons express many of the clock genes, whereas some of these genes seem to be absent from the photoreceptors. This observation has led to the suggestion that in mammalian retina the circadian pacemaker driving retinal rhythms is located in the inner nuclear layer. However, other evidence points to the photoreceptor layer as the site of the mammalian retinal clock. The goal of the present study was to demonstrate the presence of a functional circadian clock in photoreceptors. First, using laser capture microdissection and reverse transcriptase- polymerase chain reaction, we investigated which of the clock genes are expressed in rat photoreceptors. We then prepared photoreceptor layer cultures from the retina to test whether these isolated cultures were viable and could drive circadian rhythms. Our data indicated that Per1, Per3, Cry1, Cry2, Clock, Bmall, Rev-erb alpha, and Rora RNAs were present in the photoreceptors, whereas we were unable to amplify mRNA for Per2 and Npas2. Photoreceptor layers obtained from Period1- luciferase rats expressed a robust circadian rhythm in bioluminescence and melatonin synthesis. These results demonstrate that mammalian photoreceptors contain the circadian pacemaker driving rhythmic melatonin synthesis.	Morehouse Sch Med, Inst Neurosci, Circadian Rhythms & Sleep Disorders Program, Atlanta, GA USA	Morehouse School of Medicine	Tosini, G (corresponding author), Morehouse Sch Med, Inst Neurosci, 720 Westview Dr SW, Atlanta, GA 30310 USA.	gtosini@msm.edu		tosini, gianluca/0000-0003-3645-4533	NCI NIH HHS [CA116261, R21 CA116261] Funding Source: Medline; NINDS NIH HHS [R56 NS043459, R01 NS043459, R01 NS043459-05A2, NS 34194, U54 NS034194, NS-43459] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA116261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043459, R56NS043459, U54NS034194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOATRIGHT JH, 1994, VISUAL NEUROSCI, V11, P1013, DOI 10.1017/S0952523800003941; CAHILL GM, 1993, NEURON, V10, P573, DOI 10.1016/0896-6273(93)90160-S; Chansard M, 2007, NEUROSCIENCE, V145, P812, DOI 10.1016/j.neuroscience.2006.12.037; Chaurasia SS, 2005, J NEUROCHEM, V92, P158, DOI 10.1111/j.1471-4159.2004.02874.x; Chen W, 2000, MOL BRAIN RES, V81, P43, DOI 10.1016/S0169-328X(00)00160-1; Chidlow G, 2003, BRAIN RES, V963, P298, DOI 10.1016/S0006-8993(02)04052-0; Davidson AJ, 2006, INT J CANCER, V118, P1623, DOI 10.1002/ijc.21591; Dinet V, 2007, J PINEAL RES, V42, P83, DOI 10.1111/j.1600-079X.2006.00387.x; Doyle SE, 2002, VISUAL NEUROSCI, V19, P593, DOI 10.1017/S0952523802195058; Doyle SE, 2002, J NEUROCHEM, V83, P211, DOI 10.1046/j.1471-4159.2002.01149.x; DUBOCOVICH ML, 1983, NATURE, V306, P782, DOI 10.1038/306782a0; Dubocovich ML, 1997, N-S ARCH PHARMACOL, V355, P365, DOI 10.1007/PL00004956; Fukuhara C, 2004, J NEUROSCI, V24, P1803, DOI 10.1523/JNEUROSCI.4988-03.2004; Garbarino-Pico E, 2004, J BIOL CHEM, V279, P51172, DOI 10.1074/jbc.M309248200; Garcia-Fernandez JA, 2007, NEUROSCI LETT, V419, P55, DOI 10.1016/j.neulet.2007.03.054; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Green CB, 2004, J BIOL RHYTHM, V19, P91, DOI 10.1177/0748730404263002; Gustincich S, 2004, P NATL ACAD SCI USA, V101, P5069, DOI 10.1073/pnas.0400913101; IUVONE PM, 1986, BRAIN RES, V369, P168, DOI 10.1016/0006-8993(86)90525-1; Iuvone PM, 2005, PROG RETIN EYE RES, V24, P433, DOI 10.1016/j.preteyeres.2005.01.003; Kamphuis W, 2005, BIOCHEM BIOPH RES CO, V330, P18, DOI 10.1016/j.bbrc.2005.02.118; Liang J, 2004, NEUROREPORT, V15, P1497, DOI 10.1097/01.wnr.0000131007.59315.66; Liu CM, 2004, CELL TISSUE RES, V315, P197, DOI 10.1007/s00441-003-0822-1; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Namihira M, 2001, NEUROREPORT, V12, P471, DOI 10.1097/00001756-200103050-00010; NguyenLegros J, 1996, J NEUROCHEM, V67, P2514; Niki T, 1998, BIOCHEM BIOPH RES CO, V248, P115, DOI 10.1006/bbrc.1998.8916; Nir I, 2000, BRAIN RES, V870, P118, DOI 10.1016/S0006-8993(00)02409-4; PIERCE ME, 1993, NEURON, V10, P579, DOI 10.1016/0896-6273(93)90161-J; Ribelayga C, 2004, J PHYSIOL-LONDON, V554, P467, DOI 10.1113/jphysiol.2003.053710; Ruan GX, 2006, P NATL ACAD SCI USA, V103, P9703, DOI 10.1073/pnas.0601940103; Sakamoto K, 2000, NEUROREPORT, V11, P3995, DOI 10.1097/00001756-200012180-00018; Sakamoto K, 2006, MOL VIS, V12, P117; Sakamoto K, 2004, J NEUROCHEM, V90, P1019, DOI 10.1111/j.1471-4159.2004.02571.x; Sakamoto K, 1998, NEUROSCI LETT, V245, P113, DOI 10.1016/S0304-3940(98)00189-X; Sakamoto K, 2005, EUR J NEUROSCI, V22, P3536; SAKAMOTO K, 2005, EUR J NEUROSCI, V22, P3544; TERMAN JS, 1993, BRAIN RES, V605, P256; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Tosini G, 1998, BRAIN RES, V789, P221, DOI 10.1016/S0006-8993(97)01446-7; Tosini G, 2002, CELL TISSUE RES, V309, P119, DOI 10.1007/s00441-002-0578-z; Tosini G, 2000, NEUROSCI LETT, V286, P119, DOI 10.1016/S0304-3940(00)01117-4; Witkovsky P, 2003, J NEUROSCI, V23, P7670; Yujnovsky I, 2006, P NATL ACAD SCI USA, V103, P6386, DOI 10.1073/pnas.0510691103; ZAWILSKA JB, 1992, NEUROSCI LETT, V135, P71, DOI 10.1016/0304-3940(92)90138-W	45	102	102	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2007	21	14					3866	3871		10.1096/fj.07-8371com	http://dx.doi.org/10.1096/fj.07-8371com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17621597	Green Accepted			2022-12-28	WOS:000251283500011
J	Cui, F; Qu, H; Cong, J; Liu, XL; Qiao, CL				Cui, Feng; Qu, Hong; Cong, Jian; Liu, Xiao-Li; Qiao, Chuan-Ling			Do mosquitoes acquire organophosphate resistance by functional changes in carboxylesterases?	FASEB JOURNAL			English	Article						organophosphorus hydrolase; site-directed mutagenesis	AMINO-ACID SUBSTITUTION; INSECTICIDE RESISTANCE; LUCILIA-CUPRINA; CULEX-PIPIENS; SWISS-MODEL; ESTERASES; EVOLUTION; MECHANISM	Carboxylesterase-based metabolic resistance to organophosphates (OPs) in insects has been shown to originate either from mutations in esterase-encoding sequences or from amplification of esterase genes. This study aimed to test the hypothesis that mosquitoes can acquire OP resistance by functional changes in carboxylesterases. Mutations were introduced into the esterase B1 of mosquito Culex pipiens by site-directed mutagenesis at positions 110 and 224. Three single mutants (G110D, W224L, and W224S) and two double mutants ( G110D/W224L and G110D/W224S) were expressed and purified. All five mutants lost native carboxylesterase activity. Mutation W224L converted esterase B1 to an OP hydrolase and increased its malathion carboxylesterase activity. No obvious OP hydrolysis was observed by G110D or W224S. Our data strongly support our hypothesis and suggest that mutation W224L might occur in natural populations of mosquitoes. Sequence comparison shows that the site 224 is especially highly conserved among various insect carboxylesterases. This leads to another hypothesis: that the position 224 plays a key role in insect carboxylesterases' switching from their native physiological functions to other functional niches under selection pressure exerted by insecticides.	Chinese Acad Sci, Inst Zool, State Key Lab Integrated Management Pest Insects, Beijing 100080, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China; Shanghai Fisheries Univ, Coll Food Sci & Technol, Shanghai, Peoples R China; Shijiazhuang Pharmaceut Grp, Shijiazhuang, Peoples R China	Chinese Academy of Sciences; Institute of Zoology, CAS; Peking University; Shanghai Ocean University	Qiao, CL (corresponding author), Chinese Acad Sci, Inst Zool, State Key Lab Integrated Management Pest Insects, Beijing 100080, Peoples R China.	qiaocl@ioz.ac.cn	Liu, Xiaoli/HGE-7614-2022	Cui, Feng/0000-0001-6215-7159				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell PM, 1998, INSECT BIOCHEM MOLEC, V28, P139, DOI 10.1016/S0965-1748(97)00109-4; Claudianos C, 1999, INSECT BIOCHEM MOLEC, V29, P675, DOI 10.1016/S0965-1748(99)00035-1; CUANY A, 1993, PESTIC BIOCHEM PHYS, V45, P1, DOI 10.1006/pest.1993.1001; Davies AG, 1996, GENETICS, V143, P1321; DEVONSHIRE AL, 1991, BIOCHEM SOC T, V19, P755, DOI 10.1042/bst0190755; Devonshire AL, 2003, PESTIC BIOCHEM PHYS, V76, P1, DOI 10.1016/S0048-3575(03)00054-3; FOURNIER D, 1994, COMP BIOCHEM PHYS C, V108, P19, DOI 10.1016/1367-8280(94)90084-1; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hartley CJ, 2006, P NATL ACAD SCI USA, V103, P8757, DOI 10.1073/pnas.0509590103; Heidari R, 2004, INSECT BIOCHEM MOLEC, V34, P353, DOI 10.1016/j.ibmb.2004.01.001; Hemingway J, 1998, MED VET ENTOMOL, V12, P1, DOI 10.1046/j.1365-2915.1998.00082.x; Huang Jing, 2001, Acta Genetica Sinica, V28, P583; JARV J, 1984, BIOORG CHEM, V12, P259, DOI 10.1016/0045-2068(84)90010-5; JAYAWARDENA KGI, 1994, B ENTOMOL RES, V84, P39, DOI 10.1017/S000748530003220X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leng XF, 1986, SCI B, V19, P1505; Li XC, 2007, ANNU REV ENTOMOL, V52, P231, DOI 10.1146/annurev.ento.51.110104.151104; Newcomb RD, 1997, P NATL ACAD SCI USA, V94, P7464, DOI 10.1073/pnas.94.14.7464; Oakeshott JG, 1999, BIOESSAYS, V21, P1031; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Raymond M, 1998, PHILOS T R SOC B, V353, P1707, DOI 10.1098/rstb.1998.0322; Raymond M, 2001, GENETICA, V112, P287, DOI 10.1023/A:1013300108134; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520	24	24	33	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3584	3591		10.1096/fj.07-8237com	http://dx.doi.org/10.1096/fj.07-8237com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17567568				2022-12-28	WOS:000250517800021
J	Telek, A; Biro, T; Bodo, E; Toth, BI; Borbiro, I; Kunos, G; Paus, R				Telek, Andrea; Biro, Tamas; Bodo, Eniko; Toth, Balazs I.; Borbiro, Istvan; Kunos, George; Paus, Ralf			Inhibition of human hair follicle growth by endo- and exocannabinoids	FASEB JOURNAL			English	Article						cannabinoid receptor; proliferation; apoptosis; hair cycle	TUMOR-GROWTH; ENDOGENOUS CANNABINOIDS; HEMODYNAMIC PROFILE; HPA AXIS; RECEPTOR; STRESS; SKIN; ANGIOGENESIS; INVOLVEMENT; ANANDAMIDE	Recent studies strongly suggest that the cannabinoid system is a key player in cell growth control. Since the organ-culture of human hair follicles (HF) offers an excellent, clinically relevant model for complex tissue interaction systems, we have asked whether the cannabinoid system plays a role in hair growth control. Here, we show that human scalp HF, intriguingly, are both targets and sources of endocannabinoids. Namely, the endocannabinoid N-arachidonoylethanolamide ( anandamide, AEA) as well as the exocannabinnoid Delta (9)-tetrahydrocannabinol dose-dependently inhibited hair shaft elongation and the proliferation of hair matrix keratinocytes, and induced intraepithelial apoptosis and premature HF regression (catagen). These effects were inhibited by a selective antagonist of cannabinoid receptor-1 (CB1). In contrast to CB2, CB1 was expressed in a hair cycle-dependent manner in the human HF epithelium. Since we successfully identified the presence of endocannabinoids in human HF, our data strongly suggest that human HF exploit a CB1-mediated endocannabinoid signaling system for negatively regulating their own growth. Clinically, CB1 agonists may therefore help to manage unwanted hair growth, while CB1 antagonists might counteract hair loss. Finally, human HF organ culture offers an instructive, physiologically relevant new research tool for dissecting "nonclassical" effects of endocannabinoids and their receptor-mediated signaling in general.	Univ Debrecen, Dept Physiol, Med & Hlth Sci Ctr, Res Ctr Mol Med, H-4032 Debrecen, Hungary; Univ Debrecen, Cell Physiol Res Grp, Hungarian Acad Sci, Res Ctr Mol Med,Med & Hlth Sci Ctr, H-4032 Debrecen, Hungary; Med Univ Lubeck, Univ Hosp Schleswig Holstein, Dept Dermatol, D-23538 Lubeck, Germany; NIAAA, NIH, Bethesda, MD USA	University of Debrecen; Hungarian Academy of Sciences; University of Debrecen; University of Kiel; Schleswig Holstein University Hospital; University of Lubeck; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Biro, T (corresponding author), Univ Debrecen, Dept Physiol, Med & Hlth Sci Ctr, Res Ctr Mol Med, Nagyerdie Krt 98 POB 22, H-4032 Debrecen, Hungary.	biro@phys.dote.hu	Tóth, Balázs István/K-1214-2013; Paus, Ralf/F-6243-2011	Tóth, Balázs István/0000-0002-4103-4333; Borbiro, Istvan/0000-0002-8366-6881	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000350, ZIAAA000350] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Arck PC, 2005, J MOL MED, V83, P386, DOI 10.1007/s00109-004-0627-z; Arck PC, 2003, AM J PATHOL, V162, P803, DOI 10.1016/S0002-9440(10)63877-1; Arck PC, 2006, J INVEST DERMATOL, V126, P1697, DOI 10.1038/sj.jid.5700104; Batkai S, 2001, NAT MED, V7, P827, DOI 10.1038/89953; BATKAI S, 2007, FASEB J; Bifulco M, 2004, FASEB J, V18, P1606, DOI 10.1096/fj.04-1754fje; Bifulco M, 2002, NAT MED, V8, P547, DOI 10.1038/nm0602-547; Biro T, 2006, J INVEST DERMATOL, V126, P1909, DOI 10.1038/sj.jid.5700321; Blazquez C, 2003, FASEB J, V17, P529, DOI 10.1096/fj.02-0795fje; Blazquez C, 2006, FASEB J, V20, P2633, DOI 10.1096/fj.06-6638fje; Bodo E, 2005, AM J PATHOL, V166, P985, DOI 10.1016/S0002-9440(10)62320-6; Botchkarev VA, 2003, AM J PATHOL, V162, P709, DOI 10.1016/S0002-9440(10)63866-7; Carrier EJ, 2005, CNS NEUROL DISORD-DR, V4, P657, DOI 10.2174/156800705774933023; Casanova ML, 2003, J CLIN INVEST, V111, P43, DOI 10.1172/JCI200316116; Croxford JL, 2003, J CLIN INVEST, V111, P1231, DOI 10.1172/JCI200317652; De Vries TJ, 2001, NAT MED, V7, P1151, DOI 10.1038/nm1001-1151; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Di Marzo V, 2006, ANNU REV MED, V57, P553, DOI 10.1146/annurev.med.57.011205.135648; Di Marzo V, 2002, CURR OPIN NEUROBIOL, V12, P372, DOI 10.1016/S0959-4388(02)00340-9; Felder CC, 2006, MOL INTERV, V6, P149, DOI 10.1124/mi.6.3.6; Fernandez-Ruiz J, 2007, TRENDS PHARMACOL SCI, V28, P39, DOI 10.1016/j.tips.2006.11.001; Foitzik K, 2006, AM J PATHOL, V168, P748, DOI 10.2353/ajpath.2006.050468; Freund TF, 2003, PHYSIOL REV, V83, P1017, DOI 10.1152/physrev.00004.2003; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; Ito N, 2005, FASEB J, V19, P1332, DOI 10.1096/fj.04-1968fje; Jiang W, 2005, J CLIN INVEST, V115, P3104, DOI 10.1172/JCI25509; Kogan N M, 2006, J Endocrinol Invest, V29, P3; Maccarrone M, 2003, J BIOL CHEM, V278, P33896, DOI 10.1074/jbc.M303994200; Pacher P, 2005, AM J PHYSIOL-HEART C, V289, pH533, DOI 10.1152/ajpheart.00107.2005; Pacher P, 2004, J PHYSIOL-LONDON, V558, P647, DOI 10.1113/jphysiol.2004.064824; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Paus R, 2006, J CLIN INVEST, V116, P1174, DOI 10.1172/JCI28553; Paus R, 2006, TRENDS IMMUNOL, V27, P32, DOI 10.1016/j.it.2005.10.002; Paus R, 2005, TRENDS IMMUNOL, V26, P32, DOI 10.1016/j.it.2004.09.014; Paus R, 2003, J INVEST DERM SYMP P, V8, P188, DOI 10.1046/j.1087-0024.2003.00807.x; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Peters EMJ, 2006, EXP DERMATOL, V15, P1, DOI 10.1111/j.0906-6705.2005.00372.x; PHILPOTT MP, 1990, J CELL SCI, V97, P463; Piomelli Daniele, 2005, Curr Opin Investig Drugs, V6, P672; Portella G, 2003, FASEB J, V17, P1771, DOI 10.1096/fj.02-1129fje; SKOPP G, 2006, FORENSIC SCI INT; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Slominski A, 2005, J INVEST DERMATOL, V124, P13, DOI 10.1111/j.0022-202X.2004.23528.x; SLOMINSKI A, 1994, J INVEST DERMATOL, V102, P862, DOI 10.1111/1523-1747.ep12382606; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2007, MOL CELL ENDOCRINOL, V265, P143, DOI 10.1016/j.mce.2006.12.012; Stander S, 2005, J DERMATOL SCI, V38, P177, DOI 10.1016/j.jdermsci.2005.01.007; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Uhl M, 2004, FORENSIC SCI INT, V145, P143, DOI 10.1016/j.forsciint.2004.04.029; van der Stelt M, 2004, EUR J BIOCHEM, V271, P1827, DOI 10.1111/j.1432-1033.2004.04081.x; Wilkinson JD, 2007, J DERMATOL SCI, V45, P87, DOI 10.1016/j.jdermsci.2006.10.009	53	71	74	2	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3534	3541		10.1096/fj.06-7689com	http://dx.doi.org/10.1096/fj.06-7689com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17567570				2022-12-28	WOS:000250517800016
J	Shan, X; Chang, YM; Lin, CLG				Shan, Xiu; Chang, Yueming; Lin, Chien-Liang Glenn			Messenger RNA oxidation is an early event preceding cell death and causes reduced protein expression	FASEB JOURNAL			English	Article						oxidative stress; oxidative damage; Alzheimer's disease; neurodegeneration	AMYOTROPHIC-LATERAL-SCLEROSIS; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; PROMINENT FEATURE; OXIDIZED RNAS; STRESS; DAMAGE; NEURONS; BRAIN; REPAIR	We previously reported that up to 50% of messenger RNAs ( mRNA) are oxidatively damaged in the affected area of Alzheimer's disease ( AD) brains. The role of RNA oxidation in the cell death process is unknown. In the present study, we used cortical primary dissociated cultures to investigate the relationship between RNA oxidation and neuron degeneration induced by various insults, including hydrogen peroxide, glutamate, and amyloid beta peptide. These insults mediate the production of reactive oxygen species and thus induce oxidative stress. The results showed that RNA oxidation was an early event far preceding cell death, not merely a consequence of dying cells. RNA oxidation occurred primarily in a distinct group of neurons that died later. Identification of oxidized RNA species revealed that significant amounts of mRNAs were oxidized and that some mRNA species were more susceptible to oxidative damage, consistent with findings in the AD brain. The level of protein corresponding to the oxidized mRNA species was significantly decreased. Polyribosome analysis indicated that oxidized bases in mRNAs caused ribosome stalling on the transcripts, which led to a decrease of protein expression. These results suggest that RNA oxidation may be directly associated with neuronal deterioration, rather than harmless epiphenomenona, during the process of neurodegeneration.	Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Lin, CLG (corresponding author), Ohio State Univ, Dept Neurosci, 4198 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	lin.492@osu.edu	Lin, Chien-liang G/E-3513-2011		NATIONAL INSTITUTE ON AGING [R21AG027797] Funding Source: NIH RePORTER; NIA NIH HHS [AG027797] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aas PA, 2003, NATURE, V421, P859, DOI 10.1038/nature01363; Abramov AY, 2004, J NEUROSCI, V24, P565, DOI 10.1523/JNEUROSCI.4042-03.2004; Aksenov MY, 2001, NEUROSCIENCE, V103, P373, DOI 10.1016/S0306-4522(00)00580-7; Andreasen N, 2001, ARCH NEUROL-CHICAGO, V58, P373, DOI 10.1001/archneur.58.3.373; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; Butterfield DA, 1999, METHOD ENZYMOL, V309, P746; Butterfield DA, 1999, NEUROBIOL AGING, V20, P339; Davies E, 1995, METHOD CELL BIOL, V50, P209, DOI 10.1016/S0091-679X(08)61032-8; del Prete MJ, 2002, FASEB J, V16, P2003, DOI 10.1096/fj.02-0392fje; Dickey LF, 1998, PLANT CELL, V10, P475, DOI 10.1105/tpc.10.3.475; Ding QX, 2005, J NEUROSCI, V25, P9171, DOI 10.1523/JNEUROSCI.3040-05.2005; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Hall ED, 1998, J NEUROSCI RES, V53, P66, DOI 10.1002/(SICI)1097-4547(19980701)53:1<66::AID-JNR7>3.3.CO;2-K; Honda K, 2005, J BIOL CHEM, V280, P20978, DOI 10.1074/jbc.M500526200; HUANG JA, 1995, BRAIN RES, V680, P16, DOI 10.1016/0006-8993(95)00209-9; JENNER P, 1992, ANN NEUROL S, V32, P82; KASAI H, 1991, Journal of Toxicological Sciences, V16, P95; Kikuchi A, 2002, NEUROBIOL DIS, V9, P244, DOI 10.1006/nbdi.2002.0466; Lovell MA, 2000, BRAIN RES, V855, P116, DOI 10.1016/S0006-8993(99)02335-5; Lovell MA, 1997, NEUROBIOL AGING, V18, P457, DOI 10.1016/S0197-4580(97)00108-5; Lovell MA, 1999, J NEUROCHEM, V72, P771, DOI 10.1046/j.1471-4159.1999.0720771.x; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Meiners S, 1997, MOL CELL NEUROSCI, V10, P100, DOI 10.1006/mcne.1997.0643; Nunomura A, 2004, NEUROBIOL DIS, V17, P108, DOI 10.1016/j.nbd.2004.06.003; Nunomura A, 1999, J NEUROSCI, V19, P1959; OKA A, 1993, J NEUROSCI, V13, P1441; Omar Rawhi A., 1999, J Alzheimers Dis, V1, P139; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Pratico D, 2004, J ALZHEIMERS DIS, V6, P171; Ranum LPW, 2002, CURR OPIN GENET DEV, V12, P266, DOI 10.1016/S0959-437X(02)00297-6; Roediger B, 2003, NEUROBIOL DIS, V13, P222, DOI 10.1016/S0969-9961(03)00038-X; Shan X, 2006, NEUROBIOL AGING, V27, P657, DOI 10.1016/j.neurobiolaging.2005.03.022; Shan X, 2003, J NEUROSCI, V23, P4913; SHIFMAN MI, 1995, J NEUROSCI METH, V59, P205, DOI 10.1016/0165-0270(94)00184-I; SIES H, 1991, KLIN WOCHENSCHR, V69, P965, DOI 10.1007/BF01645140; Smith MA, 2006, J ALZHEIMERS DIS, V9, P305; WHITTEMORE ER, 1994, NEUROREPORT, V5, P1485, DOI 10.1097/00001756-199407000-00019; Yatin SM, 1999, NEUROBIOL AGING, V20, P325; Zhang J, 1999, AM J PATHOL, V154, P1423, DOI 10.1016/S0002-9440(10)65396-5; Zhu XW, 2005, MOL NEUROBIOL, V31, P205, DOI 10.1385/MN:31:1-3:205	41	140	144	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2753	2764		10.1096/fj.07-8200com	http://dx.doi.org/10.1096/fj.07-8200com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17496160				2022-12-28	WOS:000249237500017
J	Yoon, IS; Chen, E; Busse, T; Repetto, E; Lakshmana, MK; Koo, EH; Kang, DE				Yoon, Il-Sang; Chen, Eunice; Busse, Tracy; Repetto, Emanuela; Lakshmana, Madepalli K.; Koo, Edward H.; Kang, David E.			Low-density lipoprotein receptor-related protein promotes amyloid precursor protein trafficking to lipid rafts in the endocytic pathway	FASEB JOURNAL			English	Article						Alzheimer's disease; BACE1; secretase; Swedish; siRNA	ONSET ALZHEIMERS-DISEASE; BETA-SECRETASE CLEAVAGE; APOLIPOPROTEIN-E RECEPTOR; GAMMA-SECRETASE; CYTOPLASMIC DOMAIN; MEMBRANE MICRODOMAINS; BIOLOGICAL FUNCTIONS; ALPHA-SECRETASE; LRP; ASSOCIATION	The major defining pathological hallmark of Alzheimer's disease ( AD) is the accumulation of amyloid beta protein ( A beta), a small peptide derived from beta- and gamma- secretase cleavages of the amyloid precursor protein ( APP). Recent studies have shown that beta- and gamma- secretase activities of BACE1 and presenilin, respectively, are concentrated in intracellular lipid raft microdomains. However, the manner in which APP normally traffics to lipid rafts is unknown. In this study, using transient transfection and immuno- precipitation assays, we show that the cytoplasmic domain of low- density lipoprotein receptor- related protein ( LRP) interacts with APP and increases A beta secretion and APP beta- CTF ( C- terminal fragment) generation by promoting BACE1- APP interaction. We also employed discontinuous sucrose density gradient ultracentrifugation to show that the LRP cytoplasmic domain- mediated effect was accompanied by greatly increased localization of APP and BACE1 to lipid raft membranes, where beta- and gamma- secretase activities are highly enriched. Moreover, we provide evidence that endogenous LRP is required for the normal delivery of APP to lipid rafts and A beta generation primarily in the endocytic but not secretory pathway. These results may provide novel insights to block A beta generation by targeting LRP- mediated delivery of APP to raft microdomains.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Kang, DE (corresponding author), Univ Calif San Diego, Dept Neurosci, MC0691,Leichtag Biomed Res 380,9500 Gilman Dr, La Jolla, CA 92093 USA.	dekang@ucsd.edu	Kang, David E./E-5234-2012	Kang, David E./0000-0002-7132-821X; REPETTO, EMANUELA/0000-0002-6270-3540	NATIONAL INSTITUTE ON AGING [R01AG012376] Funding Source: NIH RePORTER; NIA NIH HHS [AG-12376] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Cam JA, 2005, J BIOL CHEM, V280, P15464, DOI 10.1074/jbc.M500613200; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; De Strooper B, 2000, J CELL SCI, V113, P1857; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Golub T, 2004, CURR OPIN NEUROBIOL, V14, P542, DOI 10.1016/j.conb.2004.08.003; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hollenbach E, 1998, NEUROLOGY, V50, P1905, DOI 10.1212/WNL.50.6.1905; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Kawarabayashi T, 2004, J NEUROSCI, V24, P3801, DOI 10.1523/JNEUROSCI.5543-03.2004; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; Lambert JC, 1998, LANCET, V351, P1787, DOI 10.1016/S0140-6736(05)78749-3; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Lleo A, 2005, J BIOL CHEM, V280, P27303, DOI 10.1074/jbc.M413969200; Lucero HA, 2004, ARCH BIOCHEM BIOPHYS, V426, P208, DOI 10.1016/j.abb.2004.03.020; Ma L, 2003, J NEUROSCI, V23, P3164; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Narita M, 1997, J NEUROCHEM, V69, P1904; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Steinhilb ML, 2002, J NEUROCHEM, V80, P1019, DOI 10.1046/j.0022-3042.2002.00764.x; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Vetrivel KS, 2005, J BIOL CHEM, V280, P25892, DOI 10.1074/jbc.M503570200; von Arnim CAF, 2005, J BIOL CHEM, V280, P17777, DOI 10.1074/jbc.M414248200; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wong W, 2004, J BIOL CHEM, V279, P444, DOI 10.1074/jbc.M304675200; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yang DS, 1999, NEUROSCIENCE, V90, P1217, DOI 10.1016/S0306-4522(98)00561-2; Yoon IS, 2005, J BIOL CHEM, V280, P20140, DOI 10.1074/jbc.M413729200	57	61	65	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2742	2752		10.1096/fj.07-8114com	http://dx.doi.org/10.1096/fj.07-8114com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17463224				2022-12-28	WOS:000249237500016
J	Birrell, SN; Butler, LM; Harris, JM; Buchanan, G; Tilley, WD				Birrell, Stephen N.; Butler, Lisa M.; Harris, Jonathan M.; Buchanan, Grant; Tilley, Wayne D.			Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer	FASEB JOURNAL			English	Review						hormone replacement therapy; medroxyprogesterone acetate; estrogen signaling	HORMONE REPLACEMENT THERAPY; PROSTATE-SPECIFIC ANTIGEN; NIPPLE ASPIRATE FLUID; CAG REPEAT LENGTH; MAMMARY-GLAND DEVELOPMENT; MEDROXYPROGESTERONE ACETATE; ESTROGEN-RECEPTOR; POSTMENOPAUSAL WOMEN; PROGESTERONE-RECEPTORS; CELL-PROLIFERATION	There is now considerable evidence that using a combination of synthetic progestins and estro-gens in hormone replacement therapy ( HRT) increases the risk of breast cancer compared with estrogen alone. Furthermore, the World Health Organization has recently cited combination contraceptives, which contain synthetic progestins, as potentially carcinogenic to humans, particularly for increased breast cancer risk. Given the above observations and the current trend toward progestin-only contraception, it is important that we have a comprehensive understanding of how progestins act in the millions of women worldwide who regularly take these medications. While synthetic progestins, such as medroxyprogesterone acetate ( MPA), which are currently used in both HRT and oral contraceptives were designed to act exclusively through the progesterone receptor, it is clear from both clinical and experimental settings that their effects may be mediated, in part, by binding to the androgen receptor ( AR). Disruption of androgen action by synthetic progestins may have serious deleterious side effects in the breast, where the balance between estrogen signaling and androgen signaling plays a critical role in breast homeostasis. Here, we review the role of androgen signaling in the normal breast and in breast cancer and present new data demonstrating that androgen receptor function can be perturbed by low doses of MPA, similar to doses achieved in serum of women taking HRT. We propose that the observed excess of breast malignancies associated with combined HRT may be explained, in part, by synthetic progestins such as MPA acting as endocrine disruptors to negate the protective effects of androgen signaling in the breast. Understanding the role of androgen signaling in the breast and how this is modulated by synthetic progestins is necessary to determine how combined HRT alters breast cancer risk, and to inform the development of optimal preventive and treatment strategies for this disease.	Univ Adelaide, Hanson Inst, Dame Roma Mitchell Canc Res Labs, Adelaide, SA 5005, Australia; Queensland Univ Technol, Sch Life Sci, Brisbane, Qld, Australia	Hanson Institute; University of Adelaide; Queensland University of Technology (QUT)	Tilley, WD (corresponding author), Univ Adelaide, Hanson Inst, Dame Roma Mitchell Canc Res Labs, POB 14,Rundle Mall, Adelaide, SA 5005, Australia.	wayne.tilley@lvms.sd.gov.au	Butler, Lisa/AAP-9088-2020; Butler, Lisa M/C-9843-2010	Butler, Lisa/0000-0003-2698-3220; Harris, Jonathan/0000-0003-4209-2380; Tilley, Wayne/0000-0003-1893-2626				Agoff SN, 2003, AM J CLIN PATHOL, V120, P725, DOI 10.1309/42F00D0DJD0J5EDT; Anim JT, 2005, ACTA HISTOCHEM, V107, P87, DOI 10.1016/j.acthis.2005.01.002; Bentel JM, 1999, MOL CELL ENDOCRINOL, V154, P11, DOI 10.1016/S0303-7207(99)00109-4; Birrell SN, 1998, J MAMMARY GLAND BIOL, V3, P95, DOI 10.1023/A:1018730519839; BIRRELL SN, 1995, J CLIN ONCOL, V13, P1572, DOI 10.1200/JCO.1995.13.7.1572; BIRRELL SN, 1995, J STEROID BIOCHEM, V52, P459, DOI 10.1016/0960-0760(95)00005-K; Boonyaratanakornkit V, 2004, ESSAYS BIOCHEM, V40, P105, DOI 10.1042/bse0400105; Brys M, 2000, Med Sci Monit, V6, P433; Buchanan G, 2005, CANCER RES, V65, P8487, DOI 10.1158/0008-5472.CAN-04-3077; BURGER HG, 2006, MENOPAUSE; Campagnoli C, 2005, J STEROID BIOCHEM, V96, P95, DOI 10.1016/j.jsbmb.2005.02.014; Campagnoli C, 2005, J STEROID BIOCHEM, V97, P441, DOI 10.1016/j.jsbmb.2005.08.015; Chabbert-Buffet N, 2005, HUM REPROD UPDATE, V11, P293, DOI 10.1093/humupd/dmi002; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Clark James H, 2006, Nucl Recept Signal, V4, pe023; Cline JM, 1996, AM J OBSTET GYNECOL, V174, P93, DOI 10.1016/S0002-9378(96)70379-4; Cogliano V, 2005, LANCET ONCOL, V6, P552, DOI 10.1016/S1470-2045(05)70273-4; Collins JA, 2005, HUM REPROD UPDATE, V11, P545, DOI 10.1093/humupd/dmi028; Conneely OM, 2003, J MAMMARY GLAND BIOL, V8, P205, DOI 10.1023/A:1025952924864; Cox DG, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1602; Dagan E, 2002, EUR J HUM GENET, V10, P724, DOI 10.1038/sj.ejhg.5200880; DAUVOIS S, 1991, CANCER RES, V51, P3131; de Lignieres B, 2002, CLIMACTERIC, V5, P332, DOI 10.1080/713605312; DELAUNOIT Y, 1991, CANCER RES, V51, P2797; DEWINTER JAR, 1991, J HISTOCHEM CYTOCHEM, V39, P927, DOI 10.1177/39.7.1865110; Dimitrakakis C, 2002, FERTIL STERIL, V77, pS26; Dunning AM, 1999, CARCINOGENESIS, V20, P2131, DOI 10.1093/carcin/20.11.2131; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fournier A, 2005, INT J CANCER, V114, P448, DOI 10.1002/ijc.20710; Ghatge RP, 2005, BREAST CANCER RES, V7, pR1036, DOI 10.1186/bcr1340; Giguere Y, 2001, CANCER RES, V61, P5869; Given HF, 2000, EUR J CANCER, V36, P533, DOI 10.1016/S0959-8049(99)00310-X; Graham JD, 1997, ENDOCR REV, V18, P502, DOI 10.1210/er.18.4.502; Greeve MA, 2004, J MOL ENDOCRINOL, V32, P793, DOI 10.1677/jme.0.0320793; HACKENBERG R, 1993, BREAST CANCER RES TR, V25, P217, DOI 10.1007/BF00689836; HACKENBERG R, 1991, CANCER RES, V51, P5722; Haiman CA, 2002, CANCER RES, V62, P1045; Haiman CA, 2003, BREAST CANCER RES TR, V77, P27, DOI 10.1023/A:1021112121782; Hall RE, 1996, BRIT J CANCER, V74, P1175, DOI 10.1038/bjc.1996.513; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; Hewitt SC, 2000, BREAST CANCER RES, V2, P345, DOI 10.1186/bcr79; Honma N, 2003, HISTOPATHOLOGY, V42, P120, DOI 10.1046/j.1365-2559.2003.01542.x; INGLE JN, 1991, CANCER-AM CANCER SOC, V67, P886, DOI 10.1002/1097-0142(19910215)67:4<886::AID-CNCR2820670405>3.0.CO;2-O; IOBAGIU C, 2005, BREAST CANC RES TREA, P1; JANSSEN PJ, 1994, J HISTOCHEM CYTOCHEM, V42, P1169, DOI 10.1177/42.8.8027537; Kadouri L, 2001, BRIT J CANCER, V85, P36, DOI 10.1054/bjoc.2001.1777; Kandouz M, 1999, J STEROID BIOCHEM, V69, P463, DOI 10.1016/S0960-0760(99)00069-2; Katzenellenbogen BS, 2004, SEMIN ONCOL, V31, P28, DOI 10.1053/j.seminoncol.2004.01.004; Kemppainen JA, 1999, MOL ENDOCRINOL, V13, P440, DOI 10.1210/me.13.3.440; Klaiber EL, 2005, FERTIL STERIL, V84, P1589, DOI 10.1016/j.fertnstert.2005.08.010; Kristiansen M, 2005, J MED GENET, V42, P877, DOI 10.1136/jmg.2005.032433; Kristiansen M, 2002, J MED GENET, V39, P30, DOI 10.1136/jmg.39.1.30; KuenenBoumeester V, 1996, EUR J CANCER, V32A, P1560, DOI 10.1016/0959-8049(96)00112-8; Kuhl H, 2004, CLIMACTERIC, V7, P319, DOI 10.1080/13697130400003337; Labrie F, 2003, ENDOCR REV, V24, P152, DOI 10.1210/er.2001-0031; Labrie F, 2003, ANN ENDOCRINOL-PARIS, V64, P95; LANGER M, 1990, ARCH GYNECOL OBSTET, V247, P203, DOI 10.1007/BF02389545; Lapointe J, 1999, ENDOCRINOLOGY, V140, P416, DOI 10.1210/en.140.1.416; LEA OA, 1989, CANCER RES, V49, P7162; Lee SA, 2005, BRIT J CANCER, V92, P2049, DOI 10.1038/sj.bjc.6602617; Li XT, 2004, MECH AGEING DEV, V125, P669, DOI 10.1016/j.mad.2004.04.007; Liao DJ, 2002, J STEROID BIOCHEM, V80, P175, DOI 10.1016/S0960-0760(01)00185-6; Liede A, 2003, CANCER EPIDEM BIOMAR, V12, P848; Lillie EO, 2004, CANCER RES, V64, P1237, DOI 10.1158/0008-5472.CAN-03-2887; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; MARTEL C, 1994, MOL CELL ENDOCRINOL, V104, P103, DOI 10.1016/0303-7207(94)90056-6; Menin C, 2001, CANCER LETT, V168, P31, DOI 10.1016/S0304-3835(01)00473-6; Moinfar F, 2003, CANCER-AM CANCER SOC, V98, P703, DOI 10.1002/cncr.11532; Nachtigall LE, 2000, MENOPAUSE, V7, P243, DOI 10.1097/00042192-200007040-00006; Ortmann J, 2002, GYNECOL ENDOCRINOL, V16, P113, DOI 10.1080/713603030; Ouatas T, 2003, CLIN CANCER RES, V9, P3763; Panet-Raymond V, 2000, MOL CELL ENDOCRINOL, V167, P139, DOI 10.1016/S0303-7207(00)00279-3; Park SS, 2000, IPAP CONFERENCE SER, V1, P60, DOI 10.1109/KDEX.1999.836610; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; Pike MC, 2000, STEROIDS, V65, P659, DOI 10.1016/S0039-128X(00)00122-7; POULIN R, 1989, ENDOCRINOLOGY, V125, P392, DOI 10.1210/endo-125-1-392; Rebbeck TR, 1999, AM J HUM GENET, V64, P1371, DOI 10.1086/302366; Riva C, 2005, VIRCHOWS ARCH, V447, P695, DOI 10.1007/s00428-005-0003-6; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Santen RJ, 2003, STEROIDS, V68, P953, DOI 10.1016/S0039-128X(03)00138-7; Sauter ER, 2004, CANCER DETECT PREV, V28, P27, DOI 10.1016/j.cdp.2003.11.003; Sauter ER, 2004, INT J CANCER, V108, P588, DOI 10.1002/ijc.11607; Sauter ER, 2002, ENVIRON HEALTH PERSP, V110, P241, DOI 10.1289/ehp.02110241; Schindler AE, 2003, MATURITAS, V46, pS7, DOI 10.1016/j.maturitas.2003.09.014; Schippinger W, 2006, VIRCHOWS ARCH, V449, P24, DOI 10.1007/s00428-006-0213-6; Shah NR, 2005, MENOPAUSE, V12, P668, DOI 10.1097/01.gme.0000184221.63459.e1; Sitruk-Ware R, 2004, MATURITAS, V47, P277, DOI 10.1016/j.maturitas.2004.01.001; Soderqvist G, 2004, MATURITAS, V49, P90, DOI 10.1016/j.maturitas.2004.06.008; Somboonporn W, 2004, ENDOCR REV, V25, P374, DOI 10.1210/er.2003-0016; Speroff L, 2004, MATURITAS, V49, P51, DOI 10.1016/j.maturitas.2004.06.006; Spurdle AB, 2005, BREAST CANCER RES, V7, pR176, DOI 10.1186/bcr971; Spurdle AB, 1999, JNCI-J NATL CANCER I, V91, P961, DOI 10.1093/jnci/91.11.961; Stahlberg C, 2003, ACTA OBSTET GYN SCAN, V82, P335, DOI 10.1034/j.1600-0412.2003.00055.x; Stahlberg C, 2004, INT J CANCER, V109, P721, DOI 10.1002/ijc.20016; Suter NM, 2003, CANCER EPIDEM BIOMAR, V12, P127; TEULINGS FAG, 1980, CANCER RES, V40, P2557; TORMEY DC, 1983, ANN INTERN MED, V98, P139, DOI 10.7326/0003-4819-98-2-139; Tran N, 2004, CANCER EPIDEM BIOMAR, V13, P2133; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Wang W, 2005, CANCER EPIDEM BIOMAR, V14, P2990, DOI 10.1158/1055-9965.EPI-05-0310; Wood CE, 2007, BREAST CANCER RES TR, V101, P125, DOI 10.1007/s10549-006-9276-y; Yeh SY, 2003, J EXP MED, V198, P1899, DOI 10.1084/jem.20031233; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Yu H, 2000, BREAST CANCER RES TR, V59, P153, DOI 10.1023/A:1006356502820; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zhou J, 2000, FASEB J, V14, P1725, DOI 10.1096/fj.99-0863com; Zhuang YH, 2003, CELL TISSUE RES, V311, P217, DOI 10.1007/s00441-002-0683-z	107	67	70	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2285	2293		10.1096/fj.06-7518com	http://dx.doi.org/10.1096/fj.06-7518com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17413000				2022-12-28	WOS:000248454400003
J	El-Remessy, AB; Al-Shabrawey, M; Platt, DH; Bartoli, M; Behzadian, MA; Ghaly, N; Tsai, N; Motamed, K; Caldwell, RB				El-Remessy, A. B.; Al-Shabrawey, M.; Platt, D. H.; Bartoli, M.; Behzadian, M. A.; Ghaly, N.; Tsai, N.; Motamed, K.; Caldwell, R. B.			RETRACTED: Peroxynitrite mediates VEGF's angiogenic signal and function via a nitration-independent mechanism in endothelial cells (Retracted article. See vol. 31, pg. 421, 2017)	FASEB JOURNAL			English	Article; Retracted Publication						angiogenesis; Src; redox signaling	OXYGEN-INDUCED RETINOPATHY; FOCAL ADHESION KINASE; GROWTH-FACTOR; NITRIC-OXIDE; TYROSINE NITRATION; NAD(P)H OXIDASE; C-SRC; EXPRESSION; RECEPTOR; ACTIVATION	The modulation of angiogenic signaling by reactive oxygen species (ROS) is an emerging area of interest in cellular and vascular biology research. We provide evidence here that peroxynitrite, the powerful oxidizing and nitrating free radical, is critically involved in transduction of the VEGF signal. We tested the hypothesis that VEGF induces peroxynitrite formation, which causes tyrosine phosphorylation and mediates endothelial cell migration and tube formation, by studies of vascular endothelial cells in vitro and in a model of hypoxia-induced neovascularization in vivo. The specific peroxynitrite decomposition catalyst FeTPPs blocked VEGF-induced phosphorylation of VEGFR2 and c-Src and inhibited endothelial cell migration and tube formation. Furthermore, exogenous peroxynitrite mimicked VEGF activity in causing phosphorylation of VEGFR2 and stimulating endothelial cell growth and tube formation in vitro and new blood vessel growth in vivo. The selective nitration inhibitor epicatechin enhanced VEGF's angiogenic function in activating VEGFR2, c-Src, and promoting endothelial cell growth, migration, and tube formation in vitro and retinal neovascularization in vivo. Decomposing peroxynitrite with FeTPPs or blocking oxidation using the thiol donor NAC blocked VEGF's angiogenic functions in vitro and in vivo. In conclusion, peroxynitrite is critically involved in transducing VEGF's angiogenic signal via nitration-independent and oxidation-mediated tyrosine phosphorylation.	Univ Georgia, Coll Pharm, Program Clin & Expt Therapeut, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Oral Biol & Maxillofacial Pathol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA; Univ S Carolina, Dept Ophthalmol, Columbia, SC 29208 USA; VA Med Ctr, Augusta, GA USA	University System of Georgia; University of Georgia; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	El-Remessy, AB (corresponding author), Univ Georgia, Coll Pharm, Program Clin & Expt Therapeut, CJ-1033,1120 15th St, Augusta, GA 30912 USA.	aelremessy@mcg.edu	Al-Shabrawey, Mohamed/P-9570-2018; El-Remessy, Azza B./AAA-3771-2020	El-Remessy, Azza B./0000-0003-4386-1989; Al-Shabrawey, Mohamed/0000-0001-5362-7972; Caldwell, Ruth/0000-0003-0168-0354	NATIONAL CANCER INSTITUTE [K01CA089689] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011766, R01EY004618] Funding Source: NIH RePORTER; NCI NIH HHS [1K01CA89689] Funding Source: Medline; NEI NIH HHS [EY04618, EY11766] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje; Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Adachi T, 2004, NAT MED, V10, P1200, DOI 10.1038/nm1119; Al-Shabrawey M, 2005, AM J PATHOL, V167, P599, DOI 10.1016/S0002-9440(10)63001-5; Aslan M, 2003, ANTIOXID REDOX SIGN, V5, P781, DOI 10.1089/152308603770380089; Beauchamp MH, 2004, FREE RADICAL BIO MED, V37, P1885, DOI 10.1016/j.freeradbiomed.2004.09.008; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Behzadian MA, 1998, GLIA, V24, P216, DOI 10.1002/(SICI)1098-1136(199810)24:2<216::AID-GLIA6>3.3.CO;2-D; Brakebusch C, 2002, J CLIN INVEST, V109, P999, DOI 10.1172/JCI200215468; Brooks SE, 2001, INVEST OPHTH VIS SCI, V42, P222; Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; Deen WM, 2002, FASEB J, V16, P1144; DENICOLA A, 1995, FREE RADICAL BIO MED, V19, P11, DOI 10.1016/0891-5849(94)00239-G; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; El-Remessy AB, 2006, AM J PATHOL, V168, P235, DOI 10.2353/ajpath.2006.050500; El-Remessy AB, 2005, J CELL SCI, V118, P243, DOI 10.1242/jcs.01612; El-Remessy AB, 2003, AM J PATHOL, V162, P1995, DOI 10.1016/S0002-9440(10)64332-5; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Finkel T, 2001, IUBMB LIFE, V52, P3, DOI 10.1080/15216540252774694; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gu WD, 2003, AM J PHYSIOL-HEART C, V285, pH1582, DOI 10.1152/ajpheart.00318.2003; Gu XL, 2003, AM J PHYSIOL-CELL PH, V285, pC546, DOI 10.1152/ajpcell.00424.2002; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Kim YM, 2002, J BIOL CHEM, V277, P6799, DOI 10.1074/jbc.M109434200; Klotz LO, 2000, BIOCHEM J, V352, P219, DOI 10.1042/0264-6021:3520219; Le Boeuf F, 2004, J BIOL CHEM, V279, P39175, DOI 10.1074/jbc.M405493200; Marumo T, 1999, J VASC RES, V36, P510, DOI 10.1159/000025694; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Platt DH, 2005, FREE RADICAL BIO MED, V39, P1353, DOI 10.1016/j.freeradbiomed.2005.06.015; Pollard SE, 2006, BIOCHEM BIOPH RES CO, V350, P960, DOI 10.1016/j.bbrc.2006.09.131; Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7; Salvemini D, 1998, P NATL ACAD SCI USA, V95, P2659, DOI 10.1073/pnas.95.5.2659; Schroeder P, 2001, BIOCHEM BIOPH RES CO, V285, P782, DOI 10.1006/bbrc.2001.5210; Serafini M, 2005, METHOD ENZYMOL, V396, P215, DOI 10.1016/S0076-6879(05)96020-5; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; van der Vliet A, 1998, J BIOL CHEM, V273, P31860, DOI 10.1074/jbc.273.48.31860; Wolin MS, 2000, ARTERIOSCL THROM VAS, V20, P1430, DOI 10.1161/01.ATV.20.6.1430; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200	45	78	81	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2528	2539		10.1096/fj.06-7854com	http://dx.doi.org/10.1096/fj.06-7854com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17384142				2022-12-28	WOS:000248454400027
J	Sariahmetoglu, M; Crawford, BD; Leon, H; Sawicka, J; Li, LJ; Ballermann, BJ; Holmes, C; Berthiaume, LG; Holt, A; Sawicki, G; Schulz, R				Sariahmetoglu, Meltem; Crawford, Bryan D.; Leon, Hernando; Sawicka, Jolanta; Li, Laiji; Ballermann, Barbara J.; Holmes, Charles; Berthiaume, Luc G.; Holt, Andrew; Sawicki, Grzegorz; Schulz, Richard			Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation	FASEB JOURNAL			English	Article						dephosphorylation; gelatinase; alkaline phosphate; protein kinase C; mass spectrometry	GELATINASE-A; REPERFUSION INJURY; IN-VITRO; ACTIVATION; INFLAMMATION; EXPRESSION; INHIBITORS; ISCHEMIA; INVASION; ACCOUNTS	The regulation of matrix metalloproteinases (MMP) has been studied extensively due to the fundamental roles these zinc-endopeptidases play in diverse physiological and pathological processes. However, phosphorylation has not previously been considered as a potential modulator of MMP activity. The ubiquitously expressed MMP-2 contains 29 potential phosphorylation sites. Mass spectrometry reveals that at least five of these sites are phosphorylated in hrMMP-2 expressed in mammalian cells. Treatment of HT1080 cells with an activator of protein kinase C results in a change in MMP-2 immunoreactivity on 2D immunoblots consistent with phosphorylation, and purified MMP-2 is phosphorylated by protein kinase C in vitro. Furthermore, MMP-2 from HT1080 cell-conditioned medium is immunoreactive with antibodies directed against phosphothreonine and phosphoserine, which suggests that it is phosphorylated. Analysis of MMP-2 activity by zymography, gelatin dequenching assays, and measurement of kinetic parameters shows that the phosphorylation status of MMP-2 significantly affects its enzymatic properties. Consistent with this, dephosphorylation of MMP-2 immunoprecipitated from HT1080 conditioned medium with alkaline phosphatase significantly increases its activity. We conclude that MMP-2 is modulated by phosphorylation on multiple sites and that protein kinase C may be a regulator of this protease in vivo.	Univ Alberta, Dept Pediat, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Cadiovasc Res Grp, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Alberta	Schulz, R (corresponding author), Univ Alberta, Dept Pediat, 462 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.	richard.schulz@ualberta.ca	Schulz, Richard/A-8739-2012; Schulz, Richard/M-3518-2019; Ballermann, Barbara J/G-5349-2016; Sawicki, Grzegorz/ABA-3357-2021	Schulz, Richard/0000-0002-5045-3193; Schulz, Richard/0000-0002-5045-3193; Ballermann, Barbara J/0000-0002-8220-6381; Berthiaume, Luc/0000-0003-0926-059X; Crawford, Bryan/0000-0002-0512-4649				Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chow AK, 2007, J MOL CELL CARDIOL, V42, P896, DOI 10.1016/j.yjmcc.2007.01.008; Fernandez-Patron C, 1999, CIRC RES, V85, P906; Frederiks WM, 2004, J HISTOCHEM CYTOCHEM, V52, P711, DOI 10.1369/jhc.4R6251.2004; Gao CQ, 2003, CARDIOVASC RES, V57, P426; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Klein G, 2004, CRIT REV ONCOL HEMAT, V50, P87, DOI 10.1016/j.critevonc.2003.09.001; Kwan JA, 2004, FASEB J, V18, P690, DOI 10.1096/fj.02-1202fje; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MURPHY G, 1994, J BIOL CHEM, V269, P6632; MURPHY G, 1994, ANN NY ACAD SCI, V732, P31, DOI 10.1111/j.1749-6632.1994.tb24722.x; Okamoto T, 2001, J BIOL CHEM, V276, P29596, DOI 10.1074/jbc.M102417200; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; Patterson ML, 2001, FEBS LETT, V503, P158, DOI 10.1016/S0014-5793(01)02723-5; Prevostel C, 2000, J CELL SCI, V113, P2575; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sawicki G, 1998, J CANCER RES CLIN, V124, P245, DOI 10.1007/s004320050161; Sawicki G, 2005, CIRCULATION, V112, P544, DOI 10.1161/CIRCULATIONAHA.104.531616; Schonbeck U, 1998, J IMMUNOL, V161, P3340; Shipley JM, 1996, J BIOL CHEM, V271, P4335; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wang FQ, 2006, INT J CANCER, V118, P879, DOI 10.1002/ijc.21421; Wang WJ, 2002, CIRCULATION, V106, P1543, DOI 10.1161/01.CIR.0000028818.33488.7B; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127; ZOELLNER HFA, 1989, J HISTOCHEM CYTOCHEM, V37, P1893, DOI 10.1177/37.12.2584695	32	114	118	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2486	2495		10.1096/fj.06-7938com	http://dx.doi.org/10.1096/fj.06-7938com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17435175				2022-12-28	WOS:000248454400023
J	Beck, JG; Mathieu, D; Loudet, C; Buchoux, S; Dufourc, EJ				Beck, Johannes G.; Mathieu, Damien; Loudet, Cecile; Buchoux, Sebastien; Dufourc, Erick J.			Plant sterols in "rafts": a better way to regulate membrane thermal shocks	FASEB JOURNAL			English	Article						2H-NMR; cholesterol; ergosterol; sitosterol; stigmasterol; sphingomyelin; glucosylcerebroside; dipalmitoylphosphatidylcholine; order parameters	NUCLEAR-MAGNETIC-RESONANCE; DIFFERENTIAL SCANNING CALORIMETRY; LIQUID-ORDERED PHASE; SOLID-STATE H-2-NMR; MODEL MEMBRANES; BILAYER-MEMBRANES; LIPID RAFTS; DIPALMITOYLPHOSPHATIDYLCHOLINE BILAYERS; NEUTRON-DIFFRACTION; DOMAINS RAFTS	Specialized lipid domains ( rafts) that are generally enriched in sterols and sphingolipids, are most likely present in cell membranes of animals, plants and fungi. While cholesterol and ergosterol are predominant in vertebrates and fungi, plants possess complex sterol profiles, dominated by sitosterol and stigmasterol in Arabidopsis thaliana. Fully hydrated model membranes of composition approaching those found in rafts of mammals, fungi and plants were investigated by means of solid-state H-2-NMR, using deuterated dipalmitoylphosphatidylcholine (H-2(62)-DPPC). The dynamics of such membranes was determined through measuring of membrane ordering or disordering properties. The presence of the liquid-ordered, lo, phase, which may be an indicator of rigid sterol-sphingolipid domains, was detected in all binary or ternary mixtures of all sterols investigated. Of great interest, the dynamics of ternary mixtures mimicking rafts in plants ( phytosterol/ glucosylcerebroside/ DPPC), showed a lesser temperature sensitivity to thermal shocks, on comparing to systems mimicking rafts in mammals and fungi. This effect was particularly marked with sitosterol. The presence of an ethyl group branched on the alkyl chain of sitosterol and stigmasterol is proposed as reinforcing the membrane cohesion by additional attractive van der Waals interactions with the alkyl chains of sphingolipids and phospholipids. As a side result, the elevated resolution of NMR spectra in the presence of sitosterol also suggests domains of smaller size than with other sterols. Finally, the role of phytosterols in maintaining plant membranes in a state of dynamics less sensitive to temperature shocks is discussed.-Johannes G. Beck, Damien Mathieu, Cecile Loudet, Sebastien Buchoux and Erick J. Dufourc. Plant sterols in "rafts": a better way to regulate membrane thermal shocks.	Univ Bordeaux 1, CNRS UMR 5248, CBMN, ENITAB,IECB, F-33607 Pessac, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite de Bordeaux	Dufourc, EJ (corresponding author), Univ Bordeaux 1, CNRS UMR 5248, CBMN, ENITAB,IECB, 2 Rue Robert Escarpit, F-33607 Pessac, France.	e.dufourc@iecb.u-bordeaux.fr	DUFOURC, Erick Joel/AAA-4992-2020; Buchoux, Sébastien/B-1822-2010	DUFOURC, Erick Joel/0000-0002-8221-9326; Buchoux, Sébastien/0000-0002-1544-2093				Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Aussenac F, 2003, BIOCHEMISTRY-US, V42, P1383, DOI 10.1021/bi026717b; Bacia K, 2005, P NATL ACAD SCI USA, V102, P3272, DOI 10.1073/pnas.0408215102; BLOOM M, 1981, CHEM PHYS LETT, V80, P198, DOI 10.1016/0009-2614(81)80089-9; BLOOM M, 1978, BIOCHEMISTRY-US, V17, P5750, DOI 10.1021/bi00619a024; Bouvier-Nave P, 1998, EUR J BIOCHEM, V256, P88, DOI 10.1046/j.1432-1327.1998.2560088.x; BouvierNave P, 1997, EUR J BIOCHEM, V246, P518, DOI 10.1111/j.1432-1033.1997.t01-1-00518.x; BURNETT LJ, 1971, J CHEM PHYS, V55, P5829, DOI 10.1063/1.1675758; Cevc G., 1993, PHOSPHOLIPIDS HDB, V2ZxaucDNWHcC; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; Douliez JP, 1996, J PHYS CHEM-US, V100, P18450, DOI 10.1021/jp961220v; DOULIEZ JP, 1995, BIOPHYS J, V68, P1727, DOI 10.1016/S0006-3495(95)80350-4; DUFOURC EJ, 1992, BIOPHYS J, V61, P42, DOI 10.1016/S0006-3495(92)81814-3; DUFOURC EJ, 1984, BIOCHEMISTRY-US, V23, P6063; DUFOURC EJ, 2002, LIPID DOMAINS BIOL M, V139; FLORINE KI, 1987, BIOCHEMISTRY-US, V26, P2978, DOI 10.1021/bi00385a004; Hsueh YW, 2005, BIOPHYS J, V88, P1799, DOI 10.1529/biophysj.104.051375; JARRELL HC, 1981, BIOPHYS J, V34, P451, DOI 10.1016/S0006-3495(81)84862-X; Kost B, 1999, J CELL BIOL, V145, P317, DOI 10.1083/jcb.145.2.317; LENZ BR, 1980, BIOCHEMISTRY-US, V19, P1943; LEONARD A, 1992, PROG COLL POL SCI S, V89, P315; LEONARD A, 1991, BIOCHIMIE, V73, P1295, DOI 10.1016/0300-9084(91)90092-F; Leonard A, 2001, LANGMUIR, V17, P2019, DOI 10.1021/la001382p; Leonard A., 1993, B MAGN RESON, V15, P124; LEYDI C, 2001, BIOPHYS J, V80, P1819; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; MARINOV R, 1995, J CHIM PHYS PCB, V92, P1727, DOI 10.1051/jcp/1995921727; MCMULLEN TPW, 1995, BBA-BIOMEMBRANES, V1234, P90, DOI 10.1016/0005-2736(94)00266-R; Mongrand S, 2004, J BIOL CHEM, V279, P36277, DOI 10.1074/jbc.M403440200; Peng LC, 2002, SCIENCE, V295, P147, DOI 10.1126/science.1064281; POTT T, 1995, BIOPHYS J, V68, P965, DOI 10.1016/S0006-3495(95)80272-9; RANCE M, 1982, BIOCHIM BIOPHYS ACTA, V688, P191, DOI 10.1016/0005-2736(82)90594-6; RUBENSTEIN JR, 1979, P NATL ACAD SCI USA, V76, P15, DOI 10.1073/pnas.76.1.15; Samsonov AV, 2001, BIOPHYS J, V81, P1486, DOI 10.1016/S0006-3495(01)75803-1; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10670, DOI 10.1021/bi00499a014; Schaeffer A, 2001, PLANT J, V25, P605, DOI 10.1046/j.1365-313x.2001.00994.x; Schaller H, 2004, PLANT PHYSIOL BIOCH, V42, P465, DOI 10.1016/j.plaphy.2004.05.012; Schaller H, 2003, PROG LIPID RES, V42, P163, DOI 10.1016/S0163-7827(02)00047-4; Schrick K, 2002, PLANT J, V31, P61, DOI 10.1046/j.1365-313X.2002.01333.x; SEELIG J, 1977, Q REV BIOPHYS, V10, P353, DOI 10.1017/S0033583500002948; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; STERNIN E, 1983, J MAGN RESON, V55, P274, DOI 10.1016/0022-2364(83)90239-1; STOCKTON GW, 1976, CHEM PHYS LIPIDS, V17, P251, DOI 10.1016/0009-3084(76)90070-0; STOCKTON GW, 1976, BIOCHEMISTRY-US, V15, P955; STOHRER J, 1991, J CHEM PHYS, V95, P672, DOI 10.1063/1.461417; Subczynski WK, 2003, BBA-BIOMEMBRANES, V1610, P231, DOI 10.1016/S0005-2736(03)00021-X; TAMPE R, 1991, BIOCHEMISTRY-US, V30, P4909, DOI 10.1021/bi00234a011; Vie V, 1998, LANGMUIR, V14, P4574, DOI 10.1021/la980203p; VIST MR, 1990, BIOCHEMISTRY-US, V29, P451, DOI 10.1021/bi00454a021; Wang TY, 2000, BIOPHYS J, V79, P1478, DOI 10.1016/S0006-3495(00)76399-5; WEISZ K, 1992, BIOCHEMISTRY-US, V31, P1100, DOI 10.1021/bi00119a019; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v	55	124	127	1	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2007	21	8					1714	1723		10.1096/fj.06-7809com	http://dx.doi.org/10.1096/fj.06-7809com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17317727				2022-12-28	WOS:000246866500013
J	Dogra, C; Changotra, H; Wedhas, N; Qin, X; Wergedal, JE; Kumar, A				Dogra, Charu; Changotra, Harish; Wedhas, Nia; Qin, Xuezhong; Wergedal, Jon E.; Kumar, Ashok			TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine	FASEB JOURNAL			English	Article						skeletal muscle atrophy; atrogin-1; MuRF1; NF-kappa B; Akt	TUMOR-NECROSIS-FACTOR; FACTOR-KAPPA-B; UBIQUITIN LIGASES; MYOGENIC DIFFERENTIATION; FUNCTIONAL EXPRESSION; SIGNAL-TRANSDUCTION; PROTEIN LOSS; PATHWAY; ACTIVATION; ATROPHY	TWEAK cytokine has been implicated in several biological responses including inflammation, angiogenesis, and osteoclastogenesis. We have investigated the role of TWEAK in regulating skeletal muscle mass. Addition of soluble TWEAK protein to cultured myotubes reduced the mean myotube diameter and enhanced the degradation of specific muscle proteins such as CK and MyHCf. The effect of TWEAK on degradation of MyHCf was stronger than its structural homologue, TNF-alpha. TWEAK increased the ubiquitination of MyHCf and the transcript levels of atrogin-1 and MuRF1 ubiquitin ligases. TWEAK inhibited phosphorylation of Akt kinase and its downstream targets GSK-3 beta, FOXO1, mTOR, and p70S6K. Furthermore, TWEAK increased the activation of NF-kappa beta transcription factor in myotubes. Adenoviral- mediated overexpression of I kappa B alpha Delta N (a degradation-resistant mutant of NF-kappa B inhibitory protein I kappa alpha) in myotubes blocked the TWEAK-induced degradation of MyHCf. Chronic administration of TWEAK in mice resulted in reduced body and skeletal muscle weight with an associated increase in the activity of ubiquitin-proteasome system and NF-kappa B. Finally, muscle-specific transgenic overexpression of TWEAK decreased the body and skeletal muscle weight in mice. Collectively, our data suggest that TWEAK induces skeletal muscle atrophy through inhibition of the PI3K/ Akt signaling pathway and activation of the ubiquitin-proteasome and NF-kappa B systems. -Dogra, C., Changotra, H., Wedhas, N., Qin, X., Wergedal, J. E., Kumar, A. TNF- related weak inducer of apoptosis ( TWEAK) is a potent skeletal muscle-wasting cytokine.	Jerry L Pettis Mem Vet Adm Med Ctr, Lab Skeletal Muscle Physiol & Neurobiol, Loma Linda, CA 92357 USA; Jerry L Pettis Mem Vet Adm Med Ctr, Musculoskeletal Dis Ctr, Loma Linda, CA 92357 USA; Loma Linda Univ, Sch Med, Loma Linda, CA USA	Loma Linda University	Kumar, A (corresponding author), Jerry L Pettis Mem Vet Adm Med Ctr, Lab Skeletal Muscle Physiol & Neurobiol, 11201 Benton St 151, Loma Linda, CA 92357 USA.	ashok.kumar2@va.gov	Changotra, Harish/H-2105-2011	Changotra, Harish/0000-0002-1465-5257; Kumar, Ashok/0000-0001-8571-2848	NIA NIH HHS [R01 AG129623, R01 AG029623, R01 AG029623-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG029623] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acharyya S, 2004, J CLIN INVEST, V114, P370, DOI 10.1172/jci200420174; Argiles JM, 2005, INT J BIOCHEM CELL B, V37, P1609, DOI 10.1016/j.biocel.2005.03.007; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Broussard SR, 2004, J IMMUNOL, V172, P7713, DOI 10.4049/jimmunol.172.12.7713; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Cao PR, 2005, INT J BIOCHEM CELL B, V37, P2088, DOI 10.1016/j.biocel.2004.11.010; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Desplat-Jego S, 2002, J NEUROIMMUNOL, V133, P116, DOI 10.1016/S0165-5728(02)00368-5; Dogra C, 2006, J BIOL CHEM, V281, P10327, DOI 10.1074/jbc.M511131200; Dogra C, 2006, J CELL PHYSIOL, V208, P575, DOI 10.1002/jcp.20696; Du J, 2000, J BIOL CHEM, V275, P19661, DOI 10.1074/jbc.M907258199; Filippatos GS, 2005, CURR OPIN CLIN NUTR, V8, P249, DOI 10.1097/01.mco.0000165002.08955.5b; Franch HA, 2005, CURR OPIN CLIN NUTR, V8, P271, DOI 10.1097/01.mco.0000165005.01331.45; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Haddad F, 2005, J APPL PHYSIOL, V98, P911, DOI 10.1152/japplphysiol.01026.2004; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Ho DH, 2004, CANCER RES, V64, P8968, DOI 10.1158/0008-5472.CAN-04-1879; Hunter RB, 2004, J CLIN INVEST, V114, P1504, DOI 10.1172/JCI200421696; Hunter RB, 2002, FASEB J, V16, P529, DOI 10.1096/fj.01-0866com; Jackman RW, 2004, AM J PHYSIOL-CELL PH, V287, pC834, DOI 10.1152/ajpcell.00579.2003; Jakubowski A, 2005, J CLIN INVEST, V115, P2330, DOI 10.1172/JCI23486; Jefferson LS, 1999, INT J BIOCHEM CELL B, V31, P191, DOI 10.1016/S1357-2725(98)00141-1; Kawakita T, 2005, INT J ONCOL, V26, P87; Kawakita T, 2004, BIOCHEM BIOPH RES CO, V318, P726, DOI 10.1016/j.bbrc.2004.04.084; Kim J, 2004, GENES CELLS, V9, P399, DOI 10.1111/j.1356-9597.2004.00731.x; Kronqvist P, 2002, AM J PATHOL, V161, P1535, DOI 10.1016/S0002-9440(10)64431-8; Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y; Kumar A, 2005, J BIOL CHEM, V280, P37782, DOI 10.1074/jbc.M505278200; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; Lecker SH, 1999, J CLIN INVEST, V104, P1411, DOI 10.1172/JCI7300; Li YP, 2000, AM J PHYSIOL-REG I, V279, pR1165, DOI 10.1152/ajpregu.2000.279.4.R1165; Li YP, 2003, FASEB J, V17, P1048, DOI 10.1096/fj.02-0759com; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Maecker H, 2005, CELL, V123, P931, DOI 10.1016/j.cell.2005.09.022; Marsters SA, 1998, CURR BIOL, V8, P525, DOI 10.1016/S0960-9822(98)70204-0; Miller SM, 1998, MOL BIOL CELL, V9, p292A; Nader GA, 2005, INT J BIOCHEM CELL B, V37, P1985, DOI 10.1016/j.biocel.2005.02.026; Nakayama M, 2003, J IMMUNOL, V170, P341, DOI 10.4049/jimmunol.170.1.341; Pallafacchina G, 2002, P NATL ACAD SCI USA, V99, P9213, DOI 10.1073/pnas.142166599; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Perper SJ, 2006, J IMMUNOL, V177, P2610, DOI 10.4049/jimmunol.177.4.2610; Polek TC, 2003, J BIOL CHEM, V278, P32317, DOI 10.1074/jbc.M302518200; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Potrovita I, 2004, J NEUROSCI, V24, P8237, DOI 10.1523/JNEUROSCI.1089-04.2004; Reid MB, 2005, AM J PHYSIOL-REG I, V288, pR1423, DOI 10.1152/ajpregu.00545.2004; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Saas P, 2000, GLIA, V32, P102, DOI 10.1002/1098-1136(200010)32:1<102::AID-GLIA100>3.0.CO;2-U; Sacheck JM, 2004, AM J PHYSIOL-ENDOC M, V287, pE591, DOI 10.1152/ajpendo.00073.2004; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Semov A, 2002, FASEB J, V16, P899, DOI 10.1096/fj.01-1002fje; Sharma R, 2002, INT J CARDIOL, V85, P161, DOI 10.1016/S0167-5273(02)00244-9; Spate U, 2004, CURR OPIN CLIN NUTR, V7, P265, DOI 10.1097/01.mco.0000126344.88494.de; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; Wedhas N, 2005, FASEB J, V19, P1986, DOI 10.1096/fj.05-4198com; Wiley SR, 2003, CYTOKINE GROWTH F R, V14, P241, DOI 10.1016/S1359-6101(03)00019-4; Xu HR, 2004, BIOCHEM BIOPH RES CO, V318, P422, DOI 10.1016/j.bbrc.2004.04.036	69	168	178	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1857	1869		10.1096/fj.06-7537com	http://dx.doi.org/10.1096/fj.06-7537com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314137	Green Accepted			2022-12-28	WOS:000246866500027
J	Hasshoff, M; Bohnisch, C; Tonn, D; Hasert, B; Schulenburg, H				Hasshoff, Martin; Boehnisch, Claudia; Tonn, Daniela; Hasert, Barbara; Schulenburg, Hinrich			The role of Caenorhabditis elegans insulin-like signaling in the behavioral avoidance of pathogenic Bacillus thuringiensis	FASEB JOURNAL			English	Article						immune system; host-pathogen evolution	TOLL-LIKE RECEPTORS; LIFE-SPAN; STRESS RESISTANCE; NATURAL VARIATION; LONGEVITY; MUTANTS; DAF-2; RECOGNITION; DROSOPHILA; SEROTONIN	Pathogens cause damage, and their elimination requires activation of the costly immune response. A highly economic defense strategy should thus be the behavioral avoidance of pathogens, as manifested in humans by all aspects of hygiene or revulsion at pathogen-rich material. Despite its potential importance, behavioral defenses have as yet received only little attention in biomedical research-in stark contrast to the physiological immune system. In the present study, the genetics of such behavioral defenses are elucidated in a simple model organism, the nematode Caenorhabditis elegans. We show for the first time that mutations in the insulin-like receptor (ILR) pathway lead to two distinct behavioral responses against pathogenic strains of the Gram-positive bacterium Bacillus thuringiensis ( BT), including the physical evasion of pathogens and their reduced oral uptake. Since this pathway also contributes to nematode stress resistance, the results surprisingly reveal a genetic link between physiological and behavioral defenses. Considering that many signaling pathways have conserved their functions across evolution, including the ILR pathway, this signaling cascade may represent an interesting candidate regulator for behavioral defenses in more complex organisms, including humans.-Hasshoff M., Bohnisch C., Tonn D., Hasert B., Schulenburg H. The role of Caenorhabditis elegans insulin-like signaling in the behavioral avoidance of pathogenic Bacillus thuringiensis.	Univ Tubingen, Inst Zool, Dept Anim Evolutionary Ecol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Schulenburg, H (corresponding author), Univ Tubingen, Inst Zool, Dept Anim Evolutionary Ecol, Morgenstelle 28, D-72076 Tubingen, Germany.	hinrich.schulenburg@uni-tuebingen.de	Schulenburg, Hinrich/A-3886-2009					Aballay A, 2000, CURR BIOL, V10, P1539, DOI 10.1016/S0960-9822(00)00830-7; Barriere A, 2005, CURR BIOL, V15, P1176, DOI 10.1016/j.cub.2005.06.022; Barsyte D, 2001, FASEB J, V15, P627, DOI 10.1096/fj.99-0966com; Beale E, 2006, APPL ENVIRON MICROB, V72, P5135, DOI 10.1128/AEM.00611-06; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bowie AG, 2005, MOL IMMUNOL, V42, P859, DOI 10.1016/j.molimm.2004.11.007; Broughton SJ, 2005, P NATL ACAD SCI USA, V102, P3105, DOI 10.1073/pnas.0405775102; Couillault C, 2004, NAT IMMUNOL, V5, P488, DOI 10.1038/ni1060; Curtis V, 2004, P ROY SOC B-BIOL SCI, V271, pS131, DOI 10.1098/rsbl.2003.0144; Curtis V, 2001, PERSPECT BIOL MED, V44, P17, DOI 10.1353/pbm.2001.0001; Estevez AO, 2006, DEV BIOL, V298, P32, DOI 10.1016/j.ydbio.2006.06.005; Finch CE, 2001, ANNU REV GENOM HUM G, V2, P435, DOI 10.1146/annurev.genom.2.1.435; Fisher R. A., 1954, STAT METHODS RES WOR, DOI DOI 10.1007/BF01603396; Garsin DA, 2003, SCIENCE, V300, P1921, DOI 10.1126/science.1080147; Gems D, 2005, MECH AGEING DEV, V126, P381, DOI 10.1016/j.mad.2004.09.001; Gems D, 1998, GENETICS, V150, P129; Griffitts JS, 2005, BIOESSAYS, V27, P614, DOI 10.1002/bies.20239; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Haber M, 2005, MOL BIOL EVOL, V22, P160, DOI 10.1093/molbev/msh264; Halaschek-Wiener J, 2005, GENOME RES, V15, P603, DOI 10.1101/gr.3274805; HAMILTON WD, 1982, SCIENCE, V218, P384, DOI 10.1126/science.7123238; HART BL, 1990, NEUROSCI BIOBEHAV R, V14, P273, DOI 10.1016/S0149-7634(05)80038-7; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Hodgkin J, 1997, GENETICS, V146, P149; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Imler JL, 2004, J ENDOTOXIN RES, V10, P241, DOI 10.1179/096805104225005887; Katic M, 2005, CELL MOL LIFE SCI, V62, P320, DOI 10.1007/s00018-004-4297-y; Kavaliers M, 2005, NEUROSCI BIOBEHAV R, V29, P1347, DOI 10.1016/j.neubiorev.2005.04.011; Kavaliers M, 2005, ANIM BEHAV, V70, P693, DOI 10.1016/j.anbehav.2004.12.016; Kavaliers M, 2005, TRENDS PARASITOL, V21, P423, DOI 10.1016/j.pt.2005.07.008; Kavaliers M, 2003, GENES BRAIN BEHAV, V2, P220, DOI 10.1034/j.1601-183X.2003.00021.x; LEYNS F, 1995, FUND APPL NEMATOL, V18, P211; Liang B, 2006, CELL METAB, V4, P429, DOI 10.1016/j.cmet.2006.11.004; Lithgow GJ, 2002, MECH AGEING DEV, V123, P765, DOI 10.1016/S0047-6374(01)00422-5; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; McElwee JJ, 2004, J BIOL CHEM, V279, P44533, DOI 10.1074/jbc.M406207200; Moore J., 2002, PARASITES BEHAV ANIM; Murakami S, 2006, EXP GERONTOL, V41, P1014, DOI 10.1016/j.exger.2006.06.061; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; OH SW, 2006, IN PRESS NAT GENET; Pasare C, 2004, MICROBES INFECT, V6, P1382, DOI 10.1016/j.micinf.2004.08.018; PRADEL E, 2007, IN PRESS P NATL ACAD; Pujol N, 2001, CURR BIOL, V11, P809, DOI 10.1016/S0960-9822(01)00241-X; Rubio-Godoy M, 2007, MED HYPOTHESES, V68, P61, DOI 10.1016/j.mehy.2006.06.036; Schmid-Hempel P, 2003, TRENDS ECOL EVOL, V18, P27, DOI 10.1016/S0169-5347(02)00013-7; Schulenburg H, 2004, IMMUNOL REV, V198, P36, DOI 10.1111/j.0105-2896.2004.0125.x; Schulenburg H, 2004, PARASITOLOGY, V128, P433, DOI 10.1017/S003118200300461X; Sicard M, 2007, ENVIRON MICROBIOL, V9, P12, DOI 10.1111/j.1462-2920.2006.01099.x; Sivasundar A, 2005, CURR BIOL, V15, P1598, DOI 10.1016/j.cub.2005.08.034; Smith MP, 2002, FEMS MICROBIOL LETT, V210, P181, DOI 10.1111/j.1574-6968.2002.tb11178.x; Sokal RR, 1995, BIOMETRY; Stiernagle T., 1999, C ELEGANS PRACTICAL, P51; Tan MW, 1999, P NATL ACAD SCI USA, V96, P715, DOI 10.1073/pnas.96.2.715; Troemel ER, 2006, PLOS GENET, V2, P1725, DOI 10.1371/journal.pgen.0020183; Vellai T, 2006, GENETICS, V174, P309, DOI 10.1534/genetics.106.061499; Wu Q, 2005, NAT NEUROSCI, V8, P1350, DOI 10.1038/nn1540; YOOK K, 2007, IN PRESS GENETICS; Zhang Y, 2005, NATURE, V438, P179, DOI 10.1038/nature04216	59	54	58	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1801	1812		10.1096/fj.06-6551com	http://dx.doi.org/10.1096/fj.06-6551com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314144				2022-12-28	WOS:000246866500022
J	Rousseau, K; Kauser, S; Pritchard, LE; Warhurst, A; Oliver, RL; Slominski, A; Wei, ET; Thody, AJ; Tobin, DJ; White, A				Rousseau, Karine; Kauser, Sobia; Pritchard, Lynn E.; Warhurst, Anne; Oliver, Robert L.; Slominski, Andrzej; Wei, Edward T.; Thody, Anthony J.; Tobin, Desmond J.; White, Anne			Proopiomelanocortin (POMC), the ACTH/melanocortin precursor, is secreted by human epidermal keratinocytes and melanocytes and stimulates melanogenesis	FASEB JOURNAL			English	Article						alpha-MSH; hair follicle melanocytes; CRH receptors	CORTICOTROPIN-RELEASING HORMONE; 2-SITE IMMUNORADIOMETRIC ASSAY; CULTURED HUMAN MELANOCYTES; HAIR-FOLLICLE MELANOCYTES; PROHORMONE CONVERTASES 1; CANCER CELL-LINES; BETA-ENDORPHIN; HUMAN SKIN; MELANOCORTIN-1 RECEPTOR; CEREBROSPINAL-FLUID	Proopiomelanocortin ( POMC) can be processed to ACTH and melanocortin peptides. However, processing is incomplete in some tissues, leading to POMC precursor release from cells. This study examined POMC processing in human skin and the effect of POMC on the melanocortin-1 receptor (MC-1R) and melanocyte regulation. POMC was secreted by both human epidermal keratinocytes ( from 5 healthy donors) and matched epidermal melanocytes in culture. Much lower levels of alpha-MSH were secreted and only by the keratinocytes. Neither cell type released ACTH. Cell extracts contained significantly more ACTH than POMC, and alpha-MSH was detected only in keratinocytes. Nevertheless, the POMC processing components, prohormone convertases 1, 2 and regulatory protein 7B2, were detected in melanocytes and keratinocytes. In contrast, hair follicle melanocytes secreted both POMC and alpha-MSH, and this was enhanced in response to corticotrophin-releasing hormone ( CRH) acting primarily through the CRH receptor 1. In cells stably transfected with the MC-1R, POMC stimulated cAMP, albeit with a lower potency than ACTH, alpha-MSH, and beta-MSH. POMC also increased melanogenesis and dendricity in human pigment cells. This release of POMC from skin cells and its functional activity at the MC-1R highlight the importance of POMC processing as a key regulatory event in the skin. Rousseau, K., Kauser, S., Pritchard, L. E., Warhurst, A., Oliver, R. L., Slominski, A., Wei, E. T., Thody, A. J., Tobin, D. J., White, A. Proopiomelanocortin ( POMC), the ACTH/melanocortin precursor, is secreted by human epidermal keratinocytes and melanocytes and stimulates melanogenesis.	Univ Manchester, Fac Life Sci & Med, Manchester M13 9PT, Lancs, England; Univ Manchester, Fac Human Sci, Manchester M13 9PT, Lancs, England; Univ Bradford, Bradford, W Yorkshire, England; Univ Tennessee Hlth Sci, Dept Pathol & Lab Med, Memphis, TN USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA USA; Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England	University of Manchester; University of Manchester; University of Bradford; University of Tennessee System; University of Tennessee Health Science Center; University of California System; University of California Berkeley; Newcastle University - UK	White, A (corresponding author), Univ Manchester, Fac Life Sci & Med, Stopford Bldg, Manchester M13 9PT, Lancs, England.	anne.white@manchester.ac.uk	White, Anne/G-7717-2015; Tobin, Desmond/A-5228-2009	White, Anne/0000-0002-7686-2884; Slominski, Andrzej/0000-0001-8963-3995; Tobin, Desmond/0000-0003-4566-9392	NIAMS NIH HHS [AR047079, R01 AR047079-03, R01 AR047079-02, R01 AR047079, R01 AR047079-01A2] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047079] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; ANCANS J, 2002, MECH SUNTANNING; BERTAGNA XY, 1978, P NATL ACAD SCI USA, V75, P5160, DOI 10.1073/pnas.75.10.5160; BHARDWAJ RS, 1994, ARCH DERMATOL RES, V287, P85, DOI 10.1007/BF00370724; Bicknell AB, 2001, CELL, V105, P903, DOI 10.1016/S0092-8674(01)00403-2; Bohm MB, 2005, ENDOCRINOLOGY, V146, P4635, DOI 10.1210/en.2005-0665; BUFFEY JA, 1994, BRIT J DERMATOL, V131, P836, DOI 10.1111/j.1365-2133.1994.tb08586.x; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; CROSBY SR, 1988, J CLIN ENDOCR METAB, V67, P1272, DOI 10.1210/jcem-67-6-1272; Dumermuth E, 1998, METHODS, V16, P188, DOI 10.1006/meth.1998.0666; GIBSON S, 1994, J CLIN ENDOCR METAB, V78, P835, DOI 10.1210/jc.78.4.835; HUNT G, 1995, PIGM CELL RES, V8, P202, DOI 10.1111/j.1600-0749.1995.tb00664.x; HUNT G, 1994, J CELL SCI, V107, P205; HUNT G, 1994, J ENDOCRINOL, V140, pR1, DOI 10.1677/joe.0.140R001; Ito N, 2005, FASEB J, V19, P1332, DOI 10.1096/fj.04-1968fje; Kadekaro AL, 2003, ANN NY ACAD SCI, V994, P359, DOI 10.1111/j.1749-6632.2003.tb03200.x; Kauser S, 2005, ENDOCRINOLOGY, V146, P532, DOI 10.1210/en.2004-1145; Kauser S, 2004, J INVEST DERMATOL, V123, P184, DOI 10.1111/j.0022-202X.2004.22724.x; Kauser S, 2003, J INVEST DERMATOL, V120, P1073, DOI 10.1046/j.1523-1747.2003.12242.x; Kauser S, 2006, FASEB J, V20, P882, DOI 10.1096/fj.05-5257com; KAUTSKY MB, 1995, J INVEST DERMATOL, V104, P545, DOI 10.1111/1523-1747.ep12606058; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; LERNER AB, 1961, NATURE, V189, P176, DOI 10.1038/189176a0; Mazurkiewicz JE, 2000, J HISTOCHEM CYTOCHEM, V48, P905, DOI 10.1177/002215540004800703; MOUNTJOY KG, 1994, MOL CELL ENDOCRINOL, V102, pR7, DOI 10.1016/0303-7207(94)90113-9; Peters EMJ, 2000, J INVEST DERMATOL, V114, P430, DOI 10.1046/j.1523-1747.2000.00913.x; Pritchard LE, 2004, J ENDOCRINOL, V180, P183, DOI 10.1677/joe.0.1800183; Pritchard LE, 2003, ENDOCRINOLOGY, V144, P760, DOI 10.1210/en.2002-220866; Pritchard LE, 2002, J ENDOCRINOL, V172, P411, DOI 10.1677/joe.0.1720411; RAY DW, 1995, J CLIN ENDOCR METAB, V80, P2430, DOI 10.1210/jc.80.8.2430; SCHAUER E, 1994, J CLIN INVEST, V93, P2258, DOI 10.1172/JCI117224; Schiller M, 2001, J INVEST DERMATOL, V117, P227, DOI 10.1046/j.0022-202x.2001.01412.x; SLOMINSKI A, 1992, LIFE SCI, V50, P1103, DOI 10.1016/0024-3205(92)90347-R; Slominski A, 2005, AM J PHYSIOL-ENDOC M, V288, pE701, DOI 10.1152/ajpendo.00519.2004; Slominski A, 1998, J CLIN ENDOCR METAB, V83, P1020, DOI 10.1210/jc.83.3.1020; SLOMINSKI A, 1993, MOL CELL ENDOCRINOL, V93, pC1, DOI 10.1016/0303-7207(93)90131-3; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2004, ENDOCRINOLOGY, V145, P941, DOI 10.1210/en.2003-0851; Slominski A, 2005, J NEUROIMMUNOL, V162, P97, DOI 10.1016/j.jneuroim.2005.01.014; Slominski A, 1999, HUM PATHOL, V30, P208, DOI 10.1016/S0046-8177(99)90278-2; Slominski A, 2006, FRONT BIOSCI-LANDMRK, V11, P2230, DOI 10.2741/1966; STEWART MF, 1989, BRIT J CANCER, V60, P20, DOI 10.1038/bjc.1989.212; Thody AJ, 1998, PIGM CELL RES, V11, P265, DOI 10.1111/j.1600-0749.1998.tb00735.x; THODY AJ, 1983, PEPTIDES, V4, P813, DOI 10.1016/0196-9781(83)90072-4; TOBIN DJ, 1995, J INVEST DERMATOL, V104, P86, DOI 10.1111/1523-1747.ep12613573; TSIGOS C, 1995, J DIABETES COMPLICAT, V9, P92, DOI 10.1016/1056-8727(94)00024-I; Wakamatsu K, 1997, PIGM CELL RES, V10, P288, DOI 10.1111/j.1600-0749.1997.tb00688.x; Wei ET, 1998, PEPTIDES, V19, P1183, DOI 10.1016/S0196-9781(98)00085-0; White A, 1998, CLIN ENDOCRINOL, V48, P251, DOI 10.1046/j.1365-2265.1998.00451.x; WHITE A, 1989, J MOL ENDOCRINOL, V3, P65, DOI 10.1677/jme.0.0030065; WHITE A, 1987, CLIN ENDOCRINOL, V26, P41, DOI 10.1111/j.1365-2265.1987.tb03637.x; Wintzen M, 1996, J INVEST DERMATOL, V106, P673, DOI 10.1111/1523-1747.ep12345496	52	121	128	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1844	1856		10.1096/fj.06-7398com	http://dx.doi.org/10.1096/fj.06-7398com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17317724	Green Accepted			2022-12-28	WOS:000246866500026
J	Sack, M; Paetz, A; Kunert, R; Bomble, M; Hesse, F; Stiegler, G; Fischer, R; Katinger, H; Stoeger, E; Rademacher, T				Sack, Markus; Paetz, Antje; Kunert, Renate; Bomble, Michael; Hesse, Friedemann; Stiegler, Gabriela; Fischer, Rainer; Katinger, Hermann; Stoeger, Eva; Rademacher, Thomas			Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures	FASEB JOURNAL			English	Article						Fc gamma RI ectodomain; surface plasmon resonance; antibody activity; recombinant pharmaceutical glycoprotein	IMMUNODEFICIENCY-VIRUS TYPE-1; OLIGOSACCHARIDE-PROTEIN INTERACTIONS; DEPENDENT CELLULAR CYTOTOXICITY; HUMAN MONOCLONAL-ANTIBODY; HAMSTER OVARY CELLS; COMPLEX N-GLYCANS; GAMMA RECEPTOR-I; SERUM HALF-LIFE; IMMUNOGLOBULIN-G; ENDOPLASMIC-RETICULUM	We report the production of an important human therapeutic antibody in plant cell suspension cultures and the functional analysis of that antibody, including a comparison with the same antibody produced in CHO cells. We established transgenic tobacco BY2 suspension cell cultures expressing the human monoclonal antibody 2F5, which shows broadly neutralizing activity against HIV-1. The antibody was directed to the endoplasmic reticulum of the plant cells and was isolated by cell disruption, followed by protein A chromatography. The plant- derived antibody was shown to be largely intact by SDS- PAGE and immunoblot. Antigen binding activity was investigated by electrophoretic mobility shift assay and quantitatively determined by ELISA and Biacore biosensor technology. Ligand binding properties were analyzed using the ectodomain of human Fc gamma RI for kinetic analysis. The plant- derived antibody showed similar kinetic properties and 89% of the binding capacity of its CHO-derived counterpart, but was only 33% as efficient in HIV- 1 neutralization assays. Our results show that plant suspension cultures can be used to produce human antibodies efficiently and that the analysis methods used in this study, including biosensor technology, provide useful functional data about antibody performance. This highlights important issues raised by the use of plant systems to produce human biologics. Sack, M., Paetz, A., Kunert, R., Bomble, M., Hesse, F., Stiegler, G., Fischer, R., Katinger, H., Stoeger, E., Rademacher, T. Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures.	RTWH Aachen Univ, Inst Mol Biotechnol, D-52074 Aachen, Germany; Univ Nat Resources & Appl Life Sci, Inst Appl Microbiol, Vienna, Austria; Polymun Sci Immunobiol Forsch GmbH, Vienna, Austria; Fraunhofer IME, Aachen, Germany	RWTH Aachen University; University of Natural Resources & Life Sciences, Vienna	Rademacher, T (corresponding author), RTWH Aachen Univ, Inst Mol Biotechnol, Worringerweg 1, D-52074 Aachen, Germany.	rademacher@molbiotech.rwth-aachen.de	Sack, Markus/K-6681-2013; Hesse, Friedemann/Y-8632-2019; Kunert, Renate E/B-9185-2018; Sack, Markus/AAP-9252-2021	Sack, Markus/0000-0002-7380-9228; Hesse, Friedemann/0000-0003-0401-1842; Kunert, Renate E/0000-0002-3397-3621; 				[Anonymous], 2006, NAT BIOTECHNOL, V24, P233; Armbruster C, 2002, AIDS, V16, P227, DOI 10.1097/00002030-200201250-00012; Armbruster C, 2004, J ANTIMICROB CHEMOTH, V54, P915, DOI 10.1093/jac/dkh428; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Bakker H, 2006, P NATL ACAD SCI USA, V103, P7577, DOI 10.1073/pnas.0600879103; Bevaart L, 2006, BRIT J HAEMATOL, V132, P317, DOI 10.1111/j.1365-2141.2005.05884.x; Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004; Cabanes-Macheteau M, 1999, GLYCOBIOLOGY, V9, P365, DOI 10.1093/glycob/9.4.365; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; Dall'Acqua WF, 2006, J BIOL CHEM, V281, P23514, DOI 10.1074/jbc.M604292200; Elbers IJW, 2001, PLANT PHYSIOL, V126, P1314, DOI 10.1104/pp.126.3.1314; Ferrara C, 2006, J BIOL CHEM, V281, P5032, DOI 10.1074/jbc.M510171200; Fischer R, 1999, EUR J BIOCHEM, V262, P810, DOI 10.1046/j.1432-1327.1999.00435.x; Fischer R, 1999, BIOTECHNOL APPL BIOC, V30, P109; Gurbaxani B, 2006, MOL IMMUNOL, V43, P1462, DOI 10.1016/j.molimm.2005.07.032; Hellwig S, 2004, NAT BIOTECHNOL, V22, P1415, DOI 10.1038/nbt1027; Hinton PR, 2006, J IMMUNOL, V176, P346, DOI 10.4049/jimmunol.176.1.346; Holland M, 2006, BBA-GEN SUBJECTS, V1760, P669, DOI 10.1016/j.bbagen.2005.11.021; Hollister J, 2002, BIOCHEMISTRY-US, V41, P15093, DOI 10.1021/bi026455d; Horn ME, 2004, PLANT CELL REP, V22, P711, DOI 10.1007/s00299-004-0767-1; Huether CM, 2005, PLANT BIOLOGY, V7, P292, DOI 10.1055/s-2005-837653; Jach G, 2001, PLANT J, V28, P483, DOI 10.1046/j.1365-313X.2001.01153.x; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Kathuria S, 2002, HUM REPROD, V17, P2054, DOI 10.1093/humrep/17.8.2054; Ko KS, 2003, P NATL ACAD SCI USA, V100, P8013, DOI 10.1073/pnas.0832472100; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; Krapp S, 2003, J MOL BIOL, V325, P979, DOI 10.1016/S0022-2836(02)01250-0; Kunert R, 2000, BIOTECHNOL BIOENG, V67, P97, DOI 10.1002/(SICI)1097-0290(20000105)67:1<97::AID-BIT11>3.0.CO;2-2; Li HJ, 2006, NAT BIOTECHNOL, V24, P210, DOI 10.1038/nbt1178; Lund J, 1996, J IMMUNOL, V157, P4963; LUND J, 1995, FASEB J, V9, P115, DOI 10.1096/fasebj.9.1.7821750; LUND J, 1990, MOL IMMUNOL, V27, P1145, DOI 10.1016/0161-5890(90)90103-7; Ma JKC, 2003, NAT REV GENET, V4, P794, DOI 10.1038/nrg1177; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; Mehandru S, 2004, J VIROL, V78, P14039, DOI 10.1128/JVI.78.24.14039-14042.2004; Mimura Y, 2000, MOL IMMUNOL, V37, P697, DOI 10.1016/S0161-5890(00)00105-X; Misaki R, 2003, GLYCOBIOLOGY, V13, P199, DOI 10.1093/glycob/cwg021; Okazaki A, 2004, J MOL BIOL, V336, P1239, DOI 10.1016/j.jmb.2004.01.007; Paetz A, 2005, BIOCHEM BIOPH RES CO, V338, P1811, DOI 10.1016/j.bbrc.2005.10.162; Palacpac NQ, 1999, P NATL ACAD SCI USA, V96, P4692, DOI 10.1073/pnas.96.8.4692; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; Petruccelli S, 2006, PLANT BIOTECHNOL J, V4, P511, DOI 10.1111/j.1467-7652.2006.00200.x; PURTSCHER M, 1994, AIDS RES HUM RETROV, V10, P1651, DOI 10.1089/aid.1994.10.1651; RADEMACHER TW, 1994, P NATL ACAD SCI USA, V91, P6123, DOI 10.1073/pnas.91.13.6123; REED L. J., 1938, AMER JOUR HYG, V27, P493; Schouten A, 1996, PLANT MOL BIOL, V30, P781, DOI 10.1007/BF00019011; Shinkawa T, 2003, J BIOL CHEM, V278, P3466, DOI 10.1074/jbc.M210665200; Sriraman R, 2004, PLANT BIOTECHNOL J, V2, P279, DOI 10.1111/j.1467-7652.2004.00078.x; Stoger E, 2005, CURR PHARM DESIGN, V11, P2439, DOI 10.2174/1381612054367535; Strasser R, 2004, FEBS LETT, V561, P132, DOI 10.1016/S0014-5793(04)00150-4; Triguero A, 2005, PLANT BIOTECHNOL J, V3, P449, DOI 10.1111/j.1467-7652.2005.00137.x; Vaccaro C, 2005, NAT BIOTECHNOL, V23, P1283, DOI 10.1038/nbt1143; Wolbank S, 2003, J VIROL, V77, P4095, DOI 10.1128/JVI.77.7.4095-4103.2003; Wormald MR, 1997, BIOCHEMISTRY-US, V36, P1370, DOI 10.1021/bi9621472; Wright A, 1998, J IMMUNOL, V160, P3393; Yamane-Ohnuki N, 2004, BIOTECHNOL BIOENG, V87, P614, DOI 10.1002/bit.20151	57	68	76	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2007	21	8					1655	1664		10.1096/fj.06-5863com	http://dx.doi.org/10.1096/fj.06-5863com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17327362				2022-12-28	WOS:000246866500007
J	van Bergeijk, J; Rydel-Konecke, K; Grothe, C; Claus, P				van Bergeijk, Jeroen; Rydel-Koenecke, Katharina; Grothe, Claudia; Claus, Peter			The spinal muscular atrophy gene product regulates neurite outgrowth: Importance of the C terminus	FASEB JOURNAL			English	Article						survival of motoneuron; neurodegeneration; actin; PC12 cells	NEURON SMN PROTEIN; FIBROBLAST GROWTH FACTOR-2; MOLECULAR ANALYSIS; ACTIN-FILAMENT; MESSENGER-RNA; COILED BODIES; NUCLEAR GEMS; CAJAL BODIES; 20S COMPLEX; SURVIVAL	Spinal muscular atrophy is a neurodegenerative disease accompanied by a loss of motoneurons. Either mutations or deletions in the survival of motoneuron ( SMN) gene are responsible for this defect. SMN is an assembly protein for RNA- protein complexes in the nucleus and is also found in axons of neurons. However, it is unclear which dysfunctions of SMN are important for disease progression. In this study we analyzed the contributions of different SMN regions for localization and neuronal differentiation associated with outgrowth of neurites. Suppression of endogenous SMN protein levels significantly decreased the growth of neurites. Down- regulation of the interacting protein gemin2 had the opposite effect. Surprisingly, selective overexpression of the SMN C- terminal domain promoted neurite outgrowth similar to fulllength protein and could rescue the SMN knock- down effects. The knock- down led to a significant change in the G-/F-actin ratio, indicating a role for SMN in actin dynamics. Therefore, our data suggest a functional role for SMN in microfilament metabolism in axons of motoneurons.	Hannover Med Sch, Dept Neuroanat, D-30625 Hannover, Germany; ZSN Hannover, Ctr Syst Neurosci, Hannover, Germany	Hannover Medical School	Claus, P (corresponding author), Hannover Med Sch, Dept Neuroanat, OE 4140,Carl Neuberg Str 1, D-30625 Hannover, Germany.	claus.peter@mh-hannover.de	Claus, Peter/A-7978-2008	Claus, Peter/0000-0003-3824-9445				Anderson K, 2003, CURR OPIN NEUROL, V16, P595, DOI 10.1097/00019052-200310000-00005; Briese M, 2005, BIOESSAYS, V27, P946, DOI 10.1002/bies.20283; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Campbell L, 1997, AM J HUM GENET, V61, P40, DOI 10.1086/513886; Carissimi C, 2006, J BIOL CHEM, V281, P8126, DOI 10.1074/jbc.M512243200; Cifuentes-Diaz C, 2001, J CELL BIOL, V152, P1107, DOI 10.1083/jcb.152.5.1107; Cifuentes-Diaz C, 2002, HUM MOL GENET, V11, P1439, DOI 10.1093/hmg/11.12.1439; Claus P, 2003, J BIOL CHEM, V278, P479, DOI 10.1074/jbc.M206056200; Claus P, 2004, BIOCHEM J, V384, P559, DOI 10.1042/BJ20040801; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; Da Silva JS, 2003, J CELL BIOL, V162, P1267, DOI 10.1083/jcb.200304021; Fan L, 2002, HUM MOL GENET, V11, P1605, DOI 10.1093/hmg/11.14.1605; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Giesemann T, 1999, J BIOL CHEM, V274, P37908, DOI 10.1074/jbc.274.53.37908; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GROTHE C, 1992, J NEUROSCI RES, V32, P317, DOI 10.1002/jnr.490320304; Gubitz AK, 2004, EXP CELL RES, V296, P51, DOI 10.1016/j.yexcr.2004.03.022; Haastert K, 2005, J NEUROSCI METH, V142, P275, DOI 10.1016/j.jneumeth.2004.09.003; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Hebert MD, 2001, GENE DEV, V15, P2720, DOI 10.1101/gad.908401; Huber K, 1997, J COMP NEUROL, V382, P189; Jablonka S, 2004, J NEUROBIOL, V58, P272, DOI 10.1002/neu.10313; Jablonka S, 2001, HUM MOL GENET, V10, P497, DOI 10.1093/hmg/10.5.497; Kalil K, 2005, CURR OPIN NEUROBIOL, V15, P521, DOI 10.1016/j.conb.2005.08.005; Kuhn TB, 2000, J NEUROBIOL, V44, P126, DOI 10.1002/1097-4695(200008)44:2<126::AID-NEU4>3.0.CO;2-Z; Le TT, 2005, HUM MOL GENET, V14, P845, DOI 10.1093/hmg/ddi078; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LINDENBAUM MH, 1988, J BIOL CHEM, V263, P5662; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; McAndrew PE, 1997, AM J HUM GENET, V60, P1411, DOI 10.1086/515465; McWhorter ML, 2003, J CELL BIOL, V162, P919, DOI 10.1083/jcb.200303168; Meister G, 2000, HUM MOL GENET, V9, P1977, DOI 10.1093/hmg/9.13.1977; Meister G, 2002, TRENDS CELL BIOL, V12, P472, DOI 10.1016/S0962-8924(02)02371-1; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Monani UR, 1999, HUM MOL GENET, V8, P1177, DOI 10.1093/hmg/8.7.1177; Navascues J, 2004, CHROMOSOMA, V112, P398, DOI 10.1007/s00412-004-0285-5; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Pellizzoni L, 2001, CURR BIOL, V11, P1079, DOI 10.1016/S0960-9822(01)00316-5; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Ponting CP, 1997, TRENDS BIOCHEM SCI, V22, P51, DOI 10.1016/S0968-0004(96)30049-2; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; Rossoll W, 2002, HUM MOL GENET, V11, P93, DOI 10.1093/hmg/11.1.93; Rossoll W, 2003, J CELL BIOL, V163, P801, DOI 10.1083/jcb.200304128; Sharma A, 2005, EXP CELL RES, V309, P185, DOI 10.1016/j.yexcr.2005.05.014; Terns MP, 2001, CURR BIOL, V11, pR862, DOI 10.1016/S0960-9822(01)00517-6; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; van Bergeijk J, 2006, CHEM BIOL DRUG DES, V67, P244, DOI 10.1111/j.1747-0285.2006.00369.x; Wang J, 2001, J BIOL CHEM, V276, P45387, DOI 10.1074/jbc.M105059200; Witke W, 2004, TRENDS CELL BIOL, V14, P461, DOI 10.1016/j.tcb.2004.07.003; Young PJ, 2000, HUM MOL GENET, V9, P2869, DOI 10.1093/hmg/9.19.2869; Young PJ, 2001, EXP CELL RES, V265, P252, DOI 10.1006/excr.2001.5186; Young PJ, 2000, EXP CELL RES, V256, P365, DOI 10.1006/excr.2000.4858; Zhang HLL, 2003, J NEUROSCI, V23, P6627; Zheng JQ, 2001, J NEUROSCI, V21, P9291, DOI 10.1523/JNEUROSCI.21-23-09291.2001; Zigmond SH, 2004, CURR TOP DEV BIOL, V63, P145, DOI 10.1016/S0070-2153(04)63005-5	61	50	50	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1492	1502		10.1096/fj.06-7136com	http://dx.doi.org/10.1096/fj.06-7136com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17317728				2022-12-28	WOS:000246117000024
J	Mohsenin, A; Burdick, MD; Molina, JG; Keane, MP; Blackburn, MR				Mohsenin, Amir; Burdick, Marie D.; Molina, Jose G.; Keane, Michael P.; Blackburn, Michael R.			Enhanced CXCL1 production and angiogenesis in adenosine-mediated lung disease	FASEB JOURNAL			English	Article						chemokine; asthma; macrophage; adenosine deaminase	DEAMINASE-DEFICIENT MICE; HUMAN ENDOTHELIAL-CELLS; AIRWAY INFLAMMATION; PULMONARY-FIBROSIS; MALIGNANT-MELANOMA; A(2B) RECEPTORS; ASTHMA; INTERLEUKIN-8; CHEMOKINES; EXPRESSION	Angiogenesis is a feature of chronic lung diseases such as asthma and pulmonary fibrosis; however, the pathways controlling pathological angiogenesis during lung disease are not completely understood. Adenosine is a signaling molecule that has been implicated in the exacerbation of chronic lung disease and in the regulation of angiogenesis; however, the relationship between these factors has not been investigated. The current study utilized adenosine deaminase (ADA)-deficient mice to determine whether chronic elevations in adenosine in vivo result in pulmonary angiogenesis. Results demonstrate substantial angiogenesis in the tracheas of ADA-deficient mice in association with adenosine elevations. ADA replacement enzyme therapy resulted in a lowering of adenosine levels and reversal of tracheal angiogenesis, indicating that the increases in vessel number are dependent on adenosine elevations. Levels of the angiogenic chemokine CXCL1 (mouse functional homologue of human IL-8) were found to be elevated in an adenosine-dependent manner in the lungs of ADA-deficient mice. Neutralization of CXCL1 and its receptor, CXCR2, resulted in the inhibition of angiogenic activity, which suggests that CXCL1 signaling through the CXCR2 receptor mediated the observed increases in angiogenesis. Our findings suggest that adenosine plays an important role, via CXCL1, in the induction of pulmonary angiogenesis.	Univ Texas, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, Sch Med, Grad Sch Biomed Sci, Houston, TX 77030 USA; Univ Calif Los Angeles, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90024 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of California System; University of California Los Angeles	Blackburn, MR (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, 6431 Fannin St, Houston, TX 77030 USA.	michael.r.blackburn@uth.tmc.edu	Keane, Michael/R-6329-2019	Blackburn, Michael/0000-0002-1394-9966	NHLBI NIH HHS [P50HL67665, HL087186, HL-70952] Funding Source: Medline; NIAID NIH HHS [AI-43572] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070952, P50HL067665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043572] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; Arenberg DA, 1998, J CLIN INVEST, V102, P465, DOI 10.1172/JCI3145; Arenberg DA, 1996, J EXP MED, V184, P981, DOI 10.1084/jem.184.3.981; Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; Belperio JA, 2005, J IMMUNOL, V175, P6931, DOI 10.4049/jimmunol.175.10.6931; Belperio JA, 2005, J CLIN INVEST, V115, P1150, DOI 10.1172/JCI200524233; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Blackburn MR, 2000, J EXP MED, V192, P159, DOI 10.1084/jem.192.2.159; Blackburn MR, 2003, J CLIN INVEST, V112, P332, DOI 10.1172/JCI200316815; Blackburn MR, 1998, J BIOL CHEM, V273, P5093, DOI 10.1074/jbc.273.9.5093; Bobryshev YV, 2006, MICRON, V37, P208, DOI 10.1016/j.micron.2005.10.007; Burdick MD, 2005, AM J RESP CRIT CARE, V171, P261, DOI 10.1164/rccm.200409-1164OC; Cavaillon JM, 2005, CRIT CARE MED, V33, pS506, DOI 10.1097/01.CCM.0000185502.21012.37; Cebe-Suarez S, 2006, CELL MOL LIFE SCI, V63, P601, DOI 10.1007/s00018-005-5426-3; Charan NB, 1997, EUR RESPIR J, V10, P1173, DOI 10.1183/09031936.97.10051173; Chunn JL, 2006, AM J PHYSIOL-LUNG C, V290, pL579, DOI 10.1152/ajplung.00258.2005; Chunn JL, 2001, J IMMUNOL, V167, P4676, DOI 10.4049/jimmunol.167.8.4676; Csoma Z, 2005, EUR RESPIR J, V25, P873, DOI 10.1183/09031936.05.00110204; Desai A, 2005, MOL PHARMACOL, V67, P1406, DOI 10.1124/mol.104.007807; Devalaraja RM, 2000, J INVEST DERMATOL, V115, P234, DOI 10.1046/j.1523-1747.2000.00034.x; DRIVER AG, 1993, AM REV RESPIR DIS, V148, P91, DOI 10.1164/ajrccm/148.1.91; DUSSEAU JW, 1986, CIRC RES, V59, P163, DOI 10.1161/01.RES.59.2.163; ETHIER MF, 1993, AM J PHYSIOL, V265, pH131, DOI 10.1152/ajpheart.1993.265.1.H131; Feoktistov I, 2002, CIRC RES, V90, P531, DOI 10.1161/01.RES.0000012203.21416.14; FEOKTISTOV I, 1995, J CLIN INVEST, V96, P1979, DOI 10.1172/JCI118245; Feoktistov I, 2004, HYPERTENSION, V44, P649, DOI 10.1161/01.HYP.0000144800.21037.a5; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; Huszar E, 2002, EUR RESPIR J, V20, P1393, DOI 10.1183/09031936.02.00005002; Jabs CM, 1998, SURGERY, V124, P65, DOI 10.1067/msy.1998.87894; Keane MP, 1997, J IMMUNOL, V159, P1437; KNUDSEN TB, 1992, TERATOLOGY, V45, P91, DOI 10.1002/tera.1420450109; Kocher AA, 2006, J MOL CELL CARDIOL, V40, P455, DOI 10.1016/j.yjmcc.2005.11.013; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; Luan J, 1997, J LEUKOCYTE BIOL, V62, P588, DOI 10.1002/jlb.62.5.588; MEININGER CJ, 1988, AM J PHYSIOL, V255, P554; Modi WS, 1999, MOL BIOL EVOL, V16, P180, DOI 10.1093/oxfordjournals.molbev.a026101; Moldobaeva A, 2005, AM J PHYSIOL-LUNG C, V288, pL1117, DOI 10.1152/ajplung.00370.2004; Montesinos MC, 2004, AM J PATHOL, V164, P1887, DOI 10.1016/S0002-9440(10)63749-2; Nocker RET, 1996, INT ARCH ALLERGY IMM, V109, P183, DOI 10.1159/000237218; Reid DW, 2003, EUR RESPIR J, V21, P994, DOI 10.1183/09031936.03.00109702; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Salvato G, 2001, THORAX, V56, P902, DOI 10.1136/thorax.56.12.902; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Sun CX, 2006, J CLIN INVEST, V116, P2173, DOI 10.1172/JCI27303; Tanaka H, 2003, AM J RESP CRIT CARE, V168, P1495, DOI 10.1164/rccm.200306-727OC; Thurston G, 1998, AM J PATHOL, V153, P1099, DOI 10.1016/S0002-9440(10)65654-4; TORRY RJ, 1992, AM J PHYSIOL, V262, pH980, DOI 10.1152/ajpheart.1992.262.4.H980; TURNER-WARWICK MARGARET, 1963, THORAX, V18, P225, DOI 10.1136/thx.18.3.225; Varney ML, 2006, AM J CLIN PATHOL, V125, P209, DOI 10.1309/VPL5R.JR7F1D6V03; Vrugt B, 2000, EUR RESPIR J, V15, P1014, DOI 10.1034/j.1399-3003.2000.01507.x; WEBER J, 1989, AM REV RESPIR DIS, V140, P1450, DOI 10.1164/ajrccm/140.5.1450; Xaus J, 1999, J IMMUNOL, V162, P3607; Young HWJ, 2004, J IMMUNOL, V173, P1380, DOI 10.4049/jimmunol.173.2.1380	55	25	26	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					1026	1036		10.1096/fj.06-7301com	http://dx.doi.org/10.1096/fj.06-7301com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17227950				2022-12-28	WOS:000245650400007
J	Wang, L; Maher, TJ; Wurtman, RJ				Wang, Lei; Maher, Timothy J.; Wurtman, Richard J.			Oral L-glutamine increases GABA levels in striatal tissue and extracellular fluid	FASEB JOURNAL			English	Article						microdialysis; glutamate; neurotransmitter precursor; hepatic encephalopathy	GAMMA-AMINOBUTYRIC-ACID; INDUCED HEPATIC-ENCEPHALOPATHY; BLOOD-BRAIN-BARRIER; RAT-BRAIN; IN-VIVO; METABOLIC COMPARTMENTATION; TRYPTOPHAN LEVELS; TRANSPORT; RELEASE; AMMONIA	We explored the possibility that circulating glutamine affects gamma-aminobutyric acid (GABA) levels in rat striatal tissue and GABA concentrations in striatal extracellular fluid (ECF). Striatal microdialysates, each collected over a 20 min interval, were obtained after no treatment, oral L-glutamine (0.5 g/kg), or glutamine followed by NMDA ( administered via the microdialysis probe). GABA concentrations were measured by HPLC using a stable OPA/sulfite precolumn derivatization and an electrochemical detection method. L-Glutamine administration significantly increased ECF GABA concentrations by 30%, and enhanced the response evoked by NMDA alone (70%) to 120% over baseline (all P < 0.05). Striatal GABA levels increased significantly 2.5 h after oral L-glutamine ( e. g., from 1.76 +/- 0.04 mu mol/g in vehicle-treated rats to 2.00 +/- 0.15 mu mol/g in those receiving 2.0 g/kg of glutamine). Striatal glutamine levels also increased significantly, but not those of glutamate. These data suggest that GABA synthesis in, and release from, rat striatum may be regulated in part by circulating glutamine. Hence, glutamine administration may provide a useful adjunct for treating disorders ( e. g., anxiety, seizures) when enhanced GABAergic transmission is desired. Moreover, the elevation in plasma and brain glutamine associated with hepatic failure may, by increasing brain GABA release, produce some of the manifestations of hepatic encephalopathy.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; Masachusetts Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Boston, MA USA	Massachusetts Institute of Technology (MIT)	Wurtman, RJ (corresponding author), MIT, Dept Brain & Cognit Sci, 43 Vassar St,46-5023B, Cambridge, MA 02139 USA.	dick@mit.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH028783] Funding Source: NIH RePORTER; NIMH NIH HHS [2 R01 MH028783-31] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ACWORTH IN, 1988, BRAIN RES BULL, V21, P473, DOI 10.1016/0361-9230(88)90161-X; Anagnostaras SG, 1999, NAT NEUROSCI, V2, P780, DOI 10.1038/12146; Bak LK, 2006, J NEUROCHEM, V98, P641, DOI 10.1111/j.1471-4159.2006.03913.x; Basile AS, 2002, NEUROCHEM INT, V41, P115, DOI 10.1016/S0197-0186(02)00032-3; BATTAGLIOLI G, 1991, NEUROCHEM RES, V16, P151, DOI 10.1007/BF00965703; Battaglioli G, 1996, NEUROSCI LETT, V209, P129, DOI 10.1016/0304-3940(96)12606-9; BENES FM, 1991, ARCH GEN PSYCHIAT, V48, P996; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; DECHELOTTE P, 1991, AM J PHYSIOL, V260, pG677, DOI 10.1152/ajpgi.1991.260.5.G677; DEJONG CHC, 1992, J NEUROCHEM, V59, P1071, DOI 10.1111/j.1471-4159.1992.tb08349.x; DONZANTI BA, 1988, LIFE SCI, V43, P913, DOI 10.1016/0024-3205(88)90267-6; Ennis SR, 1998, J NEUROCHEM, V71, P2565; FERNSTROM JD, 1971, SCIENCE, V173, P149, DOI 10.1126/science.173.3992.149; FUNOVICS JM, 1978, J NEURAL TRANSM, P61; GRIPPON P, 1986, HEPATOLOGY, V6, P682, DOI 10.1002/hep.1840060424; HILGIER W, 1994, J NEUROCHEM, V62, P197; Kanamori K, 2005, J NEUROCHEM, V94, P74, DOI 10.1111/j.1471-4159.2005.03170.x; Kanamori K, 2004, J NEUROCHEM, V90, P203, DOI 10.1111/j.1471-4159.2004.02478.x; KEEP RF, 1995, J NEUROCHEM, V65, P2571; Kohling R, 2002, SCIENCE, V298, P1350; Lacey Janet M., 1996, Journal of Parenteral and Enteral Nutrition, V20, P74, DOI 10.1177/014860719602000174; LARSSON OM, 1985, INT J DEV NEUROSCI, V3, P177, DOI 10.1016/0736-5748(85)90008-5; LAVOIE J, 1987, J NEUROCHEM, V49, P692, DOI 10.1111/j.1471-4159.1987.tb00949.x; LIEBSCHUTZ J, 1977, BIOCHEM PHARMACOL, V26, P443, DOI 10.1016/0006-2952(77)90206-4; MARTIN DL, 1993, J NEUROCHEM, V60, P395, DOI 10.1111/j.1471-4159.1993.tb03165.x; MELAMED E, 1980, P NATL ACAD SCI-BIOL, V77, P4305, DOI 10.1073/pnas.77.7.4305; Pardridge WM, 1979, GLUTAMIC ACID ADV BI, P125; Patel AB, 2001, BRAIN RES, V919, P207, DOI 10.1016/S0006-8993(01)03015-3; PATEL AJ, 1974, J NEUROCHEM, V23, P1271; Paxinos G., 2004, RAT BRAIN STEREOTAXI; Rae C, 2003, J NEUROCHEM, V85, P503, DOI 10.1046/j.1471-4159.2003.01713.x; SCHAECHTER JD, 1990, BRAIN RES, V532, P203, DOI 10.1016/0006-8993(90)91761-5; Smismans A, 1997, DIABETOLOGIA, V40, P1411, DOI 10.1007/s001250050843; SMITH QR, 1987, J NEUROCHEM, V49, P1651, DOI 10.1111/j.1471-4159.1987.tb01039.x; SMITH S, 1994, J CHROMATOGR B, V652, P228, DOI 10.1016/0378-4347(93)E0391-3; STORMMATHISEN J, 1983, NATURE, V301, P517, DOI 10.1038/301517a0; VANLEEUWEN PAM, 1991, SURGERY, V110, P169; Vogels BAPM, 1997, J HEPATOL, V26, P387, DOI 10.1016/S0168-8278(97)80057-8; Waagepetersen HS, 1999, J NEUROCHEM, V73, P1335, DOI 10.1046/j.1471-4159.1999.0731335.x; WEISER M, 1978, J NEURAL TRANSM, P95; WHITE HL, 1981, MOL CELL BIOCHEM, V39, P253, DOI 10.1007/BF00232578; WURTMAN RJ, 1980, PHARMACOL REV, V32, P315; WYSMYK U, 1992, NEUROCHEM RES, V17, P1187, DOI 10.1007/BF00968397; ZENEROLI ML, 1982, J NEUROCHEM, V38, P1219, DOI 10.1111/j.1471-4159.1982.tb07893.x	44	41	45	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1227	1232		10.1096/fj.06-7495com	http://dx.doi.org/10.1096/fj.06-7495com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17218538				2022-12-28	WOS:000245650400026
J	Liu, CH; You, ZR; Ren, JQ; Kim, YR; Eikermann-Haerter, K; Liu, PK				Liu, Christina H.; You, Zerong; Ren, JiaQian; Kim, Young R.; Eikermann-Haerter, Katharina; Liu, Philip K.			Noninvasive delivery of gene targeting probes to live brains for transcription MRI	FASEB JOURNAL			English	Article						angiogenesis; antisense technology; blood-brain barrier; bulbar conjunctiva; gene expression; molecular imaging	FOREBRAIN ISCHEMIA-REPERFUSION; CORTICAL SPREADING DEPRESSION; FIBRILLARY ACIDIC PROTEIN; CEREBRAL-ISCHEMIA; CARDIAC-ARREST; NEURONAL SENSITIVITY; MOUSE-BRAIN; EXPRESSION; DAMAGE; INJURY	We aimed to test the feasibility of detecting gliosis in living brains when the blood-brain barrier (BBB) is disrupted. We designed a novel magnetic resonance (MR) probe that contains superparamagnetic iron oxide nanoparticles (SPION, a T2 susceptibility contrast agent) linked to a short DNA sequence complementary to the cerebral mRNA of glial fibrillary acidic protein (GFAP) found in glia and astrocytes. As a control, we also used a sequence complementary to the mRNA of P-actin. Our objectives are to demonstrate that this new probe, SPION-gfap, could be delivered to the brain when administered by eyedrop solution to the conjunctival sac. We induced BBB leakage by puncture wound, global cerebral ischemia, and cortical spreading depression in C57BL6 mice; I day after probe delivery we acquired T2* MR images and R2* (R2* = 1/T2*) maps using a transcription MRI technique in live mice. We found that the SPION-gfap probe reported foci with elevated signal in subtraction R2* maps and that these foci matched areas identified as having extensive glial network (gliosis) in postmortem immunohistochemistry. Similarly, animals administered the control probe exhibited foci of R2* elevation that matched P-actin-expressing endothelia in the vascular wall. We conclude that our modular MR probe, delivered in an eyedrop solution, effectively reports gliosis associated with acute neurological disorders in living animals. As BBB leakage is often observed in acute neurological disorders, this study also served to validate noninvasive delivery of MR probes to the brains of live animals after acute neurological disorders.	[Liu, Christina H.; Ren, JiaQian; Kim, Young R.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Liu, Christina H.; Liu, Philip K.] Massachusetts Gen Hosp, Div Neuroradiol, Gene Transcript Targeting & Repair Lab, Charlestown, MA USA; [Liu, Christina H.; Ren, JiaQian; Kim, Young R.; Eikermann-Haerter, Katharina; Liu, Philip K.] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA USA; [You, Zerong] Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA USA; [You, Zerong] Harvard Univ, Sch Med, Charlestown, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University	Liu, PK (corresponding author), 149 13th St,Rm 2410, Charlestown, MA 02129 USA.	philip1@nmr.mgh.harvard.edu		Liu, Christina/0000-0002-5723-177X	NATIONAL CANCER INSTITUTE [T32CA009502] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR014075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS057556, R01NS045845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA024235, R01DA026108] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009502, 5T32CA009502] Funding Source: Medline; NCRR NIH HHS [P41RR14075, P41 RR014075] Funding Source: Medline; NIDA NIH HHS [R01 DA026108-01, R21 DA024235-01, R01 DA026108, R21 DA024235, DA024235] Funding Source: Medline; NINDS NIH HHS [NS045845, R01 NS045845-04, R01 NS045845, R21 NS057556, R21 NS057556-02, NS057556, R21 NS057556-01A1S1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADKINS ES, 1990, AM J SURG, V159, P237; Ayata C, 2000, NEUROSCIENCE, V95, P639; Bell-McGinty S, 2005, ARCH NEUROL-CHICAGO, V62, P1393, DOI 10.1001/archneur.62.9.1393; CHIAMULERA C, 1993, BRAIN RES, V606, P251, DOI 10.1016/0006-8993(93)90992-V; COLE G, 1987, CLIN NEUROPATHOL, V6, P104; Costa AMA, 1999, AM J PATHOL, V155, P1671, DOI 10.1016/S0002-9440(10)65482-X; Cramer SC, 2000, STROKE, V31, P668, DOI 10.1161/01.STR.31.3.668; Cui JK, 1999, J NEUROCHEM, V73, P1164, DOI 10.1046/j.1471-4159.1999.0731164.x; Cui JK, 2001, J BIOMED SCI, V8, P336, DOI 10.1007/BF02258375; Dickinson AJ, 2006, EYE, V20, P1145, DOI 10.1038/sj.eye.6702378; Dore-Duffy P, 2006, J CEREBR BLOOD F MET, V26, P613, DOI 10.1038/sj.jcbfm.9600272; Doughty Michael J, 2003, Optometry, V74, P485; FAHRIG T, 1994, J NEUROCHEM, V63, P1796; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; Huang DY, 2000, FASEB J, V14, P407, DOI 10.1096/fasebj.14.2.407; Johnston Miles, 2004, Cerebrospinal Fluid Res, V1, P2, DOI 10.1186/1743-8454-1-2; Kaur J, 2004, J CEREBR BLOOD F MET, V24, P945, DOI 10.1097/01.WCB.0000137868.50767.E8; Killer HE, 1999, J NEURO-OPHTHALMOL, V19, P222; Korn J, 2002, J COMP NEUROL, V442, P78, DOI 10.1002/cne.1423; Lee SR, 2006, J NEUROSCI, V26, P3491, DOI 10.1523/JNEUROSCI.4085-05.2006; LEWIS SA, 1984, P NATL ACAD SCI-BIOL, V81, P2743, DOI 10.1073/pnas.81.9.2743; Lin LH, 2000, J NEUROCHEM, V74, P1098; Lind K, 2002, J DRUG TARGET, V10, P221, DOI 10.1080/10611860290022651; Liu CH, 2007, FASEB J, V21, P3004, DOI 10.1096/fj.07-8203com; Liu CH, 2007, MOL IMAGING, V6, P156, DOI 10.2310/7290.2007.00011; Liu CH, 2007, J NEUROSCI, V27, P713, DOI 10.1523/JNEUROSCI.4660-06.2007; Liu PK, 1996, J NEUROSCI, V16, P6795; Liu PK, 2003, J BIOMED SCI, V10, P4, DOI 10.1159/000068080; MOSELEY ME, 1993, STROKE, V24, pI60; MOSSAKOWSKI MJ, 1994, ACTA NEUROCHIR, P274; Muldoon LL, 2005, NEUROSURGERY, V57, P785, DOI 10.1227/01.NEU.0000175731.25414.4c; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pluta R, 2002, ANN NY ACAD SCI, V977, P102, DOI 10.1111/j.1749-6632.2002.tb04803.x; Raymond J, 2004, J VASC SURG, V40, P1190, DOI 10.1016/j.jvs.2004.09.023; Stoub TR, 2005, NEUROLOGY, V64, P1520, DOI 10.1212/01.WNL.0000160089.43264.1A; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497	37	22	22	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1193	1203		10.1096/fj.07-9557com	http://dx.doi.org/10.1096/fj.07-9557com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	18029447	Green Accepted			2022-12-28	WOS:000254581000024
J	Noda, K; Miyahara, S; Nakazawa, T; Almulki, L; Nakao, S; Hisatomi, T; She, H; Thomas, KL; Garland, RC; Miller, JW; Gragoudas, ES; Kawai, Y; Mashima, Y; Hafezi-Moghadam, A				Noda, Kousuke; Miyahara, Shinsuke; Nakazawa, Torn; Almulki, Lama; Nakao, Shintaro; Hisatomi, Toshio; She, Haicheng; Thomas, Kennard L.; Garland, Rebecca C.; Miller, Joan W.; Gragoudas, Evangelos S.; Kawai, Yosuke; Mashima, Yukihiko; Hafezi-Moghadam, Ali			Inhibition of vascular adhesion protein-1 suppresses endotoxin-induced uveifs	FASEB JOURNAL			English	Article						semicarbazide-sensitize amine oxidase; ocular inflammation; leukocyte recruitment	SENSITIVE AMINE OXIDASE; NECROSIS-FACTOR-ALPHA; IN-VIVO EVALUATION; INDUCED UVEITIS; P-SELECTIN; RETINAL MICROCIRCULATION; ENDOTHELIAL INTERACTIONS; OCULAR INFLAMMATION; MONOAMINE-OXIDASE; LEUKOCYTE BINDING	Inflammatory leukocyte accumulation is a common feature of major ocular diseases, such as uveitis, diabetic retinopathy, and age-related macular degeneration. Vascular adhesion protein-1 (VAP-1), a cell surface and soluble molecule that possesses semicarbazide-sensitive amine oxidase (SSAO) activity, is involved in leukocyte recruitment. However, the expression of VAP-1 in the eye and its contribution to ocular inflammation are unknown. Here, we investigated the role of VAP-1 in an established model of ocular inflammation, the endotoxin-induced uveitis (EIU), using a novel and specific inhibitor. Our inhibitor has a half-maximal inhibitory concentration (IC50) of 0.007 mu M against human and 0.008 mu M against rat SSAO, while its IC50 against the functionally related monoamine oxidase (MAO) -A and MAO-B is > 10 mu M. In the retina, VAP-1 was exclusively expressed in the vasculature, and its expression level was elevated during EIU. VAP-1 inhibition in EIU animals significantly suppressed leukocyte recruitment to the anterior chamber, vitreous, and retina, as well as retinal endothelial P-selectin expression. Our data suggest an important role for VAP-1 in the recruitment of leukocytes to the immune-privileged ocular tissues during acute inflammation. VAP-1 inhibition may become a novel strategy in the treatment of ocular inflammatory diseases.	[Noda, Kousuke; Miyahara, Shinsuke; Nakazawa, Torn; Almulki, Lama; Nakao, Shintaro; Hisatomi, Toshio; She, Haicheng; Thomas, Kennard L.; Garland, Rebecca C.; Miller, Joan W.; Gragoudas, Evangelos S.; Hafezi-Moghadam, Ali] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA; [Kawai, Yosuke; Mashima, Yukihiko] Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School	Hafezi-Moghadam, A (corresponding author), Angiogenesis Lab, 325 Cambridge St,3rd Floor, Boston, MA 02114 USA.	ahm@meei.harvard.edu		Miller, Joan/0000-0003-2046-3996; Hisatomi, Toshio/0000-0003-2552-9595; Hafezi-Moghadam, Ali/0000-0002-5336-0697	NATIONAL EYE INSTITUTE [P30EY014104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050775] Funding Source: NIH RePORTER; NEI NIH HHS [EY14104] Funding Source: Medline; NIAID NIH HHS [AI-050775] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akin E, 2001, INFECT IMMUN, V69, P1774, DOI 10.1128/IAI.69.3.1774-1780.2001; Avunduk AM, 2002, CURR EYE RES, V24, P92, DOI 10.1076/ceyr.24.2.92.8157; Becker MD, 2001, INVEST OPHTH VIS SCI, V42, P2563; Bosch-Morell F, 2002, FREE RADICAL BIO MED, V33, P669, DOI 10.1016/S0891-5849(02)00954-1; Bucolo C, 2003, INVEST OPHTH VIS SCI, V44, P1178, DOI 10.1167/iovs.02-0559; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; DEARRIBA AF, 1990, J NEUR TR S, P327; Hafezi-Moghadam A, 2007, FASEB J, V21, P464, DOI 10.1096/fj.06-6390com; Holt A, 1997, ANAL BIOCHEM, V244, P384, DOI 10.1006/abio.1996.9911; Ishimoto S, 1996, INVEST OPHTH VIS SCI, V37, P630; Jaakkola K, 2000, J AM COLL CARDIOL, V36, P122, DOI 10.1016/S0735-1097(00)00706-3; Jalkanen S, 2007, BLOOD, V110, P1864, DOI 10.1182/blood-2007-01-069674; Koskinen K, 2004, BLOOD, V103, P3388, DOI 10.1182/blood-2003-09-3275; Lakshminarayanan V, 1997, J BIOL CHEM, V272, P32910, DOI 10.1074/jbc.272.52.32910; Lalor PF, 2007, HEPATOLOGY, V45, P465, DOI 10.1002/hep.21497; LO SK, 1993, AM J PHYSIOL, V264, pL406; Martelius T, 2000, AM J PATHOL, V157, P1229, DOI 10.1016/S0002-9440(10)64638-X; Marttila-Ichihara F, 2006, ARTHRITIS RHEUM-US, V54, P2852, DOI 10.1002/art.22061; MCMENAMIN PG, 1995, INVEST OPHTH VIS SCI, V36, P1949; Miyahara S, 2004, INVEST OPHTH VIS SCI, V45, P4197, DOI 10.1167/iovs.04-0192; Miyamoto K, 1998, MICROVASC RES, V55, P230, DOI 10.1006/mvre.1998.2084; Nagai N, 2005, INVEST OPHTH VIS SCI, V46, P2925, DOI 10.1167/iovs.04-1476; Nakazawa T, 2007, J NEUROCHEM, V100, P1018, DOI 10.1111/j.1471-4159.2006.04274.x; Nishijima K, 2001, INVEST OPHTH VIS SCI, V42, P2102; O'Sullivan J, 2004, NEUROTOXICOLOGY, V25, P303, DOI 10.1016/S0161-813X(03)00117-7; Rao N A, 1990, Trans Am Ophthalmol Soc, V88, P797; Reed KL, 2005, DIGEST DIS SCI, V50, P2366, DOI 10.1007/s10620-005-3066-y; ROSENBAUM JT, 1980, NATURE, V286, P611, DOI 10.1038/286611a0; Salmi M, 2005, NAT REV IMMUNOL, V5, P760, DOI 10.1038/nri1705; SALMI M, 1992, SCIENCE, V257, P1407, DOI 10.1126/science.1529341; SALMI M, 1993, J EXP MED, V178, P2255, DOI 10.1084/jem.178.6.2255; Singh B, 2003, VIRCHOWS ARCH, V442, P491, DOI 10.1007/s00428-003-0802-6; Smith DJ, 1998, J EXP MED, V188, P17, DOI 10.1084/jem.188.1.17; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Tamura H, 2005, BRIT J OPHTHALMOL, V89, P1052, DOI 10.1136/bjo.2004.061929; WELLER A, 1992, J BIOL CHEM, V267, P15176; Whitcup SM, 1997, CLIN IMMUNOL IMMUNOP, V83, P45, DOI 10.1006/clin.1996.4324; Wilhelm J, 2003, CHEMBIOCHEM, V4, P1120, DOI 10.1002/cbic.200300662; Wung BS, 2005, J BIOMED SCI, V12, P91, DOI 10.1007/s11373-004-8170-z; Yamashiro K, 2001, INVEST OPHTH VIS SCI, V42, P1553; Yu PH, 2003, BBA-PROTEINS PROTEOM, V1647, P193, DOI 10.1016/S1570-9639(03)00101-8; Zhao S, 2000, THROMB RES, V100, P501, DOI 10.1016/S0049-3848(00)00363-7; ZUO DM, 1994, BRAIN RES BULL, V33, P307, DOI 10.1016/0361-9230(94)90198-8	43	46	60	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1094	1103		10.1096/fj.07-9377com	http://dx.doi.org/10.1096/fj.07-9377com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	18032635				2022-12-28	WOS:000254581000015
J	Cordeaux, Y; Briddon, SJ; Alexander, SPH; Kellam, B; Hill, SJ				Cordeaux, Y.; Briddon, S. J.; Alexander, S. P. H.; Kellam, B.; Hill, S. J.			Agonist-occupied A(3) adenosine receptors exist within heterogeneous complexes in membrane microdomains of individual living cells	FASEB JOURNAL			English	Article						fluorescence correlation spectroscopy; GPCRs; confocal imaging	FLUORESCENCE CORRELATION SPECTROSCOPY; G-PROTEIN; MOLECULAR-CLONING; PHOSPHOLIPASE-C; A(1) RECEPTOR; INTRACELLULAR CALCIUM; LIPID RAFTS; CHO-CELLS; ACTIVATION; PHARMACOLOGY	G protein-coupled receptors are known to be organized within different membrane compartments or microdomains of individual cells. Here, we have used a fluorescent A(3) adenosine receptor (A(3)-AR) agonist, ABEA-X-BY630, and the technique of fluorescence correlation spectroscopy (FCS) to investigate the diffusional characteristics of functional agonist-occupied A(3)-AR complexes in single living cells. In Chinese hamster ovary cells expressing the human A(3)-AR, the fluorescent A(3)-AR agonist was able to inhibit forskolin-stimulated [H-3]cAMP production (pEC(50)=8.57), and this was antagonized by the A(3)-selective antagonist MRS1220 (pK(B)=9.32). The fluorescent ligand also stimulated phosphoinositide hydrolysis (pEC(50)=7.34). Ligand binding to the A(3)-AR on the membranes of single cells and subsequent increases in single cell [Ca2+](i) were monitored simultaneously in real time using confocal microscopy. FCS measurements in small-membrane microdomains (similar to 0.2 mu m(2)) revealed two agonist-occupied A(3)-AR components with differing diffusion characteristics (diffusion coefficients=2.65 x 10(-8) and 1.19x10(-9) cm(2)/s, respectively). The binding of ligand to these two components was reduced from 5.1 and 14.9 to 2.6 and 3.3 receptors/mu m(2), respectively, by MRS1220 (100 nM). These data provide direct evidence for at least two populations of agonist-occupied A(3)-receptor complexes, showing different motilities within the membrane of single living cells.	[Cordeaux, Y.; Briddon, S. J.; Alexander, S. P. H.; Hill, S. J.] Queens Med Ctr, Sch Med, Inst Cell Signalling, Sch Biomed Sci, Nottingham NG7 2UH, England; [Kellam, B.] Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Nottingham, England	University of Nottingham; University of Nottingham	Hill, SJ (corresponding author), Queens Med Ctr, Sch Med, Inst Cell Signalling, Sch Biomed Sci, C Floor, Nottingham NG7 2UH, England.	stephen.hill@nottingham.ac.uk	Kellam, Barrie/AAE-2960-2019; Hill, Stephen J/M-6243-2018; Hill, Stephen/N-6753-2013; Alexander, Steve P/B-8105-2009	Hill, Stephen J/0000-0002-4424-239X; Hill, Stephen/0000-0002-4424-239X; Alexander, Steve P/0000-0003-4417-497X; Kellam, Barrie/0000-0003-0030-9908; Briddon, Stephen/0000-0001-8514-0827	Wellcome Trust [57199, 66817] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abbracchio MP, 1995, MOL PHARMACOL, V48, P1038; ALVAREZ R, 1990, ANAL BIOCHEM, V187, P98, DOI 10.1016/0003-2697(90)90423-7; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Baker JG, 2003, MOL PHARMACOL, V64, P1357, DOI 10.1124/mol.64.6.1357; Briddon SJ, 2004, P NATL ACAD SCI USA, V101, P4673, DOI 10.1073/pnas.0400420101; Charest PG, 2007, CELL SIGNAL, V19, P32, DOI 10.1016/j.cellsig.2006.05.020; Cordeaux Y, 2004, BRIT J PHARMACOL, V143, P705, DOI 10.1038/sj.bjp.0705925; Cordeaux Y, 2000, MOL PHARMACOL, V58, P1075, DOI 10.1124/mol.58.5.1075; Daly CJ, 2003, PHARMACOL THERAPEUT, V100, P101, DOI 10.1016/j.pharmthera.2003.08.001; Dickenson JM, 1998, EUR J PHARMACOL, V355, P85, DOI 10.1016/S0014-2999(98)00468-3; DICKENSON JM, 1995, EUR J PHARM-MOLEC PH, V288, P393, DOI 10.1016/0922-4106(95)90055-1; Fishman P, 2003, CURR TOP MED CHEM, V3, P463, DOI 10.2174/1568026033392147; Fraser IDC, 2000, CURR BIOL, V10, P409, DOI 10.1016/S0960-9822(00)00419-X; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Galandrin S, 2006, MOL PHARMACOL, V70, P1575, DOI 10.1124/mol.106.026716; Gee KR, 2000, CELL CALCIUM, V27, P97, DOI 10.1054/ceca.1999.0095; Gessi S, 2004, CLIN CANCER RES, V10, P5895, DOI 10.1158/1078-0432.CCR-1134-03; Gessi S, 2004, MOL PHARMACOL, V65, P711, DOI 10.1124/mol.65.3.711; Gines S, 2001, MOL PHARMACOL, V59, P1314, DOI 10.1124/mol.59.5.1314; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Insel PA, 2005, ANN NY ACAD SCI, V1047, P166, DOI 10.1196/annals.1341.015; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; Klotz KN, 1998, N-S ARCH PHARMACOL, V357, P1; Lenne PF, 2006, EMBO J, V25, P3245, DOI 10.1038/sj.emboj.7601214; Livingston M, 2004, INFLAMM RES, V53, P171, DOI 10.1007/s00011-004-1248-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maddock HL, 2003, EUR J PHARMACOL, V477, P235, DOI 10.1016/j.ejphar.2003.08.024; Madi L, 2004, CLIN CANCER RES, V10, P4472, DOI 10.1158/1078-0432.CCR-03-0651; MARSH KA, 1994, BRIT J PHARMACOL, V112, P934, DOI 10.1111/j.1476-5381.1994.tb13170.x; Meseth U, 1999, BIOPHYS J, V76, P1619, DOI 10.1016/S0006-3495(99)77321-2; MEYERHOF W, 1991, FEBS LETT, V284, P155, DOI 10.1016/0014-5793(91)80674-R; Middleton RJ, 2007, J MED CHEM, V50, P782, DOI 10.1021/jm061279i; Middleton RJ, 2005, CURR OPIN CHEM BIOL, V9, P517, DOI 10.1016/j.cbpa.2005.08.016; Miquel M Raquel, 2005, Mol Imaging, V4, P40; Ostrom RS, 2004, BRIT J PHARMACOL, V143, P235, DOI 10.1038/sj.bjp.0705930; PALMER TM, 1995, J BIOL CHEM, V270, P16895, DOI 10.1074/jbc.270.28.16895; PEAKMAN MC, 1995, BRIT J PHARMACOL, V115, P801, DOI 10.1111/j.1476-5381.1995.tb15004.x; Pramanik A, 2004, CURR PHARM BIOTECHNO, V5, P205, DOI 10.2174/1389201043377002; Pramanik A, 2001, BIOCHEMISTRY-US, V40, P10839, DOI 10.1021/bi010514q; Ralevic V, 1998, PHARMACOL REV, V50, P413; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; Rigler R, 1999, P NATL ACAD SCI USA, V96, P13318, DOI 10.1073/pnas.96.23.13318; SALVATORE CA, 1993, P NATL ACAD SCI USA, V90, P10365, DOI 10.1073/pnas.90.21.10365; Schwille P, 2001, CELL BIOCHEM BIOPHYS, V34, P383, DOI 10.1385/CBB:34:3:383; Selbie LA, 1998, TRENDS PHARMACOL SCI, V19, P87, DOI 10.1016/S0165-6147(97)01166-8; Shneyvays V, 2001, J MOL CELL CARDIOL, V33, P1249, DOI 10.1006/jmcc.2001.1387; Zhong ZH, 2001, DIABETOLOGIA, V44, P1184, DOI 10.1007/s001250100608; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	48	60	65	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					850	860		10.1096/fj.07-8180com	http://dx.doi.org/10.1096/fj.07-8180com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17959910				2022-12-28	WOS:000254143700023
J	Head, BP; Patel, HH; Tsutsumi, YM; Hu, Y; Mejia, T; Mora, RC; Insel, PA; Roth, DM; Drummond, JC; Patel, PM				Head, Brian P.; Patel, Hemal H.; Tsutsumi, Yasuo M.; Hu, Yue; Mejia, Trisha; Mora, Rosalia C.; Insel, Paul A.; Roth, David M.; Drummond, John C.; Patel, Piyush M.			Caveolin-1 expression is essential for N-methyl-D-aspartate receptor-mediated Src and extracellular signal-regulated kinase 1/2 activation and protection of primary neurons from ischemic cell death	FASEB JOURNAL			English	Article						preconditioning; neuroprotection; neuronal apoptosis; membrane rafts; ionotropic glutamate receptors; colocalization	LONG-TERM POTENTIATION; PROTEIN-COUPLED RECEPTOR; TYROSINE PHOSPHORYLATION; NMDA RECEPTORS; HIPPOCAMPAL-NEURONS; LIPID RAFTS; SCAFFOLDING DOMAIN; PC12 CELLS; IN-VITRO; RAT	N-Methyl-D-aspartate (NMDA) receptor (NMDAR) activation and downstream signaling are important for neuronal function. Activation of prosurvival Src family kinases and extracellular signal-regulated kinase (ERK) 1/2 is initiated by NMDAR activation, but the cellular organization of these kinases in relation to NMDARs is not entirely clear. We hypothesized that caveolin-1 scaffolds and coordinates protein complexes involved in NMDAR signaling and that this organization is necessary for neuronal preconditioning, whereby NMDAR activation protects neurons from subsequent ischemic cell death. We found that sublethal ischemia (SLI) or preconditioning via NMDA treatment of primary cortical neurons from neonatal rats or mice increases expression of phosphorylated (P) caveofin-1, P-Src, and P-ERK1/2. The NMDAR antagonist, MK801, or the Src inhibitor, PP2, attenuated SLI-induced preconditioning. NMDAR2B distributed to buoyant fractions and heavy fractions, partially colocalized with caveolin-1 and the membrane raft marker, cholera toxin B. Cultures of primary neurons treated with caveolin-1 small interfering RNA or from caveolin-1(-/-) mice lacked the NMDA-mediated increase in P-Src and P-ERK, as well as SLI- and NMDA-induced preconditioning. Adenovirally mediated expression of caveolin-1 in neurons from caveolin-1(-/-) mice restored NMDA-mediated enhancement of P-Src and P-ERK1/2, redistributed NMDAR2B to buoyant fractions, and enhanced NMDAR2B localization to membrane rafts. We conclude that caveolin-1, perhaps via its ability to scaffold key signaling components, is essential for NMDAR localization to neuronal membrane rafts, NMDAR/Src tyrosine kinase family/ERK signaling, and protection of neurons from ischemic injury and cell death.	[Tsutsumi, Yasuo M.; Insel, Paul A.; Roth, David M.; Drummond, John C.; Patel, Piyush M.] Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA; [Head, Brian P.; Patel, Hemal H.; Tsutsumi, Yasuo M.; Hu, Yue; Mejia, Trisha; Roth, David M.; Drummond, John C.; Patel, Piyush M.] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; [Insel, Paul A.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Mora, Rosalia C.] Cornell Univ, Weill Med Coll, Dept Ophthalmol, Margaret Dyson Vis Res Inst, Ithaca, NY USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego; University of California System; University of California San Diego; Cornell University	Patel, PM (corresponding author), Vet Affairs San Diego Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	ppatel@ucsd.edu	Tsutsumi, Yasuo M/G-1972-2012; Patel, Hemal/C-7325-2019	Patel, Hemal/0000-0001-6722-9625	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066232, R01GM034107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047570] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 66232, GM 34107] Funding Source: Medline; NINDS NIH HHS [NS 047570] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen JA, 2007, NAT REV NEUROSCI, V8, P128, DOI 10.1038/nrn2059; Augustine GJ, 2003, NEURON, V40, P331, DOI 10.1016/S0896-6273(03)00639-1; BEHNISCH T, 1995, NEUROSCI LETT, V192, P185, DOI 10.1016/0304-3940(95)11641-9; Besshoh S, 2005, J NEUROCHEM, V93, P186, DOI 10.1111/j.1471-4159.2004.03009.x; Bu J, 2003, J NEUROSCI RES, V72, P185, DOI 10.1002/jnr.10556; Cao HM, 2004, EXP CELL RES, V294, P159, DOI 10.1016/j.yexcr.2003.11.010; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHRISTIE BR, 1995, J NEUROPHYSIOL, V73, P2553, DOI 10.1152/jn.1995.73.6.2553; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V284, pC457, DOI 10.1152/ajpcell.00380.2002; COLLINGRIDGE GL, 1995, TRENDS NEUROSCI, V18, P54, DOI 10.1016/0166-2236(95)93868-X; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Craig AM, 2006, TRENDS NEUROSCI, V29, P8, DOI 10.1016/j.tins.2005.11.002; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; Dingledine R, 1999, PHARMACOL REV, V51, P7; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Gaudreault SB, 2005, J NEUROCHEM, V92, P831, DOI 10.1111/j.1471-4159.2004.02917.x; Gaudreault SB, 2004, J BIOL CHEM, V279, P356, DOI 10.1074/jbc.M304777200; Gidday JM, 1999, J CEREBR BLOOD F MET, V19, P331, DOI 10.1097/00004647-199903000-00011; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; Grabb MC, 1999, J NEUROSCI, V19, P1657; Head BP, 2005, J BIOL CHEM, V280, P31036, DOI 10.1074/jbc.M502540200; Head BP, 2007, TRENDS CELL BIOL, V17, P51, DOI 10.1016/j.tcb.2006.11.008; Head BP, 2006, J BIOL CHEM, V281, P26391, DOI 10.1074/jbc.M602577200; Hell JW, 1996, P NATL ACAD SCI USA, V93, P3362, DOI 10.1073/pnas.93.8.3362; HEURTEAUX C, 1995, P NATL ACAD SCI USA, V92, P4666, DOI 10.1073/pnas.92.10.4666; Hibbert AP, 2006, MOL CELL NEUROSCI, V32, P387, DOI 10.1016/j.mcn.2006.06.001; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; Jasmin JF, 2007, CIRC RES, V100, P721, DOI 10.1161/01.RES.0000260180.42709.29; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kamiguchi H, 2006, J NEUROCHEM, V98, P330, DOI 10.1111/j.1471-4159.2006.03888.x; Kang MJ, 2006, EXP MOL MED, V38, P126, DOI 10.1038/emm.2006.16; Li JH, 1998, EUR J NEUROSCI, V10, P1704, DOI 10.1046/j.1460-9568.1998.00169.x; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; Ostrom RS, 2002, MOL PHARMACOL, V62, P983, DOI 10.1124/mol.62.5.983; Papadia S, 2005, J NEUROSCI, V25, P4279, DOI 10.1523/JNEUROSCI.5019-04.2005; Patel HH, 2007, FASEB J, V21, P1565, DOI 10.1096/fj.06-7719com; Peiro S, 2000, J BIOL CHEM, V275, P37846, DOI 10.1074/jbc.M000487200; Pike LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200; Raymond CR, 2007, TRENDS NEUROSCI, V30, P167, DOI 10.1016/j.tins.2007.01.007; Raymond CR, 2006, J PHYSIOL-LONDON, V570, P97, DOI 10.1113/jphysiol.2005.098947; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; Rubino A, 2000, TRENDS PHARMACOL SCI, V21, P225, DOI 10.1016/S0165-6147(00)01483-8; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Sedding DG, 2005, CIRC RES, V96, P635, DOI 10.1161/01.RES.0000160610.61306.0f; Shack S, 2003, MOL CELL BIOL, V23, P2407, DOI 10.1128/MCB.23.7.2407-2414.2003; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Sutton MA, 2005, J NEUROBIOL, V64, P116, DOI 10.1002/neu.20152; Tovar KR, 1999, J NEUROSCI, V19, P4180; Trushina E, 2006, BEHAV BRAIN RES, V172, P24, DOI 10.1016/j.bbr.2006.04.024; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Washbourne P, 2002, NAT NEUROSCI, V5, P751, DOI 10.1038/nn883; Yang M, 2001, J NEUROCHEM, V77, P580, DOI 10.1046/j.1471-4159.2001.00255.x; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Yuen EY, 2005, J BIOL CHEM, V280, P29420, DOI 10.1074/jbc.M504499200; Zinchuk O, 2004, CELL TISSUE RES, V317, P265, DOI 10.1007/s00441-004-0919-1	63	94	96	3	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					828	840		10.1096/fj.07-9299com	http://dx.doi.org/10.1096/fj.07-9299com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17905724				2022-12-28	WOS:000254143700021
J	Martin, DDO; Vilas, GL; Prescher, JA; Rajaiah, G; Falck, JR; Bertozzi, CR; Berthiaume, LG				Martin, Dale D. O.; Vilas, Gonzalo L.; Prescher, Jennifer A.; Rajaiah, Gurram; Falck, John R.; Bertozzi, Carolyn R.; Berthiaume, Luc G.			Rapid detection, discovery, and identification of post-translationally myristoylated proteins during apoptosis using a bio-orthogonal azidomyristate analog	FASEB JOURNAL			English	Article						fatty acylation; myristoylation; Staudinger ligation; cell death; triaryphosphine	N-MYRISTOYLTRANSFERASE; SUBSTRATE-SPECIFICITY; ACID; ACTIVATION; LOCALIZATION; CLEAVAGE; CELLS; PALMITOYLATION; MITOCHONDRIA; TRANSDUCTION	Myristoylation is the attachment of the 14-carbon fatty acid myristate to the N-terminal glycine residue of proteins. Typically a co-translational modification, myristoylation of proapoptotic cysteinyl-aspartyl proteases (caspase)-cleaved Bid and PAK2 was also shown to occur post-translationally and is essential for their proper localization and proapoptotic function. Progress in the identification and characterization of myristoylated proteins has been impeded by the long exposure times required to monitor incorporation of radioactive myristate into proteins (typically 1-3 months). Consequently, we developed a nonradioactive detection methodology in which a bio-orthogonal azidomyristate analog is specifically incorporated co- or post-translationally into proteins at N-terminal glycines, chemoselectively ligated to tagged triarylphosphines and detected by Western blotting with short exposure times (seconds to minutes). This represents over a million-fold signal amplification in comparison to using radioactive labeling methods. Using rational prediction analysis to recognize putative internal myristoylation sites in caspase-cleaved proteins combined with our nonradioactive chemical detection method, we identify 5 new post-translationally myristoylatable proteins (PKC epsilon, CD-IC2, Bap31, MST3, and the catalytic subunit of glutamate cysteine ligase). We also demonstrate that 15 proteins undergo post-translational myristoylation in apoptotic Jurkat T cells. This suggests that post-translational myristoylation of caspase-cleaved proteins represents a novel mechanism widely used to regulate cell death.	[Martin, Dale D. O.; Vilas, Gonzalo L.; Berthiaume, Luc G.] Univ Alberta, Fac Med & Dent, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; [Prescher, Jennifer A.; Bertozzi, Carolyn R.] Univ Calif Berkeley, HHMI, Dept Chem, Berkeley, CA 94720 USA; [Rajaiah, Gurram; Falck, John R.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA	University of Alberta; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Texas System; University of Texas Southwestern Medical Center Dallas	Berthiaume, LG (corresponding author), Univ Alberta, Fac Med & Dent, Dept Cell Biol, Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	luc.berthiaume@ualberta.ca	Martin, Dale/L-6351-2015; Falck, John R/B-3030-2011	Falck, John R/0000-0002-9219-7845; Berthiaume, Luc/0000-0003-0926-059X	Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [GM31278, R01 GM031278] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armah DA, 1999, J BIOL CHEM, V274, P5931, DOI 10.1074/jbc.274.9.5931; Basu A, 2002, J BIOL CHEM, V277, P41850, DOI 10.1074/jbc.M205997200; BERTHIAUME L, 1994, J BIOL CHEM, V269, P6498; Bologna G, 2004, PROTEOMICS, V4, P1626, DOI 10.1002/pmic.200300783; Botta D, 2004, FREE RADICAL BIO MED, V37, P632, DOI 10.1016/j.freeradbiomed.2004.05.027; DEICHAITE I, 1993, J BIOL CHEM, V268, P13738; DEVADAS B, 1992, J BIOL CHEM, V267, P7224; Ducker CE, 2005, MOL CANCER RES, V3, P463, DOI 10.1158/1541-7786.MCR-05-0037; Eisenhaber F, 2003, NUCLEIC ACIDS RES, V31, P3631, DOI 10.1093/nar/gkg537; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Galbiati F, 1996, BIOCHEM J, V313, P717, DOI 10.1042/bj3130717; Giang DG, 1998, J BIOL CHEM, V273, P6595, DOI 10.1074/jbc.273.12.6595; Granville DJ, 1998, FEBS LETT, V437, P5, DOI 10.1016/S0014-5793(98)01193-4; Hang HC, 2007, J AM CHEM SOC, V129, P2744, DOI 10.1021/ja0685001; Huang CYF, 2002, J BIOL CHEM, V277, P34367, DOI 10.1074/jbc.M202468200; Kho Y, 2004, P NATL ACAD SCI USA, V101, P12479, DOI 10.1073/pnas.0403413101; Lane JD, 2001, J CELL BIOL, V153, P1415, DOI 10.1083/jcb.153.7.1415; Laughlin ST, 2006, METHOD ENZYMOL, V415, P230, DOI 10.1016/S0076-6879(06)15015-6; Luchansky SJ, 2003, METHOD ENZYMOL, V362, P249; Maurer-Stroh S, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r21; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; McCabe JB, 2001, MOL BIOL CELL, V12, P3601, DOI 10.1091/mbc.12.11.3601; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; Ng FWH, 1998, J BIOL CHEM, V273, P3140, DOI 10.1074/jbc.273.6.3140; PAIGE LA, 1990, BIOCHEMISTRY-US, V29, P10566, DOI 10.1021/bi00498a021; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Resh MD, 2004, SUB CELL BIOCHEM, V37, P217; RESH MD, 2006, SCI STKE, pRE14, DOI DOI 10.1126/STKE.3592006RE14; Saxon E, 2002, J AM CHEM SOC, V124, P14893, DOI 10.1021/ja027748x; Selvakumar P, 2006, FEBS LETT, V580, P2021, DOI 10.1016/j.febslet.2006.02.076; Sprung R, 2005, J PROTEOME RES, V4, P950, DOI 10.1021/pr050033j; Stegert MR, 2005, MOL CELL BIOL, V25, P11019, DOI 10.1128/MCB.25.24.11019-11029.2005; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; Utsumi T, 2003, FEBS LETT, V539, P37, DOI 10.1016/S0014-5793(03)00180-7; Utsumi T, 2001, J BIOL CHEM, V276, P10505, DOI 10.1074/jbc.M006134200; Vilas GL, 2006, P NATL ACAD SCI USA, V103, P6542, DOI 10.1073/pnas.0600824103; Wyllie AH, 1997, BRIT MED BULL, V53, P451; Wyllie AH, 1999, BRIT J CANCER, V80, P34; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhao Y, 2000, MOL BIOL CELL, V11, P721, DOI 10.1091/mbc.11.2.721	41	80	82	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2008	22	3					797	806		10.1096/fj.07-9198com	http://dx.doi.org/10.1096/fj.07-9198com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17932026	Green Accepted			2022-12-28	WOS:000254143700018
J	Wu, F; Yu, J; Gehring, H				Wu, Fang; Yu, Jing; Gehring, Heinz			Inhibitory and structural studies of novel coenzyme-substrate analogs of human histidine decarboxylase	FASEB JOURNAL			English	Article						mammalian histidine decarboxylase; pyridoxylsubstrate analogs; binding specificity of histidine decarboxylase; histamine	MAST-CELL LINE; ORNITHINE-DECARBOXYLASE; DOPA DECARBOXYLASE; ENZYME-INHIBITORS; ACTIVATION; DERIVATIVES; N-(4-PYRIDOXYL)AMINES; INDUCTION; RESIDUES; ISOFORMS	Histamine, a biogenic amine with important biological functions, is produced from histidine by histidine decarboxylase (HDC), a pyridoxal 5'-phosphate-dependent enzyme. HDC is thus a potential target to attenuate histamine production in certain pathological states. Targeting mammalian HDC with novel inhibitors and elucidating the structural basis of their specificity for HDC are challenging tasks, because the three-dimensional structure of mammalian HDC is still unknown. In the present study, we designed, synthesized, and tested potentially membrane-permeable pyridoxyl-substrate conjugates as inhibitors for human (h) HDC and modeled an active site of hHDC, which is compatible with the experimental data. The most potent inhibitory compound among nine tested structural variants was the pyridoxyl-histidine methyl ester conjugate (PHME), indicating that the binding site of hHDC does not tolerate groups other than the imidazole side chain of histidine. PHME inhibited 60% of the fraction of 12-O-tetradecanoylphorbol-13-acetate-induced newly synthesized HDC in human HMC-1 cells at 200 mu M and was also inhibitory in cell extracts. The proposed model of hHDC, containing phosphopyridoxyl-histidine in the active site, revealed the binding specificity of HDC toward its substrate and the structure-activity relationship of the designed and investigated compounds.-Wu, F., Yu, J ., Gehring, H. Inhibitory and structural studies of novel coenzyme-substrate analogs of hHDC.	[Wu, Fang; Gehring, Heinz] Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland; [Yu, Jing] Univ Basel, Inst Mol Pharm, Basel, Switzerland	University of Zurich; University of Basel	Gehring, H (corresponding author), Univ Zurich, Dept Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	gehring@bioc.uzh.ch	Wu, Fang/B-1945-2008	Wu, Fang/0000-0002-4194-2243; , jingyu/0000-0002-6646-9341				Bertoldi M, 2001, EUR J BIOCHEM, V268, P2975, DOI 10.1046/j.1432-1327.2001.02187.x; Burkhard P, 2001, NAT STRUCT BIOL, V8, P963, DOI 10.1038/nsb1101-963; Dartsch C, 1998, REGUL PEPTIDES, V77, P33, DOI 10.1016/S0167-0115(98)00045-7; DEGRAW JI, 1977, J MED CHEM, V20, P1671, DOI 10.1021/jm00222a027; Eliot AC, 2004, ANNU REV BIOCHEM, V73, P383, DOI 10.1146/annurev.biochem.73.011303.074021; Facchini A, 2003, NUTR CANCER, V47, P104, DOI 10.1207/s15327914nc4701_13; Fleming JV, 2000, MOL CELL BIOL, V20, P4932, DOI 10.1128/MCB.20.13.4932-4947.2000; Fleming JV, 2004, BIOCHEM J, V379, P253, DOI 10.1042/BJ20031525; Fleming JV, 2003, J BIOL CHEM, V278, P686, DOI 10.1074/jbc.M210718200; Furuta K, 2007, J BIOL CHEM, V282, P13438, DOI 10.1074/jbc.M609943200; HAMMAR L, 1979, AGENTS ACTIONS, V9, P314, DOI 10.1007/BF01970654; HELLER JS, 1975, BIOCHIM BIOPHYS ACTA, V403, P197, DOI 10.1016/0005-2744(75)90022-4; KAMETANI T, 1972, J MED CHEM, V15, P203, DOI 10.1021/jm00272a021; KELLEY JL, 1977, J MED CHEM, V20, P506, DOI 10.1021/jm00214a009; KHOMUTOV RM, 1971, BIOCHEM J, V124, P99, DOI 10.1042/bj1240099; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; KUMAGAI H, 1969, AGR BIOL CHEM TOKYO, V33, P1210, DOI 10.1080/00021369.1969.10859449; LEVINE RJ, 1966, BIOCHEM PHARMACOL, V15, P841, DOI 10.1016/0006-2952(66)90161-4; Maeda K, 1998, EXP HEMATOL, V26, P325; Mattsson M, 1982, Agents Actions, V12, P176, DOI 10.1007/BF01965137; Medina MA, 2003, CRIT REV BIOCHEM MOL, V38, P23, DOI 10.1080/713609209; Mehta PK, 2000, ADV ENZYMOL RAMB, V74, P129; Moya-Garcia AA, 2005, BIOESSAYS, V27, P57, DOI 10.1002/bies.20174; OGIER G, 1993, BIOCHEM PHARMACOL, V45, P1631, DOI 10.1016/0006-2952(93)90304-F; ROBSON LC, 1980, VITAMIN B6 METABOLIS, P205; Rodriguez-Caso C, 2003, CELL MOL LIFE SCI, V60, P1760, DOI 10.1007/s00018-003-3135-3; SAKAMOTO Y, 1985, AGENTS ACTIONS, V17, P32, DOI 10.1007/BF01966677; Seiler N, 2003, CURR DRUG TARGETS, V4, P537, DOI 10.2174/1389450033490885; SMISSMAN EE, 1972, J MED CHEM, V15, P681, DOI 10.1021/jm00276a031; Tanaka S, 1998, J BIOL CHEM, V273, P8177, DOI 10.1074/jbc.273.14.8177; TANAKA S, 1995, BBA-PROTEIN STRUCT M, V1253, P9, DOI 10.1016/0167-4838(95)00185-W; Tang L, 2005, J BIOL CHEM, V280, P31220, DOI 10.1074/jbc.M500805200; TAYLOR RJ, 1973, BIOCHEM PHARMACOL, V22, P2299, DOI 10.1016/0006-2952(73)90011-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Watanabe T, 2002, CHEM REC, V2, P369, DOI 10.1002/tcr.10036; WATANABE T, 1990, TRENDS PHARMACOL SCI, V11, P363; Wu F, 2007, MOL CANCER THER, V6, P1831, DOI 10.1158/1535-7163.MCT-07-0045; YAMAMOTO J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P431, DOI 10.1016/0167-4781(93)90011-2; ZHANG Z, 1991, P NATL ACAD SCI USA, V88, P10407, DOI 10.1073/pnas.88.23.10407; ZHANG ZM, 1992, ARCH BIOCHEM BIOPHYS, V294, P394, DOI 10.1016/0003-9861(92)90701-W; Zhao CM, 2003, REGUL PEPTIDES, V114, P21, DOI 10.1016/S0167-0115(03)00063-6	41	22	22	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2008	22	3					890	897		10.1096/fj.07-9566com	http://dx.doi.org/10.1096/fj.07-9566com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17965265				2022-12-28	WOS:000254143700027
J	Yokota, SI; Okabayashi, T; Yokosawa, N; Fujii, N				Yokota, Shin-ichi; Okabayashi, Tamaki; Yokosawa, Noriko; Fujii, Nobuhiro			Measles virus P protein suppresses Toll-like receptor signal through up-regulation of ubiquitin-modifying enzyme A20	FASEB JOURNAL			English	Article						viral infection; immunosuppression; TLR; monocyte; NF-kappa beta	NF-KAPPA-B; NEGATIVE REGULATION; NUCLEOCAPSID PROTEIN; DENDRITIC CELLS; MUMPS-VIRUS; V PROTEIN; A20; EXPRESSION; PHOSPHOPROTEIN; INFECTION	We recently reported that the activation of NF-kappa beta and AP-1 was suppressed in monocytes infected with measles virus, but not in infected epithelial cells. This cell-type-specific suppression of the inflammatory response represents a potential for measles virus to evade host immune system. In the current study, we examined the suppression mechanism of lipopolysaccharide (LPS)induced, namely Toll-like receptor 4 (TLR4)-mediated, activation of NF-kappa beta and AP-1 in measles virus-infected monocytic cells. In the infected cells, LPS treatment failed to induce the formation of active protein kinase complex containing TAK1, TAB2 and tumor necrosis factor receptor-associated factor 6 (TRAF6), dissociate from TLR complexes containing Interleukin-1 receptor-associated kinase 1 (IRAK1). Ubiquitin-modifying enzyme A20, which is a host negative feedback regulator of NF-kappa beta, was dramatically up-regulated in infected monocytic cells, but not in infected epithelial cells. Suppression of A20 expression by siRNA restored LPS-induced signaling in infected cells. Measles virus phosphoprotein ( P protein) expression was necessary and sufficient for the induction of A20. P protein interacted indirectly with a negative regulatory motif in the A20 gene promoter, and released the suppression of A20 transcription, independent of the activation of NF-kappa beta.-Yokota, S., Okabayashi, T., Yokosawa, N., Fujii, N. Measles virus P protein suppresses Toll-like receptor signal through up-regulation of ubiquitin-modifying enzyme A20.	[Yokota, Shin-ichi; Okabayashi, Tamaki; Yokosawa, Noriko; Fujii, Nobuhiro] Sapporo Med Univ, Sch Med, Dept Microbiol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University	Fujii, N (corresponding author), Sapporo Med Univ, Sch Med, Dept Microbiol, Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	fujii@sapmed.ac.jp	Yokota, Shin-ichi/K-8139-2019	Yokota, Shin-ichi/0000-0002-0831-3429				Ainbinder E, 2004, MOL CELL BIOL, V24, P2444, DOI 10.1128/MCB.24.6.2444-2454.2004; Akira S, 2006, CURR TOP MICROBIOL, V311, P1; BELLINI WJ, 1985, J VIROL, V53, P908, DOI 10.1128/JVI.53.3.908-919.1985; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; CATTANEO R, 1989, CELL, V56, P759, DOI 10.1016/0092-8674(89)90679-X; Chen A, 2003, VIRUS RES, V98, P123, DOI 10.1016/j.virusres.2003.09.003; Chen MZ, 2006, VIRAL IMMUNOL, V19, P349, DOI 10.1089/vim.2006.19.349; Chen MZ, 2005, J VIROL, V79, P11824, DOI 10.1128/JVI.79.18.11824-11836.2005; FUJII N, 1988, J GEN VIROL, V69, P2085, DOI 10.1099/0022-1317-69-8-2085; Fujii N, 1999, VIRUS RES, V65, P175, DOI 10.1016/S0168-1702(99)00114-8; Gon Y, 2004, AM J RESP CELL MOL, V31, P330, DOI 10.1165/rcmb.2003-0438OC; Griffin D., 2001, FIELDS VIROLOGY, P1401; Hahm B, 2004, VIROLOGY, V323, P292, DOI 10.1016/j.virol.2004.03.011; HARTY RN, 1995, J GEN VIROL, V76, P2863, DOI 10.1099/0022-1317-76-11-2863; Heyninck K, 2005, TRENDS BIOCHEM SCI, V30, P1, DOI 10.1016/j.tibs.2004.11.001; HORIKAMI SM, 1994, VIROLOGY, V205, P540, DOI 10.1006/viro.1994.1676; HUBER M, 1991, VIROLOGY, V185, P299, DOI 10.1016/0042-6822(91)90777-9; Indoh T, 2007, VIROLOGY, V361, P294, DOI 10.1016/j.virol.2006.11.002; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Lin RT, 2006, J BIOL CHEM, V281, P2095, DOI 10.1074/jbc.M510326200; Naniche D, 1999, J VIROL, V73, P1894, DOI 10.1128/JVI.73.3.1894-1901.1999; Nguyen H, 2006, VIROLOGY, V354, P58, DOI 10.1016/j.virol.2006.04.028; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Onose A, 2006, EUR J PHARMACOL, V541, P198, DOI 10.1016/j.ejphar.2006.03.073; Oxman Michael N., 2002, P791; Ravanel K, 1997, J EXP MED, V186, P269, DOI 10.1084/jem.186.2.269; Saitoh T, 2005, J IMMUNOL, V174, P1507, DOI 10.4049/jimmunol.174.3.1507; Schneider-Schaulies S, 2003, CURR TOP MICROBIOL, V276, P77; Servet-Delprat C, 2003, CURR TOP MICROBIOL, V276, P103; Spehner D, 1997, VIROLOGY, V232, P260, DOI 10.1006/viro.1997.8568; Takeuchi K, 2003, FEBS LETT, V545, P177, DOI 10.1016/S0014-5793(03)00528-3; Tober C, 1998, J VIROL, V72, P8124, DOI 10.1128/JVI.72.10.8124-8132.1998; Wang M, 2003, VIRAL IMMUNOL, V16, P45, DOI 10.1089/088282403763635447; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yokota S, 2003, VIROLOGY, V306, P135, DOI 10.1016/S0042-6822(02)00026-0; Yokota S, 2001, EUR J BIOCHEM, V268, P4664, DOI 10.1046/j.1432-1327.2001.02393.x; Yonekura N, 2003, CELL DEATH DIFFER, V10, P313, DOI 10.1038/sj.cdd.4401169	37	45	51	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2008	22	1					74	83		10.1096/fj.07-8976com	http://dx.doi.org/10.1096/fj.07-8976com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17720800				2022-12-28	WOS:000252309900011
J	Dean, DM; Napolitano, AP; Youssef, J; Morgan, JR				Dean, Dylan M.; Napolitano, Anthony P.; Youssef, Jacquelyn; Morgan, Jeffrey R.			Rods, tori, and honeycombs: the directed self-assembly of microtissues with prescribed microscale geometries	FASEB JOURNAL			English	Article						aggregation; spheroid	HEPATOCYTE SPHEROIDS; EMBRYONIC-TISSUES; DISSOCIATED CELLS; CULTURE; ADHESION; CADHERIN; RECONSTRUCTION; ADHESIVENESS; EQUILIBRIUM; GENERATION	It is thought that, due to energy and surface area: volume minimization, the spheroid is the terminal structure of cellular self- assembly. We investigated whether self- assembly could be directed to generate complex- shaped structures. Using micromolded, nonadhesive agarose hydrogels seeded with rat hepatoma ( H35s), human fibroblasts ( NHFs), or their mix ( 1: 1), we show that cells can self- assemble rods, tori, and honeycombs. We found that in trough- shaped recesses up to 2.2 mm long, H35s readily formed rod- like structures stable at 49% the recess lengths. They also formed intact tori ( 88%) and fully intact honeycombs structures with patent lumens ( 9/ 9) even when released from the mold. In contrast, NHFs in trough features progressed rapidly to spheroids and formed fewer stable tori ( 30%) and honeycombs ( 0/ 9). The 1: 1 mix of cells self- assembled rapidly like NHFs but were able to form more stable structures ( tori: 30%, honeycombs: 3/ 9). Experiments with labeled cells in tori and honeycombs revealed that cells self- segregated in these complex structures, with H35s enveloping NHFs, and that NHFs had different morphologies in taut vs. relaxed structures. These data open new possibilities for in vitro tissue models for embryo- and organogenesis study as well as for tissue engineering applications.	Brown Univ, Ctr Biomed Engn, Dept Mol Pharmacol,Physiol & Biotechnol, Providence, RI 02912 USA	Brown University	Morgan, JR (corresponding author), Brown Univ, Biomed Ctr, G-B 393, 171 Meeting St, Providence, RI 02912 USA.	jeffrey_morgan@brown.edu		Morgan, Jeffrey/0000-0002-7546-3443				Abbott A, 2003, NATURE, V424, P870, DOI 10.1038/424870a; Ambrosi D, 2004, J MATH BIOL, V48, P477, DOI 10.1007/s00285-003-0238-2; Duguay D, 2003, DEV BIOL, V253, P309, DOI 10.1016/S0012-1606(02)00016-7; El Sayegh TY, 2007, FEBS LETT, V581, P167, DOI 10.1016/j.febslet.2006.12.029; Enmon RM, 2001, BIOTECHNOL BIOENG, V72, P579, DOI 10.1002/1097-0290(20010320)72:6<579::AID-BIT1023>3.3.CO;2-C; Foty RA, 1996, DEVELOPMENT, V122, P1611; Foty RA, 2005, DEV BIOL, V278, P255, DOI 10.1016/j.ydbio.2004.11.012; FOTY RA, 1994, PHYS REV LETT, V72, P2298, DOI 10.1103/PhysRevLett.72.2298; Fukuda J, 2006, BIOMATERIALS, V27, P1061, DOI 10.1016/j.biomaterials.2005.07.031; Fukuda J, 2005, TISSUE ENG, V11, P1254, DOI 10.1089/ten.2005.11.1254; Griffith CK, 2005, TISSUE ENG, V11, P257, DOI 10.1089/ten.2005.11.257; Ivascu A, 2006, J BIOMOL SCREEN, V11, P922, DOI 10.1177/1087057106292763; Jakab K, 2004, BIORHEOLOGY, V41, P371; Jakab K, 2004, P NATL ACAD SCI USA, V101, P2864, DOI 10.1073/pnas.0400164101; Jakab K, 2006, BIORHEOLOGY, V43, P509; Kelm JM, 2006, J BIOTECHNOL, V121, P86, DOI 10.1016/j.jbiotec.2005.07.009; Kelm JM, 2004, TRENDS BIOTECHNOL, V22, P195, DOI 10.1016/j.tibtech.2004.02.002; Lemmon Christopher A, 2005, Mech Chem Biosyst, V2, P1; Lin RZ, 2006, CELL TISSUE RES, V324, P411, DOI 10.1007/s00441-005-0148-2; Micoulet A, 2005, CHEMPHYSCHEM, V6, P663, DOI 10.1002/cphc.200400417; MOSCONA A, 1952, J ANAT, V86, P287; MULCAHY RT, 1985, IN VITRO CELL DEV B, V21, P513, DOI 10.1007/BF02620844; NAPOLITANO AP, 2007, IN PRESS TISSUE ENG; PHILLIPS HM, 1969, P NATL ACAD SCI USA, V64, P121, DOI 10.1073/pnas.64.1.121; Ragsdale GK, 1997, BIOPHYS J, V73, P2798, DOI 10.1016/S0006-3495(97)78309-7; Rouwkema J, 2006, TISSUE ENG, V12, P2685, DOI 10.1089/ten.2006.12.2685; STEINBERG MS, 1962, P NATL ACAD SCI USA, V48, P1577, DOI 10.1073/pnas.48.9.1577; STEINBERG MS, 1970, J EXP ZOOL, V173, P395, DOI 10.1002/jez.1401730406; STEINBERG MS, 1963, SCIENCE, V141, P401, DOI 10.1126/science.141.3579.401; STEINBERG MS, 1963, EXP CELL RES, V30, P257, DOI 10.1016/0014-4827(63)90299-4; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Yamada K, 1998, J BIOCHEM, V123, P1017	32	128	139	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2007	21	14					4005	4012		10.1096/fj.07-8710com	http://dx.doi.org/10.1096/fj.07-8710com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17627028				2022-12-28	WOS:000251283500025
J	de Lange, P; Moreno, M; Silvestri, E; Lombardi, A; Goglia, F; Lanni, A				de Lange, Pieter; Moreno, Maria; Silvestri, Elena; Lombardi, Assunta; Goglia, Fernando; Lanni, Antonia			Fuel economy in food-deprived skeletal muscle: signaling pathways and regulatory mechanisms	FASEB JOURNAL			English	Review						AMP-activated protein kinase; myosin heavy chain Ib; peroxisome proliferator-activated receptor gamma coactivator-1 alpha; peroxisome proliferator-activated receptor delta; fatty acids; time course	PROLIFERATOR-ACTIVATED-RECEPTOR; FATTY-ACID OXIDATION; ACETYL-COA CARBOXYLASE; CONTROLLING MITOCHONDRIAL BIOGENESIS; MESSENGER-RNA EXPRESSION; PROTEIN-KINASE; GENE-EXPRESSION; ENERGY-METABOLISM; COACTIVATOR-1-ALPHA PGC-1-ALPHA; TRANSCRIPTIONAL CONTROL	Energy deprivation poses a tremendous challenge to skeletal muscle. Glucose (ATP) depletion causes muscle fibers to undergo rapid adaptive changes toward the use of fatty acids ( instead of glucose) as fuel. Physiological situations involving energy deprivation in skeletal muscle include exercise and fasting. A vast body of evidence is available on the signaling pathways that lead to structural/metabolic changes in muscle during exercise and endurance training. In contrast, only recently has a systematic, overall picture been obtained of the signaling processes (and their kinetics and sequential order) that lead to adaptations of the muscle to the fasting state. It has become clear that the reaction of the organism to food restraint or deprivation involves a rapid signaling process causing skeletal muscles, which generally use glucose as their predominant fuel, to switch to the use of fat as fuel. Efficient sensing of glucose depletion in skeletal muscle guarantees maintained activity in those tissues that rely entirely on glucose (such as the brain). To metabolize fatty acids, skeletal muscle needs to activate complex transcription, translation, and phosphorylation pathways. Only recently has it become clear that these pathways are interrelated and tightly regulated in a rapid, transient manner. Food deprivation may trigger these responses with a timing/intensity that differs among animal species and that may depend on their individual ability to induce structural/metabolic changes that serve to safeguard whole-body energy homeostasis in the longer term. The increased cellular AMP/ATP ratio induced by food deprivation, which results in activation of AMP-activated protein kinase ( AMPK), initiates a rapid signaling process, resulting in the recruitment of factors mediating the structural/metabolic shift in skeletal muscle toward this change in fuel usage. These factors include peroxisome proliferator-activated receptor (PPAR)gamma coactivator-1 alpha (PGC-1 alpha), PPAR delta, and their target genes, which are involved in the formation of oxidative muscle fibers, mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation. Fatty acids, besides being the fuel for mitochondrial oxidation, have been identified as important signaling molecules regulating the transcription and/or activity of the genes or gene products involved in fatty acid metabolism during food deprivation. It is thus becoming increasingly clear that fatty acids determine the economy of their own usage. We discuss the order of events from the onset of food deprivation and their importance.	Univ Naples 2, Dipartimento Sci Vita, I-81100 Caserta, Italy; Univ Sannio, Dipartimento Sci Biol Ambientali, Benevento, Italy; Univ Naples Federico II, Sez Fisiol & Igiene, Dipartimento Sci Biol, Naples, Italy	Universita della Campania Vanvitelli; University of Sannio; University of Naples Federico II	Lanni, A (corresponding author), Univ Naples 2, Dipartimento Sci Vita, Via Vivaldi 43, I-81100 Caserta, Italy.	antonia.lanni@unina2.it	de Lange, Pieter/GXA-3052-2022	MORENO, Maria/0000-0002-6218-5501; GOGLIA, Fernando/0000-0003-0468-9645; Silvestri, Elena/0000-0002-0592-9033				Barish GD, 2006, J CLIN INVEST, V116, P590, DOI 10.1172/JCI27955; Bezaire V, 2005, FASEB J, V19, P977, DOI 10.1096/fj.04-2765fje; Bonen A, 2000, J BIOL CHEM, V275, P14501, DOI 10.1074/jbc.275.19.14501; Brunmair B, 2006, DIABETOLOGIA, V49, P2713, DOI 10.1007/s00125-006-0357-6; Campbell SE, 2004, J BIOL CHEM, V279, P36235, DOI 10.1074/jbc.M400566200; Chen ZP, 2000, AM J PHYSIOL-ENDOC M, V279, pE1202, DOI 10.1152/ajpendo.2000.279.5.E1202; de Lange P, 2003, FASEB J, V17, P350, DOI 10.1096/fj.03-0342fje; de Lange P, 2006, FASEB J, V20, DOI 10.1096/fj.06-6025fje; Escher P, 2001, ENDOCRINOLOGY, V142, P4195, DOI 10.1210/en.142.10.4195; Fluck M, 2003, REV PHYSIOL BIOCH P, V146, P159, DOI 10.1007/s10254-002-0004-7; Freyssenet D, 2007, J APPL PHYSIOL, V102, P529, DOI 10.1152/japplphysiol.01126.2005; Furuyama T, 2003, BIOCHEM J, V375, P365, DOI 10.1042/BJ20030022; Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633; Goglia F, 2003, FASEB J, V17, P1585, DOI 10.1096/fj.03-0159hyp; Gonzalez AA, 2004, AM J PHYSIOL-REG I, V287, pR1270, DOI 10.1152/ajpregu.00409.2004; Hardie DG, 2006, J PHYSIOL-LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944; HARDIE DG, 1998, ANNU REV BIOCHEM, V67; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Heilbronn LK, 2005, OBES RES, V13, P574, DOI 10.1038/oby.2005.61; Hojlund K, 2004, AM J PHYSIOL-ENDOC M, V286, pE239, DOI 10.1152/ajpendo.00326.2003; Holst D, 2003, BBA-MOL CELL BIOL L, V1633, P43, DOI 10.1016/S1388-1981(03)00071-4; Huss JM, 2004, MOL CELL BIOL, V24, P9079, DOI 10.1128/MCB.24.20.9079-9091.2004; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Irrcher I, 2003, AM J PHYSIOL-CELL PH, V284, pC1669, DOI 10.1152/ajpcell.00409.2002; Itani SI, 2003, DIABETES, V52, P1635, DOI 10.2337/diabetes.52.7.1635; Jagoe RT, 2002, FASEB J, V16, P1697, DOI 10.1096/fj.02-0312com; Jaschinski F, 1998, AM J PHYSIOL-CELL PH, V274, pC365, DOI 10.1152/ajpcell.1998.274.2.C365; Jing M, 2007, AM J PHYSIOL-CELL PH, V292, pC477, DOI 10.1152/ajpcell.00196.2006; Jobgen WS, 2006, J NUTR BIOCHEM, V17, P571, DOI 10.1016/j.jnutbio.2005.12.001; Jorgensen SB, 2005, FASEB J, V19, P1146, DOI 10.1096/fj.04-3144fje; JUNGAS RL, 1992, PHYSIOL REV, V72, P419, DOI 10.1152/physrev.1992.72.2.419; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Khurana T, 2002, PROTOPLASMA, V219, P1, DOI 10.1007/s007090200000; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; Kong YF, 1997, MOL CELL BIOL, V17, P4750, DOI 10.1128/MCB.17.8.4750; Kyrolainen H, 2003, MED SCI SPORT EXER, V35, P45, DOI 10.1249/01.MSS.0000046149.03322.BB; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101; LIN BJ, 2002, J MICROLITH MICROFAB, V1, P1; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Liu Y, 2006, BIOCHEM BIOPH RES CO, V339, P701, DOI 10.1016/j.bbrc.2005.11.068; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Long YC, 2005, DIABETOLOGIA, V48, P2354, DOI 10.1007/s00125-005-1962-5; Luiken JJFP, 2003, DIABETES, V52, P1627, DOI 10.2337/diabetes.52.7.1627; Luquet S, 2003, FASEB J, V17, P2299, DOI 10.1096/fj.03-0269fje; MacLellan JD, 2005, DIABETES, V54, P2343, DOI 10.2337/diabetes.54.8.2343; Mahoney DJ, 2005, FASEB J, V19, P1498, DOI 10.1096/fj.04-3149fje; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Mornagui B, 2006, ACTA BIOL HUNG, V57, P1, DOI 10.1556/ABiol.57.2006.1.1; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Park H, 2002, J BIOL CHEM, V277, P32571, DOI 10.1074/jbc.M201692200; Petersen KF, 2006, AM J MED, V119, p10S, DOI 10.1016/j.amjmed.2006.01.009; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; Pette D, 2002, CAN J APPL PHYSIOL, V27, P423, DOI 10.1139/h02-023; Pilegaard H, 2003, DIABETES, V52, P657, DOI 10.2337/diabetes.52.3.657; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Putman CT, 2003, J PHYSIOL-LONDON, V551, P169, DOI 10.1113/jphysiol.2003.04069; RANDLE PJ, 1963, LANCET, V1, P785; Rasmussen BB, 1999, ANNU REV NUTR, V19, P463, DOI 10.1146/annurev.nutr.19.1.463; Reznick RM, 2006, J PHYSIOL-LONDON, V574, P33, DOI 10.1113/jphysiol.2006.109512; Ruderman NB, 2003, ENDOCRINOLOGY, V144, P5166, DOI 10.1210/en.2003-0849; Sakamoto K, 2006, AM J PHYSIOL-ENDOC M, V290, pE780, DOI 10.1152/ajpendo.00443.2005; Sakamoto K, 2004, AM J PHYSIOL-ENDOC M, V287, pE310, DOI 10.1152/ajpendo.00074.2004; Sauve AA, 2006, ANNU REV BIOCHEM, V75, P435, DOI 10.1146/annurev.biochem.74.082803.133500; Schrauwen P, 2004, INT J OBESITY, V28, P824, DOI 10.1038/sj.ijo.0802629; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Shearer J, 2004, DIABETES, V53, P1429, DOI 10.2337/diabetes.53.6.1429; Shi T, 2005, J BIOL CHEM, V280, P13560, DOI 10.1074/jbc.M414670200; Solanes G, 2000, FASEB J, V14, P2141; Solanes G, 2003, MOL ENDOCRINOL, V17, P1944, DOI 10.1210/me.2002-0395; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Sriwijitkamol A, 2006, AM J PHYSIOL-ENDOC M, V290, pE925, DOI 10.1152/ajpendo.00429.2005; Sriwijitkamol A, 2007, DIABETES, V56, P836, DOI 10.2337/db06-1119; Stavinoha MA, 2004, AM J PHYSIOL-ENDOC M, V287, pE888, DOI 10.1152/ajpendo.00190.2004; Steinberg GR, 2004, J CLIN ENDOCR METAB, V89, P4575, DOI 10.1210/jc.2004-0308; Stephens TJ, 2004, CLIN EXP PHARMACOL P, V31, P419, DOI 10.1111/j.1440-1681.2004.04014.x; SUGDEN MC, 1993, ADV ENZYME REGUL, V33, P71; Suwa M, 2003, J APPL PHYSIOL, V95, P960, DOI 10.1152/japplphysiol.00349.2003; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Terada S, 2002, BIOCHEM BIOPH RES CO, V296, P350, DOI 10.1016/S0006-291X(02)00881-1; Tsintzas K, 2006, J PHYSIOL-LONDON, V575, P291, DOI 10.1113/jphysiol.2006.109892; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Vescovo G, 2005, INT J CARDIOL, V104, P298, DOI 10.1016/j.ijcard.2004.10.059; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Watt MJ, 2004, J MOL ENDOCRINOL, V33, P533, DOI 10.1677/jme.1.01499; Winder WW, 2003, BIOCHEM SOC T, V31, P182, DOI 10.1042/bst0310182; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Zhang Y, 2004, J BIOL CHEM, V279, P53963, DOI 10.1074/jbc.M406028200; Zhou M, 2000, AM J PHYSIOL-ENDOC M, V279, pE622, DOI 10.1152/ajpendo.2000.279.3.E622; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599; ZOU MH, 2003, J BIOL CHEM, V279, P20767	97	104	104	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3431	3441		10.1096/fj.07-8527rev	http://dx.doi.org/10.1096/fj.07-8527rev			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17595346				2022-12-28	WOS:000250517800005
J	Schreibelt, G; Kooij, G; Reijerkerk, A; van Doorn, R; Gringhuis, SI; van der Pol, S; Weksler, BB; Romero, IA; Couraud, PO; Piontek, J; Blasig, IE; Dijkstra, CD; Ronken, E; de Vries, HE				Schreibelt, Gerty; Kooij, Gijs; Reijerkerk, Arie; van Doorn, Ruben; Gringhuis, Sonja I.; van der Pol, Susanne; Weksler, Babette B.; Romero, Ignacio A.; Couraud, Pierre-Olivier; Piontek, Joerg; Blasig, Ingolf E.; Dijkstra, Christine D.; Ronken, Eric; de Vries, Helga E.			Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling	FASEB JOURNAL			English	Article						blood-brain barrier; claudin-5; occludin; protein kinase B	CENTRAL-NERVOUS-SYSTEM; BARRIER-SPECIFIC PROPERTIES; BLOOD-BRAIN; OXIDATIVE STRESS; IN-VITRO; MULTIPLE-SCLEROSIS; ACTIN CYTOSKELETON; PHOSPHATIDYLINOSITOL 3-KINASE; PARACELLULAR PERMEABILITY; POSSIBLE INVOLVEMENT	The blood-brain barrier (BBB) prevents the entrance of circulating molecules and immune cells into the central nervous system. The barrier is formed by specialized brain endothelial cells that are interconnected by tight junctions (TJ). A defective function of the BBB has been described for a variety of neuroinflammatory diseases, indicating that proper regulation is essential for maintaining brain homeostasis. Under pathological conditions, reactive oxygen species (ROS) significantly contribute to BBB dysfunction and inflammation in the brain by enhancing cellular migration. However, a detailed study about the molecular mechanism by which ROS alter BBB integrity has been lacking. Here we demonstrate that ROS alter BBB integrity, which is paralleled by cytoskeleton rearrangements and redistribution and disappearance of TJ proteins claudin-5 and occludin. Specific signaling pathways, including RhoA and PI3 kinase, mediated observed processes and specific inhibitors of these pathways prevented ROS-induced monocyte migration across an in vitro model of the BBB. Interestingly, these processes were also mediated by protein kinase B (PKB/Akt), a previously unknown player in cytoskeleton and TJ dynamics that acted downstream of RhoA and PI3 kinase. Our study reveals new insights into molecular mechanisms underlying BBB regulation and provides novel opportunities for the treatment of neuroinflammatory diseases.	Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, NL-1007 MB Amsterdam, Netherlands; Cornell Univ, Weill Med Coll, New York, NY USA; Open Univ, Dept Sci Biol, Milton Keynes MK7 6AA, Bucks, England; Inst Cochin, Dept Biol Cellulaire, Paris, France; Inst Mol Pharmacol, Berlin, Germany; Solvay Pharmaceut Res Labs, Weesp, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Cornell University; Open University - UK; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Solvay SA	de Vries, HE (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	he.devries@vumc.nl	Kooij, Gijs/AAA-4268-2020; Horstmann, Britta/C-2154-2008; Piontek, Joerg/K-6305-2013; Romero, Ignacio/A-7381-2008; Schreibelt, Gerty/A-1260-2016; Piontek, Joerg/F-8549-2011	Piontek, Joerg/0000-0002-0880-8915; Schreibelt, Gerty/0000-0002-0156-8365; de Vries, Helga/0000-0001-7904-7124; Romero, Ignacio/0000-0002-0322-9180; Gringhuis, Sonja/0000-0003-0383-4978; Kooij, Gijs/0000-0002-9488-2918				Adamson P, 1999, J IMMUNOL, V162, P2964; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Balda MS, 2000, J CELL BIOCHEM, V78, P85, DOI 10.1002/(SICI)1097-4644(20000701)78:1<85::AID-JCB8>3.3.CO;2-6; Basuroy S, 2003, J BIOL CHEM, V278, P11916, DOI 10.1074/jbc.M211710200; Blasig IE, 2006, CELL MOL LIFE SCI, V63, P505, DOI 10.1007/s00018-005-5472-x; Blasig IE, 2002, NEUROPHARMACOLOGY, V43, P1006, DOI 10.1016/S0028-3908(02)00180-6; Boven LA, 2000, NEUROPATH APPL NEURO, V26, P356, DOI 10.1046/j.1365-2990.2000.00255.x; Cenni V, 2003, CELL MOL LIFE SCI, V60, P2710, DOI 10.1007/s00018-003-3349-4; Dallasta LM, 1999, AM J PATHOL, V155, P1915, DOI 10.1016/S0002-9440(10)65511-3; de Vries HE, 2002, J IMMUNOL, V168, P5832, DOI 10.4049/jimmunol.168.11.5832; DeGroot CJA, 1997, J NEUROSCI RES, V49, P342, DOI 10.1002/(SICI)1097-4547(19970801)49:3<342::AID-JNR9>3.0.CO;2-C; Deli MA, 2005, CELL MOL NEUROBIOL, V25, P59, DOI 10.1007/s10571-004-1377-8; DeVries HE, 1996, J PHARMACOL EXP THER, V277, P1418; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Fischer S, 2005, EUR J CELL BIOL, V84, P687, DOI 10.1016/j.ejcb.2005.03.002; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Greenwood J, 1996, J NEUROIMMUNOL, V71, P51, DOI 10.1016/S0165-5728(96)00130-0; Haorah J, 2005, J LEUKOCYTE BIOL, V78, P1223, DOI 10.1189/jlb.0605340; Haorah J, 2007, J NEUROCHEM, V101, P566, DOI 10.1111/j.1471-4159.2006.04393.x; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Hendricks JJA, 2004, J EXP MED, V200, P1667, DOI 10.1084/jem.20040819; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Keese CR, 2004, P NATL ACAD SCI USA, V101, P1554, DOI 10.1073/pnas.0307588100; Kirk J, 2003, J PATHOL, V201, P319, DOI 10.1002/path.1434; Kooij G., 2005, BLOOD BRAIN BARRIER, P47; Lai CH, 2005, BRAIN RES REV, V50, P7, DOI 10.1016/j.brainresrev.2005.03.007; Lee HS, 2004, MICROVASC RES, V68, P231, DOI 10.1016/j.mvr.2004.07.005; Mark KS, 2002, AM J PHYSIOL-HEART C, V282, pH1485, DOI 10.1152/ajpheart.00645.2001; Massoumi R, 1998, EUR J CELL BIOL, V76, P185, DOI 10.1016/S0171-9335(98)80033-2; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Nguyen KT, 2002, J BIOL CHEM, V277, P11107, DOI 10.1074/jbc.M108166200; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Nusrat A, 2000, J BIOL CHEM, V275, P29816, DOI 10.1074/jbc.M002450200; Pachter JS, 2003, J NEUROPATH EXP NEUR, V62, P593, DOI 10.1093/jnen/62.6.593; Perez V, 2005, EUR J NEUROSCI, V21, P26, DOI 10.1111/j.1460-9568.2004.03845.x; Perriere N, 2005, J NEUROCHEM, V93, P279, DOI 10.1111/j.1471-4159.2004.03020.x; Persidsky Y, 2006, BLOOD, V107, P4770, DOI 10.1182/blood-2005-11-4721; Prasad R, 2005, J NEUROCHEM, V94, P204, DOI 10.1111/j.1471-4159.2005.03182.x; Rao RK, 2002, BIOCHEM J, V368, P471, DOI 10.1042/BJ20011804; Reijerkerk A, 2006, FASEB J, V20, P2550, DOI 10.1096/fj.06-6099fje; Saci A, 2005, MOL CELL, V17, P205, DOI 10.1016/j.molcel.2004.12.012; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Schreibelt G, 2006, J IMMUNOL, V177, P2630, DOI 10.4049/jimmunol.177.4.2630; SHATOS MA, 1992, J BIOL CHEM, V267, P597; Shen L, 2005, MOL BIOL CELL, V16, P3919, DOI 10.1091/mbc.E04-12-1089; Sheth P, 2003, J BIOL CHEM, V278, P49239, DOI 10.1074/jbc.M305654200; Song L, 2004, MICROVASC RES, V67, P78, DOI 10.1016/j.mvr.2003.07.001; STEVENSON BR, 1994, J CELL SCI, V107, P367; Traweger A, 2002, J BIOL CHEM, V277, P10201, DOI 10.1074/jbc.M111384200; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; van der Goes A, 2001, FASEB J, V15, P1852, DOI 10.1096/fj.00-0881fje; Vos CMP, 2005, NEUROBIOL DIS, V20, P953, DOI 10.1016/j.nbd.2005.06.012; Walters CE, 2002, J IMMUNOL, V168, P4087, DOI 10.4049/jimmunol.168.8.4087; Weksler BB, 2005, FASEB J, V19, P1872, DOI 10.1096/fj.04-3458fje; Wong V, 1997, AM J PHYSIOL-CELL PH, V273, pC1859, DOI 10.1152/ajpcell.1997.273.6.C1859; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010	62	249	261	3	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3666	3676		10.1096/fj.07-8329com	http://dx.doi.org/10.1096/fj.07-8329com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17586731				2022-12-28	WOS:000250517800028
J	Bondesen, BA; Jones, KA; Glasgow, WC; Pavlath, GK				Bondesen, Brenda A.; Jones, Kristen A.; Glasgow, Wayne C.; Pavlath, Grace K.			Inhibition of myoblast migration by prostacyclin is associated with enhanced cell fusion	FASEB JOURNAL			English	Article						prostaglandins; myogenesis; muscle repair	SKELETAL-MUSCLE REGENERATION; PROTEIN-TURNOVER; CYCLIC-AMP; NFATC2-DEPENDENT PATHWAY; GENE-EXPRESSION; PRECURSOR CELLS; SATELLITE CELLS; COX-2 PATHWAY; IN-VITRO; PROSTAGLANDINS	Satellite cells are stem cells that are critical for the formation and growth of skeletal muscle during myogenesis. To differentiate and fuse, proliferating satellite cells or myoblasts must migrate and establish stable cell-cell contacts. However, the factors that regulate myoblast migration and fusion are not understood completely. We have identified PGI(2) as a novel regulator of myogenesis in vitro. PGI(2) is a member of the family of prostaglandins ( PG), autocrine/paracrine signaling molecules synthesized via the cyclo-oxygenase-1 and -2 pathways. Primary mouse muscle cells both secrete PGI(2) and express the PGI(2) receptor, IP, at various stages of myogenesis. Using genetic and pharmacological approaches, we show that PGI(2) is a negative regulator of myoblast migration that also enhances cell fusion. Thus, PGI(2) may act as a "brake" on migrating cells to facilitate cell-cell contact and fusion. Together, our results highlight the importance of the balance between positive and negative regulators in cell migration and myogenesis. This work may have implications for migration of other populations of adult stem cells and/or cells that undergo fusion. Bondesen, B. A., Jones, K. A., Glasgow, W. C., Pavlath, G. K. Inhibition of myoblast migration by prostacyclin is associated with enhanced cell fusion.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Mercer Univ, Sch Med, Div Basic Med Sci, Macon, GA 31207 USA	Emory University; Mercer University	Pavlath, GK (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Rm 5027,OW Rollins Res Bldg, Atlanta, GA 30322 USA.	gpavlat@emory.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052730, R01AR051372, R01AR047314, R01AR048884] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR48884, AR47314, AR052730, AR051372] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLEN RE, 1995, J CELL PHYSIOL, V165, P307, DOI 10.1002/jcp.1041650211; BARACOS V, 1986, AM J PHYSIOL, V250, pE702, DOI 10.1152/ajpendo.1986.250.6.E702; Becciolini L, 2006, BBA-MOL CELL BIOL L, V1761, P43, DOI 10.1016/j.bbalip.2006.01.006; Birchmeier C, 2000, CURR OPIN CELL BIOL, V12, P725, DOI 10.1016/S0955-0674(00)00159-9; Bischoff R, 1997, DEV DYNAM, V208, P505, DOI 10.1002/(SICI)1097-0177(199704)208:4<505::AID-AJA6>3.0.CO;2-M; Blindt R, 2002, EUR J PHARMACOL, V444, P31, DOI 10.1016/S0014-2999(02)01607-2; Bondesen BA, 2006, AM J PHYSIOL-CELL PH, V290, pC1651, DOI 10.1152/ajpcell.00518.2005; Bondesen BA, 2004, AM J PHYSIOL-CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004; Bulin C, 2005, ARTERIOSCL THROM VAS, V25, P84, DOI 10.1161/01.ATV.0000146814.81581.68; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Corti S, 2001, EXP CELL RES, V268, P36, DOI 10.1006/excr.2001.5267; DAVID JD, 1981, DEV BIOL, V82, P308, DOI 10.1016/0012-1606(81)90454-1; Dedieu S, 2004, EXP CELL RES, V292, P187, DOI 10.1016/j.yexcr.2003.08.014; Donati C, 2004, FASEB J, V18, P449, DOI 10.1096/fj.04-1780fje; ENTWISTLE A, 1986, J CELL BIOL, V103, P857, DOI 10.1083/jcb.103.3.857; Fukuhara S, 2005, MOL CELL BIOL, V25, P136, DOI 10.1128/MCB.25.1.136-146.2005; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Galvez BG, 2006, J CELL BIOL, V174, P231, DOI 10.1083/jcb.200512085; GOLDBERG AL, 1984, FED PROC, V43, P1301; HASSELGREN PO, 1988, ANN SURG, V207, P399, DOI 10.1097/00000658-198804000-00005; HASSELGREN PO, 1990, BIOCHEM J, V270, P45, DOI 10.1042/bj2700045; Hill E, 2006, P NATL ACAD SCI USA, V103, P2494, DOI 10.1073/pnas.0506004103; Horsley V, 2001, J CELL BIOL, V153, P329, DOI 10.1083/jcb.153.2.329; Horsley V, 2003, J CELL BIOL, V161, P111, DOI 10.1083/jcb.200208085; Hui AY, 2004, PROSTAG LEUKOTR ESS, V71, P329, DOI 10.1016/j.plefa.2004.04.007; Jansen KM, 2006, J CELL BIOL, V174, P403, DOI 10.1083/jcb.200601102; Kang JS, 2003, P NATL ACAD SCI USA, V100, P3989, DOI 10.1073/pnas.0736565100; Kang JS, 2004, J CELL BIOL, V167, P493, DOI 10.1083/jcb.200405039; Kawajiri H, 2002, ARCH BIOCHEM BIOPHYS, V398, P51, DOI 10.1006/abbi.2001.2685; KERRY PJ, 1985, PROSTA LEUKOTR MED, V17, P283, DOI 10.1016/0262-1746(85)90117-9; Kohyama T, 2002, AM J PHYSIOL-LUNG C, V283, pL428, DOI 10.1152/ajplung.00432.2001; Kothapalli D, 2003, MOL PHARMACOL, V64, P249, DOI 10.1124/mol.64.2.249; Krauss RS, 2005, J CELL SCI, V118, P2355, DOI 10.1242/jcs.02397; Lindemann S, 2003, BASIC RES CARDIOL, V98, P8, DOI 10.1007/s00395-003-0383-1; MCLENNAN IS, 1991, J ANAT, V174, P115; Mitchell PO, 2004, AM J PHYSIOL-CELL PH, V287, pC1753, DOI 10.1152/ajpcell.00292.2004; Mylona E, 2006, J CELL PHYSIOL, V209, P314, DOI 10.1002/jcp.20724; NAMBA T, 1994, J BIOL CHEM, V269, P9986; NICOLINI FA, 1990, THROMB RES, V59, P669, DOI 10.1016/0049-3848(90)90426-D; NOWAK J, 1983, PROSTA LEUKOTR MED, V11, P269, DOI 10.1016/0262-1746(83)90040-9; Olguin HC, 2003, DEV BIOL, V259, P209, DOI 10.1016/S0012-1606(03)00180-5; Otis JS, 2005, EXP CELL RES, V310, P417, DOI 10.1016/j.yexcr.2005.08.009; ROBERTSON TA, 1993, EXP CELL RES, V207, P321, DOI 10.1006/excr.1993.1199; RODEMANN HP, 1982, J BIOL CHEM, V257, P1632; ROSSI MJ, 1989, J CELL PHYSIOL, V141, P142, DOI 10.1002/jcp.1041410121; SCHUTZLE UB, 1984, BIOCHIM BIOPHYS ACTA, V805, P204, DOI 10.1016/0167-4889(84)90169-1; Shen W, 2006, J APPL PHYSIOL, V101, P1215, DOI 10.1152/japplphysiol.01331.2005; Stewart SA, 2004, J BIOL CHEM, V279, P29109, DOI 10.1074/jbc.M404271200; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Trappe RA, 2002, AM J PHYSIOL-ENDOC M, V282, pE551, DOI 10.1152/ajpendo.00352.2001; Trappe TA, 2001, J CLIN ENDOCR METAB, V86, P5067, DOI 10.1210/jc.86.10.5067; VANDENBURGH HH, 1995, J CELL PHYSIOL, V163, P285, DOI 10.1002/jcp.1041630209; VANDENBURGH HH, 1990, AM J PHYSIOL, V259, pC232, DOI 10.1152/ajpcell.1990.259.2.C232; ZALIN RJ, 1987, EXP CELL RES, V172, P265, DOI 10.1016/0014-4827(87)90386-7; ZALIN RJ, 1977, DEV BIOL, V59, P241, DOI 10.1016/0012-1606(77)90258-5	55	53	54	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3338	3345		10.1096/fj.06-7070com	http://dx.doi.org/10.1096/fj.06-7070com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17488951				2022-12-28	WOS:000249781600034
J	Birukova, AA; Alekseeva, E; Mikaelyan, A; Birukov, KG				Birukova, Anna A.; Alekseeva, Elena; Mikaelyan, Arsen; Birukov, Konstantin G.			HGF attenuates thrombin-induced endothelial permeability by Tiam1-mediated activation of the Rac pathway and by Tiam1/Rac-dependent inhibition of the Rho pathway	FASEB JOURNAL			English	Article						small GTPases; pulmonary endothelium; actin; cytoskeleton	HEPATOCYTE GROWTH-FACTOR; LIGHT-CHAIN KINASE; BARRIER DYSFUNCTION; CYTOSKELETAL REARRANGEMENT; SPHINGOSINE 1-PHOSPHATE; DIFFERENTIAL REGULATION; EXCHANGE FACTORS; ARP2/3 COMPLEX; SCATTER FACTOR; CELLS	Reorganization of the endothelial cell ( EC) cytoskeleton and cell adhesive complexes provides a structural basis for increased vascular permeability implicated in the pathogenesis of many diseases, including asthma, sepsis, and acute respiratory distress syndrome ( ARDS). We have recently described the barrier- protective effects of hepatocyte growth factor ( HGF) on the human pulmonary EC. In the present study, we explored the involvement of Rac- GTPase and Rac- specific nucleotide exchange factor Tiam1 in the mechanisms of EC barrier protection by HGF. HGF protected EC monolayers from thrombin- induced hyperpermeability, disruption of intercellular junctions, and formation of stress fibers and paracellular gaps by inhibiting thrombin- induced activation of Rho GTPase, Rho association with nucleotide exchange factor p115RhoGEF, and myosin light chain phosphorylation, which was opposed by stimulation of Rac- dependent signaling. The pharmacological Rac inhibitor or silencing RNA ( siRNA) based depletion of either Rac or Tiam1 significantly attenuated HGF- induced peripheral translocation of Rac effector cortactin, cortical actin ring formation, and EC barrier enhancement. Moreover, Tiam1 knockdown using the siRNA approach, attenuated the protective effect of HGF against thrombininduced activation of Rho signaling, monolayer disruption, and EC hyperpermeability. This study demonstrates the Tiam1/ Rac- dependent mechanism of HGF- induced EC barrier protection and provides novel mechanistic insights into regulation of EC permeability via dynamic interactions between Rho- and Tiam1/ Rac- mediated pathways.	Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA	University of Chicago	Birukova, AA (corresponding author), Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, 929 E 57th St,CIS Bldg,W410, Chicago, IL 60637 USA.	abirukov@medicine.bsd.uchicago.edu	Birukov, Konstantin/FJB-5755-2022		NHLBI NIH HHS [HL-075349, HL-076259] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076259, R01HL075349] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Aoki M, 2000, J Atheroscler Thromb, V7, P71; Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Birukov KG, 2004, CIRC RES, V95, P892, DOI 10.1161/01.RES.0000147310.18962.06; Birukov KG, 2002, AM J RESP CELL MOL, V26, P453, DOI 10.1165/ajrcmb.26.4.4725; Birukov KG, 2001, J BIOL CHEM, V276, P8567, DOI 10.1074/jbc.M005270200; Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007; Birukova AA, 2006, AM J PATHOL, V168, P1749, DOI 10.2353/ajpath.2006.050431; Birukova AA, 2005, J CELL PHYSIOL, V204, P934, DOI 10.1002/jcp.20359; Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com; Birukova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL75, DOI 10.1152/ajplung.00447.2004; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Date I, 2004, BIOCHEM BIOPH RES CO, V319, P1152, DOI 10.1016/j.bbrc.2004.05.100; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Garcia JGN, 2000, J APPL PHYSIOL, V89, P2333, DOI 10.1152/jappl.2000.89.6.2333; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia Joe G. N., 1996, Seminars in Thrombosis and Hemostasis, V22, P309, DOI 10.1055/s-2007-999025; Geiser T, 2003, SWISS MED WKLY, V133, P586; Gonzalez E, 2006, J BIOL CHEM, V281, P3210, DOI 10.1074/jbc.M510434200; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Herbrand U, 2006, BIOL CHEM, V387, P311, DOI 10.1515/BC.2006.041; Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC; Liu F, 2002, FASEB J, V16, P950, DOI 10.1096/fj.01-0870com; Lum H, 1996, CAN J PHYSIOL PHARM, V74, P787, DOI 10.1139/cjpp-74-7-787; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; Malliri A, 2004, J BIOL CHEM, V279, P30092, DOI 10.1074/jbc.M401192200; Manser E, 2002, DEV CELL, V3, P323, DOI 10.1016/S1534-5807(02)00268-X; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; Noritake J, 2005, J CELL SCI, V118, P2085, DOI 10.1242/jcs.02379; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Petrache I, 2003, BIOCHEM BIOPH RES CO, V306, P244, DOI 10.1016/S0006-291X(03)00945-8; Rosen EM, 1995, ADV CANCER RES, V67, P257, DOI 10.1016/S0065-230X(08)60715-0; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com; Tamma G, 2003, J CELL SCI, V116, P1519, DOI 10.1242/jcs.00355; Tomita N, 2000, J Atheroscler Thromb, V7, P1; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Vouret-Craviari V, 2002, J CELL SCI, V115, P2475; Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639; Ware LB, 2002, AM J PHYSIOL-LUNG C, V282, pL924, DOI 10.1152/ajplung.00439.2001; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9; Wong KW, 2006, J BIOL CHEM, V281, P40379, DOI 10.1074/jbc.M605387200; Zhang LL, 2000, J NEUROSCI RES, V59, P489, DOI 10.1002/(SICI)1097-4547(20000215)59:4<489::AID-JNR3>3.0.CO;2-9; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	64	104	107	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2776	2786		10.1096/fj.06-7660com	http://dx.doi.org/10.1096/fj.06-7660com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17428964				2022-12-28	WOS:000249237500019
J	Yerbury, JJ; Poon, S; Meehan, S; Thompson, B; Kumita, JR; Dobson, CM; Wilson, MR				Yerbury, Justin J.; Poon, Stephen; Meehan, Sarah; Thompson, Brianna; Kumita, Janet R.; Dobson, Christopher M.; Wilson, Mark R.			The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures	FASEB JOURNAL			English	Article						protein aggregation; chaperone : substrate ratio; amyloid fibrils; cytoprotection	APOLIPOPROTEIN-J; ALZHEIMERS-DISEASE; PLAQUE-FORMATION; IN-VITRO; PROTEIN; AGGREGATION; SOLUBILITY; DEPOSITION; PEPTIDE; MECHANISM	Clusterin is an extracellular chaperone present in all disease-associated extracellular amyloid deposits, but its roles in amyloid formation and protein deposition in vivo are poorly understood. The current study initially aimed to characterize the effects of clusterin on amyloid formation in vitro by a panel of eight protein substrates. Two of the substrates ( Alzheimer's beta peptide and a PI3-SH3 domain) were then used in further experiments to examine the effects of clusterin on amyloid cytotoxicity and to probe the mechanism of clusterin action. We show that clusterin exerts potent effects on amyloid formation, the nature and extent of which vary greatly with the clusterin: substrate ratio, and provide evidence that these effects are exerted via interactions with prefibrillar species that share common structural features. Proamyloidogenic effects of clusterin appear to be restricted to conditions in which the substrate protein is present at a very large molar excess; under these same conditions, clusterin coincorporates with substrate protein into insoluble aggregates. However, when clusterin is present at much higher but still substoichiometric levels ( e. g., a molar ratio of clusterin: substrate = 1: 10), it potently inhibits amyloid formation and provides substantial cytoprotection. These findings suggest that clusterin is an important element in the control of extracellular protein misfolding.	Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia; Univ Cambridge, Dept Chem, Cambridge, England; Univ Adelaide, Sch Chem & Phys, Adelaide, SA, Australia	University of Wollongong; University of Cambridge; University of Adelaide	Wilson, MR (corresponding author), Univ Wollongong, Sch Biol Sci, Northfields Ave, Wollongong, NSW 2522, Australia.	mrw@uow.edu.au	Yerbury, Justin/AAC-7054-2022; Wilson, Mark R/B-3254-2018; Kumita, Janet/AAO-5254-2021	Yerbury, Justin/0000-0003-2528-7039; Wilson, Mark R/0000-0002-9551-7445; 	Biotechnology and Biological Sciences Research Council [BB/E019927/1] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Boggs LN, 1996, J NEUROCHEM, V67, P1324; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Calero M, 2000, MICROSC RES TECHNIQ, V50, P305, DOI 10.1002/1097-0029(20000815)50:4<305::AID-JEMT10>3.0.CO;2-L; Chiesa R, 1996, EUR J NEUROSCI, V8, P589, DOI 10.1111/j.1460-9568.1996.tb01244.x; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; DeMattos RB, 2004, NEURON, V41, P193, DOI 10.1016/S0896-6273(03)00850-X; DeMattos RB, 2002, P NATL ACAD SCI USA, V99, P10843, DOI 10.1073/pnas.162228299; Freixes M, 2004, ACTA NEUROPATHOL, V108, P295, DOI 10.1007/s00401-004-0891-6; GHISO J, 1995, J NEUROL SCI, V129, P74, DOI 10.1016/0022-510X(94)00274-R; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hatters DM, 2002, EUR J BIOCHEM, V269, P2789, DOI 10.1046/j.1432-1033.2002.02957.x; Heuer KH, 1996, BIOCHEMISTRY-US, V35, P9069, DOI 10.1021/bi952817o; Hughes SR, 1998, P NATL ACAD SCI USA, V95, P3275, DOI 10.1073/pnas.95.6.3275; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; Kammerer RA, 2004, P NATL ACAD SCI USA, V101, P4435, DOI 10.1073/pnas.0306786101; KIDA E, 1995, BRAIN RES, V685, P211, DOI 10.1016/0006-8993(95)00482-6; Klug GMJA, 2003, EUR J BIOCHEM, V270, P4282, DOI 10.1046/j.1432-1033.2003.03815.x; KUMITA JR, 2007, IN PRESS J MOL BIOL; Lakins JN, 2002, BIOCHEMISTRY-US, V41, P282, DOI 10.1021/bi0157666; LICHTENFELS R, 1994, J IMMUNOL METHODS, V172, P227, DOI 10.1016/0022-1759(94)90110-4; MaatSchieman MLC, 1996, BRAIN PATHOL, V6, P115, DOI 10.1111/j.1750-3639.1996.tb00794.x; Matsubara E, 1996, BIOCHEM J, V316, P671, DOI 10.1042/bj3160671; McHattie S, 1999, BIOCHEM BIOPH RES CO, V259, P336, DOI 10.1006/bbrc.1999.0781; Morrissey C, 2001, J BIOCHEM BIOPH METH, V48, P13, DOI 10.1016/S0165-022X(00)00137-8; Nishida I, 1999, BRIT J OPHTHALMOL, V83, P1178, DOI 10.1136/bjo.83.10.1178; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; Poon S, 2000, BIOCHEMISTRY-US, V39, P15953, DOI 10.1021/bi002189x; Poon S, 2002, J BIOL CHEM, V277, P39532, DOI 10.1074/jbc.M204855200; Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; WILSON MR, 1992, BIOCHIM BIOPHYS ACTA, V1159, P319, DOI 10.1016/0167-4838(92)90062-I; WITTE DP, 1993, AM J PATHOL, V143, P763; Yerbury JJ, 2005, EMBO REP, V6, P1131, DOI 10.1038/sj.embor.7400586; Zenkel M, 2006, INVEST OPHTH VIS SCI, V47, P1982, DOI 10.1167/iovs.05-1580	36	233	241	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2312	2322		10.1096/fj.06-7986com	http://dx.doi.org/10.1096/fj.06-7986com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17412999				2022-12-28	WOS:000248454400006
J	Liu, L; Kodibagkar, VD; Yu, JX; Mason, RP				Liu, Li; Kodibagkar, Vikram D.; Yu, Jian-Xin; Mason, Ralph P.			F-19-NMR detection of lacZ gene expression via the enzymic hydrolysis of 2-fluoro-4-nitrophenyl beta-D-galactopyranoside in vivo in PC3 prostate tumor xenografts in the mouse	FASEB JOURNAL			English	Article; Proceedings Paper	97th Annual Meeting of the American-Association-for-Cancer-Research (AACR)	APR 01-05, 2006	Washington, DC	Amer Assoc Canc Res		beta-galactosidase; F-19 CSI; F-19 MRS; gene reporter	NUCLEAR-MAGNETIC-RESONANCE; GALACTOSIDASE ACTIVITY; PHASE-I; TRANSGENE EXPRESSION; REPORTER MOLECULES; CYTOSINE DEAMINASE; THERAPY; QUANTITATION; NMR; TRANSFECTION	Gene therapy shows promise for treating prostate cancer and has been evaluated in several clinical trials. A major challenge that remains is to establish a method for verifying transgene activity in situ. The lacZ gene encoding beta-galactosidase historically has been the most popular reporter gene for molecular biology. We have designed a F-19 NMR approach to reveal lacZ gene expression by assessing beta-galactosidase (beta-gal) activity in vivo. The substrate 2-fluoro-4-nitrophenyl beta-D-galactopyranoside (OFPNPG) is readily hydrolyzed by beta-gal with a corresponding decrease in the F-19-NMR signal from OFPNPG and the appearance of a new signal shifted 4-6 ppm upfield from the aglycone 2-fluoro-4-nitrophenol (OFPNP). We report proof of principle in cultures of PC3 prostate cancer cells using F-19 NMR spectroscopy and F-19 chemical shift imaging. More importantly, we demonstrate for the first time the ability to differentiate wild-type and lacZ-expressing prostate tumor xenografts in mice using this approach.	Univ Texas, SW Med Ctr, Dept Radiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mason, RP (corresponding author), Univ Texas, SW Med Ctr, Dept Radiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	ralph.mason@utsouthwestern.edu	Liu, LI/B-6912-2013; Mason, Ralph/C-8472-2012	Liu, LI/0000-0002-9731-6145; Mason, Ralph/0000-0001-7517-3721	NCI NIH HHS [P20 CA086354, P20 CA086354-03, P20 CA086354-02, U24 CA126608] Funding Source: Medline; NCRR NIH HHS [P41-RR02584] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P20CA086354, U24CA126608] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002584] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Corban-Wilhelm H, 2002, GENE THER, V9, P1564, DOI 10.1038/sj.gt.3301834; Cui WN, 2004, MAGN RESON MED, V51, P616, DOI 10.1002/mrm.10719; Davies LC, 2005, J MED CHEM, V48, P5321, DOI 10.1021/jm0502182; Freytag SO, 2002, CANCER RES, V62, P4968; Gambhir SS, 2000, NEOPLASIA, V2, P118, DOI 10.1038/sj.neo.7900083; Gambhir SS, 1998, J NUCL MED, V39, P2003; Haberkorn U, 2005, CURR MED CHEM, V12, P779, DOI 10.2174/0929867053507351; Harrison G S, 1997, Oncology (Williston Park), V11, P845; Herman JR, 1999, HUM GENE THER, V10, P1239, DOI 10.1089/10430349950018229; Heuermann K, 2001, BIOTECHNIQUES, V30, P1142, DOI 10.2144/01305pf01; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; James AL, 1996, APPL ENVIRON MICROB, V62, P3868, DOI 10.1128/AEM.62.10.3868-3870.1996; James AL, 2000, LETT APPL MICROBIOL, V30, P336, DOI 10.1046/j.1472-765X.2000.00669.x; Kodibagkar VD, 2006, MAGN RESON IMAGING, V24, P959, DOI 10.1016/j.mri.2006.04.003; Koeneman K S, 2001, Curr Opin Urol, V11, P489, DOI 10.1097/00042307-200109000-00007; Lee KH, 2004, EUR J NUCL MED MOL I, V31, P433, DOI 10.1007/s00259-003-1395-7; Louie AY, 2000, NAT BIOTECHNOL, V18, P321, DOI 10.1038/73780; MacRae EJ, 2006, PROSTATE, V66, P470, DOI 10.1002/pros.20388; POCSI I, 1993, BIOCHIM BIOPHYS ACTA, V1163, P54, DOI 10.1016/0167-4838(93)90278-Y; Russell PJ, 2006, EXPERT OPIN INV DRUG, V15, P947, DOI 10.1517/13543784.15.8.947; Schmidt F, 2002, J CHEM SOC PERK T 1, P1302, DOI 10.1039/b111549a; Small EJ, 2006, MOL THER, V14, P107, DOI 10.1016/j.ymthe.2006.02.011; Stegman LD, 1999, P NATL ACAD SCI USA, V96, P9821, DOI 10.1073/pnas.96.17.9821; Tetzlaff MT, 2006, TECHNOL CANCER RES T, V5, P23, DOI 10.1177/153303460600500104; Tung CH, 2004, CANCER RES, V64, P1579, DOI 10.1158/0008-5472.CAN-03-3226; Wilson CJ, 2007, CELL MOL LIFE SCI, V64, P3, DOI 10.1007/s00018-006-6296-z; Yu Jianxin, 2005, Med Chem, V1, P255, DOI 10.2174/1573406053765495; Yu J, 2006, P UNIV GOVT IND MICR, P191; Yu JX, 2006, J MED CHEM, V49, P1991, DOI 10.1021/jm051049o; Yu JX, 2006, BIOORGAN MED CHEM, V14, P326, DOI 10.1016/j.bmc.2005.08.021; Yu JX, 2005, CURR MED CHEM, V12, P819, DOI 10.2174/0929867053507342; Yu JX, 2004, BIOCONJUGATE CHEM, V15, P1334, DOI 10.1021/bc049936d	33	43	43	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2014	2019		10.1096/fj.06-7366lsf	http://dx.doi.org/10.1096/fj.06-7366lsf			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17351127				2022-12-28	WOS:000247500300011
J	Jakobsson, L; Domogatskaya, A; Tryggvason, K; Edgar, D; Claesson-Welsh, L				Jakobsson, Lars; Domogatskaya, Anna; Tryggvason, Karl; Edgar, David; Claesson-Welsh, Lena			Laminin deposition is dispensable for vasculogenesis but regulates blood vessel diameter independent of flow	FASEB JOURNAL			English	Article						angiogenesis; sprouting; basement membrane; VEGF	FIBROBLAST-GROWTH-FACTOR; BASEMENT-MEMBRANES; ENDOTHELIAL-CELLS; ALPHA-5 CHAIN; LAMC1 GENE; ANGIOGENESIS; VEGF; DIFFERENTIATION; EXPRESSION; MATURATION	Basement membranes (BMs) consisting of laminins, collagens, and heparan sulfate proteoglycans (HSPGs) are vital for proper endothelial cell function, but many aspects of their role in vascular development remain unknown. Here, we demonstrate that vascular structures within differentiating embryoid bodies are wrapped in a BM composed of alpha 4- and alpha 5-chain laminins, fibronectin, collagen IV, and HSPGs. In sprouting angiogenesis, laminins were produced by stalk cells, as well as the leading tip cell, and deposited along the sprout length, including tip cell filopodia. In embryonic stem cells deficient in laminins, due to lamc1 (laminin gamma 1) deletion, vascular development and organization were largely unaffected. However, the frequency of vessels with wide lumens was increased 4-fold. Laminin-deficient vessels were moreover characterized by increased fibronectin levels and enhanced endothelial cell proliferation. We conclude that laminins are dispensable for vascular development but that they regulate lumen formation in the absence of flow and vascular tone.	[Jakobsson, Lars; Claesson-Welsh, Lena] Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, SE-75185 Uppsala, Sweden; [Domogatskaya, Anna; Tryggvason, Karl] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden; [Edgar, David] Univ Liverpool, Dept Human Anat, Liverpool, Merseyside, England	Uppsala University; Karolinska Institutet; University of Liverpool	Claesson-Welsh, L (corresponding author), Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, Dag Hammarskjoldsv 20, SE-75185 Uppsala, Sweden.	lena.welsh@genpat.uu.se	Jakobsson, Lars/B-4200-2011; Domogatskaya, Anna/F-5794-2012	Jakobsson, Lars/0000-0001-7956-587X; Domogatskaya, Anna/0000-0002-6468-1963	BBSRC [BB/D014638/1] Funding Source: UKRI; MRC [G0300296] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D014638/1] Funding Source: Medline; Medical Research Council [G0300296] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Darland DC, 2003, DEV BIOL, V264, P275, DOI 10.1016/j.ydbio.2003.08.015; Dixelius J, 2004, J BIOL CHEM, V279, P23766, DOI 10.1074/jbc.M311675200; Doi M, 2002, J BIOL CHEM, V277, P12741, DOI 10.1074/jbc.M111228200; George EL, 1997, BLOOD, V90, P3073, DOI 10.1182/blood.V90.8.3073; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Hallmann R, 2005, PHYSIOL REV, V85, P979, DOI 10.1152/physrev.00014.2004; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Jakobsson L, 2007, J CELL BIOL, V177, P751, DOI 10.1083/jcb.200701146; Jakobsson L, 2006, DEV CELL, V10, P625, DOI 10.1016/j.devcel.2006.03.009; Kortesmaa J, 2000, J BIOL CHEM, V275, P14853, DOI 10.1074/jbc.275.20.14853; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Li XF, 2001, J CELL BIOL, V153, P811, DOI 10.1083/jcb.153.4.811; Ljubimova JY, 2001, CANCER RES, V61, P5601; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Miner JH, 2000, DEV BIOL, V217, P278, DOI 10.1006/dbio.1999.9546; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Miner JH, 2004, DEVELOPMENT, V131, P2247, DOI 10.1242/dev.01112; Murray P, 2000, J CELL BIOL, V150, P1215, DOI 10.1083/jcb.150.5.1215; Nyberg P, 2005, CANCER RES, V65, P3967, DOI 10.1158/0008-5472.CAN-04-2427; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Parsons MJ, 2002, DEVELOPMENT, V129, P3137; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Poschl E, 2004, DEVELOPMENT, V131, P1619, DOI 10.1242/dev.01037; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Smyth N, 1998, ANN NY ACAD SCI, V857, P283, DOI 10.1111/j.1749-6632.1998.tb10133.x; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Sottile J, 2004, BBA-REV CANCER, V1654, P13, DOI 10.1016/j.bbcan.2003.07.002; Thyboll J, 2002, MOL CELL BIOL, V22, P1194, DOI 10.1128/MCB.22.4.1194-1202.2002; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; Wang J, 2006, J NEUROCHEM, V96, P148, DOI 10.1111/j.1471-4159.2005.03521.x; Yu W, 2005, MOL BIOL CELL, V16, P433, DOI 10.1091/mbc.e04-05-0435	34	45	45	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2008	22	5					1530	1539		10.1096/fj.07-9617com	http://dx.doi.org/10.1096/fj.07-9617com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18073332				2022-12-28	WOS:000255898700025
J	Danik, SB; Rosner, G; Lader, J; Gutstein, DE; Fishman, GI; Morley, GE				Danik, Stephan B.; Rosner, Gregg; Lader, Joshua; Gutstein, David E.; Fishman, Glenn I.; Morley, Gregory E.			Electrical remodeling contributes to complex tachyarrhythmias in connexin43-deficient mouse hearts	FASEB JOURNAL			English	Article						gap junction channels; ion channel remodeling	ISOLATED RABBIT HEART; VENTRICULAR-FIBRILLATION; POTASSIUM CURRENT; SLOW CONDUCTION; MICE; EXPRESSION; JUNCTION; ACTIVATION; MECHANISMS; DYNAMICS	Loss of connexin43 (Cx43) gap junction channels in the heart results in a marked increase in the incidence of spontaneous and inducible polymorphic ventricular tachyarrhythmias (PVTs). The mechanisms resulting in this phenotype remain unclear. We hypothesized that uncoupling promotes regional ion channel remodeling, thereby increasing electrical heterogeneity and facilitating the development of PVT. In isolated-perfused control hearts, programmed electrical stimulation elicited infrequent monomorphic ventricular tachyarrhythmias (MVT), and dominant frequencies (DFs) during MVT were similar in the right ventricle (RV) and left ventricle (LV). Moreover, conduction properties, action potential durations (APDs), and repolarizing current densities were similar in RV and LV myocytes. In contrast, PVT was common in Cx43 conditional knockout (OCKO) hearts, and arrhythmias were characterized by significantly higher DFs in the RV compared to the LV. APDs in OCKO myocytes were significantly shorter than those from chamber-matched controls, with RV OCKO myocytes being most affected. APD shortening was associated with higher levels of sustained current in myocytes from both chambers as well as higher levels of the inward rectifier current only in RV myocytes. Thus, alterations in cell-cell coupling lead to regional changes in potassium current expression, which in this case facilitates the development of reentrant arrhythmias. We propose a new mechanistic link between electrical uncoupling and ion channel remodeling. These findings may be relevant not only in cardiac tissue but also to other organ systems where gap junction remodeling is known to occur.	[Danik, Stephan B.; Rosner, Gregg; Lader, Joshua; Gutstein, David E.; Fishman, Glenn I.; Morley, Gregory E.] NYU, Sch Med, Leon H Charney Div Cardiol, New York, NY 10016 USA	New York University	Morley, GE (corresponding author), NYU, Sch Med, Leon H Charney Div Cardiol, 522 1St Ave,8th Floor,Smilow Bldg, New York, NY 10016 USA.	gregory.morley@nyumc.org		Fishman, Glenn/0000-0002-2366-8527	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082727, R01HL076751, R01HL064757] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64757, R01 HL082727-03, HL76751, R01 HL076751-01A1, HL82727, R01 HL082727, R01 HL076751-03, R01 HL064757-09, R01 HL064757, R01 HL076751-04, R01 HL076751, R01 HL076751-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chen J, 2000, CIRC RES, V86, P86, DOI 10.1161/01.RES.86.1.86; Danik SB, 2004, CIRC RES, V95, P1035, DOI 10.1161/01.RES.0000148664.33695.2a; Gray RA, 1998, NATURE, V392, P75, DOI 10.1038/32164; GRAY RA, 1995, SCIENCE, V270, P1222, DOI 10.1126/science.270.5239.1222; Guo WN, 2005, CIRC RES, V97, P1342, DOI 10.1161/01.RES.0000196559.63223.aa; Gutstein DE, 2005, AM J PHYSIOL-HEART C, V289, pH1091, DOI 10.1152/ajpheart.00095.2005; Gutstein DE, 2003, AM J PHYSIOL-HEART C, V285, pH1091, DOI 10.1152/ajpheart.00100.2003; Gutstein DE, 2001, CELL COMMUN ADHES, V8, P345, DOI 10.3109/15419060109080751; Gutstein DE, 2001, CIRC RES, V88, P333, DOI 10.1161/01.RES.88.3.333; Iacobas DA, 2005, BBA-BIOMEMBRANES, V1711, P183, DOI 10.1016/j.bbamem.2004.12.002; Iacobas DA, 2005, PHYSIOL GENOMICS, V20, P211, DOI 10.1152/physiolgenomics.00229.2003; IBARRA J, 1991, BIOPHYS J, V60, P1534, DOI 10.1016/S0006-3495(91)82187-7; Jalife J, 2000, ANNU REV PHYSIOL, V62, P25, DOI 10.1146/annurev.physiol.62.1.25; Kaprielian R, 2002, AM J PHYSIOL-HEART C, V283, pH1157, DOI 10.1152/ajpheart.00518.2001; Kardami E, 2007, PROG BIOPHYS MOL BIO, V94, P245, DOI 10.1016/j.pbiomolbio.2007.03.009; Lerner DL, 2000, CIRCULATION, V101, P547, DOI 10.1161/01.CIR.101.5.547; Libbus I, 2003, J CARDIOVASC ELECTR, V14, P394, DOI 10.1046/j.1540-8167.2003.02436.x; Mandapati R, 1998, CIRCULATION, V98, P1688, DOI 10.1161/01.CIR.98.16.1688; Morley GE, 2005, P NATL ACAD SCI USA, V102, P4126, DOI 10.1073/pnas.0500881102; Morley GE, 1999, J CARDIOVASC ELECTR, V10, P1361, DOI 10.1111/j.1540-8167.1999.tb00192.x; Nerbonne JM, 2002, J CARDIOVASC ELECTR, V13, P406, DOI 10.1046/j.1540-8167.2002.00406.x; Noujaim SF, 2007, J PHYSIOL-LONDON, V578, P315, DOI 10.1113/jphysiol.2006.121475; Patel PM, 2001, J CARDIOVASC ELECTR, V12, P570, DOI 10.1046/j.1540-8167.2001.00570.x; Petkova-Kirova PS, 2006, AM J PHYSIOL-HEART C, V290, pH2098, DOI 10.1152/ajpheart.00097.2005; Rose J, 2005, AM J PHYSIOL-HEART C, V288, pH2077, DOI 10.1152/ajpheart.00526.2003; Rubart M, 2005, J CLIN INVEST, V115, P2305, DOI 10.1172/JCI26381; Samie FH, 2001, CIRC RES, V89, P1216, DOI 10.1161/hh2401.100818; Tamaddon HS, 2000, CIRC RES, V87, P929, DOI 10.1161/01.RES.87.10.929; Trepanier-Boulay W, 2001, CIRC RES, V89, P437, DOI 10.1161/hh1701.095644; Vaidya D, 1999, CIRC RES, V85, P174, DOI 10.1161/01.RES.85.2.174; Vaidya D, 2001, CIRC RES, V88, P1196, DOI 10.1161/hh1101.091107; van Rijen HVM, 2004, CIRCULATION, V109, P1048, DOI 10.1161/01.CIR.0000117402.70689.75; Warren M, 2003, J CARDIOVASC ELECTR, V14, P621, DOI 10.1046/j.1540-8167.2003.03006.x; Wickenden AD, 1999, CIRC RES, V85, P1067	34	50	53	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1204	1212		10.1096/fj.07-8974com	http://dx.doi.org/10.1096/fj.07-8974com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	17984180	Green Accepted			2022-12-28	WOS:000254581000025
J	Schubert, M; Drephal, C; Albrecht, D				Schubert, Mania; Drephal, Christian; Albrecht, Doris			Gender-dependent ATPA-induced changes in long-term potentiation in the rat lateral amygdala	FASEB JOURNAL			English	Article						lateral nucleus of the amygdala; high-frequency stimulation; UBP296; SKF 86002; horizontal brain slice	ACTIVATED PROTEIN-KINASE; KAINATE RECEPTORS; SYNAPTIC-TRANSMISSION; BASOLATERAL AMYGDALA; MAP KINASE; HORIZONTAL SLICES; IN-VITRO; GLUR5; PLASTICITY; NEURONS	There is increasing evidence that kainate receptors contribute to both postsynaptic and presynaptic signaling not only in the hippocampus but also in the amygdala. The present study demonstrates that low concentrations of the specific kainate GLU(K5) receptor agonist, ATPA, depressed baseline activity in the lateral nucleus of the rat amygdala (LA), induced by stimulation of external capsule fibers or by intranuclear stimulation in. horizontal brain slices. ATPA reduced high-frequency-induced long-term potentiation (LTP) in males while it enhanced LTP in females during certain phases of the estrus cycle. In untreated slices from females, LA-LTP differed depending on the phase of the estrus cycle. In addition, we show for the first time that the p38 mitogen-activated protein (MAP) kinase inhibitor, SKF 86002, reduced LA-LTP. In males, the effects of ATPA and SKF 86002 were not additive. To the contrary, in females, the exposure to ATPA in control plus SKF 86002 increases LTP relative to control plus SKF 86002 alone. Thus, we demonstrate that the effectiveness of GLU(K5) stimulation on plasticity changes in the amygdala is gender-dependent and that the MAP kinase pathway might be involved in males.	[Albrecht, Doris] Charite, Inst Neurophysiol, CCM, D-10117 Berlin, Germany; [Schubert, Mania] Univ Auckland, Fac Med & Hlth Sci, Dept Physiol, Auckland 1, New Zealand; [Drephal, Christian] Ev Krankenhaus Bielefeld, Med Klin, Bielefeld, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Auckland	Albrecht, D (corresponding author), Charite, Inst Neurophysiol, CCM, Tucholskystr 2, D-10117 Berlin, Germany.	doris.albrecht@charite.de	Schubert, Manja/AAJ-9575-2021	Schubert, Manja/0000-0003-3592-2470				Aroniadou-Anderjaska V, 2007, AMINO ACIDS, V32, P305, DOI 10.1007/s00726-006-0415-x; Bi RF, 2001, P NATL ACAD SCI USA, V98, P13391, DOI 10.1073/pnas.241507698; Bolshakov VY, 2000, NAT NEUROSCI, V3, P1107, DOI 10.1038/80624; Braga MFM, 2003, J NEUROSCI, V23, P442, DOI 10.1523/JNEUROSCI.23-02-00442.2003; Christensen J, 2005, EPILEPSIA, V46, P956, DOI 10.1111/j.1528-1167.2005.51204.x; Clarke VRJ, 1997, NATURE, V389, P599, DOI 10.1038/39315; Cui CH, 1999, J NEUROSCI, V19, P8281; Doyere V, 2003, EUR J NEUROSCI, V17, P2703, DOI 10.1046/j.1460-9568.2003.02707.x; Drephal C, 2006, NEUROBIOL LEARN MEM, V85, P272, DOI 10.1016/j.nlm.2005.11.004; FERKING M, 2000, CURR OPIN NEUROBIOL, V10, P342; Fuller G, 2001, MOL BRAIN RES, V89, P126, DOI 10.1016/S0169-328X(01)00071-7; Galanopoulou AS, 2003, NEUROSCI LETT, V342, P201, DOI 10.1016/S0304-3940(03)00282-9; Good M, 1999, EUR J NEUROSCI, V11, P4476, DOI 10.1046/j.1460-9568.1999.00920.x; Gryder DS, 2003, J NEUROSCI, V23, P7069, DOI 10.1523/JNEUROSCI.23-18-07069.2003; Gu Q, 1996, J NEUROSCI, V16, P3620; Heinbockel T, 2000, J NEUROSCI, V20; Huang CC, 2004, J BIOL CHEM, V279, P12286, DOI 10.1074/jbc.M312868200; Huang YY, 2000, J NEUROSCI, V20, P6317, DOI 10.1523/JNEUROSCI.20-17-06317.2000; Huettner JE, 2003, PROG NEUROBIOL, V70, P387, DOI 10.1016/S0301-0082(03)00122-9; Kaschel T, 2004, SYNAPSE, V53, P141, DOI 10.1002/syn.20045; Li H, 1998, NEUROPHARMACOLOGY, V37, P1279, DOI 10.1016/S0028-3908(98)00109-9; Li H, 2001, NAT NEUROSCI, V4, P612, DOI 10.1038/88432; Lin CH, 2001, NEURON, V31, P841, DOI 10.1016/S0896-6273(01)00433-0; More JCA, 2004, NEUROPHARMACOLOGY, V47, P46, DOI 10.1016/j.neuropharm.2004.03.005; Mulle C, 1998, NATURE, V392, P601, DOI 10.1038/33408; Palomero-Gallagher N, 2003, J COMP NEUROL, V459, P468, DOI 10.1002/cne.10638; Paternain AV, 2000, J NEUROSCI, V20, P196, DOI 10.1523/JNEUROSCI.20-01-00196.2000; Pozzo-Miller LD, 1999, J NEUROPHYSIOL, V81, P1404, DOI 10.1152/jn.1999.81.3.1404; Rogawski MA, 2003, ANN NY ACAD SCI, V985, P150; Romeo RD, 2005, NEUROENDOCRINOLOGY, V81, P391, DOI 10.1159/000089557; Schafe GE, 2000, J NEUROSCI, V20, P8177; SCHUBERT M, 2008, IN PRESS NEUROPSYCHO; Smolders I, 2002, NAT NEUROSCI, V5, P796, DOI 10.1038/nn880; Szymczak S, 2006, HIPPOCAMPUS, V16, P453, DOI 10.1002/hipo.20172; Vignes M, 1998, NEUROPHARMACOLOGY, V37, P1269, DOI 10.1016/S0028-3908(98)00148-8; von Bohlen und Halbach O, 2002, NEUROSCI RES, V44, P91, DOI 10.1016/S0168-0102(02)00092-5; von Bohlen und Halbach O, 1998, J NEUROSCI METH, V81, P169, DOI 10.1016/S0165-0270(98)00026-0; Warren SG, 1995, BRAIN RES, V703, P26, DOI 10.1016/0006-8993(95)01059-9; WATANABE Y, 1995, NEUROSCI RES, V21, P317, DOI 10.1016/0168-0102(94)00867-F; Woolley CS, 2000, EPILEPSIA, V41, P510, DOI 10.1111/j.1528-1157.2000.tb00203.x	41	2	2	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1268	1274		10.1096/fj.07-9415com	http://dx.doi.org/10.1096/fj.07-9415com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	18024837				2022-12-28	WOS:000254581000031
J	Wang, QW; Pang, S				Wang, Qiuwei; Pang, Shen			An intercellular adhesion molecule-3 (ICAM-3)- grabbing nonintegrin (DC-SIGN) efficiently blocks HIV viral budding	FASEB JOURNAL			English	Article						gp120; viral production	IMMUNODEFICIENCY-VIRUS TYPE-1; DENDRITIC CELLS; TRANS-ENHANCEMENT; LANGERHANS CELLS; T-CELLS; INFECTION; BINDING; EXPRESSION; RECEPTORS; TRANSMISSION	Efficient inhibition of the HIV infection, life cycle at the stages of viral infection, reverse transcription, and post-translational processing has been extensively studied. However, efficient inhibition of HIV assembly and budding has not been reported. Here, we report that dendritic cell-specific intercellular adhesion molecule-3 (ICAM-3) -grabbing nonintegrin (DC-SIGN) and its related protein, DC-SIGNR, effectively block HIV budding from infected cells. Cotransfection of DC-SIGN or DC-SIGNR with HIV demonstrated 95-99.5% inhibition of viral production from host cells. DC-SIGN or DC-SIGNR can also effectively inhibit 90-95% of HIV generation from infected cells. DC-SIGN efficiently reduces the amount of gp120 present on the cell plasma membrane, and completely strips off gp120 from the virions produced by the host cells, suggesting that blockage of HIV budding is due to internalization of gp120 by DC-SIGN.	[Wang, Qiuwei; Pang, Shen] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Pang, S (corresponding author), Univ Calif Los Angeles, Sch Dent, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	spang@ucla.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047722] Funding Source: NIH RePORTER; NIAID NIH HHS [AI047722] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balzarini J, 2007, MOL PHARMACOL, V71, P3, DOI 10.1124/mol.106.030155; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Baribaud F, 2001, VIROLOGY, V286, P1, DOI 10.1006/viro.2001.0975; Boggiano C, 2007, J VIROL, V81, P2519, DOI 10.1128/JVI.01661-06; CAMERON PU, 1992, CLIN EXP IMMUNOL, V88, P226, DOI 10.1111/j.1365-2249.1992.tb03066.x; Chow YH, 2002, J ACQ IMMUN DEF SYND, V30, P1, DOI 10.1097/00126334-200205010-00001; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; EARL PL, 1993, AIDS RES HUM RETROV, V9, P589, DOI 10.1089/aid.1993.9.589; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Granelli-Piperno A, 1998, J VIROL, V72, P2733, DOI 10.1128/JVI.72.4.2733-2737.1998; Granelli-Piperno A, 1999, CURR BIOL, V9, P21, DOI 10.1016/S0960-9822(99)80043-8; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; Jameson B, 2002, J VIROL, V76, P1866, DOI 10.1128/JVI.76.4.1866-1875.2002; Kawamura T, 2003, P NATL ACAD SCI USA, V100, P8401, DOI 10.1073/pnas.1432450100; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; MCILROY D, 1995, J VIROL, V69, P4737, DOI 10.1128/JVI.69.8.4737-4745.1995; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Moris A, 2004, BLOOD, V103, P2648, DOI 10.1182/blood-2003-07-2532; Mummidi S, 2001, J BIOL CHEM, V276, P33196, DOI 10.1074/jbc.M009807200; Nabatov AA, 2006, FEBS J, V273, P4944, DOI 10.1111/j.1742-4658.2006.05491.x; Pang S, 2000, J VIROL, V74, P10994, DOI 10.1128/JVI.74.23.10994-11000.2000; Patterson S, 2001, J VIROL, V75, P6710, DOI 10.1128/JVI.75.14.6710-6713.2001; Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; Rubbert A, 1998, J IMMUNOL, V160, P3933; Smed-Sorensen A, 2005, J VIROL, V79, P8861, DOI 10.1128/JVI.79.14.8861-8869.2005; Snyder GA, 2005, J VIROL, V79, P4589, DOI 10.1128/JVI.79.8.4589-4598.2005; Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937; Steinman RM, 2003, CURR TOP MICROBIOL, V276, P1; Turville SG, 2002, NAT IMMUNOL, V3, P975, DOI 10.1038/ni841; Wang QC, 2004, CHINESE MED J-PEKING, V117, P1395; Wang QW, 2007, AIDS RES HUM RETROV, V23, P508, DOI 10.1089/aid.2006.0119; Wu L, 2004, VIROLOGY, V318, P17, DOI 10.1016/j.virol.2003.09.028; Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960; Zaitseva M, 1997, NAT MED, V3, P1369, DOI 10.1038/nm1297-1369; Zheng JY, 2006, JAIDS-J ACQ IMM DEF, V43, P127, DOI 10.1097/01.qai.0000228149.17669.08	37	4	4	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1055	1064		10.1096/fj.07-9443com	http://dx.doi.org/10.1096/fj.07-9443com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	17962491	Bronze			2022-12-28	WOS:000254581000011
J	Norling, LV; Sampaio, ALF; Cooper, D; Perretti, M				Norling, Lucy V.; Sampaio, Andre L. F.; Cooper, Dianne; Perretti, Mauro			Inhibitory control of endothelial galectin-1 on in vitro and in vivo lymphocyte trafficking	FASEB JOURNAL			English	Article						small interfering RNA; homing; delayed-type hypersensitivity	CELL-INTERACTIONS; IL-10 PRODUCTION; EXPRESSION; ADHESION; INFLAMMATION; NEUTROPHILS; LEUKOCYTES; RESOLUTION; INDUCTION; MIGRATION	Galectin-1 (Gal-1) is a beta-galactoside-binding protein, the expression of which is increased in endothelial cells on exposure to proinflammatory stimuli. Through binding of several receptors (CD7, CD45, and CD43) Gal-1 is known to induce apoptosis of activated T lymphocytes, an effect thought to mediate the beneficial effects it exerts in various inflammatory models. The data presented here highlights another function for Gal-1, that of a negative regulator of T-cell recruitment to the endothelium under both physiological and pathophysiological conditions. We have shown, using siRNA to knockdown Gal-1 in endothelial cells, that endogenous Gal-1 limits T-cell capture, rolling, and adhesion to activated endothelial cells under flow. Furthermore, the reverse effect is observed when exogenous human recombinant Gal-1 is added to activated endothelial monolayers whereby a dramatic reduction in lymphocyte recruitment is seen. These findings are corroborated by studies in Gal-1 nun mice in which homing of wild-type (WT) T lymphocytes is significantly increased to mesenteric lymph nodes and to the inflamed paw in a model of delayed-type hypersensitivity. In conclusion, mimicking endothelial Gal-1 actions would be a novel strategy for controlling aberrant T-cell trafficking, hence for the development of innovative anti-inflammatory therapeutics.	[Norling, Lucy V.; Sampaio, Andre L. F.; Cooper, Dianne; Perretti, Mauro] The London, Queen Mary Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England	University of London; Queen Mary University London	Perretti, M (corresponding author), The London, Queen Mary Sch Med & Dent, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	m.perretti@qmul.ac.uk	Norling, Lucy/W-9523-2019; Norling, Lucy/AAO-4645-2020	Norling, Lucy/0000-0001-5316-9115	Arthritis Research UK [18103] Funding Source: Medline; Versus Arthritis [18103] Funding Source: Medline	Arthritis Research UK(Versus Arthritis); Versus Arthritis(Versus Arthritis)		BAUM LG, 1995, GLYCOCONJUGATE J, V12, P63, DOI 10.1007/BF00731870; Baum LG, 2003, CLIN IMMUNOL, V109, P295, DOI 10.1016/j.clim.2003.08.003; Baum LG, 2002, IMMUNITY, V16, P5, DOI 10.1016/S1074-7613(02)00265-0; Cao TV, 2004, MICROCIRCULATION, V11, P615, DOI 10.1080/10739680490503438; Cinamon G, 2001, NAT IMMUNOL, V2, P515, DOI 10.1038/88710; Colnot C, 1998, DEV DYNAM, V211, P306, DOI 10.1002/(SICI)1097-0177(199804)211:4<306::AID-AJA2>3.0.CO;2-L; Gil CD, 2006, INFLAMM RES, V55, P99, DOI 10.1007/s00011-005-0059-4; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Hayhoe RPG, 2006, BLOOD, V107, P2123, DOI 10.1182/blood-2005-08-3099; He J, 2006, LAB INVEST, V86, P578, DOI 10.1038/labinvest.3700420; He JL, 2004, J BIOL CHEM, V279, P4705, DOI 10.1074/jbc.M311183200; HILGENBERG L, 1995, J CELL SCI, V108, P51; La M, 2003, AM J PATHOL, V163, P1505, DOI 10.1016/S0002-9440(10)63507-9; Nguyen JT, 2001, J IMMUNOL, V167, P5697, DOI 10.4049/jimmunol.167.10.5697; Nieminen M, 2006, NAT CELL BIOL, V8, P156, DOI 10.1038/ncb1355; Nolte MA, 2002, IMMUNOLOGY, V106, P299, DOI 10.1046/j.1365-2567.2002.01443.x; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; POIRIER F, 1993, DEVELOPMENT, V119, P1229; Rabinovich G, 1999, J EXP MED, V190, P385, DOI 10.1084/jem.190.3.385; Rabinovich GA, 2000, EUR J IMMUNOL, V30, P1331, DOI 10.1002/(SICI)1521-4141(200005)30:5<1331::AID-IMMU1331>3.3.CO;2-8; Rabinovich GA, 1999, IMMUNOLOGY, V97, P100; Rao RM, 2004, J EXP MED, V200, P713, DOI 10.1084/jem.20040499; Rittner HL, 2001, ANESTHESIOLOGY, V95, P500, DOI 10.1097/00000542-200108000-00036; Santucci L, 2003, GASTROENTEROLOGY, V124, P1381, DOI 10.1016/S0016-5085(03)00267-1; Santucci L, 2000, HEPATOLOGY, V31, P399, DOI 10.1002/hep.510310220; Schreiber TH, 2007, BLOOD, V109, P1381, DOI 10.1182/blood-2006-07-032995; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Shamri R, 2005, NAT IMMUNOL, V6, P497, DOI 10.1038/ni1194; Stillman BN, 2006, J IMMUNOL, V176, P778, DOI 10.4049/jimmunol.176.2.778; Stowell SR, 2007, BLOOD, V109, P219, DOI 10.1182/blood-2006-03-007153; Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482; van der Leij J, 2004, J PATHOL, V204, P511, DOI 10.1002/path.1671; van der Leij J, 2007, MOL IMMUNOL, V44, P506, DOI 10.1016/j.molimm.2006.02.011	35	80	81	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					682	690		10.1096/fj.07-9268com	http://dx.doi.org/10.1096/fj.07-9268com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17965266				2022-12-28	WOS:000254143700007
J	Falagas, ME; Pitsouni, EI; Malietzis, GA; Pappas, G				Falagas, Matthew E.; Pitsouni, Eleni I.; Malietzis, George A.; Pappas, Georgios			Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses	FASEB JOURNAL			English	Article						citation analysis; open access; Medline Institute of Scientific Information (ISI); education electronic databases	WORLD-WIDE-WEB; RESOURCES	The evolution of the electronic age has led to the development of numerous medical databases on the World Wide Web, offering search facilities on a particular subject and the ability to perform citation analysis. We compared the content coverage and practical utility of PubMed, Scopus, Web of Science, and Google Scholar. The official Web pages of the databases were used to extract information on the range of journals covered, search facilities and restrictions, and update frequency. We used the example of a keyword search to evaluate the usefulness of these databases in biomedical information retrieval and a specific published article to evaluate their utility in performing citation analysis. All databases were practical in use and offered numerous search facilities. PubMed and Google Scholar are accessed for free. The keyword search with PubMed offers optimal update frequency and includes online early articles; other databases can rate articles by number of citations, as an index of importance. For citation analysis, Scopus offers about 20% more coverage than Web of Science, whereas Google Scholar offers results of inconsistent accuracy. PubMed remains an optimal tool in biomedical electronic research. Scopus covers a wider journal range, of help both in keyword searching and citation analysis, but it is currently limited to recent articles ( published after 1995) compared with Web of Science. Google Scholar, as for the Web in general, can help in the retrieval of even the most obscure information but its use is marred by inadequate, less often updated, citation information.	[Falagas, Matthew E.; Pitsouni, Eleni I.; Malietzis, George A.] Alfa Inst Biomed Sci, Athens, Greece; [Falagas, Matthew E.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; [Pappas, Georgios] Inst Continuing Med Educ Ioannina, Ioannina, Greece	Alfa Institute Of Biomedical Sciences; Tufts University	Falagas, ME (corresponding author), Alfa Inst Biomed Sci, 9 Neapoleos St, Maroussi 15123, Greece.	m.falagas@aibs.gr	Pappas, Georgios/A-1525-2008; Pappas, Georgios/AAQ-1893-2021	Pappas, Georgios/0000-0002-8425-6091; Malietzis, George/0000-0003-2028-2677				[Anonymous], 2006, PLOS MED, V3, P707, DOI 10.1371/journal.pmed.0030291; Bakkalbasi Nisa, 2006, Biomed Digit Libr, V3, P7, DOI 10.1186/1742-5581-3-7; Banks Marcus A, 2005, Biomed Digit Libr, V2, P2, DOI 10.1186/1742-5581-2-2; Eysenbach G, 2003, CA-CANCER J CLIN, V53, P356, DOI 10.3322/canjclin.53.6.356; Falagas ME, 2006, CLIN INFECT DIS, V43, P630, DOI 10.1086/506443; Henderson J, 2005, CAN MED ASSOC J, V172, P1549, DOI 10.1503/cmaj.050404; Henzinger M, 2004, P NATL ACAD SCI USA, V101, P5186, DOI 10.1073/pnas.0307528100; Pappas G, 2007, J CLIN VIROL, V38, P161, DOI 10.1016/j.jcv.2006.11.006; Tang HW, 2006, BRIT MED J, V333, P1143, DOI 10.1136/bmj.39003.640567.AE; Vine R, 2006, J MED LIBR ASSOC, V94, P97	10	1776	1821	31	523	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2008	22	2					338	342		10.1096/fj.07-9492LSF	http://dx.doi.org/10.1096/fj.07-9492LSF			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17884971				2022-12-28	WOS:000252822600003
J	Lai, TS; Liu, Y; Li, W; Greenberg, CS				Lai, Thung-S.; Liu, Yusha; Li, Weidong; Greenberg, Charles S.			Identification of two GTP-independent alternatively spliced forms of tissue transglutaminase in human leukocytes, vascular smooth muscle, and endothelial cells	FASEB JOURNAL			English	Article						neurodegenerative disease; aging; cell differentiation; extracellular matrix; vascular disease	FACTOR-KAPPA-B; CROSS-LINKING ENZYMES; BINDING PROTEIN; PHOSPHOLIPASE C-DELTA-1; TRANSAMIDATION ACTIVITY; CONFORMATIONAL-CHANGES; NUCLEOTIDE-BINDING; STRUCTURAL BASIS; RETINOIC ACID; MESSENGER-RNA	Tissue transglutaminase (tTG) is a multifunctional enzyme with transglutaminase crosslinking ( TGase), GTP binding, and hydrolysis activities that play a role in many different disorders. We identified, characterized, and investigated the function and stability of two alternatively spliced forms of tTG using biochemical, cellular, and molecular biological approaches. Using a human aortic vascular smooth muscle cells (VSMC) cDNA library, we identified two cDNAs encoding C-terminal truncated forms, tTG(V1) and tTG(V2). tTG(V1,2) mRNAs were synthesized by a rare splicing event using alternate splice sites within exons 12 and 13 of the tTG gene, respectively. Quantitative PCR and immunoblotting demonstrated that there was unique expression and localization of tTG(V1,2) compared with tTG in human umbilical vein endothelial cells ( HUVECs), VSMC, and leukocytes. The loss of C-terminal 52 amino acid residues (AAs) in tTG(V1,2) altered GTP binding, enhanced GTP hydrolysis, rendered the variants insensitive to GTP inhibition, and resulted in < 10% residual Ca+2- dependent TGase activity. Transfection in HEK293 demonstrated a 28- and 5-fold reduction in the expression of tTG(V1) and tTG(V2), respectively, demonstrating that the C-terminal GTP-binding domain is important in stabilizing and promoting the half-life of tTG. The altered affinity for GTP allowed tTG(V1,2) to exhibit enhanced TGase activity when there is a transient increase in Ca+2 levels. The abundance of tTG(V1,2) and its distinct intracellular expression patterns in human vascular cells and leukocytes indicate these isoforms likely have unique physiological functions.	Duke Univ, Med Ctr, Dept Med, Durham, NC USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC USA	Duke University; Duke University	Greenberg, CS (corresponding author), Duke Univ, Med Ctr, Durham, NC 27710 USA.	charles.greenberg@duke.edu		, Thung-Shen/0000-0002-8791-9698; Liu, Yusha/0000-0001-9253-9916	NHLBI NIH HHS [R01 HL072184-02, R01 HL072184-04, R01 HL072184-03, R01 HL072184-01A1, HL072184, R01 HL072184] Funding Source: Medline; NINDS NIH HHS [R21 NS050541-02, R21 NS050541-01A2, NS050541, R21 NS050541] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS050541] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Achyuthan KE, 1996, MOL CELL BIOCHEM, V162, P43; ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Antonyak MA, 2004, J BIOL CHEM, V279, P41461, DOI 10.1074/jbc.M404976200; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; ANTONYAK MA, 2006, P NATL ACAD SCI US; Ast G, 2004, NAT REV GENET, V5, P773, DOI 10.1038/nrg1451; Balajthy Z, 2006, BLOOD, V108, P2045, DOI 10.1182/blood-2004-02-007948; Begg GE, 2006, J BIOL CHEM, V281, P12603, DOI 10.1074/jbc.M600146200; Begg GE, 2006, P NATL ACAD SCI USA, V103, P19683, DOI 10.1073/pnas.0609283103; Boehm JE, 2002, J BIOL CHEM, V277, P20127, DOI 10.1074/jbc.C200147200; BOYUM A, 1964, NATURE, V204, P793, DOI 10.1038/204793a0; Caccamo D, 2005, J NEUROSCI RES, V82, P858, DOI 10.1002/jnr.20683; Cacciamani T, 2002, GENE, V297, P103, DOI 10.1016/S0378-1119(02)00874-0; Casadio R, 1999, EUR J BIOCHEM, V262, P672, DOI 10.1046/j.1432-1327.1999.00437.x; Citron BA, 2002, NEUROCHEM INT, V40, P69, DOI 10.1016/S0197-0186(01)00062-6; Citron BA, 2001, J BIOL CHEM, V276, P3295, DOI 10.1074/jbc.M004776200; Datta S, 2006, BIOCHEMISTRY-US, V45, P13163, DOI 10.1021/bi0606795; Di Venere A, 2000, J BIOL CHEM, V275, P3915, DOI 10.1074/jbc.275.6.3915; Festoff BW, 2002, J NEUROCHEM, V81, P708, DOI 10.1046/j.1471-4159.2002.00850.x; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; Fox JH, 2004, J NEUROCHEM, V91, P413, DOI 10.1111/j.1471-4159.2004.02726.x; Fraij BM, 1997, BBA-GENE STRUCT EXPR, V1354, P65, DOI 10.1016/S0167-4781(97)00132-2; Fraij BM, 1996, BBA-GENE STRUCT EXPR, V1306, P63, DOI 10.1016/0167-4781(95)00219-7; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hang J, 2005, J BIOL CHEM, V280, P23675, DOI 10.1074/jbc.M503323200; Haroon ZA, 2001, LAB INVEST, V81, P83, DOI 10.1038/labinvest.3780214; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Iismaa Siiri E, 2006, Sci STKE, V2006, ppe34, DOI 10.1126/stke.3532006pe34; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P586, DOI 10.1038/nrm1152; Jeon JH, 2002, BIOCHEM BIOPH RES CO, V294, P818, DOI 10.1016/S0006-291X(02)00582-X; Karpuj MV, 1999, P NATL ACAD SCI USA, V96, P7388, DOI 10.1073/pnas.96.13.7388; Lai TS, 1998, J BIOL CHEM, V273, P1776, DOI 10.1074/jbc.273.3.1776; Lai TS, 2004, J NEUROCHEM, V88, P1253, DOI 10.1046/j.1471-4159.2003.02249.x; Lai TS, 1996, J BIOL CHEM, V271, P31191, DOI 10.1074/jbc.271.49.31191; Lee JM, 2004, J BIOL CHEM, V279, P53725, DOI 10.1074/jbc.M407627200; Lesort M, 1998, J BIOL CHEM, V273, P11991, DOI 10.1074/jbc.273.20.11991; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Lu S, 1997, P NATL ACAD SCI USA, V94, P4692, DOI 10.1073/pnas.94.9.4692; Mann AP, 2006, CANCER RES, V66, P8788, DOI 10.1158/0008-5472.CAN-06-1457; Mariani P, 2000, BIOPHYS J, V78, P3240, DOI 10.1016/S0006-3495(00)76860-3; McEwen DP, 2002, METHOD ENZYMOL, V344, P403; McEwen DP, 2001, ANAL BIOCHEM, V291, P109, DOI 10.1006/abio.2001.5011; MIAN S, 1995, FEBS LETT, V370, P27, DOI 10.1016/0014-5793(95)00782-5; Minghetti L, 2005, CURR OPIN NEUROL, V18, P315, DOI 10.1097/01.wco.0000169752.54191.97; Mishra S, 2004, J BIOL CHEM, V279, P23863, DOI 10.1074/jbc.M311919200; MISHRA S, 2006, J BIOL CHEM; Monsonego A, 1998, J MOL BIOL, V282, P713, DOI 10.1006/jmbi.1998.2052; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; Mueller WH, 2000, J CELL PHYSIOL, V182, P50, DOI 10.1002/(SICI)1097-4652(200001)182:1<50::AID-JCP6>3.0.CO;2-6; Murthy SNP, 1999, P NATL ACAD SCI USA, V96, P11815, DOI 10.1073/pnas.96.21.11815; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Otake Yoko, 2004, Curr Opin Investig Drugs, V5, P616; Peng XJ, 1999, FEBS LETT, V446, P35, DOI 10.1016/S0014-5793(99)00018-6; Sane DC, 2007, FRONT BIOSCI-LANDMRK, V12, P2530, DOI 10.2741/2253; Shin Joo-Ho, 2004, Proteome Sci, V2, P2, DOI 10.1186/1477-5956-2-2; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; Tolentino PJ, 2004, J NEUROCHEM, V89, P1301, DOI 10.1111/j.1471-4159.2004.02436.x; Tolentino PJ, 2002, J NEUROCHEM, V80, P579, DOI 10.1046/j.0022-3042.2001.00726.x; Willard FS, 2005, ANAL BIOCHEM, V340, P341, DOI 10.1016/j.ab.2005.02.015; Xu L, 2006, P NATL ACAD SCI USA, V103, P9023, DOI 10.1073/pnas.0602681103; Yamaga M, 1999, J BIOL CHEM, V274, P28537, DOI 10.1074/jbc.274.40.28537	66	35	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4131	4143		10.1096/fj.06-7598com	http://dx.doi.org/10.1096/fj.06-7598com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17609251	Green Accepted			2022-12-28	WOS:000251283500038
J	Lau, E; Tsuji, T; Guo, L; Lu, SH; Jiang, W				Lau, Eric; Tsuji, Toshiya; Guo, Liping; Lu, Shih-Hsin; Jiang, Wei			The role of pre-replicative complex (pre-RC) components in oncogenesis	FASEB JOURNAL			English	Review						DNA replication; pre-RC formation; tumorigenesis	S-PHASE CHECKPOINT; MINICHROMOSOME MAINTENANCE PROTEIN-2; ORIGIN RECOGNITION COMPLEX; CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; CELL-CYCLE; RE-REPLICATION; MULTIPROTEIN COMPLEX; GENOMIC INSTABILITY; ATP-HYDROLYSIS	Normal DNA replication is stringently regulated to ensure a timely occurrence no more than once per cell cycle. Abrogation of the exquisite control mechanisms that maintain this process results in detrimental gains and losses of genomic DNA commonly seen in cancer and developmental defects. Replication initiation proteins, known as prereplicative complex (pre-RC) proteins, serve as a primary level of regulation, controlling when DNA replication can begin. Unsurprisingly, several pre-RC proteins are overexpressed in cancer and serve as good tumor markers. However, their direct correlation with increasing tumor grade and poor prognosis has posed a long- standing question: Are pre-RC proteins oncogenic? Recently, a growing body of data indicates that deregulation of individual pre- RC proteins, either by overexpression or functional deficiency in several organismal models, results in significant and consistently perturbed cell cycle regulation, genomic instability, and, potentially, tumorigenesis. In this review, we examine this broad range of evidence suggesting that pre- RC proteins play roles during oncogenesis that are more than simply indicative of proliferation, supporting the notion that pre- RC proteins may potentially have significant diagnostic and therapeutic value.	Burnham Inst Med Res, La Jolla, CA 92037 USA; Univ Calif San Diego, Grad Program Mol Pathol, La Jolla, CA 92093 USA; Chinese Acad Med Sci, Inst Canc, Beijing, Peoples R China	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; Chinese Academy of Medical Sciences - Peking Union Medical College	Jiang, W (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wjiang@burnham.org		Jiang, Wei/0000-0002-2309-9571	NATIONAL CANCER INSTITUTE [R01CA097950, T32CA077109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067859] Funding Source: NIH RePORTER; NCI NIH HHS [CA97950, 2T32 CA77109-06A2] Funding Source: Medline; NIGMS NIH HHS [GM67859] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anger M, 2005, BIOL REPROD, V72, P188, DOI 10.1095/biolreprod.104.035451; Aparicio T, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-18; Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; Arias EE, 2005, GENE DEV, V19, P114, DOI 10.1101/gad.1255805; Ball HL, 2005, MOL BIOL CELL, V16, P2372, DOI 10.1091/mbc.e04-11-1006; Ballabeni A, 2004, EMBO J, V23, P3122, DOI 10.1038/sj.emboj.7600314; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Blow J J, 1987, Philos Trans R Soc Lond B Biol Sci, V317, P483, DOI 10.1098/rstb.1987.0075; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Bonds Lian, 2002, Arch Pathol Lab Med, V126, P1164; Bravou V, 2005, INT J ONCOL, V27, P1511; Clay-Farrace L, 2003, EMBO J, V22, P704, DOI 10.1093/emboj/cdg046; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6; Davidson IF, 2006, MOL CELL, V24, P433, DOI 10.1016/j.molcel.2006.09.010; DEPAMPHILIS ML, 2006, DNA REPLICATION HUMA; Duesberg P, 2006, CONTRIB MICROBIOL, V13, P16, DOI 10.1159/000092963; Dutta A, 2007, NAT GENET, V39, P10, DOI 10.1038/ng0107-10; Feng DR, 2003, CANCER RES, V63, P7356; Fujita M, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-22; Gambus A, 2006, NAT CELL BIOL, V8, P358, DOI 10.1038/ncb1382; Gibson DG, 2006, GENES CELLS, V11, P557, DOI 10.1111/j.1365-2443.2006.00967.x; Going JJ, 2002, GUT, V50, P373, DOI 10.1136/gut.50.3.373; Gonzalez MA, 2005, NAT REV CANCER, V5, P135, DOI 10.1038/nrc1548; Gonzalez MA, 2003, J CLIN ONCOL, V21, P4306, DOI 10.1200/JCO.2003.04.121; Gonzalez S, 2006, NATURE, V440, P702, DOI 10.1038/nature04585; Green BM, 2006, MOL BIOL CELL, V17, P2401, DOI 10.1091/mbc.E05-11-1043; Guo BQ, 2005, EUR J CELL BIOL, V84, P927, DOI 10.1016/j.ejcb.2005.09.016; Hermand D, 2007, MOL CELL, V26, P553, DOI 10.1016/j.molcel.2007.04.014; Hess GF, 1998, GENE, V211, P133, DOI 10.1016/S0378-1119(98)00094-8; Higa LA, 2006, CELL CYCLE, V5, P1675, DOI 10.4161/cc.5.15.3149; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Honeycutt KA, 2006, ONCOGENE, V25, P4027, DOI 10.1038/sj.onc.1209435; Huang HK, 2005, MOL CELL BIOL, V25, P9000, DOI 10.1128/MCB.25.20.9000-9015.2005; Jin JP, 2006, MOL CELL, V23, P709, DOI 10.1016/j.molcel.2006.08.010; Karakaidos P, 2004, AM J PATHOL, V165, P1351, DOI 10.1016/S0002-9440(10)63393-7; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Kim JM, 2002, EMBO J, V21, P2168, DOI 10.1093/emboj/21.9.2168; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lau E, 2006, EMBO REP, V7, P425, DOI 10.1038/sj.embor.7400624; Lau E, 2006, CELL CYCLE, V5, P1602, DOI 10.4161/cc.5.15.3124; Lei M, 2001, J CELL SCI, V114, P1447; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; Li A, 2005, EMBO J, V24, P395, DOI 10.1038/sj.emboj.7600520; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; Lutzmann M, 2006, EMBO J, V25, P5764, DOI 10.1038/sj.emboj.7601436; Machida YJ, 2005, J BIOL CHEM, V280, P27624, DOI 10.1074/jbc.M502615200; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Masai H, 2005, IUBMB LIFE, V57, P323, DOI 10.1080/15216540500092419; Masai H, 2006, J BIOL CHEM, V281, P39249, DOI 10.1074/jbc.M608935200; McNairn AJ, 2005, J CELL BIOCHEM, V96, P879, DOI 10.1002/jcb.20609; Melixetian M, 2004, J CELL BIOL, V165, P473, DOI 10.1083/jcb.200403106; Montagnoli A, 2004, CANCER RES, V64, P7110, DOI 10.1158/0008-5472.CAN-04-1547; Montanari M, 2005, J CELL PHYSIOL, V202, P215, DOI 10.1002/jcp.20120; Moyer SE, 2006, P NATL ACAD SCI USA, V103, P10236, DOI 10.1073/pnas.0602400103; Murphy N, 2005, J CLIN PATHOL, V58, P525, DOI 10.1136/jcp.2004.018895; Obama K, 2005, ONCOL REP, V14, P701; Oehlmann M, 2004, J CELL BIOL, V165, P181, DOI 10.1083/jcb.200311044; Ohta S, 2001, ONCOL REP, V8, P1063; Pacek M, 2006, MOL CELL, V21, P581, DOI 10.1016/j.molcel.2006.01.030; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Randell JCW, 2006, MOL CELL, V21, P29, DOI 10.1016/j.molcel.2005.11.023; Ryu S, 2005, P NATL ACAD SCI USA, V102, P18467, DOI 10.1073/pnas.0506187102; Semple JW, 2006, EMBO J, V25, P5150, DOI 10.1038/sj.emboj.7601391; Seo J, 2005, ONCOGENE, V24, P8176, DOI 10.1038/sj.onc.1208881; Shechter D, 2004, J BIOL CHEM, V279, P45586, DOI 10.1074/jbc.M407772200; Shetty A, 2005, BRIT J CANCER, V93, P1295, DOI 10.1038/sj.bjc.6602829; Sheu YJ, 2006, MOL CELL, V24, P101, DOI 10.1016/j.molcel.2006.07.033; Shima N, 2007, NAT GENET, V39, P93, DOI 10.1038/ng1936; Shimada K, 2002, GENE DEV, V16, P3236, DOI 10.1101/gad.239802; Shreeram S, 2002, ONCOGENE, V21, P6624, DOI 10.1038/sj.onc.1205910; Shrestha P, 2007, CANCER-AM CANCER SOC, V109, P949, DOI 10.1002/cncr.22474; Speck C, 2005, NAT STRUCT MOL BIOL, V12, P965, DOI 10.1038/nsmb1002; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Tada S, 2007, FRONT BIOSCI-LANDMRK, V12, P1629, DOI 10.2741/2175; Takayama Y, 2003, GENE DEV, V17, P1153, DOI 10.1101/gad.1065903; Takeda DY, 2005, J BIOL CHEM, V280, P23416, DOI 10.1074/jbc.M501208200; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Tatsumi Y, 2003, J BIOL CHEM, V278, P41528, DOI 10.1074/jbc.M307534200; Tatsumi Y, 2006, J CELL SCI, V119, P3128, DOI 10.1242/jcs.03031; Teer JK, 2006, J BIOL CHEM, V281, P6253, DOI 10.1074/jbc.M507150200; Tsao CC, 2004, EMBO J, V23, P4660, DOI 10.1038/sj.emboj.7600463; Tsuji T, 2006, MOL BIOL CELL, V17, P4459, DOI 10.1091/mbc.E06-03-0241; Tye BK, 2004, FRONT BIOSCI-LANDMRK, V9, P2548, DOI 10.2741/1416; Vashee S, 2003, GENE DEV, V17, P1894, DOI 10.1101/gad.1084203; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; Weinreich M, 2001, P NATL ACAD SCI USA, V98, P11211, DOI 10.1073/pnas.201387198; Wharton SB, 2004, BRIT J CANCER, V91, P262, DOI 10.1038/sj.bjc.6601949; Williams GH, 2004, BRIT J CANCER, V91, P714, DOI 10.1038/sj.bjc.6602028; Williams GH, 1998, P NATL ACAD SCI USA, V95, P14932, DOI 10.1073/pnas.95.25.14932; Wolf DA, 1996, J BIOL CHEM, V271, P32503, DOI 10.1074/jbc.271.51.32503; Woodward AM, 2006, J CELL BIOL, V173, P673, DOI 10.1083/jcb.200602108; Xouri G, 2004, EUR J BIOCHEM, V271, P3368, DOI 10.1111/j.1432-1033.2004.04271.x; Yoo HY, 2004, J BIOL CHEM, V279, P53353, DOI 10.1074/jbc.M408026200; Yoshida K, 2004, ONCOGENE, V23, P58, DOI 10.1038/sj.onc.1206987; Zhu WG, 2006, MOL CELL BIOL, V26, P4601, DOI 10.1128/MCB.02141-05; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	104	38	45	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3786	3794		10.1096/fj.07-8900rev	http://dx.doi.org/10.1096/fj.07-8900rev			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17690155				2022-12-28	WOS:000251283500003
J	Taboubi, S; Milanini, J; Delamarre, E; Parat, F; Garrouste, F; Pommier, G; Takasaki, J; Hubaud, JC; Kovacic, H; Lehmann, M				Taboubi, Salma; Milanini, Julie; Delamarre, Estelle; Parat, Fabrice; Garrouste, Francoise; Pommier, Gilbert; Takasaki, Jun; Hubaud, Jean-Claude; Kovacic, Herve; Lehmann, Maxime			G alpha(q/11)-coupled P2Y(2) nucleotide receptor inhibits human keratinocyte spreading and migration	FASEB JOURNAL			English	Article						GPCR; wound healing; PI3K/Akt; MAPK; UTP	MUSCLE CELL-MIGRATION; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; EXTRACELLULAR NUCLEOTIDES; EPIDERMAL HOMEOSTASIS; ACTIN POLYMERIZATION; HACAT KERATINOCYTES; INDUCE CHEMOTAXIS; EPITHELIAL-CELLS; FOCAL ADHESION	Reepithelialization is a critical step in wound healing. It is initiated by keratinocyte migration at the wound edges. After wounding, extracellular nucleotides are released by keratinocytes and other skin cells. Here, we report that activation of P2Y(2) nucleotide receptor by ATP/UTP inhibits keratinocyte cell spreading and induces lamellipodium withdrawal. Kymography analysis demonstrates that these effects correlate with a durable decrease of lamellipodium dynamics. P2Y2 receptor activation also induces a dramatic dismantling of the actin network, the loss of alpha 3 integrin expression at the cell periphery, and the dissolution of focal contacts as indicated by the alteration of alpha v integrins and focal contact protein distribution. In addition, activation of P2Y(2)R prevents growth factor-induced phosphorylation of Erk(1,2) and Akt/ PkB. The use of a specific pharmacological inhibitor (YM-254890), the depletion of G alpha((q/ 11)) by siRNA, or the expression of a constitutively active G alpha(( q/ 11)) mutant (Q209L) show that activation of G alpha((q/ 11)) is responsible for these ATP/UTP-induced effects. Finally, we report that ATP delays growth factor-induced wound healing of keratinocyte monolayers. Collectively, these findings provide evidence for a unique and important role for extracellular nucleotides as efficient autocrine/paracrine regulators of keratinocyte shape and migration during wound healing. -Taboubi, S., Milanini, J., Delamarre, E., Parat, F., Garrouste, F., Pommier, G., Takasaki, J., Hubaud, J-C., Kovacic, H., Lehmann, M. G alpha((q/ 11))coupled P2Y2 Nucleotide Receptor Inhibits Human Keratinocyte Spreading and Migration.	Univ Aix Marseille 1, CISMET, FRE, CNRS,Fac Pharm, Marseille, France; Astellas Pharma Inc, Drug Discovery Res & Mol Med Res Lab, Ibaraki, Japan; DIPTA, Aix En Provence, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Astellas Pharmaceuticals	Lehmann, M (corresponding author), CISMET, FRE, CNRS, Fac Pharm, 27 Bd Jean Moulin, F-13005 Marseille, France.	maxime.lehmann@pharmacie.univ-mrs.fr	kovacic, hervé/ABF-2451-2020	Kovacic, Herve/0000-0001-6509-4210; Milanini, Julie/0000-0002-5861-2830				Arthur DB, 2005, P NATL ACAD SCI USA, V102, P19138, DOI 10.1073/pnas.0505913102; Atkinson PJ, 2006, MOL PHARMACOL, V69, P174, DOI 10.1124/mol.105.014258; Bagchi S, 2005, J BIOL CHEM, V280, P39050, DOI 10.1074/jbc.M504819200; Ballou LM, 2006, BIOCHEM J, V394, P557, DOI 10.1042/BJ20051493; Ballou LM, 2003, J BIOL CHEM, V278, P23472, DOI 10.1074/jbc.M212232200; Ballou LM, 2000, J BIOL CHEM, V275, P4803, DOI 10.1074/jbc.275.7.4803; Barnes WG, 2005, J BIOL CHEM, V280, P8041, DOI 10.1074/jbc.M412924200; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Bommakanti RK, 2000, J BIOL CHEM, V275, P38870, DOI 10.1074/jbc.M007403200; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Burnstock G, 2006, BRIT J PHARMACOL, V147, pS172, DOI 10.1038/sj.bjp.0706429; Burrell HE, 2005, J BIOL CHEM, V280, P29667, DOI 10.1074/jbc.M505381200; Burrell HE, 2003, J INVEST DERMATOL, V120, P440, DOI 10.1046/j.1523-1747.2003.12050.x; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Chaulet H, 2001, CIRC RES, V89, P772, DOI 10.1161/hh2101.098617; Chen Y, 2006, SCIENCE, V314, P1792, DOI 10.1126/science.1132559; Choma DP, 2004, J CELL SCI, V117, P3947, DOI 10.1242/jcs.01251; Czajkowski R, 2004, BRIT J PHARMACOL, V141, P497, DOI 10.1038/sj.bjp.0705639; Decline F, 2001, J CELL SCI, V114, P811; Denda M, 2002, J INVEST DERMATOL, V119, P1034, DOI 10.1046/j.1523-1747.2002.19505.x; Dixon CJ, 1999, BRIT J PHARMACOL, V127, P1680, DOI 10.1038/sj.bjp.0702653; Erb L, 2001, J CELL BIOL, V153, P491, DOI 10.1083/jcb.153.3.491; Erb L, 2006, PFLUG ARCH EUR J PHY, V452, P552, DOI 10.1007/s00424-006-0069-2; Fan GF, 2003, J BIOL CHEM, V278, P52432, DOI 10.1074/jbc.M310982200; Greig AVH, 2003, EXP DERMATOL, V12, P860, DOI 10.1111/j.0906-6705.2003.00110.x; Greig AVH, 2003, J INVEST DERMATOL, V120, P1007, DOI 10.1046/j.1523-1747.2003.12261.x; Haase I, 2003, J CELL SCI, V116, P3227, DOI 10.1242/jcs.00610; Hinz B, 1999, EXP CELL RES, V251, P234, DOI 10.1006/excr.1999.4541; Howes AL, 2003, J BIOL CHEM, V278, P40343, DOI 10.1074/jbc.M305964200; Hubbard KB, 2006, CELL SIGNAL, V18, P135, DOI 10.1016/j.cellsig.2005.08.004; Idzko M, 2002, BLOOD, V100, P925, DOI 10.1182/blood.V100.3.925; Kaczmarek E, 2005, THROMB HAEMOSTASIS, V93, P735, DOI 10.1160/TH04-09-0576; Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105; Klepeis VE, 2004, J CELL BIOCHEM, V93, P1115, DOI 10.1002/jcb.20258; Koizumi S, 2004, BIOCHEM J, V380, P329, DOI 10.1042/BJ20031089; Laforest S, 2005, MOL CELL NEUROSCI, V30, P418, DOI 10.1016/j.mcn.2005.08.006; Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785; Lee WK, 2001, J DERMATOL SCI, V25, P97, DOI 10.1016/S0923-1811(00)00117-1; Lenz G, 2001, J NEUROCHEM, V77, P1001, DOI 10.1046/j.1471-4159.2001.00299.x; Liu J, 2004, J BIOL CHEM, V279, P8212, DOI 10.1074/jbc.M312230200; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Motley ED, 2003, HYPERTENSION, V41, P775, DOI 10.1161/01.HYP.0000051891.90321.12; Pankow S, 2006, J CELL SCI, V119, P4033, DOI 10.1242/jcs.03175; Pasquier E, 2005, CANCER RES, V65, P2433, DOI 10.1158/0008-5472.CAN-04-2624; Pillois X, 2002, CIRC RES, V90, P678, DOI 10.1161/01.RES.0000013700.98464.8E; Pintor J, 2004, OPHTHAL PHYSL OPT, V24, P186, DOI 10.1111/j.1475-1313.2004.00182.x; Pullar CE, 2006, FASEB J, V20, P76, DOI 10.1096/fj.05-4188com; Pullar CE, 2006, J CELL SCI, V119, P592, DOI 10.1242/jcs.02772; Pullar CE, 2003, J BIOL CHEM, V278, P22555, DOI 10.1074/jbc.M300205200; Rigot V, 1998, J CELL SCI, V111, P3119; RODIUS S, 2004, UNPUB LOSS INTEGRIN; Russell AJ, 2003, J CELL SCI, V116, P3543, DOI 10.1242/jcs.00663; Santoro MM, 2005, EXP CELL RES, V304, P274, DOI 10.1016/j.yexcr.2004.10.033; Sauzeau V, 2000, AM J PHYSIOL-HEART C, V278, pH1751, DOI 10.1152/ajpheart.2000.278.6.H1751; Schnurr M, 2003, BLOOD, V102, P613, DOI 10.1182/blood-2002-12-3745; Seye CI, 2004, J BIOL CHEM, V279, P35679, DOI 10.1074/jbc.M401799200; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; Taniguchi M, 2003, J ANTIBIOT, V56, P358, DOI 10.7164/antibiotics.56.358; Ueda H, 2004, EXP CELL RES, V298, P207, DOI 10.1016/j.yexcr.2004.04.015; Verghese MW, 1996, J BIOL CHEM, V271, P15597, DOI 10.1074/jbc.271.26.15597; Wang M, 2005, J NEUROCHEM, V95, P630, DOI 10.1111/j.1471-4159.2005.03408.x; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Wu EHT, 2006, FEBS J, V273, P2388, DOI 10.1111/j.1742-4658.2006.05245.x; Yin J, 2007, J CELL SCI, V120, P815, DOI 10.1242/jcs.03389; Yoshida H, 2006, EUR J PHARMACOL, V540, P1, DOI 10.1016/j.ejphar.2006.04.008	67	39	40	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4047	4058		10.1096/fj.06-7476com	http://dx.doi.org/10.1096/fj.06-7476com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17609252				2022-12-28	WOS:000251283500029
J	Levine, SM; Lin, EA; Emara, W; Kang, J; DiBenedetto, M; Ando, T; Falush, D; Blaser, MJ				Levine, Steven M.; Lin, Edward A.; Emara, Walid; Kang, Josephine; DiBenedetto, Michael; Ando, Takafumi; Falush, Daniel; Blaser, Martin J.			Plastic cells and populations: DNA substrate characteristics in Helicobacter pylori transformation define a flexible but conservative system for genomic variation	FASEB JOURNAL			English	Article						bacterial genetics; microbiology; pathogenesis; molecular biology; colonization; microbial diversity	RESTRICTION-MODIFICATION SYSTEMS; NATURAL TRANSFORMATION; GENETIC-TRANSFORMATION; HEMOPHILUS-INFLUENZAE; MISMATCH-REPAIR; STREPTOCOCCUS-PNEUMONIAE; SALMONELLA-TYPHIMURIUM; NEISSERIA-GONORRHOEAE; MOLECULAR-MECHANISMS; GASTRIC COLONIZATION	Helicobacter pylori, bacteria that colonize the human gastric mucosa, are naturally competent for transformation by exogenous DNA, and show a panmictic population structure. To understand the mechanisms involved in its horizontal gene transfer, we sought to define the interval required from exposure to substrate DNA until DNA uptake and expression of a selectable phenotype, as well as the relationship of transforming fragment length, concentration, homology, symmetry, and strandedness, to the transformation frequency. We provide evidence that natural transformation in H. pylori differs in efficiency among wild-type strains but is saturable and varies with substrate DNA length, symmetry, strandedness, and species origin. We show that H. pylori cells can be transformed within one minute of contact with DNA, by DNA fragments as small as 50 bp, and as few as 5 bp on one flank of a selectable single nucleotide mutation is sufficient substrate for recombination of a transforming fragment, and that double-stranded DNA is the preferred (1000-fold > single-stranded) substrate. The high efficiency of double-stranded DNA as transformation substrate, in conjunction with strain-specific restriction endonucleases suggests a model of short-fragment recombination favoring closest relatives, consistent with the observed H. pylori population biology.	NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; Nagoya Univ, Grad Sch Med, Dept Gastroenterol, Nagoya, Aichi, Japan; Peter Medawar Bldg Pathogen Res, Dept Stat, Oxford, England	New York University; New York University; Nagoya University; University of Oxford	Blaser, MJ (corresponding author), NYU, Sch Med, Dept Med, 550 1st Ave, New York, NY 10016 USA.	martin.blaser@med.nyu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T35DK007421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063270] Funding Source: NIH RePORTER; NIDDK NIH HHS [T35 DK007421] Funding Source: Medline; NIGMS NIH HHS [R01 GM63270] Funding Source: Medline; Wellcome Trust [069662] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Akopyants NS, 1998, P NATL ACAD SCI USA, V95, P13108, DOI 10.1073/pnas.95.22.13108; ALBRITTON WL, 1984, MOL GEN GENET, V193, P358, DOI 10.1007/BF00330693; ALM RA, 1999, HELICOBACTER PYLORI, V397, P176; Ando T, 2000, MOL MICROBIOL, V37, P1052, DOI 10.1046/j.1365-2958.2000.02049.x; Ando T, 1999, J BACTERIOL, V181, P5572, DOI 10.1128/JB.181.18.5572-5580.1999; Aras RA, 2002, NUCLEIC ACIDS RES, V30, P5391, DOI 10.1093/nar/gkf686; Ausubel FM, 1988, MOL REPROD DEV; Baltrus DA, 2006, FEMS MICROBIOL LETT, V255, P148, DOI 10.1111/j.1574-6968.2005.00066.x; BAROUKI R, 1986, J BIOL CHEM, V261, P8617; Bart A, 2000, MICROBIOL-UK, V146, P1255, DOI 10.1099/00221287-146-6-1255; Berg DE, 1997, CLIN INFECT DIS, V25, P996, DOI 10.1086/516081; Bik EM, 2006, P NATL ACAD SCI USA, V103, P732, DOI 10.1073/pnas.0506655103; CARLSON CA, 1983, J BACTERIOL, V153, P93, DOI 10.1128/JB.153.1.93-99.1983; Chen I, 2004, NAT REV MICROBIOL, V2, P241, DOI 10.1038/nrmicro844; Donahue JP, 2000, MOL MICROBIOL, V37, P1066, DOI 10.1046/j.1365-2958.2000.02036.x; Dubnau D, 2000, RES MICROBIOL, V151, P475, DOI 10.1016/S0923-2508(00)00166-2; Dubois A, 1999, GASTROENTEROLOGY, V116, P90, DOI 10.1016/S0016-5085(99)70232-5; Falush D, 2001, P NATL ACAD SCI USA, V98, P15056, DOI 10.1073/pnas.251396098; FERRERO RL, 1994, INFECT IMMUN, V62, P4981, DOI 10.1128/IAI.62.11.4981-4989.1994; Ghose C, 2005, J CLIN MICROBIOL, V43, P2635, DOI 10.1128/JCM.43.6.2635-2641.2005; Guruge JL, 1998, P NATL ACAD SCI USA, V95, P3925, DOI 10.1073/pnas.95.7.3925; Hoffman PS, 1996, J BACTERIOL, V178, P4822, DOI 10.1128/jb.178.16.4822-4829.1996; Hofreuter D, 2000, RES MICROBIOL, V151, P487, DOI 10.1016/S0923-2508(00)00164-9; Hofreuter D, 1998, MOL MICROBIOL, V28, P1027, DOI 10.1046/j.1365-2958.1998.00879.x; Hofreuter D, 2001, MOL MICROBIOL, V41, P379, DOI 10.1046/j.1365-2958.2001.02502.x; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Israel DA, 2000, FEMS MICROBIOL LETT, V186, P275, DOI 10.1016/S0378-1097(00)00156-7; Israel DA, 2001, J CLIN INVEST, V107, P611, DOI 10.1172/JCI11450; Kamba M, 2001, INT J PHARM, V228, P209, DOI 10.1016/S0378-5173(01)00844-4; Kang J, 2005, J BACTERIOL, V187, P3528, DOI 10.1128/JB.187.10.3528-3537.2005; Kang J, 2004, J BACTERIOL, V186, P7704, DOI 10.1128/JB.186.22.7704-7713.2004; Kang J, 2006, NAT REV MICROBIOL, V4, P826, DOI 10.1038/nrmicro1528; Kong HM, 2000, NUCLEIC ACIDS RES, V28, P3216, DOI 10.1093/nar/28.17.3216; Kuipers EJ, 2000, J INFECT DIS, V181, P273, DOI 10.1086/315173; Kuipers EJ, 1998, J BACTERIOL, V180, P2901, DOI 10.1128/JB.180.11.2901-2905.1998; LORENZ MG, 1994, MICROBIOL REV, V58, P563, DOI 10.1128/MMBR.58.3.563-602.1994; Lundstrom AM, 2001, HELICOBACTER, V6, P44, DOI 10.1046/j.1523-5378.2001.00006.x; MATHIS LS, 1982, J GEN MICROBIOL, V128, P1159; McGowan CC, 1998, MOL MICROBIOL, V30, P19, DOI 10.1046/j.1365-2958.1998.t01-1-01079.x; MEJEAN V, 1988, MOL GEN GENET, V213, P444, DOI 10.1007/BF00339614; MORRISON DA, 1972, J BACTERIOL, V112, P220, DOI 10.1128/JB.112.1.220-223.1972; NEDENSKOVSORENSEN P, 1990, J INFECT DIS, V161, P365, DOI 10.1093/infdis/161.2.365; Normark S, 2003, ADV CANCER RES, V90, P63, DOI 10.1016/S0065-230X(03)90002-9; Oh JD, 2006, P NATL ACAD SCI USA, V103, P9999, DOI 10.1073/pnas.0603784103; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; Pasta F, 1999, P NATL ACAD SCI USA, V96, P2943, DOI 10.1073/pnas.96.6.2943; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Pinto AV, 2005, MOL CELL, V17, P113, DOI 10.1016/j.molcel.2004.11.035; POSTEL EH, 1966, J MOL BIOL, V16, P317, DOI 10.1016/S0022-2836(66)80175-4; Pot RGJ, 2001, ANTIMICROB AGENTS CH, V45, P2975, DOI 10.1128/AAC.45.10.2975-2976.2001; Pride DT, 2002, J MOL BIOL, V316, P629, DOI 10.1006/jmbi.2001.5311; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; Sambrook J., 2002, MOL CLONING LAB MANU; Saunders NJ, 1999, MICROBIOL-SGM, V145, P3523, DOI 10.1099/00221287-145-12-3523; SCHMID EN, 1990, J MED MICROBIOL, V32, P101, DOI 10.1099/00222615-32-2-101; Schofield MJ, 2003, ANNU REV MICROBIOL, V57, P579, DOI 10.1146/annurev.micro.57.030502.090847; SCOCCA JJ, 1974, J BACTERIOL, V118, P369, DOI 10.1128/JB.118.2.369-373.1974; Smeets LC, 2000, J BACTERIOL, V182, P3948, DOI 10.1128/JB.182.14.3948-3954.2000; Smeets LC, 2002, TRENDS MICROBIOL, V10, P159, DOI 10.1016/S0966-842X(02)02314-4; Smeets LC, 2000, FEMS IMMUNOL MED MIC, V27, P99; STEIN DC, 1991, CAN J MICROBIOL, V37, P345, DOI 10.1139/m91-056; Suerbaum S, 1998, P NATL ACAD SCI USA, V95, P12619, DOI 10.1073/pnas.95.21.12619; Takata T, 2002, NUCLEIC ACIDS RES, V30, P2444, DOI 10.1093/nar/30.11.2444; THOMPSON SA, 1995, INFECT IMMUN, V63, P2185, DOI 10.1128/IAI.63.6.2185-2193.1995; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TSUDA M, 1993, MICROBIOL IMMUNOL, V37, P85, DOI 10.1111/j.1348-0421.1993.tb03184.x; WANG Y, 1993, J GEN MICROBIOL, V139, P2485, DOI 10.1099/00221287-139-10-2485; WILSON GG, 1991, NUCLEIC ACIDS RES, V19, P2539, DOI 10.1093/nar/19.10.2539; Wirth HP, 1996, INFECT IMMUN, V64, P4598, DOI 10.1128/IAI.64.11.4598-4605.1996; Xu Q, 2000, P NATL ACAD SCI USA, V97, P9671, DOI 10.1073/pnas.97.17.9671; Yeh YC, 2003, INFECT IMMUN, V71, P5427, DOI 10.1128/IAI.71.9.5427-5431.2003; Zahrt TC, 1997, P NATL ACAD SCI USA, V94, P9786, DOI 10.1073/pnas.94.18.9786	72	44	45	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3458	3467		10.1096/fj.07-8501com	http://dx.doi.org/10.1096/fj.07-8501com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17567566				2022-12-28	WOS:000250517800009
J	Pederson, T				Pederson, Thoru			Ribosomal protein mutations in Diamond-Blackfan anemia: might they operate upstream from protein synthesis?	FASEB JOURNAL			English	Article						pediatric hematology; nucleolus; cell cycle control	S19 GENE; NUCLEOLUS; RNA	The inherited bone marrow failure syndromes are clinically distinct but share some common features. Difficult to treat and typified by a poor prognosis, their pathogenesis is unknown. Recent findings that some patients with the erythroblastopenia Diamond-Blackfan anemia (DBA) have mutations in ribosomal proteins have led to the idea that this and perhaps other bone marrow failure disorders result from an inadequate supply of normally functioning ribosomes. According to this hypothesis, an insufficiency of the protein synthetic capacity limits the replicative potential of cells, with the DBA disease phenotype in particular arising from a block of one or more of the two to four critical, temporally compressed cell divisions in the differentiation program of the erythroid lineage in the fetal liver and the postnatal bone marrow. Here I propose an alternative ( but not mutually exclusive) hypothesis centered on nucleoli: the specialized intranuclear domains within which ribosomes are assembled. It was recently discovered that the nucleoli contain cell cycle machinery in close proximity to nascent ribosomes. Although mutations in ribosomal proteins might be expected to negatively influence the cell's protein synthetic capacity, I suggest it is also possible that the DBA mutations directly affect the nucleolus to destabilize or otherwise deregulate the coresident cell cycle machinery. This hypothesis envisions that the ribosomal protein mutations discovered in DBA act upstream from ribosome assembly by interfering with the staging of cell cycle progression machinery in the nucleolus, in a pretranslational mode of pathogenesis.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Program Cell Dynam, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Pederson, T (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Program Cell Dynam, 377 Plantat St, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021595] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-21595] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alter BP, 1998, NATHAN OSKIS HEMATOL, P237; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Choesmel V, 2007, BLOOD, V109, P1275, DOI 10.1182/blood-2006-07-038372; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Ebert BL, 2005, BLOOD, V105, P4620, DOI 10.1182/blood-2004-08-3313; GAULDEN ME, 1958, P NATL ACAD SCI USA, V44, P553, DOI 10.1073/pnas.44.6.553; Gazda HT, 2006, AM J HUM GENET, V79, P1110, DOI 10.1086/510020; Gazda HT, 2006, BRIT J HAEMATOL, V135, P149, DOI 10.1111/j.1365-2141.2006.06268.x; Gazda HT, 2004, BRIT J HAEMATOL, V127, P105, DOI 10.1111/j.1365-2141.2004.05152.x; Giordano E, 1999, J CELL BIOL, V144, P1123, DOI 10.1083/jcb.144.6.1123; Lipton JM, 2006, SEMIN HEMATOL, V43, P167, DOI 10.1053/j.seminhematol.2006.04.002; Ma HH, 2007, MOL BIOL CELL, V18, P2630, DOI 10.1091/mbc.E07-03-0244; Matsson H, 2006, BLOOD CELL MOL DIS, V36, P259, DOI 10.1016/j.bcmd.2005.12.002; Matsson H, 2004, MOL CELL BIOL, V24, P4032, DOI 10.1128/MCB.24.9.4032-4037.2004; Matsson H, 1999, HUM GENET, V105, P496, DOI 10.1007/s004390051136; Oliver ER, 2004, DEVELOPMENT, V131, P3907, DOI 10.1242/dev.01268; Pederson T, 1998, J CELL BIOL, V143, P279, DOI 10.1083/jcb.143.2.279; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; PEDERSON T, 1970, J CELL BIOL, V45, P183, DOI 10.1083/jcb.45.1.183; Pederson T, 2002, TRENDS BIOCHEM SCI, V27, P111, DOI 10.1016/S0968-0004(02)02063-7; Politz JC, 2002, J CELL BIOL, V159, P411, DOI 10.1083/jcb.200208037; Politz JCR, 2005, MOL BIOL CELL, V16, P3401, DOI 10.1091/mbc.E05-02-0106; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; Willig TN, 1999, BLOOD, V94, P4294	24	13	13	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3442	3445		10.1096/fj.07-8766hyp	http://dx.doi.org/10.1096/fj.07-8766hyp			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17586729				2022-12-28	WOS:000250517800006
J	Wong, KF; Luk, JM; Cheng, RH; Klickstein, LB; Fan, ST				Wong, Kwong-Fai; Luk, John M.; Cheng, R. Holland; Klickstein, Lloyd B.; Fan, Sheung-Tat			Characterization of two novel LPS-binding sites in leukocyte integrin beta A domain	FASEB JOURNAL			English	Article						lipopolysaccharide; endotoxin-neutralizing peptide; NF-kappa B; sepsis; prophylaxis; TNF-alpha	MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; LIPOPOLYSACCHARIDE; PROTEIN; ENDOTOXIN; RECEPTOR; CD14; EXPRESSION; BACTERIAL; MACROPHAGES	Lipopolysaccharide (LPS), a bacterial endotoxin, triggers deleterious systemic inflammatory responses when released into blood circulation, causing organ dysfunction and death. In response to LPS stimulation, CD14 and toll-like receptor (TLR)-4 elicit inflammatory signaling cascades. Although leukocyte integrins (CD11b/CD18 and CD11c/CD18) were reported to bind LPS and induce NF-kappa B translocation, the evidence on such epitope location remains elusive. The present study aims to delineate the LPS-binding sites on the integrin CD18 antigen and to design peptide(s) as potential prophylactic and/or therapeutic agents to modulate LPS effects in activated Jurkat cells. Epitope mapping analysis using a series of CD18 truncated variants revealed two putative LPS-binding sites within the beta A region (216 -248 and 266 -318 a. a.), which were further confirmed by point mutation studies. Inhibition assay demonstrated that the CD18- beta A(266)(318)(-) peptide could block LPS binding in a dose-dependent manner. Our data also indicated that treatment with the CD18-peptide modulated TNF-alpha mRNA transcription via the NF-kappa B signaling pathway in LPS-activated Jurkat cells. In conclusion, we have identified two novel LPS-binding sites located at the CD18 beta A domain of leukocyte integrin, and the integrin peptide beta A266 -318 is shown to inhibit LPS binding and subsequent inflammatory events, having therapeutic implications to cure Gram-negative endotoxemia.	Univ Hong Kong, Jockey Club Clin Res Ctr, Dept Surg, Pokfulam, Hong Kong, Peoples R China; Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	University of Hong Kong; University of California System; University of California Davis; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Luk, JM (corresponding author), Univ Hong Kong, Jockey Club Clin Res Ctr, Dept Surg, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	jmluk@hkucc.hku.hk	Fan, Sheung Tat/C-4138-2009; Luk, John/A-4085-2008; Wong, Kwong Fai/C-4702-2009; Cheng, Holland/A-8973-2008	Luk, John/0000-0002-6323-7940; 				Andra J, 2006, J ENDOTOXIN RES, V12, P261, DOI 10.1179/096805106X118852; BATTAFARANO RJ, 1995, SURGERY, V118, P318, DOI 10.1016/S0039-6060(05)80340-X; BONE RC, 1995, CRIT CARE MED, V23, P994, DOI 10.1097/00003246-199506000-00003; BRANDENBURG K, 1993, EUR J BIOCHEM, V218, P555, DOI 10.1111/j.1432-1033.1993.tb18409.x; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Flaherty SF, 1997, J SURG RES, V73, P85, DOI 10.1006/jsre.1997.5195; GESSANI S, 1993, J IMMUNOL, V151, P3758; Gopinath RS, 2005, INFECT IMMUN, V73, P6179, DOI 10.1128/IAI.73.9.6179-6182.2005; Hack CE, 1997, ADV IMMUNOL, V66, P101, DOI 10.1016/S0065-2776(08)60597-0; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; Heumann D, 2002, CLIN CHIM ACTA, V323, P59, DOI 10.1016/S0009-8981(02)00180-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473; Lee NPY, 2006, PROTEIN PEPTIDE LETT, V13, P431, DOI 10.2174/092986606776819493; LITTLE RG, 1994, J BIOL CHEM, V269, P1865; Lo CY, 2005, EUR J ENDOCRINOL, V152, P545, DOI 10.1530/eje.1.01883; Luk JM, 1995, ANAL BIOCHEM, V232, P217, DOI 10.1006/abio.1995.0010; LUK JMC, 1991, J BIOL CHEM, V266, P23215; LYNN WA, 1993, INFECT IMMUN, V61, P4452, DOI 10.1128/IAI.61.10.4452-4461.1993; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Nagaoka I, 2001, J IMMUNOL, V167, P3329, DOI 10.4049/jimmunol.167.6.3329; OSBORN MJ, 1964, SCIENCE, V145, P783, DOI 10.1126/science.145.3634.783; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Reinhart K, 2004, CRIT CARE MED, V32, P1100, DOI 10.1097/01.CCM.0000124870.42312.C4; Rice TW, 2005, ANNU REV MED, V56, P225, DOI 10.1146/annurev.med.56.082103.104356; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WARREN HS, 1993, J EXP MED, V177, P89, DOI 10.1084/jem.177.1.89; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211	39	34	36	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3231	3239		10.1096/fj.06-7579com	http://dx.doi.org/10.1096/fj.06-7579com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17522381				2022-12-28	WOS:000249781600023
J	Baltz, KM; Krusch, M; Bringmann, A; Brossart, P; Mayer, F; Kloss, M; Baessler, T; Kumbier, I; Peterfi, A; Kupka, S; Kroeber, S; Menzel, D; Radsak, MP; Rammensee, HG; Salih, HR				Baltz, Katrin M.; Krusch, Matthias; Bringmann, Anita; Brossart, Peter; Mayer, Frank; Kloss, Mercedes; Baessler, Tina; Kumbier, Ingrid; Peterfi, Andrea; Kupka, Susan; Kroeber, Stefan; Menzel, Dagmar; Radsak, Markus P.; Rammensee, Hans-Georg; Salih, Helmut R.			Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions	FASEB JOURNAL			English	Article						tumor immunity; TNF family; TNFRSF18; immune escape	FACTOR RECEPTOR SUPERFAMILY; REGULATORY T-CELLS; TUMOR-IMMUNITY; FAMILY; ACTIVATION; EXPRESSION; SUPPRESSION; APOPTOSIS; IMMUNOSURVEILLANCE; DIFFERENTIATION	Glucocorticoid-induced TNF-related protein ( GITR) has been shown to stimulate T cell-mediated antitumor immunity in mice. However, the functional relevance of GITR and its ligand ( GITRL) for non-T cells has yet to be fully explored. In addition, recent evidence suggests that GITR plays different roles in mice and humans. We studied the role of GITR-GITRL interaction in human tumor immunology and report for the first time that primary gastrointestinal cancers and tumor cell lines of different histological origin express substantial levels of GITRL. Signaling through GITRL down-regulated the expression of the immunostimulatory molecules CD40 and CD54 and the adhesion molecule EpCAM, and induced production of the immunosuppressive cytokine TGF-beta by tumor cells. On NK cells, GITR is constitutively expressed and up-regulated following activation. Blocking GITR- GITRL interaction in cocultures of tumor cells and NK cells substantially increased cytotoxicity and IFN- gamma production of NK cells demonstrating that constitutive expression of GITRL by tumor cells diminishes NK cell antitumor immunity. GITRL-Ig fusion protein or cell surface-expressed GITRL did not induce apoptosis in NK cells, but diminished nuclear localized c-Rel and RelB, indicating that GITR might negatively modulate NK cell NF-B-k activity. Taken together, our data indicate that tumor-expressed GITRL mediates immunosubversion in humans.	Univ Tubingen, Dept Internal Med, D-72076 Tubingen, Germany; Univ Tubingen, Dept Surg, D-72076 Tubingen, Germany; Univ Tubingen, Dept Pathol, D-72076 Tubingen, Germany; Univ Tubingen, Ctr Clin Transfus Med, D-72076 Tubingen, Germany; Univ Mainz, Dept Internal Med, Mainz, Germany; Univ Tubingen, Dept Immunol, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Johannes Gutenberg University of Mainz; Eberhard Karls University of Tubingen	Salih, HR (corresponding author), Univ Tubingen, Dept Internal Med, Otfried Mueller Str 10, D-72076 Tubingen, Germany.	helmut.salih@med.uni-tuebingen.de	Radsak, Markus P/L-3651-2013	Radsak, Markus P/0000-0002-3991-5721				Agostini M, 2005, INFECT IMMUN, V73, P7502, DOI 10.1128/IAI.73.11.7502-7508.2005; Appel S, 2004, BLOOD, V103, P538, DOI 10.1182/blood-2003-03-0975; Barber DF, 2004, J IMMUNOL, V173, P3653, DOI 10.4049/jimmunol.173.6.3653; Basak S, 1998, JNCI-J NATL CANCER I, V90, P691, DOI 10.1093/jnci/90.9.691; Calmels B, 2005, CANCER GENE THER, V12, P198, DOI 10.1038/sj.cgt.7700781; Carbone E, 1997, J EXP MED, V185, P2053, DOI 10.1084/jem.185.12.2053; Cohen AD, 2006, CANCER RES, V66, P4904, DOI 10.1158/0008-5472.CAN-05-2813; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Eissner G, 2004, CYTOKINE GROWTH F R, V15, P353, DOI 10.1016/j.cytogfr.2004.03.011; Esparza EM, 2006, J BIOL CHEM, V281, P8559, DOI 10.1074/jbc.M512915200; Gurney AL, 1999, CURR BIOL, V9, P215, DOI 10.1016/S0960-9822(99)80093-1; Hanabuchi S, 2006, BLOOD, V107, P3617, DOI 10.1182/blood-2005-08-3419; Ji HB, 2004, J IMMUNOL, V172, P5823, DOI 10.4049/jimmunol.172.10.5823; Kim BJ, 2004, INVEST OPHTH VIS SCI, V45, P3170, DOI 10.1167/iovs.03-0919; Kim HJ, 2006, J IMMUNOL, V176, P3507, DOI 10.4049/jimmunol.176.6.3507; Kim JD, 2003, GENES IMMUN, V4, P564, DOI 10.1038/sj.gene.6364026; Ko K, 2005, J EXP MED, V202, P885, DOI 10.1084/jem.20050940; Kwon BS, 1999, J BIOL CHEM, V274, P6056, DOI 10.1074/jbc.274.10.6056; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Levin S, 2002, FAM COMMUNITY HEALTH, V25, P10, DOI 10.1097/00003727-200210000-00005; Levings MK, 2002, J EXP MED, V196, P1335, DOI 10.1084/jem.20021139; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Nocentini G, 2005, EUR J IMMUNOL, V35, P1016, DOI 10.1002/eji.200425818; Ramirez-Montagut T, 2006, J IMMUNOL, V176, P6434, DOI 10.4049/jimmunol.176.11.6434; Roncagalli R, 2005, NAT IMMUNOL, V6, P1002, DOI 10.1038/ni1242; Salih HR, 2003, BLOOD, V102, P1389, DOI 10.1182/blood-2003-01-0019; Salih HR, 2000, J IMMUNOL, V165, P2903, DOI 10.4049/jimmunol.165.5.2903; Shevach EM, 2006, NAT REV IMMUNOL, V6, P613, DOI 10.1038/nri1867; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Shin HH, 2002, FEBS LETT, V514, P275, DOI 10.1016/S0014-5793(02)02379-7; Shin HH, 2005, BONE, V36, P832, DOI 10.1016/j.bone.2005.02.014; Shin HH, 2004, BIOCHEM BIOPH RES CO, V316, P24, DOI 10.1016/j.bbrc.2004.02.012; Stephens GL, 2004, J IMMUNOL, V173, P5008, DOI 10.4049/jimmunol.173.8.5008; Tone M, 2003, P NATL ACAD SCI USA, V100, P15059, DOI 10.1073/pnas.2334901100; Turk MJ, 2004, J EXP MED, V200, P771, DOI 10.1084/jem.20041130; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	42	80	93	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2442	2454		10.1096/fj.06-7724com	http://dx.doi.org/10.1096/fj.06-7724com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17360848				2022-12-28	WOS:000248454400019
J	Gutierrez-Fernandez, A; Inada, M; Balbin, M; Fueyo, A; Pitiot, AS; Astudillo, A; Hirose, K; Hirata, M; Shapiro, SD; Noel, A; Werb, Z; Krane, SM; Lopez-Otin, C; Puente, XS				Gutierrez-Fernandez, Ana; Inada, Masaki; Balbin, Milagros; Fueyo, Antonio; Pitiot, Ana S.; Astudillo, Aurora; Hirose, Kenji; Hirata, Michiko; Shapiro, Steven D.; Noel, Agnes; Werb, Zena; Krane, Stephen M.; Lopez-Otin, Carlos; Puente, Xose S.			Increased inflammation delays wound healing in mice deficient in collagenase-2 (MMP-8)	FASEB JOURNAL			English	Article						neutrophil; MMP-9; cancer; protease; degradome	MATRIX-METALLOPROTEINASE; KERATINOCYTE MIGRATION; NEUTROPHIL GELATINASE; RESISTANT MOUSE; EXPRESSION; CELLS; CANCER; GROWTH; TISSUE; REGENERATION	Matrix metalloproteinases (MMPs) have been implicated in numerous tissue-remodeling processes. The finding that mice deficient in collagenase-2 (MMP-8) are more susceptible to develop skin cancer, prompted us to investigate the role of this protease in cutaneous wound healing. We have observed a significant delay in wound closure in MMP8(-/-) mice and an altered inflammatory response in their wounds, with a delay of neutrophil infiltration during the first days and a persistent inflammation at later time points. These changes were accompanied by alterations in the TGF-beta 1 signaling pathway and by an apoptosis defect in MMP8(-/-) mice. The delay in wound healing observed in MMP8(-/-) mice was rescued by bone marrow transplantation from wildtype mice. Analysis of other MMPs showed that MMP8(-/-) mice had a significant increase in the expression of MMP-9, suggesting that both proteases might act coordinately in this process. This possibility was further supported by the novel finding that MMP-8 and MMP-9 form specific complexes in vivo. Taken together, these data indicate that MMP-8 participates in wound repair by contributing to the resolution of inflammation and open the possibility to develop new strategies for treating wound healing defects.	Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; Univ Oviedo, Fac Med, Inst Univ Oncol, E-33006 Oviedo, Spain; Univ Oviedo, Hosp Cent Asturias, Serv Oncol Mol, E-33080 Oviedo, Spain; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med Pulm & Crit Care, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Univ Liege, Lab Tumor & Dev Biol, Liege, Belgium; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	University of Oviedo; University of Oviedo; Instituto Universitario de Oncologia de Asturias; Central University Hospital Asturias; University of Oviedo; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Liege; University of California System; University of California San Francisco	Puente, XS (corresponding author), Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain.	xspuente@uniovi.es	inada, masaki/D-1581-2013; Puente, Xosé S./ADB-0672-2022; Pitiot, Ana S/AAA-9161-2020; Hirata, Michiko/D-2351-2013; Gutierrez-Fernandez, Ana/AAS-9954-2021; Fueyo, Antonio/ABH-3243-2020; Balbín, Milagros/I-4206-2015; Gutierrez-Fernandez, Ana/ABG-6678-2020; López-Otín, Carlos/AAB-2106-2020	inada, masaki/0000-0002-5066-8506; Puente, Xosé S./0000-0001-9525-1483; Pitiot, Ana S/0000-0002-5318-3168; Hirata, Michiko/0000-0002-5291-6112; Gutierrez-Fernandez, Ana/0000-0002-9287-8843; Fueyo, Antonio/0000-0002-7121-9398; Balbín, Milagros/0000-0001-5325-0407; López-Otín, Carlos/0000-0001-6964-1904; Astudillo Gonzalez, Maria Aurora/0000-0001-8947-8809; Noel, Agnes/0000-0002-7670-6179	NCI NIH HHS [CA105379, P01 CA072006, U01 CA105379-05, CA072006, P01 CA072006-10, U01 CA105379] Funding Source: Medline; NIAMS NIH HHS [R01 AR044815-10, R01 AR044815, AR044815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072006, U01CA105379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahokas K, 2005, J INVEST DERMATOL, V124, P849, DOI 10.1111/j.0022-202X.2005.23640.x; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Balbin M, 1998, J BIOL CHEM, V273, P23959, DOI 10.1074/jbc.273.37.23959; Balbin M, 2001, J BIOL CHEM, V276, P10253, DOI 10.1074/jbc.M009586200; Beare AHM, 2005, WOUND REPAIR REGEN, V13, P27, DOI 10.1111/j.1067-1927.2005.130105.x; Beare AHM, 2003, J INVEST DERMATOL, V120, P153, DOI 10.1046/j.1523-1747.2003.12019.x; Bullard KM, 1999, ANN SURG, V230, P260, DOI 10.1097/00000658-199908000-00017; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Gueders MM, 2005, J IMMUNOL, V175, P2589, DOI 10.4049/jimmunol.175.4.2589; Hart R, 2006, J MINIM INVAS GYN, V13, P126, DOI 10.1016/j.jmig.2005.11.015; Herman MP, 2001, CIRCULATION, V104, P1899, DOI 10.1161/hc4101.097419; Hieta N, 2003, J INVEST DERMATOL, V121, P997, DOI 10.1046/j.1523-1747.2003.12533.x; Hosokawa R, 2005, J INVEST DERMATOL, V125, P1302, DOI 10.1111/j.0022-202X.2005.23963.x; Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101; Kiili M, 2002, J CLIN PERIODONTOL, V29, P224, DOI 10.1034/j.1600-051x.2002.290308.x; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Lobmann R, 2002, DIABETOLOGIA, V45, P1011, DOI 10.1007/s00125-002-0868-8; Low QEH, 2001, AM J PATHOL, V159, P457, DOI 10.1016/S0002-9440(10)61717-8; Lund LR, 2006, EMBO J, V25, P2686, DOI 10.1038/sj.emboj.7601173; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; Marini S, 2000, J BIOL CHEM, V275, P18657, DOI 10.1074/jbc.M000283200; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Mirastschijski U, 2004, EXP CELL RES, V299, P465, DOI 10.1016/j.yexcr.2004.06.007; Mirastschijski U, 2004, J INVEST DERMATOL, V123, P600, DOI 10.1111/j.0022-202X.2004.23230.x; Mohan R, 2002, J BIOL CHEM, V277, P2065, DOI 10.1074/jbc.M107611200; Nwomeh BC, 1999, J SURG RES, V81, P189, DOI 10.1006/jsre.1998.5495; Nwomeh Benedict C., 1998, Wound Repair and Regeneration, V6, P127, DOI 10.1046/j.1524-475X.1998.60206.x; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Owen CA, 2004, J IMMUNOL, V172, P7791, DOI 10.4049/jimmunol.172.12.7791; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; Peters KS, 2005, J PHYS ORG CHEM, V18, P1, DOI 10.1002/poc.849; Peters T, 2005, EMBO J, V24, P3400, DOI 10.1038/sj.emboj.7600809; Pirila E, 2001, CURR MED CHEM, V8, P281, DOI 10.2174/0929867013373552; Pirila E, 2003, DIGEST DIS SCI, V48, P93, DOI 10.1023/A:1021790532723; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Ravanti L, 2001, FASEB J, V15, P1098, DOI 10.1096/fj.00-0588fje; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Salonurmi T, 2004, CELL TISSUE RES, V315, P27, DOI 10.1007/s00441-003-0814-1; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Van Lint P, 2005, J IMMUNOL, V175, P7642, DOI 10.4049/jimmunol.175.11.7642; Van Lint P, 2006, CYTOKINE GROWTH F R, V17, P217, DOI 10.1016/j.cytogfr.2006.04.001; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Westerhof GR, 2000, CANCER RES, V60, P5470; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200	51	193	198	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2580	2591		10.1096/fj.06-7860com	http://dx.doi.org/10.1096/fj.06-7860com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17392479	Green Accepted			2022-12-28	WOS:000248454400031
J	Garner, CE; Smith, S; Costello, BD; White, P; Spencer, R; Probert, CSJ; Ratcliffe, NM				Garner, Catherine E.; Smith, Stephen; Costello, Ben de Lacy; White, Paul; Spencer, Robert; Probert, Chris S. J.; Ratcliffe, Norman M.			Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease	FASEB JOURNAL			English	Article						campylobacter; Clostridium difficile; ulcerative colitis	CHROMATOGRAPHY-MASS SPECTROMETRY; SULFATE-REDUCING BACTERIA; HUMAN LARGE-INTESTINE; CHAIN FATTY-ACIDS; DAUCUS-CAROTA L.; HEALTHY-VOLUNTEERS; RAT-LIVER; METABOLISM; IDENTIFICATION; ACETALDEHYDE	Little is known about the volatile organic compounds ( VOCs) in feces and their potential health consequences. Patients and healthcare professionals have observed that feces often smell abnormal during gastrointestinal disease. The aim of this work was to define the volatiles emitted from the feces of healthy donors and patients with gastrointestinal disease. Our hypotheses were that i) VOCs would be shared in health; ii) VOCs would be constant in individuals; and iii) specific changes in VOCs would occur in disease. Volatile emissions in health were defined in a cohort and a longitudinal study. Subsequently, the pattern of volatiles found in the cohort study were compared to that found from patients with ulcerative colitis, Campylobacter jejuni, and Clostridium difficile. Volatiles from feces were collected by solid-phase microextraction and analyzed by gas chromatography/ mass spectrometry. In the cohort study, 297 volatiles were identified. In all samples, ethanoic, butanoic, pentanoic acids, benzaldehyde, ethanal, carbon disulfide, dimethyldisulfide, acetone, 2- butanone, 2,3- butanedione, 6- methyl- 5- hepten-2- one, indole, and 4-methylphenol were found. Forty-four compounds were shared by 80% of subjects. In the longitudinal study, 292 volatiles were identified, with some inter and intra subject variations in VOC concentrations with time. When compared to healthy donors, volatile patterns from feces of patients with ulcerative colitis, C. difficile, and C. jejuni were each significantly different. These findings could lead the way to the development of a rapid diagnostic device based on VOC detection.-Garner, C. E., Smith, S., de Lacy Costello, B., White, P., Spencer, R., Probert, C. S. J., Ratcliffe, N. M. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease.	Bristol Royal Infirm & Gen Hosp, Hlth Protect Agcy, Bristol BS2 8HW, Avon, England; Univ W England, Fac Sci Appl, Ctr Res Analyt Mat & Sensor Sci, Bristol BS16 1QY, Avon, England	Bristol Royal Infirmary; Health Protection Agency; University of West England	Probert, CSJ (corresponding author), Bristol Royal Infirm & Gen Hosp, Hlth Protect Agcy, Marlborough St, Bristol BS2 8HW, Avon, England.	c.s.j.probert@bristol.ac.uk	de Lacy Costello, Ben/ABG-2043-2021; De Lacy Costello, Ben/I-8259-2019	de Lacy Costello, Ben/0000-0003-2999-6801; Probert, Christopher/0000-0003-4550-0239; White, Paul/0000-0002-7503-9896	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alasalvar C, 2001, J AGR FOOD CHEM, V49, P1410, DOI 10.1021/jf000595h; ALLOWAY BJ, 1993, CHEM PRINCIPLES ENV, P216; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Blaut M, 2002, BRIT J NUTR, V87, pS203, DOI 10.1079/BJN/2002539; Costello BPJD, 2001, PLANT PATHOL, V50, P489, DOI 10.1046/j.1365-3059.2001.00594.x; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; DECOMBAZ J, 1983, EUR J APPL PHYSIOL O, V52, P9, DOI 10.1007/BF00429018; DENERIS ES, 1985, J BIOL CHEM, V260, P1382; Diczfalusy MA, 2001, J LIPID RES, V42, P1025; Elgaali H, 2002, J BASIC MICROB, V42, P373, DOI 10.1002/1521-4028(200212)42:6<373::AID-JOBM373>3.0.CO;2-4; Ewen RJ, 2004, MYCOL RES, V108, P806, DOI 10.1017/S095375620400022X; GIBSON GR, 1993, GUT, V34, P437, DOI 10.1136/gut.34.4.437; GORBACH SL, 1971, GASTROENTEROLOGY, V60, P1110; Gostner A, 2006, BRIT J NUTR, V95, P40, DOI 10.1079/BJN20051589; HERRENFREUND SL, 1986, ENVIRON HEALTH PERSP, V69, P59, DOI 10.2307/3430371; Homann N, 2001, ADDICT BIOL, V6, P309, DOI 10.1080/13556210020077028; Johnson W, 2002, INT J TOXICOL, V21, P9, DOI 10.1080/10915810290096388; Kjeldsen F, 2003, J AGR FOOD CHEM, V51, P5400, DOI 10.1021/jf030212q; Kjeldsen F, 2001, J AGR FOOD CHEM, V49, P4342, DOI 10.1021/jf010213n; KLECKA WR, 1980, QUANTITATIVE APPL SO, V19; LACHENBRUCH PA, 1975, DISCRIMINANT ANAL; Lechner M, 2005, CURR MICROBIOL, V51, P267, DOI 10.1007/s00284-005-0018-x; Lington A.W., 1994, PATTYS IND HYGIENE T, P2585; Locas CP, 2004, J AGR FOOD CHEM, V52, P6830, DOI 10.1021/jf0490403; Logan BK, 2003, J PEDIATR GASTR NUTR, V36, P419, DOI 10.1097/00005176-200303000-00026; MAY T, 1994, SCAND J GASTROENTERO, V29, P916, DOI 10.3109/00365529409094863; MILLER TL, 1986, SYST APPL MICROBIOL, V7, P223; MOORE JG, 1987, GASTROENTEROLOGY, V93, P1321, DOI 10.1016/0016-5085(87)90262-9; Mortensen PB, 1996, SCAND J GASTROENTERO, V31, P132, DOI 10.3109/00365529609094568; Ott A, 2000, J AGR FOOD CHEM, V48, P724, DOI 10.1021/jf990487z; Pitcher MCL, 2000, GUT, V46, P64, DOI 10.1136/gut.46.1.64; Probert CSJ, 2004, GUT, V53, P58, DOI 10.1136/gut.53.1.58; Ruge E., 1861, SITZBER KAISER AKA, V44, P739; Salerno-Kennedy R, 2005, WIEN KLIN WOCHENSCHR, V117, P180, DOI 10.1007/s00508-005-0336-9; Smith EA, 1997, ANAEROBE, V3, P327, DOI 10.1006/anae.1997.0121; Suarez FL, 1998, GUT, V43, P100, DOI 10.1136/gut.43.1.100; SURAEZ F, 1997, AM J PHYSIOL, V272, pG1028; TOMLIN J, 1991, GUT, V32, P665, DOI 10.1136/gut.32.6.665; Vakevainen S, 2000, ALCOHOL CLIN EXP RES, V24, P873, DOI 10.1111/j.1530-0277.2000.tb02068.x; WEISIGER RA, 1980, BIOCHEM PHARMACOL, V29, P2885, DOI 10.1016/0006-2952(80)90029-5; Willis CL, 1997, CURR MICROBIOL, V35, P294, DOI 10.1007/s002849900257; YOKOYAMA MT, 1979, AM J CLIN NUTR, V32, P173	42	299	312	3	99	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1675	1688		10.1096/fj.06-6927com	http://dx.doi.org/10.1096/fj.06-6927com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314143				2022-12-28	WOS:000246866500009
J	Sredni, B; Geffen-Aricha, R; Duan, WZ; Albeck, M; Shalit, F; Lander, HM; Kinor, N; Sagi, O; Albeck, A; Yosef, S; Brodsky, M; Sredni-Kenigsbuch, D; Sonino, T; Longo, DL; Mattson, MP; Yadid, G				Sredni, Benjamin; Geffen-Aricha, Revital; Duan, Wenzhen; Albeck, Michael; Shalit, Frances; Lander, Harry M.; Kinor, Noa; Sagi, Ortal; Albeck, Amnon; Yosef, Sigal; Brodsky, Miri; Sredni-Kenigsbuch, Dvora; Sonino, Tali; Longo, Dan L.; Mattson, Mark P.; Yadid, Gal			Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models	FASEB JOURNAL			English	Article						6neuroprotection; apoptosis; inflammation; cytokines; neurotrophic	THIOL REDOX STATUS; IMMUNOMODULATOR AS101; NEUROTROPHIC FACTOR; APOPTOTIC DEATH; NIGROSTRIATAL SYSTEM; CELL-DEATH; TNF-ALPHA; NEURODEGENERATION; INTERLEUKIN-10; INHIBITION	In Parkinson's disease ( PD) dopaminergic neurons in the substantia nigra ( SN) become dysfunctional and many ultimately die. We report that the tellurium immunomodulating compound ammonium trichloro(dioxoethylene-O, O'-) tellurate(AS101) protects dopaminergic neurons and improves motor function in animal models of PD. It is effective when administered systemically or by direct infusion into the brain. Multifunctional activities of AS101 were identified in this study. These were mainly due to the peculiar Tellur(IV)- thiol chemistry of the compound, which enabled the compound to interact with cysteine residues on both inflammatory and apoptotic caspases, resulting in their inactivation. Conversely, its interaction with a key cysteine residue on p21(ras), led to its activation, an obligatory activity for AS101-induced neuronal differentiation. Furthermore, AS101 inhibited IL-10, resulting in up-regulation of GDNF in the SN. This was associated with activation of the neuroprotective kinases Akt and mitogen-activated protein kinases, and up- regulation of the antiapoptotic protein Bcl-2. Inhibition of caspase-1 and caspase-3 activities were associated with decreased neuronal death and inhibition of IL-1 beta. We suggest that, because multiple mechanisms are involved in the dysfunction and death of neurons in PD, use of a multifunctional compound, exerting antiapoptotic, anti-inflammatory, and neurotrophic-inducing capabilities may be potentially efficacious for the treatment of PD.-Sredni B., Geffen R., Duan W., Albeck M., Shalit F., Lander H., Kinor N., Sagi O., Albeck A., Yosef S., Brodsky M., Sredni-Kenigsbuch D., Sonino T., Longo D., Mattson M., Yadid G. Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models.	Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, CAIR Inst, Ramat Gan, Israel; Bar Ilan Univ, Interdisiplinary Dept, Ramat Gan, Israel; Bar Ilan Univ, Dept Chem, Ramat Gan, Israel; Bar Ilan Univ, Multidisciplinary Brain Res Ctr, Ramat Gan, Israel; Natl Inst Aging Intramural Res Program, Lab Neurosci, Baltimore, MD USA; Natl Inst Aging Intramural Res Program, Lab Immunol, Baltimore, MD USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY USA	Bar Ilan University; Bar Ilan University; Bar Ilan University; Bar Ilan University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Cornell University	Sredni, B (corresponding author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, CAIR Inst, Keren Hayessod St, Ramat Gan, Israel.	srednib@mail.biu.ac.il	Longo, Dan L./F-6022-2011; Mattson, Mark P/F-6038-2012		Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AKANEYA Y, 1995, EXP NEUROL, V136, P44, DOI 10.1006/exnr.1995.1082; Akhtar RS, 2004, BBA-MOL CELL RES, V1644, P189, DOI 10.1016/j.bbamcr.2003.10.013; Albeck A, 1998, INORG CHEM, V37, P1704, DOI 10.1021/ic971456t; ARIMOTO T, 2006, NEUROBIOL AGING 0610; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; COHEN BL, 1984, GEOCHIM COSMOCHIM AC, V48, P203, DOI 10.1016/0016-7037(84)90363-6; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Desire L, 2000, J NEUROCHEM, V75, P151, DOI 10.1046/j.1471-4159.2000.0750151.x; Di Monte DA, 2003, LANCET NEUROL, V2, P531, DOI 10.1016/S1474-4422(03)00501-5; Eriksen JL, 2005, ARCH NEUROL-CHICAGO, V62, P353, DOI 10.1001/archneur.62.3.353; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Hartmann A, 2001, J NEUROSCI, V21, P2247, DOI 10.1523/JNEUROSCI.21-07-02247.2001; Heerssen HM, 2002, TRENDS NEUROSCI, V25, P160, DOI 10.1016/S0166-2236(02)02144-6; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Hirsch EC, 2003, ANN NY ACAD SCI, V991, P214; IRGOLIC KJ, 1990, ORGANOTELLURIUM E B, V12; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Kalechman Y, 1997, J IMMUNOL, V159, P2658; Kalechman Y, 2004, J BIOL CHEM, V279, P24724, DOI 10.1074/jbc.M312006200; Kalechman Y, 2003, J AM SOC NEPHROL, V14, P620, DOI 10.1097/01.ASN.0000053415.29636.4F; Kalechman Y, 2002, J IMMUNOL, V169, P384, DOI 10.4049/jimmunol.169.1.384; Kirik D, 2002, J NEUROSCI, V22, P2780, DOI 10.1523/JNEUROSCI.22-07-02780.2002; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Makarovsky D, 2003, ANN NY ACAD SCI, V1010, P659, DOI 10.1196/annals.1299.120; Mandel S, 2003, CNS DRUGS, V17, P729, DOI 10.2165/00023210-200317100-00004; Maswood N, 2004, P NATL ACAD SCI USA, V101, P18171, DOI 10.1073/pnas.0405831102; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Muller T, 2004, J NEUROL, V251, P44, DOI 10.1007/s00415-004-1610-x; Murata Y, 2002, MOL IMMUNOL, V38, P747, DOI 10.1016/S0161-5890(01)00111-0; Murata Y, 2002, INT IMMUNOL, V14, P201, DOI 10.1093/intimm/14.2.201; Nagatsu T, 2005, CURR PHARM DESIGN, V11, P999, DOI 10.2174/1381612053381620; Okun E, 2006, DEV COMP IMMUNOL, V30, P441, DOI 10.1016/j.dci.2005.07.002; Orike N, 2001, J CELL BIOL, V154, P995, DOI 10.1083/jcb.200101068; Patel NK, 2005, ANN NEUROL, V57, P298, DOI 10.1002/ana.20374; QIAN L, 2006, J PHARM EXP THE 0808; RAMSAY RR, 1986, J BIOL CHEM, V261, P7585; Rosenblatt-Bin H, 1998, CELL IMMUNOL, V184, P12, DOI 10.1006/cimm.1998.1251; SACCHETTA P, 1986, ANAL BIOCHEM, V154, P205, DOI 10.1016/0003-2697(86)90516-6; Schulz JB, 2004, CELL TISSUE RES, V318, P135, DOI 10.1007/s00441-004-0954-y; Sherer TB, 2002, NEUROSCIENTIST, V8, P192, DOI 10.1177/1073858402008003004; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; Slevin JT, 2005, J NEUROSURG, V102, P216, DOI 10.3171/jns.2005.102.2.0216; Smith AD, 2002, NEUROPSYCHOPHARMACOL, V26, P756, DOI 10.1016/S0893-133X(01)00420-1; Sredni B, 2003, FASEB J, V17, P400, DOI 10.1096/fj.03-0552fje; Sredni B, 2004, CANCER RES, V64, P1843, DOI 10.1158/0008-5472.CAN-03-3179; SREDNI B, 1987, NATURE, V330, P173, DOI 10.1038/330173a0; Sredni B, 1996, J NATL CANCER I, V88, P1276, DOI 10.1093/jnci/88.18.1276; SREDNI B, 1995, J CLIN ONCOL, V13, P2342, DOI 10.1200/JCO.1995.13.9.2342; Sredni B, 1996, INT J CANCER, V65, P97, DOI 10.1002/(SICI)1097-0215(19960103)65:1<97::AID-IJC17>3.0.CO;2-F; Strassmann G, 1997, CELL IMMUNOL, V176, P180, DOI 10.1006/cimm.1997.1087; Vila M, 2004, NAT MED, V10, pS58, DOI 10.1038/nm1068; Williams L, 2004, J IMMUNOL, V172, P567, DOI 10.4049/jimmunol.172.1.567; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504	59	56	57	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1870	1883		10.1096/fj.06-7500com	http://dx.doi.org/10.1096/fj.06-7500com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314138				2022-12-28	WOS:000246866500028
J	McColl, BK; Paavonen, K; Karnezis, T; Harris, NC; Davydova, N; Rothacker, J; Nice, EC; Harder, KW; Roufail, S; Hibbs, ML; Rogers, PAW; Alitalo, K; Stacker, SA; Achen, MG				McColl, Bradley K.; Paavonen, Karri; Karnezis, Tara; Harris, Nicole C.; Davydova, Natalia; Rothacker, Julie; Nice, Edouard C.; Harder, Kenneth W.; Roufail, Sally; Hibbs, Margaret L.; Rogers, Peter A. W.; Alitalo, Kari; Stacker, Steven A.; Achen, Marc G.			Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2	FASEB JOURNAL			English	Article						furin; PC5; PC7; angiogenesis; lymphatic	ENDOTHELIAL GROWTH-FACTOR; LYMPHATIC ENDOTHELIUM; CANCER METASTASIS; TYROSINE KINASES; TUMOR-METASTASIS; TRANSGENIC MICE; BREAST-CANCER; FURIN; LYMPHANGIOGENESIS; EXPRESSION	Vascular endothelial growth factor ( VEGF)-D is a secreted glycoprotein that induces angiogenesis and lymphangiogenesis. It consists of a central domain, containing binding sites for VEGF receptor-2 (VEGFR-2) and VEGFR-3, and N- and C-terminal propeptides. It is secreted from the cell as homodimers of the full-length form that can be proteolytically processed to remove the propeptides. It was recently shown, using adenoviral gene delivery, that fully processed VEGF-D induces angiogenesis in vivo, whereas full-length VEGF-D does not. To better understand these observations, we monitored the effect of VEGF-D processing on receptor binding using a full-length VEGF-D mutant that cannot be processed. This mutant binds VEGFR-2, the receptor signaling for angiogenesis, with similar to 17,000-fold lower affinity than mature VEGF-D, indicating the importance of processing for interaction with this receptor. Further, we show that members of the proprotein convertase ( PC) family of proteases promote VEGF-D processing, which facilitates the VEGF-D/VEGFR-2 interaction. The PCs furin and PC5 promote cleavage of both propeptides, whereas PC7 promotes cleavage of the C-terminal propeptide only. The finding that PCs promote activation of VEGF-D and other proteins with roles in cancer such as matrix metalloproteinases, emphasizes the importance of these enzymes as potential regulators of tumor progression and metastasis.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; Monash Univ, Monash Med Ctr, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia; Univ Helsinki, Ludwig Inst Canc Res, Mol Canc Biol Lab, Helsinki, Finland	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Monash University; Ludwig Institute for Cancer Research; University of Helsinki	Achen, MG (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Melbourne, Vic 3050, Australia.	marc.achen@ludwig.edu.au	Rogers, Peter AW/C-2651-2008; Nice, Edouard C/B-1026-2011; Stacker, Steven A/J-2205-2012; Alitalo, Kari K/J-5013-2014; Hibbs, Margaret L/D-7013-2011	Rogers, Peter AW/0000-0002-7399-8997; Stacker, Steven A/0000-0003-4096-9273; Alitalo, Kari K/0000-0002-7331-0902; Hibbs, Margaret L/0000-0002-3751-6751; Rothacker, Julie/0000-0001-7560-4982; Achen, Marc/0000-0002-3791-803X				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Achen MG, 2005, CANCER CELL, V7, P121, DOI 10.1016/j.ccr.2005.01.017; Baldwin ME, 2001, J BIOL CHEM, V276, P19166, DOI 10.1074/jbc.M100097200; Baldwin ME, 2005, MOL CELL BIOL, V25, P2441, DOI 10.1128/MCB.25.6.2441-2449.2005; Baldwin ME, 2001, J BIOL CHEM, V276, P44307, DOI 10.1074/jbc.M106188200; Bassi DE, 2001, MOL CARCINOGEN, V31, P224, DOI 10.1002/mc.1057; Byzova TV, 2002, BLOOD, V99, P4434, DOI 10.1182/blood.V99.12.4434; Cheng M, 1997, INT J CANCER, V71, P966, DOI 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.3.CO;2-A; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Duguay SJ, 1997, J BIOL CHEM, V272, P6663, DOI 10.1074/jbc.272.10.6663; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Joukov V, 1996, EMBO J, V15, P290; Kahn HJ, 2002, MODERN PATHOL, V15, P434, DOI 10.1038/modpathol.3880543; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Karpanen T, 2006, AM J PATHOL, V169, P708, DOI 10.2353/ajpath.2006.051200; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; Khatib AM, 2001, J BIOL CHEM, V276, P30686, DOI 10.1074/jbc.M101725200; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; Lehmann M, 1996, BIOCHEM J, V317, P803, DOI 10.1042/bj3170803; Lehmann M, 1998, ENDOCRINOLOGY, V139, P3763, DOI 10.1210/en.139.9.3763; Lissitzky JC, 2000, BIOCHEM J, V346, P133, DOI 10.1042/0264-6021:3460133; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Mattila MMT, 2002, INT J CANCER, V98, P946, DOI 10.1002/ijc.10283; Mbikay M, 1997, BRIT J CANCER, V75, P1509, DOI 10.1038/bjc.1997.258; McColl BK, 2003, J EXP MED, V198, P863, DOI 10.1084/jem.20030361; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nice EC, 1999, BIOESSAYS, V21, P339, DOI 10.1002/(SICI)1521-1878(199904)21:4<339::AID-BIES11>3.0.CO;2-C; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Schacht V, 2005, AM J PATHOL, V166, P913, DOI 10.1016/S0002-9440(10)62311-5; Siegfried G, 2005, ONCOGENE, V24, P6925, DOI 10.1038/sj.onc.1208838; Siegfried G, 2003, J CLIN INVEST, V111, P1723, DOI 10.1172/JCI200317220; Siegfried G, 2003, CANCER RES, V63, P1458; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Stacker SA, 2002, NAT REV CANCER, V2, P573, DOI 10.1038/nrc863; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002; Taylor NA, 2003, FASEB J, V17, P1215, DOI 10.1096/fj.02-0831rev; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; Von Marschall Z, 2005, INT J ONCOL, V27, P669; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387	54	80	84	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					1088	1098		10.1096/fj.06-7060com	http://dx.doi.org/10.1096/fj.06-7060com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17242158				2022-12-28	WOS:000245650400013
J	Serhan, CN; Brain, SD; Buckley, CD; Gilroy, DW; Haslett, C; O'Neill, LAJ; Perretti, M; Rossi, AG; Wallace, JL				Serhan, Charles N.; Brain, Sue D.; Buckley, Christopher D.; Gilroy, Derek W.; Haslett, Christopher; O'Neill, Luke A. J.; Perretti, Mauro; Rossi, Adriano G.; Wallace, John L.			Resolution of inflammation: state of the art, definitions and terms	FASEB JOURNAL			English	Review						anti-inflammatories; leukocytes; lipid mediators; chemokines; cytokines	ASPIRIN TREATMENT; PHAGOCYTOSIS; MEDIATORS; EXPRESSION; RESOLVINS; CIRCUITS; ACTIVATE	A recent focus meeting on Controlling Acute Inflammation was held in London, April 27-28, 2006, organized by D.W. Gilroy and S.D. Brain for the British Pharmacology Society. We concluded at the meeting that a consensus report was needed that addresses the rapid progress in this emerging field and details how the specific study of resolution of acute inflammation provides leads for novel anti-inflammatory therapeutics, as well as defines the terms and key components of interest in the resolution process within tissues as appreciated today. The inflammatory response protects the body against infection and injury but can itself become dysregulated with deleterious consequences to the host. It is now evident that endogenous biochemical pathways activated during defense reactions can counter-regulate inflammation and promote resolution. Hence, resolution is an active rather than a passive process, as once believed, which now promises novel approaches for the treatment of inflammation-associated diseases based on endogenous agonists of resolution.	Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Oral Med Infect & Immun, Harvard Sch Dent Med, Boston, MA 02115 USA; Kings Coll London, Div Cardiovasc, London WC2R 2LS, England; UCL, Ctr Clin Pharmacol & Therapeut, Div Med, London, England; Univ Edinburgh, MRC Ctr Inflammat Res, Queens Med Res Inst, Edinburgh, Midlothian, Scotland; Trinity Coll Dublin, Sch Biochem & Immunol, Dublin, Ireland; Queen Mary Univ London, William Harvey Res Inst, London, England; Univ Calgary, Inflammat Res Network, Calgary, AB, Canada	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard School of Dental Medicine; University of London; King's College London; University of London; University College London; University of Edinburgh; Trinity College Dublin; University of London; Queen Mary University London; University of Calgary	Serhan, CN (corresponding author), Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, 75 Francis St,Thorn 724, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu	Buckley, Christopher/AAN-6378-2021; Wallace, John/AAL-3763-2021; Gilroy, Derek W/C-2588-2009; Brain, Susan/L-3681-2013; Gilroy, Derek/AAP-7227-2020	Buckley, Christopher/0000-0001-6924-6402; Gilroy, Derek/0000-0003-3476-0844; Brain, Susan/0000-0002-9684-8342; O'Neill, Luke/0000-0002-4333-2748	MRC [G116/131, G0601481] Funding Source: UKRI; Medical Research Council [G9818340B] Funding Source: researchfish; Arthritis Research UK [16390] Funding Source: Medline; Medical Research Council [G116/131, G0601481] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Arthritis Research UK(Versus Arthritis); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Buckley CD, 2001, TRENDS IMMUNOL, V22, P199, DOI 10.1016/S1471-4906(01)01863-4; Cotran R. S., 1999, ROBBINS PATHOLOGIC B, V6th; Creagh EM, 2006, TRENDS IMMUNOL, V27, P352, DOI 10.1016/j.it.2006.06.003; Cronstein BN, 2006, ANN RHEUM DIS, V65, P421, DOI 10.1136/ard.2005.049601; Damazo AS, 2006, J IMMUNOL, V176, P4410, DOI 10.4049/jimmunol.176.7.4410; Filer A, 2006, CURR OPIN PHARMACOL, V6, P393, DOI 10.1016/j.coph.2006.03.007; Giles KM, 2001, J IMMUNOL, V167, P976, DOI 10.4049/jimmunol.167.2.976; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Liu HY, 2006, P NATL ACAD SCI USA, V103, P7048, DOI 10.1073/pnas.0601554103; Liu YQ, 1999, J IMMUNOL, V162, P3639; Maderna P, 2005, J IMMUNOL, V174, P3727, DOI 10.4049/jimmunol.174.6.3727; Majno G., 2004, CELLS TISSUES DIS PR; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Parsonage G, 2005, TRENDS IMMUNOL, V26, P150, DOI 10.1016/j.it.2004.11.014; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Perretti M, 1997, TRENDS PHARMACOL SCI, V18, P418; Pinho V, 2005, J LEUKOCYTE BIOL, V77, P800, DOI 10.1189/jlb.0704386; Rossi AG, 2006, NAT MED, V12, P1056, DOI 10.1038/nm1468; Sawatzky DA, 2006, AM J PATHOL, V168, P33, DOI 10.2353/ajpath.2006.050058; Serhan CN, 2004, HISTOCHEM CELL BIOL, V122, P305, DOI 10.1007/s00418-004-0695-8; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; SONYA MA, 2006, IN PRESS J EXP MED; Sutmuller RPM, 2006, J CLIN INVEST, V116, P485, DOI 10.1172/JCI25439; WEISSMANN G, 1980, NEW ENGL J MED, V303, P27	32	817	841	1	89	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					325	332		10.1096/fj.06-7227rev	http://dx.doi.org/10.1096/fj.06-7227rev			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17267386	Green Accepted			2022-12-28	WOS:000244686300006
J	Adriouch, S; Bannas, P; Schwarz, N; Fliegert, R; Guse, AH; Seman, M; Haag, F; Koch-Nolte, F				Adriouch, Sahil; Bannas, Peter; Schwarz, Nicole; Fliegert, Ralf; Guse, Andreas H.; Seman, Michel; Haag, Friedrich; Koch-Nolte, Friedrich			ADP-ribosylation at R125 gates the P2X7 ion channel by presenting a covalent ligand to its nucleotide binding site	FASEB JOURNAL			English	Article						post-translational modification; purinoceptors; ADP-ribosyltransferases; leukocyte ecto-enzymes	CELL-SURFACE-PROTEINS; P2X(7) RECEPTOR; BACTERIAL TOXINS; DIPHTHERIA-TOXIN; T-CELLS; ATP; RIBOSYLTRANSFERASE; PURINOCEPTOR; LYMPHOCYTES; ACTIVATION	ADP-ribosylation is a post-translational modification regulating protein function in which amino acid-specific ADP-ribosyltransferases (ARTs) transfer ADP-ribose from NAD onto specific target proteins. Attachment of the bulky ADP-ribose usually inactivates the target by sterically blocking its interaction with other proteins. P2X7, an ATP-gated ion channel with important roles in inflammation and cell death, in contrast, is activated by ADP-ribosylation. Here, we report the structural basis for this gating and present the first molecular model for the activation of a target protein by ADP-ribosylation. We demonstrate that the ecto-enzyme ART2.2 ADP-ribosylates P2X7 at arginine 125 in a prominent, cysteine-rich region at the interface of 2 receptor subunits. ADP-ribose shares an adenine-ribonculeotide moiety with ATP. Our results indicate that ADP-ribosylation of R125 positions this common chemical framework to fit into the nucleotide-binding site of P2X7 and thereby gates the channel.	[Adriouch, Sahil; Bannas, Peter; Schwarz, Nicole; Haag, Friedrich; Koch-Nolte, Friedrich] Univ Hamburg, Hosp Eppendorf, Ctr Diagnost, Inst Immunol, D-20246 Hamburg, Germany; [Fliegert, Ralf; Guse, Andreas H.] Univ Hamburg, Hosp Eppendorf, Inst Biochem & Mol Biol 1, D-20246 Hamburg, Germany; [Adriouch, Sahil; Seman, Michel] Univ Rouen, Fac Med & Pharm, INSERM, U 519, Rouen, France	University of Hamburg; University of Hamburg; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie	Koch-Nolte, F (corresponding author), Univ Hamburg, Hosp Eppendorf, Ctr Diagnost, Inst Immunol, Martinistr 52, D-20246 Hamburg, Germany.	nolte@uke.uni-hamburg.de	ADRIOUCH, Sahil/G-8999-2012	ADRIOUCH, Sahil/0000-0002-0265-7773; Bannas, Peter/0000-0002-7102-534X; Koch-Nolte, Friedrich/0000-0003-1730-6674				Adriouch S, 2005, CELL IMMUNOL, V236, P72, DOI 10.1016/j.cellimm.2005.08.011; Adriouch S, 2002, J IMMUNOL, V169, P4108, DOI 10.4049/jimmunol.169.8.4108; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; Aktories K, 2000, BACTERIAL PROTEIN TO; Bannas P, 2005, BLOOD, V105, P3663, DOI 10.1182/blood-2004-08-3325; Cabrini G, 2005, J IMMUNOL, V175, P82, DOI 10.4049/jimmunol.175.1.82; Clyne JD, 2002, J NEUROSCI, V22, P3873, DOI 10.1523/JNEUROSCI.22-10-03873.2002; Collier RJ, 2001, TOXICON, V39, P1793, DOI 10.1016/S0041-0101(01)00165-9; Corda D, 2003, EMBO J, V22, P1953, DOI 10.1093/emboj/cdg209; Coutinho-Silva R, 2003, IMMUNITY, V19, P403, DOI 10.1016/S1074-7613(03)00235-8; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Domenighini M, 1996, MOL MICROBIOL, V21, P667, DOI 10.1046/j.1365-2958.1996.321396.x; Ennion SJ, 2002, MOL PHARMACOL, V61, P303, DOI 10.1124/mol.61.2.303; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Ferrero E, 2000, CHEM IMMUNOL, V75, P1; Ganesan AK, 1999, J BIOL CHEM, V274, P9503, DOI 10.1074/jbc.274.14.9503; GRIMALDI JC, 1995, J IMMUNOL, V155, P811; Gudipaty L, 2003, AM J PHYSIOL-CELL PH, V285, pC286, DOI 10.1152/ajpcell.00070.2003; Haag F, 2007, PURINERG SIGNAL, V3, P71, DOI 10.1007/s11302-006-9038-7; Holbourn KP, 2006, FEBS J, V273, P4579, DOI 10.1111/j.1742-4658.2006.05442.x; HONJO T, 1968, J BIOL CHEM, V243, P3553; Jorgensen R, 2005, NATURE, V436, P979, DOI 10.1038/nature03871; Kawamura H, 2005, J IMMUNOL, V174, P1971, DOI 10.4049/jimmunol.174.4.1971; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Koch-Nolte F, 1999, J IMMUNOL, V163, P6014; KochNolte F, 1996, J BIOL CHEM, V271, P7686, DOI 10.1074/jbc.271.13.7686; Krebs C, 2005, J IMMUNOL, V174, P3298, DOI 10.4049/jimmunol.174.6.3298; Kunerth S, 2003, CELL SIGNAL, V15, P783, DOI 10.1016/S0898-6568(03)00015-9; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; Lund FE, 1998, IMMUNOL REV, V161, P79, DOI 10.1111/j.1600-065X.1998.tb01573.x; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Margarit SM, 2006, STRUCTURE, V14, P1219, DOI 10.1016/j.str.2006.05.022; Moreschi I, 2006, J BIOL CHEM, V281, P31419, DOI 10.1074/jbc.M606625200; Mueller-Dieckmann C, 2002, J MOL BIOL, V322, P687, DOI 10.1016/S0022-2836(02)00818-5; Nagaya N, 2005, J BIOL CHEM, V280, P25982, DOI 10.1074/jbc.M504545200; Nemoto E, 1996, J IMMUNOL, V157, P3341; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Okazaki IJ, 1998, J BIOL CHEM, V273, P23617, DOI 10.1074/jbc.273.37.23617; Paone G, 2002, P NATL ACAD SCI USA, V99, P8231, DOI 10.1073/pnas.122238899; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Schuber F, 2004, CURR MOL MED, V4, P249, DOI 10.2174/1566524043360708; Seman M, 2003, IMMUNITY, V19, P571, DOI 10.1016/S1074-7613(03)00266-8; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Stojilkovic SS, 2005, ANN NY ACAD SCI, V1048, P116, DOI 10.1196/annals.1342.011; Sun JJ, 2004, NAT STRUCT MOL BIOL, V11, P868, DOI 10.1038/nsmb818; VANDEKERCKHOVE J, 1988, J BIOL CHEM, V263, P696; Vial C, 2004, TRENDS PHARMACOL SCI, V25, P487, DOI 10.1016/j.tips.2004.07.008; Yates SP, 2006, TRENDS BIOCHEM SCI, V31, P123, DOI 10.1016/j.tibs.2005.12.007; Young MT, 2007, MOL PHARMACOL, V71, P92, DOI 10.1124/mol.106.030163; ZANOVELLO P, 1990, J IMMUNOL, V145, P1545; Zolkiewska A, 2005, PHYSIOLOGY, V20, P374, DOI 10.1152/physiol.00028.2005	53	100	105	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					861	869		10.1096/fj.07-9294com	http://dx.doi.org/10.1096/fj.07-9294com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17928361				2022-12-28	WOS:000254143700024
J	Iyer, J; Reich, NC				Iyer, Janaki; Reich, Nancy C.			Constitutive nuclear import of latent and activated STAT5a by its coiled coil domain	FASEB JOURNAL			English	Article						transcription factor; nuclear trafficking; tyrosine phosphorylation; live cell imaging	DNA-BINDING DOMAIN; GENE-EXPRESSION; TRANSCRIPTION FACTOR; NUCLEOCYTOPLASMIC TRANSPORT; UNPHOSPHORYLATED STAT1; LYMPHOID DEVELOPMENT; MAMMARY EPITHELIUM; CELL-PROLIFERATION; GROWTH; ALPHA	Signal transducer and activator of transcription 5a (STAT5a) is a critical transcription factor for a number of physiological processes including hematopoiesis and mammary gland development. Cytokines such as growth hormone, prolactin, erythropoietin, and interleukin-2 stimulate the activation of STAT5a by tyrosine phosphorylation. Tyrosine phosphorylation confers a conformational change and the ability to bind specific target DNA. To execute its function as a signaling molecule and transcription factor, accurate cellular localization of STAT5a is essential. This study explores the nuclear trafficking of STAT5a both before phosphorylation and after tyrosine phosphorylation. With the use of live cell imaging we demonstrate the continuous shuttling of STAT5a in and out of the nucleus. Evaluation of a series of mutations and deletions identifies a region within the coiled coil domain of STAT5a that is critical for nuclear import of both unphosphorylated and tyrosine-phosphorylated forms. The mechanism that regulates transport of STAT5a through nuclear pore complexes into the nucleus is therefore independent of tyrosine phosphorylation. However, after tyrosine phosphorylation, STAT5a accumulates in the nucleus because of its retention by DNA binding. These findings should provide a foundation for further studies that involve targeting the activity of STAT5a.	[Iyer, Janaki; Reich, Nancy C.] SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Reich, NC (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	nreich@notes.cc.sunysb.edu			NCI NIH HHS [P01CA2814, R01CA122910] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA122910] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banninger G, 2004, J BIOL CHEM, V279, P39199, DOI 10.1074/jbc.M400815200; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bednenko J, 2003, TRAFFIC, V4, P127, DOI 10.1034/j.1600-0854.2003.00109.x; Brierley MM, 2005, J INTERF CYTOK RES, V25, P733, DOI 10.1089/jir.2005.25.733; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Clarkson RWE, 2006, MOL ENDOCRINOL, V20, P675, DOI 10.1210/me.2005-0392; Constantino S, 2001, ONCOGENE, V20, P2080, DOI 10.1038/sj.onc.1204308; Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Gatzka M, 2006, CYTOKINE, V34, P143, DOI 10.1016/j.cyto.2006.04.003; Gomez D, 2003, J IMMUNOL, V170, P5373, DOI 10.4049/jimmunol.170.11.5373; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; Groner B, 2000, BREAST CANCER RES, V2, P149, DOI 10.1186/bcr47; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; Hoelbl A, 2006, BLOOD, V107, P4898, DOI 10.1182/blood-2005-09-3596; Kawashima T, 2006, J CELL BIOL, V175, P937, DOI 10.1083/jcb.200604073; Koster M, 2005, CURR OPIN BIOTECH, V16, P28, DOI 10.1016/j.copbio.2004.11.002; Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liu L, 2005, P NATL ACAD SCI USA, V102, P8150, DOI 10.1073/pnas.0501643102; Ma J, 2003, J BIOL CHEM, V278, P29252, DOI 10.1074/jbc.M304196200; Mao X, 2005, MOL CELL, V17, P761, DOI 10.1016/j.molcel.2005.02.021; Marg A, 2004, J CELL BIOL, V165, P823, DOI 10.1083/jcb.200403057; MartinezMoczygemba M, 1997, J BIOL CHEM, V272, P20070, DOI 10.1074/jbc.272.32.20070; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; McBride KM, 2002, EMBO J, V21, P1754, DOI 10.1093/emboj/21.7.1754; Melen K, 2003, J BIOL CHEM, V278, P28193, DOI 10.1074/jbc.M303571200; Melen K, 2001, J BIOL CHEM, V276, P16447, DOI 10.1074/jbc.M008821200; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Neculai D, 2005, J BIOL CHEM, V280, P40782, DOI 10.1074/jbc.M507682200; NISHI K, 1994, J BIOL CHEM, V269, P6320; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Peters Reiner, 2006, V322, P235; Phung-Koskas T, 2005, J BIOL CHEM, V280, P1123, DOI 10.1074/jbc.M409918200; Pranada AL, 2004, J BIOL CHEM, V279, P15114, DOI 10.1074/jbc.M312530200; Reich NC, 2006, NAT REV IMMUNOL, V6, P602, DOI 10.1038/nri1885; Schuringa JJ, 2004, J EXP MED, V200, P623, DOI 10.1084/jem.20041024; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; Snow JW, 2002, BLOOD, V99, P95, DOI 10.1182/blood.V99.1.95; Takeda K, 2000, CYTOKINE GROWTH F R, V11, P199, DOI 10.1016/S1359-6101(00)00005-8; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; van Boxel-Dezaire AHH, 2006, IMMUNITY, V25, P361, DOI 10.1016/j.immuni.2006.08.014; Yang J, 2005, CANCER RES, V65, P939; Yao ZJ, 2006, P NATL ACAD SCI USA, V103, P1000, DOI 10.1073/pnas.0507350103; Ye D, 2006, BLOOD, V107, P4917, DOI 10.1182/blood-2005-10-4110; Zeng R, 2002, J IMMUNOL, V168, P4567, DOI 10.4049/jimmunol.168.9.4567	52	32	33	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2008	22	2					391	400		10.1096/fj.07-8965com	http://dx.doi.org/10.1096/fj.07-8965com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17846080				2022-12-28	WOS:000252822600009
J	Hinz, B; Cheremina, O; Bachmakov, J; Renner, B; Zolk, O; Fromm, MF; Brune, K				Hinz, Burkhard; Cheremina, Olga; Bachmakov, Jouri; Renner, Bertold; Zolk, Oliver; Fromm, Martin F.; Brune, Kay			Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic	FASEB JOURNAL			English	Article						dipyrone metabolites; human whole blood assay; pharmacokinetics	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NONNARCOTIC ANALGESICS; METAMIZOL DIPYRONE; HEALTHY-SUBJECTS; PHARMACOKINETICS; INFLAMMATION; METABOLITES; DICLOFENAC; DAMAGE; COX-3	Dipyrone ( INN, metamizol) is a common analgesic used worldwide. Its widespread prescription or over-the-counter use in many countries ( e. g., Brazil, Israel, Mexico, Russia, Spain) requires insight into its mode of action. This study therefore addressed the impact of its metabolites 4-methyl-amino-antipyrine ( MAA) and 4-amino-antipyrine ( AA) on peripheral cyclooxygenases ( COX). Pharmacokinetics of metabolites and ex vivo COX inhibition were assessed in five volunteers receiving dipyrone at single oral doses of 500 or 1000 mg. Coagulation-induced thromboxane B-2 formation and lipopolysaccharide-induced prostaglandin E-2 synthesis were measured in vitro and ex vivo in human whole blood as indices of COX-1 and COX-2 activity. In vitro, metabolites elicited no substantial COX-1/COX-2 selectivity with MAA ( IC50 = 2.55 mu mol/ L for COX-1; IC50 = 4.65 mu mol/ L for COX-2), being similar to 8.2- or 9-fold more potent than AA. After administration of dipyrone, MAA plasma concentrations remained above the IC50 values for each isoform for at least 8 h ( 500 mg) and 12 h ( 1000 mg) postdose. COX inhibition correlated with MAA plasma levels ( ex vivo IC50 values of 1.03 mu mol/ L [COX-1] and 0.87 mu mol/ L [ COX-2]). By contrast, plasma peak concentrations of AA after the 1000 mg dose were 2.8- and 6.5- fold below its IC50 values for COX-1 and COX-2, respectively. Maximal inhibitions of COX-1 and COX-2 were 94% and 87% ( 500 mg), 97% and 94% ( 1000 mg). Taken together, dipyrone elicits a substantial and virtually equipotent inhibition of COX isoforms via MAA. Given the profound COX-2 suppression by dipyrone, which was considerably above COX-2 inhibition by single analgesic doses of celecoxib and rofecoxib, a significant portion of its analgesic action may be ascribed to peripheral mechanisms. In view of the observed COX-1 suppression, physicochemical factors ( lack of acidity) rather than differential COX-1 inhibition may be responsible for dipyrone's favorable gastrointestinal tolerability compared with acidic COX inhibitors.	Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Hinz, B (corresponding author), Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol, Fahrstr 17, D-91054 Erlangen, Germany.	hinz@pharmakologie.uni-erlangen.de	Renner, Bertold/ABD-8212-2021	Renner, Bertold/0000-0003-0845-6793; Zolk, Oliver/0000-0002-8220-3834				Ahmadi S, 2002, NAT NEUROSCI, V5, P34, DOI 10.1038/nn778; Andrade SE, 1998, J CLIN EPIDEMIOL, V51, P1357, DOI 10.1016/S0895-4356(98)00076-6; ASMARDI G, 1983, J CHROMATOGR, V277, P183, DOI 10.1016/S0378-4347(00)84835-5; ASMARDI G, 1985, EUR J DRUG METAB PH, V10, P121, DOI 10.1007/BF03189705; *AV PHARM DEUTSCHL, 2004, NOV FACH PROD INF; Beiche F, 1996, FEBS LETT, V390, P165, DOI 10.1016/0014-5793(96)00604-7; BRUNE K, 1983, AGENTS ACTIONS, V13, P360, DOI 10.1007/BF01971489; BRUNE K, 1980, BRIT J CLIN PHARMACO, V10, pS279, DOI 10.1111/j.1365-2125.1980.tb01810.x; Campos C, 1999, EUR J PHARMACOL, V378, P339, DOI 10.1016/S0014-2999(99)00477-X; CARLSSON KH, 1986, PAIN, V27, P373, DOI 10.1016/0304-3959(86)90161-2; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; DEMBINSKAKIEC A, 1976, ADV PROSTAG THROMB R, V1, P99; Dinchuk JE, 2003, IMMUNOL LETT, V86, P121, DOI 10.1016/S0165-2478(02)00268-7; ELDOR A, 1984, EUR J CLIN PHARMACOL, V26, P171, DOI 10.1007/BF00630282; Ergun H, 2004, J PHARMACEUT BIOMED, V35, P479, DOI 10.1016/j.jpba.2004.02.004; Frolich J C, 1986, Agents Actions Suppl, V19, P155; Galati G, 2002, CHEM-BIOL INTERACT, V142, P25, DOI 10.1016/S0009-2797(02)00052-2; Geisslinger G, 1996, THROMB HAEMOSTASIS, V76, P592; GELGOR L, 1992, PAIN, V50, P323, DOI 10.1016/0304-3959(92)90038-D; Hackenthal E, 1997, SCHMERZ, V11, P269, DOI 10.1007/s004820050097; Hinz B, 2007, Handb Exp Pharmacol, P65; Hinz B, 2006, ARTHRITIS RHEUM-US, V54, P282, DOI 10.1002/art.21540; Hinz B, 2003, CLIN PHARMACOL THER, V74, P222, DOI 10.1016/S0009-9236(03)00167-X; Ibanez L, 2005, EUR J CLIN PHARMACOL, V60, P821, DOI 10.1007/s00228-004-0836-y; KAUFMAN DW, 1981, MONOGRAPHS EPIDEMIOL, V18; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LANZ R, 1986, EUR J PHARMACOL, V130, P105, DOI 10.1016/0014-2999(86)90188-3; LAPORTE JR, 1987, LANCET, V1, P809; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LEVY M, 1995, CLIN PHARMACOKINET, V28, P216, DOI 10.2165/00003088-199528030-00004; Levy M, 1998, CLIN PHARMACOL THER, V64, P117, DOI 10.1016/S0009-9236(98)90029-7; LORENZETTI BB, 1985, EUR J PHARMACOL, V114, P375, DOI 10.1016/0014-2999(85)90383-8; Mazario J, 1999, NEUROSCI LETT, V274, P179, DOI 10.1016/S0304-3940(99)00721-1; MCCORMACK K, 1987, ARCH TOXICOL, V60, P261, DOI 10.1007/BF01234664; NEUGEBAUER V, 1994, AGENTS ACTIONS, V41, P62, DOI 10.1007/BF01986396; NODA A, 1976, CHEM PHARM BULL, V24, P1502; PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705; PATRIGNANI P, 1982, J CLIN INVEST, V69, P1366, DOI 10.1172/JCI110576; Patrono C, 2001, CLIN EXP RHEUMATOL, V19, pS45; PESKAR BM, 1983, MED TOXICOL S1, V1, P39; Pigoso AA, 1998, INT J BIOCHEM CELL B, V30, P961, DOI 10.1016/S1357-2725(98)00030-2; Porro GB, 1996, DIGESTION, V57, P186; PRICE AH, 1990, DRUGS, V40, P1, DOI 10.2165/00003495-199000405-00003; Qin N, 2005, J PHARMACOL EXP THER, V315, P1298, DOI 10.1124/jpet.105.090944; REILLY IAG, 1987, BLOOD, V69, P180; Sanchez S, 2002, INFLAMM RES, V51, P385, DOI 10.1007/PL00000319; Sanchez S, 2002, DIGEST DIS SCI, V47, P1389, DOI 10.1023/A:1015395103160; Schwab JM, 2003, FASEB J, V17, P2174, DOI 10.1096/fj.03-0595lte; SHIMADA SG, 1994, AGENTS ACTIONS, V41, P188, DOI 10.1007/BF02001915; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Somasundaram S, 1997, GUT, V41, P344, DOI 10.1136/gut.41.3.344; TATSUO MAKF, 1994, INFLAMMATION, V18, P399, DOI 10.1007/BF01534437; TORTORICI V, 1995, EUR J NEUROSCI, V7, P1857, DOI 10.1111/j.1460-9568.1995.tb00706.x; VLAHOV V, 1990, EUR J CLIN PHARMACOL, V38, P61, DOI 10.1007/BF00314805; VOLZ M, 1980, BR J CLIN PHARM, V10, P299; Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264; WEISS R, 1974, ARZNEIMITTEL-FORSCH, V24, P345; WEITHMANN KU, 1985, ARZNEIMITTEL-FORSCH, V35-1, P947; 1986, J AM MED ASS, V256, P1749	59	92	98	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2343	2351		10.1096/fj.06-8061com	http://dx.doi.org/10.1096/fj.06-8061com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17435173				2022-12-28	WOS:000248454400009
J	Crigler, L; Kazhanie, A; Yoon, TJ; Zakhari, J; Anders, J; Taylor, B; Virador, VM				Crigler, Lauren; Kazhanie, Amita; Yoon, Tae-Jin; Zakhari, Julia; Anders, Joanna; Taylor, Barbara; Virador, Victoria M.			Isolation of a mesenchymal cell population from murine dermis that contains progenitors of multiple cell lineages	FASEB JOURNAL			English	Article						epidermal precursors; murine organotypic culture; keratinocytes	KERATINOCYTE STEM-CELLS; HAIR FOLLICLE DEVELOPMENT; BONE-MARROW; PROTEIN-KINASE; IN-VIVO; SKIN; EXPRESSION; MOUSE; DIFFERENTIATION; MARKERS	The skin contains two known subpopulations of stem cells/epidermal progenitors: a basal keratinocyte population found in the interfollicular epithelium and cells residing in the bulge region of the hair follicle. The major role of the interfollicular basal keratinocyte population may be epidermal renewal, whereas the bulge population may only be activated and recruited to form a cutaneous epithelium in case of trauma. Using 3-dimensional cultures of murine skin under stress conditions in which only reserve epithelial cells would be expected to survive and expand, we demonstrate that a mesenchymal population resident in neonatal murine dermis has the unique potential to develop an epidermis in vitro. In monolayer culture, this dermal subpopulation has long-term survival capabilities in restricted serum and an inducible capacity to evolve into multiple cell lineages, both epithelial and mesenchymal, depending on culture conditions. When grafted subcutaneously, this dermal subpopulation gave rise to fusiform structures, reminiscent of disorganized muscle, that stained positive for smooth muscle actin and desmin; on typical epidermal grafts, abundant melanocytes appeared throughout the dermis that were not associated with hair follicles. The multipotential cells can be repeatedly isolated from neonatal murine dermis by a sequence of differential centrifugation and selective culture conditions. These results suggest that progenitors capable of epidermal differentiation exist in the mesenchymal compartment of an abundant tissue source and may have a function in mesenchymal-epithelial transition upon insult. Moreover, these cells could be available in sufficient quantities for lineage determination or tissue engineering applications.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Gyeongsang Natl Univ, Coll Med, Dept Dermatol, Jinju, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Gyeongsang National University	Virador, VM (corresponding author), 9000 Rockville Pike,Bldg 10,Rm 2A33, Bethesda, MD 20892 USA.	vvirador@helix.nih.gov	Virador, Victoria M./A-8173-2009		Intramural NIH HHS [Z99 CA999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Amoh Y, 2005, P NATL ACAD SCI USA, V102, P5530, DOI 10.1073/pnas.0501263102; Andriani F, 2004, INT J CANCER, V108, P348, DOI 10.1002/ijc.11525; Arosarena Oneida, 2005, Curr Opin Otolaryngol Head Neck Surg, V13, P233, DOI 10.1097/01.moo.0000170526.51393.c5; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Baddoo M, 2003, J CELL BIOCHEM, V89, P1235, DOI 10.1002/jcb.10594; Bickenbach JR, 2004, DIFFERENTIATION, V72, P371, DOI 10.1111/j.1432-0436.2004.07208003.x; Carroll JM, 2000, EXP DERMATOL, V9, P20, DOI 10.1034/j.1600-0625.2000.009001020.x; Ceradini DJ, 2005, TRENDS CARDIOVAS MED, V15, P57, DOI 10.1016/j.tcm.2005.02.002; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Dunn KJ, 2005, PIGM CELL RES, V18, P167, DOI 10.1111/j.1600-0749.2005.00226.x; Eckfeldt CE, 2005, NAT REV MOL CELL BIO, V6, P726, DOI 10.1038/nrm1713; Fernandes KJL, 2004, NAT CELL BIOL, V6, P1082, DOI 10.1038/ncb1181; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Kalcheim C, 2005, CURR OPIN GENET DEV, V15, P371, DOI 10.1016/j.gde.2005.05.004; KARTASOVA T, 1995, J INVEST DERMATOL, V104, P611; Lavker RM, 2000, P NATL ACAD SCI USA, V97, P13473, DOI 10.1073/pnas.250380097; Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341; Li A, 1998, P NATL ACAD SCI USA, V95, P3902, DOI 10.1073/pnas.95.7.3902; Li LW, 1999, MOL CELL BIOL, V19, P8547; LICHTI U, 1991, J INVEST DERMATOL, V96, pS81, DOI 10.1111/1523-1747.ep12472042; LICHTI U, 1993, J INVEST DERMATOL, V101, pS124, DOI 10.1111/1523-1747.ep12363165; LICHTI U, 1995, J INVEST DERMATOL, V104, P614; Lyle S, 1998, J CELL SCI, V111, P3179; Maas-Szabowski N, 2003, J CELL SCI, V116, P2937, DOI 10.1242/jcs.00474; Maas-Szabowski N, 2001, J INVEST DERMATOL, V116, P816, DOI 10.1046/j.1523-1747.2001.01349.x; MADISON KC, 1990, J INVEST DERMATOL, V95, P657, DOI 10.1111/1523-1747.ep12514333; Masson-Gadais B, 2006, J CELL PHYSIOL, V206, P831, DOI 10.1002/jcp.20529; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; McGowan KM, 2002, GENE DEV, V16, P1412, DOI 10.1101/gad.979502; Medalie DA, 1996, J INVEST DERMATOL, V107, P121, DOI 10.1111/1523-1747.ep12298363; Medina RJ, 2006, J CELL BIOCHEM, V98, P174, DOI 10.1002/jcb.20757; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Miyahara Y, 2006, NAT MED, V12, P459, DOI 10.1038/nm1391; Mori L, 2005, EXP CELL RES, V304, P81, DOI 10.1016/j.yexcr.2004.11.011; MORRIS RJ, 1990, CELL TISSUE KINET, V23, P587, DOI 10.1111/j.1365-2184.1990.tb01348.x; Ng WA, 1997, PEDIATR RES, V41, P285, DOI 10.1203/00006450-199702000-00021; Nishimura EK, 2002, NATURE, V416, P854, DOI 10.1038/416854a; Pasonen-Seppanen S, 2001, HISTOCHEM CELL BIOL, V116, P287, DOI 10.1007/s004180100312; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Petiot A, 2003, DEVELOPMENT, V130, P5493, DOI 10.1242/dev.00788; POTTEN CS, 1983, EXPERIENTIA, V39, P1125, DOI 10.1007/BF01943142; Rahimi F, 2005, FEBS J, V272, P2811, DOI 10.1111/j.1742-4658.2005.04703.x; Ramos CA, 2003, BIOTECHNIQUES, V34, P572, DOI 10.2144/03343rv01; Reddy ST, 2004, J INVEST DERMATOL, V123, P275, DOI 10.1111/j.0022-202X.2004.23215.x; ROGERS G, 1987, J INVEST DERMATOL, V89, P369, DOI 10.1111/1523-1747.ep12471760; Rokhlin OW, 1995, CANCER LETT, V98, P103, DOI 10.1016/0304-3835(95)90210-4; Rombouts WJC, 2003, LEUKEMIA, V17, P160, DOI 10.1038/sj.leu.2402763; Spradling AC, 2004, NATURE, V428, P133, DOI 10.1038/428133b; Tani H, 2000, P NATL ACAD SCI USA, V97, P10960, DOI 10.1073/pnas.97.20.10960; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Terunuma A, 2003, J INVEST DERMATOL, V121, P1095, DOI 10.1046/j.1523-1747.2003.12531.x; Thorey IS, 2001, J BIOL CHEM, V276, P35818, DOI 10.1074/jbc.M104871200; Tosney KW, 2004, DEV DYNAM, V229, P99, DOI 10.1002/dvdy.10492; Trempus CS, 2003, J INVEST DERMATOL, V120, P501, DOI 10.1046/j.1523-1747.2003.12088.x; Troy TC, 2005, DEV DYNAM, V232, P293, DOI 10.1002/dvdy.20223; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Wan H, 2003, J CELL SCI, V116, P4239, DOI 10.1242/jcs.00701; Wang DJ, 2004, J BIOL CHEM, V279, P43725, DOI 10.1074/jbc.M407368200; Watt FM, 1998, PHILOS T R SOC B, V353, P831, DOI 10.1098/rstb.1998.0247; Webb A, 2004, DIFFERENTIATION, V72, P387, DOI 10.1111/j.1432-0436.2004.07208005.x; WEINBERG WC, 1993, J INVEST DERMATOL, V100, P229, DOI 10.1111/1523-1747.ep12468971; YUSPA SH, 1993, J INVEST DERMATOL, V101, pS27, DOI 10.1111/1523-1747.ep12362567; Zeisberg M, 2005, J BIOL CHEM, V280, P8094, DOI 10.1074/jbc.M413102200; Zheng Y, 2005, J INVEST DERMATOL, V124, P867, DOI 10.1111/j.0022-202X.2005.23716.x; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	65	76	83	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2050	2063		10.1096/fj.06-5880com	http://dx.doi.org/10.1096/fj.06-5880com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17384147	Green Accepted			2022-12-28	WOS:000247500300015
J	Lee, SH; Lee, H; Park, JS; Choi, H; Han, KY; Seo, HS; Ahn, KY; Han, SS; Cho, Y; Lee, KH; Lee, J				Lee, Sung-Hyun; Lee, Hyewon; Park, Jin-Seung; Choi, Hyoung; Han, Kyung-Yeon; Seo, Hyuk-Seong; Ahn, Keum-Young; Han, Sung-Sik; Cho, Yunjung; Lee, Kee-Hyoung; Lee, Jeewon			A novel approach to ultrasensitive diagnosis using supramolecular protein nanoparticles	FASEB JOURNAL			English	Article						human ferritin heavy chain; nanoprobe system; attomoloar sensitivity	GLUTAMIC-ACID DECARBOXYLASE; STIFF-MAN SYNDROME; DIABETES-MELLITUS; HUMAN FERRITIN; H-CHAIN; EPITOPE; AUTOANTIBODIES; EXPRESSION; IDENTIFICATION; ANTIBODIES	We report on the ultrasensitive protein nanoprobe system that specifically captures disease marker ( autoantibodies of Type I diabetes in this case) with attomolar sensitivity. The system relies on supramolecular protein nanoparticles that bind a specific antibody [ 65 kDa glutamate decarboxylase ( GAD(65))- specific autoantibody, i.e., the early marker of Type I diabetes]. The ultrasensitive detection of early marker of Type I diabetes during the early phase of pancreatic beta-cell destruction is important because individuals at high risk of developing Type I diabetes can be identified several years before the clinical onset of the ailment. The bacterial expression of chimera genes encoding N-[human ferritin heavy chain (hFTN- H)]::[ specific antigenic epitope]- C produces supramolecular nanoparticles with uniform diameters ( 10 - 15 nm), owing to self-assembly activity of hFTN- H. Each nanoparticle, formed by intermolecular self-assembly between the chimera protein molecules, is subjected to carrying a large number ( presumably, 24) of epitopes with a homogeneous and stable conformation per autoantibody binding, thereby allowing substantial enhancement of sensitivity. The sensitivity was finally boosted to 3 attomolar concentration of the autoantibodies, 4 - 9 orders of magnitude more sensitive than conventional immunoassays. Also, this ultrasensitive protein nanoprobe successfully detected natural autoantibodies in the sera from Type I diabetic patients. The attomolar sensitivity was successfully reproduced on the detection of other antibodies, i.e., monoclonal antibodies against hepatitis B surface antigen. With the two antibody markers above, the feasibility of simultaneous and multiplexing-mode detection was also demonstrated.	Korea Univ, Dept Chem & Biol Engn, Seoul 136713, South Korea; Korea Univ, Sch Life Sci & Biotechnol, Seoul 136713, South Korea; Korea Univ, Coll Med, Seoul 136713, South Korea	Korea University; Korea University; Korea University; Korea University Medicine (KU Medicine)	Lee, J (corresponding author), Korea Univ, Dept Chem & Biol Engn, Anam Dong 5-1, Seoul 136713, South Korea.	leejw@korea.ac.kr	Lee, Jeewon/J-1781-2015; Lee, Jeewon/F-7620-2013	Cho, Yunjung/0000-0002-6942-8385				Ahn JY, 2005, NUCLEIC ACIDS RES, V33, P3751, DOI 10.1093/nar/gki692; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; Bonifacio E, 2000, DIABETES, V49, P202, DOI 10.2337/diabetes.49.2.202; BU DF, 1992, P NATL ACAD SCI USA, V89, P2115, DOI 10.1073/pnas.89.6.2115; Daw K, 1996, J IMMUNOL, V156, P818; HAGOPIAN WA, 1993, DIABETES, V42, P631, DOI 10.2337/diabetes.42.4.631; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KIM J, 1993, DIABETES, V42, P1799, DOI 10.2337/diabetes.42.12.1799; LEVI S, 1989, BIOCHEM J, V264, P381, DOI 10.1042/bj2640381; LUZZAGO A, 1989, EMBO J, V8, P569, DOI 10.1002/j.1460-2075.1989.tb03411.x; Notkins AL, 2001, J CLIN INVEST, V108, P1247, DOI 10.1172/JCI200114257; PETERSEN JS, 1995, DIABETES, V43, P459; RICHTER W, 1992, P NATL ACAD SCI USA, V89, P8467, DOI 10.1073/pnas.89.18.8467; RICHTER W, 1993, P NATL ACAD SCI USA, V90, P2832, DOI 10.1073/pnas.90.7.2832; Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f; Santambrogio P, 1997, BIOCHEM J, V322, P461, DOI 10.1042/bj3220461; Sohnlein P, 2000, DIABETOLOGIA, V43, P210, DOI 10.1007/s001250050031; SOLIMENA M, 1988, NEW ENGL J MED, V318, P1012, DOI 10.1056/NEJM198804213181602; TUOMI T, 1994, CLIN IMMUNOL IMMUNOP, V71, P53, DOI 10.1006/clin.1994.1051; UJIHARA N, 1994, DIABETES, V43, P968, DOI 10.2337/diabetes.43.8.968; Wang J, 2004, ANGEW CHEM INT EDIT, V43, P2158, DOI 10.1002/anie.200453832; Yoon JW, 1999, SCIENCE, V284, P1183, DOI 10.1126/science.284.5417.1183	22	29	34	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1324	1334		10.1096/fj.06-7303com	http://dx.doi.org/10.1096/fj.06-7303com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17283220				2022-12-28	WOS:000246117000008
J	Bengrine, A; Li, JQ; Awayda, MS				Bengrine, Abderrahmane; Li, Jinqing; Awayda, Mouhamed S.			The A-kinase anchoring protein 15 regulates feedback inhibition of the epithelial Na+ channel	FASEB JOURNAL			English	Article						PKA; ENaC activity; intracellular Na+; AKAP15	RENAL PRINCIPAL CELLS; ENAC TRAFFICKING; CALCIUM-CHANNELS; SODIUM-CHANNEL; ION CHANNELS; IDENTIFICATION; AQUAPORIN-2; ASSOCIATION; ACTIVATION; ISOFORMS	Protein kinase A anchoring proteins or AKAPs regulate the activity of many ion channels. Protein kinase A (PKA) is a well-recognized target of AKAPs, with other kinases now emerging as additional targets. We examined the roles of epithelial-expressed AKAPs in regulating the epithelial Na+ channel ( ENaC). Experiments used heterologous expression with AKAP15, AKAP-KL, and AKAP79 in Xenopus oocytes. Experiments were carried out under high and low Na+ conditions, as Na+ loading is known to affect the baseline activity of ENaC in a PKC-dependent mechanism. ENaC activity was unaffected by AKAP79 and AKAP-KL expression. However, oocytes coexpressing AKAP15 exhibited an 80% and 91% reduction in the amiloride-sensitive, whole-cell conductance in high and low Na+ conditions, respectively. The reduced channel activity was unaffected by PKA activation or inhibition, indicating a PKA-independent mechanism. Expression with a membrane-targeting domain, mutant form of AKAP15 (AKAP15m) prevented the decrease of ENaC activity, but only under low Na+ conditions. In high sodium conditions, coexpression with AKAP15m led to an increase of ENaC activity to levels similar to those observed under low Na+. These results indicate that membrane- associated AKAP15 reduces ENaC activity whereas the cytoplasmically associated one may participate in the channel's feedback inhibition by intracellular Na+, a process known to involve PKC. This hypothesis was further confirmed in coexpression experiments, which demonstrated functional and physical interaction between AKAP15 and PKC alpha. We propose that AKAP15 regulates ENaC via a novel PKA-independent pathway.	SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Awayda, MS (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, 124 Sherman Hall,3435 Main St, Buffalo, NY 14214 USA.	awayda@buffalo.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055626] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55626] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali S, 2001, CELL PHYSIOL BIOCHEM, V11, P135, DOI 10.1159/000047801; Ali S, 1998, P NATL ACAD SCI USA, V95, P10274, DOI 10.1073/pnas.95.17.10274; Awayda Mouhamed S., 2006, V337, P101; Awayda MS, 1998, J GEN PHYSIOL, V112, P97, DOI 10.1085/jgp.112.2.97; Awayda MS, 2000, J GEN PHYSIOL, V115, P559, DOI 10.1085/jgp.115.5.559; Awayda MS, 2004, J GEN PHYSIOL, V123, P709, DOI 10.1085/jgp.200308983; AWAYDA MS, 1995, AM J PHYSIOL-CELL PH, V268, pC1450, DOI 10.1152/ajpcell.1995.268.6.C1450; Awayda MS, 2002, AM J PHYSIOL-CELL PH, V283, pC1122, DOI 10.1152/ajpcell.00142.2002; Awayda MS, 1996, J GEN PHYSIOL, V108, P49, DOI 10.1085/jgp.108.1.49; Awayda MS, 1999, AM J PHYSIOL-CELL PH, V277, pC216, DOI 10.1152/ajpcell.1999.277.2.C216; Butterworth MB, 2005, AM J PHYSIOL-RENAL, V289, pF969, DOI 10.1152/ajprenal.00390.2003; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chraibi A, 2001, J MEMBRANE BIOL, V183, P15, DOI 10.1007/s00232-001-0049-6; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; CUNNINGHAM SA, 1992, AM J PHYSIOL, V262, pC783, DOI 10.1152/ajpcell.1992.262.3.C783; Dong F, 1998, J BIOL CHEM, V273, P6533, DOI 10.1074/jbc.273.11.6533; ELS WJ, 1991, J GEN PHYSIOL, V98, P1197, DOI 10.1085/jgp.98.6.1197; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Fraser IDC, 1999, NEURON, V23, P423, DOI 10.1016/S0896-6273(00)80795-3; Frindt G, 1996, AM J PHYSIOL-RENAL, V270, pF371, DOI 10.1152/ajprenal.1996.270.2.F371; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Gorski JA, 2005, MOL BIOL CELL, V16, P3574, DOI 10.1091/mbc.E05-02-0134; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; Gray PC, 1997, J BIOL CHEM, V272, P6297, DOI 10.1074/jbc.272.10.6297; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; Henn V, 2004, J BIOL CHEM, V279, P26654, DOI 10.1074/jbc.M312835200; Higashida H, 2005, NEUROSCI RES, V51, P231, DOI 10.1016/j.neures.2004.11.009; Hulme JT, 2003, P NATL ACAD SCI USA, V100, P13093, DOI 10.1073/pnas.2135335100; Hulme JT, 2002, J BIOL CHEM, V277, P4079, DOI 10.1074/jbc.M109814200; Khundmiri SJ, 2003, J BIOL CHEM, V278, P10134, DOI 10.1074/jbc.M211775200; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Klussmann E, 2001, KIDNEY INT, V60, P446, DOI 10.1046/j.1523-1755.2001.060002446.x; Klussmann E, 1999, J BIOL CHEM, V274, P4934, DOI 10.1074/jbc.274.8.4934; Kunzelmann K, 2005, FASEB J, V19, P969, DOI 10.1096/fj.04-2469fje; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; McSorley T, 2006, EUR J CELL BIOL, V85, P673, DOI 10.1016/j.ejcb.2006.01.005; Peters KW, 2001, PFLUG ARCH EUR J PHY, V443, pS65, DOI 10.1007/s004240100647; Pochynyuk O, 2005, J BIOL CHEM, V280, P37565, DOI 10.1074/jbc.M509071200; Schnizler M, 2001, J COMP PHYSIOL B, V171, P369; Schnizler M, 2000, PFLUG ARCH EUR J PHY, V439, P579, DOI 10.1007/s004240050981; Scott JD, 1997, SOC GEN PHY, V52, P227; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Staruschenko A, 2005, J BIOL CHEM, V280, P39161, DOI 10.1074/jbc.M509608200; Trotter KW, 1999, J CELL BIOL, V147, P1481, DOI 10.1083/jcb.147.7.1481; Wang HY, 2006, EUR J CELL BIOL, V85, P643, DOI 10.1016/j.ejcb.2005.12.003; Wang H, 2006, J BIOL CHEM, V281, P14129, DOI 10.1074/jbc.M512511200; Xie GF, 2001, AM J PHYSIOL-GASTR L, V281, pG1051, DOI 10.1152/ajpgi.2001.281.4.G1051	48	14	16	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1189	1201		10.1096/fj.06-6046com	http://dx.doi.org/10.1096/fj.06-6046com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17244820				2022-12-28	WOS:000245650400023
J	Dvir-Ginzberg, M; Elkayam, T; Cohen, S				Dvir-Ginzberg, Mona; Elkayam, Tsiona; Cohen, Smadar			Induced differentiation and maturation of newborn liver cells into functional hepatic tissue in macroporous alginate scaffolds	FASEB JOURNAL			English	Article						cell-to-cell contacts; spheroids; cell polarity; collagen scaffolds; tissue engineering	HEMATOPOIETIC STEM-CELLS; ONCOSTATIN-M; HEPATOCYTE SPHEROIDS; BIOARTIFICIAL LIVER; FETAL LIVER; MOUSE-LIVER; IN-VITRO; GROWTH; SURFACES; COLLAGEN	The present work explores cell cultivation in macroporous alginate scaffolds as a means to reproduce hepatocyte terminal differentiation in vitro. Newborn rat liver cell isolates, consisting of proliferating hepatocytes and progenitors, were seeded at high cell density of 125 x 10(6)/cm(3) within the scaffold and then cultivated for 6 wk in chemically defined medium. Within 3 days, the alginate-seeded cells expressed genes for mature liver enzymes, such as trypthophan oxygenase, secreted a high level of albumin, and performed phase I drug metabolism. The cells formed compacted spheroids, establishing homotypic and heterotypic cell-to-cell interactions. By 6 wk, the spheroids developed into organoids, with an external mature hepatocyte layer covered by a laminin layer encasing inner vimentin-positive cells within a laminin-rich matrix also containing collagen. The hepatocytes presented a distinct apical surface between adjacent cells and a basolateral surface with microvilli facing extracellular matrix deposits. By contrast, viable adherent cells within collagen scaffolds presenting the identical porous structure did not express adult liver enzymes or secrete albumin after 6 wk. This study thus illustrates the benefits of cell cultivation in macroporous; alginate scaffolds as an effective promoter for the maturation of newborn liver cells into functional hepatic tissue, capable of maintaining prolonged hepatoceffular functions.	[Dvir-Ginzberg, Mona; Cohen, Smadar] Ben Gurion Univ Negev, Dept Biotechnol Engn, IL-84105 Beer Sheva, Israel; [Elkayam, Tsiona; Cohen, Smadar] Ben Gurion Univ Negev, Dept Biomed Engn, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University	Cohen, S (corresponding author), Ben Gurion Univ Negev, Dept Biotechnol Engn, Bldg 39,Rm 222,POB 653, IL-84105 Beer Sheva, Israel.	scohen@bgu.ac.il	Dvir-Ginzberg, Mona/AAZ-9858-2021; COHEN, SMADAR/F-1901-2012	Dvir-Ginzberg, Mona/0000-0003-3089-6875; 				Beaulieu Jean-Francois, 1999, Frontiers in Bioscience, V4, pD310, DOI 10.2741/Beaulieu; Behnia K, 2000, TISSUE ENG, V6, P467, DOI 10.1089/107632700750022125; Bosman FT, 2003, J PATHOL, V200, P423, DOI 10.1002/path.1437; Brill S, 1999, DIGEST DIS SCI, V44, P364, DOI 10.1023/A:1026666820422; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CLEMENT B, 1988, HEPATOLOGY, V8, P794, DOI 10.1002/hep.1840080417; Demetriou AA, 2004, ANN SURG, V239, P660, DOI 10.1097/01.sla.0000124298.74199.e5; Dvir-Ginzberg M, 2004, TISSUE ENG, V10, P1806, DOI 10.1089/ten.2004.10.1806; Ehashi T, 2005, J CELL PHYSIOL, V202, P698, DOI 10.1002/jcp.20167; Fox IJ, 2004, J HEPATOL, V40, P878, DOI 10.1016/j.jhep.2004.04.009; Fukuda J, 2006, BIOMATERIALS, V27, P5259, DOI 10.1016/j.biomaterials.2006.05.044; Glicklis R, 2004, BIOTECHNOL BIOENG, V86, P672, DOI 10.1002/bit.20086; Glicklis R, 2000, BIOTECHNOL BIOENG, V67, P344, DOI 10.1002/(SICI)1097-0290(20000205)67:3<344::AID-BIT11>3.0.CO;2-2; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; HANSEN LK, 1994, MOL BIOL CELL, V5, P967, DOI 10.1091/mbc.5.9.967; Hoshiba T, 2007, BIOCHEM BIOPH RES CO, V359, P151, DOI 10.1016/j.bbrc.2007.05.079; Jiang JL, 2004, TISSUE ENG, V10, P1577, DOI 10.1089/ten.2004.10.1577; JUNKER JL, 1987, CANCER RES, V47, P3802; Kamiya A, 2002, HEPATOLOGY, V35, P1351, DOI 10.1053/jhep.2002.33331; Kedem A, 2005, TISSUE ENG, V11, P715, DOI 10.1089/ten.2005.11.715; Krasteva N, 2004, BIOMATERIALS, V25, P2467, DOI 10.1016/j.biomaterials.2003.09.031; Lazaro CA, 2003, HEPATOLOGY, V38, P1095, DOI 10.1053/jhep.2003.50448; Lee BC, 2007, MICROSC RES TECHNIQ, V70, P34, DOI 10.1002/jemt.20383; Mahieu-Caputo D, 2004, HUM GENE THER, V15, P1219, DOI 10.1089/hum.2004.15.1219; Majka M, 2001, BLOOD, V97, P3075, DOI 10.1182/blood.V97.10.3075; MOONEY D, 1992, J CELL PHYSIOL, V151, P497, DOI 10.1002/jcp.1041510308; Ohashi K, 2007, NAT MED, V13, P880, DOI 10.1038/nm1576; OJAKIAN GK, 1994, J CELL SCI, V107, P561; Schmelzer E, 2006, STEM CELLS, V24, P1852, DOI 10.1634/stemcells.2006-0036; Shapiro L, 1997, BIOMATERIALS, V18, P583, DOI 10.1016/S0142-9612(96)00181-0; Shimano K, 2003, AM J PATHOL, V163, P3, DOI 10.1016/S0002-9440(10)63624-3; Smith MK, 2007, J BIOMED MATER RES A, V80A, P520, DOI 10.1002/jbm.a.30930; Tsang VL, 2007, FASEB J, V21, P790, DOI 10.1096/fj.06-7117com; Uchida N, 2001, J CLIN INVEST, V108, P1071, DOI 10.1172/JCI13297; Uchida N, 2002, EXP HEMATOL, V30, P862, DOI 10.1016/S0301-472X(02)00879-2; van de Kerkhove MP, 2004, ANN SURG, V240, P216, DOI 10.1097/01.sla.0000132986.75257.19; Van Poll D, 2006, TISSUE ENG, V12, P2965; Weadock KS, 1996, J BIOMED MATER RES, V32, P221, DOI 10.1002/(SICI)1097-4636(199610)32:2<221::AID-JBM11>3.0.CO;2-M; Zinchenko YS, 2005, J BIOMED MATER RES A, V75A, P242, DOI 10.1002/jbm.a.30399; Zmora S, 2002, BIOMATERIALS, V23, P4087, DOI 10.1016/S0142-9612(02)00146-1	41	47	54	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1440	1449		10.1096/fj.07-9277com	http://dx.doi.org/10.1096/fj.07-9277com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18070820				2022-12-28	WOS:000255898700016
J	D'Addario, C; Ming, Y; Ogren, SO; Terenius, L				D'Addario, Claudio; Ming, Yu; Ogren, Sven-Ove; Terenius, Lars			The role of acetaldehyde in mediating effects of alcohol on expression of endogenous opioid system genes in a neuroblastoma cell line	FASEB JOURNAL			English	Article						ethanol; gene expression; opioid peptides/receptors; 4-methylpyrazole	MESSENGER-RNA LEVELS; CHRONIC DAILY ETHANOL; GROWTH-INHIBITION; RAT PITUITARY; RECEPTOR; PROOPIOMELANOCORTIN; CONSUMPTION; PROTEIN; WITHDRAWAL; QUANTIFICATION	Ethanol (EtOH) alters neural activity through interaction with various neurotransmitters and neuromodulators. The endogenous opioid system seems to play a key role in the activities of EtOH, since the opioid antagonist naltrexone (ReVia (R)) attenuates craving. We have investigated the tran criptional regulation of opioid system genes in response to EtOH exposure for up to 96 h in human neuroblastoma SH-SY5Y cells using quantitative real-time polymerase chain reaction. We observed a significant decrease in the expression of opioid peptide precursors (proopiomelanocortin, proenkephalin, and prodynorphin) and of the kappa opioid receptor after 48 and 72 h of EtOH exposure (10 and 40 mM). These alterations were not present when the EtOH metabolism was blocked by 4-methylpyrazole. To evaluate whether the effects evoked by EtOH were possibly due to the first product of EtOH metabolism, cells were exposed to 0.4 mM acetaldehyde. We observed the same pattern of changes for prodynorphin, proenkephalin, and the kappa opioid receptor as after 72 h exposure to EtOH. These results contribute to our understanding of EtOH action at a cellular level and provide evidence of the role of acetaldehyde in mediating some of the EtOH-induced effects.	[D'Addario, Claudio; Ming, Yu; Terenius, Lars] Karolinska Inst, Dept Clin Neurosci, S-17176 Stockholm, Sweden; [D'Addario, Claudio; Ogren, Sven-Ove] Karolinska Inst, Dept Neurosci, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	D'Addario, C (corresponding author), Karolinska Inst, Dept Clin Neurosci, CMM L8 01, S-17176 Stockholm, Sweden.	claudio.daddario@ki.se	DAddario, Claudio/A-5970-2010	Ogren, Sven Ove/0000-0003-2573-5276; d'addario, claudio/0000-0002-1275-098X				ANGELOGIANNI P, 1993, NEUROENDOCRINOLOGY, V57, P106, DOI 10.1159/000126348; Asher O, 2002, J PHARMACOL EXP THER, V301, P66, DOI 10.1124/jpet.301.1.66; Beadles-Bohling AS, 2005, BRAIN RES, V1046, P77, DOI 10.1016/j.brainres.2005.03.043; Boyadjieva N, 1997, ALCOHOL CLIN EXP RES, V21, P477; Chen CP, 2004, J NEUROCHEM, V88, P1547, DOI 10.1046/j.1471-4159.2003.02300.x; Chumakova OV, 2000, B EXP BIOL MED+, V130, P921, DOI 10.1007/BF02682270; Cowen M. S., 2006, CNS & Neurological Disorders-Drug Targets, V5, P233, DOI 10.2174/187152706776359646; Cowen MS, 2001, ALCOHOL CLIN EXP RES, V25, P1126, DOI 10.1111/j.1530-0277.2001.tb02326.x; DAVE JR, 1986, ENDOCRINOLOGY, V118, P280, DOI 10.1210/endo-118-1-280; Deitrich RA, 2004, J STUD ALCOHOL, V65, P557, DOI 10.15288/jsa.2004.65.557; Faingold CL, 1998, PROG NEUROBIOL, V55, P509, DOI 10.1016/S0301-0082(98)00027-6; GIANOULAKIS C, 1988, ENDOCRINOLOGY, V122, P817, DOI 10.1210/endo-122-3-817; GRAFSTROM RC, 1994, CARCINOGENESIS, V15, P985, DOI 10.1093/carcin/15.5.985; Hall FS, 2001, PSYCHOPHARMACOLOGY, V154, P43, DOI 10.1007/s002130000622; Holownia A, 1997, NEUROTOXICOL TERATOL, V19, P141, DOI 10.1016/S0892-0362(96)00226-7; Holownia A, 1999, BRAIN RES, V833, P202, DOI 10.1016/S0006-8993(99)01529-2; Holownia A, 1996, ALCOHOL, V13, P93, DOI 10.1016/0741-8329(95)02019-5; Jope RS, 1998, J NEUROCHEM, V70, P763; Koob GF, 1998, ALCOHOL CLIN EXP RES, V22, P3, DOI 10.1097/00000374-199802000-00001; Koob GF, 2003, ALCOHOL CLIN EXP RES, V27, P232, DOI 10.1097/01.ALC.0000057122.36127.C2; Kovacs KM, 2005, ALCOHOL CLIN EXP RES, V29, P730, DOI 10.1097/01.ALC.0000164361.62346.D6; Kuriyama K, 1987, Alcohol Alcohol Suppl, V1, P685; Lamarche F, 2004, CELL BIOL TOXICOL, V20, P361, DOI 10.1007/s10565-004-0087-9; Lin MCM, 1997, FASEB J, V11, P1145, DOI 10.1096/fasebj.11.13.9367349; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo J, 1997, BRAIN RES, V770, P139, DOI 10.1016/S0006-8993(97)00762-2; Lyon E, 2001, CLIN CHEM, V47, P844; Maas JW, 2005, J NEUROSCI, V25, P4118, DOI 10.1523/JNEUROSCI.4273-04.2005; Muhlbauer E, 2003, EUR J PHARMACOL, V459, P121, DOI 10.1016/S0014-2999(02)02855-8; Narahashi T, 2001, ALCOHOL CLIN EXP RES, V25, p182S, DOI 10.1111/j.1530-0277.2001.tb02394.x; NICHOLLS R, 1992, INT J BIOCHEM, V24, P1899, DOI 10.1016/0020-711X(92)90285-9; NYLANDER I, 1994, ALCOHOL CLIN EXP RES, V18, P1272, DOI 10.1111/j.1530-0277.1994.tb00118.x; Oswald LM, 2004, PHYSIOL BEHAV, V81, P339, DOI 10.1016/j.physbeh.2004.02.008; PASTORCIC M, 1994, MOL CELL NEUROSCI, V5, P580, DOI 10.1006/mcne.1994.1071; Peoples RW, 1996, ANNU REV PHARMACOL, V36, P185, DOI 10.1146/annurev.pa.36.040196.001153; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Poplawski MM, 2005, ALCOHOL CLIN EXP RES, V29, P648, DOI 10.1097/01.ALC.0000158834.11252.2E; Quertemont E, 2005, ALCOHOL CLIN EXP RES, V29, P221, DOI 10.1097/01.ALC.0000156185.39073.D2; Quertemont E, 2004, TRENDS PHARMACOL SCI, V25, P130, DOI 10.1016/j.tips.2004.01.001; Rao MN, 1999, METABOLISM, V48, P797, DOI 10.1016/S0026-0495(99)90182-8; Rasmussen DD, 2002, ALCOHOL CLIN EXP RES, V26, P535, DOI 10.1097/00000374-200204000-00015; Rasmussen DD, 2000, ALCOHOL CLIN EXP RES, V24, P1836, DOI 10.1097/00000374-200012000-00013; Ray LA, 2004, ALCOHOL CLIN EXP RES, V28, P1789, DOI 10.1097/01.ALC.0000148114.34000.B9; Roberts AJ, 2001, ALCOHOL CLIN EXP RES, V25, P1249, DOI 10.1111/j.1530-0277.2001.tb02344.x; Rosin A, 1999, NEUROSCI LETT, V275, P1, DOI 10.1016/S0304-3940(99)00675-8; Sarkola T, 2002, ALCOHOL CLIN EXP RES, V26, P239, DOI 10.1111/j.1530-0277.2002.tb02530.x; Scott HC, 1998, ALCOHOL CLIN EXP RES, V22, P2111, DOI 10.1111/j.1530-0277.1998.tb05924.x; SEIZINGER BR, 1984, J PHARMACOL EXP THER, V230, P455; SINGH NP, 1995, MUTAT RES-DNA REPAIR, V337, P9, DOI 10.1016/0921-8777(95)00006-6; Thibault C, 2000, MOL PHARMACOL, V58, P1593, DOI 10.1124/mol.58.6.1593; Turner RT, 1998, ALCOHOL CLIN EXP RES, V22, P1591, DOI 10.1097/00000374-199810000-00031; Uddin S, 1996, ALCOHOL CLIN EXP RES, V20, P556, DOI 10.1111/j.1530-0277.1996.tb01092.x; Wallington CL, 2002, BRAIN RES, V944, P73, DOI 10.1016/S0006-8993(02)02720-8; WHITFIELD JB, 1994, ALCOHOL CLIN EXP RES, V18, P238, DOI 10.1111/j.1530-0277.1994.tb00007.x; Wilke N, 2000, J PHARMACOL EXP THER, V292, P173; WINKLER A, 1995, ALCOHOL ALCOHOLISM, V30, P231; Worst TJ, 2005, ALCOHOL ALCOHOLISM, V40, P63, DOI 10.1093/alcalc/agh119; Xuei X, 2006, MOL PSYCHIATR, V11, P1016, DOI 10.1038/sj.mp.4001882; Yoshimura M, 2006, ALCOHOL CLIN EXP RES, V30, P1824, DOI 10.1111/j.1530-0277.2006.00219.x; Zhou Y, 2000, ALCOHOL CLIN EXP RES, V24, P1575, DOI 10.1111/j.1530-0277.2000.tb04577.x; ZIMMERMAN BT, 1995, ALCOHOL CLIN EXP RES, V19, P434, DOI 10.1111/j.1530-0277.1995.tb01527.x	61	22	22	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					662	670		10.1096/fj.07-8346com	http://dx.doi.org/10.1096/fj.07-8346com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17934066				2022-12-28	WOS:000254143700005
J	Konig, O; Ruttiger, L; Muller, M; Zimmermann, U; Erdmann, B; Kalbacher, H; Gross, M; Knipper, M				Koenig, Ovidiu; Ruettiger, Lukas; Mueller, Marcus; Zimmermann, Ulrike; Erdmann, Bettina; Kalbacher, Hubert; Gross, Manfred; Knipper, Marlies			Estrogen and the inner ear: megalin knockout mice suffer progressive hearing loss	FASEB JOURNAL			English	Article						cochlea; stria vascularis; LDL-receptor; sex hormone; presbycusis	HORMONE-BINDING GLOBULIN; DENSITY-LIPOPROTEIN RECEPTOR; SCANNING ELECTRON-MICROSCOPY; BRAIN-STEM RESPONSE; GUINEA-PIG COCHLEA; STRIA VASCULARIS; HEYMANN NEPHRITIS; AUDITORY FUNCTION; THYROID-HORMONE; MARGINAL CELLS	Megalin, the largest member of the low-density lipoprotein receptor-related protein family, functions as an endocytic receptor for a variety of essential lipophilic metabolites, including the steroid hormone estrogen. In the cochlea, megalin is strongly expressed within the marginal cells of the stria vascularis, and previous studies demonstrated that beta-estrogen receptors are also expressed in megalin-expressing marginal cells. In the present study, we demonstrate that homozygous megalin mutant mice exhibit profound hearing loss at 3 months of age associated with features of presbycusis, enrichment of lipofuscin granules, and a reduced number of microvilli in marginal cells of the stria vascularis. FITC-labeled beta-estrogen is taken up into the strial marginal cells; however, in megalin-deficient mice the uptake of FITC-labeled beta-estrogen is reduced. This highlights beta-estrogen as a possible carrier-bound candidate ligand for megalin and supports the concept that estrogen may function via megalin within the inner ear. A crucial role of megalin in hearing should be considered and the megalin/estrogen interaction needs to be discussed in the context of early presbycusis in estrogen-deficient humans and mice.	[Koenig, Ovidiu; Gross, Manfred] Charite Univ Clin Berlin, Berlin, Germany; [Mueller, Marcus] Univ Tubingen, Dept Otorhinolaryngol, Hearing Res Ctr Tubingen, Tubingen, Germany; [Kalbacher, Hubert] Univ Tubingen, Med Nat Sci Res Ctr, Tubingen, Germany; [Erdmann, Bettina] Max Delbruck Ctr Mol Med, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Knipper, M (corresponding author), Univ HNO Klin, Elfriede Aulhorn Str 5, D-72076 Tubingen, Germany.	marlies.knipper@uni-tuebingen.de	Müller, Marcus/B-3877-2016	Müller, Marcus/0000-0001-5881-7708				ANNIKO M, 1976, ACTA OTO-LARYNGOL, V82, P343, DOI 10.3109/00016487609120918; BOHNE BA, 1990, HEARING RES, V48, P79, DOI 10.1016/0378-5955(90)90200-9; BROOKES GB, 1983, J LARYNGOL OTOL, V97, P405, DOI 10.1017/S0022215100094330; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; Christensen EI, 1999, J AM SOC NEPHROL, V10, P685; COLEMAN JR, 1994, HEARING RES, V80, P209, DOI 10.1016/0378-5955(94)90112-0; Cui SY, 1996, AM J PHYSIOL-RENAL, V271, pF900, DOI 10.1152/ajprenal.1996.271.4.F900; Czekay RP, 1997, MOL BIOL CELL, V8, P517, DOI 10.1091/mbc.8.3.517; Dickersin RG., 2000, DIAGNOSTIC ELECT MIC; FARQUHAR MG, 1995, J AM SOC NEPHROL, V6, P35; Fettiplace R, 2006, NAT REV NEUROSCI, V7, P19, DOI 10.1038/nrn1828; FORGE A, 1980, CLIN OTOLARYNGOL, V5, P87, DOI 10.1111/j.1365-2273.1980.tb01633.x; Gamp AC, 2003, HUM MOL GENET, V12, P631, DOI 10.1093/hmg/ddg062; Geneser F, 1990, HISTOLOGIE; Guitton MJ, 2005, EUR J NEUROSCI, V22, P2675, DOI 10.1111/j.1460-9568.2005.04436.x; Hammes A, 2005, CELL, V122, P751, DOI 10.1016/j.cell.2005.06.032; HAMMOND GL, 1995, J STEROID BIOCHEM, V53, P543, DOI 10.1016/0960-0760(95)00110-L; Hammond TG, 1997, AM J PHYSIOL-RENAL, V272, pF117, DOI 10.1152/ajprenal.1997.272.1.F117; Hilpert J, 2001, BIOCHEM J, V360, P609, DOI 10.1042/0264-6021:3600609; Hultcrantz M, 2006, ACTA OTO-LARYNGOL, V126, P10, DOI 10.1080/00016480510038617; Hultcrantz M, 2000, HEARING RES, V143, P182, DOI 10.1016/S0378-5955(00)00042-3; ISHII T, 1977, ARCH OTO-RHINO-LARYN, V215, P213, DOI 10.1007/BF00463059; Jentsch TJ, 2004, NAT CELL BIOL, V6, P1039, DOI 10.1038/ncb1104-1039; JERGER J, 1980, ARCH OTOLARYNGOL, V106, P387; Jonsson R, 1998, SCAND AUDIOL, V27, P81, DOI 10.1080/010503998420324; KANEKO Y, 1978, ACTA OTO-LARYNGOL, V86, P375; Kim SH, 2002, OBSTET GYNECOL, V99, P726, DOI 10.1016/S0029-7844(02)01963-4; Knipper M, 2000, J NEUROPHYSIOL, V83, P3101, DOI 10.1152/jn.2000.83.5.3101; Knipper M, 2006, J PHYSIOL-LONDON, V576, P73, DOI 10.1113/jphysiol.2006.116889; KONISHI T, 1978, ACTA OTO-LARYNGOL, V86, P22, DOI 10.3109/00016487809124717; KRSTIC RV, 1997, HUMAN MICROSCOPIC AN; MASON DY, 1978, J CLIN PATHOL, V31, P454, DOI 10.1136/jcp.31.5.454; MAUNSBACH AB, 1999, BIOMED ELECT MICROSC; Mizuta K, 1999, HEARING RES, V129, P83, DOI 10.1016/S0378-5955(98)00221-4; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; Muller M, 1997, HEARING RES, V114, P259, DOI 10.1016/S0378-5955(97)00175-5; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; Nykjaer A, 2001, P NATL ACAD SCI USA, V98, P13895, DOI 10.1073/pnas.241516998; Oliver D, 2003, J NEUROSCI, V23, P2141; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; Rink Timothy L, 2004, Occup Health Saf, V73, P179; Romeo G, 1985, Acta Vitaminol Enzymol, V7 Suppl, P85; Ruttiger L, 2004, P NATL ACAD SCI USA, V101, P12922, DOI 10.1073/pnas.0402660101; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Schimmang T, 2003, DEVELOPMENT, V130, P4741, DOI 10.1242/dev.00676; Scholtz AW, 2001, HEARING RES, V157, P77, DOI 10.1016/S0378-5955(01)00279-9; SCHUKNECHT HF, 1993, ANN OTO RHINOL LARYN, V102, P1; SCROCCHI LA, 1993, ENDOCRINOLOGY, V132, P903, DOI 10.1210/en.132.2.903; Stenberg AE, 2001, HEARING RES, V157, P87, DOI 10.1016/S0378-5955(01)00280-5; Stenberg AE, 1999, HEARING RES, V136, P29, DOI 10.1016/S0378-5955(99)00098-2; SUGA F, 1976, ANN OTO RHINOL LARYN, V85, P169, DOI 10.1177/000348947608500201; Vasyutina E, 2007, P NATL ACAD SCI USA, V104, P4443, DOI 10.1073/pnas.0610647104; WANGEMANN P, 1995, HEARING RES, V90, P149, DOI 10.1016/0378-5955(95)00157-2; Wangemann P, 2002, HEARING RES, V165, P1, DOI 10.1016/S0378-5955(02)00279-4; Weber T, 2002, P NATL ACAD SCI USA, V99, P2901, DOI 10.1073/pnas.052609899; WHARTON JA, 1990, AUDIOLOGY, V29, P196; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; WRIGHT A, 1980, ARCH OTO-RHINO-LARYN, V229, P39, DOI 10.1007/BF00453750; Zeginiadou T, 1997, EUR J DRUG METAB PH, V22, P229, DOI 10.1007/BF03189812	60	27	29	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2008	22	2					410	417		10.1096/fj.07-9171com	http://dx.doi.org/10.1096/fj.07-9171com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	17846082				2022-12-28	WOS:000252822600011
J	Rossiter, H; Barresi, C; Ghannadan, M; Gruber, F; Mildner, M; Fodinger, D; Tschachler, E				Rossiter, Heidemarie; Barresi, Caterina; Ghannadan, Minoo; Gruber, Florian; Mildner, Michael; Fodinger, Dagmar; Tschachler, Erwin			Inactivation of VEGF in mammary gland epithelium severely compromises mammary gland development and function	FASEB JOURNAL			English	Article						angiogenesis; lactation; alveologenesis; mammary gland differentiation	ENDOTHELIAL-GROWTH-FACTOR; MICROVASCULAR PERMEABILITY; EXPRESSION; PREGNANCY; PROTEINS; MILK; CELLS; CONNEXIN-26; RECEPTORS; DIFFERENTIATION	To investigate the role of the angiogenic cytokine vascular endothelial growth factor ( VEGF) during pregnancy and lactation, we used mice in which VEGF had been inactivated in mammary gland epithelial cells. Pups born to mutant mothers failed to thrive, displaying little milk in their stomachs. However, when they were transferred to control mothers they developed normally. Investigation of the mammary gland morphology revealed that lobulo- alveolar expansion into the fat pad was not complete in lactating mutant glands, and an accumulation of fat globules was evident in their secretory epithelium. In contrast to control glands, lactating mutant glands failed to up- regulate mRNAs for genes involved in milk secretion. Blood vessel density was comparable in pregnant mice of both groups but was only half that of controls in lactating mutant mice. FITC- labeled albumin injected intravenously (i.v.) into lactating mice extravasated rapidly and accumulated in the mammary gland epithelial cells in control animals, but was almost completely retained within the vessels in the mutants. Injection of recombinant VEGF i.v. reversed this effect. These findings demonstrate that mammary epithelium- derived VEGF is partially dispensable for angiogenesis during pregnancy and lactation, and by regulating vascular function during lactation, this factor is crucial to mammary gland differentiation and milk production.	Med Univ Vienna, Dept Dermatol, A-1090 Vienna, Austria; Ctr Rec Invest Epidermiques & Sensorielles, Neuilly Sur Seine, France	Medical University of Vienna	Tschachler, E (corresponding author), Med Univ Vienna, Dept Dermatol, A-1090 Vienna, Austria.	erwin.tschachler@meduniwien.ac.at		Mildner, Michael/0000-0002-6892-925X; Gruber, Florian/0000-0003-1094-5641; Tschachler, Erwin/0000-0002-0248-1798				ABDUL AM, 1996, J VET MED SCI, V58, P29; Bates DO, 2002, J ANAT, V200, P581, DOI 10.1046/j.1469-7580.2002.00066.x; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bry C, 2004, DEV BIOL, V267, P418, DOI 10.1016/j.ydbio.2003.11.022; Cebe-Suarez S, 2006, CELL MOL LIFE SCI, V63, P601, DOI 10.1007/s00018-005-5426-3; Chen J, 2002, AM J PHYSIOL-CELL PH, V282, pC1053, DOI 10.1152/ajpcell.00292.2001; Djonov V, 2001, MICROSC RES TECHNIQ, V52, P182, DOI 10.1002/1097-0029(20010115)52:2<182::AID-JEMT1004>3.3.CO;2-D; Dunbar ME, 2001, MICROSC RES TECHNIQ, V52, P163, DOI 10.1002/1097-0029(20010115)52:2<163::AID-JEMT1002>3.0.CO;2-R; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; Evans WH, 2006, BIOCHEM J, V397, P1, DOI 10.1042/BJ20060175; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Gerber HP, 1999, DEVELOPMENT, V126, P1149; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Hovey RC, 2004, ADV EXP MED BIOL, V554, P219; Hovey RC, 2001, MOL ENDOCRINOL, V15, P819, DOI 10.1210/me.15.5.819; Kadl A, 2002, VASC PHARMACOL, V38, P219, DOI 10.1016/S1537-1891(02)00172-6; Locke D, 2004, EXP CELL RES, V298, P643, DOI 10.1016/j.yexcr.2004.05.003; Locke D, 2000, J CELL PHYSIOL, V183, P228; MATSUMOTO M, 1992, J VET MED SCI, V54, P937, DOI 10.1292/jvms.54.937; MATSUMOTO M, 1994, J VET MED SCI, V56, P65, DOI 10.1292/jvms.56.65; McManaman JL, 2003, ADV DRUG DELIVER REV, V55, P629, DOI 10.1016/S0169-409X(03)00033-4; Mikaelian I, 2006, VET PATHOL, V43, P36, DOI 10.1354/vp.43-1-36; Minshall RD, 2002, HISTOCHEM CELL BIOL, V117, P105, DOI 10.1007/s00418-001-0367-x; Muller-Decker K, 2005, AM J PATHOL, V166, P575, DOI 10.1016/S0002-9440(10)62279-1; Nishimura S, 2002, CYTOKINE, V18, P191, DOI 10.1006/cyto.2002.1032; Odorisio T, 2002, J CELL SCI, V115, P2559; Ogg SL, 2004, P NATL ACAD SCI USA, V101, P10084, DOI 10.1073/pnas.0402930101; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Pepper MS, 2000, DEV DYNAM, V218, P507, DOI 10.1002/1097-0177(200007)218:3<507::AID-DVDY1012>3.0.CO;2-5; PEREZARMENDARIZ EM, 1995, DEV GROWTH DIFFER, V37, P421; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; ROBERTS WG, 1995, J CELL SCI, V108, P2369; Rossiter H, 2004, CANCER RES, V64, P3508, DOI 10.1158/0008-5472.CAN-03-2581; Seagroves TN, 2003, DEVELOPMENT, V130, P1713, DOI 10.1242/dev.00403; Siafakas CG, 1999, PEDIATR RES, V45, P652, DOI 10.1203/00006450-199905010-00007; Silberstein GB, 2001, MICROSC RES TECHNIQ, V52, P155, DOI 10.1002/1097-0029(20010115)52:2<155::AID-JEMT1001>3.0.CO;2-P; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Teuliere J, 2005, DEVELOPMENT, V132, P267, DOI 10.1242/dev.01583; Visvader JE, 2006, CANCER RES, V66, P9798, DOI 10.1158/0008-5472.CAN-06-2254; Vorbach C, 2002, GENE DEV, V16, P3223, DOI 10.1101/gad.1032702; Vuorela P, 2000, AM J CLIN NUTR, V72, P1196; Yamanaka I, 2001, HISTOCHEM CELL BIOL, V115, P277; YASUGI T, 1989, ARCH HISTOL CYTOL, V52, P115, DOI 10.1679/aohc.52.115	45	47	48	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3994	4004		10.1096/fj.07-8720com	http://dx.doi.org/10.1096/fj.07-8720com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17625068				2022-12-28	WOS:000251283500024
J	Evseenko, DA; Murthi, P; Paxton, JW; Reid, G; Emerald, BS; Mohankumar, KM; Lobie, PE; Brennecke, SP; Kalionis, B; Keelan, JA				Evseenko, Denis A.; Murthi, Padma; Paxton, James W.; Reid, Glen; Emerald, B. Starling; Mohankumar, K. M.; Lobie, Peter E.; Brennecke, Shaun P.; Kalionis, Bill; Keelan, J. A.			The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction	FASEB JOURNAL			English	Article						breast cancer resistance protein; cytokines; ceramide	CANCER RESISTANCE PROTEIN; FUNCTIONAL-ACTIVITY; VILLOUS DEVELOPMENT; CELL-SURVIVAL; TNF-ALPHA; CERAMIDE; APOPTOSIS; EFFLUX; BCRP; PREGNANCIES	The efflux pump ATP binding cassette superfamily member G2 (ABCG2)/breast cancer resistance protein ( BCRP) is highly expressed in human placenta. We have investigated the role of BCRP in the protection of the human placental trophoblasts from apoptosis and its expression in idiopathic fetal growth restriction, a condition associated with abnormal placental apoptosis. Inhibition of BCRP activity with the selective inhibitor Ko143 augmented cytokine ( tumor necrosis factor-alpha/interferon-gamma)-induced apoptosis and phosphatidylserine externalization in primary trophoblast and trophoblast-like BeWo cells. Silencing of BCRP expression in BeWo cells significantly increased their sensitivity to apoptotic injury in response to cytokines and exogenous C6 and C8 ceramides. BCRP silencing also increased intracellular ceramide levels after cytokine exposure but did not affect cellular protoporphyrin IX concentrations or sensitivity to activators of the intrinsic apoptotic pathway. BCRP expression in placentas from pregnancies complicated by idiopathic fetal growth restriction was decreased compared with controls, suggesting reduced transport of its substrates from the placenta. We conclude that BCRP may play a hitherto unrecognized survival role in the placenta, protecting the trophoblast against cytokine-induced apoptosis and possibly other extrinsic activators via modulation of ceramide signaling. Decreased placental BCRP expression may result in reduced viability and hence functional deficit, contributing to the fetal growth restriction phenotype.	Univ Auckland, Liggins Inst, Auckland 1, New Zealand; Univ Auckland, Dept Pharmacol & Clin Pharmacol, Fac Med & Hlth Sci, Auckland 1, New Zealand; Genesis Res & Dev Corp, Auckland, New Zealand; Royal Hosp Women, Dept Perinatal Med, Pregnancy Res Ctr, Carlton, Vic, Australia; Royal Hosp Women, Dept Obstet & Gynaecol, Carlton, Vic, Australia; Univ Melbourne, Carlton, Vic 3053, Australia	University of Auckland; University of Auckland; University of Melbourne	Keelan, JA (corresponding author), Univ Auckland, Liggins Inst, Private Bag 92019, Auckland 1, New Zealand.	j.keelan@auckland.ac.nz	Brennecke, Shaun/AFV-3919-2022; Keelan, JA/G-2170-2011; Kumarasamypet Murugesan, Mohankumar/F-4231-2012; Murthi, Padma/AAY-5395-2021; David, Starling Emerald Bright/R-6034-2019; KALIONIS, BILL/B-4766-2011	Brennecke, Shaun/0000-0003-3070-6971; Keelan, JA/0000-0002-5403-6266; David, Starling Emerald Bright/0000-0001-6875-2258; Paxton, James/0000-0002-2530-7047; KM, Mohankumar/0000-0001-9407-1800; Reid, Glen/0000-0001-6465-5223				Abbott Brian L, 2006, Clin Adv Hematol Oncol, V4, P63; Allikmets R, 1998, CANCER RES, V58, P5337; Bakketeig LS, 1998, EUR J CLIN NUTR, V52, pS94; BAMBERG C, 2004, FETAL NEONATAL MED, V9, P387; Bartha JL, 2003, ACTA OBSTET GYN SCAN, V82, P1099, DOI 10.1046/j.1600-0412.2003.00259.x; Black S, 2004, CELL DEATH DIFFER, V11, P90, DOI 10.1038/sj.cdd.4401307; Blumenstein M, 2002, PLACENTA, V23, P735, DOI 10.1053/plac.2002.0868; Brodsky Dara, 2004, J Intensive Care Med, V19, P307, DOI 10.1177/0885066604269663; Ceckova M, 2006, CLIN EXP PHARMACOL P, V33, P58, DOI 10.1111/j.1440-1681.2006.04324.x; Chaddha Vandana, 2004, Semin Fetal Neonatal Med, V9, P357, DOI 10.1016/j.siny.2004.03.006; Choudhuri S, 2006, INT J TOXICOL, V25, P231, DOI 10.1080/10915810600746023; Daleke DL, 2003, J LIPID RES, V44, P233, DOI 10.1194/jlr.R200019-JLR200; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Dumitru CA, 2006, ONCOGENE, V25, P5612, DOI 10.1038/sj.onc.1209568; Evseenko DA, 2007, PLACENTA, V28, pS116, DOI 10.1016/j.placenta.2006.12.003; Evseenko DA, 2006, AM J PHYSIOL-REG I, V290, pR1357, DOI 10.1152/ajpregu.00630.2005; Evseenko DA, 2007, DRUG METAB DISPOS, V35, P595, DOI 10.1124/dmd.106.011478; Gagnon R, 2003, EUR J OBSTET GYN R B, V110, pS99, DOI 10.1016/S0301-2115(03)00179-9; Gentil B, 2003, MOL CELL BIOCHEM, V254, P203, DOI 10.1023/A:1027359832177; Ghering AB, 2006, J LIPID RES, V47, P2781, DOI 10.1194/jlr.M600380-JLR200; Ghidini A, 1996, Obstet Gynecol Surv, V51, P376, DOI 10.1097/00006254-199606000-00023; GUARAN RL, 1994, AUST NZ J OBSTET GYN, V34, P39, DOI 10.1111/j.1479-828X.1994.tb01037.x; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hojjati MR, 2005, J BIOL CHEM, V280, P10284, DOI 10.1074/jbc.M412348200; Holcberg G, 2001, EUR J OBSTET GYN R B, V94, P69, DOI 10.1016/S0301-2115(00)00321-3; Johnstone ED, 2005, PLACENTA, V26, P548, DOI 10.1016/j.placenta.2004.08.012; Johnstone RW, 1999, BLOOD, V93, P1075, DOI 10.1182/blood.V93.3.1075.403k35_1075_1085; Jonker JW, 2000, JNCI-J NATL CANCER I, V92, P1651, DOI 10.1093/jnci/92.20.1651; Jonker JW, 2005, STEM CELLS, V23, P1059, DOI 10.1634/stemcells.2005-0150; Jonker JW, 2005, NAT MED, V11, P127, DOI 10.1038/nm1186; Kilani RT, 2007, REPRODUCTION, V133, P257, DOI 10.1530/REP-06-0080; Kingdom J, 2000, EUR J OBSTET GYN R B, V92, P35, DOI 10.1016/S0301-2115(00)00423-1; Kingdom JCP, 1997, PLACENTA, V18, P613, DOI 10.1016/S0143-4004(97)90000-X; Krishnamurthy P, 2004, J BIOL CHEM, V279, P24218, DOI 10.1074/jbc.M313599200; Laskowska M, 2006, J MATERN-FETAL NEO M, V19, P347, DOI 10.1080/14767050600637937; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mayhew TM, 2004, PLACENTA, V25, P829, DOI 10.1016/j.placenta.2004.04.011; Morrish DW, 1998, J REPROD IMMUNOL, V39, P179, DOI 10.1016/S0165-0378(98)00021-7; Myatt L, 2006, J PHYSIOL-LONDON, V572, P25, DOI 10.1113/jphysiol.2006.104968; Otake M, 2003, BRIT J CANCER, V89, P730, DOI 10.1038/sj.bjc.6601135; Pallis M, 2000, BLOOD, V95, P2897, DOI 10.1182/blood.V95.9.2897.009k14_2897_2904; Paumi CM, 2003, BIOCHEMISTRY-US, V42, P5429, DOI 10.1021/bi027347u; Payne SG, 1999, J CELL PHYSIOL, V180, P263, DOI 10.1002/(SICI)1097-4652(199908)180:2<263::AID-JCP14>3.0.CO;2-H; Sanchez-Vera I, 2005, OBSTET GYNECOL, V106, P345, DOI 10.1097/01.AOG.0000171112.95083.86; Straszewski-Chavez SL, 2005, ENDOCR REV, V26, P877, DOI 10.1210/er.2005-0003; SULLARDS MC, 2001, SCI STKE, V67, pPL1; van Meer G, 2006, FEBS LETT, V580, P1171, DOI 10.1016/j.febslet.2005.12.019; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; WOEHLECKE H, 2003, BIOCHEM J, V376, P789; Wollmann HA, 1998, HORM RES, V49, P1, DOI 10.1159/000053079	51	86	88	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3592	3605		10.1096/fj.07-8688com	http://dx.doi.org/10.1096/fj.07-8688com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17595345				2022-12-28	WOS:000250517800022
J	Campbell, EL; Louis, NA; Tomassetti, SE; Canny, GO; Arita, M; Serhan, CN; Colgan, SP				Campbell, Eric L.; Louis, Nancy A.; Tomassetti, Sarah E.; Canny, Geraldine O.; Arita, Makoto; Serhan, Charles N.; Colgan, Sean P.			Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution	FASEB JOURNAL			English	Article						transmigration; CD55; ICAM-1 transmigration; lipid mediator; epithelia	DECAY-ACCELERATING FACTOR; VASCULAR ENDOTHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; COMPLEMENT; MIGRATION; EXPRESSION; PROTECTS; INDUCTION; LIGAND; CD47	Migration of neutrophils (PMN) across epithelia is a pathological hallmark of numerous mucosal diseases. Whereas lesions at mucosal surfaces are generally self-limiting, endogenous mechanisms of resolution are incompletely understood. Previous studies revealed that resolvins directly act on PMN to attenuate transendothelial migration, less is known about the influence of resolvins on PMN-epithelial interactions and whether they act on epithelia. We studied the dynamics of resolvin E1 (RvE1) actions on leukocyte transepithelial migration. PMN exposure to RvE1 or chemerin (peptide agonist of ChemR23) reduced transepithelial migration in a concentration-dependent manner. Conversely, activation of epithelial ChemR23 promoted apical clearance of PMN. A nonbiased screen of known PMN ligands expressed on epithelial cells in response to RvE1 revealed selective induction of CD55, an apically expressed antiadhesive molecule. CD55 promoter analysis demonstrated that both RvE1 and chemerin activate the CD55 promoter. Inhibition of CD55 by neutralizing antibody prevented RvE1-dependent augmentation of apical PMN clearance. Taken together these findings implicate a "two-hit" model of inflammatory resolution, whereby activation of the PMN RvE1 receptor attenuates transepithelial migration and subsequent actions on the epithelium promote CD55-dependent clearance of PMN across the epithelial cell surface promoting active inflammatory resolution.	Univ Colorado, Hlth Sci Ctr, Mucosal Inflammat Program, Div Gastroenterol, Denver, CO 80262 USA; Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Colgan, SP (corresponding author), Univ Colorado, Hlth Sci Ctr, Mucosal Inflammat Program, Div Gastroenterol, Biomed Res Bldg Rm 702,4200 E 9th Ave, Denver, CO 80262 USA.	sean.colgan@uchsc.edu	Louis, Nancy/G-5163-2011; Campbell, Eric/N-5357-2015	Louis, Nancy/0000-0001-7092-8136; Campbell, Eric/0000-0003-0744-6577; Tomassetti, Sarah/0000-0001-6087-8788; Canny, Geraldine/0000-0003-0632-7365; Arita, Makoto/0000-0001-9902-0463	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013499, P50DE016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050189, R29DK050189, R01DK050189] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-60569] Funding Source: Medline; NIDCR NIH HHS [P50-DE016191, DE-13499] Funding Source: Medline; NIDDK NIH HHS [DK-50189] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad SR, 2003, IMMUNOLOGY, V110, P258, DOI 10.1046/j.1365-2567.2003.01733.x; Arita M, 2005, P NATL ACAD SCI USA, V102, P7671, DOI 10.1073/pnas.0409271102; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; BERGER M, 1987, J CLIN INVEST, V79, P214, DOI 10.1172/JCI112786; Borregaard N, 2005, J LEUKOCYTE BIOL, V77, P439, DOI 10.1189/jlb.0704381; Freire-de-Lima CG, 2006, J BIOL CHEM, V281, P38376, DOI 10.1074/jbc.M605146200; Gronert K, 1998, J EXP MED, V187, P1285, DOI 10.1084/jem.187.8.1285; Hasturk H, 2006, FASEB J, V20, P401, DOI 10.1096/fj.05-4724fje; Huber D, 2000, J BIOL CHEM, V275, P5773, DOI 10.1074/jbc.275.8.5773; Hudert CA, 2006, P NATL ACAD SCI USA, V103, P11276, DOI 10.1073/pnas.0601280103; Jaye DL, 2000, ANN NY ACAD SCI, V915, P151; Khoury J, 2007, J CLIN INVEST, V117, P703, DOI 10.1172/JCI30049; Lawrence DW, 2003, J EXP MED, V198, P999, DOI 10.1084/jem.20030380; Lin F, 2004, J IMMUNOL, V172, P3836, DOI 10.4049/jimmunol.172.6.3836; Liu Y, 2002, J BIOL CHEM, V277, P10028, DOI 10.1074/jbc.M109720200; Liu Y, 2001, J BIOL CHEM, V276, P40156, DOI 10.1074/jbc.M104138200; Louis NA, 2005, FASEB J, V19, P950, DOI 10.1096/fj.04-3251com; Louis NA, 2005, PROSTAG LEUKOTR ESS, V73, P197, DOI 10.1016/j.plefa.2005.05.006; Mason JC, 1999, BLOOD, V94, P1673, DOI 10.1182/blood.V94.5.1673.417a05_1673_1682; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; Millan J, 2006, NAT CELL BIOL, V8, P113, DOI 10.1038/ncb1356; Mitchell S, 2002, J AM SOC NEPHROL, V13, P2497, DOI 10.1097/01.ASN.0000032417.73640.72; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; Parkos CA, 1996, MOL MED, V2, P489, DOI 10.1007/BF03401908; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Shafren DR, 2000, J GEN VIROL, V81, P889, DOI 10.1099/0022-1317-81-4-889; Solomon KR, 1998, BIOCHEM J, V334, P325, DOI 10.1042/bj3340325; Song WC, 2004, CURR DIRECT AUTOIMMU, V7, P181; SUN YP, 2007, J BIOL CHEM, V23, P23; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; Zabel BA, 2006, EXP HEMATOL, V34, P1106, DOI 10.1016/j.exphem.2006.03.011; Zen K, 2003, CURR OPIN CELL BIOL, V15, P557, DOI 10.1016/S0955-0674(03)00103-0; Zen K, 2004, MOL BIOL CELL, V15, P3926, DOI 10.1091/mbc.E04-04-0317; Zhuang LY, 2002, CANCER RES, V62, P2227	37	151	157	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3162	3170		10.1096/fj.07-8473com	http://dx.doi.org/10.1096/fj.07-8473com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17496159				2022-12-28	WOS:000249781600017
J	Gungor, N; Godschalk, RWL; Pachen, DM; Van Schooten, FJ; Knaapen, AM				Gungor, Nejla; Godschalk, Roger W. L.; Pachen, Danielle M.; Van Schooten, Frederik J.; Knaapen, Ad M.			Activated neutrophils inhibit nucleotide excision repair in human pulmonary epithelial cells: role of myeloperoxidase	FASEB JOURNAL			English	Article						DNA adducts; DNA repair; inflammation; lung cancer	DNA ADDUCT LEVELS; HYPOCHLOROUS ACID; LUNG-CANCER; POTENT INHIBITOR; INFLAMMATION; OXIDATION; RISK; (+/-)-TRANS-7,8-DIHYDROXY-7,8-DIHYDROBENZO<A>PYRENE; SENSITIVITY; MUTAGENESIS	Neutrophils are thought to affect pulmonary carcinogenesis by promoting the metabolism of inhaled chemical carcinogens, causing enhanced formation of promutagenic DNA adducts. We hypothesized that neutrophils interfere with the removal of such DNA adducts by inhibiting nucleotide excision repair ( NER) in target cells. Human alveolar epithelial cells ( A549) were cocultured with activated neutrophils, and we observed a significant reduction of NER in the A549 cells, which was abrogated by addition of the myeloper-oxidase (MPO) inhibitor 4-aminobenzoic acid hydrazide. The inhibitory effect of neutrophils could be mimicked by the MPO product hypochlorous acid ( HOCl), which caused an acute, dose-dependent inhibition of NER in A549 cells. This was independent of cytotoxicity or ATP loss and persisted up to 24 h. These data were supported by showing that HOCl caused a delayed removal of DNA adducts in benzo[ a] pyrenediolepoxide-exposed A549 cells. The acute HOCl-induced inhibition of NER can only partly be explained by oxidative modification of repair proteins. To explain the more persistent effects of HOCl, we analyzed the expression of NER genes and found that HOCl significantly reduced XPC expression. In conclusion, these data indicate that neutrophils are potent inhibitors of nucleotide excision repair. This may provide a further biological explanation for the association between inflammation and lung cancer development.	Maastricht Univ, Dept Hlth Risk Anal & Toxicol, Nutr & Toxicol Res Inst, NL-6200 MD Maastricht, Netherlands	Maastricht University	Knaapen, AM (corresponding author), Maastricht Univ, Dept Hlth Risk Anal & Toxicol, Nutr & Toxicol Res Inst, POB 616, NL-6200 MD Maastricht, Netherlands.	a.knaapen@grat.unimaas.nl						Borm PJA, 1997, ENVIRON HEALTH PERSP, V105, P1089, DOI 10.2307/3433514; Buss IH, 2000, PEDIATR RES, V47, P640, DOI 10.1203/00006450-200005000-00014; Chien YH, 2004, FREE RADICAL BIO MED, V36, P1011, DOI 10.1016/j.freeradbiomed.2004.01.011; COCHRANE CG, 1991, AM J MED, V91, pS23, DOI 10.1016/0002-9343(91)90280-B; Collins AR, 2001, MUTAGENESIS, V16, P297, DOI 10.1093/mutage/16.4.297; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dalle-Donne I, 2006, J CELL MOL MED, V10, P389, DOI 10.1111/j.1582-4934.2006.tb00407.x; DALLEGRI F, 1988, J LAB CLIN MED, V112, P765; Dally H, 2002, INT J CANCER, V102, P530, DOI 10.1002/ijc.10756; den Hartog GJM, 2002, TOXICOL APPL PHARM, V181, P228, DOI 10.1006/taap.2002.9419; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Feng ZH, 2004, P NATL ACAD SCI USA, V101, P8598, DOI 10.1073/pnas.0402794101; Feng ZH, 2006, MUTAT RES-FUND MOL M, V601, P125, DOI 10.1016/j.mrfmmm.2006.06.003; FLISS H, 1988, MOL CELL BIOCHEM, V84, P177, DOI 10.1007/BF00421053; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; Gillet LCJ, 2006, CHEM REV, V106, P253, DOI 10.1021/cr040483f; Godschalk RWL, 1998, CARCINOGENESIS, V19, P819, DOI 10.1093/carcin/19.5.819; HUNNINGHAKE GW, 1981, J CLIN INVEST, V68, P259, DOI 10.1172/JCI110242; Ide F, 2000, CARCINOGENESIS, V21, P1263, DOI 10.1093/carcin/21.6.1263; JANZ S, 1993, MUTAT RES, V293, P173, DOI 10.1016/0921-8777(93)90068-R; KETTLE AJ, 1995, BIOCHEM J, V308, P559, DOI 10.1042/bj3080559; Klebanoff SJ, 1999, P ASSOC AM PHYSICIAN, V111, P383, DOI 10.1111/paa.1999.111.5.383; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; Knaapen AM, 2006, MUTAGENESIS, V21, P225, DOI 10.1093/mutage/gel032; Knaapen AM, 2005, CARCINOGENESIS, V26, P1642, DOI 10.1093/carcin/bgi116; Knaapen AM, 2004, INT J CANCER, V109, P799, DOI 10.1002/ijc.11708; Knaapen AM, 1999, FREE RADICAL BIO MED, V27, P234, DOI 10.1016/S0891-5849(98)00285-8; Kulcharyk PA, 2001, BIOCHEMISTRY-US, V40, P3648, DOI 10.1021/bi001962l; Langie SAS, 2006, MUTAGENESIS, V21, P153, DOI 10.1093/mutage/gel013; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luch A, 2005, NAT REV CANCER, V5, P113, DOI 10.1038/nrc1546; MALLET WG, 1991, CARCINOGENESIS, V12, P521, DOI 10.1093/carcin/12.3.521; Noguera A, 2001, THORAX, V56, P432, DOI 10.1136/thorax.56.6.432; Pattison DI, 2001, CHEM RES TOXICOL, V14, P1453, DOI 10.1021/tx0155451; Pero RW, 1996, CARCINOGENESIS, V17, P13, DOI 10.1093/carcin/17.1.13; PETRUSKA JM, 1992, CARCINOGENESIS, V13, P1075, DOI 10.1093/carcin/13.7.1075; Pullar JM, 1999, AM J PHYSIOL-HEART C, V277, pH1505, DOI 10.1152/ajpheart.1999.277.4.H1505; Redaelli A, 1998, TERATOGEN CARCIN MUT, V18, P17, DOI 10.1002/(SICI)1520-6866(1998)18:1<17::AID-TCM3>3.0.CO;2-H; REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543; Schottenfeld D, 2006, CA-CANCER J CLIN, V56, P69, DOI 10.3322/canjclin.56.2.69; Spencer JPE, 2000, FREE RADICAL BIO MED, V28, P1039, DOI 10.1016/S0891-5849(00)00190-8; van Haaften RIM, 2001, CHEM-BIOL INTERACT, V138, P77, DOI 10.1016/S0009-2797(01)00262-9; Van Schooten FJ, 2004, CANCER EPIDEM BIOMAR, V13, P828; VANRENSBURG CEJ, 1991, FREE RADICAL BIO MED, V11, P285, DOI 10.1016/0891-5849(91)90125-M; Whiteman M, 2002, P NATL ACAD SCI USA, V99, P12061, DOI 10.1073/pnas.152462399; Winterbourn CC, 2000, FREE RADICAL BIO MED, V29, P403, DOI 10.1016/S0891-5849(00)00204-5; Wu XF, 2003, CARCINOGENESIS, V24, P505, DOI 10.1093/carcin/24.3.505; Zienolddiny S, 2006, CARCINOGENESIS, V27, P560, DOI 10.1093/carcin/bgi232	49	62	63	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2359	2367		10.1096/fj.07-8163com	http://dx.doi.org/10.1096/fj.07-8163com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17440118				2022-12-28	WOS:000248454400011
J	Rosenberger, P; Khoury, J; Kong, TQ; Weissmuller, T; Robinson, AM; Colgan, SP				Rosenberger, Peter; Khoury, Joseph; Kong, Tianqing; Weissmuller, Thomas; Robinson, Andreas M.; Colgan, Sean P.			Identification of vasodilator-stimulated phosphoprotein (VASP) as an HIF-regulated tissue permeability factor during hypoxia	FASEB JOURNAL			English	Article						barrier function; actin	INDUCIBLE FACTOR-I; ALVEOLAR EPITHELIAL-CELLS; ENDOTHELIAL-CELLS; BARRIER FUNCTION; NITRIC-OXIDE; INDUCTION; SPECTRIN; GENE; EXPRESSION; ISCHEMIA	Increased tissue permeability is commonly associated with hypoxia of many origins. Since hypoxia-inducible factor (HIF) represents a predominant hypoxia signaling mechanism, we compared hypoxia-elicited changes in tissue barrier function in mice conditionally lacking intestinal epithelial hypoxia-inducible factor-1 alpha (hif1a). Somewhat surprisingly, these studies revealed that mutant hif1a mice were protected from hypoxia-induced increases in intestinal permeability in vivo. Guided by microarray analysis of tissues derived from these mutant hif1a mice, we identified HIF-1-dependent repression of vasodilator-stimulated phosphoprotein ( VASP), a molecule known to be important in the control of cytoskeletal dynamics, including barrier function. Studies at the mRNA and protein level confirmed hypoxia-elicited repression of VASP in murine tissue, cultured epithelia and endothelia, as well as human saphenous vein ex vivo. Targeted repression of VASP by siRNA recapitulated our findings with hypoxia and directed overexpression of VASP abolished hypoxia-induced barrier dysfunction. Studies in the cloned human VASP promoter revealed hypoxia-dependent transcriptional repression, and functional studies by chromatin immunoprecipitation (ChIP) and site-directed mutagenesis revealed hypoxia-dependent binding of HIF-1 alpha to the human VASP promoter. These studies identify HIF-1-dependent repression of VASP as a control point for hypoxia-regulated barrier dysfunction.	Univ Colorado, Hlth Sci Ctr, Mucosal Inflammat Program, Denver, CO 80220 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Childrens Hosp, Dept Anesthesia & Perioperat Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Univ Tubingen Hosp, Dept Anesthesiol & Intens Care Med, Tubingen, Germany	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Colgan, SP (corresponding author), Univ Colorado, Hlth Sci Ctr, Mucosal Inflammat Program, 4200 E 9th Ave,Biochem Res Bldg,Rm 702, Denver, CO 80220 USA.	colgan@zeus.bwh.harvard.edu	Colgan, Sean P./B-4573-2009		NHLBI NIH HHS [R01 HL060569] Funding Source: Medline; NIDDK NIH HHS [R37 DK050189] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050189] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Bouvry D, 2006, AM J RESP CELL MOL, V35, P519, DOI 10.1165/rcmb.2005-0478OC; Cavanaugh KJ, 2001, AM J RESP CELL MOL, V25, P584, DOI 10.1165/ajrcmb.25.5.4486; Comerford KM, 2002, CANCER RES, V62, P3387; Comerford KM, 2002, FASEB J, V16, P583, DOI 10.1096/fj.01-0739fje; COMERFORD KM, 2002, FASEB J, V282, pC1235; DOCTOR RB, 1993, AM J PHYSIOL, V264, pC1003, DOI 10.1152/ajpcell.1993.264.4.C1003; Eltzschig HK, 2005, J EXP MED, V202, P1493, DOI 10.1084/jem.20050177; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; GARCIA JGN, 1986, J CELL PHYSIOL, V128, P96, DOI 10.1002/jcp.1041280115; Garcia Joe G. N., 1996, Seminars in Thrombosis and Hemostasis, V22, P309, DOI 10.1055/s-2007-999025; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HU RJ, 1991, J BIOL CHEM, V266, P18200; Ibla JC, 2006, AM J PHYSIOL-CELL PH, V291, pC282, DOI 10.1152/ajpcell.00564.2005; Karhausen J, 2004, J CLIN INVEST, V114, P1098, DOI 10.1172/JCI200421086; Kayyali US, 2002, J BIOL CHEM, V277, P42596, DOI 10.1074/jbc.M205863200; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; Kong TQ, 2006, FASEB J, V20, P2242, DOI 10.1096/fj.06-6419com; Kwon O, 2002, AM J PHYSIOL-RENAL, V282, pF1012, DOI 10.1152/ajprenal.00294.2001; Laukoetter MG, 2006, CURR OPIN GASTROEN, V22, P85, DOI 10.1097/01.mog.0000203864.48255.4f; Lawrence DW, 2002, AM J PHYSIOL-CELL PH, V282, pC1235, DOI 10.1152/ajpcell.00288.2001; Lee A, 2001, J BIOL CHEM, V276, P20735, DOI 10.1074/jbc.M009723200; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; MANALO DJ, 2004, BLOOD, V16, P16; MIZUNOYAGYU Y, 1987, BIOCHEM PHARMACOL, V36, P3809; MOLITORIS BA, 1991, AM J PHYSIOL, V260, pF769; Molitoris BA, 1996, AM J PHYSIOL-RENAL, V271, pF790, DOI 10.1152/ajprenal.1996.271.4.F790; Price CJ, 2000, ARTERIOSCL THROM VAS, V20, P2051, DOI 10.1161/01.ATV.20.9.2051; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Semenza GL, 2000, GENE DEV, V14, P1983; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Sporbert A, 1999, MOL BRAIN RES, V67, P258, DOI 10.1016/S0169-328X(99)00067-4; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Wang FS, 2003, AM J RESP CELL MOL, V29, P62, DOI 10.1165/rcmb.2002-0180OC; Wojciak-Stothard B, 2006, AM J PHYSIOL-LUNG C, V290, pL1173, DOI 10.1152/ajplung.00309.2005; Wojciak-Stothard B, 2005, AM J PHYSIOL-LUNG C, V288, pL749, DOI 10.1152/ajplung.00361.2004; Woroniecki R, 2003, AM J PHYSIOL-RENAL, V284, pF358, DOI 10.1152/ajprenal.00100.2002; WU NZ, 1992, AM J PHYSIOL, V262, pH1238; Yamashita R, 2006, NUCLEIC ACIDS RES, V34, pD86, DOI 10.1093/nar/gkj129	44	50	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2613	2621		10.1096/fj.06-8004com	http://dx.doi.org/10.1096/fj.06-8004com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17412998	Green Accepted			2022-12-28	WOS:000248454400034
J	Tchantchou, F; Xu, YN; Wu, YJ; Christen, Y; Luo, Y				Tchantchou, Flaubert; Xu, Yanan; Wu, Yanjue; Christen, Yves; Luo, Yuan			EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						AD; dementia; neuronal cells; memory	GINKGO-BILOBA EXTRACT; ELEMENT-BINDING PROTEIN; AMYLOID-BETA-PEPTIDE; DENTATE GYRUS; RANDOMIZED-TRIAL; DOUBLE-BLIND; IN-VIVO; SYNAPTIC PLASTICITY; CELLS; MEMORY	Standardized Ginkgo biloba extract EGb 761 exhibits beneficial effects to patients with Alzheimer's disease ( AD). It was previously demonstrated that EGb 761 inhibits amyloid beta ( A beta) oligomerization in vitro, protects neuronal cells against A beta toxicity, and improves cognitive defects in a mouse model of AD ( Tg 2576). In this study, the neurogenic potential of EGb 761 and its effect on cAMP response element binding protein ( CREB) were examined in a double transgenic mouse model ( TgAPP/ PS1). EGb 761 significantly increases cell proliferation in the hippocampus of both young ( 6 months) and old ( 22 months) TgAPP/ PS1 mice, and the total number of neuronal precursor cells in vitro in a dose-dependent manner. Furthermore, A beta oligomers inhibit phosphorylation of CREB and cell proliferation in the hippocampus of TgAPP/ PS1 mice. Administration of EGb 761 reduces A beta oligomers and restores CREB phosphorylation in the hippocampus of these mice. The present findings suggest that 1) enhanced neurogenesis by EGb 761 may be mediated by activation of CREB, 2) stimulation of neurogenesis by EGb 761 may contribute to its beneficial effects in AD patients and improved cognitive functions in the mouse model of AD, and 3) EGb 761 has therapeutic potential for the prevention and improved treatment of AD.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD USA; Ipsen, Paris, France	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Luo, Y (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.	yluo@rx.umaryland.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001928] Funding Source: NIH RePORTER; NCCIH NIH HHS [R01AT001928-03A1] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Barker N, 2000, ADV CANCER RES, V77, P1; Bastianetto S, 2000, J NEUROCHEM, V74, P2268, DOI 10.1046/j.1471-4159.2000.0742268.x; Beglopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P33, DOI 10.1016/j.tips.2005.11.010; Bender RA, 2001, EUR J NEUROSCI, V13, P679, DOI 10.1046/j.1460-9568.2001.01432.x; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brinton Roberta Diaz, 2006, Current Alzheimer Research, V3, P185; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Colciaghi F, 2004, NEUROBIOL DIS, V16, P454, DOI 10.1016/j.nbd.2004.03.011; DeFeudis F. V., 2000, Current Drug Targets, V1, P25, DOI 10.2174/1389450003349380; DeKosky ST, 2006, CONTEMP CLIN TRIALS, V27, P238, DOI 10.1016/j.cct.2006.02.007; Donovan MH, 2006, J COMP NEUROL, V495, P70, DOI 10.1002/cne.20840; Dusek JA, 1997, P NATL ACAD SCI USA, V94, P7109, DOI 10.1073/pnas.94.13.7109; Feng RB, 2001, NEURON, V32, P911, DOI 10.1016/S0896-6273(01)00523-2; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gohil K, 2002, ANN NY ACAD SCI, V957, P70, DOI 10.1111/j.1749-6632.2002.tb02906.x; Gould E, 1999, TRENDS COGN SCI, V3, P186, DOI 10.1016/S1364-6613(99)01310-8; Gross CG, 2000, NAT REV NEUROSCI, V1, P67, DOI 10.1038/35036235; Hattiangady B, 2005, EXP NEUROL, V195, P353, DOI 10.1016/j.expneurol.2005.05.014; Haughey NJ, 2002, J NEUROCHEM, V83, P1509, DOI 10.1046/j.1471-4159.2002.01267.x; Jiang W, 2005, J CLIN INVEST, V115, P3104, DOI 10.1172/JCI25509; Jin KL, 2004, P NATL ACAD SCI USA, V101, P13363, DOI 10.1073/pnas.0403678101; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; Lee SJ, 2004, NEUROSCIENCE, V124, P549, DOI 10.1016/j.neuroscience.2003.11.035; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; Luo Y, 2002, P NATL ACAD SCI USA, V99, P12197, DOI 10.1073/pnas.182425199; MacKenzie SJ, 2000, BIOCHEM J, V347, P571, DOI 10.1042/0264-6021:3470571; Mattson MP, 2006, TRENDS NEUROSCI, V29, P632, DOI 10.1016/j.tins.2006.09.001; Mazza M, 2006, EUR J NEUROL, V13, P981, DOI 10.1111/j.1468-1331.2006.01409.x; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Mix JA, 2002, HUM PSYCHOPHARM CLIN, V17, P267, DOI 10.1002/hup.412; Nakagawa S, 2002, J NEUROSCI, V22, P3673; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Parent JM, 1997, J NEUROSCI, V17, P3727; PHILLIPS HS, 1991, NEURON, V7, P695, DOI 10.1016/0896-6273(91)90273-3; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Puzzo D, 2005, J NEUROSCI, V25, P6887, DOI 10.1523/JNEUROSCI.5291-04.2005; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Smith JV, 2002, CELL MOL BIOL, V48, P699; Smith JV, 2004, APPL MICROBIOL BIOT, V64, P465, DOI 10.1007/s00253-003-1527-9; Spencer JPE, 2003, J BIOL CHEM, V278, P34783, DOI 10.1074/jbc.M305063200; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Stackman RW, 2003, EXP NEUROL, V184, P510, DOI 10.1016/S0014-4886(03)00399-6; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Vitolo OV, 2002, P NATL ACAD SCI USA, V99, P13217, DOI 10.1073/pnas.172504199; Ward CP, 2002, PHARMACOL BIOCHEM BE, V72, P913, DOI 10.1016/S0091-3057(02)00768-2; Wu YJ, 2006, J NEUROSCI, V26, P13102, DOI 10.1523/JNEUROSCI.3448-06.2006; Yamamoto-Sasaki M, 1999, BRAIN RES, V824, P300, DOI 10.1016/S0006-8993(99)01220-2; Yao ZX, 2001, BRAIN RES, V889, P181, DOI 10.1016/S0006-8993(00)03131-0; Zhu DY, 2004, P NATL ACAD SCI USA, V101, P9453, DOI 10.1073/pnas.0401063101	58	146	158	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2400	2408		10.1096/fj.06-7649com	http://dx.doi.org/10.1096/fj.06-7649com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17356006				2022-12-28	WOS:000248454400015
J	Wendeler, MW; Nufer, O; Hauri, HP				Wendeler, Markus W.; Nufer, Oliver; Hauri, Hans-Peter			Improved maturation of CFTR by an ER export signal	FASEB JOURNAL			English	Article						cystic fibrosis; membrane traffic; transport signal	TRANSMEMBRANE CONDUCTANCE REGULATOR; EARLY SECRETORY PATHWAY; COPII-DEPENDENT EXPORT; CYSTIC-FIBROSIS; ENDOPLASMIC-RETICULUM; DELTA-F508 CFTR; PDZ DOMAINS; CHLORIDE CHANNEL; MOLECULAR-BASIS; GENE-THERAPY	The cystic fibrosis transmembrane conductance regulator ( CFTR) is a cAMP-regulated chloride channel in the plasma membrane of several epithelial cells. Maturation of CFTR is inefficient in most cells, with only a fraction of nascent chains being properly folded and transported to the cell surface. The most common mutation in CFTR, CFTR- Delta F508, leads to the genetic disease cystic fibrosis. CFTR- Delta F508 has a temperature-sensitive folding defect and is almost quantitatively degraded in the endoplasmic reticulum ( ER). Here we tested whether a strong ER export signal appended to CFTR improves its transport and surface expression. We show that a single valine ER export signal at the C terminus of the cytoplasmic tail of CFTR improves maturation of wild-type CFTR by 2-fold. This conservative mutation interfered with neither plasma membrane localization nor stability of mature CFTR. In contrast, the valine signal was unable to rescue CFTR- Delta F508 from ER-associated degradation. Our finding of improved maturation of CFTR mediated by a valine signal may be of potential use in gene therapy of cystic fibrosis. Moreover, failure of the valine signal to rescue CFTR- Delta F508 from ER degradation indicates that the inability of CFTR-Delta F508 to leave the ER is unlikely to be due to a malfunctioning ER export signal.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	University of Basel	Hauri, HP (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.	hans-peter.hauri@unibas.ch						Bannykh SI, 2000, TRAFFIC, V1, P852, DOI 10.1034/j.1600-0854.2000.011105.x; Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; Bobadilla JL, 2002, HUM MUTAT, V19, P575, DOI 10.1002/humu.10041; Bradbury NA, 1999, PHYSL REV S, V79, P175, DOI DOI 10.1152/physrev.1999.79.1.S175; Chang XB, 1999, MOL CELL, V4, P137, DOI 10.1016/S1097-2765(00)80196-3; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Cyr DM, 2005, NAT STRUCT MOL BIOL, V12, P2, DOI 10.1038/nsmb0105-2; Davidson MH, 2006, ATHEROSCLEROSIS SUPP, V7, P1, DOI 10.1016/S1567-5688(06)80003-6; Davies JC, 2001, J GENE MED, V3, P409, DOI 10.1002/jgm.200; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; Gilbert A, 1998, EXP CELL RES, V242, P144, DOI 10.1006/excr.1998.4101; Griesenbach U, 2002, GENE THER, V9, P1344, DOI 10.1038/sj.gt.3301791; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Jilling T, 1997, INT REV CYTOL, V172, P193, DOI 10.1016/S0074-7696(08)62361-X; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Kleizen B, 2000, EUR J CELL BIOL, V79, P544, DOI 10.1078/0171-9335-00078; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Liu SS, 2005, J PHARMACOL EXP THER, V314, P846, DOI 10.1124/jpet.105.083519; Liu XH, 2006, J BIOL CHEM, V281, P8275, DOI 10.1074/jbc.M512458200; Liu XM, 2002, NAT BIOTECHNOL, V20, P47, DOI 10.1038/nbt0102-47; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Mickle JE, 1998, HUM MOL GENET, V7, P729, DOI 10.1093/hmg/7.4.729; Miller E, 2002, EMBO J, V21, P6105, DOI 10.1093/emboj/cdf605; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Mu YY, 2003, NEURON, V40, P581, DOI 10.1016/S0896-6273(03)00676-7; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nufer O, 2003, J CELL SCI, V116, P4429, DOI 10.1242/jcs.00759; Nufer O, 2002, J CELL SCI, V115, P619; Ostrowski LE, 2003, MOL THER, V8, P637, DOI 10.1016/S1525-0016(03)00221-1; PIND S, 1994, J BIOL CHEM, V269, P12784; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; Riordan JR, 2005, ANNU REV PHYSIOL, V67, P701, DOI 10.1146/annurev.physiol.67.032003.154107; Riordan JR, 1999, AM J HUM GENET, V64, P1499, DOI 10.1086/302429; RIORDAN JR, 1989, SCIENCE, V245, P1066; Riordan JR, 1999, PEDIATR PULM, P83; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sun F, 2006, J BIOL CHEM, V281, P36856, DOI 10.1074/jbc.M607085200; Sun WM, 2006, GENET MED, V8, P339, DOI 10.1097/01.gim.0000223549.57443.16; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Varga K, 2004, J BIOL CHEM, V279, P22578, DOI 10.1074/jbc.M401522200; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Wang XD, 2004, J CELL BIOL, V167, P65, DOI 10.1083/jcb.200401035; Wang XD, 2006, CELL, V127, P803, DOI 10.1016/j.cell.2006.09.043; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; YANG YP, 1993, HUM MOL GENET, V2, P1253, DOI 10.1093/hmg/2.8.1253; Yoo JS, 2002, J BIOL CHEM, V277, P11401, DOI 10.1074/jbc.M110263200; Younger JM, 2006, CELL, V126, P571, DOI 10.1016/j.cell.2006.06.041; ZHAO W, 2006, J BIOL CHEM	55	5	5	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2352	2358		10.1096/fj.07-8128com	http://dx.doi.org/10.1096/fj.07-8128com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17392477				2022-12-28	WOS:000248454400010
J	Chamberlain, JS; Metzger, J; Reyes, M; Townsend, DW; Faulkner, JA				Chamberlain, Jeffrey S.; Metzger, Joseph; Reyes, Morayma; Townsend, DeWayne; Faulkner, John A.			Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma	FASEB JOURNAL			English	Article						muscular dystrophy; aging	DUCHENNE MUSCULAR-DYSTROPHY; CONTRACTION-INDUCED INJURY; SKELETAL-MUSCLE MYOPATHY; FULL-LENGTH DYSTROPHIN; ALVEOLAR RHABDOMYOSARCOMA; TRANSGENIC MDX; GENE-THERAPY; GLYCOPROTEIN COMPLEX; DIAPHRAGM MUSCLE; MOLECULAR-BASIS	Duchenne muscular dystrophy (DMD) is the most common, lethal genetic disorder of children. A number of animal models of muscular dystrophy exist, but the most effective model for characterizing the structural and functional properties of dystrophin and therapeutic interventions has been the mdx mouse. Despite the similar to 20 years of investigations of the mdx mouse, the impact of the disease on the life span of mdx mice and the cause of death remain unresolved. Consequently, a life span study of the mdx mouse was designed that included cohorts of male and female mdx and wild-type C57BL/10 mice housed under specific pathogen-free conditions with deaths restricted to natural causes and with examination of the carcasses for pathology. Compared with wild-type mice, both mdx male and female mice had reduced life spans and displayed a progressively dystrophic muscle histopathology. Surprisingly, old mdx mice were prone to develop muscle tumors that resembled the human form of alveolar rhabdomyosarcoma, a cancer associated with poor prognosis. Rhabdomyosarcomas have not been observed previously in nontransgenic mice. The results substantiate the mdx mouse as an important model system for studies of the pathogenesis of and potential remedies for DMD.	Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI USA	University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Chamberlain, JS (corresponding author), Univ Washington, Sch Med, Dept Neurol, K243b HSB,Box 357720,1959, Seattle, WA 98195 USA.	jsc5@u.washington.edu		Chamberlain, Jeffrey/0000-0001-5299-0059	NIA NIH HHS [P01 AG015434] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG015434] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abe Shinichi, 2002, Anatomical Science International, V77, P145, DOI 10.1046/j.0022-7722.2002.00019.x; ABMAYR S, 2006, MOL MECH MUSCULAR DY; Allen DL, 2001, AM J PHYSIOL-CELL PH, V280, pC637, DOI 10.1152/ajpcell.2001.280.3.C637; Anderson JE, 1998, MUSCLE NERVE, V21, P1153, DOI 10.1002/(SICI)1097-4598(199809)21:9<1153::AID-MUS6>3.0.CO;2-6; Anderson MJ, 2001, P NATL ACAD SCI USA, V98, P1589, DOI 10.1073/pnas.98.4.1589; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BROOKS SV, 1988, J PHYSIOL-LONDON, V404, P71, DOI 10.1113/jphysiol.1988.sp017279; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CARNWATH JW, 1987, J NEUROL SCI, V80, P39, DOI 10.1016/0022-510X(87)90219-X; Chamberlain JS, 2002, HUM MOL GENET, V11, P2355, DOI 10.1093/hmg/11.20.2355; Cobos AR, 2001, J ANAT, V198, P283, DOI 10.1046/j.1469-7580.2001.19830283.x; Consolino CM, 2004, J APPL PHYSIOL, V96, P633, DOI 10.1152/japplphysiol.00587.2003; COOPER BJ, 1988, NATURE, V334, P154, DOI 10.1038/334154a0; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P299, DOI 10.1111/j.1365-2990.1988.tb00890.x; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; DANGAIN J, 1984, MUSCLE NERVE, V7, P700, DOI 10.1002/mus.880070903; Danialou G, 2001, FASEB J, V15, P1655, DOI 10.1096/fj.01-0030fje; DelloRusso C, 2002, P NATL ACAD SCI USA, V99, P12979, DOI 10.1073/pnas.202300099; Dellorusso C, 2001, J MUSCLE RES CELL M, V22, P467, DOI 10.1023/A:1014587918367; Dias P, 2000, AM J PATHOL, V156, P399, DOI 10.1016/S0002-9440(10)64743-8; DICK J, 1993, CLIN SCI, V84, P145, DOI 10.1042/cs0840145; Duchenne G., 1868, ARCH GEN MED, V11, P5; DUPONTVERSTEEGDEN EE, 1992, MUSCLE NERVE, V15, P1105, DOI 10.1002/mus.880151008; Eagle M, 2002, NEUROMUSCULAR DISORD, V12, P926, DOI 10.1016/S0960-8966(02)00140-2; EMERY AEH, 1976, BMJ-BRIT MED J, V2, P637, DOI 10.1136/bmj.2.6036.637; Emery AEH, 2003, DUCHENNE MUSCULAR DY; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Faulkner JA, 1997, BASIC APPL MYOL, V7, P257; Gillis JM, 1996, ACTA PHYSIOL SCAND, V156, P397, DOI 10.1046/j.1365-201X.1996.201000.x; Gregorevic P, 2004, NAT MED, V10, P828, DOI 10.1038/nm1085; Harper SQ, 2002, NAT MED, V8, P253, DOI 10.1038/nm0302-253; Hartmann N, 2001, J CELL BIOCHEM, P222; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1990, J NEUROL SCI, V99, P9, DOI 10.1016/0022-510X(90)90195-S; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; Hostein I, 2004, CANCER-AM CANCER SOC, V101, P2817, DOI 10.1002/cncr.20711; HUTTER OF, 1991, J MUSCLE RES CELL M, V12, P585, DOI 10.1007/BF01738447; Jakab Z, 2002, MED PEDIATR ONCOL, V39, P66, DOI 10.1002/mpo.10043; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; Lagutina I, 2002, MOL CELL BIOL, V22, P7204, DOI 10.1128/MCB.22.20.7204-7216.2002; LEFAUCHEUR JP, 1995, ANAT REC, V242, P70, DOI 10.1002/ar.1092420109; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; Lynch GS, 2001, J PHYSIOL-LONDON, V535, P591, DOI 10.1111/j.1469-7793.2001.00591.x; Lynch GS, 1997, AM J PHYSIOL-CELL PH, V272, pC2063, DOI 10.1152/ajpcell.1997.272.6.C2063; Lynch GS, 2000, AM J PHYSIOL-CELL PH, V279, pC1290, DOI 10.1152/ajpcell.2000.279.4.C1290; McClung JR, 2000, ANAT REC, V260, P378, DOI 10.1002/1097-0185(20001201)260:4<378::AID-AR70>3.0.CO;2-A; MCCULLY KK, 1985, J APPL PHYSIOL, V59, P119, DOI 10.1152/jappl.1985.59.1.119; Meryon E, 1852, Med Chir Trans, V35, P73; Meyer WH, 2004, CANCER TREAT REV, V30, P269, DOI 10.1016/j.ctrv.2003.11.001; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; MOSER H, 1984, CURRENT CLIN PRACTIC, V20, P41; PARTRIDGE T, 1991, NEUROPATH APPL NEURO, V17, P353, DOI 10.1111/j.1365-2990.1991.tb00735.x; PASTORET C, 1993, NEUROMUSCULAR DISORD, V3, P471, DOI 10.1016/0960-8966(93)90099-6; PASTORET C, 1995, MUSCLE NERVE, V18, P1147, DOI 10.1002/mus.880181011; Petrof BJ, 1998, MOL CELL BIOCHEM, V179, P111, DOI 10.1023/A:1006812004945; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Quinlan JG, 2004, NEUROMUSCULAR DISORD, V14, P491, DOI 10.1016/j.nmd.2004.04.007; Rossbach HC, 1999, J PEDIAT HEMATOL ONC, V21, P528, DOI 10.1097/00043426-199911000-00016; RUBIN E, 1994, PATHOLOGY, V1, P1343; Sebire NJ, 2003, PEDIATR DEVEL PATHOL, V6, P94, DOI 10.1007/s10024-002-0047-4; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Tiffin N, 2003, BRIT J CANCER, V89, P327, DOI 10.1038/sj.bjc.6601040; TONIN PN, 1991, CANCER RES, V51, P5100; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; VALENTINE BA, 1992, AM J MED GENET, V42, P352, DOI 10.1002/ajmg.1320420320; Wang B, 2000, P NATL ACAD SCI USA, V97, P13714, DOI 10.1073/pnas.240335297; WEBSTER C, 1990, SOMAT CELL MOLEC GEN, V16, P557, DOI 10.1007/BF01233096; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8; Yasuda S, 2005, NATURE, V436, P1025, DOI 10.1038/nature03844; Yue YP, 2004, HUM MOL GENET, V13, P1669, DOI 10.1093/hmg/ddh174; ZACHARIAS JM, 1991, J NEUROL SCI, V104, P190, DOI 10.1016/0022-510X(91)90309-U	77	239	244	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2195	2204		10.1096/fj.06-7353com	http://dx.doi.org/10.1096/fj.06-7353com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17360850	Green Submitted			2022-12-28	WOS:000247500300028
J	Farioli-Vecchioli, S; Tanori, M; Micheli, L; Mancuso, M; Leonardi, L; Saran, A; Ciotti, MT; Ferretti, E; Gulino, A; Pazzaglia, S; Tirone, F				Farioli-Vecchioli, Stefano; Tanori, Mirella; Micheli, Laura; Mancuso, Mariateresa; Leonardi, Luca; Saran, Anna; Ciotti, Maria Teresa; Ferretti, Elisabetta; Gulino, Alberto; Pazzaglia, Simonetta; Tirone, Felice			Inhibition of medulloblastoma tumorigenesis by the antiproliferative and pro-differentiative gene PC3	FASEB JOURNAL			English	Article						tumor suppressor gene; neurogenesis; cyclin D1; Math1	GRANULE CELL-DIFFERENTIATION; DEVELOPING MOUSE CEREBELLUM; CENTRAL-NERVOUS-SYSTEM; SONIC HEDGEHOG; HUMAN HOMOLOG; NEURONAL PRECURSORS; HETEROZYGOUS MICE; MAMMALIAN-CELLS; GROWTH-FACTOR; N-MYC	Medulloblastoma, the most common brain tumor in childhood, appears to originate from cerebellar granule cell precursors (GCPs), located in the external granular layer (EGL) of the cerebellum. The antiproliferative gene PC3 (Tis21/BTG2) promotes cerebellar neurogenesis by inducing GCPs to shift from proliferation to differentiation. To assess whether PC3 can prevent the neoplastic transformation of GCPs and medulloblastoma development, we crossed transgenic mice conditionally expressing PC3 (TgPC3) in GCPs with Patched1 heterozygous mice (Ptc(+/-)), a model of medulloblastoma pathogenesis characterized by hyperactivation of the Sonic Hedgehog pathway. Perinatal up-regulation of PC3 in Ptc(+/-)/TgPC3 mice results in a decrease of medulloblastoma incidence of similar to 40% and in a marked reduction of preneoplastic abnormalities, such as hyperplastic EGL areas and lesions. Moreover, overexpression of cyclin D1, hyperproliferation, and defective differentiation-observed in Ptc(+/-) GCPs-are restored to normality in Ptc(+/-)/TgPC3 mice. The PC3-mediated inhibition of cyclin D1 expression correlates with recruitment of PC3 to the cyclin D1 promoter, which is accompanied by histone deacetylation. Remarkably, down-regulation of PC3 is observed in preneoplastic lesions, as well as in human and murine medulloblastomas. As a whole, this indicates that PC3 may prevent medulloblastoma development by controlling cell cycle and promoting differentiation of GCPs.-Farioli-Vecchioli, S., Tanori, M., Micheli, L., Mancuso, M., Leonardi, L., Saran, A., Ciotti, M. T., Ferretti, E., Gulino, A., Pazzaglia, S., Tirone, F. Inhibition of medulloblastoma tumorigenesis by the antiproliferative and pro-differentiative gene PC3.	CNR, Inst Neurobiol & Mol Med, I-00143 Rome, Italy; ENEA CR Casaccia, Biotechnol Unit, Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Italian National Agency New Technical Energy & Sustainable Economics Development; Sapienza University Rome	Tirone, F (corresponding author), CNR, Inst Neurobiol & Mol Med, Via Fosso Fiorano 64, I-00143 Rome, Italy.	tirone@inmm.cnr.it	Micheli, Laura/AAY-1641-2020; vecchioli, stefano farioli/ABE-2288-2020; Tirone, Felice/P-6745-2014; Ferretti, Elisabetta/G-5413-2013	MICHELI, LAURA/0000-0001-8647-7261; Ferretti, Elisabetta/0000-0001-7265-6429; Saran, Anna/0000-0002-5587-064X; farioli vecchioli, stefano/0000-0001-7059-7779; Tirone, Felice/0000-0002-0980-4377	Telethon [GGP04168] Funding Source: Medline	Telethon(Fondazione Telethon)		Alder J, 1996, NEURON, V17, P389, DOI 10.1016/S0896-6273(00)80172-5; BenArie N, 1997, NATURE, V390, P169, DOI 10.1038/36579; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; Canzoniere D, 2004, J NEUROSCI, V24, P3355, DOI 10.1523/JNEUROSCI.3860-03.2004; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Farah MH, 2000, DEVELOPMENT, V127, P693; Ficazzola MA, 2001, CARCINOGENESIS, V22, P1271, DOI 10.1093/carcin/22.8.1271; FUJITA S, 1966, J COMP NEUROL, V128, P191, DOI 10.1002/cne.901280206; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gazit R, 2004, DEVELOPMENT, V131, P903, DOI 10.1242/dev.00982; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gotz M, 2005, NAT REV MOL CELL BIO, V6, P777, DOI 10.1038/nrm1739; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Iacopetti P, 1999, P NATL ACAD SCI USA, V96, P4639, DOI 10.1073/pnas.96.8.4639; IACOPETTI P, 1994, MECH DEVELOP, V47, P127, DOI 10.1016/0925-4773(94)90085-X; Kawakubo H, 2004, ONCOGENE, V23, P8310, DOI 10.1038/sj.onc.1208008; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Kim JYH, 2003, DEV BIOL, V263, P50, DOI 10.1016/S0012-1606(03)00434-2; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Lee Y, 2003, CANCER RES, V63, P5428; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MARES V, 1970, BRAIN RES, V23, P323, DOI 10.1016/0006-8993(70)90060-0; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X; Micheli L, 2005, MOL CELL BIOL, V25, P2242, DOI 10.1128/MCB.25.6.2242-2259.2005; Miyata T, 1999, GENE DEV, V13, P1647, DOI 10.1101/gad.13.13.1647; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Park S, 2004, MOL CELL BIOL, V24, P10256, DOI 10.1128/MCB.24.23.10256-10262.2004; Passeri D, 2006, MOL CELL BIOL, V26, P5023, DOI 10.1128/MCB.01360-05; Pazzaglia S, 2006, ONCOGENE, V25, P1165, DOI 10.1038/sj.onc.1209032; Pazzaglia S, 2002, ONCOGENE, V21, P7580, DOI 10.1038/sj.onc.1205973; Pietsch T, 1997, CANCER RES, V57, P2085; Pogoriler J, 2006, DEVELOPMENT, V133, P3929, DOI 10.1242/dev.02556; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Raffel C, 1997, CANCER RES, V57, P842; Struckmann K, 2004, CANCER RES, V64, P1632, DOI 10.1158/0008-5472.CAN-03-1687; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wetmore C, 2000, CANCER RES, V60, P2239; Weyer A, 2003, J NEUROSCI RES, V73, P400, DOI 10.1002/jnr.10655; Wolter M, 1997, CANCER RES, V57, P2581; Zhao Q, 2002, P NATL ACAD SCI USA, V99, P5704, DOI 10.1073/pnas.082092399	52	56	60	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					2215	2225		10.1096/fj.06-7548com	http://dx.doi.org/10.1096/fj.06-7548com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17371797				2022-12-28	WOS:000247500300030
J	Poulaki, V; Iliaki, E; Mitsiades, N; Mitsiades, CS; Paulus, YN; Bula, DV; Gragoudas, ES; Miller, JW				Poulaki, Vassiliki; Iliaki, Eirini; Mitsiades, Nicholas; Mitsiades, Constantine S.; Paulus, Yiannis N.; Bula, Deisy V.; Gragoudas, Evangelos S.; Miller, Joan W.			Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis	FASEB JOURNAL			English	Article						lipopolysaccharide; EIU; inflammatory eye disease	TUMOR-NECROSIS-FACTOR; ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; ALPHA MESSENGER-RNA; HEAT-SHOCK PROTEINS; NF-KAPPA-B; DIABETIC-RETINOPATHY; GENE-EXPRESSION; IN-VIVO	Heat shock protein (Hsp) 90 inhibitors, such as 17-allylamino-17-demethoxy-geldanamycin (17AAG), constitute promising novel therapeutic agents. We investigated the anti-inflammatory activity of 17AAG in endotoxin-induced uveitis (EIU) in rats. After the induction of EIU with a footpad injection of lipopolysaccharide (LPS), female Lewis rats received a single intraperitoneal. (i.p.) injection of 17-AAG or vehicle. Twenty-four hours later, the retinas were extracted and assayed for leukocyte adhesion; blood-retinal barrier breakdown; VEGF, TNF-alpha, IL-1 beta, and CD14 protein levels; NF-kappa B and HIF-1 alpha activity; hsp90 and 70 levels and expression and phosphorylation of the tight junction proteins ZO-1 and occludin. 17-AAG treatment significantly suppressed the LPS-induced increase in retinal leukocyte adhesion; vascular leakage; NF-kappa B, HIF-1 alpha, p38, and PI-3K activity; and VEGF, TNF-alpha, and IL-1 beta levels. 17-AAG also suppressed phosphorylation of ZO-1 and occludin by inhibiting their association with p38 and PI-3K. Although 17-AAG treatment did not reduce the LPS-induced increase in total CD14 levels in leukocytes, it significantly decreased membrane CD14 levels. These data suggest that Hsp90 inhibition suppresses several cardinal manifestations of endotoxin-induced uveitis in the rat. 17-AAG has demonstrated a favorable safety profile in clinical trials in cancer patients and represents a promising therapeutic agent for the treatment of inflammatory eye diseases.	Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol,Angiogenesis Laser Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Miller, JW (corresponding author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol,Angiogenesis Laser Lab, 243 Charles St, Boston, MA 02114 USA.	jwmiller@meei.harvard.edu		Paulus, Yannis/0000-0002-0615-628X; Miller, Joan/0000-0003-2046-3996				Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; Bijlmakers MJJE, 2000, MOL BIOL CELL, V11, P1585, DOI 10.1091/mbc.11.5.1585; Brito BE, 1999, INVEST OPHTH VIS SCI, V40, P2583; Bucci M, 2000, BRIT J PHARMACOL, V131, P13, DOI 10.1038/sj.bjp.0703549; Chavany C, 1996, J BIOL CHEM, V271, P4974; Citri A, 2002, EMBO J, V21, P2407, DOI 10.1093/emboj/21.10.2407; Conde AG, 1997, J MOL CELL CARDIOL, V29, P1927, DOI 10.1006/jmcc.1997.0431; COUSINS SW, 1984, EXP EYE RES, V39, P665, DOI 10.1016/0014-4835(84)90065-4; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Guo F, 2005, CANCER RES, V65, P10536, DOI 10.1158/0008-5472.CAN-05-1799; HOEKZEMA R, 1991, INVEST OPHTH VIS SCI, V32, P88; Hollander AP, 2001, ARTHRITIS RHEUM-US, V44, P1540, DOI 10.1002/1529-0131(200107)44:7<1540::AID-ART277>3.0.CO;2-7; Joly GA, 1997, FEBS LETT, V403, P40, DOI 10.1016/S0014-5793(97)00004-5; Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje; Joussen AM, 2002, FASEB J, V16, P76, DOI 10.1096/fj.02-0157fje; Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje; Kaarniranta K, 2005, MOL BRAIN RES, V137, P126, DOI 10.1016/j.molbrainres.2005.02.027; KONARI K, 1995, EXP EYE RES, V61, P99, DOI 10.1016/S0014-4835(95)80063-8; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lawson B, 1998, J CELL PHYSIOL, V174, P170, DOI 10.1002/(SICI)1097-4652(199802)174:2<170::AID-JCP4>3.3.CO;2-A; Lu AG, 2002, J NEUROCHEM, V81, P355, DOI 10.1046/j.1471-4159.2002.00835.x; LYNN WA, 1993, INFECT IMMUN, V61, P4452, DOI 10.1128/IAI.61.10.4452-4461.1993; Malhotra V, 2001, AM J RESP CELL MOL, V25, P92, DOI 10.1165/ajrcmb.25.1.4384; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Mitsiades CS, 2006, BLOOD, V107, P1092, DOI 10.1182/blood-2005-03-1158; Mitsiades N, 1999, J NATL CANCER I, V91, P1678, DOI 10.1093/jnci/91.19.1678; Mo JS, 1998, EXP EYE RES, V66, P547, DOI 10.1006/exer.1997.0451; Neckers Len, 2002, Expert Opin Emerg Drugs, V7, P277, DOI 10.1517/14728214.7.2.277; NUSSENBLATT RB, 1990, INT OPHTHALMOL, V14, P303, DOI 10.1007/BF00163549; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Poulaki V, 2004, AM J PATHOL, V165, P457, DOI 10.1016/S0002-9440(10)63311-1; Poulaki V, 2002, J CLIN INVEST, V109, P805, DOI 10.1172/JCI200213776; Rao JN, 2000, AM J PHYSIOL-CELL PH, V279, pC1034, DOI 10.1152/ajpcell.2000.279.4.C1034; Rao R, 1999, BIOCHEM PHARMACOL, V57, P685, DOI 10.1016/S0006-2952(98)00333-5; ROSENBAUM JT, 1980, NATURE, V286, P611, DOI 10.1038/286611a0; Russ PK, 1998, INVEST OPHTH VIS SCI, V39, P2479; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; SCHLETTER J, 1995, INFECT IMMUN, V63, P2576, DOI 10.1128/IAI.63.7.2576-2580.1995; Spek CA, 2003, J CLIN IMMUNOL, V23, P132, DOI 10.1023/A:1022528912387; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Traweger A, 2002, J BIOL CHEM, V277, P10201, DOI 10.1074/jbc.M111384200; Triantafilou M, 2002, J CELL SCI, V115, P2603; Tsukamoto T, 1999, J BIOL CHEM, V274, P24579, DOI 10.1074/jbc.274.35.24579; Vega VL, 2003, MOL BIOL CELL, V14, P764, DOI 10.1091/mbc.E02-08-0498; Verbon A, 2001, J IMMUNOL, V166, P3599, DOI 10.4049/jimmunol.166.5.3599; Wax S, 2003, ARTHRITIS RHEUM, V48, P541, DOI 10.1002/art.10780; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Winklhofer KF, 2001, J BIOL CHEM, V276, P45160, DOI 10.1074/jbc.M104873200; Wong HR, 1999, CELL STRESS CHAPERON, V4, P1; Workman P, 2003, CURR CANCER DRUG TAR, V3, P297, DOI 10.2174/1568009033481868; WRIGHT SD, 1991, CURR OPIN IMMUNOL, V3, P83, DOI 10.1016/0952-7915(91)90082-C; Xiao NQ, 1999, J NEUROCHEM, V72, P95, DOI 10.1046/j.1471-4159.1999.0720095.x; Xiong M, 1998, AM J PATHOL, V153, P587, DOI 10.1016/S0002-9440(10)65601-5	56	70	73	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2113	2123		10.1096/fj.06-7637com	http://dx.doi.org/10.1096/fj.06-7637com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17400913				2022-12-28	WOS:000247500300021
J	Rosenbaum, JT; Martin, TM; Farris, KH; Rosenbaum, RB; Neuwelt, EA				Rosenbaum, James T.; Martin, Tammy M.; Farris, Kendra H.; Rosenbaum, Richard B.; Neuwelt, Edward A.			Can medical schools teach high school students to be scientists?	FASEB JOURNAL			English	Article						education; secondary school; science; scientific inquiry		The preeminence of science in the United States is endangered for multiple reasons, including mediocre achievement in science education by secondary school students. A group of scientists at Oregon Health and Science University has established a class to teach the process of scientific inquiry to local high school students. Prominent aspects of the class include pairing of the student with a mentor; use of a journal club format; preparation of a referenced, hypothesis driven research proposal; and a "hands-on" laboratory experience. A survey of our graduates found that 73% were planning careers in health or science. In comparison to conventional science classes, including chemistry, biology, and algebra, our students were 7 times more likely to rank the scientific inquiry class as influencing career or life choices. Medical schools should make research opportunities widely available to teenagers because this experience dramatically affects one's attitude toward science and the likelihood that a student will pursue a career in science or medicine. A federal initiative could facilitate student opportunities to pursue research.	Oregon Hlth & Sci Univ, Portland, OR 97239 USA; Portland VA Med Ctr, Portland, OR USA	Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center	Rosenbaum, JT (corresponding author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd L467Ad, Portland, OR 97239 USA.	rosenbaj@ohsu.edu						Committee on Prospering in the Global Economy of the 21stCentury: An Agenda for American Science and Technology, 2006, RIS GATH STORM EN EM; *ENG COMM MAX POT, 2007, BIAS BARR FULF POT W; Olefsky JM, 2007, J CLIN INVEST, V117, P270, DOI 10.1172/JCI31318; Stephan PE, 2001, POPUL RES POLICY REV, V20, P59, DOI 10.1023/A:1010682017950	4	8	8	2	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					1954	1957		10.1096/fj.06-7845lsf	http://dx.doi.org/10.1096/fj.06-7845lsf			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17351126				2022-12-28	WOS:000247500300005
J	Mrosek, M; Labeit, D; Witt, S; Heerklotz, H; von Castelmur, E; Labeit, S; Mayans, O				Mrosek, Michael; Labeit, Dietmar; Witt, Stephanie; Heerklotz, Heiko; von Castelmur, Eleonore; Labeit, Siegfried; Mayans, Olga			Molecular determinants for the recruitment of the ubiquitin-ligase MuRF-1 onto M-line titin	FASEB JOURNAL			English	Article						elastic filament titin; muscle atrophy; X-ray crystallography; binding studies	KINASE DOMAIN; PROTEIN TITIN; IG TANDEMS; MUSCLE; IDENTIFICATION; ACTIVATION; INTERACTS; DYNAMICS; SYSTEM; MODEL	Titin forms an intrasarcomeric filament system in vertebrate striated muscle, which has elastic and signaling properties and is thereby central to mechanotransduction. Near its C-terminus and directly preceding a kinase domain, titin contains a conserved pattern of Ig and FnIII modules ( Ig(A168)- Ig(A169)-FnIII(A170), hereby A168-A170) that recruits the E3 ubiquitinligase MuRF-1 to the filament. This interaction is thought to regulate myofibril turnover and the trophic state of muscle. We have elucidated the crystal structure of A168-A170, characterized MuRF-1 variants by circular dichroism ( CD) and SEC-MALS, and studied the interaction of both components by isothermal calorimetry, SPOTS blots, and pull- down assays. This has led to the identification of the molecular determinants of the binding. A168-A170 shows an extended, rigid architecture, which is characterized by a shallow surface groove that spans its full length and a distinct loop protrusion in its middle point. In MuRF-1, a C- terminal helical domain is sufficient to bind A168-A170 with high affinity. This helical region predictably docks into the surface groove of A168-A170. Furthermore, pull- down assays demonstrate that the loop protrusion in A168-A170 is a key mediator of MuRF-1 recognition. Our findings indicate that this region of titin could serve as a target to attempt therapeutic inhibition of MuRF-1-mediated muscle turnover, where binding of small molecules to its distinctive structural features could block MuRF-1 access.	Univ Basel, Biozentrum, Div Struct Biol, CH-4056 Basel, Switzerland; Univ Klinikum Mannheim, Inst Anasthesiol & Operat Intesivmed, Mannheim, Germany	University of Basel; Ruprecht Karls University Heidelberg	Mayans, O (corresponding author), Univ Basel, Biozentrum, Div Struct Biol, Klingelbergstr 70, CH-4056 Basel, Switzerland.	olga.mayans@unibas.ch	Mayans, Olga/A-3954-2008	von Castelmur, Eleonore/0000-0001-7061-4890; Mayans, Olga/0000-0001-6876-8532; Heerklotz, Heiko/0000-0003-4615-7022				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Centner T, 2001, J MOL BIOL, V306, P717, DOI 10.1006/jmbi.2001.4448; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Dai KS, 2001, J BIOL CHEM, V276, P23992, DOI 10.1074/jbc.M011208200; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Freiburg A, 1996, EUR J BIOCHEM, V235, P317, DOI 10.1111/j.1432-1033.1996.00317.x; Granzier HL, 2004, CIRC RES, V94, P284, DOI 10.1161/01.RES.0000117769.88862.F8; Grater F, 2005, BIOPHYS J, V88, P790, DOI 10.1529/biophysj.104.052423; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Lange S, 2005, SCIENCE, V308, P1599, DOI 10.1126/science.1110463; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Marino M, 2005, J MUSCLE RES CELL M, V26, P355, DOI 10.1007/s10974-005-9017-6; Marino M, 2006, STRUCTURE, V14, P1437, DOI 10.1016/j.str.2006.07.009; Mayans O, 1998, NATURE, V395, P863, DOI 10.1038/27603; McElhinny AS, 2002, J CELL BIOL, V157, P125, DOI 10.1083/jcb.200108089; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481; Strelkov SV, 2004, J MOL BIOL, V343, P1067, DOI 10.1016/j.jmb.2004.08.093; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Witt CC, 1998, J STRUCT BIOL, V122, P206, DOI 10.1006/jsbi.1998.3993; Witt SH, 2005, J MOL BIOL, V350, P713, DOI 10.1016/j.jmb.2005.05.021; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zou PJ, 2006, NATURE, V439, P229, DOI 10.1038/nature04343	33	75	75	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1383	1392		10.1096/fj.06-7644com	http://dx.doi.org/10.1096/fj.06-7644com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17215480				2022-12-28	WOS:000246117000014
J	Su, QN; Zhou, YF; Johns, RA				Su, Qingning; Zhou, Yifu; Johns, Roger A.			Bruton's tyrosine kinase (BTK) is a binding partner for hypoxia induced mitogenic factor (HIMF/FIZZ1) and mediates myeloid cell chemotaxis	FASEB JOURNAL			English	Article						resistin; LFM-A13; migration	X-LINKED AGAMMAGLOBULINEMIA; GENE FAMILY; INFLAMMATION; PLATELETS; DOMAIN	Hypoxia induced mitogenic factor (HIMF) is a member of the FIZZ/ resistin/RELM family of proteins that we have shown to have potent mitogenic, angiogenic, and vasoconstrictive effects in the lung vasculature. In the current report, we identified Bruton's tyrosine kinase (BTK) as a functional HIMF binding partner through glutathione S-transferase (GST)-HIMF pull-down studies and mass spectrometry. Using primary cultured HIMF-stimulated murine bone marrow cells, we demonstrated that HIMF causes redistribution of BTK to the leading edge of the cells. HIMF stimulation induced BTK autophosphorylation, which peaked at 2.5 min. A transwell migration assay showed that treatment with recombinant murine HIMF induced migration of primary cultured bone marrow cells that was completely blocked by the BTK inhibitor, LFM-A13. Our results demonstrate BTK as the first known functional binding partner of the HIMF/FIZZ family of proteins and that HIMF acts as a chemotatic molecule in stimulating the migration of myeloid cells through activation of the BTK pathway.	Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA	Johns Hopkins University	Johns, RA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Ross 361,720 Rutland Ave, Baltimore, MD 21205 USA.	rajohns@jhmi.edu						Abassi YA, 2003, J BIOL CHEM, V278, P35636, DOI 10.1074/jbc.M306438200; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Bertini R, 1999, J EXP MED, V189, P1783, DOI 10.1084/jem.189.11.1783; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Chumakov AM, 2004, ONCOGENE, V23, P3414, DOI 10.1038/sj.onc.1207126; Hamazaki Y, 1998, ONCOGENE, V16, P2773, DOI 10.1038/sj.onc.1201799; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; Jefferies CA, 2004, IMMUNOL LETT, V92, P15, DOI 10.1016/j.imlet.2003.11.017; Laffargue M, 1999, FEBS LETT, V443, P66, DOI 10.1016/S0014-5793(98)01680-9; Mangla A, 2004, BLOOD, V104, P1191, DOI 10.1182/blood-2004-01-0207; Scapini P, 2004, J IMMUNOL, V172, P5034, DOI 10.4049/jimmunol.172.8.5034; Teng XW, 2003, CIRC RES, V92, P1065, DOI 10.1161/01.RES.0000073999.07698.33; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wagner KF, 2004, AM J RESP CELL MOL, V31, P276, DOI 10.1165/rcmb.2003-0319OC; Xu K, 2000, J IMMUNOL, V164, P4916, DOI 10.4049/jimmunol.164.9.4916; YAMAJIKEGAN K, 2006, AM J PHYSL LUNG CELL	18	29	33	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1376	1382		10.1096/fj.06-6527com	http://dx.doi.org/10.1096/fj.06-6527com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264170				2022-12-28	WOS:000246117000013
J	Vincent, SG; Waddell, AE; Caron, MG; Walker, JKL; Fisher, JT				Vincent, Sandra G.; Waddell, Andrea E.; Caron, Marc G.; Walker, Julia K. L.; Fisher, John T.			A murine model of hyperdopaminergic state displays altered respiratory control	FASEB JOURNAL			English	Article						DAT; hypoxia; ADHD; chemoreception; respiration; circadian rhythm; body temperature	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DOPAMINE TRANSPORTER; CAROTID-BODY; VENTILATORY SENSITIVITY; AFFERENT PATHWAY; CHRONIC HYPOXIA; MESSENGER-RNA; RECEPTORS; MICE; HYPERACTIVITY	The dopamine transporter (DAT) protein plays an important role in the termination of dopamine signaling. We addressed the hypothesis that loss of DAT function would result in a distinctive cardiorespiratory phenotype due to the significant role of dopamine in the control of breathing, especially with respect to chemical control, metabolism, and thermoregulation. The DAT knockout mouse ( DAT(-/-)) displays a state of functional hyperdopaminergia characterized by marked novelty driven hyperactivity. Certain behavioral and drug responses in these mice are reminiscent of endophenotypes of individuals with attention deficit hyperactivity disorders ( ADHD). We performed experiments on conscious, unrestrained DAT(-/-) mice ( KO) and littermate DAT(+/+) wild- type ( WT) controls. Ventilation was measured by the barometric technique during normoxia, hypoxia, or hypercapnia. We measured core body temperature and CO2 production as an index of metabolism. DAT(-/-) mice displayed a significantly lower respiratory frequency than WT mice, reflecting a prolonged inspiratory time. DAT(-/-) mice exhibited a reduced ventilatory response to hypoxia characterized by an attenuation of both the respiratory frequency and tidal volume responses. Both groups showed similar metabolic responses to hypoxia. Circadian measurements of body temperature were significantly lower in DAT(-/-) mice than WT mice during inactive periods. We conclude that loss of the DAT protein in this murine model of altered dopaminergic neurotransmission results in a significant respiratory and thermal phenotype that has possible implications for understanding of conditions associated with altered dopamine regulation.	Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Paediat & Med, Kingston, ON K7L 3N6, Canada; Duke Univ, Dept Med, Durham, NC 27706 USA; Duke Univ, Dept Cell Biol, Durham, NC 27706 USA	Queens University - Canada; Queens University - Canada; Duke University; Duke University	Fisher, JT (corresponding author), Queens Univ, Dept Physiol, 4th Floor,Botterell Hall, Kingston, ON K7L 3N6, Canada.	fisherjt@post.queensu.ca	Walker, Julia/R-7585-2017; Fisher, John/E-2568-2012; Waddell, Andrea/ABA-9390-2020	Fisher, John/0000-0001-6185-5940; Waddell, Andrea/0000-0003-1155-6015				Barros RCH, 2002, J APPL PHYSIOL, V92, P975, DOI 10.1152/japplphysiol.00852.2001; BISGARD GE, 1979, RESP PHYSIOL, V37, P61, DOI 10.1016/0034-5687(79)90092-6; Bradley JDD, 2001, CLIN PSYCHOL REV, V21, P907, DOI 10.1016/S0272-7358(00)00073-8; Brown TE, 2001, ANN NY ACAD SCI, V931, P271; Chervin RD, 2002, PEDIATRICS, V109, P449, DOI 10.1542/peds.109.3.449; COX B, 1978, J PHYSIOL-LONDON, V282, P471, DOI 10.1113/jphysiol.1978.sp012476; Davids E, 2003, BRAIN RES REV, V42, P1, DOI 10.1016/S0165-0173(02)00274-6; FRAPPELL P, 1992, AM J PHYSIOL, V262, pR1040, DOI 10.1152/ajpregu.1992.262.6.R1040; Gainetdinov RR, 1999, BIOL PSYCHIAT, V46, P303, DOI 10.1016/S0006-3223(99)00122-5; Gainetdinov RR, 1999, SCIENCE, V283, P397, DOI 10.1126/science.283.5400.397; Gainetdinov RR, 2001, J AM ACAD CHILD PSY, V40, P380, DOI 10.1097/00004583-200103000-00020; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GOINY M, 1991, J APPL PHYSIOL, V70, P2395, DOI 10.1152/jappl.1991.70.6.2395; GONZALEZ C, 1994, PHYSIOL REV, V74, P829, DOI 10.1152/physrev.1994.74.4.829; HSIAO C, 1989, RESP PHYSIOL, V76, P327, DOI 10.1016/0034-5687(89)90073-X; Huey KA, 2000, RESP PHYSIOL, V123, P177, DOI 10.1016/S0034-5687(00)00175-4; Huey KA, 2000, J APPL PHYSIOL, V89, P1142, DOI 10.1152/jappl.2000.89.3.1142; Jackson DM, 2000, PULM PHARMACOL THER, V13, P39, DOI 10.1006/pupt.2000.0229; LAWRENCE AJ, 1995, BRIT J PHARMACOL, V114, P1329, DOI 10.1111/j.1476-5381.1995.tb13352.x; LIN MT, 1982, AM J PHYSIOL, V242, pR471, DOI 10.1152/ajpregu.1982.242.5.R471; Madras BK, 2005, BIOL PSYCHIAT, V57, P1397, DOI 10.1016/j.biopsych.2004.10.011; Mortola JP, 2000, J APPL PHYSIOL, V88, P365, DOI 10.1152/jappl.2000.88.2.365; NIELSEN AM, 1984, EUR J PHARMACOL, V106, P69, DOI 10.1016/0014-2999(84)90679-4; NIELSEN AM, 1983, RESP PHYSIOL, V53, P71, DOI 10.1016/0034-5687(83)90017-8; Nigg JT, 2005, BIOL PSYCHIAT, V57, P1424, DOI 10.1016/j.biopsych.2004.11.011; OLSON LG, 1982, AM REV RESPIR DIS, V126, P783; Pedersen MEF, 1999, J APPL PHYSIOL, V86, P222, DOI 10.1152/jappl.1999.86.1.222; Pliszka SR, 2005, BIOL PSYCHIAT, V57, P1385, DOI 10.1016/j.biopsych.2004.08.026; Sapru HN, 1996, ADV EXP MED BIOL, V410, P357; Serebrovskaya TV, 2000, RESPIRATION, V67, P253, DOI 10.1159/000029507; SMATRESK NJ, 1983, J APPL PHYSIOL, V54, P1567, DOI 10.1152/jappl.1983.54.6.1567; Wisor JP, 2001, J NEUROSCI, V21, P1787, DOI 10.1523/JNEUROSCI.21-05-01787.2001; ZAPATA P, 1984, NEUROSCI LETT, V51, P359, DOI 10.1016/0304-3940(84)90403-8	36	23	25	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1463	1471		10.1096/fj.06-7248com	http://dx.doi.org/10.1096/fj.06-7248com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17255472				2022-12-28	WOS:000246117000021
J	Sheerin, NS; Risley, P; Abe, K; Tang, ZY; Wong, WL; Lin, T; Sacks, SH				Sheerin, Neil S.; Risley, Paul; Abe, Katsu; Tang, Ziyong; Wong, Wilson; Lin, Tao; Sacks, Steven H.			Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury	FASEB JOURNAL			English	Article						proteinuria; renal failure; innate immunity	MEMBRANE ATTACK COMPLEX; TUBULOINTERSTITIAL DAMAGE; ADRIAMYCIN NEPHROPATHY; ALTERNATIVE PATHWAY; COMPONENT C3; C5B-9; PROGRESSION; EXPRESSION; DISEASE; RATS	Increased exposure of the tubular epithelium to filtered protein is a proposed mechanism of progressive renal failure associated with glomerular disease, but how this protein overload translates into tubular damage remains unclear. We have examined a model of adriamycin-induced proteinuria to determine the effect of locally synthesized C3, the central proinflammatory protein of the complement cascade. C3(-/-) kidney isografts placed in wild-type C3+/+ mice were protected from proteinuria-associated complement activation, tubular damage, and progressive renal failure despite the presence of abundant circulating C3. The quantity of urinary protein was unaffected by the absence of C3, and thus the influence of C3 was not explained by alteration in the filtered protein load. These results suggest that local synthesis of complement from renal epithelial cells is a critical mediator of tubular damage in proteinuria-associated renal disease. Our results concur with previous findings of increased synthesis of C3 in human tubular epithelium exposed to high concentrations of protein in vitro. Because progressive renal damage in humans associates with proteinuria regardless of cause, our findings have implications for the pathogenesis and treatment of renal failure from many common causes, immunological and nonimmunological.	[Sheerin, Neil S.; Risley, Paul; Tang, Ziyong; Wong, Wilson; Lin, Tao; Sacks, Steven H.] Kings Coll London, Guys Hosp, Dept Nephrol Transplantat, London WC2R 2LS, England; [Sheerin, Neil S.] Newcastle Univ, Sch Med, Sch Clin Med Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Abe, Katsu] Nagasaki Univ, Sch Med, Dept Internal Med 2, Div Nephrol, Nagasaki 852, Japan; [Tang, Ziyong] Peking Univ, Hosp 3, Dept Nephrol, Beijing 100871, Peoples R China	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Newcastle University - UK; Nagasaki University; Peking University	Sheerin, NS (corresponding author), Newcastle Univ, Sch Med, Sch Clin Med Sci, 4th Fl,William Leech Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	neil.sheerin@ncl.ac.uk	Risley, Paul/E-2489-2013	Sacks, Steven/0000-0001-6361-9095	Medical Research Council [G0000771, G0600892] Funding Source: Medline; MRC [G0000771, G0600892] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abe K, 2004, CLIN EXP IMMUNOL, V136, P60, DOI 10.1111/j.1365-2249.2004.02411.x; Anders HJ, 2002, J CLIN INVEST, V109, P251, DOI 10.1172/JCI14040; ANDREWS PA, 1994, TRANSPLANTATION, V58, P637, DOI 10.1097/00007890-199409150-00023; Braun MC, 2004, J IMMUNOL, V173, P4190, DOI 10.4049/jimmunol.173.6.4190; Brown KM, 2006, NEW ENGL J MED, V354, P2014, DOI 10.1056/NEJMoa052825; CAMUSSI G, 1983, ANN NY ACAD SCI, V420, P321, DOI 10.1111/j.1749-6632.1983.tb22219.x; David S, 1997, NEPHROL DIAL TRANSPL, V12, P51, DOI 10.1093/ndt/12.1.51; De Boer E, 1999, J AM SOC NEPHROL, V10, P2359; Farrar CA, 2006, FASEB J, V20, P217, DOI 10.1096/fj.05-4747com; He C, 2005, J IMMUNOL, V174, P5750, DOI 10.4049/jimmunol.174.9.5750; ICHIDA S, 1994, KIDNEY INT, V46, P89, DOI 10.1038/ki.1994.247; Montinaro V, 2000, KIDNEY INT, V57, P137, DOI 10.1046/j.1523-1755.2000.00812.x; Mosolits S, 1997, NEPHRON, V75, P179, DOI 10.1159/000189529; Nangaku M, 1999, J AM SOC NEPHROL, V10, P2323; Nangaku M, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134928; NATH KA, 1992, AM J KIDNEY DIS, V20, P1; Nomura A, 1997, AM J PATHOL, V151, P539; OGRODOWSKI JL, 1991, KIDNEY INT, V40, P1141, DOI 10.1038/ki.1991.326; Pratt JR, 2002, NAT MED, V8, P582, DOI 10.1038/nm0602-582; Rangan GK, 2004, KIDNEY INT, V66, P1838, DOI 10.1111/j.1523-1755.2004.00957.x; Remuzzi G, 1997, KIDNEY INT, V51, P2, DOI 10.1038/ki.1997.2; Ruggenenti P, 1997, LANCET, V349, P1857; SACKS SH, 1993, LANCET, V342, P1273, DOI 10.1016/0140-6736(93)92362-W; Sasaki O, 1997, AM J PATHOL, V151, P1249; Sheerin NS, 2006, J AM SOC NEPHROL, V17, P686, DOI 10.1681/ASN.2004070515; Tang S, 1999, J AM SOC NEPHROL, V10, P69; Tang S, 1999, J IMMUNOL, V162, P4336; Turnberg D, 2006, J IMMUNOL, V177, P4094, DOI 10.4049/jimmunol.177.6.4094; Wang Y, 2000, KIDNEY INT, V58, P1797, DOI 10.1046/j.1523-1755.2000.00342.x; Wang Y, 2001, KIDNEY INT, V59, P941, DOI 10.1046/j.1523-1755.2001.00577.x; Welch TR, 1996, KIDNEY INT, V50, P521, DOI 10.1038/ki.1996.344; Welch TR, 2002, CLIN EXP IMMUNOL, V130, P43, DOI 10.1046/j.1365-2249.2002.01957.x; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; Zandi-Nejad K, 2004, KIDNEY INT, V66, pS76, DOI 10.1111/j.1523-1755.2004.09220.x; Zheng ZY, 2005, P NATL ACAD SCI USA, V102, P2502, DOI 10.1073/pnas.0409786102	35	59	65	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1065	1072		10.1096/fj.07-8719com	http://dx.doi.org/10.1096/fj.07-8719com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	18039928				2022-12-28	WOS:000254581000012
J	Kibaly, C; Meyer, L; Patte-Mensah, C; Mensah-Nyagan, AG				Kibaly, Cherkaouia; Meyer, Laurence; Patte-Mensah, Christine; Mensah-Nyagan, Ayikoe G.			Biochemical and functional evidence for the control of pain mechanisms by dehydroepiandrosterone endogenously synthesized in the spinal cord	FASEB JOURNAL			English	Article						biochemistry of steroidogenic enzymes; cytochrome P450c17; HPLC; neurosteroids; real-time PCR	CENTRAL-NERVOUS-SYSTEM; SUPERFICIAL DORSAL-HORN; METHYL-D-ASPARTATE; NEUROPATHIC PAIN; ADULT-RAT; 3-BETA-HYDROXYSTEROID DEHYDROGENASE; IMMUNOCYTOCHEMICAL LOCALIZATION; STEROIDOGENIC ENZYME; BIOLOGICAL-ACTIVITY; SIGMA-RECEPTORS	We investigated the role and mechanism of action of dehydroepiandrosterone (DHEA) produced by the spinal cord (SC) in pain modulation in sciatic-neuropathic and control rats. Real-time polymerase chain reaction (PCR) after reverse transcription revealed cytochrome P450c17 (DHEA-synthesizing enzyme) gene repression in neuropathic rat SC. A combination of pulse-chase experiments, high performance liquid chromatography (HPLC), and flow-scintillation detection showed decreased DHEA biosynthesis from pregnenolone in neuropathic SC slices. Radioimmunoassays demonstrated endogenous DHEA level drop in neuropathic SC. Behavioral analysis showed a rapid pronociceptive and a delayed antinociceptive action of acute DHEA treatment. Inhibition of DHEA biosynthesis in the SC by intrathecally administered ketoconazole (P450c17 inhibitor) induced analgesia in neuropathic rats. BD1047 (sigma-1 receptor antagonist) blocked the transient pronociceptive effect evoked by acute DHEA administration. Chronic DHEA treatment increased and maintained elevated the basal nociceptive thresholds in neuropathic and control rats, suggesting that androgenic metabolites generated from daily administered DHEA exerted analgesic effects while DHEA itself (before being metabolized) induced a rapid pronociceptive action. Indeed, intrathecal administration of testosterone, an androgen deriving from DHEA, caused analgesia in neuropathic rats. Together, these molecular, biochemical, and functional results demonstrate that DHEA synthesized in the SC controls pain mechanisms. Possibilities are opened for pain modulation by drugs regulating P450c17 in nerve cells.-Kibaly, C., Meyer, L., Patte-Mensah, C., Mensah-Nyagan, A. G. Biochemical and functional evidence for the control of pain mechanisms by dehydroepiandrosterone endogenously synthesized in the spinal cord.	[Kibaly, Cherkaouia; Meyer, Laurence; Patte-Mensah, Christine; Mensah-Nyagan, Ayikoe G.] Univ Strasbourg, Inst Neurosci Cellulaires & Integrat, LC2,Ctr Natl Rech Sci,Dept Nocept & Douleur, Unite Mixte Rech 7168,Equipe Steroides & Syst Noc, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Mensah-Nyagan, AG (corresponding author), Univ Strasbourg, Inst Neurosci Cellulaires & Integrat, LC2,Ctr Natl Rech Sci,Dept Nocept & Douleur, Unite Mixte Rech 7168,Equipe Steroides & Syst Noc, 21 Rue Rene Descartes, F-67084 Strasbourg, France.	gmensah@neurochem.u-strasbg.fr	Mensah-Nyagan, Ayikoe G/D-5951-2011; Meyer, Laurence/D-5967-2011; Patte-Mensah, Christine/D-5961-2011	Mensah-Nyagan, Ayikoe G/0000-0003-4454-511X; Meyer, Laurence/0000-0002-6113-936X; Patte-Mensah, Christine/0000-0002-9970-8214				Aicher SA, 1997, BRAIN RES, V772, P71, DOI 10.1016/S0006-8993(97)00637-9; Aloisi AM, 2006, HORM BEHAV, V50, P1, DOI 10.1016/j.yhbeh.2005.12.002; Alonso G, 2000, NEUROSCIENCE, V97, P155, DOI 10.1016/S0306-4522(00)00014-2; ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; AYUB M, 1987, J STEROID BIOCHEM, V28, P521, DOI 10.1016/0022-4731(87)90511-5; Baulieu EE, 2000, P NATL ACAD SCI USA, V97, P4279, DOI 10.1073/pnas.97.8.4279; BAULIEU EE, 1999, CONTEMPORARY ENDOCRI, V16; BELLINO FL, 1995, DEHYDROEPIANDROSTERO, V774; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Bergeron R, 1996, J NEUROSCI, V16, P1193; Collo G, 1996, J NEUROSCI, V16, P2495; CORPECHOT C, 1981, P NATL ACAD SCI-BIOL, V78, P4704, DOI 10.1073/pnas.78.8.4704; De Roo M, 2003, J PHYSIOL-LONDON, V552, P59, DOI 10.1113/jphysiol.2003.046078; Edinger KL, 2005, PSYCHONEUROENDOCRINO, V30, P418, DOI 10.1016/j.psyneuen.2004.11.001; Gambhir Mridula, 2002, Indian Journal of Physiology and Pharmacology, V46, P202; Goodchild CS, 2001, BRIT J ANAESTH, V86, P528, DOI 10.1093/bja/86.4.528; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Kibaly C, 2005, J NEUROCHEM, V93, P1220, DOI 10.1111/j.1471-4159.2005.03113.x; Kingery WS, 1997, PAIN, V73, P123, DOI 10.1016/S0304-3959(97)00049-3; Koltzenburg M, 1998, CURR OPIN NEUROL, V11, P515, DOI 10.1097/00019052-199810000-00014; LACROIX C, 1987, J STEROID BIOCHEM, V28, P317, DOI 10.1016/0022-4731(87)91025-9; Lu CR, 2005, J COMP NEUROL, V486, P169, DOI 10.1002/cne.20525; MATHUR C, 1993, P NATL ACAD SCI USA, V90, P85, DOI 10.1073/pnas.90.1.85; MATSUMOTO RR, 1995, EUR J PHARMACOL, V280, P301, DOI 10.1016/0014-2999(95)00208-3; Maurice T, 2006, PHARMACOL BIOCHEM BE, V84, P581, DOI 10.1016/j.pbb.2006.07.009; Mensah-Nyagan AG, 1999, PHARMACOL REV, V51, P63; MENSAHNYAGAN AG, 1994, J NEUROSCI, V14, P7306; MensahNyagan AG, 1996, P NATL ACAD SCI USA, V93, P1423, DOI 10.1073/pnas.93.4.1423; MESTRE C, 1994, J PHARMACOL TOX MET, V32, P197, DOI 10.1016/1056-8719(94)90087-6; Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3; Monnet FP, 2003, J PHARMACOL EXP THER, V307, P705, DOI 10.1124/jpet.103.053447; Morales AJ, 1998, CLIN ENDOCRINOL, V49, P421, DOI 10.1046/j.1365-2265.1998.00507.x; Patte-Mensah C, 2006, J MOL NEUROSCI, V28, P17, DOI 10.1385/JMN:28:1:17; Patte-Mensah C, 2005, P NATL ACAD SCI USA, V102, P9044, DOI 10.1073/pnas.0502968102; Patte-Mensah C, 2004, J COMP NEUROL, V477, P286, DOI 10.1002/cne.20251; Patte-Mensah C, 2004, CELL MOL LIFE SCI, V61, P2274, DOI 10.1007/s00018-004-4235-4; Patte-Mensah C, 2003, J NEUROCHEM, V86, P1233, DOI 10.1046/j.1471-4159.2003.01935.x; PETRALIA RS, 1994, J NEUROSCI, V14, P667; RAIGORODSKY G, 1990, EUR J PHARMACOL, V182, P37, DOI 10.1016/0014-2999(90)90491-N; Sakaue M, 2002, J VET MED SCI, V64, P107, DOI 10.1292/jvms.64.107; Saredi S, 2005, NEUROSCIENCE, V135, P869, DOI 10.1016/j.neuroscience.2005.06.033; Shirayama Y, 2002, SCHIZOPHR RES, V58, P69, DOI 10.1016/S0920-9964(01)00367-X; Strous Rael D, 2005, Essent Psychopharmacol, V6, P141; SU TP, 1988, SCIENCE, V240, P219, DOI 10.1126/science.2832949; TRACHTENBERG J, 1988, CLIN INVEST MED, V11, P1; VANWEERDEN WM, 1992, LIFE SCI, V50, P857, DOI 10.1016/0024-3205(92)90204-3; Woolf CJ, 2004, ANN INTERN MED, V140, P441, DOI 10.7326/0003-4819-140-8-200404200-00010; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	49	65	67	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					93	104		10.1096/fj.07-8930com	http://dx.doi.org/10.1096/fj.07-8930com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17720801				2022-12-28	WOS:000252309900013
J	Pecqueur, C; Bui, T; Gelly, C; Hauchard, J; Barbot, C; Bouillaud, F; Ricquier, D; Miroux, B; Thompson, CB				Pecqueur, Claire; Bui, Thi; Gelly, Chantal; Hauchard, Julie; Barbot, Celine; Bouillaud, Frederic; Ricquier, Daniel; Miroux, Bruno; Thompson, Craig B.			Uncoupling protein-2 controls proliferation by promoting fatty acid oxidation and limiting glycolysis-derived pyruvate utilization	FASEB JOURNAL			English	Article						carrier; mitochondria; metabolism	BETA-CELL DYSFUNCTION; KAPPA-B ACTIVATION; HYDROGEN-PEROXIDE; INSULIN-SECRETION; EXPRESSION; SUPEROXIDE; MITOCHONDRIA; MICE; APOPTOSIS; STRESS	Uncoupling protein-2 (UCP2) belongs to the mitochondrial carrier family and has been thought to be involved in suppressing mitochondrial ROS production through uncoupling mitochondrial respiration from ATP synthesis. However, we show here that loss of function of UCP2 does not result in a significant increase in ROS production or an increased propensity for cells to undergo senescence in culture. Instead, Ucp2-/- cells display enhanced proliferation associated with a metabolic switch from fatty acid oxidation to glucose metabolism. This metabolic switch requires the unrestricted availability of glucose, and Ucp2-/- cells more readily activate autophagy than wild- type cells when deprived of glucose. Altogether, these results suggest that UCP2 promotes mitochondrial fatty acid oxidation while limiting mitochondrial catabolism of pyruvate. The persistence of fatty acid catabolism in Ucp2-/- cells during a proliferative response correlates with reduced cell proliferation and enhances resistance to glucose starvation-induced autophagy. Pecqueur, C., Bui, T., Gelly, C., Hauchard, J., Barbot, C., Bouillaud, F., Ricquier, D., Miroux, B., Thompson, C. B. Uncoupling protein-2 controls proliferation by promoting fatty acid oxidation and limiting glycolysis-derived pyruvate utilization.	[Pecqueur, Claire; Gelly, Chantal; Hauchard, Julie; Barbot, Celine; Bouillaud, Frederic; Ricquier, Daniel; Miroux, Bruno] Univ Paris 05, CNRS, UPR9078, Fac Med Necker, F-75730 Paris 15, France; [Pecqueur, Claire; Bui, Thi] Biomed Res, Philadelphia, PA USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Pecqueur, C (corresponding author), Univ Paris 05, CNRS, UPR9078, Fac Med Necker, 156 Rue Vaugrard, F-75730 Paris 15, France.	pecqueuc@necker.fr	Miroux, Bruno/E-9267-2017; Pecqueur, Claire/L-3073-2015; Bouillaud, Frédéric R/L-3238-2017	Pecqueur, Claire/0000-0002-7612-1672; Bouillaud, Frédéric R/0000-0002-7518-9237; Miroux, Bruno/0000-0002-3066-4700				Alves-Guerra MC, 2003, J BIOL CHEM, V278, P42307, DOI 10.1074/jbc.M306951200; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Asanuma K, 2003, FASEB J, V17, P1165, DOI 10.1096/fj.02-0580fje; Aubert J, 1997, BIOCHEM BIOPH RES CO, V238, P606, DOI 10.1006/bbrc.1997.7348; Bai Y, 2005, J BIOL CHEM, V280, P19062, DOI 10.1074/jbc.M500566200; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Blanc J, 2003, CIRCULATION, V107, P388, DOI 10.1161/01.CIR.0000051722.66074.60; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; BURDON RH, 1990, FREE RADICAL RES COM, V11, P65, DOI 10.3109/10715769009109669; Burdon RH, 1996, FREE RADICAL RES, V24, P81, DOI 10.3109/10715769609088004; CASTEILLA L, 1990, P NATL ACAD SCI USA, V87, P5124, DOI 10.1073/pnas.87.13.5124; Couplan E, 2002, J BIOL CHEM, V277, P26268, DOI 10.1074/jbc.M202535200; DeBerardinis RJ, 2006, J BIOL CHEM, V281, P37372, DOI 10.1074/jbc.M608372200; Derdak Z, 2006, CARCINOGENESIS, V27, P956, DOI 10.1093/carcin/bgi335; Dulloo AG, 2001, BIOCHEM SOC T, V29, P785, DOI 10.1042/BST0290785; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Emre Y, 2007, BIOCHEM J, V402, P271, DOI 10.1042/BJ20061430; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Hurtaud C, 2007, CELL MOL LIFE SCI, V64, P1853, DOI 10.1007/s00018-007-7039-5; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kadowaki Motoni, 2006, Molecular Aspects of Medicine, V27, P426, DOI 10.1016/j.mam.2006.08.010; Krauss S, 2003, J CLIN INVEST, V112, P1831, DOI 10.1172/JCI200319774; Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Mozo J, 2006, BIOCHEM J, V393, P431, DOI 10.1042/BJ20050494; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Newell MK, 1999, ANN NY ACAD SCI, V887, P77, DOI 10.1111/j.1749-6632.1999.tb07923.x; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; Reilly JM, 2000, BIOCHEM BIOPH RES CO, V277, P541, DOI 10.1006/bbrc.2000.3705; Ryu JW, 2004, ARTERIOSCL THROM VAS, V24, P864, DOI 10.1161/01.ATV.0000125705.28058.eb; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667; Stuart JA, 2001, J BIOL CHEM, V276, P18633, DOI 10.1074/jbc.M011566200; Van der Lee KAJM, 2000, FASEB J, V14, P495, DOI 10.1096/fasebj.14.3.495; Vogler S, 2006, AM J PATHOL, V168, P1570, DOI 10.2353/ajpath.2006.051069; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	41	152	153	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2008	22	1					9	18		10.1096/fj.07-8945com	http://dx.doi.org/10.1096/fj.07-8945com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17855623				2022-12-28	WOS:000252309900004
J	Lee, SS; Gao, W; Mazzola, S; Thomas, MN; Csizmadia, E; Otterbein, LE; Bach, FH; Wang, H				Lee, Soo Sun; Gao, Wenda; Mazzola, Silvia; Thomas, Michael N.; Csizmadia, Eva; Otterbein, Leo E.; Bach, Fritz H.; Wang, Hongjun			Heme oxygenase-1, carbon monoxide, and bilirubin induce tolerance in recipients toward islet allografts by modulating T regulatory cells	FASEB JOURNAL			English	Article						islet transplantation; allograft survival	CUTTING EDGE; IN-VIVO; TRANSPLANTATION TOLERANCE; DIABETES-MELLITUS; NOD MICE; TGF-BETA; CD4(+)CD25(+); PROTECTION; IMMUNOSUPPRESSION; INFLAMMATION	Heme oxygenase-1 (HO-1) induction in, or carbon monoxide (CO), or bilirubin administration to, donors and/or recipients frequently lead to long-term survival (> 100 days) of DBA/2 islets into B6AF1 recipients. We tested here whether similar treatments show value in a stronger immunogenetic combination, i.e., BALB/c to C57BL/6, and attempted to elucidate the mechanism accounting for tolerance. Induction of HO-1, administering CO or bilirubin to the donor, the islets or the recipient, prolonged islet allograft survival to different extents. Combining all the above treatments (the "combined" protocol) led to survival for > 100 days and antigen-specific tolerance to 60% of the transplanted grafts. A high level of forkhead box P3 (Foxp3) and transforming growth factor beta (TGF-beta) expression was detected in the long-term surviving grafts. With the combined protocol, significantly more T regulatory cells (Tregs) were observed surrounding islets 7 days following transplantation. No prolongation of graft survival was observed using the combined protocol when CD4(+) CD25(+) T cells were predepleted from the recipients before transplantation. In conclusion, our combined protocol led to long-term survival and tolerance to islets in the BALB/c to C57BL/6 combination by promoting Foxp3(+) Tregs; these cells played a critical role in the induction and maintenance of tolerance in the recipient.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg, Boston, MA 02215 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA; Univ Milan, Dipartimento Patol Anim, I-20122 Milan, Italy	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Milan	Wang, H (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg, 99 Brookline Ave, Boston, MA 02215 USA.	hwang3@bidmc.harvard.edu	Wang, Hongjun/AAA-1319-2021; Mazzola, Silvia Michela/J-8137-2012	Mazzola, Silvia Michela/0000-0001-8131-4340	NHLBI NIH HHS [HL077721] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077721] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benghiat FS, 2005, TRANSPLANTATION, V79, P648, DOI 10.1097/01.TP.0000155179.61445.78; Bertuzzi F, 2006, CURR MOL MED, V6, P369, DOI 10.2174/156652406777435453; Choi BM, 2005, BIOCHEM BIOPH RES CO, V327, P1066, DOI 10.1016/j.bbrc.2004.12.106; Dai ZH, 2004, J CLIN INVEST, V113, P310, DOI 10.1172/JCI200419727; Emerich DF, 2002, EXPERT OPIN BIOL TH, V2, P793, DOI 10.1517/14712598.2.8.793; Erdmann K, 2005, AAPS J, V7, pE195, DOI 10.1208/aapsj070118; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Graca L, 2002, J IMMUNOL, V168, P5558, DOI 10.4049/jimmunol.168.11.5558; Hara M, 2001, J IMMUNOL, V166, P3789, DOI 10.4049/jimmunol.166.6.3789; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Huber S, 2004, J IMMUNOL, V173, P6526, DOI 10.4049/jimmunol.173.11.6526; Kingsley CI, 2002, J IMMUNOL, V168, P1080, DOI 10.4049/jimmunol.168.3.1080; Kohyama M, 2004, P NATL ACAD SCI USA, V101, P4192, DOI 10.1073/pnas.0400214101; Koksoy S, 2005, TRANSPLANTATION, V79, P1492, DOI 10.1097/01.TP.0000159870.01567.02; Kryczek I, 2006, J IMMUNOL, V177, P40, DOI 10.4049/jimmunol.177.1.40; Kumagai N, 2002, TRANSPLANTATION, V74, P1223, DOI 10.1097/00007890-200211150-00005; Lee K, 2004, J IMMUNOL, V172, P6539, DOI 10.4049/jimmunol.172.11.6539; Li M, 2007, CELL CYCLE, V6, P567, DOI 10.4161/cc.6.5.3917; Maerten P, 2005, J AUTOIMMUN, V25, P112, DOI 10.1016/j.jaut.2005.04.001; Molano RD, 2003, DIABETES, V52, P957, DOI 10.2337/diabetes.52.4.957; Nakao A, 2005, AM J TRANSPLANT, V5, P282, DOI 10.1111/j.1600-6143.2004.00695.x; Nanji SA, 2004, BIODRUGS, V18, P315, DOI 10.2165/00063030-200418050-00004; Pace L, 2006, J IMMUNOL, V176, P3900, DOI 10.4049/jimmunol.176.7.3900; Pileggi A, 2001, DIABETES, V50, P1983, DOI 10.2337/diabetes.50.9.1983; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; RICORDI C, 1990, ACTA DIABETOL LAT, V27, P185, DOI 10.1007/BF02581331; Ryan Edmond A, 2004, Curr Diab Rep, V4, P304, DOI 10.1007/s11892-004-0083-8; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Shevach EM, 2001, IMMUNOL REV, V182, P58, DOI 10.1034/j.1600-065X.2001.1820104.x; Tang QZ, 2004, EUR J IMMUNOL, V34, P2996, DOI 10.1002/eji.200425143; Trani J, 2003, J IMMUNOL, V170, P279, DOI 10.4049/jimmunol.170.1.279; Wang HJ, 2006, ENDOCRINOLOGY, V147, P762, DOI 10.1210/en.2005-0632; Wang HJ, 2005, DIABETES, V54, P1400, DOI 10.2337/diabetes.54.5.1400; Xia ZW, 2006, J IMMUNOL, V177, P5936, DOI 10.4049/jimmunol.177.9.5936; YAMASHITA K, 2006, FASEB J, DOI DOI 10.1096/05-4791FJE; Zelenay S, 2007, INT IMMUNOL, V19, P11, DOI 10.1093/intimm/dxl116; Zhang N, 2006, DIABETES, V55, P2429, DOI 10.2337/db06-0173	39	77	81	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3450	3457		10.1096/fj.07-8472com	http://dx.doi.org/10.1096/fj.07-8472com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17551098				2022-12-28	WOS:000250517800008
J	Silva, RLE; Shen, J; Hackett, SF; Kachi, S; Akiyama, H; Kiuchi, K; Yokoi, K; Hatara, MC; Lauer, T; Aslam, S; Gong, YY; Xiao, WH; Khu, NH; Thut, C; Campochiaro, PA				Silva, Raquel Lima e; Shen, Jikui; Hackett, Sean F.; Kachi, Shu; Akiyama, Hideo; Kiuchi, Katsuji; Yokoi, Katsutoshi; Hatara, Maria C.; Lauer, Thomas; Aslam, Sadia; Gong, Yuan Yuan; Xiao, Wei-Hong; Khu, Naw Htee; Thut, Catherine; Campochiaro, Peter A.			The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization	FASEB JOURNAL			English	Article						age-related macular degeneration; angiogenesis; chemokines; diabetic retinopathy; inflammation	ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; LYMPHOCYTE CHEMOATTRACTANT; CHEMOKINE RECEPTORS; MOLECULAR-CLONING; PROGENITOR CELLS; EXPRESSION; SDF-1; RETINOPATHY; MODEL	Hypoxia causes increased expression of several proteins that have the potential to promote neovascularization. Vascular endothelial growth factor (VEGF) is up-regulated by hypoxia in the retina and plays a central role in the development of several types of ocular neovascularization, but the effects of other hypoxia-regulated proteins are less clear. Stromal-derived factor-1 (SDF-1) and its receptor, CXCR4, have hypoxia response elements in the promoter regions of their genes and are increased in hypoxic liver and heart. In this study, we found that SDF-1 and CXCR4 are increased in hypoxic retina, with SDF-1 localized in glial cells primarily near the surface of the retina and CXCR4 localized in bone marrow-derived cells. Glial cells also expressed CXCR4, which suggested the possibility of autocrine stimulation, but influx of bone marrow-derived cells is the major source of increased levels of CXCR4. High levels of VEGF in the retina in the absence of hypoxia also increased levels of Cxcr4 and Sdf1 mRNA. CXCR4 antagonists reduced influx of bone marrow-derived cells into ischemic retina and strongly suppressed retinal neovascularization, VEGF-induced subretinal neovascularization, and choroidal neovascularization. These data suggest that SDF-1 and CXCR4 contribute to the involvement of bone marrow-derived cells and collaborate with VEGF in the development of several types of ocular neovascularization. They provide new targets for therapeutic intervention that may help to bolster and supplement effects obtained with VEGF antagonists.	Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; Merck & Co Inc, Dept Ophthalm Res, West Point, PA USA	Johns Hopkins University; Johns Hopkins University; Merck & Company	Campochiaro, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.	pcampo@jhmi.edu			NEI NIH HHS [P30EY1765, EY012609] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001765, R01EY012609] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; AMOAKU WMK, 1990, EYE, V4, P195, DOI 10.1038/eye.1990.26; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Brooks HL, 2004, ARCH OPHTHALMOL-CHIC, V122, P1801, DOI 10.1001/archopht.122.12.1801; Butler JM, 2005, J CLIN INVEST, V115, P86, DOI 10.1172/JCI200522869; Chan-Ling T, 2006, AM J PATHOL, V168, P1031, DOI 10.2353/ajpath.2006.050697; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; Jin DK, 2006, NAT MED, V12, P557, DOI 10.1038/nm1400; Jo DY, 2000, J CLIN INVEST, V105, P101, DOI 10.1172/JCI7954; KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659; Klein R, 1992, Trans Am Ophthalmol Soc, V90, P561; KLEIN R, 1995, DIABETES AM, P293; Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158; Lewis GP, 2003, INT REV CYTOL, V230, P263, DOI 10.1016/S0074-7696(03)30005-1; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405; Murdoch C, 1999, CYTOKINE, V11, P704, DOI 10.1006/cyto.1998.0465; Nambu H, 2003, INVEST OPHTH VIS SCI, V44, P3650, DOI 10.1167/iovs.02-0985; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; OBERLIN E, 1996, NATURE, P382; Ohno S, 2004, J RHEUMATOL, V31, P1362; Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2; Okamoto N, 1997, AM J PATHOL, V151, P281; Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246; Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5; Sawano A, 2001, BLOOD, V97, P785, DOI 10.1182/blood.V97.3.785; Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180; TROWBRIDGE IS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P46, DOI 10.1016/0167-4889(91)90043-W; Verbeke G, 2000, LINEAR MIXED MODELS	50	119	130	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3219	3230		10.1096/fj.06-7359com	http://dx.doi.org/10.1096/fj.06-7359com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17522382				2022-12-28	WOS:000249781600022
J	Lu, YS; Lv, YB; Ye, YH; Wang, YL; Hong, Y; Fortini, ME; Zhong, Y; Xie, ZP				Lu, Yisheng; Lv, Yubing; Ye, Yihong; Wang, Yalin; Hong, Yu; Fortini, Mark E.; Zhong, Yi; Xie, Zuoping			A role for presenilin in post-stress regulation: effects of presenilin mutations on Ca2+ currents in Drosophila	FASEB JOURNAL			English	Review						L-type Ca2+ channel; heat shock; Alzheimer's disease; synaptic function	VOLTAGE-DEPENDENT FACILITATION; SENSITIVE CALCIUM-CHANNELS; ALZHEIMERS-DISEASE; GAMMA-SECRETASE; ENDOPLASMIC-RETICULUM; MUTANT PRESENILIN-1; SYNAPTIC PLASTICITY; WILD-TYPE; A-BETA; NEUROMUSCULAR-JUNCTION	It has been shown that presenilin is involved in maintaining Ca2+ homeostasis in neurons, including regulating endoplasmic reticulum ( ER) Ca2+ storage. From studies of primary cultures and cell lines, however, its role in stress- induced responses is still controversial. In the present study we analyzed the effects of presenilin mutations on membrane currents and synaptic functions in response to stress using an in vivo preparation. We examined voltage-gated K+ and Ca2+ currents at the Drosophila larval neuromuscular junction ( NMJ) with voltage-clamp recordings. Our data showed that both currents were generally unaffected by loss-of-function or Alzheimer's disease (AD)-associated presenilin mutations under normal or stress conditions induced by heat shock ( HS) or ER stress. In larvae expressing the mutant presenilins, prolonged Ca2+ tail current, reflecting slower deactivation kinetics of Ca2+ channels, was observed 1 day after stress treatments were terminated. It was further demonstrated that the L-type Ca2+ channel was specifically affected under these conditions. Moreover, synaptic plasticity at the NMJ was reduced in larvae expressing the mutant presenilins. At the behavioral level, memory in adult flies was impaired in the presenilin mutants 1 day after HS. The results show that presenilin function is important during the poststress period and its impairment contributes to memory dysfunction observed during adaptation to normal conditions after stress. Our findings suggest a new stress- related mechanism by which presenilin may be implicated in the neuropathology of AD.	Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; Cold Spring Harbor Lab, Spring Harbor, NY 11724 USA; NIDDK, Lab Mol Biol, NIH, Bethesda, MD USA; NCI, Canc & Dev Biol Lab, Frederick, MD USA	Tsinghua University; Cold Spring Harbor Laboratory; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Xie, ZP (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China.	zhongyi@cshl.edu; zuopingx@mail.tsinghua.edu.cn	Lu, Yubing/G-2644-2011; Wang, Yalin/C-8362-2011	Lu, Yubing/0000-0002-7715-9867; Zhong, Yi/0000-0002-7927-5976; Zhong, Yi/0000-0001-7810-9899	Intramural NIH HHS Funding Source: Medline; NIA NIH HHS [R01 AG14583] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010913, Z01BC010529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014583] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akaishi T, 2004, NEUROSCI LETT, V356, P25, DOI 10.1016/j.neulet.2003.11.012; Bangalore R, 1996, AM J PHYSIOL-HEART C, V270, pH1521, DOI 10.1152/ajpheart.1996.270.5.H1521; Bhattacharya A, 1999, J NEUROBIOL, V39, P491, DOI 10.1002/(SICI)1097-4695(19990615)39:4<491::AID-NEU3>3.0.CO;2-6; Blatow M, 2003, NEURON, V38, P79, DOI 10.1016/S0896-6273(03)00196-X; Boulianne GL, 1997, NEUROREPORT, V8, P1025, DOI 10.1097/00001756-199703030-00041; BOURINET E, 1994, EMBO J, V13, P5032, DOI 10.1002/j.1460-2075.1994.tb06832.x; Brandt A, 2005, J NEUROSCI, V25, P11577, DOI 10.1523/JNEUROSCI.3411-05.2005; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cecchi C, 1999, NEUROSCI LETT, V275, P152, DOI 10.1016/S0304-3940(99)00751-X; Cens T, 1998, J BIOL CHEM, V273, P18308, DOI 10.1074/jbc.273.29.18308; Chen L, 2005, J NEUROPHYSIOL, V94, P4131, DOI 10.1152/jn.00755.2004; De Sarno P, 2001, BRAIN RES, V903, P226, DOI 10.1016/S0006-8993(01)02428-3; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 2001, NAT CELL BIOL, V3, pE221, DOI 10.1038/ncb1001-e221; Desmadryl G, 1998, EUR J NEUROSCI, V10, P545, DOI 10.1046/j.1460-9568.1998.00055.x; FORTI L, 1993, NEURON, V10, P437, DOI 10.1016/0896-6273(93)90332-L; Fossgreen A, 1998, P NATL ACAD SCI USA, V95, P13703, DOI 10.1073/pnas.95.23.13703; FU WM, 1994, NEUROSCIENCE, V58, P131, DOI 10.1016/0306-4522(94)90160-0; Gamliel A, 2003, NEUROSCIENCE, V117, P19, DOI 10.1016/S0306-4522(02)00830-8; GIELOW ML, 1995, J NEUROSCI, V15, P6085; GORCZYCA MG, 1991, J MEMBRANE BIOL, V121, P237, DOI 10.1007/BF01951557; Gruol DL, 2006, CEREBELLUM, V5, P146, DOI 10.1080/14734220600719692; Gu GG, 1997, J NEUROBIOL, V33, P265, DOI 10.1002/(SICI)1097-4695(199709)33:3<265::AID-NEU5>3.0.CO;2-#; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Hampton RY, 2000, CURR BIOL, V10, pR518, DOI 10.1016/S0960-9822(00)00583-2; Herms J, 2003, J BIOL CHEM, V278, P2484, DOI 10.1074/jbc.M206769200; Hong CS, 1997, NEUROREPORT, V8, P665, DOI 10.1097/00001756-199702100-00017; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Iwatsubo T, 2004, CURR OPIN NEUROBIOL, V14, P379, DOI 10.1016/j.conb.2004.05.010; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; Johnson BD, 1997, J NEUROSCI, V17, P1243; Jurkat-Rott K, 2004, J PHYSIOL-LONDON, V554, P609, DOI 10.1113/jphysiol.2003.052712; Kammermeier PJ, 1998, J NEUROPHYSIOL, V79, P410, DOI 10.1152/jn.1998.79.1.410; Karst H, 2002, EUR J NEUROSCI, V16, P1083, DOI 10.1046/j.1460-9568.2002.02172.x; Katayama T, 2004, J CHEM NEUROANAT, V28, P67, DOI 10.1016/j.jchemneu.2003.12.004; Katayama T, 2001, J BIOL CHEM, V276, P43446, DOI 10.1074/jbc.M104096200; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KAVALALI ET, 1994, J PHYSIOL-LONDON, V480, P475, DOI 10.1113/jphysiol.1994.sp020376; Keller JN, 1998, J NEUROSCI, V18, P4439; Keshishian H, 1996, ANNU REV NEUROSCI, V19, P545, DOI 10.1146/annurev.ne.19.030196.002553; Kimberly WT, 2003, J NEUROSCI RES, V74, P353, DOI 10.1002/jnr.10736; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Lleo A, 2004, AM J GERIAT PSYCHIAT, V12, P146, DOI 10.1176/appi.ajgp.12.2.146; Lleo A, 2002, MED CLIN-BARCELONA, V118, P698, DOI 10.1016/S0025-7753(02)72501-3; Lopera F, 1997, JAMA-J AM MED ASSOC, V277, P793, DOI 10.1001/jama.277.10.793; Lu FM, 2002, J NEUROPHYSIOL, V87, P1222, DOI 10.1152/jn.00323.2001; Lukinova NI, 1999, GENETICS, V153, P1789; MA J, 1992, BIOPHYS J, V63, P639, DOI 10.1016/S0006-3495(92)81634-X; Mattson MP, 2003, CELL CALCIUM, V34, P385, DOI 10.1016/S0143-4160(03)00128-3; Mattson MP, 2001, BIOESSAYS, V23, P733, DOI 10.1002/bies.1103; Mejia S, 2003, INT PSYCHOGERIATR, V15, P337, DOI 10.1017/S1041610203009591; MENDELOWITZ D, 1995, J NEUROPHYSIOL, V73, P872, DOI 10.1152/jn.1995.73.2.872; Moerman AM, 1999, J NEUROSCI RES, V57, P962, DOI 10.1002/(SICI)1097-4547(19990915)57:6<962::AID-JNR22>3.3.CO;2-D; Moosmang S, 2005, J NEUROSCI, V25, P9883, DOI 10.1523/JNEUROSCI.1531-05.2005; Nakajima M, 2001, J NEUROCHEM, V78, P807, DOI 10.1046/j.1471-4159.2001.00478.x; Nakayama S, 2000, J PHYSIOL-LONDON, V526, P47, DOI 10.1111/j.1469-7793.2000.00047.x; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Pamidimukkala J, 2006, BRAIN RES, V1078, P1, DOI 10.1016/j.brainres.2006.01.044; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Parri HR, 1996, J NEUROSCI, V16, P4890; PAULI D, 1992, EXPERIENTIA, V48, P623, DOI 10.1007/BF02118306; Periz G, 2004, J NEUROSCI RES, V77, P309, DOI 10.1002/jnr.20203; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Sato N, 2000, NAT CELL BIOL, V2, P863, DOI 10.1038/35046500; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Schneider I, 2001, J BIOL CHEM, V276, P11539, DOI 10.1074/jbc.M010977200; Scragg JL, 2004, FASEB J, V18, P150, DOI 10.1096/fj.04-2659fje; SCULPTOREANU A, 1995, AM J PHYSIOL-CELL PH, V269, pC725, DOI 10.1152/ajpcell.1995.269.3.C725; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Siman R, 2000, J NEUROSCI, V20, P8717; SINGH S, 1989, NEURON, V2, P1325, DOI 10.1016/0896-6273(89)90070-6; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Song WJ, 1996, J NEUROPHYSIOL, V76, P2290, DOI 10.1152/jn.1996.76.4.2290; Striessnig J, 2006, BIOCHEM SOC T, V34, P903, DOI 10.1042/BST0340903; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Tandon A, 2002, GENOME BIOL, V3; Terro F, 2002, J NEUROSCI RES, V69, P530, DOI 10.1002/jnr.10312; Thinakaran G, 2004, PHARMACOL RES, V50, P411, DOI 10.1016/j.phrs.2003.12.026; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thomson AM, 2000, TRENDS NEUROSCI, V23, P305, DOI 10.1016/S0166-2236(00)01580-0; Tu HP, 2006, CELL, V126, P981, DOI 10.1016/j.cell.2006.06.059; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; van Gemert NG, 2006, J NEUROENDOCRINOL, V18, P732, DOI 10.1111/j.1365-2826.2006.01472.x; Vornanen M, 1998, J EXP BIOL, V201, P533; Walsh DM, 2003, BIOCHEMISTRY-US, V42, P6664, DOI 10.1021/bi027375c; WU CF, 1985, J NEUROSCI, V5, P2626; Ye YH, 1999, J CELL BIOL, V146, P1351, DOI 10.1083/jcb.146.6.1351; Ye YH, 1998, MECH DEVELOP, V79, P199, DOI 10.1016/S0925-4773(98)00169-5; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2; Zhang DM, 2000, NEUROREPORT, V11, P3227, DOI 10.1097/00001756-200009280-00035; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	106	9	10	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2368	2378		10.1096/fj.06-6380com	http://dx.doi.org/10.1096/fj.06-6380com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17428965				2022-12-28	WOS:000248454400012
J	Gavins, FNE; Dalli, J; Flower, RJ; Granger, DN; Perretti, M				Gavins, Felicity N. E.; Dalli, Jesmond; Flower, Roderick J.; Granger, D. Neil; Perretti, Mauro			Activation of the annexin 1 counter-regulatory circuit affords protection in the mouse brain microcirculation	FASEB JOURNAL			English	Article						endogenous anti-inflammation; intravital microscopy	FORMYL-PEPTIDE RECEPTORS; N-FORMYLPEPTIDE RECEPTOR; LIPOXIN A(4) RECEPTOR; REPERFUSION INJURY; NITRIC-OXIDE; LIPOCORTIN 1; IN-VIVO; DISEASE; NEUTROPHIL; INFLAMMATION	The purpose of this study was to investigate the role of the homeostatic antiinflammatory axis centered on annexin 1 ( AnxA1) in cerebral microvascular dysfunction and tissue injury associated with middle cerebral artery ( MCA) occlusion and reperfusion. Intravital fluorescence microscopy was used to visualize the mouse cerebral microcirculation: AnxA1 null mice exhibited more white blood cell adhesion in cerebral venules than their wild-type counterparts, and this was accompanied by a larger cerebral infarct vol and worse neurological score. All parameters were rescued by delivery of human recombinant AnxA1. To further explore these findings using pharmacological tools, the effect of a short AnxA1 peptidomimetic was tested. When given during the reperfusion phase, peptide Ac2-26 produced similar cerebroprotection, which was associated with a marked attenuation of cell adhesion and markers of inflammation as measured in tissue homogenates. The pharmacological effects of peptide Ac2-26 occurred via receptors of the formyl-peptide receptor (FPR) family, most likely FPR-rs2, as deduced by displacement assays with transfected cells and in vivo experiments with transgenic mice and receptor antagonists. Our findings indicate that the endogenous antiinflammatory circuit centered on AnxA1 produces significant cerebral protection, and that these properties might have therapeutic potential for stroke treatment. -Gavins, F. N. E., Dalli, J., Flower, R. J., Granger, D. N., Perretti, M. Activation of the annexin 1 counter-regulatory circuit affords protection in the mouse brain microcirculation.	William Harvey Res Inst, London EC1M 6BQ, England; Louisiana State Univ, Sch Med, Shreveport, LA 71105 USA	University of London; Queen Mary University London; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Perretti, M (corresponding author), William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	m.perretti@qmul.ac.uk	Gavins, Felicity N. E./AAU-6010-2020	Gavins, Felicity N. E./0000-0001-7008-5423; Dalli, Jesmond/0000-0001-6328-3640	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026441] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26441] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Babbin BA, 2006, J BIOL CHEM, V281, P19588, DOI 10.1074/jbc.M513025200; Chatterjee BE, 2005, J LEUKOCYTE BIOL, V78, P639, DOI 10.1189/jlb.0405206; Chiang N, 2003, BRIT J PHARMACOL, V139, P89, DOI 10.1038/sj.bjp.0705220; Chiang N, 2005, PROSTAG LEUKOTR ESS, V73, P163, DOI 10.1016/j.plefa.2005.05.003; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; COMERA C, 1995, BRIT J PHARMACOL, V115, P1043, DOI 10.1111/j.1476-5381.1995.tb15916.x; D'Amico M, 2000, FASEB J, V14, P1867; Damazo AS, 2005, AM J PATHOL, V166, P1607, DOI 10.1016/S0002-9440(10)62471-6; Ernst S, 2004, J IMMUNOL, V172, P7669, DOI 10.4049/jimmunol.172.12.7669; Frijns CJM, 2002, STROKE, V33, P2115, DOI 10.1161/01.STR.0000021902.33129.69; Frizzell JP, 2005, AACN ADV CRIT CARE, V16, P421, DOI 10.1097/00044067-200510000-00002; Frizzell JP., 2005, AACN CLIN ISSUES, V16, P597; Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657; Gavins FNE, 2003, BLOOD, V101, P4140, DOI 10.1182/blood-2002-11-3411; Gavins FNE, 2004, FASEB J, V18, P100, DOI 10.1096/fj.04-2178fje; Getting SJ, 1997, BRIT J PHARMACOL, V120, P1075, DOI 10.1038/sj.bjp.0701029; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Granger DN, 1999, MICROCIRCULATION, V6, P167; Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923; Hannon R, 2002, FASEB J, V16, P253, DOI 10.1096/fj.02-0239fje; Hartt JK, 1999, J EXP MED, V190, P741, DOI 10.1084/jem.190.5.741; Hayhoe RPG, 2006, BLOOD, V107, P2123, DOI 10.1182/blood-2005-08-3099; Hughes PM, 2002, J CEREBR BLOOD F MET, V22, P308, DOI 10.1097/00004647-200203000-00008; Ishikawa M, 2005, CIRCULATION, V111, P1690, DOI 10.1161/01.CIR.0000160349.42665.0C; Ishikawa M, 2003, STROKE, V34, P1777, DOI 10.1161/01.STR.0000074921.17767.F2; Kenakin T, 2002, NAT REV DRUG DISCOV, V1, P103, DOI 10.1038/nrd722; Kieran NE, 2004, KIDNEY INT, V65, P1145, DOI 10.1111/j.1523-1755.2004.00487.x; Knott C, 2000, MOL CELL NEUROSCI, V16, P724, DOI 10.1006/mcne.2000.0914; Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5; Liu N, 2004, J NEUROSCI RES, V77, P391, DOI 10.1002/jnr.20167; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maderna P, 2005, J IMMUNOL, V174, P3727, DOI 10.4049/jimmunol.174.6.3727; Matsumoto T, 1997, J LEUKOCYTE BIOL, V62, P581, DOI 10.1002/jlb.62.5.581; Minami M, 2003, LIFE SCI, V74, P321, DOI 10.1016/j.lfs.2003.09.019; Minghetti L, 1999, BRIT J PHARMACOL, V126, P1307, DOI 10.1038/sj.bjp.0702423; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Morgan L, 2005, CURR OPIN LIPIDOL, V16, P193, DOI 10.1097/01.mol.0000162324.85290.ac; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; Perretti M, 2003, TRENDS PHARMACOL SCI, V24, P574, DOI 10.1016/j.tips.2003.09.010; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; RELTON JK, 1991, J EXP MED, V174, P305, DOI 10.1084/jem.174.2.305; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Wada K, 2006, FASEB J, V20, P1785, DOI 10.1096/fj.06-5809com; Wang ZG, 2002, GENE, V299, P57, DOI 10.1016/S0378-1119(02)01012-0; Yang YH, 1999, ARTHRITIS RHEUM, V42, P1538, DOI 10.1002/1529-0131(199907)42:7<1538::AID-ANR29>3.0.CO;2-3; Ying GG, 2004, J IMMUNOL, V172, P7078, DOI 10.4049/jimmunol.172.11.7078; Yona S, 2004, BRIT J PHARMACOL, V142, P890, DOI 10.1038/sj.bjp.0705858; YONA S, 2006, BR J PHARM; Young KA, 1999, GLIA, V26, P333, DOI 10.1002/(SICI)1098-1136(199906)26:4<333::AID-GLIA7>3.0.CO;2-S	51	99	103	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1751	1758		10.1096/fj.06-7842com	http://dx.doi.org/10.1096/fj.06-7842com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17317721				2022-12-28	WOS:000246866500017
J	Uhles, S; Moede, T; Leibiger, B; Berggren, PO; Leibiger, IB				Uhles, Sabine; Moede, Tilo; Leibiger, Barbara; Berggren, Per-Olof; Leibiger, Ingo B.			Selective gene activation by spatial segregation of insulin receptor B signaling	FASEB JOURNAL			English	Article						insulin signaling; gene expression regulation; pancreatic beta cell; endosomes; life cell imaging; c-fos gene; glucokinase gene	GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; IN-VITRO; ENDOCYTOSIS; SHC; CELLS; TRANSCRIPTION; DOMAINS; PHOSPHORYLATION; INTERNALIZATION	Insulin exerts pleiotropic effects at the cellular level. Signaling via the two isoforms of the insulin receptor (IR) may explain the activation of different signaling cascades, while it remains to be explored how selectivity is achieved when utilizing the same IR isoform. We now demonstrate that insulin-stimulated transcription of c-fos and glucokinase genes is activated simultaneously in the insulin-producing beta-cell via IR-B localized in different cellular compartments. Insulin activates the glucokinase gene from plasma membrane-standing IR-B, while c-fos gene activation is dependent on clathrin-mediated IR-B-endocytosis and signaling from early endosomes. Moreover, glucokinase gene up-regulation requires the integrity of the juxtamembrane IR-B NPEY-motif and signaling via PI3K-C2 alpha-like/ PDK1/PKB, while c-fos gene activation requires the intact C-terminal YTHM-motif and signaling via PI3K Ia/Shc/MEK1/ERK. By using IR-B as an example it is thus possible to demonstrate how spatial segregation allows simultaneous and selective signaling via the same receptor isoform in the same cell.	Karolinska Inst, Rolf Luft Res Ctr Diabet & Endocrinol, S-17176 Stockholm, Sweden	Karolinska Institutet	Leibiger, IB (corresponding author), Karolinska Inst, Rolf Luft Res Ctr Diabet & Endocrinol, S-17176 Stockholm, Sweden.	ingo.leibiger@ki.se		Moede, Tilo/0000-0002-2045-9244; Uhles, Sabine/0000-0002-2836-8726; Berggren, Per-Olof/0000-0001-8991-413X				BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; Boura-Halfon S, 2003, J BIOL CHEM, V278, P16397, DOI 10.1074/jbc.M212385200; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Denley A, 2003, HORM METAB RES, V35, P778; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HAFT CR, 1994, J BIOL CHEM, V269, P26286; Hribal ML, 2003, FASEB J, V17, P1340, DOI 10.1096/fj.02-0685fje; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Leibiger B, 1998, P NATL ACAD SCI USA, V95, P9307, DOI 10.1073/pnas.95.16.9307; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; OBRAIN RM, 1996, PHYSIOL REV, V76, P1109; Olusanya O, 2001, CURR BIOL, V11, P896, DOI 10.1016/S0960-9822(01)00240-8; Paz K, 1996, J BIOL CHEM, V271, P6998, DOI 10.1074/jbc.271.12.6998; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Sasaoka T, 2000, ENDOCR J, V47, P373, DOI 10.1507/endocrj.47.373; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Ugi S, 2002, J BIOL CHEM, V277, P18592, DOI 10.1074/jbc.M201019200; Uhles S, 2003, J CELL BIOL, V163, P1327, DOI 10.1083/jcb.200306093; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; VANSCHRAVENDIJK CFH, 1987, ENDOCRINOLOGY, V121, P1784, DOI 10.1210/endo-121-5-1784; VEGA MA, 1989, P NATL ACAD SCI USA, V86, P2688, DOI 10.1073/pnas.86.8.2688; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; VOGT B, 1991, BIOCHEM BIOPH RES CO, V177, P1013, DOI 10.1016/0006-291X(91)90639-O; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YAMAGUCHI Y, 1991, ENDOCRINOLOGY, V129, P2058, DOI 10.1210/endo-129-4-2058; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	41	32	36	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1609	1621		10.1096/fj.06-7589com	http://dx.doi.org/10.1096/fj.06-7589com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264162				2022-12-28	WOS:000246117000035
J	Roy, A; Lin, YN; Agno, JE; DeMayo, FJ; Matzuk, MM				Roy, Angshumoy; Lin, Yi-Nan; Agno, Julio E.; DeMayo, Francesco J.; Matzuk, Martin M.			Absence of tektin 4 causes asthenozoospermia and subfertility in male mice	FASEB JOURNAL			English	Article						coiled-coil; axoneme; outer dense fiber; knockout mice	OUTER DENSE FIBERS; INNER-ARM DYNEIN; FLAGELLAR MICROTUBULES; MAMMALIAN SPERMATOZOA; RODENT SPERMATOZOA; PROTEOMIC ANALYSIS; REDUCED FERTILITY; MOLECULAR-CLONING; SPERM FLAGELLUM; HUMAN-DISEASE	Sperm flagellar motion is the outcome of a dynamic interplay between the axonemal cytoskeleton, the peri-axonemal accessory structures, and multiple regulatory networks that coordinate to produce flagellar beat and waveform. Tektins are conserved components of the flagellar proteome in evolutionarily diverse species and are believed to play essential roles in the mechanics of sperm motility. Using database mining, we identified multiple new paralogs of previously annotated tektins, including tektin 4 (TEKT4), which shares 77.1% identity with its nearest human homologue. Mouse Tekt4 is a germ cell-enriched gene, most abundantly expressed in haploid round spermatids in the testis, and the protein is localized to the sperm flagella. Male mice lacking TEKT4 on a 129S5/SvEvBrd inbred background are subfertile. Tekt4-null sperm exhibit drastically reduced forward progressive velocity and uncoordinated waveform propagation along the flagellum. In Tekt4-null sperm, flagellar ultrastructure is grossly unaltered as revealed by transmission electron microscopy. However, the ineffective flagellar strokes lead to similar to 10-fold higher consumption of intracellular ATP in Tekt4-null sperm as compared to wild-type, and null spermatozoa rapidly lose progressive motility when incubated for >= 1.5 h. Our studies demonstrate that TEKT4 is necessary for the proper coordinated beating of the sperm flagellum and male reproductive physiology.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Matzuk, MM (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Pl, Houston, TX 77030 USA.	mmatzuk@bcm.tmc.edu	DeMayo, Francesco/C-6255-2019; Lin, Yi-Nan/B-4986-2009	DeMayo, Francesco/0000-0002-9480-7336; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD007495] Funding Source: NIH RePORTER; NICHD NIH HHS [U54 HD-07495] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adham IM, 2001, MOL HUM REPROD, V7, P513, DOI 10.1093/molehr/7.6.513; Afzelius BA, 2004, J PATHOL, V204, P470, DOI 10.1002/path.1652; AMOS WB, 1986, J CELL SCI, P55; BALTZ JM, 1990, BIOL REPROD, V43, P485, DOI 10.1095/biolreprod43.3.485; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; Brody SL, 2004, AM J RESP CELL MOL, V30, P435, DOI 10.1165/rcmb.2004-0004PS; BURFEIND P, 1993, EUR J BIOCHEM, V216, P497, DOI 10.1111/j.1432-1033.1993.tb18168.x; Cao WL, 2006, MOL CELL PROTEOMICS, V5, P801, DOI 10.1074/mcp.M500322-MCP200; Eddy EM, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P3; Eddy EM, 2003, MICROSC RES TECHNIQ, V61, P103, DOI 10.1002/jemt.10320; Henkel R, 2005, FERTIL STERIL, V84, P1430, DOI 10.1016/j.fertnstert.2005.05.020; Henkel R, 1999, FERTIL STERIL, V71, P1138, DOI 10.1016/S0015-0282(99)00141-7; HOYERFENDER S, 1995, CYTOGENET CELL GENET, V70, P200, DOI 10.1159/000134033; Iguchi N, 1999, FEBS LETT, V456, P315, DOI 10.1016/S0014-5793(99)00967-9; Iguchi N, 2002, MOL HUM REPROD, V8, P525, DOI 10.1093/molehr/8.6.525; Iida H, 2006, MOL REPROD DEV, V73, P342, DOI 10.1002/mrd.20419; Iida H, 2006, MOL REPROD DEV, V73, P929, DOI 10.1002/mrd.20486; Kleene KC, 2003, CYTOGENET GENOME RES, V103, P217, DOI 10.1159/000076807; Larsson M, 2000, EUR J CELL BIOL, V79, P718, DOI 10.1078/0171-9335-00097; Li JB, 2004, CELL, V117, P541, DOI 10.1016/S0092-8674(04)00450-7; Linck R.W., 1982, Progress in Clinical and Biological Research, V80, P127; LINCK RW, 1985, J CELL BIOL, V100, P126, DOI 10.1083/jcb.100.1.126; LINCK RW, 1982, J CELL SCI, V58, P1; Lindemann CB, 1996, CELL MOTIL CYTOSKEL, V34, P258, DOI 10.1002/(SICI)1097-0169(1996)34:4<258::AID-CM1>3.0.CO;2-4; Matsuyama T, 2005, MOL REPROD DEV, V72, P120, DOI 10.1002/mrd.20331; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; Miki K, 2002, DEV BIOL, V248, P331, DOI 10.1006/dbio.2002.0728; Mortimer ST, 1997, HUM REPROD UPDATE, V3, P403, DOI 10.1093/humupd/3.5.403; Nayernia K, 2002, MOL CELL BIOL, V22, P3046, DOI 10.1128/MCB.22.9.3046-3052.2002; Norrander J, 1998, J NEUROSCI, V18, P8912; OLSON GE, 1986, J ULTRA MOL STRUCT R, V94, P131, DOI 10.1016/0889-1605(86)90059-5; OLSON GE, 1990, J STRUCT BIOL, V103, P13, DOI 10.1016/1047-8477(90)90081-M; Ostrowski LE, 2002, MOL CELL PROTEOMICS, V1, P451, DOI 10.1074/mcp.M200037-MCP200; Pazour GJ, 2005, J CELL BIOL, V170, P103, DOI 10.1083/jcb.200504008; Pearse RV, 1997, P NATL ACAD SCI USA, V94, P7555, DOI 10.1073/pnas.94.14.7555; PIRNER MA, 1994, J BIOL CHEM, V269, P31800; Quill TA, 2003, P NATL ACAD SCI USA, V100, P14869, DOI 10.1073/pnas.2136654100; Roy A, 2004, MOL REPROD DEV, V67, P295, DOI 10.1002/mrd.20025; Shao XP, 1997, J BIOL CHEM, V272, P6105, DOI 10.1074/jbc.272.10.6105; Tanaka H, 2004, MOL CELL BIOL, V24, P7958, DOI 10.1128/MCB.24.18.7958-7964.2004; Yan W, 2002, MOL ENDOCRINOL, V16, P1168, DOI 10.1210/me.16.6.1168; Yanagisawa H, 2004, MOL BIOL CELL, V15, P2105, DOI 10.1091/mbc.E03-11-0854; Yu YE, 2000, P NATL ACAD SCI USA, V97, P4683, DOI 10.1073/pnas.97.9.4683	43	75	80	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1013	1025		10.1096/fj.06-7035com	http://dx.doi.org/10.1096/fj.06-7035com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17244819				2022-12-28	WOS:000245650400006
J	Choi, SH; Langenbach, R; Bosetti, F				Choi, Sang Ho; Langenbach, Robert; Bosetti, Francesca			Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury	FASEB JOURNAL			English	Article						microglia; astrocytes; prostaglandin; NADPH oxidase; oxidative stress	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN E-2 SYNTHESIS; NEURONAL OXIDATIVE DAMAGE; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; NADPH OXIDASE; HIPPOCAMPAL-NEURONS; ACTIVATED MICROGLIA; CONTROLLED-TRIAL; RAT HIPPOCAMPUS	Cyclooxygenase (COX) -1 and -2 metabolize arachidonic acid to prostanoids and reactive oxygen species, major players in the neuroinflammatory process. While most reports have focused on the inducible isoform, COX-2, the contribution of COX-1 to the inflammatory response is unclear. In the present study, the contribution of COX-1 in the neuroinflammatory response to intracerebroventricular lipopolysaccharide (LPS) was investigated using COX-1 deficient (COX-1 ) mice or wild-type (COX-1(+/+)) mice pretreated with SC-560, a selective COX-1 inhibitor. Twenty-four hours after lipopolysaccharide (LPS) injection, COX-1(-/-) mice showed decreased protein oxidation and LPS-induced neuronal damage in the hippocampus compared with COX-1(+/+) mice. COX-1(-/-) mice showed a significant reduction of microglial activation, proinflammatory mediators, and expression of COX-2, inducible NOS, and NADPH oxidase. The transcriptional down-regulation of cytokines and other inflammatory markers in COX-1(-/-) mice was mediated by a reduced activation of NF-kappa B and signal transducer and activator of transcription 3. Administration of SC-560 prior to LPS injection also attenuated the neuroinflammatory response by decreasing brain levels of prostaglandin (PG)E-2, PGD(2), PGF(2 alpha), and thromboxane B-2, as well as the expression of proinflammatory cytokines and chemokine. These findings suggest that COX-1 plays a previously unrecognized role in neuroinflammatory damage.	[Choi, Sang Ho; Bosetti, Francesca] NIA, Brain Physiol & Metab Sect, NIH, Bethesda, MD 20892 USA; [Langenbach, Robert] Natl Inst Environm Hlth Sci, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Bosetti, F (corresponding author), NIA, Brain Physiol & Metab Sect, NIH, Bethesda, MD 20892 USA.	frances@mail.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES021179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000423, ZIAAG000425] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AG000423-04] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aid S, 2007, BRAIN RES BULL, V73, P108, DOI 10.1016/j.brainresbull.2007.02.015; Aisen PS, 2003, JAMA-J AM MED ASSOC, V289, P2819, DOI 10.1001/jama.289.21.2819; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; Bate C, 2003, NEUROREPORT, V14, P2099, DOI 10.1097/00001756-200311140-00018; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bosetti F, 2007, J NEUROCHEM, V102, P577, DOI 10.1111/j.1471-4159.2007.04558.x; BREITNER JCS, 1995, NEUROBIOL AGING, V16, P523, DOI 10.1016/0197-4580(95)00049-K; Candelario-Jalil E, 2003, J NEUROCHEM, V86, P545, DOI 10.1046/j.1471-4159.2003.01812.x; Choi SH, 2006, J NEUROCHEM, V98, P801, DOI 10.1111/j.1471-4159.2006.03926.x; Choi SH, 2005, J NEUROSCI, V25, P4082, DOI 10.1523/JNEUROSCI.4306-04.2005; Delgado M, 2003, FASEB J, V17, P1922, DOI 10.1096/fj.02-1029fje; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; Herber DL, 2006, GLIA, V53, P382, DOI 10.1002/glia.20272; Hoozemans JJM, 2001, ACTA NEUROPATHOL, V101, P2, DOI 10.1007/s004010000251; Hoozemans JJM, 2003, CURR DRUG TARGETS, V4, P461, DOI 10.2174/1389450033490902; Hoozemans JJM, 2002, BRAIN RES, V951, P218, DOI 10.1016/S0006-8993(02)03164-5; Ikeda-Matsuo Y, 2005, J NEUROCHEM, V94, P1546, DOI 10.1111/j.1471-4159.2005.03302.x; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Jeohn GH, 1998, J NEUROIMMUNOL, V85, P1, DOI 10.1016/S0165-5728(97)00204-X; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; Kim HY, 2003, J IMMUNOL, V171, P6072, DOI 10.4049/jimmunol.171.11.6072; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Langenbach R, 1999, BIOCHEM PHARMACOL, V58, P1237, DOI 10.1016/S0006-2952(99)00158-6; Liberatore GT, 1999, NAT MED, V5, P1403; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; MCGEER PL, 1987, NEUROSCI LETT, V79, P195, DOI 10.1016/0304-3940(87)90696-3; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Milatovic D, 2003, J NEUROCHEM, V87, P1518, DOI 10.1046/j.1471-4159.2003.02120.x; Milatovic D, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-20; Montine TJ, 2002, J NEUROCHEM, V83, P463, DOI 10.1046/j.1471-4159.2002.01157.x; Moore AH, 2005, INT J RADIAT ONCOL, V62, P267, DOI 10.1016/j.ijrobp.2005.01.035; Nelson PT, 2002, ANN MED, V34, P491, DOI 10.1080/078538902321117698; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pepicelli O, 2005, J NEUROCHEM, V93, P1561, DOI 10.1111/j.1471-4159.2005.03150.x; Perry VH, 2003, NAT REV NEUROSCI, V4, P103, DOI 10.1038/nrn1032; Phillis JW, 2006, BRAIN RES REV, V52, P201, DOI 10.1016/j.brainresrev.2006.02.002; Planas AM, 2006, BIOCHEM SOC T, V34, P1267, DOI 10.1042/BST0341267; POWELL WS, 1985, ANAL BIOCHEM, V148, P59, DOI 10.1016/0003-2697(85)90628-1; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Reines SA, 2004, NEUROLOGY, V62, P66, DOI 10.1212/WNL.62.1.66; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; Rummel C, 2006, AM J PHYSIOL-REG I, V291, pR1316, DOI 10.1152/ajpregu.00301.2006; Scharf S, 1999, NEUROLOGY, V53, P197, DOI 10.1212/WNL.53.1.197; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schwab JM, 2000, J NEUROIMMUNOL, V111, P122, DOI 10.1016/S0165-5728(00)00372-6; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Suzumura A, 2006, ANN NY ACAD SCI, V1088, P219, DOI 10.1196/annals.1366.012; Thal LJ, 2005, NEUROPSYCHOPHARMACOL, V30, P1204, DOI 10.1038/sj.npp.1300690; Tsuboi K, 2002, PROSTAG OTH LIPID M, V68-9, P535, DOI 10.1016/S0090-6980(02)00054-0; Xia Y, 2006, BRAIN RES, V1095, P85, DOI 10.1016/j.brainres.2006.03.112; Yermakova AV, 1999, J NEUROPATH EXP NEUR, V58, P1135, DOI 10.1097/00005072-199911000-00003	54	133	136	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2008	22	5					1491	1501		10.1096/fj.07-9411com	http://dx.doi.org/10.1096/fj.07-9411com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18162486	Green Accepted			2022-12-28	WOS:000255898700021
J	Sellers, ZM; Mann, E; Smith, A; Ko, KH; Giannella, R; Cohen, MB; Barrett, KE; Dong, H				Sellers, Zachary M.; Mann, Elizabeth; Smith, Anders; Ko, Kwang Hyun; Giannella, Ralph; Cohen, Mitchell B.; Barrett, Kim E.; Dong, Hui			Heat-stable enterotoxin of Escherichia coli (STa) can stimulate duodenal HCO(3)(-) secretion via a novel GC-C- and CFTR-independent pathway	FASEB JOURNAL			English	Article						cystic fibrosis; guanylyl cyclase C knockout mice; STa-binding receptor	GUANYLYL CYCLASE-C; MUCOSAL BICARBONATE SECRETION; RAT INTESTINAL MEMBRANES; CYSTIC-FIBROSIS; AFFINITY RECEPTORS; MICE LACKING; UROGUANYLIN; BINDING; CELLS; PH	The heat-stable enterotoxin of Escherichia coli (STa) is a potent stimulant of intestinal chloride and bicarbonate secretion. Guanylyl cyclase C (GC-C) has been shown to be the primary receptor involved in mediating this response. However, numerous studies have suggested the existence of an alternative STa-binding receptor. The aims of this study were to determine whether a non-GC-C receptor exists for STa and what is the functional relevance of this for intestinal bicarbonate secretion in mice. (125)I-STa-binding experiments were performed with intestinal mucosae from GC-C knockout (KO) and wild type (WT) mice. Subsequently, the functional relevance of an alternative STa-binding receptor was explored by examining STa-, uroguanylin-, and guanylin-stimulated duodenal bicarbonate secretion (DBS) in GC-C KO mice in vitro and in vivo. Significant (125)I-STa-binding occurred in the proximal small intestines of GC-C KO and WT mice. Analysis of binding coefficients and pH dependence showed that (125)I-STa-binding in GC-C KO mice involved a receptor distinct from that of WT mice. Functionally, STa, uroguanylin, and guanylin all stimulated a significant increase in DBS in GC-C KO mice. Uroguanylin-and guanylin-stimulated DBS were significantly inhibited by glibenclamide, but not by 4,4'-diisothiocyanato-stilbene-2,2'-disulfonic acid (DIDS). However, STa-stimulated DBS was unaffected by glibenclamide but inhibited by DIDS. Taken together, our results suggest that alternative, non-GC-C, receptors likely exist for STa, uroguanylin, and guanylin in the intestines of mice. While uroguanylin- and guanylin-stimulated DBS are cystic fibrosis transmembrane conductance regulator (CFTR) dependent, STa-stimulated DBS is CFTR independent. Further understanding of this alternative receptor and its signaling pathway may provide important insights into rectification of intestinal bicarbonate secretion in cystic fibrosis.	[Sellers, Zachary M.; Smith, Anders; Ko, Kwang Hyun; Barrett, Kim E.; Dong, Hui] Univ Calif San Diego, Dept Med, Div Gastroenterol, La Jolla, CA 92093 USA; [Mann, Elizabeth; Giannella, Ralph; Cohen, Mitchell B.] Univ Cincinnati, Div Digest Dis, Cincinnati, OH USA; [Mann, Elizabeth; Cohen, Mitchell B.] Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol Hepatol & Nutr, Cincinnati, OH USA	University of California System; University of California San Diego; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center	Dong, H (corresponding author), Univ Calif San Diego, Dept Med, Div Gastroenterol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	h2dong@ucsd.edu	Barrett, Kim/AAE-2794-2022; Sellers, Zachary/AAI-1356-2020; Barrett, Kim Elaine/AAE-7762-2019	Sellers, Zachary/0000-0001-5352-7760; Barrett, Kim Elaine/0000-0002-6704-998X; Cohen, Mitchell/0000-0002-4412-350X	NIDDK NIH HHS [R01-DK-33491, R01-DK-47318] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047318, R01DK033491] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barmeyer C, 2007, PFLUG ARCH EUR J PHY, V454, P441, DOI 10.1007/s00424-007-0213-7; Barraclough M, 1996, J PEDIATR GASTR NUTR, V23, P45, DOI 10.1097/00005176-199607000-00009; Carrithers SL, 2004, KIDNEY INT, V65, P40, DOI 10.1111/j.1523-1755.2004.00375.x; Clarke LL, 1996, LAB ANIM SCI, V46, P612; COHEN M, 1998, GASTROENTEROLOGY, V94, P367; COHEN MB, 1986, PEDIATR RES, V20, P555, DOI 10.1203/00006450-198606000-00017; COHEN MB, 2002, INFECT GASTROINTESTI, P579; CRANE MR, 1992, MOL PHARMACOL, V41, P1073; DAHLQVIST A, 1968, ANAL BIOCHEM, V22, P99, DOI 10.1016/0003-2697(68)90263-7; DESAUVAGE FJ, 1992, J BIOL CHEM, V267, P6479; DESHMANE SP, 1995, BIOCHEMISTRY-US, V34, P9095, DOI 10.1021/bi00028a019; Deshmane SP, 1997, BIOCHEMISTRY-US, V36, P12921, DOI 10.1021/bi971077b; EGGERMONT E, 1991, EUR J PEDIATR, V150, P824, DOI 10.1007/BF01954999; Freel RW, 2006, AM J PHYSIOL-GASTR L, V290, pG719, DOI 10.1152/ajpgi.00481.2005; Giblin MF, 2006, BREAST CANCER RES TR, V98, P7, DOI 10.1007/s10549-005-9040-8; Gilljam M, 2003, CHEST, V123, P37, DOI 10.1378/chest.123.1.37; GUARINO A, 1987, DIGEST DIS SCI, V32, P1017, DOI 10.1007/BF01297193; HAKKI S, 1993, BIOCHIM BIOPHYS ACTA, V1152, P1, DOI 10.1016/0005-2736(93)90224-N; Hasegawa M, 2005, J PEPT RES, V65, P261, DOI 10.1111/j.1399-3011.2005.00218.x; Hirokawa M, 2004, AM J PHYSIOL-GASTR L, V286, pG891, DOI 10.1152/ajpgi.00458.2003; Hogan DL, 1997, AM J PHYSIOL-GASTR L, V272, pG872, DOI 10.1152/ajpgi.1997.272.4.G872; HUGUES M, 1991, BIOCHEMISTRY-US, V30, P10738, DOI 10.1021/bi00108a019; IVENS K, 1990, INFECT IMMUN, V58, P1817, DOI 10.1128/IAI.58.6.1817-1820.1990; Kaur S, 2004, AM J PHYSIOL-GASTR L, V287, pG480, DOI 10.1152/ajpgi.00035.2004; London RM, 1999, AM J PHYSIOL-RENAL, V276, pF882, DOI 10.1152/ajprenal.1999.276.6.F882; London RM, 1997, AM J PHYSIOL-GASTR L, V273, pG93, DOI 10.1152/ajpgi.1997.273.1.G93; MANN EA, 1993, AM J PHYSIOL, V264, pG172, DOI 10.1152/ajpgi.1993.264.1.G172; Mann EA, 1997, BIOCHEM BIOPH RES CO, V239, P463, DOI 10.1006/bbrc.1997.7487; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nandi A, 1997, J CELL BIOCHEM, V66, P500, DOI 10.1002/(SICI)1097-4644(19970915)66:4<500::AID-JCB9>3.0.CO;2-P; Pratha VS, 2000, GASTROENTEROLOGY, V118, P1051, DOI 10.1016/S0016-5085(00)70358-1; Rao SP, 2004, AM J PHYSIOL-GASTR L, V286, pG95, DOI 10.1152/ajpgi.00087.2003; ROBINSON PJ, 1990, DIGEST DIS SCI, V35, P1299, DOI 10.1007/BF01536423; SCHMITZ J, 1973, BIOCHIM BIOPHYS ACTA, V323, P98, DOI 10.1016/0005-2736(73)90434-3; Seidler U, 1997, J PHYSIOL-LONDON, V505, P411, DOI 10.1111/j.1469-7793.1997.411bb.x; Sellers ZM, 2005, AM J PHYSIOL-GASTR L, V288, pG654, DOI 10.1152/ajpgi.00386.2004; Simpson JE, 2007, AM J PHYSIOL-GASTR L, V292, pG1079, DOI 10.1152/ajpgi.00354.2006; Sindic A, 2005, KIDNEY INT, V68, P1008, DOI 10.1111/j.1523-1755.2005.00518.x; Sindice A, 2002, J BIOL CHEM, V277, P17758, DOI 10.1074/jbc.M110627200; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STAPLES SJ, 1980, J BIOL CHEM, V255, P4716; THOMPSON MR, 1984, J CLIN MICROBIOL, V20, P59, DOI 10.1128/JCM.20.1.59-64.1984; THOMPSON MR, 1990, J RECEPTOR RES, V10, P97, DOI 10.3109/10799899009064660; Tuo BG, 2003, GASTROENTEROLOGY, V125, P805, DOI 10.1016/S0016-5085(03)01045-X; Vaandrager AB, 2002, MOL CELL BIOCHEM, V230, P73, DOI 10.1023/A:1014231722696; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; YOUNGBERG CA, 1987, DIGEST DIS SCI, V32, P472, DOI 10.1007/BF01296029	47	21	21	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2008	22	5					1306	1316		10.1096/fj.06-7540com	http://dx.doi.org/10.1096/fj.06-7540com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18096816				2022-12-28	WOS:000255898700004
J	David, HN; Haelewyn, B; Rouillon, C; Lecoq, M; Chazalviel, L; Apiou, G; Risso, JJ; Lemaire, M; Abraini, JH				David, Helene N.; Haelewyn, Benoit; Rouillon, Christophe; Lecoq, Myriam; Chazalviel, Laurent; Apiou, Gabriela; Risso, Jean-Jacques; Lemaire, Marc; Abraini, Jacques H.			Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia	FASEB JOURNAL			English	Article						oxygen-glucose deprivation; N-methyl-D-aspartate; neurotoxicity; dopamine release; lactate dehydrogenase; neurological outcome	BRAIN BLOOD-FLOW; NITROUS-OXIDE; CARDIOPULMONARY BYPASS; GLUCOSE DEPRIVATION; CHANNEL BLOCKERS; NEURONAL INJURY; NMDA ANTAGONIST; CELL-CULTURE; SHORT-TERM; MEMANTINE	Brain insults are a major cause of acute mortality and chronic morbidity. Given the largely ineffective current therapeutic strategies, the development of new and efficient therapeutic interventions is clearly needed. A series of previous investigations has shown that the noble and anesthetic gas xenon, which has low-affinity antagonistic properties at the N-methyl-D-aspartate (NMDA) receptor, also exhibits potentially neuroprotective properties with no proven adverse side effects. Surprisingly and in contrast with most drugs that are being developed as therapeutic agents, the dose-response neuroprotective effect of xenon has been poorly studied, although this effect could be of major critical importance for its clinical development as a neuroprotectant. Here we show, using ex vivo and in vivo models of excitotoxic insults and transient brain ischemia, that xenon, administered at subanesthetic doses, offers global neuroprotection from reduction of neurotransmitter release induced by ischemia, a critical event known to be involved in excitotoxicity, to reduction of subsequent cell injury and neuronal death. Maximal neuroprotection was obtained with xenon at 50 vol%, a concentration at which xenon further exhibited significant neuroprotective effects in vivo even when administered up to 4 h after intrastriatal NMDA injection and up to at least 2 h after induction of transient brain ischemia.	[Rouillon, Christophe; Lecoq, Myriam; Chazalviel, Laurent; Abraini, Jacques H.] Univ Caen, CNRS, Ctr CYCERON, UMR 6185, F-14074 Caen, France; [David, Helene N.; Haelewyn, Benoit; Abraini, Jacques H.] NNOXe Pharmaceut, Quebec City, PQ, Canada; [Apiou, Gabriela; Lemaire, Marc] Ctr Rech Claude Delorme, Les Loges En Josas, France; [Risso, Jean-Jacques] Inst Med Navale, Serv Sante Armees, Toulon, France	Centre National de la Recherche Scientifique (CNRS); Universite de Caen Normandie	Abraini, JH (corresponding author), Univ Caen, CNRS, Ctr CYCERON, UMR 6185, BP 5229,Blvd Becquerel, F-14074 Caen, France.	abraini@cyceron.fr						Abraini JH, 2005, ANN NY ACAD SCI, V1053, P289, DOI 10.1196/annals.1344.025; Arrowsmith JE, 1998, STROKE, V29, P2357, DOI 10.1161/01.STR.29.11.2357; Bresink I, 1996, BRIT J PHARMACOL, V119, P195, DOI 10.1111/j.1476-5381.1996.tb15971.x; Colloc'h N, 2007, BIOPHYS J, V92, P217, DOI 10.1529/biophysj.106.093807; CULLEN SC, 1969, ANESTHESIOLOGY, V31, P305, DOI 10.1097/00000542-196910000-00003; David HN, 2006, BIOL PSYCHIAT, V60, P49, DOI 10.1016/j.biopsych.2005.10.007; David HN, 2003, J CEREBR BLOOD F MET, V23, P1168, DOI 10.1097/01.WCB.0000087342.31689.18; Davis SM, 2000, STROKE, V31, P347, DOI 10.1161/01.STR.31.2.347; DESHPANDE SS, 1995, ARCH TOXICOL, V69, P384, DOI 10.1007/s002040050188; Dingley J, 2006, STROKE, V37, P501, DOI 10.1161/01.STR.0000198867.31134.ac; Dinse A, 2005, BRIT J ANAESTH, V94, P479, DOI 10.1093/bja/aei080; Endres M, 2002, ADV EXP MED BIOL, V513, P455; FERRER I, 1995, ACTA NEUROPATHOL, V90, P504; Fisher CM, 1998, NEUROLOGY, V50, P841; Frietsch T, 2001, ANESTHESIOLOGY, V94, P290, DOI 10.1097/00000542-200102000-00019; GEMBA T, 1994, NEUROSCIENCE, V63, P789, DOI 10.1016/0306-4522(94)90523-1; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Goto T, 1998, BRIT J ANAESTH, V80, P255, DOI 10.1093/bja/80.2.255; Goto T, 2000, ANESTHESIOLOGY, V93, P1188, DOI 10.1097/00000542-200011000-00009; Gruss M, 2004, MOL PHARMACOL, V65, P443, DOI 10.1124/mol.65.2.443; HAELEWYN B, 2007, IN PRESS J NEUROSCI; Henninger N, 2006, EXP NEUROL, V201, P316, DOI 10.1016/j.expneurol.2006.04.011; Heurteaux C, 2004, EMBO J, V23, P2684, DOI 10.1038/sj.emboj.7600234; Homi HM, 2003, ANESTHESIOLOGY, V99, P876, DOI 10.1097/00000542-200310000-00020; Jevtovic-Todorovic V, 1998, NAT MED, V4, P460, DOI 10.1038/nm0498-460; KIM KW, 1995, CLIN EXP PHARMACOL P, V22, P301, DOI 10.1111/j.1440-1681.1995.tb02003.x; Koblin DD, 1998, ANESTH ANALG, V87, P419, DOI 10.1097/00000539-199808000-00035; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Kollmar R, 2007, STROKE, V38, P1585, DOI 10.1161/STROKEAHA.106.475897; Konstas AA, 2006, NEUROCRIT CARE, V4, P168, DOI 10.1385/NCC:4:2:168; Ma D, 2002, BRIT J ANAESTH, V89, P739, DOI 10.1093/bja/aef258; Ma DQ, 2006, J CEREBR BLOOD F MET, V26, P199, DOI 10.1038/sj.jcbfm.9600184; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; Ma DQ, 2003, ANESTHESIOLOGY, V98, P690, DOI 10.1097/00000542-200303000-00017; McCarran WJ, 2007, J NEUROSCI, V27, P4220, DOI 10.1523/JNEUROSCI.5542-06.2007; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1989, BRAIN RES, V483, P347, DOI 10.1016/0006-8993(89)90179-0; Nagata A, 2001, ANESTH ANALG, V92, P362, DOI 10.1213/00000539-200102000-00016; Natale G, 2006, ANN NY ACAD SCI, V1074, P650, DOI 10.1196/annals.1369.063; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; Palmer GC, 2000, AMINO ACIDS, V19, P151, DOI 10.1007/s007260070043; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; Parsons CG, 1998, DRUG NEWS PERSPECT, V11, P523, DOI 10.1358/dnp.1998.11.9.863689; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Petzelt C, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-55; Petzelt C, 2003, LIFE SCI, V72, P1909, DOI 10.1016/S0024-3205(02)02439-6; PORTER RHP, 1995, J NEUROCHEM, V64, P614; PRIESTLEY T, 1990, BRAIN RES, V531, P183, DOI 10.1016/0006-8993(90)90772-4; ROGAWSKI MA, 1993, TRENDS PHARMACOL SCI, V14, P325, DOI 10.1016/0165-6147(93)90005-5; Schmidt M, 2001, ANAESTHESIA, V56, P1154, DOI 10.1046/j.1365-2044.2001.02322.x; Sobrado M, 2004, NEUROSCI LETT, V365, P132, DOI 10.1016/j.neulet.2004.04.067; Wilhelm S, 2002, ANESTHESIOLOGY, V96, P1485, DOI 10.1097/00000542-200206000-00031; Yamakura T, 2000, ANESTHESIOLOGY, V93, P1095, DOI 10.1097/00000542-200010000-00034; YAO LP, 1992, STROKE, V23, P69, DOI 10.1161/01.STR.23.1.69; YAO LP, 1992, J NEUROSURG ANESTH, V4, P268, DOI 10.1097/00008506-199210000-00007; Zhou M, 2006, J NEUROSCI, V26, P2956, DOI 10.1523/JNEUROSCI.4299-05.2006	57	92	101	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					1275	1286		10.1096/fj.07-9420com	http://dx.doi.org/10.1096/fj.07-9420com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	18024836				2022-12-28	WOS:000254581000032
J	Allende, ML; Zhou, D; Kalkofen, DN; Benhamed, S; Tuymetova, G; Borowski, C; Bendelac, A; Proia, RL				Allende, Maria L.; Zhou, Dapeng; Kalkofen, Danielle N.; Benhamed, Sonia; Tuymetova, Galina; Borowski, Christine; Bendelac, Albert; Proia, Richard L.			S1P(1) receptor expression regulates emergence of NKT cells in peripheral tissues	FASEB JOURNAL			English	Article						lipid signaling; G-protein coupled receptors; lymphocyte trafficking; conditional knockout mice	KILLER T-CELLS; SPHINGOSINE 1-PHOSPHATE RECEPTOR; SELECTIN-DEFICIENT MICE; SECONDARY LYMPHOID ORGANS; PROTEIN-COUPLED RECEPTOR; IMMUNE MODULATOR FTY720; IMMUNOSUPPRESSANT FTY720; VASCULAR MATURATION; THYMIC EMIGRATION; SPHINGOSINE-1-PHOSPHATE	The S1P(1) receptor, on the surface of lymphocytes and endothelial cells, regulates the unique trafficking behavior of certain lymphocyte populations. We have examined whether the S1P(1) receptor also dictates the distinctive tissue distribution of V alpha 14-J alpha 18 natural killer T (NKT) cells, whose trafficking pattern is not well understood. Mice (TCS1P(1)KO) were established with a conditional deletion of the S1P(1) receptor in thymocytes that included precursors of NKT cells. Within the thymus, NKT cells were found at normal or increased levels, indicating that S1P(1) receptor expression was dispensable for NKT cell development. However, substantially reduced numbers of NKT cells were detected in the peripheral tissues of the TCS1P(1)KO mice. Short-term S1P(1) deletion after NKT cells had established residence in the periphery did not substantially alter their distribution in tissues, except for a partial decrease in the spleen. FTY720, a S1P(1) receptor ligand that has potent effects on the trafficking of conventional T cells, did not alter the preexisting distribution of NKT cells within peripheral tissues of wild-type mice. Our results indicate that the S1P(1) receptor expression on NKT cells is dispensable for development within thymus but is essential for the establishment of their tissue residency in the periphery.	[Allende, Maria L.; Kalkofen, Danielle N.; Benhamed, Sonia; Tuymetova, Galina; Proia, Richard L.] NIDDK, Natl Inst Hlth, Genet Dev & Dis Branch, Bethesda, MD 20892 USA; [Zhou, Dapeng] Univ Texas Houston, MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA; [Borowski, Christine; Bendelac, Albert] Univ Chicago, Comm Immunol, Chicago, IL 60637 USA; [Borowski, Christine; Bendelac, Albert] Howard Hughes Med Inst, Chicago, IL USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Chicago; Howard Hughes Medical Institute	Allende, ML (corresponding author), NIDDK, Natl Inst Hlth, Genet Dev & Dis Branch, Bldg 10,Room 9D-06,10 Ctr DR MSC 1821, Bethesda, MD 20892 USA.	mariaa@intra.niddk.nih.gov; proia@nih.gov	Zhou, Dapeng/A-6446-2019; zhou, dapeng/GXG-9715-2022; Proia, Richard L/A-7908-2012	Zhou, Dapeng/0000-0003-1347-3811; Proia, Richard/0000-0003-0456-1270	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056015] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIAID NIH HHS [AI038338] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alfonso C, 2006, EUR J IMMUNOL, V36, P149, DOI 10.1002/eji.200535127; Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Allende ML, 2003, BLOOD, V102, P3665, DOI 10.1182/blood-2003-02-0460; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Benlagha K, 2002, SCIENCE, V296, P553, DOI 10.1126/science.1069017; Berzins SP, 2006, J IMMUNOL, V176, P4059, DOI 10.4049/jimmunol.176.7.4059; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2000, TRENDS PHARMACOL SCI, V21, P49, DOI 10.1016/S0165-6147(99)01419-4; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Chiba K, 1998, J IMMUNOL, V160, P5037; Cinamon G, 2004, NAT IMMUNOL, V5, P713, DOI 10.1038/ni1083; Cyster JG, 2005, ANNU REV IMMUNOL, V23, P127, DOI 10.1146/annurev.immunol.23.021704.115628; Egawa T, 2005, IMMUNITY, V22, P705, DOI 10.1016/j.immuni.2005.03.011; Eger KA, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000050; Forrest M, 2004, J PHARMACOL EXP THER, V309, P758, DOI 10.1124/jpet.103.062828; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Franki AS, 2006, P NATL ACAD SCI USA, V103, P9160, DOI 10.1073/pnas.0508892103; Fu S, 2004, AM J TRANSPLANT, V4, P65, DOI 10.1046/j.1600-6143.2003.00293.x; Gapin L, 2001, NAT IMMUNOL, V2, P971, DOI 10.1038/ni710; Godfrey DI, 2000, IMMUNOL TODAY, V21, P573, DOI 10.1016/S0167-5699(00)01735-7; Godfrey DI, 2004, J CLIN INVEST, V114, P1379, DOI 10.1172/JCI200423594; Goetzl EJ, 2004, J CLIN INVEST, V114, P1531, DOI 10.1172/JCI200423704; Gonzalez-Cabrera PJ, 2007, J BIOL CHEM, V282, P7254, DOI 10.1074/jbc.M610581200; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; Hanel P, 2007, FASEB J, V21, P1202, DOI 10.1096/fj.06-7433com; Hale JJ, 2004, BIOORG MED CHEM LETT, V14, P3351, DOI 10.1016/j.bmcl.2004.02.106; Hammond KJL, 1999, EUR J IMMUNOL, V29, P3768, DOI 10.1002/(SICI)1521-4141(199911)29:11<3768::AID-IMMU3768>3.3.CO;2-7; Hashimoto D, 2007, EUR J IMMUNOL, V37, P271, DOI 10.1002/eji.200636123; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; Hla T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI 10.1016/j.semcdb.2004.05.002; Kabashima K, 2006, J EXP MED, V203, P2683, DOI 10.1084/jem.20061289; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Kharel Y, 2005, J BIOL CHEM, V280, P36865, DOI 10.1074/jbc.M506293200; Kim CH, 2002, BLOOD, V100, P11, DOI 10.1182/blood-2001-12-0196; Kinjo Y, 2005, NATURE, V434, P520, DOI 10.1038/nature03407; Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Laloux W, 2002, J IMMUNOL, V168, P3251, DOI 10.4049/jimmunol.168.7.3251; Lee A, 2002, MED TEACH, V24, P637, DOI 10.1080/0142159021000063970; Ley K, 2005, NAT IMMUNOL, V6, P1215, DOI 10.1038/ni1205-1215; Liu Y, 2006, J IMMUNOL METHODS, V312, P34, DOI 10.1016/j.jim.2006.02.009; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Lo CG, 2005, J EXP MED, V201, P291, DOI 10.1084/jem.20041509; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Massberg S, 2006, NEW ENGL J MED, V355, P1088, DOI 10.1056/NEJMp068159; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Mattner J, 2005, NATURE, V434, P525, DOI 10.1038/nature03408; Mempel M, 2002, J IMMUNOL, V168, P365, DOI 10.4049/jimmunol.168.1.365; Nagahara Y, 2000, IMMUNOPHARMACOLOGY, V48, P75, DOI 10.1016/S0162-3109(00)00181-8; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Oo ML, 2007, J BIOL CHEM, V282, P9082, DOI 10.1074/jbc.M610318200; Pappu R, 2007, SCIENCE, V316, P295, DOI 10.1126/science.1139221; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Pellicci DG, 2002, J EXP MED, V195, P835, DOI 10.1084/jem.20011544; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; Sawicka E, 2005, J IMMUNOL, V175, P7973, DOI 10.4049/jimmunol.175.12.7973; Schwab SR, 2005, SCIENCE, V309, P1735, DOI 10.1126/science.1113640; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Sugito K, 2006, TRANSPLANT P, V38, P3058, DOI 10.1016/j.transproceed.2006.08.147; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; Thomas SY, 2003, J IMMUNOL, V171, P2571, DOI 10.4049/jimmunol.171.5.2571; Wei DG, 2005, J EXP MED, V202, P239, DOI 10.1084/jem.20050413; Wei SH, 2005, NAT IMMUNOL, V6, P1228, DOI 10.1038/ni1269; Xu JC, 1996, J EXP MED, V183, P589, DOI 10.1084/jem.183.2.589; Yagi H, 2000, EUR J IMMUNOL, V30, P1435, DOI 10.1002/(SICI)1521-4141(200005)30:5<1435::AID-IMMU1435>3.0.CO;2-O; Yatomi Y, 1997, J BIOL CHEM, V272, P5291, DOI 10.1074/jbc.272.8.5291; Yatomi Y, 2001, PROSTAG OTH LIPID M, V64, P107, DOI 10.1016/S0090-6980(01)00103-4; Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science.1103440	72	49	53	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					307	315		10.1096/fj.07-9087com	http://dx.doi.org/10.1096/fj.07-9087com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17785606				2022-12-28	WOS:000252309900032
J	Choi, HS; Kang, BS; Shim, JH; Cho, YY; Choi, BY; Bode, AM; Dong, ZG				Choi, Hong Seok; Kang, Bong Seok; Shim, Jung-Hyun; Cho, Yong-Yeon; Choi, Bu Young; Bode, Ann M.; Dong, Zigang			Cot, a novel kinase of histone H3, induces cellular transformation through up-regulation of c-fos transcriptional activity	FASEB JOURNAL			English	Article						c-fos promoter; AP-1	IMMEDIATE-EARLY GENE; ACTIVATED T-CELLS; GROWTH-FACTORS; MAP KINASE; SER-10 PHOSPHORYLATION; SIGNALING PATHWAYS; NUCLEAR FACTOR; TPL-2; EXPRESSION; JUN	Post-translational modification of histones is critical for gene expression, mitosis, cell growth, apoptosis, and cancer development. Thus, finding protein kinases that are responsible for the phosphorylation of histones at critical sites is considered an important step in understanding the process of histone modification. The serine/threonine kinase Cot is a member of the mitogen-activated protein kinase (MAPK) kinase kinase family. We show here that Cot can phosphorylate histone H3 at Ser-10 in vivo and in vitro, and that the phosphorylation of histone H3 at Ser-10 is required for Cot-induced cell transformation. We found that activated Cot is recruited to the c-fos promoter resulting in increased activator protein-1 (AP-1) transactivation. The formation of the Cot-c-fos promoter complex was also apparent when histone H3 was phosphorylated at Ser-10. Furthermore, the use of dominant negative mutants of histone H3 revealed that Cot was required for phosphorylation of histone H3 at Ser-10 to induce neoplastic cell transformation. These results revealed an important function of Cot as a newly discovered histone H3 kinase. Moreover, the transforming ability of Cot results from the coordinated activation of histone H3, which ultimately converges on the regulation of the transcriptional activity of the c-fos promoter, followed by AP-1 transactivation activity. -Choi, H. S., Kang, B. S., Shim, J. H., Cho, Y. Y., Choi, B. Y., Bode, A. M., Dong, Z. Cot, a novel kinase of histone H3, induces cellular transformation through up-regulation of c-fos transcriptional activity.	[Choi, Hong Seok; Kang, Bong Seok; Shim, Jung-Hyun; Cho, Yong-Yeon; Choi, Bu Young; Bode, Ann M.; Dong, Zigang] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; [Choi, Hong Seok] Chosun Univ, Coll Pharm, Kwangju, South Korea	University of Minnesota System; Chosun University	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	Cho, Yong-Yeon/AAD-4263-2020	Cho, Yong-Yeon/0000-0003-1107-2651; Shim, Jung-Hyun/0000-0002-4062-4016	NATIONAL CANCER INSTITUTE [R01CA081064, R01CA077646, R01CA120388, R01CA111356, R37CA081064] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA111356-03, R01 CA077646, R01 CA111356, CA120388, R01 CA077646-09, R01 CA120388, R01 CA120388-04, R01 CA081064-03, R01 CA081064, CA111356, R37 CA081064, CA77646, CA81064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI M, 1991, ONCOGENE, V6, P1515; BALL AR, 1988, COLD SPRING HARB SYM, V53, P687, DOI 10.1101/SQB.1988.053.01.078; Ballester A, 1998, J BIOL CHEM, V273, P14099, DOI 10.1074/jbc.273.23.14099; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; BENBROOK DM, 1990, ONCOGENE, V5, P295; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; CHAN AML, 1993, ONCOGENE, V8, P1329; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Choi HS, 2005, CANCER RES, V65, P5818, DOI 10.1158/0008-5472.CAN-05-0197; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davie JR, 1999, BIOCHEM CELL BIOL, V77, P265, DOI 10.1139/bcb-77-4-265; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIMARCO E, 1990, NAT IMMUN CELL GROW, V9, P209; Dunn KL, 2005, ONCOGENE, V24, P3492, DOI 10.1038/sj.onc.1208521; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Erny KM, 1996, ONCOGENE, V13, P2015; Gavrin LK, 2005, BIOORG MED CHEM LETT, V15, P5288, DOI 10.1016/j.bmcl.2005.08.029; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; MATSUI M, 1990, ONCOGENE, V5, P249; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OHARA R, 1993, JPN J CANCER RES, V84, P518, DOI 10.1111/j.1349-7006.1993.tb00170.x; OKUNO H, 1991, ONCOGENE, V6, P1491; Ota T, 2002, CANCER RES, V62, P5168; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Royds JA, 1998, J CLIN PATHOL-MOL PA, V51, P55; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Soncini C, 2006, CLIN CANCER RES, V12, P4080, DOI 10.1158/1078-0432.CCR-05-1964; Strelkov IS, 2002, CANCER RES, V62, P75; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199	58	26	27	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					113	126		10.1096/fj.07-9078com	http://dx.doi.org/10.1096/fj.07-9078com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17724252	Green Accepted			2022-12-28	WOS:000252309900015
J	Zeidan, YH; Wu, BX; Jenkins, RW; Obeid, LM; Hannun, YA				Zeidan, Youssef H.; Wu, Bill X.; Jenkins, Russell W.; Obeid, Lina M.; Hannun, Yusuf A.			A novel role for protein kinase C delta-mediated phosphorylation of acid sphingomyelinase in UV light-induced mitochondrial injury	FASEB JOURNAL			English	Article						ceramide; sphingolipids; apoptosis	RADIATION-INDUCED APOPTOSIS; N-TERMINAL KINASE; HUMAN KERATINOCYTES; SKIN-CANCER; FAS LIGAND; PHOSPHOLIPASE-D; MASS-SPECTROMETRY; CELL CARCINOMA; CYTOCHROME-C; B RADIATION	Multiple studies have addressed the mechanisms by which ultraviolet (UV) light induces cell death, and a few have focused on stress mediators such as acid sphingomyelinase (ASMase) or protein kinase C delta (PKC delta). Based on a recent study that identified a novel mechanism of activation of ASMase through phosphorylation (1), the current study was undertaken to determine the upstream mechanisms regulating ASMase in response to UV and to investigate the role of ASMase and its phosphorylation at S508 as an integral event during UV light-induced cell death. Exposure of MCF-7 breast cancer cells to UV light type C (UVC) transiently activated ASMase with maximal activity detected at 10 min postirradiation. A significant increase in C-16-ceramide was detected concomitant with a decrease in C-16-sphingomyelin. In marked contrast, cells overexpressing the ASMase(S508A) mutant, which could not be phosphorylated, had no change in either ASMase activity or ceramide levels post-UV radiation. Loss of PKC delta by RNA interference or its inhibition by rottlerin blocked ASMase phosphorylation and membrane targeting, thus implicating PKC delta upstream of ASMase activation by UV light. Further investigations revealed that UV radiation altered mitochondrial morphology from elongated tubules to fragmented perinuclear organelles, consistent with the onset of the apoptotic cascade. Importantly, cells overexpressing ASMaseS508A were protected (> 50%) from UV light-induced mitochondrial fragmentation. Mechanistically, the results showed that ASMaseS508A cells had 50% less active Bax than ASMase(WT) cells. These molecular differences culminated in resistance of ASMase(S508) cells to UVC-induced cell death (25%) as compared to ASMaseWT cells (46%). Taken together, this study provides key molecular insights into activation of ASMase in response to UV light, the role of PKC delta in this activation, and the role of ASMase in mediating apoptotic responses. -Zeidan, Y. H., Wu, B. X., Jenkins, R. W., Obeid, L. M., Hannun, Y. A. A novel role for protein kinase c delta-mediated phosphorylation of acid sphingomyelinase in UV light-induced mitochondrial injury.	[Zeidan, Youssef H.; Wu, Bill X.; Jenkins, Russell W.; Hannun, Yusuf A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 175 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hannun@musc.edu	Zeidan, Youssef H./H-7578-2019	Zeidan, Youssef H./0000-0002-1951-8585; obeid, lina/0000-0002-0734-0847	NATIONAL CANCER INSTITUTE [P01CA097132] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR018823] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA97132] Funding Source: Medline; NCRR NIH HHS [C06 RR018823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Barsoum MJ, 2006, EMBO J, V25, P3900, DOI 10.1038/sj.emboj.7601253; Bielawski J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004; Birbes H, 2005, BIOCHEM J, V386, P445, DOI 10.1042/BJ20041627; Birbes H, 2002, ADV ENZYME REGUL, V42, P113, DOI 10.1016/S0065-2571(01)00026-7; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Charruyer A, 2005, J BIOL CHEM, V280, P19196, DOI 10.1074/jbc.M412867200; Charruyer A, 2007, BIOCHEM J, V405, P77, DOI 10.1042/BJ20061528; Chaturvedi V, 2005, ONCOGENE, V24, P5299, DOI 10.1038/sj.onc.1208650; Cheng WC, 2006, ONCOGENE, V25, P4697, DOI 10.1038/sj.onc.1209596; Choi SY, 2006, NAT CELL BIOL, V8, P1255, DOI 10.1038/ncb1487; Chow J, 2005, J CUTAN MED SURG, V9, P289, DOI 10.1007/s10227-005-0109-0; D'Costa AM, 2005, CELL DEATH DIFFER, V12, P224, DOI 10.1038/sj.cdd.4401558; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fannjiang Y, 2004, GENE DEV, V18, P2785, DOI 10.1101/gad.1247904; Faris M, 1998, J IMMUNOL, V160, P134; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FRANCIS B, 2001, SEX ED, V1, P1; Fukunaga M, 2001, BIOCHEM BIOPH RES CO, V289, P573, DOI 10.1006/bbrc.2001.6025; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; Gutierrez-Steil C, 1998, J CLIN INVEST, V101, P33, DOI 10.1172/JCI1165; Hardwick JM, 2002, MOL CELL, V10, P963, DOI 10.1016/S1097-2765(02)00751-7; Heinrich M, 2004, CELL DEATH DIFFER, V11, P550, DOI 10.1038/sj.cdd.4401382; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Jacotot E, 1999, ANN NY ACAD SCI, V887, P18, DOI 10.1111/j.1749-6632.1999.tb07919.x; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kashkar H, 2005, J BIOL CHEM, V280, P20804, DOI 10.1074/jbc.M410869200; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Komatsu M, 2001, BBA-MOL CELL BIOL L, V1533, P47, DOI 10.1016/S1388-1981(01)00139-1; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; Magnoni C, 2002, TOXICOL IN VITRO, V16, P349, DOI 10.1016/S0887-2333(02)00024-3; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; Morales A, 2004, GLYCOCONJUGATE J, V20, P579; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Novgorodov SA, 2005, J BIOL CHEM, V280, P16096, DOI 10.1074/jbc.M411707200; Radin NS, 2003, BIOORGAN MED CHEM, V11, P2123, DOI 10.1016/S0968-0896(02)00609-0; Rotolo JA, 2005, J BIOL CHEM, V280, P26425, DOI 10.1074/jbc.M414569200; Singh IN, 2001, BIOCHEMISTRY-US, V40, P11227, DOI 10.1021/bi010787l; Siskind LJ, 2006, MITOCHONDRION, V6, P118, DOI 10.1016/j.mito.2006.03.002; Siskind LJ, 2005, J BIOENERG BIOMEMBR, V37, P143, DOI 10.1007/s10863-005-6567-7; Sitailo LA, 2004, J INVEST DERMATOL, V123, P434, DOI 10.1111/j.0022-202X.2004.23403.x; Sitailo LA, 2006, J BIOL CHEM, V281, P29703, DOI 10.1074/jbc.M607351200; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Szabadkai G, 2004, MOL CELL, V16, P59, DOI 10.1016/j.molcel.2004.09.026; Taha TA, 2005, FASEB J, V19, P482, DOI 10.1096/fj.05-4412fje; Tomassini B, 2002, BIOCHIMIE, V84, P123, DOI 10.1016/S0300-9084(02)01377-9; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; van Montfort BA, 2002, J MASS SPECTROM, V37, P322, DOI 10.1002/jms.288; Venable ME, 1996, J BIOL CHEM, V271, P24800, DOI 10.1074/jbc.271.40.24800; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Zeidan YH, 2007, J BIOL CHEM, V282, P11549, DOI 10.1074/jbc.M609424200; Zeidan YH, 2006, J BIOL CHEM, V281, P24695, DOI 10.1074/jbc.M604713200; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	65	59	64	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					183	193		10.1096/fj.07-8967com	http://dx.doi.org/10.1096/fj.07-8967com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17698617				2022-12-28	WOS:000252309900021
J	Chen, RR; Silva, EA; Yuen, WW; Brock, AA; Fischbach, C; Lin, AS; Guldberg, RE; Mooney, DJ				Chen, Ruth R.; Silva, Eduardo A.; Yuen, William W.; Brock, Andrea A.; Fischbach, Claudia; Lin, Angela S.; Guldberg, Robert E.; Mooney, David J.			Integrated approach to designing growth factor delivery systems	FASEB JOURNAL			English	Article						tissue engineering; in vitro models; angiogenesis	ANGIOGENESIS; VEGF; MIGRATION; RECEPTORS; VEGF(165); CELLS; ASSAY	Growth factors have been widely used in strategies to regenerate and repair diseased tissues, but current therapies that go directly from bench to bedside have had limited clinical success. We hypothesize that engineering successful therapies with recombinant proteins will often require specific quantitative information of the spatiotemporal role of the factors and the development of sophisticated delivery approaches that provide appropriate tissue exposures. This hypothesis was tested in the context of therapeutic angiogenesis. An in vitro model of angiogenesis was adapted to quantify the role of the concentration/ gradient of vascular endothelial growth factor [VEGF( 165)] on microvascular endothelial cells, and a delivery system was then designed, based on a mathematical model, to provide the desired profile in ischemic mice hindlimbs. This system significantly enhanced blood vessel formation, and perfusion and recovery from severe ischemia. This general approach may be broadly applicable to growth factor therapies.	Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; St Louis Univ, Dept Biochem Med, St Louis, MO 63103 USA; Sch Mech Engn, Georgia Inst Technol, Atlanta, GA 30332 USA	University of Michigan System; University of Michigan; Harvard University; Saint Louis University; University System of Georgia; Georgia Institute of Technology	Mooney, DJ (corresponding author), Harvard Univ, 319 Pierce Hall, Cambridge, MA 02138 USA.	mooneyd@deas.harvard.edu	Fischbach, Claudia/C-8550-2009; Silva, Eduardo A./M-2711-2015	Fischbach, Claudia/0000-0002-9368-0150; Silva, Eduardo A./0000-0003-3173-7622; Mooney, David/0000-0001-6299-1194	NHLBI NIH HHS [R01 HL-069957] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069957] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chen RR, 2003, PHARM RES-DORDR, V20, P1103, DOI 10.1023/A:1025034925152; Chen RR, 2007, MICROCIRCULATION, V14, P77, DOI 10.1080/10739680601131101; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479; Davenport A.P., 2005, RECEPTOR BINDING TEC, V2nd; Dietrich Franziska, 2006, Angiogenesis, V9, P111, DOI 10.1007/s10456-006-9037-x; Eichmann A, 2005, CURR OPIN NEUROBIOL, V15, P108, DOI 10.1016/j.conb.2005.01.008; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Harris LD, 1998, J BIOMED MATER RES, V42, P396, DOI 10.1002/(SICI)1097-4636(19981205)42:3<396::AID-JBM7>3.0.CO;2-E; Hutchings H, 2003, FASEB J, V17, P1520, DOI 10.1096/fj.02-0691fje; Khurana R, 2005, CIRCULATION, V112, P1813, DOI 10.1161/CIRCULATIONAHA.105.535294; Lazarous DF, 1996, CIRCULATION, V94, P1074, DOI 10.1161/01.CIR.94.5.1074; LIMBIRD LE, 1996, CELL SURFACE RECEPTO; Nakatsu MN, 2003, LAB INVEST, V83, P1873, DOI 10.1097/01.LAB.0000107160.81875.33; NEHLS V, 1995, MICROVASC RES, V50, P311, DOI 10.1006/mvre.1995.1061; Peters MC, 2002, J BIOMED MATER RES, V60, P668, DOI 10.1002/jbm.10134; Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029; Rosinberg Audrey, 2004, Expert Rev Cardiovasc Ther, V2, P271, DOI 10.1586/14779072.2.2.271; Ruhrberg C, 2003, BIOESSAYS, V25, P1052, DOI 10.1002/bies.10351; Russ J. C., 2002, IMAGE PROCESSING HDB, V4th, DOI DOI 10.1201/9781420040760; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Sun QH, 2005, PHARM RES-DORDR, V22, P1110, DOI 10.1007/s11095-005-5644-2; VAISMAN N, 1990, J BIOL CHEM, V265, P19461	24	110	128	1	40	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3896	3903		10.1096/fj.06-7873com	http://dx.doi.org/10.1096/fj.06-7873com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17644610	Green Submitted			2022-12-28	WOS:000251283500015
J	Sainte-Marie, Y; Cat, AND; Perrier, R; Mangin, L; Soukaseum, C; Peuchmaur, M; Tronche, F; Farman, N; Escoubet, B; Benitah, JP; Jaisser, F				Sainte-Marie, Yannis; Cat, Aurelie Nguyen Dinh; Perrier, Romain; Mangin, Laurence; Soukaseum, Christelle; Peuchmaur, Michel; Tronche, Francois; Farman, Nicolette; Escoubet, Brigitte; Benitah, Jean-Pierre; Jaisser, Frederic			Conditional glucocorticoid receptor expression in the heart induces atrio-ventricular block	FASEB JOURNAL			English	Article						corticosteroids; electrical remodeling; ion channel; conditional model	SARCOPLASMIC-RETICULUM FUNCTION; MINERALOCORTICOID RECEPTOR; CA2+ CURRENT; RAT; ALDOSTERONE; DEXAMETHASONE; MICE; DENSITY; DISEASE; CONSEQUENCES	Corticosteroid hormones (aldosterone and glucocorticoids) and their receptors are now recognized as major modulators of cardiovascular pathophysiology, but their specific roles remain elusive. Glucocorticoid hormones (GCs), which are widely used to treat acute and chronic diseases, often have adverse cardiovascular effects such as heart failure, hypertension, atherosclerosis, or metabolic alterations. The direct effects of GC on the heart are difficult to evaluate, as changes in plasma GC concentrations have multiple consequences due to the ubiquitous expression of the glucocorticoid receptor (GR), resulting in secondary effects on cardiac function. We evaluated the effects of GR on the heart in a conditional mouse model in which the GR was overexpressed solely in cardiomyocytes. The transgenic mice displayed electrocardiogram (ECG) abnormalities: a long PQ interval, increased QRS and QTc duration as well as chronic atrio-ventricular block, without cardiac hypertrophy or fibrosis. The ECG alterations were reversible on GR expression shutoff. Isolated ventricular cardiomyocytes showed major ion channel remodeling, with decreases in I-Na, I-to, and I-Kslow activity and changes in cell calcium homeostasis (increase in C-a1, in Ca2+ transients and in sarcoplasmic reticulum Ca2+ load). This phenotype differs from that observed in mice overexpressing the mineralocorticoid receptor in the heart, which displayed ventricular arrhythmia. Our mouse model highlights novel effects of GR activation in the heart indicating that GR has direct and specific cardiac effects in the mouse.	INSERM, U772, F-75231 Paris, France; Coll France, F-75231 Paris, France; Univ Paris 05, Paris, France; INSERM, U673 IFR3, F-75231 Paris, France; Univ Montpellier 1, Montpellier, France; INSERM, U698, F-75231 Paris, France; Hop Bichat Claude Bernard, AP HP, F-75877 Paris, France; Univ Paris 07, Fac Med 10, Paris, France; Hop Robert Debre, AP HP, Serv Pathol, F-75019 Paris, France; Univ Paris 07, EA3102, Paris, France; CNRS, FRE2401, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	Jaisser, F (corresponding author), INSERM, U772, 11 Pl Marcelin Berthelot, F-75231 Paris, France.	frederic.jaisser@college-de-france.fr	TRONCHE, François/F-3895-2011; CAT, Aurelie NGUYEN DINH/H-8182-2013; Benitah, Jean-Pierre/L-6060-2018; Jaisser, Frederic/P-4287-2017	Benitah, Jean-Pierre/0000-0002-9866-9081; Jaisser, Frederic/0000-0001-9051-1901; Perrier, Romain/0000-0003-2229-4700; Sainte-Marie, Yannis/0000-0002-0646-1591				BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Benitah JP, 2001, J PHYSIOL-LONDON, V537, P151, DOI 10.1111/j.1469-7793.2001.0151k.x; Brotman DJ, 2005, J CLIN ENDOCR METAB, V90, P3202, DOI 10.1210/jc.2004-2379; Brunner M, 2001, AM J PHYSIOL-HEART C, V281, pH1201, DOI 10.1152/ajpheart.2001.281.3.H1201; Bujard H, 1999, J GENE MED, V1, P372; Couette B, 1996, BIOCHEM J, V315, P421, DOI 10.1042/bj3150421; Delano FA, 2004, MICROCIRCULATION, V11, P69, DOI 10.1080/10739680490266207; Dobrzynski H, 2006, J MOL CELL CARDIOL, V41, P855, DOI 10.1016/j.yjmcc.2006.07.018; EVANS N, 1994, ARCH DIS CHILD-FETAL, V70, P25; Funder JW, 2004, TRENDS ENDOCRIN MET, V15, P139, DOI 10.1016/j.tem.2004.03.006; Girod JP, 2004, CARDIOVASC RES, V64, P217, DOI 10.1016/j.cardiores.2004.07.006; Guo J, 2006, AM J PHYSIOL-HEART C, V291, pH2669, DOI 10.1152/ajpheart.01247.2005; Guo WN, 2000, CIRC RES, V87, P73, DOI 10.1161/01.RES.87.1.73; Gutstein DE, 2001, CELL COMMUN ADHES, V8, P345, DOI 10.3109/15419060109080751; ISRAEL BA, 1993, AM J PERINAT, V10, P307, DOI 10.1055/s-2007-994747; LEFER AM, 1968, AM J PHYSIOL, V214, P518, DOI 10.1152/ajplegacy.1968.214.3.518; Luo WS, 1996, CIRC RES, V78, P839, DOI 10.1161/01.RES.78.5.839; Narayanan N, 2004, MOL CELL BIOCHEM, V266, P31, DOI 10.1023/B:MCBI.0000049130.58074.73; Ouvrard-Pascaud A, 2005, CIRCULATION, V111, P3025, DOI 10.1161/CIRCULATIONAHA.104.503706; Ouvrard-Pascaud A, 2003, PFLUG ARCH EUR J PHY, V445, P477, DOI 10.1007/s00424-002-0953-3; Papadatos GA, 2002, P NATL ACAD SCI USA, V99, P6210, DOI 10.1073/pnas.082121299; PENEFSKY ZJ, 1971, EUR J PHARMACOL, V15, P259, DOI 10.1016/0014-2999(71)90091-4; Perrier R, 2005, J PHYSIOL-LONDON, V569, P153, DOI 10.1113/jphysiol.2005.092692; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Rao MK, 2001, AM J PHYSIOL-HEART C, V281, pH325, DOI 10.1152/ajpheart.2001.281.1.H325; Sheppard KE, 2003, VITAM HORM, V66, P77, DOI 10.1016/S0083-6729(03)01003-3; Souverein PC, 2004, HEART, V90, P859, DOI 10.1136/hrt.2003.020180; Struthers AD, 2002, AM HEART J, V144, pS2, DOI 10.1067/mhj.2002.129969; Takimoto K, 1997, J MOL CELL CARDIOL, V29, P3035, DOI 10.1006/jmcc.1997.0532; TAKIMOTO K, 1994, CIRC RES, V75, P1006, DOI 10.1161/01.RES.75.6.1006; WANG Z, 1999, P 2 INT S AN DIG SOL, V2, P85; Wei L, 2004, ANN INTERN MED, V141, P764, DOI 10.7326/0003-4819-141-10-200411160-00007; Whitehurst RM, 1999, J MOL CELL CARDIOL, V31, P1551, DOI 10.1006/jmcc.1999.0990; Yoshida Masahiro, 2005, Congest Heart Fail, V11, P12, DOI 10.1111/j.1527-5299.2005.03722.x; Yu ZH, 1996, CIRC RES, V79, P691, DOI 10.1161/01.RES.79.4.691	36	44	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3133	3141		10.1096/fj.07-8357com	http://dx.doi.org/10.1096/fj.07-8357com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17517920				2022-12-28	WOS:000249781600014
J	Zanone, MM; Favaro, E; Ferioli, E; Huang, GC; Klein, NJ; Perin, PC; Peakman, M; Conaldi, PG; Camussi, G				Zanone, Maria M.; Favaro, Enrica; Ferioli, Elena; Huang, Guo C.; Klein, Nigel J.; Perin, Paolo Cavallo; Peakman, Mark; Conaldi, Pier G.; Camussi, Giovanni			Human pancreatic islet endothelial cells express coxsackievirus and adenovirus receptor and are activated by coxsackie B virus infection	FASEB JOURNAL			English	Article						autoimmunity; adhesion molecules; cytokines; viral infection	DILATED CARDIOMYOPATHY; PERSISTENT INFECTION; ADHESION MOLECULE-1; ALPHA-INTERFERON; T-CELLS; BETA; INDUCTION; DAMAGE; IDENTIFICATION; LYMPHOTACTIN	Enteroviruses, such as the coxsackievirus ( CV) group, have been linked to the induction of inflammatory and autoimmune diseases. Virus tropism and tissue access are modulated by endothelial cells. To examine the susceptibility of microvascular endothelial cells ( MECs) derived from pancreatic islets to infection with CV group B ( CVB), purified cultured human islet MECs were infected with CVB-4 strain, and the immunological phenotype of the infected cells was analyzed. CVB-4 persistently infected the islet MECs, which expressed the CV receptors human coxsackievirus and adenovirus receptor ( HCAR) and decay accelerating factor ( DAF) and maintained EC characteristics, without overt cytopathic effects. CVB-4 infection transiently upregulated expression of the adhesion molecules ICAM-1 and VCAM-1 and increased production of the proinflammatory cytokines IL-1 beta and IL-6, and chemokines IL-8 and lymphotactin, as well as IFN-alpha. Mononuclear cell adhesion to CVB infected monolayers was increased, compared to uninfected monolayers. Moreover, infection up-regulated the viral receptors HCAR and DAF and coreceptor alpha(v)beta(3) integrin on islet MECs, while down-regulating expression of HCAR on human aortic endothelial cells, indicating potential tissue-specific influence on the pathological outcome of infection. These results provide evidence that islet MECs are natural targets and reservoirs for persistent CVB infection resulting in acute endothelial cell activation by virus, which may contribute to selective recruitment of subsets of leukocytes during inflammatory immune responses, such as insulitis in type 1 diabetes. - Zanone, M. M., Favaro, E., Ferioli, E., Huang, G. C., Klein, N. J., Perin, P. C., Peakman, M., Conaldi, P. G., Camussi, G. Human pancreatic islet endothelial cells express coxsackievirus and adenovirus receptor and are activated by coxsackie B virus infection.	Univ Turin, Dept Internal Med, Div Univ Med 1, I-10126 Turin, Italy; Univ Insubria, Dept Med & Publ Hlth, Varese, Italy; Guys Kings & St Thomas Hosp, Dept Immunobiol & Diabet, London, England; Inst Child Hlth, Dept Immunobiol, London, England	University of Turin; University of Insubria; University of London; King's College London; University of London; University College London	Zanone, MM (corresponding author), Univ Turin, Dept Internal Med, Div Univ Med 1, Corso Dogliotti 4, I-10126 Turin, Italy.	mmz@libero.it	Camussi, Giovanni/J-7624-2016; Conaldi, Pier Giulio/AAC-1573-2019	Camussi, Giovanni/0000-0003-2795-232X; Conaldi, Pier Giulio/0000-0003-1994-8005; Klein, Nigel/0000-0003-3925-9258				Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Blaschke S, 2003, ARTHRITIS RHEUM, V48, P1858, DOI 10.1002/art.11171; CAMUSSI G, 1983, J IMMUNOL, V131, P2397; CARLOS TM, 1994, BLOOD, V84, P2068; Carson SD, 1999, J VIROL, V73, P7077, DOI 10.1128/JVI.73.8.7077-7079.1999; Chakrabarti D, 1996, J IMMUNOL, V157, P522; Charakida M, 2005, CIRCULATION, V111, P1660, DOI 10.1161/01.CIR.0000160365.18879.1C; CHATTERJEE NK, 1988, J MED VIROL, V26, P57, DOI 10.1002/jmv.1890260109; Chehadeh T, 2000, J INFECT DIS, V181, P1929, DOI 10.1086/315516; Chehadeh W, 2000, J VIROL, V74, P10153, DOI 10.1128/JVI.74.21.10153-10164.2000; Conaldi PG, 1997, J VIROL, V71, P9180, DOI 10.1128/JVI.71.12.9180-9187.1997; Conaldi PG, 1997, J INFECT DIS, V175, P693, DOI 10.1093/infdis/175.3.693; Fechner H, 2003, CIRCULATION, V107, P876, DOI 10.1161/01.CIR.0000050150.27478.C5; Feldman AM, 2000, NEW ENGL J MED, V343, P1388, DOI 10.1056/NEJM200011093431908; Flodstrom M, 2003, DIABETES, V52, P2025, DOI 10.2337/diabetes.52.8.2025; Flodstrom M, 2002, NAT IMMUNOL, V3, P373, DOI 10.1038/ni771; FOULIS AK, 1987, LANCET, V2, P1423; FRIEDMAN HM, 1981, J INFECT DIS, V143, P266, DOI 10.1093/infdis/143.2.266; Greening JE, 2003, DIABETES, V52, P717, DOI 10.2337/diabetes.52.3.717; HANNINEN A, 1993, J CLIN INVEST, V92, P2509, DOI 10.1172/JCI116859; HANNINEN A, 1992, J CLIN INVEST, V90, P1901, DOI 10.1172/JCI116067; Hedrick JA, 1997, J IMMUNOL, V158, P1533; HEIM A, 1992, J INFECT DIS, V166, P958, DOI 10.1093/infdis/166.5.985; Hingorani AD, 2000, CIRCULATION, V102, P994, DOI 10.1161/01.CIR.102.9.994; Horwitz MS, 1998, NAT MED, V4, P781, DOI 10.1038/nm0798-781; Huang GC, 2004, TRANSPLANTATION, V77, P143, DOI 10.1097/01.TP.0000100401.62912.B2; HUANG XJ, 1995, DIABETES, V44, P658, DOI 10.2337/diabetes.44.6.658; HUBER SA, 1990, J VIROL, V64, P4516, DOI 10.1128/JVI.64.9.4516-4522.1990; Hyoty H, 2002, DIABETOLOGIA, V45, P1353, DOI 10.1007/s00125-002-0852-3; Ito M, 2000, CIRC RES, V86, P275, DOI 10.1161/01.RES.86.3.275; KENNEDY J, 1995, J IMMUNOL, V155, P203; KLINGEL K, 1992, P NATL ACAD SCI USA, V89, P314, DOI 10.1073/pnas.89.1.314; Lidington EA, 1999, TRANSPL IMMUNOL, V7, P239, DOI 10.1016/S0966-3274(99)80008-2; Luppi P, 1998, CIRCULATION, V98, P777, DOI 10.1161/01.CIR.98.8.777; Middel P, 2001, AM J PATHOL, V159, P1751, DOI 10.1016/S0002-9440(10)63022-2; Noutsias M, 1999, CIRCULATION, V99, P2124, DOI 10.1161/01.CIR.99.16.2124; Noutsias M, 2001, CIRCULATION, V104, P275; Olsson R, 2006, INT J BIOCHEM CELL B, V38, P492, DOI 10.1016/j.biocel.2005.06.021; Peterson FC, 2004, J BIOL CHEM, V279, P12598, DOI 10.1074/jbc.M311633200; Roivainen M, 2000, J CLIN ENDOCR METAB, V85, P432, DOI 10.1210/jc.85.1.432; ROSE NR, 1993, CLIN IMMUNOL IMMUNOP, V68, P95, DOI 10.1006/clin.1993.1102; Saijets S, 2003, J MED VIROL, V70, P430, DOI 10.1002/jmv.10413; Savinov AY, 2003, J EXP MED, V197, P643, DOI 10.1084/jem.20021378; SEKO Y, 1993, J CLIN INVEST, V91, P1327, DOI 10.1172/JCI116333; Selinka HC, 2004, MED MICROBIOL IMMUN, V193, P127, DOI 10.1007/s00430-003-0193-y; Shafren DR, 1998, J VIROL, V72, P9407, DOI 10.1128/JVI.72.11.9407-9412.1998; SOMOZA N, 1994, J IMMUNOL, V153, P1360; STEWART TA, 1993, SCIENCE, V260, P1942, DOI 10.1126/science.8100367; SWERLICK RA, 1992, J IMMUNOL, V148, P78; Tough DF, 1996, IMMUNOL REV, V150, P129, DOI 10.1111/j.1600-065X.1996.tb00699.x; Varela-Calvino R, 2003, DIABETES-METAB RES, V19, P431, DOI 10.1002/dmrr.407; Wucherpfennig KW, 2001, J CLIN INVEST, V108, P1097, DOI 10.1172/JCI200114235; Zanone MM, 2005, DIABETOLOGIA, V48, P1789, DOI 10.1007/s00125-005-1865-5; Zanone MM, 2003, J IMMUNOL, V171, P438, DOI 10.4049/jimmunol.171.1.438	54	25	26	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3308	3317		10.1096/fj.06-7905com	http://dx.doi.org/10.1096/fj.06-7905com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17494992				2022-12-28	WOS:000249781600031
J	Donnini, S; Finetti, F; Solito, R; Terzuoli, E; Sacchetti, A; Morbidelli, L; Patrignani, P; Ziche, M				Donnini, Sandra; Finetti, Federica; Solito, Raffaella; Terzuoli, Erika; Sacchetti, Andrea; Morbidelli, Lucia; Patrignani, Paola; Ziche, Marina			EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways	FASEB JOURNAL			English	Article						nitric oxide; prostaglandin E-2; invasiveness	NITRIC-OXIDE SYNTHASE; CANCER CELLS; CYCLOOXYGENASE-2 COX-2; TYROSINE KINASE; PROTEIN-KINASE; CROSS-TALK; ACTIVATION; EXPRESSION; HEAD; PHOSPHORYLATION	In squamous cell carcinoma, the levels of nitric oxide ( NO) derived from inducible NO synthase ( iNOS) and prostaglandin E-2 ( PGE(2)) derived from cyclooxygenase-2 ( COX-2) originated from tumor cells or tumor-associated inflammatory cells have been reported to correlate with tumor growth, metastasis, and angiogenesis. The present study examined the role of the iNOS signaling pathway in PGE(2)-mediated tumor invasiveness and proliferation in squamous cell carcinoma, A431, and SCC-9 cells. Cell invasion and proliferation promoted by PGE2 were blocked by iNOS silencing RNA or iNOS/guanylate cyclase ( GC) pharmacological inhibition. Consistently, iNOS-GC pathway inhibitors blocked mitogen-activated protein kinase-ERK1/2 phosphorylation, which was required to mediate PGE2 functions. In vivo, in A431 cells implanted in nude mice, GC inhibition also decreased the tumor proliferation index and ERK1/2 activation. PGE2 effects were confined to the selective stimulation of the EP2 receptor subtype, leading to epidermal growth factor receptor ( EGFR) transactivation via protein kinase A ( PKA) and c-Src activation. EP2-mediated ERK1/2 activation and cell functions were abolished by inhibitors of PKA, c-Src, and EGFR, as well as by inhibiting iNOS pathway. Silencing of iNOS also impaired EGFR-induced ERK1/2 phosphorylation. These results indicate that iNOS/GC signaling is a downstream player in the control of EP2/EGFR-mediated tumor cell proliferation and invasion.	Univ Siena, Pharmacol Angiogenesis Lab, Dept Mol Biol, I-53100 Siena, Italy; Univ G dAnnunzio, Dept Pharmacol, Chieti, Italy	University of Siena; G d'Annunzio University of Chieti-Pescara	Ziche, M (corresponding author), Univ Siena, Pharmacol Angiogenesis Lab, Dept Mol Biol, Via Aldo Moro 2, I-53100 Siena, Italy.	ziche@unisi.it	Sacchetti, Andrea/H-8763-2019; Finetti, Federica/J-9089-2016; Morbidelli, Lucia/K-4053-2016; Patrignani, Paola/B-4844-2011; Donnini, Sandra/K-9252-2019; Morbidelli, Lucia/AAC-7858-2020; Terzuoli, Erika/M-7346-2016	Morbidelli, Lucia/0000-0001-8148-7049; Patrignani, Paola/0000-0003-1419-2691; Donnini, Sandra/0000-0001-6617-1644; Terzuoli, Erika/0000-0001-9248-4505				Bae SH, 2001, CLIN CANCER RES, V7, P1410; BREYER RM, 2001, ANN REV PHARM TOXICO, V41, P561; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Cantara S, 2004, FASEB J, V18, P1943, DOI 10.1096/fj.04-2114fje; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chen ZG, 2004, CLIN CANCER RES, V10, P5930, DOI 10.1158/1078-0432.CCR-03-0677; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Denkert C, 2002, AM J PATHOL, V160, P893, DOI 10.1016/S0002-9440(10)64912-7; Donnini S, 2004, LIFE SCI, V74, P2975, DOI 10.1016/j.lfs.2003.09.075; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fujino H, 2005, MOL PHARMACOL, V68, P251, DOI 10.1124/mol.105.011833; Fujino H, 2003, TRENDS PHARMACOL SCI, V24, P335, DOI 10.1016/S0165-6147(03)00162-7; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; FUNK CD, 1993, J BIOL CHEM, V268, P26767; Galisteo M, 1999, J PHARMACOL EXP THER, V290, P1270; Gallo O, 2002, BIOCHEM BIOPH RES CO, V299, P517, DOI 10.1016/S0006-291X(02)02683-9; Gallo O, 1998, J NATL CANCER I, V90, P587, DOI 10.1093/jnci/90.8.587; Gullick WJ, 2001, ENDOCR-RELAT CANCER, V8, P75, DOI 10.1677/erc.0.0080075; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Harborth J, 2001, J CELL SCI, V114, P4557; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; HONDA A, 1993, J BIOL CHEM, V268, P7759; Hood J, 1998, J BIOL CHEM, V273, P23504, DOI 10.1074/jbc.273.36.23504; HOOD JD, 1999, AM J PHYSIOL, V274, pH1054; Iwakiri Y, 2002, AM J PHYSIOL-HEART C, V282, pH2084, DOI 10.1152/ajpheart.00675.2001; Jadeski LC, 2003, INT J CANCER, V106, P496, DOI 10.1002/ijc.11268; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Krysan K, 2005, CANCER RES, V65, P6275, DOI 10.1158/0008-5472.CAN-05-0216; Lui VWY, 2002, ANTICANCER RES, V22, P1; Majima M, 2003, TRENDS PHARMACOL SCI, V24, P524, DOI 10.1016/j.tips.2003.08.005; Mutoh M, 2002, CANCER RES, V62, P28; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Pai R, 2003, FASEB J, V17, P1640, DOI 10.1096/fj.02-1011com; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Park SW, 2003, INT J CANCER, V107, P729, DOI 10.1002/ijc.11498; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; REGAN JW, 1994, MOL PHARMACOL, V46, P213; Sales KJ, 2004, MOL ENDOCRINOL, V18, P1533, DOI 10.1210/me.2004-0022; Salvemini D, 1996, J CLIN INVEST, V97, P2562, DOI 10.1172/JCI118704; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Shah J P, 1993, Curr Probl Surg, V30, P1; Shao JY, 2004, J BIOL CHEM, V279, P14287, DOI 10.1074/jbc.M313276200; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; Taraboletti G, 2000, FASEB J, V14, P1674; Thomas SM, 2006, CANCER RES, V66, P11831, DOI 10.1158/0008-5472.CAN-06-2876; THOMSEN LL, 1995, BRIT J CANCER, V72, P41, DOI 10.1038/bjc.1995.274; Timoshenko AV, 2004, INT J CANCER, V108, P384, DOI 10.1002/ijc.11575; Timoshenko AV, 2003, EXP CELL RES, V289, P265, DOI 10.1016/S0014-4827(03)00269-6; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Wendum D, 2004, VIRCHOWS ARCH, V445, P327, DOI 10.1007/s00428-004-1105-2; Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133; Yarden Y, 2001, EUR J CANCER, V37, pS3	57	77	79	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2418	2430		10.1096/fj.06-7581com	http://dx.doi.org/10.1096/fj.06-7581com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17384145				2022-12-28	WOS:000248454400017
J	Karunakaran, S; Diwakar, L; Saeed, U; Agarwal, V; Ramakrishnan, S; Iyengar, S; Ravindranath, V				Karunakaran, Smitha; Diwakar, Latha; Saeed, Uzma; Agarwal, Varsha; Ramakrishnan, Sujanitha; Iyengar, Soumya; Ravindranath, Vijayalakshmi			Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid	FASEB JOURNAL			English	Article						MAPK signaling; MPTP; DJ-1; oxidative stress; cell death	MITOCHONDRIAL COMPLEX-I; OXIDATIVE STRESS; BRAIN MITOCHONDRIA; S-THIOLATION; AMINO-ACIDS; CELL-DEATH; MPTP; VIVO; NEURODEGENERATION; THIOREDOXIN	Parkinson's disease (PD), a neurodegenerative disorder, causes severe motor impairment due to loss of dopaminergic neurons in substantia nigra pars compacta (SNpc). MPTP, a neurotoxin that causes dopaminergic cell loss in mice, was used in an animal model to study the pathogenic mechanisms leading to neurodegeneration. We observed the activation of apoptosis signal regulating kinase (ASK1, MAPKKK) and phosphorylation of its downstream targets MKK4 and JNK, 12 h after administration of a single dose of MPTP. Further, Daxx, the death-associated protein, translocated to the cytosol selectively in SNpc neurons seemingly due to MPTP mediated down-regulation of DJ-1, the redox-sensitive protein that binds Daxx in the nucleus. Coadministration of alpha-lipoic acid (ALA), a thiol antioxidant, abolished the activation of ASK1 and phosphorylation of downstream kinases, MKK4, and JNK and prevented the down-regulation of DJ-1 and translocation of Daxx to the cytosol seen after MPTP. ALA also attenuated dopaminergic cell loss in SNpc seen after subchronic MPTP treatment. Our studies demonstrate for the first time that MPTP triggers death signaling pathway by activating ASK1 and translocating Daxx, in vivo, in dopaminergic neurons in SNpc of mice and thiol antioxidants, such as ALA terminate this cascade and afford neuroprotection.-Karunakaran, S., Diwakar, L., Saeed, U., Agarwal, V., Ramakrishnan, S., Iyengar, S., Ravindranath, V. Activation of apoptosis signal regulating kinase 1 ( ASK1) and translocation of death associated protein, Daxx in substantia nigra pars compacta in a mouse model of Parkinson's disease: Protection by alpha-lipoic acid.	Natl Brain Res Ctr, Div Mol & Cellular Neurosci, Manesar 122050, India; Natl Brain Res Ctr, Div Syst Neurosci, Manesar 122050, India	Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC); Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC)	Ravindranath, V (corresponding author), Natl Brain Res Ctr, Div Mol & Cellular Neurosci, Manesar 122050, India.	vijir@nbrc.ac.in		Karunakaran, Smitha/0000-0002-9489-7431				Akterin S, 2006, CELL DEATH DIFFER, V13, P1454, DOI 10.1038/sj.cdd.4401818; Annepu J, 2000, NEUROSCI LETT, V289, P209, DOI 10.1016/S0304-3940(00)01300-8; Beer SM, 2004, J BIOL CHEM, V279, P47939, DOI 10.1074/jbc.M408011200; Bezard E, 1999, EXP NEUROL, V155, P268, DOI 10.1006/exnr.1998.6995; Bharath S, 2002, NEUROTOXICOLOGY, V23, P479, DOI 10.1016/S0161-813X(02)00035-9; BLOEM BR, 1990, J NEUROL SCI, V97, P273, DOI 10.1016/0022-510X(90)90225-C; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN P, 1991, J NEUROCHEM, V57, P348, DOI 10.1111/j.1471-4159.1991.tb02134.x; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Diwakar L, 2007, NEUROCHEM INT, V50, P418, DOI 10.1016/j.neuint.2006.09.014; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627; HEINONEN K, 1973, BIOCHEM J, V136, P1011, DOI 10.1042/bj1361011; Hornykiewicz O, 1975, Natl Inst Drug Abuse Res Monogr Ser, P13; Junn E, 2005, P NATL ACAD SCI USA, V102, P9691, DOI 10.1073/pnas.0409635102; Keeney PM, 2006, J NEUROSCI, V26, P5256, DOI 10.1523/JNEUROSCI.0984-06.2006; Kenchappa RS, 2003, FASEB J, V17, P717, DOI 10.1096/fj.02-0771fje; Khelifi AF, 2005, CELL DEATH DIFFER, V12, P724, DOI 10.1038/sj.cdd.4401559; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Nishida K, 2006, ANTIOXID REDOX SIGN, V8, P1729, DOI 10.1089/ars.2006.8.1729; Ouyang MX, 2006, J NEUROCHEM, V97, P234, DOI 10.1111/j.1471-4159.2006.03730.x; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Peng J, 2004, J BIOL CHEM, V279, P32626, DOI 10.1074/jbc.M404596200; RAVINDRANATH V, 1990, BIOCHEM BIOPH RES CO, V169, P1075, DOI 10.1016/0006-291X(90)92004-J; Ricchelli F, 2005, INT J BIOCHEM CELL B, V37, P1858, DOI 10.1016/j.biocel.2005.04.001; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Saporito MS, 1999, J PHARMACOL EXP THER, V288, P421; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; SHIVAKUMAR BR, 1995, J PHARMACOL EXP THER, V274, P1167; Song JJ, 2003, J BIOL CHEM, V278, P47245, DOI 10.1074/jbc.M213201200; Song JJ, 2004, J BIOL CHEM, V279, P30573, DOI 10.1074/jbc.M404512200; Sriram K, 1998, J NEUROSCI, V18, P10287; SRIRAM K, 1995, J NEUROCHEM, V64, P1203; Sriram K, 1997, BRAIN RES, V749, P44, DOI 10.1016/S0006-8993(96)01271-1; Takahashi-Niki K, 2004, BIOCHEM BIOPH RES CO, V320, P389, DOI 10.1016/j.bbrc.2004.05.187; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	41	112	123	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2226	2236		10.1096/fj.06-7580com	http://dx.doi.org/10.1096/fj.06-7580com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17369508				2022-12-28	WOS:000247500300031
J	Kislin, KL; Marron, MT; Li, G; Graner, MW; Katsanis, E				Kislin, Kerri L.; Marron, Marilyn T.; Li, Gang; Graner, Michael W.; Katsanis, Emmanuel			Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia	FASEB JOURNAL			English	Article						heat-shock proteins; peptide antigens; anticancer vaccine; T-cells; isoelectric focusing	HEAT-SHOCK PROTEINS; CHRONIC MYELOGENOUS LEUKEMIA; CD8(+) T-CELLS; DENDRITIC CELLS; ANTIGEN PRESENTATION; IMATINIB MESYLATE; CANCER VACCINES; TUMOR REJECTION; STRESS-PROTEINS; IMMUNITY	Chaperone proteins are effective antitumor vaccines when purified from a tumor source, some of which are in clinical trials. Such vaccines culminate in tumor-specific T cell responses, implicating the role of adaptive immunity. We have developed a rapid and efficient procedure utilizing an isoelectric focusing technique to obtain vaccines from tumor or normal tissues called chaperone-rich cell lysate (CRCL). Tumor-associated peptides, the currency of T cell-mediated anticancer immunity, are believed to be purveyed by chaperone vaccines. Our purpose was to demonstrate our ability to manipulate the peptide antigen repertoire of CRCL vaccines as a novel anticancer strategy. Our methods allow us to prepare "designer" CRCL, utilizing the immunostimulation activity and the carrying capacity of CRCL to quantitatively acquire and deliver exogenous antigenic peptides (e. g., derived from the oncogenic BCR/ABL protein in chronic myelogenous leukemia). Using fluorescence-based and antigen-presentation assays, we determined that significant quantities of exogenously added peptide could accumulate in "designer" CRCL and could stimulate T cell activation. Further, we concluded that peptideembedded CRCL, devoid of other antigens, could generate potent immunity against pre-established murine leukemia. Designer CRCL allows for the development of personalized vaccines against cancers expressing known antigens, by embedding antigens into CRCL derived from normal tissue.	Duke Univ, Med Ctr, Pathol Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27706 USA; Univ Arizona, Canc Biol Interdisciplinary Program, Tucson, AZ USA; Duke Univ, Ctr Med, Durham, NC USA; Univ Arizona, Steele Childrens Res Ctr, Tucson, AZ USA	Duke University; University of Arizona; Duke University; University of Arizona	Graner, MW (corresponding author), Duke Univ, Med Ctr, Pathol Preston Robert Tisch Brain Tumor Ctr, Box 3156 Med Sci Res Bldg 173A, Durham, NC 27706 USA.	michael.graner@duke.edu	Katsanis, Emmanuel/D-9600-2011	Katsanis, Emmanuel/0000-0003-1466-6965	NATIONAL CANCER INSTITUTE [R01CA104926, P30CA023074, T32CA009213] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104926, CA023074-26, T32 CA09213] Funding Source: Medline; NIEHS NIH HHS [ES06694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baker-LePain JC, 2004, J IMMUNOL, V172, P4195, DOI 10.4049/jimmunol.172.7.4195; Baker-LePain JC, 2003, CURR OPIN IMMUNOL, V15, P89, DOI 10.1016/S0952791502000067; Baker-LePain JC, 2002, J EXP MED, V196, P1447, DOI 10.1084/jem.20020436; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Becker T, 2002, J CELL BIOL, V158, P1277, DOI 10.1083/jcb.200208083; Berwin B, 2003, EMBO J, V22, P6127, DOI 10.1093/emboj/cdg572; Binder RJ, 2005, NAT IMMUNOL, V6, P593, DOI 10.1038/ni1201; Binder RJ, 2001, J BIOL CHEM, V276, P17163, DOI 10.1074/jbc.M011547200; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Calderwood SK, 2005, INT J HYPERTHER, V21, P713, DOI 10.1080/02656730500340794; Chen XC, 2006, BIOL BLOOD MARROW TR, V12, P275, DOI 10.1016/j.bbmt.2006.01.001; Delneste Y, 2002, IMMUNITY, V17, P353, DOI 10.1016/S1074-7613(02)00388-6; Facciponte JG, 2005, IMMUNOL INVEST, V34, P325, DOI 10.1081/IMM-200064505; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; Feng HP, 2003, BLOOD, V101, P245, DOI 10.1182/blood-2002-05-1580; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Graner M, 2000, CANCER IMMUNOL IMMUN, V49, P476, DOI 10.1007/s002620000138; Graner MW, 2003, CANCER IMMUNOL IMMUN, V52, P226, DOI 10.1007/s00262-002-0359-2; He L, 2001, CANCER IMMUNOL IMMUN, V50, P31, DOI 10.1007/PL00006680; HORIMOTO M, 1995, BRIT J CANCER, V72, P676, DOI 10.1038/bjc.1995.393; Indrova M, 2004, FOLIA BIOL-PRAGUE, V50, P184; Kobie JJ, 2003, CANCER RES, V63, P1860; Kunisawa J, 2003, MOL CELL, V12, P565, DOI 10.1016/j.molcel.2003.08.009; Li Z, 1997, Semin Immunol, V9, P315, DOI 10.1006/smim.1997.0087; Li ZH, 2005, CLIN CANCER RES, V11, P4460, DOI 10.1158/1078-0432.CCR-05-0250; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; Liau LM, 2005, CLIN CANCER RES, V11, P5515, DOI 10.1158/1078-0432.CCR-05-0464; MacAry PA, 2004, IMMUNITY, V20, P95, DOI 10.1016/S1074-7613(03)00357-1; Manjili MH, 2002, CANCER RES, V62, P1737; Mosca PJ, 2005, CANC TREAT, V123, P369; Nicchitta CV, 2004, CELL STRESS CHAPERON, V9, P325, DOI 10.1379/CSC-62.1; Nicchitta CV, 2003, NAT REV IMMUNOL, V3, P427, DOI 10.1038/nri1089; Nieda M, 1998, BLOOD, V91, P977, DOI 10.1182/blood.V91.3.977.977_977_983; Oki Yasuhiro, 2004, Expert Rev Vaccines, V3, P403, DOI 10.1586/14760584.3.4.403; Park JE, 2006, CANCER RES, V66, P1161, DOI 10.1158/0008-5472.CAN-05-2609; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Renkvist N, 2001, CANCER IMMUNOL IMMUN, V50, P3, DOI 10.1007/s002620000169; Rosser MFN, 2004, BIOCHEMISTRY-US, V43, P8835, DOI 10.1021/bi049539q; Shah M, 1998, HISTOCHEM J, V30, P509, DOI 10.1023/A:1003259907014; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Speiser DE, 2003, SEMIN CANCER BIOL, V13, P461, DOI 10.1016/j.semcancer.2003.09.010; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; tenBosch GJA, 1996, BLOOD, V88, P3522, DOI 10.1182/blood.V88.9.3522.bloodjournal8893522; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; VandenEynde BJ, 1997, CURR OPIN IMMUNOL, V9, P684, DOI 10.1016/S0952-7915(97)80050-7; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Wang XY, 2004, METHODS, V32, P13, DOI 10.1016/S1046-2023(03)00181-6; Wang XY, 2001, J IMMUNOL, V166, P490, DOI 10.4049/jimmunol.166.1.490; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; Wells AD, 2000, IMMUNOL TODAY, V21, P129, DOI 10.1016/S0167-5699(99)01558-3; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; Yotnda P, 1998, J CLIN INVEST, V101, P2290, DOI 10.1172/JCI488; Yu JS, 2001, CANCER RES, V61, P842; Zeng Y, 2005, BLOOD, V105, P2016, DOI 10.1182/blood-2004-05-1915; Zeng Y, 2004, INT J CANCER, V110, P251, DOI 10.1002/ijc.20115; Zeng Y, 2003, BLOOD, V101, P4485, DOI 10.1182/blood-2002-10-3108	58	14	18	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2173	2184		10.1096/fj.06-7843com	http://dx.doi.org/10.1096/fj.06-7843com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17327358				2022-12-28	WOS:000247500300026
J	Michelotti, GA; Brinkley, DM; Morris, DP; Smith, MP; Louie, RJ; Schwinn, DA				Michelotti, Gregory A.; Brinkley, D. Marshall; Morris, Daniel P.; Smith, Michael P.; Louie, Raphael J.; Schwinn, Debra A.			Epigenetic regulation of human alpha(1d)-adrenergic receptor gene expression: a role for DNA methylation in Sp1-dependent regulation	FASEB JOURNAL			English	Article						transcription; cell-specific; promoter	CPG-BINDING-PROTEIN; SUBTYPE MESSENGER-RNAS; DE-NOVO METHYLATION; BREAST-CANCER CELLS; LOWER URINARY-TRACT; GROWTH-FACTOR; ALPHA(1B)-ADRENERGIC RECEPTOR; CARDIAC-HYPERTROPHY; PROMOTER REGION; ALPHA(1)-ADRENERGIC RECEPTORS	A growing body of evidence implicates alpha(1)-adrenergic receptors (alpha(1)ARs) as potent regulators of growth pathways. The three alpha(1)AR subtypes (alpha(1a)AR, alpha(1b)AR, alpha(1d)AR) display highly restricted tissue expression that undergoes subtype switching with many pathological stimuli, the mechanistic basis of which remains unknown. To gain insight into transcriptional pathways governing cell-specific regulation of the human alpha(1d)AR subtype, we cloned and characterized the alpha(1d)AR promoter region in two human cellular models that display disparate levels of endogenous alpha(1d)AR expression (SK-N-MC and DU145). Results reveal that alpha(1d)AR basal expression is regulated by Sp1-dependent binding of two promoter-proximal GC boxes, the mutation of which attenuates alpha(1d)AR promoter activity 10-fold. Mechanistically, chromatin immunoprecipitation data demonstrate that Sp1 binding correlates with expression of the endogenous gene in vivo, correlating highly with alpha(1d)AR promoter methylation-dependent silencing of both episomally expressed reporter constructs and the endogenous gene. Further, analysis of methylation status of proximal GC boxes using sodium bisulfite sequencing reveals differential methylation of proximal GC boxes in the two cell lines examined. Together, the data support a mechanism of methylation-dependent disruption of Sp1 binding in a cell-specific manner resulting in repression of basal alpha(1d)AR expression.	Duke Univ, Med Ctr, Dept Pharmacol Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Cardiol & Surg, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Michelotti, GA (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol Canc Biol, Durham, NC 27710 USA.	miche007@mc.duke.edu		Schwinn, Debra/0000-0002-9696-5231; Michelotti, Gregory/0000-0002-7908-1979	NHLBI NIH HHS [R01 HL049103, R37 HL049103, R37 HL049103-13, R37 HL049103-12, R37 HL049103-11, HL49103] Funding Source: Medline; NIA NIH HHS [AG17566, R01 AG017566] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049103, R37HL049103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017566] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLEN KB, 1992, J VASC SURG, V16, P391, DOI 10.1016/0741-5214(92)90372-F; Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; ANYUKHOVSKY EP, 1994, CIRC RES, V74, P937, DOI 10.1161/01.RES.74.5.937; Aoyama T, 2004, J BIOL CHEM, V279, P28789, DOI 10.1074/jbc.M401273200; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Bahouth SW, 2002, MOL PHARMACOL, V61, P379, DOI 10.1124/mol.61.2.379; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Brero A, 2006, CURR TOP MICROBIOL, V301, P21; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Chen JP, 1997, J BIOL CHEM, V272, P23144, DOI 10.1074/jbc.272.37.23144; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; de Mey C, 1998, EUR UROL, V34, P18, DOI 10.1159/000052284; Doerfler W, 2006, CURR TOP MICROBIOL, V301, P125; Dunn CJ, 2002, DRUG AGING, V19, P135, DOI 10.2165/00002512-200219020-00004; Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GAO B, 1994, J BIOL CHEM, V269, P15762; GAO Y, 1993, APPL SUPERCOND, V1, P131, DOI 10.1016/0964-1807(93)90389-J; GEE JE, 1992, J BIOL CHEM, V267, P11163; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gonzalez-Cabrera PJ, 2004, ENDOCRINOLOGY, V145, P5157, DOI 10.1210/en.2004-0728; Gonzalez-Cabrera PJ, 2003, MOL PHARMACOL, V63, P1104, DOI 10.1124/mol.63.5.1104; Hampel C, 2002, J UROLOGY, V167, P1513, DOI 10.1016/S0022-5347(05)65355-4; Holmes R, 2006, CYTOGENET GENOME RES, V113, P122, DOI 10.1159/000090823; Ibarra M, 1997, EUR J PHARMACOL, V322, P221, DOI 10.1016/S0014-2999(97)00092-7; Jin SG, 2005, J BIOL CHEM, V280, P12700, DOI 10.1074/jbc.M413492200; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Keffel S, 2000, BIOCHEM BIOPH RES CO, V272, P906, DOI 10.1006/bbrc.2000.2850; Koshimizu T, 2003, PHARMACOL THERAPEUT, V98, P235, DOI 10.1016/S0163-7258(03)00033-0; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113; Leech CJ, 1996, AM J PHYSIOL-HEART C, V270, pH710, DOI 10.1152/ajpheart.1996.270.2.H710; LI HT, 1995, CIRCULATION, V92, P918, DOI 10.1161/01.CIR.92.4.918; Lin G, 2001, CIRC RES, V89, P343, DOI 10.1161/hh1601.095912; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; Majumder S, 2006, J CELL BIOCHEM, V97, P1300, DOI 10.1002/jcb.20738; Malloy BJ, 1998, J UROLOGY, V160, P937, DOI 10.1016/S0022-5347(01)62836-2; Michelotti GA, 2003, J BIOL CHEM, V278, P8693, DOI 10.1074/jbc.M211986200; Michelotti GA, 2000, PHARMACOL THERAPEUT, V88, P281, DOI 10.1016/S0163-7258(00)00092-9; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; Minneman KP, 2000, J NEUROCHEM, V74, P2392, DOI 10.1046/j.1471-4159.2000.0742392.x; Morris DP, 2005, J BIOL CHEM, V280, P31368, DOI 10.1074/jbc.M501546200; Morris DP, 2004, MOL PHARMACOL, V66, P843, DOI 10.1124/mol.104.000430; Mulero-Navarro S, 2006, CARCINOGENESIS, V27, P1099, DOI 10.1093/carcin/bgi344; Narayan P, 2001, UROLOGY, V57, P466, DOI 10.1016/S0090-4295(00)01042-6; O'Connell TD, 2001, MOL PHARMACOL, V59, P1225, DOI 10.1124/mol.59.5.1225; Podgoreanu MV, 2005, J THORAC CARDIOV SUR, V130, P330, DOI 10.1016/j.jtcvs.2004.11.052; Price D, 2001, EUR UROL, V40, P5, DOI 10.1159/000049889; Price DT, 2000, J UROLOGY, V164, P2145, DOI 10.1016/S0022-5347(05)66987-X; PRICE DT, 1994, MOL PHARMACOL, V45, P171; PRICE DT, 1994, MOL PHARMACOL, V46, P221; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; Razik MA, 1997, J BIOL CHEM, V272, P28237, DOI 10.1074/jbc.272.45.28237; REILLY PM, 1993, CRIT CARE MED, V21, pS55, DOI 10.1097/00003246-199302001-00011; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Rokosh DG, 1996, J BIOL CHEM, V271, P5839, DOI 10.1074/jbc.271.10.5839; Rudner XL, 1999, CIRCULATION, V100, P2336, DOI 10.1161/01.CIR.100.23.2336; RUFFOLO RR, 1985, PHARMACOL BIOCHEM BE, V22, P827, DOI 10.1016/0091-3057(85)90535-0; Sado T, 2005, HUM MOL GENET, V14, pR59, DOI 10.1093/hmg/ddi117; SCHWINN DA, 1995, J PHARMACOL EXP THER, V272, P134; Schwinn DA, 2000, BJU INT, V85, P6, DOI 10.1046/j.1464-410X.2000.00061.x; Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011; Shibata K, 2003, J BIOL CHEM, V278, P672, DOI 10.1074/jbc.M201375200; STEWART AFR, 1994, CIRC RES, V75, P796, DOI 10.1161/01.RES.75.4.796; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Wang GL, 2003, J BIOL CHEM, V278, P40550, DOI 10.1074/jbc.M302879200; Wenger RH, 1998, EUR J BIOCHEM, V253, P771, DOI 10.1046/j.1432-1327.1998.2530771.x; Xin XH, 1999, MOL PHARMACOL, V56, P1152, DOI 10.1124/mol.56.6.1152; Xin XH, 1997, MOL PHARMACOL, V51, P764, DOI 10.1124/mol.51.5.764; Yun J, 2003, CARDIOVASC RES, V57, P443, DOI 10.1016/S0008-6363(02)00696-X; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zhang Q, 2005, MOL ENDOCRINOL, V19, P2390, DOI 10.1210/me.2005-0096; Zhang Y, 2005, MOL CELL BIOL, V25, P7929, DOI 10.1128/MCB.25.18.7929-7939.2005; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003; Zuscik MJ, 1999, MOL PHARMACOL, V56, P1288, DOI 10.1124/mol.56.6.1288	79	35	37	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					1979	1993		10.1096/fj.06-7118com	http://dx.doi.org/10.1096/fj.06-7118com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17384146	Green Accepted			2022-12-28	WOS:000247500300008
J	Lorenz, M; Hewing, B; Hui, JY; Zepp, A; Baumann, G; Bindereif, A; Stangl, V; Stangl, K				Lorenz, Mario; Hewing, Bernd; Hui, Jingyi; Zepp, Angela; Baumann, Gert; Bindereif, Albrecht; Stangl, Verena; Stangl, Karl			Alternative splicing in intron 13 of the human eNOS gene: a potential mechanism for regulating eNOS activity	FASEB JOURNAL			English	Article						NOS; endothelium NO; CA repeats	NITRIC-OXIDE SYNTHASE; PRE-MESSENGER-RNA; CA-REPEAT; EXPRESSION; PROTEINS; DISEASE; INHIBITION; ACTIVATION; ISOFORMS; SUBUNIT	NO, the product of endothelial NOS ( eNOS), is a major regulator of vascular homeostasis and a critical factor in preventing cardiovascular diseases. We previously established a positive correlation between the number of variable CA repeats in intron 13 of human eNOS and the risk of coronary artery disease, and demonstrated that these polymorphic CA repeats function as a length-dependent splicing enhancer. By 5'-RACE polymerase chain reaction (PCR), we detected three splice variants containing novel 3' splice sites within intron 13 - termed eNOS13A, eNOS13B, and eNOS13C - which share the first 13 exons of human eNOS and the same polyadenylation site at the end of the novel exon. When translated, all these splice variants would result in truncated proteins lacking eNOS activity. Coexpression of full- length eNOS with eNOS13A diminished eNOS enzyme activity in COS- 7 cells by formation of heterodimers. The splice variants were expressed in endothelial cells and various human tissues. Finally, we demonstrate, using minigene transfection, that the expression of the eNOS13A splice variant is increased with high CA repeat numbers in intron 13. These data suggest a new mechanism for the regulation of eNOS activity and NO production in the cardiovascular system by truncated, dominant- negative splice variants of human eNOS.	Charite Univ Med Berlin, CCM, Med Klin Schwerpunkt Kardiol & Angiol, D-10117 Berlin, Germany; Univ Giessen, Inst Biochem, Giessen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Justus Liebig University Giessen	Stangl, K (corresponding author), Charite Univ Med Berlin, CCM, Med Klin Schwerpunkt Kardiol & Angiol, Charite Pl 1, D-10117 Berlin, Germany.	karl.stangl@charite.de		Lorenz, Mario/0000-0001-5267-4101				Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; BEHRENDS S, 1995, J BIOL CHEM, V270, P21109, DOI 10.1074/jbc.270.36.21109; Bodo I, 2001, BLOOD, V98, P2973, DOI 10.1182/blood.V98.10.2973; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Chavez-Gutierrez L, 2005, J NEUROCHEM, V92, P807, DOI 10.1111/j.1471-4159.2004.02916.x; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Eissa NT, 1996, J BIOL CHEM, V271, P27184, DOI 10.1074/jbc.271.43.27184; Eliasson MJL, 1997, P NATL ACAD SCI USA, V94, P3396, DOI 10.1073/pnas.94.7.3396; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; GOUX O, 1996, ANNU REV BIOCHEM, V65, P801; Hui JY, 2005, EMBO J, V24, P1988, DOI 10.1038/sj.emboj.7600677; Hui JY, 2003, NAT STRUCT BIOL, V10, P33, DOI 10.1038/nsb875; Jiang JH, 2003, J BIOL CHEM, V278, P49332, DOI 10.1074/jbc.M304738200; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Magee T, 1996, BIOCHEM BIOPH RES CO, V226, P145, DOI 10.1006/bbrc.1996.1324; NADAUD S, 1994, BIOCHEM BIOPH RES CO, V198, P1027, DOI 10.1006/bbrc.1994.1146; Park CS, 2000, NITRIC OXIDE-BIOL CH, V4, P459, DOI 10.1006/niox.2000.0300; RodriguezCrespo I, 1996, ARCH BIOCHEM BIOPHYS, V336, P151, DOI 10.1006/abbi.1996.0543; SESSA WC, 1993, HYPERTENSION, V21, P934, DOI 10.1161/01.HYP.21.6.934; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stangl K, 2000, PHARMACOGENETICS, V10, P133, DOI 10.1097/00008571-200003000-00005; Stangl V, 2005, J NUTR, V135, P172, DOI 10.1093/jn/135.2.172; Stangl V, 2004, FASEB J, V18, P272, DOI 10.1096/fj.03-0054com; Stasiv Y, 2004, GENE DEV, V18, P1812, DOI 10.1101/gad.298004; Stasiv Y, 2001, J BIOL CHEM, V276, P42241, DOI 10.1074/jbc.M105066200; Tiscornia AC, 2004, LEUKEMIA, V18, P48, DOI 10.1038/sj.leu.2403169; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; Wang Y, 1997, J BIOL CHEM, V272, P11392; XU WM, 1998, CELL RES, V4, P251	32	35	36	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1556	1564		10.1096/fj.06-7434com	http://dx.doi.org/10.1096/fj.06-7434com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264164				2022-12-28	WOS:000246117000030
J	Nussbaum, J; Minami, E; Laflamme, MA; Virag, JAI; Ware, CB; Masino, A; Muskheli, V; Pabon, L; Reinecke, H; Murry, CE				Nussbaum, Jeannette; Minami, Elina; Laflamme, Michael A.; Virag, Jitka A. I.; Ware, Carol B.; Masino, Amanda; Muskheli, Veronica; Pabon, Lil; Reinecke, Hans; Murry, Charles E.			Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response	FASEB JOURNAL			English	Article						cardiomyocyte differentiation; rejection; tolerance; fusion; autofluorescence	SKELETAL MYOBLAST TRANSPLANTATION; INFARCTED MYOCARDIUM; GENE-EXPRESSION; IN-VITRO; CELLULAR CARDIOMYOPLASTY; CARDIAC-FUNCTION; CARDIOMYOCYTES; DIFFERENTIATION; BODIES; REPAIR	Embryonic stem (ES) cells are promising for cardiac repair, but directing their differentiation toward cardiomyocytes remains challenging. We investigated whether the heart guides ES cells toward cardiomyocytes in vivo and whether allogeneic ES cells were immunologically tolerated. Undifferentiated mouse ES cells consistently formed cardiac teratomas in nude or immunocompetent syngeneic mice. Cardiac teratomas contained no more cardiomyocytes than hind-limb teratomas, suggesting lack of guided differentiation. ES cells also formed teratomas in infarcted hearts, indicating injury-related signals did not direct cardiac differentiation. Allogeneic ES cells also caused cardiac teratomas, but these were immunologically rejected after several weeks, in association with increased inflammation and up-regulation of class I and II histocompatibility antigens. Fusion between ES cells and cardiomyocytes occurred in vivo, but was rare. Infarct autofluorescence was identified as an artifact that might be mistaken for enhanced GFP expression and true regeneration. Hence, undifferentiated ES cells were not guided toward a cardiomyocyte fate in either normal or infarcted hearts, and there was no evidence for allogeneic immune tolerance of ES cell derivatives. Successful cardiac repair strategies involving ES cells will need to control cardiac differentiation, avoid introducing undifferentiated cells, and will likely require immune modulation to avoid rejection.	Univ Washington, Inst Stem Cell & Regenerat Med, Ctr Cardiovasc Biol, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98109 USA; Univ Washington, Dept Med Cardiol, Seattle, WA 98109 USA; Univ Washington, Dept Comparat Med, Seattle, WA 98109 USA; Univ Washington, Ctr Cardiovasc Biol, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Murry, CE (corresponding author), Univ Washington, Inst Stem Cell & Regenerat Med, Ctr Cardiovasc Biol, 815 Mercer St, Seattle, WA 98109 USA.	murry@u.washington.edu	Virag, Jitka/AAW-6690-2020; Laflamme, Michael/AAV-6791-2021; Virag, Jitka Amira Ismail/AAW-7427-2020	Laflamme, Michael/0000-0001-5908-880X; Virag, Jitka Amira Ismail/0000-0003-3321-9861	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL003174, R24HL064387, R01HL061553] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL03174, R01 HL61553, R24 HL64387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Atkins BZ, 1999, J HEART LUNG TRANSPL, V18, P1173, DOI 10.1016/S1053-2498(99)00096-0; Behfar A, 2002, FASEB J, V16, P1558, DOI 10.1096/fj.02-0072com; BOER PH, 1994, BIOCHEM BIOPH RES CO, V199, P954, DOI 10.1006/bbrc.1994.1322; CHEN U, 1993, DEV DYNAM, V197, P217, DOI 10.1002/aja.1001970306; CHIU RCJ, 1995, ANN THORAC SURG, V60, P12; Choi DH, 2002, CELL TRANSPLANT, V11, P359; Damjanov I, 1974, Curr Top Pathol, V59, P69; GANIM JR, 1992, CIRC RES, V71, P1021, DOI 10.1161/01.RES.71.5.1021; Hodgson DM, 2004, AM J PHYSIOL-HEART C, V287, pH471, DOI 10.1152/ajpheart.01247.2003; Ikawa M, 1999, CURR TOP DEV BIOL, V44, P1; ILES SA, 1977, J EMBRYOL EXP MORPH, V38, P63; Jackson KA, 2004, STEM CELLS, V22, P180, DOI 10.1634/stemcells.22-2-180; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; Kolossov E, 2006, J EXP MED, V203, P2315, DOI 10.1084/jem.20061469; Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117; Laflamme MA, 2005, AM J PATHOL, V167, P663, DOI 10.1016/S0002-9440(10)62041-X; Mallory GK, 1939, AM HEART J, V18, P647; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; Menasche P, 2003, J AM COLL CARDIOL, V41, P1078, DOI 10.1016/S0735-1097(03)00092-5; MILLERHANCE WC, 1993, J BIOL CHEM, V268, P25244; Min JY, 2002, J APPL PHYSIOL, V92, P288, DOI 10.1152/jappl.2002.92.1.288; Min JY, 2003, J THORAC CARDIOV SUR, V125, P361, DOI 10.1067/mtc.2003.101; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Murry CE, 1996, J CLIN INVEST, V98, P2512, DOI 10.1172/JCI119070; MUTHUCHAMY M, 1993, MOL CELL BIOL, V13, P3311, DOI 10.1128/MCB.13.6.3311; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Reinecke H, 1999, CIRCULATION, V100, P193, DOI 10.1161/01.CIR.100.2.193; Reinecke H, 2004, CIRC RES, V94, pE56, DOI 10.1161/01.RES.0000125294.04612.81; Reinecke Hans, 2003, Methods Mol Biol, V219, P97; ROBBINS J, 1990, J BIOL CHEM, V265, P11905; Robinson SW, 1996, CELL TRANSPLANT, V5, P77, DOI 10.1016/0963-6897(95)02016-0; Rubart M, 2003, CIRC RES, V92, P1217, DOI 10.1161/01.RES.0000075089.39335.8C; SANCHEZ A, 1991, J BIOL CHEM, V266, P22419; Scorsin M, 1997, CIRCULATION, V96, P188; Singla DK, 2006, J MOL CELL CARDIOL, V40, P195, DOI 10.1016/j.yjmcc.2005.09.001; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Sun Y, 2000, CARDIOVASC RES, V46, P250, DOI 10.1016/S0008-6363(00)00032-8; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; Teng CJ, 2006, J THORAC CARDIOV SUR, V132, P628, DOI 10.1016/j.jtcvs.2006.05.034; Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600; Virag JI, 2003, AM J PATHOL, V163, P2433, DOI 10.1016/S0002-9440(10)63598-5; Wakitani S, 2003, RHEUMATOLOGY, V42, P162, DOI 10.1093/rheumatology/keg024; Wang JF, 2002, CELL TRANSPLANT, V11, P753; Ware CB, 2003, TRANSGENIC RES, V12, P743, DOI 10.1023/B:TRAG.0000005246.35812.c8; Welikson RE, 2006, J MOL CELL CARDIOL, V40, P520, DOI 10.1016/j.yjmcc.2006.01.009; Yang YK, 2002, J APPL PHYSIOL, V93, P1140, DOI 10.1152/japplphysiol.00307.2002	50	462	485	0	46	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1345	1357		10.1096/fj.06-6769com	http://dx.doi.org/10.1096/fj.06-6769com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17284483				2022-12-28	WOS:000246117000010
J	Scholl, I; Ackermann, U; Ozdemir, C; Blumer, N; Dicke, T; Sel, S; Sel, S; Wegmann, M; Szalai, K; Knittelfelder, R; Untersmayr, E; Scheiner, O; Garn, H; Jensen-Jarolim, E; Renz, H				Schoell, Isabella; Ackermann, Ute; Ozdemir, Cevdet; Bluemer, Nicole; Dicke, Tanja; Sel, Serdar; Sel, Sarper; Wegmann, Michael; Szalai, Krisztina; Knittelfelder, Regina; Untersmayr, Eva; Scheiner, Otto; Garn, Holger; Jensen-Jarolim, Erika; Renz, Harald			Anti-ulcer treatment during pregnancy induces food allergy in mouse mothers and a Th2-bias in their offspring	FASEB JOURNAL			English	Article						sensitization against food; sucralfate; digestion; children; lactation	BREAST-MILK; HYPERSENSITIVITY; IMMUNIZATION; SUCRALFATE; CHEMOKINES; EXPOSURE; PROTEIN; CELLS; MICE	The treatment of dyspeptic disorders with anti-acids leads to an increased risk of sensitization against food allergens. As these drugs are taken by 30-50% of pregnant women due to reflux and heartburn, we aimed here to investigate the impact of maternal therapy with anti-acids on the immune response in the offspring in a murine model. Codfish extract as model allergen was fed with or without sucralfate, an anti-acid drug, to pregnant BALB/c mice during pregnancy and lactation. These mothers developed a codfish-specific allergic response shown as high IgG1 and IgE antibody levels and positive skin tests. In the next step we analyzed whether this maternal sensitization impacts a subsequent sensitization in the offspring. Indeed, in stimulated splenocytes of these offspring we found a relative Th2-dominance, because the Th1- and T-regulatory cytokines were significantly suppressed. Our data provide evidence that the anti-acid drug sucralfate supports sensitization against food in pregnant mice and favors a Th2-milieu in their offspring. From these results we propose that anti-acid treatment during pregnancy could be responsible for the increasing number of sensitizations against food allergens in young infants.	Med Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Hosp Univ Marburg, Dept Clin Chem & Mol Diagnost, Marburg, Germany; Marmara Univ, Sch Med, Pediat Allergy & Immunol Div, Istanbul, Turkey	Medical University of Vienna; Marmara University	Jensen-Jarolim, E (corresponding author), Med Univ Vienna, Dept Pathophysiol, Wahringer Gurtel, A-1090 Vienna, Austria.	erika.jensen-jarolim@meduniwien.ac.at	Ozdemir, Cevdet/X-5856-2018; Jensen-Jarolim, Erika/C-5120-2018; Untersmayr, Eva/GRY-4470-2022	Ozdemir, Cevdet/0000-0002-9284-4520; Jensen-Jarolim, Erika/0000-0003-4019-5765; Garn, Holger/0000-0002-5178-4023; Wegmann, Michael/0000-0002-1658-1554; Untersmayr, Eva/0000-0002-1963-499X	Austrian Science Fund FWF [H 220, F 1808] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Akdis M, 2006, CHEM IMMUNOL ALLERGY, V91, P159; BARON TH, 1993, ANN INTERN MED, V118, P366, DOI 10.7326/0003-4819-118-5-199303010-00008; Bauer M, 2002, AM J OBSTET GYNECOL, V186, P117, DOI 10.1067/mob.2002.118306; Bednar-Tantscher E, 2001, INT ARCH ALLERGY IMM, V126, P300, DOI 10.1159/000049527; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bredehorst R, 2001, J CHROMATOGR B, V756, P33, DOI 10.1016/S0378-4347(01)00069-X; Cogswell JJ, 2000, CLIN EXP ALLERGY, V30, P1; FISHER RS, 1978, AM J PHYSIOL, V234, pE243, DOI 10.1152/ajpendo.1978.234.3.E243; Hawrylowicz CM, 2005, J EXP MED, V202, P1459, DOI 10.1084/jem.20052211; JARRETT EEE, 1983, IMMUNOLOGY, V48, P49; Keski-Nisula L, 2003, J REPROD IMMUNOL, V60, P25, DOI 10.1016/S0165-0378(03)00079-2; Kruse A, 2002, BIOL REPROD, V66, P333, DOI 10.1095/biolreprod66.2.333; Michie CA, 1998, EUR CYTOKINE NETW, V9, P123; NAGASHIMA R, 1981, J CLIN GASTROENTEROL, V3, P117; NAGASHIMA R, 1981, J CLIN GASTROENTEROL, V3, P103; Ranchet GGO., 1990, G ITAL OBSTET GINECO, P1; Richter JE, 2005, ALIMENT PHARM THER, V22, P749, DOI 10.1111/j.1365-2036.2005.02654.x; Richter JE, 2003, GASTROENTEROL CLIN N, V32, P235, DOI 10.1016/S0889-8553(02)00065-1; Schoell I., 2002, Clinical and Experimental Allergy, V32, P1583, DOI 10.1046/j.1365-2222.2002.01527.x; Scholl L, 2005, AM J CLIN NUTR, V81, P154; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; STUART CA, 1984, CLIN ALLERGY, V14, P533, DOI 10.1111/j.1365-2222.1984.tb02240.x; Szepfalusi Z, 2000, PEDIATR RES, V48, P404, DOI 10.1203/00006450-200009000-00024; Takahata Y, 2003, ACTA PAEDIATR, V92, P659, DOI 10.1080/08035250310002614; Thornton CA, 2003, CLIN EXP ALLERGY, V33, P306, DOI 10.1046/j.1365-2222.2003.01614.x; Thornton Catherine A., 2002, Clinical and Experimental Allergy, V32, P1537, DOI 10.1046/j.1365-2222.2002.01543.x; Untersmayr E, 2005, FASEB J, V19, P656, DOI 10.1096/fj.04-3170fje; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI [10.1016/S0091-6749(03)01719-6, 10.1016/mai.2003.1681]; Uthoff H, 2003, J IMMUNOL, V171, P3485, DOI 10.4049/jimmunol.171.7.3485; Vadas P, 2001, JAMA-J AM MED ASSOC, V285, P1746, DOI 10.1001/jama.285.13.1746; Vance GHS, 2005, CLIN EXP ALLERGY, V35, P1318, DOI 10.1111/j.1365-2222.2005.02346.x; Venter C, 2006, J ALLERGY CLIN IMMUN, V117, P1118, DOI 10.1016/j.jaci.2005.12.1352; Victor JR, 2003, J ALLERGY CLIN IMMUN, V111, P269, DOI 10.1067/mai.2003.39; WALDEGRAVE W, 1986, J OFFICIEL COMMUNA L, V358, P1; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D	35	57	60	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1264	1270		10.1096/fj.06-7223com	http://dx.doi.org/10.1096/fj.06-7223com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17227952	Green Accepted			2022-12-28	WOS:000245650400030
J	Zuckerbraun, BS; Chin, BY; Bilban, M; d'Avila, JC; Rao, J; Billiar, TR; Otterbein, LE				Zuckerbraun, Brian S.; Chin, Beek Yoke; Bilban, Martin; d'Avila, Joana de Costa; Rao, Jayashree; Billiar, Timothy R.; Otterbein, Leo E.			Carbon monoxide signals via inhibition of cytochrome c oxidase and generation of mitochondrial reactive oxygen species	FASEB JOURNAL			English	Article						macrophage; p38 MAPK; tumor necrosis factor-alpha	ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE; RESPIRATORY-CHAIN; RAT-BRAIN; IN-VIVO; HEME; SUPPRESSES; HYPOXIA; INJURY; CYTOPROTECTION	Carbon monoxide ( CO), which is produced endogenously in the breakdown of heme, has been recognized as an important physiological second messenger similar to NO. Additionally, pharmacological delivery of CO is protective in numerous models of injury, including ischemia/reperfusion, transplantation, hemorrhagic shock, and endotoxemia. However, the mechanism of action of CO is only partially elucidated focused primarily on how it modulates the cellular response to stress. The purpose of these investigations is to test the hypothesis that CO acts via inhibition of cytochrome c oxidase leading to the generation of low levels of reactive oxygen species (ROS) that in turn mediate subsequent adaptive signaling. We show here that CO increases ROS generation in RAW 264.7 cells, which is inhibited by antimycin A and is absent in respiration-deficient rho(0) cells. CO inhibits cytochrome c oxidase, while maintaining cellular ATP levels and increasing mitochondrial membrane potential. The addition of antioxidants or inhibition of complex III of the electron transport chain by antimycin A attenuates the inhibitory effects of CO on lipopolysaccharide ( LPS)-induced TNF-alpha and blocked CO-induced p38 MAPK phosphorylation, which we previously have shown to be important in the anti-inflammatory effects of CO.	Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Cambridge, MA 02138 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Beth Israel Deaconess Medical Center	Zuckerbraun, BS (corresponding author), Univ Pittsburgh, Sch Med, Dept Surg, NW653 MUH,3459 5th Ave, Pittsburgh, PA 15213 USA.	zuckerbraunbs@upmc.edu	d'Avila, Joana/L-8970-2013	d'Avila, Joana/0000-0002-2045-0813; Bilban, Martin/0000-0001-7043-7142				Almeida A, 2001, P NATL ACAD SCI USA, V98, P15294, DOI 10.1073/pnas.261560998; Amersi F, 2002, HEPATOLOGY, V35, P815, DOI 10.1053/jhep.2002.32467; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Beltran B, 2002, P NATL ACAD SCI USA, V99, P8892, DOI 10.1073/pnas.092259799; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; BROWN SD, 1990, J APPL PHYSIOL, V68, P604, DOI 10.1152/jappl.1990.68.2.604; BROWN SD, 1992, J CLIN INVEST, V89, P666, DOI 10.1172/JCI115633; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHANDEL N, 1995, AM J PHYSIOL-LUNG C, V268, pL918, DOI 10.1152/ajplung.1995.268.6.L918; Chandel NS, 1997, J BIOL CHEM, V272, P18808, DOI 10.1074/jbc.272.30.18808; Chandel NS, 1999, FEBS LETT, V454, P173, DOI 10.1016/S0014-5793(99)00783-8; CHRZANOWSKALIGHTOWLERS ZMA, 1993, ANAL BIOCHEM, V214, P45, DOI 10.1006/abio.1993.1454; Clementi E, 1999, P NATL ACAD SCI USA, V96, P1559, DOI 10.1073/pnas.96.4.1559; Desmard M, 2005, CELL MOL BIOL, V51, P403, DOI 10.1170/T644; Emerling BM, 2005, MOL CELL BIOL, V25, P4853, DOI 10.1128/MCB.25.12.4853-4862.2005; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Katori M, 2002, TRANSPL IMMUNOL, V9, P227, DOI 10.1016/S0966-3274(02)00043-6; Kulisz A, 2002, AM J PHYSIOL-LUNG C, V282, pL1324, DOI 10.1152/ajplung.00326.2001; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Nakao A, 2003, SURGERY, V134, P285, DOI 10.1067/msy.2003.238; Nakao A, 2003, AM J PATHOL, V163, P1587, DOI 10.1016/S0002-9440(10)63515-8; Nakao A, 2003, GUT, V52, P1278, DOI 10.1136/gut.52.9.1278; Nystul TG, 2004, P NATL ACAD SCI USA, V101, P9133, DOI 10.1073/pnas.0403312101; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Otterbein LE, 2005, HEME OXYGENASE: THE ELEGANT ORCHESTRATION OF ITS PRODUCTS IN MEDICINE, pVII; Palacios-Callender M, 2004, P NATL ACAD SCI USA, V101, P7630, DOI 10.1073/pnas.0401723101; PIANTADOSI CA, 1989, AM J PHYSIOL, V256, pC840, DOI 10.1152/ajpcell.1989.256.4.C840; Piantadosi CA, 2002, ANTIOXID REDOX SIGN, V4, P259, DOI 10.1089/152308602753666316; Sarady JK, 2004, FASEB J, V18, P854, DOI 10.1096/fj.03-0643fje; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Sawle P, 2005, BRIT J PHARMACOL, V145, P800, DOI 10.1038/sj.bjp.0706241; Song RP, 2003, AM J PATHOL, V163, P231, DOI 10.1016/S0002-9440(10)63646-2; Srisook K, 2006, BIOCHEM PHARMACOL, V71, P307, DOI 10.1016/j.bcp.2005.10.042; Taille C, 2005, J BIOL CHEM, V280, P25350, DOI 10.1074/jbc.M503512200; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Zuckerbraun BS, 2003, J EXP MED, V198, P1707, DOI 10.1084/jem.20031003; Zuckerbraun BS, 2005, SHOCK, V23, P527, DOI 10.1097/01.shk.0000163206.22032.a1	41	241	246	4	47	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1099	1106		10.1096/fj.06-6644com	http://dx.doi.org/10.1096/fj.06-6644com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17264172				2022-12-28	WOS:000245650400014
